<SEC-DOCUMENT>0001493152-21-014911.txt : 20210622
<SEC-HEADER>0001493152-21-014911.hdr.sgml : 20210622
<ACCEPTANCE-DATETIME>20210622094934
ACCESSION NUMBER:		0001493152-21-014911
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		90
FILED AS OF DATE:		20210622
DATE AS OF CHANGE:		20210622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257272
		FILM NUMBER:		211033294

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>forms-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the Securities and Exchange Commission on June 21, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-______ </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Form
S-4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><B>Enveric
Biosciences, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>95-4484725</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State
    or other jurisdiction of</I></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary
    Standard Industrial</I></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
    Employer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>incorporation
    or organization)</I></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Classification
    Code Number)</I></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Identification
    No.)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4851
Tamiami Trail N, Suite 200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Naples,
FL 34103</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(239)
302-1707</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Address,
including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
Johnson</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4851
Tamiami Trail N, Suite 200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Naples,
FL 34103</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(239)
302-1707</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I></I></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rick
    A. Werner</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
    Joseph Tucker</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Syd
    Abougoush</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jason
    K. Zachary</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
    Industries Inc.</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Burnet,
    Duckworth &amp; Palmer LLP</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Haynes
    and Boone, LLP</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>777
    Hornby Street, Suite 600,</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>525
    - 8th Ave SW, Suite 2400</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>30
    Rockefeller Plaza, 26th Floor</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vancouver,
    British Columbia, </B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calgary,
    AB T2P 1G1</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, New York 10112</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V6Z
    1S4</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel.
    (403) 260-0399</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel.
    (212) 659-7300</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel.
    (508) 627-0485</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration statement
and the satisfaction or waiver of all other conditions under the Amalgamation Agreement described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the securities being registered on this Form are to be offered in connection with the formation of a holding company and there is compliance
with General Instruction G, check the following box. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
[&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
applicable, place an [X] in the box to designate the appropriate rule provision relied upon in conducting this transaction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Amount</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>Proposed
                                            Maximum</B></P>
                                                                  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>Offering</B></P></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>Proposed
                                            Maximum</B></P>
                                                                  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>Aggregate</B></P></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"><B>Amount of</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-weight: bold"><B>Title of Each Class of</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"><B>to be</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"><B>Price per</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"><B>Offering</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold"><B>Registration</B></TD><TD STYLE="text-align: center; font-weight: bold"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><B>Securities to be Registered</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><B>Registered(1)</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><B>Share</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><B>Price(2)</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><B>Fee(3)</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Common Stock, $0.01 par value per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right"></TD><TD STYLE="width: 11%; text-align: right">17,350,022</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">N/A</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: center"><SUP></SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the maximum number of shares of common stock, par value $0.01 per share, of Enveric Biosciences, Inc. estimated to be issued in connection
    with the amalgamation described in the proxy statement/prospectus contained herein based upon: (A)(i) 37,418,673 common shares, no
    par value (&ldquo;MagicMed  Shares&rdquo;), of MagicMed Industries Inc. issued and outstanding as of June 18, 2021; (ii) 3,683,830
    outstanding options to purchase MagicMed  Shares under MagicMed&rsquo;s equity compensation plan; (iii) 22,246,830 MagicMed
     Shares potentially issuable in respect of MagicMed warrants, and (iv) 1,283,501 MagicMed broker warrants, each of which may
    be converted in accordance with their terms into one MagicMed Share and 1/2 of a MagicMed warrant, and (B) the exchange ratio, as
    set forth in that certain amalgamation agreement described herein, of 0.2658 shares of Enveric common stock per MagicMed
    Share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Estimated solely for purposes of calculation of the
    registration fee in accordance with Rule 457(f)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).
    MagicMed is a private company. No market exists for MagicMed&rsquo;s equity securities and MagicMed has an accumulated capital deficit;
    therefore, pursuant to Rule 457(f)(2) under the Securities Act, the proposed maximum offering price is one-third of the aggregate
    par value of MagicMed&rsquo;s capital stock being acquired or cancelled in the Amalgamation described herein. However, because MagicMed&rsquo;s
    securities have no par value, this value is $0.00.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined
    in accordance with Section 6(b) of the Securities Act at a rate equal to $109.10 per $1,000,000 of the proposed maximum aggregate
    offering price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
    information in this preliminary proxy statement/prospectus is not complete and may be changed. The securities being offered by the
    use of this preliminary proxy statement/prospectus may not be sold nor may offers to buy be accepted prior to the time the registration
    statement filed with the Securities and Exchange Commission is declared effective. This preliminary proxy statement/prospectus is
    not an offer to sell these securities nor a solicitation of any offer to buy these securities in any jurisdiction where the offer,
    solicitation or sale is not permitted. </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
PROXY STATEMENT/PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
TO COMPLETION, DATED JUNE 21, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="s4_001.jpg" ALT="" STYLE="height: 62px; width: 263px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AN
AMALGAMATION PROPOSAL &mdash; YOUR VOTE IS VERY IMPORTANT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders of Enveric Biosciences, Inc.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, Enveric Biosciences, Inc., a Delaware corporation (&ldquo;ENVB&rdquo;), entered into an Amalgamation Agreement (the &ldquo;Amalgamation
Agreement&rdquo;) with 1306432 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned
subsidiary of ENVB (&ldquo;HoldCo&rdquo;), 1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia
and a wholly-owned subsidiary of HoldCo (&ldquo;Purchaser&rdquo;), and MagicMed Industries Inc., a corporation existing under the laws
of the Province of British Columbia (&ldquo;MagicMed&rdquo;), which provides for, among other things, the amalgamation of Purchaser,
a wholly-owned subsidiary of ENVB, with MagicMed pursuant to Section 269 of the <I>Business Corporations Act</I> (British Columbia) (the
&ldquo;Amalgamation&rdquo;), such that, upon completion of the Amalgamation, the amalgamated corporation (&ldquo;AmalCo&rdquo;) will
be an indirect, wholly-owned subsidiary of ENVB. The boards of directors of each of ENVB and MagicMed have unanimously approved the
Amalgamation Agreement and the transactions contemplated by the Amalgamation Agreement, including the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Amalgamation is completed, at the effective time of the Amalgamation (the &ldquo;Effective Time&rdquo;), holders of outstanding common
shares of MagicMed (the &ldquo;MagicMed Shares&rdquo;) will receive such number of shares of common stock of ENVB (the &ldquo;ENVB Shares&rdquo;)
representing, together with ENVB Shares issuable upon exercise of the MagicMed Warrants and the MagicMed Converted Options (each as defined
below), approximately 36.6% of the issued and outstanding ENVB Shares (on a fully-diluted basis). In connection with the Amalgamation,
the MagicMed Shares will initially be converted into AmalCo redeemable preferred shares, which immediately following the Amalgamation
will be redeemed for 0.000001 of an ENVB Share. Following such redemption, each shareholder of MagicMed will be entitled to receive additional
ENVB Shares equal to the product of 0.2658 (the &ldquo;Exchange Ratio&rdquo;) multiplied by the number of MagicMed Shares held
by each such shareholder. In addition, following the Effective Time (i) each outstanding MagicMed stock option will be converted into
and become an option to purchase (the &ldquo;MagicMed Converted Options&rdquo;) the number of ENVB Shares equal to the Exchange Ratio
multiplied by the number of MagicMed Shares subject to such MagicMed stock option, and (ii) each holder of an outstanding MagicMed warrant
(including Company Broker Warrants (as defined in the Amalgamation Agreement), the &ldquo;MagicMed Warrants&rdquo;) will be entitled
to receive upon exercise of such MagicMed Warrant that number of ENVB Shares which the holder would have been entitled to receive as
a result of the Amalgamation if, immediately prior to the date of the Amalgamation, such holder had been the registered holder of the
number of MagicMed Shares to which such holder would have been entitled if such holder had exercised such holder&rsquo;s MagicMed Warrants
immediately prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate number of ENVB Shares that ENVB intends to issue in connection with the Amalgamation (assuming all of the MagicMed Warrants
and MagicMed Converted Options are exercised) will be in excess of 20% of ENVB&rsquo;s pre-transaction outstanding ENVB Shares. Accordingly,
ENVB is seeking stockholder approval of the issuance of ENVB Shares to be issued in connection with the Amalgamation in accordance with
NASDAQ Listing Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
common stock is currently listed on The NASDAQ Capital Market under the symbol &ldquo;ENVB.&rdquo; On May 21, 2021, the last full trading
day before the announcement of the Amalgamation, the last reported sale price of ENVB common stock was $2.72 per share, and, on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ],
2021, the latest practicable date prior to the date of this proxy statement/prospectus, the last reported sale price of ENVB common stock
was $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per share. <B>We urge you to obtain current market quotations for the price of ENVB common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of ENVB and MagicMed expect that the Amalgamation will qualify as a &ldquo;reorganization&rdquo; within the meeting of Section 368(a)
of the Internal Revenue Code of 1986, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
and MagicMed will each hold a special meeting of their respective stockholders. ENVB is soliciting proxies for use at the special
meeting of its stockholders to consider and vote upon (i) a proposal to approve the issuance of shares of ENVB common stock to
MagicMed equity holders in the Amalgamation pursuant to the terms and conditions of the Amalgamation Agreement (the &ldquo;ENVB
Share Issuance Proposal&rdquo;) and (ii) a proposal to adjourn its special meeting, if necessary, to solicit additional
proxies if a quorum is not present or if there are not sufficient votes cast in favor of the ENVB Share Issuance Proposal or to
ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to ENVB stockholders (the
&ldquo;ENVB Adjournment Proposal&rdquo;). The ENVB special meeting will be held virtually on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2021 at [_____] [a.m./p.m.], Eastern Time, at
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MagicMed special meeting is expected to be held on or about [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2021. MagicMed shareholders will be asked to consider and vote upon a resolution to adopt and approve the Amalgamation Agreement
and the transactions contemplated thereby, including the Amalgamation (the &ldquo;MagicMed Amalgamation Proposal&rdquo;). The MagicMed
special meeting is expected to be held prior to the ENVB special meeting. <B>Neither ENVB nor MagicMed is soliciting proxies for use
at the MagicMed special meeting as part of this proxy statement/prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
of the Amalgamation is conditioned upon, among other things (i) the adoption and approval of the MagicMed Amalgamation Proposal by the
holders of MagicMed shares and (ii) the approval of  the ENVB Share Issuance Proposal  by holders
of ENVB common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
directors and executive officers of MagicMed, collectively representing approximately 30% of the outstanding shares of MagicMed, have
entered into voting agreements with ENVB, pursuant to which such holders have agreed, among other things, to vote in favor of the adoption
and approval of the MagicMed Amalgamation Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
careful consideration, the ENVB board of directors has (i) determined that the Amalgamation Agreement and the other transactions contemplated
thereby, including the Amalgamation of Purchaser with MagicMed and the issuance of ENVB common stock contemplated by the ENVB
Share Issuance Proposal, are advisable and in the best interests of ENVB and the ENVB stockholders, (ii) authorized and approved ENVB&rsquo;s
execution, delivery and performance of the Amalgamation Agreement in accordance with its terms and ENVB&rsquo;s consummation of the transactions
contemplated thereby, including the Amalgamation and the issuance of ENVB common stock contemplated by the ENVB Share Issuance Proposal,
(iii) resolved that the approval of the ENVB Share Issuance Proposal be submitted to a vote at a meeting of the holders of ENVB common
stock and (iv) recommended that the holders of ENVB common stock approve the ENVB Share Issuance Proposal. <B>ENVB&rsquo;s board of directors
unanimously recommends that ENVB stockholders vote &ldquo;FOR&rdquo; the ENVB Share Issuance Proposal and &ldquo;FOR&rdquo; the ENVB
Adjournment Proposal.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus provides you with important information about the ENVB special meeting, ENVB, MagicMed, the proposed Amalgamation
and the documents related to the Amalgamation. <B>Please carefully read this entire proxy statement/prospectus, including &ldquo;Risk
Factors&rdquo; beginning on page 46</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
vote is very important. </B>Whether or not you plan to virtually attend the ENVB special meeting, please take the time to vote by completing
and returning the enclosed proxy card to us or by granting your proxy electronically over the Internet or by telephone. If your shares
are held in &ldquo;street name,&rdquo; you must instruct your broker in order to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Biosciences, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved the Amalgamation described in
this proxy/prospectus nor have they approved or disapproved the ENVB common stock to be issued in the Amalgamation, or determined if
this proxy statement/prospectus is accurate or complete. Any representation to the contrary is a criminal offense. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus is dated [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, and is first being mailed or otherwise delivered to the stockholders of ENVB on or about
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="s4_001.jpg" ALT="" STYLE="height: 62px; width: 263px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4851
Tamiami Trail N, Suite 200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Naples,
Florida 34103</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(239)
302-1707</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF SPECIAL MEETING OF STOCKHOLDERS<BR>
To Be Held on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders of Enveric Biosciences, Inc.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
IS HEREBY GIVEN that a special meeting of stockholders of Enveric Biosciences, Inc., a Delaware corporation (&ldquo;ENVB&rdquo;), will
be held virtually on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2021 at [_____] [a.m./p.m.], Eastern Time, at [__________], to consider and vote upon the following matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(a), the issuance of shares of ENVB common stock to the
    equity holders of MagicMed Industries, Inc.,   a corporation existing under the laws of the Province of British Columbia (&ldquo;MagicMed&rdquo;),
    pursuant to the terms and conditions of the Amalgamation Agreement, dated as of May 24, 2021 (as may be amended from time to time,
    the &ldquo;Amalgamation Agreement&rdquo;), by and among ENVB, 1306432 B.C. Ltd., a corporation existing under the laws of the Province
    of British Columbia and a wholly-owned subsidiary of ENVB (&ldquo;HoldCo&rdquo;), 1306436 B.C. Ltd., a corporation existing under
    the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo (&ldquo;Purchaser&rdquo;), and MagicMed (the
    &ldquo;ENVB Share Issuance Proposal&rdquo;); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    proposal to approve any motion to adjourn the ENVB special meeting, or any adjournments thereof, if necessary or appropriate, to
    solicit additional proxies if a quorum is not present or if there are insufficient votes at the time of the ENVB special meeting
    to approve the ENVB Share Issuance Proposal or to ensure that any supplement or amendment to this proxy statement/prospectus is
    timely provided to ENVB stockholders (the &ldquo;ENVB Adjournment Proposal&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
will only transact business at the special meeting that is properly brought before the special meeting or any adjournment or postponement
thereof. Please refer to this proxy statement/prospectus of which this notice is a part for further information with respect to
the business to be transacted at the special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors of ENVB has fixed the close of business on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2021 as the record date for the ENVB special meeting for the purpose of determining the holders of shares of ENVB common stock who
are entitled to receive notice of, and to vote at, the ENVB special meeting and any adjournment or postponement thereof, unless a new
record date is fixed in connection with any adjournment or postponement of the ENVB special meeting. Only holders of record of shares
of ENVB common stock at the close of business on such date are entitled to receive notice of, and vote at, the ENVB special meeting or
at any postponement(s) or adjournment(s) of the ENVB special meeting. A complete list of stockholders entitled to vote at the ENVB special
meeting will be available for a period of at least ten days prior to the ENVB special meeting. If you would like to inspect the list
of ENVB stockholders of record, please call ENVB&rsquo;s Investor Relations contact at (212) 896-1254 to schedule an appointment or request
access. A certified list of eligible ENVB stockholders will be available for inspection during the special meeting at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
by entering the control number provided on your proxy card, voting instruction form or notice. The presence, either in person or
represented by proxy, of the holders of a majority of the voting power of the stock issued, outstanding and entitled to vote at
the ENVB special meeting is necessary to constitute a quorum for the transaction of business at the special meeting. Virtual attendance
by stockholders of record at the ENVB special meeting will constitute the presence in person for the purpose of determining the presence
of a quorum for the transaction of business at the ENVB special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval of the ENVB Share Issuance Proposal requires the affirmative vote of a majority of the votes cast by holders of ENVB&rsquo;s
common stock as of the Record Date present in person or represented by proxy at the ENVB special meeting. The approval of the ENVB Adjournment
Proposal requires the affirmative vote of a majority of the voting power of the shares of ENVB common stock present in person
or represented by proxy at the ENVB special meeting and entitled to vote on the proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After
careful consideration, the board of directors of ENVB unanimously recommend that ENVB stockholders vote &ldquo;FOR&rdquo; the ENVB Share
Issuance Proposal (Proposal 1) and &ldquo;FOR&rdquo; the ENVB Adjournment Proposal (Proposal 2). </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
vote is very important. </B>If your shares are registered in your name as a stockholder of record of ENVB, even if you plan to virtually
attend the special meeting or any postponement or adjournment of the special meeting, we encourage you to authorize a proxy to vote your
shares at the special meeting by telephone or on the Internet, or, by completing, signing, dating and returning your proxy card as promptly
as possible to ensure that your shares will be represented at the special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are held in the name of a broker, trust, bank or other nominee, and you receive notice of the special meeting through
your broker or through another intermediary, please vote or complete and return the materials in accordance with the instructions provided
to you by such broker or other intermediary or contact your broker directly in order to obtain a proxy issued to you by your nominee
holder to virtually attend the special meeting and vote. Failure to do so may result in your shares not being eligible to be voted by
proxy at the special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can revoke a proxy at any time prior to its exercise at the ENVB special meeting by following the instructions in the enclosed
proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPORTANT
NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ENVB SPECIAL MEETING TO BE HELD ON [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2021:</B> We urge you to read the accompanying proxy statement/prospectus, including the section entitled &ldquo;Risk Factors&rdquo;
beginning on page 46, and its annexes carefully and in their entirety. If you have any questions concerning the Amalgamation,
the Amalgamation Agreement, the proposals, the ENVB special meeting or the accompanying proxy statement/prospectus, would like additional
copies of the accompanying proxy statement/prospectus or need help voting your shares of ENVB common stock, please contact Kingsdale
Advisors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kingsdale
Advisors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
Shareholder Advisor and Proxy Solicitation Agent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">745
Fifth Avenue, 5th Floor, New York, NY 10151</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
May Call or Email:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">North
American Toll Free Phone: 1-866-851-2468</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>contactus@kingsdaleadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">o<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">r</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Call
Collect Outside North America: (416) 867-2272</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know of any other matters to be presented at the special meeting, but if other matters are properly presented, the persons named
as proxies will vote on such matters at their discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    Order of the Board of Directors,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chairman</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
    Florida</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REFERENCES
TO ADDITIONAL INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus includes important business and financial information about ENVB and MagicMed. Additional information about
ENVB is available to you without charge upon request. You can obtain copies of this proxy statement/prospectus or any of the documents
filed with or furnished to the Securities and Exchange Commission, or SEC, by ENVB at no cost from the SEC&rsquo;s website at http://www.sec.gov.
You may also request copies of these documents at no cost by requesting them in writing or by telephone at the following address and
telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
Florida 34103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Corporate Secretary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(239) 302-1707</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
receive timely delivery of the documents in advance of the special meeting, you should make your request no later than five (5) business
days prior to the date of the special meeting, or no later than [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ], 2021.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not incorporating the contents of the websites of the SEC, ENVB, MagicMed or any other entity into this proxy statement/prospectus.
We are providing the information about how you can obtain certain documents referred to in this proxy statement/prospectus at these websites
only for your convenience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>In
addition, if you have questions about the Amalgamation or this proxy statement/prospectus, would like additional copies of
this proxy statement/prospectus or need to obtain proxy cards or other information related to the proxy solicitation, contact
Kingsdale Advisors, the proxy solicitor for ENVB, by North American Toll Free Phone: 1-866-851-2468, or Email: <U>contactus@kingsdaleadvisors.com, </U>or
call collect Outside North America: (416) 867-2272. You will not be charged for any of these documents that you
request.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TABLE
OF CONTENTS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_001">ABOUT THIS PROXY STATEMENT/PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_002">QUESTIONS AND ANSWERS ABOUT THE AMALGAMATION AND SPECIAL MEETING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_003">SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_004">SELECTED HISTORICAL FINANCIAL INFORMATION OF ENVB</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_005">SELECTED HISTORICAL FINANCIAL INFORMATION OF MAGICMED</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_006">HISTORICAL AND UNAUDITED PRO FORMA COMBINED PER SHARE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_007">UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_008">COMPARATIVE PER SHARE MARKET PRICE AND DIVIDEND INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_009">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_010">Risks Related to the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_011">Risks Related to the Combined Company</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_012">Risks Related to ENVB&rsquo;s Business</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_013">Risks Related to Regulatory Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_014">Risks Related to ENVB&rsquo;s Intellectual Property</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_015">Risks Related to the Ownership of ENVB Common Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_016">Risks Related to MagicMed&rsquo;s Business</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_017">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_018">THE ENVB SPECIAL MEETING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_019">General</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_020">Date, Time and Place</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_021">Purpose of the ENVB Special Meeting</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_022">Recommendation of the ENVB Board of Directors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_023">Record Date; Stockholders Entitled to Vote</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_024">Quorum; Adjournment</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_025">Vote Required for Approval</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_026">Abstentions</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_027">Failure to Vote</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#o_030">Shares Held in Street Name</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">89</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_028">Voting by ENVB&rsquo;s Directors and Executive Officers</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_029">Voting at the ENVB Special Meeting</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_031">Revocation of Proxies and Voting Instructions</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_032">Tabulation of Votes</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_033">Solicitation of Proxies</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_034">Appraisal Rights</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_035">Householding of ENVB Special Meeting Materials</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_036">Questions and Assistance</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_037">THE PARTIES TO THE AMALGAMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_038">Enveric Biosciences, Inc.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_039">1306432 B.C. Ltd.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_040">1306436 B.C. Ltd.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_041">MagicMed Industries Inc.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_042">THE AMALGAMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_043">Transaction Structure</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_044">Consideration to MagicMed Shareholders</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_045">Background of the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_046">Recommendation of the ENVB Board of Directors; ENVB&rsquo;s Reasons for the Transactions</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_047">Opinion of ENVB&rsquo;s Financial Advisor</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_048">Interests of MagicMed&rsquo;s Directors and Executive Officers in the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_049">Interests of ENVB&rsquo;s Directors and Executive Officers in the Amalgamation</A></FONT></TD>
    <TD STYLE="padding-left: -10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_050">Ownership of ENVB after the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_051">Governance of ENVB After the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_052">Directors&rsquo; and Officers&rsquo; Indemnification Insurance</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_053">Dividend Policy</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_054">Accounting Treatment of the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_055">U.S. Federal Income Tax Consequences of the Amalgamation Generally</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_056">Listing of ENVB Common Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_057">Restrictions on Sales of Shares of ENVB Common Stock Received in the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_058">Regulatory Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_059">No Appraisal Rights</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_061">THE AMALGAMATION AGREEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_062">Form, Effective Time and Closing of Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_063">Effects of Amalgamation; Amalgamation Consideration</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_064">Treatment of MagicMed Shares</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_065">Treatment of MagicMed Stock Options</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_066">Treatment of MagicMed Warrants</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_067">Exchange Ratio</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_068">Exchange Procedures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_069">Directors and Executive Officers of ENVB Following the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_070">Dissenting Shares</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_071">Conditions to the Completion of the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_072">Representations and Warranties</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_073">No Solicitation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_074">Meetings of Stockholders</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_075">Conduct of Business Pending the Amalgamation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_076">Covenants and Other Agreements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_077">Termination of the Amalgamation Agreement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_078">Termination Fee</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_079">Amendment</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_080">Third Party Beneficiaries</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_081">Governing Law; Jurisdiction</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_082">Injunctive Relief</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_083">ANCILLARY AGREEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_084">Voting Agreement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_085">Lock-Up Agreement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_086">ENVB PROPOSAL 1 &ndash; APPROVAL OF THE ENVB SHARE ISSUANCE PROPOSAL</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_087">ENVB
    PROPOSAL 2 &ndash; APPROVAL OF THE ENVB ADJOURNMENT PROPOSAL</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">131</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_089">ENVB&rsquo;S BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_090">Company Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_091">Recent Developments</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_092">Business Overview</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_093">Conditions Currently Targeted by Enveric</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_094">Additional Potential Development Projects</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_095">Research &amp; Development</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_096">Clinical Studies</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">142</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_097">Government Regulation and Product Approvals</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_098">Employees</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">152</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_099">Legal Proceedings</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">152</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_100">Corporate Developments</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_101">ENVB MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">155</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 94%"><FONT STYLE="font-size: 10pt"><A HREF="#o_102">Business Overview</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font-size: 10pt">155</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_103">Corporate Developments</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">155</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_104">Recent Developments</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">159</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_105">Key Components of Our Results of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">162</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_106">Results of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">162</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_107">Liquidity and Capital Resources</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">164</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_108">Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">166</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_109">Off-Balance Sheet Arrangements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">167</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_110">Warrant Liability</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">167</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_111">Recent Accounting Standards</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">168</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_112">Critical Accounting Policies and Significant Judgments and Estimates</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">169</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_113">Concentration of Credit Risk</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">169</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_114">Foreign Currency Risk</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">169</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_115">Quantitative and Qualitative Disclosures About Market Risk</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">169</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_116">MAGICMED&rsquo;S BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">170</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_117">General</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">170</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_118">History</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">177</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_119">MAGICMED&rsquo;S MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">180</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_120">Overview of MagicMed</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">180</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_121">Overall Performance</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">180</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_122">Selected Financial Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">181</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_123">Results of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">181</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_124">Summary of Quarterly Results</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">181</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_125">Changes to Accounting Policies Including Initial Adoption</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">182</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_126">Critical Accounting Estimates and Judgements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">183</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_127">DESCRIPTION OF ENVB CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">184</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_128">Authorized Capital Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">184</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_129">Common Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">184</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_130">Preferred Stock</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">184</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_131">Anti-Takeover Effects of Certain Provisions of ENVB&rsquo;s Certificate of Incorporation, Bylaws and the DGCL</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">184</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_132">COMPARISON OF RIGHTS OF HOLDERS OF ENVB CAPITAL STOCK AND MAGICMED CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">185</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_133">INFORMATION ABOUT THE MAGICMED DIRECTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">200</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_134">Term of Office of Directors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">201</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_135">Aggregate Ownership of Securities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">201</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_136">MagicMed Option Plan</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">201</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_137">MagicMed Warrants</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">202</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_138">MagicMed Broker Warrants</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">202</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_139">Stock Appreciation Rights Plan</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">202</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_140">PRINCIPAL STOCKHOLDERS OF ENVB</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">203</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_141">PRINCIPAL STOCKHOLDERS OF MAGICMED</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">206</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_142">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">208</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_143">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">208</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_144">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">208</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_145">OTHER MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">209</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_146">Future Stockholder Proposals</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">209</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#o_147">Householding of Proxy Statement/Prospectus</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">209</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><A HREF="#o_148">Audited Consolidated Financial Statements of Enveric Biosciences, Inc.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><A HREF="#o_149">Unaudited Condensed Consolidated Financial Statements of Enveric Biosciences, Inc.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><A HREF="#o_150">Audited Financial Statements of MagicMed Industries Inc.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">F-31</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#o_151">Unaudited Condensed Consolidated Financial Statements of MagicMed Industries Inc.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-53</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A HREF="#o_152">Annexes</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_152">A. Amalgamation Agreement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_153">B-1. Voting and Support Agreement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-1-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_154">B-2. Voting Agreement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-2-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#ct_002">C-1. Lock-Up Agreement</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C-1-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#ct_001">C-2. Lock-Up/Leak-Out
    Agreement</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">C-2-1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_156">D. Opinion of ENVB&rsquo;s Financial Advisor</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">D-1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_157">PART II INFORMATION NOT REQUIRED IN PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">II-1</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_001"></A>ABOUT
THIS PROXY STATEMENT/PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus, which forms part of a registration statement on Form S-4 filed with the SEC by ENVB, constitutes a prospectus
of ENVB under Section 5 of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), with respect to the common stock,
par value $0.01 per share, of ENVB to be issued to MagicMed equity holders in connection with the amalgamation of Purchaser with MagicMed
and pursuant to the terms and conditions of the Amalgamation Agreement and the transactions contemplated thereby. This proxy statement/prospectus
also constitutes a proxy statement for ENVB under Section 14(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and notice of meeting with respect to the special meeting of ENVB stockholders. As allowed by SEC rules, this proxy
statement/prospectus does not contain all the information you can find in the registration statement or the exhibits to the registration
statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You
should rely only on the information contained in, or incorporated by reference into, if any, this proxy statement/prospectus. No one
has been authorized to provide you with information that is different from that contained in, or incorporated by reference into, this
proxy statement/prospectus and ENVB does not take any responsibility for, and cannot provide any assurances as to the reliability of,
any other information that others may give you. This proxy statement/prospectus is dated [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021. You should not assume that the information
contained in this proxy statement/prospectus is accurate as of any date other than that date or that the information incorporated by
reference into this proxy statement/prospectus is accurate as of any date other than the date of the incorporated document. Neither the
mailing of this proxy statement/prospectus to ENVB stockholders nor the issuance by ENVB of its common stock in connection with the transactions
contemplated by the Amalgamation Agreement will create any implication to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
document does not constitute an offer to sell, or a solicitation of an offer to buy any securities, or the solicitation of a proxy, in
any jurisdiction to or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. Except where
the context otherwise indicates, information contained in this document regarding ENVB has been provided by ENVB and information contained
in this document regarding MagicMed has been provided by MagicMed. See &ldquo;Where You Can Find More Information&rdquo; beginning on
page 208 for more details.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
the context otherwise requires, references in this proxy statement/prospectus to (1) &ldquo;ENVB&rdquo; refer to Enveric Biosciences,
Inc., a Delaware corporation, and its subsidiaries, (2) &ldquo;HoldCo&rdquo; refers to 1306432 B.C. Ltd., a corporation existing under
the laws of the Province of British Columbia and a wholly-owned subsidiary of ENVB; (3) &ldquo;Purchaser&rdquo; refers to 1306436 B.C.
Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo and (4) &ldquo;MagicMed&rdquo;
refers to MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_002"></A>QUESTIONS
AND ANSWERS ABOUT THE AMALGAMATION AND SPECIAL MEETING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following are brief answers to certain questions that you may have regarding the proposals being considered at the special meeting
of ENVB stockholders and the proposed Amalgamation. ENVB urges you to read carefully this entire proxy statement/prospectus, including
its annexes, and the other documents to which this proxy statement/prospectus refers or incorporates by reference, because this
section does not provide all the information that might be important to you as a ENVB stockholder. Also see the section entitled
&ldquo;Where You Can Find More Information&rdquo; beginning on page 208.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Why
    am I receiving this proxy statement/prospectus?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            proxy statement/prospectus serves as a proxy statement for the ENVB special meeting. You
                                            are receiving this proxy statement/prospectus because ENVB and MagicMed have agreed to an
                                            all stock amalgamation transaction pursuant to that certain Amalgamation Agreement, dated
                                            as of May 24, 2021 (as may be amended from time to time, the &ldquo;Amalgamation Agreement&rdquo;),
                                            between ENVB, HoldCo, a wholly-owned subsidiary of ENVB, Purchaser, a wholly-owned subsidiary
                                            of HoldCo, and MagicMed.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the terms and subject to the conditions set forth in the Amalgamation Agreement, and in accordance with the <I>Business Corporations
    Act</I> (British Columbia) (the &ldquo;BCBCA&rdquo;), at the Effective Time of the Amalgamation, Purchaser, a wholly-owned subsidiary
    of HoldCo, will be amalgamated with MagicMed. Upon completion of the Amalgamation, the separate corporate existences of Purchaser
    and MagicMed will cease, and the amalgamated corporation (&ldquo;AmalCo&rdquo;) will continue as the surviving corporation and as
    a wholly-owned subsidiary of HoldCo under the name &ldquo;Enveric Biosciences Canada Inc.&rdquo; As referred to in this proxy statement/prospectus,
    the &ldquo;Effective Time&rdquo; means the effective time of the Amalgamation and as set forth in the Amalgamation Agreement. The
    Amalgamation Agreement governs the terms of the Amalgamation of Purchaser with MagicMed and is attached to this proxy statement/prospectus
    as <U>Annex A</U>.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation cannot be completed unless, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    stockholders approve the ENVB Share Issuance Proposal (as defined below); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    shareholders adopt the Amalgamation Agreement and approve the Amalgamation of Purchaser with MagicMed pursuant to Section 269 of
    the <I>Business Corporations Act</I> (British Columbia) and the transactions contemplated by the Amalgamation Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
will hold a special meeting of its stockholders and MagicMed will hold a special meeting of its shareholders to obtain these approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus serves as both the proxy statement through which ENVB will solicit proxies to obtain the necessary stockholder
approval of the ENVB Share Issuance Proposal for the Amalgamation and the prospectus by which ENVB will issue shares of ENVB common
stock as consideration in the Amalgamation. This proxy statement/prospectus contains important information about the Amalgamation and
the ENVB special meeting. You should read all the available information carefully and its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    are the proposals on which I am being asked to vote?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the ENVB special meeting, ENVB stockholders will consider and vote on a proposal to approve the issuance of shares of ENVB common
    stock to MagicMed equity holders in the Amalgamation pursuant to the terms and conditions of the Amalgamation Agreement (the &ldquo;ENVB
    Share Issuance Proposal&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
stockholders will also be asked to approve the proposal to adjourn the ENVB special meeting to solicit additional proxies if a quorum
is not present or if there are not sufficient votes at the time of the ENVB special meeting to approve the ENVB Share Issuance Proposal
 or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided
to ENVB stockholders (the &ldquo;ENVB Adjournment Proposal&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors recommends that ENVB stockholders vote their shares &ldquo;FOR&rdquo; approval of each of the above proposals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    constitutes a quorum for the ENVB special meeting and what vote is required to approve each proposal at the ENVB special meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            presence, either in person or represented by proxy, of the holders of a majority of
                                            the voting power of the stock issued, outstanding and entitled to vote at the ENVB special
                                            meeting is necessary to constitute a quorum for the transaction of business at the special
                                            meeting. Virtual attendance  at the special meeting will constitute
                                            presence in person for the purpose of determining the presence of a quorum for the transaction
                                            of business at the ENVB special meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstentions
    will be counted for purpose of determining that a quorum is present; however, any broker non-votes (i.e., the failure to instruct
    your bank or broker how to vote if you hold your shares in &ldquo;street name&rdquo;) will not be counted for purpose of determining
    that a quorum is present. If a quorum is not present or represented at the ENVB special meeting, the chairperson of the meeting or
    the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting
    to another date, without notice other than announcement at the meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval of the ENVB Share Issuance Proposal requires the affirmative vote of a majority of the votes cast by holders of ENVB&rsquo;s
common stock as of the Record Date. Failures to vote, broker non-votes and abstentions will have no effect on such proposal.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    approval of the ENVB Adjournment Proposal requires the affirmative vote of a majority of the voting power of the shares of
    ENVB common stock present in person or represented by proxy at the ENVB special meeting and entitled to vote on the proposal. Failures
    to vote  and abstentions will have the same effect as a vote cast &ldquo;AGAINST&rdquo; the approval of such proposal;
    however, broker non-votes will have no effect on such proposal.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
    can I attend the ENVB Special Meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    stockholders as of the record date may attend, vote and submit questions virtually at the ENVB special meeting by logging in at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]. To log in, ENVB stockholders (or their authorized representatives) will need the control number provided on their proxy card,
    voting instruction form or notice. If you are not a ENVB stockholder or do not have a control number, you may still access the meeting
    as a guest, but you will not be able to participate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Are
    there any stockholders who have already committed to voting in favor of any of the proposals at the ENVB special meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    Contemporaneously with the execution of the Amalgamation Agreement, certain directors and officers of ENVB entered into the voting
    agreements (a copy of which is attached as <U>Annex B-2</U> to this proxy statement/prospectus) with MagicMed, pursuant
    to which those directors and officers of ENVB agreed, among other things, subject to the terms and conditions thereof, to
    vote all of the shares of ENVB common stock held by them as of such date in favor of the ENVB Share Issuance Proposal at the ENVB
    special meeting. The directors and officers of ENVB who signed the voting agreements beneficially owned less than 1%
    of the outstanding shares of ENVB common stock as of June 18, 2021. For more information, please see &ldquo;The Ancillary
    Agreements&mdash;Voting Agreements.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Why
are the two companies proposing to amalgamate (or merge)?</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    and MagicMed believe that combining the two companies will result in a company with a robust pipeline, strong leadership team and
    substantial capital resources, positioning it to become a leading company researching, developing and commercializing therapies for
    cancer support care and CNS conditions. For a more complete description of the reasons for the Amalgamation, please see the
    section titled &ldquo;The Amalgamation&mdash;Recommendation of the ENVB Board of Directors; ENVB&rsquo;s Reasons for the Transactions&rdquo;
    beginning on page 99 of this proxy statement/prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    will MagicMed shareholders receive if the Amalgamation is completed?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the Amalgamation is completed, at the Effective Time, holders of outstanding common shares
                                            of MagicMed (the &ldquo;MagicMed Shares&rdquo;) will receive such number of shares of common
                                            stock of ENVB (the &ldquo;ENVB Shares&rdquo;) representing, together with ENVB Shares issuable
                                            upon exercise of the MagicMed Warrants and the MagicMed Converted Options (each as defined
                                            below), approximately 36.6% of the issued and outstanding ENVB Shares (on a fully-diluted
                                            basis).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Amalgamation, the MagicMed Shares will initially be converted into AmalCo redeemable preferred shares,
    which immediately following the Amalgamation will be redeemed for 0.000001 of an ENVB Share. Following such redemption, each
    shareholder of MagicMed will be entitled to receive additional ENVB Shares equal to the product of 0.2658 (the &ldquo;Exchange
    Ratio&rdquo;) multiplied by the number of MagicMed Shares held by each such shareholder. In addition, following the Effective
    Time (i) each outstanding MagicMed stock option will be converted into and become an option to purchase (the &ldquo;MagicMed
    Converted Options&rdquo;) the number of ENVB Shares equal to the Exchange Ratio multiplied by the number of MagicMed Shares
    subject to such MagicMed stock option, and (ii) each holder of an outstanding MagicMed warrant (including Company Broker Warrants
    (as defined in the Amalgamation Agreement), the &ldquo;MagicMed Warrants&rdquo;) will be entitled to receive upon exercise
    of such MagicMed Warrant that number of ENVB Shares which the holder would have been entitled to receive as a result of the
    Amalgamation if, immediately prior to the date of the Amalgamation, such holder had been the registered holder of the number
    of MagicMed Shares to which such holder would have been entitled if such holder had exercised such holder&rsquo;s MagicMed
    Warrants immediately prior to the Effective Time. The terms of the options and warrants have not yet been finalized.
Once the terms of the options and warrants are finalized, this may or may not impact the classification and accounting for such
options and warrants.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &ldquo;The Amalgamation Agreement&rdquo; beginning on page 110. A copy of the Amalgamation Agreement is attached to this proxy
    statement/prospectus as <U>Annex A</U>.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Who
    will own ENVB immediately following the Amalgamation?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    and MagicMed estimate that upon the completion of the Amalgamation, current ENVB stockholders, collectively, will own approximately
    63.4% of the outstanding shares of ENVB common stock, and current MagicMed shareholders, collectively, will own approximately 36.6%
    of the outstanding ENVB common stock (in each case, based on fully diluted shares outstanding of each company).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    will the composition of the board of directors of ENVB be following completion of the Amalgamation?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to the Amalgamation Agreement, immediately after the Effective Time, ENVB&rsquo;s board of
                                            directors will consist of a minimum of seven (7) members, of which two (2) directors will
                                            be a designee of MagicMed and the remaining five (5) shall be designated by ENVB.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the date of this proxy statement/prospectus, the parties expect that the ENVB board of directors immediately after the Effective
    Time will be comprised of (i) David Johnson, Sol Myer, George Kegler, Dr. Doug Lind and Dr. Marcus Schabacker  and (ii) Dr. Joseph Tucker and Brad Thompson. For additional information
    regarding the ENVB board of directors following the completion of the Amalgamation, please see &ldquo;The Amalgamation Agreement&mdash;Directors
    and Executive Oficers of ENVB Following the Amalgamation.&rdquo;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Does
    the ENVB board of directors support the Amalgamation? How does the ENVB board of directors recommend that I vote?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
                                            The ENVB board of directors has determined that the terms of the Amalgamation Agreement and
                                            the transactions contemplated by it are advisable and in the best interests of ENVB and its
                                            stockholders. The ENVB board of directors recommends that the ENVB stockholders vote:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679; &ldquo;FOR&rdquo; the ENVB Share
    Issuance Proposal; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    &ldquo;FOR&rdquo; the ENVB Adjournment Proposal.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    more information on the recommendation of the ENVB board of directors, see the section entitled &ldquo;The Amalgamation&mdash;Recommendation
    of the ENVB Board of Directors; ENVB&rsquo;s Reasons for the Transactions&rdquo; beginning on page 99.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Who
    is entitled to vote at the ENVB special meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    record date for the ENVB special meeting is [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021
    (the &ldquo;Record Date&rdquo;). All holders of shares of ENVB common stock who held shares at the close of business on the Record
    Date are entitled to receive notice of, and to vote at, the ENVB special meeting.  Please see &ldquo;The ENVB Special Meeting&mdash;Voting at the ENVB Special Meeting&rdquo;
    for instructions on how to vote your shares without attending the ENVB special meeting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
    many votes do I have for the ENVB Special Meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    ENVB stockholder is entitled to one vote for each share of ENVB common stock held of record as of the close of business on the Record
    Date for each proposal. As of the close of business on the Record Date, there were [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] outstanding shares of ENVB common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    will happen to my shares of ENVB common stock?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing.
    You will continue to own the same shares of ENVB common stock that you own prior to the Effective Time. As a result of the ENVB Share
    Issuance Proposal, however, the overall ownership percentage of current ENVB stockholders will be diluted after it acquires MagicMed
    in connection with the Amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    happens if the Amalgamation is not completed?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the MagicMed shareholders do not approve the MagicMed Amalgamation Proposal or the ENVB stockholders do not approve the ENVB Share
    Issuance Proposal, or if the Amalgamation is not completed for any other reason, MagicMed equity holders will not receive any shares
    of ENVB common stock for their equity in MagicMed pursuant to the Amalgamation Agreement or otherwise. Instead, ENVB and MagicMed
    will remain separate companies, and ENVB expects that its common stock will continue to be registered under the Securities Exchange
    Act of 1934, as amended, and traded on The NASDAQ Capital Market. In specified circumstances, either ENVB or MagicMed may be required
    to pay to the other party a termination fee, as described in &ldquo;The Amalgamation Agreement &mdash; Termination of the Amalgamation
    Agreement; Termination Fee&rdquo; beginning on page 126 of this proxy statement/prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
    can I vote my shares and participate at the ENVB Special Meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            you are an ENVB stockholder of record as of the close of business on the Record Date, you
                                            may submit your proxy before the ENVB special meeting in one of the following ways:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Telephone</B>&mdash;use
    the toll-free number shown on your proxy card;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Internet</B>&mdash;visit
    the website shown on your proxy card to vote via the Internet; or</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Mail</B>&mdash;complete,
    sign, date and return the enclosed proxy card in the enclosed postage-paid envelope.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you are an ENVB stockholder of record, you may also cast your vote virtually at the ENVB special meeting by following the instructions
    at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]. If you decide to attend the ENVB special meeting virtually and vote at the meeting, your vote will revoke any proxy previously
    submitted.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB special meeting will begin promptly at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] [a.m./p.m.], Eastern Time, on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021. ENVB encourages its stockholders to access
    the meeting prior to the start time leaving ample time for check-in. Please follow the instructions as outlined in this proxy statement/prospectus.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if you plan to attend the ENVB special meeting virtually, ENVB recommends that you vote your shares in advance as described below
    so that your vote will be counted if you later decide not to or become unable to attend the ENVB special meeting.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
    can I vote my shares without attending the ENVB Special Meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
                                            you hold your shares directly as a stockholder of record of ENVB or beneficially in &ldquo;street
                                            name,&rdquo; you may direct your vote by proxy without attending the ENVB special meeting.
                                            You can vote by proxy by mail, over the Internet or by telephone by following the instructions
                                            provided on the enclosed proxy card. Please note that if you hold shares beneficially in
                                            &ldquo;street name,&rdquo; you should follow the voting instructions provided by your bank,
                                            broker, trust or other nominee.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    information on voting procedures can be found under the section entitled &ldquo;ENVB Special Meeting.&rdquo;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>When
    and where is the ENVB Special Meeting? What must I bring to attend the ENVB Special Meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            ENVB special meeting will be held virtually at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] [a.m./p.m.], Eastern
                                            Time. Online access will begin at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] [a.m./p.m.], Eastern Time, and ENVB encourages stockholders
                                            to access the meeting prior to the start time.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    has chosen to hold the ENVB special meeting solely via the Internet and not in a physical location given the public health impact
    of COVID-19 and the desire to promote the health and safety of the ENVB stockholders, directors, officers, employees and other constituents.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if you plan to attend the ENVB special meeting virtually, ENVB recommends that you vote your shares in advance as described above
    so that your vote will be counted if you later decide not to or become unable to attend the special meeting.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    is the difference between holding shares as a stockholder of record and as a beneficial owner of shares held in &ldquo;street name?&rdquo;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            your shares are held in &ldquo;street name&rdquo; in a stock brokerage account or by a bank
                                            or other nominee, you must provide your bank, broker, trust or other nominee with instructions
                                            on how to vote your shares. Please follow the voting instructions provided by your broker,
                                            bank or other nominee.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    note that you may not vote shares held in street name by returning a proxy card directly to ENVB or by voting in person at the ENVB
    special meeting, unless you provide a &ldquo;legal proxy,&rdquo; which you must obtain from your broker, bank or other nominee.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
    my shares of ENVB common stock are held in &ldquo;street name&rdquo; by my bank, broker, trust or other nominee, will my bank,
    broker, trust or other nominee automatically vote those shares for me?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
                                            the rules of NASDAQ and the New York Stock Exchange (NYSE), your bank, broker, trust or other
                                            nominee will only be permitted to vote your shares of ENVB common stock with respect to &ldquo;non-routine&rdquo;
                                            matters if you instruct your bank, broker, trust or other nominee how to vote. All of the
                                            proposals scheduled for consideration at the ENVB special meeting are &ldquo;non-routine&rdquo;
                                            matters. As a result, if you fail to provide voting instructions to your broker, bank or
                                            other nominee, your shares will not be counted as present at the ENVB special meeting for
                                            purposes of determining a quorum and will not be voted on any of the proposals. If you provide
                                            voting instructions to your broker, bank or other nominee on one or more of the proposals
                                            but not on one or more of the other proposals, then your shares will be counted
                                            as present for the purposes of determining a quorum but will not be voted on any proposal
                                            for which you fail to provide instructions. To make sure that your shares are voted with
                                            respect to each of the proposals, you should instruct your bank, broker, trust or other nominee
                                            how you wish to vote your shares in accordance with the procedures provided by your bank,
                                            broker, trust or other nominee regarding the voting of your shares.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    </B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>instructing your bank, broker, trust or other nominee how
    you wish to vote your shares will not have any effect on the outcome of the ENVB Adjournment Proposal or the ENVB Share Issuance
    Proposal.</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    should I do if I receive more than one set of voting materials for a stockholder meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            you hold shares of ENVB common stock in &ldquo;street name&rdquo; and also directly in your
                                            name as a stockholder of record or otherwise, or if you hold shares of ENVB common stock
                                            in more than one brokerage account, you may receive more than one set of voting materials
                                            relating to the ENVB special meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Record
    Holders</U></I>. For shares held directly, please complete, sign, date and return each proxy card, or you may cast your vote by telephone
    or Internet as provided on each proxy card, or otherwise follow the voting instructions provided in this proxy statement/prospectus
    in order to ensure that all of your shares of ENVB common stock are voted.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>&ldquo;Street
    name&rdquo; Holders</U></I>. For shares held in &ldquo;street name&rdquo; through a bank, broker, trust or other nominee, you should
    follow the procedures provided by your bank, broker, trust or other nominee to vote your shares.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
    a stockholder gives a proxy, how are the shares of ENVB common stock voted?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
    of the method you choose to vote, the individuals named on the enclosed proxy card will vote your shares of ENVB common stock in
    the way that you indicate. When completing the proxy card or the Internet or telephone processes, you may specify whether your shares
    of ENVB common stock should be voted for or against, or abstain from voting on, all, some or none of the specific items of business
    to come before the ENVB special meeting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
    will my shares of ENVB common stock be voted if I return a blank proxy?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you sign, date and return your proxy card and do not indicate how you want your shares of ENVB common stock to be voted, then your
    shares of ENVB common stock will be voted &ldquo;FOR&rdquo; the ENVB Share Issuance Proposal and &ldquo;FOR&rdquo; the ENVB Adjournment Proposal.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Can
    I change my vote of shares of ENVB common stock after I have submitted my proxy?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
                                            Any stockholder giving a proxy has the right to revoke it before the proxy is voted at the
                                            ENVB special meeting by:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subsequently
submitting a new proxy, whether by submitting a new proxy card or by submitting a proxy</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;via
    the Internet or telephone, that is received by the deadline specified on the accompanying proxy card;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;giving
    written notice of your revocation to ENVB&rsquo;s Corporate Secretary;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;voting
    virtually at the ENVB special meeting; or</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;revoking
    your proxy and voting at the ENVB special meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
    attendance at the ENVB special meeting will not revoke your proxy unless you give written notice of revocation to ENVB&rsquo;s Corporate
    Secretary before your proxy is exercised or unless you vote your shares in person at the ENVB special meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
    or revocation of a proxy will not in any way affect your right to attend the ENVB special meeting and vote. Written notices of revocation
    and other communications with respect to the revocation of proxies should be addressed to:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
Florida 34103</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Corporate Secretary</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    more information, please see &ldquo;ENVB Special Meeting&mdash;Revocation of Proxies.&rdquo;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
    I hold my shares in &ldquo;street name,&rdquo; can I change my voting instructions after I have submitted voting instructions to
    my bank, broker, trust or other nominee?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    your shares are held in the name of a bank, broker, trust or other nominee and you previously provided voting instructions to your
    bank, broker, trust or other nominee, you should follow the instructions provided by your bank, broker, trust or other nominee to
    revoke or change your voting instructions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    are the material U.S. federal income tax consequences of the Amalgamation to U.S. holders of ENVB common stock?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Amalgamation is intended to qualify as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Internal Revenue
    Code of 1986, as amended, for U.S. federal income tax purposes. It is further expected that no gain or loss should be recognized
    by ENVB or ENVB stockholders for U.S. federal income tax purposes as a result of the Amalgamation. The completion of the Amalgamation
    is not conditioned upon the receipt of an opinion of counsel to the effect that the Amalgamation qualifies for its intended tax treatment.
    In addition, neither ENVB nor MagicMed intends to request a ruling from the IRS regarding the U.S. federal income tax consequences
    of the Amalgamation. Accordingly, no assurance can be given that the IRS will not challenge the intended tax treatment or that a
    court would not sustain such a challenge.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Do
    I have any dissenters&rsquo; or appraisal rights with respect to any of the matters to be voted on at the ENVB special meeting?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
    ENVB stockholders do not have any dissenters&rsquo; or appraisal rights under Delaware law in connection with the proposed Amalgamation
    or with respect to any of the matters to be voted on at the ENVB special meeting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    a ENVB stockholder, are there any risks that I should consider in deciding whether to vote for the approval of the ENVB Share Issuance
    Proposal?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    You should read and carefully consider the risk factors set forth in &ldquo;Risk Factors,&rdquo; including the risk factors
    of ENVB and MagicMed set forth therein. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Do
    any of ENVB&rsquo;s directors or executive officers have interests in the Amalgamation that may differ from or be in addition to
    my interests as a ENVB stockholder?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    In considering the recommendation of the ENVB board of directors that ENVB stockholders vote to approve the ENVB Share Issuance Proposal, ENVB stockholders should be aware that ENVB&rsquo;s directors and executive officers have interests
    in the Amalgamation that are different from, or in addition to, the interests of ENVB stockholders generally. The ENVB board of directors
    was aware of and considered these differing interests, to the extent such interests existed at the time, among other matters, in
    evaluating and negotiating the Amalgamation Agreement and the Amalgamation and in unanimously recommending that the ENVB Share Issuance
    Proposal  be approved by ENVB stockholders. See &ldquo;The Amalgamation&mdash;Interests of ENVB&rsquo;s
    Directors and Executive Officers in the Amalgamation.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
happens if I sell my shares of ENVB common stock before the applicable special meeting?</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    record date for the ENVB special meeting is earlier than the date of the ENVB special meeting and the date that the Amalgamation
    is expected to be completed. If you transfer your shares of ENVB common stock after the ENVB record date but before the ENVB special
    meeting, you will retain your right to vote at the ENVB special meeting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Who
    will solicit and pay the cost of soliciting proxies?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB board of directors is soliciting your proxy for use at the ENVB special meeting and any adjournment or postponement thereof.
    ENVB will bear the cost of soliciting such proxies, including the costs of printing and mailing this proxy statement/prospectus to
    the ENVB stockholders. ENVB has Kingsdale Advisors as proxy solicitor to assist with the solicitation of proxies in connection with
    the ENVB special meeting. Solicitation initially will be made by mail. Forms of proxies and proxy materials may also be distributed
    through banks, brokers and other nominees to the beneficial owners of shares of ENVB common stock, in which case these parties will
    be reimbursed for their reasonable out-of-pocket expenses. Proxies may also be solicited in person or by telephone, facsimile, electronic
    mail, or other electronic medium by certain of ENVB&rsquo;s directors, officers and employees, without additional compensation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>When
    do you expect to complete the Amalgamation?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    and MagicMed expect to complete the Amalgamation during the fourth quarter of 2021, subject to the receipt of any required
    approvals and the satisfaction or waiver of the conditions to the Amalgamation contained in the Amalgamation Agreement. However,
    it is possible that factors outside the control of ENVB and MagicMed could require ENVB and MagicMed to complete the Amalgamation
    at a later time or not complete it at all. See &ldquo;The Amalgamation Agreement&mdash;Conditions to the Completion
    of the Amalgamation&rdquo; on page 115 of this proxy statement/prospectus for a more complete summary of the conditions
    that must be satisfied prior to closing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    are the conditions to completion of the Amalgamation?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Amalgamation is subject to a number of conditions to Closing as specified in the Amalgamation Agreement. These Closing conditions
    include, among others, (i) the approval of the ENVB Share Issuance Proposal by ENVB stockholders at the ENVB special meeting; (ii)
    the approval of the MagicMed Amalgamation Proposal by MagicMed shareholders at the MagicMed special meeting; (iii) the ENVB
    common stock to be issued in connection with the ENVB Share Issuance Proposal has been approved for listing on NASDAQ; (iv)
    this proxy statement/prospectus is effective under the Securities Act and no stop order suspending the use of this proxy
    statement/prospectus has been issued by the SEC, and (v) various regulatory matters. More information may be found in
    &ldquo;The Amalgamation Agreement&mdash;Conditions to the Completion of the Amalgamation.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
    do I need to do now?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    should read this proxy statement/prospectus carefully and in its entirety, including the annexes, and return your completed, signed
    and dated proxy card by mail in the enclosed postage-paid envelope, or you may submit your voting instructions by telephone or over
    the Internet as soon as possible so that your shares will be voted in accordance with your instructions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Whom
    do I call if I have questions about the ENVB Special Meeting or the Amalgamation?</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information provided above in this &ldquo;Question and Answer&rdquo; format is for your convenience
                                            only and is merely a summary of the information contained in this proxy statement/prospectus.
                                            We urge you to carefully read this entire proxy statement/prospectus, including the documents
                                            referred to herein.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you have any questions, or need additional material, please feel free to contact Kingsdale Advisors, the proxy solicitor for
    ENVB, by North American Toll-Free Phone: 1-866-851-2468, or Email: contactus@kingsdaleadvisors.com, or call collect
    Outside North America: (416) 867-2272. You will not be charged for any of these documents that you request.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_003"></A>SUMMARY<B><SUP></SUP></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important
to you. You are urged to carefully read this entire document, including the Annexes, and the other documents to which we refer for a
more complete understanding of the Amalgamation. In addition, ENVB encourages you to read the information in the section entitled &ldquo;ENVB&rsquo;s
Business,&rdquo; which includes important business and financial information about ENVB, and to read the information in the section
entitled &ldquo;MagicMed&rsquo;s Business,&rdquo; which includes important business and financial information about MagicMed,
beginning on pages 132 and 170, respectively, of this proxy statement/prospectus. Each item in this summary refers to the
page of this proxy statement/prospectus on which that subject is discussed in more detail.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary and the balance of this document contain forward-looking statements about events that are not certain to occur, and you
should not place undue reliance on those statements. Please carefully read &ldquo;Cautionary Statement Regarding Forward-Looking
Statements&rdquo; on page 86 of this document.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Parties to the Amalgamation (see page 93)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enveric
Biosciences, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. is a Delaware corporation with its headquarters in Naples, Florida. ENVB is an early-development-stage biosciences
company with an initial focus on developing innovative, evidence-based prescription products and combination therapies containing cannabinoids
to address unmet needs in cancer care. ENVB seeks to improve the lives of patients suffering from cancer, initially by developing palliative
and supportive care products for people suffering from certain side effects of cancer and cancer treatment such as pain or skin irritation.
ENVB intends to offer such palliative and supportive care products in the United States, following approval through established regulatory
pathways. ENVB is also aiming to advance a pipeline of novel cannabinoid combination therapies for hard-to-treat cancers, including glioblastoma
multiforme (GBM) and several other indications which are currently being researched.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
principal executive offices are located at 4851 Tamiami Trail N, Suite 200 in Naples, Florida 34103 and its telephone number is (239)
302-1707. ENVB common stock trades on the NASDAQ Capital Market under the symbol &ldquo;ENVB.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>HoldCo</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1306432
B.C. Ltd. is a wholly-owned subsidiary of ENVB that was  incorporated on May 20, 2021 under the BCBCA solely for the purpose
of entering into the Amalgamation Agreement and effecting the Amalgamation and the other transactions contemplated by the Amalgamation
Agreement. It is not engaged in any business and has no material assets, liabilities or other obligations of any nature other than
as set forth in the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HoldCo&rsquo;s
principal executive offices are located at 4851 Tamiami Trail N, Suite 200 in Naples, Florida 34103 and its telephone number is (239)
302-1707. HoldCo&rsquo;s registered office is located at 666 Burrard St., Suite 1700, Vancouver, British Columbia, V6C 2X8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Purchaser</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1306436
B.C. Ltd. is an indirect, wholly-owned subsidiary of ENVB that was  incorporated on May 20, 2021 under the BCBCA solely
for the purpose of entering into the Amalgamation Agreement and effecting the Amalgamation and the other transactions contemplated by
the Amalgamation Agreement. It is not engaged in any business and has no material assets, liabilities or other obligations of any
nature other than as set forth in the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser&rsquo;s
principal executive offices are located at 4851 Tamiami Trail N, Suite 200 in Naples, Florida 34103 and its telephone number is (239)
302-1707. Purchaser&rsquo;s registered office is located at 666 Burrard St., Suite 1700, Vancouver, British Columbia, V6C 2X8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>MagicMed
Industries Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is a neuro-pharmaceutical drug discovery and development platform. MagicMed has focused on assembling a portfolio of intellectual property
(referred to as the PsybraryTM described further below) relating to the synthesis, production and manufacturing of novel psychedelic
molecular compounds and derivatives (&ldquo;Psychedelic Derivatives&rdquo;) along with processes relating to their synthesis, production
and manufacturing. These Psychedelic Derivatives are intended to be essential building blocks in the development of psychedelic therapies
and medicines for diverse psychological and neuropsychiatric indications. MagicMed considers its business and related activities to be
typical for a biopharma business focused on preclinical drug discovery and development. MagicMed&rsquo;s business is centered on the
development of the PsybraryTM, a proprietary physical and knowledgebase collection of novel Psychedelic Derivative drug candidates, manufacturing
methods, pharmacological data, and patent filings that protect the foregoing. MagicMed has 13 patent applications filed for derivatives
of psilocybin and DMT, 2 patent applications filed for derivatives of mescaline and MDMA with further intellectual property protection
for mescaline, MDMA, ibogaine and LSD in process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
principal executive offices are located at 777 Hornby Street, Suite 600, Vancouver, British Columbia, V6Z 1S and its telephone number
is (508) 627-0485. MagicMed Shares are not traded on a national securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Amalgamation Agreement (see page 112 and Annex A)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, ENVB, HoldCo, Purchaser, and MagicMed entered into an Amalgamation Agreement. The Amalgamation Agreement is a legal document
governing the Amalgamation and is included in this proxy statement/prospectus as <U>Annex A</U>. All descriptions in this summary and
elsewhere in this proxy statement/prospectus of the terms and conditions of the Amalgamation are qualified in their entirety by reference
to the full text of the Amalgamation Agreement. Please read the Amalgamation Agreement carefully for a more complete understanding of
the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Amalgamation (see page 94)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amalgamation Agreement,</FONT> at the effective time of the Amalgamation, Purchaser, a wholly owned subsidiary of HoldCo, will
be amalgamated with MagicMed. Upon completion of the Amalgamation, the separate corporate existences of Purchaser and MagicMed will cease,
and the surviving corporation (&ldquo;AmalCo&rdquo;) will be a wholly owned subsidiary of HoldCo under the name &ldquo;Enveric Biosciences Canada
Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><B>Consideration to MagicMed
Shareholders (see page 94)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black">At
the effective time of the Amalgamation (the &ldquo;Effective Time&rdquo;), each outstanding common share of MagicMed (the &ldquo;MagicMed
Shares&rdquo;) held by MagicMed shareholders will be converted into one fully paid and non-assessable AmalCo redeemable preferred share,
which shall immediately following the Amalgamation be redeemed by AmalCo for the AmalCo redemption consideration. Immediately following
the redemption of the AmalCo redeemable preferred shares, each holder of MagicMed Shares shall receive from ENVB as additional consideration
for the disposition of their MagicMed Shares that number of shares of ENVB common stock equal to the product of the Exchange Ratio multiplied
by the number of MagicMed Shares held by such MagicMed shareholder (collectively, the &ldquo;Amalgamation Consideration&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black">At
the Effective Time of the Amalgamation, each outstanding MagicMed option shall be amended such that each holder of MagicMed options shall
be entitled to receive, for each option held, that number of shares of ENVB common stock equal to the product of the Exchange Ratio multiplied
by the number of MagicMed  Shares subject to such option. Such options (the &ldquo;Converted Options&rdquo;) shall have an exercise
price per share of ENVB common stock equal to the exercise price per MagicMed  Share of such option immediately prior to the effective
time divided by the Exchange Ratio, rounded up to the nearest whole cent.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black">Following
the Effective Time of the Amalgamation, each holder of a MagicMed warrant shall be entitled to receive (and such holder shall accept)
upon the exercise of such holder&rsquo;s warrants, in lieu of MagicMed Shares to which such holder was theretofore entitled upon such
exercise, and for the same aggregate consideration payable therefor, that number of shares of ENVB common stock which the holder would
have been entitled to receive as a result of the amalgamation if, immediately prior to the effective time of the amalgamation, such holder
had been the registered holder of the number of MagicMed Shares to which such holder would have been entitled if such holder had exercised
such holder&rsquo;s warrants immediately prior to the effective time of the amalgamation. The terms of the options and warrants have not yet been finalized.
Once the terms of the options and warrants are finalized, this may or may not impact the classification and accounting for such
options and warrants.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
will not issue any fractional shares of ENVB common stock in the Amalgamation. In lieu of such fractional shares, (a) the number of shares
of ENVB common stock to be received by a MagicMed shareholder will be rounded up to the nearest whole share of ENVB common stock for
MagicMed shareholders entitled to receive a fractional share representing one-half (1/2) or more of a share of ENVB common stock, or
(b) the number of shares of ENVB common stock to be received by a MagicMed shareholder will be rounded down to the nearest whole share
of ENVB common stock in the event that a MagicMed shareholder is entitled to receive a fractional share representing less than one-half
(1/2) of share of ENVB common stock. After the Amalgamation is completed, MagicMed equity holders will have only the right to receive
the Amalgamation Consideration and will no longer have any rights as MagicMed stockholders, including voting or other rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
a full description of the Amalgamation Consideration, see the sections titled &ldquo;The Amalgamation Agreement&mdash;Effects of Amalgamation;
Amalgamation Consideration&rdquo; on page 112; &ldquo;&mdash;Treatment of MagicMed Shares&rdquo; on page 113, &ldquo;&mdash;Treatment
of MagicMed Stock Options&rdquo; beginning on page 113, and &ldquo;&mdash;Treatment of MagicMed Warrant&rdquo; on page 114 of this proxy
statement/prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparative
Per Share Market Price and Dividend Information (see page 45)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
common stock is listed on The NASDAQ Capital Market under the symbol &ldquo;ENVB.&rdquo; Currently there is no established
public trading market for MagicMed Shares. The following table sets forth the closing sale prices per share of ENVB common stock on May
21, 2021, the last full trading day immediately preceding the public announcement of the Amalgamation Agreement, and on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021,
the latest practicable date prior to the date of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
                                            Stock</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
                                            Stock</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    21, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.72</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
    2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
                                            </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recommendation
of the ENVB Board of Directors; ENVB&rsquo;s Reasons for the Transactions (see page 99)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">After
careful consideration, the ENVB board of directors has (i) determined that the Amalgamation Agreement and the other transactions contemplated
thereby, including the Amalgamation of Purchaser with MagicMed and the issuance of ENVB common stock contemplated by the ENVB Share Issuance
Proposal, are advisable and in the best interests of ENVB and the ENVB stockholders, (ii) authorized and approved ENVB&rsquo;s execution,
delivery and performance of the Amalgamation Agreement in accordance with its terms and ENVB&rsquo;s consummation of the transactions
contemplated thereby, including the Amalgamation and the issuance of ENVB common stock contemplated by the ENVB Share Issuance Proposal,
(iii) resolved that the approval of the ENVB Share Issuance Proposal be submitted to a vote at a meeting of the holders of ENVB common
stock and (iv) recommended that the holders of ENVB common stock approve the ENVB Share Issuance Proposal. ENVB&rsquo;s board of
directors unanimously recommends that ENVB stockholders vote &ldquo;FOR&rdquo; the ENVB Share Issuance Proposal and &ldquo;FOR&rdquo;
the ENVB Adjournment Proposal. For the factors considered by ENVB&rsquo;s board of directors in reaching its decision to approve the
Amalgamation and Amalgamation Agreement, see the section titled &ldquo;The Amalgamation&mdash;Recommendation of the ENVB Board of
Directors; ENVB&rsquo;s Reasons for the Transactions&rdquo; beginning on page 99 of this proxy statement/prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
ENVB Special Meeting (see page 87)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB special meeting will be held virtually on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, at [_____] [a.m.][p.m],
 Eastern Time.  At the special meeting, ENVB stockholders will be asked to consider and vote upon the following
matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    proposal to</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> approve the ENVB Share Issuance Proposal; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    proposal to</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> approve the ENVB Adjournment Proposal.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
the holders of record of shares of ENVB common stock at the close of business on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2021 (the &ldquo;Record Date&rdquo;) will be entitled to vote at the ENVB special meeting. Each share of ENVB
common stock is entitled to one vote on each proposal to be considered at the ENVB special meeting. As of the  Record Date, there
were [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of ENVB common stock outstanding and entitled to vote at the ENVB special meeting.</FONT></P>

</DIV>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the close of business on the Record Date, the directors and executive officers of ENVB and their affiliates were entitled to
vote [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of ENVB common stock, which represent, in the aggregate, [less than 1]% of the
issued and outstanding shares of ENVB common stock on that date. In accordance with the voting agreements entered into between
the directors and executive officers of ENVB and MagicMed, ENVB currently expects that ENVB&rsquo;s directors and executive officers
will vote their shares in favor of the ENVB Share Issuance Proposal and the ENVB Adjournment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
the presence of a quorum, the affirmative vote of a majority of the votes cast by holders of ENVB common stock as of the Record Date
present in person or represented by proxy is required to approve the ENVB Share Issuance Proposal. Whether or not a quorum
is present, the approval of the ENVB Adjournment Proposal requires the affirmative vote of a majority of the voting power of shares of
ENVB common stock present in person or represented by proxy at the ENVB special meeting and entitled to vote on the proposal. If
you are an ENVB stockholder and mark &ldquo;ABSTAIN&rdquo; on your proxy with respect to the ENVB Share Issuance Proposal or the ENVB
Adjournment Proposal, it will not be counted with respect to the ENVB Share Issuance Proposal and will have no effect on such
proposal, but it will be counted as a vote &ldquo;AGAINST&rdquo; the ENVB Adjournment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; background-color: white">If
you are a stockholder of record and you do not sign and return your proxy card or vote over the Internet, by telephone or at the ENVB
special meeting, your shares will not be voted at the ENVB special meeting, will not be counted as present in person or by proxy at the
ENVB special meeting and will not be counted as present for purposes of determining whether a quorum exists. For purposes of the ENVB
Share Issuance Proposal, provided a quorum is present, a failure to vote will have no effect on the outcome of a vote on the ENVB Share
Issuance Proposal. For purposes of the ENVB Adjournment Proposal, provided a quorum is present, a failure to vote will have the effect
of a vote &ldquo;AGAINST&rdquo; the ENVB Adjournment Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Interests of ENVB&rsquo;s
Directors and Executive Officers in the Amalgamation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Other
than with respect to continued service for, employment by and the right to continued indemnification by ENVB, as of the date of this
proxy statement/prospectus, ENVB&rsquo;s directors and executive officers do not have interests in the Amalgamation that are different
from, or in addition to, the interests of other ENVB stockholders generally. The ENVB board of directors was aware of and considered
these factors, among other matters, in determining that the terms of the Amalgamation Agreement and the Amalgamation are fair to and
in the best interests of ENVB and ENVB stockholders, approving and adopting the Amalgamation Agreement and the transactions contemplated
thereby, including the Amalgamation and the shares of ENVB common stock to be issued in connection with the ENVB Share Issuance Proposal,
and recommending that the ENVB stockholders approve the ENVB Share Issuance Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">For
a more complete description of these interests, see &ldquo;The Amalgamation&mdash;Interests of ENVB&rsquo;s Directors and Executive Officers
in the Amalgamation&rdquo; and &ldquo;The Amalgamation&mdash;Governance of ENVB After the Amalgamation&rdquo; beginning on page 109 of
this proxy statement/prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interests
of Executive Officers and Directors of MagicMed in the Amalgamation (see page 108)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of MagicMed&rsquo;s directors and officers have interests in the Amalgamation and have arrangements that are different from, or in addition
to, those of MagicMed equity holders generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interests include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    employment agreement with ENVB and related</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> appointment of Dr. Joseph
    Tucker, the President and Chief Executive Officer of MagicMed; Dr. Peter Facchini, Chief Scientific Officer of MagicMed; and Dr.
    Jillian Hagel, Chief Technology Officer of MagicMed, to the positions of Chief Executive Officer, Chief Scientific Officer, and Chief
    Technology Officer of ENVB, respectively, upon the effective time of the Amalgamation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    appointment of Dr. Joseph Tucker and Brad Thompson, directors of MagicMed, to the ENVB board of directors upon the effective time
    of the Amalgamation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of Dr. Tucker, Dr. Facchini and Dr. Hagel have agreed to waive their rights to certain payments upon a change of control of MagicMed
    pursuant to the terms of their respective employment agreement with MagicMed to which they may have been entitled;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant
    to the terms of the Amalgamation Agreement, MagicMed&rsquo;s current and former directors and officers will be entitled to certain
    ongoing indemnification and insurance coverage for their prior acts for a period of time after the Effective Time and MagicMed may
    purchase directors&rsquo; and officers&rsquo; &ldquo;run-off&rdquo; insurance to further supplement any current coverage in connection
    with the Amalgamation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    of MagicMed&rsquo;s shareholders who have entered into voting agreements with ENVB, pursuant to which, among other things, such shareholders
    have agreed to vote or to execute and deliver a written consent with respect to all the MagicMed shares owned by them as of the applicable
    record date in favor of the adoption and approval of the Amalgamation Agreement and Amalgamation, are affiliated with directors of
    MagicMed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a more complete description of these interests, see &ldquo;The Amalgamation&mdash;Interests of MagicMed&rsquo;s Directors and Executive
Officers in the Amalgamation and &ldquo;The Amalgamation&mdash;Governance of ENVB After the Amalgamation&rdquo; beginning on pages
108 and 109, respectively of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>
Governance of ENVB After the Amalgamation (see page 109)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors and officers of ENVB immediately prior to the effective time of the Amalgamation will continue to be directors and officers
of ENVB immediately following the Amalgamation. Pursuant to the terms of the Amalgamation Agreement, ENVB has agreed to appoint Dr. Joseph
Tucker and Dr. Brad Thompson, both directors of MagicMed, to the ENVB board of directors upon the effective time of the Amalgamation.
</FONT>In addition, at the effective time of the Amalgamation, Dr. Joseph Tucker, the President and Chief Executive Officer of MagicMed;
Dr. Peter Facchini, Chief Scientific Officer of MagicMed; and Dr. Jillian Hagel, Chief Technology Officer of MagicMed, will be appointed
to the positions of Chief Executive Officer, Chief Scientific Officer, and Chief Technology Officer of ENVB, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appraisal
Rights (see page 92)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
stockholders are not entitled to appraisal or dissenters&rsquo; rights in connection with the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Solicitation (see page 119)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of ENVB and MagicMed agreed that, subject to certain exceptions, during the pre-closing period, ENVB and MagicMed and any of their respective
subsidiaries will not, whether directly or indirectly, through their respective officers, directors, employees, representatives or
other agents retained by ENVB, MagicMed or their respective subsidiaries, or otherwise, and will not permit any such person to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">solicit, assist, initiate, encourage or otherwise knowingly
    facilitate (including by way of furnishing or providing copies of, access to, or disclosure of, any confidential information, properties,
    facilities, books or records of ENVB, MagicMed and their respective subsidiaries or entering into any form of agreement, arrangement
    or understanding) any inquiry, proposal or offer that constitutes or may reasonably be expected to constitute or lead to, an acquisition
    proposal;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">enter into or otherwise engage or participate in any
    discussions or negotiations with any person (other than the parties to the Amalgamation Agreement) regarding any inquiry, proposal
    or offer that constitutes or may reasonably be expected to constitute or lead to, an acquisition proposal for MagicMed or ENVB, provided
    that, for greater certainty, MagicMed and ENVB, as applicable, may advise any Person making an unsolicited acquisition proposal that
    such acquisition proposal does not constitute a superior proposal when applicable board has so determined;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">subject to certain exceptions, change the recommendation
    of the ENVB or MagicMed board of directors with regard the amalgamation;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">accept, approve, endorse or recommend, or publicly propose
    to accept, approve, endorse or recommend, or take no position or remain neutral with respect to, any acquisition proposal; or</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">accept or enter into or publicly propose to accept or
    enter into any agreement, understanding or arrangement in respect of an acquisition proposal.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; text-indent: 31.5pt">However, if ENVB
or MagicMed receives an acquisition proposal from a third party and the receipt of such acquisition proposal was not initiated, sought,
solicited, knowingly encouraged or knowingly induced by ENVB, MagicMed or their respective subsidiaries, then ENVB or MagicMed may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contact
    the person who has made such acquisition proposal in order to clarify the terms of such acquisition proposal so that the applicable
    board of directors (or any committee thereof) may inform itself about such acquisition proposal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
    in discussions and negotiations with the person making the proposal, its representatives and potential financing sources; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">furnish
    information concerning its business, properties or assets to any person pursuant to a confidentiality agreement, and negotiate and
    participate in discussions and negotiations with such person concerning an acquisition proposal if the applicable board of directors
    determines in good faith that such acquisition proposal constitutes a &ldquo;superior proposal.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
receiving party must provide prompt notice to the other party of any acquisition proposal and terms and conditions of the superior proposal,
and a list of, and, at the request of the responding party, copies of, the information provided to such person and immediately provided
with access to similar information to which such person was provided. The receiving party agrees that it will not accept, approve or
enter into any agreement, other than a confidentiality and standstill agreement as contemplated by the Amalgamation Agreement, with any
person providing for or to facilitate any acquisition proposal unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    board of directors of the receiving party determines that the acquisition proposal constitutes a Superior Proposal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of MagicMed, the MagicMed special meeting has not occurred;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of ENVB, the ENVB special meeting has not occurred;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receiving party has provided the responding party with a notice in writing that there is a superior proposal together with all documentation
    related to and detailing the superior proposal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ten
    business days shall have elapsed from the date the responding party received the notice and documentation referred to in the Amalgamation
    Agreement from receiving party and, if the responding party has proposed to amend the terms of the Amalgamation Agreement and the
    transaction in accordance with the Amalgamation Agreement, the board of directors of the receiving party shall have determined, in
    good faith, after consultation with its financial advisors and outside legal counsel, that the acquisition proposal continues to
    constitute a superior proposal compared to the proposed amendment to the terms of the Amalgamation Agreement and the transactions
    contemplated thereby by the responding party; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receiving party terminates the Amalgamation Agreements by paying the amounts required thereunder pursuant to the terms of the
    Amalgamation Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
either ENVB or MagicMed accepts a superior proposal, such party is required to pay $4.5 million pursuant to the termination fee payment
terms therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conditions
to Completion of the Amalgamation (see page 115)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party&rsquo;s obligation to complete the amalgamation is subject to the satisfaction or waiver by each of the parties, at or prior to
the closing of the amalgamation, of various conditions, which include, in addition to other customary closing conditions, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    affirmative vote of not less than 66 2/3% of the votes cast at the MagicMed special meeting or represented by proxy for the approval
    of the MagicMed Amalgamation Proposal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the approval by ENVB stockholders of the ENVB Share Issuance Proposal and related amalgamation;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    temporary restraining order, preliminary or permanent injunction or other order (whether temporary, preliminary or permanent) issued
    by any court of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the amalgamation will
    be in effect, nor will any legal action or proceeding brought by any administrative agency or commission or other governmental authority
    or instrumentality, domestic or foreign, seeking any of the foregoing be pending. There will not be any action taken, or any statute,
    rule, regulation or order enacted, entered, enforced or deemed applicable to the amalgamation, which makes the consummation of the
    amalgamation illegal; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    required regulatory approval has been made, given or obtained and each such regulatory approval is in force and has not been modified.
    Any waiting period applicable to the consummation of the amalgamation under any regulatory approval will have expired or been terminated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    shares of ENVB common stock issued in connection with the amalgamation shall have been approved for listing on NASDAQ; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    registration statement on Form S-4 (including a prospectus) in connection with the issuance of shares of ENVB common stock as amalgamation
    consideration in the amalgamation, which will include a proxy statement to be sent to the stockholders of ENVB shall have become
    effective under the Securities Act, and shall not be the subject of any stop order.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 10pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligation of ENVB and Purchaser to complete the amalgamation is subject to the satisfaction or waiver of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 10pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    representations and warranties of MagicMed in the Amalgamation Agreement qualified as to materiality shall be true and correct in
    all respects, and those not so qualified shall be true and correct in all material respects as of the date of the Amalgamation Agreement
    and the closing date as though made on and as of the date of the Amalgamation Agreement and the closing date (as applicable), except
    to the extent such representations and warranties speak as of another date (in which case, such representations and warranties shall
    be true and correct as of such date);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    shall have performed or complied with in all material respects with each of the covenants of MagicMed contained in the Amalgamation
    Agreement to be fulfilled or complied with by it on or prior to the closing of the amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    shall have delivered certain certificates and other documents required under the Amalgamation Agreement for the closing of the amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    shall have delivered audited financial statements for fiscal year 2020 and year-to-date 2021 in accordance with U.S. GAAP to ENVB
    as required by SEC rules, as well as any other financial statements as may be required by the rules and regulations of the Securities
    Act and the Exchange Act;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    legal action or proceeding can be pending or threatened (excluding any such action or proceeding initiated by ENVB) to (a) cease
    trade, enjoin, prohibit, or impose any limitations, damages or conditions on, the Purchaser&rsquo;s ability to acquire, hold, or
    exercise full rights of ownership over, any MagicMed Shares, including the right to vote the MagicMed Shares, (b) prohibit,
    restrict or impose terms or conditions on, the amalgamation, or the ownership or operation by ENVB and the Purchaser of the business
    or assets of ENVB, HoldCo, the Purchaser, MagicMed or their respective subsidiaries, or compel ENVB or the Purchaser to dispose of
    or hold separate any of the business or assets of ENVB, HoldCo, the Purchaser, MagicMed or their respective subsidiaries as a result
    of the amalgamation, or (c) prevent or materially delay the consummation of the amalgamation, or if the amalgamation were to be consummated,
    have a material adverse effect with respect to MagicMed or its subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    shall not have been any result, change, event, occurrence, effect, state of facts or circumstance (whether or not constituting a
    breach of a representation, warranty or covenant set forth in the Amalgamation Agreement) that, either individually or in the aggregate
    is or would reasonably be expected to be material and adverse to the business, operations, results of operations, assets, properties,
    condition (financial or otherwise) or liabilities (contingent or otherwise) or prospects of MagicMed and its subsidiaries, taken
    as a whole, and would, or would be reasonably expected to, prevent or materially delay MagicMed from consummating the transactions
    contemplated by the Amalgamation Agreement by December 31, 2021, except any such change, event, occurrence, effect, state of facts
    or circumstance resulting from or relating to: (a) any change in general political, economic, financial, currency exchange, securities,
    capital or credit market conditions in Canada or the United States; (b) any change or proposed change in applicable laws, IFRS or
    U.S. GAAP; (c) any change affecting the industries or markets in which MagicMed operates; (d) any natural disaster or the commencement
    or continuity of any act of war, armed hostilities or acts of terrorism; (e) the announcement of the Amalgamation Agreement or the
    transactions contemplated thereby; (f) any action taken (or omitted to be taken) by MagicMed or its subsidiaries which is required
    to be taken (or omitted to be taken) pursuant to the Amalgamation Agreement; (g) any change in the market price or trading volume
    of any securities of MagicMed (it being understood that the causes underlying such change in market price or trading volume may be
    taken into account in determining whether a material adverse effect has occurred); (h) any epidemic, pandemic, disease outbreak (including
    COVID-19), other health crisis or public health event; or (i) any matter which has been publicly disclosed or communicated in writing
    by MagicMed to ENVB as of the date of the Amalgamation Agreement and ENVB has acknowledged receipt of such written communication;
    provided, however, that with respect to clauses; (a) through to and including (c), such matters do not have a materially disproportionate
    effect on MagicMed and its subsidiaries, taken as a whole, relative to companies of similar size operating in the industries or markets
    in which MagicMed operates (in which case the incremental disproportionate effect may be taken into account in determining whether
    there has been, or is reasonably expected to be, a material adverse effect), and provided further, however, that unless expressly
    provided in any particular section of the Amalgamation Agreement, references in certain sections of the Amalgamation Agreement to
    dollar amounts are not intended to be, and shall be deemed not to be, illustrative or interpretive for the purpose of determining
    whether a &ldquo;Material Adverse Effect&rdquo; has occurred;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    shall have unencumbered, unrestricted cash on hand of at least C$4,000,000 minus any cash expended or to be expended on reasonable
    and documented out-of-pocket costs primarily related to the transaction contemplated by the Amalgamation Agreement; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evidence
    in form and substance reasonably satisfactory to ENVB that (i) MagicMed shall have obtained or made any consent, approval, order
    or authorization of, or registration, declaration or filing with, any governmental authority required to be obtained or made in connection
    with the execution and delivery of the Amalgamation Agreement or the consummation of the transactions contemplated hereby and (ii)
    MagicMed shall have obtained all consents, waivers and approvals set forth on <U>Schedule 8.2(l)</U> of the Amalgamation Agreement
    in a form and substance reasonably satisfactory to ENVB and copies thereof shall have been delivered to ENVB.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 10pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 10pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 10pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligation of MagicMed to complete the amalgamation is subject to the satisfaction or waiver of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 10pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    representations and warranties of ENVB and the Purchaser set forth in the Amalgamation Agreement shall be true and correct as of
    the date of the Amalgamation Agreement and the closing date as though made on and as of the date of the Amalgamation Agreement and
    the closing date (as applicable), except to the extent such representations and warranties speak as of another date (in which case,
    such representations and warranties shall be true and correct as of such date);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    and Purchaser shall have fulfilled or complied in all material respects with each of the covenants of ENVB and the Purchaser contained
    in this Agreement to be fulfilled or complied with by it on or prior to the closing of the amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    and Purchaser shall have delivered certain certificates and other documents required under the Amalgamation Agreement for the closing
    of the amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evidence
    in form and substance reasonably satisfactory to MagicMed that (i) ENVB shall have obtained or made any consent, approval, order
    or authorization of, or registration, declaration or filing with, any governmental authority required to be obtained or made in connection
    with the execution and delivery of the Amalgamation Agreement or the consummation of the transactions contemplated hereby and (ii)
    ENVB shall have obtained all consents, waivers and approvals set forth on <U>Schedule 8.3(f)</U> of the Amalgamation Agreement in
    a form and substance reasonably satisfactory to MagicMed and copies thereof shall have been delivered to MagicMed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    shall not have been any result, change, event, occurrence, effect, state of facts or circumstance (whether or not constituting a
    breach of a representation, warranty or covenant set forth in the Amalgamation Agreement) that, either individually or in the aggregate
    is or would reasonably be expected to be material and adverse to the business, operations, results of operations, assets, properties,
    condition (financial or otherwise) or liabilities (contingent or otherwise) or prospects of ENVB and its subsidiaries, taken as a
    whole, and would, or would be reasonably expected to, prevent or materially delay ENVB from consummating the transactions contemplated
    by the Amalgamation Agreement by the end date, except any such change, event, occurrence, effect, state of facts or circumstance
    resulting from or relating to: (a) any change in general political, economic, financial, currency exchange, securities, capital or
    credit market conditions in Canada or the United States; (b) any change or proposed change in applicable laws, IFRS or U.S. GAAP;
    (c) any change affecting the industries or markets in which ENVB operates; (d) any natural disaster or the commencement or continuity
    of any act of war, armed hostilities or acts of terrorism; (e) the announcement of the Amalgamation Agreement or the transactions
    contemplated thereby; (f) any action taken (or omitted to be taken) by ENVB or its subsidiaries which is required to be taken (or
    omitted to be taken) pursuant to the Amalgamation Agreement; (g) any change in the market price or trading volume of any securities
    of ENVB (it being understood that the causes underlying such change in market price or trading volume may be taken into account in
    determining whether a material adverse effect has occurred); (h) any epidemic, pandemic, disease outbreak (including COVID-19), other
    health crisis or public health event; or (i) any matter which has been publicly disclosed or communicated in writing by ENVB to MagicMed
    as of the date of the Amalgamation Agreement and MagicMed has acknowledged receipt of such written communication; provided, however,
    that with respect to clauses; (a) through to and including (c), such matters do not have a materially disproportionate effect on
    ENVB and its subsidiaries, taken as a whole, relative to companies of similar size operating in the industries or markets in which
    ENVB operates (in which case the incremental disproportionate effect may be taken into account in determining whether there has been,
    or is reasonably expected to be, a material adverse effect), and provided further, however, that unless expressly provided in any
    particular section of the Amalgamation Agreement, references in certain sections of the Amalgamation Agreement to dollar amounts
    are not intended to be, and shall be deemed not to be, illustrative or interpretive for the purpose of determining whether a &ldquo;Material
    Adverse Effect&rdquo; has occurred;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    shall have unencumbered, unrestricted cash on hand of at least $15.0 million minus any cash expended or to be expended on reasonable
    and documented out-of-pocket costs primarily related to the transaction contemplated by the Amalgamation Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    shall have prepared a Form 8-K as required by SEC rules and regulations, in a form and substance reasonably satisfactory to MagicMed;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    shall have provided MagicMed evidence satisfactory to MagicMed, acting reasonably, that the appointments and elections contemplated
    by the Amalgamation Agreement will become effective as of the closing. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
MagicMed nor ENVB can be certain when, or if, the conditions to the amalgamation will be satisfied or waived, or that the amalgamation
will be completed. See &ldquo;The Amalgamation Agreement&mdash;Conditions to the Completion of the Amalgamation&rdquo;
on page 115 of this proxy statement/prospectus for a more complete summary of the conditions that must be satisfied prior
to closing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory
Matters (see page 111)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
completion of the Amalgamation is subject to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    temporary restraining order, preliminary or permanent injunction or other order (whether temporary, preliminary or permanent) issued
    by any court of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the Amalgamation will
    be in effect, nor will any legal action or proceeding brought by any administrative agency or commission or other governmental authority
    or instrumentality, domestic or foreign, seeking any of the foregoing be pending;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    will not be any action taken, or any statute, rule, regulation or order enacted, entered, enforced or deemed applicable to the Amalgamation,
    which makes the consummation of the Amalgamation illegal; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    required regulatory approval has been made, given or obtained and each such regulatory approval is in force and has not been modified;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    waiting period applicable to the consummation of the Amalgamation under any regulatory approval will have expired or been terminated;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    parties shall have obtained or made any consent, approval, order or authorization of, or registration, declaration or filing with,
    any governmental authority required to be obtained or made in connection with the execution and delivery of the Amalgamation Agreement
    or the consummation of the transactions contemplated thereby and the parties shall have obtained all consents, waivers and approvals
    set forth in the schedules to the Amalgamation Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
ENVB and MagicMed have agreed to use their commercially reasonable efforts and cooperate to prepare and file, as promptly as possible,
all necessary documentation and to obtain as promptly as practicable all regulatory and other governmental approvals or orders required
or advisable to complete the transactions contemplated by the Amalgamation Agreement. Although neither ENVB nor MagicMed knows of any
reason why these regulatory approvals cannot be obtained, ENVB and MagicMed cannot be certain when or if they will be obtained, as the
length of the review process may vary based on, among other things, requests by regulators for additional information or materials.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing
of ENVB Common Stock (see page 111)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Amalgamation Agreement, application will be made to have the shares of ENVB common stock issued to MagicMed equity
holders in the Amalgamation approved for listing on the NASDAQ Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ancillary
Agreements (see page 129)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Agreements (see page 129 and Annex B-1 and Annex B-2) </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the execution of the Amalgamation Agreement, holders of approximately 30% of the MagicMed Shares entered into voting agreements
with ENVB, and certain directors and executive officers of ENVB entered into voting agreements with MagicMed pursuant to
which such individuals have agreed, among other things, to execute and deliver a written consent with respect to their respective voting
shares in favor of the approval of the Amalgamation Agreement or, if applicable, vote such shares in favor of the adoption of the Amalgamation
Agreement at a meeting of stockholders called for such purpose. The forms of voting agreement are included in this proxy statement/prospectus
as <U>Annex B-1</U> and <U>Annex B-2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lock-Up
Agreements (see page 129 and Annex C-1 and Annex C-2)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
shareholders of MagicMed have also entered into lock-up agreements with ENVB pursuant to which the holders have agreed not to sell shares
of ENVB common stock to be received in the Amalgamation in excess of certain limits specified in the lock-up agreements for a period
of either five (5) or twenty (20) months after the effective time of the Amalgamation. The lock-up agreements will survive for
five months or twenty months, respectively after the effective time of the Amalgamation.</FONT> The forms of lock-up agreement
are included in this proxy statement/prospectus as <U>Annex C-1</U> and <U>Annex C-2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination
of Amalgamation Agreement (see page 126)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation Agreement may be terminated at any time prior to the effective time of the amalgamation, whether before or after the required
stockholder approvals to complete the amalgamation and related matters have been obtained, as set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    mutual written consent of ENVB, Purchaser, HoldCo and MagicMed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    either MagicMed or the Purchaser if the ENVB stockholder approval is not obtained at the ENVB special meeting of the stockholders;
    provided, however, that neither MagicMed or the Purchaser may terminate the Amalgamation Agreement if the failure to obtain such
    approval was caused by, or is a result of, a breach by such terminating party of its representations or warranties or failure to
    perform its covenants or agreements under the Amalgamation Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    either MagicMed or the Purchaser if the MagicMed shareholder approval is not obtained at the MagicMed special meeting; provided,
    however, that neither MagicMed or the Purchaser may terminate the Amalgamation Agreement if the failure to obtain such approval was
    caused by, or is a result of, a breach by such terminating party of its representations or warranties or failure to perform its covenants
    or agreements under the Amalgamation Agreement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    either MagicMed or the Purchaser if, after the date of the Amalgamation Agreement, any applicable law is enacted, made, enforced
    or amended that makes the consummation of the amalgamation illegal or otherwise permanently prohibits or enjoins ENVB, MagicMed or
    the Purchaser from consummating the amalgamation, and such applicable law has, if applicable, become final and non-appealable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    either MagicMed or the Purchaser if the effective time does not occur by December 31, 2021; provided that a party may not terminate
    if the failure of the effective time to occur is a result of a breach by such party of its representations or warranties or the failure
    of such party to perform its covenants or agreements; provided, however, in the event that the SEC has not concluded its review of
    the S-4 Registration Statement by the date which is sixty (60) days prior to December 31, 2021, then either ENVB or MagicMed shall
    be entitled to extend the end date for an additional sixty (60) days by providing written notice to the other party;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    either MagicMed or the Purchaser if there shall be in effect a final nonappealable order of a governmental authority of competent
    jurisdiction restraining, enjoining or otherwise prohibiting the consummation of the transactions contemplated by the Amalgamation
    Agreement; provided, that the right to terminate shall not be available to a party if such order was primarily due to the failure
    of such party to perform any of its obligations under the Amalgamation Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    MagicMed if a breach of any representation or warranty or failure to perform any covenant or agreement on the part of ENVB or the
    Purchaser under the Amalgamation Agreement occurs that would cause any condition precedent to the closing of the amalgamation not
    to be satisfied, and such breach or failure is incapable of being cured on or prior to December 31, 2021 or is not cured in the manner
    described above; provided that (a) any willful breach is deemed incurable and (b) MagicMed is not in breach so as to cause any condition
    to the closing of the amalgamation to not be satisfied;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    MagicMed if it wishes to enter into a binding written agreement with respect to a superior proposal (other than a confidentiality
    and standstill agreement permitted by the Amalgamation Agreement), in compliance with the Amalgamation Agreement and provided that
    no termination shall be effective unless and until MagicMed shall have paid to the Purchaser the termination fee required to be paid
    pursuant to the Amalgamation Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    MagicMed if (a) ENVB&rsquo;s board or any committee of thereof fails to unanimously recommend or withdraws, amends, modifies or qualifies
    its approval of the amalgamation, or publicly proposes or states its intention to do so; (b) ENVB&rsquo;s board or a committee thereof
    shall have approved or recommended any acquisition proposal or authorized ENVB to enter into binding written agreement with respect
    to a superior proposal (other than a confidentiality and standstill agreement permitted by the Amalgamation Agreement); or (c) ENVB
    breaches the non-solicitation provisions in any material respect, provided, however, no termination shall be effective unless and
    until MagicMed shall have paid to the Purchaser the termination fee required to be paid pursuant to the Amalgamation Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    MagicMed if there is a material adverse effect with respect to ENVB that has not been disclosed by ENVB prior to the date of the
    Amalgamation Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    ENVB if a breach of any representation or warranty or failure to perform any covenant or agreement on the part of MagicMed under
    the Amalgamation Agreement occurs that would cause any condition precedent to the closing of the amalgamation not to be satisfied,
    and such breach or failure is incapable of being cured on or prior to December 31, 2021 or is not cured in the manner described above;
    provided that (a) any willful breach is deemed incurable and (b) ENVB is not in breach so as to cause any condition to the closing
    of the amalgamation to not be satisfied;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    ENVB if it wishes to enter into a binding written agreement with respect to a superior proposal (other than a confidentiality and
    standstill agreement permitted by the Amalgamation Agreement), subject to compliance with the Amalgamation Agreement and provided
    that no termination shall be effective unless and until ENVB shall have paid to MagicMed the termination fee required to be paid
    pursuant to the Amalgamation Agreement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    ENVB if (a) the MagicMed Board or any committee of thereof fails to unanimously recommend or withdraws, amends, modifies or qualifies
    the its approval of the amalgamation, or publicly proposes or states its intention to do so; (b) the MagicMed board or a committee
    thereof shall have approved or recommended any acquisition proposal or authorized MagicMed to enter into binding written agreement
    with respect to a superior proposal (other than a confidentiality and standstill agreement permitted by the Amalgamation Agreement);
    or (c) MagicMed breaches the non-solicitation provisions in any material respect; provided, however, no termination pursuant to shall
    be effective unless and until ENVB shall have paid to MagicMed the termination fee required to be paid pursuant to Amalgamation Agreement;
    or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    ENVB if there is a material adverse effect with respect to MagicMed that has not been disclosed by MagicMed prior to the date of
    the Amalgamation Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination
Fees (see page 128)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
termination fee of $4.5 million is payable by (i) MagicMed, if the Agreement is terminated by (a) ENVB as a result of (1) a change
in recommendation by the MagicMed board of directors, (2) an approval or recommendation by the MagicMed board of directors of a different
acquisition proposal or authorization by the MagicMed board of directors of a Superior Proposal (as defined in the Amalgamation Agreement),
or (3) a breach of the non-solicit covenant by MagicMed, or (b) MagicMed in order to accept a Superior Proposal; or (ii) ENVB, if the
Amalgamation Agreement is terminated by (a) MagicMed as a result of (1) a change in recommendation by the ENVB board of directors, (2)
an approval or recommendation by the ENVB board of directors of a different acquisition proposal or authorization by the ENVB board of
directors of a Superior Proposal or (3) a breach of the non-solicit covenant by ENVB, or (b) ENVB in order to accept a Superior Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Rights of Holders of ENVB Common Stock and MagicMed Shares (see page 185)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the completion of the Amalgamation, holders of MagicMed Shares and, upon exercise, in-the-money options and warrants to acquire
MagicMed Shares will become holders of ENVB common stock. ENVB is a Delaware corporation governed by the DGCL, while MagicMed is a corporation
existing under the laws of the Province of British Columbia, governed by the <I>Business Corporations Act</I> (British Columbia). The
rights of ENVB stockholders currently are, and from and after the Amalgamation will be, governed by the ENVB amended and restated certificate
of incorporation, as amended, and the ENVB amended and restated bylaws, while the rights of MagicMed
shareholders are currently governed by the MagicMed organizational documents. This proxy statement/prospectus includes summaries of the
material differences between the rights of ENVB stockholders and MagicMed shareholders arising because of differences between the ENVB
organizational documents  and the MagicMed organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
Treatment (see page 110)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation will be accounted for using the acquisition method of accounting in accordance with ASC 805 &mdash; <I>Business Combinations</I>,
which we refer to as &ldquo;ASC 805.&rdquo; ENVB&rsquo;s management has evaluated the guidance contained in ASC 805 with respect to the
identification of the acquirer in the Amalgamation and concluded, based on a consideration of the pertinent facts and circumstances,
that ENVB will be the acquirer for financial accounting purposes. Accordingly, ENVB&rsquo;s cost to acquire MagicMed has been allocated
to MagicMed&rsquo;s acquired assets, liabilities and commitments based upon their estimated fair values. The allocation of the purchase
price is estimated and is dependent upon estimates of certain valuations that are subject to change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U.S.
Federal Income Tax Considerations (see page 110)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation is intended to qualify as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Internal Revenue
Code of 1986, as amended, for U.S. federal income tax purposes. It is further expected that no gain or loss should be recognized
by ENVB or ENVB stockholders for U.S. federal income tax purposes as a result of the Amalgamation. The completion of the Amalgamation
is not conditioned upon the receipt of an opinion of counsel to the effect that the Amalgamation qualifies for its intended tax
treatment. In addition, neither ENVB nor MagicMed intends to request a ruling from the IRS regarding the U.S. federal income tax
consequences of the Amalgamation. Accordingly, no assurance can be given that the IRS will not challenge the intended tax treatment
or that a court would not sustain such a challenge. For further information, see &ldquo;The Amalgamation&mdash;U.S. Federal Income
Tax Consequences of the Amalgamation Generally&rdquo; on page 110 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
of ENVB&rsquo;s Financial Advisor (see page 103 and Annex D)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an engagement letter, ENVB retained Gemini Valuation Services, LLC (&ldquo;Gemini&rdquo;) as its financial advisor in connection with
the proposed Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the meeting of the ENVB board of directors on May 21, 2021, Gemini rendered its oral opinion to the ENVB board of directors that, as
of such date and based upon and subject to the assumptions made, procedures followed, matters considered and limitations on the review
undertaken by Gemini in preparing the opinion, the consideration for the ENVB stockholders in the Amalgamation was fair, from a financial
point of view, to ENVB. Gemini confirmed its May 21, 2021 oral opinion by delivering its written opinion, dated May 21, 2021, to the
ENVB board of directors that, as of such date,  the consideration for the ENVB stockholders in the Amalgamation was fair, from a financial
point of view, to ENVB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full text of the written opinion of Gemini, dated May 21, 2021, which sets forth the assumptions made, procedures followed, matters considered
and limitations on the review undertaken by Gemini in preparing the opinion, is attached as <U>Annex D</U> to this proxy statement/prospectus
and is incorporated herein by reference. The summary of the opinion of Gemini set forth in this proxy statement/prospectus is qualified
in its entirety by reference to the full text of such opinion. <B>ENVB stockholders are urged to read the opinion in its entirety. Gemini&rsquo;s
opinion was addressed to the ENVB board of directors (in its capacity as such) in connection with and for the purposes of its evaluation
of the proposed Amalgamation, was directed only to the consideration in the proposed Amalgamation and did not address any other aspect
of the proposed Amalgamation. The opinion does not constitute a recommendation to any stockholder of ENVB as to how such stockholder
should vote with respect to the ENVB Share Issuance Proposal or any other matter. For a description of
the opinion that the ENVB Board received from Gemini, see the section entitled &ldquo;The Amalgamation&mdash;Opinion of ENVB&rsquo;s
Financial Advisor.&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
Factors (see page 46)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Both
ENVB and MagicMed are subject to various risks associated with their businesses and their industries. In addition, the amalgamation,
including the possibility that the amalgamation may not be completed, poses a number of risks to each company and its respective securityholders,
including the following risks:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risks
Related to the Amalgamation</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">There is no assurance
    when or if the Amalgamation will be completed. Any delay in completing the Amalgamation may substantially reduce the benefits that
    ENVB expects to obtain from the Amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">ENVB is expected to incur
    substantial expenses related to the Amalgamation and the integration of MagicMed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The announcement and pendency
    of the Amalgamation could have an adverse effect on ENVB&rsquo;s and/or MagicMed&rsquo;s business, financial condition, results of
    operations or business prospects.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Some ENVB and MagicMed
    directors and executive officers have interests in the Amalgamation that are different from yours and that may influence them to
    support or approve the Amalgamation without regard to your interests.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Because the Exchange Ratio
    is fixed and because the market price of ENVB common stock will fluctuate prior to the completion of the Amalgamation, MagicMed shareholders
    cannot be sure of the market value of ENVB common stock they will receive as Amalgamation consideration relative to the value of
    the MagicMed shares they will exchange in connection with the Amalgamation. </FONT><FONT STYLE="font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The issuance of ENVB common
    stock in connection with the Amalgamation could decrease the market price of ENVB common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">ENVB and MagicMed securityholders
    will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company
    following the completion of the Amalgamation as compared to their current ownership and voting interests in the respective companies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">During the pendency of
    the Amalgamation, ENVB and MagicMed may not be able to enter into a business combination with another party on more favorable terms
    because of restrictions in the Amalgamation Agreement, which could adversely affect their respective business prospects.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Certain provisions of
    the Amalgamation Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior
    to the transactions contemplated by the Amalgamation Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Failure to complete the
    Amalgamation could negatively affect the value of ENVB common stock and ENVB&rsquo;s future business and financial results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">There has been no public
    market for MagicMed common shares and the lack of a public market makes it difficult to determine the fair market value of MagicMed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The Amalgamation may be
    completed even though material adverse changes may result from the announcement of the Amalgamation, industry-wide changes or other
    causes.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The fairness opinion of
    ENVB&rsquo;s financial advisor in connection with the Amalgamation does not reflect changes in circumstances between the date of
    the signing of the Amalgamation Agreement and the closing of the Amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Shareholders of the combined
    company may experience dilution of their ownership interests due to the future issuance of additional shares of stock of the combined
    company which could have an adverse effect on the price of the combined company&rsquo;s stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
risks and other risks, including risks related to the combined company, risks related to ENVB&rsquo;s business, risks related to certain
regulatory matters, risks related to ENVB&rsquo;s intellectual property, risks related to the ownership of ENVB common stock, and risks
related to MagicMed&rsquo;s business are discussed in greater detail under the section titled &ldquo;Risk Factors&rdquo; beginning
on page 46 of this proxy statement/prospectus. ENVB and MagicMed both encourage you to read and consider all of these risks carefully.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B>&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_004"></A>SELECTED
HISTORICAL FINANCIAL INFORMATION OF ENVB</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are selected historical consolidated financial data for ENVB. The consolidated financial data as of December 31, 2020 and
December 31, 2019, and for the fiscal years ended 2020 and 2019 are derived from ENVB&rsquo;s audited consolidated financial statements
that are included elsewhere in this proxy statement/prospectus. The consolidated financial data as of March 31, 2021, and for the three
months ended March 31, 2021, are derived from ENVB&rsquo;s unaudited condensed consolidated financial statements included elsewhere in
this proxy statement/prospectus. The consolidated balance sheet data as of March 31, 2021 are derived from ENVB&rsquo;s unaudited condensed
consolidated financial statements included elsewhere in this proxy statement/prospectus. ENVB&rsquo;s management believes that ENVB&rsquo;s
unaudited condensed consolidated financial statements have been prepared on a basis consistent with its audited consolidated financial
statements and include all normal and recurring adjustments necessary for a fair presentation of the results for each interim period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statement data provided below is only a summary, and you should read it in conjunction with the historical consolidated
financial statements of ENVB and the related notes included elsewhere in this proxy statement/prospectus. See &ldquo;Where You Can Find
More Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> March 31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 46%">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">43,714</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,578,460</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">22,657,150</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Prepaids and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">700,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">767,298</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,817,721</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,362,177</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">108,789</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,096,891</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">25,786,625</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,157,645</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">681,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">626,947</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Warrant liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,168,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Advance from related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">446,415</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Convertible notes payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">293,921</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">TOTAL LIABILITIES</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,920,390</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">681,250</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,794,947</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">32,754</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">194,499</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,039,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,222,770</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,952,988</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,894,881</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,759,557</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,010,268</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,622</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(181,277</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(145,541</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,811,601</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,415,641</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18,991,678</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">108,789</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,096,891</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">25,786,625</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statement of Operations and Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fiscal Year Ended December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR> March 31, 2021<BR> (Unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">General and administrative</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">5,443,234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">6,607,045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">174,083</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">157,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,617,317</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,764,997</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Inducement expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(802,109</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(298,714</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,813,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(445,250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expense)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,247,359</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,514,286</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">Net loss before other comprehensive loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(6,864,676</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(3,250,711</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Foreign currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(169,655</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,736</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(7,034,331</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,214,975</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Net loss per share - basic &amp; diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.20</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Weighted average shares - basic &amp; diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,753,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,220,661</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Accumulated deficit, beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,906,503</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,940,834</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,034,331</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,214,975</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 2.5pt">Accumulated deficit, end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(11,940,834</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(15,155,809</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="o_005"></A>selected
Historical Financial Information of MagicMed</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected historical consolidated financial data for the periods indicated below. MagicMed derived the selected
historical statements of loss and comprehensive loss data for the period from May 26, 2020 (incorporation) through June 30, 2020 and
the statement of financial position data as of June 30, 2020, from its audited consolidated financial statements included elsewhere in
this proxy statement/prospectus. The selected historical consolidated financial data for the nine months ended March 31, 2021, and as
of March 31, 2021, are derived from MagicMed&rsquo;s unaudited interim condensed consolidated financial statements and related notes
thereto included elsewhere in this proxy statement/prospectus. The following information is only a summary and does not provide all of
the information contained in MagicMed&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements
and, in the opinion of MagicMed&rsquo;s management, include all adjustments necessary for a fair presentation of the information set
forth therein. The results of interim periods are not necessarily indicative of results that may be expected for the full year or any
future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following information should be read in conjunction with &ldquo;MagicMed&rsquo;s Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; and MagicMed&rsquo;s consolidated financial statements, including the related notes, included
elsewhere in this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">(all amounts below are expressed in Canadian dollars)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nine
                                            Months Ended March 31, 2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period<BR> May 26, 2020 (incorporation)
    to June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Selected Statement of Loss and Comprehensive Loss Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%">Expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">2,379,369</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">42,476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from Operation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,379,369</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(42,476</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,381,683</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(42,476</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Net Loss per Common Share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.093</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.005</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fully Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.093</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.005</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Cash Dividend per Common Share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">(all amounts below are expressed in Canadian
    dollars)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                            31, 2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Selected Statement of Financial Position Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 56%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">6,953,091</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">544,977</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,383,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">556,527</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Total Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">380,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,217</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Shareholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,003,276</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">505,310</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_006"></A>HISTORICAL
AND UNAUDITED PRO FORMA COMBINED PER SHARE INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth (i) historical per share information of ENVB for the three months ended March 31, 2021, and the year
ended December 31, 2020, (ii) the unaudited pro forma consolidated per share information of ENVB after giving pro forma effect
to the Amalgamation, including ENVB&rsquo;s issuance of 0.265801 of a share of ENVB common stock for each outstanding MagicMed
Share not owned by ENVB or its subsidiaries for the three months ended March 31, 2021 and the year ended December 31, 2020
and (iii) the historical per share information of MagicMed for the three months ended March 31, 2021 and the year ended December
31, 2020. The financial information below in the MagicMed and Pro Forma columns gives effect to the conversion of MagicMed&rsquo;s
financial information from Canadian dollars to United States dollars at the exchange rate of 1.00/1.2575 and 1.00/1.2732, based
on the daily rate of exchange as reported by the Bank of Canada for conversion of Canadian dollars into United States dollars
on March 31, 2021 and December 31, 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
information should be read in conjunction with (i) the summary consolidated historical financial information included elsewhere in this
proxy statement/prospectus, (ii) the consolidated historical financial statements of ENVB and MagicMed and related notes that are included
elsewhere in this proxy statement/prospectus and (iii) the &ldquo;Unaudited Pro Forma Condensed Consolidated Financial Information&rdquo;
included in this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="margin-top: 0; margin-bottom: 0">Historical</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">MagicMed</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="margin-top: 0; margin-bottom: 0">Historical</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">ENVB</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Pro Forma</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-weight: bold; text-align: left">Basic net earnings (loss) per share of common stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Three months ended March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.03</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.20</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.18</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Year ended December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.83</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Diluted net earnings (loss) per share of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Three months March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.03</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.20</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.18</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Year ended December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.83</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Cash dividends declared per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Three months ended March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Year ended December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Book value per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>As of March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.36</TD><TD STYLE="text-align: left"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_007"></A>UNAUDITED
PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
May 24, 2021, ENVB, HoldCo, and Purchaser entered into the Amalgamation Agreement with MagicMed. Upon the terms and subject to the conditions
set forth in the Amalgamation Agreement, and in accordance with the BCBCA, at the effective time of the amalgamation, Purchaser, a wholly-owned
subsidiary of Holdco, will be amalgamated with MagicMed. Upon completion of the amalgamation, the separate corporate existences of Purchaser
and MagicMed will cease, and the amalgamated corporation (&ldquo;AmalCo&rdquo;) will continue as the surviving corporation and as a wholly-owned
subsidiary of HoldCo under the name &ldquo;Enveric Biosciences Canada Inc.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
unaudited pro forma condensed consolidated financial information is presented to illustrate the estimated effects of the Amalgamation
and the other transactions contemplated by the Amalgamation Agreement based on the historical financial position and results of operations
of ENVB and MagicMed. The unaudited pro forma condensed consolidated financial information is presented as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">the
                                            unaudited pro forma condensed consolidated balance sheet as of March 31, 2021 prepared
                                            based on (i) the historical unaudited condensed consolidated balance sheet of ENVB as of
                                            March 31, 2021 and (ii) the historical unaudited consolidated balance sheet of MagicMed as
                                            of March 31, 2021;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">the
                                            unaudited pro forma condensed consolidated statement of income for the period ended March
                                            31, 2021 prepared based on (i) the historical unaudited condensed consolidated statement
                                            of operations and comprehensive loss of ENVB for the period ended March 31, 2021 and (ii)
                                            the historical unaudited consolidated statement of operations of MagicMed for the period
                                            ended March 31, 2021; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">the
                                         unaudited pro forma condensed consolidated statement of income for the year ended December
                                         31, 2020 prepared based on (i) the historical audited consolidated statement of operations
                                         and comprehensive loss of ENVB for the fiscal year ended December 31, 2020 and (ii) the
                                         historical unaudited consolidated statement of operations of MagicMed for the period
                                         from May 26, 2020 (MagicMed's date of incorporation) through December 31, 2020. MagicMed&rsquo;s fiscal year end is June 30, 2020 and such fiscal
year-end financial statements have been subject to audit procedures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Regulation S-X Article 11, Pro
Forma Financial Information. Regulation S-X Article 11 requires that pro forma financial information include the following pro forma
adjustments to the historical financial information of the registrant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Transaction
                                            Accounting Adjustments &ndash; Adjustments that reflect only the application of required
                                            accounting to the acquisition, disposition, or other transaction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Autonomous
                                            Entity Adjustments &ndash; Adjustments that are necessary to reflect the operations and financial
                                            position of the registrant as an autonomous entity when the registrant was previously part
                                            of another entity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
transaction accounting adjustments are based on available information and assumptions that ENVB&rsquo;s management believes are reasonable.
However, such adjustments are estimates and actual experience may differ from expectations. There are no autonomous entity adjustments
included in the unaudited pro forma condensed consolidated financial statements. Additionally, Regulation S-X Article 11 permits registrants
to reflect in the notes to the pro forma financial information forward-looking information that depicts the synergies and dis-synergies
identified by management in determining to consummate or integrate the transaction for which pro forma effect is being given. Such adjustments
have not been reflected in the notes to the unaudited pro forma condensed consolidated financial statements because ENVB&rsquo;s management
does not believe these adjustments would enhance an understanding of the pro forma effects of the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Amalgamation will be accounted for using the acquisition method of accounting in accordance ASC 805, &ldquo;<I>Business
Combinations</I>,&rdquo; (&ldquo;ASC 805&rdquo;) with ENVB designated as the accounting acquirer of MagicMed. The unaudited pro
forma condensed consolidated financial information set forth below primarily gives effect to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">the
    alignment of accounting policies and financial statement classifications of MagicMed to those of ENVB;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">the
    application of the acquisition method of accounting in connection with the Amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">each
    MagicMed common share will be converted into the right to receive 0.265801 shares of ENVB in connection with the Amalgamation; </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">the
    conversion of MagicMed&rsquo;s financial information from Canadian dollars to United States dollars; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; background-color: white">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">the
    application of Amalgamation costs in connection with the Amalgamation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed consolidated financial information has been presented for informational purposes only and is not necessarily
indicative of what the combined company&rsquo;s financial position or results of operations actually would have been had the Amalgamation
been completed as of the dates indicated. In addition, the unaudited pro forma condensed consolidated financial information does not
purport to project the future financial position or operating results of the combined company. The actual financial position and results
of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma
adjustments represent management&rsquo;s estimates based on information available as of the date of these unaudited pro forma condensed
consolidated financial statements and are subject to change as additional information becomes available and analyses are performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed consolidated financial information has been prepared in accordance with Article 11 of Regulation S-X
of the Exchange Act, as amended by the final rule, Release 33-10786 &ldquo;Amendments to Financial Disclosures about Acquired and Disposed
Businesses.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed consolidated financial information has been prepared using the acquisition method of accounting
under existing United States generally accepted accounting principles (U.S. &ldquo;GAAP&rdquo;) standards, which are subject to
change. ENVB will be deemed the acquirer for accounting purposes and MagicMed will be treated as the acquiree, based on a number
of factors considered at the time of preparation of this filing, such as the legal form of the Amalgamation, relative size (assets,
revenues, or earnings), terms of the exchange, relative voting rights in the combined company after the business combination,
etc. The acquisition accounting is dependent upon certain valuations and other studies. ENVB has developed an initial estimate
of value. ENVB will finalize the purchase price allocation as soon as practicable within the measurement period, but in no event
later than one year following the Closing Date. The assets and liabilities of MagicMed have been measured based on various initial
estimates using assumptions that ENVB believes are reasonable, based on information that is currently available. The terms of the options and warrants have not yet been finalized.
Once the terms of the options and warrants are finalized, this may or may not impact the classification and accounting for such
options and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
the pro forma adjustments are preliminary and have been made solely for the purpose of providing pro forma condensed consolidated financial
information prepared in accordance with the rules and regulations of the SEC. Differences between these preliminary estimates and the
final acquisition accounting will exist, and these differences could have a material impact on the accompanying unaudited pro forma condensed
consolidated financial information and the combined company&rsquo;s future results of operations and financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed consolidated financial information has been compiled in a manner consistent with the accounting policies
adopted by ENVB in all material aspects. ENVB has performed a high-level review of MagicMed&rsquo;s accounting policies. Subsequent to
the Amalgamation, ENVB may identify additional differences between the accounting policies of the two companies that, when conformed,
could have a material impact on the financial statements of the combined company. Additionally, certain financial information of MagicMed
as presented in its historical financial statements has been reclassified to conform to the historical presentation in ENVB&rsquo;s financial
statements for purposes of preparation of the unaudited pro forma condensed consolidated financial information (see Note 5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed consolidated financial information gives effect to the Amalgamation, as if the Amalgamation had been
completed on Mach 31, 2021, for balance sheet purposes and December 31, 2020, for statement of income purposes. This unaudited pro forma
condensed consolidated financial information was derived from and should be read in conjunction with the separate (i) unaudited financial
statements of ENVB as of and for the period ended March 31, 2021 and the related notes included elsewhere in this proxy statement/prospectus,
(ii) audited financial statements of ENVB as of and for the fiscal year ended December 31, 2020 and the related notes included elsewhere
in this proxy statement/prospectus, (iii) unaudited financial statements of MagicMed as of and for the period ended March 31, 2021 and
the related notes included elsewhere in this proxy statement/prospectus, and (iv) audited financial statements of MagicMed as of and
for the fiscal year ended December 31, 2020 and the related notes included elsewhere in this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Pro Forma Consolidated Balance Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
of March 31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Historical </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVB</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Historical<BR> MagicMed</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma<BR> Transaction<BR> Accounting Adjustments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro Forma</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 35%">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">22,657,150</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,529,098</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">28,186,248</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,009</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">767,298</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">153,715</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">921,013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total Current Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">23,424,448</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,754,822</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,179,270</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,990</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,990</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Intangible assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,362,177</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,537,323</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1C, 1D</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,919,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total Other Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,362,177</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">12,990</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,537,323</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">17,932,490</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">25,786,625</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,767,812</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">15,537,323</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">47,111,760</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accounts payable &amp; accrued liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">626,947</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">302,213</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">929,160</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total Current Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">626,947</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">302,213</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">929,160</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrant liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,168,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,168,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">TOTAL LIABILITIES</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,794,947</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">302,213</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,097,160</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">194,499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">99,446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">1A</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">293,945</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,952,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,496,696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,649,255</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1B, 1C</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,098,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,010,268</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,029,257</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(193,218</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1C, 1D</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,232,743</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(145,541</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,840</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,840</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">1C</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(145,541</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">TOTAL SHAREHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18,991,678</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,465,600</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,557,323</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">40,014,601</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">TOTAL LIABILITIES AND SHAREHOLDERS EQUITY</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">25,786,625</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,767,812</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">15,557,323</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">47,111,760</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Pro Forma Consolidated Statement of Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Three Months Ended March 31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Historical ENVB</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Historical MagicMed</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma Transaction Accounting
    Adjustments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma Consolidated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,607,045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">870,874</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,477,919</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,952</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">217,812</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375,764</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">585</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">444,495</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">444,495</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,764,997</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,089,271</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">444,495</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,298,763</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Inducement expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(298,714</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(298,714</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of warrant liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,813,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,813,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total other income (expense)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,514,286</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,514,286</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">Net Loss before other comprehensive loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(3,250,711</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(1,089,271</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(444,495</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(4,784,477</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Foreign currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,736</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,828</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">33,908</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,214,975</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,091,098</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(444,495</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,750,568</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net loss per share - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.20</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.03</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.18</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Weighted average shares - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,220,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,403,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,165,216</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Pro Forma Consolidated Statement of Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Year Ended December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Historical</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">ENVB</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Historical</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Magic Med</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(Note 4)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Pro Forma <BR>Transaction</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Accounting Adjustments</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Pro Forma</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Consolidated </B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp; &nbsp;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,443,234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">741,013</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,184,247</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147,956</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">322,039</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,777,980</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,777,980</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,617,317</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">889,412</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,777,980</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,284,709</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Inducement expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(802,109</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(802,109</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of warrant liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(445,250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(445,250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total other income (expense)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,247,359</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,247,359</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net Loss before other comprehensive loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(6,864,676</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(889,412</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(1,777,980</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(9,532,068</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Foreign currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(169,655</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(31,781</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(201,436</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(7,034,331</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(921,194</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,777,980</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,733,504</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net loss per share &ndash; basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.83</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Weighted average shares - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,753,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,059,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,720,331</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note 1. </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance Sheet Adjustments</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A. <U>Par value of Purchase Shares issued</U></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 80%">Common shares issued</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">9,944,555</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">Par value per share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.01</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Common stock at par value</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">99,446</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B. <U>Additional Paid in Capital</U></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total purchase consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,245,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">Less: par value of purchase shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">99,446</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Additional paid in capital</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">23,145,952</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C. <U>Record excess of consideration over net assets</U></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Total purchase consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,245,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Less: MM Net Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">MM Paid in Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,496,696</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">MM Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,029,257</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">MM Comprehensive Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,840</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(5,465,600</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net excess of consideration</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,779,798</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><B>D</B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amortization of IP/Technology</U></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">12 months ended 12/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,777,980</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">3 months ended 3/31/2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">444,495</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Total Amortization</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,222,475</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note 2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation of Weighted Average Shares</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 12pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">ENVB</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">MagicMed</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighting date, From</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">01/01/21</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">01/01/21</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Weighting date, To</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">03/31/21</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">03/31/21</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; width: 60%"># of Days</TD><TD STYLE="padding-bottom: 2.5pt; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 16%; font-weight: bold; text-align: center">89</TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 16%; font-weight: bold; text-align: center">89</TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighting Factor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>ENVB Weighted Avg Shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,220,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Transaction shares issued to MM</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,944,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold">Weighted Avg Shares, Consolidated</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">26,165,216</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 12pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note 3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization of Intellectual Property/Technology</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">Purchase price allocated to IP</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">17,779,798</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Estimated useful life (years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Amortization of 3 months ended 13/31/2021</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">444,495</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note. 4</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis of Presentation</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of operations presented for the period from May 26, 2020 (MagicMed&rsquo;s date of incorporation) through December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note 5.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation of Weighted Average Shares</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">ENVB</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">MagicMed</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighting date, From</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">01/01/20</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">05/26/20</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Weighting date, To</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">12/31/20</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">12/31/20</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; width: 60%"># of Days</TD><TD STYLE="padding-bottom: 2.5pt; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 16%; font-weight: bold; text-align: center">365</TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; width: 16%; font-weight: bold; text-align: center">219</TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighting Factor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>ENVB Weighted Avg Shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,753,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Transaction shares issued to MM</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,944,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">60</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold">Weighted Avg Shares, Consolidated</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,720,331</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 12pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 12pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 12pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 12pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note 6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization of Intellectual Property/Technology</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">Purchase price allocated to IP</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">17,779,798</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Estimated useful life (years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Amortization of 12 months ended 12/31/2020</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,777,980</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note 7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed Financial Information Translated From IFRS
    to U.S. GAAP</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Three Months Ended March 31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">IFRS</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">GAAP</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">GAAP</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Jan 2021 to Mar 2021<BR> (CAD)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">GAAP<BR> Adjustments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Jan 2021 to Mar 2021<BR> (CAD)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Jan 2021 to Mar 2021<BR> (USD)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline">Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 35%; text-align: left">Salaries &amp; benefits</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">347,682</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">347,682</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">274,637</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Marketing fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">272,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">272,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215,107</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Research &amp; development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,768</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">217,812</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Consulting services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,405</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">General &amp; administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,893</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Foreign currency translation loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,314</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Share-based compensation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,416</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Total Expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,315,216</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">63,768</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,378,984</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,089,271</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">Net Loss before other comprehensive loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,315,216</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(63,768</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,378,984</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,089,271</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Other Comprehensive Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on translation of foreign operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,828</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Net loss and comprehensive loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,317,530</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(63,768</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,381,298</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,091,098</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss per share-basic &amp; diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.035</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.037</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.029</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Weighted avg shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,403,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,403,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,403,860</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Notes</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 3%">1</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left">Capitalized patent costs-Mar 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">130,037</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Capitalized patent costs-Dec 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,269</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net activity during 3 mos ended Mar 2021</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">63,768</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Financial Information<BR>
As Of and For The Six Months Ended December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Audited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-style: italic"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Not
    Audited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-style: italic"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">GAAP</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">GAAP</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">CAD TO USD</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">GAAP FINANCIALS</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">IFRS</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Adjustments</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Financials</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">ADJUST</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">IN
    USD</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Balance Sheet</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Dec
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Dec
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Dec
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> June 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> Mar 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Dec
    2020<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8.5pt">ASSETS</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 40%"><FONT STYLE="font-size: 8.5pt">Cash</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">544,977</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">8,247,865</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">544,977</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">8,247,865</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">399,904</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">6,477,873</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Prepaid expenses</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">4,843</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">47,105</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">4,843</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">47,105</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">3,554</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">36,996</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Gov&rsquo;t remittances recoverable</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">49,029</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">49,029</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,043</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">38,507</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Equipment</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">11,079</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">11,079</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">8,701</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Intangible assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">66,269</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(60,984</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL ASSETS</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">556,527</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">8,421,347</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(60,984</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">551,242</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">8,355,078</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">404,501</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">6,562,078</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8.5pt">LIABILITIES</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Accounts payable &amp; accrued
    liabs</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">133,578</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">133,578</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">37,583</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">104,913</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL LIABILITIES</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">133,578</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">133,578</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">37,583</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">104,913</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">SHAREHOLDERS EQUITY</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Share capital</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">396,590</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">7,617,873</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">396,590</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">7,617,873</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">291,018</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">5,983,077</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Warrants reserve</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">151,196</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,738,014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">151,196</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,738,014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">110,948</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,365,036</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Options reserve</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">38,510</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">38,510</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">30,246</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Accumulated other comprehensive loss</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,106,629</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(60,984</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,172,898</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(921,194</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL SHAREHOLDERS EQUITY</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">505,310</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">8,287,768</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(60,984</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">500,025</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">8,221,499</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">366,918</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">6,457,165</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL LIABILITIES &amp; EQUITY</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">556,527</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">8,421,346</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(60,984</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">551,242</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">8,355,077</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">404,501</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">6,562,078</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">GAAP
    Adjustments</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">GAAP
    Financials</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">CAD
    TO USD ADJUST</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">P &amp; L Statement<BR>
    (June 2020 Audited &amp; 6 Months Ended Dec 2020)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Six
    Months<BR> Ended<BR> Dec 31 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Six
    Months<BR> Ended<BR> Dec 31 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Six
    Months<BR> Ended<BR> Dec 31 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> June 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> Mar 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Six
    Months<BR> Ended<BR> Dec 31 2020<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> Dec 31 2020<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 8.5pt">Revenue</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 8.5pt">Expenses</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 34%; text-align: left"><FONT STYLE="font-size: 8.5pt">Salaries &amp; benefits</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">324,558</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">324,558</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">246,393</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">246,393</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Professional fees</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">24,190</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">211,977</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">24,190</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">211,977</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">17,853</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">160,925</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">178,778</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Marketing fees</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">15,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">281,407</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">15,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">281,407</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">11,439</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">213,634</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">225,073</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Research &amp; development costs</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">128,772</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">60,984</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">189,756</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">3,900</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">144,056</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">147,956</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Consulting services</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">62,398</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">62,398</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">47,370</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">47,370</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">General &amp; administrative</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">15,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">15,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">11,604</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">11,604</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Depreciation</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">583</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">583</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">443</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">443</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Foreign currency translation loss</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">663</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">663</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">503</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">503</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Share-based compensation</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">2,786</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">38,510</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">2,786</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">38,510</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">2,056</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">29,235</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">31,292</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Total Expenses</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">1,064,153</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">60,984</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">1,125,137</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">35,249</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">854,164</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">889,412</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Net Loss before other comprehensive
    loss</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,064,153</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(60,984</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,125,137</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,249</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(854,164</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(889,412</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left"><FONT STYLE="font-size: 8.5pt">Other Comprehensive Loss</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Loss on translation of foreign
    operations</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8.5pt">202</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">(31,983</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">202</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(31,983</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(31,781</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">Net loss and comprehensive
    loss</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,064,153</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(60,984</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,125,137</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(886,147</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(921,194</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Loss per share-basic &amp;
    diluted</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(0.005</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(0.054</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(0.005</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(0.057</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD COLSPAN="5" STYLE="border-bottom: Black 1.5pt solid; font-style: italic; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><I>Share
                                            Weighting Factors</I></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(0.051</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Weighted avg shares outstanding</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">8,701,389</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">19,840,116</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">8,701,389</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">19,840,116</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">15.98</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">%</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">84.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">%</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">18,059,954</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Accumulated deficit, beginning of period</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Net Loss &amp; comprehensive
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,064,153</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,125,137</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(886,147</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">Accumulated deficit, end of period</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,106,629</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,172,898</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(921,194</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
Of and For The Nine Months Ended March 31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Audited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-style: italic"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-style: italic; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Not
    Audited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-style: italic"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">GAAP</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">GAAP</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">CAD
    TO USD</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">GAAP
    FINANCIALS</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">IFRS</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Adjustments</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Financials</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">ADJUST</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">USD</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Balance Sheet</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Mar
    2021<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Mar
    2021<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Mar
    2021<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> June 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> Mar 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">June
    2020<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8.5pt">Mar
    2021<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8.5pt">ASSETS</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 40%"><FONT STYLE="font-size: 8.5pt">Cash</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">544,977</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">6,953,091</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">544,977</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">6,953,091</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">399,904</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">5,529,098</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Prepaid expenses</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">4,843</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">193,304</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">4,843</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">193,304</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">3,554</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">153,715</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Gov&rsquo;t remittances recoverable</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">90,554</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">90,554</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,043</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">72,009</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Equipment</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">16,336</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">16,336</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">12,990</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Intangible assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">130,037</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(124,752</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL ASSETS</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">556,527</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">7,383,322</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(124,752</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">551,242</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">7,253,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">404,501</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">5,767,812</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8.5pt">LIABILITIES</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Accounts payable &amp; accrued
    liabs</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">380,046</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">380,046</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">37,583</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">302,213</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL LIABILITIES</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">380,046</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">51,217</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">380,046</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">37,583</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">302,213</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">SHAREHOLDERS EQUITY</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Share capital</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">396,590</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">7,630,103</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">396,590</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">7,630,103</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">291,018</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">6,067,458</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Warrants reserve</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">151,196</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,735,508</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">151,196</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,735,508</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">110,948</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,380,076</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Options reserve</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">61,824</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">61,824</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">49,162</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Accumulated other comprehensive loss</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(2,314</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(2,314</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(1,840</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,421,845</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(124,752</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,551,882</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,029,257</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL SHAREHOLDERS EQUITY</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">505,310</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">7,003,276</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(124,752</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">500,025</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">6,873,239</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">366,918</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">5,465,600</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">TOTAL LIABILITIES &amp; EQUITY</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">556,527</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">7,383,322</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(124,752</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">551,242</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">7,253,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">404,501</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">5,767,812</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">GAAP
    Adjustments</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">GAAP
    Financials</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">CAD
    TO USD ADJUST</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">P &amp; L Statement<BR>
    (June 2020 Audited &amp; 9 Months Ended March 2021)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">Nine
    Months<BR> Ended<BR> Mar 31 2021<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">Nine
    Months<BR> Ended<BR> Mar 31 2021<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">Nine
    Months<BR> Ended<BR> Mar 31 2021<BR> (CAD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> June 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">FOREX
    Adj<BR> Mar 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">May
    26 2020<BR> to<BR> June 30 2020<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8.5pt">Nine
    Months<BR> Ended<BR> Mar 31 2021<BR> (USD)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 8.5pt">Revenue</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 8.5pt">Expenses</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 40%; text-align: left"><FONT STYLE="font-size: 8.5pt">Salaries &amp; benefits</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">672,240</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">672,240</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; text-align: right"><FONT STYLE="font-size: 8.5pt">517,193</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Professional fees</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">24,190</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">541,258</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">24,190</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">541,258</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">17,853</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">416,421</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Marketing fees</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">15,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">553,726</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">15,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">553,726</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">11,439</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">426,013</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Research &amp; development costs</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">340,747</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">124,752</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">465,499</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">3,900</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">358,135</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Consulting services</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">156,592</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">156,592</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">120,475</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">General &amp; administrative</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">45,194</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">45,194</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">34,770</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Depreciation</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,325</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,325</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">1,019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Foreign currency translation loss</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">6,463</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">6,463</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">4,972</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Share-based compensation</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">2,786</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">61,824</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">2,786</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">61,824</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">2,056</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">47,565</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Total Expenses</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">2,379,369</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">124,752</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">2,504,121</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">35,249</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">1,926,564</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Net Loss before other comprehensive
    loss</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,379,369</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(124,752</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,504,121</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,249</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,926,564</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left"><FONT STYLE="font-size: 8.5pt">Other Comprehensive Loss</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Loss on translation of foreign
    operations</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,314</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,314</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8.5pt">202</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">(65,865</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">202</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(67,646</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">Net loss and comprehensive
    loss</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,381,683</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(5,285</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(124,752</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,506,435</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,994,209</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8.5pt">Loss per share-basic &amp; diluted</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(0.005</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(0.093</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(0.005</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(0.098</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Weighted avg shares outstanding</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">8,701,389</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">25,609,298</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">8,701,389</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">25,609,298</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 8.5pt">Accumulated deficit, beginning of period</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">Net Loss &amp; comprehensive
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,381,683</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,506,435</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8.5pt">(1,994,209</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">Accumulated deficit, end of period</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(42,476</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,424,159</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(47,761</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,554,196</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(35,047</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8.5pt">(2,029,256</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8.5pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_008"></A>COMPARATIVE
PER SHARE MARKET PRICE AND DIVIDEND INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
common stock is listed on The NASDAQ Capital Market under the symbol &ldquo;ENVB.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is a privately held company, and there is no established public trading market for its securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the closing sale prices per share of ENVB common stock on May 21, 2021, the last full trading day immediately
preceding the public announcement of the Amalgamation Agreement, and on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2021, the latest practicable date prior to the date of this proxy statement/prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 12pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">ENVB &nbsp;Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">MagicMed &nbsp;Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 60%">May 21, 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2.72</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"> [&nbsp;&nbsp;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of ENVB and MagicMed are urged to obtain current market quotations for ENVB common stock and to review carefully the other information
contained in this proxy statement/prospectus or documents filed with the SEC. See &ldquo;Where You Can Find More Information&rdquo;
beginning on page 208 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, the latest practicable date prior to the date of this proxy statement/prospectus, there were [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
holders of record of ENVB common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_], 2021, the latest practicable date prior to the date of this proxy statement, there were approximately [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
holders of record of MagicMed&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
has not declared or paid any cash or other dividends to its stockholders and does not plan to declare or pay cash or other dividends
in the foreseeable future. ENVB currently intends to retain earnings, if any, for use in the operation and expansion of its business.
Subject to the foregoing, the payment of cash dividends in the future, if any, will be at the discretion of the ENVB board of directors
and will depend on such factors as earnings levels, contractual restrictions, capital requirements, ENVB&rsquo;s overall financial condition
and any other factors deemed relevant by the ENVB board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has never paid any dividends to its stockholders since its inception. While subject to periodic review, the current policy of MagicMed&rsquo;s
board of directors is to retain all earnings, if any, primarily to finance future growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_009"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
addition to general investment risks and the other information included in this proxy statement/prospectus, including the matters
addressed in the section titled &ldquo;Cautionary Statement Regarding Forward-Looking Statements&rdquo; beginning on page 86
of this proxy statement/prospectus, ENVB stockholders should carefully consider the following risk factors before deciding
whether to vote for approval of the issuance of ENVB common stock in connection with the Amalgamation and approval of the adoption
of the Amalgamation Agreement. ENVB stockholders should also read and consider the risks associated with the business of MagicMed
set forth on page 72 herein because these risk factors may affect the operations of the combined company.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_010"></A>Risks
Related to the Amalgamation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no assurance when or if the Amalgamation will be completed. Any delay in completing the Amalgamation may substantially reduce the
benefits that ENVB expects to obtain from the Amalgamation. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
of the Amalgamation is subject to the satisfaction or waiver of a number of conditions as set forth in the Amalgamation Agreement.
There can be no assurance that ENVB or MagicMed will be able to satisfy the closing conditions or that closing conditions beyond
their control will be satisfied or waived. For a discussion of the conditions to the completion of the Amalgamation, see the section
titled &ldquo;The Amalgamation Agreement&mdash;Conditions to the Completion of the Amalgamation&rdquo; beginning on page
115 of this proxy statement/prospectus. If the Amalgamation and the integration of the companies&rsquo; respective businesses
are not completed within the expected timeframe, such delay may materially and adversely affect the synergies and other benefits
that ENVB expects to achieve as a result of the Amalgamation and could result in additional transaction costs, loss of revenue
or other effects associated with uncertainty about the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
and MagicMed can agree at any time to terminate the Amalgamation Agreement, even if ENVB and/or MagicMed stockholders have already
adopted the Amalgamation Agreement and thereby approved the Amalgamation and the other transactions contemplated by the Amalgamation
Agreement. ENVB and MagicMed can also terminate the Amalgamation Agreement under other specified circumstances. See the section
titled &ldquo;The Amalgamation Agreement&mdash;Termination of the Amalgamation Agreement&rdquo; beginning on page 126 of
this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ENVB
is expected to incur substantial expenses related to the Amalgamation and the integration of MagicMed. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
is expected to incur substantial expenses in connection with the Amalgamation and the integration of MagicMed. Specifically, based on
estimates as of June 15, 2021, ENVB expects to incur approximately $1.0 million of transaction costs related to the Amalgamation.
Additionally, in connection with the plan to integrate the operations of ENVB and MagicMed, ENVB expects to incur various nonrecurring
expenses, such as costs associated with legal, regulatory, IP and tax review. ENVB is not able to determine the exact timing,
nature and amount of these expenses as of the date of this proxy statement/prospectus. However, these expenses could have an adverse
effect on the financial condition or results of operations of ENVB and MagicMed, as well as those of the combined company following the
completion of the Amalgamation, during the period in which they are recorded. Although ENVB and MagicMed expect that the realization
of efficiencies related to the integration of the businesses may offset incremental transaction, Amalgamation-related and restructuring
costs over time, ENVB and MagicMed cannot give any assurance that this net benefit will be achieved in the near term, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
announcement and pendency of the Amalgamation could have an adverse effect on ENVB&rsquo;s and/or MagicMed&rsquo;s business, financial
condition, results of operations or business prospects. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
announcement and pendency of the Amalgamation could disrupt ENVB&rsquo;s and/or MagicMed&rsquo;s businesses in the following ways, among
others:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
    and/or MagicMed&rsquo;s employees may experience uncertainty regarding their future roles in the combined company, which might adversely
    affect ENVB&rsquo;s and/or MagicMed&rsquo;s ability to retain, recruit and motivate key personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    attention of ENVB&rsquo;s and/or MagicMed&rsquo;s management may be directed towards the completion of the Amalgamation and other
    transaction-related considerations and may be diverted from the day-to-day business operations of ENVB and/or MagicMed, as applicable,
    and matters related to the Amalgamation may require commitments of time and resources that could otherwise have been devoted to other
    opportunities that might have been beneficial to ENVB and/or MagicMed, as applicable; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customers,
    suppliers and other third parties with business relationships with ENVB and/or MagicMed may decide not to renew or may decide to
    seek to terminate, change and/or renegotiate their relationships with ENVB and/or MagicMed as a result of the Amalgamation, whether
    pursuant to the terms of their existing agreements with ENVB and/or MagicMed or otherwise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these matters could adversely affect the businesses of, or harm the financial condition, results of operations or business prospects
of, ENVB and/or MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Some
ENVB and MagicMed directors and executive officers have interests in the Amalgamation that are different from yours and that may influence
them to support or approve the Amalgamation without regard to your interests.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and executive officers of ENVB and MagicMed may have interests in the Amalgamation that are different from, or in addition to, the interests
of other ENVB stockholders generally. These interests with respect to ENVB&rsquo;s directors and executive officers may include, among
others, acceleration of stock option vesting, retention bonus payments, extension of exercisability periods of previously issued stock
option grants, severance payments if employment is terminated in a qualifying termination in connection with the Amalgamation and rights
to continued indemnification, expense advancement and insurance coverage. All of the current members of the ENVB board of directors
will continue as directors of the combined company after the effective time of the Amalgamation, and, following the closing of the Amalgamation,
will remain eligible to be compensated as non-employee directors of the combined company pursuant to the ENVB non-employee director
compensation policy that is expected to remain in place following the effective time of the Amalgamation. These interests with respect
to MagicMed&rsquo;s directors and executive officers may include, among others, that certain of MagicMed&rsquo;s directors and executive
officers have options, subject to vesting, to purchase shares of MagicMed common stock which, after the effective time of the Amalgamation,
will be converted into and become options to purchase shares of the common stock of the combined company; certain of MagicMed&rsquo;s
executive officers are expected to continue as executive officers of the combined company after the effective time of the Amalgamation;
and all of MagicMed&rsquo;s directors and executive officers are entitled to certain indemnification and liability insurance coverage
pursuant to the terms of the Amalgamation Agreement. Further, two current members of MagicMed&rsquo;s board of directors will
continue as directors of the combined company after the effective time of the Amalgamation, and, following the closing of the Amalgamation,
will be eligible to be compensated as non-employee directors of the combined company pursuant to the ENVB non-employee director compensation
policy that is expected to remain in place following the effective time of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors was aware of and considered those interests, among other matters, in reaching its decision to approve and adopt
the Amalgamation Agreement, approve the Amalgamation, and recommend the approval of the ENVB Share Issuance Proposal to ENVB stockholders.
These interests, among other factors, may have influenced the directors and executive officers of ENVB and MagicMed to support or approve
the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information regarding the interests of ENVB and MagicMed directors and executive officers in the Amalgamation, please see
the sections titled &ldquo;The Amalgamation&mdash;Interests of ENVB&rsquo;s Directors and Executive Officers in the Amalgamation&rdquo;
beginning on page 108 and &ldquo;The Amalgamation&mdash;Interests of MagicMed&rsquo;s Directors and Executive Officers
in the Amalgamation&rdquo; beginning on page 109 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Because
the Exchange Ratio is fixed and because the market price of ENVB common stock will fluctuate prior to the completion of the Amalgamation,
MagicMed shareholders cannot be sure of the market value of ENVB common stock they will receive as Amalgamation consideration
relative to the value of the MagicMed shares they will exchange in connection with the Amalgamation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
market value of the consideration that MagicMed shareholders will receive in the Amalgamation will depend on the trading price
of ENVB common stock at the Closing. The Exchange Ratio that determines the number of shares of ENVB common stock that MagicMed
shareholders will receive in the Amalgamation is fixed at 0.2658 shares of ENVB common stock for each MagicMed share they own.
This means that there is no mechanism contained in the Amalgamation Agreement that would adjust the number of shares of ENVB common
stock that MagicMed shareholders will receive based on any decreases or increases in the trading price of ENVB common stock. Changes
in per share price may result from a variety of factors (many of which are beyond ENVB&rsquo;s and MagicMed&rsquo;s control),
including:</FONT></P>

<P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in ENVB&rsquo;s
    or MagicMed&rsquo;s business, operations and prospects;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in market
    assessments of ENVB&rsquo;s or MagicMed&rsquo;s business, operations and prospects;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in market
    assessments of the likelihood that the Amalgamation will be completed;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in interest
    rates, general market, industry and economic conditions and other factors generally affecting the price of ENVB common stock;
    and</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal, state
    and local legislation, governmental regulation and legal developments in the businesses in which ENVB and MagicMed operate.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the price of ENVB common stock at the Closing is less than the price of ENVB common stock on the date that the Amalgamation Agreement
was signed, then the market value of the Amalgamation consideration will be less than contemplated at the time the Amalgamation
Agreement was signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
issuance of ENVB common stock in connection with the Amalgamation could decrease the market price of ENVB common stock. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Amalgamation and as part of the Amalgamation Consideration, ENVB will issue shares of ENVB common stock to MagicMed
equity holders. The issuance of ENVB common stock in the Amalgamation may result in fluctuations in the market price of ENVB common stock,
including a stock price decrease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ENVB
and MagicMed securityholders will have a reduced ownership and voting interest in, and will exercise less influence over the
management of, the combined company following the completion of the Amalgamation as compared to their current ownership and voting
interests in their respective companies.</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the Amalgamation, the current stockholders of ENVB and MagicMed will own a smaller percentage of the combined company than
their ownership of their respective companies prior to the Amalgamation. In addition, the consummation of the Amalgamation and the issuance
of ENVB common stock as part of the Amalgamation consideration will dilute the ownership position of current ENVB stockholders. Upon
completion of the Amalgamation, ENVB stockholders as of immediately prior to the Amalgamation are expected to own approximately 63.4%
of the outstanding shares of ENVB and former MagicMed equity holders are expected to own approximately 36.6% of the outstanding
shares of ENVB on a fully-diluted basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
upon the Effective Time of the Amalgamation and pursuant to the Amalgamation Agreement, Dr. Joseph Tucker, the President and Chief Executive
Officer of MagicMed; Dr. Peter Facchini, Chief Scientific Officer of MagicMed; and Dr. Jillian Hagel, Chief Technology Officer of MagicMed,
will be appointed to the positions of Chief Executive Officer, Chief Scientific Officer, and Chief Technology Officer of ENVB, respectively,
and Dr. Tucker and Brad Thompson, directors of MagicMed, will be appointed to the ENVB board of directors. Consequently, ENVB stockholders,
as a general matter, will have less influence over the management and policies of ENVB after the effective time of the Amalgamation than
they currently exercise now over the management and policies of ENVB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>During
the pendency of the Amalgamation, ENVB and MagicMed may not be able to enter into a business combination with another party on more favorable
terms because of restrictions in the Amalgamation Agreement, which could adversely affect their respective business prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenants
in the Amalgamation Agreement impede the ability of ENVB and MagicMed to make acquisitions during the pendency of the Amalgamation, subject
to specified exceptions. As a result, if the Amalgamation is not completed, the parties may be at a disadvantage to their competitors
during that period. In addition, while the Amalgamation Agreement is in effect, each party is generally prohibited from soliciting, proposing,
seeking or knowingly encouraging, facilitating or supporting any inquiries, indications of interest, proposals or offers that constitute
or may reasonably be expected to lead to certain transactions involving a third party, including an amalgamation, merger, sale of assets
or other business combination, subject to specified exceptions. Any such transactions could be favorable to such party&rsquo;s stockholders,
but the parties may be unable to pursue them. For more information, see the section titled &ldquo;The Amalgamation Agreement&mdash;No
Solicitation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
provisions of the Amalgamation Agreement may discourage third parties from submitting competing proposals, including proposals that may
be superior to the transactions contemplated by the Amalgamation Agreement.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Amalgamation Agreement prohibit each of ENVB and MagicMed from soliciting competing proposals or cooperating with persons
making unsolicited takeover proposals, except in limited circumstances as described in further detail in the section titled &ldquo;The
Amalgamation Agreement&mdash;No Solicitation.&rdquo; In addition, if the Amalgamation Agreement is terminated under specified
circumstances, ENVB would be required to pay MagicMed a termination fee of $4.5 million. This termination fee may discourage third
parties from submitting competing proposals to ENVB or its stockholders and may cause the ENVB board of directors to be less inclined
to recommend a competing proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to complete the Amalgamation could negatively affect the value of ENVB common stock and ENVB&rsquo;s future business and financial results.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Amalgamation is not completed, the ongoing business of ENVB could be adversely affected and ENVB will be subject to a variety of
risks associated with the failure to complete the Amalgamation, including without limitation the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    being required, under certain circumstances, to pay to MagicMed a reverse termination fee equal to $4.5 million;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management focus and resources from operational matters and other strategic opportunities while working to implement the Amalgamation;
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational
    harm due to the adverse perception of any failure to successfully complete the Amalgamation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
to pay certain costs relating to the Amalgamation, such as legal, accounting, financial advisory, filing and printing fees.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Amalgamation is not completed, these risks could materially affect the market price of ENVB common stock and the business and financial
results of ENVB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
has been no public market for MagicMed common shares and the lack of a public market makes it difficult to determine the fair
market value of MagicMed. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding capital stock of MagicMed is privately held and is not traded on any public market. The lack of a public market may make
it more difficult to determine the fair market value of MagicMed than if MagicMed common stock were traded publicly. The value ascribed
to MagicMed&rsquo;s securities in other contexts may not be indicative of the price at which MagicMed common shares may have traded
if it were traded on a public market. The Amalgamation consideration to be paid to MagicMed shareholders was determined based
on negotiations between the parties and likewise may not be indicative of the price at which MagicMed common shares may have traded
if it were traded on a public market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Amalgamation may be completed even though material adverse changes may result from the announcement of the Amalgamation, industry-wide
changes or other causes. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, ENVB may refuse to complete the Amalgamation if there is a material adverse effect (as defined in the Amalgamation Agreement)
affecting MagicMed prior to the closing of the Amalgamation. However, some types of changes do not permit either party to refuse
to complete the Amalgamation, even if such changes would have a material adverse effect on ENVB or MagicMed. If adverse changes
occur but ENVB and MagicMed must still complete the Amalgamation, the market price of ENVB common stock may suffer. For a more
complete discussion of what constitutes a material adverse effect on ENVB or MagicMed under the Amalgamation Agreement, see the
section titled &ldquo;The Amalgamation Agreement&mdash;Representations and Warranties&rdquo; beginning on page 118 of this
proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
fairness opinion of ENVB&rsquo;s financial advisor in connection with the Amalgamation does not reflect changes in circumstances between
the date of the signing of the Amalgamation Agreement and the closing of the Amalgamation. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors received an opinion from Gemini Valuation Services, LLC, that as of the date of the opinion, and based upon and
subject to the various assumptions made, procedures followed, matters considered, limitations of the review undertaken, qualifications
contained and other matters set forth therein, the consideration for the ENVB stockholders in the Amalgamation was fair, from a financial
point of view, to ENVB. Subsequent changes in the operation and prospects of ENVB or MagicMed, general market and economic conditions
and other factors may significantly alter the value of ENVB or MagicMed or the price of the shares of ENVB common stock by the time the
Amalgamation is to be completed. The opinion does not address the fairness, from a financial point of view, of the consideration to be
paid by ENVB at the time the Amalgamation is to be completed, or as of any other date other than the date of such opinion. Gemini Valuation
Services, LLC&rsquo;s opinion is attached as <U>Annex D</U> to this proxy statement/prospectus. For a description of the opinion,
see &ldquo;The Amalgamation&mdash;Opinion of ENVB&rsquo;s Financial Advisor&rdquo; beginning on page 103.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shareholders
of the combined company may experience dilution of their ownership interests due to the future issuance of additional shares of stock
of the combined company which could have an adverse effect on the price of the combined company&rsquo;s stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ENVB may in the future
issue additional shares of its stock which could result in the dilution of the ownership interests of its shareholders. Upon consummation
of the Amalgamation, ENVB will be authorized to issue 100,000,000 shares of common stock and 20,000,000 shares of preferred stock.
Upon consummation of the Amalgamation, based on currently available information (including the number of ENVB shares of common stock
and shares of MagicMed common shares outstanding as of June 15, 2021), ENVB is expected to have outstanding approximately
40.4 million shares of common stock and no shares of preferred stock. The potential issuance of additional shares of stock may
create downward pressure on the trading price of ENVB&rsquo;s stock. ENVB may also issue additional shares of its stock
in connection with the hiring or compensation of personnel or directors, future acquisitions, future issuance of its securities for capital
raising purposes or for other business purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_011"></A>Risks
Related to the Combined Company</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Successful
integration of MagicMed with ENVB and successful operation of the combined company are not assured. Also, integrating ENVB&rsquo;s business
with that of MagicMed may divert the attention of management away from operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Amalgamation is completed, AmalCo will possess all of the business and assets of MagicMed and will continue operating as a wholly
owned indirect subsidiary of ENVB. There can be no assurance that, after the Amalgamation, AmalCo will be able to maintain and grow the
acquired business and operations of MagicMed. In addition, the market segments in which MagicMed operates may experience declines in
demand and/or new competitors. Integrating and coordinating certain aspects of the operations, portfolio of products and personnel of
MagicMed with ENVB will involve complex operational, technological and personnel-related challenges. This process will be time-consuming
and expensive, may disrupt the businesses of either or both of the companies and may not result in the full benefits expected by ENVB,
including cost synergies expected to arise from supply chain efficiencies and overlapping general and administrative functions. The potential
difficulties, and resulting costs and delays, include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    a larger combined company; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidating
    corporate and administrative infrastructures; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues
    in integrating research and development and sales forces; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    attracting and retaining key personnel; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of customers and suppliers and inability to attract new customers and suppliers; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    issues in integrating information technology, communications and other systems; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incompatibility
    of purchasing, logistics, marketing, administration and other systems and processes; and </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    and unexpected liabilities related to the Amalgamation or MagicMed&rsquo;s business. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the integration of ENVB&rsquo;s and MagicMed&rsquo;s operations, products and personnel may place a significant burden on management
and other internal resources. The diversion of management&rsquo;s attention, and any difficulties encountered in the transition and integration
process, could harm the combined company&rsquo;s business, financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
combined company may not be able to adequately protect or enforce its intellectual property rights, which could harm its competitive
position.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company&rsquo;s success and future revenue growth will depend, in part, on its ability to protect its intellectual property.
The combined company will primarily rely on patent, copyright, trademark and trade secret laws, as well as nondisclosure agreements,
know-how of the scientific team, and other methods], to protect its proprietary technologies and processes. It is possible that competitors
or other unauthorized third parties may obtain, copy, use or disclose proprietary technologies and processes, despite efforts by the
combined company to protect its proprietary technologies and processes. While the combined company will hold a number of patents, there
can be no assurances that any additional patents will be issued. Even if new patents are issued, the claims allowed may not be sufficiently
broad to protect the combined company&rsquo;s technology. In addition, any of ENVB&rsquo;s or MagicMed&rsquo;s existing patents, and
any future patents issued to the combined company, may be challenged, invalidated or circumvented. As such, any rights granted under
these patents may not provide the combined company with meaningful protection. ENVB and MagicMed may not have, and in the future the
combined company may not have, foreign patents or pending applications corresponding to its U.S. patents and applications. Even if foreign
patents are granted, effective enforcement in foreign countries may not be available. If the combined company&rsquo;s patents do not
adequately protect its technology, competitors may be able to offer products similar to the combined company&rsquo;s products. The combined
company&rsquo;s competitors may also be able to develop similar technology independently or design around its patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
pro forma financial statements are presented for illustrative purposes only and may not be an indication of the combined company&rsquo;s
financial condition or results of operations following the completion of the Amalgamation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma financial statements contained in this proxy statement/prospectus are presented for illustrative purposes only and may not
be an indication of the combined company&rsquo;s financial condition or results of operations following the completion of the Amalgamation
for several reasons. The pro forma financial statements have been derived from the historical financial statements of ENVB and MagicMed
and adjustments and assumptions have been made regarding the combined company after giving effect to the Amalgamation. The information
upon which these adjustments and assumptions have been made is preliminary, and these kinds of adjustments and assumptions are difficult
to make with accuracy. Moreover, the pro forma financial statements do not reflect all costs that are expected to be incurred by the
combined company in connection with the Amalgamation. For example, the impact of any incremental costs incurred in integrating ENVB and
MagicMed are not reflected in the pro forma financial statements. As a result, the actual financial condition and results of operations
of the combined company following the completion of the Amalgamation may not be consistent with, or evident from, these pro forma financial
statements. The assumptions used in preparing the pro forma financial information may not prove to be accurate, and other factors may
affect the combined company&rsquo;s financial condition or results of operations following the Amalgamation. Any decline or potential
decline in the combined company&rsquo;s financial condition or results of operations may cause significant variations in the market price
of ENVB common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of ENVB common stock after the Amalgamation may be subject to significant fluctuations and may be affected by factors different
from those currently affecting the market price of ENVB common stock. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of the Amalgamation, MagicMed equity holders who receive shares of ENVB common stock will become ENVB stockholders. While
ENVB common stock has an observable trading history, ENVB common stock on a post-Amalgamation basis may trade differently than its pre-Amalgamation
trading history, and the market price of ENVB common stock could be subject to significant fluctuations following the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the businesses of ENVB differ from those of MagicMed in important respects and, accordingly, the results of operations
of the combined company and the market price of ENVB common stock following the Amalgamation may be affected by factors different
from those currently affecting the independent results of operations of ENVB and MagicMed. For a discussion of the business of
ENVB and of certain factors to consider in connection with ENVB&rsquo;s business, see the section titled &ldquo;ENVB&rsquo;s Business&rdquo;
beginning on page 132 of this proxy statement/prospectus. For a discussion of the business of MagicMed and of certain factors
to consider in connection with MagicMed&rsquo;s business, see the section titled &ldquo;MagicMed&rsquo;s Business&rdquo; beginning
on page 170 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Amalgamation may cause dilution to ENVB&rsquo;s earnings per share, which may negatively affect the market price of ENVB common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
ENVB anticipates that the Amalgamation will have an immediate accretive impact on the adjusted earnings per share of ENVB common stock,
ENVB&rsquo;s current expectation is based on preliminary estimates as of the date of the public announcement of the Amalgamation, which
may materially change. ENVB could also encounter additional transaction-related costs or other factors, such as the failure to realize
all of the benefits anticipated to result from the Amalgamation. In addition, ENVB expects that MagicMed equity holders immediately prior
to the Amalgamation will own, in the aggregate, approximately 36.6% of the outstanding shares of ENVB common stock upon completion
of the Amalgamation (on a fully diluted basis). Once its shares are issued in the Amalgamation, ENVB&rsquo;s earnings
per share may be lower than it would have been in the absence of the Amalgamation. All of these factors could cause dilution to ENVB&rsquo;s
earnings per share or decrease or delay the expected accretive effect of the Amalgamation and cause a decrease in the market price of
ENVB common stock. There can be no assurance that any increase in ENVB&rsquo;s earnings per share will occur, even over the long term.
Any increase in ENVB&rsquo;s earnings per share as a result of the Amalgamation is likely to require, among other things, ENVB to successfully
manage the operations of MagicMed and increase the consolidated earnings of ENVB after the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Once
ENVB is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, ENVB will be subject to additional
laws and regulations affecting public companies that will increase ENVB&rsquo;s costs and the demands on management and could harm ENVB&rsquo;s
operating results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
is subject to the reporting requirements of the Exchange Act, which requires, among other things, that ENVB file with the SEC, annual,
quarterly and current reports with respect to ENVB&rsquo;s business and financial condition as well as other disclosure and corporate
governance requirements. However, as a &ldquo;smaller reporting company&rdquo; ENVB may take advantage of certain exemptions from disclosure
requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act
and reduced disclosure obligations regarding executive compensation in ENVB&rsquo;s periodic reports and proxy statements. Once ENVB
is no longer a smaller reporting company or otherwise qualifies for these exemptions, ENVB will be required to comply with these additional
legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do
so. If ENVB is not able to comply with the requirements in a timely manner or at all, ENVB&rsquo;s financial condition or the market
price of ENVB&rsquo;s common stock may be harmed. For example, if ENVB or its independent auditor identifies deficiencies in the ENVB&rsquo;s,
including the combined company, internal control over financial reporting that are deemed to be material weaknesses ENVB could face additional
costs to remedy those deficiencies, the market price of ENVB&rsquo;s stock could decline or ENVB could be subject to sanctions or investigations
by the SEC or other regulatory authorities, which would require additional financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_012"></A>Risks
Related to ENVB&rsquo;s Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are dependent on the success of our prospective product candidates, which are in early stages of development, and there can be no assurances
that any such prospects will reach a particular stage in development, receive regulatory approval or be successfully commercialized.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend on our ability to successfully develop and commercialize our prospective product candidates through our development
programs. We intend to develop at least three product candidates by undergoing the long, costly clinical-trial process for each candidate
under an Investigational New Drug Application (&ldquo;IND&rdquo;) and, eventually, obtaining FDA approval under a New Drug Application
(&ldquo;NDA&rdquo;) before proceeding to market. In order to proceed with development of our pharmaceutical product candidates under
the NDA pathway, we must obtain the FDA&rsquo;s approval of our IND application and conduct preclinical and clinical trials in compliance
with the applicable IND regulations, clinical-study protocols, and other applicable regulations and related requirements. We may never
be able to develop products which are commercially viable or receive regulatory approval in the U.S. or elsewhere. There can be no assurance
that the FDA or any other regulatory authority will approve of our current or future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or &ldquo;FDCA,&rdquo; and implementing regulations.
Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and
the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. The process required by the FDA before a new drug or biological product may be marketed in the United States
generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of preclinical laboratory tests, animal studies, and formulation studies according to Good Laboratory Practices and other applicable
    regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
    to the FDA of an IND, which must become effective before human clinical trials may begin in the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    of adequate and well-controlled human clinical trials according to the FDA&rsquo;s current good clinical practices, or GCPs, which
    sufficiently demonstrate the safety and efficacy of the proposed drug or biologic for its intended uses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
    to the FDA of a New Drug Application, or an NDA, for a new drug product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess
    compliance with the FDA&rsquo;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and
    controls are adequate to preserve the drug&rsquo;s or biologic&rsquo;s identity, strength, quality and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or biologics license application;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and, potentially, approval of the NDA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require
the expenditure of substantial resources. There can be no certainty that approvals will be granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may encounter difficulties that may delay, suspend or scale back our efforts to advance additional early research programs through preclinical
development and IND application filings and into clinical development.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to advance early research programs through preclinical development and to file an IND application for human clinical trials evaluating
the prospective product candidates in our pipeline. The preparation and submission of IND applications requires rigorous and time-consuming
preclinical testing, the results of which must be sufficiently documented to establish, among other things, the toxicity, safety, manufacturing,
chemistry and clinical protocol of the product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent
us from successfully executing our current development strategy. In addition, our ability to complete and file certain IND applications
may depend on the support of our partners and the timely performance of their obligations under relevant collaboration agreements. If
our relevant partners are not able to perform such obligations, or if they otherwise delay the progress, we may not be able to prepare
and file the intended IND applications on a timely basis or at all. Any delay, suspension or reduction of our efforts to pursue our preclinical
and IND strategy could have a material adverse effect on our business and cause our share price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
novel coronavirus could adversely impact our business, including our current plans for product development, as well as any currently
ongoing preclinical studies and clinical trials and any future studies or other development or commercialization activities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
COVID-19 was initially reported to have surfaced in Wuhan, China in December 2019, it has spread globally, including countries in which
we are currently, or plans to, conduct preclinical or clinical studies or other development activities. There is significant uncertainty
as to the likely effects of this pandemic. As the ongoing COVID-19 pandemic continues, we will likely experience disruptions that could
severely impact our business, including, but not limited to, our current or future preclinical studies, clinical trials, regulatory progress,
or any other development or commercialization activities, including (among others):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrolling patients in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial
    sites and hospital staff supporting the conduct of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by
    federal or state governments, employers and others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees
    or their families or the desire of employees to avoid contact with large groups of people;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in receiving approval from local regulatory authorities to initiate our planned clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical
    trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in local regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical
    trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations
    in employee resources or forced furlough of government employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in the timing of interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention
    to approval of other therapeutics or other activities related to COVID-19; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to accept data from clinical trials in affected geographies outside the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the COVID-19 pandemic could disrupt our operations due to absenteeism by infected or ill members of management or other employees,
or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in our
office or laboratory facilities, or due to quarantines. COVID-19 could also impact members of our board of directors, resulting in absenteeism
from meetings of the directors or committees of directors, and making it more difficult to convene the quorums of the full board of directors
or our committees needed to conduct meetings for the management of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global COVID-19 pandemic continues to rapidly evolve. The extent to which COVID-19 may impact our business, preclinical studies and clinical
trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic
spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries,
business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain
and treat the disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have significant and increasing liquidity needs and may require additional funding.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development, management and administrative expenses and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new and continued research and development initiatives and our pursuit of IND authorization(s)
for some or all of our product candidates, as is required to initiate clinical trials in human subjects in the United States. We will
need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications, and to fund commercialization of our current and future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, number, initiation, progress, timing, costs, design, duration, delays (if any), and results of preclinical and clinical studies
    for our current or future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA,
    and comparable foreign regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and amount of revenue generated or received, including any revenue from grants or other sources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of progress and cost of our clinical trials and other product development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our current
    and future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel,
    facilities and equipment requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any additional collaborative, licensing, co-promotion or other arrangements that we may establish.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we expect to fund our future capital requirements from financing arrangements, we cannot assure you that any such financing arrangements
will be available to it on favorable terms, or at all. Further, even if we can raise funds from financing arrangements, the amounts raised
may not be sufficient to meet our future capital requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend on our current key personnel and our ability to attract and retain employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future growth and success depends on our ability to recruit, retain, manage and motivate our employees. We are highly dependent on our
current management and scientific personnel, including David Johnson, Avani Kanubaddi, and Dr. Robert Wilkins. The inability to hire
or retain experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results.
Due to the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified
scientific, technical and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense and we
may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
has been limited study on the effects of medical cannabinoids, and future clinical research studies may lead to conclusions that dispute
or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing, and social acceptance
of cannabinoids.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
relating to the medical benefits, viability, safety, efficacy, and dosing of cannabinoids remains in relatively early stages. There have
been few clinical trials on the benefits of cannabinoids conducted by us or by others. Future research and clinical trials may draw opposing
conclusions to statements contained in the articles, reports and studies We have relied on, or could reach different or negative conclusions
regarding the medical benefits, viability, safety, efficacy, dosing or other facts and perceptions related to cannabinoids, which could
adversely affect social acceptance of cannabinoids and the demand for our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Political,
economic, and military instability in Israel may impede our development programs, which could have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to conduct a clinical cancer study consisting of a Phase 1/2 study in Israel of oral synthetic CBD extract, given alone or in combination
with clomiphene concurrently with dose-dense temolozomide chemotherapy for patients with recurrent or progressive GBM, designed as an
open label, two-arm, randomized prospective study. We are currently waiting on primary approval from the Israeli Ministry of Health,
Center for Cannabis (Yakar) to proceed with such study. Since the establishment of the State of Israel in 1948, a number of armed conflicts
have taken place between Israel and its neighboring countries. In May 2021, hostilities between Israel and Hamas escalated and there
has been cross-border attacks in Israel and Gaza, including rocket attacks targeting Tel Aviv, where some of our key partners for the
planned GBM study are located. The ongoing conflict and any hostilities involving Israel or political, economic, and military conditions
in Israel and the surrounding region may directly affect our ability to obtain approvals needed for our GBM study and cause interruptions
or delays in conducting such study or future studies we may conduct in Israel for an indeterminate time. Any armed conflicts, terrorist
activities, or political instability in the region could impeded our development programs, which could have a material adverse effect
on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to face intense competition, often from companies with greater resources and experience than us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is highly competitive and subject to rapid change. The industry continues to expand and evolve as an increasing
number of competitors and potential competitors enter the market. Many of these competitors and potential competitors have substantially
greater financial, technological, managerial and research and development resources and experience than us. Some of these competitors
and potential competitors have more experience than us in the development of pharmaceutical products, including validation procedures
and regulatory matters. In addition, our future product candidates, if successfully developed, will compete with product offerings from
large and well-established companies that have greater marketing and sales experience and capabilities than us or our collaboration partners
have. Other companies with greater resources than we may announce similar plans in the future. In addition, there are other non-FDA approved
CBD preparations being made available from other companies, which might attempt to compete with our future product candidates. If we
are unable to compete successfully, our commercial opportunities will be reduced and our business, results of operations and financial
conditions may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current and future preclinical and clinical studies may be conducted outside the United States, and the FDA may not accept data from
such studies to support any NDAs we may submit after completing the applicable developmental and regulatory prerequisites.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting, or may conduct, preclinical and/or clinical studies outside the United States. For example, we have conducted preclinical
studies in Israel, and plan to conduct clinical studies for one or more product candidates in Israel or other non-U.S. countries. To
the extent we do not conduct these clinical trials under an IND, the FDA may not accept data from such trials. Although the FDA may accept
data from clinical trials conducted outside the United States that are not conducted under an IND, the FDA&rsquo;s acceptance of these
data is subject to certain conditions. For example, the clinical trial must be well designed and conducted and performed by qualified
investigators in accordance with ethical principles and all applicable FDA regulations. The trial population must also adequately represent
the intended U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems
clinically meaningful. In general, the patient population for any clinical trials conducted outside of the United States must be representative
of the population for whom we intend to market the product candidate in the United States, if approved. In addition, while these clinical
trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon our ability to verify the data and
our determination that the trials also complied with all applicable U.S. laws and regulations. We cannot guarantee that the FDA will
accept data from trials conducted outside of the United States. If the FDA does not accept the data from such clinical trials, we would
likely result in the need for additional trials and the completion of additional regulatory steps, which would be costly and time-consuming
and could delay or permanently halt our development of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
the results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, we may not have favorable
results in our planned and future clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
development of therapeutic products is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Product
candidates that appear promising in the early phases of development may fail to reach the market for several reasons including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    study results that may show the product to be less effective than desired (e.g., the study failed to meet our primary objectives)
    or to have harmful or problematic side effects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused
    by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis
    or an IND and later NDA, preparation, discussions with the FDA, an FDA request for additional preclinical or clinical data or unexpected
    safety or manufacturing issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    costs, pricing, or reimbursement issues or other factors that make the product not economical; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proprietary rights of others and their competing products and technologies that may prevent the product from being commercialized.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
positive results from our preclinical testing of our prospective product candidates may not necessarily be predictive of the results
from planned or future clinical trials for such product candidates. Many companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in clinical trials after achieving positive results in preclinical and early clinical development,
and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical
findings while clinical trials were underway or safety or efficacy observations in clinical trials, including adverse events. Moreover,
our interpretation of clinical data or our conclusions based on the preclinical in vitro and in vivo models may prove inaccurate, as
preclinical and clinical data can be susceptible to varying interpretations and analyses, and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory approvals.
If we fail to produce positive results in our planned clinical trial for our product candidates for the treatment of GBM, or our future
clinical trials, the development timeline and regulatory approval and commercialization prospects for such product candidates, and, correspondingly,
our business and financial prospects, would be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business
interruptions could delay us in the process of developing our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
of our stored materials or facilities through fire, theft, or other causes could have an adverse effect on our ability to continue product
development activities and to conduct our business. Even if we obtain insurance coverage to compensate us for such business interruptions,
such coverage may prove insufficient to fully compensate us for the damage to our business resulting from any significant property or
casualty loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and legal requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA, SEC or Office of Inspector General regulations, or regulations of any other applicable regulatory authority, failure to provide
accurate information to the FDA or the SEC, comply with applicable manufacturing standards, other federal, state or foreign laws and
regulations, report information or data accurately or disclose unauthorized activities. Employee misconduct could also involve the improper
use of confidential or protected information, including information obtained in the course of clinical trials, or illegal pre-approval
promotion of drug candidates, which could result in government investigations, enforcement actions and serious harm to our reputation.
We have adopted a Corporate Code of Conduct and Ethics and Whistleblower Policy, but employee misconduct is not always possible to identify
and deter. The precautions we take to detect and prevent these prohibited activities may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending our Company or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our future customers, suppliers and business partners,
and personally identifiable information of our customers, clinical trial subjects and employees, patients, in our data centers and on
our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security
measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance
or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed,
lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under
laws that protect the privacy of personal information, regulatory penalties, disrupt our operations, damage our reputation, and cause
a loss of confidence in our products and our ability to conduct clinical trials, which could adversely affect our business and reputation
and lead to delays in gaining regulatory approvals for our future product candidates. Although we may obtain business interruption insurance
coverage in the future, our insurance might not cover all losses from any future breaches of our systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
the operation of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on the use of information technologies. Our ability to execute our business plan and to comply with regulators&rsquo;
requirements with respect to data control and data integrity, depends, in part, on the uninterrupted performance of our information technology
systems, or IT systems and the IT systems supplied by third-party service providers. Our IT systems are vulnerable to damage from a variety
of sources, including telecommunications or network failures, malicious human acts, natural disasters and more sophisticated and targeted
cyber-related attacks that pose a risk to the security of our information systems and networks and the confidentiality, availability
and integrity of data and information. A successful cybersecurity attack or other data security incident could result in the misappropriation
and/or loss of confidential or personal information, create system interruptions, or deploy malicious software that attacks our systems.
It is also possible that a cybersecurity attack might not be noticed for some period of time. In addition, sustained or repeated system
failures or problems arising during the upgrade of any of our IT systems that interrupt our ability to generate and maintain data could
adversely affect our ability to operate our business. The occurrence of a cybersecurity attack or incident could result in business interruptions
from the disruption of our IT systems, or negative publicity resulting in reputational damage with our shareholders and other stakeholders
and/or increased costs to prevent, respond to or mitigate cybersecurity events. In addition, the unauthorized dissemination of sensitive
personal information or proprietary or confidential information could expose us or other third-parties to regulatory fines or penalties,
litigation and potential liability, or otherwise harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Security
breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent it from accessing
critical information or expose it to liability, which could adversely affect our business and its reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to collect and store sensitive data, including legally protected patient health information,
credit card information, personally identifiable information about our employees, intellectual property, and proprietary business information.
We expect to manage and maintain its applications and data utilizing on-site systems. These applications and data encompass a wide variety
of business-critical information including research and development information, commercial information and business and financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy,
and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized
access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches or
interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any
such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties,
publicly disclosed, lost or stolen. In the future, any such access, disclosure or other loss of information could result in legal claims
or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability
Act and European Union General Data Protection Regulation, government enforcement actions and regulatory penalties. Unauthorized access,
loss or dissemination could also disrupt our operations, including our ability to process samples, provide test results, share and monitor
safety data, bill payors or patients, provide customer support services, conduct research and development activities, process and prepare
company financial information, manage various general and administrative aspects of our business and may damage our reputation, any of
which could adversely affect our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
operating results may vary significantly in future periods.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the early stages of product development and expects to focus substantial efforts for, at least, the next several years on preclinical
and clinical trials and other research and development activities. We have not obtained regulatory approval for any product candidates.
Our revenues, expenses and operating results are likely to fluctuate significantly in the future. We expect to incur substantial additional
operating expenses over the next several years as our research, development, and preclinical and clinical study activities increase.
Our financial results are unpredictable and may fluctuate, for among other reasons, due to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, number, progress, duration, endpoints, cost, results, and timing of our preclinical testing and clinical studies of current
    or potential future product candidates</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funding to develop product candidates; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrollment and timing of clinical studies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_013"></A>Risks
Related to Regulatory Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
prospective products will be subject to the various federal and state laws and regulations relating to health and safety.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of developing investigational new drugs for which we intend to pursue FDA approval via the New Drug Application (&ldquo;NDA&rdquo;)
process. In these product candidates, cannabinoid(s) will be the active pharmaceutical ingredient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our development and future commercialization (if applicable) of the above-described prospective products, we and each
contemplated product candidate are subject to the Federal Food Drug and Cosmetic Act (FDCA). The FDCA is intended to assure the consumer,
in part, that drugs and devices are safe and effective for their intended uses and that all labeling and packaging is truthful, informative,
and not deceptive. The FDCA and FDA regulations define the term &ldquo;drug,&rdquo; in part, by reference to its intended use, as &ldquo;articles
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease&rdquo; and &ldquo;articles (other than food)
intended to affect the structure or any function of the body of man or other animals.&rdquo; Therefore, almost any ingested or topical
or injectable product that, through its label or labeling (including internet websites, promotional pamphlets, and other marketing material),
that is claimed to be beneficial for such uses will be regulated by FDA as a drug. The definition also includes components of drugs,
such as active pharmaceutical ingredients. Drugs must generally either receive premarket approval by FDA through the NDA process or conform
to a &ldquo;monograph&rdquo; for a particular drug category, as established by FDA&rsquo;s Over-the-Counter (OTC) Drug Review. If the
FDA does not award premarket approval for our product candidates through the NDA process, this could have a material adverse effect on
our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials are expensive, time-consuming, uncertain and susceptible to change, delay or termination. The results of clinical trials are open
to differing interpretations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two potential product candidates that are in preclinical development as an investigational combination therapy for GBM
and other forms of cancer and intends to pursue preclinical and clinical development for other prospective candidates as well, including,
but not limited to, a candidate targeting radiodermatitis. After completing the requisite preclinical testing, IND submission, internal
review board (&ldquo;IRB&rdquo;) review, and any other applicable early-development obligations, we must conduct extensive clinical trials
to demonstrate the safety and efficacy of the product candidates. Clinical testing is expensive, time consuming, and uncertain as to
outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. Failures in connection
with one or more clinical trials can occur at any stage of testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
agencies may analyze or interpret the results of clinical trials differently than us. Even if the results of our clinical trials are
favorable, the clinical trials for a number of our product candidates are expected to continue for several years and may take significantly
longer to complete. Events that may prevent successful or timely completion of clinical development include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory authorities on trial design;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective contract research organization (&ldquo;CRO&rdquo;) and clinical trial
    sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or perceived lack of effectiveness of any product candidate during clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects for the entire duration of applicable clinical studies (as study subjects may withdraw at any time due to adverse
    side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process or for any other reason;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or product candidate formulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory authorization s, such as INDs and any others that must be obtained, maintained, and/or satisfied to commence
    a clinical trial, including &ldquo;clinical holds&rdquo; or delays requiring suspension or termination of a trial by a regulatory
    agency, such as the FDA, before or after a trial is commenced;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature or timing of studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper dosing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    results from ongoing pre-clinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our CROs, or other third-party contractors to comply with all contractual requirements or to perform their services in a timely
    or acceptable manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees to comply with all applicable FDA or other regulatory requirements relating to
    the conduct of clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    concerns with cannabinoid products, generally, and the potential for abuse;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
failure by us to comply with existing regulations could harm our reputation and operating results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by U.S. federal and state and foreign governments in each of the U.S., European and Canadian markets,
in which we plan to sell our product candidates. We must adhere to all regulatory requirements, including FDA&rsquo;s Good Laboratory
Practice (&ldquo;GLP&rdquo;), GCP, and GMP requirements, pharmacovigilance requirements, advertising and promotion restrictions, reporting
and recordkeeping requirements, and their European equivalents. If we or our suppliers fail to comply with applicable regulations, including
FDA pre-or post-approval requirements, then the FDA or other foreign regulatory authorities could sanction our Company. Even if a drug
is approved by the FDA or other competent authorities, regulatory authorities may impose significant restrictions on a product&rsquo;s
indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing trials. Any of our product candidates
which may be approved in the U.S. will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage,
distribution, import, export, advertising, promotion, sampling, recordkeeping and submission of safety and other post-market information,
including both federal and state requirements. In addition, manufacturers and manufacturers&rsquo; facilities are required to comply
with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to GMP. As such, we and
our contract manufacturers (in the event contract manufacturers are appointed in the future) are subject to continual review and periodic
inspections to assess compliance with GMP. Accordingly, we and others with whom we work will have to spend time, money and effort in
all areas of regulatory compliance, including manufacturing, production, quality control and quality assurance. We will also be required
to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising
and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory
restrictions and must be consistent with the information in the product&rsquo;s approved label. Similar restrictions and requirements
exist in the European Union and other markets where we operate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of the product,
it may impose restrictions on that product or on us, including requiring withdrawal of the product from the market. If we fail to comply
with applicable regulatory requirements, a regulatory agency or enforcement authority may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    civil or criminal penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any of our ongoing clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications submitted by us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including by requiring us to enter in to a Corporate Integrity Agreement or closing our contract
    manufacturers&rsquo; facilities, if any; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products or require a product recall.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to federal, state and foreign healthcare laws and regulations and implementation of or changes to such healthcare laws
and regulations could adversely affect our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we successfully complete the requisite preclinical and clinical testing, make the required regulatory submissions and obtain any corresponding
authorizations or licenses (as applicable), fulfill all other applicable development-related regulatory obligations, and, eventually,
obtain FDA approval to market one or more of our current or future product candidates in the United States, we may be subject to certain
healthcare laws and regulations. In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory
proposals to change the healthcare system in ways that could impact our ability to sell our future product candidates. If we are found
to be in violation of any of these laws or any other federal, state or foreign regulations, we may be subject to administrative, civil
and/or criminal penalties, damages, fines, individual imprisonment, exclusion from federal health care programs and the restructuring
of our operations. Any of these could have a material adverse effect on our business and financial results. Since many of these laws
have not been fully interpreted by the courts, there is an increased risk that we may be found in violation of one or more of their provisions.
Any action against us for violation of these laws, even if we are ultimately successful in our defense, will cause us to incur significant
legal expenses and divert our management&rsquo;s attention away from the operation of our business. In addition, in many foreign countries,
particularly the countries of the European Union, the pricing of prescription drugs is subject to government control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. For example, some European Union jurisdictions operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate
to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company
profits. Such differences in national pricing regimes may create price differentials between European Union member states. There can
be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price
structures of the U.S. In the European Union, the downward pressure on healthcare costs in general, particularly prescription medicines,
has become intense. As a result, barriers to entry of new products are becoming increasingly high and patients are unlikely to use a
drug product that is not reimbursed by their government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition,
the importation of foreign products may compete with any future product that we may market, which could negatively impact our profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically
in the U.S., we expect that the 2010 Affordable Care Act (&ldquo;ACA&rdquo;), as well as other healthcare reform measures that may be
adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive
for any approved product. There have been judicial challenges to certain aspects of the ACA and numerous legislative attempts to repeal
and/or replace the ACA in whole or in part, and we expect there will be additional challenges and amendments to the ACA in the future.
At this time, the full effect that the ACA will have on our business in the future remains unclear. An expansion in the government&rsquo;s
role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription drug products, lower reimbursements
or any other product for which we obtain regulatory approval, reduce product utilization and adversely affect our business and results
of operations. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability, or commercialize any of our future product candidates for which we may receive regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is a high rate of failure for drug candidates proceeding through clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products on the market, and our new potential cannabinoid-based drug product candidates are currently either in preclinical development
or the research and discovery phase. Accordingly, none of our prospective products or investigational candidates have ever been tested
in a human subject. Our ability to achieve and sustain profitability with respect to our product candidates in which cannabinoids are
featured as the active pharmaceutical ingredient depends on obtaining regulatory approvals for and, if approved, successfully commercializing
our product candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our
product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate
the safety, purity and potency of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
there is a high rate of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical
trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving
promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, the FDA or other regulatory
authorities may disagree with our interpretation of the data. In the event that we obtain negative results from clinical trials for product
candidates or other problems related to potential chemistry, manufacturing and control issues or other hurdles occur and our future product
candidates are not approved, we may not be able to generate sufficient revenue or obtain financing to continue our operations, our ability
to execute on our current business plan may be materially impaired, and our reputation in the industry and in the investment community
might be significantly damaged. In addition, our inability to properly design, commence and complete clinical trials may negatively impact
the timing and results of our clinical trials and ability to seek approvals for our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing, marketing and manufacturing of any new drug product for use in the United States will require approval from the FDA. We cannot
predict with any certainty the amount of time necessary to obtain such FDA approval and whether any such approval will ultimately be
granted. Preclinical and clinical trials may reveal that one or more products are ineffective or unsafe, in which event further development
of such products could be seriously delayed or terminated. Moreover, obtaining approval for certain products may require testing on human
subjects of substances whose effects on humans are not fully understood or documented. Delays in obtaining FDA or any other necessary
regulatory approvals of any proposed drug and failure to receive such approvals would have an adverse effect on the drug&rsquo;s potential
commercial success and on our business, prospects, financial condition and results of operations. In addition, it is possible that a
proposed drug may be found to be ineffective or unsafe due to conditions or facts that arise after development has been completed and
regulatory approvals have been obtained. In this event, we may be required to withdraw such proposed drug from the market. To the extent
that our success will depend on any regulatory approvals from government authorities outside of the United States that perform roles
similar to that of the FDA, uncertainties similar to those stated above will also exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Serious
adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our prospective
products or current or future product candidates, limit the scope of any approved label or market acceptance, or cause the recall or
loss of marketing approval of products that are already marketed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our prospective products or current or future product candidates, prior to or after any approval for commercial sale, cause serious
or unexpected side effects, or are associated with other safety risks such as misuse, abuse or diversion, a number of potentially significant
negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may interrupt, delay or halt clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may deny regulatory approval of our future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for
    use, and/or impose restrictions on distribution in the form of a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) in
    connection with approval or post-approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval, require more onerous labeling statements, impose a more restrictive REMS, or require it
    to recall any product that is approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered or conduct additional clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with our collaboration partners may suffer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer. The reputational risk is heightened with respect to those of our future product candidates that are being
    developed for pediatric indications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may voluntarily suspend or terminate our clinical trials if at any time we believe that the product candidates present an unacceptable
risk to participants, or if preliminary data demonstrates that our future product candidates are unlikely to receive regulatory approval
or unlikely to be successfully commercialized.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completing preclinical testing and obtaining the requisite regulatory authorizations, as applicable, we may voluntarily suspend or terminate
our clinical trials for any number of reasons, including if we believe that a product&rsquo;s use, or a person&rsquo;s exposure to it,
may cause adverse health consequences or death. In addition, regulatory agencies, IRBs or data safety monitoring boards may at any time
recommend the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical
trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, or that
they present an unacceptable safety risk to participants. Although we have never been asked by a regulatory agency, IRB or data safety
monitoring board to temporarily or permanently discontinue a clinical trial, if we elect or are forced to suspend or terminate a clinical
trial of any of our future product candidates, the commercial prospects for that product will be harmed and our ability to generate product
revenue from that product may be delayed or eliminated. Furthermore, any of these events may result in labeling statements such as warnings
or contraindications. In addition, such events or labeling could prevent us or our partners from achieving or maintaining market acceptance
of the affected product and could substantially increase the costs of commercializing our future product candidates and impair our ability
to generate revenue from the commercialization of these products either by us or by our collaboration partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
success of our prospective product candidates and future approved products, if any, especially those containing hemp-derived CBD, is
subject to a number of constantly-evolving state and federal laws, regulations, and enforcement policies pertaining to hemp-derived CBD
and/or cannabis more generally.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agriculture Improvement Act of 2018, or the &ldquo;2018 Farm Bill,&rdquo; was signed into law on December 20, 2018. This 2018 Farm Bill
expressly excluded &ldquo;hemp&rdquo; from the federal Controlled Substances Act of 1970 and the Controlled Substances Import and Export
Act&rsquo;s, as amended (the &ldquo;CSA&rdquo;)&rsquo;s definition of marijuana and, accordingly, declassified substances derived from
or containing any part(s) of the cannabis plant containing not more than 0.3% THC on a dry-weight basis from Schedule I. In effect, the
2018 Farm Bill legalized the cultivation and commercial sale of hemp in the United States, subject to applicable state laws and regulations
and applicable FDCA provisions, including any implementing regulations, as interpreted and enforced by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local,
state, federal, and international hemp and CBD laws and regulations are broad in scope and subject to evolving interpretations, which
could require us to incur substantial costs associated with compliance requirements. In addition, violations of these laws, or allegations
of such violations, could disrupt our business and result in a material adverse effect on our operations. In addition, it is possible
that regulations may be enacted in the future that will be directly applicable to our proposed business regarding cannabinoid production.
It is also possible that the federal government will begin strictly enforcing existing laws, which may limit the legal uses of the hemp
plant and its derivatives and extracts, such as cannabinoids. we cannot predict the nature of any future laws, regulations, interpretations,
or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when
and if promulgated, could have on our activities in the cannabis industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the 2018 Farm Bill did not alter the FDA&rsquo;s authority to regulate products containing cannabis or cannabis-derived compounds,
including cannabinoids, under the FDCA. Hemp products, including cannabinoids, that qualify as drugs, food, dietary supplements, veterinary
products, and cosmetics, for example, are subject to regulation by the FDA. Following passage of the 2018 Farm Bill, the FDA reaffirmed
its enforcement authority and reiterated the requirement that a product containing CBD or other cannabinoid(s) (hemp-derived or otherwise)
that is marketed with a claim of therapeutic benefit implicitly or explicitly attributed to, or based on, the presence of the cannabinoid
as an ingredient, or any other health/medical claim, must be approved by the FDA for its intended use(s) before it may be introduced
into interstate commerce. Our prospective product candidates are currently intended for development under an IND and, eventually, approval
under an NDA, which will mean that, if approved, we can market such products with claims about their proven medical benefits for the
applicable indications for use to the extent consistent with the product&rsquo;s NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we believe that the 2018 Farm Bill and analogous state legislation has reduced the amount of DEA oversight of hemp-derived cannabinoids,
this is a rapidly evolving area of U.S. law and substantial uncertainty remains as to the future of federal and state regulation of cannabinoid
products. In addition, the FDA has approved only one natural cannabis-based drug product, which contains only hemp-derived CBD. There
can be no assurance that our product candidates containing cannabinoids (as the active drug ingredient(s)) will be similarly approved
for commercialization in the United States at any time in the near or distant future. Any regulations the FDA issues relating to the
sale, marketing, and/or other activities involving cannabinoid or certain cannabinoid-containing products could have a material adverse
effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the uncertainty surrounding future state regulations and the continuing barriers that still exist for cannabinoids in certain product
categories due to FDA regulation, it is unknown what impact the removal of hemp from the CSA, and any resulting commercialization of
hemp products, may have on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Costs
associated with compliance with numerous laws and regulations could impact our financial results. In addition, we could become subject
to increased enforcement and/or litigation risks associated with the CBD industry.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture, labeling and distribution of products containing CBD or other cannabinoids is governed by various federal, state and local
agencies. To the extent we are able to successfully commercialize any of our currently contemplated product candidates via the FDA&rsquo;s
NDA approval pathway, the presence of cannabinoids as active or inactive ingredients, as applicable, may give rise to heightened regulatory
scrutiny and greater risk of consumer litigation, either of which could further restrict the permissible scope of our marketing claims
about such products or our ability to sell them in the United States at all. The shifting compliance environment and the need to build
and maintain robust systems to comply with different hemp or CBD-related regulations in jurisdictions may increase costs and/or the risk
that we may violate one or more applicable regulatory requirements. If our operations, or any of our activities or prospective products,
are found to be in violation of any such laws or any other governmental regulations that apply to the manufacture, distribution, or sale
of prescription drug products, generally, and to products containing hemp or CBD, we may be subject to penalties, including, without
limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, any of which could adversely
affect our ability to operate our business or our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with any applicable FDA requirements, relating to CBD or otherwise, may result in, among other things, injunctions, product
withdrawals, recalls, product seizures, fines and criminal prosecutions. Our advertising is also subject to regulation by the FTC under
the Federal Trade Commission Act. Additionally, analogous state advertising and labeling laws are often enforced by state attorneys general,
and any state or federal enforcement action based on potentially misleading or deceptive advertising is often followed by costly class-action
complaints under state consumer-protection laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, on its own and in collaboration with the FTC, has issued numerous warning letters to companies offering for sale of topical, oral,
and other types of products containing CBD, which were not approved under the FDA&rsquo;s NDA process, in response to their making unsubstantiated
claims on product webpages, online stores, and social media websites about the products&rsquo; purported therapeutic or other drug-like
benefits in connection with CBD or other cannabinoids. The FDA deemed that companies &ldquo;used these online platforms to make unfounded,
egregious claims about their products&rsquo; ability to limit, treat or cure cancer, neurodegenerative conditions, autoimmune diseases,
opioid use disorder, and other serious diseases, without sufficient evidence and the legally required FDA approval.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agency has continuously demonstrated its commitment to taking action against companies making medical claims about products containing
CBD (as the active ingredient), as selling unapproved products with unsubstantiated therapeutic claims can put patients and consumers
at risk. The FDA does not believe CBD has been shown to be safe and effective for any therapeutic use, except as used in Epidiolex, the
only new drug containing CBD that has been approved by FDA under the NDA process, which was approved for the treatment of seizures associated
with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. The agency&rsquo;s principal concern with CBD products
on the market that are unlawfully claiming to treat serious medical conditions is that deceptive marketing of unproven treatments may
keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases. Additionally, because they
are not evaluated by the FDA, there may be other ingredients that are not disclosed, which may be harmful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has pledged to continue to monitor the marketplace and take enforcement action as-needed to protect the public against companies
illegally selling products containing CBD as the active ingredient, claiming to prevent, diagnose, treat, or cure serious diseases, such
as cancer, Alzheimer&rsquo;s disease, psychiatric disorders and diabetes; illegally selling cannabis and cannabis-derived products that
can put consumers at risk; and marketing and distributing such products in violation of the FDA&rsquo;s authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Negative
public perception of hemp and cannabinoid-related businesses, misconceptions about the nature of our business and regulatory uncertainties
could have a material adverse effect on our business, financial condition, and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the cannabinoid industry is highly dependent upon consumer perception regarding the safety, efficacy, quality, and legality of
cannabinoid, whether derived from hemp or marijuana. Consumer perception of cannabinoid products can be significantly influenced by scientific
research or findings, regulatory investigations, litigation, media attention, and other publicity regarding the consumption of cannabinoid
products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention, or
other research findings or publicity will be favorable to the cannabinoid market or any particular product, or consistent with earlier
publicity. Our dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings,
litigation, media attention, or other publicity relating to cannabinoid products, generally or any particular cannabinoid products or
derivatives, in particular, regardless of merit or accuracy, could have a material adverse effect on our business, the demand for our
product candidates or any products for which we obtain regulatory approval in the future. Such adverse publicity or other negative media
attention could arise even if the adverse effects reportedly associated with such products resulted from consumers&rsquo; failure to
consume such products appropriately or as directed. Any adverse publicity or other similar occurrences affecting consumer perception
may have a material adverse impact on our reputation, perception of our product candidates, our ability to obtain the necessary regulatory
approvals for our product candidates, and the commercial viability of the products for which regulatory approval is obtained in the future,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management will be required to devote a substantial time to comply with public company regulations</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;), the Dodd-Frank Wall Street Reform and Consumer Protection Act as well as rules implemented
by the SEC and Nasdaq, impose various requirements on public companies, including those related to corporate governance practices. Our
management and other personnel must devote a substantial amount of time to these requirements. Moreover, these rules and regulations
increase our legal and financial compliance costs and make some activities more time consuming and costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure
controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial
reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section
404 of the Sarbanes-Oxley Act. Our compliance with these requirements will require that we incur substantial accounting and related expenses
and expend significant management efforts. We will likely need to hire additional accounting and financial staff to satisfy the ongoing
requirements of Section 404 of the Sarbanes-Oxley Act. The costs of hiring such staff may be material and there can be no assurance that
such staff will be immediately available to us. Moreover, if we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley
Act, or if we identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, investors
could lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline and
we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which could require additional
financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have identified a material weakness in our internal control over financial reporting. If we are unable to remediate the material weakness,
or if we experience additional material weaknesses in the future, our business may be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and
reporting on the effectiveness of our system of internal control. Internal control over financial reporting is a process used to provide
reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external
purposes in accordance with generally accepted accounting principles in the United States. As a public company, we are required to comply
with the Sarbanes-Oxley Act and other rules that govern public companies. In particular, we are required to certify our compliance with
Section 404 of the Sarbanes-Oxley Act, which requires us to furnish annually a report by management on the effectiveness of our internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management performed an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2020 and
concluded our internal control over financial reporting was not effective as of December 31, 2020 due to the material weakness related
to segregation of duties. Specifically, due to the small size of our Company, we do not maintain sufficient segregation of duties to
ensure the processing, review and authorization of all transactions including non-routine transactions. We are in the process of remediating
our material weaknesses and designing an effective internal control environment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remediation
efforts place a significant burden on management and add increased pressure to our financial resources and processes. If we are unable
to successfully remediate our existing material weakness or any additional material weaknesses in our internal control over financial
reporting that may be identified in the future in a timely manner, the accuracy and timing of our financial reporting may be adversely
affected; our liquidity, our access to capital markets, the perceptions of our creditworthiness may be adversely affected; we may be
unable to maintain or regain compliance with applicable securities laws, the listing requirements of the Nasdaq Stock Market; we may
be subject to regulatory investigations and penalties; investors may lose confidence in our financial reporting; our reputation may be
harmed; and our stock price may decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_014"></A>Risks
Related to ENVB&rsquo;s Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to adequately protect or enforce our intellectual property rights, which could harm our competitive position</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently hold full or limited rights to several patents as an in-licensee covering the use of CBD including with current cancer treatments,
both broadly, as well as for specific cancer types. Our success will depend, in part, on our ability to obtain additional patents, protect
our trade secrets and operate without infringing on the proprietary rights of others. We rely upon a combination of patents, trade secret
protection (i.e., know-how), and confidentiality agreements to protect the intellectual property of our future product candidates. The
strengths of patents in the pharmaceutical field involve complex legal and scientific questions and can be uncertain. Where appropriate,
we seek patent protection for certain aspects of our products and technology. Filing, prosecuting and defending patents globally can
be prohibitively expensive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to look to patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However,
patent protection may not be available for some of the products or technology we are developing. If we must spend significant time and
money protecting, defending or enforcing our patents, designing around patents held by others or licensing, potentially for large fees,
patents or other proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may
not develop additional proprietary products that are patentable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical products are complex and uncertain. The scope and extent of patent protection for our future product
candidates are particularly uncertain. Our future product candidates will be based on medicinal chemistry instead of cannabis plants.
While we have sought patent protection, where appropriate, directed to, among other things, composition-of-matter for our specific formulations,
their methods of use, and methods of manufacture, we do not have and will not be able to obtain composition of matter protection on these
previously known CBD derivatives per se. Although we have sought, and will continue to seek, patent protection in the U.S., Europe and
other countries for our proprietary technologies, future product candidates, their methods of use, and methods of manufacture, any or
all of them may not be subject to effective patent protection. If any of our products is approved and marketed for an indication for
which we do not have an issued patent, our ability to use our patents to prevent a competitor from commercializing a non-branded version
of our commercial products for that non-patented indication could be significantly impaired or even eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of information related to our future product candidates by us or others may prevent us from obtaining or enforcing patents relating to
these products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or
may design around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable.
If we fail to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product
to compete with our future product candidates. We may also face competition from companies who develop a substantially similar product
to our future product candidates that is not covered by any of our patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
success depends on our ability to obtain additional intellectual property and operate without infringing the proprietary rights of others.
Infringement claims by third parties may result in liability for damages or prevent or delay our developmental and commercialization
efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success and ability to compete depend in part on our ability to obtain additional patents, protect our trade secrets, and operate without
infringing on the proprietary rights of others. If we fail to adequately protect our intellectual property, we may face competition from
companies who develop a substantially similar product to our future product candidates that is not covered by any of our intellectual
property. Many companies have encountered significant problems in protecting, defending, and enforcing intellectual property rights in
foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement
of patents and other intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for
us to stop the infringement of our intellectual property and other proprietary rights. There is also a substantial amount of litigation,
both within and outside the U.S., involving patient and other intellectual property rights in the pharmaceutical industry. We may, from
time to time, be notified of claims that we are infringing upon the proprietary rights of third parties, and we cannot provide assurances
that other companies will not, in the future, pursue such infringement claims against it, our commercial partners, or any third-party
proprietary technologies we have licensed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unsuccessful in licensing additional intellectual property to develop new product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future seek to in-license additional intellectual property that we believe could complement or expand our product candidates
or otherwise offer growth opportunities. The pursuit of such licenses may cause us to incur various expenses in identifying, investigating
and pursuing suitable intellectual property. If we acquire additional intellectual property to develop new therapeutic product candidates,
we may not be able to realize anticipated cost savings or synergies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
third parties claim that intellectual property used by us infringes upon their intellectual property, our operating profits could be
adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the
pharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights
or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the
future, pursue such infringement claims against us, our commercial partners or any third-party proprietary technologies we have licensed.
If we were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a
patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found
to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including
damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain
products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. Any such claims
could also be expensive and time-consuming to defend and divert management&rsquo;s attention and resources. Our competitive position
could suffer as a result. In addition, if we have declined or failed to enter into a valid non-disclosure or assignment agreement for
any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected. Thus, we cannot
guarantee that any of our future product candidates, or our commercialization thereof, does not and will not infringe any third party&rsquo;s
intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and
products could be significantly diminished.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets to protect our proprietary technologies, especially where it does not believe patent protection is appropriate
or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our current and former
employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors and other advisors to
protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition,
we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets. Any
party with whom we or they have executed such an agreement may breach that agreement and disclose our proprietary information, including
our trade secrets, and we may not be able to obtain adequate remedies for such breaches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcing
a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome
is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
them, or those to whom they disclose such trade secrets, from using that technology or information to compete with us. If any of our
trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would
be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_015"></A>Risks
Related to the Ownership of ENVB Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our common stock may be subject to significant fluctuations and volatility, and our stockholders may be unable to resell
their shares at a profit and incur losses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price our common stock could be subject to significant fluctuation. Market prices for securities of life sciences and biopharma
companies in particular have historically been particularly volatile and have shown extreme price and volume fluctuations that have often
been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general
economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common
stock, regardless of our actual operating performance. Some of the factors that may cause the market price of our common stock to fluctuate
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors
    react negatively to the effect on our business and prospects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    announcement of new products, new developments, services or technological innovations by us or our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and changes in our business, operations or
    prospects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or
    other events by us or our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in the life sciences and biopharma industries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of other life sciences and biopharma companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock by stockholders, including executives and directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in the market prices and trading volumes of companies in the life sciences and biopharma industries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to finance our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to secure resources and the necessary personnel to pursue our plans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to meet external expectations or management guidance;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales or distributions of large blocks of common stock
    by stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigation related to intellectual properties, proprietary rights, and contractual obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investigations
    by regulators into our operations or those of our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which may be out of our control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the overall market and the market prices of particular companies&rsquo; securities, securities
class action litigations have often been instituted against these companies. Litigation of this type, if instituted against us, could
result in substantial costs and a diversion of our management&rsquo;s attention and resources. Any adverse determination in any such
litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty in recent months. A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital,
on our business, results of operations and financial condition, and on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may issue additional equity securities in the future, which may result in dilution to existing investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may, from
time to time, sell additional equity securities in one or more transactions at prices and in a manner we determine. If we sell additional
equity securities, existing stockholders may be materially diluted. New investors could gain rights superior to existing stockholders,
such as liquidation and other preferences. In addition, the number of shares available for future grant under our equity compensation
plans may be increased in the future. Also, the exercise or conversion of outstanding options or warrants to purchase shares of capital
stock may result in dilution to our stockholders upon any such exercise or conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
stockholders could attempt to influence changes within our Company which could adversely affect our operations, financial condition and
the value of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stockholders may from time to time seek to acquire a controlling stake in our Company, engage in proxy solicitations, advance stockholder
proposals or otherwise attempt to effect changes. Campaigns by stockholders to effect changes at publicly-traded companies are sometimes
led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special
dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders
can be costly and time-consuming and could disrupt our operations and divert the attention of our board of directors and senior management
from the operation of our business. These actions could adversely affect our operations, financial condition and the value of our common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our
common stock could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will rely in part on the availability of research and reports that third-party industry or financial
analysts publish about our Company. There are many large, publicly traded companies active in the life sciences and biopharma industries,
which may mean it will be less likely that we receive widespread analyst coverage. Furthermore, if one or more of the analysts who do
cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our Company, we
could lose visibility in the market, which in turn could cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be required to take write-downs or write-offs, restructuring and impairment or other charges in connection with the Offer that could
have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some
or all of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Ameri and Jay Pharma conducted due diligence on each other prior to the completion of the Offer, there can be no assurances that their
diligence revealed all material issues that may be present in the other company&rsquo;s business, that all material issues through a
customary amount of due diligence will be uncovered, or that factors outside of our control will not later arise. As a result, we may
be forced to write-down or write-off assets, restructure operations, or incur impairment or other charges that could result in losses.
Even if due diligence successfully identifies certain risks, unexpected risks may arise, and previously known risks may materialize in
a manner not consistent with each company&rsquo;s preliminary risk analysis. Even though these charges may be non-cash items and not
have an immediate impact on liquidity, the fact that we report charges of this nature could contribute to negative market perceptions
about our securities. In addition, charges of this nature may make future financing difficult to obtain on favorable terms or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-takeover
provisions under Delaware corporate law may make it difficult for our stockholders to replace or remove our board of directors and could
deter or delay third parties from acquiring our Company, which may be beneficial to our stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Amended and Restated Certificate of Incorporation, we are subject to the anti-takeover provisions of the Delaware General Corporation
Law (&ldquo;DGCL&rdquo;), including Section 203 of the DGCL. Under these provisions, if anyone becomes an &ldquo;interested stockholder,&rdquo;
we may not enter into a &ldquo;business combination&rdquo; with that person for three (3) years without special approval, which could
discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203 of
the DGCL, &ldquo;interested stockholder&rdquo; means, generally, someone owning fifteen percent (15%) or more of our outstanding voting
stock or an affiliate of ours that owned fifteen percent (15%) or more of our outstanding voting stock during the past three (3) years,
subject to certain exceptions as described in Section 203 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying any cash dividends in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result,
capital appreciation, if any, of our common stock will be our stockholders&rsquo; sole source of gain, if any, for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>In
the event that we fail to satisfy any of the listing requirements of NASDAQ, our common stock may be delisted, which could affect our
market price and liquidity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on NASDAQ. For continued listing on NASDAQ, we will be required to comply with the continued listing requirements,
including the minimum market capitalization standard, the corporate governance requirements and the minimum closing bid price requirement,
among other requirements. In the event that we fail to satisfy any of the listing requirements of NASDAQ, our common stock may be delisted.
If we are unable to list on NASDAQ, we would likely be more difficult to trade in or obtain accurate quotations as to the market price
of our common stock. If our common stock is delisted from trading on NASDAQ, and we are not able to list our common stock on another
exchange or to have it quoted on NASDAQ, our securities could be quoted on the OTC Bulletin Board or on the &ldquo;pink sheets.&rdquo;
As a result, we could face significant adverse consequences including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is a &ldquo;penny stock&rdquo; which will require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage for our Company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3 or obtain
    additional financing in the future).</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active trading market for our common stock may not develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing of our common stock on NASDAQ does not assure that a meaningful, consistent and liquid trading market exists. If an active market
for our common stock does not develop, it may be difficult for investors to sell their shares without depressing the market price for
the shares or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe
will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able
to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a
strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is
no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which
could result in a material adverse effect on our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_016"></A>Risks
Related to MagicMed&rsquo;s Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Relating to the MagicMed Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Additional
funding and possibility of dilution</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operation of MagicMed&rsquo;s business may require substantial additional capital. When such additional capital is required, MagicMed
will need to pursue various financing transactions or arrangements, including debt financing, equity financing or other means. Additional
financing may not be available when needed or, if available, the terms of such financing might not be favourable to MagicMed and might
involve substantial dilution to existing MagicMed shareholders As discussed in further detail below under the heading &ldquo;<I>Risks
Related to the Business &ndash; MagicMed may require substantial additional funding, which may not be available to it on acceptable terms,
or at all, and, if not so available, may require MagicMed to delay, limit, reduce or cease its operation</I>s.&rdquo; MagicMed may not
be successful in locating suitable financing transactions in the time period required or at all. A failure to raise capital when needed
would have a material adverse effect on MagicMed&rsquo;s business, financial condition and results of operations. Any future issuance
of securities to raise required capital will likely be dilutive to existing MagicMed shareholders. In addition, debt and other debt financing
may involve a pledge of assets and may be senior to interests of equity holders. MagicMed may incur substantial costs in pursuing future
capital requirements, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution
expenses and other costs. The ability to obtain needed financing may be impaired by such factors as the capital markets (both generally
and in the biotechnology and drug research and development industries in particular), MagicMed&rsquo;s status as a new enterprise with
a limited history and/or the loss of key management personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Relating to the Business</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
limited operating history</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business of MagicMed began in May 2020, and as such MagicMed has a limited operating history and has yet to generate any revenue. Therefore,
MagicMed will be subject to all of the business risks and uncertainties associated with any new business enterprise, including under-capitalization,
cash shortages, limitations with respect to personnel, financial and other resources and lack of revenues. Should the Amalgamation not
be completed, MagicMed&rsquo;s business will likely require additional expenditures before cash flow will be generated. Although MagicMed
possesses an experienced management team, there is no assurance that MagicMed will be successful in achieving a return on MagicMed shareholders&rsquo;
investment and the likelihood of success of MagicMed must be considered in light of MagicMed&rsquo;s early stage operations and the problems,
expenses, difficulties, complications and delays frequently encountered in connection with the establishment of any business. There is
no assurance that MagicMed can generate revenues, operate profitably, or provide a return on investment, or that it will successfully
implement its plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
ongoing costs and obligations</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a neuro-pharmaceutical drug discovery and development platform company, MagicMed expects to spend substantial funds on the research,
development and testing of psychedelic molecular derivatives. In addition, MagicMed expects to incur significant ongoing costs and obligations
related to its investment in infrastructure and growth and for regulatory compliance, which could have a material adverse impact on MagicMed&rsquo;s
results of operations, financial condition and cash flows. In the event that the Amalgamation is not completed, MagicMed will have to
fund all of its operations and development expenditures from cash on hand, equity financings, through collaborations with other biotechnology
or pharmaceutical companies or through financings from other sources. MagicMed will also require significant additional funds if it expands
the scope of current plans for research and development or if it were to acquire any other assets and advance their development. It is
possible that future financing will not be available or, if available, may not be on favorable terms. The availability of financing will
be affected by the achievement of MagicMed&rsquo;s corporate goals, the results of scientific and clinical research, the need and ability
to obtain regulatory approvals and the state of the capital markets generally. If adequate funding is not available, MagicMed may be
required to delay, reduce or eliminate one or more of its research and development programs, or obtain funds through corporate partners
or others who may require MagicMed to relinquish significant rights to its Psychedelic Derivatives or compounds or obtain funds on less
favourable terms than MagicMed would otherwise accept. To the extent that external sources of capital become limited or unavailable or
available on onerous terms, MagicMed&rsquo;s intangible assets and its ability to continue its business plans may become impaired, and
MagicMed&rsquo;s assets, liabilities, business, financial condition and results of operations may be materially or adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, future changes in regulations, changes in legal status of psychedelic products, more vigorous enforcement thereof or other
unanticipated events could require extensive changes to MagicMed&rsquo;s operations, increased compliance costs or give rise to material
liabilities, which could have a material adverse effect on the business, results of operations and financial condition of MagicMed. MagicMed&rsquo;s
efforts to grow its business may be costlier than expected. MagicMed may incur significant losses in the future for a number of reasons,
including risks associated with the Amalgamation, as disclosed under &ldquo;<I>Risks Related to the Amalgamation,</I>&rdquo;
&ldquo;<I>Risks Related to ENVB</I>&rdquo; and unforeseen expenses, difficulties, complications and delays, and other unknown events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may rely on third parties to plan and conduct preclinical and clinical trials</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may rely on third parties to conduct preclinical development activities and intends to partner with third parties who may conduct clinical
development activities with MagicMed&rsquo;s Psychedelic Derivatives. Preclinical activities include &ldquo;in vivo&rdquo; studies providing
access to specific disease models, pharmacology and toxicology studies, and assay development. Clinical development activities include
trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring, clinical data management and analysis,
safety monitoring and project management. If there is any dispute or disruption in its relationship with third parties, or if such third
parties are unable to provide quality services in a timely manner and at a feasible cost, or if such third parties fail to meet certain
development milestones, MagicMed&rsquo;s active development programs may face delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
if any of these third parties fails to perform as MagicMed expects or if their work fails to meet regulatory requirements, the testing
and eventual development of viable Psychedelic Derivative drug candidates could be delayed, cancelled or rendered ineffective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance
on third party contract manufacturers</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
MagicMed&rsquo;s completion of the &ldquo;in vitro&rdquo; portion of the preclinical testing it intends to conduct, when only lab-grade
and lab-scale psychedelic molecules are required, MagicMed intends to manufacture the required psychedelic molecules at the University
of Calgary pursuant to certain agreements with the University of Calgary and under the authority of Dr. Facchini&rsquo;s drug license
(the &ldquo;Facchini Drug License&rdquo;). However, when larger quantities and higher quality psychedelic molecules are required (<I>e.g.,
</I>for animal model testing), MagicMed intends to contract with appropriate third party CMOs to, among other things, supply the active
pharmaceutical ingredients (&ldquo;API&rdquo;) used in its Psychedelic Derivatives over which it may have limited control. MagicMed intends
to rely on CMOs to supply APIs in compliance with local GMP regulations applicable to its Psychedelic Derivatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
applicable jurisdictions, including Health Canada, and the FDA, ensure the quality of drug products by carefully monitoring drug manufacturers&rsquo;
compliance with GMP regulations. The GMP regulations for drugs contain minimum requirements for the methods, facilities and controls
used in manufacturing, processing and packing of a drug product. There can be no assurances that CMOs will be able to meet MagicMed&rsquo;s
timetable and requirements or carry out their contractual obligations in accordance with the applicable regulations. In addition, the
API they supply to MagicMed may not meet its specifications and quality policies and procedures or they may not be able to supply the
API in commercial quantities. If MagicMed is unable to arrange for alternative third-party supply sources on commercially reasonable
terms or in a timely manner, it may delay the development of its Psychedelic Derivatives and could have a material adverse effect on
MagicMed&rsquo;s business operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the failure of CMOs to operate in compliance with GMP regulations could result in, among other things, certain product liability claims
in the event such failure to comply results in defective products (containing MagicMed&rsquo;s Psychedelic Derivatives) that caused injury
or harm. In general, MagicMed&rsquo;s dependence upon third parties for the supply of MagicMed&rsquo;s APIs may adversely affect profit
margins and MagicMed&rsquo;s ability to develop and deliver viable Psychedelic Derivatives on a timely and competitive basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
or non-renewal of key licenses and agreements</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
business is highly dependent on a number of key licenses and agreements which expire in a short time period. Specifically, in conducting
research and preclinical studies in compliance with current legislation, MagicMed substantially relies on: (i) the Facchini Drug License
which expires on December 31, 2021; and (ii) the two material contracts with the Governors of the University of Calgary, which expire
on August 17, 2022 and October 31, 2021 (the &ldquo;Calgary Agreements&rdquo;). Health Canada renews drug licenses annually and Dr. Facchini
has held the Facchini Drug License since October 5, 1995 and it has been renewed each year without issue. Until MagicMed obtains its
own Dealer&rsquo;s License or Section 56 Exemption necessary for its business, the termination, non-renewal or hinderance of use, as
applicable of the Facchini Drug License or the Calgary Agreements would have a material adverse effect on MagicMed&rsquo;s ability to
develop Psychedelic Derivatives, conduct research or operate its business as it currently does. This could have a material adverse impact
on MagicMed&rsquo;s financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negative
results from clinical trials or studies of others and adverse safety events involving MagicMed&rsquo;s Psychedelic Derivatives</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, studies or clinical trials on various aspects of biopharmaceutical or natural health products (&ldquo;NHPs&rdquo;) are
conducted by academic researchers, competitors or others. The results of these studies or trials, when published, may have a significant
effect on the market for the biopharmaceutical or NHP that is the subject of the study. The publication of negative results of studies
or clinical trials or adverse safety events related to the psychedelic compounds used by MagicMed in the development of its Psychedelic
Derivatives, or the therapeutic areas in which MagicMed&rsquo;s Psychedelic Derivatives compete, could adversely affect its share price
and MagicMed&rsquo;s ability to finance future development of its Psychedelic Derivatives, and its business and financial results could
be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of MagicMed&rsquo;s Psychedelic Derivatives may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities
or not otherwise produce positive results</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
third parties are able to obtain marketing approval from regulatory authorities for the sale of products containing MagicMed&rsquo;s
Psychedelic Derivatives, the completion of preclinical studies in animals and extensive clinical trials in humans to demonstrate the
safety and efficacy of the Psychedelic Derivatives will be required. Clinical testing is expensive and difficult to design and implement,
can take many years to complete and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict
the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies
in the pharmaceutical, NHP and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of
efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. MagicMed does not know whether the clinical
trials that third parties may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any products
containing its Psychedelic Derivatives in any jurisdiction. A product/compound candidate may fail for safety or efficacy reasons at any
stage of the testing process. A major risk MagicMed faces is the possibility that none of the products containing its Psychedelic Derivatives
will successfully gain market approval from Health Canada, the FDA or other regulatory authorities, resulting in MagicMed being unable
to derive any royalty-based revenue from them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
raw materials used by MagicMed will require regulatory approval by Health Canada because the plant or fungi may contain a controlled
substance. While MagicMed believes that it can acquire, or indirectly make use of, the requisite licenses to conduct its intended research
and development activities, there is a risk that Health Canada can either reject or require further action to approve the requisite licenses
which would cause delays or result in losses for MagicMed and could result in the abandonment of a specific research programs. Raw materials
and supplies are generally available in quantities to meet the needs of MagicMed&rsquo;s business. An inability to obtain raw materials
or product supply could have a material adverse impact on MagicMed&rsquo;s business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
will require substantial additional funding, which may not be available to it on acceptable terms, or at all, and, if not so available,
may require MagicMed to delay, limit, reduce or cease its operations</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has used the proceeds from its previous equity offerings, and should the Amalgamation not be completed, MagicMed intends to use the proceeds
from any possible future offerings, to, among other uses, continue to develop novel Psychedelic Derivatives for its Psybrary<SUP>TM</SUP>,
file patent applications to protect these Psychedelic Derivatives and advance its existing Psychedelic Derivative portfolio through preclinical
studies (including in vitro and in vivo testing) and into IND&rsquo;s or their equivalent, all of which will require substantial additional
capital. Because of the uncertainty surrounding the successful development of viable Psychedelic Derivatives, MagicMed is unable to estimate
the actual amount of funding it will require to complete such activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount and timing of MagicMed&rsquo;s future funding requirements will depend on many factors, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    its plan for preclinical studies will be completed on a timely basis and, if completed, whether MagicMed will be able to publicly
    announce results from these preclinical studies in accordance with its announced milestones;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    MagicMed, or its third party partners as applicable, are successful in obtaining the benefits of Health Canada&rsquo;s expedited
    development and review programs related to its Psychedelic Derivatives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    MagicMed is successful in obtaining interest for possible co-development and licensing out partners;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress, costs, results of and timing of its preclinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, costs and timing of seeking and obtaining Health Canada and any other regulatory approvals that may be required;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    MagicMed&rsquo;s Psychedelic Derivatives are scheduled as controlled substances under the CDSA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with securing and establishing commercialization and manufacturing capabilities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    acceptance of its Psychedelic Derivatives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring, licensing or investing in businesses, products, psychedelic therapies and technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to maintain, expand and enforce the scope of its intellectual property portfolio, including the amount and timing of any
    payments MagicMed may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense
    and enforcement of any patents or other intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    need and ability to hire additional management and scientific and medical personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing Psychedelic Derivatives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    need to implement additional internal systems and infrastructure, including financial and reporting systems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    may be applicable, research grant terms that change over time or whose terms MagicMed is unable to meet;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to attract and retain competent staff;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the political and economic environment in the jurisdictions in which MagicMed operates, including adverse economic circumstances
    beyond COVID-19;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    duration and effects of COVID-19 on MagicMed&rsquo;s personnel, business, operations and financial condition;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    duration and effects of COVID-19 on the personnel, business, operations and financial condition of MagicMed&rsquo;s research partners
    and suppliers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    safety hazards associated with the Psychedelic Derivatives MagicMed develops; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    economic and other terms, timing of and success of any collaboration, licensing or other transactions into which MagicMed may enter
    in the future.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Some
of these factors are outside of MagicMed&rsquo;s control. Without entering into successful partnerships with third-party product development
companies that provide MagicMed with substantial financial resources, MagicMed does not believe that its existing capital resources are
sufficient to enable MagicMed to complete the development and commercialization of its Psybrary<SUP>TM</SUP> and the Psychedelic Derivatives
contained therein. Accordingly, MagicMed expects that it will need to raise additional funds in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization,
marketing and distribution transactions and other collaborations, strategic alliances and licensing transactions. Additional funding
may not be available to MagicMed on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings
or the rights of MagicMed securityholders and the issuance of additional MagicMed Shares, or the possibility of such issuance, may cause
the market price of the MagicMed Shares to decline. Any additional equity financing may be dilutive to investors and debt financing,
if available, may involve restrictions on financing and operating activities. If MagicMed is unable to obtain funding on a timely basis,
it may be required to significantly curtail one or more of its research or development programs and/or incur financial penalties. MagicMed
also could be required to seek funds through transactions with collaborative partners or otherwise that may require MagicMed to relinquish
rights to some of its intellectual property or preclinical assets or otherwise agree to terms unfavourable to MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible
increase in costs beyond what is currently expected as a result of regulatory review</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
Canada has not yet determined whether MagicMed&rsquo;s Psychedelic Derivatives will be scheduled as controlled substances. In the event
Health Canada determines that these products are controlled substances and therefore, require regulatory approval, (a) MagicMed&rsquo;s
licensees will be required to obtain such approval; and (b) to the extent that MagicMed produces Psychedelic Derivatives, it will require
similar regulatory approval. Such additional regulatory requirements may increase MagicMed&rsquo;s costs and cause a delay in MagicMed&rsquo;s
operations. Further, if Health Canada requires that MagicMed perform additional preclinical studies, or if MagicMed determines that additional
preclinical studies are required for its Psychedelic Derivatives, its expenses would further increase beyond what is currently expected
and the anticipated timing of any potential approval of its Psychedelic Derivatives or licensing out agreement would likely be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has a limited operating history and expects a number of factors to cause its operating results to fluctuate on an annual basis, which
may make it difficult to predict the future performance of MagicMed</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is a neuro-pharmaceutical drug discovery and development platform company with a limited operating history. MagicMed&rsquo;s operations
to date have been focused on conducting in-house research, preparing proprietary forms of psychedelic compounds and molecules into Health
Canada approved models for inclusion in MagicMed&rsquo;s Psybrary<SUP>TM</SUP> and eventual use in clinical trials, and establishing
key relationships. At this stage, MagicMed does not have any partnership agreements in place and no third party has agreed to complete
clinical trials of the Psychedelic Derivatives contained in MagicMed&rsquo;s Psybrary<SUP>TM</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequently,
any predictions made about MagicMed&rsquo;s future success or viability may not be as accurate as they could be if MagicMed had a longer
operating history or had definitive partnership agreements in place. MagicMed&rsquo;s operating results are expected to significantly
fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond its control. Factors relating
to MagicMed&rsquo;s business that may contribute to these fluctuations include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays or issues in finding, and establishing successful business arrangements with, pharmaceutical and product development partners
    to assist in moving its Psychedelic Derivatives through the development and commercialization processes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrolment and timing of preclinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of its preclinical studies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    side effects of its Psychedelic Derivatives that could delay or prevent approval or license-out agreements or cause an approved drug
    candidate to be eliminated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to obtain additional funding to develop its Psychedelic Derivatives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to attract and retain talented and experienced people;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing Psychedelic Derivatives or new Psychedelic Derivatives that continue to emerge;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assuming
    market authorization has been obtained for a product containing MagicMed&rsquo;s Psychedelic Derivatives, the ability of patients
    or healthcare providers to obtain coverage or sufficient reimbursement for its Psychedelic Derivatives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to adhere to preclinical study requirements directly or with third parties such as CROs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    dependency on third-party manufacturers to manufacture products and key ingredients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to establish or maintain collaborations, licensing or other transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to defend against any challenges to its intellectual property including, claims of patent infringement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to enforce its intellectual property rights against potential competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to secure additional intellectual property protection for its Psychedelic Derivatives and associated manufacturing methods
    currently under development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    ability to attract and retain key personnel to manage its business effectively;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    biological or chemical effect that MagicMed does not predict;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    economic circumstances;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    liability claims; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    duration and effects of COVID-19 on MagicMed&rsquo;s personnel, business, operations and financial condition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
the results of any historical financial periods should not be relied upon as indications of future operating performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has never been profitable, it has no products approved for commercial sale, and to date it has not generated any revenue</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has never been profitable and should the Amalgamation not be completed, MagicMed does not expect to be profitable in the foreseeable
future. Neither MagicMed, nor any third-party partner, have submitted any products containing MagicMed&rsquo;s Psychedelic Derivatives
for approval by regulatory authorities in Canada, the United States or elsewhere. For the period from incorporation on May 26, 2020 to
June 30, 2020 MagicMed incurred a net and comprehensive loss of $42,476. For the period from July 1, 2020 to March 31, 2021, MagicMed
incurred a net loss of $2,379,369 and comprehensive loss of $2,381,683. To date, MagicMed has devoted most of its financial resources
to research and development, including drug discovery research, preclinical development activities, patent application filing and media
relation efforts, as well as corporate overhead.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has not generated any revenues from licensing its agreements or product sales. MagicMed expects to continue to incur losses for the foreseeable
future, and expects these losses to increase as MagicMed continues its development of its Psychedelic Derivatives. If MagicMed&rsquo;s
Psychedelic Derivatives do not achieve market acceptance, MagicMed may never become profitable. As a result of the foregoing, MagicMed
expects to continue to experience net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows
have had, and will continue to have, an adverse effect on MagicMed&rsquo;s stockholders&rsquo; equity and working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with psychedelic drug development, MagicMed is unable to accurately predict the timing
or amount of increased expenses or when, or if, MagicMed will be able to achieve profitability. In addition, MagicMed&rsquo;s expenses
could increase if it is required by Health Canada to perform preclinical studies or trials in addition to those currently expected, or
if there are any delays in completing its preclinical studies or the development of any of its Psychedelic Derivatives. The amount of
future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
MagicMed (or a third party conducting clinical trials) has difficulty enrolling patients in clinical trials, the completion of the trials
may be delayed or cancelled</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, as MagicMed&rsquo;s Psychedelic Derivatives advance from preclinical testing to clinical testing, and then through progressively
larger and more complex clinical trials, third party companies conducting the clinical trials will need to enroll an increasing number
of patients that meet its eligibility criteria. There is significant competition for recruiting patients in clinical trials, and third-party
companies conducting the clinical trials may be unable to enroll the patients it needs to complete clinical trials on a timely basis
or at all. The factors that affect the ability to enroll patients are largely uncontrollable and include, but are not limited to, the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility
    and exclusion criteria for the trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
    of the study protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    with other companies for clinical sites or patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    perceived risks and benefits of the product/compound candidate under study;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient referral practices of physicians; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number, availability, location and accessibility of clinical trial sites.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure of third-party companies to conduct clinical trials of MagicMed&rsquo;s Psychedelic Derivatives would adversely affect MagicMed&rsquo;s
ability to earn royalty-based revenue from the eventual commercialization of psychedelic therapies that are comprised of, among other
ingredients, MagicMed&rsquo;s Psychedelic Derivatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has no licensing, marketing or distribution experience and it will have to invest significant resources to develop those capabilities
or enter into acceptable third-party sales and marketing transactions</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has no licensing, marketing or distribution experience. To develop licensing, distribution and marketing capabilities, MagicMed will
have to invest significant amounts of financial and management resources, some of which will need to be committed prior to any confirmation
that its Psychedelic Derivatives will be approved by Health Canada for Psychedelic Derivatives where MagicMed decides to perform licensing,
marketing and distribution functions itself or through third parties, it could face a number of additional risks, including that MagicMed
or its third-party collaborators may not be able to build and maintain an effective marketing or sales force. If MagicMed uses third
parties to market and license its Psychedelic Derivatives, it may have limited or no control over their licensing, marketing and distribution
activities on which its future revenues may depend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may from time to time seek to enforce its intellectual property rights against infringers when it determines that a successful outcome
is probable and may lead to an increase in the value of the intellectual property. If MagicMed chooses to enforce its patent rights against
a party, then that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced.
Additionally, the validity of its patents and the patents it has licensed may be challenged if a petition for post grant proceedings
such as inter-partes review and post grant review is filed within the statutorily applicable time with the Canadian Intellectual Property
Office or the United States Patent and Trademark Office. These lawsuits and proceedings are expensive and would consume time and resources
and divert the attention of managerial and scientific personnel even if MagicMed were successful in stopping the infringement of such
patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there is a risk that the court will decide that such patents are not valid and that MagicMed does not have the right to stop
the other party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will
refuse to stop the other party on the ground that such other party&rsquo;s activities do not infringe its intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
MagicMed is unable to adequately protect and enforce its intellectual property, MagicMed&rsquo;s competitors may take advantage of its
development efforts and compromise its prospects of marketing and licensing its Psychedelic Derivatives</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
success will depend in part upon its ability to protect its intellectual property and proprietary technologies and upon the nature and
scope of the intellectual property protection MagicMed receives. The ability to compete effectively and to achieve partnerships will
depend on its ability to develop and maintain proprietary aspects of MagicMed&rsquo;s Psychedelic Derivatives and to operate without
infringing on the proprietary rights of others. The presence of such proprietary rights of others could severely limit its ability to
develop and commercialize its Psychedelic Derivatives, to conduct its existing research and could require financial resources to defend
litigation, which may be in excess of MagicMed&rsquo;s ability to raise such funds. There is no assurance that MagicMed will be able
to obtain patent protection of its intangible preclinical assets, including its Psychedelic Derivatives, related manufacturing methods,
pharmacological data and trade secrets in a form that will be sufficient to protect the contents of its Psybrary<SUP>TM</SUP> and gain
or keep any competitive advantage that MagicMed may have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific and factual questions for
which important legal principles remain unresolved. Patents issued to MagicMed may be challenged, invalidated or circumvented. To the
extent MagicMed&rsquo;s intellectual property offers inadequate protection, or is found to be invalid or unenforceable, MagicMed is exposed
to a greater risk of direct competition. If its intellectual property does not provide adequate protection against MagicMed&rsquo;s competitors&rsquo;
products, its competitive position could be adversely affected, as could MagicMed&rsquo;s business, financial condition and results of
operations. Both the patent application process and the process of managing patent disputes can be time consuming and expensive, and
the laws of some foreign countries may not protect MagicMed&rsquo;s intellectual property rights to the same extent as do the laws of
Canada and the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
will be able to protect its intellectual property from unauthorized use by third parties only to the extent that the contents of its
Psybrary<SUP>TM</SUP> are covered by valid and enforceable intellectual property rights including patents or are effectively maintained
as trade secrets, and provided MagicMed has the funds to enforce its rights, if necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in patent law and its interpretation could diminish the value of patents in general, thereby impairing MagicMed&rsquo;s ability to protect
its Psychedelic Derivatives</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other NHP, biotechnology and pharmaceutical companies, MagicMed&rsquo;s success is heavily dependent on intellectual
property rights, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal
complexity, and obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. The Supreme Court
of Canada and the U.S. Supreme Court have ruled on several patent cases in recent years, either narrowing the scope of patent protection
available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty
with regard to MagicMed&rsquo;s ability to obtain patents in the future, this combination of events has created uncertainty with respect
to the value of patents, once obtained. Depending on decisions by the Canadian House of Representative, the Federal Court of Canada,
the Canadian Intellectual Property Office, U.S. Congress, the federal courts, and the U.S. Patent and Trademark Office and international
treaties entered into by these nations, the laws and regulations governing patents could change in unpredictable ways that would weaken
MagicMed&rsquo;s ability to obtain patents or to enforce patents MagicMed may obtain in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
MagicMed is not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of its Psychedelic
Derivatives could be significantly diminished</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases MagicMed relies on trade secrets to protect its proprietary information, especially where it does not believe patent protection
is appropriate or obtainable. However, trade secrets are difficult to protect. MagicMed relies in part on confidentiality agreements
with its employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect its trade secrets
and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide
an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover
its trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope
of its proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect its competitive business
position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to manage growth</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
MagicMed advances its Psychedelic Derivatives through preclinical studies and seeks business arrangements and partnerships with third
parties to advance its Psychedelic Derivatives through clinical development, MagicMed will need to increase its preclinical development,
scientific, management and administrative headcount to manage these programs and negotiate these arrangements. In addition, to meet obligations
as a public company, MagicMed may need to increase its general and administrative capabilities and improve its operational and financial
controls and reporting procedures. MagicMed&rsquo;s management, personnel and systems currently in place may not be adequate to support
this future growth. In managing its growing operations, MagicMed is also subject to the risks of over-hiring and/or overcompensating
its employees and over-expanding its operating infrastructure. As a result, MagicMed may be unable to manage its expenses effectively
in the future, which may negatively impact its gross profit or operating expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dependence
on management and key personnel</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of MagicMed is currently largely dependent on the performance of its directors, officers and scientific advisors. The loss of
the services of any of these persons could have a materially adverse effect on MagicMed&rsquo;s business and prospects. There is no assurance
MagicMed can maintain the services of its directors, officers, scientific advisors, or other qualified personnel required to operate
its business. As MagicMed&rsquo;s business activity grows, MagicMed will require additional key financial, administrative, scientific,
and clinical personnel as well as additional operations staff. There can be no assurance that any recruitment efforts will be successful
in attracting, training and retaining qualified personnel as competition for persons with these skill sets increase. If MagicMed is not
successful in attracting, training and retaining qualified personnel, the efficiency of its operations could be impaired, which could
have an adverse impact on MagicMed&rsquo;s operations and financial condition. In addition, the COVID-19 pandemic may cause MagicMed
to have inadequate access to available skilled workforce and qualified personnel, which could have an adverse impact on MagicMed&rsquo;s
financial performance and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance
and uninsured risks</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
business is subject to a number of risks and hazards generally, including adverse preclinical trial results, accidents, labour disputes
and changes in the regulatory environment. Such occurrences could result in damage to assets, personal injury or death, environmental
damage, delays in operations, monetary losses and possible legal liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
insurance will not cover all the potential risks associated with its operations. MagicMed may also be unable to maintain insurance to
cover these risks at economically feasible premiums. Insurance coverage may not be available or may not be adequate to cover any resulting
liability. Moreover, insurance against risks such as environmental pollution or other hazards encountered in the operations of MagicMed
is not generally available on acceptable terms. MagicMed might also become subject to liability for pollution or other hazards which
may not be insured against or which MagicMed may elect not to insure against because of premium costs or other reasons. Losses from these
events or any significant uninsured liability may require MagicMed to pay substantial amounts, which would adversely affect its financial
position and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may be materially adversely affected in the event of cyber-based attacks, network security breaches, service interruptions, or data corruption</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
relies on information technology to process and transmit sensitive electronic information and to manage or support a variety of business
processes and activities. MagicMed uses technology systems to record, process, and summarize financial information and results of operations
for internal reporting purposes and to comply with regulatory financial reporting, legal, and tax requirements. MagicMed&rsquo;s information
technology systems, some of which are managed by third-parties, may be susceptible to damage, disruptions or shutdowns due to computer
viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof,
power outages, hardware failures, telecommunication failures, user errors or catastrophic events. Although MagicMed has developed systems
and processes that are designed to protect proprietary or confidential information and prevent data loss and other security breaches,
such measures cannot provide absolute security. If its systems are breached or suffer severe damage, disruption or shutdown and MagicMed
is unable to effectively resolve the issues in a timely manner, its business and operating results may significantly suffer and it may
be subject to litigation, government enforcement actions or potential liability. Security breaches could also cause MagicMed to incur
significant remediation costs, result in product development delays, disrupt key business operations, including development of its Psychedelic
Derivatives, and divert attention of management and key information technology resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal
controls</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls are necessary for MagicMed to provide reliable financial reports and to help prevent fraud. Although MagicMed will
undertake a number of procedures and will implement a number of safeguards, in each case, in order to help ensure the reliability of
its financial reports, including those imposed on MagicMed under Canadian securities law, MagicMed cannot be certain that such measures
will ensure that MagicMed will maintain adequate control over financial processes and reporting. Failure to implement required new or
improved controls, or difficulties encountered in their implementation, could harm MagicMed&rsquo;s results of operations or cause it
to fail to meet its reporting obligations. If MagicMed or its auditors discover a material weakness, the disclosure of that fact, even
if quickly remedied, could reduce the market&rsquo;s confidence in MagicMed&rsquo;s consolidated financial statements and materially
adversely affect the  value of the MagicMed shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
of MagicMed will ensure the accounting cycle, payroll administration, operational activities, and financial reporting controls to assess
internal control risks and to ensure proper internal control are in place. One of the deficiencies in internal control is the lack of
segregation of accounting duties due to the limited size of MagicMed. However, the threat of this deficiency is considered immaterial
as management has taken effective measures to mitigate this weakness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential risk that flows from the identified deficiencies and weaknesses is the risk of potential fraud. However, the risk of fraud
is considered low as management anticipates taking a number of measures as stated above to mitigate the potential risk of fraud, including
without limitation: (i) all purchase and payment, including payroll, must be authorized by management; (ii) all capital expenditures
must be preapproved by the MagicMed Board; (iii) all source documents in any other language other than English must be translated and
scanned for accounting entries and recordkeeping purposes; (iv) and almost all of MagicMed&rsquo;s cash will be deposited with a Canadian
bank in Calgary Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MagicMed Board will continue to monitor the operations of MagicMed, evaluate the internal controls, and develop measures in the future
to mitigate any potential risks and weaknesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should
any litigation in which MagicMed becomes involved be determined against MagicMed such a decision could adversely affect MagicMed&rsquo;s
ability to continue operating and the market price for the MagicMed shares and could use significant resources. Even if MagicMed is involved
in litigation and wins, litigation can redirect significant company resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflicts
of interest</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of MagicMed&rsquo;s directors and officers do not devote their full time to the affairs of MagicMed and certain of MagicMed&rsquo;s directors
and officers are also directors, officers and shareholders of other biotechnology and research and development companies or other public
companies in general, and as a result they may find themselves in a position where their duty to another company conflicts with their
duty to MagicMed. Although MagicMed has policies which address such potential conflicts and the BCBCA has provisions governing directors
in the event of such a conflict, none of MagicMed&rsquo;s constating documents or any of its other agreements contain any provisions
mandating a procedure for addressing such conflicts of interest. There is no assurance that any such conflicts will be resolved in favour
of MagicMed. If any such conflicts are not resolved in favour of MagicMed, MagicMed may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
of COVID-19</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
business, operations and financial condition could be materially and adversely affected by the outbreak of epidemics or pandemics or
other health crises, including the recent outbreak of COVID-19. On January 30, 2020, the World Health Organization declared the outbreak
of a global health emergency and on March 13, 2020 the U.S. declared that the COVID-19 outbreak in the United States constitutes a national
emergency. To date, there have been a large number of temporary business closures, quarantines and a general reduction in consumer activity
in Canada, the United States, Europe and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak has caused companies and various international jurisdictions to impose travel, gathering and other public health restrictions.
While these effects are expected to be temporary, the duration of the various disruptions to businesses locally and internationally and
the related financial impact cannot be reasonably estimated at this time. Similarly, MagicMed cannot estimate whether or to what extent
this outbreak and the potential financial impact may extend to countries outside of those currently impacted. MagicMed is actively assessing
and responding where possible to the potential impact of the COVID-19 pandemic. MagicMed may face disruption to restrictions on operations,
delays and uncertainties to planned preclinical studies, travel restrictions, impact on personnel and the impact on the economic activity
in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat
to maintaining a skilled workforce industry and could be a major health care challenge for MagicMed. There can be no assurance that MagicMed&rsquo;s
personnel will not be impacted by this pandemic and ultimately that MagicMed would see its workforce productivity reduced or incur increased
medical costs/insurance premiums as a result of these health risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. Depending on the length and severity of the pandemic,
COVID-19 could impact MagicMed&rsquo;s operations, could cause delays relating to preclinical studies and as applicable receipt of approval
from Health Canada, could postpone research activities, and could impair MagicMed&rsquo;s ability to raise funds depending on COVID-19&rsquo;s
effect on capital markets. The duration of the COVID-19 pandemic outbreak and the resultant travel restrictions, social distancing, government
response actions, business closures and business disruptions, can all have an impact on MagicMed&rsquo;s operations and access to capital.
There can be no assurance that MagicMed will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic
on global financial markets, share prices and financial liquidity and thereby that may severely limit the financing capital available.
Finally, the duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank
interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial
results and condition of MagicMed in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
and Accounting Risks</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
and future financing risk</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
will likely operate at a loss until its business becomes established and it may require additional financing in order to fund future
operations and expansion plans. MagicMed&rsquo;s ability to secure any required financing to sustain operations and expansion plans will
depend in part upon prevailing capital market conditions and business success. There can be no assurance that MagicMed will be successful
in its efforts to secure any additional financing or additional financing on terms satisfactory to management. Moreover, future activities
may require MagicMed to alter its capitalization significantly and, if additional financing is raised by issuance of additional MagicMed
Shares from treasury, control may change and MagicMed Shareholders may suffer dilution. The inability of MagicMed to access sufficient
capital for its operations could have a material adverse effect on MagicMed&rsquo;s financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
financial condition would be adversely impacted if its intangible assets become impaired</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangibles
are evaluated quarterly and are tested for impairment at least annually or when events or changes in circumstances indicate the carrying
value of each segment, and collectively MagicMed taken as a whole, might exceed its fair value. If MagicMed determines that the value
of its intangible assets is less than the amounts reflected on its balance sheet, it will be required to reflect an impairment of its
intangible assets in the period in which such determination is made. An impairment of its intangible assets would result in it recognizing
an expense in the amount of the impairment in the relevant period, which would also result in the reduction of its intangible assets
and a corresponding reduction in its stockholders&rsquo; equity in the relevant period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
risk</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is subject to various taxes including, but not limited to the following: Canadian income tax, goods and services tax, sales tax, land
transfer tax, payroll tax; and, as applicable, equivalent taxes imposed by the taxing authorities in the United States in respect of
the US Sub and any United States resident employees of MagicMed. MagicMed&rsquo;s tax filings will be subject to audit by various taxation
authorities. While MagicMed intends to base its tax filings and compliance on the advice of its tax advisors, there can be no assurance
that its tax filing positions will never be challenged by a relevant taxation authority resulting in a greater than anticipated tax liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Relating to the Psychedelic Therapy Market and Biotechnology Industry</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic therapy industry and market are relatively new and this industry and market may not continue to exist or grow as anticipated</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
operates its business in a relatively new industry and market. In addition to being subject to general business risks, MagicMed must
continue to build brand awareness in this industry and market through significant investments in its strategy, its operational capacity,
quality assurance and compliance with regulations. In addition, there is no assurance that the industry and market will continue to exist
and grow as currently estimated or anticipated or function and evolve in the manner consistent with management&rsquo;s expectations and
assumptions. Any event or circumstance that adversely affects the psychedelic therapy industry and market could have a material adverse
effect on MagicMed&rsquo;s business, financial conditions and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic medicine market will face specific marketing challenges given the products&rsquo; status as a controlled substance which
resulted in past and current public perception that the products have negative health and lifestyle effects and have the potential to
cause physical and social harm due to psychoactive and potentially addictive effects. Any marketing efforts by MagicMed would need to
overcome this perception to build consumer confidence, brand recognition and goodwill.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfavourable
publicity or consumer perception</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
believes the psychedelic medicine industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of
the psychedelic formulations developed. Consumer perception of MagicMed&rsquo;s Psychedelic Derivatives can be significantly influenced
by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption
of psychedelic-derived products in general. There can be no assurance that future scientific research, findings, regulatory proceedings,
litigation, media attention or other research findings or publicity will be favourable to the psychedelic drug market or any particular
solution, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention
or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could
have a material adverse effect on the demand for MagicMed&rsquo;s Psychedelic Derivatives and the business, results of operations, financial
condition and cash flows of MagicMed. MagicMed&rsquo;s dependence upon consumer perceptions means that adverse scientific research reports,
findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a
material adverse effect on MagicMed, the demand for Psychedelic Derivatives, and the business, results of operations, financial condition
and cash flows of MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
adverse publicity reports or other media attention regarding the safety, efficacy and quality of psychedelic drugs in general, animal
trials being conducted, or MagicMed&rsquo;s Psychedelic Derivatives specifically, or associating the consumption of psychedelic drugs
with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other
media attention could arise even if the adverse effects associated with such products resulted from consumers&rsquo; failure to consume
such products legally, appropriately or as directed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expansion of the use of psychedelics in the medical industry may require new clinical research into effective medical therapies</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
in Canada and internationally regarding the medical benefits, viability, safety, efficacy, addictiveness, dosing and social acceptance
of psychedelic and psychoactive products remains in early stages. There have been relatively few clinical trials on the benefits of such
products. Although MagicMed believes that the articles, reports and studies support its beliefs regarding the medical benefits, viability,
safety, efficacy, dosing and social acceptance of psychedelic and psychoactive products, future research and clinical trials may prove
such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, psychedelic and psychoactive products.
Given these risks, uncertainties and assumptions, readers should not place undue reliance on such articles and reports. Future research
studies and clinical trials may draw opposing conclusions to those stated in this proxy statement/prospectus or reach negative conclusions
regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to psychedelic
and psychoactive products, which could have a material adverse effect on the demand for MagicMed&rsquo;s Psychedelic Derivatives with
the potential to lead to a material adverse effect on MagicMed&rsquo;s business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic therapy industry is difficult to quantify and investors will be reliant on their own estimates of the accuracy of market
data</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the psychedelic therapy industry is in a nascent stage with uncertain boundaries, there is a lack of information about comparable companies
available for potential investors to review in deciding about whether to invest in MagicMed and, few, if any, established companies whose
business model MagicMed can follow or upon whose success MagicMed can build. Accordingly, investors will have to rely on their own estimates
in deciding about whether to invest in MagicMed. There can be no assurance that MagicMed&rsquo;s estimates are accurate or that the market
size is sufficiently large for its business to grow as projected, which may negatively impact its financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic therapy and biotechnology industries are experiencing rapid growth and increased competition</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic therapy and biotechnology industries are undergoing rapid growth and substantial change, which has resulted in an increase
in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions could harm MagicMed
in a number of ways, including by losing strategic partners if they are acquired by or enter into relationships with a competitor, losing
customers, revenue and market share, or forcing MagicMed to expend greater resources to meet new or additional competitive threats, all
of which could harm MagicMed&rsquo;s operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.
MagicMed has competitors in Canada, the United States, Europe and other jurisdictions, including major multinational pharmaceutical companies,
established biotechnology companies, specialty pharmaceutical and generic drug companies and universities and other research institutions.
Many of its competitors have greater financial and other resources, such as larger research and development staff and more experienced
marketing and manufacturing organizations than it does. Large pharmaceutical companies, in particular, have extensive experience in,
and substantial capital resources for, conducting research, molecular derivative development, obtaining regulatory approvals, obtaining
intellectual property protection and establishing key relationships. These companies also have significantly greater sales and marketing
capabilities and experience in completing collaborative transactions in MagicMed&rsquo;s target markets with leading companies and research
institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
competitors may introduce new Psychedelic Derivatives or develop technological advances that compete with MagicMed. MagicMed cannot predict
the timing or impact of competitors introducing new Psychedelic Derivatives or technological advances. Such competing Psychedelic Derivatives
may be safer, more effective, more effectively marketed, licensed or sold or have lower prices or superior performance features than
MagicMed&rsquo;s Psychedelic Derivatives, and this could negatively impact MagicMed&rsquo;s business and results of operations. Established
pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds
that could make the Psychedelic Derivatives that MagicMed develops obsolete. As a result of all of these factors, its competitors may
succeed in obtaining patent protection and/or Health Canada or discovering, developing and commercializing Psychedelic Derivatives before
it does or may develop Psychedelic Derivatives that are deemed to be more effective or gain greater market acceptance than those of MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative transactions with large, established
companies. In addition, many universities and private and public research institutes may become active in the development of novel compounds.
MagicMed&rsquo;s competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and Psychedelic Derivatives
that are more effective or less costly than any of the Psychedelic Derivatives that MagicMed is currently developing or that it may develop,
which could render its Psychedelic Derivatives obsolete or non-competitive. If MagicMed&rsquo;s competitors market Psychedelic Derivatives
that are more effective, safer or less expensive or that reach the market sooner than its Psychedelic Derivatives, if any, it may not
achieve commercial success. In addition, because of its limited resources, it may be difficult for MagicMed to stay abreast of the rapid
changes in each technology. If MagicMed fails to stay at the forefront of technological change, it may be unable to compete effectively.
Technological advances or products developed by its competitors may render its technologies or Psychedelic Derivatives obsolete, less
competitive or not economical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in legislation, regulations and guidelines</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
operations are subject to various laws, regulations and guidelines relating to, among other things, drug research, development, marketing
practices, health and safety, the conduct of operations and preclinical trials. In addition to Health Canada restrictions on the marketing
of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in
the pharmaceutical and medical industries in recent years, as well as consulting or other service agreements with physicians or other
potential referral sources. While to the knowledge of management, MagicMed is currently in compliance with all such laws, changes to
applicable laws, regulations and guidelines may cause adverse effects to its operations. The risks to the business of MagicMed represented
by this or similar risks are that they could significantly reduce the addressable market for MagicMed&rsquo;s Psychedelic Derivatives
and could materially and adversely affect the business, financial condition and results of its operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
risks related to Psychedelic Derivatives</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
execution of MagicMed&rsquo;s strategy is contingent, in part, upon compliance with regulatory requirements from time to time enacted
by governmental authorities and obtaining all regulatory approvals, where necessary, for the development and license of its Psychedelic
Derivatives. Health Canada has not yet determined whether MagicMed&rsquo;s Psychedelic Derivatives will be scheduled as controlled substances.
The psychedelic therapy industry is a new and emerging industry with ambiguous existing regulations and uncertainty as to future regulations;
MagicMed cannot predict the impact of the ever-evolving compliance regime in respect of this industry. In the event Health Canada determines
that MagicMed&rsquo;s Psychedelic Derivatives are controlled substances and therefore, require regulatory approval, to the extent that
MagicMed produces Psychedelic Derivatives, it will be required to obtain such regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
MagicMed may not be able to predict the time required to secure all appropriate regulatory approvals for its Psychedelic Derivatives,
or the extent of testing and documentation that may, from time to time, be required by governmental authorities. The impact of compliance
regimes, any delays in obtaining, or failure to obtain regulatory approvals may significantly delay or impact the development of markets,
its business and Psychedelic Derivatives, and licensing initiatives and could have a material adverse effect on the business, financial
condition and operating results of MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional
costs for corrective measures, penalties or result in restrictions on MagicMed&rsquo;s operations. In addition, changes in regulations,
more vigorous enforcement thereof or other unanticipated events could require extensive changes to MagicMed&rsquo;s operations, increased
compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, financial condition
and operating results of MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_017"></A>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements and information in this proxy statement/prospectus and the documents included herein may constitute &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section
21E of the Exchange Act. The words &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo;
&ldquo;foresee,&rdquo; &ldquo;predict,&rdquo; &ldquo;budget,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;attempt,&rdquo;
&ldquo;appears,&rdquo; &ldquo;forecast,&rdquo; &ldquo;outlook,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;project,&rdquo;
&ldquo;projection,&rdquo; &ldquo;goal,&rdquo; &ldquo;model,&rdquo; &ldquo;target,&rdquo; &ldquo;potential,&rdquo; &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;objective,&rdquo; &ldquo;guidance,&rdquo; &ldquo;outlook,&rdquo; &ldquo;effort,&rdquo; &ldquo;are likely&rdquo;
and other similar expressions are intended to identify forward-looking statements, which are generally not historical in nature and convey
the uncertainty of future events or outcomes, although not all forward-looking statements contain such identifying words. These forward-looking
statements are based on ENVB&rsquo;s and MagicMed&rsquo;s respective current expectations and beliefs concerning future developments
and their potential effect on their respective businesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this document speak only as of the date of this proxy statement/prospectus and are largely based
on ENVB&rsquo;s and MagicMed&rsquo;s respective expectations for the future, which reflect certain estimates and assumptions made by
their respective managements. These estimates and assumptions reflect ENVB&rsquo;s and MagicMed&rsquo;s best judgment based on currently
known market conditions, operating trends and other factors. Although ENVB and MagicMed believe such estimates and assumptions to be
reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond ENVB&rsquo;s and MagicMed&rsquo;s
control. As such, managements&rsquo; assumptions about future events may prove to be inaccurate. For a more detailed description of the
risks and uncertainties involved, see &ldquo;Risk Factors&rdquo; beginning on page 46.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
cautionary statements qualify all forward-looking statements attributable to ENVB or MagicMed, or persons acting on either&rsquo;s
behalf. ENVB management and MagicMed management caution you that the forward-looking statements contained in this proxy statement/prospectus
are not guarantees of future performance, and neither ENVB nor MagicMed can assure you that such statements will be realized or
that the events and circumstances they describe will occur. These risks and uncertainties also include those set forth under &ldquo;Risk
Factors,&rdquo; beginning on page 46. Factors that could cause actual results to differ materially from those anticipated
or implied in the forward-looking statements herein include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that ENVB or MagicMed may be unable to obtain governmental and regulatory approvals required for the transaction, or that required
    governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated
    benefits from the Amalgamation or cause the parties to abandon the Amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that a condition to Closing may not be satisfied;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    length of time necessary to consummate the Amalgamation, which may be longer than anticipated for various reasons;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that the businesses will not be integrated successfully;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that the cost savings, synergies and growth from the Amalgamation may not be fully realized or may take longer to realize than
    expected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of management time on transaction-related issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of future regulatory or legislative actions on the companies or the industries in which they operate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential impact of the announcement or consummation of the Amalgamation on relationships with customers, providers, vendors, competitors,
    management and other employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
    dependence on the success of its prospective product candidates, which are in early stages of development and may not reach a particular
    stage in development, receive regulatory approval or be successfully commercialized;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    difficulties that may delay, suspend, or scale back ENVB&rsquo;s efforts to advance additional early research programs through preclinical
    development and IND application filings and into clinical development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the novel coronavirus (COVID-19) on ENVB&rsquo;s business, including current plans for product development, as well as
    any currently ongoing preclinical studies and clinical trials and any future studies or other development or commercialization activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    limited study on the effects of medical cannabinoids, and the chance that future clinical research studies may lead to conclusions
    that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing, and
    social acceptance of cannabinoids;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expensive, time-consuming, and uncertain nature of clinical trials, which are susceptible to change, delays, termination, and differing
    interpretations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to establish that potential products are efficacious or safe in preclinical or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    fact that current and future preclinical and clinical studies may be conducted outside the United States, and the United States Food
    and Drug Administration may not accept data from such studies to support any new drug applications ENVB may submit after completing
    the applicable developmental and regulatory prerequisites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to establish or maintain collaborations on the development of therapeutic candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to obtain appropriate or necessary governmental approvals to market potential products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
    ability to manufacture product candidates on a commercial scale or in collaborations with third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
    significant and increasing liquidity needs and potential requirements for additional funding;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
    ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable
    terms;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    intense competition ENVB faces, often from companies with greater resources and experience than ENVB;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
    ability to retain key executives and scientists;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to secure and enforce legal rights related to ENVB and MagicMed&rsquo;s products, including intellectual property rights
    and patent protection; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">political,
    economic, and military instability in Israel which may impede ENVB&rsquo;s development programs.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
subsequent written and oral forward-looking statements concerning ENVB, MagicMed, the Amalgamation, the combined company or other matters
and attributable to ENVB or MagicMed or any person acting on their behalf are expressly qualified in their entirety by the cautionary
statements above. ENVB and MagicMed assume no duty to update or revise their respective forward-looking statements based on new information,
future events changes in circumstances or otherwise, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_018"></A>THE
ENVB SPECIAL MEETING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_019"></A>General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus is being provided to ENVB stockholders as part of a solicitation of proxies by the ENVB board of directors
for use at the ENVB special meeting and at any adjournment or postponement of the ENVB special meeting. ENVB stockholders are encouraged
to read the entire document carefully, including the annexes to this document, for more detailed information regarding the Amalgamation
Agreement and the transactions contemplated by the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus is first being mailed on or about [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ], 2021 and constitutes notice of the ENVB special meeting in conformity
with the requirements of the DGCL and the ENVB amended and restated bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_020"></A>Date,
Time and Place</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB special meeting will be held virtually at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ], on [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] [a.m.][p.m.], Eastern Time. The ENVB special meeting can be
accessed by visiting [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], where ENVB stockholders will be able to participate and vote online.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_021"></A>Purpose
of the ENVB Special Meeting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the ENVB special meeting, ENVB stockholders will be asked to consider and vote upon the following matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
    ENVB Share Issuance Proposal</I> &ndash; a proposal to approve the issuance of shares of ENVB common stock to MagicMed equity holders
    in connection with the Amalgamation on the terms and conditions of the Amalgamation Agreement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
    ENVB Adjournment Proposal </I>&ndash; a proposal to approve one or more adjournments of the ENVB special meeting, if necessary, to
    solicit additional proxies in favor of the ENVB Share Issuance Proposal if there are insufficient votes at the time of such adjournment
    to approve such proposal or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to
    ENVB stockholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ENVB
will transact no other business at the ENVB special meeting or any adjournment or postponement thereof, except such business as may properly
be brought before the ENVB special meeting by or at the direction of the ENVB board of directors in accordance with the ENVB amended
and restated bylaws. This proxy statement/prospectus, including the Amalgamation Agreement attached hereto as <U>Annex A</U>, contains
further information with respect to these matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_022"></A>Recommendation
of the ENVB Board of Directors</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
careful consideration, the ENVB board of directors has (i) determined that the Amalgamation Agreement and the other transactions
contemplated thereby, including the Amalgamation of Purchaser with MagicMed and the issuance of ENVB common stock contemplated
by the ENVB Share Issuance Proposal, are advisable and in the best interests of ENVB and the ENVB stockholders, (ii) authorized and approved
ENVB&rsquo;s execution, delivery and performance of the Amalgamation Agreement in accordance with its terms and ENVB&rsquo;s consummation
of the transactions contemplated thereby, including the Amalgamation and the issuance of ENVB common stock contemplated by the ENVB Share
Issuance Proposal, (iii) resolved that the approval of the ENVB Share Issuance Proposal be submitted to a vote at a meeting of the holders
of ENVB common stock and (iv) recommended that the holders of ENVB common stock approve the ENVB Share Issuance Proposal. Certain factors
considered by the ENVB board of directors in reaching its decision to approve and adopt the Amalgamation Agreement and the Amalgamation
can be found in the section of this proxy statement/prospectus entitled &ldquo;The Amalgamation &ndash; Recommendation of the ENVB
Board of Directors; ENVB&rsquo;s Reasons for the Transactions&rdquo; beginning on page 99.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
ENVB board of directors unanimously recommends that ENVB stockholders vote &ldquo;FOR&rdquo; the ENVB Share Issuance Proposal and &ldquo;FOR&rdquo; the ENVB Adjournment Proposal.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
stockholders&rsquo; approval of the ENVB Share Issuance Proposal is a condition for the Amalgamation to occur. If ENVB stockholders fail
to approve the ENVB Share Issuance Proposal by the requisite vote, the Amalgamation will not occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_023"></A>Record
Date; Stockholders Entitled to Vote</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors has fixed the close of business on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ], 2021 as the record date for the ENVB special meeting (the &ldquo;Record
Date&rdquo;). Only holders of record of shares of ENVB common stock at the close of business on the Record Date are entitled to receive
notice of, and to vote at, the ENVB special meeting or at any postponement(s) or adjournment(s) of the ENVB special meeting. As of the
Record Date, there were [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of ENVB common stock outstanding and entitled to vote at the ENVB special meeting held by approximately
[ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] holders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of ENVB common stock entitles the holder to one vote at the ENVB special meeting on each proposal to be considered at the ENVB
special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
complete list of stockholders entitled to vote at the ENVB special meeting will be available for examination during normal business
hours by any ENVB stockholder in the Corporate Secretary&rsquo;s Office at Enveric Biosciences, Inc., 4851 Tamiami Trail N, Suite 200,
Naples, Florida 34103 for a period of at least ten days prior to the ENVB special meeting. If you would like to inspect the list
of ENVB stockholders of record, please call ENVB&rsquo;s Investor Relations contact at (212) 896-1254 to schedule an appointment or request
access. A certified list of eligible ENVB stockholders will be available for inspection during the special meeting at [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
by entering the control number provided on your proxy card, voting instruction form or notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_024"></A>Quorum;
Adjournment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB amended and restated bylaws provide that the</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> presence, in person
or by proxy, of the holders of a majority of the voting power of the stock issued, outstanding and entitled to vote at the ENVB special
meeting is necessary to constitute a quorum to transact business. Based on the number of shares of ENVB common stock issued and outstanding
as of the Record Date, [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] shares of ENVB common stock must be present in
person or represented by proxy at the ENVB special meeting to constitute a quorum. Virtual attendance at the special meeting will constitute
presence in person for the purpose of determining the presence of a quorum for the transaction of business at the ENVB special meeting.
Abstentions will count for the purpose of determining the presence of a quorum for the transaction of business at the ENVB special
meeting. Broker non-votes, if any, will not be counted for the purpose of determining the presence of a quorum for the transaction of
business at the ENVB special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a quorum is not present or represented at the ENVB special meeting, the chairperson of the meeting or the stockholders entitled to vote
at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting to another date, without notice other
than announcement at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
of a quorum to be represented at the ENVB special meeting will result in an adjournment of the ENVB special meeting and may subject ENVB
to additional expense. Even if a quorum is present, the ENVB special meeting may also be adjourned in order to provide more time to solicit
additional proxies in favor of approval of the ENVB Share Issuance Proposal if sufficient votes are cast in favor of the ENVB Adjournment
Proposal or the chairman of the meeting so moves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken
unless the adjournment is for more than 30 days, in which case a notice of the adjourned meeting will be given to each stockholder of
record entitled to vote at the meeting. If after the adjournment a new record date for the stockholders entitled to vote is fixed for
the adjourned meeting, the ENVB board of directors must fix a record date for the adjourned meeting in accordance with the DGCL and provide
a new notice of the adjourned meeting to each stockholder of record entitled to vote at the meeting. In addition, the ENVB special meeting
could be postponed before it commences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the ENVB special meeting is adjourned or postponed for the purpose of soliciting additional votes, stockholders who have already submitted
their proxies will be able to revoke them at any time prior to the final vote on the proposals. If you submit your proxy over the Internet
or by telephone or submit a properly executed proxy card, even if you abstain from voting, your shares will be counted as present for
purposes of determining whether a quorum exists at the ENVB special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_025"></A>Vote
Required for Approval</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
approval of the ENVB Share Issuance Proposal requires the affirmative vote of a majority of the votes cast by holders of ENVB&rsquo;s
common stock as of the Record Date present in person or represented by proxy at the ENVB special meeting. The approval of the ENVB Adjournment
Proposal requires the affirmative vote of a majority of the voting power of the shares of ENVB common stock present in person or represented
by proxy at the ENVB special meeting and entitled to vote on the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_026"></A>Abstentions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the ENVB special meeting, an abstention occurs when a ENVB stockholder attends the ENVB special meeting, either in
person (via the special meeting website) or by proxy, but abstains from voting. For the ENVB Share Issuance Proposal, if a ENVB
stockholder present in person (via the virtual meeting website) at the ENVB special meeting abstains from voting, or responds by
proxy with an &ldquo;abstain&rdquo; vote, it will have no effect on the outcome such proposal. For the ENVB Adjournment Proposal, if
a ENVB stockholder present in person (via the virtual meeting website) at the ENVB special meeting abstains from voting, or responds
by proxy with an &ldquo;abstain&rdquo; vote, it will have the same effect as a vote cast &ldquo;AGAINST&rdquo; such
proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_027"></A>Failure
to Vote</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of record and you do not sign and return your proxy card or vote over the Internet, by telephone or at the ENVB
special meeting, your shares will not be voted at the ENVB special meeting, will not be counted as present in person or by proxy at the
ENVB special meeting and will not be counted as present for purposes of determining whether a quorum exists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the ENVB Share Issuance Proposal, provided a quorum is present, a failure to vote will have no effect on the outcome of a
vote on the ENVB Share Issuance Proposal. For purposes of the ENVB Adjournment Proposal, provided a quorum is present, a failure to vote
will have the effect of a vote &ldquo;AGAINST&rdquo; the ENVB Adjournment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_030"></A>Shares
Held in Street Name</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares of ENVB common stock are held in an account at a bank, broker or other nominee holder of record (<I>i.e.,</I> in &ldquo;street
name&rdquo;), you must provide the record holder of your shares with instructions on how to vote the shares. Please follow the voting
instructions provided by the bank, broker or other nominee. You may not vote shares held in street name by returning a ENVB proxy card
directly to ENVB or by voting in person at the ENVB special meeting unless you provide a &ldquo;legal proxy,&rdquo; which you must obtain
from your bank, broker or other nominee. Further, banks, brokers or other nominees who hold shares of ENVB common stock on behalf of
their customers may not give a proxy to ENVB to vote those shares with respect to the ENVB Share Issuance Proposal and the ENVB Adjournment
Proposal without specific instructions from their customers, as banks, brokers and other nominees do not have discretionary voting power
on these &ldquo;non-routine&rdquo; matters. Under the current rules of the NYSE, each of the proposals to be considered at the ENVB special
meeting as described in this proxy statement/prospectus are considered non-routine. Therefore banks, brokers and other nominee holders
of record do not have discretionary authority to vote on any of the proposals to be considered at the ENVB special meeting. Broker non-votes
occur when a broker or nominee is not instructed by the beneficial owner of shares to vote on a particular proposal for which the broker
does not have discretionary voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore,
if you are a ENVB stockholder and you do not instruct your bank, broker or other nominee on how to vote your shares, your bank, broker
or other nominee may not vote your shares on the ENVB Share Issuance Proposal or the ENVB Adjournment Proposal, which broker non-votes,
if any, will have no effect on the vote count for such proposal.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_028"></A>Voting
by ENVB&rsquo;s Directors and Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the close of business on the Record Date, directors and executive officers of ENVB and their affiliates were entitled to vote [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
shares of ENVB common stock, or [less than 1%] of the issued and outstanding shares of ENVB common stock on that date. The
number and percentage of shares of ENVB common stock owned by directors and executive officers of ENVB and their affiliates as of the
Record Date are not expected to be meaningfully different from the number and percentage as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021. In accordance with the voting
agreements entered into between the directors and executive officers of ENVB and MagicMed, ENVB currently expects that the ENVB directors
and executive officers will vote their shares of ENVB common stock in favor of the ENVB Share Issuance Proposal and the ENVB Adjournment
Proposal. For
information with respect to the voting agreements between the directors and executive officers of ENVB and MagicMed and the ENVB common
stock owned by directors and executive officers of ENVB, please see the sections entitled &ldquo;Ancillary Agreements&rdquo; and &ldquo;Principal
Stockholders of ENVB.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_029"></A>Voting
at the ENVB Special Meeting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB special meeting will be a completely virtual meeting. There will be no physical meeting location and the meeting will only be conducted
via live webcast. The virtual ENVB special meeting will be held on [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021 at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] [a.m./p.m.], Eastern Time. To participate in the
ENVB special meeting and submit questions during the special meeting, visit [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] and enter the 16-digit control number on the proxy card,
voting instruction form or notice you received. Online check-in will begin at [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] [a.m./p.m.], Eastern Time. Please allow time for online
check-in procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors has appointed David I. Johnson, Chief Executive Officer of ENVB, and Carter J. Ward, Chief Financial Officer
of ENVB, to serve as the proxies for the ENVB special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
virtual stockholder meeting format uses technology designed to increase stockholder access, save ENVB and ENVB stockholders time and
money, and provide ENVB stockholders rights and opportunities to participate in the meeting similar to what they would have at an in-person
meeting. In addition to online attendance, ENVB provides stockholders with an opportunity to hear all portions of the official meeting,
submit written questions and comments during the meeting, and vote online during the open poll portion of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Although
ENVB offers four different voting methods, ENVB encourages you to submit a proxy to vote either over the Internet or by telephone to
ensure that your shares are represented and voted at the ENVB special meeting.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
    Submit a Proxy to Vote over the Internet:</B> To submit a proxy to vote over the Internet, go to [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] and follow the steps outlined
    on the secured website. You will need the number included on your proxy card to obtain your records and to create an electronic voting
    instruction form. If you submit your proxy to vote over the Internet, you do not have to mail in a proxy card. If you choose to submit
    your vote via proxy over the Internet, you must do so prior to 11:59 p.m., Eastern Time, on [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
    Submit a Proxy by Telephone:</B> To submit a proxy to vote by telephone, call toll-free [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] within the U.S., U.S. territories and
    Canada on a touch-tone telephone. Please have your proxy card available for reference because you will need the validation details
    that are located on your proxy card in order to submit your vote by proxy by telephone. If you submit your proxy to vote by telephone,
    you do not have to mail in a proxy card. If you choose to submit your vote via proxy by telephone, you must do so prior to 11:59
    p.m., Eastern Time, on [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
    Submit a Proxy by Mail:</B> To submit a proxy to vote by mail, complete, sign and date the proxy card and return it promptly to the
    address indicated on the proxy card in the postage paid enveloped provided. If you sign and return your proxy card without indicating
    how you want your shares of ENVB common stock to be voted with regard to a particular proposal, your shares of ENVB common stock
    will be voted in favor of such proposal. If you return your proxy card without a signature, your shares will not be counted as present
    at the ENVB special meeting and cannot be voted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
    Virtually at the ENVB Special Meeting:</B> Voting virtually at the ENVB special meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your shares are held by your bank, broker, trust or other nominee, you are considered the beneficial owner of shares held in &ldquo;street
name&rdquo; and you will receive a vote instruction form from your bank, broker, trust or other nominee seeking instruction from you
as to how your shares should be voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you sign your proxy, but do not indicate how you wish to vote, your shares will be voted &ldquo;FOR&rdquo; the ENVB Share Issuance Proposal and &ldquo;FOR&rdquo; the ENVB Adjournment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this proxy statement/prospectus, ENVB has no knowledge of any business that will be presented for consideration at the
ENVB special meeting and which would be required to be set forth in this proxy statement/prospectus other than the matters set forth
in the accompanying Notice of Special Meeting of Stockholders of ENVB. In accordance with ENVB&rsquo;s amended and restated bylaws and
Delaware law, business transacted at the ENVB special meeting will be limited to those matters set forth in such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
vote as an ENVB stockholder is very important. Please submit your proxy as soon as possible, whether or not you plan to virtually attend
the ENVB special meeting.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_031"></A>Revocation
of Proxies and Voting Instructions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can change or revoke your proxy at any time before the final vote at the ENVB special meeting. If you are the stockholder of record of
your shares, you may revoke your proxy by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submitting
    another proxy over the Internet or by telephone prior to 11:59 p.m., Eastern Time, on [ ], 2021;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
    delivering a written notice that you are revoking your proxy to ENVB&rsquo;s Corporate Secretary;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
    delivering a valid, later-dated proxy; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attending
    the ENVB special meeting and voting. Your attendance at the ENVB special meeting will not revoke your proxy unless you give written
    notice of revocation to ENVB&rsquo;s Corporate Secretary before your proxy is exercised or unless you vote your shares in person
    at the ENVB special meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
your shares of ENVB common stock are held in street name, your bank, broker or other nominee should provide instructions explaining how
you may change or revoke your voting instructions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_032"></A>Tabulation
of Votes</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
will appoint an inspector of election for the ENVB special meeting to tabulate the affirmative and negative votes, broker non-votes and
abstentions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_033"></A>Solicitation
of Proxies</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors is soliciting your proxy in connection with the ENVB special meeting, and ENVB will bear the cost of soliciting
such proxies, including the costs of printing and mailing this proxy statement/prospectus. ENVB has retained Kingsdale Advisors as proxy
solicitor to assist with the solicitation of proxies in connection with the ENVB special meeting. ENVB estimates it will pay Kingsdale
Advisors a fee of approximately $12,000, in addition to the reimbursement of expenses, for these services. Solicitation initially
will be made by mail. Forms of proxies and proxy materials may also be distributed through banks, brokers and other nominees to the beneficial
owners of shares of ENVB common stock, in which case these parties will be reimbursed for their reasonable out-of-pocket expenses. Proxies
may also be solicited in person or by telephone, facsimile, electronic mail, or other electronic medium by certain of ENVB&rsquo;s directors,
officers and employees, without additional compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_034"></A>Appraisal
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
stockholders are not entitled to appraisal or dissenters&rsquo; rights in connection with the Amalgamation. For additional information,
please see &ldquo;The Amalgamation&mdash;No Appraisal Rights.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_035"></A>Householding
of ENVB Special Meeting Materials</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -4.3pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
registered ENVB stockholder will receive one copy of this proxy statement/prospectus per account, regardless of whether you have the
same address as another stockholder of record. SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements
for proxy statements and notices with respect to two or more stockholders sharing the same address by delivering a single proxy statement
or a single notice addressed to those stockholders. This process, commonly called &ldquo;householding,&rdquo; provides cost savings for
companies. Some brokers household proxy materials, delivering a single proxy statement or notice to multiple stockholders sharing an
address unless contrary instructions have been received from the affected stockholders. For more details, see &ldquo;Householding of
Proxy Materials.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_036"></A>Questions
and Assistance</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you need assistance in completing your proxy card or have questions regarding the various voting options with respect to the ENVB special
meeting, please contact Kingsdale Advisors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kingsdale
Advisors<BR>
</B>Strategic Shareholder Advisor and Proxy Solicitation Agent<BR>
745 Fifth Avenue, 5th Floor, New York, NY 10151<BR>
Stockholders May Call or Email:<BR>
North American Toll Free Phone: 1-866-851-2468<BR>
or<BR>
Email: <U>contactus@kingsdaleadvisors.com</U><BR>
or<BR>
Call Collect Outside North America: (416) 867-2272</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_037"></A>THE
PARTIES TO THE AMALGAMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_038"></A>Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>4851
Tamiami Trail N, Suite 200&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Naples,
Florida 34103&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>(239)
302-1707</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ENVB
is an early-development-stage biosciences company with an initial focus on developing innovative, evidence-based prescription products
and combination therapies containing cannabinoids to address unmet needs in cancer care. ENVB seeks to improve the lives of patients
suffering from cancer, initially by developing palliative and supportive care products for people suffering from certain side effects
of cancer and cancer treatment such as pain or skin irritation. ENVB intends to offer such palliative and supportive care products in
the United States, following approval through established regulatory pathways. ENVB is also aiming to advance a pipeline of novel cannabinoid
combination therapies for hard-to-treat cancers, including glioblastoma multiforme (GBM) and several other indications which are currently
being researched. ENVB is incorporated in Delaware with its principal executive offices located at 4851 Tamiami Trail N, Suite 200
in Naples, Florida 34103 and its telephone number is (239) 302-1707. ENVB common stock trades on the NASDAQ Capital Market under
the symbol &ldquo;ENVB.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">For
more information about ENVB, please visit ENVB&rsquo;s website at www.enveric.com. The information contained on ENVB&rsquo;s website
or accessible through it does not constitute a part of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><A NAME="o_039"></A>1306432
B.C. Ltd.</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>4851
Tamiami Trail N, Suite 200&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Naples,
Florida 34103&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>(239)
302-1707</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">HoldCo
is a wholly-owned subsidiary of ENVB that was incorporated on May 20, 2021 under the BCBCA solely for the purpose of entering
into the Amalgamation Agreement and effecting the Amalgamation and the other transactions contemplated by the Amalgamation Agreement.
It is not engaged in any business and has no material assets, liabilities or other obligations of any nature other than as set forth
in the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><A NAME="o_040"></A>1306436
B.C. Ltd.</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>4851
Tamiami Trail N, Suite 200&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Naples,
Florida 34103&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>(239)
302-1707</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Purchaser
is an indirect wholly-owned subsidiary of ENVB that was incorporated on May 20, 2021 under the BCBCA solely for the
purpose of entering into the Amalgamation Agreement and effecting the Amalgamation and the other transactions contemplated by the
Amalgamation Agreement. It is not engaged in any business and has no material assets, liabilities or other obligations of any nature
other than as set forth in the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><A NAME="o_041"></A>MagicMed
Industries Inc.</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>777
Hornby Street, Suite 600,&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Vancouver,
British Columbia,&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>V6Z
1S4&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>(508)
627-0485</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
was incorporated under the BCBCA on May 26, 2020. MagicMed is a neuro-pharmaceutical drug discovery and development platform. MagicMed
has focused on assembling a portfolio of intellectual property (referred to as the Psybrary<SUP>TM</SUP> described further below) relating
to the synthesis, production and manufacturing of novel psychedelic molecular compounds and derivatives (&ldquo;Psychedelic Derivatives&rdquo;)
along with processes relating to their synthesis, production and manufacturing. These Psychedelic Derivatives are intended to be essential
building blocks in the development of psychedelic therapies and medicines for diverse psychological and neuropsychiatric indications.
MagicMed considers its business and related activities to be typical for a biopharma business focused on preclinical drug discovery and
development. MagicMed&rsquo;s business is centered on the development of the Psybrary<SUP>TM</SUP>, a proprietary physical and knowledgebase
collection of novel Psychedelic Derivative drug candidates, manufacturing methods, pharmacological data, and patent filings that protect
the foregoing. MagicMed has 13 patent applications filed for derivatives of psilocybin and DMT, 2 patent applications filed for derivatives
of mescaline and MDMA with further intellectual property protection for mescaline, MDMA, ibogaine and LSD in process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
principal executive offices are located at 777 Hornby Street, Suite 600, Vancouver, British Columbia, V6Z 1S4. MagicMed shares are not
traded on a national securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_042"></A>THE
AMALGAMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion contains certain information about the Amalgamation between ENVB and MagicMed. The discussion is subject, and qualified
in its entirety by reference, to the Amalgamation Agreement attached as <U>Annex A</U> to this proxy statement/prospectus, and incorporated
by reference into this proxy statement/prospectus. This summary does not purport to be complete and may not contain all of the information
about the Amalgamation that is important to you. We urge you to read carefully this entire proxy statement/prospectus, including the
Amalgamation Agreement attached as <U>Annex A</U>, for a more complete understanding of the Amalgamation.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_043"></A>Transaction
Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in the Amalgamation Agreement, and in accordance with the BCBCA, at the effective time
of the amalgamation, Purchaser, a wholly-owned subsidiary of HoldCo, will be amalgamated with MagicMed. Upon completion of the
amalgamation, the separate corporate existences of Purchaser and MagicMed will cease, and the amalgamated corporation (&ldquo;AmalCo&rdquo;)
will continue as the surviving corporation and as a wholly-owned subsidiary of HoldCo under the name &ldquo;Enveric Biosciences
Canada Inc.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_044"></A>Consideration
to MagicMed Shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Amalgamation, holders of outstanding common shares of MagicMed (the &ldquo;MagicMed Shares&rdquo;) will receive
such number of shares of ENVB common stock representing, together with the shares of ENVB common stock issuable upon exercise of the
MagicMed Warrants and the MagicMed Converted Options (as defined below), approximately 36.6% of the issued and outstanding shares of
ENVB common stock (on a fully-diluted basis).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MagicMed Shares will initially be converted into AmalCo Redeemable Preferred Shares (as defined in the Amalgamation Agreement),
which immediately following the Amalgamation will be redeemed for 0.000001 of a share of ENVB common stock. Following the redemption,
the shareholders of MagicMed will be entitled to receive additional shares of ENVB common stock equal to the product of the Exchange
Ratio multiplied by the number of MagicMed Shares held by each such shareholder. In addition, following the effective time: (i)
each outstanding MagicMed stock option will be converted into and become an option to purchase (the &ldquo;MagicMed Converted
Options&rdquo;) the number of shares of ENVB common stock equal to the Exchange Ratio multiplied by the number of MagicMed Shares
subject to such MagicMed stock option, and (ii) each holder of an outstanding MagicMed warrant (including Company Broker Warrants
(as defined in the Amalgamation Agreement), the &ldquo;MagicMed Warrants&rdquo;) will be entitled to receive upon exercise of
such MagicMed Warrant that number of shares of ENVB common stock which the holder would have been entitled to receive as a result
of the Amalgamation if, immediately prior to the date of the Amalgamation, such holder had been the registered holder of the number
of MagicMed Shares to which such holder would have been entitled if such holder had exercised such holder&rsquo;s MagicMed Warrants
immediately prior to the effective time of the Amalgamation. The terms of the options and warrants have not yet been finalized.
Once the terms of the options and warrants are finalized, this may or may not impact the classification and accounting for such
options and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_045"></A>Background
of the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ENVB&rsquo;s ongoing strategic planning process, members of the ENVB board of directors and members of ENVB senior management
periodically review and assess ENVB&rsquo;s operations, financial performance and competitive position, as well as industry trends and
potential strategic initiatives. In addition, members of ENVB senior management meet with members of the ENVB board of directors in the
ordinary course of business to discuss strategic alternatives in order to enhance shareholder value, including, among other things, business
combinations, acquisitions, divestitures and share repurchases. In connection with these reviews and assessments, from time to time,
the ENVB board of directors and members of ENVB senior management enlist the assistance of financial advisors and outside legal advisors.
In furtherance of its strategy, over the past several years, ENVB has from time-to-time considered potential strategic transaction partners.
In particular, at various times between 2019 and 2020, ENVB conducted periodic assessments of a potential strategic transaction with
companies with products and services substantially similar to MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26 and 27, 2021, Mr. Avani Kanubaddi, Chief Operating Officer of ENVB, attended the inaugural virtual Psychedelics Investor Conference
hosted by KCSA Strategic Communications (the &ldquo;KCSA Conference&rdquo;). During the course of the two-day KCSA Conference, Mr. Kanubaddi
heard virtual presentations from approximately twelve companies, including a virtual presentation by Mr. Joseph Tucker, President and
Chief Executive Officer of MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the course of the next several months, Mr. David Johnson, Chief Executive Officer of ENVB, and Mr. Kanubaddi discussed from time to time
the merits of a potential acquisition of MagicMed by ENVB. During this same period, Mr. Johnson discussed from to time the merits of
a potential acquisition of MagicMed with various members of the ENVB board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2021, the ENVB board of directors held a virtual regular meeting at which representatives of ENVB&rsquo;s senior management
team were present. Among other things, the ENVB board of directors discussed the merits of a potential business development transaction
with a number of companies, including MagicMed. At the conclusion of the meeting, the ENVB board of directors authorized Mr. Johnson
to initiate a preliminary discussion regarding the potential merits of a business combination or partnership between ENVB and a number
of companies including MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2021, Mr. Johnson sent an email to Mr. Tucker at MagicMed to introduce himself, learn more about MagicMed&rsquo;s business,
and discuss potential opportunities for ENVB and MagicMed to partner together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, Mr. Johnson, Mr. Kanubaddi, Mr. Tucker and Mr. Richard Sherwin, a consultant with API Consulting Limited engaged by MagicMed,
attended a video conference to discuss the culture and strategic direction of each company, as well as potential opportunities for MagicMed
to provide research and development services to ENVB regarding various products and therapies under development at ENVB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 14, 2021, Messrs. Johnson and Kanubaddi contacted Messrs. Tucker and Sherwin by telephone to discuss their views on a potential
business combination between ENVB and MagicMed. Mr. Johnson suggested that there was strategic rationale for a business combination between
the companies and indicated his belief that a business combination could enhance value for both companies&rsquo; stockholders and offered
potential synergies. No proposal was made by Mr. Johnson during this conversation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 14, 2021, Mr. Tucker sent Mr. Johnson a mutual non-disclosure agreement. The parties exchanged comments to the non-disclosure agreement
over the next five days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2021, the parties signed the mutual non-disclosure agreement, after which the parties began to conduct mutual due diligence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2021, Mr. Tucker contacted Mr. Johnson by telephone to schedule a call over the next few days to discuss the merits of a potential
business combination. In addition, Mr. Tucker advised Mr. Johnson that MagicMed was also considering a direct listing on the Canadian
Securities Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2021, Mr. Tucker contacted Mr. Johnson by telephone to discuss the merits of a potential business combination, including the
business plan and strategy of the combined company, the potential management team of the combined company, and potential capitalization
of the combined company. Mr. Tucker also informed Mr. Johnson that a leading Canadian psychedelic medicine biotech company had its subordinate
voting shares approved for listing on The Nasdaq Capital Market (&ldquo;NASDAQ&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 27, 2021, the ENVB board of directors held a virtual meeting at which representatives of ENVB&rsquo;s senior management
team  ,and Haynes and Boone LLP, outside legal counsel to ENVB (&ldquo;HaynesBoone&rdquo;), were present to discuss the strategic
merits of a potential acquisition of MagicMed, potential transaction terms, potential value creation for each party&rsquo;s shareholders
and various financial metrics. Mr. Johnson provided details regarding his recent communications with Mr. Tucker and the directors discussed
the terms of a potential proposal to be formally submitted to MagicMed. The ENVB board of directors also determined that it would be
advisable to convene recurring special meetings going forward in order for management to provide frequent updates to the directors regarding
the status of the potential opportunity and management&rsquo;s further discussions with MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, Mr. Johnson provided a non-binding term sheet to Mr. Tucker for an all-stock transaction that valued MagicMed
common shares at C$0.75 per share (with an approximate exchange ratio of 0.2284 shares of ENVB common stock for
each MagicMed common share). Following submission of this proposal, Mr. Johnson called Mr. Tucker to discuss the proposal. During this
conversation, Mr. Johnson expressed his views as to the strategic rationale for the proposed business combination and indicated that
a combined company could achieve significant synergies and create significant value for each company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the next three days, Messrs. Johnson and Kanubaddi and representatives of Palladium held several telephone calls with representatives
of MagicMed to discuss ENVB&rsquo;s proposal. During this same period, representatives of MagicMed proposed certain changes to the
exchange ratio methodology, the lock-ups of certain key persons of MagicMed and an increase to the threshold for breach of the no-shop
provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 2, 2021, the ENVB board of directors held a virtual meeting at which representatives of ENVB&rsquo;s senior management team, Palladium
and HaynesBoone were present to update the ENVB board of directors on the information exchanged during the due diligence sessions and
its effect on management&rsquo;s estimates of the financial impacts of the proposed transaction, and to summarize the discussions between
ENVB&rsquo;s and MagicMed&rsquo;s management teams and representatives since the prior board meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on May 2, 2021, ENVB executed an engagement letter with Palladium to serve as its financial advisor in connection with a potential acquisition
of MagicMed. In connection therewith, Palladium provided information about its investment banking relationships during the prior two-year
period such that ENVB determined that Palladium did not have any disqualifying conflicts of interest in serving as its financial advisor
in connection with the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 2, 2021, ENVB and MagicMed signed a non-binding term sheet for an all-stock transaction that valued MagicMed common shares at $0.75
per share (with an approximate exchange ratio of 0.2284 shares of ENVB common stock for each share of MagicMed common share).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2021, ENVB, MagicMed and their respective financial and legal advisors commenced several discussions and exchanged information
as part of the reciprocal due diligence process in order to further refine each party&rsquo;s view of potential synergies and better
understand the other&rsquo;s businesses.<SUP></SUP> Over the next several days, each of ENVB&rsquo;s and MagicMed&rsquo;s senior management
teams and representatives of HaynesBoone, Stikeman Elliott LLP (&ldquo;Stikeman&rdquo;), outside Canadian counsel to ENVB, and MagicMed&rsquo;s
outside Canadian counsel, Greenfields Law (&ldquo;Greenfields&rdquo;) and Burnet, Duckworth &amp; Palmer, LLP (&ldquo;Burnet&rdquo;),
engaged in several discussions regarding the key terms to be included in the definitive transaction agreement. Also on May 3, 2021, ENVB
engaged Torys LLP, outside legal counsel, to conduct a review of certain due diligence matters in connection with a potential acquisition
of MagicMed</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2021, MagicMed opened a virtual data room and invited ENVB and its advisors to review due diligence materials. On May 5, 2021,
ENVB opened a virtual data room and invited MagicMed and its advisors to review certain due diligence materials relating to ENVB. Thereafter,
the parties and their advisors continued to conduct financial, accounting, tax, operational and legal due diligence through mid-May 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2021, ENVB delivered an initial draft of the Amalgamation Agreement to Mr. Tucker. The draft Amalgamation Agreement contemplated,
among other things, (i) a transaction in which a wholly-owned subsidiary of ENVB would be amalgamated with MagicMed, with the amalgamated
company surviving the Amalgamation; (ii) a regulatory framework in line with the terms previously discussed by the parties; (iii) largely
reciprocal non-solicitation provisions applicable to ENVB and MagicMed that would allow each of the MagicMed board of directors and the
ENVB board of directors, under certain circumstances, to change its recommendation in the event of a superior proposal or intervening
event; and (iv) a so-called &ldquo;force the vote&rdquo; provision requiring each of ENVB and MagicMed to submit the approval and adoption
of the Amalgamation Agreement and the issuance of ENVB common stock, respectively, to its stockholders notwithstanding any change in
recommendation by the MagicMed board of directors and the ENVB board of directors, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
early May through May 24, 2021, ENVB and MagicMed and their respective legal counsel exchanged multiple drafts of the Amalgamation Agreement
and other ancillary documents, as applicable, and held multiple conference calls to discuss due diligence, the transaction agreements
and various issues. The discussions and negotiations included numerous telephone conversations between the parties&rsquo; management
teams, representatives and advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, ENVB&rsquo;s board of directors held a meeting via video conference at which representatives of ENVB&rsquo;s senior management
team were present. At the prior invitation of ENVB&rsquo;s board of directors, Dr. Tucker joined the virtual meeting to provide a presentation
to ENVB&rsquo;s board of directors about MagicMed&rsquo;s business and responded to various questions from ENVB&rsquo;s board of directors.
Also on May 11, 2021, HaynesBoone, Greenfields and Burnet had a conference call to discuss certain issues related to the Amalgamation
Agreement, including the proposed timing for closing the amalgamation, timing of the required shareholder meetings of ENVB and MagicMed,
the required governmental and third-party filings for closing, and any additional steps needed to sign and close the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
mid-May, ENVB&rsquo;s nominating and corporate governance committee held interviews with certain directors on the MagicMed board of directors
for purposes of selecting the two MagicMed representatives that would serve on ENVB&rsquo;s board of directors after the closing of the
proposed transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, ENVB engaged Gemini Valuation Services, LLC (&ldquo;Gemini&rdquo;) to issue a fairness opinion in connection with the proposed
transaction with MagicMed.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2021, Greenfields circulated a revised draft of the Amalgamation Agreement to HaynesBoone that included certain meaningful changes,
including the addition of a fiduciary out provision based upon receipt of a superior proposal and provisions covering a termination fee
if a party terminated the Amalgamation Agreement for certain reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2021, HaynesBoone updated ENVB&rsquo;s senior management on the status of negotiations of the Amalgamation Agreement, including
with respect to superior proposals, covenants, termination rights and fees and related considerations regarding closing certainty, as
well as a potential timeline for the completion of due diligence and summarized key due diligence findings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2021 and May 19, 2021, ENVB and HaynesBoone attended conference calls with MagicMed and Greenfields and Burnet to discuss the
documents needed for signing and the status of each of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2021 MagicMed and ENVB attended a conference call to discuss the status of various open issues in the Amalgamation Agreement.
Also on May 19, 2021, HaynesBoone and Greensfields attended a conference call to discuss certain issues in the Amalgamation Agreement,
including the superior proposal provisions, proposed changes to the shareholder meeting requirements and the definition of material adverse
effect, as well as proposed changes to the termination fee provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2021, ENVB&rsquo;s board of directors had a telephonic meeting at which representatives of ENVB&rsquo;s senior management team,
Palladium, and HaynesBoone were present to discuss the strategic rationale of the proposed business combination, the framework of the
amalgamation and the potential benefits of the business combination to ENVB. In addition, HaynesBoone provided ENVB&rsquo;s board of
directors with a detailed summary of the latest draft of the Amalgamation Agreement. During the May 20, 2021 meeting, Gemini advised
the ENVB board of directors that it was prepared to render an opinion to the ENVB board of directors to the effect that, subject to the
factors and assumptions described by Gemini, the consideration for the shareholders of ENVB in the Amalgamation is fair from a financial
point of view to ENVB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2021, ENVB&rsquo;s senior management team and HaynesBoone and MagicMed&rsquo;s senior management team and Dorsey &amp; Whitney
LLP, outside U.S. counsel to MagicMed (&ldquo;Dorsey&rdquo;), attended a conference call to discuss the status of the transaction and
related documents needed for signing. Later that evening, Dorsey circulated a draft of the MagicMed disclosure statement to HaynesBoone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, ENVB&rsquo;s board of directors held a virtual meeting at which representatives of ENVB&rsquo;s senior management team,
Gemini, and HaynesBoone were present to discuss the status of the negotiations with MagicMed. During this board meeting, Gemini provided
a presentation to ENVB&rsquo;s board of directors about MagicMed&rsquo;s business and responded to various questions from ENVB&rsquo;s
board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the afternoon of May 21, 2021, the ENVB board of directors held a virtual meeting at which representatives of ENVB&rsquo;s senior
management team, Gemini, and HaynesBoone were present to review the changes to the Amalgamation Agreement that had been made since
the ENVB board of director&rsquo;s last meeting. Representatives of HaynesBoone summarized the directors&rsquo; fiduciary duties
and reviewed the material terms of the final draft of the Amalgamation Agreement, including (i) the non-solicitation obligations
of each party, (ii) the ability of each party to terminate the Amalgamation Agreement in certain circumstances and to receive
expense reimbursement and certain termination fees, (iii) provisions affecting certainty of the closing, and (iv) conduct of each
of ENVB&rsquo;s and MagicMed&rsquo;s respective businesses during the period of time between signing and closing. Representatives
of Gemini then rendered Gemini&rsquo;s oral opinion, subsequently confirmed by the delivery of a written opinion dated May 21,
2021, to the effect that, as of May 21, 2021 and based upon and subject to the limitations, assumptions and qualifications described
by Gemini, the consideration for the shareholders of ENVB in the Amalgamation is fair from a financial point of view to ENVB.
Please see the section of this proxy statement/prospectus entitled &ldquo;&mdash;Opinion of ENVB&rsquo;s Financial Advisor&rdquo;
beginning on page 103 for further description of Gemini&rsquo;s opinion and analysis. Thereafter, the ENVB board of directors
unanimously (i) determined that the Amalgamation Agreement and the transactions contemplated thereby, including the Amalgamation
and the issuance of shares of ENVB common stock contemplated by the ENVB Share Issuance Proposal, were advisable and in
the best interests of ENVB and ENVB&rsquo;s stockholders, (ii) authorized and approved ENVB&rsquo;s execution, delivery and performance
of the Amalgamation Agreement in accordance with its terms and ENVB&rsquo;s consummation of the transactions contemplated thereby,
including the Amalgamation and the issuance of shares of ENVB common stock contemplated by the ENVB Share Issuance Proposal,
(iii) resolved that the approval of the ENVB Share Issuance Proposal be submitted to a vote at a meeting of the holders
of ENVB common stock and (iv) recommended that the holders of ENVB common stock approve the ENVB Share Issuance Proposal.
For a description of the various factors considered by the ENVB board of directors, see the section entitled &ldquo;The Amalgamation&mdash;Recommendation
of the ENVB Board of Directors; ENVB&rsquo;s Reasons for the Transactions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Later
that same day, ENVB&rsquo;s senior management and HaynesBoone attended a conference call with MagicMed&rsquo;s senior management and
Dorsey to discuss the documents that needed to be finalized for signing the Amalgamation Agreement. Shortly following the conference
call, HaynesBoone sent Dorsey a revised draft of the Amalgamation Agreement to clarify the transaction structure and forms of consideration
agreed to by the parties, as well as an initial draft of the ENVB disclosure statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, Mr. Johnson notified Mr. Tucker that Mr. Tucker and Mr. Brad Thompson each had been unanimously selected by the ENVB board&rsquo;s
nominating and corporate governance committee to serve on the ENVB board of directors upon the closing, which was subsequently disclosed
to the MagicMed board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2021, HaynesBoone, Greenfields, Burnet, Stikeman and Dorsey attended a conference call to further clarify certain procedural
items and the transactions structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 23, 2021, ENVB&rsquo;s senior management and HaynesBoone held several discussions to finalize the open points in the various documents,
including the various parties that needed to enter into support agreements, the termination rights included in the support agreements
entered into with certain MagicMed shareholders, and disclosures in the MagicMed disclosure statement. Later that afternoon, Dorsey sent
HaynesBoone a revised draft of the Amalgamation Agreement to reflect certain changes to the tax structure in the Amalgamation Agreement.
HaynesBoone then had a conference call with ENVB&rsquo;s senior management to discuss the proposed changes to the Amalgamation Agreement.
Later that evening, HaynesBoone sent a proposed final draft of the MagicMed disclosure statement and the Amalgamation Agreement to Dorsey.
ENVB&rsquo;s senior management and HaynesBoone and MagicMed&rsquo;s senior management and Dorsey attended a conference call to confirm
the Amalgamation Agreement, ENVB disclosure statement, MagicMed disclosure statement and related documents were in agreed form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the open of trading on NASDAQ on the morning of May 24, 2021, ENVB and MagicMed executed and delivered the Amalgamation Agreement
and related agreements and issued a joint press release announcing the transactions contemplated by the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of the Amalgamation Agreement and related documents, see section titled &ldquo;The Amalgamation Agreement&rdquo; beginning
on page 112 and &ldquo; Ancillary Agreements&rdquo; beginning on page 129 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_046"></A>Recommendation
of the ENVB Board of Directors; ENVB&rsquo;s Reasons for the Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
a meeting held on May 21, 2021, the ENVB board of directors (i) determined that the Amalgamation Agreement and the transactions
contemplated thereby, including the amalgamation of Purchaser with MagicMed and the issuance of ENVB common stock contemplated by the
ENVB Share Issuance Proposal, are advisable and in the best interests of ENVB and the ENVB stockholders, (ii) authorized and approved
ENVB&rsquo;s execution, delivery and performance of the Amalgamation Agreement in accordance with its terms and ENVB&rsquo;s consummation
of the transactions contemplated thereby, including the Amalgamation and the issuance of ENVB common stock contemplated by the ENVB Share
Issuance Proposal, (iii) resolved that the approval of the ENVB Share Issuance Proposal be submitted to a vote at a meeting of the holders
of ENVB common stock and (iv) recommended that the holders of ENVB common stock approve the ENVB Share Issuance Proposal. <B>Accordingly,
the ENVB board of directors unanimously recommends that the stockholders of ENVB vote &ldquo;FOR&rdquo; the ENVB Share Issuance Proposal
and &ldquo;FOR&rdquo; the ENVB Adjournment Proposal, if necessary or appropriate to reach a quorum or solicit additional proxies.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
reaching its determinations and recommendations, the ENVB board of directors, as described above in the section entitled &ldquo;&mdash;Background
of the Amalgamation&rdquo; of this proxy statement/prospectus, held a number of meetings, consulted with ENVB&rsquo;s management and
its legal and financial advisors at HaynesBoone and Gemini, reviewed a significant amount of information, and considered a number of
factors. After such discussions and deliberations, the ENVB board of directors determined that the amalgamation agreement, the voting
agreement and the transactions contemplated thereby, including the amalgamation, are fair to, and in the best interests of ENVB and its
stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board&rsquo;s decision to approve the amalgamation agreement, the voting agreement and the other transactions contemplated by the
amalgamation agreement and to recommend to ENVB&rsquo;s stockholders that they vote to adopt the amalgamation agreement was based on
a number of factors that weighed positively in favor of the amalgamation and the transactions contemplated by the amalgamation agreement,
including the following (which are not necessarily presented in order of relative importance):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    current and prospective competitive climate for ENVB&rsquo;s novel prescription therapeutic drugs, the impact of the
    Psybrary, psychedelic medicines, synthetic chemistry of cannabinoids, the demand for therapies that impact the body and
    the mind, as well as the financial condition of the U.S. and global economy in general and the impact that such trends have
    had on ENVB&rsquo;s results and operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    overall cost structure of operating ENVB&rsquo;s business, including the costs associated with administrative and support functions,
    as a standalone company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB board&rsquo;s knowledge of, and discussions with ENVB management regarding, ENVB&rsquo;s business, operations, financial condition,
    earnings and prospects and its knowledge of MagicMed&rsquo;s business, operations, financial condition, earnings and prospects, the
    result of ENVB&rsquo;s due diligence review of MagicMed conducted during the course of discussions and the synergies assessment conducted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    creation of a strong supportive care focused biotechnology organization with an expanded and diversified portfolio consisting of
    MagicMed&rsquo;s novel derivative psychedelic molecules and ENVB&rsquo;s pipeline of clinical trial-ready palliative and supportive
    care products for people suffering from certain side effects of cancer, cancer treatment and CNS conditions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
    to MagicMed&rsquo;s novel derivative psychedelic molecules, synthetic chemistry expertise, and scientific expertise in psychedelics
    and cannabinoids product development and commercialization infrastructure to provide ENVB with the potential to most effectively
    maximize the value of ENVB&rsquo;s current and future pipeline of clinical trial-ready palliative and supportive care products
    program for oncology support care and CNS conditions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that, since the amalgamation consideration will consist entirely of ENVB&rsquo;s common stock, ENVB stockholders will still own
    approximately 63.4% of ENVB upon completion of the Amalgamation (on a fully-diluted basis), allowing current ENVB
    stockholders to participate in the future earnings and expected growth of the combined company and enjoy the benefits of the
    amalgamation through realization of synergies, as well as the risks and uncertainties associated with the realization of a combined
    business strategy and synergies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    the exchange ratio represents a fixed number of shares of MagicMed&rsquo;s common stock, which affords ENVB stockholders the benefit
    of any increase in the fair market value of MagicMed&rsquo;s common stock between the announcement and consummation of the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB&rsquo;s
    management&rsquo;s expectation, based on assessments conducted by both ENVB and MagicMed and the demonstrated ability of both companies
    to achieve the projected synergies in previous transactions, that the combined company is expected to realize approximately $1.54
    million in net synergies within the first 24 months after the consummation of the amalgamation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    stockholders are expected to benefit from the synergies and growth from the transaction, considering factors including MagicMed&rsquo;s
    business, assets, financial condition, results of operations, business plan and prospects, the size and scale of the combined company
    and the expected pro forma effect of the amalgamation on the combined company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    expectation that, following the amalgamation, the combined company would have a strong and healthy balance sheet that will provide
    continued financial flexibility to strategically deploy capital between investing back into the business and making strategic
    acquisitions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that, following the consummation of the amalgamation, two members of the MagicMed board of directors will be added to the ENVB
    board and the MagicMed chief executive officer will become the chief executive officer of ENVB, continuing to provide knowledge and
    insight regarding MagicMed&rsquo;s legacy business, leadership, and to be integrally involved in the strategy of the combined company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the current directors of ENVB will initially continue to be members of the ENVB board of directors following closing of
    the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    opinion of Gemini Valuation Services, LLC, dated May 21, 2021, to the ENVB board of directors as to the fairness from a financial
    point of view to the holders of ENVB common stock of the consideration provided for in the Amalgamation. See section entitled
    &ldquo;The Amalgamation&mdash;Opinion of ENVB&rsquo;s Financial Advisor&rdquo; beginning on page 103. The full text
    of the written opinion of Gemini Valuation Services, LLC is attached as <U>Annex D</U> to this proxy statement/prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    holders of approximately 30% of the issued and outstanding shares of MagicMed common shares have entered into voting agreements with
    ENVB pursuant to which, among other things, they will vote all of the MagicMed common shares they hold, directly or indirectly, or
    have the right to vote or direct the voting of, in favor of the approval of the amalgamation agreement and against any alternative
    acquisition involving MagicMed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that closing of the amalgamation is subject to obtaining the approval of the ENVB stockholders of the issuance of the securities
    of ENVB necessary to effect the transactions contemplated by the amalgamation agreement, and that the directors and officers
    of ENVB have entered into agreements to vote their shares in favor of the resolutions approving such matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    review by the ENVB board of directors with its legal and financial advisors of the structure of the proposed amalgamation and the
    terms of the amalgamation agreement, including MagicMed&rsquo;s representations, warranties and covenants, the conditions to its
    obligations and the termination provisions and related termination fees, as well as the likelihood of consummation of the proposed
    amalgamation and the ENVB board&rsquo;s evaluation of the likely time period necessary to close the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amalgamation agreement was negotiated on an arm&rsquo;s-length basis and executed following a strategic process starting in early
    2020, during which the ENVB board of directors considered, with the assistance of ENVB senior management and advisors, potential
    strategic alternatives and business combinations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    ENVB expects that, for U.S. federal income tax purposes, the amalgamation will be treated as a &ldquo;reorganization&rdquo; within
    the meaning of Section 368(a) of the Internal Revenue Code.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    impact of the amalgamation on all stakeholders in ENVB, including holders of ENVB common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors also considered the following specific aspects of the amalgamation agreement (which are not necessarily
presented in order of relative importance):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB board of directors&rsquo; belief that the terms of the amalgamation agreement, including ENVB&rsquo;s representations, warranties
    and covenants and the conditions to each party&rsquo;s obligations, are reasonable and consistent with applicable market practice.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the amalgamation agreement contains customary exclusions from the definition of &ldquo;material adverse effect,&rdquo;
    making it unlikely that MagicMed could assert the existence of a material adverse effect giving them a right not to consummate
    the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fixed exchange ratio will not adjust to compensate for changes in the fair market value of MagicMed common shares or ENVB common
    stock prior to the effective time of the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the amalgamation agreement provides that, under certain circumstances, and subject to certain conditions, ENVB is permitted
    to furnish information to and conduct negotiations with a third party in connection with an unsolicited acquisition proposal for
    an acquisition of ENVB that constitutes or would reasonably be expected to result in a superior proposal.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the ENVB board, subject to certain conditions, has the right to make a company adverse change recommendation in connection
    with a superior proposal or terminate the amalgamation agreement to enter into a definitive agreement with respect to a superior
    proposal, subject to giving MagicMed notice and an opportunity to propose changes to the amalgamation agreement, and the payment
    of a termination fee of $4.5 million in the event of actual termination.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the ENVB board of directors believed that the termination fee of $4.5 million payable under certain circumstances is reasonable
    and customary in size in transactions similar to the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that there are limited circumstances in which the MagicMed board may terminate the amalgamation agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the amalgamation agreement is not subject to any financing condition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of its deliberations, the ENVB board of directors also considered a variety of risks, uncertainties and other potentially
negative factors, including the following (which are not necessarily presented in order of relative importance):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risks and costs to ENVB if the amalgamation is not consummated, including the diversion of management and employee attention, potential
    employee attrition, the potential effect on ENVB&rsquo;s business and relations with its customers, suppliers, vendors, employees
    and independent contractors and the potential impact on its stock price and that, while the transactions are expected to be consummated,
    there is no assurance that all conditions to the parties&rsquo; obligations to consummate the transactions will be satisfied or waived,
    and, as a result, it is possible that the transactions might not be consummated even if approved by ENVB stockholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    possibility that governmental bodies may not approve the amalgamation, that such approval could be conditioned upon the taking of
    certain actions such as divestitures that MagicMed is not obligated to take under the amalgamation agreement or that such approval
    could take an extended period of time to obtain.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    transaction costs to be incurred in connection with the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            fact that ENVB stockholders could be adversely affected by a decrease in the fair market
                                            value of MagicMed&rsquo;s common shares relative to the price of ENVB&rsquo;s common stock
                                            during the pendency of the amalgamation and the fact that the amalgamation agreement does
                                            not provide ENVB with a price-based termination right, a pricing collar or cap, or other
                                            similar protection because MagicMed&rsquo;s shares are not traded publicly.</FONT></P>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    possibility that the combined company will not realize any or all of the anticipated strategic and other benefits of the amalgamation,
    including as a result of the challenges of combining the businesses, operations and workforces of ENVB and MagicMed, and the risk
    that expected operating efficiencies and cost savings synergies may not be realized or will take longer to realize than expected.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dilution to ENVB stockholders resulting from the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that MagicMed may become subject to other potential future liabilities related to past activities that are not covered by the
    indemnification provisions in the amalgamation agreement or adjustment to the exchange ratio.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk that changes in law or regulation could adversely impact the expected benefits of the amalgamation to ENVB and its stockholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the amalgamation agreement contains restrictions on the conduct of ENVB&rsquo;s business prior to the consummation of the
    amalgamation, including the requirement that ENVB conduct its business only in the ordinary course, subject to specific exceptions,
    which could delay or prevent ENVB from undertaking business opportunities that may arise pending the consummation of the amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that the amalgamation agreement imposes limitations on ENVB&rsquo;s ability to solicit alternative acquisitions prior to closing
    and its ability to terminate the amalgamation agreement, including a requirement that ENVB pay a $4.5 million termination fee in
    certain circumstances in the event of termination.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    possibility that the termination fee of $4.5 million to be paid to MagicMed if the amalgamation agreement is terminated under certain
    circumstances specified in the amalgamation agreement may potentially deter a potential acquirer from proposing an alternative acquisition
    that would provide value to ENVB stockholders superior to that of the proposed amalgamation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that ENVB&rsquo;s directors and executive officers may have interests in the amalgamation that are different from, or
    in addition to, those of ENVB&rsquo;s stockholders generally, including certain interests arising from the employment and
    compensation arrangements of ENVB&rsquo;s executive officers, and the manner in which they would be affected by the amalgamation
    as detailed in the section &ldquo;The Amalgamation&mdash;Interests of ENVB&rsquo;s Directors and Executive Officers in the Amalgamation&rdquo; beginning on page 108.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk that ENVB&rsquo;s stockholders may vote against adoption of the amalgamation agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
    other risks described in the section entitled &ldquo;Risk Factors&rdquo; beginning on page 46.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB board of directors considered all of these factors as a whole and concluded that the potentially negative factors associated with
the amalgamation agreement and the other ENVB transaction agreements and the other transactions contemplated by the amalgamation agreement
and the other ENVB transaction agreements, were outweighed by the potential benefits that it expected the ENVB stockholders would achieve
as a result of entering into the amalgamation agreement and the other ENVB transaction agreements, and consummating the transactions
contemplated thereby. Accordingly, the ENVB board of directors determined that the amalgamation agreement, the other ENVB transaction
agreements, and the other transactions contemplated by the amalgamation agreement and the other ENVB transaction agreements were advisable
and in the best interest of ENVB and the stockholders of ENVB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing discussion of the information and factors considered by the ENVB board of directors is not exhaustive. In view of the wide
variety of factors considered by the ENVB board of directors in connection with its evaluation of the amalgamation and complexity of
these matters, the ENVB board of directors did not consider it practical to, nor did it attempt to, quantify, rank or otherwise assign
relative weights to the specific factors that it considered in reaching its decision. In considering the factors described above and
any other factors, individual members of the ENVB board of directors may have viewed factors differently or given different weight or
merit to different factors. The ENVB board of directors considered all these factors as a whole, including discussions with, and questioning
of, ENVB&rsquo;s management and ENVB&rsquo;s financial and legal advisors, and overall considered the factors to be favorable to, and
to support, its determination. The ENVB board of directors also relied on the experience of Gemini, its financial advisor, for its opinion
that, as of the date of the amalgamation agreement, and based on and subject to the various assumptions made, procedures followed, factors
considered, and qualifications and limitations described in the opinion, the consideration for the shareholders of ENVB in the Amalgamation
is fair from a financial point of view to ENVB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
considering the recommendation of the ENVB board of directors that the ENVB stockholders vote to adopt the amalgamation agreement,
the ENVB board of directors was aware that the directors and executive officers of ENVB may have certain interests in the amalgamation
that may be different from, or in addition to, the interests of ENVB stockholders generally. The ENVB board of directors was aware
of these interests and considered them when approving the amalgamation agreement and recommending that ENVB stockholders vote
to adopt the amalgamation agreement. See the section entitled &ldquo;The Amalgamation&mdash;Interests of ENVB&rsquo;s Directors
and Executive Officers in the Amalgamation&rdquo; beginning on page 109.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing discussion of the information and factors considered by the ENVB board of directors is forward-looking in nature. This
information should be read in light of the factors described in the section entitled &ldquo;Cautionary Statement Regarding Forward-Looking
Statements&rdquo; beginning on page 86.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_047"></A>Opinion
of ENVB&rsquo;s Financial Advisor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2021, Gemini rendered its oral opinion to the ENVB board of directors (which was confirmed in writing by delivery of Gemini&rsquo;s
written opinion dated the same date), as to, as of May 19, 2021, the fairness, from a financial point of view, of the contribution made
and consideration received by the holders of ENVB common stock pursuant to the draft Amalgamation Agreement dated May 19, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of the opinion in this proxy statement/prospectus is qualified in its entirety by reference to the full text of the written opinion,
which is included as <U>Annex D</U> to this proxy statement/prospectus and sets forth the procedures followed, assumptions made, qualifications
and limitations on the review undertaken and other matters considered by Gemini in preparing its opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion was addressed to the ENVB board of directors for the use and benefit of the members of the ENVB board (in their capacities as
such) in connection with the ENVB board of directors&rsquo; evaluation of the Amalgamation Agreement. Neither the opinion nor the summary
of the opinion and related analyses set forth in this proxy statement/prospectus is intended to and they do not constitute advice or
a recommendation to any of the stockholders of ENVB or any other security holders as to how such holder should vote or act with respect
to any matter relating to the transaction or otherwise. Gemini&rsquo;s opinion should not be construed as creating any fiduciary duty
on Gemini&rsquo;s part to ENVB, any other party to the Amalgamation Agreement, any security holder of ENVB or such other party, any creditor
of ENVB or such other party, or any other person. Gemini&rsquo;s opinion was just one of the several factors the ENVB board of directors
took into account in making its determination to approve the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini&rsquo;s
opinion only addressed whether, as of the date of the opinion, the consideration received by the stockholders of ENVB as part of the
Amalgamation Agreement, pursuant to the Amalgamation Agreement was fair, from a financial point of view, to ENVB stockholders. It did
not address any other terms, aspects, or implications of the transaction or the Amalgamation Agreement, including, without limitation,
(i) any term or aspect of the transaction that was not susceptible to financial analysis, (ii) fairness to any security holders of ENVB,
MagicMed or any other person or any creditors or other constituencies of ENVB, MagicMed or any other person, nor (iii) the fairness of
the amount or nature, or any other aspect, of any compensation or consideration payable to or received by any officers, directors, or
employees of any parties to the transaction, or any class of such persons, relative to the consideration received by ENVB stockholders
pursuant to the Amalgamation Agreement, or otherwise. Gemini expressed no opinion as to (i) what the value of shares of ENVB common stock
actually would be when issued to the MagicMed shareholders pursuant to the Amalgamation Agreement, (ii) the price at which MagicMed shares
or any other security of MagicMed may be issued or sold in a private placement, the price at which shares of ENVB common stock or any
other security of ENVB may be issued or sold in a private placement, or (iii) the prices at which MagicMed shares or ENVB common stock
may trade, be purchased or sold at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini&rsquo;s
opinion did not address the relative merits of the transaction as compared to any alternative transaction or business strategy that might
exist for ENVB, or the merits of the underlying decision by the ENVB board of directors or ENVB to engage in or consummate the transaction.
The financial and other terms of the transaction were determined pursuant to negotiations between the parties to the Amalgamation Agreement
and were not determined by or pursuant to any recommendation from Gemini.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini&rsquo;s
analyses and opinion were necessarily based upon market, economic, and other conditions as they existed on, and could be evaluated as
of, the date of the opinion. Accordingly, although subsequent developments could arise that would otherwise affect its opinion, Gemini
did not assume any obligation to update, review, or reaffirm its opinion to the ENVB board of directors or any other person or otherwise
to comment on or consider events occurring or coming to Gemini&rsquo;s attention after the date of its opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
arriving at its opinion, Gemini made such reviews, analyses, and inquiries as Gemini deemed necessary and appropriate under the circumstances.
Among other things, Gemini:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewed
    a draft copy, received by Gemini on May 19, 2021, of the Amalgamation Agreement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewed
    certain publicly available financial information and other data with respect to MagicMed that Gemini deemed relevant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewed
    certain other information and data with respect to MagicMed made available to Gemini by ENVB, including historical financial statements
    for FY2019 and FY2020, and other internal financial information furnished to Gemini by or on behalf of MagicMed;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considered
    and compared the financial and operating performance of MagicMed with that of companies with publicly traded equity securities that
    Gemini deemed relevant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considered
    the publicly available financial terms of certain transactions that Gemini deemed relevant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discussed
    the business, operations, and prospects of MagicMed, and the proposed transaction with ENVB&rsquo;s management and certain of ENVB&rsquo;s
    representatives; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducted
    such other analyses and inquiries, and considered such other information and factors, as Gemini deemed appropriate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
arriving at its opinion, Gemini, with the ENVB board&rsquo;s consent, relied upon and assumed, without independently verifying, the accuracy
and completeness of all of the financial and other information that was supplied or otherwise made available to Gemini or available from
public sources, and Gemini further relied upon the assurances of ENVB&rsquo;s and MagicMed&rsquo;s management that they were not aware
of any facts or circumstances that would make any such information inaccurate or misleading. Gemini also relied upon, without independent
verification, the assessments of the management of ENVB as to MagicMed&rsquo;s existing and future technology, products and services
and the validity and marketability of, and risks associated with, such technology, products and services (including, without limitation,
the development, testing and marketing of such technology, products and services; the receipt of all necessary governmental and other
regulatory approvals for the development, testing and marketing thereof; and the life of all relevant patents and other intellectual
and other property rights associated with such technology, products and services), and Gemini assumed, at the ENVB board&rsquo;s direction,
that there would be no developments with respect to any such matters that would adversely affect Gemini&rsquo;s analyses or opinion.
Gemini is not legal, tax, accounting, environmental or regulatory advisors, and Gemini did not express any views or opinions as to any
legal, tax, accounting, environmental or regulatory matters relating to ENVB, MagicMed, the transaction or otherwise. Gemini understood
and assumed that ENVB obtained or would obtain such advice as it deemed necessary or appropriate from qualified legal, tax, accounting,
environmental, regulatory and other professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
did not evaluate the solvency or creditworthiness of ENVB, MagicMed or any other party to the transaction, or whether ENVB, MagicMed
or any other party to the transaction is paying or receiving reasonably equivalent value in the transaction under any applicable foreign,
state, or federal laws relating to bankruptcy, insolvency, fraudulent transfer, or similar matters, nor did Gemini evaluate, in any way,
the ability of ENVB, MagicMed or any other party to the transaction to pay its obligations when they come due. Gemini did not physically
inspect ENVB&rsquo;s or MagicMed&rsquo;s properties or facilities and did not make or obtain any evaluations or appraisals of ENVB&rsquo;s
or MagicMed&rsquo;s assets or liabilities (including any contingent, derivative, or off-balance-sheet assets and liabilities). Gemini
did not attempt to confirm whether ENVB or MagicMed had good title to their respective assets. Gemini&rsquo;s role in reviewing any information
was limited solely to performing such reviews as it deemed necessary to support its own advice and analysis and was not on behalf of
the ENVB board, ENVB, or any other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
assumed, with the ENVB board&rsquo;s consent, that the transaction would be consummated in a manner that complies in all respects with
applicable foreign, federal, state, and local laws, rules, and regulations and that, in the course of obtaining any regulatory or third
party consents, approvals, or agreements in connection with the transaction, no delay, limitation, restriction, or condition would be
imposed that would have an adverse effect on ENVB, MagicMed or the transaction. Gemini also assumed, with the ENVB board&rsquo;s consent,
that the final executed form of the Amalgamation Agreement would not differ in any material respect from the copy of such agreement that
Gemini reviewed and that the transaction would be consummated on the terms set forth in the Amalgamation Agreement, without waiver, modification,
or amendment of any term, condition, or agreement thereof material to Gemini&rsquo;s analyses or opinion. Gemini also assumed that the
representations and warranties of the parties to the Amalgamation Agreement contained therein were true and correct and that each such
party would perform all of the covenants and agreements to be performed by it under the Amalgamation Agreement. Gemini offered no opinion
as to the contractual terms of the Amalgamation Agreement or the likelihood that the conditions to the consummation of Amalgamation Agreement,
set forth in the Amalgamation Agreement, including, without limitation, any of the ancillary transactions, would be satisfied. Gemini
further assumed that for U.S. federal tax income purposes, the Amalgamation Agreement would qualify as a plan of reorganization within
the meaning of Section 368 of the Internal Revenue Code of 1986, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with preparing its opinion, Gemini performed a variety of financial analyses. The following is a summary of the material financial
analyses performed by Gemini in connection with the preparation of its opinion. It is not a complete description of all analyses underlying
such opinion. The preparation of an opinion is a complex process involving various determinations as to the most appropriate and relevant
methods of financial analysis and the application of those methods to the particular circumstances. As a consequence, neither Gemini&rsquo;s
opinion nor the respective analyses underlying its opinion is readily susceptible to partial analysis or summary description. In arriving
at its opinion, Gemini assessed as a whole the results of all analyses undertaken by it with respect to the opinion. While it took into
account the results of each analysis in reaching its overall conclusions, Gemini did not make separate or quantifiable judgments regarding
individual analyses and did not draw, in isolation, conclusions from or with regard to any individual analysis or factor. Therefore,
Gemini believes that the analyses underlying the opinion must be considered as a whole and that selecting portions of its analyses or
the factors it considered, without considering all analyses and factors underlying the opinion collectively, could create a misleading
or incomplete view of the analyses performed by Gemini in preparing the opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
implied multiple ranges and implied value reference ranges indicated by Gemini&rsquo;s analyses are not necessarily indicative of actual
values nor predictive of future results, which may be significantly more or less favorable than those suggested by such analyses. Much
of the information used in, and accordingly the results of, Gemini&rsquo;s analyses are inherently subject to substantial uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the material financial analyses performed by Gemini in connection with the preparation of its opinion includes information
presented in tabular format. The tables alone do not constitute a complete description of these analyses. Considering the data in the
tables below without considering the full narrative description of the analyses, as well as the methodologies and assumptions underlying
the analyses, could create a misleading or incomplete view of the financial analyses Gemini performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of its analyses, Gemini reviewed a number of financial metrics, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enterprise
Value</B> &mdash; generally the value as of a specified date of the relevant company&rsquo;s outstanding equity securities (taking into
account its options and other outstanding convertible securities) plus the value as of such date of its net debt (the value of its outstanding
indebtedness, preferred stock and minority interests less the amount of cash on its balance sheet).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context indicates otherwise, (1) share prices for the selected companies used in the selected companies analysis described below
were as of May 18, 2021, (2) the relevant values for the selected transactions analysis described below were calculated on an enterprise
value basis based on the consideration proposed to be paid in the selected transactions, (3) estimates of financial performance for the
selected companies listed below were based on publicly available research analyst estimates for those companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selected
Companies Analysis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;Gemini
considered certain financial data for selected companies with publicly traded equity securities Gemini deemed relevant with regards to
MagicMed. The financial data reviewed included equity and enterprise value of these companies. The selected companies with publicly traded
equity securities from the cannabis industry were:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entheon
    Biomedical Corp.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HAVN
    Life Sciences Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tryp
    Therapeutics Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BetterLife
    Pharma Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core
    One Labs Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revive
    Therapeutics Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmadrug
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NervGen
    Pharma Corp. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
looked at the above psychedelic/mental health focused biotech companies that are publicly listed and are deemed to be relevant based
on their business profiles and financial metrics, including product portfolios, end-markets, customers, size, growth and profitability,
among others. Gemini believes that the groups of companies listed above have business models similar to those of MagicMed but noted that
none of these companies has the same management, composition, size, operations, financial profile or combination of businesses as MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Ticker</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">Company Name</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Share Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Market Cap</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Enterprise Value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Revenue (LTM)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">EBITDA (LTM)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>CNSX:ENBI</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: left">Entheon Biomedical Corp.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">0.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">15.8</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">11.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">-$</TD><TD STYLE="width: 6%; text-align: right">3.6</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CNSX:HAVN</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">HAVN Life Sciences Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">62.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>CNSX:TRYP</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Tryp Therapeutics Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>OTCPK:BETR.F</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">BetterLife Pharma Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">-$</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>CNSX:COOL</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Core One Labs Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">61.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">61.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">-$</TD><TD STYLE="text-align: right">8.4</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CNSX:RVV</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Revive Therapeutics Ltd.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">115.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">112.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">-$</TD><TD STYLE="text-align: right">8.5</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>CNSX:BUZZ</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Pharmadrug Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">-$</TD><TD STYLE="text-align: right">2.1</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>TSXV:NGEN</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">NervGen Pharma Corp.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">-$</TD><TD STYLE="text-align: right">9.2</TD><TD STYLE="text-align: left"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*Source:
Capital IQ.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the management discussion and internal analysis of various factors including intellectual property, product lifecycle stage, historical
and current evidences with regards to product development, licenses and partnerships and current business plan, MagicMed&rsquo;s enterprise
value is estimated between the median to average enterprise values from the set of comparable companies. Based on this, the enterprise
value for MagicMed is estimated between $38.7 million and $47.8 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selected
Transactions Analysis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
considered certain financial data and the financial terms of the following business transactions Gemini deemed relevant for MagicMed.
The financial data reviewed included the enterprise value (calculated based on the consideration to be paid in the relevant transaction)
and the selected transactions were:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Date</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Target</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Buyer / Investor</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Trans. Value</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%">14-Dec-20</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: left">Adelia Therapeutics</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: left">Cybin Inc.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">15.8</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>4-Feb-21</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">GHP Noetic Science-Psychedelic Pharma</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Diamond Therapeutics</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">39.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>25-May-20</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Altum Pharmaceuticals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">BetterLife Pharma Inc</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Gemini
looked at the above transactions in the psychedelic/mental health industry that are deemed to be relevant based on their business profiles
and financial metrics, including product portfolios, end-markets, customers, size, growth and profitability, among others. Gemini believes
that the groups of companies listed above have business models similar to those of MagicMed but noted that none of these companies has
the same management, composition, size, operations, financial profile or combination of businesses as MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the management discussion and internal analysis of various factors including intellectual property, product lifecycle stage, historical
and current evidences with regards to product development, licenses and partnerships and current business plan, MagicMed&rsquo;s enterprise
value is estimated between the average to high enterprise values from the set of comparable transactions. Based on this, the enterprise
value for MagicMed is estimated between $36.5 million and $39.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
also reviewed some of the recent reverse mergers/IPO listings in the psychedelic market for early stage and small cap companies to understand
the value assigned to the enterprise in an exit/going public event. This approach analyzes the accretive value assigned to the invested
capital of the business that reflects the progress made on the business plan. Gemini analyzed the recent four small cap transactions
(listed below) in the industry and assigned a lower and median multiple to arrive at the enterprise value for MagicMed based on the invested
capital of the business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Company Name</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Valuation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Invested Capital</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">MVIP Multiple</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%">5-Nov-20</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: left">Entheon Biomedical Corp</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">17.35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.86</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.1x</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>8-Sep-20</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">HAVN Life Sciences Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.1x</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>12-Nov-20</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Tryp Therapeutics Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0x</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>2/2/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Wesana Health Holdings Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.0x</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on this, the enterprise value for MagicMed is estimated between $26.6 million and $38.9 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Concluded
Equity Value</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the above determined equity value ranges for MagicMed and averaging the low and high ranges under each valuation method, the equity
value for MagicMed is estimated to range between $37.9 million and $46.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Relative
Valuation Analysis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
compared the above calculated equity value of MegicMed against the value of contribution by ENVB&rsquo;s stockholders to the Amalgamation
Agreement below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Amalgamation Agreement, ENVB is offering 9.7 million shares of ENVB common stock to the MagicMed shareholders and also exchanging
7.0 million of ENVB warrants with the MagicMed warrant holders with a total aggregate cash exercise price of approximately $10 million.
Based on the above and 20-day VWAP as of May 19, 2021 of $2.35, ENVB&rsquo;s contribution to the Amalgamation Agreement was (after adjusting
for the aggregate cash exercise price of approximately $10 million) calculated at $29.3 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the above analyses, Gemini noted that the implied contribution made by the holders of ENVB common stock is lower than the consideration
received by the holders of ENVB common stock pursuant to the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Matters Relating to GVS&rsquo;s Opinion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of a fairness opinion is a complex analytical process involving various determinations as to the most appropriate and relevant
methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a fairness opinion
is not readily susceptible to summary description. In arriving at its opinion, Gemini did not draw, in isolation, conclusions from or
with regard to any factor or analysis that it considered. Rather, Gemini made its determination as to fairness on the basis of its experience
and professional judgment after considering the results of all of the analyses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Gemini opinion was one of the many factors taken into consideration by ENVB&rsquo;s board of directors in making its determination to
approve the Amalgamation Agreement. Consequently, the analyses as described above should not be viewed as determinative of the opinion
of ENVB&rsquo;s board of directors with respect to the contribution made/consideration received for the shares of ENVB common stock in
Amalgamation Agreement or of whether ENVB&rsquo;s board of directors would have been willing to agree to different exchange ratio. The
contribution made/consideration received for the shares of ENVB common stock in the Amalgamation Agreement was determined through arm&rsquo;s-
length negotiations between ENVB and MagicMed and was approved by ENVB&rsquo;s board of directors. Neither Gemini nor any of its affiliates
recommended any specific exchange ratio to ENVB or ENVB&rsquo;s board of directors or that any specific exchange ratio constituted the
only appropriate exchange ratio for Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of its financial advisory business, Gemini regularly is engaged in the evaluation of businesses and their securities in connection
with mergers, acquisitions, corporate restructurings, private placements and other purposes. Gemini is a recognized advisory firm that
has substantial experience in providing financial advice in connection with proposed mergers, acquisitions, sales of companies, businesses
and other assets and other transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
has consented to the use of its opinion in this registration statement on Form S-4 of which this proxy statement/prospectus forms a part.
Gemini has not assumed any responsibility for the form or content of this registration statement on Form S-4 of which this proxy statement/prospectus
forms a part, other than the Gemini opinion itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the two years preceding the date of the Gemini opinion, neither Gemini nor its affiliates was engaged by, performed services for, or
received any compensation from, ENVB (other than the engagements and any amounts that were paid under the engagement letter described
in this registration statement on Form S-4 of which this proxy statement/prospectus forms a part) or MagicMed. Gemini received a fee
of $100,000 for rendering its opinion, no portion of which was contingent upon any conclusion reached in Gemini&rsquo;s opinion
or the completion of the Amalgamation. In addition, ENVB agreed to reimburse Gemini for certain expenses incurred by it in connection
with its engagement and to indemnify Gemini and its related parties for certain liabilities that may arise out of its engagement or the
rendering of its opinion. In accordance with Gemini&rsquo;s policies and procedures, a fairness committee was not required to, and did
not, approve the issuance of the opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_048"></A>Interests
of MagicMed&rsquo;s Directors and Executive Officers in the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as disclosed below, MagicMed is not aware of any material interest, direct or indirect, by way of beneficial ownership of securities
or otherwise, of any director, executive officer or nominee for election as a director or anyone who has held office as such since the
beginning of MagicMed&rsquo;s last financial year or of any associate or affiliate of any of the foregoing to be acted on, other than
elections to office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of MagicMed&rsquo;s directors and officers have interests in the Amalgamation and have arrangements that are different from, or in addition
to, those of MagicMed equity holders generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interests include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    employment agreement with ENVB and related</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">  appointment
    of Dr. Joseph Tucker, the President and Chief Executive Officer of MagicMed; Dr. Peter Facchini, Chief Scientific Officer
    of MagicMed; and Dr. Jillian Hagel, Chief Technology Officer of MagicMed, to the positions of Chief Executive Officer, Chief
    Scientific Officer, and Chief Technology Officer of ENVB, respectively, upon the effective time of the Amalgamation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    appointment of Dr. Joseph Tucker and Brad Thompson, directors of MagicMed, to the ENVB board of directors upon the effective time
    of the Amalgamation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of Dr. Tucker, Dr. Facchini and Dr. Hagel have agreed to waive their rights to certain payments upon a change of control of MagicMed
    pursuant to the terms of their respective employment agreement with MagicMed to which they may have been entitled;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant
    to the terms of the Amalgamation Agreement, MagicMed&rsquo;s current and former directors and officers will be entitled to certain
    ongoing indemnification and insurance coverage for their prior acts for a period of time after the Effective Time and MagicMed may
    purchase directors&rsquo; and officers&rsquo; &ldquo;run-off&rdquo; insurance to further supplement any current coverage in connection
    with the Amalgamation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    of MagicMed&rsquo;s shareholders who have entered into voting agreements with ENVB, pursuant to which, among other things, such shareholders
    have agreed to vote or to execute and deliver a written consent with respect to all the MagicMed shares owned by them as of the applicable
    record date in favor of the adoption and approval of the Amalgamation Agreement and Amalgamation, are affiliated with directors of
    MagicMed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information about each of the employment agreements between ENVB and Dr. Tucker, Dr. Hagel, and Dr. Facchini, please see
the section titled &ldquo;The Amalgamation&mdash;Governance of ENVB After the Amalgamation&rdquo; beginning on page 109 of this
proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_049"></A>Interests
of ENVB&rsquo;s Directors and Executive Officers in the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than with respect to continued service for, employment by and the right to continued indemnification by ENVB, as of the date of this
proxy statement/prospectus, ENVB&rsquo;s directors and executive officers do not have interests in the Amalgamation that are different
from, or in addition to, the interests of other ENVB stockholders generally. The ENVB board of directors was aware of and considered
these factors, among other matters, in determining that the terms of the Amalgamation Agreement and the Amalgamation are fair to and
in the best interests of ENVB and ENVB stockholders, approving and adopting the Amalgamation Agreement and the transactions contemplated
thereby, including the Amalgamation and the shares of ENVB common stock to be issued in connection with the ENVB Share Issuance Proposal,
and recommending that the ENVB stockholders approve the ENVB Share Issuance Proposal. See &ldquo;&mdash;Background of the Amalgamation&rdquo;
and &ldquo;&mdash;Recommendation of the ENVB Board of Directors and its Reasons for the Merger.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_050"></A>Ownership
of ENVB after the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the number of shares of ENVB common stock and MagicMed common shares outstanding on [&nbsp;&nbsp;&nbsp;], 2021, the latest practicable
date prior to the date of this proxy statement/prospectus, upon completion of the Amalgamation, former MagicMed shareholders are expected
to own approximately 36.6% of the outstanding shares of ENVB common stock (on a fully-diluted basis) and ENVB stockholders immediately
prior to the Amalgamation are expected to own approximately 63.4% of the outstanding shares of ENVB common stock (on a fully-diluted
basis). The relative ownership interests of ENVB stockholders and former MagicMed shareholders in ENVB immediately following the
Amalgamation will depend on the number of shares of ENVB common stock and MagicMed common shares issued and outstanding immediately prior
to the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_051"></A>Governance
of ENVB After the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ENVB
Charter and Bylaws</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Amalgamation, the ENVB amended and restated certificate of incorporation, as in effect immediately prior to
the effective time of the Amalgamation, will be the charter of ENVB until thereafter amended in accordance with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Amalgamation, the ENVB amended and restated bylaws, as in effect immediately prior to the effective time of
the Amalgamation, will be the bylaws of ENVB until thereafter amended in accordance with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
of Directors After the Amalgamation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amalgamation Agreement, immediately after the effective time of the Amalgamation, ENVB&rsquo;s board of directors will consist
a minimum of seven (7) members, of which two (2) directors will be a designee of MagicMed and the remaining five (5) shall be designated
by ENVB, and to be appointed as of the date of closing. Designees to the board of directors are expected to satisfy the requisite independence
requirements for ENVB board of directors, as well as the sophistication and independence requirements for committee members pursuant
to NASDAQ listing requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MagicMed designees will be Dr. Joseph Tucker and Brad Thompson, and the ENVB designees will be David Johnson, Sol Myer, George Kegler,
Dr. Doug Lind and Dr. Marcus Schabacker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Executive
Officers After the Amalgamation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing of the Amalgamation, the following appointments will become effective:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph Tucker will be appointed as Chief Executive Officer of ENVB;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Jillian Hagel will be appointed as Chief Technical Officer of ENVB;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Peter Facchini will be appointed as Chief Scientific Officer of ENVB.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other executive officers of ENVB will remain in their respective positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of Dr. Tucker,
Dr. Hagel and Dr. Facchini have entered into an employment agreement with ENVB in connection with the execution of the Amalgamation
Agreement, which will become effective as of the closing date of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Dr. Joseph Tucker</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 24, 2021, Dr.
Joseph Tucker entered into an employment agreement (the &ldquo;Tucker Employment Agreement&rdquo;) with ENVB pursuant to which
he will become ENVB&rsquo;s Chief Executive Officer, effective as of the closing date of the Amalgamation (the &ldquo;Tucker Effective
Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Tucker has served
as chief executive officer and president of MagicMed since May 2020. From 2019 until 2020, Dr. Tucker acted as the Executive Chairman
and Chief Operating Officer of Willow Biosciences Inc. (TSX:WLLW) until leaving to join MagicMed in May 2020. From 2015 to 2019,
his principal employment was acting as CEO, President, Director and Founder of Epimeron Inc., which merged with BioCan Technologies
Inc. in 2018 and then listed by reverse-takeover with Makena Resources Inc. in 2019 as Willow Biosciences Inc. Dr. Tucker earned
a Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Tucker
Employment Agreement, effective as of the Tucker Effective Date Dr. Tucker will receive a base salary of $350,000 annually (&ldquo;Tucker
Base Salary&rdquo;). Dr. Tucker will also receive a one-time signing bonus of $100,000, as well as up to 175,000 restricted stock
units (&ldquo;RSUs&rdquo;), depending on the price of ENVB shares at the Tucker Effective Date. Half of any such RSUs shall be
subject to time-based vesting, and the remaining half of any such RSUs shall be subject to performance-based vesting. Beginning
in calendar year 2022, Dr. Tucker is eligible to receive annual performance bonuses of up to 75% of the Tucker Base Salary, as
determined from time to time by ENVB&rsquo;s board of directors. Additionally, Dr. Tucker will receive 750,000 RSUs as equity
compensation. 375,500 of such RSUs shall be subject to time-based vesting (the &ldquo;Tucker Time Based RSUs&rdquo;), and the
remaining 375,500 of such RSUs shall be subject to performance-based vesting (the &ldquo;Tucker Performance RSUs&rdquo;). The
RSUs shall be subject to the terms and conditions of ENVB&rsquo;s 2020 Long-Term Incentive Plan (the &ldquo;LTIP&rdquo;). The
Tucker Time Based RSUs shall vest in quarters on each of the first four anniversaries of the Tucker Effective Date, and the Tucker
Performance RSUs shall vest based on the achievement of performance milestones established by ENVB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Tucker Employment
Agreement will remain in effect until terminated by either party, unless ENVB or Dr. Tucker delivers advance written notice of
termination to the other party at least 30 days prior. In addition, the Tucker Employment Agreement is subject to early termination
by him or ENVB in accordance with the terms of the Tucker Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Tucker
Employment Agreement, if Dr. Tucker&rsquo;s employment is terminated by ENVB without cause or by Dr. Tucker for good reason, then
ENVB must pay Dr. Tucker, in addition to any then-accrued and unpaid obligations owed to him, 12 months of the then-current Tucker
Base Salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Tucker Employment
Agreement also contains covenants restricting Dr. Tucker from soliciting ENVB&rsquo;s employees or customers for a period of 12
months after the termination of Dr. Tucker&rsquo;s employment with ENVB and prohibiting him from disclosure of confidential information
regarding ENVB at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Dr. Jillian Hagel</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 24, 2021, Dr.
Jillian Hagel entered into an employment agreement (the &ldquo;Hagel Employment Agreement&rdquo;) with ENVB pursuant to which
she will become ENVB&rsquo;s Chief Technology Officer, effective as of the closing date of the Amalgamation (the &ldquo;Hagel
Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Hagel has served
as chief technology officer of MagicMed since April 2020. From 2019 until 2020, she acted as Vice President of Applied Sciences
for Willow Biosciences Inc. until leaving in April 2020 to co-found MagicMed. From 2013 until 2019, Dr. Hagel&rsquo;s primary
employment was acting as Chief Operating Officer of Epimeron Inc. Dr. Hagel received her PhD in plant biochemistry from the University
of Calgary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Hagel
Employment Agreement, effective as of the Hagel Effective Date Dr. Hagel will receive a base salary of C$295,000 annually (&ldquo;Hagel
Base Salary&rdquo;). Dr. Hagel will also receive a one-time signing bonus of C$50,000 as well as up to 130,000 RSUs, depending
on the price of ENVB Shares at the Hagel Effective Date. Half of any such RSUs shall be subject to time-based vesting, and the
remaining half of any such RSUs shall be subject to performance-based vesting. Beginning in calendar year 2022, Dr. Hagel is eligible
to receive annual performance bonuses of up to 50% of the Hagel Base Salary, as determined from time-to-time by ENVB&rsquo;s board
of directors. Additionally, Dr. Hagel will receive 525,000 RSUs as equity compensation. 262,500 of such RSUs shall be subject
to time-based vesting (the &ldquo;Hagel Time Based RSUs&rdquo;), and the remaining 262,500 of such RSUs shall be subject to performance-based
vesting (the &ldquo;Hagel Performance RSUs&rdquo;). The RSUs shall be subject to the terms and conditions of the LTIP. The Hagel
Time Based RSUs shall vest in quarters on each of the first four anniversaries of the Hagel Effective Date, and the Hagel Performance
RSUs shall vest based on the achievement of performance milestones established by ENVB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Hagel Employment
Agreement will remain in effect until terminated by either party, unless ENVB delivers advance written notice of termination to
Dr. Hagel or Dr. Hagel delivers advance written notice of termination to ENVB at least 30 days prior. In addition, the Hagel Employment
Agreement is subject to early termination by her or ENVB in accordance with the terms of the Hagel Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Hagel
Employment Agreement, if Dr. Hagel&rsquo;s employment is terminated by ENVB without cause or by Dr. Hagel for good reason, then
ENVB must pay Dr. Hagel, in addition to any then-accrued and unpaid obligations owed to her, 12 months of the then-current Hagel
Base Salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Hagel Employment
Agreement also contains covenants restricting Dr. Hagel from soliciting ENVB&rsquo;s employees or customers for a period of 12
months after the termination of Dr. Hagel&rsquo;s employment with ENVB and prohibiting her from disclosure of confidential information
regarding ENVB at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Dr. Peter Facchini</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 24, 2021, Dr.
Peter Facchini entered into an employment agreement (the &ldquo;Facchini Employment Agreement&rdquo;) with ENVB pursuant to which
he will become ENVB&rsquo;s Chief Scientific Officer, effective as of the closing date of the Amalgamation (the &ldquo;Facchini
Effective Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Facchini has served
as chief scientific officer of MagicMed since April 2020. From 2019 until 2020, he held the role of Chief Scientific Officer at
Willow Biosciences Inc. until leaving to co-found MagicMed. From 2013 until 2019, Dr. Facchini held the role of Chief Scientific
Officer, Director and Founder of Epimeron Inc. Dr. Facchini has also been a Professor of Plant Biochemistry in the Department
of Biological Sciences at the University of Calgary for 25 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Facchini
Employment Agreement, effective as of the Facchini Effective Date, Dr. Facchini will receive a base salary of C$295,000 annually
(&ldquo;Facchini Base Salary&rdquo;). Dr. Facchini will also receive a one-time signing bonus of C$50,000 as well as up to 130,000
RSUs, depending on the price of ENVB shares at the Facchini Effective Date. Half of any such RSUs shall be subject to time-based
vesting, and the remaining half of any such RSUs shall be subject to performance-based vesting. Beginning in calendar year 2022,
Dr. Facchini is eligible to receive annual performance bonuses of up to 50% of the Facchini Base Salary, as determined from time
to time by ENVB&rsquo;s board of directors. Additionally, Dr. Facchini will receive 525,000 RSUs as equity compensation. 262,500
of such RSUs shall be subject to time-based vesting (the &ldquo;Facchini Time Based RSUs&rdquo;), and the remaining 262,500 of
such RSUs shall be subject to performance-based vesting (the &ldquo;Facchini Performance RSUs&rdquo;). The RSUs shall be subject
to the terms and conditions of the LTIP. The Facchini Time Based RSUs shall vest in quarters on each of the first four anniversaries
of the Facchini Effective Date, and the Facchini Performance RSUs shall vest based on the achievement of performance milestones
established by ENVB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Facchini Employment
Agreement will remain in effect until terminated by either party, unless ENVB delivers advance written notice of termination to
Dr. Facchini or Dr. Facchini delivers advance written notice of termination to ENVB at least 30 days prior. In addition, the Facchini
Employment Agreement is subject to early termination by him or ENVB in accordance with the terms of the Facchini Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Facchini
Employment Agreement, if Dr. Facchini&rsquo;s employment is terminated by ENVB without cause or by Dr. Facchini for good reason,
then ENVB must pay Dr. Facchini, in addition to any then-accrued and unpaid obligations owed to him, 12 months of the then-current
Facchini Base Salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Facchini Employment
Agreement also contains covenants restricting Dr. Facchini from soliciting ENVB&rsquo;s employees or customers for a period of
12 months after the termination of Dr. Facchini&rsquo;s employment with ENVB and prohibiting him from disclosure of confidential
information regarding ENVB at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; text-indent: 0.5in">Each of the foregoing summaries of the Tucker Employment Agreement,
Hagel Employment Agreement, and the Facchini Employment Agreement is qualified in its entirety by reference to the full text of
each of the respective employment agreements, a copy of which has been incorporated by reference as Exhibits 10.5, 10.6, and 10.7,
respectively, to this registration statement. Additional information about ENVB and each of the employment agreements may be found
elsewhere in this registration statement and ENVB&rsquo;s other public filings, which are available without charge through the
SEC&rsquo;s website at www.sec.gov. See &ldquo;Where You Can Find More Information&rdquo; beginning on page 208.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_052"></A>Directors&rsquo;
and Officers&rsquo; Indemnification Insurance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting any additional rights that any director or officer may have under any agreement, from the Effective Time, ENVB and its successor
will not take any action to terminate or materially adversely affect any indemnities of, and will indemnify and hold harmless, each present
(as of the Effective Time) and former director and officer of MagicMed and its subsidiaries (the &ldquo;D&amp;O Indemnified Parties&rdquo;)
to the fullest extent permitted under the provisions of the articles, by-laws or other constituent documents of MagicMed, applicable
corporate legislation and any indemnity agreements, which have been entered into between MagicMed and its past or current officers or
directors effective as of the date of the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Effective Time, MagicMed will purchase a customary &ldquo;tail&rdquo; policy of directors&rsquo; and officers&rsquo; liability
insurance, with protections that are no less favorable in the aggregate than the coverage provided under MagicMed&rsquo;s policies of
directors&rsquo; and officers&rsquo; liability insurance and fiduciary liability insurance existing as of the Effective Time, with respect
to matters arising on or before the Effective Time (including in connection with the Amalgamation Agreement and the transactions or actions
contemplated by the Amalgamation Agreement), and ENVB will not take any action following the Effective Time to terminate or adversely
affect such policy.<B>&#9;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_053"></A>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
does not currently pay cash dividends on the ENVB common stock. Any future payment of cash dividends on the ENVB common stock will be
at the discretion of the ENVB board of directors and will depend upon ENVB&rsquo;s results of operations, earnings, capital requirements,
contractual restrictions and other factors deemed relevant by the ENVB board of directors. The ENVB board of directors currently intends
to retain any future earnings to support its operations and to finance the growth and development of ENVB&rsquo;s business and does not
intend to declare or pay cash dividends on ENVB common stock for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_054"></A>Accounting
Treatment of the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation will be accounted for using the acquisition method of accounting in accordance with ASC 805 &mdash; <I>Business Combinations</I>,
which we refer to as &ldquo;ASC 805.&rdquo; ENVB&rsquo;s management has evaluated the guidance contained in ASC 805 with respect to the
identification of the acquirer in the Amalgamation and concluded, based on a consideration of the pertinent facts and circumstances,
that ENVB will be the acquirer for financial accounting purposes. Accordingly, ENVB&rsquo;s cost to acquire MagicMed has been allocated
to MagicMed&rsquo;s acquired assets, liabilities and commitments based upon their estimated fair values. The allocation of the purchase
price is estimated and is dependent upon estimates of certain valuations that are subject to change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
unaudited pro forma combined financial information contained in this proxy statement/prospectus was prepared using the acquisition method
of accounting. The final allocation of the purchase price will be determined after the Amalgamation is completed and after completion
of an analysis to determine the estimated net fair value of MagicMed&rsquo;s assets and liabilities. Accordingly, the final acquisition
accounting adjustments may be materially different from the unaudited pro forma adjustments. Any decrease in the estimated net fair value
of the assets and liabilities of MagicMed as compared to the unaudited pro forma information included in this proxy statement/prospectus
will have the effect of increasing the goodwill recognized related to the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_055"></A>U.S.
Federal Income Tax Consequences of the Amalgamation Generally</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation is intended to qualify as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Internal Revenue Code
of 1986, as amended, for U.S. federal income tax purposes. It is further expected that no gain or loss should be recognized by ENVB or
ENVB stockholders for U.S. federal income tax purposes as a result of the Amalgamation. The completion of the Amalgamation is not conditioned
upon the receipt of an opinion of counsel to the effect that the Amalgamation qualifies for its intended tax treatment. In addition,
neither ENVB nor MagicMed intends to request a ruling from the IRS regarding the U.S. federal income tax consequences of the Amalgamation.
Accordingly, no assurance can be given that the IRS will not challenge the intended tax treatment or that a court would not sustain such
a challenge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_056"></A>Listing
of ENVB Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the Amalgamation, ENVB has agreed to take all actions necessary to cause the shares of ENVB common stock to be issued
in connection with the Amalgamation to be approved for listing on the NASDAQ. The listing of the shares of ENVB common stock on the NASDAQ,
subject to official notice of issuance, is also a condition to completion of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_057"></A>Restrictions
on Sales of Shares of ENVB Common Stock Received in the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
shares of ENVB common stock received by MagicMed shareholders in the Amalgamation will be freely tradable for purposes of the Securities
Act and the Exchange Act, except for shares of ENVB common stock received by any MagicMed shareholder who becomes an &ldquo;affiliate&rdquo;
of ENVB after completion of the Amalgamation. This proxy statement/prospectus does not cover resales of shares of ENVB common stock received
by any person upon completion of the Amalgamation, and no person is authorized to make any use of this proxy statement/prospectus in
connection with any resale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_058"></A>Regulatory
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
completion of the Amalgamation is subject to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    temporary restraining order, preliminary or permanent injunction or other order (whether temporary, preliminary or permanent) issued
    by any court of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the Amalgamation will
    be in effect, nor will any legal action or proceeding brought by any administrative agency or commission or other governmental authority
    or instrumentality, domestic or foreign, seeking any of the foregoing be pending;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    will not be any action taken, or any statute, rule, regulation or order enacted, entered, enforced or deemed applicable to the Amalgamation,
    which makes the consummation of the Amalgamation illegal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    required regulatory approval has been made, given or obtained and each such regulatory approval is in force and has not been modified;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    waiting period applicable to the consummation of the Amalgamation under any regulatory approval will have expired or been terminated;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    parties shall have obtained or made any consent, approval, order or authorization of, or registration, declaration or filing with,
    any governmental authority required to be obtained or made in connection with the execution and delivery of the Amalgamation Agreement
    or the consummation of the transactions contemplated thereby and the parties shall have obtained all consents, waivers and approvals
    set forth in the schedules to the Amalgamation Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_059"></A>No
Appraisal Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appraisal
rights are statutory rights that, if applicable under law, enable stockholders of a corporation to dissent from a merger and to demand
that such corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the
consideration offered to such stockholders in connection with the transaction. Under the DGCL, stockholders do not have appraisal rights
if the shares of stock they hold are either listed on a national securities exchange or held of record by more than 2,000 holders. In
addition, stockholders of the constituent corporation surviving the merger are not entitled to appraisal rights if the merger did not
require the vote of the stockholders of the surviving corporation pursuant to Section 251(f) of the DGCL. Notwithstanding the foregoing,
appraisal rights are available if stockholders are required by the terms of the Amalgamation Agreement to accept for their shares anything
other than (i) shares of stock of the surviving or resulting corporation, (ii) shares of stock of another corporation that will either
be listed on a national securities exchange or held of record by more than 2,000 holders, (iii) cash in lieu of fractional shares or
(iv) any combination of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
dissenters&rsquo; or appraisal rights will be available to stockholders of ENVB with respect to the Amalgamation, the ENVB Share Issuance
Proposal or any of the other transactions contemplated by the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="o_061"></A>THE
AMALGAMATION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following describes certain aspects of the Amalgamation, including certain material provisions of the Amalgamation Agreement. The following
description of the Amalgamation Agreement is subject to, and qualified in its entirety by reference to, the full text of the Amalgamation
Agreement, which is attached to this proxy statement/prospectus as <U>Annex A</U> and is incorporated by reference into this proxy statement/prospectus.
We urge you to read the Amalgamation Agreement carefully in its entirety, as it is the legal document governing the Amalgamation and
the other transactions contemplated thereby.</I></FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; padding: 3pt 0in; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Amalgamation Agreement has been included to provide you with information regarding its terms and the transactions described in this proxy
statement/prospectus. Neither ENVB nor MagicMed intends that the Amalgamation Agreement will be a source of business or operational information
about ENVB or MagicMed. The Amalgamation Agreement contains representations and warranties made by and to ENVB, MagicMed, HoldCo
and Purchaser as of specific dates. The statements embodied in those representations and warranties were made for purposes of the Amalgamation
Agreement between the parties and are subject to qualifications and limitations agreed by the parties in connection with negotiating
the terms of the Amalgamation Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one
of the parties if those statements prove to be incorrect. The representations and warranties may also be subject to a contractual standard
of materiality or material adverse effect different from those generally applicable to shareholders and reports and documents filed with
the SEC and in some cases may be qualified by disclosures made by one party to the other, which are not necessarily reflected in the
Amalgamation Agreement. In addition, certain representations and warranties were made as of a specified date and may be subject to contractual
standards of materiality different from those generally applicable to stockholders. For the foregoing reasons, the representations and
warranties should not be read alone or relied upon as characterizations of the actual state of facts or condition of ENVB, MagicMed,
HoldCo, Purchaser or any of their respective subsidiaries or affiliates. Instead, such provisions or descriptions should be read
only in conjunction with the other information provided elsewhere in this proxy statement/prospectus.</I></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_062"></A>Form,
Effective Time and Closing of Amalgamation</B></FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; padding: 3pt 0in 3pt 3pt; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black; border-left-width: 0in; border-left-color: Black; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation Agreement provides that, at the effective time of the Amalgamation, Purchaser, a wholly owned subsidiary of HoldCo,
will be amalgamated with MagicMed. Upon completion of the Amalgamation, the separate corporate existences of Purchaser and MagicMed will
cease, and AmalCo will continue as the surviving corporation and as a wholly owned subsidiary of HoldCo under the name &ldquo;Enveric
Biosciences Canada Inc.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the Amalgamation will occur on the date the articles of amalgamation are filed in accordance with the BCBCA, which
will be such date as is mutually agreed on by ENVB and MagicMed following the satisfaction or waiver of all of the conditions
to completion of the amalgamation (other than conditions to be satisfied on the closing date), which conditions are described
below under &ldquo;&mdash; Conditions to the Completion of the Amalgamation&rdquo; beginning on page 115. At the closing
of the amalgamation, ENVB and MagicMed will cause the articles of amalgamation to be filed with the with the appropriate authority
in Canada as prescribed in the BCBCA. The amalgamation will become effective upon the filing of such articles.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_063"></A>Effects
of Amalgamation; Amalgamation Consideration </B></FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; padding: 3pt 0in; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the amalgamation, each outstanding common share of MagicMed held by MagicMed shareholders will be converted
into one fully paid and non-assessable AmalCo redeemable preferred share, which shall immediately following the amalgamation be
redeemed by AmalCo for the AmalCo redemption consideration. Immediately following the redemption of the AmalCo redeemable preferred
shares, each holder of MagicMed common shares shall each receive from ENVB as additional consideration for the disposition of
their MagicMed common shares that number of shares of ENVB common stock equal to the product of the Exchange Ratio multiplied
by the number of MagicMed common shares held by such MagicMed shareholder, which such transactions are described below under &ldquo;&mdash;
Treatment of MagicMed Shares&rdquo; beginning on page 113.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the amalgamation, each outstanding MagicMed option shall be amended such that each holder of MagicMed options shall
be entitled to receive, for each option held, that number of shares of ENVB common stock equal to the product of the Exchange Ratio multiplied
by the number of MagicMed common shares subject to such option. Such options shall have an exercise price per share of ENVB common stock
equal to the exercise price per MagicMed common share of such option immediately prior to the effective time divided by the Exchange
Ratio, rounded up to the nearest whole cent.</FONT></P>

</DIV>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; padding: 3pt 0in; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the effective time of the amalgamation, each holder of a MagicMed warrants shall be entitled to receive (and such holder shall accept)
upon the exercise of such holder&rsquo;s warrants, in lieu of MagicMed common shares to which such holder was theretofore entitled upon
such exercise, and for the same aggregate consideration payable therefor, that number of shares of ENVB common stock which the holder
would have been entitled to receive as a result of the amalgamation if, immediately prior to the effective time of the amalgamation,
such holder had been the registered holder of the number of MagicMed common shares to which such holder would have been entitled if such
holder had exercised such holder&rsquo;s warrants immediately prior to the effective time of the amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stated capital of the AmalCo redeemable preferred shares shall be equal to the value of the aggregate AmalCo redemption consideration.
The stated capital of the AmalCo common shares shall be equal to the aggregate paid up capital for purposes of the Income Tax Act, R.S.C.
1985 (5th Supp.) c.1, and the regulations thereunder (the &ldquo;Tax Act&rdquo;), of the Purchaser common shares and the MagicMed common
shares immediately prior to the amalgamation, less the amount of the stated capital added to the AmalCo redeemable preferred shares.
The stated capital accounts shall be adjusted to recognize payments that may be made to dissenting MagicMed shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Purchaser common share issued and outstanding immediately prior to the Effective Time shall be converted into one (1) AmalCo common share.
As consideration for ENVB issuing the shares of common stock and the AmalCo redemption consideration to the MagicMed shareholders pursuant
to the Amalgamation Agreement, HoldCo shall issue to ENVB one common share of HoldCo for each such share issued by ENVB,
and HoldCo shall add to its stated capital an amount equal to the aggregate fair market value of all such shares issued by ENVB.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_064"></A>Treatment
of MagicMed Shares</B></FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; padding: 3pt 0in; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
outstanding common share of MagicMed will be converted into one (1) fully paid and non-assessable AmalCo redeemable preferred share,
which AmalCo redeemable preferred share shall, immediately following the amalgamation, be redeemed by AmalCo for the AmalCo redemption
consideration (consisting of 0.000001 of an ENVB share of common stock) in accordance with the terms of the AmalCo redeemable preferred
shares. Immediately following the redemption of the AmalCo redeemable preferred shares, the MagicMed shareholders (other than dissenting
shareholders) shall each receive from ENVB, as additional consideration for the disposition of their MagicMed common shares, that number
of shares of ENVB common stock equal to the product of the Exchange Ratio multiplied by the number of MagicMed shares held by such MagicMed
shareholder, and all MagicMed shares shall be cancelled. The effects of the amalgamation on shareholders of MagicMed are described above
at &ldquo;&mdash; Effects of Amalgamation; Amalgamation Consideration.&rdquo;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_065"></A>Treatment
of MagicMed Stock Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Amalgamation, MagicMed shall amend the terms of the MagicMed stock options in accordance with MagicMed&rsquo;s
stock option plan such that the holders of MagicMed stock options shall be entitled to receive, for each stock option held, that number
of shares of ENVB common stock equal to the product of the Exchange Ratio multiplied by the number of MagicMed common shares subject
to such MagicMed stock option, provided that the aggregate number of shares of ENVB common stock issuable to a holder of MagicMed stock
options shall be rounded down to the nearest whole number of shares of ENVB common stock. The MagicMed stock options shall have an exercise
price per share of ENVB common stock equal to the exercise price per MagicMed common share of such MagicMed stock option (for any stock
options with an exercise price set in Canadian dollars, as converted to United States dollars based on the exchange rate quoted by the
Bank of Canada on the effective date of the Amalgamation) immediately prior to the effective time of the Amalgamation divided by the
Exchange Ratio, rounded up to the nearest whole cent, provided that the exercise price of such stock option shall be, and shall be deemed
to be, adjusted by the amount, and only to the extent, necessary to ensure that the in-the-money stock options do not exceed the in-the-money
MagicMed stock options before the amendment. All other terms and conditions of the MagicMed stock options will be the same prior to such
amendment, and any document or agreement previously evidencing such MagicMed stock option shall thereafter evidence and be deemed to
evidence such MagicMed stock option as amended. As of the date of this proxy statement/prospectus, an aggregate of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares
of ENVB common stock were subject to issuance pursuant to such MagicMed stock options.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the request of a holder of MagicMed stock option, MagicMed and ENVB shall enter into an agreement with the applicable holder of a MagicMed
stock option (in form and substance satisfactory to MagicMed and ENVB, each acting reasonably) whereby such holder of a MagicMed stock
option would agree to the exchange of all of their MagicMed stock options immediately following the effective time of the Amalgamation
for ENVB stock options to purchase the same number of shares of ENVB common stock subject to such MagicMed stock option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
and the Purchaser agreed that any MagicMed stock option that may expire in accordance with the terms of (a) the MagicMed stock option
plan or (b) the ENVB stock incentive plan, as applicable, as a result of the holder thereof ceasing to be a service provider to MagicMed
or ENVB (or any affiliate thereof) after the closing of the amalgamation shall be confirmed to expire on their normal expiry date (and
ENVB and the Purchaser shall not revoke, and will cause AmalCo not to revoke, any authority or approval taken by MagicMed prior to the
closing of the amalgamation in this regard).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_066"></A>Treatment
of MagicMed Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the effective time of the amalgamation, each holder of a MagicMed warrant shall be entitled to receive (and such holder shall
accept) upon the exercise of such holder&rsquo;s warrants, in lieu of MagicMed common shares to which such holder was theretofore
entitled upon such exercise, and for the same aggregate consideration payable therefor, that number of shares of ENVB common stock
which the holder would have been entitled to receive as a result of the amalgamation if, immediately prior to the effective time
of the amalgamation, such holder had been the registered holder of the number of MagicMed common shares to which such holder would
have been entitled if such holder had exercised such holder&rsquo;s warrants immediately prior to the effective time of the amalgamation.
Each MagicMed warrant shall continue to be governed by and be subject to the terms of the applicable warrant following the effective
time of the amalgamation. The terms of the options and warrants have not yet been finalized.
Once the terms of the options and warrants are finalized, this may or may not impact the classification and accounting for such
options and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_067"></A>Exchange
Ratio</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange Ratio is equal to 0.2658. No fractional shares of ENVB common stock will be issued to MagicMed shareholders. In lieu of such
fractional shares, (a) the number of ENVB shares to be received by a MagicMed shareholder will be rounded up to the nearest whole ENVB
share in the event that a MagicMed shareholder is entitled to receive a fractional share representing one-half (1/2) or more of an ENVB
share, or (b) the number of ENVB shares to be received by a MagicMed shareholder will be rounded down to the nearest whole ENVB share
in the event that a MagicMed shareholder is entitled to receive a fractional share representing less than one-half (1/2) of an ENVB share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_068"></A>Exchange
Procedures </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the amalgamation, (a) the original share certificate of Purchaser registered in the name of HoldCo will
be cancelled and HoldCo will be issued a share certificate for one AmalCo common share and (b) certificates or other evidence
representing the MagicMed common shares will be cancelled and such holders thereof will only reflect the right of the holder to receive
shares of ENVB common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the delivery and surrender by the holder of certificates representing, or evidence of ownership on MagicMed&rsquo;s share or securities
register of, MagicMed common shares to HoldCo and ENVB, which are to be exchanged for ENVB shares, ENVB shall, as soon as practicable
following the date of receipt by ENVB of the certificates or other evidence, deliver to each such holder certificates or other evidence
representing the number of ENVB shares to which such holder is entitled.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_069"></A>Directors
and Executive Officers of ENVB Following the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
of Directors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amalgamation Agreement, immediately after the effective time of the amalgamation, ENVB&rsquo;s board of directors will consist
a minimum of seven (7) members, of which two (2) directors will be a designee of MagicMed and the remaining five (5) shall be designated
by ENVB, and to be appointed as of the date of closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designees
to the board of directors are expected to satisfy the requisite independence requirements for ENVB board of directors, as well as the
sophistication and independence requirements for committee members pursuant to NASDAQ listing requirements. The MagicMed designees will
be Dr. Joseph Tucker and Brad Thompson, and the ENVB designees will be David Johnson, Sol Myer, George Kegler, Dr. Doug Lind and Dr.
Marcus Schabacker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information about the directors expected to serve on the board of directors of ENVB, see section titled &ldquo;Governance of
ENVB After the Amalgamation&rdquo; beginning on page 109 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Executive
Officers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the closing, Dr. Joseph Tucker shall be appointed as Chief Executive Officer of ENVB; Dr. Jillian Hagel shall be appointed as Chief Technical
Officer of ENVB; Dr. Peter Facchini shall be appointed as Chief Scientific Officer of ENVB; and all other executive officers of ENVB
shall remain in their respective positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information about the executive officers expected to serve as the executive officers of ENVB, see section titled &ldquo;Governance
of ENVB After the Amalgamation&rdquo; beginning on page 109 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_070"></A>Dissenting
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
shareholders entitled to vote at the MagicMed special meeting may exercise dissent rights with respect to their MagicMed common shares
in connection with the Amalgamation and in accordance with, and subject to the terms and conditions of the BCBCA. MagicMed will provide
ENVB notice of any written notice of dissent, withdrawal of such notice, and any other instruments served pursuant to such dissent rights
and received by MagicMed and will provide ENVB with copies of such notices and written objections. If a dissenting shareholder is ultimately
entitled to be paid fair value for his, her or its MagicMed common shares, such shares shall be deemed to have been surrendered to MagicMed
for cancellation immediately prior to the effective time of the Amalgamation. If a dissenting shareholder is ultimately determined not
to be entitled, for any reason, to be paid fair value for his, her or its MagicMed common shares, such dissenting shareholder shall be
deemed to have participated in the amalgamation, as of the effective time, on the same basis as a holder of MagicMed common shares who
did not exercise dissent rights in respect of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_071"></A>Conditions
to the Completion of the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party&rsquo;s obligation to complete the amalgamation is subject to the satisfaction or waiver by each of the parties, at or prior to
the closing of the amalgamation, of various conditions, which include, in addition to other customary closing conditions, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            affirmative vote of not less than 66 2/3% of the votes cast at the MagicMed special meeting
                                            or represented by proxy for the approval of the MagicMed Amalgamation Proposal;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                            <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            approval by ENVB stockholders of the ENVB Share Issuance Proposal and related amalgamation;</TD></TR>
                                                                                                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            temporary restraining order, preliminary or permanent injunction or other order (whether
                                            temporary, preliminary or permanent) issued by any court of competent jurisdiction or other
                                            legal restraint or prohibition preventing the consummation of the amalgamation will be in
                                            effect, nor will any legal action or proceeding brought by any administrative agency or commission
                                            or other governmental authority or instrumentality, domestic or foreign, seeking any of the
                                            foregoing be pending. There will not be any action taken, or any statute, rule, regulation
                                            or order enacted, entered, enforced or deemed applicable to the amalgamation, which makes
                                            the consummation of the amalgamation illegal;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            required regulatory approval has been made, given or obtained and each such regulatory approval
                                            is in force and has not been modified. Any waiting period applicable to the consummation
                                            of the amalgamation under any regulatory approval will have expired or been terminated;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            shares of ENVB common stock issued in connection with the amalgamation shall have been approved
                                            for listing on NASDAQ; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            registration statement on Form S-4 (including a prospectus) in connection with the issuance
                                            of shares of ENVB common stock as amalgamation consideration in the amalgamation, which will
                                            include a proxy statement to be sent to the stockholders of ENVB shall have become effective
                                            under the Securities Act, and shall not be the subject of any stop order.</FONT></TD></TR></TABLE>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black; border-left-width: 0in; border-left-color: Black"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligation of ENVB and Purchaser to complete the amalgamation is subject to the satisfaction or waiver of the following additional conditions:</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            representations and warranties of MagicMed in the Amalgamation Agreement qualified as to
                                            materiality shall be true and correct in all respects, and those not so qualified shall be
                                            true and correct in all material respects as of the date of the Amalgamation Agreement and
                                            the closing date as though made on and as of the date of the Amalgamation Agreement and the
                                            closing date (as applicable), except to the extent such representations and warranties speak
                                            as of another date (in which case, such representations and warranties shall be true and
                                            correct as of such date);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            shall have performed or complied with in all material respects with each of the covenants
                                            of MagicMed contained in the Amalgamation Agreement to be fulfilled or complied with by it
                                            on or prior to the closing of the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            shall have delivered certain certificates and other documents required under the Amalgamation
                                            Agreement for the closing of the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            shall have delivered audited financial statements for fiscal year 2020 and year-to-date 2021
                                            in accordance with U.S. GAAP to ENVB as required by SEC rules, as well as any other financial
                                            statements as may be required by the rules and regulations of the Securities Act and the
                                            Exchange Act;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            legal action or proceeding can be pending or threatened (excluding any such action or proceeding
                                            initiated by ENVB) to (a) cease trade, enjoin, prohibit, or impose any limitations, damages
                                            or conditions on, the Purchaser&rsquo;s ability to acquire, hold, or exercise full rights
                                            of ownership over, any MagicMed common shares, including the right to vote the MagicMed common
                                            shares, (b) prohibit, restrict or impose terms or conditions on, the amalgamation, or the
                                            ownership or operation by ENVB and the Purchaser of the business or assets of ENVB, HoldCo,
                                            the Purchaser, MagicMed or their respective subsidiaries, or compel ENVB or the Purchaser
                                            to dispose of or hold separate any of the business or assets of ENVB, HoldCo, the Purchaser,
                                            MagicMed or their respective subsidiaries as a result of the amalgamation, or (c) prevent
                                            or materially delay the consummation of the amalgamation, or if the amalgamation were to
                                            be consummated, have a material adverse effect with respect to MagicMed or its subsidiaries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            shall not have been any result, change, event, occurrence, effect, state of facts or circumstance
                                            (whether or not constituting a breach of a representation, warranty or covenant set forth
                                            in the Amalgamation Agreement) that, either individually or in the aggregate is or would
                                            reasonably be expected to be material and adverse to the business, operations, results of
                                            operations, assets, properties, condition (financial or otherwise) or liabilities (contingent
                                            or otherwise) or prospects of MagicMed and its subsidiaries, taken as a whole, and would,
                                            or would be reasonably expected to, prevent or materially delay MagicMed from consummating
                                            the transactions contemplated by the Amalgamation Agreement by December 31, 2021, except
                                            any such change, event, occurrence, effect, state of facts or circumstance resulting from
                                            or relating to: (a) any change in general political, economic, financial, currency exchange,
                                            securities, capital or credit market conditions in Canada or the United States; (b) any change
                                            or proposed change in applicable laws, IFRS or U.S. GAAP; (c) any change affecting the industries
                                            or markets in which MagicMed operates; (d) any natural disaster or the commencement or continuity
                                            of any act of war, armed hostilities or acts of terrorism; (e) the announcement of the Amalgamation
                                            Agreement or the transactions contemplated thereby; (f) any action taken (or omitted to be
                                            taken) by MagicMed or its subsidiaries which is required to be taken (or omitted to be taken)
                                            pursuant to the Amalgamation Agreement; (g) any change in the market price or trading volume
                                            of any securities of MagicMed (it being understood that the causes underlying such change
                                            in market price or trading volume may be taken into account in determining whether a material
                                            adverse effect has occurred); (h) any epidemic, pandemic, disease outbreak (including COVID-19),
                                            other health crisis or public health event; or (i) any matter which has been publicly disclosed
                                            or communicated in writing by MagicMed to ENVB as of the date of the Amalgamation Agreement
                                            and ENVB has acknowledged receipt of such written communication; provided, however, that
                                            with respect to clauses; (a) through to and including (c), such matters do not have a materially
                                            disproportionate effect on MagicMed and its subsidiaries, taken as a whole, relative to companies
                                            of similar size operating in the industries or markets in which MagicMed operates (in which
                                            case the incremental disproportionate effect may be taken into account in determining whether
                                            there has been, or is reasonably expected to be, a material adverse effect), and provided
                                            further, however, that unless expressly provided in any particular section of the Amalgamation
                                            Agreement, references in certain sections of the Amalgamation Agreement to dollar amounts
                                            are not intended to be, and shall be deemed not to be, illustrative or interpretive for the
                                            purpose of determining whether a &ldquo;Material Adverse Effect&rdquo; has occurred;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            shall have unencumbered, unrestricted cash on hand of at least C$4,000,000 minus any cash
                                            expended or to be expended on reasonable and documented out-of-pocket costs primarily related
                                            to the transaction contemplated by the Amalgamation Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evidence
                                            in form and substance reasonably satisfactory to ENVB that (i) MagicMed shall have obtained
                                            or made any consent, approval, order or authorization of, or registration, declaration or
                                            filing with, any governmental authority required to be obtained or made in connection with
                                            the execution and delivery of the Amalgamation Agreement or the consummation of the transactions
                                            contemplated hereby and (ii) MagicMed shall have obtained all consents, waivers and approvals
                                            set forth on <U>Schedule 8.2(l)</U> of the Amalgamation Agreement in a form and substance
                                            reasonably satisfactory to ENVB and copies thereof shall have been delivered to ENVB.</FONT></TD></TR></TABLE>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; border-top-width: 0in; border-top-color: Black; border-bottom-width: 0in; border-bottom-color: Black; border-left-width: 0in; border-left-color: Black"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligation of MagicMed to complete the amalgamation is subject to the satisfaction or waiver of the following additional conditions:</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            representations and warranties of ENVB and the Purchaser set forth in the Amalgamation Agreement
                                            shall be true and correct as of the date of the Amalgamation Agreement and the closing date
                                            as though made on and as of the date of the Amalgamation Agreement and the closing date (as
                                            applicable), except to the extent such representations and warranties speak as of another
                                            date (in which case, such representations and warranties shall be true and correct as of
                                            such date);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            and Purchaser shall have fulfilled or complied in all material respects with each of the
                                            covenants of ENVB and the Purchaser contained in this Agreement to be fulfilled or complied
                                            with by it on or prior to the closing of the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            and Purchaser shall have delivered certain certificates and other documents required under
                                            the Amalgamation Agreement for the closing of the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evidence
                                            in form and substance reasonably satisfactory to MagicMed that (i) ENVB shall have obtained
                                            or made any consent, approval, order or authorization of, or registration, declaration or
                                            filing with, any governmental authority required to be obtained or made in connection with
                                            the execution and delivery of the Amalgamation Agreement or the consummation of the transactions
                                            contemplated hereby and (ii) ENVB shall have obtained all consents, waivers and approvals
                                            set forth on <U>Schedule 8.3(f)</U> of the Amalgamation Agreement in a form and substance
                                            reasonably satisfactory to MagicMed and copies thereof shall have been delivered to MagicMed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            shall not have been any result, change, event, occurrence, effect, state of facts or circumstance
                                            (whether or not constituting a breach of a representation, warranty or covenant set forth
                                            in the Amalgamation Agreement) that, either individually or in the aggregate is or would
                                            reasonably be expected to be material and adverse to the business, operations, results of
                                            operations, assets, properties, condition (financial or otherwise) or liabilities (contingent
                                            or otherwise) or prospects of ENVB and its subsidiaries, taken as a whole, and would, or
                                            would be reasonably expected to, prevent or materially delay ENVB from consummating the transactions
                                            contemplated by the Amalgamation Agreement by the end date, except any such change, event,
                                            occurrence, effect, state of facts or circumstance resulting from or relating to: (a) any
                                            change in general political, economic, financial, currency exchange, securities, capital
                                            or credit market conditions in Canada or the United States; (b) any change or proposed change
                                            in applicable laws, IFRS or U.S. GAAP; (c) any change affecting the industries or markets
                                            in which ENVB operates; (d) any natural disaster or the commencement or continuity of any
                                            act of war, armed hostilities or acts of terrorism; (e) the announcement of the Amalgamation
                                            Agreement or the transactions contemplated thereby; (f) any action taken (or omitted to be
                                            taken) by ENVB or its subsidiaries which is required to be taken (or omitted to be taken)
                                            pursuant to the Amalgamation Agreement; (g) any change in the market price or trading volume
                                            of any securities of ENVB (it being understood that the causes underlying such change in
                                            market price or trading volume may be taken into account in determining whether a material
                                            adverse effect has occurred); (h) any epidemic, pandemic, disease outbreak (including COVID-19),
                                            other health crisis or public health event; or (i) any matter which has been publicly disclosed
                                            or communicated in writing by ENVB to MagicMed as of the date of the Amalgamation Agreement
                                            and MagicMed has acknowledged receipt of such written communication; provided, however, that
                                            with respect to clauses; (a) through to and including (c), such matters do not have a materially
                                            disproportionate effect on ENVB and its subsidiaries, taken as a whole, relative to companies
                                            of similar size operating in the industries or markets in which ENVB operates (in which case
                                            the incremental disproportionate effect may be taken into account in determining whether
                                            there has been, or is reasonably expected to be, a material adverse effect), and provided
                                            further, however, that unless expressly provided in any particular section of the Amalgamation
                                            Agreement, references in certain sections of the Amalgamation Agreement to dollar amounts
                                            are not intended to be, and shall be deemed not to be, illustrative or interpretive for the
                                            purpose of determining whether a &ldquo;Material Adverse Effect&rdquo; has occurred;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            shall have unencumbered, unrestricted cash on hand of at least $15.0 million minus any cash
                                            expended or to be expended on reasonable and documented out-of-pocket costs primarily related
                                            to the transaction contemplated by the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            shall have prepared a Form 8-K as required by SEC rules and regulations, in a form and substance
                                            reasonably satisfactory to MagicMed; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27.35pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 26.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            shall have provided MagicMed evidence satisfactory to MagicMed, acting reasonably, that the
                                            appointments and elections contemplated by the Amalgamation Agreement will become effective
                                            as of the closing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_072"></A>Representations
and Warranties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation Agreement contains customary representations and warranties of ENVB, MagicMed, Purchaser, and HoldCo for a transaction
of this type relating to, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">corporate
                                            organization, authority and power, and similar corporate and shareholder matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subsidiaries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">capitalization;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
                                            statements and with respect to ENVB, documents filed with the SEC and the accuracy of information
                                            contained in those documents since January 1, 2021;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">internal
                                            accounting controls and audit matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">absence
                                            of certain changes or events, including, with respect to ENVB and MagicMed since December
                                            31, 2020;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operation
                                            of the business in the ordinary course;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the operation of the business;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">title
                                            to assets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real
                                            property and leaseholds;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual
                                            property;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            validity of material contracts to which the parties or their subsidiaries are a party and
                                            any violation, default or breach under such contracts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-contravention
                                            and required consents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">absence
                                            of undisclosed liabilities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            and legal compliance, permits and restrictions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax
                                            matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee
                                            and labor matters and benefit plans;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">environmental
                                            matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">board
                                            approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
                                            proceedings and orders;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authority
                                            to enter into the Amalgamation Agreement and the related agreements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">governmental
                                            authorization;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
                                            with affiliates and interested party transactions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">corrupt
                                            practices legislation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounts
                                            and notes receivable and payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            brokerage or finder&rsquo;s fee or other fee or commission in connection with the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to Merger Sub and HoldCo, that such entities were incorporated solely to effect
                                            the amalgamation and have not carried on any business;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to ENVB, the sufficiency of the authorized and unissued in the amalgamation for the
                                            consummation of the amalgamation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accuracy
                                            of the information supplied by ENVB, MagicMed, Purchaser and HoldCo for inclusion
                                            in this proxy statement/prospectus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations and warranties are, in many respects, qualified by materiality and knowledge and their accuracy forms the basis of some
of the conditions to the obligations of ENVB and MagicMed to complete the amalgamation. Additionally, the representations and warranties
of ENVB, Purchaser, MagicMed and HoldCo do not survive the closing and are not subject to indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_073"></A>No
Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of ENVB and MagicMed agreed that, subject to certain exceptions, during the pre-closing period, ENVB and MagicMed and any of their respective
subsidiaries will not, whether directly or indirectly, through their respective officers, directors, employees, representatives or other
agents retained by ENVB, MagicMed or their respective subsidiaries, or otherwise, and will not permit any such person to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solicit,
                                            assist, initiate, encourage or otherwise knowingly facilitate (including by way of furnishing
                                            or providing copies of, access to, or disclosure of, any confidential information, properties,
                                            facilities, books or records of ENVB, MagicMed and their respective subsidiaries or entering
                                            into any form of agreement, arrangement or understanding) any inquiry, proposal or offer
                                            that constitutes or may reasonably be expected to constitute or lead to, an acquisition proposal;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                            into or otherwise engage or participate in any discussions or negotiations with any person
                                            (other than the parties to the Amalgamation Agreement) regarding any inquiry, proposal or
                                            offer that constitutes or may reasonably be expected to constitute or lead to, an acquisition
                                            proposal for MagicMed or ENVB, provided that, for greater certainty, MagicMed and ENVB, as
                                            applicable, may advise any Person making an unsolicited acquisition proposal that such acquisition
                                            proposal does not constitute a superior proposal when applicable board has so determined;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to certain exceptions, change the recommendation of the ENVB or MagicMed board of directors
                                            with regard the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accept,
                                            approve, endorse or recommend, or publicly propose to accept, approve, endorse or recommend,
                                            or take no position or remain neutral with respect to, any acquisition proposal; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accept
                                            or enter into or publicly propose to accept or enter into any agreement, understanding or
                                            arrangement in respect of an acquisition proposal.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;acquisition proposal&rdquo; means any offer, proposal or inquiry (written or oral) from any person or group of persons other than
the parties after the date of the Amalgamation Agreement relating to: (a) any direct or indirect sale, disposition, alliance or joint
venture (or any lease, long-term supply agreement or other arrangement having the same economic effect as a sale), in a single transaction
or a series of related transactions, of assets representing 20% or more of the consolidated assets or contributing 20% or more of the
revenue of (as applicable) ENVB, MagicMed or their respective subsidiaries (in each case, on a consolidated basis) or of 20% or more
of the voting, equity or other securities of (as applicable) the ENVB or MagicMed (or rights or interests therein or thereto); (b) any
direct or indirect take-over bid, tender offer, exchange offer, treasury issuance (excluding treasury issuances resulting from the exercise
or conversion of currently outstanding securities) or other transaction that, if consummated, would result in a person or group of persons
beneficially owning 20% or more of any class of voting, equity or other securities or any other equity interests (including securities
convertible into or exercisable or exchangeable for securities or equity interests) of (as applicable) ENVB or MagicMed; (c) any plan
of arrangement, merger, amalgamation, consolidation, share exchange, business combination, reorganization, recapitalization, liquidation,
dissolution, winding up or exclusive license involving ENVB, MagicMed or their respective subsidiaries; (d) any other similar transaction
or series of transactions involving ENVB, MagicMed or their respective subsidiaries; or (e) any other transaction, the consummation of
which could reasonably be expected to impede, prevent or delay the transactions contemplated by the Amalgamation Agreement, including
the amalgamation.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
if ENVB or MagicMed receives an acquisition proposal from a third party and the receipt of such acquisition proposal was not initiated,
sought, solicited, knowingly encouraged or knowingly induced by ENVB, MagicMed or their respective subsidiaries, then ENVB or MagicMed
may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contact
                                            the person who has made such acquisition proposal in order to clarify the terms of such acquisition
                                            proposal so that the applicable board of directors (or any committee thereof) may inform
                                            itself about such acquisition proposal;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
                                            in discussions and negotiations with the person making the proposal, its representatives
                                            and potential financing sources; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">furnish
                                            information concerning its business, properties or assets to any person pursuant to a confidentiality
                                            agreement, and negotiate and participate in discussions and negotiations with such person
                                            concerning an acquisition proposal if the applicable board of directors determines in good
                                            faith that such acquisition proposal constitutes a &ldquo;superior proposal&rdquo; as defined
                                            below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;superior proposal&rdquo; means an unsolicited bona fide written acquisition proposal made after the Execution Date by a third
party to (as applicable): (a) MagicMed or its shareholders, to acquire all of the issued and outstanding MagicMed common shares (other
than the shares owned by the person making the Superior Proposal, if any); (b) ENVB or its shareholders, to acquire all of the ENVB common
stock (other than stock owned by the person making the Superior Proposal, if any); (c) MagicMed, to acquire all or substantially all
of the consolidated assets of MagicMed and its subsidiaries taken as a whole; or (d) ENVB, to acquire all or substantially all of the
consolidated assets of ENVB and its subsidiaries taken as a whole; provided, however, in the case of the immediately preceding clauses
(a) through (d), (i) such acquisition proposal is reasonably likely to be completed without undue delay, taking into account all legal,
financial, regulatory and other aspects of such proposal and the person making such proposal; (ii) any required financing to complete
such acquisition proposal is available to the satisfaction of the applicable board, acting reasonably; (iii) such acquisition proposal
did not result from a breach of the Amalgamation Agreement by (as applicable) MagicMed, ENVB or their applicable representatives; (iv)
the proceeds of such acquisition proposal are made available to all applicable shareholders, on the same terms and conditions; and (v)
the applicable board determines in good faith (after receipt of advice from its financial advisors) that such acquisition proposal would,
taking into account all of the terms and conditions of such acquisition proposal, if consummated in accordance with its terms (but not
assuming away any risk of non-completion), result in a transaction more favorable to the applicable shareholders from a financial point
of view than the amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
receiving party must provide prompt notice to the other party of any acquisition proposal and terms and conditions of the superior proposal,
and a list of, and, at the request of the responding party, copies of, the information provided to such person and immediately provided
with access to similar information to which such person was provided. The receiving party agrees that it will not accept, approve or
enter into any agreement, other than a confidentiality and standstill agreement as contemplated by the Amalgamation Agreement, with any
person providing for or to facilitate any acquisition proposal unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            board of directors of the receiving party determines that the acquisition proposal constitutes
                                            a Superior Proposal;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of MagicMed, the MagicMed special meeting has not occurred;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of the ENVB, the ENVB special meeting has not occurred;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            receiving party has provided the responding party with a notice in writing that there is
                                            a superior proposal together with all documentation related to and detailing the superior
                                            proposal;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ten
                                            business days shall have elapsed from the date the responding party received the notice and
                                            documentation referred to in the Amalgamation Agreement from receiving party and, if the
                                            responding party has proposed to amend the terms of the Amalgamation Agreement and the transaction
                                            in accordance with the Amalgamation Agreement, the board of directors of the receiving party
                                            shall have determined, in good faith, after consultation with its financial advisors and
                                            outside legal counsel, that the acquisition proposal continues to constitute a superior proposal
                                            compared to the proposed amendment to the terms of the Amalgamation Agreement and the transactions
                                            contemplated thereby by the responding party; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            receiving party terminates the Amalgamation Agreements pays the amounts required thereunder
                                            pursuant to the terms of the Amalgamation Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
either ENVB or MagicMed accepts a superior proposal, such party is required to pay $4.5 million pursuant to the termination fee payment
terms therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_074"></A>Meetings
of Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is obligated to convene and conduct a special meeting on or before the date of the ENVB special meeting, or such later date as may be
mutually agreed to by ENVB and MagicMed, and not adjourn, postpone or cancel (or propose the adjournment, postponement or cancellation
of) the special meeting without the prior written consent of ENVB, except in the case of an adjournment, as required for quorum purposes
or to otherwise be held on or about the same date as the ENVB special meeting or if reasonably required to solicit proxies in support
of the MagicMed Amalgamation Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
will convene and conduct a special meeting on or before sixty-five (65) days after the SEC has declared the registration statement on
Form S-4 effective, or such later date as may be mutually agreed to by ENVB and MagicMed, and not adjourn, postpone or cancel (or propose
the adjournment, postponement or cancellation of) the special meeting without the prior written consent of MagicMed, except in the case
of an adjournment, as required for quorum purposes or to otherwise be held on or about the same date as the MagicMed special meeting
or if reasonably required to solicit proxies in support of the ENVB Share Issuance Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_075"></A>Conduct
of Business Pending the Amalgamation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has agreed that, except as permitted by the Amalgamation Agreement, as required by law, or unless ENVB shall have provided written consent,
during the period commencing on the date of the Amalgamation Agreement and continuing until the earlier to occur of the closing of the
amalgamation and the termination of the Amalgamation Agreement, MagicMed will conduct its business and operations in the ordinary course
consistent with past practices and in compliance with all applicable laws and regulations. MagicMed has also agreed that, subject to
certain limited exceptions, without the consent of ENVB, it will not, during the period commencing on the date of the Amalgamation Agreement
and continuing until the earlier to occur of the closing of the amalgamation and the termination of the Amalgamation Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any change in its certificate of incorporation, by-laws or other organizational documents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">split,
                                            combine, consolidate or reclassify any shares of its capital stock, undertake any capital
                                            reorganization or declare, set aside or pay any dividend or other distribution (whether in
                                            cash, stock or property or any combination thereof);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redeem,
                                            repurchase, or otherwise acquire or offer to redeem, repurchase or otherwise acquire any
                                            shares of its capital stock or reduce the stated capital in respect of the MagicMed common
                                            shares or any other shares of MagicMed or its subsidiaries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue,
                                            grant, deliver, sell, pledge or otherwise encumber, or authorize the issuance, grant, delivery,
                                            sale, pledge or other encumbrance of any shares of capital stock, securities, options, warrants
                                            or similar rights exercisable or exchangeable for or convertible into such capital stock,
                                            of MagicMed and its subsidiaries, except for the issuance of MagicMed common shares (A) issuable
                                            upon the exercise of the currently outstanding MagicMed options or (B) pursuant to outstanding
                                            MagicMed warrants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
                                            (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly,
                                            in one transaction or in a series of related transactions, assets, securities, properties,
                                            interests or businesses of any other person (other than pursuant to the transactions contemplated
                                            by the Amalgamation Agreement);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reorganize,
                                            amalgamate, combine or merge MagicMed or its subsidiaries with any other person (other than
                                            pursuant to the transactions contemplated by the Amalgamation Agreement);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adopt
                                            a plan of liquidation or resolutions providing for the liquidation or dissolution of MagicMed
                                            or its subsidiaries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
                                            pledge, lease, dispose of, surrender, lose the right to use, mortgage, license, encumber
                                            (other than permitted liens) or otherwise dispose of or transfer any assets of MagicMed or
                                            its subsidiaries or any interest in any assets of MagicMed or its subsidiaries, other than
                                            the sale of inventory in the ordinary course;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any capital expenditure or similar commitments, other than in the ordinary course in accordance
                                            with the 2021 fiscal year budget made available to ENVB;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any loan or advance to, or any capital contribution or investment in, or assume, guarantee
                                            or otherwise become liable with respect to the liabilities or obligations of, any person;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prepay
                                            any long-term indebtedness before its scheduled maturity or increase, create, incur, assume
                                            or otherwise become liable, in one transaction or in a series of related transactions, with
                                            respect to any indebtedness for borrowed money or guarantees thereof, other than in the ordinary
                                            course; provided that any indebtedness created, incurred, refinanced, assumed or for which
                                            MagicMed or its subsidiaries becomes liable in accordance with the any of the foregoing shall
                                            be prepayable at the effective time of the amalgamation without premium, penalty or other
                                            incremental costs (including breakage costs);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                            into any interest rate, currency, equity or commodity swaps, hedges, derivatives, forward
                                            sales contracts or similar financial instruments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any bonus or profit sharing distribution or similar payment of any kind;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">grant
                                            any general increase in the rate of wages, salaries, bonuses or other remuneration of any
                                            MagicMed employees;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any change in MagicMed&rsquo;s or its subsidiaries&rsquo; methods of accounting (except as
                                            required by IFRS);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any tax election, information schedule, return or designation, except as required by applicable
                                            law and in a manner consistent with past practice, settle or compromise any material tax
                                            claim, assessment, reassessment or liability, file any amended tax return, enter into any
                                            material agreement with a governmental authority with respect to taxes, surrender any right
                                            to claim a material tax abatement, reduction, deduction, exemption, credit or refund, consent
                                            to the extension or waiver of the limitation period applicable to any material tax matter
                                            or materially amend or change any of its methods or reporting income, deductions or accounting
                                            for income tax purposes except as may be required by applicable law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create,
                                            enter into or increase any severance, change of control or termination pay to (or amend any
                                            similar existing arrangement with) any MagicMed employees, director or executive officer
                                            of MagicMed or its subsidiaries or change the benefits payable under any existing severance
                                            or termination pay policies with any MagicMed employee, director or executive officer of
                                            MagicMed or its subsidiaries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
                                            as required by applicable law: (A) adopt, enter into or amend any employee plan (other than
                                            entering into an employment agreement in the ordinary course with a new MagicMed employee
                                            who was not employed by MagicMed or its subsidiaries on the date of this Agreement); (B)
                                            pay any benefit to any director or officer of MagicMed or its subsidiaries or to any MagicMed
                                            employee that is not required under the terms of any employee plan in effect on the date
                                            of the Amalgamation Agreement; (C) grant, accelerate, increase or otherwise amend any payment,
                                            award or other benefit payable to, or for the benefit of, any director or officer of MagicMed
                                            or its subsidiaries or to any MagicMed employee; (D) make any material determination under
                                            any Employee Plan; or (E) take or propose any action to effect any of the foregoing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel,
                                            waive, release, assign, settle or compromise any material claims or rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commence,
                                            waive, release, assign, settle or compromise any litigation, proceedings or governmental
                                            investigations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend,
                                            modify, terminate or waive any right under any material contract or enter into any contract
                                            or agreement that would be a material contract if in effect on the date of the Amalgamation
                                            Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend,
                                            modify, terminate, cancel or let lapse any material insurance (or re-insurance) policy of
                                            the MagicMed or its subsidiaries in effect on the date of the Amalgamation Agreement, unless
                                            simultaneously with such termination, cancellation or lapse, replacement policies underwritten
                                            by insurance and re-insurance companies of nationally recognized standing providing coverage
                                            equal to or greater than the coverage under the terminated, cancelled or lapsed policies
                                            for substantially similar premiums are in full force and effect;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of any assets of MagicMed or its subsidiaries, waive, release, surrender, let lapse,
                                            grant or transfer any material right or value or amend, modify or change, or agree to amend,
                                            modify or change any existing material: (i) government authorization or (ii) right to use,
                                            lease, contract, production sharing agreement, intellectual property, or other material document;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">abandon
                                            or fail to diligently pursue any application for any material government authorizations,
                                            licenses, leases, or registrations or take any action, or fail to take any action, that could
                                            lead to the termination of any material government authorizations, licenses, leases or registrations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                            into or amend any contract with any broker, finder or investment banker (excluding for greater
                                            certainty such agreement noted in Section 4.1(q) of the MagicMed Disclosure Statement); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize,
                                            agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB,
Purchaser and HoldCo have agreed that, except as permitted by the Amalgamation Agreement, as required by law, or unless MagicMed
shall have provided written consent, during the period commencing on the date of the Amalgamation Agreement and continuing until the
earlier to occur of the closing of the amalgamation and the termination of the Amalgamation Agreement, ENVB, Purchaser and HoldCo
will conduct their respective businesses and operations in the ordinary course consistent with past practices and in compliance with
all applicable laws and regulations. ENVB, Purchaser and HoldCo have also agreed that, subject to certain limited exceptions,
without the consent of MagicMed, neither ENVB, Purchaser nor HoldCo will, during the period commencing on the date of the Amalgamation
Agreement and continuing until the earlier to occur of the closing of the amalgamation and the termination of the Amalgamation Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any change in its certificate of incorporation, by-laws or other organizational documents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">split,
                                            combine, consolidate or reclassify any shares of its capital stock, undertake any capital
                                            reorganization or declare, set aside or pay any dividend or other distribution (whether in
                                            cash, stock or property or any combination thereof);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redeem,
                                            repurchase, or otherwise acquire or offer to redeem, repurchase or otherwise acquire any
                                            shares of its capital stock or reduce the stated capital in respect of ENVB common stock
                                            or any other shares of ENVB, HoldCo, the Purchaser and their respective subsidiaries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
                                            in connection with an equity or convertible or exchangeable security financing, issue, grant,
                                            deliver, sell, or authorize the issuance, grant, delivery, sale, pledge or other encumbrance
                                            of any shares of capital stock, securities, options, warrants or similar rights exercisable
                                            or exchangeable for or convertible into such capital stock, of ENVB, HoldCo, the Purchaser
                                            or their respective subsidiaries, except for the issuance of ENVB capital stock (A) issuable
                                            upon the exercise of the currently outstanding ENVB options, or (B) pursuant to outstanding
                                            ENVB warrants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
                                            (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly,
                                            in one transaction or in a series of related transactions, assets, securities, properties,
                                            interests or businesses of any other person (other than pursuant to the transactions contemplated
                                            by the Amalgamation Agreement);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reorganize,
                                            amalgamate, combine or merge ENVB, HoldCo, the Purchaser or their respective subsidiaries
                                            with any other person (other than pursuant to the transactions contemplated by the Amalgamation
                                            Agreement);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adopt
                                            a plan of liquidation or resolutions providing for the liquidation or dissolution of ENVB,
                                            HoldCo, the Purchaser or their respective subsidiaries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
                                            lease, dispose of, surrender, lose the right to use, license or otherwise dispose of or transfer
                                            any assets of ENVB, HoldCo, the Purchaser or their respective subsidiaries or any
                                            interest in any assets of ENVB, HoldCo, the Purchaser or their respective subsidiaries,
                                            other than in the ordinary course;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any capital expenditure or similar commitments, other than in the ordinary course;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any loan or advance to, or any capital contribution or investment in, or assume, guarantee
                                            or otherwise become liable with respect to the liabilities or obligations of, any person;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prepay
                                            any long-term indebtedness before its scheduled maturity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                            into any interest rate, currency, equity or commodity swaps, hedges, derivatives, forward
                                            sales contracts or similar financial instruments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any change in the ENVB&rsquo;s or its subsidiaries&rsquo; methods of accounting (except as
                                            required by U.S. GAAP);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any material tax election, information schedule, return or designation, except as required
                                            by applicable law and in a manner consistent with past practice, settle or compromise any
                                            material tax claim, assessment, reassessment or liability, file any amended tax return, enter
                                            into any material agreement with a governmental authority with respect to taxes, surrender
                                            any right to claim a material tax abatement, reduction, deduction, exemption, credit or refund,
                                            consent to the extension or waiver of the limitation period applicable to any material tax
                                            matter or materially amend or change any of its methods or reporting income, deductions or
                                            accounting for income tax purposes except as may be required by applicable law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel,
                                            waive, release, assign, settle or compromise any material claims or rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend
                                            or modify or terminate or waive any right under any material contract or enter into any contract
                                            or agreement that would be a material contract if in effect on the date of the Amalgamation
                                            Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend,
                                            modify, terminate, cancel or let lapse any material insurance (or re-insurance) policy of
                                            ENVB, HoldCo, the Purchaser or their respective subsidiaries in effect on the date
                                            of the Amalgamation Agreement, unless simultaneously with such termination, cancellation
                                            or lapse, replacement policies underwritten by insurance and re-insurance companies of nationally
                                            recognized standing providing coverage equal to or greater than the coverage under the terminated,
                                            cancelled or lapsed policies for substantially similar premiums are in full force and effect;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of any assets of ENVB, HoldCo, the Purchaser or their respective subsidiaries,
                                            waive, release, surrender, let lapse, grant or transfer any material right or value or amend,
                                            modify or change, or agree to amend, modify or change any existing material: (i) government
                                            authorization or (ii) right to use, lease, contract, production sharing agreement, intellectual
                                            property, or other material document;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">abandon
                                            or fail to diligently pursue any application for any material government authorizations,
                                            licenses, leases, or registrations or take any action, or fail to take any action, that could
                                            lead to the termination of any material government authorizations, licenses, leases or registrations;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize,
                                            agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_076"></A>Covenants
and Other Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of ENVB and MagicMed has agreed to, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">carry
                                            out the Amalgamation Agreement in accordance with and subject to the terms of the Amalgamation
                                            Agreement, and comply promptly with all requirements imposed by applicable law on it with
                                            respect to the Amalgamation Agreement or the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                            its commercially reasonable efforts to obtain and maintain all third party or other consents,
                                            waivers, permits, exemptions, orders, approvals, agreements, amendments or confirmations
                                            that are (i) necessary or advisable to be obtained under the material contracts in connection
                                            with the amalgamation or (ii) required in order to maintain the material contracts in full
                                            force and effect following completion of the amalgamation, in each case, on terms that are
                                            reasonably satisfactory to ENVB and the Purchaser, and without paying, and without committing
                                            itself or ENVB or the Purchaser to pay, any consideration or incur any liability or obligation
                                            without the prior written consent of ENVB and the Purchaser;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                            reasonable best efforts (or with respect to ENVB, commercially reasonable efforts) to effect
                                            all necessary registrations, filings and submissions of information required by governmental
                                            authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                            reasonable best efforts, on prior written approval of ENVB and the Purchaser, (or with respect
                                            to ENVB, commercially reasonable efforts) to oppose, lift or rescind any injunction, restraining
                                            or other order, decree, judgment or ruling seeking to restrain, enjoin or otherwise prohibit
                                            or adversely affect the consummation of the amalgamation and defend, or cause to be defended,
                                            any legal proceedings or actions to which it is a party or brought against it or its directors
                                            or officers challenging the amalgamation or the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            take any action, or refrain from taking any action, or permitting any action to be taken
                                            or not taken, which is inconsistent with the Amalgamation Agreement or which would reasonably
                                            be expected to prevent, delay or otherwise impede the consummation of the amalgamation or
                                            the transactions contemplated by the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                            all commercially reasonable efforts to, as promptly as practicable, prepare and file all
                                            necessary documents, registrations, statements, petitions, filings and applications for any
                                            regulatory approvals and use its reasonable best efforts to obtain and maintain all regulatory
                                            approvals (provided that, notwithstanding anything to the contrary set forth in the Amalgamation
                                            Agreement, each of ENVB and the Purchaser are under no obligation to take any steps or actions
                                            that would, in their sole discretion, affect ENVB or the Purchaser&rsquo;s right to own,
                                            use or exploit its business, operations or assets or those of MagicMed);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to MagicMed, use all commercially reasonable efforts to cooperate with ENVB and the
                                            Purchaser in connection with obtaining any regulatory approvals including providing ENVB
                                            and the Purchaser with copies of all notices and information or other correspondence supplied
                                            to, filed with or received from any governmental authority;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to MagicMed, concurrently with the closing of the amalgamation, use its reasonable
                                            best efforts to cause each of shareholders set forth on <U>Schedule 7.3(h)</U> to the Amalgamation
                                            Agreement to execute a lock-up agreement substantially in the form attached as <U>Schedule
                                            &ldquo;D&rdquo;</U> to the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solicit
                                            proxies to be voted at each applicable special meeting in favor of the matters to be considered
                                            at such meeting, including approval of the amalgamation and against any resolution submitted
                                            by any person that is inconsistent with such resolution and the completion of the Transaction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promptly
                                            notify the other party in writing of:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            material adverse effect;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            notice or other communication from any person alleging that a consent or authorization is
                                            or may be required in connection with the Amalgamation Agreement or the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            notice or other communication from any material supplier, customer or other third party to
                                            the effect that such supplier, customer or third party is terminating, may terminate or is
                                            otherwise materially adversely modifying or may materially adversely modify its relationship
                                            as a result of the Amalgamation Agreement or the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            notice or other communication from any governmental authority in connection with the Amalgamation
                                            Agreement; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            filing, actions, suits, claims, investigations or legal proceedings commenced or, to its
                                            knowledge, threatened against, relating to or involving or otherwise affecting a party to
                                            the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
                                            itself, in all material respects, subject to applicable law, so as to keep the other party
                                            fully informed as to the material decisions required to be made or actions required to be
                                            taken with respect to the operation of the applicable business; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to ENVB, prepare and submit the NASDAQ listing application and use commercially reasonably
                                            efforts to cause such NASDAQ listing application to be conditionally approved prior to the
                                            Effective Time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
and MagicMed agreed that at or prior to the closing, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            will cause certain specified shareholders to execute a lock-up agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            will prepare and submit the NASDAQ listing application and use commercially reasonable efforts
                                            to cause such NASDAQ listing application to be conditionally approved prior to the effective
                                            time;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            will obtain the approvals required under its organizational documents to approve the issuance
                                            of ENVB common stock in connection with the amalgamation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            shall prepare and file with the SEC a proxy statement to be sent to the stockholders of ENVB
                                            relating to the meeting of stockholders, and a registration statement on Form S-4 (including
                                            a prospectus) in connection with the issuance of ENVB common stock in the amalgamation, of
                                            which such proxy statement will form a part, and MagicMed shall cooperate in the preparation
                                            of such documents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            shall prepare and file with applicable securities regulators the MagicMed circular to be
                                            sent to the shareholders of MagicMed relating to the meeting of shareholders, and ENVB shall
                                            cooperate in the preparation of the circular;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB,
                                            MagicMed, HoldCo and Purchaser shall use commercially reasonable efforts to cause
                                            this proxy statement and Form S-4 to comply with the rules and regulations promulgated by
                                            the SEC, to respond promptly to any comments of the SEC or its staff;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
                                            to the closing, ENVB shall cause HoldCo to become an unlimited liability company pursuant
                                            to, and in accordance with, the provisions of the BCBCA;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            will file a &ldquo;Notification to Acquire Control of an Existing Canadian Business&rdquo;
                                            pursuant to the Investment Canada Act within 30 days after the effective date; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            will maintain directors&rsquo; and officers&rsquo; liability insurance policies from and
                                            after the effective time and will also purchase a &ldquo;tail policy&rdquo; for the non-cancellable
                                            extension of the directors&rsquo; and officers&rsquo; liability coverage of MagicMed&rsquo;s
                                            existing directors&rsquo; and officers&rsquo; insurance policies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_077"></A>Termination
of the Amalgamation Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notice
and Cure of Breach</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amalgamation Agreement, each of ENVB and MagicMed has an obligation to notify the other of any event, occurrence, or state of
facts that would cause, or would reasonably be likely to result in, (a) a representation or warranty of ENVB or MagicMed to be untrue
or inaccurate in any material respect at any time between the signing of the Amalgamation Agreement and the closing of the amalgamation,
or (b) a failure, in any material respect, to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied
by ENVB or MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
party seeking to terminate the Amalgamation Agreement must provide a written notice to the other parties specifying in reasonable detail
all of the breaches of covenants, representations and warranties or other matters which the party seeking to terminate asserts as its
basis for termination. After delivering a termination notice, providing such party that received the notice is diligently proceeding
to cure such matter and such matter is capable of being cured prior to December 31, 2021, the terminating party may not exercise its
right of termination until the earlier of (a) December 31, 2021 and (b) the date that is 20 business days following receipt of such termination
notice by the party in receipt of such notice, if such matter has not been cured by such date. If a termination notice is provided before
the ENVB or MagicMed special meetings, such meetings must be postponed or adjourned to the earlier of (a) five Business Days prior to
December 31, 2021 and (b) the date that is 20 business days following the receipt of the termination notice by the breaching party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Termination</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation Agreement may be terminated at any time prior to the effective time of the amalgamation, whether before or after the required
stockholder approvals to complete the amalgamation and related matters have been obtained, as set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            mutual written consent of ENVB, Purchaser, HoldCo and MagicMed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either MagicMed or the Purchaser if the ENVB stockholder approval is not obtained at the
                                            ENVB special meeting of the stockholders; provided, however, that neither MagicMed or the
                                            Purchaser may terminate the Amalgamation Agreement if the failure to obtain such approval
                                            was caused by, or is a result of, a breach by such terminating party of its representations
                                            or warranties or failure to perform its covenants or agreements under the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either MagicMed or the Purchaser if the MagicMed shareholder approval is not obtained at
                                            the MagicMed special meeting; provided, however, that neither MagicMed or the Purchaser may
                                            terminate the Amalgamation Agreement if the failure to obtain such approval was caused by,
                                            or is a result of, a breach by such terminating party of its representations or warranties
                                            or failure to perform its covenants or agreements under the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either MagicMed or the Purchaser if, after the date of the Amalgamation Agreement, any applicable
                                            law is enacted, made, enforced or amended that makes the consummation of the amalgamation
                                            illegal or otherwise permanently prohibits or enjoins ENVB, MagicMed or the Purchaser from
                                            consummating the amalgamation, and such applicable law has, if applicable, become final and
                                            non-appealable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either MagicMed or the Purchaser if the effective time does not occur by December 31, 2021;
                                            provided that a party may not terminate if the failure of the effective time to occur is
                                            a result of a breach by such party of its representations or warranties or the failure of
                                            such party to perform its covenants or agreements; provided, however, in the event that the
                                            SEC has not concluded its review of the S-4 Registration Statement by the date which is sixty
                                            (60) days prior to December 31, 2021, then either ENVB or MagicMed shall be entitled to extend
                                            the end date for an additional sixty (60) days by providing written notice to the other party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            either MagicMed or the Purchaser if there shall be in effect a final nonappealable order
                                            of a governmental authority of competent jurisdiction restraining, enjoining or otherwise
                                            prohibiting the consummation of the transactions contemplated by the Amalgamation Agreement;
                                            provided, that the right to terminate shall not be available to a party if such order was
                                            primarily due to the failure of such party to perform any of its obligations under the Amalgamation
                                            Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            MagicMed if a breach of any representation or warranty or failure to perform any covenant
                                            or agreement on the part of ENVB or the Purchaser under the Amalgamation Agreement occurs
                                            that would cause any condition precedent to the closing of the amalgamation not to be satisfied,
                                            and such breach or failure is incapable of being cured on or prior to December 31, 2021 or
                                            is not cured in the manner described above; provided that (a) any willful breach is deemed
                                            incurable and (b) MagicMed is not in breach so as to cause any condition to the closing of
                                            the amalgamation to not be satisfied;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            MagicMed if it wishes to enter into a binding written agreement with respect to a superior
                                            proposal (other than a confidentiality and standstill agreement permitted by the Amalgamation
                                            Agreement), in compliance with the Amalgamation Agreement and provided that no termination
                                            shall be effective unless and until MagicMed shall have paid to the Purchaser the termination
                                            fee required to be paid pursuant to the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            MagicMed if (a) ENVB&rsquo;s board or any committee of thereof fails to unanimously recommend
                                            or withdraws, amends, modifies or qualifies its approval of the amalgamation, or publicly
                                            proposes or states its intention to do so; (b) ENVB&rsquo;s board or a committee thereof
                                            shall have approved or recommended any acquisition proposal or authorized ENVB to enter into
                                            binding written agreement with respect to a superior proposal (other than a confidentiality
                                            and standstill agreement permitted by the Amalgamation Agreement); or (c) ENVB breaches the
                                            non-solicitation provisions in any material respect, provided, however, no termination shall
                                            be effective unless and until MagicMed shall have paid to the Purchaser the termination fee
                                            required to be paid pursuant to the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            MagicMed if there is a material adverse effect with respect to ENVB that has not been disclosed
                                            by ENVB prior to the date of the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            ENVB if a breach of any representation or warranty or failure to perform any covenant or
                                            agreement on the part of MagicMed under the Amalgamation Agreement occurs that would cause
                                            any condition precedent to the closing of the amalgamation not to be satisfied, and such
                                            breach or failure is incapable of being cured on or prior to December 31, 2021 or is not
                                            cured in the manner described above; provided that (a) any willful breach is deemed incurable
                                            and (b) ENVB is not in breach so as to cause any condition to the closing of the amalgamation
                                            to not be satisfied;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            ENVB if it wishes to enter into a binding written agreement with respect to a superior proposal
                                            (other than a confidentiality and standstill agreement permitted by the Amalgamation Agreement),
                                            subject to compliance with the Amalgamation Agreement and provided that no termination shall
                                            be effective unless and until ENVB shall have paid to MagicMed the termination fee required
                                            to be paid pursuant to the Amalgamation Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            ENVB if (a) the MagicMed Board or any committee of thereof fails to unanimously recommend
                                            or withdraws, amends, modifies or qualifies the its approval of the amalgamation, or publicly
                                            proposes or states its intention to do so; (b) the MagicMed board or a committee thereof
                                            shall have approved or recommended any acquisition proposal or authorized MagicMed to enter
                                            into binding written agreement with respect to a superior proposal (other than a confidentiality
                                            and standstill agreement permitted by the Amalgamation Agreement); or (c) MagicMed breaches
                                            the non-solicitation provisions in any material respect; provided, however, no termination
                                            pursuant to shall be effective unless and until ENVB shall have paid to MagicMed the termination
                                            fee required to be paid pursuant to Amalgamation Agreement; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            ENVB if there is a material adverse effect with respect to MagicMed that has not been disclosed
                                            by MagicMed prior to the date of the Amalgamation Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_078"></A>Termination
Fee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
shall pay to ENVB and ENVB shall be entitled to the termination fee (on its own behalf and on behalf of the Purchaser) upon the occurrence
of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            MagicMed board has a change in recommendation, MagicMed has an agreement with respect to
                                            an acquisition proposal or MagicMed breaches the non-solicit provisions of the Amalgamation
                                            Agreement; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            enters into a Superior Proposal;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                             <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">provided
that the termination fee shall not be payable if ENVB or Purchaser are then in breach of any of their respective representations and
warranties or any of their covenants or agreements under the Amalgamation Agreement.</TD></TR>
                                                                                             </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
shall pay to MagicMed and MagicMed shall be entitled to the termination upon the occurrence of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ENVB board has a change in recommendation, ENVB has an agreement with respect to an acquisition
                                            proposal or ENVB breaches the non-solicit provisions of the Amalgamation Agreement; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
                                            enters into a Superior Proposal;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that the termination fee shall not be payable if MagicMed is then in breach of any of its representations and warranties or any of their
covenants or agreements under the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a termination fee is due with respect to a change in recommendation, an agreement with respect to an acquisition proposal or breaches
the non-solicit provisions of the Amalgamation Agreement, the termination fee shall be payable within three (3) business days following
such termination. If a termination fee is due with respect to a superior proposal, the termination fee shall be payable concurrently
with the execution of the definitive agreement with respect to the Superior Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_079"></A>Amendment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation Agreement may be amended by the parties at any time prior to the effective time without further notice or authorization
by the MagicMed securityholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_080"></A>Third
Party Beneficiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights and benefits under the Amalgamation Agreement are not for the benefit of any person that is not a party to the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_081"></A>Governing
Law; Jurisdiction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation Agreement is governed by the laws of the Province of British Columbia and the federal laws of Canada applicable therein.
Each party submitted to the exclusive jurisdiction of the Province of British Columbia for any legal proceedings under the Amalgamation
Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_082"></A>Injunctive
Relief</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties to the Amalgamation Agreement have agreed that if any of the provisions of the Amalgamation Agreement were not performed in accordance
with their specific terms or were otherwise breached, irreparable harm would occur for which money damages would not be adequate, and
that the parties shall be entitled to injunctive or other equitable relief to prevent breaches of the merger agreement and to specific
performance of the terms of the merger agreement, without the requirement of posting bond or other security (any requirements therefor
being expressly waived).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_083"></A>ANCILLARY
AGREEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary describes the material provisions of certain ancillary agreements entered into by ENVB and certain beneficial
owners of MagicMed common shares, by MagicMed and certain beneficial owners of ENVB shares, and by ENVB and cetrain officers of
MagicMed. This summary does not purport to be complete and is qualified in its entirety by reference to the form of voting
agreement and lock-up agreement attached to this proxy statement/prospectus as <U>Annex B-1 and Annex&nbsp;B-2</U> and <U>Annex C-1
and Annex&nbsp;C-2</U>, respectively. We urge you to read carefully the entire form of voting agreement and lock-up
agreement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_084"></A>Voting
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the execution of the Amalgamation Agreement, certain stockholders of MagicMed, collectively representing approximately 30% of the
outstanding MagicMed common shares, entered into voting agreements with ENVB (the &ldquo;ENVB Voting Agreements&rdquo;). Pursuant
to the terms and conditions of the ENVB Voting Agreements, each holder agreed to vote all shares of MagicMed common shares
owned by them as of the applicable record date in favor of the approval of the Amalgamation, any other transactions contemplated in the
Amalgamation Agreement and any other matter necessary for the consummation of the Amalgamation at a meeting of MagicMed shareholders
called for such purpose, each granting a proxy and power of attorney that will be coupled with an interest and will be irrevocable prior
to the termination of the voting agreements in accordance with their terms. The holders also agreed to vote against any competing action,
proposal, transaction or agreement that (i) would result in a breach of any obligation of MagicMed under the Amalgamation Agreement or
the holder under the voting agreement and (ii) would delay, prevent, impede or frustrate the successful completion of the Amalgamation
or any of the transactions contemplated by the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ENVB Voting Agreements contain certain other covenants, including, among other things, the waiver of appraisal or dissenters&rsquo;
rights with respect to the Amalgamation. The ENVB Voting Agreements will terminate on the earliest to occur of the effective
time of the Amalgamation and the termination of the Amalgamation Agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">In
addition, simultaneously with the execution of the Amalgamation Agreement, certain directors and officers of ENVB, collectively representing
less than 1% of the outstanding ENVB common shares, entered into voting agreements with MagicMed (the &ldquo;MagicMed Voting Agreements&rdquo;).
Pursuant to the terms and conditions of the MagicMed Voting Agreements, those directors and officers agreed to vote all ENVB common shares owned by them
as of the applicable record date in favor of the approval of the Amalgamation, any other transactions contemplated in the Amalgamation
Agreement and any other matter necessary for the consummation of the Amalgamation at a meeting of ENVB shareholders called for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
MagicMed Voting Agreements will terminate on the earliest to occur of the effective time of the Amalgamation and the termination of the
Amalgamation Agreement in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_085"></A>Lock-Up
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Certain
stockholders of MagicMed have also entered into lock-up agreements with ENVB (the &ldquo;Insider Lock-Up Agreements&rdquo;) pursuant
to which the holders have agreed not to sell shares of ENVB common stock to be received in the Amalgamation in excess of certain limits
specified in the lock-up agreements for a period of five (5) months after the effective time of the Amalgamation. The Insider Lock-Up
Agreements will survive for five months after the effective time of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white">In
addition, certain directors and officers of MagicMed have entered into lock-up agreements with ENVB (the &ldquo;Founder Lock-Up Agreements&rdquo;)
pursuant to which the holders have agreed not to sell shares of ENVB common stock to be received in the Amalgamation in excess of certain
limits specified in the lock-up agreements for a period of twenty (20) months after the effective time of the Amalgamation. The Founder
Lock-Up Agreements will survive for five months after the effective time of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white">For
information about each of the employment agreements between ENVB and Dr. Tucker, Dr. Hagel, and Dr. Facchini, please see the section
titled &ldquo;The Amalgamation&mdash;Governance of ENVB After the Amalgamation&rdquo; beginning on page 109 of this proxy statement/prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 129; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSALS
SUBMITTED TO ENVB STOCKHOLDERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_086"></A>ENVB
PROPOSAL 1 &ndash; APPROVAL OF THE ENVB SHARE ISSUANCE PROPOSAL</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in this proxy statement/prospectus, ENVB is asking its stockholders to approve the ENVB Share Issuance Proposal. For
a summary of and detailed information regarding this proposal, see the information about the Amalgamation Agreement and the issuance
of shares of ENVB common stock in the Amalgamation throughout this proxy statement/prospectus, including the information set forth
in sections entitled &ldquo;The Amalgamation&rdquo; beginning on page 94 and &ldquo;The Amalgamation Agreement&rdquo; beginning
on page 112. A copy of the Amalgamation Agreement is attached as <U>Annex A</U> to this proxy statement/prospectus and
incorporated herein by reference. You are urged to read carefully this proxy statement/prospectus and the Amalgamation Agreement
attached hereto in their entirety before voting on this proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amalgamation Agreement provides that as part of the Amalgamation Consideration, ENVB will issue shares of ENVB common stock to
the MagicMed equity holders in connection with the Amalgamation. The total number of shares of common stock that ENVB will be required
to issue pursuant to the Amalgamation Agreement will be in excess of 20% of ENVB&rsquo;s pre-Amalgamation outstanding shares of common
stock. Accordingly, ENVB is asking its stockholders to approve the ENVB Share Issuance Proposal in accordance with NASDAQ listing rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amalgamation Agreement, approval of the ENVB Share Issuance Proposal is a condition to the closing of the Amalgamation. If this
proposal is not approved, the Amalgamation will not be completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Required
Vote</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
a quorum is present, the</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> approval of the ENVB Share Issuance Proposal
requires the affirmative vote of a majority of the votes cast by holders of ENVB&rsquo;s common stock as of the Record Date present in
person or represented by proxy at the ENVB special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vote on the ENVB Share Issuance Proposal is a vote separate and apart from the vote to approve the ENVB Adjournment Proposal. Accordingly,
an ENVB stockholder may vote to approve the ENVB Share Issuance Proposal and vote not to approve the ENVB Adjournment Proposal, and vice
versa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recommendation
of the ENVB Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
ENVB board of directors unanimously recommends that ENVB stockholders vote &ldquo;FOR&rdquo; the ENVB Share Issuance Proposal.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="o_087"></A>ENVB PROPOSAL 2 &ndash;
APPROVAL OF THE ENVB ADJOURNMENT PROPOSAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there are insufficient votes at the time of the ENVB special meeting to approve  the ENVB Share Issuance Proposal, or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to
ENVB stockholders, the ENVB special meeting may be adjourned to another time or place, if necessary or appropriate, to permit the solicitation
of additional proxies; provided, that the special meeting may not be adjourned, without further notice, to a date that is more than 30
days after the date for which the special meeting was originally noticed or if a new record date is fixed for the adjourned meeting.
ENVB does not intend to propose adjournment at the ENVB special meeting if there are sufficient votes to approve  the ENVB Share
Issuance Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the ENVB special meeting, the number of shares of ENVB common stock present or represented by proxy and voting in favor of
the ENVB Share Issuance Proposal  is insufficient to approve  the ENVB Share Issuance Proposal, ENVB may move to adjourn the ENVB special meeting in order to enable the ENVB board of directors
to solicit additional proxies for approval of the ENVB Share Issuance Proposal. In
that event, ENVB&rsquo;s stockholders will be asked to vote upon the ENVB Adjournment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ENVB Adjournment Proposal, ENVB is asking its stockholders to authorize the holder of any proxy solicited by the ENVB board of directors
to vote in favor of granting discretionary authority to the ENVB board of directors to adjourn the ENVB special meeting to another time
and place for the purpose of soliciting additional proxies. If ENVB&rsquo;s stockholders approve the ENVB Adjournment Proposal, ENVB
could adjourn the ENVB special meeting and any adjourned session of the ENVB special meeting and use the additional time to solicit additional
proxies, including the solicitation of proxies from ENVB stockholders who have previously voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Required
Vote</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Whether
or not a quorum is present, t<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
approval of the ENVB Adjournment Proposal requires the affirmative vote of a majority of the voting power of shares of ENVB common
stock present in person or represented by proxy at the ENVB special meeting and entitled to vote on the proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vote on the ENVB Adjournment Proposal is a vote separate and apart from the vote to approve the ENVB Share Issuance Proposal. Accordingly,
an ENVB stockholder may vote to approve the ENVB Adjournment Proposal and vote not to approve the ENVB Share Issuance Proposal,
and vice versa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recommendation
of the ENVB Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
ENVB board of directors unanimously recommends that ENVB stockholders vote &ldquo;FOR&rdquo; the ENVB Adjournment Proposal.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 131; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_089"></A>ENVB&rsquo;S
BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unless
the context indicates otherwise, references in this section to the &ldquo;Company,&rdquo; &ldquo;Enveric,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo; and similar terms refer to Enveric Biosciences, Inc. and its subsidiaries. ENVB was formerly known as AMERI Holdings,
Inc. (&ldquo;Ameri&rdquo;). Following the completion of our offer to purchase all of the issued and outstanding shares of Jay Pharma,
Inc. on December 30, 2020, we changed the name of our company from AMERI Holdings, Inc. to Enveric Biosciences, Inc. For more detail
on the transaction with Jay Pharma, Inc. and related transactions, see the section entitled &ldquo;Corporate Developments&rdquo; below.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_090"></A>Company
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell
company immediately prior to the completion of a &ldquo;reverse merger&rdquo; transaction on May 26, 2015, whereby Ameri100 Acquisition,
Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc. (&ldquo;Ameri
and Partners&rdquo;), a Delaware corporation (the &ldquo;2015 Merger&rdquo;). As a result of the 2015 Merger, Ameri and Partners became
Ameri&rsquo;s wholly owned subsidiary with Ameri and Partners&rsquo; former stockholders acquiring a majority of the outstanding shares
of Ameri common stock. The 2015 Merger was consummated under Delaware law pursuant to an Agreement of Merger and Plan of Reorganization,
dated as of May 26, 2015 (the &ldquo;2015 Merger Agreement&rdquo;), and in connection with the 2015 Merger, Ameri changed its name to
AMERI Holdings, Inc. Ameri did business under the brand name &ldquo;Ameri100.&rdquo; Ameri, along with its eleven operating subsidiaries,
provided SAP cloud, digital and enterprise services to clients worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ameri business ceased to be part of the Company on December 30, 2020, pursuant to the Spin-Off. On December 30, 2020, we completed the
Offer and changed our name to &ldquo;Enveric Biosciences, Inc.&rdquo; Our principal corporate office is located at Enveric Biosciences,
Inc., 4851 Tamiami Trail N, Suite 200, telephone (239) 302-1707. Our internet address is https://www.enveric.com/, and the information
included in, or linked to our website is not part of this prospectus. We have included our website address in this prospectus solely
as a textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_091"></A>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>January
2021 Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2021, we closed a registered direct offering of 1,610,679 shares of common stock and pre-funded warrants to purchase 610,679
shares of common stock, pursuant to a Securities Purchase Agreement (the &ldquo;January 2021 Purchase Agreement&rdquo;) with certain
institutional investors at an offering price of $4.5018 per share and $4.4918 per pre-funded warrant (the &ldquo;Pre-funded Warrant&rdquo;),
for gross proceeds of approximately $10.0 million before the deduction of fees and offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-funded Warrants have an exercise price of $0.01 per share. The Pre-funded Warrants are immediately exercisable and may be exercised
at any time after their original issuance until such Pre-funded Warrants are exercised in full. A holder of a Pre-funded Warrant may
not exercise any portion of such holder&rsquo;s Pre-funded Warrants to the extent that the holder, together with its affiliates, would
beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company&rsquo;s outstanding shares of common stock
immediately after exercise (the &ldquo;Beneficial Ownership Limitation&rdquo;), except that upon at least 61 days&rsquo; prior notice
from the holder to the Company, the holder may increase the Beneficial Ownership Limitation to up to 9.99% of the number of shares of
common stock outstanding immediately after giving effect to the exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the January 2021 Purchase Agreement, in a concurrent private placement (the &ldquo;January 2021 Private Placement&rdquo;) that also
closed on January 14, 2021, the Company issued to the investors unregistered warrants to purchase up to 1,666,018 shares of common stock
(the &ldquo;January 2021 Warrants&rdquo;). The January 2021 Warrants are exercisable immediately upon issuance and terminate five years
following issuance and are exercisable at an exercise price of $4.9519 per share, subject to adjustment as set forth therein. A holder
of January 2021 Warrants does not have the right to exercise any portion of its January 2021 Warrants if the holder, together with its
affiliates, would beneficially own in excess of the Beneficial Ownership Limitation; provided, however, that upon 61 days&rsquo; prior
notice to the Company, the holder may increase or decrease the Beneficial Ownership Limitation, provided that in no event shall the Beneficial
Ownership Limitation exceed 9.99%.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 132; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>February
2021 Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2021, we closed a registered direct offering of 3,007,026 shares of common stock, pursuant to a Securities Purchase Agreement
(the &ldquo;February 2021 Purchase Agreement&rdquo;) with certain institutional investors at an offering price of $4.27 per share, for
gross proceeds of approximately $12.8 million before the deduction of fees and offering expenses. The shares were offered by the Company
pursuant to a shelf registration statement on Form S-3 (File No. 333-233260), previously filed with the SEC on August 14, 2019, and declared
effective by the SEC on November 19, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the February 2021 Purchase Agreement, in a concurrent private placement (the &ldquo;February 2021 Private Placement&rdquo;) that also
closed on February 11, 2021, the Company issued to the investors unregistered warrants to purchase up to 1,503,513 shares of common stock
(the &ldquo;February 2021 Warrants&rdquo;). The February 2021 Warrants are exercisable immediately upon issuance and terminate five years
following issuance and are exercisable at an exercise price of $4.90 per share, subject to adjustment as set forth therein. A holder
of February 2021 Warrants does not have the right to exercise any portion of its February 2021 Warrants if the holder, together with
its affiliates, would beneficially own in excess of the Beneficial Ownership Limitation; provided, however, that upon 61 days&rsquo;
prior notice to the Company, the holder may increase or decrease the Beneficial Ownership Limitation, provided that in no event shall
the Beneficial Ownership Limitation exceed 9.99%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Palladium
Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with its role as financial advisor to the Company in the January 2021 Direct Offering, the January 2021 Private Placement,
the February 2021 Direct Offering, and the February 2021 Private Placement, the Company issued Palladium 155,493 warrants with an exercise
price of $4.9519 and 210,492 warrants with an exercise price of $4.90 (the &ldquo;Palladium Warrants&rdquo;) on February 11, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Development
and Clinical Supply Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &ldquo;Agreement&rdquo;) with PureForm Global,
Inc. (&ldquo;PureForm&rdquo;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&ldquo;API&rdquo;)
for the Company&rsquo;s development plans for cancer treatment and supportive care. Under the terms of the Agreement, PureForm has granted
the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term of the Agreement
(contingent upon an initial minimum order volume during the first thirty (30) days from the effective date) and has agreed to manufacture,
package and test the API and related product in accordance with specifications established by the parties. All inventions that are developed
jointly by the parties in the course of performing activities under the Agreement will be owned jointly by the parties in accordance
with applicable law; however, if the Company funds additional research and development efforts by PureForm, the parties may enter into
a further agreement whereby PureForm would assign any resulting inventions or technical information to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the Agreement is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual agreement
of the parties. The Agreement may be terminated by either party upon thirty (30) days written notice of an uncured material breach or
immediately in the event of bankruptcy or insolvency. The Agreement contains, among other provisions, representation and warranties,
indemnification obligations and confidentiality provisions in favor of each party that are customary for an agreement of this nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diverse
Biotech License Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2021, the Company entered into an Exclusive License Agreement (the &ldquo;DB Agreement&rdquo;) with Diverse Biotech, Inc. (&ldquo;Diverse&rdquo;),
pursuant to which the Company acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively, the &ldquo;Agents&rdquo;)
with the goal of alleviating the side effects that cancer patients experience. Under the terms of the DB Agreement, Diverse granted the
Company an exclusive license to its intellectual property rights covering the Agents and its products. In exchange, the Company has granted
Diverse the right to information relating to the Agents developed for the express purpose of using such information to obtain patent
rights, which right terminates upon the issuance or denial of the patent rights.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DB Agreement, the Company will maintain sole responsibility and ownership of the development and commercialization of the Agents
and its products. Diverse has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its
products containing the Agents, at any time during or after the term of the DB Agreement. If Diverse intends to license, sell, or transfer
any other molecules linked with cannabinoids not granted to the Company under the terms of the DB Agreement, the Company will have the
first right, but not the obligation, to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay
Diverse an up-front investment payment in the amount of $675,000, as well as a running royalty starting with the first commercial sale
by the Company to a third party in an arms&rsquo;-length transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the DB Agreement shall continue for as long as the Company intends to develop or commercialize the new drugs, unless earlier
terminated by either Party. The DB Agreement may be terminated by either party upon ninety (90) days written notice of an uncured material
breach or in the event of bankruptcy or insolvency. In addition, the Company has the right to terminate the DB Agreement at any time
upon sixty (60) days&rsquo; prior written notice to Diverse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Appointment
of Chief Financial Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, John M. Van Buiten resigned from his position as the Company&rsquo;s chief financial officer, effective May 15, 2021.
Mr. Van Buiten&rsquo;s resignation was not the result of any disagreement regarding any matter relating to the Company&rsquo;s operations,
policies, or practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, Carter J. Ward, 56, was appointed as the Company&rsquo;s chief financial officer, effective May 15, 2021 (the &ldquo;Effective
Date&rdquo;). In connection with Mr. Ward&rsquo;s appointment as chief financial officer, Mr. Ward entered into an employment agreement
with the Company on April 9, 2021 (the &ldquo;Ward Employment Agreement&rdquo;), effective as of May 15, 2021, pursuant to which Mr.
Ward will receive a base salary of $295,000 (&ldquo;Base Salary&rdquo;) and is eligible to receive annual performance bonuses of up to
50% of his Base Salary, as determined from time-to-time by the Company&rsquo;s board of directors. Additionally, Mr. Ward will receive
525,000 restricted stock units (&ldquo;RSUs&rdquo;), 262,500 of such RSUs shall be subject to time-based vesting (the &ldquo;Time Based
RSUs&rdquo;), and the remaining 262,500 of such RSUs shall be subject to performance-based vesting (the &ldquo;Performance RSUs&rdquo;).
The RSUs shall be subject to the terms and conditions of the Company&rsquo;s 2020 Long-Term Incentive Plan. The Time Based RSUs shall
vest in quarters on each anniversary of the Effective Date, and the Performance RSUs shall vest based on the achievement of performance
milestones established by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_092"></A>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-development-stage biosciences company with an initial focus on developing innovative, evidence-based prescription products
and combination therapies containing cannabinoids to address unmet needs in cancer care. We seek to improve the lives of patients suffering
from cancer, initially by developing palliative and supportive care products for people suffering from certain side effects of cancer
and cancer treatment such as pain or skin irritation. We currently intend to offer such palliative and supportive care products in the
United States, following approval through established regulatory pathways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aiming to advance a pipeline of novel cannabinoid combination therapies for hard-to-treat cancers, including glioblastoma multiforme
(GBM) and several other indications which are currently being researched.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to bring together leading oncology clinicians, researchers, academic and industry partners so as to develop both external proprietary
products and a robust internal pipeline of product candidates aimed at improving quality of life and outcomes for cancer patients. We
intend to evaluate options to out-license its proprietary technology as it moves along the regulatory pathway and evaluates the building
of a small, targeted selling organization and will potentially utilize a hybrid approach based on the product indication and the market
opportunity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
developing our product candidates, we intend to focus on cannabinoids derived from hemp, other botanical sources, and synthetic materials
containing no tetrahydrocannabinol (THC) in order to comply with U.S. federal regulations. Of the potential cannabinoids to be used in
therapeutic formulations, THC, which is responsible for the psychoactive properties of marijuana, can result in undesirable mood effects.
Cannabidiol (CBD) and cannabigerol (CBG), on the other hand, are not psychotropic and are therefore more attractive candidates for translation
into therapeutic practice. In the future, we may utilize cannabinoids that are derived from cannabis plants, which may contain THC; however,
we only intend to do so in jurisdictions where THC is legal. These product candidates will then be studied through a typical Food and
Drug Administration (&ldquo;FDA&rdquo;) drug approval process.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 134; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Strengths</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we offer the following key distinguishing characteristics:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unique
    Dedication to Prescription Cancer Supportive Care</I>. We believe that we are one of the only companies currently developing evidence-based
    prescription-only therapies containing cannabinoids that are exclusively focused on the unique unmet needs of cancer patients. We
    intend to develop such therapies by conforming its product candidates to GMP and obtaining FDA approval for such product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patient-Centric
    Product Development</I>. We are focusing on a patient-centric approach to our product development that will uniquely position us
    to meet the needs of oncology patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>First
    Mover Advantage</I>. We believe we are among the first companies working towards creating a leading brand utilizing cannabinoids
    in oncology supportive care. We seek to build upon our first mover advantage and expertise in cannabinoid research to accelerate
    the discovery, development, and commercialization of therapies for persons affected by cancer that are safe, effective, and trusted
    by patients and physicians globally.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Collaboration
    with Global Research Partner</I>. We enjoy an exclusive license with our global cannabinoid research partner, Tikun Olam. We hold
    exclusive global rights to Tikun Olam&rsquo;s proprietary treatment database and cannabinoid derivatives for the development of oncology-focused
    pharmaceutical products. We intend to leverage Tikun Olam&rsquo;s large-scale human datasets and expand upon Tikun Olam&rsquo;s existing
    research by conducting new studies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sophisticated
    Leadership Team and Scientific Advisors</I>. We have a world-class leadership team with extensive regulated pharmaceutical industry
    backgrounds and deep expertise in oncology, skin and wound care, and clinical research. In addition, we closely collaborate with
    a broad network of leading physicians and scientists at major institutions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Always
    Seeking Growth and Enhancement Opportunities</I>. We have identified a pathway to business growth and shareholder value creation
    based on our planned development programs and eventually plan to leverage the credibility of that expertise into broader offerings.
    We will continue to expand our opportunities to add assets that are complementary or accretive to our plans to serve patients through
    acquisition and in-licensing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Go-to
Market Strategy and Business Approach</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a two-step go-to-market strategy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Skincare
    Product Candidates</I>: Develop product candidates that target skincare-related ailments common among cancer patients, such as radiodermatitis,
    chemotherapy-induced neuropathy, pruritus, rashes, and dry skin.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Combination
    Therapy</I>: Advance novel cannabinoid combination therapies for persons with cancer, starting with programs in glioblastoma multiforme
    (GBM).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing approach to development, and a future ongoing emphasis on data collection, will differentiate us from our peers
and improve the quality of care we are able to provide.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 135; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Product
Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline of product candidates and key ongoing development programs are shown in the tables below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
    Candidate</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Targeted</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Indications</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Partner(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected
    Next Steps</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cannabinoid-Infused
    Topical Product</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncology-
    related skincare conditions (e.g., radiodermatitis)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.-Based
    Center of Excellence</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    &amp; Development / Discovery</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    submission; Exploratory Phase 1/2 trial </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cannabinoid
    + Chemotherapy Combination Therapy</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Oral
    synthetic CBD extract given alone or in combination with clomiphene, concurrently with dose-dense Temolozomide chemotherapy</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glioblastoma
    Multiforme</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recurrent
    or progressive</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Tali Siegal,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rabin
    Medical Center, Davidoff Institute of Oncology</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    &amp; Development / Discovery</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploratory
    Phase 1/2 trial </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
    Potential Development Programs</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 28%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Potential
    Target Indications</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cannabinoid
    + Chemotherapy Combination Therapy</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clomiphene
    in combination with CBD in patients with selected locally advanced or metastatic breast cancer treated with standard adjuvant chemotherapy
    regimens</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast
    Cancer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Prevalence</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the U.S. Department of Health and Human Services, based on 2013-2015 data, approximately 38% of men and women will be diagnosed with
cancer at some point during their lifetime. In 2015, there were an estimated 15,112,098 people living with cancer in the U.S. The number
of new cases of cancer was 439 per 100,000 men and women per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
widespread demand, the pharmaceutical market lacks products that address the unique supportive care needs of cancer patients. However,
we believe that research suggests that cannabis, as a palliative treatment for cancer patients, appears to be a well-tolerated option
to help patients cope with malignancy-related symptoms. For example, researchers from the Soroka Medical Center in Beersheba, Israel
analyzed data gathered at Tikun Olam&rsquo;s central clinic from cancer patients to whom medical cannabis was given for palliative-care
purposes between March 2015 and February 2017 (Schleiderab, European Journal of Internal Medicine, 2018). The primary symptoms prior
to treatment reported among the patients to whom medical cannabis was given during the relevant timeframe were sleep problems (78.4%),
pain (77.7%), weakness (72.7%), nausea (64.6%), and lack of appetite (48.9%). Approximately 51% of the applicable patients reported an
8 out of 10 on the pain scale. Of the relevant patient population, 17% were given Tikun Olam&rsquo;s cannabidiol-dominant strain &ldquo;Avidekel,&rdquo;
and after six months, 95.9% of patients reported improvement in their condition. Note, however, that these are anecdotal reports, which
may or may not be indicative of the results that we may see from clinical studies conducted pursuant to an IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a separate survey of 237 oncologists, 80% of these oncologists discussed medical cannabinoids with patients where nearly half recommended
them clinically (Braun IM, J Clin Oncol, 2018). The same survey found that 67% of the oncologists viewed cannabinoids as a helpful adjunct
to standard pain management strategies, and 65% viewed cannabinoids as equally or more effective than standard treatments for anorexia
and cachexia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patient
Interest</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
also shows that most cancer patients have a strong interest in learning about cannabinoids during treatment. According to the Washington
State Survey of Cancer Patients, 74% of surveyed patients wanted information from cancer care providers (Pergam SA, Cancer, 2017). The
same survey found that 66% of patients had used cannabis in the past, 24% used in the last year, and 21% used in the last month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
cancer patients tend to be heavy cannabis users. A survey of active cannabis users who have cancer (Pergam SA, Cancer, 2017) found that
74% used cannabis at least once a week, 56% used cannabis at least daily, and 31% used cannabis multiple times a day. Active users consumed
cannabis primarily for physical symptoms such as pain and nausea or for psychological reasons such as coping with stress, depression,
and sleep difficulty.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lack
of Research</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a 2017 report, the National Academy of Sciences noted that, although cannabis has both therapeutic value and public health risks, there
is a systemic lack of research aimed at properly evaluating cannabis-based therapies. The National Academy of Sciences offered recommendations
that included developing standards and benchmarks to guide cannabis research, addressing research gaps to evaluate the short- and long-term
health effects of cannabis use, improving surveillance capacity to ensure that sufficient data is available, and addressing regulatory
barriers to cannabis research and proposing strategies for supporting a comprehensive cannabis research agenda.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critically,
only 30% of oncologists felt sufficiently informed to make recommendations regarding medical cannabis, suggesting a large unmet opportunity
to educate oncologists and provide research that supports the safety and efficacy of Enveric product candidates. Among the oncologists
who discussed medical cannabis with patients, 78% said that patients were the ones to express interest on most occasions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Potential
for Premium Pricing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to conduct extensive clinical research in an effort to establish the safety of its prospective product candidates in cancer patients,
and, eventually, help to identify and/or develop cannabinoid medicines intended to reduce various unwanted side effects that commonly
affect cancer patients, target specific patient sequelae (<I>e.g.</I>, cancer pain, anxiety, or nausea), and target specific side effects
to the skin as a result of radiation and chemotherapy treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that prescription only medicines containing cannabinoids (including product with hemp-based ingredients) will carry a price premium.
Upon obtaining FDA approval for our product candidates, we are striving to distinguish ourselves from a rising tide of cannabis industry
participants by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Creating
    product candidates specific to the side effects of cancer and cancer treatment, with a novel focus on skincare.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employing
    evidence-based best practices specific to cancer patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generating
    clinical research to support the safety and effectiveness of its product candidates in cancer patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
    FDA approval, as most over-the-counter (&ldquo;OTC&rdquo;) products sold are not FDA approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe these will be an important differentiator for people with cancer and oncologists who are faced with high patient demand and in
still relatively novel, unproven field of medical cannabis. Accordingly, we anticipate eventually being able to charge a premium for
those of our prospective product candidates that are successfully commercialized. Further, more than one-third of cancer patients who
used medical cannabis were new users (K. Martell, Curr Oncol, 2018), suggesting the potential to establish strong brand loyalty from
cancer patients and oncologists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_093"></A>Conditions
Currently Targeted by Enveric</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Radiodermatitis
and Other Skin Conditions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
therapy is considered an essential component of cancer treatment, with nearly 50% of cancer patients undergoing radiation therapy at
some point during the course of their treatments. Radiodermatitis, or radiation-induced skin injury, is one of the most common adverse
effects of radiation therapy. Of those receiving radiation therapy, approximately 90% experience some form of radiodermatitis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dry
skin is another common adverse side effect of certain cancer therapies. For example, a recent study of patients being treated with chemotherapy
for breast cancer found that 57.9% of the patients reported dry skin. Rashes are the most common side effect from targeted cancer therapies
with some treatments. The incidence of rash varies based on the type of cancer and drug used. For instance, skin rash occurs in up to
90% of patients treated with Erbitux, while other drugs may only affect half of patients. Pruritus (itchy skin) is a common adverse side
effect of cancer therapies; a recent survey of 379 cancer survivors reported that 36% experienced pruritus during treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address the unique skincare needs of persons with cancer, we are seeking to formulate a cannabinoid-based ointment or other topical drug
product for skincare conditions, such as radiodermatitis (among other conditions, as applicable).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Current
Standard of Care</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current standard of care for radiodermatitis consists of a combination of preventative routines and symptomatic management based on dermatitis
grade. Preventative skin care routines generally involve keeping the area clean and dry while avoiding skin irritants and unnecessary
friction or skin stress (Salvo, Curr Onvol, 2010; Wong, Supp Care Canc, 2013). Applying lanolin-free moisturizer 2-3 times a day throughout
the duration of treatment is also recommended, with some evidence suggesting that topical corticosteroids used after radiotherapy sessions
may provide some benefit as well (Salvo, Curr Onvol, 2010; Wong, Supp Care Canc, 2013).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the use of these interventions, up to 85% of individuals will experience a moderate to severe skin reaction during their disease course
(Salvo, Curr Oncol, 2010). This highlights the need for better preventative strategies to reduce the incidence and severity of skin toxicity.
The incomplete success of therapies to date likely relates to the multiple toxic mechanisms of radiation, including direct DNA toxicity,
oxidative stress, and both acute and chronic inflammatory reactions. Therapies that can address multiple aspects of radiation toxicity
on the cellular level are likely to have the most success as prophylaxis and treatment for these patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
Current Development Plans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to develop products that address unmet medical needs in palliative and supportive care for cancer patients. The first product
will address radiodermatitis and will enter into clinical trials after an IND submission has been filed. We then intend to seek FDA approval
via the new-drug-application (NDA 505(b)(1)) pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Glioblastoma
Multiforme (GBM)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glioblastoma
multiforme (GBM) is a highly aggressive and almost universally fatal disease. Even with the most extensive surgical resections and the
most aggressive radiation and chemotherapy regimens, median overall survival is as low as 15- to 19-months (Stupp, NEJM, 2005). This
is likely due, in part, to an intrinsic propensity for treatment resistance and, as a result, the essentially unavoidable event of tumor
recurrence. The current prognosis for most patients necessitates significant advances in the standard of care to improve both overall
survival and patient quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that CBD has the potential to influence many of the key pathways involved in GBM pathogenesis, from tumor stemness and proliferation
to angiogenesis and local invasion. GBM tumors express CB2 receptors, through which CBD and other cannabinoids are thought to exert their
anti-cancer efforts (Ellert-Miklaszewska, Adv Exp Med Biol, 2013). The prospect of CBD used in combination with other pharmacologic interventions
holds promise for the treatment of GBM. The development of clinical trials to evaluate the efficacy of CBD combination therapies may
represent an important step towards improving the clinical outcomes in a population of patients with few other effective therapeutic
options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a study by Kenyon in 2018, seven out of seven patients with GBM experienced a positive clinical response, although four ultimately
succumbed to the disease. CBD was hypothesized to be able to reduce the growth and survival of GBM cell lines by disrupting the normal
function of the cell, or cell cycle arrest, and the induction of programmed cell death, or apoptosis (Marcu, Mol Cancer Ther, 2010).
Cannabinoids have been shown to promote cancer cell death through the overproduction of a lipid subset, called ceramides, as accumulation
of ceramides in GBM cells may prevent the cell from functioning normally. Additionally, the generation of unstable oxygen molecules,
or reactive oxygen species, can damage nearby molecules and trigger cell death (Dumitru, Front Mol Neurosci, 2018).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Enveric&rsquo;s
Prospective Product Candidates</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to evaluate a novel combination of CBD and an existing chemotherapeutic agent for treating GBM. We intend to use, as part of the
study, a patent pending formulation developed by a partnership of three Israeli universities led by the Weizmann Institute, and now owned
by Enveric.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proposed clinical cancer study plan consists of a Phase 1/2 study in Israel of oral synthetic CBD extract, given alone or in combination
with clomiphene concurrently with dose-dense temolozomide chemotherapy for patients with recurrent or progressive GBM, designed as an
open label, two-arm, randomized prospective study. An initial dose limiting toxicity (DLT) cohort will be investigated in a phase 1 study
in order to rule out any toxicity related to the combination. If successful, recruitment would continue, and then 40 patients would be
randomized into two arms, with 20 patients in each arm: (i) synthetic CBD extract plus clomiphene and temolozomide, and (ii) synthetic
CBD extract plus temolozomide. The primary endpoints would be progression free survival. The progression of the disease would be determined
from a Response Assessment in Neuro-Oncology (RANO) and a tumor assessment based on MRI scans. Safety parameters would include serious
adverse events and other adverse events as reported by the patients and caregivers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 1, 2021, all pre-clinical studies, and the draft clinical study protocol related to our clinical cancer program, have been
completed. Dr. Tali Siegal has been selected as the primary investigator, and the protocol is currently under review by the
hospital&rsquo;s internal review board (IRB). Enveric is currently awaiting approval from the Israeli Ministry of Health,
Center for Cannabis (Yakar). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Neuropathy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to conduct a clinical study to validate the efficacy of topical cream or oral medication infused with high-potency CBD and/or
CBG to help prevent and treat the painful discomfort of chemotherapy-induced neuropathy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_094"></A>Additional
Potential Development Projects</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Supportive
Care Product Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may also develop additional prescription medicines that are derived from natural sources that are targeted to major cancer
treatment side effects, including other skin conditions, cancer-related distress, chemotherapy-induced nausea and vomiting (CINV), lack
of appetite, pain, and insomnia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
many patients, the concept of palliative care often carries a negative connotation, conjuring ideas and fears of the end of life. However,
the purpose of palliative care is to improve the patient experience and reduce suffering in all areas of life, including physical, emotional,
psychological, and spiritual well-being. In fact, incorporating palliative care into cancer management has the potential to not only
improve quality of life, but may also prolong survival (Temei, NEJM, 2010; Ferrell, J Clin Oncol, 2017). We avoid the negative connotations
of palliative care by using the term &ldquo;supportive care.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
physical ailments experienced by cancer patients vary widely based on the individual, the type and stage of cancer, and the choice of
therapy. Three of the most common and perhaps most debilitating complaints addressed by palliative care are chronic pain, chemotherapy-induced
nausea and vomiting, and severe body wasting (Reeve, JNCI, 2014). Although efforts have been made to ameliorate these symptoms, many
patients do not achieve adequate relief. The need for new therapeutics to improve these debilitating symptoms has gained increasing attention
in recent years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Combination
Therapies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to advance novel treatment for cancer based on a combination of cannabidiol (CBD) and chemotherapeutic agents, including clomiphene,
an anti-estrogen binding site (AEBS) inhibitor, which can regulate cell growth, with a potential for activity in multiple cancer cell
lines, including breast cancer, pancreatic cancer, and acute myeloid leukemia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data suggests that combination therapies may improve the activity of certain chemotherapies or dendritic cell-based cancer immunotherapies,
potentially enabling more potent or longer-lasting therapeutic effects. In multiple <I>in vitro </I>and <I>in vivo </I>models of solid
tumors and blood cancers, CBD has been shown to reduce tumor size, potential for invasion and metastasis, and development of new tumor-associated
blood vessels. In combination with CBD, clomiphene has been shown to reduce cell viability and increase rates of programmed cell death
in certain cancer cell lines, while also inhibiting tumor growth <I>in vivo</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
cancer cells contain largely the same proteins and other targets as the healthy cells in the body, there are few cancer-specific druggable
targets; chemotherapies often simply target all rapidly proliferating cells in the body. While chemotherapy can be successful in suppressing
tumors, there are many side effects associated with use; side effects may increase with higher doses. The ability to provide the same
or greater therapeutic effect with a smaller overall dose of the chemotherapeutic agent may minimize the risk and severity of side effects
in subjects and allow for the treatment of certain patients with weakened immune systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cannabinoid
Combination with AEBS Inhibitors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of cannabis in cancer management has traditionally been relegated to symptomatic management, including as an analgesic, anti-emetic,
and appetite stimulant. However, more recently, mounting evidence has suggested a therapeutic, anti-tumor effect of certain naturally
occurring cannabinoids. Specifically, CBD has been shown to reduce tumor size, the potential for invasion and metastasis, and development
of new tumor-associated blood vessels in multiple in vitro and in vivo models of solid tumors and blood cancers (Ladin, Front Pharmacol,
2016; Massi, Br J Pharmacol, 2013).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also evidence to suggest that CBD used in combination with traditional chemotherapies and a certain class of compounds, the cholesterol
epoxide hydrolase (ChEH) / antiestrogen binding site (AEBS) inhibitors, may be more efficacious than CBD alone (Scott, Int J Oncol, 2017).
AEBS regulates cholesterol metabolism and, consequently, cell growth (Payre, Mol Cancer Ther, 2008).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
AEBS inhibitors that we believe may be especially promising are clomiphene citrate and DPPE. Clomiphene is an estrogen modulator typically
used to treat infertility. However, in combination with CBD, clomiphene was recently shown to synergistically reduce cell viability and
increase rates of programmed cell death in certain cancer cell lines, while also inhibiting tumor growth <I>in vivo</I> (WO2017072773A1).
DPPE, on the other hand, is a tamoxifen derivative that is thought to sensitize cancer cells to the activities of chemotherapies. As
a tumor grows and mutates, cancer cells can become resistant to therapies in several ways &ndash; tumors can overexpress efflux pumps
that remove certain agents from the cell or can upregulate enzymes that metabolize and inactivate chemotherapies. DPPE was shown to potentiate
the toxicity of multiple chemotherapeutic drugs by both mechanisms (Georges, Biochemical Pharm, 2014; Brandes, Cancer Chemother Pharmacol,
2000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cannabinoid
Combination with Immunotherapies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dendritic
cells (DCs) process antigen material and present it on the cell surface to the T-cells of the immune system. A range of cancer immunotherapies
involving DCs have been used to generate tumor-specific immune responses that have had variable success in clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBD
may cause DCs to increase their production of IL-12 p70, an interleukin-12 (IL-12) family cytokine that may heighten the immune system&rsquo;s
response against certain cancers. IL-12 is closely linked to the activity of the immune system and is produced by DCs. IL-12 can bring
T-cells and natural killer cells out of dormancy so that a heightened immune response against tumors is possible. By aiding in the generation
of CD4+ (T helper cells), IL-12 also can also elicit a longer lasting and amplified anti-tumor response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injected
IL-12 has presented challenges in terms of its toxicity and dosage control and there is a need for generating heightened levels of IL-12,
particularly in immunocompromised patients. Preclinical research suggests that CBD may induce DCs to increase their production of IL-12
p70.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to certain license agreements as described below, and going forward it intends to both develop intellectual property and
license intellectual property from pharmaceutical and biotechnology companies and research institutions which would cover research stage
and clinical stage assets to build a pipeline of product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Tikun
Olam In-License</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold limited rights to several plant patent applications as an in-licensee of Tikun Olam.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tikun
Olam employs evidence-based medicine and other best practices, and its products have been studied in numerous medical trials. Tikun Olam&rsquo;s
patient databases include 12,000+ persons treated across a variety of conditions, with a primary focus on cancer care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold limited rights to use the data included in the Tikun Olam patient database.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Diverse
Biotech, Inc. In-License</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold limited rights to patent applications owned by Diverse Biotech, Inc. for the use of cannabinoids with five existing, standard-of-care
drugs via Diverse Biotech&rsquo;s patent pending conjugate drug delivery platform. Our rights extend to all fields of use. We plan to
engage in targeted research and development to apply such conjugates to alleviate the side effects that cancer patients experience, with
the goal of achieving novel therapeutic outcomes for patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Diverse Biotech, Inc. patent application portfolio includes two patent applications licensed to us. Those two patent applications disclose
conjugate chemistry that combines cannabinoids with existing drugs in conjugate form that we believe will provide differentiation in
use and efficacy from combination therapy of drugs and cannabinoids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Patents and Patent Applications</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own full rights to several families of patent applications covering the use of CBD in combination with current cancer treatments, both
broadly, as well as for specific cancer types, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Combination
    Therapy (WO2017072773 and national phase filings in the U.S. and other countries/regions)</I>: Combinations of compositions comprising
    CBD and a therapeutic pharmaceutical cancer agents (ChEH/AEBS inhibitors, naphthoquinone or derivatives) for the treatment of cancer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Combination
    Therapy (EP 18165731.3 and WO2019/193112 and national patent filings in the U.S. and other countries/regions):</I> Relates to regimes
    of drug administration and drug combinations that include a cannabinoid for use in the treatment of breast cancer, including triple-negative
    breast cancer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cannabinoids
    in Combination with Chemotherapy (WO2021/028646): </I>Relates to regimes of drug administration and cannabinoid administration for
    treatment of bladder, brain and spinal cord, colorectal, head and neck, lung, lymphoma, neuroendocrine, oesophageal, ovarian, pancreatic
    and prostate cancer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
Supply Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, we entered into an exclusive supply agreement (the &ldquo;Development and Clinical Supply Agreement&rdquo;) with PureForm
Global, Inc. (&ldquo;PureForm&rdquo;), a biotechnology company focused on the research, development and commercialization of synthesized
CBD and other cannabinoids not derived from hemp or cannabis, for use in development and commercialization of products for cancer supportive/palliative
care associated with radiodermatitis, chemotherapy induced peripheral neuropathy, and glioblastoma. Pursuant to the Development and Clinical
Supply Agreement, PureForm will be the exclusive provider of synthetic cannabidiol (&ldquo;API&rdquo;) for Enveric&rsquo;s development
plans for cancer treatment and supportive care. Under the terms of the Development and Clinical Supply Agreement, PureForm has granted
Enveric the exclusive right to purchase API and related products for cancer treatment and supporting care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_095"></A>Research
&amp; Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
view of the urgent need for new and more effective oncology drugs, we intend to combine innovative science and accelerated clinical development
to create and develop novel therapies using cannabinoid-based medications and similar compounds. Our past research and development efforts
were limited to investigative work surrounding cannabinoids, including creating and developing novel formulations, and evaluating potential
opportunities to license technologies from pharmaceutical companies and leading research institutions. Our principal research efforts
to date have been with Soroka Medical Center, MSKCC, Tikun Olam and St. George&rsquo;s University of London.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_096"></A>Clinical
Studies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently assembling a team of principal investigators with of clinical experience across multiple cancer types to be responsible
for the management, monitoring, and integrity of the clinical research. The following studies are being evaluated for potential advancement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Radiodermatitis:
    </I>A Phase 1/2 evaluating a CBD-infused formulation for skin.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recurrent
    or Progressive Glioblastoma Multiforme: </I>A Phase 1/2 study of oral CBD extract in combination with Clomiphene or oral CBD extract
    alone given concurrently with dose-dense Temolozomide to patients with recurrent or progressive glioblastoma.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to submit INDs and, eventually, NDAs to seek FDA approval in connection with the Radiodermatitis and Recurrent or Progressive Glioblastoma
Multiforme product candidates. The selection, timing, duration, and design of any prospective studies are subject to approval and finalization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Scientific
Advisory Board</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a scientific advisory board and regularly seeks advice and input from these experienced clinical leaders on matters
related to its research and development programs. The members of our scientific advisory board consist of experts across a range of key
disciplines relevant to its programs. We intend to continue to leverage the broad expertise of its advisors by seeking their counsel
on important topics relating to its product development and clinical development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
scientific advisors are not our employees and have commitments to, or consulting or advisory contracts with, other entities that may
limit their availability to us. In addition, its scientific advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with us. All of our scientific advisors are affiliated with other entities and
devote a limited portion of their time to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric&rsquo;s
current scientific advisors are set forth in the table below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Specialization</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    J. Zelefsky, M.D. (Chair)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    Chair, Department of Radiation Oncology, Chief, Brachytherapy Service, Memorial Sloan Kettering Cancer Center</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Arash Asher, M.D.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Director, Cancer Rehabilitation and Survivorship, Cedars-
    Sinai Cancer Center</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Cancer Rehabilitation and Survivorship</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Angus
    Dagleish, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor,
    St. George&rsquo;s University of London</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncology
    Research</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Perry, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuro-Oncologist,
    Sunnybrook Research Institute; Professor, University of Toronto</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zvi
    Vogel, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor,
    Neurobiology, Weizmann Institute</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncology
    Research, Patent Contributor</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Michael
J. Zelefsky, M.D.</I> has served as a Scientific Advisor of Enveric since April 2019. Dr. Zelefsky, is a board-certified radiation oncologist
and co-leader of Memorial Sloan Kettering&rsquo;s Genitourinary Disease Management Team, a multidisciplinary group of physicians who
work together to treat patients with urologic malignancies. Dr. Zelefsky is Chief of Memorial Sloan Kettering&rsquo;s Brachytherapy Service.
The prostate brachytherapy program at Memorial Sloan Kettering, which Dr. Zelefsky helped develop and enhance since joining the staff
in 1990, is known for its depth of experience and cutting-edge approach in treating men with prostate cancer. Dr. Zelefsky was instrumental
in pioneering the use of IMRT (intensity-modulated radiation therapy, which is computer-guided delivery of high doses of radiation directly
to the tumor) and IGRT (image-guided radiotherapy, radiation beams targeted precisely to the tumor) for treating men with prostate cancer.
Dr. Zelefsky is Editor-in-Chief of Brachytherapy, a medical journal that addresses all aspects of this sub-specialty, and Chairman of
the National Patterns of Care Study for Genitourinary Cancers. He is also a past president of the American Brachytherapy Society. For
his work in this field, Dr. Zelefsky has been honored to receive several awards including the Boyer Award for Excellence in Clinical
research, the Outstanding Teaching Award in the Department of Radiation Oncology at Memorial Sloan Kettering, the 2009 Henschke Medal
(the highest award of the American Brachytherapy Society for achievements in Brachytherapy), and the 2009 Emanuel Van Descheuren Award
for Excellence in Translational Research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Angus
Dalgleish, M.D. </I>has served as a Scientific Advisor of Enveric since January 2019. Dr. Dalgleish, is an oncologist practicing in the
United Kingdom at St. George&rsquo;s University of London. Dr. Dalgleish divides his time between clinical practice and research, and
also serves as an advisor to several biopharmaceutical companies. Dr. Dalgleish has been a Professor of Medical Oncology at St. George&rsquo;s
University of London and Consultant Physician at St. George&rsquo;s Hospital since 1991. He has served as the President of the Clinical
Immunology and Allergy Section of the Royal Society of Medicine and is a Fellow of The Royal College of Physicians. Dr. Dalgleish studied
Medicine at University College London, where he obtained an MBBS and a BSc in Anatomy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>James
Perry, M.D. </I>has served as a Scientific Advisor of Enveric since April 2019. Dr. James Perry is a neuro-oncologist at Sunnybrook&rsquo;s
Odette Cancer Centre and Hurvitz Brain Sciences Program. Dr. Perry is also a Professor of medicine at the University of Toronto and the
central nervous system cancers lead at Cancer Care Ontario. Dr. Perry is a clinician-investigator interested in the design, conduct and
analysis of clinical trials testing innovative therapies for primary brain tumors. His research unit is focused on outcomes research.
He is the chair of the Canadian Brain Tumour Consortium (CBTC), a national not-for-profit investigator network.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Zvi
Vogel, Ph.D.</I> has served as a Scientific Advisor of Enveric since February 2018. Professor Vogel is currently a Professor Emeritus
at the Weizmann Institute of science serving as the Head of the Adelson Center for the Biology of Addictive Diseases at Tel-Aviv University.
Professor Vogel previously served as the Chairman of the Department of Neurobiology at the Weizmann Institute. He has published more
than 170 scientific manuscripts. Professor Vogel earned a M.Sc in Biochemistry and a Ph.D. from the Weizmann Institute of Science. He
performed his post-doctorate studies at the National Institutes of Health (Bethesda, MD) in the Laboratory of Marshall Nirenberg, a Nobel
Prize winner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Academic
and Industry Partners</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also established relationships with certain academic and industry partners, whom we believe have the potential to accelerate product
development, market entry, data collection, analysis and advancement of clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current academic and industry partners are set forth in the table below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 72%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tikun
    Olam Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tikun
    Olam Ltd. brings proprietary products and data, clinical research experience, and access to resources in Israel.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">St.
    George&rsquo;s University of London</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">St.
    George&rsquo;s University of London brings research capabilities and relevant domain expertise in cancer and cannabinoids.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Soroka Medical Cancer Center</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Soroka Medical Cancer Center brings clinical research capabilities and extensive patient access.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products. While we believe that our scientific knowledge and technology and development experience provide us with competitive
advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology
companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we
successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
GBM, we believe that only one drug product (Epidiolex, developed by GW Pharmaceuticals) is a potential late-stage competitor. Other than
Epidiolex, we are aware of exploratory research into the effects of cannabinoid drug formulations. We are also aware of discovery research
within the pharmaceutical industry into synthetic agonists and antagonists of CB1 and CB2 receptors, as well as companies that supply
synthetic cannabinoids and cannabis extracts to researchers for pre-clinical and clinical investigation, and various companies that cultivate
cannabis plants with a view to supplying herbal cannabis or nonpharmaceutical cannabis-based formulations to patients. These therapies
have not been approved by the FDA. In addition, Lutris Pharma has a topical B-Raf Inhibitor in Phase &frac12; studies that is intended
to treat radiation dermatitis, which is also a potential competitor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
suffering from GBM in the U.S. are treated with a variety of FDA-approved products, including, but not limited to, Bevacizumab, Carmustine
Implant, Lomustine, and Temozolomide. Our potential competitors regarding the GBM product candidate include pharmaceutical and biopharmaceutical
companies such as Pfizer, Genentech, Arbor Pharmaceuticals, Next Source Pharmaceuticals, and Merck, among others, depending on when the
candidate is approved for commercialization, if ever (and what, if any, new therapies are approved in the interim). Such competitors
may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting
clinical trials, obtaining regulatory approvals, and marketing approved medicines than we do. These competitors also compete with us
in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to CBD, a number of nonapproved and non-standardized CBD preparations derived from crude herbal cannabis have been made available
in limited quantities by producers of &ldquo;medical marijuana&rdquo; in the U.S. We do not believe prescription cannabinoids are the
same as distributing or legalizing crude herbal cannabis, or preparations derived from crude herbal cannabis, and therefore we do not
believe they are competitive with, crude herbal cannabis. We believe that only a cannabinoid medication, one that is standardized in
composition, formulation and dose, administered by means of an appropriate delivery system, and tested in properly controlled pre-clinical
and clinical studies, can meet the standards of regulatory authorities around the world, including those of the FDA. We also believe
that these regulatory processes provide important protections for patients, and that any cannabinoid medication must be subjected to,
and satisfy, such rigorous scrutiny.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunities could be reduced or eliminated if its competitors develop and commercialize medicines that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our
competitors also may obtain approval from the FDA or other regulatory agencies for their medicines more rapidly than us, which could
result in our competitors establishing a strong market position before we are able to enter the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_097"></A>Government
Regulation and Product Approvals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic
Act, or the FDCA, and, to a lesser extent, by state and local governments. Before our prescription products may be marketed in the U.S.,
they must be approved by the FDA for commercial distribution. Certain OTC products must comply with applicable FDA regulations, known
as OTC Monographs, in order to be marketed, but do not have the benefit of FDA review and approval before marketing. We are also subject
to regulation under federal, state and local laws, including requirements regarding occupational safety, laboratory practices, environmental
protection and hazardous substance control, and may be subject to other present and future local, state, federal and foreign regulations.
We cannot predict the extent to which we may be affected by legislative and other regulatory developments concerning our products and
the healthcare industry in general.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDCA and other federal and state statutes and regulations govern the testing, manufacture, quality control, export and import, labeling,
storage, record keeping, approval, pricing, advertising, promotion, sale and distribution of pharmaceutical products. Noncompliance with
applicable requirements both before and after approval, can subject us, our third party manufacturers and other collaborative partners
to administrative and judicial sanctions, such as, among other things, warning letters, fines and other monetary payments, recall or
seizure of products, criminal proceedings, suspension or withdrawal of regulatory approvals, interruption or cessation of clinical trials,
total or partial suspension of production or distribution, injunctions, limitations on or the limitation of claims we can make for our
products, and refusal of the government to enter into supply contracts for distribution directly by governmental agencies, or delay in
approving or refusal to approve new drug applications. The FDA also has the authority to revoke or withhold approvals of new drug applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval is required before any &ldquo;new drug,&rdquo; can be marketed. Our products are new drugs and require prior FDA approval. Such
approval must be based on extensive information and data submitted in a NDA, including, but not limited to, adequate and well controlled
laboratory and clinical investigations to demonstrate the safety and effectiveness of the drug product for its intended use(s) as well
as the manufacturing suitability of the product. In addition to providing required safety and effectiveness data for FDA approval, a
drug manufacturer&rsquo;s practices and procedures must comply with current Good Manufacturing Practices (&ldquo;cGMPs&rdquo;), which
apply to manufacturing, receiving, holding and shipping, and include, among other things, demonstration of product purity, consistent
manufacturing and quality and at least six months of data supporting product expiration dating based on clinical registration batches.
Accordingly, manufacturers must continue to expend time, money and effort in all applicable areas relating to quality assurance and regulatory
compliance, including production and quality control to comply with cGMPs. Failure to so comply risks delays in approval of drug products
and possible FDA enforcement actions, such as an injunction against shipment of products, the seizure of non-complying products, criminal
prosecution and/or any of the other possible consequences described above. We are subject to periodic inspection by the FDA and the Drug
Enforcement Administration (&ldquo;DEA&rdquo;), which inspections may or may not be announced in advance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>FDA
New Drug Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDCA,
and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage,
recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import
and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as imposition of clinical holds, FDA refusal to approve pending new drug applications (&ldquo;NDA&rdquo;),
warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals
of government contracts, restitution, disgorgement, civil penalties and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
product development in the U.S. typically involves pre-clinical laboratory and animal tests and the submission to the FDA of an Investigational
New Drug applications (&ldquo;IND&rdquo;), which must become effective before clinical testing may commence. For commercial approval,
the sponsor must submit adequate tests by all methods reasonably applicable to show that the drug is safe for use under the conditions
prescribed, recommended or suggested in the proposed labeling. The sponsor must also submit substantial evidence, generally consisting
of adequate, well-controlled clinical trials to establish that the drug will have the effect it purports or is represented to have under
the conditions of use prescribed, recommended or suggested in the proposed labeling. In certain cases, the FDA may determine that a drug
is effective based on one clinical study plus confirmatory evidence. Satisfaction of FDA pre-market approval requirements typically takes
many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics
and potential safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements,
including the FDA&rsquo;s good laboratory practices regulations and the U.S. Department of Agriculture&rsquo;s (USDA&rsquo;s) regulations
implementing the Animal Welfare Act. The results of pre-clinical testing are submitted to the FDA as part of an IND along with other
information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term
pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA
has not imposed a clinical hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical trial
proposed in the IND may begin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified
investigator. Clinical trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP, an international
standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors,
and (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness
criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the
FDA as part of the IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other sanctions if it believes that
the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical
trial patients. The trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional
review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB&rsquo;s requirements or may impose other conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general,
in Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics,
pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. Phase 2 usually
involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance
and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and
an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical
efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to
evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most
cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. The FDA may,
however, determine that a drug is effective based on one clinical study plus confirmatory evidence. Only a small percentage of investigational
drugs complete all three phases and obtain marketing approval. In some cases, the FDA may require post-market studies, known as Phase
4 studies, to be conducted as a condition of approval in order to gather additional information on the drug&rsquo;s effect in various
populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements
may be imposed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. The FDA approval of the NDA is required before
marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and
a compilation of data relating to the product&rsquo;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting
an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&rsquo;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the
FDA begins an in-depth review. Under the statute and implementing regulations, the FDA has 180 days (the initial review cycle) from the
date of filing to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement
between the FDA and the applicant or as a result of the applicant submitting a major amendment. In practice, the performance goals established
pursuant to the Prescription Drug User Fee Act have effectively extended the initial review cycle beyond 180 days. The FDA&rsquo;s current
performance goals call for the FDA to complete review of 90 percent of standard (non-priority) NDAs within 10 months of receipt and within
six months for priority NDAs, but two additional months are added to standard and priority NDAs for a new molecular entity (NME).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to
an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation
as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally
follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance
with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve
the product unless compliance with current GMP is satisfactory and the NDA contains data that provide substantial evidence that the drug
is safe and effective in the indication studied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete
response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&rsquo;s satisfaction
in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within
two to six months depending on the type of information included.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition
of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug
outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and elements to
assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing,
dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially
affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and
surveillance to monitor the drug&rsquo;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory
standards is not maintained or problems are identified following initial marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disclosure
of Clinical Trial Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical
trial information on a public website maintained by the U.S. National Institutes of Health. Information related to the product, patient
population, phase of investigation, study sites and investigator, and other aspects of the clinical trial is made public as part of the
registration. Sponsors are also obligated to disclose the results of these trials after completion. Disclosure of the results of these
trials can be delayed for up to two years if the sponsor certifies that it is seeking approval of an unapproved product or that it will
file an application for approval of a new indication for an approved product within one year. Competitors may use this publicly available
information to gain knowledge regarding the design and progress of our development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
Protocol Assessment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
company may reach an agreement with the FDA under the Special Protocol Assessment, or &ldquo;SPA,&rdquo; process as to the required
design and size of clinical trials intended to form the primary basis of an efficacy claim. According to its performance goals, the FDA
is supposed to evaluate the protocol within 45 days of the request to assess whether the proposed trial is adequate, and that evaluation
may result in discussions and a request for additional information. A SPA request must be made before the proposed trial begins, and
all open issues must be resolved before the trial begins. If a written agreement is reached, it will be documented and made part of the
administrative record. Under the FDCA and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA
except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy
after the study begins, public health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and
the FDA agree to the change in writing, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advertising
and Promotion</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-approval
promotion of investigational drug candidates is prohibited by the FDA. Therefore, sponsors must ensure that any pre-approval communications
disseminated about its drug candidates do not state or imply that such candidates have been proven safe or effective for the applicable
use(s) or that they have been approved for commercialization in the United States. Further, once an NDA for a given candidate is approved,
if ever, the product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval
marketing and promotion of drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of
the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities,
require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new
indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions
in reviewing NDA supplements as it does in reviewing NDAs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adverse
Event Reporting and GMP Compliance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing
testing, known as Phase 4 testing, may require under a REMS special communication regarding the safety of the drug or heightened surveillance
to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or
use of the product. In addition, quality-control, drug manufacture, packaging, and labeling procedures must continue to conform to GMP,
after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and
certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the
agency inspects manufacturing facilities to assess compliance with GMP. Accordingly, manufacturers must continue to expend time, money
and effort in the areas of production and quality control to maintain compliance with GMP. Regulatory authorities may withdraw product
approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial
marketing or if previously unrecognized problems are subsequently discovered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 147; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pediatric
Exclusivity and Pediatric Use</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Best Pharmaceuticals for Children Act, or &ldquo;BPCA,&rdquo; provides NDA holders a six-month period of exclusivity attached
to any other exclusivity listed with the FDA&thinsp;&mdash;&thinsp;patent or non-patent&thinsp;&mdash;&thinsp;for a drug, if certain
conditions are met. Conditions for pediatric exclusivity include a determination by the FDA that information relating to the use of a
new drug in the pediatric population may produce health benefits in that population; a written request by the FDA for pediatric studies;
and agreement by the applicant to perform the requested studies and the submission to the FDA, completion of the studies in accordance
with the written request, and the acceptance by the FDA, of the reports of the requested studies within the statutory time frame. Applications
under the BPCA are treated as priority applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act, or &ldquo;PREA,&rdquo; NDAs or supplements to NDAs must contain data to assess
the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and
administration for each pediatric subpopulation for which the drug is safe and effective, unless the sponsor has received a deferral
or waiver from the FDA. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation
has been granted. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations.
A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric
studies are complete or that additional safety or effectiveness data need to be collected before the pediatric studies begin. Under PREA,
the FDA must send a noncompliance letter requesting a response within 45 days to any sponsor that fails to submit the required assessment,
keep a deferral current or fails to submit a request for approval of a pediatric formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Controlled
Substances</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Controlled Substances Act of 1970, or &ldquo;CSA,&rdquo; and its implementing regulations establish a &ldquo;closed system&rdquo;
of regulations for controlled substances. The CSA imposes registration, security, recordkeeping and reporting, storage, manufacturing,
distribution, importation and other requirements under the oversight of the DEA. The DEA is the federal agency responsible for regulating
controlled substances, and requires those individuals or entities that manufacture, import, export, distribute, research, or dispense
controlled substances to comply with the regulatory requirements in order to prevent the diversion of controlled substances to illicit
channels of commerce.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA categorizes controlled substances into one of five schedules&thinsp;&mdash;&thinsp;Schedule I, II, III, IV or V&thinsp;&mdash;&thinsp;with
varying qualifications for listing in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently
accepted medical use in treatment in the U.S., and lack accepted safety for use under medical supervision. Marijuana is currently a Schedule
I controlled substance, which means that no preclinical or clinical studies of product candidates containing marijuana may be conducted
in the United States without the required DEA registration(s) and related approvals, as applicable. Pharmaceutical products having a
currently accepted medical use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances, with
Schedule II substances presenting the highest potential for abuse and physical or psychological dependence, and Schedule V substances
presenting the lowest relative potential for abuse and dependence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facilities
that manufacture, distribute, import, or export any controlled substance must register annually with the DEA. The DEA registration is
specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required
for importation and manufacturing activities, and each registration authorizes which schedules of controlled substances the registrant
may handle. However, certain coincidental activities are permitted without obtaining a separate DEA registration, such as distribution
of controlled substances by the manufacturer that produces them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA inspects all manufacturing facilities to review security, recordkeeping, reporting, and handling prior to issuing a controlled substance
registration. The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances
handled. The most stringent requirements apply to manufacturers of Schedules I and Schedule II substances. Required security measures
commonly include background checks on employees and physical control of controlled substances through storage in approved vaults, safes
and cages, and through use of alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk manufacturer
(not a dosage form manufacturer or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal Register,
and is open for 60 days to permit interested persons to submit comments, objections or requests for a hearing. A copy of the notice of
the Federal Register publication is simultaneously forwarded by DEA to all those registered, or applicants for registration, as bulk
manufacturers of that substance. Once registered, manufacturing facilities must maintain records documenting the manufacture, receipt
and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedules
I and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled
substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. As with applications
for registration as a bulk manufacturer, an application for an importer registration for a Schedule I or II substance must also be published
in the Federal Register, which remains open for 30 days for comments. Imports of Schedules I and II controlled substances for commercial
purposes are generally restricted to substances not already available from a domestic supplier or where there is not adequate competition
among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must obtain a permit for every
import or export of a Schedules I and II substance or Schedules III, IV and V narcotic, and submit import or export declarations for
Schedules III, IV and V non-narcotics. In some cases, Schedule III non-narcotic substances may be subject to the import/export permit
requirement, if necessary to ensure that the U.S. complies with its obligations under international drug control treaties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
drugs manufactured in the U.S., the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II
that may be manufactured or produced in the U.S. based on the DEA&rsquo;s estimate of the quantity needed to meet legitimate medical,
scientific, research and industrial needs. This limited aggregate amount of cannabis that the DEA allows to be produced in the U.S. each
year is allocated among individual companies, which, in turn, must annually apply to the DEA for individual manufacturing and procurement
quotas. The quotas apply equally to the manufacturing of the active pharmaceutical ingredient and production of dosage forms. The DEA
may adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during
the year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
states also maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution,
and dispensing requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure
to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can
result in enforcement action that could have a material adverse effect on our business, operations and financial condition. The DEA may
seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances,
violations could lead to criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Europe/Rest
of World Government Regulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the U.S., we are and will be subject, either directly or through our distribution partners, to a variety of
regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales (including pricing and reimbursement)
and distribution of our product candidates, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, it must obtain the requisite approvals from regulatory authorities in non-U.S. countries
prior to the commencement of clinical trials or marketing of the product in those countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, medicinal products are subject to extensive pre- and post-marketing regulation by regulatory authorities at both
the European Union and national levels. Additional rules also apply at the national level to the manufacture, import, export, storage,
distribution and sale of controlled substances. In many European Union member states the regulatory authority responsible for medicinal
products is also responsible for controlled substances. Responsibility is, however, split in some member states, such as the U.K. Generally,
any company manufacturing or distributing a medicinal product containing a controlled substance in the European Union will need to hold
a controlled substances license from the competent national authority and will be subject to specific record-keeping and security obligations.
Separate import or export certificates are required for each shipment into or out of the member state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Trials and Marketing Approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
countries outside of the U.S. have a process that requires the submission of a clinical trial application much like an IND prior to the
commencement of human clinical trials. In Europe, for example, a clinical trial application, or &ldquo;CTA,&rdquo; must be submitted
to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct
clinical trials. Once the CTA is approved in accordance with a country&rsquo;s requirements and a company has received favorable ethics
committee approval, clinical trial development may proceed in that country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to
country, even though there is already some degree of legal harmonization in the European Union member states resulting from the national
implementation of underlying European Union legislation. In all cases, the clinical trials must be conducted in accordance with the International
Conference on Harmonization, or &ldquo;ICH,&rdquo; guidelines on GCP and other applicable regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain regulatory approval to place a drug on the market in European Union countries, Enveric must submit a marketing authorization application.
This application is similar to the NDA in the U.S., with the exception of, among other things, country-specific document requirements.
All application procedures require an application in the common technical document, or CTD, format, which includes the submission of
detailed information about the manufacturing and quality of the product, and nonclinical and clinical trial information. Drugs can be
authorized in the European Union by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the
decentralized procedure, or (iv) national authorization procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Commission created the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are
valid throughout the European Union and, by extension (after national implementing decisions) in Iceland, Liechtenstein and Norway, which,
together with the European Union. member states, comprise the European Economic Area, or &ldquo;EEA.&rdquo; Applicants file marketing
authorization applications with the EMA, where they are reviewed by a relevant scientific committee, in most cases the Committee for
Medicinal Products for Human Use (the &ldquo;CHMP&rdquo;). The EMA forwards CHMP opinions to the European Commission, which uses them
as the basis for deciding whether to grant a marketing authorization. This procedure results in a single marketing authorization granted
by the European Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway. The centralized
procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain
a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases,
autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated &ldquo;orphan drugs&rdquo; (drugs used for rare
human diseases), and (iv) advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The
centralized procedure may at the voluntary request of the applicant also be used for human drugs that do not fall within the above-mentioned
categories if the CHMP agrees that the human drug (a) contains a new active substance not yet approved on November 20, 2005; (b) constitutes
a significant therapeutic, scientific or technical innovation, or (c) authorization under the centralized procedure is in the interests
of patients at the European Union level.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure in the European Union, the maximum time frame for the evaluation of a marketing authorization application by
the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response
to questions asked by the CHMP), with adoption of the actual marketing authorization by the European Commission thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest
from the point of view of therapeutic innovation, defined by three cumulative criteria: the seriousness of the disease to be treated;
the absence of an appropriate alternative therapeutic approach, and anticipation of exceptional high therapeutic benefit. In this circumstance,
EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization applications
to the national medicines regulators through one of three procedures: (i) the mutual recognition procedure (which must be used if the
product has already been authorized in at least one other European Union member state, and in which the European Union member states
are required to grant an authorization recognizing the existing authorization in the other European Union member state, unless they identify
a serious risk to public health), (ii) the decentralized procedure (in which applications are submitted simultaneously in two or more
European Union member states), or (iii) national authorization procedures (which results in a marketing authorization in a single European
Union member state).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 150; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Mutual
Recognition Procedure</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mutual recognition procedure, or &ldquo;MRP,&rdquo; for the approval of human drugs is an alternative approach to facilitate individual
national marketing authorizations within the European Union. Basically, the MRP may be applied for all human drugs for which the centralized
procedure is not obligatory. The MRP is applicable to the majority of conventional medicinal products, and must be used if the product
has already been authorized in one or more member states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
characteristic of the MRP is that the procedure builds on an already-existing marketing authorization in a member state of the European
Union that is used as a reference in order to obtain marketing authorizations in other European Union member states. In the MRP, a marketing
authorization for a drug already exists in one or more member states of the European Union and subsequently marketing authorization applications
are made in other European Union member states by referring to the initial marketing authorization. The member state in which the marketing
authorization was first granted will then act as the reference member state. The member states where the marketing authorization is subsequently
applied for act as concerned member states. The concerned member states are required to grant an authorization recognizing the existing
authorization in the reference member state, unless they identify a serious risk to public health.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MRP is based on the principle of the mutual recognition by European Union member states of their respective national marketing authorizations.
Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member
states. In such case, the reference member state shall update its existing assessment report about the drug in 90 days. After the assessment
is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling
and package leaflet. The concerned member states then have 90 days to recognize the decision of the reference member state and the summary
of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement
of the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any Member State refuse to recognize the marketing authorization by the reference member state, on the grounds of potential serious risk
to public health, the issue will be referred to a coordination group. Within a time frame of 60 days, member states shall, within the
coordination group, make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for
arbitration. The opinion of this EMA Committee is then forwarded to the European Commission, for the start of the decision-making process.
As in the centralized procedure, this process entails consulting various European Commission Directorates General and the Standing Committee
on Human Medicinal Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data
Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, marketing authorization applications for generic medicinal products do not need to include the results of pre-clinical
and clinical trials, but instead can refer to the data included in the marketing authorization of a reference product for which regulatory
data exclusivity has expired. If a marketing authorization is granted for a medicinal product containing a new active substance, that
product benefits from eight years of data exclusivity, during which generic marketing authorization applications referring to the data
of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such generic
products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic
indication with significant clinical benefit over existing therapies is approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orphan
Medicinal Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA&rsquo;s Committee for Orphan Medicinal Products (&ldquo;COMP&rdquo;) may recommend orphan medicinal product designation to promote
the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating
conditions affecting not more than 5 in 10,000 persons in the European Union. Additionally, designation is granted for products intended
for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without
incentives, it is unlikely that sales of the product in the European Union would be sufficient to justify the necessary investment in
developing the medicinal product. The COMP may only recommend orphan medicinal product designation when the product in question offers
a significant clinical benefit over existing approved products for the relevant indication. Following a positive opinion by the COMP,
the European Commission adopts a decision granting orphan status. The COMP will reassess orphan status in parallel with EMA review of
a marketing authorization application and orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for
instance because in the meantime a new product was approved for the indication and no convincing data are available to demonstrate a
significant benefit over that product). Orphan medicinal product designation entitles a party to financial incentives such as reduction
of fees or fee waivers and ten years of market exclusivity is granted following marketing authorization. During this period, the competent
authorities may not accept or approve any similar medicinal product, unless it offers a significant clinical benefit. This period may
be reduced to six years if the orphan medicinal product designation criteria are no longer met, including where it is shown that the
product is sufficiently profitable not to justify maintenance of market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pediatric
Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, companies developing a new medicinal product must agree to a Pediatric Investigation Plan, or &ldquo;PIP,&rdquo;
with the EMA and must conduct pediatric clinical trials in accordance with that PIP unless a waiver applies, for example, because
the relevant disease or condition occurs only in adults. The marketing authorization application for the product must include the results
of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which
case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis
of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under
a supplementary protection certificate (if the product covered by it qualifies for one at the time of approval). This pediatric reward
is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical
trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, most countries are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic
control of narcotic substances, including cannabis extracts. Countries may interpret and implement their treaty obligations in a way
that creates a legal obstacle to us obtaining marketing approval for our product candidates in those countries. These countries may not
be willing or able to amend or otherwise modify their laws and regulations to permit our product candidates to be marketed, or achieving
such amendments to the laws and regulations may take a prolonged period of time. In that case, we would be unable to market our product
candidates in those countries in the near future or perhaps at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_098"></A>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to build on our leadership expertise. We employ two full-time and one part-time employee. We also work with scientific advisors,
consultants and service providers, mainly through academic institutions and contract research organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never had a work stoppage and none of its employees are covered by collective bargaining agreements or represented by a labor union.
We believe that we have good relationships with our employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_099"></A>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be a party to litigation that arises in the ordinary course of its business. Other than as described below, we do
not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect
on its results of operations, financial condition or cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2021, we received a stockholder litigation demand letter from the law firm of Purcell Julie &amp; Lefkowitz LLP, on behalf
of James Self, a purported stockholder of our Company. The letter demands that we (i) deem ineffective the December 30, 2020 amendment
to its Amended and Restated Certificate of Incorporation in which we effected a reverse stock split due to the manner in which non-votes
by brokers were tabulated, (ii) seek appropriate relief for damages allegedly suffered by the company and its stockholders or seek a
valid stockholder approval of the amendment and reverse stock split, and (iii) adopt adequate internal controls to prevent a recurrence
of the alleged misconduct. The Company disputed that the amendment was ineffective or that there were any inadequate internal controls
related to the same. However, to eliminate any questions about the amendment, the Company ratified the amendment at a special stockholders&rsquo;
meeting pursuant to Section 204 of the Delaware General Corporation Law. This special stockholders&rsquo; meeting occurred on May 14,
2021. On May 14, 2021, the Company filed a Certificate of Validation with the State of Delaware to ratify the reverse stock split on
December 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 152; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_100"></A>Corporate
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Tender
Offer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, pursuant to the Tender Offer Support Agreement and Termination of Amalgamation Agreement, dated August 12, 2020, as
amended by that certain Amendment No. 1 to the Tender Offer Support Agreement and Termination of Amalgamation Agreement, dated December
18, 2020 (as amended, the &ldquo;Tender Agreement&rdquo;), by and among us, Jay Pharma Inc., a Canada corporation and a wholly owned
subsidiary of the Company (&ldquo;Jay Pharma&rdquo;), and certain other signatories thereto, we completed a tender offer (the &ldquo;Offer&rdquo;)
to purchase all of the outstanding common shares of Jay Pharma for the number of shares of Company common stock or Series B Preferred
Stock, as applicable, equal to the exchange ratio of 0.8849 (the &ldquo;Exchange Ratio&rdquo;), and Jay Pharma became a wholly-owned
subsidiary of the Company, on the terms and conditions set forth in the Tender Agreement. Following the effective time of the Offer,
we changed the name of our company from AMERI Holdings, Inc. to Enveric Biosciences, Inc. and effected a 1-for-4 reverse stock split
of our issued and outstanding common stock. Immediately following completion of the Offer and the transactions contemplated in the Tender
Agreement, but without giving effect to the issuance of the Series B Warrants (as defined below), (i) the former Jay Pharma equity holders
(including certain investors in private placements that closed prior to the completion of the Offer) owned approximately 82.3% of the
Company; (ii) former Ameri equity holders owned approximately 14.5% of the Company; and (iii) a financial advisor to Jay Pharma and Ameri
owned approximately 3.2% of the Company. The Offer has been accounted for as a &ldquo;reverse merger&rdquo; under the acquisition method
of accounting for business combinations with Jay Pharma treated as the accounting acquirer of Ameri. As such, the historical financial
statements of Jay Pharma have become the historical financial statements of Ameri, or the combined company, and are included herein labeled
&ldquo;Enveric Biosciences, Inc.&rdquo; As a result of the Offer, historical common stock, stock options and additional paid-in capital,
including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including
the effect of the Exchange Ratio and the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock on The Nasdaq Capital Market, previously trading through the close of business on December 30, 2020 under the ticker symbol
&ldquo;AMRH,&rdquo; commenced trading on The Nasdaq Capital Market, on a post-reverse stock split adjusted basis, under the ticker symbol
&ldquo;ENVB&rdquo; on December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Closing
of Spin-Off</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, Ameri and Ameri100 Inc. (&ldquo;Private Ameri&rdquo;) entered into a Share Purchase Agreement (the &ldquo;Ameri Share
Purchase Agreement&rdquo;) pursuant to which Ameri agreed to contribute, transfer and convey to Private Ameri all of the issued and outstanding
equity interests of the existing subsidiaries of Ameri, constituting the entire business and operations of Ameri and its subsidiaries,
and wherein Private Ameri agreed to assume the liabilities of such subsidiaries (the &ldquo;Spin-Off&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, pursuant to the Ameri Share Purchase Agreement, Ameri consummated the Spin-Off and all of the issued and outstanding
shares of Series A preferred stock of Ameri (the &ldquo;Series A Preferred Stock&rdquo;) were redeemed for an equal number of shares
of Series A preferred stock of Private Ameri (&ldquo;Private Ameri Preferred Stock&rdquo;). Ameri contributed, transferred and conveyed
to Private Ameri all of the issued and outstanding equity interests of the existing subsidiaries of Ameri, constituting the entire business
and operations of Ameri and its subsidiaries, and Private Ameri assumed the liabilities of such subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reverse
Stock Split</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of 4:02 pm Eastern Time on December 30, 2020, we filed an amendment to our Amended and Restated Certificate of Incorporation to effect
a reverse stock split of the issued and outstanding shares of our common stock, at a ratio of one share for four shares. The net result
of the reverse stock split was a 1-for-4 reverse stock split. We made proportionate adjustments to the per share exercise price and/or
the number of shares issuable upon the exercise or vesting of all stock options, restricted stock units (if any) and warrants outstanding
as of the effective times of the reverse stock split in accordance with the terms of each security based on the split ratio. Also, we
reduced the number of shares reserved for issuance under our equity compensation plans proportionately based on the split ratios. Except
for adjustments that resulted from the rounding up of fractional shares to the next whole share, the reverse stock split affected all
stockholders uniformly and did not change any stockholder&rsquo;s percentage ownership interest in our Company. As a result of the reverse
stock split, the per share exercise price of, and the number of shares of Company common stock underlying, our stock options and warrants
outstanding immediately prior to the reverse stock split were automatically proportionally adjusted based on the 1-for-4 split ratio
in accordance with the terms of such options and warrants, as the case may be. Share and per-share amounts of common stock, options and
warrants included herein have been adjusted to give effect to the reverse stock split. The reverse stock split did not alter the par
value of the common stock or modify any voting rights or other terms of the common stock. Unless otherwise noted, the accompanying financial
statements and notes thereto, including the Exchange Ratio applied to historical Jay Pharma common stock and stock options, give retroactive
effect to the reverse stock split for all periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amended
and Restated Certificate of Incorporation and Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Tender Agreement, we filed an Amended and Restated Certificate of Incorporation and adopted amended and restated
bylaws on December 30, 2020. For additional information regarding our organizational documents, please see our Current Report on Form
8-K filed with the SEC on January 6, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delisting
of Ameri Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, we received a written notice (the &ldquo;Notice&rdquo;) from Listing Qualifications Department of The Nasdaq Stock
Market LLC (&ldquo;Nasdaq&rdquo;) indicating that our listed warrants (the &ldquo;AMRHW Warrants&rdquo;) would be suspended from listing
on the Nasdaq Capital Market. A Form 25-NSE was filed with the SEC on December 30, 2020, which removed the AMRHW Warrants from listing
and registration on the Nasdaq Capital Market. The terms of the AMRHW Warrants are not affected by the delisting, and the AMRHW Warrants
may still be exercised in accordance with their terms to purchase common stock of the Company. The listing of the common stock, which
is traded on the Nasdaq Capital Market under the symbol ENVB, was not affected by the delisting of the AMRHW Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_101"></A>ENVB
MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should read this discussion of ENVB&rsquo;s financial condition and results of operations in conjunction with the sections entitled &ldquo;Selected
Historical Financial Information of ENVB,&rdquo; &ldquo;Risks Related to ENVB&rsquo;s Business,&rdquo; &ldquo;Risks Related to Regulatory
Matters,&rdquo; &ldquo;Risks Related to ENVB&rsquo;s Intellectual Property,&rdquo; and &ldquo;Risks Related to the Ownership of ENVB Common
Stock&rdquo; and ENVB&rsquo;s financial statements and notes thereto included elsewhere in this proxy statement/prospectus. The financial
information presented for the years ended December 31, 2020 and December 31, 2019 is based on ENVB&rsquo;s audited financial statements
and related notes. This discussion and analysis contains certain statements that are not strictly historical and are &ldquo;forward-looking&rdquo;
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks, uncertainties and assumptions.
ENVB&rsquo;s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>As
used in this section, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and &ldquo;the Company&rdquo; refer collectively
to ENVB.</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_102"></A>Business
Overview</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-development-stage biosciences company that is developing innovative, evidence-based prescription products and combination
therapies containing cannabinoids to address unmet needs in cancer care. We seek to improve the lives of patients suffering from cancer,
initially by developing palliative and supportive care products for people suffering from certain side effects of cancer and cancer treatment
such as pain or skin irritation. We currently intend to offer such palliative and supportive care products in the United States, following
approval through established regulatory pathways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aiming to advance a pipeline of novel cannabinoid combination therapies for hard-to-treat cancers, including glioblastoma multiforme
(GBM) and several other indications, which are currently being researched.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to bring together leading oncology clinicians and researchers, academic and industry partners so as to develop both external proprietary
products and a robust internal pipeline of product candidates aimed at improving quality of life and outcomes for cancer patients. We
intend to evaluate options to out-license its proprietary technology as it moves along the regulatory pathway as well as evaluating building
a small, targeted selling organization and will potentially utilize a hybrid approach based on the product indication and the market
opportunity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
developing its product candidates, we intend to focus on cannabinoids derived from hemp, other botanical sources, and synthetic materials
containing no tetrahydrocannabinol (THC) in order to comply with U.S. federal regulations. Of the potential cannabinoids to be used in
therapeutic formulations, THC, which is responsible for the psychoactive properties of marijuana, can result in undesirable mood effects.
Cannabidiol (CBD) and cannabigerol (CBG), on the other hand, are not psychotropic and are therefore more attractive candidates for translation
into therapeutic practice. In the future, we may utilize cannabinoids that are derived from cannabis plants, which may contain THC; however,
we only intend to do so in jurisdictions where THC is legal. These product candidates will then be studied through a typical FDA drug
approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_103"></A>Corporate
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Tender
Agreement, Reverse Stock Split and Related Transactions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, pursuant to the Tender Offer Support Agreement and Termination of Amalgamation Agreement dated August 12, 2020 (&ldquo;Original
Amalgamation Agreement&rdquo;), as amended by that certain Amendment No. 1 to the Tender Offer Support Agreement and Termination of Amalgamation
Agreement dated December 18, 2020 (as amended the &ldquo;Tender Agreement&rdquo;), the Company completed a tender offer (&ldquo;Offer&rdquo;)
to purchase all of the outstanding common shares of Jay Pharma, Inc., a Canadian corporation and a wholly-owned subsidiary of the Company
(&ldquo;Jay Pharma&rdquo;), for the number of shares of Company common stock, par value $0.01 per share (&ldquo;Common Stock&rdquo;)
or Series B Preferred Stock, as applicable, equal to the exchange ratio of 0.8849 (the &ldquo;Exchange Ratio&rdquo;), and Jay Pharma
became a wholly-owned subsidiary of the Company, on the terms and conditions set forth in the Tender Agreement. In connection with the
Offer, the Company changed its name from AMERI Holdings, Inc. to Enveric Biosciences, Inc. The Offer was accounted for as a &ldquo;reverse
merger&rdquo; under the acquisition method of accounting for business combinations with Jay Pharma treated as the accounting acquirer
of Ameri. As such, the historical financial statements of Jay Pharma have become the historical financial statements of Ameri, or the
combined company, and are included in this filing labeled &ldquo;Enveric Biosciences, Inc.&rdquo; As a result of the Offer, historical
common stock, stock options and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to
reflect the equity structure of the combined company, including the effect of the Exchange Ratio and the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the completion of the Offer, on December 30, 2020, the Company effected a 1-for-4 reverse stock split of the issued and outstanding
Common Stock (the &ldquo;Reverse Stock Split&rdquo;). As a result of the Reverse Stock Split, the per share exercise price of, and the
number of shares of Company common stock underlying, Company stock options and warrants outstanding immediately prior to the Reverse
Stock Split were automatically proportionally adjusted based on the 1-for-4 split ratio in accordance with the terms of such options
and warrants, as the case may be. Share and per-share amounts of common stock, options and warrants included herein have been adjusted
to give effect to the Reverse Stock Split. The Reverse Stock Split did not alter the par value of the common stock, $0.01 per share,
or modify any voting rights or other terms of the common stock. Unless otherwise noted, the accompanying financial statements and notes
thereto, including the Exchange Ratio applied to historical Jay Pharma common stock and stock options, give retroactive effect to the
Reverse Stock Split for all periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of the Offer, (i) holders of outstanding common shares of Jay Pharma (referred to herein as the Jay Pharma equity holders)
other than Alpha Capital Anstalt (&ldquo;Alpha&rdquo;) and Bezalel Partners, LLC (&ldquo;Bezalel&rdquo;) received the number of shares
of common stock in accordance with the Exchange Ratio of 0.8849, as calculated in accordance with the Tender Agreement, (ii) each of
Alpha and Bezalel, as an investor who would have beneficially owned more than 10.0% of the Company if it received common stock, received
shares of Series B Preferred Stock, which were convertible into shares of common stock subject to a 9.99% beneficial ownership blocker,
pursuant to the terms of the respective exchange agreement entered into by and between Ameri and such stockholder. Each outstanding Jay
Pharma option, whether vested or unvested, and warrant that had not previously been exercised was exchanged for Company stock options
and Company warrants, in each case convertible into the number of shares of common stock equal to the Exchange Ratio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series B Preferred Stock was non-voting and was convertible into one share of Company common stock (subject to adjustment) at
any time at the option of the holder, provided that each holder would be prohibited from converting Series B Preferred Stock into shares
of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total
number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder&rsquo;s
provision of not less than 61 days&rsquo; prior written notice to the Company. Shares of Series B Preferred Stock are not entitled to
receive any dividends, unless and until specifically declared by the Company&rsquo;s board of directors. However, holders of Series B
Preferred Stock were entitled to receive dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common stock
basis) to and in the same form as dividends actually paid on shares of the common stock when such dividends are specifically declared
by the Company&rsquo;s board of directors. The Company had no right to require a holder to surrender its Series B Preferred Stock for
redemption. Shares of Series B Preferred Stock were not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous
fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of the Offer and the transactions contemplated in the Tender Agreement, but without giving effect to the issuance of the Series
B Warrants to purchase 1,791,923 shares of common stock at an exercise price of $0.01 per share to Alpha following the completion of
the Offer, (i) Jay Pharma equity holders, including those who received Series B Preferred Stock in the Offer, own approximately 82.3%
of the outstanding equity of the Company, assuming conversion of the Series B Preferred Stock, (ii) the Ameri equity holders at the time
of the completion of the Offer own approximately 14.5% of the outstanding equity of the Company, and (iii) the financial advisor to Jay
Pharma and Ameri owns approximately 3.2% of the outstanding equity of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a significant investor in Jay Pharma, Alpha received Series B Preferred Stock in the Offer instead of common stock, as well as Series
B Warrants with a nominal exercise price, which were issued to Alpha following the completion of the Offer to account for an adjustment
in pricing of the transactions in light of global economic conditions. Because the Series B Preferred Stock were convertible into common
stock at any time for no consideration, such shares have been included in basic earnings per share. The Series B Warrants are accounted
for as a cost of equity as part of the capital issuance. The estimated fair value implied for shares of the Company based on the series
of transactions with Alpha is $1.62 per share, which is equal to the $5,300,000 investment made by Alpha divided by 3,262,907, or the
number of post-Reverse Stock Split shares of Series B Preferred Stock (convertible into common stock) that Alpha received in the Offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the execution of the Original Amalgamation Agreement, Jay Pharma issued a Secured Promissory Note, dated January 10, 2020 (the &ldquo;Original
Note&rdquo;), to Alpha, pursuant to which, on January 10, 2020, Jay Pharma received a $1,500,000 loan from Alpha. The Original Note was
amended to reflect an additional investment of $500,000, resulting in a total principal amount of $2,000,000. The Original Note was further
amended on August 12, 2020, to account for the termination of the Original Amalgamation Agreement and the change in the structure of
the transaction from an amalgamation to a stock-for-stock exchange offer (as amended, the &ldquo;Note&rdquo;). Upon the closing of the
Offer, the Note was converted into the right to receive 2,473,848 common shares of Jay Pharma and warrants to purchase 2,333,970 common
shares of Jay Pharma at an exercise price of $1.03 per share immediately prior to the Offer. In connection with the Offer, such common
shares and warrants of Jay Pharma acquired by Alpha upon conversion of the Note were converted into the right to receive (i) 547,278
shares of Series B Preferred Stock that are convertible into up to 547,278 shares of common stock, after giving effect to the Reverse
Stock Split, and (ii) warrants to purchase up to 516,333 shares of common stock at an exercise price of $4.64 per share, after giving
effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
also acquired 3,500,954 common shares of Jay Pharma and warrants to purchase 3,500,954 common shares of Jay Pharma at an exercise price
of $1.03 per share, immediately prior to the Offer, in connection with the $3 million private placement completed prior to the completion
of the Offer (the &ldquo;Alpha Investment&rdquo;). In connection with the Offer, such common shares and warrants of Jay Pharma acquired
by Alpha in the Alpha Investment were converted into, as applicable, the right to receive (i) 774,499 shares of Series B Preferred Stock
that were convertible into up to 774,499 shares of common stock, after giving effect to the Reverse Stock Split, and (ii) warrants to
purchase up to 774,499 shares of common stock at an exercise price of $4.64 per share, after giving effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 4, 2020, Jay Pharma and Alpha executed a securities purchase agreement whereby Alpha purchased an additional 1,000,000 common
shares of Jay Pharma and warrants to purchase 500,000 common shares of Jay Pharma at an exercise price of $0.30 per share for an aggregate
purchase price of $300,000 (the &ldquo;Alpha December Investment&rdquo;). In connection with the Offer, such shares were exchanged for
221,225 shares of common stock, and such warrants were exchanged for warrants to purchase 110,613 shares of common stock at $1.36 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, at the effective time of the Offer, the Company issued five-year warrants (the &ldquo;Series B Warrants&rdquo;) to purchase
1,791,923 shares of common stock at an exercise price of $0.01 to Alpha, after giving effect to the Reverse Stock Split. The number of
shares of common stock issuable upon the exercise of the Series B Warrants is equal to the product of (i) 8,100,000 and (ii) the Exchange
Ratio of 0.8849, post-Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the conversion of its Series B Preferred Stock, the warrants issued to Alpha in connection with the Alpha Investment
and the Alpha Bridge Loan and the Series B Warrants, Alpha&rsquo;s total ownership interest in the Company was 5,008,078 common shares,
or 33.9%, without giving effect to the beneficial ownership limitations in its Series B Preferred Stock. However, under the terms of
each of such securities, Alpha may not convert such security to the extent such conversion would cause Alpha, together with its affiliates,
to beneficially own a number of shares of common stock which would exceed 9.99% of the common stock then issued and outstanding following
such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intellectual
Property Acquisition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Offer, Jay Pharma entered into a series of assignment and assumption agreements with affiliates of a third party,
Tikkun Pharma, Inc. (&ldquo;Tikkun&rdquo;), pursuant to which, on October 2, 2020, Tikkun assigned to Jay Pharma all of Tikkun&rsquo;s
(i) rights to certain skin care treatment assets and (ii) intellectual property rights to certain formulations for the development of
therapeutic candidates for the prevention, management and treatment of graft versus host disease (GVHD) in exchange for an aggregate
of 10,360,007 common shares of Jay Pharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
Alpha required additional shares of the Company, at no or a nominal cost, for Alpha to consummate the Alpha Bridge Loan and the Alpha
Investment at the planned valuation, Alpha entered into an agreement with Tikkun pursuant to which, immediately following such assignment,
Tikkun sold 7,774,463 of these common shares of Jay Pharma to Alpha for the nominal aggregate purchase price of $10.00 (the &ldquo;Alpha
Nominal Shares&rdquo;), leaving Tikkun with 2,585,544 common shares of Jay Pharma (the &ldquo;Tikkun Shares&rdquo;). In connection with
the Offer, the Tikkun Shares were exchanged for 571,987 shares of common stock, after giving effect to the Reverse Stock Split, and the
Alpha Nominal Shares were exchanged for 1,719,906 shares of Series B Preferred Stock that are convertible into up to 1,719,906 shares
of common stock, after giving effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 157; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Spin-Off</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the Offer, on December 30, 2020, pursuant to the Ameri Share Purchase Agreement, Ameri and Private Ameri completed
the Spin-Off, pursuant to which Ameri contributed, transferred and conveyed to Private Ameri all of the issued and outstanding equity
interests of the existing subsidiaries of Ameri, constituting the entire business and operations of Ameri and its subsidiaries, and Private
Ameri assumed the liabilities of such subsidiaries, and all of the issued and outstanding shares of Series A preferred stock of Ameri
were redeemed for an equal number of shares of Series A preferred stock of Private Ameri.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Series
B Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Tender Agreement, on December 31, 2020, we issued Series B Warrants (the &ldquo;Series B Warrants&rdquo;) to purchase 1,791,923
shares of common stock at an exercise price of $0.01 to Alpha Capital Anstalt (&ldquo;Alpha&rdquo;). We were obligated, among other things,
to file a registration statement with SEC for purposes of registering the resale of the shares of common stock issuable upon exercise
of the Series B Warrants by the investors. The issuance of the Series B Warrants was exempt from the registration requirements of the
Securities Act pursuant to an exemption provided by Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering.
As described below under &ldquo;Letter Agreement with Alpha,&rdquo; on January 12, 2021, we waived the lock-up restrictions on
Alpha with respect to dispositions of the shares of common stock issuable upon exercise of the Series B Warrants (the &ldquo;Series B
Warrant Shares&rdquo;), and Alpha agreed to limit its sales of shares of our common stock on each trading day to no more than 10% of
the daily reported trading volume of common stock on the Nasdaq Stock Market for such trading day, provided, such limitation shall terminate
if the closing price of our shares of common stock on the Nasdaq Stock Market exceeds $5.29 per share for five consecutive trading days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Director
and Officer Resignations and Appointments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
upon completion of the Offer, Srinidhi &ldquo;Dev&rdquo; Devanur, our former Executive Chairman and a former director of the board of
directors, Brent Kelton, our former Chief Executive Officer, Barry Kostiner, our former Chief Financial Officer, Carmo Martella, a former
director of the board of directors, Thoranath Sukumaran, a former director of the board of directors and Dimitrios Angelis, a former
director of the board of directors, all tendered their resignations from their respective positions as officers and directors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Tender Agreement, the board of directors appointed David Johnson, George Kegler, Sol Mayer and Marcus Schabacker
to the board of directors at the effective time of the Offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
upon the completion of the Offer, the board of directors appointed David Johnson as our Chief Executive Officer and Chairman, Avani Kanubaddi
as our Chief Operating Officer, John Van Buiten as our Chief Financial Officer, and Robert Wilkins as our Chief Medical Officer. On April
9, 2021, John M. Van Buiten resigned from his position as the Company&rsquo;s chief financial officer, effective May 15, 2021. Mr. Van
Buiten&rsquo;s resignation was not the result of any disagreement regarding any matter relating to the Company&rsquo;s operations, policies,
or practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, Carter J. Ward, 56, was appointed as the Company&rsquo;s chief financial officer, effective May 15, 2021 (the &ldquo;Effective
Date&rdquo;). In connection with Mr. Ward&rsquo;s appointment as chief financial officer, Mr. Ward entered into an employment agreement
with the Company on April 9, 2021 (the &ldquo;Ward Employment Agreement&rdquo;), effective as of May 15, 2021, pursuant to which Mr.
Ward will receive a base salary of $295,000 (&ldquo;Base Salary&rdquo;) and is eligible to receive annual performance bonuses of up to
50% of his Base Salary, as determined from time-to-time by the Company&rsquo;s board of directors. Additionally, Mr. Ward will receive
525,000 restricted stock units (&ldquo;RSUs&rdquo;), 262,500 of such RSUs shall be subject to time-based vesting (the &ldquo;Time Based
RSUs&rdquo;), and the remaining 262,500 of such RSUs shall be subject to performance-based vesting (the &ldquo;Performance RSUs&rdquo;).
The RSUs shall be subject to the terms and conditions of the Company&rsquo;s 2020 Long-Term Incentive Plan. The Time Based RSUs shall
vest in quarters on each anniversary of the Effective Date, and the Performance RSUs shall vest based on the achievement of performance
milestones established by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2020 at the special meeting of Ameri stockholders held to approve the Tender Agreement, the shareholders ratified the bonus
shares proposal resulting in the issuance of shares previously awarded by Ameri&rsquo;s board of directors to Mr. Devanur, Mr. Kelton,
Mr. Kostiner and Brandon Gordon, our Executive Vice President, Business Development in lieu of cash bonuses, with a total of 156,318
post-split shares being awarded on December 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 158; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
these shares, 67,635 had originally been awarded, subject to Ameri&rsquo;s shareholders&rsquo; approval, on January 9, 2020, representing
aggregate bonus payments of $675,000 divided by a price of $9.98, the closing price on the day immediately preceding board approval.
A further 88,683 shares had been awarded, subject to Ameri&rsquo;s shareholders&rsquo; approval, and subject to continued service through
the end of 2020, on October 19, 2020, represent aggregate bonus payments of $525,000 divided by a price of $5.92, the closing price on
the day immediately preceding board approval, resulting in a total of 156,318 shares granted to officers and directors. The issuance
of these shares was exempt from the registration requirements of the Securities Act pursuant to an exemption provided by Section 4(a)(2)
thereof as a transaction by an issuer not involving a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_104"></A>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Change
in Certifying Accountant</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2021, our Audit Committee of the board of directors approved the dismissal of Ram Associates, CPA (&ldquo;Ram&rdquo;) as our
independent registered public accounting firm, effective December 31, 2020, and engaged Marcum LLP (&ldquo;Marcum&rdquo;) as our independent
registered public accounting firm for the year ending December 31, 2020. Prior to the completion of the Offer, Marcum served as the independent
registered public accounting firm of Jay Pharma, and we believed the change in auditors will be more efficient for reporting purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>January
2021 Registered Direct Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2021, we entered into a Securities Purchase Agreement (the &ldquo;January 2021 Purchase Agreement&rdquo;) with Alpha, The
Hewlett Fund LP, Alto Opportunity Master Fund, SPC &ndash; Segregated Master Portfolio B (&ldquo;Alto&rdquo;), Iroquois Master Fund Ltd.,
Iroquois Capital Investment Group LLC and Hudson Bay Master Fund Ltd (collectively, the &ldquo;Subsequent Investors&rdquo;), pursuant
to which the Company issued and sold in a registered direct offering (the &ldquo;January 2021 Direct Offering&rdquo;) an aggregate of
2,221,334 shares of Company common stock at an offering price of $4.5018 per share, for gross proceeds of approximately $10,000,000 before
the deduction of fees and offering expenses. Under the January 2021 Purchase Agreement, the Subsequent Investors could choose to purchase
pre-funded warrants (the &ldquo;Pre-funded Warrants&rdquo;) in lieu of shares of common stock. The offering closed on January 14, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-funded Warrants have an exercise price of $0.01 per share. The Pre-funded Warrants are immediately exercisable and may be exercised
at any time after their original issuance until such Pre-funded Warrants are exercised in full. A holder of a Pre-funded Warrant may
not exercise any portion of such holder&rsquo;s Pre-funded Warrants to the extent that the holder, together with its affiliates, would
beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company&rsquo;s outstanding shares of common stock
immediately after exercise (the &ldquo;Beneficial Ownership Limitation&rdquo;), except that upon at least 61 days&rsquo; prior notice
from the holder to the Company, the holder may increase the Beneficial Ownership Limitation to up to 9.99% of the number of shares of
common stock outstanding immediately after giving effect to the exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;The
shares, the Pre-funded Warrants, and the shares of Company common stock issuable upon the exercise of the Pre-funded Warrants (the &ldquo;Pre-funded
Warrant Shares&rdquo;) were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-233260), previously
filed with the SEC on August 14, 2019, and declared effective by the SEC on November 19, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the January 2021 Purchase Agreement, in a concurrent private placement (the &ldquo;January 2021 Private Placement&rdquo;) that also
closed on January 14, 2021, the Company issued to the Subsequent Investors, unregistered warrants to purchase up to 1,666,018 shares
of common stock (the &ldquo;January 2021 Warrants&rdquo;). The January 2021 Warrants are exercisable immediately upon issuance and terminate
five years following issuance and are exercisable at an exercise price of $4.9519 per share, subject to adjustment as set forth therein.
A holder of January 2021 Warrants will not have the right to exercise any portion of its January 2021 Warrants if the holder, together
with its affiliates, would beneficially own in excess of the Beneficial Ownership Limitation; provided, however, that upon 61 days&rsquo;
prior notice to the Company, the holder may increase or decrease the Beneficial Ownership Limitation, provided that in no event shall
the Beneficial Ownership Limitation exceed 9.99%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
January 2021 Warrants and the shares of Company common stock issuable upon the exercise of the January 2021 Warrants (the &ldquo;January
2021 Warrant Shares&rdquo;) were not registered under the Securities Act, were not offered pursuant to the shelf registration statement,
and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder
as a transaction by the issuer not involving a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
induce the Subsequent Investors into the January 2021 Purchase Agreement, the Company also entered into a registration rights agreement,
dated January 12, 2021 (the &ldquo;January Registration Rights Agreement&rdquo;), with the Subsequent Investors, pursuant to which, among
other things, the Company agreed to prepare and file with the SEC a registration statement to register for resale of all of the January
2021 Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Letter
Agreement with Alpha</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2021, the Company entered into a letter agreement (the &ldquo;Letter Agreement&rdquo;) with Alpha. Under the Letter Agreement,
(i) we agreed to register 1,791,923 of the Series B Warrant Shares issuable upon the exercise of Series B Warrants, (ii) the Series B
Warrant Shares will not be subject to an existing lock-up agreement between us and Alpha, and Alpha will no longer be subject to any
limitations on its ability to dispose of the Series B Warrant Shares that are imposed by us to the extent permitted by applicable rules
and regulations, (iii) Alpha agreed to limit its sales of Company common stock on each trading day to no more than 10% of the daily reported
trading volume of Company common stock on the Nasdaq Stock Market for such trading day, provided, such limitation shall terminate if
the closing price of our shares of common stock on the Nasdaq Stock Market exceeds $5.29 per share for five consecutive trading days
and (iv) we will be free to waive the terms and conditions of any lock-up agreement between us and any of the former shareholders of
Jay Pharma Inc. without the consent of, or notice to, Alpha once this registration statement registering the Series B Warrant Shares
is declared effective by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
Demand Letter</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2021, we received a stockholder litigation demand letter from the law firm of Purcell Julie &amp; Lefkowitz LLP, on behalf
of James Self, a purported stockholder of our Company. The letter demands that we (i) deem ineffective the December 30, 2020 amendment
to our Amended and Restated Certificate of Incorporation in which we effected a one-for-four reverse stock split of our common stock
due to the manner in which non-votes by brokers were tabulated, (ii) seek appropriate relief for damages allegedly suffered by the company
and its stockholders or seek a valid stockholder approval of the amendment and reverse stock split, and (iii) adopt adequate internal
controls to prevent a recurrence of the alleged misconduct. We dispute that the amendment was ineffective or that there were any inadequate
internal controls related to the same. However, to eliminate any questions about the amendment, the Company ratified the amendment at
a special stockholders&rsquo; meeting pursuant to Section 204 of the Delaware General Corporation Law. This special stockholders&rsquo;
meeting occurred on May 14, 2021. On May 14, 2021, the Company filed a Certificate of Validation with the State of Delaware to ratify
the reverse stock split on December 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>February
2021 Registered Direct Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2021, we entered into a Securities Purchase Agreement (the &ldquo;February 2021 Purchase Agreement&rdquo;) with the Subsequent
Investors, pursuant to which the Company issued and sold in a registered direct offering (the &ldquo;February 2021 Direct Offering&rdquo;)
an aggregate of 3,007,026 shares of our common stock at an offering price of $4.27 per share, for gross proceeds of approximately $12,800,000
before the deduction of fees and offering expenses. The offering closed on February 11, 2021. The shares were offered by the Company
pursuant to a shelf registration statement on Form S-3 (File No. 333-233260), previously filed with the SEC on August 14, 2019, and declared
effective by the SEC on November 19, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the February 2021 Purchase Agreement, in a concurrent private placement (the &ldquo;February 2021 Private Placement&rdquo;) that also
closed on February 11, 2021, the Company issued to the Subsequent Investors, unregistered warrants to purchase up to 1,503,513 shares
of Company common stock (the &ldquo;February 2021 Warrants&rdquo;). The February 2021 Warrants are exercisable immediately upon issuance
and terminate five years following issuance and are exercisable at an exercise price of $4.90 per share, subject to adjustment as set
forth therein. A holder of February 2021 Warrants will not have the right to exercise any portion of its February 2021 Warrants if the
holder, together with its affiliates, would beneficially own in excess of the Beneficial Ownership Limitation; provided, however, that
upon 61 days&rsquo; prior notice to the Company, the holder may increase or decrease the Beneficial Ownership Limitation, provided that
in no event shall the Beneficial Ownership Limitation exceed 9.99%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 160; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;The
February 2021 Warrants and the shares of our common stock issuable upon the exercise of the February 2021 Warrants (the &ldquo;February
2021 Warrant Shares&rdquo;) were not registered under the Securities Act, were not offered pursuant to the shelf registration statement,
and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder
as a transaction by the issuer not involving a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
induce the Subsequent Investors into the February 2021 Purchase Agreement, the Company also entered into a registration rights agreement,
dated February 8, 2021 (the &ldquo;February Registration Rights Agreement&rdquo;), with the Subsequent Investors, pursuant to which,
among other things, the Company agreed to prepare and file with the SEC a registration statement to register for resale of all of the
February 2021 Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Palladium
Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with its role as financial advisor to the Company in the January 2021 Direct Offering, the January 2021 Private Placement,
the February 2021 Direct Offering and the February 2021 Private Placement, the Company issued Palladium 155,493 warrants with an exercise
price of $4.9519 and 210,492 warrants with an exercise price of $4.90 (the &ldquo;Palladium Warrants&rdquo;) on February 11, 2021. The
Palladium Warrants and the shares of our common stock issuable upon the exercise of the Palladium Warrants (the &ldquo;Palladium Warrant
Shares&rdquo;) were not registered under the Securities Act and were offered pursuant to the exemption provided in Section 4(a)(2) under
the Securities Act and Rule 506(b) promulgated thereunder as a transaction by the issuer not involving a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Resale
Registration Statement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, we filed a resale registration statement on Form S-3 (File No. 333-253196) (the &ldquo;Resale Registration Statement&rdquo;)
registering 5,497,878 shares of our common stock, consisting of the Series B Warrant Shares, the January 2021 Warrant Shares, the February
2021 Warrant Shares, the Palladium Warrant Shares, 156,318 shares issued to former directors and officers of Ameri and 14,121 shares
issued to a former consultant of the Company. The Resale Registration Statement was declared effective by the SEC on April 7, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Development
and Clinical Supply Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &ldquo;Agreement&rdquo;) with PureForm Global,
Inc. (&ldquo;PureForm&rdquo;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&ldquo;API&rdquo;)
for the Company&rsquo;s development plans for cancer treatment and supportive care. Under the terms of the Agreement, PureForm has granted
the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term of the Agreement
(contingent upon an initial minimum order volume during the first thirty (30) days from the effective date) and has agreed to manufacture,
package and test the API and related product in accordance with specifications established by the parties. All inventions that are developed
jointly by the parties in the course of performing activities under the Agreement will be owned jointly by the parties in accordance
with applicable law; however, if the Company funds additional research and development efforts by PureForm, the parties may enter into
a further agreement whereby PureForm would assign any resulting inventions or technical information to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the Agreement is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual agreement
of the parties. The Agreement may be terminated by either party upon thirty (30) days written notice of an uncured material breach or
immediately in the event of bankruptcy or insolvency. The Agreement contains, among other provisions, representation and warranties,
indemnification obligations and confidentiality provisions in favor of each party that are customary for an agreement of this nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diverse
Biotech License Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2021, the Company entered into an Exclusive License Agreement (the &ldquo;DB Agreement&rdquo;) with Diverse Biotech, Inc. (&ldquo;Diverse&rdquo;),
pursuant to which the Company acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively, the &ldquo;Agents&rdquo;)
with the goal of alleviating the side effects that cancer patients experience. Under the terms of the DB Agreement, Diverse granted the
Company an exclusive license to its intellectual property rights covering the Agents and its products. In exchange, the Company has granted
Diverse the right to information relating to the Agents developed for the express purpose of using such information to obtain patent
rights, which right terminates upon the issuance or denial of the patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DB Agreement, the Company will maintain sole responsibility and ownership of the development and commercialization of the Agents
and its products. Diverse has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its
products containing the Agents, at any time during or after the term of the DB Agreement. If Diverse intends to license, sell, or transfer
any other molecules linked with cannabinoids not granted to the Company under the terms of the DB Agreement, the Company will have the
first right, but not the obligation, to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay
Diverse an up-front investment payment in the amount of $675,000, as well as a running royalty starting with the first commercial sale
by the Company to a third party in an arms&rsquo;-length transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the DB Agreement shall continue for as long as the Company intends to develop or commercialize the new drugs, unless earlier
terminated by either Party. The DB Agreement may be terminated by either party upon ninety (90) days written notice of an uncured material
breach or in the event of bankruptcy or insolvency. In addition, the Company has the right to terminate the DB Agreement at any time
upon sixty (60) days&rsquo; prior written notice to Diverse.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_105"></A>Key
Components of Our Results of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Operating
Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses include financial statement preparation services, tax compliance, various consulting and director fees, legal services,
auditing fees, and stock-based compensation. These expenses have increased in connection with the Company&rsquo;s product development
and the Company&rsquo;s management expects these expenses to continue to increase as the Company continues to develop its potential product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_106"></A>Results
of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth key components of our results of operations for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 40%; text-align: left">General and administrative</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">5,443,234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2,296,534</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">6,607,045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">836,702</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">174,083</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">157,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,617,317</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,296,534</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,764,997</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">836,702</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,617,317</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,296,534</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,764,997</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(836,702</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Extinguishment of note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Inducement expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802,109</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(298,714</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,813,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">442,250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">81,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261,759</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,247,359</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">114,139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,514,286</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261,759</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,864,676</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,410,673</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,250,711</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,098,461</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Foreign currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(169,655</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,667</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,736</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(12,698</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,034,331</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,417,340</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,214,975</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,111,159</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.46</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,753,598</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,287,145</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,220,661</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,607,042</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
Months Ended March 31, 2021 Compared to Three Months Ended March 31, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses increased to $6,607,045, for the three months ended March 31, 2021 from $836,702 for the three months
ended March 31, 2020, with an increase of $5,770,343, or 690%. This change was primarily driven by stock-based compensation of $3,591,565,
stock option modification expense of $298,714, and an increase in public company costs of $582,667.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expense for the three months ended March 31, 2021 was $157,952 compared to $0 for the three months ended March
31, 2020. This increase was primarily driven by the preparations ongoing for our glioblastoma study and the formulation costs for our
radio-dermatitis study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Change
in Fair Value of Warrant Liability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s change in fair value warrant liability was a gain of $3,813,000 for the three months ended March 31, 2021 due primarily
to a decrease in the Company&rsquo;s stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
Expense </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
interest expense for the three months ended March 31, 2021 was $0 compared to $261,759 for the three months ended March 31, 2020. This
decrease was primarily driven by promissory notes that were entered into by the Company during 2020, which no longer remained outstanding
in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Currency Translation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
foreign currency translation gain (loss) was $35,736 for the three months ended March 31, 2021 as compared to $(12,698) for the three
months ended March 31, 2020, for an increase in $48,434. The increase in foreign exchange gain is primarily due to the U.S. Dollar weakening
against the Canadian Dollar and the conversion of the Canadian Dollars into United States Dollars for payment of United States Dollar
denominated expenses.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
Year 2020 Compared to Fiscal Year 2019</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Operating
Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses increased to $5,617,317, for the year ended December 31, 2020 from $2,296,534 for the year ended December 31, 2019,
with an increase of $3,320,783, or 145%. This change was primarily driven by an increase in stock-based compensation of $1,440,583, an
increase in legal and professional fees of $1,147,381, and an increase in research and development costs of $174,083.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Interest
Expense</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
interest expense for the year ended December 31, 2020 was $445,250 compared to $81,823 for the year ended December 31, 2019. This increase
was primarily driven by promissory notes that were entered into by the Company during 2020, with an aggregate principal amount of $2,143,925,
which it did not have during 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 163; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Inducement
Expense </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inducement expense was $802,109 for the year December 31, 2020 as compared to $0 for the year ended December 31, 2019. The expense is
related to inducement incurred related to the conversion of warrants, resulting in a charge of $802,109.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Foreign
Exchange</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
foreign exchange loss was $169,655 for the year December 31, 2020 as compared to $6,667 for the year ended December 31, 2019, for an
increase in $162,988. The increase in foreign exchange loss is primarily due to the U.S. Dollar weakening against the Canadian Dollar
and the conversion of the Canadian Dollars into United States Dollars for payment of United States Dollar denominated expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_107"></A>Liquidity
and Capital Resources</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred continuing losses from its operations. As of March 31, 2021, the Company has had an accumulated deficit of $15,010,268
and working capital of $16,629,501. As of December 31, 2020, the Company has had an accumulated deficit of $11,759,557 and working capital
of $1,597,920. Since inception, the Company&rsquo;s operations have been funded principally through the issuance of debt and equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>February
2019 Note</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2019, Jay Pharma received $60,000 in exchange for a promissory note to David Stefansky with an aggregate face value of $66,000,
including an original issue discount of $6,000 (the &ldquo;February 2019 Note&rdquo;). The February 2019 Note bore no stated interest
rate. On July 21, 2020, Jay Pharma converted the February 2019 Note into shares of ENVB common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>March
2019 Note</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2019, Jay Pharma entered into a consulting agreement with David Stefansky. In connection with the consulting agreement, on
March 5, 2019, Jay Pharma issued a note payable to its executive director for $150,000 (the &ldquo;March 2019 Note&rdquo;). The note
bore no interest. On July 21, 2020, Jay Pharma converted the March 2019 Note into shares of ENVB common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>April
2019 Note</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
April 2019, Jay Pharma received $300,000 in exchange for convertible notes in an aggregate principal amount of $300,000 (the &ldquo;April
2019 Convertible Notes&rdquo;) and warrants to purchase 250,000 common shares of Jay Pharma. The April 2019 Convertible Notes bore interest
at a rate of 6% per annum. On December 30, 2020, the April 2019 Notes were converted into shares of ENVB common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
2019 Note</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 8, 2019, Jay Pharma entered into a note agreement (the &ldquo;July 2019 Note&rdquo;) with a limited liability company (the &ldquo;Lender&rdquo;).
The Note&rsquo;s face value was $157,714 and the original issue discount was $19,714 for total gross proceeds of $138,000, implying an
interest rate of 12.5% per annum. Jay Pharma could, without premium or penalty, at any time and from time to time, prepay all or any
portion of the Note. The maturity date of the Note was September 8, 2019. On September 20, 2019, Jay Pharma entered into an amendment
to the July 2019 Note (the &ldquo;Amendment&rdquo;). The Amendment extended the maturity date for the Note until the earlier of (a) the
completion of a bridge financing of greater than or equal to $1,500,000, or (b) November 7, 2019. On November 21, 2019, Jay Pharma entered
into an amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge
financing of greater than or equal to $1,500,000, or (b) December 9, 2019. In consideration for this amendment, Jay Pharma agreed to
pay an aggregate extension fee of $33,926, which was added to the principal balance of the note. On December 9, 2019, Jay Pharma entered
into an additional amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion
of a bridge financing of greater than or equal to $1,500,000, or (b) January 7, 2020. Jay Pharma also agreed to pay the previously outstanding
extension fees of $33,926 on or before March 1, 2020.</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 164; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2020, Jay Pharma entered into an amendment to the July 2019 Note (the &ldquo;January 8 Amendment&rdquo;). The January 8 Amendment
extended the maturity date for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal to $1,500,000,
or (b) April 1, 2020. In consideration for the January 8 Amendment, Jay Pharma granted 55,000 shares of the Company&rsquo;s common stock
to the Lender. On May 6, 2020, Jay Pharma entered into an amendment (the &ldquo;May 2020 Amendment&rdquo;) whereby both parties agreed
to extend the maturity date of the July 2019 Note to September 30, 2020. On January 12, 2020, Jay Pharma repaid $157,714 of the July
2019 Note. On December 31, 2020 the Company paid the remaining unpaid balance of the July 2019 Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>December
2019 Note</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2019, Jay Pharma received $40,000 in exchange for a promissory note with a lender, including an original issue discount
of $4,000 (the &ldquo;December 2019 Note&rdquo;). The December 2019 Note bore interest at a rate of ten percent (10%) on its face value
per annum. In the case of an event of default, the interest rate would increase to 24% per year. The December 2019 Note matured on January
31, 2020. The promissory note with the lender and Jay Pharma was converted into 170,333 shares of ENVB common stock on December 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>February
2020 Note</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2020, Jay Pharma received $50,000 in exchange for a promissory note with a lender (the &ldquo;February 2020 Note&rdquo;).
The February 2020 Note bore interest at a rate of 10% on its face value per annum. In the case of an event of default, the interest rate
would increase to 24% per year. The note matured on July 31, 2020. The February 2020 Note was convertible into common shares of Jay Pharma
at any time at a conversion price of $0.38 per share. On December 30, 2020, the February 2020 Note was converted into 190,004 shares
of the Company&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alpha
Note</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the execution of the Original Amalgamation Agreement, Jay Pharma issued the Original Note, dated January 10, 2020, to Alpha, pursuant
to which, on January 10, 2020, Jay Pharma received a $1,500,000 loan from Alpha. The Original Note was amended to reflect an additional
investment of $500,000, resulting in a total principal amount of $2,000,000. The Original Note was further amended on August 12, 2020,
to account for the termination of the Original Amalgamation Agreement and the change in the structure of the transaction from an amalgamation
to a stock-for-stock exchange offer. Upon the closing of the Offer, the Note was converted into the right to receive 2,473,848 common
shares of Jay Pharma and warrants to purchase 2,333,970 common shares of Jay Pharma at an exercise price of $1.03 per share immediately
prior to the Offer. In connection with the Offer, such common shares and warrants of Jay Pharma acquired by Alpha upon conversion of
the Note were converted into the right to receive (i) 547,278 shares of Series B Preferred Stock that are convertible into up to 547,278
shares of Common Stock, after giving effect to the Reverse Stock Split, and (ii) warrants to purchase up to 516,333 shares of Common
Stock at an exercise price of $4.64 per share, after giving effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alpha
Investment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
also acquired 3,500,954 common shares of Jay Pharma and warrants to purchase 3,500,954 common shares of Jay Pharma at an exercise price
of $1.03 per share, immediately prior to the Offer, in connection with the $3 million private placement completed prior to the completion
of the Offer. In connection with the Offer, such common shares and warrants of Jay Pharma acquired by Alpha in the Alpha Investment were
converted into, as applicable, the right to receive (i) 774,499 shares of Series B Preferred Stock that are convertible into up to 774,499
shares of Common Stock, after giving effect to the Reverse Stock Split, and (ii) warrants to purchase up to 774,499 shares of Common
Stock at an exercise price of $4.64 per share, after giving effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alpha
December Investment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 4, 2020, Jay Pharma and Alpha executed a securities purchase agreement whereby Alpha purchased an additional 1,000,000 common
shares of Jay Pharma and warrants to purchase 500,000 common shares of Jay Pharma at an exercise price of $0.30 per share for an aggregate
purchase price of $300,000 (the &ldquo;Alpha December Investment&rdquo;). In connection with the Offer, such shares were exchanged for
221,225 shares of Common Stock, and such warrants were exchanged for warrants to purchase 110,613 shares of Common Stock at $1.36 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 165; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Series
B Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
at the effective time of the Offer, the Company issued five-year warrants (the &ldquo;Series B Warrants&rdquo;) to purchase 1,791,923
shares of Common Stock at an exercise price of $0.01 to Alpha, after giving effect to the Reverse Stock Split. The number of shares of
Common Stock issuable upon the exercise of the Series B Warrants is equal to the product of (i) 8,100,000 and (ii) the Exchange Ratio
of 0.8849, post-Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Registered
Direct Offerings</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2021, the Company completed a registered direct offering of 2,221,458 shares of Common Stock at approximately $4.50 per share
for gross proceeds of approximately $10,000,000. The net proceeds to the Company after deducting financial advisory fees and other costs
and expenses were approximately $8,806,087. On February 11, 2021, the Company completed a registered direct offering of 3,007,026 shares
of Common Stock for gross proceeds of approximately $12.8 million. The net proceeds to the Company after deducting financial advisory
fees and other costs and expenses were approximately $11,624,401. As of March 30, 2021, the Company had cash on hand of approximately
$22.9 million. As of May 14, 2021, the Company had cash on hand of approximately $22.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that, as a result of recent transactions involving the issuance of debt and equity, we currently have sufficient cash and financing
commitments to meet our funding requirements over the next year. Notwithstanding, we expects that we will need to raise additional financing
to accomplish our development plan over the next several years. We may seek to obtain additional funding through debt or equity financing
in the future. There are no assurances that we will be able to raise capital on terms acceptable to us or at all, or that cash flows
generated from our operations will be sufficient to meet our current operating costs. Our ability to obtain additional capital may depend
on prevailing economic conditions and financial, business and other factors beyond our control. The COVID-19 pandemic has caused an unstable
economic environment globally. Disruptions in the global financial markets may adversely impact the availability and cost of credit,
as well as our ability to raise money in the capital markets. Current economic conditions have been and continue to be volatile. Continued
instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business. If we are
unable to obtain sufficient amounts of additional capital, we may be required to reduce the scope of our planned development, which could
harm our financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_108"></A>Cash
Flows</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have primarily used our available cash to fund our product development expenditures. The following table sets forth a summary
of cash flows for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(3,888,785</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(647,860</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(3,162,278</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(893,922</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(44,143</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(675,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,531,270</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">560,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,881,733</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,212,196</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effect of foreign exchange rate on cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(63,596</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,235</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(86,667</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,534,746</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(69,957</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,078,690</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">231,597</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Operating
Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $3,162,278 during the three months ended March 31, 2021, which consisted primarily of a net loss
of $3,250,711, offset by amortization of intangibles of $136,640, change in fair value of warrant liability of $3,813,000, stock-based
compensation of $3,591,565, induced conversion of warrants of $298,714, and increases in prepaid expenses and other current assets for
$66,208, offset by increases in accounts payable and accrued liabilities of $59,278.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $893,922 during the three months ended March 31, 2020, which consisted primarily of a net loss
of $1,098,461, offset by amortization of note discount of $233,240 and accrued interest of $28,519, increases in prepaid expenses and
other current assets of $49,588, and decreases in accounts payable and accrued liabilities of $7,632.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 166; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $3,888,785 during the year ended December 31, 2020, which consisted primarily of a net loss of
$6,864,676, offset by amortization of note discount of $288,631, stock-based compensation of $1,977,155, induced conversion of warrants
of $802,109, amortization of intangible assets of $120,872, increases in prepaid expenses and other current assets for $636,497, and
increases in accounts payable and accrued liabilities of $267,002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $647,860 during the year ended December 31, 2019, which consisted primarily of a net loss of $2,410,673,
offset by amortization of note discount of $68,453, increases in stock-based compensation of $624,052, increases in prepaid expenses
and other current assets of $104,340, and increases in accounts payable and accrued liabilities of $919,968.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Investing
Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $675,000 during the three months ended March 31, 2021, which consisted of the acquisition of intellectual
property from Diverse Bio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not have any investing activities during the three months ended March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $44,143 during the year ended December 31, 2020, which consisted of the acquisition of intellectual
property from Tikkun Pharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not have any investing activities during the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Financing
Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $24,881,733 during the three months ended March 31, 2021, which consisted primarily of $9,463,087
in net proceeds from the January registered direct offering, $12,151,401 in net proceeds from February registered direct offering, and
proceeds from the exercise of warrants of $3,267,245.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $1,212,196 during the three months ended March 31, 2020, which consisted of $50,000 in proceeds
from convertible notes payable, and $1,319,910 in proceeds from notes payable, offset by $157,714 in repayment of notes payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $5,531,270 during the year ended December 31, 2020, which consisted primarily of $50,000 in
proceeds from convertible notes payable, $1,812,410 in proceeds from note payable, proceeds from the offering and reverse merger of $3,372,500,
September 2020 private placement of $227,500, December 2020 private placement of $260,500 and a decrease of $191,640 in repayment of
note payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $560,000 during the year ended December 31, 2019, which consisted of $300,000 in proceeds from
convertible notes payable, $238,000 in proceeds from notes payable and $22,000 in advances from a related party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_109"></A>Off-Balance
Sheet Arrangements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not have any off-balance sheet financing arrangements or liabilities, guarantee contracts, retained or contingent interests
in transferred assets, or any obligation arising out of a material variable interest in an unconsolidated entity. The Company does not
have any subsidiaries to include or otherwise consolidate into the financial statements. Additionally, the Company does not have interests
in, nor relationships with, any special purpose entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_110"></A>Warrant
Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants for shares of the Company&rsquo;s common stock that are not indexed to its own stock as liabilities at
fair value on the balance sheet. Such warrants are subject to remeasurement at each balance sheet date and any change in fair value is
recognized as a component of other expense on the statement of operations. The Company will continue to adjust the liability for changes
in fair value until the earlier of the exercise or expiration of such common stock warrants. At that time, the portion of the warrant
liability related to such common stock warrants will be reclassified to additional paid-in capital.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 167; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_111"></A>Recent
Accounting Standards</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any recently issued, but not yet effective accounting standards, when adopted, will have a material effect on the
accompanying financial statements, other than those disclosed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;)
2016-02, Leases (Topic 842). This update will require organizations that lease assets to recognize on the balance sheet the assets and
liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosures about the
amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim
periods beginning after December 15, 2019. On January 1, 2020, the Company adopted this ASU, which will did not have a material impact
on the Company&rsquo;s financial position and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2018, the FASB issued ASU 2018-10, &ldquo;Codification Improvements to Topic, 842, Leases,&rdquo; which clarifies how to
apply certain aspects of the new leases standard, ASC 842. The amendments address the rate implicit in the lease, impairment of the net
investment in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase options, variable
payments that depend on an index or rate and certain transition adjustments, among other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2018, the FASB issued ASU 2018-11, &ldquo;Leases (Topic 842): Targeted Improvements,&rdquo; which provides entities with
relief from the costs of implementing certain aspects of the new leasing standard, ASC 842. Specifically, under the amendments in ASU
2018-11, (1) entities may elect not to recast the comparative periods presented when transitioning to ASC 842 and (2) lessors may elect
not to separate lease and non-lease components when certain conditions are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740: Simplifying the Accounting for Income Taxes (&ldquo;ASU 2019-12&rdquo;),
which removes certain exceptions to the general principles in Topic 740. ASU 2019-12 is effective for the fiscal years beginning after
December 15, 2020, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&rsquo;s
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the FASB issued ASU 2020-10, &ldquo;Codification Improvements.&rdquo; The new accounting rules improve the consistency
of the Codification by including all disclosure guidance in the appropriate Disclosure Section (Section 50) that had only been included
in the Other Presentation Matters Section (Section 45) of the Codification. Additionally, the new rules also clarify guidance across
various topics including defined benefit plans, foreign currency transactions, and interest expense. The new accounting rules were effective
for the Company in the first quarter of 2021. The adoption of the new accounting rules did not have a material impact on the Company&rsquo;s
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&mdash;Modifications and Extinguishments (Subtopic 470-50),
Compensation&mdash;Stock Compensation (Topic 718), and Derivatives and Hedging&mdash;Contracts in Entity&rsquo;s Own Equity (Subtopic
815-40): Issuer&rsquo;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The
amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&rsquo;s accounting for modifications or
exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification
or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021,
and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As
a result, the Company will not be required to adopt ASU 2021-04 until October 1, 2022. The Company is currently evaluating the impact
of the adoption of this principle on the Company&rsquo;s condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 168; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_112"></A>Critical
Accounting Policies and Significant Judgments and Estimates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s accounting policies are fundamental to understanding its management&rsquo;s discussion and analysis. The Company&rsquo;s
significant accounting policies are presented in Note 3 to its financial statements for the year ended December 31, 2020, which are included
in this proxy statement/prospectus. The Company&rsquo;s financial statements have been prepared in accordance and in conformity with
the accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) and the applicable rules and regulations
of the SEC regarding consolidated financial information. The preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the report amount of assets and liabilities at the date of the financial statements
and expenses during the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on
the financial statements of changes in such estimates in future periods could be significant. Significant areas requiring management&rsquo;s
estimates and assumptions include determining the fair value of transactions involving common stock and the valuation of stock-based
compensation. Actual results could differ from estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_113"></A>Concentration
of Credit Risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts
and management believes the Company is not exposed to significant risks on such accounts. As of December 31, 2020, the Company did not
have greater than $250,000 at any US or Canadian financial institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_114"></A>Foreign
Currency Risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through March 31, 2021, the reporting currency of the Company is the United States dollar while the functional currency of
the Company is the Canadian dollar. As a result, the Company is subject to exposure from changes in the exchange rates of the Canadian
dollar and the U.S. dollar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency fluctuations in
the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_115"></A>Quantitative
and Qualitative Disclosures About Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through March 31, 2021, the reporting currency of the Company is the United States dollar while the functional currency of
the Company is the Canadian dollar. As a result, the Company is subject to exposure from changes in the exchange rates of the Canadian
dollar and the U.S. dollar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 169; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_116"></A>MAGICMED&rsquo;S
BUSINESS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_117"></A>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is a neuro-pharmaceutical drug discovery and development platform. MagicMed has focused on assembling a portfolio of intellectual property
(referred to as the Psybrary<SUP>TM</SUP> described further below) relating to the synthesis, production and manufacturing of novel <FONT STYLE="background-color: white">psychedelic
molecular compounds and derivatives (&ldquo;Psychedelic Derivatives&rdquo;) </FONT>along with processes relating to their synthesis,
production and manufacturing. These Psychedelic Derivatives are intended to be essential building blocks in the development of psychedelic
therapies and medicines for diverse psychological and neuropsychiatric indications. MagicMed considers its business and related activities
to be typical for a biopharma business focused on preclinical drug discovery and development. The goal of preclinical drug discovery
and development is to identify, screen and select new Psychedelic Derivatives that have efficacy characteristics and a safety profile
that would make them promising and acceptable candidates to bring to the clinical (<I>i.e.</I>, human) trials that are required before
any new medicine is accepted by health regulators. Given the expense and time required to bring a drug to market through clinical trials,
qualified new molecular compounds and derivatives with promising efficacy and safety data developed through sophisticated preclinical
development practices can have significant value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Psybrary<SUP>TM</SUP></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
business is centered on the development of the Psybrary<SUP>TM</SUP>, a proprietary physical and knowledgebase collection of novel Psychedelic
Derivative drug candidates, manufacturing methods, pharmacological data, and patent filings that protect the foregoing. Further, MagicMed
has been seeking to employ a diversified partnership model; while MagicMed intends to focus on the development of novel and viable Psychedelic
Derivatives, it does not itself intend to conduct any clinical trials or develop consumer ready psychedelic medicines. Instead, MagicMed
intends to partner with pharmaceutical and other drug development and biotechnology companies in developing and commercializing psychedelic-derived
drugs for diverse psychological and neuropsychiatric indications, of which will be fundamentally composed of the Psychedelic Derivatives
contained in the Psybrary<SUP>TM</SUP>. Pursuant to these partnerships:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
                                            will offer its drug developing partners access to the Psybrary<SUP>TM</SUP> whereby they
                                            will be able to search, select, test and license out the Psychedelic Derivatives of their
                                            choice based on the indication that they are targeting (<I>i.e.</I>, anxiety, depression,
                                            addiction, PTSD and etc.) and use them as building blocks to accelerate and enhance the development
                                            of new psychedelic-derived drugs; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            consideration for access to the Psybrary<SUP>TM</SUP> and the license of MagicMed&rsquo;s
                                            Psychedelic Derivatives, MagicMed&rsquo;s drug developing partners will pay the research,
                                            clinical testing and market authorization costs and provide MagicMed with future milestone
                                            payments as they advance MagicMed&rsquo;s Psychedelic Derivatives through clinical trials
                                            and market authorization processes. Thereafter, if a psychedelic-derived drug reaches commercialization,
                                            MagicMed would receive royalty payments at a rate that will be negotiated between MagicMed
                                            and its partners.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
business model is expected to allow MagicMed to generate revenue at an earlier stage and forego the costs and risk associated with moving
a drug candidate through the clinical testing and market authorization processes itself. MagicMed has initiated conversations with several
biotechnology research and development companies, however at this stage MagicMed does not have any partnerships in place and has not
entered into any definitive agreements to initiate the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, MagicMed has focused on and has completed the development of a portfolio of psilocybin-based Psychedelic Derivatives for its Psybrary<SUP>TM
</SUP>and eventually intends to broaden the composition of the Psybrary<SUP>TM</SUP> with Psychedelic Derivatives based on other psychedelic
molecules such as MDMA, LSD, ibogaine, mescaline, and DMT. The novel Psychedelic Derivatives contained within the Psybrary<SUP>TM</SUP>
are patentable, as are MagicMed&rsquo;s proprietary methods of manufacturing such Psychedelic Derivatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
PsyAI<SUP>TM</SUP></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Collaboration (defined and discussed further under the heading &ldquo;<I>MagicMed&rsquo;s Business &ndash; Description
of the Business &ndash; History</I>,&rdquo;) on March 3, 2021, MagicMed engaged April19 to, among other things, assist in the development
of PsyAI<SUP>TM</SUP>, an artificial intelligence tool intended to provide comprehensive, pharmaceutical design, manufacturing, pharmacology
predictive and validating methodologies in an effort to modernize psychedelic medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 170; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has assembled a team of highly specialized scientists with substantial experience in new drug development. The team has considerable
expertise in preclinical drug development including ideation, native biochemical pathway elucidation, creation of new biosynthetic and
semi-synthetic manufacturing methods, creation of new molecules and derivatives and completion of IND enabling studies. Additionally,
MagicMed&rsquo;s science team includes scientist managers who have overseen new drug development from preclinical phases through to phase
II human clinical trials. MagicMed&rsquo;s in-house expertise combined with an approach that uses large pharmaceutical companies and
drug developers to provide the necessary infrastructure and scalable personnel makes MagicMed ideally suited to develop novel intellectual
property and to evaluate and develop that intellectual property in the preclinical setting. MagicMed intends to both outsource certain
of its preclinical analysis activities and add additional internal preclinical specialists to its team to further strengthen MagicMed&rsquo;s
capabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the breakthrough potential of psychedelic-derived drugs, MagicMed anticipates there will be demand from larger psychedelic drug companies
as well as traditional pharmaceutical businesses to access optimized, patentable next generation Psychedelic Derivatives and as discussed
above MagicMed intends to enter into partnerships and licensing agreements with these types of companies to commercialize its related
preclinical assets. To this end, MagicMed has had preliminary conversations with psychedelic-based companies currently in clinical development
who have validated the need and expressed a very strong interest for novel efficacious and safer next-generation psychedelic medicines
that are patent protected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Preclinical
Drug Discovery and Development</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
drug discovery and development typically encompass a range of activities starting with (i) new molecule ideation and design, (ii) synthesis
of compounds, (iii) testing of the synthesized compounds through &ldquo;in vitro&rdquo; screening in order to assess preliminary efficacy
(i.e. testing that takes place in controlled artificial environments with selected chemical or biological agents), (iv) testing of a
subset of the synthesized compounds through &ldquo;in vivo&rdquo; testing (<I>i.e.</I>, testing in live animals using established models
correlating the effect of a type of drug on animals to desired outcomes in humans), and (v) preparation of an IND summarizing safety
and efficacy findings, which is required in order to seek permission from regulators to proceed to clinical trials. Rational drug design
is now a common method used by the pharmaceutical industry to identify potential compounds to take forward for further development. Generally,
the rational development of a new drug follows a three-step process. Initially, a target, such as a receptor or enzyme, has to be identified
relating to a particular disease state. This target then has to be fully characterized and, finally, a molecule must be designed that
binds to it. With respect to psychedelics, it is generally agreed upon that the biological target is the 5-HT2A receptor. This is a subtype
of the 5-HT2 receptor that belongs to the serotonin receptor family. It is a well understood scientific concept, which substantially
de-risks the drug development process for MagicMed compared to traditional drug discovery processes. MagicMed is applying these typical
drug preclinical development steps to &ldquo;classic&rdquo; psychedelic drugs (described further below) in order to develop new Psychedelic
Derivatives for complex physiological and neuropsychiatric indications that have high prevalence rates and unmet treatment needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
July 9, 2020, MagicMed has filed 13 provisional patent applications with the United States Patent and Trademark Office relating to
the composition of matter, drug formulation and process of preparation claims for novel psilocybin and DMT Psychedelic Derivatives.
For more information on the patent applications filed to date, see information under the heading &ldquo;Intangible Properties&rdquo;
below. Additionally, as of the date hereof, MagicMed has established a portfolio of psilocybin-based Psychedelic Derivatives
included in the Psybrary<SUP>TM</SUP>. This portfolio, which also captures DMT-based Psychedelic Derivatives, now includes the 13
filed patent applications directed to nine different chemical compound categories covering over 125 million individual molecules.
Further, MagicMed has launched its candidate selection program which is a program that allows MagicMed to narrow down the best drug
candidates out of its portfolio of newly developed Psychedelic Derivatives based on the characteristics of the molecules through
both &ldquo;in vitro&rdquo; screening (i.e. testing that takes place in controlled artificial environments with selected chemical or
biological agents) and &ldquo;in vivo&rdquo; testing (i.e. testing in live animals using established models correlating the effect
of a type of drug on animals to desired outcomes in humans), in each case to assess preliminary efficacy (the &ldquo;Candidate
Selection Program&rdquo;). The determination of which Psychedelic Derivatives are the best drug candidates is also anticipated to
depend on the targeted indication. Certain molecules that are effective for one indication may not necessarily be so for a different
indication. As MagicMed intends to work with several different types of drug developing companies, targeting different indications,
it intends to provide a broad selection of viable Psychedelic Derivatives from which these companies can chose from. Lastly, as of
the date hereof, MagicMed has synthesized approximately 200 distinct psilocybin-based Psychedelic Derivatives in its research and
development facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 171; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Contracts</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a summary of the two arms-length material contracts that MagicMed has entered into as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2020, MagicMed entered into a research contract, as amended on January 7, 2021 (the &ldquo;Calgary Research Contract&rdquo;)
with the Governors of the University of Calgary (&ldquo;UofC&rdquo;). On November 1, 2020 MagicMed entered into a facilities use agreement
(the &ldquo;Calgary Facilities Use Agreement&rdquo; and collectively with the Calgary Research Agreement, the &ldquo;Calgary Agreements&rdquo;)
with, among others, UofC. As described further below, pursuant to the Calgary Agreements, UofC has agreed to provide MagicMed with scientific
and laboratory support to accelerate development of the Psybrary<SUP>TM</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Calgary Facilities Use Agreement, UofC has granted MagicMed permission to use UofC&rsquo;s lab for the purpose of developing biosynthetic
methods for novel, patentable drugs of the tryptamine, phenethylamine, psychedelic, hallucinogenic and dissociative anesthetic classes
(the &ldquo;Project&rdquo;). The Calgary Facilities Use Agreement expires on October 31, 2021 unless otherwise extended or terminated
earlier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Calgary Research Contract, UofC has agreed to perform the Project in accordance with a workplan and Budget, as set out therein.
The Calgary Research Contract expires on August 17, 2022, unless otherwise amended or terminated earlier. In consideration for undertaking
and completing the Project, MagicMed agreed to pay the UofC the sum of $467,312 (the &ldquo;Budget&rdquo;) in accordance with the payment
schedule set out in the Calgary Research Contract. Two payments of $33,938.00, one payment of $33,937.00 and one payment
of $40,031.25 have been paid under the Calgary Research Contract, with $325,468.25 due in the next 13 months. All research
results flowing from the Project are owned by MagicMed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Classic
Psychedelic Drugs </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psychedelic
drugs are psychoactive drugs which can cause in their users altered states of consciousness, along with auditory and visual hallucinations.
Classic psychedelic drugs include LSD, &ldquo;magic mushrooms&rdquo; or their active constituents such as psilocybin and psilocin, DMT,
and MDMA, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classic
psychedelics have been well described in literature of the past several decades and as a result, obtaining intellectual property rights
over the classic psychedelics is challenging. It is not possible to receive a &ldquo;composition of matter&rdquo; patent, which would
protect any use of the molecules. While it is possible to patent specific formulations of these drugs, the relative protection provided
by this strategy is far less meaningful than a composition of matter patent. MagicMed believes that this presents a significant opportunity
to create novel and viable Psychedelic Derivatives, which are patentable, as are MagicMed&rsquo;s proprietary methods of manufacturing
such Psychedelic Derivatives. While there may be a modest role for classic psychedelics in the treatment of psychological indications,
and a commensurate modest ability to attract the type of investment required to complete the clinical development process, MagicMed believes
that there is a greater treatment potential and patient applicability with derivatives that have been improved for safety and efficacy.
MagicMed believes that this potential of larger and more effective market penetration will provide a greater economic incentive for pharmaceutical
companies to provide the required investment to complete the clinical development process. MagicMed believes that designing Psychedelic
Derivatives, which improve upon the pharmacological and therapeutic efficacy of the classic psychedelics described herein presents a
significant potential market opportunity given the following factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            substantial number of patients suffering from psychiatric and neurological conditions that
                                            are not well-treated by or are refractory to currently approved pharmaceuticals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            growing evidence and research in support of the therapeutic benefit of psychedelics and the
                                            increased willingness of regulators to consider psychedelic drugs as a valid treatment option
                                            for neuropsychiatric disorders;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 172; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            under-explored potential to optimize &ldquo;classic&rdquo; psychedelic drugs by creating
                                            more stable and predictable pharmaceutical drugs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential value in creating new psychedelic molecular derivatives that will enjoy patent
                                            protection; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ongoing clinical evidence currently establishing the utility and clinical processes for psychedelic-
                                            assisted therapies reduces the risk associated with the drug development pathway being undertaken
                                            by MagicMed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Production</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
does not currently market or distribute any products and will formulate product information and distribution plans as and when MagicMed
is at the stage of commercializing the contents of the Psybrary<SUP>TM</SUP>. Nonetheless, MagicMed&rsquo;s Chief Scientific Officer,
Dr. Peter Facchini, has been issued a license by Health Canada, pursuant to the provisions of the CDSA, which authorizes the possession
and production of certain controlled substances, including psilocybin, psilocin and DMT, and which expires on December 31, 2021 (the
&ldquo;Facchini Drug License&rdquo;). As discussed under the heading &ldquo;<I>Description of the Business &ndash; Business of MagicMed
&ndash; Research and Development</I>,&rdquo; MagicMed intends to complete a number of preclinical studies involving the use of different
psychedelic molecules; during the completion of the &ldquo;in vitro&rdquo; portion of these preclinical studies when only lab-grade and
lab-scale psychedelic molecules are required, MagicMed intends to manufacture the required psychedelic molecules at UofC pursuant to
the Calgary Agreements and under the authority of the Facchini Drug License. For more information on the Calgary Agreements, see &ldquo;<I>Description
of the Business &ndash; Business of MagicMed &ndash; Contracts.</I>&rdquo; However, when larger quantities and higher quality
psychedelic molecules are required (<I>i.e.</I>, for animal model testing and etc.), MagicMed intends to contract with appropriate third
party CMOs service providers as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivatives
of certain psychedelic compounds like psilocin, psilocybin and DMT are not currently scheduled under the CDSA and are not captured by
the Facchini Drug License. As such, MagicMed intends to work with the Canadian Office of Controlled Substances to determined how to address
regulatory considerations for these derivatives for which there are currently no regulatory provisions. Additionally, MagicMed has made
Health Canada aware of its plans to develop derivatives of these and other psychedelic compounds and of its intention to work with the
Canadian Office of Controlled Substances to determined how to address regulatory considerations. In the event Health Canada determines
that MagicMed&rsquo;s Psychedelic Derivatives are controlled substances and therefore, require regulatory approval, (a) MagicMed&rsquo;s
licensees will be required to obtain such approval; and (b) to the extent that MagicMed produces Psychedelic Derivatives, it will require
similar regulatory approval. Such additional regulatory requirements may increase MagicMed&rsquo;s costs and cause a delay in MagicMed&rsquo;s
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Specialized
Skills and Knowledge</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
aspects of MagicMed&rsquo;s business require specialized skills and knowledge. Such skills and knowledge include, but are not limited
to, expertise related to the discovery and development of patentable drug candidates, discovery and deployment into manufacturing systems
of genetic elements that confer beneficial activities (such as catalytic enzymes, transporter, sequestration activities) to biosynthetic
or semi-synthetic processes, quality assurance, laboratory synthesis and preclinical testing. MagicMed expects to rely upon various legal
and financial advisors, scientific and clinical consultants and others in the operation and management of its business. See &ldquo;<I>Risk
Factors &ndash; Risks Related to the Business &ndash; Dependence on Management and Key Personnel.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competitive
Conditions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several other companies pursuing the research and development of psychedelic-derived drugs for the purposes of treating physiological
and neuropsychiatric indications. Some notable entities in the psychedelic-drug and biotechnology market include: (i) Mindset Pharma
Inc., a neuro-pharmaceutical drug discovery and development platform MagicMed; (ii) Mind Medicine Inc., a public MagicMed exploring the
use of Ibogaine and microdoses of LSD in the treatment of substance use and psychological disorders; (iii) Compass Pathways Limited,
a public mental health care MagicMed pursuing the development of a psilocybin-based drug via the clinical trial pathway. MagicMed received
&ldquo;Breakthrough Therapy&rdquo; designation from the FDA in 2018 and is presently conducting randomized controlled phase 2 studies
of psilocybin therapy, testing safety and efficacy of psilocybin in participants with treatment resistant depression; (iv) Field Trip
Health Inc., a MagicMed focused on offering technology-enabled ketamine enhanced psychotherapy, psychedelic enhanced psychotherapy and
psychedelic-integration psychotherapy in clinical settings; (v) Eleusis Ltd., a private clinical stage life science MagicMed that is
dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists through the mitigation and management of psychoactivity;
and (vi) Gilgamesh Pharmaceuticals Inc., a mental health science preclinical biotechnology MagicMed focused on developing ketamine-based
new chemical entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 173; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distinct
from MagicMed, to MagicMed&rsquo;s knowledge, these entities are either focused on: (i) the clinical trial pathway and/or providing fully
developed psychedelic-derived end products to consumers; (ii) directing their attention on other psychedelic molecules that MagicMed
is not focused on; and/or (iii) developing psychedelic-derived solutions for specific psychological indications. As discussed under the
heading &ldquo;<I>Description of the Business</I>&rdquo; contrastingly, MagicMed seeks to provide a portfolio of Psychedelic Derivatives
from which companies like those described above can chose from in developing their psychedelic-derived consumer products. Additionally,
MagicMed does not intend to conduct any clinical trials itself, but rather, MagicMed intends to: (i) partner with other drug development
companies to carry the costs and risks associated with clinical trials; and (ii) set up milestone based revenue arrangements such that
it starts earning revenue prior to a fully developed product being ready for sale to consumers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Components</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
makes its novel Psychedelic Derivatives in the lab at a small scale, the ingredients of which are sourced from scientific research ingredient
suppliers such as Toronto Research Chemicals Inc. and MilliporeSigma. Occasionally when certain plants and other more complex materials
are required to isolate novel molecular sequences, MagicMed intends to grow them at UofC pursuant to the Calgary Agreements and under
the Facchini Drug License. For more information on the Calgary Agreements, see &ldquo;<I>Description of the Business &ndash; Business
of MagicMed &ndash; Contracts.</I>&rdquo; For more information on the Facchini Drug License see &ldquo;<I>Description of the Business
&ndash; Business of MagicMed &ndash; Production</I>.&rdquo; When MagicMed moves to larger scale production, MagicMed intends to rely
on CMOs who similarly source their raw materials from scientific ingredient supply houses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intangible
Properties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
July 9, 2020, MagicMed has filed 13 provisional patent applications with the United States Patent and Trademark Office relating to
the composition of matter, drug formulation and process of preparation claims for novel psilocybin and DMT derivatives. These patent
filings are anticipated to be the first in a series of applications that together will protect MagicMed&rsquo;s broad portfolio of
novel psilocybin, DMT, MDMA, mescaline and LSD Psychedelic Derivatives in the Psybrary<SUP>TM</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on January 18, 2021 and January 19, 2021, MagicMed filed applications for registered trademark protection in Canada and the United
States, respectively, for MagicMed&rsquo;s logo and for the following words: (i) MagicMed; (ii) MagicMed Industries; (iii) PSYBRARY;
and (iv) MAGIC MOMENTS. Further MagicMed has purchased the domain name &ldquo;ThePsybrary.com.&rdquo; On February 3, 2021 and February
4, 2021, MagicMed filed applications for registered trademark protection in Canada and the United States, respectively, for the
word mark &ldquo;PsyAI.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cycles</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
MagicMed does not believe that its business is cyclical or seasonal in nature, it expects to experience some variation in operating results
from quarter to quarter. MagicMed believes that the factors which influence this variability of quarterly results include general economic,
political and industry conditions that affect current news on psychedelic-based medicinal therapies, the timing of MagicMed&rsquo;s introduction
of new patents, the level of acceptance of psychedelic-based therapies by medical professionals, the seasonality of the markets in which
MagicMed participates and the actions of competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Economic
Dependence</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
business is substantially dependent on the Calgary Agreements as these agreements enable MagicMed to develop Psychedelic Derivatives
in compliance with current legislation. The loss of both of the Calgary Agreements (<I>i.e.</I>, not just one or the other) could substantially
hinder MagicMed&rsquo;s ability to develop Psychedelic Derivatives until MagicMed obtains the requisite Dealer&rsquo;s License or Section
56 Exemption on its own. MagicMed has not yet applied for its own Dealer&rsquo;s License or Section 56 Exemption, as it has not yet invested
in building its own substantial lab facility sufficient to meet the requirements for licensure or to obtain the Section 56 Exemption.
See &ldquo;<I>Description of the Business &ndash; Business of MagicMed &ndash; Regulatory Environment</I>&rdquo; for more information
on the Dealer&rsquo;s License and Section 56 Exemption required to undertake preclinical studies. For more information on the Calgary
Agreements, see &ldquo;<I>Description of the Business &ndash; Business of MagicMed &ndash; Contracts.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 174; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
to Contracts</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
may increase the scope of the Calgary Agreements to allow MagicMed greater capabilities to synthesize Psychedelic Derivatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Personnel</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date hereof, MagicMed has 14 employees and 4 consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
Operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is not dependent upon foreign operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulatory
Environment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a discussion of the current legal framework and applicable legislation relating to psychedelic drugs and MagicMed&rsquo;s
operations in Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Drug
Scheduling Regulations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            psychoactive compounds, such as psilocybin, LSD (lysergic acid diethylamide), DMT (N,N&ndash;Dimethyltryptamine)
                                            and mescaline, are considered controlled substances under the CDSA (Canada Controlled Drugs
                                            and Substances Act). Specifically, psilocybin, LSD, mescaline and DMT any salts thereof,
                                            are listed under Schedule III of the CDSA and MDMA and ketamine are Schedule I controlled
                                            substance. The possession, sale or distribution of controlled substances is prohibited unless
                                            specifically permitted by the Government of Canada. Penalties for contravention of the CDSA
                                            related to Schedule I substances are the most punitive, with Schedule II being less punitive
                                            than Schedule I, Schedule III being less punitive than Schedule I and II and so forth. A
                                            party may seek government approval for a Section 56 Exemption to allow for the possession,
                                            transport or production of a controlled substance for medical or scientific purposes, as
                                            discussed in further detail below under the heading &ldquo;<I>Regulatory Approvals Required
                                            for Studies &ndash; Canada</I>.&rdquo; Health Canada regulates all health products in Canada,
                                            and a health product may only be sold in Canada with the permission of Health Canada. During
                                            its evaluation of the safety, efficacy and quality of each health product, Health Canada
                                            determines whether a drug should be a controlled substance, a prescription drug or a non-prescription
                                            drug. A substance may be deemed a controlled substance but also a prescription drug. As discussed
                                            above, scheduling the substance in the CDSA means that there are criminal consequences to
                                            possessing the drug unlawfully. If Health Canada determines that a drug requires a prescription,
                                            it is placed on the Health Canada Prescription Drug List (&ldquo;PDL&rdquo;). Neither psilocybin,
                                            mescaline, LSD nor DMT are currently on the PDL. After Health Canada determines if a drug
                                            may be sold in Canada and if it requires a prescription, the individual provinces, territories
                                            and the National Association of Pharmaceutical Regulatory Authorities (&ldquo;NAPRA&rdquo;)
                                            decide where it may be sold, under advisement from the National Drug Scheduling Advisory
                                            Committee (&ldquo;NDSAC&rdquo;). NAPRA maintains a harmonized list referred to as the National
                                            Drug Schedules. NAPRA may decide to be more restrictive in scheduling drugs, but never less
                                            restrictive than has already been determined at the federal level.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Regulatory
Approvals Required for Studies</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
approvals are required for clinical (human) studies for all investigational products in all member countries of the International Council
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, which includes Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CDSA
                                            &ndash; In order to conduct any scientific research, including preclinical (animal) and clinical
                                            (human) trials using a controlled substance (such as psilocybin, LSD, mescaline, or DMT)
                                            in Canada, a Section 56 Exemption under the CDSA is required. This exemption allows the holder
                                            to possess and use the controlled substance without being subject to the restrictions set
                                            out in the CDSA, subject to obtaining any additional approvals such as ethics and clinical
                                            trial approvals. Specifically, the final approved clinical study protocol and a Health Canada
                                            issued No Objection Letter are required to obtain an exemption under subsection 56(1) of
                                            the CDSA to conduct clinical investigations with psilocybin, LSD, mescaline, and DMT in Canada.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 175; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada
                                            FDR &ndash; Products that contain a controlled substance such as psilocybin, LSD, mescaline
                                            and DMT cannot be made, transported or sold without proper authorization from the government.
                                            A party can apply for a Dealer&rsquo;s License under Part J of the Canada Food and Drug Regulations
                                            (&ldquo;Canada FDR&rdquo;), which allows the party to produce, assemble, sell, provide, transport,
                                            send, deliver, import or export a restricted drug (as listed in Part J in the Canada FDR&ndash;
                                            which includes psilocybin, LSD, mescaline and DMT), assuming compliance with all relevant
                                            laws (the CDSA and Canada) and subject to any restrictions placed on the license by Health
                                            Canada. In order to qualify as a licensed dealer, a party must meet all regulatory requirements
                                            mandated by the regulations including having compliant facilities, compliant materials and
                                            staff that meet the qualifications under the regulations of a senior person in charge and
                                            a qualified person in charge.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivatives
of certain psychedelic compounds like psilocin, psilocybin and DMT are not currently scheduled under the CDSA. Nonetheless, as discussed
under the heading &ldquo;<I>Description of the Business &ndash; Business of MagicMed &ndash; Production</I>,&rdquo; Health Canada is
aware of MagicMed&rsquo;s plans to: (i) develop derivatives of these and other psychedelic compounds; and (ii) work with the Canadian
Office of Controlled Substances to determined how to address regulatory considerations for these derivatives for which there are currently
no regulatory provisions. In the event Health Canada determines that MagicMed&rsquo;s Psychedelic Derivatives are controlled substances
and therefore, require regulatory approval, (a) MagicMed&rsquo;s licensees will be required to obtain such approval; and (b) to the extent
that MagicMed produces Psychedelic Derivatives, it will require similar regulatory approval. Such additional regulatory requirements
may increase MagicMed&rsquo;s costs and cause a delay in MagicMed&rsquo;s operations. Subject to the foregoing, MagicMed currently relies
on the Facchini Drug License and the Dealer&rsquo;s License held by UofC to conduct the research work related to its Psychedelic Derivatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Studies and Market Authorization Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
aims to partner with pharmaceutical and drug development companies in the development and commercialization of psychedelic drugs for
several psychological and neuropsychiatric indications. MagicMed does not intend to complete any clinical testing itself, but rather
provide the Psychedelic Derivatives and other assistance to its drug developing partners who will move viable drug candidates (made from
MagicMed&rsquo;s Psychedelic Derivatives) through the clinical testing and market authorization processes. As a result, MagicMed does
not expect it will need to obtain the requisite licenses and approvals or incur the costs associated of clinical testing and market authorization.
Nonetheless set forth below is a description of the regulatory regimes in Canada that MagicMed&rsquo;s drug developing partners will
be subject to as they move through both: (i) the clinical study regulatory processes; and the (ii) market authorization regulatory process,
in each case in respect of the development of psychedelic therapies and medicines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Health
Canada Clinical Study Regulatory Process</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Canada, a Clinical Trial Application (&ldquo;CTA&rdquo;) is composed of three modules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Module
                                            1 contains administrative and clinical information about the proposed trial, and includes
                                            an investigator&rsquo;s brochure, which details all safety, preclinical and clinical data
                                            for the drug under study. Other components of Module 1 are the clinical study synopsis and
                                            full protocol, informed consent documents, clinical trial site information, and letters of
                                            access;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Module
                                            2 contains common technical document summaries, including Chemistry, Manufacturing and Control
                                            (&ldquo;CMC&rdquo;) information about the drug product(s) to be used in the proposed trial;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Module
                                            3 contains additional supporting quality information including literature references.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 176; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
modules are organized and numbered consistently in an internationally adopted format, the Common Technical Document (&ldquo;CTD&rdquo;).
Adhering to the CTD format facilitates evaluation by Health Canada and ensures consistency of documents in subsequent stages of the drug
authorization process. Additional documents including a Clinical Trial Site Initiation Form, Qualified Investigator Undertaking and a
Research Ethics MagicMed Board Attestation must be completed for each clinical trial site. Once prepared, the CTA is sent to the Therapeutic
Products Directorate at the Health Product and Food Branch (&ldquo;HPFB&rdquo;) of Health Canada for review. The review process is 30
days, although during the current COVID-19 pandemic environment, Health Canada is able to extend review timelines for non COVID-19 related
studies to 45 days. Health Canada invites sponsors to request a pre-CTA consultation meeting. Such consultations may be particularly
useful for new active substances or applications that will include complex issues that may be new to Health Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Market
Authorization Regulatory Process </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HPFB is the national authority that regulates, evaluates and monitors the safety, efficacy, and quality of therapeutic and diagnostic
products available to Canadians. When a manufacturer decides that it would like to market a drug in Canada, MagicMed must first file
a &ldquo;New Drug Submission&rdquo; (&ldquo;NDS&rdquo;) with one of the Directorates (e.g. Therapeutic Products Directorate) within the
HPFB. The NDS contains information and data about the drug&rsquo;s safety, effectiveness and quality. It includes the results of the
preclinical and clinical studies, whether done in Canada or elsewhere, details regarding the production of the drug, packaging and labeling
details, and information regarding therapeutic claims and side effects. The HPFB performs a thorough review of the submitted information,
sometimes using external consultants and advisory committees. HPFB evaluates the safety, efficacy and quality data to assess the potential
benefits and risks of the drug. HPFB reviews the labeling information that the sponsor proposes to provide to health care practitioners
and consumers about the drug (e.g. the drug label, product monograph, patient brochure). If, at the completion of the review, the conclusion
is that the benefits outweigh the risks and that the risks can be mitigated, the drug is issued a Notice of Compliance, as well as a
Drug Identification Number which permits the sponsor to market the drug in Canada and indicates the drug&rsquo;s official approval in
Canada. In addition, Health Canada laboratories may test certain biological products before and after authorization to sell in Canada
has been issued. This is done through its Lot Release Process, in order to monitor safety, efficacy and quality. This process is predominantly
utilized for biologic products seeking a marketing license. Once a drug is on the market, regulatory controls continue. The manufacturer
(license holder) and distributors of the drug must report any new information received concerning serious side effects including failure
of the drug to produce the desired effect. The manufacturer (license holder) must also notify HPFB about any studies that have provided
new safety information and request approval for any major changes to the manufacturing processes, dose regime or recommended uses for
the drug. HPFB conducts market surveillance, monitors adverse reaction reports, investigates complaints and problem reports, and manages
recalls, should the necessity arise. In addition, HPFB licenses most drug production sites and conducts regular inspections as a condition
for licensing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restructuring
Transactions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
MagicMed nor any of its Subsidiaries has completed any material restructuring transaction since its incorporation nor are any such transactions
proposed for the current financial year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bankruptcy
and Similar Procedures</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
does not and has not had any bankruptcy (whether voluntary or otherwise), receivership or other similar proceedings instituted by it
or against it since its incorporation nor are any such proceedings being contemplated or threatened in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_118"></A>History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
was incorporated under the BCBCA on May 26, 2020. MagicMed has not generated any revenue since incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2020, MagicMed completed a private placement offering pursuant to which it sold 8,000,000 units of MagicMed (the &ldquo;Primary
Founder Units&rdquo;) at a price of $0.005 per Primary Founder Unit for gross proceeds of $40,000. Each Primary Founder Unit is comprised
of one MagicMed Share and one MagicMed Warrant with each MagicMed Warrant being exercisable at a price of $0.25 until May 26, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 26, 2020 MagicMed completed a private placement offering pursuant to which MagicMed sold 5,690,000 units of MagicMed (the &ldquo;Secondary
Founder Units&rdquo;) at a price of $0.10 per Secondary Founder Unit for gross proceeds of $569,000. Each Secondary Founder Unit is comprised
of one MagicMed Share and one MagicMed Warrant with each MagicMed Warrant being exercisable at a price of $0.25 until May 26, 2025. 640,000
of the Secondary Founder Units for total gross proceeds of $64,000 under this offering were received in July 2020 and were thus, not
reflected in the audited financials of MagicMed from the period from incorporation on May 26, 2020 to June 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 177; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
July 9, 2020, MagicMed has filed 13 provisional patent applications with the United States Patent and Trademark Office relating to
the composition of matter, drug formulation and process of preparation claims for novel psilocybin and DMT Psychedelic Derivatives.
These patent filings are the first in a series of applications that together will protect MagicMed&rsquo;s broad portfolio of novel
Psychedelic Derivatives contained in the Psybrary<SUP>TM</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 14, 2020, August 31, 2020 and September 3, 2020, MagicMed completed three tranches of a brokered private placement (the &ldquo;August
Offering&rdquo;) for gross proceeds of $1,652,880. Pursuant to the August Offering, MagicMed issued 6,611,520 MagicMed Shares at a price
of $0.25 per MagicMed Share. Mackie Research Capital Corporation (&ldquo;Mackie&rdquo;) acted as agent in connection with the August
Offering and was paid a cash commission equal to 8.0% of the aggregate gross proceeds of the August Offering raised from eligible purchasers
in addition to a work fee and cash for certain expenses incurred by Mackie.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2020, MagicMed entered into the Calgary Research Contract with UofC in connection with the Project (developing biosynthetic
methods for novel, patentable drugs of the tryptamine, phenethylamine, psychedelic, hallucinogenic and dissociative anesthetic classes,
all of which will be incorporated in the Psybrary<SUP>TM</SUP>). On January 7, 2021, the Calgary Research Contract was amended to provide
for additional financial support from MagicMed to UofC for the purposes of hiring additional personnel and covering the cost of additional
supplies in connection with the Project. See &ldquo;<I>Description of the Business &ndash; Business of MagicMed &ndash; Contracts</I>&rdquo;
for further details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 5, 2020, MagicMed entered into a financial services advisory agreement (the &ldquo;Financial Advisory Agreement&rdquo;). MagicMed
pays a monthly fee of $15,000 for a strategic advisor to assist MagicMed in assessing future business opportunities and developing a
capital markets strategy. There were also 679,830 stock MagicMed Options granted pursuant to the Financial Advisory Agreement exercisable
at $0.25 per option. Such MagicMed Options carry an escrow release of 10% upon signing of the Financial Advisory Agreement and 15% every
six months over the 36-month term of the Financial Advisory Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2020 MagicMed entered into the Calgary Facilities Use Agreement with UofC. Pursuant to the Calgary Facilities Use Agreement
(and the Calgary Research Contract), UofC has agreed to provide MagicMed with scientific and laboratory support to accelerate the development
of the Psybrary<SUP>TM</SUP>. See &ldquo;<I>Description of the Business &ndash; Business of MagicMed &ndash; Contracts</I>&rdquo; for
further details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 17, 2020 and December 23, 2020, MagicMed completed two tranches of a brokered and non-brokered private placement offering (the
&ldquo;December Offering&rdquo;) of units of MagicMed (the &ldquo;Units&rdquo;) for aggregate gross proceeds of $8,141,883, pursuant
to which MagicMed issued an aggregate of 16,283,766 Units at a price of $0.50 per Unit. Each Unit is comprised of one MagicMed Share
and one-half of one MagicMed Warrant. Each MagicMed Warrant entitles the holder thereof to purchase one additional MagicMed Share, at
an exercise price of $0.75 for a period of two (2) years from the date of a Liquidity Event. Gravitas acted as lead agent and sole bookrunner
in respect of the brokered December Offering and financial advisor in respect of the non-brokered December Offering. Gravitas received
a cash commission equal to 8.0% of the gross proceeds from the sale of Units pursuant to the December Offering. In addition to the commission,
MagicMed issued to Gravitas: (i) MagicMed Broker Warrants equal to 8.0% of the aggregate number of Units sold under the December Offering,
with each MagicMed Broker Warrant exercisable at $0.50 for a period of two years from the date of a Liquidity Event to acquire one Unit;
and (ii) a corporate finance fee paid in 814,187 Units, being equal to 5% of the aggregate number of Units sold under the December Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2020, MagicMed established the portfolio of psilocybin-based Psychedelic Derivatives included in the PsybraryTM and launched
the Candidate Selection Program. For more information on the Candidate Selection Program, see &ldquo;<I>Description of the Business &ndash;
Research and Development &ndash; Preclinical Drug Discovery and Development</I>.&rdquo; Additionally, as of December 22, 2020, MagicMed
has synthesized more than 200 distinct psilocybin-based Psychedelic Derivatives in its research and development facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 178; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 3, 2021, MagicMed entered into the April19 Services Agreement and the Cognistic Services Agreement, each as defined below, for
the purposes of developing PsyAI<SUP>TM</SUP>, an artificial intelligence tool intended to provide comprehensive, pharmaceutical design,
manufacturing, pharmacology predictive and validating methodologies in an effort to modernize psychedelic medicine (the &ldquo;Collaboration&rdquo;).
In connection with the Collaboration, on March 3, 2021 MagicMed entered into:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            services agreement with April19 (the &ldquo;April19 Services Agreement&rdquo;), pursuant
                                            to which MagicMed has engaged April19 to, among other things: (i) support and assist MagicMed
                                            in the recruitment and hiring of two or more personnel with experience in the development
                                            of machine learning algorithms; and (ii) train such personnel using April19&rsquo;s experience
                                            and knowledge to deliver a work program related to the development of the PsyAI<SUP>TM</SUP>.
                                            In consideration for the services provided by April19, MagicMed has agreed to pay a fee of
                                            USD$50,000 per calendar month; additionally, MagicMed is subject to a 36-month non-solicitation
                                            restriction pursuant to which MagicMed may not directly or indirectly, solicit or attempt
                                            to solicit any of April19&rsquo;s employees or consultants. Dr. Suran Goonatilake, Visiting
                                            Professor of UCL Centre for Artificial Intelligence, is a co-founder of April19 and will
                                            be primarily responsible for performing the services under the April19 Services Agreement;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            services agreement with Cognisitic (the &ldquo;Cognistic Services Agreement&rdquo; and together
                                            with the April19 Services Agreement, the &ldquo;PsyAI<SUP>TM</SUP> Services Agreements&rdquo;),
                                            pursuant to which MagicMed has engaged Cognisitic to perform certain services relating to
                                            the development of the PsyAI<SUP>TM</SUP>. In consideration for the services provided by
                                            Cognistic, MagicMed has agreed to pay a fee of USD$50,000 per calendar month. Dr. Eric Nyberg,
                                            Chief Data Scientist of Cognisitic and Professor at Carnegie Mellon University will be primarily
                                            responsible for performing the services under the Cognistic Services Agreement; Dr. Eric
                                            Nyberg was a member of the original IBM Watson development team and also developed scalable
                                            architecture for multi-strategy question-answering systems.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
intellectual property developed under the PsyAI<SUP>TM</SUP> Services Agreements will be owned exclusively by MagicMed. The initial term
of each of the PsyAI<SUP>TM</SUP> Services Agreements is one year, after which MagicMed may extend the term, subject to a renegotiation
by the parties of a revised scope of services and rates for such additional term. Additionally, MagicMed may terminate the PsyAI<SUP>TM
</SUP>Services Agreements at any time by providing 90 days&rsquo; prior written notice. The PsyAI<SUP>TM</SUP> Services Agreements contain
standard confidentiality provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, MagicMed entered into the Amalgamation Agreement, providing for the Amalgamation as further described in the accompanying
Information Circular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expected
Changes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
strategies and business objectives may be impacted by changes in the global economy, changes in legislation, changes in the psychedelic
therapeutic industry, unanticipated costs and adverse novel discoveries regarding the psychedelic compounds/molecules that MagicMed intends
to use in its operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
also is keeping apprised of the latest developments and is currently in the process of evaluating the ongoing impact of COVID-19 on its
business, including, but not limited to, the impact on MagicMed&rsquo;s operations, personnel and financial condition, the impact on
the operations, personnel and financial condition of the research partners and suppliers of MagicMed, and MagicMed&rsquo;s eligibility
to receive benefits made available through announced government relief programs. In addition, due to the potential impact of COVID-19
on the overall economic environment, there is a risk that MagicMed may require further financial support to fund its operations in the
future should COVID-19 impact its profitability and/or cash flows. At this time, management is unable to quantify the potential financial
impact associated with this event. See &ldquo;<I>Available Funds &ndash; Impact of COVID-19</I>&rdquo; and &ldquo;<I>Risk Factors &ndash;
Impact of COVID-19.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
Health Canada has not yet determined whether MagicMed&rsquo;s Psychedelic Derivatives will be scheduled as controlled substances. In
the event Health Canada determines that these products are controlled substances and therefore, require regulatory approval, (a) MagicMed&rsquo;s
licensees will be required to obtain such approval; and (b) to the extent that MagicMed produces Psychedelic Derivatives, it will require
similar regulatory approval. Such additional regulatory requirements may increase MagicMed&rsquo;s costs and cause a delay in MagicMed&rsquo;s
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 179; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="o_119"></A>MagicMed&rsquo;S
Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following is management&rsquo;s discussion and analysis of MagicMed&rsquo;s financial condition and results of operations
(&ldquo;MD&amp;A&rdquo;) for the period from May 26, 2020 (date of incorporation) to March 31, 2021. This MD&amp;A should be read in
conjunction with MagicMed&rsquo;s audited financial statements as at and for the period from May 26, 2020 (date of incorporation) to
June 30, 2020, and MagicMed&rsquo;s unaudited financial statements for the period from July 1, 2020 to March 31, 2021, in each case
including the notes thereto, all of which have been prepared in accordance with IFRS and are included elsewhere in this proxy
statement/prospectus. All amounts are expressed in Canadian dollars, unless otherwise identified. This MD&amp;A is presented as of
the date of this proxy statement/prospectus and is current to that date unless otherwise stated.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
MD&amp;A contains forward-looking information. Forward-looking information is necessarily based on a number of opinions, estimates and
assumptions that MagicMed considered appropriate and reasonable as of the date such statements are made, and are subject to known and
unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements
to be materially different from those expressed or implied by such forward-looking information, including but not limited to the risk
factors described under &ldquo;Risk Factors.&rdquo; There can be no assurance that such forward-looking information will prove
to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly,
prospective investors should not place undue reliance on forward-looking information, which speaks only as of the date made. See &ldquo;Cautionary
Statement Regarding Forward-Looking Statements&rdquo; on page 86 of this document.</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_120"></A>Overview
of MagicMed</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a neuro-pharmaceutical drug discovery and development platform company <FONT STYLE="background-color: white">focused on </FONT>assembling
a portfolio of intellectual property referred to as the Psybrary<SUP>TM</SUP> relating to the synthesis, production and manufacturing
of <FONT STYLE="background-color: white">Psychedelic Derivatives </FONT>along with processes relating to their synthesis, production
and manufacturing. These <FONT STYLE="background-color: white">Psychedelic Derivatives are intended to be essential building blocks in
the development of psychedelic therapies and medicines for diverse psychological and </FONT>neuropsychiatric <FONT STYLE="background-color: white">indications.
MagicMed considers its business and related activities to be typical for a biopharma business focused on preclinical drug discovery and
development. The goal of preclinical drug discovery and development is to identify, screen and select new molecular compounds and derivatives
that have efficacy characteristics and a safety profile that would make them promising and acceptable candidates to bring to the clinical
(<I>i.e.</I> human) trials that are required before any new medicine is accepted by health regulators. Given the expense and time required
to bring a drug to market through clinical trials, qualified new molecular compounds and derivatives with promising efficacy and safety
data developed through sophisticated preclinical development practices can have significant value. </FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_121"></A>Overall
Performance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
incorporation in 2020, MagicMed has been focused on establishing its research capabilities, laying the foundation for its intellectual
property patent applications and developing its Psybrary<SUP>TM</SUP>. MagicMed had a net and comprehensive loss of $42,476 for the period
from incorporation on May 26, 2020 to June 30, 2020 and a net loss of $2,379,369 and comprehensive loss of $2,381,683 for the period
from July 1, 2020 to March 31, 2021. MagicMed has, since incorporation, accumulated a deficit to March 31, 2021 of $2,421,845, an accumulated
other comprehensive loss of $2,314, and expects to incur further losses in the development of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has not yet generated any revenue and has funded its operations from capital raises. MagicMed will continue to rely on third party financing
until it generates sufficient revenue from operating activities. Although, to date, MagicMed has been successful in raising third party
financing, there is no assurance that it will continue to be. See &ldquo;Risk Factors.&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 180; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_122"></A>Selected
Financial Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets out selected financial information for MagicMed as at and for the period from May 26, 2020 (date of incorporation)
to June 30, 2020 (audited) and the period from July 1, 2020 to March 31, 2021 (unaudited):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the period from incorporation on May 26, 2020 to June 30, 2020</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(audited)</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the period from July 1, 2020 to March 31, 2021</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    revenues</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,476</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,379,369</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss for the period</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Comprehensive loss for the period</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0.2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,476</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0.2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,476</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 8.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,379,369</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 8.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,381,683</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    loss per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.005</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.093</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">551,242</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,236,949</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">556,527</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,383,322</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,217</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">380,046</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,217</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">380,046</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    shareholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">505,310</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,003,276</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_123"></A>Results
of Operations</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
period from incorporation on May 26, 2020 to December 31, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total loss and comprehensive loss for the period from incorporation on May 26, 2020 to June 30, 2020, was $42,476 ($0.005 per share)
and from July 1, 2020 to March 31, 2021 was $2,379,369 and $2,381,683 respectively ($0.093 per share).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows from (used) in operating activities for the period from incorporation on May 26, 2020 to June 30, 2020 was $5,262 and from July
1, 2020 to March 31, 2021 was $(2,264,985).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows from (used) in investing activities for the period from incorporation on May 26, 2020 to June 30, 2020 was $(5,285) and from July
1, 2020 to March 31, 2020 was $(142,412). The cash outflows during the period from incorporation on May 26, 2020 to June 30, 2020 were
comprised of investments in acquisition of patents $5,285. The cash outflows during the period from July 1, 2020 to March 31, 2021 were
comprised of investments in acquisition of patents and other intangibles $124,752 and acquisition of equipment $17,660.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows provided from financing activities for the period from incorporation on May 26, 2020 to June 30, 2020 were $545,000 representing
proceeds from non-brokered private placement completed on May 26, 2020 and June 26, 2020 raising gross proceeds of $545,000. Cash flows
provided from the period July 1, 2020 to March 31, 2021 were $8,817,825, net of share issuance costs of $1,050,538, representing proceeds
from brokered and non-brokered private placements completed on July 7, 2020, August 14, 2020, August 31, 2020, September 3, 2020, December
17, 2020December 23, 2020 and February 15, 2021 raising gross proceeds of $9,868,363.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_124"></A>Summary
of Quarterly Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
had a loss and comprehensive loss of $42,476 for the period from incorporation on May 26, 2020 to June 30, 2020 (audited) and for the
period from July 1, 2020 to March 31, 2021 (unaudited) $2,379,369 and $2,381,683 respectively. MagicMed has accumulated a deficit to
March 31, 2021, of $2,421,845 and accumulated other comprehensive loss of $2,314 (unaudited).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at March 31, 2021, MagicMed had $6,953,091 in cash and cash equivalents and working capital of $6,856,903.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 181; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at March 31, 2021, MagicMed has the following contractual obligations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD ROWSPAN="2" STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
    Obligations</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payments
    Due by Period</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Less
    than 1 year</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1-3
    years</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4-5
    years</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After
    5 years</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: right; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$380,046</FONT></TD>
    <TD STYLE="text-align: right; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$380,046</FONT></TD>
    <TD STYLE="text-align: right; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    Lease Obligations</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Leases</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    Obligations<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,328,062</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,995,187</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$332,875</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Obligations</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Contractual Obligations</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$2,708,108</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$2,375,233</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$332,875</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nil</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nil</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            $380,046 debt shown is the accounts payable balance as at March 31, 2021 from the Interim
                                            Financial Statements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
                                            due are amounts under contracts for services. Included in this figure is: (i) an aggregate
                                            sum of $450,000 payable at $15,000 per month ($270,000 is due beyond 1 year) under the Financial
                                            Advisory Agreement with a 36-month term and a 30-day termination clause; and (ii) $399,436
                                            payable under the Calgary Research Contract (two payments of $33,938 and one payment of $33,937
                                            having already been made under the Calgary Research Contract as of the date hereof) with
                                            one payment of $33,937, one payment remaining of $40,031 (due on April 30, 2021), one payment
                                            remaining of $73,968 (due no earlier than June 1, 2021) and four payments remaining of $62,875
                                            (due no earlier than September 1, 2021, December 1, 2021, March 1, 2022, and June 1, 2022),
                                            with a 60 day termination clause; (iii) USD$1,100,000 (approximately CDN$1,383,250 based
                                            on the Bank of Canada exchange rate on March 31, 2021 of 1.2575) due on the PsyAI<SUP>TM
                                            </SUP>Services Agreements ($50,000 USD monthly for 11 months remaining on the one year terms,
                                            however both agreements have a 90 day termination clause so if both terminated the maximum
                                            obligation is $300,000 USD in total); and (iv) there are other purchase obligations due within
                                            one year for marketing services totaling $95,375 for marketing services due within 1 year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
believes it has sufficient cash and cash equivalents to maintain corporate capacity, meet its current financial obligations and execute
planned activities in the development of its business over the ensuing 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
approach to managing liquidity is to ensure, to the extent possible, that it always has sufficient liquidity to meet its liabilities
as they become due. MagicMed does so by monitoring cash flow and performing budget-to-actual analysis on a regular basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
does not currently have revenue-generating activities and its financial success is dependent on management&rsquo;s ability to execute
MagicMed&rsquo;s business plan, which may take longer than anticipated and cost more than expected. To date MagicMed has relied on equity
financings to fund its development activities and its corporate and overhead expenses. Many factors influence MagicMed&rsquo;s ability
to raise funds, including the health of the capital markets, MagicMed&rsquo;s track record, and the experience and caliber of its Board
and management. There is no guarantee that MagicMed will be able to secure additional financings in the future at terms that are favorable,
or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
capability to continue as a going concern is dependent upon its ability to generate revenue by entering into partnership agreements with
drug development companies to commercialize the contents of the Psybrary<SUP>TM</SUP> or obtain additional equity financing to meet its
obligations as they come due. If MagicMed was to become unable to continue as a going concern, then significant adjustments would be
required to the carrying value of assets and liabilities, and to the balance sheet classifications currently used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no capital expenditure commitments at March 31, 2021 other than for general and administrative costs, marketing and research and
development activities. These commitments will be funded primarily through working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial information above does not include any additional adjustments to the recoverability and classification of certain recorded
asset amounts, classification of certain liabilities and changes to the statement of loss and comprehensive loss that might be necessary
if MagicMed was unable to continue as a going concern.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_125"></A>Changes
to Accounting Policies Including Initial Adoption</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
new standards, interpretations, amendments and improvements to existing standards were issued by the IASB or IFRS Interpretations Committee
that are mandatory for fiscal periods beginning on or after January 1, 2021. The standards impacted that may be applicable to MagicMed
are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
                                            date of IAS 1 amendments on classification</I> &ndash; On 23 January 2020, the IASB issued
                                            &lsquo;Classification of Liabilities as Current or Non-current (Amendments to IAS 1)&rsquo;
                                            providing a more general approach to the classification of liabilities under IAS 1 based
                                            on the contractual arrangements in place at the reporting date. The amendments were originally
                                            effective for annual reporting periods beginning on or after 1 January 2022, however, their
                                            effective date has been delayed to 1 January 2023.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 182; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
                                            date of 2018-2020 annual improvements cycle</I> &ndash; On 14 May 2020, the IASB issued &lsquo;Annual
                                            Improvements to IFRS Standards 2018&ndash;2020&rsquo;. The pronouncement contains amendments
                                            to four IFRSs as result of the IASB&rsquo;s annual improvements project. The amendments are
                                            effective for annual reporting periods beginning on or after 1 January 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
                                            date of IAS 37 amendments regarding onerous contracts</I> &ndash; On 14 May 2020, the IASB
                                            issued &lsquo;Onerous Contracts &mdash; Cost of Fulfilling a Contract (Amendments to IAS
                                            37)&rsquo; amending the standard regarding costs a company should include as the cost of
                                            fulfilling a contract when assessing whether a contract is onerous. The amendments are effective
                                            for annual reporting periods beginning on or after 1 January 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
                                            date of IFRS 3 amendments updating a reference to the Conceptual Framework</I> &ndash; On
                                            14 May 2020, the IASB issued &lsquo;Reference to the Conceptual Framework (Amendments to
                                            IFRS 3)&rsquo; with amendments to IFRS 3 &lsquo;Business Combinations&rsquo; that update
                                            an outdated reference in IFRS 3 without significantly changing its requirements. The amendments
                                            are effective for annual reporting periods beginning on or after 1 January 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
                                            date of IBOR reform Phase 2 amendments</I> &ndash; On 27 August 2020, the IASB issued &lsquo;Interest
                                            Rate Benchmark Reform &mdash; Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS
                                            16)&rsquo; with amendments that address issues that might affect financial reporting after
                                            the reform of an interest rate benchmark, including its replacement with alternative benchmark
                                            rates. The amendments are effective for annual periods beginning on or after 1 January 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accounting standards or amendments to existing accounting standards that have been issued, but have future effective dates, are either
not applicable or are not expected to have a significant impact on MagicMed&rsquo;s annual financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_126"></A>Critical
accounting estimates and judgements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of MagicMed&rsquo;s financial statements requires management to make certain estimates, judgments and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting
year. Actual outcomes could differ from these estimates. These financial statements include estimates which, by their nature, are uncertain.
The impacts of such estimates are pervasive throughout the financial statements and may require accounting adjustments based on future
occurrences. Revisions to accounting estimates are recognized in the year in which the estimate is revised and future years if the revision
affects both current and future years. These estimates are based on historical experience, current and future economic conditions and
other factors, including expectations of future events that are believed to be reasonable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
judgements, estimates and assumptions that have the most significant effect on the amounts recognized in the financial statements include
the fair value of financial instruments, warrants and fair value of share-based payments, and intangible assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share
based payments </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of share-based compensation expenses are estimated using the Black-Scholes option pricing model and rely on a number of estimates,
such as the expected life of the option, the volatility of the underlying share price, the risk free rate of return, and the estimated
rate of forfeiture of options or warrants granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intangible
assets valuation </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
intangible assets valuation requires management to use judgment in estimating the fair value of its patents. The fair value of patents
are estimated on the basis of costs incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Estimated
useful lives, impairment considerations and amortization of intangible assets </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of property, plant and equipment, and intangible assets is dependent upon estimates of useful lives based on management&rsquo;s judgment.
Impairment of definite long-lived assets is influenced by judgment in defining a CGU and determining the indicators of impairment, and
estimates used to measure impairment losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 183; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_127"></A>DESCRIPTION
OF ENVB CAPITAL STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the completion of the Amalgamation, MagicMed equity holders who receive shares of ENVB common stock in the Amalgamation
will become stockholders of ENVB. Rights of holders of ENVB common stock will be governed by the DGCL and the ENVB amended and
restated certificate of incorporation, as amended, and the ENVB amended and restated bylaws. The following description briefly
summarizes the material terms of ENVB common stock. For more complete terms, please refer to the applicable provisions of the
DGCL and the full text of ENVB&rsquo;s amended and restated certificate of incorporation, as amended, and amended and restated
bylaws. See the section titled &ldquo;Comparison of Rights of Holders of ENVB Capital Stock and MagicMed Capital Stock&rdquo;
beginning on page 185 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_128"></A>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
has authorized 120,000,000 shares of capital stock, par value $0.01 per share, of which 100,000,000 are shares of common stock and 20,000,000
are shares of &ldquo;blank check&rdquo; preferred stock. As of the record date for the ENVB special meeting, there were [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
shares of ENVB common stock issued and outstanding and no shares of preferred stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_129"></A>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of ENVB common stock are entitled to one vote for each share held on all matters submitted to a vote of ENVB&rsquo;s stockholders and
have no cumulative voting rights. Holders of ENVB common stock are entitled to receive any dividends as may be declared by the ENVB board
of directors, subject to any preferential dividend or other rights of any then outstanding preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of ENVB common stock do not have preemptive or conversion rights or other subscription rights. Upon liquidation, dissolution or winding-up,
holders of ENVB common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences
of any of ENVB&rsquo;s outstanding shares of preferred stock. The rights, preferences and privileges of holders of ENVB common stock
are subject to and may be adversely affected by the rights of the holders of shares of any series of ENVB preferred stock that ENVB may
designate and issue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided by law, ENVB&rsquo;s charter, or ENVB&rsquo;s amended and restated bylaws, at each meeting of stockholders the holders
of a majority of the voting power of the stock issued, outstanding and entitled to vote thereat, present in person or represented by
proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. Unless otherwise provided by law,
ENVB&rsquo;s charter, or ENVB&rsquo;s amended and restated bylaws, where a separate vote by a class or series or classes or series is
required, a majority of the voting power of the then-issued and outstanding shares of such class or series or classes or series, present
in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_130"></A>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of ENVB&rsquo;s amended and restated certificate of incorporation, as amended, ENVB&rsquo;s board of directors have the authority,
without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the
designations, powers, preferences, privileges, and relative participating, optional, or special rights as well as the qualifications,
limitations, or restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption,
and liquidation preferences, any or all of which may be greater than the rights of the common stock. ENVB&rsquo;s board of directors,
without stockholder approval, can issue convertible preferred stock with voting, conversion, or other rights that could adversely affect
the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms calculated to delay
or prevent a change of control or make removal of management more difficult. In addition, the issuance of preferred stock may have the
effect of decreasing the market price of the ENVB&rsquo;s common stock, and may adversely affect the voting and other rights of the holders
of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_131"></A>Anti-Takeover
Effects of Certain Provisions of ENVB&rsquo;s Certificate of Incorporation, Bylaws and the DGCL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of ENVB&rsquo;s amended and restated certificate of incorporation, as amended, ENVB is subject to the provisions of Section
203 of the Delaware General Corporation Law regulating corporate takeovers through a &ldquo;business combination&rdquo; with a stockholder
who owns 15% or more of ENVB&rsquo;s outstanding voting stock (otherwise known as an &ldquo;interested stockholder&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 184; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_132"></A>COMPARISON
OF RIGHTS OF</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDERS
OF ENVB CAPITAL STOCK AND MAGICMED CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the transactions contemplated by the Amalgamation Agreement are completed, MagicMed stockholders will receive shares of ENVB common stock
and become stockholders of ENVB as a result of an amalgamation under the <I>Business Corporations Act</I> (British Columbia) (the &ldquo;BCBCA&rdquo;)
and pursuant to the terms of the Amalgamation Agreement. ENVB is incorporated under the laws of the State of Delaware. MagicMed is a
corporation existing under the laws of the Province of British Columbia in Canada. The rights of ENVB stockholders are generally governed
by the Delaware General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;). The rights of MagicMed shareholders are generally
governed by the BCBCA. Upon completion of the Amalgamation, MagicMed shareholders will become stockholders of ENVB, and their rights
will be governed by the DGCL, the Amended and Restated Bylaws of ENVB and the Amended and Restated Certificate of Incorporation of ENVB,
as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain differences between (i) the current rights of ENVB stockholders under Delaware law, the ENVB amended
and restated certificate of incorporation, as amended (referred to in this section as the &ldquo;ENVB charter&rdquo;) and the ENVB amended
and restated bylaws and (ii) the current rights of MagicMed shareholders under the BCBCA and the articles of incorporation of MagicMed
(referred to in this section as the &ldquo;MagicMed articles&rdquo;). MagicMed does not have bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and
the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this
entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding
of the differences between being a stockholder of ENVB or MagicMed before the Amalgamation and being a stockholder of ENVB following
the completion of the Amalgamation. For more information on how to obtain these documents, please see the section titled &ldquo;Where
You Can Find More Information&rdquo; beginning on page 208 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVB</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized
    Capital Stock; Outstanding Capital Stock</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    is authorized to issue two classes of capital stock which are designated, respectively, &ldquo;common stock&rdquo; and &ldquo;preferred
    stock.&rdquo; The total number of shares that ENVB is authorized to issue is 120,000,000, of which 100,000,000 shares are common
    stock, par value $0.01 per share, and 20,000,000 shares are preferred stock, par value $0.01 per share.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding)
    by the affirmative vote of the holders representing a majority of the votes represented by all outstanding shares of common stock
    entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of authorized shares of ENVB preferred stock may be increased or decreased (but not below the number of shares thereof then
    outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock of ENVB entitled to vote
    thereon, without a vote of the holders of the preferred stock, or of any series thereof, unless a vote of any such holders is required
    pursuant to the terms of any preferred stock designation.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the close of business on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, the latest practicable date prior to the date of this proxy statement/prospectus, ENVB
    had [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of ENVB common stock and no shares of preferred stock issued and outstanding.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
    authorized share capital consists of an unlimited number of common shares without par value and with special rights and restrictions
    attached.</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the close of business on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, the latest practicable
    date prior to the date of this proxy statement/prospectus, MagicMed had [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
    MagicMed shares issued and outstanding.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 185; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Common
    Stock</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise provided in the ENVB charter, each holder of a share of ENVB common stock is entitled to one vote for each such share
    held of record on the applicable record date on each matter voted on at a meeting of stockholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise required by law, holders of common stock are not entitled to vote on any amendment to the ENVB charter that relates
    solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either
    separately or together as a class with the holders of one or more other such series, to vote thereon.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise provided by law, the ENVB charter, the ENVB amended and restated bylaws, in all matters other than the election of directors,
    the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and
    entitled to vote on the subject matter shall be the act of the stockholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise provided by law, the ENVB charter, the ENVB amended and restated bylaws, directors shall be elected by a plurality of
    the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
    a separate vote by a class or series or classes or series is required, in all matters other than the election of directors, the affirmative
    vote of the majority of the voting power of shares of such class or series or classes or series present in person or represented
    by proxy at the meeting shall be the act of such class or series or classes or series, except as otherwise provided by law, the ENVB
    charter, the ENVB amended and restated bylaws.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    holders of the ENVB common stock do not have cumulative voting rights for the election of directors or for any other purpose.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    common stock is listed on The Nasdaq Capital Market.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    a poll is directed by the chair of a meeting of the shareholders or demanded by a shareholder with the right to vote, motions are
    voted on by a show of hands with each person having one vote (regardless of the number of shares such person is entitled to vote).
    If voting is conducted by poll, each person is entitled to one vote (or such other number as may be provided in the articles) for
    each share such person is entitled to vote. However, if one or more shareholders votes at a meeting by telephone or other communications
    medium, motions will be voted on by poll or another method that adequately discloses the intentions of the shareholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    holders of MagicMed shares do not have cumulative voting rights for the election of directors or for any other purpose.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise provided by law, the ENVB charter, the ENVB amended and restated bylaws, directors shall be elected by a plurality of
    the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 186; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preferred
    Stock</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    is authorized to issue up to 20,000,000 shares of preferred stock in one or more classes or series. The ENVB charter authorizes the
    ENVB board, without any further stockholder action or approval, to issue from time to time one or more series of preferred stock,
    and to determine and fix the powers, rights, privileges, preferences and priorities, of each series of ENVB preferred stock, including
    without limitation authority to fix the number of shares to constitute any such series and the designation thereof, voting rights
    and terms thereof, the dividend rate, dividend rights, the rights and terms of redemption, liquidation preferences, retirement and
    sinking fund provisions, and conversion rights of any such series.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    shares of ENVB preferred stock are currently outstanding.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
    applicable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Number
    and Qualification of Directors</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB board of directors consists of one or more members, and the number of directors is fixed from time to time by resolution of
    the ENVB board of directors. The ENVB board of directors currently consists of five members. No decrease in the authorized number
    of directors constituting the ENVB board of directors will shorten the term of any incumbent director. Directors of ENVB need not
    be stockholders of ENVB.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
    articles provide that it will have a board of directors consisting the number of directors set by ordinary resolution of the shareholders
    from time to time. Directors are generally elected by shareholders by ordinary resolutions; however, MagicMed&rsquo;s articles also
    provide that the directors may appoint one or more directors to hold office until the close of the next annual meeting of shareholders,
    but the total number of directors so appointed may not exceed one third of the number of directors elected at the previous annual
    meeting of shareholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BCBCA does not place any residency restrictions on the boards of director.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Structure
    of Board of Directors; Term of Directors; Election of Directors</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as provided in the ENVB amended and restated bylaws, each director, including a director elected to fill a vacancy, shall hold office
    until the next annual meeting of stockholders. Each director shall hold office until the expiration of the term for which elected
    or appointed and until such director&rsquo;s successor is elected and qualified or until such director&rsquo;s earlier death, resignation
    or removal.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    directors are not divided into classes of directors with terms of office that are greater than one year and which terms of office
    expire at different times.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
    articles do not specify a term for which directors shall hold office. However, according to MagicMed&rsquo;s articles, all directors
    cease to hold office immediately before the election or appointment of directors at every annual general meeting, but are eligible
    for re-election or re- appointment</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal
    of Directors</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the special rights of the holders of one or more series of ENVB preferred stock to elect directors, or except as otherwise provided
    by the DGCL, a director may be removed from office by ENVB stockholders with or without cause. No reduction of the authorized number
    of directors shall have the effect of removing any director prior to the expiration of such director&rsquo;s term of office.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
    articles allow for the removal of a director by special resolution of the shareholders. </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 187; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vacancies
    on the Board of Directors</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    director may resign at any time upon notice in writing or electronic transmission to ENVB. Such resignation shall be effective upon
    delivery unless it is specified to be effective at some later time or upon the happening of some later event. A resignation which
    is conditioned upon the director failing to receive a specified vote for reelection as a director may provide that it is irrevocable.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise provided in the ENVB charter or the ENVB bylaws, when one or more directors resign from the board of directors, effective
    at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such
    vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective and each director
    so chosen will hold office for the unexpired portion of the term of the director whose place will be vacated and until his successor
    is duly elected and qualified.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise provided in the ENVB charter or the ENVB bylaws or if authorized by resolution of the board of directors, vacancies and
    newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders
    having the right to vote as a single class shall be filled only by a majority of the directors then in office, although less than
    a quorum, or by a sole remaining director, and not by the stockholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
    at the time of filling any vacancy or any newly created directorship, the directors then in office constitute less than a majority
    of the board of directors (as constituted immediately prior to any such increase), the Court of Chancery may, upon application of
    any stockholder or stockholders holding at least 10% of the voting power of the capital stock of ENVB at the time outstanding having
    the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships,
    or to replace the directors chosen by the directors then in office, which election shall be governed by the provisions of Section
    211 of the DGCL as far as applicable.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a vacancy among the directors created by the removal of a director may be filled by the shareholders at the meeting at
    which the director is removed or, if not filled by the shareholders at such meeting, by the shareholders or by the remaining directors.
    In the case of a casual vacancy under the BCBCA, the remaining directors may fill the vacancy. Under the BCBCA, if as a result of
    one or more vacancies, the number of directors in office falls below the number required for a quorum, the remaining directors may
    appoint as directors the number of individuals that, when added to the number of remaining directors, will constitute a quorum and/or
    call a shareholders&rsquo; meeting to fill any or all vacancies among directors and to conduct such other business that may be dealt
    with at that meeting, but must not take any other action until a quorum is obtained.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 188; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
    Action by Written Consent</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise provided in the ENVB charter, any action required by statute to be taken at any annual or special meeting of the stockholders,
    or any action which may be taken at an annual or special meeting of stockholders, may be taken without a meeting, without prior notice
    and without a vote, if consents in writing, setting forth the action so taken, are signed by the holders of record on the record
    date of outstanding shares of ENVB having not less than the minimum number of votes that would be necessary to authorize or take
    such action at a meeting at which all shares entitled to vote thereon were present and voted.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of the election or removal of directors by written consent, such consent shall be effective only if signed by the holders
    of all outstanding shares entitled to vote for the election of directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prompt
    notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders
    who have not consented in writing.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, shareholder action without a meeting may be taken by a consent resolution of shareholders provided that it satisfies the
    thresholds for approval in the company&rsquo;s articles, the BCBCA and the regulations thereunder. A consent resolution is as valid
    and effective as if it was a resolution passed at a meeting of shareholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quorum</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise provided by law, ENVB&rsquo;s charter, or ENVB&rsquo;s amended and restated bylaws, at each meeting of stockholders the
    holders of a majority of the voting power of the stock issued, outstanding and entitled to vote thereat, present in person or represented
    by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise provided by law, ENVB&rsquo;s charter, or ENVB&rsquo;s amended and restated bylaws, where a separate vote by a class or
    series or classes or series is required, a majority of the voting power of the then-issued and outstanding shares of such class or
    series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect
    to that vote on that matter.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a quorum fails to attend any meeting, the chairperson of the meeting or the stockholders entitled to vote at the meeting, present
    in person or represented by proxy, shall have power to adjourn the meeting, without notice other than announcement at the meeting,
    until a quorum is present or represented.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted
    at the meeting as originally noticed.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    quorum for the transaction of business at a meeting of shareholders is at least one person who is, or who represents by proxy, two
    or more shareholders who, in the aggregate, hold at least 5% of the issued shares entitled to be voted at the meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    business, other than the election of a chair of the meeting and the adjournment of the meeting, may be transacted at any meeting
    of shareholders unless a quorum of shareholders entitled to vote is present at the commencement of the meeting, but such quorum need
    not be present throughout the meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
    within one-half hour from the time set for the holding of a meeting of shareholders, a quorum is not present: (a) in the case of
    a general meeting requisitioned by shareholders, the meeting is dissolved, and (b) in the case of any other meeting of shareholders,
    the meeting stands adjourned to the same day in the next week at the same time and place.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
    at the meeting to which the meeting referred to above was adjourned, a quorum is not present within one-half hour from the time set
    for the holding of the meeting, the person or persons present and being, or representing by proxy, two or more shareholders entitled
    to attend and vote at the meeting shall be deemed to constitute a quorum.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 189; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->189<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Record
    Date</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    order that ENVB may determine the ENVB stockholders entitled to notice of any meeting of ENVB stockholders or any adjournment thereof,
    the ENVB board may fix a record date, which record date may not precede the date upon which the resolution fixing the record date
    is adopted by the ENVB board, and which record date may not be more than 60 nor less than 10 days before the date of such meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the ENVB board so fixes a date, such date will also be the record date for determining the ENVB stockholders entitled to vote at
    such meeting unless the ENVB board determines, at the time it fixes such record date, that a later date on or before the date of
    the meeting will be the date for making such determination.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    no record date is fixed by the ENVB board, the record date for determining ENVB stockholders entitled to notice of and to vote at
    a meeting of stockholders will be at the close of business on the day next preceding the day on which notice is given, or, if notice
    is waived, at the close of business on the day next preceding the day on which the meeting is held.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    determination of stockholders of record entitled to notice of or to vote at a meeting of ENVB stockholders will not apply to any
    adjournment of the meeting; provided, however, that ENVB may fix a new record date for determination of ENVB stockholders entitled
    to vote at the adjourned meeting, and in such case shall also fix as the record date for ENVB stockholders entitled to notice of
    such adjourned meeting the same or an earlier date as that fixed for determination of ENVB stockholders entitled to vote in accordance
    with the foregoing provisions.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    directors may set a date as the record date for the purpose of determining shareholders entitled to notice of any meeting of shareholders.
    The record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general
    meeting requisitioned by shareholders under the BCBCA, by more than four months. The record date must not precede the date on which
    the meeting is held by fewer than: (a) if the company is a public company, 21 days; (b) otherwise, 10 days.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    no record date is set, the record date is 5:00 p.m. on the day immediately preceding the first date on which the notice is sent or,
    if no notice is sent, the beginning of the meeting.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
    Inspection Rights; Stockholder Lists</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    Section 220 of the DGCL, a stockholder or his or her agent has a right to inspect the corporation&rsquo;s stock ledger, a list of
    its stockholders and its other books and records during the usual hours of business upon written demand stating a proper purpose
    (which must be reasonably related to such person&rsquo;s interest as a stockholder). If the corporation refuses to permit such inspection
    or fails to reply to the request within five business days of the demand, the stockholder may apply to the Court of Chancery for
    an order to compel such inspection.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to the DGCL and ENVB&rsquo;s amended and restated bylaws, ENVB must, at least 10 days in advance of any ENVB stockholder meeting,
    make a complete list of the ENVB stockholders entitled to vote thereat; if the record date is less than 10 days before the meeting,
    the list must reflect the ENVB stockholders entitled to vote as of the tenth day before the meeting date. ENVB stockholders will
    appear in alphabetical order with their address and the number of shares registered in their name; email or other electronic contact
    information is not required. Such list will be open to the examination of any ENVB stockholder for any purpose germane to the meeting
    for a period of at least 10 days prior to the meeting:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &#9;on a reasonably accessible electronic network; provided that the access information is provided with the notice of the meeting,
    or</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &#9;during ordinary business hours, at ENVB&rsquo;s principal place of business.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    list will also be available to any ENVB stockholder during the entire meeting at the place of such meeting or, if the meeting is
    to be held solely by means of remote communication, on a reasonably accessible electronic network (access information will be provided
    with the notice of the meeting).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
ENVB makes the list available on an electronic network, it may take reasonable steps to ensure that such information is available only
to the ENVB stockholders.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, directors and shareholders may, without charge, inspect certain of the records of a company. Former shareholders and directors
    may also inspect certain of the records, free of charge, but only those records pertaining to the times that they were shareholders
    or directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a person may apply to a company, or to the person who has custody or control of its central securities register, for a
    list setting out the following: (a) the names and last known addresses of the shareholders; (b) the number of shares of each class
    or series of shares held by each of those shareholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    application in connection with the above must be in writing and must include (a) an affidavit of the person seeking the list (i)stating
    the name and mailing address of the applicant or, if the applicant is a corporation, its name and the mailing address, and, if different,
    the delivery address, of its registered office or equivalent, and (ii) stating that the list will not be used except as permitted
    under subsection (3), and (b) payment of the fee.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    person must not use a list obtained under this section except in connection with an effort to (a) influence the voting of shareholders
    of the company at any meeting of shareholders, (b)acquire or sell securities of the company,(c) effect an amalgamation or a similar
    process involving the company or a reorganization of the company, (d) call a meeting under certain circumstances, or (e) identify
    the shareholders of an unlimited liability company.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 190; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->190<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
    Meetings of Stockholders</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
    meetings of stockholders for any purpose or purposes may be called at any time by the board of directors, the Chairperson of the
    ENVB board of directors, the chief executive officer of ENVB or the president of ENVB.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB board of directors will determine the time and place, if any, of such special meeting. The board of directors may cancel, postpone
    or reschedule any previously scheduled special meeting at any time, before or after the notice for such meeting has been sent to
    the stockholders. Special meetings may not be called by any other person or persons.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    notice of a special meeting shall include the purpose for which the meeting is called. Only such business shall be conducted at a
    special meeting of stockholders as shall have been brought before the meeting by or at the direction of the board of directors, the
    chairperson of the board of directors, the chief executive officer, or the president.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a meeting of shareholders is to consider special business (within the meaning of the MagicMed articles), the notice of meeting must:
    (a) state the general nature of the special business; and (b) if the special business includes considering, approving, ratifying,
    adopting or authorizing any document or the signing of or giving of effect to any document, have attached to it a copy of the document
    or state that a copy of the document will be available for inspection by shareholders: (i) at MagicMed&rsquo;s records office, or
    at such other reasonably accessible location in British Columbia as is specified in the notice; and (ii) during statutory business
    hours on any one or more specified days before the day set for the holding of the meeting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notice
    of Stockholder Meetings</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
    of all meetings of stockholders is to be given in writing or by electronic transmission in the manner provided by law and ENVB&rsquo;s
    amended and restated bylaws, stating the place, if any, date and hour, of the meeting and, in the case of a special meeting, the
    purpose or purposes of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed
    to be present in person and vote at any such meeting, and the record date for determining the stockholders entitled to vote at the
    meeting. Unless otherwise required by applicable law, ENVB charter or the ENVB amended and restated bylaws, such notice is to be
    given not less than ten nor more than 60 days before the date of the meeting to each stockholder of record entitled to vote at such
    meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
    limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the ENVB charter or
    the ENVB bylaws, any notice to stockholders given by ENVB under any provision of the DGCL, the ENVB charter or the ENVB bylaws shall
    be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such
    consent shall be revocable by the stockholder by written notice to ENVB.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    must send notice of the date, time and location of any meeting of shareholders (including, without limitation, any notice specifying
    the intention to propose a resolution as an exceptional resolution, a special resolution or a special separate resolution, and any
    notice to consider approving an amalgamation into a foreign jurisdiction, an arrangement or the adoption of an amalgamation agreement,
    and any notice of a general meeting, class meeting or series meeting), in the manner provided in the MagicMed articles, or in such
    other manner, if any, as may be prescribed by ordinary resolution (whether previous notice of the resolution has been given or not),
    to each shareholder entitled to attend the meeting, to each director and to the auditor of the Company, unless the MagicMed articles
    otherwise provides, at least the following number of days before the meeting: (a) if the company is a public company, 21 days; (b)
    otherwise, 10 days.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 191; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->191<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
    Notice Requirements for Stockholder Proposals</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    stockholder may properly bring business before an annual meeting if it is brought: (A) pursuant to ENVB&rsquo;s proxy materials with
    respect to such meeting, (B) by or at the direction of the board of directors, or (C) by a stockholder of who is a stockholder of
    record at the time of the giving of the notice required and on the record date for the determination of stockholders entitled to
    vote at the annual meeting and has timely complied in proper written form with the notice procedures set forth in the ENVB amended
    and restated bylaws.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    business to be properly brought before an annual meeting by a stockholder, such business must be a proper matter for stockholder
    action pursuant to these bylaws and applicable law. Except for proposals properly made in accordance with Rule 14a-8 under the Securities
    and Exchange Act of 1934, and the rules and regulations thereunder, clause (C) above shall be the exclusive means for a stockholder
    to bring business before an annual meeting of stockholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    stockholder&rsquo;s notice must set forth all information required by the ENVB amended and restated bylaws and must be timely received
    by the secretary of ENVB. To be timely, a stockholder&rsquo;s notice must be received by the secretary at the principal executive
    offices of the Corporation not later than the 45th day nor earlier than the 75th day before the one-year anniversary of the date
    on which ENVB first mailed its proxy materials or a notice of availability of proxy materials (whichever is earlier) for the preceding
    year&rsquo;s annual meeting, subject to certain exceptions.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be in proper written form, a stockholder&rsquo;s notice to the secretary must set forth as to each matter of business the stockholder
    intends to bring before the annual meeting: (1) a brief description of the business intended to be brought before the annual meeting,
    the text of the proposed business (including the text of any resolutions proposed for consideration) and the reasons for conducting
    such business at the annual meeting, (2) the name and address, as they appear on ENVB&rsquo;s books, of the stockholder proposing
    such business and any stockholder associated person, (3) the class and number of shares of ENVB that are held of record or are beneficially
    owned by the stockholder or any stockholder associated person and any derivative positions held or beneficially held by the stockholder
    or any stockholder associated person as of the date of delivery of such notice, (4) whether and the extent to which any hedging or
    other transaction or series of transactions has been entered into by or on behalf of such stockholder or any stockholder associated
    person with respect to any securities of ENVB, and a description of any other agreement, arrangement or understanding (including
    any short position or any borrowing or lending of shares), the effect or intent of which is to mitigate loss to, or to manage the
    risk or benefit from share price changes for, or to increase or decrease the voting power of, such stockholder or any stockholder
    associated person with respect to any securities of ENVB, (5) any material interest of the stockholder or a stockholder associated
    person in such business, and (6) a statement whether either such stockholder or any stockholder associated person will deliver a
    proxy statement and form of proxy to holders of at least the percentage of the voting power of ENVB&rsquo;s voting shares required
    under applicable law to carry the proposal.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a proposal may be made by certain registered or beneficial holders of shares entitled to be voted at an annual meeting
    of shareholders. To be eligible to submit such a proposal, a shareholder must be the registered or beneficial holder of, or have
    the support of the registered or beneficial holders of, (i) at least 1% of the total number of outstanding voting shares of the company;
    or (ii) voting shares whose fair market value is at least $2,000. Such registered or beneficial holder(s) must have held such shares
    for an uninterrupted period of at least two years immediately prior to the date of the signing of the proposal and such shareholder
    shall not have, within two years before the date of the signing of the proposal, failed to present, in person or by proxy, at an
    annual general meeting, an earlier proposal submitted by such shareholder in response to which the company complied with its obligations
    under the BCBCA. A proposal under the BCBCA must include the name and address of the person submitting the proposal, the names and
    addresses of the person&rsquo;s supporters and the number of shares of the company, carrying the right to vote at annual general
    meetings that are owned by such person(s).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the proposal and a written statement in support of the proposal (if any) are submitted at least three months before the anniversary
    date the previous annual meeting and the proposal and written statement (if any) meet other specified requirements, then the company
    must either set out the proposal, including the names and mailing addresses of the submitting person and supporters and the written
    statement (if any), in the proxy circular of the company or attach the proposal and written statement thereto.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the submitter is a qualified shareholder at the time of the annual general meeting to which its proposal relates, the company must
    allow the submitter to present the proposal, in person or by proxy, at such meeting. If two or more proposals received by the company
    in relation to the same annual general meeting are substantially the same, the company only needs to comply with such requirements
    in relation to the first proposal received and not any others.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    company may also refuse to process a proposal in certain other circumstances including when the directors have called an annual general
    meeting to be held after the date the proposal is received and have sent a notice of that meeting, when substantially the same proposal
    was submitted to shareholders in a notice of meeting or an information circular relating to an annual general meeting of shareholders
    held within five years preceding the receipt of the request and the proposal did not obtain the prescribed level of support or a
    proposal that deals with matters beyond the company&rsquo;s power to implement.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a company refuses to process a proposal, the company shall notify the person making such proposal in writing within 21 days after
    its receipt of the proposal of its decision in relation to the proposal and the reasons therefor. In any such event, the person submitting
    the proposal may make application to a court for a review of the company&rsquo;s decision and a court may restrain the holding of
    the annual general meeting and make any further order it considers appropriate. In addition, a company or any person claiming to
    be aggrieved by a proposal may apply to a court for an order permitting or requiring the company to refrain from processing the proposal
    and the court may make such order as it considers appropriate.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 192; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->192<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
    Notice of Director Nominations at Annual Meetings</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominations
    of persons for election or re-election to the ENVB board of directors must be made at an annual meeting of stockholders only (A)
    by the board of directors or (B) by an ENVB stockholder who is a stockholder of record at the time of the giving of the notice required
    by the ENVB amended and restated bylaws on the record date and has complied with the notice procedures set forth in the ENVB amended
    and restated bylaws. In addition to any other applicable requirements, for a nomination to be made by a stockholder, the stockholder
    must have given timely notice thereof in proper written form to the secretary of ENVB.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event the number of directors to be elected to the board of directors is increased and there is no public announcement naming
    all of the nominees for director or specifying the size of the increased board made by ENVB at least ten (10) days before the last
    day a stockholder may deliver notice of nomination, a stockholder&rsquo;s notice will be considered timely, but only with respect
    to nominees for any new positions created by such increase.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    stockholder&rsquo;s notice to the secretary must set forth specific information about the nominee, their stock ownership of ENVB,
    and any arrangements or understandings between the stockholder and the nominee, each as outlined in the ENVB amended and restated
    bylaws.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
    exception, no person shall be eligible for election or re-election as a director of ENVB at an annual meeting of stockholders unless
    nominated in accordance with the provisions set forth in the ENVB amended and restated bylaws.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    has noted adopted &ldquo;advance notice provisions&rdquo; for nomination of directors in the MagicMed articles.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 193; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->193<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
    Notice of Director Nominations for Special Meetings</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the board of directors has authorized in the specific case that stockholders may fill a vacancy or newly created directorship at
    a special meeting of stockholders, and a special meeting has been properly called for such purpose, nominations of persons for election
    or appointment to the board of directors at the special meeting shall be made only (1) by the board of directors or (2) by any stockholder
    of ENVB who (A) is a stockholder of record at the time of the giving of the notice on the record date and (B) delivers a timely written
    notice of the nomination to the secretary of ENVB.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be timely, such notice must be received by the secretary of ENVB not later than the close of business on the later of the 90th day
    prior to such special meeting or the tenth day following the day on which public announcement is first made of the date of the special
    meeting and of the nominees proposed by the board of directors to be elected or appointed at such meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    person shall not be eligible for election or appointment as a director at a special meeting unless the person is nominated (i) by
    or at the direction of the board of directors or (ii) by a stockholder in accordance with the notice procedures set forth in ENVB
    amended and restated bylaws.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    has noted adopted &ldquo;advance notice provisions&rdquo; for nomination of directors in the MagicMed articles.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 194; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->194<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
    of Certificate of Incorporation</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    Section 242 of the DGCL, a company&rsquo;s certificate of incorporation may be amended upon a resolution of the board of directors
    and, subject to certain exceptions, approved by:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &#9;the holders of a majority of the outstanding shares entitled to vote; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &#9;a majority of the outstanding shares of each class entitled to a class vote if the amendment would increase or decrease the aggregate
    number of authorized shares of such class, increase or decrease the par value of the shares of such class or alter or change the
    powers, preference, or special rights of the shares of such class so as to affect them adversely; provided that if the amendment
    would alter or change the powers, preferences or special rights of one or more series of a class so as to affect them adversely,
    but shall not so affect the entire class, then only the shares of the series so affected shall be considered a separate class for
    purposes of the vote.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a company may amend its articles or notice of articles by (i) the type of resolution specified in the BCBCA, (ii) if the
    BCBCA does not specify a type of resolution, then by the type specified in the company&rsquo;s articles, or (iii) if the company&rsquo;s
    articles do not specify a type of resolution, then by special resolution. The BCBCA permits many substantive changes to a company&rsquo;s
    articles (such as a change in the company&rsquo;s authorized share structure or a change in the special rights or restrictions that
    may be attached to a certain class or series of shares) to be changed by the resolution specified in that company&rsquo;s articles.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
    articles provide that certain changes to the MagicMed&rsquo;s share structure and any creation or alteration of special rights and
    restrictions to a series or class of shares be done by way of ordinary resolution, provided that, if a right or special right attached
    to a class or series of shares would be prejudiced or interfered with by such an alteration, the holders of such class or series
    of shares must approve the alteration by a special separate resolution of those shareholders.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed&rsquo;s
    articles also provide that, the shareholders may from time to time, by ordinary resolution, make any alteration to MagicMed&rsquo;s
    notice of articles and articles as permitted by the BCBCA.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
    of Bylaws</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB amended and restated bylaws may be adopted, amended or repealed by the stockholders entitled to vote; provided, however, that
    the affirmative vote of the holders of at least 66 2/3% of the total voting power of all outstanding shares of capital stock of ENVB
    entitled to vote thereon, voting together as a single class, shall be required for the stockholders of ENVB to alter, amend or repeal,
    or adopt any bylaw inconsistent with certain provisions in the ENVB amended and restated bylaws as noted therein</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors, acting by the affirmative vote of at least a majority of the board of directors, shall also have the power to
    adopt, amend or repeal bylaws; provided, however, that a bylaw amendment adopted by stockholders which specifies the votes that shall
    be necessary for the election of directors shall not be further amended or repealed by the board of directors.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    does not have by-laws. See &ldquo;Amendment of Certificate of Incorporation&rdquo; above.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 195; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->195<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
    on Director Liability</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    liability of the ENVB directors for monetary damages for a breach of fiduciary duty is and will be eliminated to the fullest extent
    under applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability
    of directors, then the liability of a director to ENVB will be eliminated or limited to the fullest extent permitted by applicable
    law as so amended.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a director or officer of a company must (i) act honestly and in good faith with a view to the best interest of the company;
    (ii) exercise the care, diligence and skill that a reasonably prudent individual would exercise in comparable circumstances; (iii)
    act in accordance with the BCBCA and the regulations thereunder; and (iv) subject to (i) to (iii), act in accordance with the articles
    of the company. These statutory duties are in addition to duties under common law and equity.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, the directors of a company who vote for or consent to a resolution that authorizes the company to (i) carry on any business
    or exercise any power that it is restricted by its articles from carrying on or exercising or exercise any of its powers in a manner
    inconsistent with such restrictions as a result of such act or exercise the company has paid compensation to any person; (ii) to
    pay a commission or allow as discount in violation of the BCBCA to in connection with the sale of share of the company; (iii) to
    pay a dividend, purchase, redeem or otherwise acquire shares in circumstances where the company is insolvent, or the payment of the
    dividend would render the company insolvent; or (iv) to make a payment or give an indemnity to an indemnifiable person in violation
    of the BCBCA, are, in each case, jointly and severally liable to restore to the company any amount paid or distributed as a result
    and not otherwise recovered by the company. In addition, the directors of a company who vote for or consent to a resolution that
    authorizes the issue of a share that is not fully paid are jointly and severally liable to compensate the company or any shareholder
    for any losses, damages and costs sustained as a result.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the fullest extent permitted by applicable law, ENVB is authorized to provide indemnification of (and advancement of expenses to)
    directors, officers and agents of ENVB (and any other persons to which applicable law permits ENVB to provide indemnification) through
    provisions of ENVB&rsquo;s amended and restated bylaws and agreements with such agents or other persons. If applicable law is amended
    to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director
    to ENVB will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a company may indemnify: (i) a current or former director or officer of that company; (ii) a current or former director
    or officer of another corporation if, at the time such individual held such office, the corporation was an affiliate of the company,
    or if such individual held such office at the company&rsquo;s request; or (iii) an individual who, at the request of the company,
    held, or holds, an equivalent position in another entity (an &ldquo;indemnifiable person&rdquo;) against all costs, charges and expenses,
    including an amount paid to settle an action or satisfy a judgment, reasonably incurred by him or her in respect of any civil, criminal,
    administrative or other legal proceeding or investigative action (whether current, threatened, pending or completed) in which he
    or she is involved because of that person&rsquo;s position as an indemnifiable person, if: (i) the individual acted honestly and
    in good faith with a view to the best interests of such company or the other entity, as the case may be; and (ii) in the case of
    a proceeding other than a civil proceeding, the individual had reasonable grounds for believing that the individual&rsquo;s conduct
    was lawful. A company cannot indemnify an indemnifiable person if it is prohibited from doing so under its memorandum or articles,
    even if it had agreed to do so by an indemnification agreement (provided that the memorandum or articles prohibited indemnification
    when the indemnification agreement was made). A company may pay, as they are incurred in advance of the final disposition of an eligible
    proceeding, the expenses actually and reasonably incurred by an indemnifiable person in respect of that proceeding only if the indemnifiable
    person has provided an undertaking that, if it is ultimately determined that the payment of expenses was prohibited, the indemnifiable
    person will repay any amounts advanced. Subject to the aforementioned prohibitions on indemnification, a company must, after the
    final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an indemnifiable person in respect
    of such eligible proceeding if such indemnifiable person has not been reimbursed for such expenses, and was wholly successful, on
    the merits or otherwise, in the outcome of such eligible proceeding or was substantially successful on the merits in the outcome
    of such eligible proceeding. On application from an indemnifiable person, a court may make any order the court considers appropriate
    in respect of an eligible proceeding, including the indemnification of penalties imposed or expenses incurred in any such proceedings
    and the enforcement of an indemnification agreement.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    permitted by the BCBCA, MagicMed&rsquo;s articles require MagicMed to indemnify directors or officers of MagicMed, former directors
    or officers of MagicMed or other individuals who, at MagicMed&rsquo;s request, act or acted as directors or officers or in a similar
    capacity of another entity (and such individual&rsquo;s respective heirs and personal representatives) to the extent permitted by
    the BCBCA.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 196; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->196<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
    Business Combinations</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    general, Section 203 of the DGCL, subject to certain exceptions set forth therein, prohibits a business combination between a corporation
    and an interested stockholder within three years of the time such stockholder became an interested stockholder, unless (i) prior
    to such time, the board of directors approved either the business combination or the transaction that resulted in the stockholder
    becoming an interested stockholder, (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested
    stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction
    commenced, exclusive of shares owned by directors who are also officers and by certain employee stock plans or (iii) at or subsequent
    to such time, the business combination is approved by the board of directors and authorized by the affirmative vote at a stockholders&rsquo;
    meeting of at least 66 2/3% of the outstanding voting stock of the corporation which is not owned by the interested stockholder.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    203 defines a &ldquo;business combination&rdquo; as a merger, sale or lease of assets, issuance of securities, or other similar transaction.
    Section 203 defines an &ldquo;interested stockholder&rdquo; as a person who owns, or is an affiliate or associate of the corporation
    and within three years prior did own, 15% or more of such corporation&rsquo;s outstanding voting stock, and the affiliates and associates
    of such person.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    has not opted out of Section 203 of the DGCL.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA and MagicMed&rsquo;s articles, certain extraordinary company alterations, such as changes to authorized share structure,
    continuances, into or out of province, certain amalgamations, sales, leases or other dispositions of all or substantially all of
    the undertaking of a company (other than in the ordinary course of business) liquidations, dissolutions, and certain arrangements
    are required to be approved by ordinary or special resolution as applicable.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    ordinary resolution is a resolution (i) passed at a shareholders&rsquo; meeting by a simple majority, or (ii) passed, after being
    submitted to all of the shareholders, by being&#9;consented to in writing by shareholders who, in the aggregate, hold shares carrying
    at least two-thirds of the votes entitled to be cast on the resolution. A special resolution is a resolution (i) passed by not less
    than two-thirds of the votes cast by the shareholders who voted in respect of the resolution at a meeting duly called and held for
    that purpose or (ii) signed by all shareholders entitled to vote on the resolution.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    certain cases, an action that prejudices, adds restrictions to or interferes with a right or special right attached to issued shares
    of a class or series of shares must be approved separately by the holders of the class or series of shares being affected by special
    resolution.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, arrangements are permitted and a company may make any proposal it considers appropriate &ldquo;despite any other provision&rdquo;
    of the BCBCA. In general, a plan of arrangement is approved by a company&rsquo;s board of directors and then is submitted to a court
    for approval. It is not unusual for a company in such circumstances to apply to a court initially for an interim order governing
    various procedural matters prior to calling any security holder meeting to consider the proposed arrangement. Plans of arrangement
    involving shareholders must be approved by shareholders by a special resolution (on which holders of shares not normally entitled
    to vote are entitled to a vote). The court may, in respect of an arrangement proposed with persons other than shareholders and creditors,
    require that those persons approve the arrangement in the manner and to the extent required by the court. The court determines, among
    other things, to whom notice shall be given and whether, and in what manner, approval of any person is to be obtained and also determines
    whether any shareholders may dissent from the proposed arrangement and receive payment of the fair value of their shares. Following
    compliance with the procedural steps contemplated in any such interim order (including as to obtaining security holder approval),
    the court would conduct a final hearing and approve or reject the proposed arrangement.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion
    Rights</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    does not have any outstanding shares of preferred stock.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    does not have any outstanding preferred shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
    of First Refusal</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    does not have a right of first refusal in place.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    does not have a right of first refusal in place.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
    of Co-Sale</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    does not have a right of co-sale in place.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    does not have a right of co-sale in place.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 197; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->197<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
    Rights</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    stockholders do not have preemptive rights. As a result, if additional shares of ENVB common stock are issued, the current holders
    of ENVB common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the
    extent that they do not participate in the additional issuance.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    shareholders do not have preemptive rights. As a result, if additional shares of MagicMed Shares are issued, the current holders
    of MagicMed Shares will own a proportionately smaller interest in a larger number of outstanding shares to the extent that they do
    not participate in the additional issuance.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Appraisal
    Rights</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    stockholders of ENVB have those appraisal rights provided by Section 262 of the DGCL, to the extent applicable, provided they satisfy
    the special criteria and conditions set forth in Section 262 of the DGCL.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    Section 262 of the DGCL, ENVB stockholders are not entitled to appraisal or dissenters&rsquo; rights in connection with the amalgamation.
    Please see &ldquo;The Amalgamation&mdash;No Appraisal Rights.&rdquo;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BCBCA provides that shareholders of a company are entitled to exercise dissent rights in respect of certain matters and to be paid
    the fair value of their shares in connection therewith. The dissent right is applicable where the company resolves to (i) alter its
    articles to alter the restrictions on the powers of the company or on the business it is permitted to carry on; (ii) approve certain
    amalgamations; (iii) approve an arrangement, where the terms of the arrangement permit dissent; (iv) sell, lease or otherwise dispose
    of all or substantially all of its undertaking; or (v) continue the company into another jurisdiction.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    court may also make an order permitting a shareholder to dissent in certain circumstances.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Distributions
    to Stockholders</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    upon ENVB capital stock, subject to the provisions of ENVB&rsquo;s charter and applicable law, if any, may be declared by the ENVB
    board of directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of
    the capital stock, subject to the provisions of ENVB&rsquo;s charter and applicable law.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, a company may pay a dividend in money or other property unless there are reasonable grounds for believing that the company
    is insolvent, or the payment of the dividend would render the company insolvent.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may also pay a dividend by issuing shares or warrants.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    BCBCA provides that no special rights or restrictions attached to a series of shares confer on the series a priority in respect of
    dividends or return of capital over any other series of shares of the same class.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, the purchase or other acquisition by a company of its shares is generally subject to solvency tests similar to those applicable
    to the payment of dividends, as set out above. MagicMed is permitted, under its articles, to acquire any of its shares, subject to
    the special rights and restrictions attached to such class or series of shares and the approval of its board of directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the BCBCA, subject to solvency tests similar to those applicable to the payment of dividends (as set out above), a company may redeem,
    on the terms and in the manner provided in its articles, any of its shares that has a right of redemption attached to it. The MagicMed
    Shares are not subject to a right of redemption.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 198; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->198<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exclusive
    Forum</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    for an action in which the Court of Chancery in the State of Delaware concludes that an indispensable party is not subject to the
    jurisdiction of the Delaware courts, such Court of Chancery shall be the sole and exclusive forum for (i) any derivative action or
    proceeding brought on behalf of ENVB, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer
    of ENVB to ENVB or ENVB&rsquo;s stockholders, (iii) any action asserting a claim against ENVB arising pursuant to any provision of
    the DGCL or ENVB&rsquo;s charter or the ENVB amended and restated bylaws, or (iv) any action asserting a claim against ENVB based
    on a violation of Delaware decisional law relating to the internal affairs of the Corporation.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    may consent to an alternative forum for any such proceeding upon the approval of the ENVB board of directors.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting
    a cause of action arising under the Securities Act of 1933 or the Securities Exchange Act of 1934.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    has not adopted an &ldquo;exclusive forum&rdquo; or similar provision in the MagicMed articles.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Business
    Opportunities</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ENVB charter and the ENVB amended and restated bylaws are silent on business opportunities.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MagicMed articles are silent on business opportunities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Registration
    Rights</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
    does not have registration rights in place.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    does not have registration rights in place.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 199; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->199<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="o_133"></A>information
about the MAGICMED directorS AND CERTAIN OFFICERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name of each director and executive officer of MagicMed as of the date of this proxy statement/prospectus,
their province or state and country of residence, their position(s) and office(s) held with MagicMed, their principal occupation(s) during
the preceding five years, and the date they became a director of MagicMed, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information about each of the employment agreements between ENVB and Dr. Tucker, Dr. Hagel, and Dr. Facchini, please see the section
titled &ldquo;The Amalgamation&mdash;Governance of ENVB After the Amalgamation&rdquo; beginning on page 109 of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name,
    Province and Country of Residence</B></FONT></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current
    Position</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
    and/or Officer Since</B></FONT></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48%"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    Occupation During Past Five Years</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Norwell,
Massachusetts, U.S.A</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, Secretary and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    26, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2014 &ndash; April 2019, Chief Executive Officer, President, director and founder of Epimeron Inc., (acquired by Makena Resources
    Inc. in 2019); April 2019 &ndash; March 2020, Executive Chairman and Chief Operating Officer of Willow Biosciences Inc.; May 2020
    &ndash; present, Chief Executive Officer and President of MagicMed. June 2016 &ndash; present, Chief Executive Officer and President
    of VirTech Bio, Inc., a biotechnology company; September 2008 &ndash;present, Adjunct Assistant Professor at the University of Calgary.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Facchini</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alberta,
    Canada</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    26, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    1995 &ndash; present, Professor at UofC; March 2014 &ndash; April 2019, Chief Scientific Officer, director and founder of Epimeron
    Inc. (acquired by Makena Resources Inc. in 2019); April 2019 &ndash; April 2020, Chief Scientific Officer of Willow Biosciences Inc.;
    May 2020 &ndash; present, Chief Scientific Officer of MagicMed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jillian
    Hagel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alberta,
    Canada</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Technology Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    26, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2014 &ndash; April 2019, Chief Operating Officer of Epimeron Inc. (acquired by Makena Resources Inc. in 2019); April 2019 &ndash;
    April 2020, Vice President of Applied Sciences of Willow Biosciences Inc.; Jan 2015 &ndash; April 2020, Research Associate at University
    of Calgary; May 2020 &ndash; present General Associate &amp; Contractor at University of Calgary; May 2020 &ndash; present, Chief
    Technology Officer of MagicMed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terry
    Zimaro</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alberta,
    Canada</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    26, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
    October 2014, Co-founder and Accountant of Weller &amp; Zimaro Chartered Professional Accountants; May 2020 &ndash; present, Chief
    Financial Officer of MagicMed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Flach,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alberta,
    Canada</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director<SUP>(1)(2)(3)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    22, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2014 &ndash; April 2019, Corporate Secretary of Epimeron Inc. (acquired by Makena Resources Inc. in 2019); July 2014 &ndash; present,
    principal at Greenfields Law; December 2017 &ndash; present, Vice President, Legal and General Counsel of PTW Energy Services Ltd.,
    a company that provides construction, fabrication and maintenance services </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Henri
    Sant-Cassia</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Wardija,
    Malta</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director<SUP>(1)(2)(3)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    22, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2016 &ndash; November 2018, Chief Executive Officer of CBD Virtue Ltd.; January 2019 &ndash; present, Partner at The Conscious Fund.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Thompson</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alberta,
    Canada</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director<SUP>(1)(2)(3)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    22, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1999 &ndash; November 2016, Chief Executive Officer and a director of Oncolytics Biotech Inc.; November 2016 &ndash; present, Chief
    Executive Officer of Kickshaw Ventures Ltd., a biotechnology company; November 2017 &ndash; present, Chief Executive Officer and
    Chief Science Officer of Wyvern Pharmaceuticals Inc., a biopharmaceutical company</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
                                            Committee member.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
                                            Committee member.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
                                            Governance Committee member.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 200; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->200<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_134"></A>Term
of Office of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of office of the directors expires annually at the time of MagicMed&rsquo;s annual general meeting. The term of office of the executive
officers expires at the discretion of the MagicMed Board.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_135"></A>Aggregate
Ownership of Securities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
MagicMed&rsquo;s knowledge as at the date of this Information Circular, its directors and executive officers as a group will beneficially
own, or control or direct, directly or indirectly, 7,500,000 MagicMed Shares, representing approximately 20.04% of the outstanding MagicMed
Shares on a non-diluted basis.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_136"></A>MagicMed
Option Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the MagicMed Board approved the MagicMed Option Plan. As of the date of this proxy statement/prospectus, there were
3,683,830 MagicMed options outstanding under the MagicMed Option Plan, 679,830 of which are exercisable at a price of $0.25 per MagicMed
share until October 5, 2030 and 3,004,000 of which are exercisable at a price of $0.50 per MagicMed share until April 5, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the MagicMed Option Plan is to provide MagicMed with a share-related mechanism to attract, retain and motivate qualified directors,
officers, employees and consultants, to reward those individuals from time to time for their contributions toward the long terms goals
of MagicMed and to enable and encourage those individuals to acquire MagicMed Shares as long-term investments. The general terms and
conditions of the MagicMed Option Plan are reflected in the disclosure below. Any capitalized terms used below, but not otherwise defined,
shall have the meanings ascribed thereto in the MagicMed Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
    Terms</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Administration</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MagicMed Option Plan will be administered by the MagicMed Board, or such director or other senior officer of MagicMed as may be designated
    as administrator by the MagicMed Board. The MagicMed Board or such committee may make, amend and repeal at any time, and from time
    to time, such regulations not inconsistent with the MagicMed Option Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of MagicMed Shares</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    aggregate number of MagicMed Shares that may be reserved for issuance pursuant to MagicMed Options shall not exceed 10% of the outstanding
    MagicMed Shares at the time of the granting of an Option, <I>less</I> the aggregate number of MagicMed Shares then reserved for issuance
    pursuant to any Other Share Compensation Arrangement. If an Option is <FONT STYLE="letter-spacing: -0.15pt">exercised, </FONT>surrendered,
    terminated or expires without being exercised, the MagicMed Shares reserved for issuance pursuant to such Option shall be available
    for new MagicMed Options granted under the MagicMed Option Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Option entitles the Participant to purchase one MagicMed Share at an exercise price determined by the MagicMed Board.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participation</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    Options shall only be granted to Eligible Persons.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option
    Agreement</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
    Option shall be evidenced by an Option Agreement executed by MagicMed and the Participant, which shall, if the Participant is an
    Employee, Consultant or Management MagicMed Employee, contain a representation and MagicMed Warranty by MagicMed and such Participant
    that such Participant is a bona fide Employee, Consultant or Management MagicMed Employee, as the case may be, of MagicMed or an
    affiliate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    must not grant MagicMed Options with an exercise price lower than the greater of: (i) the closing market prices of the underlying
    securities on: (a) the trading day prior to the date of grant of the MagicMed Options; and (b) the date of grant of the MagicMed
    Options; or (ii) in the event that the MagicMed Shares are not listed on any stock exchange, the Fair Market Value of the MagicMed
    Shares on the business day immediately prior to the date of the grant of the MagicMed Options.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 201; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->201<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Period</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 71%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    exercise period of an Option will be the period from and including the award date through to and including the expiry date that will
    be determined by the MagicMed Board at the time of grant (the &ldquo;Expiry Date&rdquo;), provided that every Option shall have a
    term not exceeding, and shall therefore expire no later than, <FONT STYLE="letter-spacing: -0.15pt">10 </FONT>years after the date
    of grant, subject to extension where the Expiry Date falls within a blackout period as detailed in Section 5.2(b) <FONT STYLE="letter-spacing: -0.4pt">of
    the MagicMed Option Plan</FONT>.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vesting</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MagicMed Board shall determine the manner in which an Option shall vest and become exercisable. MagicMed Options granted to Eligible
    Persons performing Investor Relations Activities shall vest over a minimum of 12 months with no more than 1/4 of such MagicMed Options
    vesting in any three month period.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cessation
    of being an Eligible Person</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to certain limitations, in the event that an Participant ceases to be an Officer, or Consultant of MagicMed or ceases to be employed
    by MagicMed, other than by reason of death, each Option held by such Participant shall terminate and shall therefore cease to be
    exercisable no later than the earlier of the Expiry Date and the date which is 30 days after such event, provided that the MagicMed
    Board may, in its discretion, extend the date of such termination and the resulting period in which such Option remains exercisable
    to a date not exceeding the earlier of the Expiry Date and the date which is twelve months after such event, and further provided
    that the MagicMed Board may, in its discretion, on a case-by-case basis and only with the approval of the CSE, further extend the
    date of such termination and the resulting period in which such Option remains exercisable to a date exceeding the date which is
    after twelve months of such event. If a Participant dies prior to otherwise ceasing to be an Eligible Person, each Option held by
    such Participant shall terminate and shall therefore cease to be exercisable no later than the earlier of the Expiry Date and the
    date which is six months after the date of the Participant&rsquo;s death, provided that the MagicMed Board may extend the exercise
    period to the earlier of the Expiry Date and the date which is twelve months after the date of the Participant&rsquo;s death.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
    any one person.</B> The number of MagicMed Shares reserved for issuance to any one person in any 12 month period under <FONT STYLE="letter-spacing: -0.4pt">the
    MagicMed Option Plan</FONT> and any Other Share Compensation Arrangement shall not exceed 10% of the outstanding MagicMed Shares
    at the time of the grant, unless MagicMed has obtained Disinterested Shareholder Approval to exceed such limit.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
    Consultants. </B>The number of MagicMed Shares reserved for issuance to any one Consultant in any 12 month period under <FONT STYLE="letter-spacing: -0.4pt">the
    MagicMed Option Plan</FONT> and any Other Share Compensation Arrangement shall not exceed 2% of the outstanding MagicMed Shares (on
    a non-diluted basis) at the time of the grant, except in the case where and for so long as MagicMed has not been listed on any stock
    exchange, shall not exceed 2% of the outstanding MagicMed Shares (on a fully diluted basis) at the time of the grant.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.75pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
    persons conducting Investor Relations Activities. </B>The aggregate number of MagicMed Shares reserved for issuance to all Eligible
    Persons conducting Investor Relations Activities in any 12 month period under the MagicMed Option Plan and any Other Share Compensation
    Arrangement shall not exceed 2% of the outstanding MagicMed Shares at the time of the grant.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.75pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
    Insiders. </B>Unless MagicMed has received Disinterested Shareholder Approval to do so, the aggregate number of MagicMed Shares reserved
    for issuance to Insiders under the MagicMed Option Plan and any Other Share Compensation Arrangement shall not exceed 10% of the
    outstanding MagicMed Shares at the time of the grant; the aggregate number of MagicMed Shares reserved for issuance to Insiders in
    any 12 month period under the MagicMed Option Plan and any Other Share Compensation Arrangement shall not exceed 10% of the outstanding
    MagicMed Shares at the time of the grant.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendments,
    Suspension and Termination</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MagicMed Board may amend, subject to the approval of any regulatory authority whose approval is required, suspend or terminate the
    MagicMed Option Plan or any portion thereof. No such amendment, suspension or termination shall alter or impair any outstanding unexercised
    MagicMed Options or any rights without the consent of such Participant. If the MagicMed Option Plan is suspended or terminated, the
    provisions of the MagicMed Option Plan and any administrative guidelines, rules and regulations relating to the MagicMed Option Plan
    shall continue in effect for the duration of such time as any Option remains outstanding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_137"></A>MagicMed
Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this proxy statement/prospectus there were 22,248,577 issued and outstanding MagicMed warrants each exercisable into one
MagicMed share. 13,690,000 of the MagicMed Warrants are exercisable at a price of $0.25 until May 26, 2025. 8,558,577 of the MagicMed
Warrants are exercisable at a price of $0.75 until two years from the date of a liquidity event (as defined in the warrant agreement).</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_138"></A>MagicMed
Broker Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this proxy statement/prospectus there were 1,283,501 issued and outstanding &ldquo;MagicMed Broker Warrants.&rdquo;
The MagicMed Broker Warrants are each exercisable into one unit of MagicMed (an &ldquo;Advisor Unit&rdquo;) at a price of $0.50 per
Advisor Unit until the date that is two years from the date of a Liquidity Event. Each Advisor Unit is comprised of one MagicMed Share
and one-half of one MagicMed Share purchase warrant of MagicMed (each whole MagicMed Warrant an &ldquo;Underlying Broker Warrant&rdquo;).
Each Underlying Broker Warrant is exercisable into one MagicMed Share at an exercise price of $0.75 per share for a period of two years
from the date of a Liquidity Event.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_139"></A>Stock
Appreciation Rights Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
has adopted a stock appreciation rights plan effective as of January 22, 2021 (the &ldquo;SARs Plan&rdquo;) which provides that the MagicMed
Board may from time to time, in its discretion, grant to employees, officers, directors, consultants or other service providers of MagicMed
or any of its affiliates (as defined in the SARs Plan)(collectively &ldquo;Service Providers&rdquo;) non-transferable unit appreciation
rights (&ldquo;SARs&rdquo;). Each SAR grants a Service Provider (the &ldquo;Grantee&rdquo;) the right to receive, from MagicMed, a cash
payment in an amount determined by multiplying: (i) the amount that the Fair Market Value (as defined in the SARs Plan) of one MagicMed
Share on the date of exercise of such SAR exceeds the relevant Base Price (as defined below); by (ii) the number of MagicMed Shares in
respect of which such SARs are so exercised, multiplied by the Adjustment Ratio (as defined in the SARs Plan) applicable in respect of
such SARs. Unless otherwise provided in the grant agreement or in the Grantee&rsquo;s employment or similar written agreement, SARs will
either: (i) immediately vest; or (ii) vest as to one-third of the number of SARs granted on the first anniversary of the date of grant
and as to one-third of the number of SARs granted on the anniversary of the date of grant on each of the next two succeeding anniversaries;
provided, however that in the event of a Change of Control (as defined in the SARs Plan) all SARs that have not yet been exercised as
of such time shall become exercisable on the date which is immediately prior to the date upon which a Change of Control (as defined in
the SARs Plan) is completed. The Amalgamation will trigger the Change of Control provisions in the SARs Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 202; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->202<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the SARs Plan, the aggregate number of MagicMed Shares in respect of which SARs have been granted and not yet exercised
shall not at any time exceed 5% of the aggregate number of MagicMed Shares that are then issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
SARs are outstanding as at the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Securities
Authorized for Issuance under Equity Compensation Plans </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan
    Category</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of securities to</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>be issued upon exercise</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>of outstanding options, warrants and rights</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted-average</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>exercise price of</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>outstanding options, warrants and rights</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of securities remaining available for future issuance under</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>equity compensation</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>plans (excluding</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>securities reflected in</B></FONT></P>
                                                                                                       <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>column (a))</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
    compensation plans approved by security holders</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
    compensation plans not approved by security holders</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#9;3,683,380
    Options</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#9;22,248,577
    warrants</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#9;1,283,501
    Broker Warrants (as defined below)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#9;641,750.5
    Underlying Broker Warrants (as defined below)</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.45
    per Option</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.44
    per warrant</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.50
    per Broker Warrant</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.75
    per Underlying Broker Warrant</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,487.3
    Options</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>27,857,208.5</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$0.45
    per security</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>58,487.3
    </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 203; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->203<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="o_140"></A>principal
stockholders of envb</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership of ENVB common stock as of March 17, 2021, by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person known by ENVB to be the beneficial owner of more than five percent of the outstanding
                                            shares of ENVB common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            director;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of the named executive officers identified in the &ldquo;Summary Compensation Table&rdquo;
                                            under Executive Compensation in the Company&rsquo;s Proxy Statement filed with the SEC on
                                            November 4, 2020 as well as the executive officers of the Company as of June 16, 2021; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            directors and executive officers of the Company as a group.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentages of ENVB common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of
beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a beneficial owner of a security if that person
has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes
the power to dispose of or to direct the disposition of the security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated in the footnotes to this table, each beneficial owner named in the table below has sole voting and sole investment power
with respect to all shares beneficially owned and each person&rsquo;s address is c/o Enveric Biosciences, Inc. 4851 Tamiami Trail N.,
Suite 200, Naples, FL 34103. As of March 17, 2021, ENVB had 19,449,975 shares of common stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares Beneficially Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Percentage of Shares</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Outstanding</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">5% Owners:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha Capital Anstalt<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">2,159,220</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">9.99</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Stefansky<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,288,816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.56</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO Pharmaceuticals<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2299,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.82</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Officers and Directors:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">David Johnson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Carter Ward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Avani Kanubaddi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Van Buiten<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Robert G. Wilkins</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">George Kegler</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Sol Mayer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Marcus Schabacker</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Douglas Lind</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brent Kelton<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barry Kostiner<SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Srinidhi (Dev) Devanur<SUP>(7)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All current directors and executive officers as a group (8 persons))</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents less than 1%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            address of Alpha Capital Anstalt is Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein.
                                            Alpha Capital Anstalt is the beneficial owner of 2,159,220 shares of ENVB common stock including
                                            (i) 513 shares of common stock and (ii) 2,158,707 shares of common stock underlying warrants
                                            that are currently exercisable. Alpha Capital Anstalt has sole voting power and sole dispositive
                                            power over such shares of ENVB common stock. As of March 17, 2021, Alpha Capital Anstalt
                                            owns additional warrants that would be exercisable up to 1,500,440 additional shares of ENVB
                                            common stock, except for a limitation set forth in the warrant agreements that restricts
                                            Alpha Capital Anstalt&rsquo;s ability to exercise the warrants if such exercise would result
                                            in Alpha Capital Anstalt (including its affiliates) owning more than 9.99% of ENVB&rsquo;s
                                            currently outstanding number of shares of common stock. Thus, the number of shares of ENVB&rsquo;s
                                            common stock beneficially owned by Alpha Capital Anstalt as of March 17, 2021 was 2,159,220,
                                            which represents 9.99% beneficial ownership of the 19,449,975 shares of ENVB common stock
                                            that were outstanding as of March 17, 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 204; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->204<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            address of David Stefansky and Bezalel Partners, LLC is 265 E. 66th St., Apt. 6C, New York,
                                            NY 10065. Includes (i) 931,855 shares of ENVB common stock held through Bezalel Partners,
                                            LLC (&ldquo;Bezalel&rdquo;), (ii) 150,836 shares of common stock held by Mr. Stefansky, and
                                            (iii) options held by Mr. Stefansky to purchase up to 206,125 shares of ENVB common stock
                                            that are currently exercisable. Mr. Stefansky is the natural person with voting and dispositive
                                            power over shares of Bezalel and is deemed to have beneficial ownership of the shares held
                                            by Bezalel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on a Schedule 13G filed February 10, 2021 by TO Pharmaceuticals LLC and TOP Invest LLC. The
                                            address of TO Pharmaceuticals and TOP Invest LLC is TO Pharmaceuticals, 77 Water St., 8th
                                            Floor, New York, New York 10005. According to the Schedule 13G, TO Pharmaceuticals LLC and
                                            TOP Invest LLC each have sole voting power and sole dispositive power with respect to 2,299,001
                                            shares of common stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
                                            Chief Financial Officer resigned effective May 15, 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
                                            Chief Executive Officer resigned December 30, 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
                                            Chief Financial Officer resigned December 30, 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
                                            Executive Chairman resigned December 30, 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<!-- Field: Page; Sequence: 205; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->205<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="o_141"></A>Principal
Stockholders of MAGICMED</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of June 17, 2021, certain information with respect to the beneficial ownership of MagicMed common
shares by (i) each shareholder known by MagicMed to be the beneficial owner of more than 5% of MagicMed&rsquo;s common shares; (ii) each
director of MagicMed; (iii) the executive officers of MagicMed; and (iv) all current directors and executive officers of MagicMed as
a group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
MagicMed common shares that may be acquired by an individual or group within 60 days of June 17, 2021, pursuant to the exercise
of options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group,
but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
is authorized to issue an unlimited number of MagicMed common shares. As of June 17, 2021, there were 37,418,673 MagicMed common
shares issued and outstanding. Each holder of MagicMed common shares is entitled to one vote per MagicMed common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
address of the directors and executive officers listed below is c/o MagicMed Industries Inc., 777 Hornby Street, Suite 600, Vancouver,
British Columbia, V6Z 1S4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Security
Ownership of Certain Beneficial Owners</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides certain information with respect to any person who is known to MagicMed to be the beneficial owner of more than
5% of MagicMed Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Title of Class</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name and Address of Beneficial Owner</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount and Nature of Beneficial Owner</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent of Class</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: justify">Common shares</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 46%; text-align: center">Shpirtrat Trust</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">2,002,000</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">5.34</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
                                            not include 1,600,000 MagicMed Warrants held by the Shpirtrat Trust.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Security
Ownership of Management/Directors of MagicMed</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Title of Class</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Beneficial Owner</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount and Nature of Beneficial Owner<SUP>(1)(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent of Class</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: center">Common shares</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 46%; text-align: center">Joseph Tucker</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">2,600,000</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">6.95</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Peter Facchini</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,320,000</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.20</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Jillian Hagel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,310,000</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.17</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Terry Zimaro</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Michael Flach</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.67</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Henri Sant Cassia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Brad Thompson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
                                            note include 750,000 MagicMed stock options held by Dr. Tucker, 375,000 MagicMed stock options
                                            held by Dr. Facchini, 375,000 MagicMed stockoptions held by Dr. Hagel, 375,000 MagicMed stock
                                            options held by Terry Zimaro, 350,000 MagicMed stock options held by Michael Flach, 200,000
                                            MagicMed stock options held by Henri Sant Cassia and 200,000 MagicMed stock options held
                                            by Brad Thompson.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 206; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->206<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
                                            note include 2,550,000 MagicMed Warrants held by Dr. Tucker, 2,310,000, MagicMed Warrants
                                            held by Dr. Facchini, 2,305,000 MagicMed Warrants held by Dr. Hagel and 250,000 MagicMed
                                            Warrants held by Adorn Inc., a corporation owned and controlled by Mr. Flach&rsquo;s wife,
                                            Larissa Flach.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,600,000
                                            of these common shares are held indirectly through the Tucker 2020 Family Trust, a trust
                                            controlled by Dr. Tucker.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000
                                            of these common shares are held indirectly through the Facchini 2020 Family Trust, a trust
                                            controlled by Dr. Facchini.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000
                                            of these common shares are held indirectly through the Hagel 2020 Family Trust, a trust controlled
                                            by Dr. Hagel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            MagicMed shares are owned by Adorn Inc., a corporation owned and controlled by Mr. Flach&rsquo;s
                                            wife, Larissa Flach.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 207; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->207<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_142"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of ENVB common stock offered hereby in connection with the Amalgamation will be passed upon for ENVB by Haynes
and Boone, LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_143"></A>EXPERTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVB</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Enveric Biosciences, Inc. as of and for the years ended December 31, 2020 and 2019, have been audited
by Marcum LLP, independent registered public accounting firm, as stated in their report which is included herein. Such financial statements
have been included in this registration statement in reliance on the reports of such firm given upon their authority as experts in accounting
and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements for MagicMed Industries Inc. as of and for the period from May 26, 2020 (inception) through June 30,
2020 have been included herein and in this registration statement in reliance upon the report of Zeifmans LLP, independent registered
public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_144"></A>WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and current reports,
proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements,
and other information regarding registrants that file electronically with the SEC. The address of the SEC&rsquo;s website is www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
makes available free of charge on or through its website at www.enveric.com, its Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange
Act, as soon as reasonably practicable after ENVB electronically files such material with or otherwise furnishes it to the SEC. The website
addresses for the SEC and ENVB are inactive textual references and information on those websites is not part of this proxy statement/prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
has filed with the SEC a registration statement on Form S-4, of which this proxy statement/prospectus is a part, under the Securities
Act to register the shares of ENVB common stock to be issued to MagicMed shareholders in connection with the Amalgamation. The registration
statement, including the attached annexes, exhibits and schedules, contains additional relevant information about ENVB and ENVB common
stock. However, this proxy statement/prospectus does not contain all of the information set forth in the registration statement and the
exhibits and schedules to the registration statement. ENVB and MagicMed encourage you to carefully read the registration statement and
the exhibits and schedules to the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
has supplied all the information contained in this proxy statement/prospectus relating to ENVB, and MagicMed has supplied all the information
contained in this proxy statement/prospectus relating to MagicMed. Each of ENVB and MagicMed is relying on the correctness of the information
supplied by the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained in this proxy statement/prospectus. Neither ENVB nor MagicMed has authorized anyone to
provide you with different information. Therefore, if anyone gives you different or additional information, you should not rely on it.
The information contained in this proxy statement/prospectus is correct as of its date. It may not continue to be correct after this
date. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 208; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->208<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_145"></A>OTHER
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_146"></A>Future
Stockholder Proposals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you want ENVB to consider including a proposal in its proxy statement for its 2021 Annual Meeting of Stockholders, you must deliver a
copy of your proposal to ENVB&rsquo;s Secretary at our corporate office at 4851 Tamiami Trail N, Suite 200, Naples, Florida 34103 no
later than July 8, 2021, or, if the date of our 2021 Annual Meeting of Stockholders is more than 30 days from the anniversary date of
the 2020 Annual Meeting of Stockholders, then the deadline is a reasonable time before we begin to print and send our proxy materials
for our 2021 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you intend to present a proposal at our 2021 Annual Meeting of Stockholders, including director nominations, but you do not intend to
have it included in our 2021 Proxy Statement, you must deliver a copy of your proposal to ENVB&rsquo;s Secretary at our corporate office
listed above no earlier than August 24, 2021 and no later than the close of business on September 25, 2021. The proposal must contain
certain information specified in our Bylaws; provided, however, that in the event that the date of our 2021 Annual Meeting of Stockholders
is advanced by more than 30 days or delayed by more than 60 days from the anniversary date of the 2020 Annual Meeting of Stockholders,
your notice will be timely if we receive it no earlier than the close of business on the 120th day prior to the 2021 Annual Meeting and
no later than the close of business on the later of (i) the 90th day prior to such annual meeting, or (ii) the tenth day following the
earlier of the date on which a public announcement setting forth the date of such meeting is first made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_147"></A>Householding
of Proxy Statement/Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that permit companies and intermediaries, such as brokers, to satisfy delivery requirements for the ENV special
meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of ENVB special meeting
materials addressed to those stockholders. This process, commonly referred to as &ldquo;householding,&rdquo; potentially provides extra
convenience for stockholders and cost savings for companies. Because we utilize the &ldquo;householding&rdquo; rules for special meeting
materials, stockholders who share the same address will receive only one copy of the ENVB special meeting materials, unless we receive
contrary instructions from any stockholder at that address. If you prefer to receive multiple copies of the ENVB special meeting materials
at the same address you share with other stockholders, additional copies will be provided to you promptly upon request. If you are a
stockholder of record, you may obtain additional copies at the same address you share with other stockholders by contacting Broadridge
Financial Solutions, Inc., either by calling (866) 540-7095, or by writing to Broadridge Householding Department, 51 Mercedes Way, Edgewood,
New York 11717. Eligible stockholders of record receiving multiple copies of the ENVB special meeting materials can request householding
by contacting Broadridge Financial Solutions, Inc. in the same manner. If you are a beneficial owner and hold your shares in a brokerage
or custody account, you can request additional copies of the ENVB special meeting materials at the same address you share with other
stockholders or you can request householding by notifying your broker, bank or other nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 209; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->209<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_148"></A>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></P>
                                                                                <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Audited Consolidated
    Financial Statements of Enveric Biosciences, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_001"><FONT STYLE="font-size: 10pt">Report
    of Independent Registered Accounting Firm</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_002"><FONT STYLE="font-size: 10pt">Consolidated
    Balance Sheets as of December 31, 2019 and December 31, 2020</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_003"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Operations and Comprehensive Loss for the years ended December 31, 2019 and December 31, 2020</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#cr_004">Consolidated
    Statements of Changes in Shareholders&rsquo; Equity (Deficit) for the years ended December 31, 2019 and December 31, 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_005"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Cash Flows for the years ended December 31, 2019 and December 31, 2020</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_006"><FONT STYLE="font-size: 10pt">Notes
    to the Consolidated Financial Statements</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.65in"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></P>
                                                                                <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unaudited Condensed
    Consolidated Financial Statements of Enveric Biosciences, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_007"><FONT STYLE="font-size: 10pt">Condensed
    Consolidated Balance Sheets as of March 31, 2021 (Unaudited) and December 31, 2020</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_008"><FONT STYLE="font-size: 10pt">Condensed
    Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2020 and March 31, 2021</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_009"><FONT STYLE="font-size: 10pt">Condensed
    Consolidated Statement of Changes in Stockholders&rsquo; Equity (Unaudited) for the three months ended March 31, 2020 and March 31,
    2021</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_010"><FONT STYLE="font-size: 10pt">Condensed
    Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2020 and March 31, 2021</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#cr_011"><FONT STYLE="font-size: 10pt">Notes
    to the Unaudited Condensed Consolidated Financial Statements</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-23</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><A HREF="#e_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audited Financial Statements of MagicMed Industries Inc.</B></FONT></A></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.65in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page<BR>
    Number </B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Auditor</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-32</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Financial Position as at June 30, 2020</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>34</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Loss and Comprehensive Loss for the period from Incorporation (May 26, 2020) to <BR> June 30, 2020</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>35</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Changes in Shareholders&rsquo; Equity for the period from Incorporation (May 26, 2020) to <BR> June 30, 2020</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>36</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Cash Flows for the period from Incorporation (May 26, 2020) to June 30, 2020</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-37</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Financial Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-38</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.65in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page<BR>
    Number </B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#e_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited Condensed Consolidated Financial Statements of MagicMed Industries Inc. </B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Condensed Consolidated Statement of Financial Position as at March 31, 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-54</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Condensed Consolidated Statement of Loss and Comprehensive Loss for the Three and Nine <BR> Month Periods Ended March 31, 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-55</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Condensed Consolidated Statement of Shareholders&rsquo; Equity for the Nine Month Period <BR> Ended March 31, 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-56</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Condensed Consolidated Statement of Cash Flows for the Nine-Month Period Ended<BR> March 31, 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-57</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#e_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Interim Condensed Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT>58</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 210; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_001"></A>REPORT
OF INDEPENDENT REGISTERED ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences, Inc. and Subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Enveric Biosciences, Inc. and Subsidiary (the &ldquo;Company&rdquo;) as
of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, changes in stockholders&rsquo;
equity (deficit) and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively
referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States
of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (the &ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Audit Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 211 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Common Stock Used in the Purchase of Intangible Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 5 to the financial statements, on October 2, 2020, the Company purchased skincare assets for an aggregate purchase
price of $1,944,689, which included cash consideration of $44,413 and the issuance of common stock, which was valued at $1,900,546. At
the time of the transaction, the Company was a private company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation of private company common stock requires significant judgment in weighting the various indicators of fair value. The principals
and considerations to be applied include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicators
    of value are those comparable transactions between informed, willing, buyers and sellers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comparable
    transaction must be orderly and not in a distressed situation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximize
    the weight of observable inputs, where possible;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    issued as the indicator of value must be similar or identical to the securities being valued;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timing
    of comparable transactions must be close to the valuation date</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration
    as to whether the valuation of the technology is more indicative of the fair value of the assets acquired in comparison to the consideration
    paid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significance of the intangible assets to the Company&rsquo;s financial statements and the inherent judgment necessary to estimate
the valuation of the common stock, we determined that the fair value of common stock used in the purchase of intangible assets was a
critical audit matter, which required significant auditor judgment and specialized skill and knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
the Critical Audit Matter Was Addressed in the Audit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addressing
the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included, but were not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    evaluated management&rsquo;s process for the selection of the valuation methodology and the methods and significant assumptions used
    by management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    the assistance of our valuation specialists, we evaluated the reasonableness of the valuation methodology used;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    evaluated the reasonableness of the inputs subject to assumptions and verified the accuracy and completeness of those inputs to the
    underlying transaction data utilized in the valuation of the common stock and verified; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    performed sensitivity analyses of the significant assumptions used in the valuation model to evaluate the change in fair value resulting
    from changes in the significant assumptions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Marcum LLP</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
    LLP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
1, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 212 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_002"></A>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    assets:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,578,460</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,714</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">700,710</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">65,075</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,279,170</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">108,789</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intangible
    assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,817,721</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,096,891</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">108,789</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities
    and Shareholders&rsquo; Equity (Deficit)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    liabilities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">681,250</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,157,645</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advance
    from related party</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,409</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">446,415</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">293,921</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">681,250</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,920,390</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments
    and Contingencies (Note 6)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo;
    Equity (Deficit)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred
    Stock, $0.01 par value, 20,000,000 shares authorized, 3,275,407 and 262,500 shares issued and outstanding as of December 31, 2020
    and December 31, 2019, respectively</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,754</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,625</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock, $0.01 par value, 100,000,000 shares authorized, 10,095,109 and 5,311,414 shares issued and outstanding as of December 31,
    2020 and December 31, 2019, respectively</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,951</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">53,114</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,222,770</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,039,163</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,759,557</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,894,881</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    other comprehensive loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(181,277</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,622</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    shareholders&rsquo; equity (deficit)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,415,641</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,811,601</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities and shareholders&rsquo; equity (deficit)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,096,891</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">108,789</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are in integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 213 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_003"></A>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,443,234</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,296,534</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">174,083</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    from operations</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,617,317</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,296,534</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Extinguishment
    of note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,316</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">445,250</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81,823</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inducement
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">802,109</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    other expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,247,359</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">114,139</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,864,676</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,410,673</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    comprehensive loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
    exchange loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(169,655</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,667</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Comprehensive
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,034,331</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,417,340</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss per share - basic and diluted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1.19</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.46</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average shares outstanding, basic and diluted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,753,598</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,287,145</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are in integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 214 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_004"></A>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; EQUITY (DEFICIT)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECMEBER 31, 2020 AND 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    B Preferred Stock</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other
    Comprehensive</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">capital</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 24%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of January 1, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">262,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,625</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,262,042</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">52,620</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,368,464</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,484,208</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,955</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(65,454</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    stock issued for services</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">38,116</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">381</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">88,084</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">88,465</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants
    issued in conjunction with notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">24,875</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">24,875</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares
    issued in connection with note extension</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">11,256</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">113</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">22,153</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">22,266</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    based compensation - stock options</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">535,587</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">535,587</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    exchange loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,667</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,667</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,410,673</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,410,673</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of December 31, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">262,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,625</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,311,414</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">53,114</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,039,163</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,894,881</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(11,622</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,811,601</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of January 1, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">262,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,625</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,311,414</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">53,114</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,039,163</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,894,881</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(11,622</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,811,601</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">September
    2020 private placement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">36,871</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">369</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">227,131</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">227,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">December
    2020 private placement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">221,225</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,212</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">258,288</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">260,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Acquisition
    of Tikkun Pharma IP</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">571,987</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,720</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,894,826</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,900,546</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Alpha
    financing and conversion of Alpha Note, including Palladium shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,041,682</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,417</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">402,988</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,030</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,781,742</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,816,189</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exchange
    of warrants for common shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">330,122</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,301</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">838,577</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">841,878</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion
    of related party advance and notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">512,978</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,130</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">674,439</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">679,569</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    stock issued for accounts payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">433,047</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,330</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">752,193</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">756,523</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants
    issued in conjunction with notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">32,149</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">32,149</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Beneficial
    conversion feature issued with note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,851</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,851</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    stock issued in conjunction with note payable modification</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">21,625</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">216</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">101,497</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">101,713</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    option expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,977,155</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,977,155</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion
    of Series B preferred stock to common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(250,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">250,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Merger
    with Ameri Holdings, Inc.</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,224,077</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">22,241</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">627,759</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">650,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    exchange loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(169,655</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(169,655</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,864,676</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,864,676</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,275,407</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">32,754</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,095,109</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">100,951</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,222,770</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(11,759,557</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(181,277</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,415,641</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are in integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 215 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_005"></A>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Operating Activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,864,676</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,410,673</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to cash used in operating activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Extinguishment
    of note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,316</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    interest</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">156,619</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,684</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of debt discount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">288,631</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,453</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,977,155</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">624,052</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inducement
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">802,109</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of intangible assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">120,872</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in operating assets and liabilities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(636,497</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">104,340</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">267,002</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">919,968</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,888,785</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(647,860</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Investing Activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase
    of Tikkun Pharma license agreement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(44,143</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(44,143</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Financing Activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from convertible notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">300,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from note payable, net of offering costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,812,410</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">238,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advances
    from related party</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Offering
    and Reverse Merger proceeds</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,372,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">September
    2020 private placement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">227,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    2020 private placement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">260,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment
    of note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(191,640</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,531,270</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">560,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect
    of foreign exchange rate on cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(63,596</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,903</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    increase (decrease) in cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,534,746</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(69,957</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - beginning of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,714</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">113,671</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,578,460</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,714</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    non-cash financing activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
    conversion feature issued with note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,851</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    issued in conjunction with notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,149</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,875</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock issued for accounts payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">756,523</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock issued in conjunction with note payable modification</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">101,713</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,266</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable issued to consultant for prepaid services</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion
    of related party advances and notes payable into common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">679,569</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock issued for skincare license</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,900,546</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are in integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 30pt"></P>

<!-- Field: Page; Sequence: 216 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="cr_006"></A>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none">NOTE
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 - Business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nature
of operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&ldquo;Enveric Biosciences, Inc.,&rdquo; &ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;) (formerly known as Ameri
Holdings, Inc.) (&ldquo;Ameri&rdquo;) is a pharmaceutical company developing innovative, evidence-based cannabinoid medicines. The head
office of the Company is located in Naples, Florida.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, the Company entered into an Amalgamation Agreement (as amended on May 6, 2020), (the &ldquo;Amalgamation Agreement&rdquo;)
with Jay Pharma Merger Sub, Inc., a company organized under the laws of Canada and a wholly owned subsidiary of the Company (&ldquo;Merger
Sub&rdquo;), Jay Pharma Inc., a company organized under the laws of Canada (&ldquo;Jay Pharma&rdquo;), Jay Pharma ExchangeCo., Inc. a
company organized under the laws of British Columbia and a wholly owned subsidiary of the Company (&ldquo;ExchangeCo&rdquo;), and Barry
Kostiner, as the Company Representative, which provided that, among other things, Merger Sub and Jay Pharma would be amalgamated and
would continue as one corporation (&ldquo;Amalco&rdquo;), with Amalco continuing as a direct wholly owned subsidiary of ExchangeCo and
an indirect wholly owned subsidiary of Ameri, on the terms and conditions set forth in the Amalgamation Agreement. On August 12, 2020,
the Company, Jay Pharma and certain other signatories thereto entered into a tender agreement (the &ldquo;Tender Agreement&rdquo;), which
provided that, among other things, Ameri would make a tender offer (the &ldquo;Offer&rdquo;) to purchase all of the outstanding common
shares of Jay Pharma for the number of shares of Enveric common stock equal to the exchange ratio set forth in the Tender Agreement,
and Jay Pharma would become a wholly-owned subsidiary of Ameri, on the terms and conditions set forth in the Tender Agreement. The Tender
Agreement terminated and replaced in its entirety the Amalgamation Agreement. On December 30, 2020, the Company, Jay Pharma, Merger Sub,
and ExchangeCo consummated the Tender Agreement and Jay Pharma became a wholly owned subsidiary of the Company. The transaction was treated
as a reverse acquisition and recapitalization and accordingly, the historical financial statements prior to the date of the Business
Combination in these consolidated financial statements are those of Jay Pharma. The transaction is further described in Note 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>COVID-19</I></FONT></P>



<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-transform: uppercase; text-indent: -35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-transform: uppercase; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread
to multiple countries, including the United States. As the COVID-19 continues to spread in the United States, the Company may experience
disruptions that could severely impact the Company. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which
COVID-19 may impact the Company&rsquo;s business will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social
distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken
in the United States to contain and treat the disease. The Company is in process of monitoring COVID-19&rsquo;s potential impact on the
Company&rsquo;s operations.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-transform: uppercase; text-indent: -35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-transform: uppercase; text-indent: -35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Liquidity</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-transform: uppercase; text-indent: -35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred continuing losses from its operations and as of December 31, 2020, had an accumulated deficit of $11,759,557 and
working capital of $1,597,920. Since inception, the Company&rsquo;s operations have been funded principally through the issuance of debt
and equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2021, the Company completed a registered direct offering of 2,221,458 shares of common stock at approximately $4.50 per share
for gross proceeds of approximately $10,000,000. On February 11, 2021, the Company completed a registered direct offering of 3,007,026
shares of common stock for gross proceeds of approximately $12.8 million. As of March 30, 2021, the Company had cash on hand of approximately
$22.9 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that, as a result of these transactions, it currently has sufficient cash and financing commitments to meet its funding
requirements. Accordingly, management has since reevaluated the Company&rsquo;s liquidity and financial condition and determined that
sufficient capital exists to sustain operations through one year from the issuance of these financial statements and therefore substantial
doubt has been alleviated. Notwithstanding, the Company expects that it will need to raise additional financing to accomplish its development
plan over the next several years. The Company will require additional funding through debt or equity financing in the future. If the
Company is unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope of its planned development,
which could impact its financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 217 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-transform: uppercase; text-indent: -35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
3 &ndash; SUMMARY OF Significant Accounting Policies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of Presentation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance and in conformity with the accounting principles generally
accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) and the applicable rules and regulations of the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) regarding consolidated financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their
nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates
in future periods could be significant. Significant areas requiring management&rsquo;s estimates and assumptions include determining
the fair value of transactions involving common stock and the valuation of stock-based compensation. Actual results could differ from
those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
Currency Translation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reporting currency of the Company is the United States dollar. The financial statements of companies located outside of the U.S. are
measured in their functional currency, which is the local currency. The functional currency of the Company is the Canadian dollar. Monetary
assets and liabilities are translated using public exchange rates at the balance sheet date. Income and expense items are translated
using average monthly exchange rates. Shareholders&rsquo; equity accounts and non-monetary assets are translated at their historical
exchange rates. Translation adjustments are included in accumulated other comprehensive loss in the accompanying balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
and cash equivalents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2020 and December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intangibles</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has finite-lived intangible assets. Finite-lived intangible assets are amortized over their estimated useful lives. Research
and development costs are expensed as incurred. Following initial recognition of the finite-lived intangible asset, the asset is carried
at cost less any accumulated amortization. Amortization of the asset begins when the asset is available for use. Amortization is recorded
in general and administrative expenses on the Company&rsquo;s consolidated statement of operations. The Company periodically reviews
its owned intangible assets for recoverability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of Long Term Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company evaluates the carrying value of long-lived assets subject to amortization whenever events or changes in circumstances indicate
that an impairment may exist. An impairment charge is recognized when the asset&rsquo;s carrying value exceeds its net undiscounted future
cash flows and its fair market value. The amount of the charge is the difference between the asset&rsquo;s carrying value and fair market
value.<FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leases</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 25, 2016, FASB issued ASU 2016-02, Leases (Topic 842). This update will require organizations that lease assets to recognize
on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require
additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. On January 1, 2020, the Company adopted
this ASU, which did not have a material impact on the Company&rsquo;s financial position and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&rsquo;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&rsquo;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">amount recognized is measured as the largest amount of benefit
that is greater than 50 percent likely to be realized upon settlement. A liability for &ldquo;unrecognized tax benefits&rdquo; is recorded
for any tax benefits claimed in the Company&rsquo;s tax returns that do not meet these recognition and measurement standards. As of December
31, 2020 and December 31, 2019, no liability for unrecognized tax benefits was required to be recorded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 218 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>Note
3 &ndash; SUMMARY OF Significant Accounting Policies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2020 and 2019. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its United States and Canadian federal tax return, its state and provincial tax returns in Florida and Ontario,
CA as its &ldquo;major&rdquo; tax jurisdictions. The Company is in the process of filing its corporate tax returns for the years ended
December 31, 2020 and December 31, 2019. Net operating losses for these periods will not be available to reduce future taxable income
until the returns are filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows Accounting Standards Codification (&ldquo;ASC&rdquo;) 718, Compensation - Stock Compensation, which addresses the accounting
for stock-based payment transactions, requiring such transactions to be accounted for using the fair value method. Awards of shares for
property or services are recorded at the more readily measurable of the estimated fair value of the stock award and the estimated fair
value of the service. The Company uses the Black-Scholes option-pricing model to determine the grant date fair value of stock-based awards
under ASC 718. The estimated fair value is amortized as a charged to earnings on a straight-line basis depending on the terms and conditions
of the award, and the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair
value in line with the period over which it was earned. For employees and consultants, this is typically considered to be the vesting
period of the award. The Company estimates the expected forfeitures and updates the valuation accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Loss per Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method) and convertible notes. The computation of basic net loss per share for the years ended December 31,
2020 and 2019 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the same
for both basic and fully diluted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the year ended December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the year ended December 31, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    to purchase shares of common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,251,406</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">303,891</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    notes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">55,306</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
    B Preferred Stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,275,407</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">262,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options
    to purchase shares of common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">929,765</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">797,373</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    potentially dilutive securities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,456,578</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,419,070</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentration
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts
and management believes the Company is not exposed to significant risks on such accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&rsquo;s financial instruments, including cash and accounts payable, notes payable and convertible notes
payable, approximate fair value because of the short-term nature of such financial instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 219 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>Note
3 &ndash; SUMMARY OF Significant Accounting Policies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Subsequent
Events</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">financial
statements were issued. Other than as described in these financial statements, the Company did not identify any</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subsequent
events that would have required adjustment to or disclosure in the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020 the Company had no notes payable or convertible notes payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2019, the Company&rsquo;s notes payable and convertible notes payable consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gross</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Discount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif">February
    2019 Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">March 2019 Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2019 Convertible
    Notes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">300,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,079</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">293,921</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">July 2019 Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">191,640</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,700</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">188,940</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    2019 Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,525</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,475</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">751,640</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,304</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">740,336</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">451,640</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,225</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">446,415</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">300,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,079</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">293,921</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2020 and 2019, interest expense and amortization of debt discount consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="22" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    Expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of Debt Discount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    Expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of Debt Discount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif">February
    2019 Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,840</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,840</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2019 Convertible
    Notes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,970</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,842</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,812</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,370</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,142</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">30,512</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">July 2019 Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">53,342</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,704</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">98,046</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,836</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,836</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 2019
    Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,427</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,427</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,475</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,475</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">February 2020
    Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,545</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,912</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">53,457</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alpha
    Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">86,762</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">181,906</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">268,668</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">156,619</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">288,631</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">445,250</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,370</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,453</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81,823</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notes
Payable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2019, the Company received $60,000 in exchange for a promissory note with a director for $66,000, including an original issue
discount of $6,000 (the &ldquo;February 2019 Note&rdquo;). The note had no stated interest rate and was due on May 8, 2019. The Company
amortized the full $6,000 original issue discount in the statement of operations and comprehensive loss through December 31, 2019. On
July 21, 2020, the Company converted the February 2019 Note into common stock, as further described in Note 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 220 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE, CONTINUED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notes
Payable, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2019, the Company entered into a consulting agreement with its former executive director. In connection with the consulting
agreement, on March 5, 2019, the Company issued a note payable to its former executive director for $150,000 (the &ldquo;March 2019 Note&rdquo;).
The note had no interest and was due and payable on March 4, 2020. The consulting agreement expired on February 1, 2020. On July 21,
2020, the Company converted the March 2019 Note into common stock, as further described in Note 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 8, 2019, the Company entered into a note agreement (the &ldquo;July 2019 Note&rdquo;) with a limited liability company (the &ldquo;Lender&rdquo;).
One of the principals of the Lender is the brother of a former member of the Company&rsquo;s Board of Directors. The Note&rsquo;s face
value was $157,714 and the original issue discount was $19,714 for total gross proceeds of $138,000, implying an interest rate of 12.5%
per annum. The Company could, without premium or penalty, at any time and from time to time, prepay all or any portion of the Note. The
maturity date of the Note was September 8, 2019. On September 20, 2019, the Company entered into an amendment to the July 2019 Note (the
&ldquo;Amendment&rdquo;). The Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing
of greater than or equal to $1,500,000, or (b) November 7, 2019. On November 21, 2019, the Company entered into an amendment for the
July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater
than or equal to $1,500,000, or (b) December 9, 2019. In consideration for this amendment, the Company agreed to pay an aggregate extension
fee of $33,926, which was added to the principal balance of the note. On December 9, 2019, the Company entered into an additional amendment
for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of
greater than or equal to $1,500,000, or (b) January 7, 2020. The Company also agreed to pay the previously outstanding extension fees
of $33,926 on or before March 1, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2020 the Company entered into an amendment to the July 2019 Note (the &ldquo;January 8 Amendment&rdquo;). The January 8 Amendment
extended the maturity date for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal to $1,500,000,
or (b) April 1, 2020. In consideration for the January 8 Amendment, the Company granted 55,000 shares of the Company&rsquo;s common stock
to the Lender. The Company accounted for this amendment as a modification, where the shares paid as a fee were valued at $45,725 and
recorded as a discount against the note payable and amortization over the term. On May 6, 2020, the Company entered into an amendment
(the &ldquo;May 2020 Amendment&rdquo;) whereby both parties agreed to extend the maturity date of the July 2019 Note to September 30,
2020. The Company accounted for this amendment as a modification, as the present value of the future cash flows pre-modification and
post-modification were not greater than or equal to 10%. On January 12, 2020, the Company repaid $157,714 of the July 2019 Note. On December
31, 2020 the Company paid the remaining unpaid balance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2019, the Company received $40,000 in exchange for a promissory note with a lender, including an original issue </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">discount
of $4,000 (the &ldquo;December 2019 Note&rdquo;). The December 2019 Note bore interest at a rate of ten percent (10%) on its face value
per annum. In the case of an event of default, the interest rate would increase to 24% per year. The December 2019 Note matured on January
31, 2020. The promissory note with the lender and the Company was converted into 170,333 shares of common stock on December 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2020, the Company received $50,000 in exchange for a promissory note with a lender (the &ldquo;February 2020 Note&rdquo;).
The February 2020 Note bore interest at a rate of 10% on its face value per annum. In the case of an event of default, the interest rate
would increase to 24% per year. The note matured on July 31, 2020. The February 2020 Note was convertible into the Company&rsquo;s common
stock at any time at a conversion price of $0.38 per share. The Company recorded a beneficial conversion feature of $17,851 and valued
the warrants issued (using relative fair value) at $32,149. The Company recorded the total value as a note discount and is amortizing
the discount over the term of the February 2020 Note using the effective interest method. The Company valued the beneficial conversion
feature and warrants using the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
    Conversion Feature</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock Price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAD
                                            $ 1.10</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAD
                                            $ 1.10</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise Price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAD
                                            $ 0.51</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAD
                                            $ 0.51</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
    Yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    Volatility</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">96.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted Average
    Risk-Free Interest Rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.31</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of Shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">130,920</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Value (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,851</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,149</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Term
    (in years)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 221 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE, CONTINUED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notes
Payable, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, the February 2020 Note was converted into 190,004 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a Secured Promissory Note, dated January 10, 2020 (the &ldquo;Note&rdquo;), by and among Enveric Biosciences, Inc.
and Alpha Capital Anstalt (&ldquo;Alpha&rdquo;), pursuant to which, on January 10, 2020, Enveric Biosciences, Inc. received aggregate
gross proceeds of $1,500,000. Pursuant to the Note, the aggregate obligations of Enveric Biosciences, Inc. under the Note were automatically,
immediately prior to the consummation of the amalgamation, converted into shares of Enveric Biosciences, Inc. common stock, subject to
the terms and provisions of the Note. Pursuant to the Note, upon conversion of the term loans made by the lenders subject to the terms
of the Note, Enveric Biosciences, Inc. was required to cause Ameri to issue each lender warrants to purchase Ameri Common Stock. Upon
consummation of the amalgamation, Enveric Biosciences, Inc. agreed to cause Ameri to register the resale of the warrant shares. The Note
bears interest at 7% per annum and was due on March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2020, the Company entered into an amendment to the Note (the &ldquo;First Note Amendment&rdquo;). Pursuant to the First Note Amendment,
Alpha waived previous defaults on the Note, and extended the maturity date of the Note to June 30, 2020. In exchange for the First Note
Amendment, the Company and Alpha agreed that (i) at the Effective Time, Ameri would issue to the holder of a certain note issued by Enveric
Biosciences, Inc., series B warrants (the &ldquo;Series B Warrants&rdquo;) to acquire 8,100,000 shares of common stock of the Company
resulting from the amalgamation, and (ii) providing for certain registration rights, pursuant to a registration rights agreement, of
the Series B Warrants and the shares issuable upon exercise of the Series B Warrants. The Series B Warrants shall be exercisable for
a period of five years commencing on the ninetieth (90th) day after the later of the last day of the Lock-up Period and leak-out Period
(accelerated or otherwise) set forth in the Lock-up agreement to be executed by the holders of Enveric Biosciences, Inc. securities in
connection with the Amalgamation, at a price of $0.01 per share, and shall also be exercisable on a cashless basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2020, the Company and Alpha entered into a second amendment to the Note (the &ldquo;Second Note Amendment&rdquo;). The Second
Note Amendment revised the principal amount of the Note from $1,500,000 to $2,000,000, which was advanced as of the date of the Second
Note Amendment. The rights and securities granted to Alpha under the terms of the Note were extended to the additional $500,000 advance
contemplated by the Second Note Amendment pursuant to the terms of the Second Note Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, the Company and Alpha entered into the Third Note Amendment. The Third Note Amendment extended the maturity date to
be the earlier of (a) January 1, 2021 and (b) an event of default that accelerates the maturity of the Note. The Third Note Amendment
also revised the Note to account for the change in structure from an amalgamation to a stock-for-stock exchange offer. As a result, references
to the Amalgamation Agreement and the amalgamation were revised to be references to the Tender Agreement and the Offer. The Third Note
Amendment also revised the event of default regarding a failure of the amalgamation to be consummated by March 31, 2020 to be an event
of default if the Offer was not consummated by January 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, the Note in the amount of $2,000,000 was converted into 2,473,848 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &ndash; INTANGIBLE ASSETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2020, the Company purchased skincare assets for an aggregate of $1,944,689 in stock and cash, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 80%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,143</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,900,546</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,944,689</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the skincare assets as a definite lived intangible asset with a four year useful life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, the Company&rsquo;s intangible assets consisted of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gross
    <BR>Carrying <BR>Amount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    <BR>Amortization</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 43%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Skincare
    Assets and License Agreements</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,944,689</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(126,968</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,817,721</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 222 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &ndash; COMMITMENTS AND CONTINGENGIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2019, the Company entered into a business advisor services agreement. Pursuant to the terms of the agreement, the consultant
provided business advisory, marketing, and investor relations services in exchange for $15,000 per month, of which $7,500 was payable
in cash and $7,500 was payable in the Company&rsquo;s common shares. On January 6, 2020, the Company terminated its business advisory
services agreement and agreed to settle the amounts due under the agreement by (a) paying $12,500 in cash upon the completion of a bridge
financing; and (b) issuing 127,856 shares of the Company&rsquo;s common stock, as described in Note 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2020, the Company entered into an agreement with Mr. David Stefansky to serve as President and Secretary of the Company to
serve until the closing Amalgamation Agreement. The Company agreed to pay Mr. Stefansky $15,000 per month and future issuance of options
to purchase 650,000 shares of common stock subject to the approval of the Board of Directors. On May 1, 2020, this agreement was terminated
(see Note 8). On May 1, 2020, the Company and Mr. David Stefansky terminated Mr. Stefansky&rsquo;s agreement to serve as President and
Secretary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020, the Company entered into an agreement with Mr. Henoch Cohn to serve as the Company&rsquo;s President and Secretary until
the consummation of the Amalgamation Agreement. The Company paid Mr. Cohn $10,000 per month. On December 30, 2020 the agreement between
the Company and Mr. Henoch Cohn was terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&rsquo;s
financial position, results of operations or cash flows. On January 21, 2012, the Company received a demand letter from an individual
purporting to be a stockholder. See Note 10 for more information.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Company&rsquo;s common stock are entitled to one vote per share. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share rateably in all assets of the Company that are legally available
for distribution. As of December 31, 2020, 100,000,000 shares of common stock were authorized under the Company&rsquo;s articles of incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, the Company amended its articles of incorporation to designate and authorize 20,000,000 shares of Series B preferred
stock. The Company&rsquo;s Series B preferred stock is convertible by the holder at any time into common stock at a rate of one to one.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion
of Series B Preferred Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, a holder of the Company&rsquo;s Series B Preferred Stock converted 250,000 shares of Series B Preferred Stock into
250,000 shares of common stock.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Issuance
of Common Stock for Accounts Payable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued 433,047 shares of common stock to various vendors in connection with the payment
of accounts payable of $756,523. The shares were valued at the book value of the accounts payable, as that value was more readily determinable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
Issued in Exchange for Services</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2019, the Company issued 38,116 shares to consultants in exchange for services. The Company valued these
shares at $88,465.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>September
Private Placement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 25, 2020, the Company issued 36,871 shares of its common stock for gross proceeds of $250,000 and net proceeds of $227,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>December
Private Placement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 8, 2020, the Company issued 221,225 shares of its Series B preferred stock for gross proceeds of $300,000 and net proceeds of
$260,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 223 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS, CONTINUED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion
of Related Party Advance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2020, the Company issued 239,326 shares of common stock in exchange for the February 2019 Note (face value of $66,000), the
March 2019 Note (face value of $150,000) and related party advances in the amount of $22,000. Given that the holder of these notes and
advances is a related party, this was treated as a capital transaction and no gain or loss was recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Remaining Contractual Term (years)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Value (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    &ndash; January 1, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">689,832</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.94</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.94</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">448,713</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.99</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.49</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expired,
    forfeited, or cancelled</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(341,172</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.99</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.36</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding &ndash;
    December 31, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">797,373</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.99</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.72</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">378,800</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.94</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.22</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expired
    forfeited, or cancelled</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(246,408</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.94</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.88</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    &ndash; December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">929,765</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.53</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.50</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,537,245</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable
    at December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">929,765</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.53</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.50</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,537,245</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s stock based compensation expense related to stock options for the years ended December 31, 2020 and 2019 was $1,977,155
and $535,587, respectively. As of December 31, 2020, the Company had $0 in unamortized stock option expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the Black-Scholes option-pricing model to determine the fair value of these stock options, using the assumptions as
outlined below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 80%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    Price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.92</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
    Yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    Volatility</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84.7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Risk-Free Interest Rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.37</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    life (in years)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5
                                            &ndash; 4.2</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
price &ndash; Based on closing price of the Company&rsquo;s common stock on the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average risk-free interest rate &mdash;Based on the daily yield curve rates for U.S. Treasury obligations with maturities, which correspond
to the expected term of the Company&rsquo;s stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield &mdash;The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its
common stock in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
volatility &mdash;Based on the historical volatility of comparable companies in a similar industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term &mdash;The Company has had no stock options exercised since inception. The expected option term represents the period that stock-based
awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&ldquo;SAB&rdquo;) No. 107,
Share-Based Payment, which averages an award&rsquo;s weighted-average vesting period and expected term for &ldquo;plain vanilla&rdquo;
share options.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2020, the Company issued warrants to purchase 130,920 shares of common stock to the lender of the February 2020 Note. The
warrants are exercisable at $0.38 USD ($0.50 CAD) per share, are fully vested at the date of issuance, and expire on February 24, 2025.
The warrants were accounted for as a component of equity, as the instrument contains no features which would preclude such classification.
As discussed in Note 4, the warrants were recorded as a discount in the amount of $50,000 on the note payable and amortized over the
term of the note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
    <BR>shares <BR>outstanding</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    <BR> average<BR> exercise price (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average remaining life</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intrinsic
    value</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    at January 1, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">219,510</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.95</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.08</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84,381</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.21</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding at
    December 31, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">303,891</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.02</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.06</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,222,331</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.96</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(274,816</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,251,406</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.95</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.97</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable
    at December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,251,406</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.95</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.97</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,040,545</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 224 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &ndash; TENDER AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, the Company entered into an amalgamation agreement (the &ldquo;Amalgamation Agreement&rdquo;) with Enveric Biosciences,
Inc. Merger Sub, Inc. (&ldquo;Merger Sub&rdquo;), a wholly owned subsidiary of Ameri, and Enveric Biosciences, Inc. Exchange Co, Inc.
(&ldquo;ExchangeCo&rdquo;), a wholly owned subsidiary of Ameri. The Amalgamation Agreement provided that the Company would merge into
Merger Sub and be amalgamated and operate as one company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the execution and delivery of the Amalgamation Agreement, Alpha entered into agreements with Enveric Biosciences, Inc. pursuant to
which Alpha agreed, subject to the terms and conditions of such agreements, to purchase, immediately prior to the consummation of the
Amalgamation, shares of Enveric Biosciences, Inc.&rsquo;s common stock (or common stock equivalents) and warrants to purchase Enveric
Biosciences, Inc.&rsquo;s common stock for an aggregate purchase price of $3.5 million. The consummation of the transactions contemplated
by such agreements was conditioned upon the satisfaction or waiver of the conditions set forth in the Amalgamation Agreement. After consummation
of the Amalgamation, Enveric Biosciences, Inc. agreed to cause Ameri to register the resale of the Ameri Common Stock issued and issuable
pursuant to the warrants issued to the investors in the Jay Pharma Pre-Closing Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contemporaneously
with the Amalgamation Agreement, the Company entered into sublicense agreements with Tikkun Pharma, Inc. (&ldquo;Tikkun Pharma&rdquo;).
The sublicense agreements with Tikkun Pharma allows the Company to utilize (a) Tikkun Pharma&rsquo;s sublicense with a third party for
certain autoimmune applications, and (b) acquire and use Tikkun Pharma&rsquo;s internally developing intellectual property, branding,
and formulations in regards to skincare.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2020, the Company received a notice from the lenders of the Note, stating that the Company was in default for not closing the
amalgamation with Ameri by March 31, 2020, and that the entire Note was due in full. On May 6 and May 26, 2020, the Company and Alpha
amended the Note and the Amalgamation Agreement, as described in below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2020, the Company entered into an Amalgamation Amendment Agreement (the &ldquo;Amendment&rdquo;) to amend the Amalgamation Agreement
described in Note 7. Pursuant to the Amendment, the parties agreed that (i) at the Effective Time, Ameri Holdings, Inc. shall issue to
the holder of a certain note issued by Enveric Biosciences, Inc., series B warrants (the &ldquo;Series B Warrants&rdquo;) to acquire
8,100,000 shares of common stock of the company resulting from the amalgamation, and (ii) providing for certain registration rights,
pursuant to a Registration Statement on Form S-4, of the Series B Warrants and the shares issuable upon exercise of the Series B Warrants.
The Series B Warrants shall be exercisable for a period of five years commencing on the ninetieth (90th) day after the later of the last
day of the Lock-up Period and leak-out Period (accelerated or otherwise) set forth in the Lock-up agreement to be executed by the holders
of Enveric Biosciences, Inc. securities in connection with the Amalgamation, at a price of $0.01 per share, and shall also be exercisable
on a cashless basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2020, the Company entered into the second amendment to the Amalgamation Agreement (the &ldquo;Second Amendment&rdquo;) to amend
the Amalgamation Agreement described in Note 7. The purpose of this amendment was to clarify that the Series B Warrants were to acquire
8,100,000 shares of common stock Enveric Biosciences, Inc. (to be approximately 3,675,035 shares of common stock of the company resulting
from the Amalgamation), as well as to clarify the exchange ratio already agreed upon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 225 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &ndash; TENDER AGREEMENT, CONTINUED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, Ameri, Enveric Biosciences, Inc., and certain other signatories thereto entered into a tender agreement (the &ldquo;Tender
Agreement&rdquo;), which provided that, among other things, Enveric Biosciences, Inc. would become a wholly owned subsidiary of Ameri,
on the terms and conditions set forth in the Tender Agreement. The Tender Agreement terminated and replaced in its entirety the Amalgamation
Agreement. Upon completion of the Tender Agreement on December 30, 2020, (i) holders of outstanding common shares of Enveric Biosciences,
Inc. other than Alpha will be entitled to receive the number of shares of Resulting Issuer common stock issuable in accordance with the
Exchange Ratio, and (ii) Alpha will be entitled to receive shares of Series B Preferred Stock, which are convertible into shares of Resulting
Issuer common stock subject to a 9.99% beneficial ownership blocker, pursuant to the Alpha Exchange Agreement. Each outstanding Enveric
Biosciences, Inc. option, whether vested or unvested, and warrant that has not previously been exercised will exchanged for Resulting
Issuer stock options and Resulting Issuer warrants, in each case convertible into the number of shares of Resulting Issuer common stock
equal to the Exchange Ratio. Each outstanding Enveric Biosciences, Inc. option, whether vested or unvested, and warrant that has not
previously been exercised will be exchanged for Resulting Issuer stock options and Resulting Issuer warrants, in each case, convertible
into the number of shares of Resulting Issuer common stock equal to the Exchange Ratio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &ndash; INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    tax assets:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    operating loss carryovers</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,340,152</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,004,029</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    tax assets, gross</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,340,152</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,004,029</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:
    valuation allowance</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,340,152</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,004,029</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    tax assets, net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    tax assets (liabilities), net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in the Company&rsquo;s valuation allowance is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the year ended December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the year ended December 31, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beginning
    of year</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,004,029</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">505,871</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase
    in valuation allowance</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,340,152</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">498,158</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">End
    of year</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,344,180</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,004,029</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the provision for income taxes with the amounts computed by applying the statutory federal income tax rate to loss
from operations before the provision for income taxes is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the year ended December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the year ended December 31, 2019</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Canada
    federal statutory rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provincial
    taxes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11.5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11.5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Permanent
    differences</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-deductible
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.9</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation
    allowance</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.1</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.6</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
    income tax rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 226 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &ndash; INCOME TAXES, CONTINUED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020 and 2019, the Company had net operating loss carryovers of $5,057,176 and $3,788,788, respectively, for Canadian
federal income tax purposes, which begin to expire in 2029. The ultimate realization of the net operating loss is dependent upon future
taxable income, if any, of the Company. Based on losses from inception, the Company determined that as of December 31, 2020 and 2019
it is more likely than not that the Company will not realize benefits from the deferred tax assets. The Company will not record income
tax benefits in the financial statements until it is determined that it is more likely than not that the Company will generate sufficient
taxable income to realize the deferred income tax assets. As a result of the analysis, the Company determined that a valuation allowance
against the deferred tax assets was required of $1,340,152 and $1,004,029 as of December 31, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
10 - <FONT STYLE="font-variant: small-caps; text-transform: uppercase">SUBSEQUENT EVENTS</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Registered
Direct Offerings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2021, the Company completed a registered direct offering of 2,221,458 shares of common stock at approximately $4.50 per share
for gross proceeds of approximately $10,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2021, the Company completed a registered direct offering of 3,007,026 shares of common stock for gross proceeds of approximately
$12.8 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
Demand Letter</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2021, the Company received a stockholder litigation demand letter from the law firm of Purcell Julie &amp; Lefkowitz LLP,
on behalf of James Self, a purported stockholder of our Company. The letter demands that the Company (i) deem ineffective the December
30, 2020 amendment to our Amended and Restated Certificate of Incorporation in which the Company effected a one-for-four reverse stock
split of its common stock due to the manner in which non-votes by brokers were tabulated, (ii) seek appropriate relief for damages allegedly
suffered by the company and its stockholders or seek a valid stockholder approval of the amendment and reverse stock split, and (iii)
adopt adequate internal controls to prevent a recurrence of the alleged misconduct. The Company disputes that the amendment was ineffective
or that there were any inadequate internal controls related to the same. However, to eliminate any questions about the amendment, the
Company intends to seek to ratify the amendment at a special stockholders&rsquo; meeting pursuant to Section 204 of the Delaware General
Corporation Law. This special stockholders&rsquo; meeting is scheduled to occur on May 14, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Development
and Clinical Supply Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &ldquo;Agreement&rdquo;) with PureForm Global,
Inc. (&ldquo;PureForm&rdquo;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&ldquo;API&rdquo;)
for the Company&rsquo;s development plans for cancer treatment and supportive care. Under the terms of the Agreement, PureForm has granted
the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term of the Agreement
(contingent upon an initial minimum order volume during the first thirty (30) days from the effective date) and has agreed to manufacture,
package and test the API and related product in accordance with specifications established by the parties. All inventions that are developed
jointly by the parties in the course of performing activities under the Agreement will be owned jointly by the parties in accordance
with applicable law; however, if the Company funds additional research and development efforts by PureForm, the parties may enter into
a further agreement whereby PureForm would assign any resulting inventions or technical information to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the Agreement is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual agreement
of the parties. The Agreement may be terminated by either party upon thirty (30) days written notice of an uncured material breach or
immediately in the event of bankruptcy or insolvency. The Agreement contains, among other provisions, representation and warranties,
indemnification obligations and confidentiality provisions in favor of each party that are customary for an agreement of this nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2021, the Company entered into an Exclusive License Agreement (the &ldquo;Agreement&rdquo;) with Diverse Biotech, Inc. (&ldquo;Diverse&rdquo;),
pursuant to which the Company has acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively, the
&ldquo;Agents&rdquo;) with the goal of alleviating the side effects that cancer patients experience. Under the terms of the Agreement,
Diverse has granted the Company an exclusive license to its intellectual property rights covering the Agents and its products. In exchange,
the Company has granted Diverse the right to information relating to the Agents developed for the express purpose of using such information
to obtain patent rights, which right terminates upon the issuance or denial of the patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Agreement, the Company will maintain sole responsibility and ownership of the development and commercialization of the Agents and
its products. Diverse has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its products
containing the Agents, at any time during or after the term of the Agreement. If Diverse intends to license, sell, or transfer any other
molecules linked with cannabinoids not granted to the Company under the terms of this Agreement, the Company will have the first right,
but not the obligation, to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay Diverse an up-front
investment payment of $675,000, as well as a running royalty starting with the first commercial sale by the Company to a third party
in an arms&rsquo;-length transaction. The term of the Agreement shall continue for as long as the Company intends to develop or commercialize
the new drugs, unless earlier terminated by either Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Exercise
of Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 10, 2021, the Company received $3,267,245 from the exercise of warrants to purchase 851,099 shares of common stock.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 227 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_149"></A>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_007"></A>CONDENSED
CONSOLIDATED BALANCE SHEETS</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of March 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    assets:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,657,150</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,578,460</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">767,298</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">700,710</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23,424,448</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,279,170</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,362,177</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,817,721</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,786,625</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,096,891</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities
    and Shareholders&rsquo; Equity (Deficit)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    liabilities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">626,947</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">681,250</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">626,947</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">681,250</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><P STYLE="font-family: Times New Roman, Times, Serif; margin: 0 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
                                            liabilities</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,168,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><P STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total
                                            liabilities</B></FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,794,947</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">681,250</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments
    and contingencies (Note 6)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo;
    Equity</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred
    Stock, $0.01 par value, 20,000,000 shares authorized, 0 and 3,275,407 shares issued and outstanding as of March 31, 2021 and December
    31, 2020, respectively</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,754</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock, $0.01 par value, 100,000,000 shares authorized, 19,449,975 and 10,095,109 shares issued and outstanding as of March 31, 2021
    and December 31, 2020, respectively</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">194,499</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,951</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">33,952,988</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,222,770</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15,010,268</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,759,557</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    other comprehensive loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(145,541</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(181,277</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    shareholders&rsquo; equity</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,991,678</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,415,641</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities and shareholders&rsquo; equity</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,786,625</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,096,891</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are in integral part of these unaudited condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 228 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_008"></A>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></FONT></P>



<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended March 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,607,045</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">836,702</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">157,952</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,764,997</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">836,702</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    from operations</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,764,997</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(836,702</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    income (expense)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Inducement
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(298,714</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
                                            in fair value of warrant liabilities</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,813,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(261,759</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    other income (expense)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,514,286</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(261,759</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,250,711</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,098,461</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    comprehensive loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
    currency translation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,736</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,698</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Comprehensive
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,214,975</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,111,159</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss per share - basic and diluted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.20</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.19</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average shares outstanding, basic and diluted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,220,661</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,653,820</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are in integral part of these unaudited condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 229 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_009"></A>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; EQUITY (DEFICIT)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020</B></FONT></P>



<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B Preferred Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    Other Comprehensive</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of January 1, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,573,915</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,739</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,039,163</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,894,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,622</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,811,601</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock issued for accounts payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,942</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">859</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,623</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">173,482</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued in conjunction with notes payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,149</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,149</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    conversion feature issued with note payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,851</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,851</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,698</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,698</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,098,461</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,098,461</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of March 31, 2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,659,857</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,598</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,261,786</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,993,342</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,320</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,699,278</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of January 1, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,275,407</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,754</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,095,109</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,951</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,222,770</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,759,557</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(181,277</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,415,641</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2021 registered direct offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,221,334</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,213</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,594,874</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,617,087</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    2021 registered direct offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,007,026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,070</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,986,331</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,016,401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,591,565</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,591,565</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induced
    conversion of stock options into restricted stock awards</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">298,714</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">298,714</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
    of Series B Preferred Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,275,407</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,754</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,275,407</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,754</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    of warrants</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">851,099</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,511</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,258,734</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,267,245</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange gain</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,736</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,736</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,250,711</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,250,711</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of March 31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,449,975</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">194,499</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,952,988</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,010,268</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(145,541</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,991,678</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are in integral part of these unaudited condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 230 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="cr_010"></A>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended March 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Operating Activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,250,711</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,098,461</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to cash used in operating activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Extinguishment
    of note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">233,240</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    interest</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,519</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
                                            in fair value of warrant liability</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,813,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,591,565</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inducement
    expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">298,714</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
    of intangible assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">136,640</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in operating assets and liabilities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(66,208</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(49,588</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(59,278</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,632</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,162,278</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(893,922</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Investing Activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase
    of license agreement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(675,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(675,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows From Financing Activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from sale of common stock, net of offering costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,614,488</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from convertible notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,000</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,319,910</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment
    of note payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(157,714</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from warrant exercises</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,267,245</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,881,733</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,212,196</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect
    of foreign exchange rate on cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34,235</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(86,677</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    increase in cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,078,690</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">231,597</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - beginning of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,578,460</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,714</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,657,150</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,311</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    non-cash financing activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    issued in conjunction with notes payable issuances</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,851</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
    of common stock issued for note payable extensions</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,149</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
    of common stock issued for accounts payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">173,482</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are in integral part of these unaudited condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 231 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="cr_011"></A>NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none">NOTE
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 - Business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-align: justify; text-indent: 111pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nature
of operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&ldquo;Enveric Biosciences, Inc.&rdquo; &ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;) (formerly known as Ameri
Holdings, Inc.) (&ldquo;Ameri&rdquo;) is a pharmaceutical company developing innovative, evidence-based cannabinoid medicines. The head
office of the Company is located in Naples, Florida.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, the Company entered into an Amalgamation Agreement (as amended on May 6, 2020), (the &ldquo;Amalgamation Agreement&rdquo;)
with Jay Pharma Merger Sub, Inc., a company organized under the laws of Canada and a wholly owned subsidiary of the Company (&ldquo;Merger
Sub&rdquo;), Jay Pharma Inc., a company organized under the laws of Canada (&ldquo;Jay Pharma&rdquo;), Jay Pharma ExchangeCo., Inc. a
company organized under the laws of British Columbia and a wholly owned subsidiary of the Company (&ldquo;ExchangeCo&rdquo;), and Barry
Kostiner, as the Company Representative, which provided that, among other things, Merger Sub and Jay Pharma would be amalgamated and
would continue as one corporation (&ldquo;Amalco&rdquo;), with Amalco continuing as a direct wholly owned subsidiary of ExchangeCo and
an indirect wholly owned subsidiary of Ameri, on the terms and conditions set forth in the Amalgamation Agreement. On August 12, 2020,
the Company, Jay Pharma and certain other signatories thereto entered into a tender agreement (the &ldquo;Tender Agreement&rdquo;), which
provided that, among other things, Ameri would make a tender offer (the &ldquo;Offer&rdquo;) to purchase all of the outstanding common
shares of Jay Pharma for the number of shares of Enveric common stock equal to the exchange ratio set forth in the Tender Agreement,
and Jay Pharma would become a wholly-owned subsidiary of Ameri, on the terms and conditions set forth in the Tender Agreement. The Tender
Agreement terminated and replaced in its entirety the Amalgamation Agreement. On December 30, 2020, the Company, Jay Pharma, Merger Sub,
and ExchangeCo completed the Offer and Jay Pharma became a wholly owned subsidiary of the Company. The transaction was treated as a reverse
acquisition and recapitalization and accordingly, the historical financial statements prior to the date of the Business Combination in
these unaudited condensed consolidated financial statements are those of Jay Pharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>COVID-19</I></B></FONT></P>



<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-transform: uppercase; text-align: justify; text-indent: -35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
2020 and continuing into 2021, the world has been, and continues to be, impacted by the novel coronavirus (COVID-19) pandemic. COVID-19
and measures to prevent its spread impacted our business in a number of ways. The impact of these disruptions and the extent of their
adverse impact on our financial and operating results will be dictated by the length of time that such disruptions continue, which will,
in turn, depend on the currently unknowable duration and severity of the impacts of COVID-19, and among other things, the impact of governmental
actions imposed in response to COVID-19 and individuals&rsquo; and companies&rsquo; risk tolerance regarding health matters going forward
and developing strain mutations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 232 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>Note
2 &ndash; SUMMARY OF Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of Presentation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (&ldquo;U.S. GAAP&rdquo;) for interim financial information and Article 10 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Management&rsquo;s
opinion is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating
results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending
December 31, 2021. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements for the year ended December 31, 2020 and related notes thereto included in the Company&rsquo;s Annual Report on Form 10-K
filed with the SEC on April 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their
nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates
in future periods could be significant. Significant areas requiring management&rsquo;s estimates and assumptions include determining
the fair value of transactions involving common stock and the valuation of stock-based compensation. Actual results could differ from
those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
Currency Translation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reporting currency of the Company is the United States Dollar. The financial statements of companies located outside of the U.S. are
measured in their functional currency, which is the local currency. The functional currency of the Company is the Canadian dollar. Monetary
assets and liabilities are translated using public exchange rates at the balance sheet date. Income and expense items are translated
using average monthly exchange rates. Shareholders&rsquo; equity accounts and non-monetary assets are translated at their historical
exchange rates. Translation adjustments are included in accumulated other comprehensive loss in the accompanying balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
and cash equivalents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of March 31, 2021 and December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrant
Liability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">The
Company accounts for warrants for shares of the Company&rsquo;s common stock that are not indexed to its own stock as liabilities at
fair value on the balance sheet. Such warrants are subject to remeasurement at each balance sheet date and any change in fair value is
recognized as a component of other expense on the statement of operations. The Company will continue to adjust the liability for changes
in fair value until the earlier of the exercise or expiration of such common stock warrants. At that time, the portion of the warrant
liability related to such common stock warrants will be reclassified to additional paid-in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Offering
Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&rsquo;s statement of operations.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Loss per Share </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method) and convertible notes. The computation of basic net loss per share for the three months ended March
31, 2021 and 2020 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the same
for both basic and fully diluted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the three months ended March&nbsp;31,&nbsp;2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the three months ended March&nbsp;31,&nbsp;2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    to purchase shares of common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,979,611</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,504,593</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    notes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">380,920</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted
    stock units</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,279,284</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted
    stock awards</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">70,986</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options
    to purchase shares of common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">369,361</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,604,348</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    potentially dilutive securities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,699,242</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,489,861</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 233 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>Note
2 &ndash; SUMMARY OF Significant Accounting Policies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentration
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts
and management believes the Company is not exposed to significant risks on such accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value Measurement </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows Accounting Standards Codification (&ldquo;ASC&rdquo;) 820&ndash;10 &ldquo;Fair Value Measurement&rdquo; of the Financial
Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting Standards Codification to measure the fair value of its financial
instruments and disclosures about fair value of its financial instruments. ASC 820&ndash;10 establishes a framework for measuring fair
value and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and
related disclosures, ASC 820&ndash;10 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to
measure fair value into three (3) broad levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three (3) levels of fair value hierarchy defined by ASC 820&ndash;10 are described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    1</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    market prices available in active markets for identical assets or liabilities as of the reporting date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    2</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the
    reporting date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    3</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs that are generally unobservable inputs and not corroborated by market data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets or liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies
or similar techniques and at least one significant model assumption or input is unobservable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and
the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than
one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of
the instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&rsquo;s financial assets and liabilities, such as cash, prepaid expenses and other current assets, accounts
payable and accrued expenses approximate their fair values due to the short-term nature of these instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses Level 3 of the fair value hierarchy to measure the fair value of its warrant liabilities. The Company revalues such liabilities
at every reporting period and recognizes gains or losses as change in fair value of warrant liabilities in the condensed consolidated
statements of operations that are attributable to the change in the fair value of the warrant liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
March 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
    liabilities &ndash; January Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,164,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
    liabilities &ndash; February Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,004,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value as
    of March 31, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,168,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no assets or liabilities measured at fair value at December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the January and February Warrants are classified as Level 3, for which there is no current market for these securities such as the determination
of fair value requires significant judgment or estimation. Changes in fair value measurement categorized within Level 3 of the fair value
hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 234 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>Note
2 &ndash; SUMMARY OF Significant Accounting Policies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value Measurement, continued</I></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Initial
Measurement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations are
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>January
    Warrants</B></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>February
    Warrants</B> &nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>January
    13, 2021</I></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>February
    12, 2021</I></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Term
    (years)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.21</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.62</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.95</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.95</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
    yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    volatility</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84.7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84.7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk
    free interest rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,821,514</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,714,005</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Value (per share)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.66</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Subsequent
measurement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of the warrant liabilities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">January
    Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">February
    Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Warrant Liability</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value as
    of December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial
    value of warrant liability</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,846,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,135,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,981,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,682,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,131,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,813,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair
    value as of March 31, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,164,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,004,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,168,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations as of March 31, 2021 are below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">January
    Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">February
    Warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Term
    (years)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.8</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.9</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.07</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.07</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.95</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.95</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
    yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    volatility</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84.7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84.7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk
    free interest rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.9</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.9</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,821,514</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,714,005</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Value (per share)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.74</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.75</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 235 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>Note
2 &ndash; SUMMARY OF Significant Accounting Policies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Recent
Accounting Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2019, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued ASU No. 2019-12, Income Taxes (Topic 740: Simplifying
the Accounting for Income Taxes (&ldquo;ASU 2019-12&rdquo;), which removes certain exceptions to the general principles in Topic 740.
ASU 2019-12 is effective for the fiscal years beginning after December 15, 2020, with early adoption permitted. The adoption of this
guidance did not have a material impact on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
October 2020, the FASB issued ASU 2020-10, &ldquo;Codification Improvements.&rdquo; The new accounting rules improve the consistency
of the Codification by including all disclosure guidance in the appropriate Disclosure Section (Section 50) that had only been included
in the Other Presentation Matters Section (Section 45) of the Codification. Additionally, the new rules also clarify guidance across
various topics including defined benefit plans, foreign currency transactions, and interest expense. The new accounting rules were effective
for the Company in the first quarter of 2021. The adoption of the new accounting rules did not have a material impact on the Company&rsquo;s
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&mdash;Modifications and Extinguishments (Subtopic 470-50),
Compensation&mdash;Stock Compensation (Topic 718), and Derivatives and Hedging&mdash;Contracts in Entity&rsquo;s Own Equity (Subtopic
815-40): Issuer&rsquo;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The
amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&rsquo;s accounting for modifications or
exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification
or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021,
and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As
a result, the Company will not be required to adopt ASU 2021-04 until October 1, 2022. The Company is currently evaluating the impact
of the adoption of this principle on the Company&rsquo;s condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Subsequent
Events</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial
statements were issued. Other than as described in these financial statements, the Company did not identify any subsequent events that
would have required adjustment to or disclosure in the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 &ndash; INTANGIBLE ASSETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2021, the Company&rsquo;s intangible assets consisted of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Useful
    Life</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gross
    <BR>Carrying <BR>Amount</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    <BR>Amortization</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 41%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Skincare
    Assets and License Agreements</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4
    years</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,944,689</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(257,512</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,687,177</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diverse
    Bio License Agreement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4
    years</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">675,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">675,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,619,689</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(257,512</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,362,177</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the three months ended March 31, 2021 and 2020, the Company recognized amortization expense of $136,640 and $0, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquisition
of Diverse Bio License Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2021, the Company entered into an Exclusive License Agreement (the &ldquo;DB Agreement&rdquo;) with Diverse Biotech, Inc. (&ldquo;Diverse&rdquo;),
pursuant to which the Company acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively, the &ldquo;Agents&rdquo;)
with the goal of alleviating the side effects that cancer patients experience. Under the terms of the DB Agreement, Diverse has granted
the Company an exclusive license to its intellectual property rights covering the Agents and its products. In exchange, the Company has
granted Diverse the right to information relating to the Agents developed for the express purpose of using such information to obtain
patent rights, which right terminates upon the issuance or denial of the patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DB Agreement, the Company will maintain sole responsibility and ownership of the development and commercialization of the Agents
and its products. Diverse has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its
products containing the Agents, at any time during or after the term of the DB Agreement. If Diverse intends to license, sell, or transfer
any other molecules linked with cannabinoids not granted to the Company under the terms of the DB Agreement, the Company will have the
first right, but not the obligation, to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay
Diverse an up-front investment payment in the amount of $675,000, as well as a running royalty starting with the first commercial sale
by the Company to a third party in an arms&rsquo;-length transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the DB Agreement shall continue for as long as the Company intends to develop or commercialize the new drugs, unless earlier
terminated by either Party. The Agreement may be terminated by either party upon ninety (90) days written notice of an uncured material
breach or in the event of bankruptcy or insolvency. In addition, the Company has the right to terminate the DB Agreement at any time
upon sixty (60) days&rsquo; prior written notice to Diverse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 236 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; COMMITMENTS AND CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&rsquo;s
financial position, results of operations or cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
Demand Letter</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2021, the Company received a stockholder litigation demand letter from the law firm of Purcell Julie &amp; Lefkowitz LLP,
on behalf of James Self, a purported stockholder of the Company. The letter demands that the Company (i) deem ineffective the December
30, 2020 amendment to our Amended and Restated Certificate of Incorporation in which the Company effected a one-for-four reverse stock
split of its common stock due to the manner in which non-votes by brokers were tabulated, (ii) seek appropriate relief for damages allegedly
suffered by the company and its stockholders or seek a valid stockholder approval of the amendment and reverse stock split, and (iii)
adopt adequate internal controls to prevent a recurrence of the alleged misconduct. The Company disputes that the amendment was ineffective
or that there were any inadequate internal controls related to the same. However, to eliminate any questions about the amendment, the
Company ratified the amendment at a special stockholders&rsquo; meeting pursuant to Section 204 of the Delaware General Corporation Law.
This special stockholders&rsquo; meeting occurred on May 14, 2021. On May 14, 2021, the Company filed a certificate of validation with
the State of Delaware to ratify the reverse stock split on December 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Development
and Clinical Supply Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &ldquo;PureForm Agreement&rdquo;) with PureForm
Global, Inc. (&ldquo;PureForm&rdquo;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&ldquo;API&rdquo;)
for the Company&rsquo;s development plans for cancer treatment and supportive care. Under the terms of the PureForm Agreement, PureForm
has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term
of the Agreement (contingent upon an initial minimum order volume during the first thirty (30) days from the effective date) and has
agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties. All
inventions that are developed jointly by the parties in the course of performing activities under the PureForm Agreement will be owned
jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development efforts by
PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the PureForm Agreement is three (3) years commencing on the effective date of the Agreement, subject to extension by
mutual agreement of the parties. The PureForm Agreement may be terminated by either party upon thirty (30) days written notice of an
uncured material breach or immediately in the event of bankruptcy or insolvency. The Agreement contains, among other provisions, representation
and warranties, indemnification obligations and confidentiality provisions in favor of each party that are customary for an agreement
of this nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Appointment
of Chief Financial Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
April 9, 2021, John M. Van Buiten resigned from his position as the Company&rsquo;s chief financial officer, effective May 15, 2021.
Mr. Van Buiten&rsquo;s resignation was not the result of any disagreement regarding any matter relating to the Company&rsquo;s operations,
policies, or practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
April 9, 2021, Carter J. Ward, 56, was appointed as the Company&rsquo;s chief financial officer, effective May 15, 2021 (the &ldquo;Effective
Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with Mr. Ward&rsquo;s appointment as chief financial officer, Mr. Ward entered into an employment agreement with the Company
on April 9, 2021 (the &ldquo;Ward Employment Agreement&rdquo;), effective as of May 15, 2021, pursuant to which Mr. Ward will receive
a base salary of $295,000 (&ldquo;Base Salary&rdquo;) and is eligible to receive annual performance bonuses of up to 50% of his Base
Salary, as determined from time-to-time by the Company&rsquo;s board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Company&rsquo;s common stock are entitled to one vote per share. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share rateably in all assets of the Company that are legally available
for distribution. As of December 31, 2020, 100,000,000 shares of common stock and 20,000,000 shares of Series B Preferred Stock were
authorized under the Company&rsquo;s articles of incorporation. The Company&rsquo;s Series B preferred stock is convertible by the holder
at any time into common stock at a rate of one to one.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion
of Series B Preferred Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2021, holders of an aggregate of 3,275,407 shares of Series B Preferred Stock converted their shares
into 3,275,407 shares of common stock. Following those conversions, no Series B Preferred stock shares remain outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 237 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS, CONTINUED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Offerings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
January 14, 2021, the Company completed an offering of 2,221,458 shares of Common Stock and pre-funded warrants at approximately $4.50
per share and a concurrent private placement of warrants to purchase 1,666,019 shares of Common Stock at $4.9519 per share, exercisable
immediately and terminating five years after the date of issuance for gross proceeds of approximately $10,000,000. The net proceeds to
the Company after deducting financial advisory fees and other costs and expenses were approximately $8,806,087.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 11, 2021, the Company completed an offering of 3,007,026 shares of Common Stock and a concurrent private placement of warrants
to purchase 1,503,513 shares of Common Stock at $4.90 per share, exercisable immediately and terminating five year from the date of issuance
for gross proceeds of approximately $12,800,000. The net proceeds to Enveric from the offering after deducting financial advisory fees
and other costs and expenses were approximately $11,624,401.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Remaining Contractual Term (years)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Value (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    &ndash; January 1, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">929,765</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.53</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.50</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expired
    forfeited, or cancelled</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(560,404</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.65</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.66</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    &ndash; December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">369,361</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.35</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.80</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">636,156</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable
    at December 31, 2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">369,361</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.35</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.80</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">636,156</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s stock based compensation expense related to stock options for the three months ended March 31, 2021 and 2020 was $0 and
$0, respectively. As of March 31, 2021, the Company had $0 in unamortized stock option expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2021, the Company exchanged options to purchase 560,404 shares of common stock for 325,410 restricted
stock units and 42,125 restricted stock awards. In connection with this exchange, the Company recognized $298,714 in inducement expense
related to the increase in fair value of the new awards over the old awards, which is included in general and administrative expenses
on the Company&rsquo;s statement of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s activity in restricted common stock was as follows for the three months ended March 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
                                            of</FONT></P>
                                                                                <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">shares</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted<BR>
    average<BR> grant date<BR> fair<BR> value</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non&ndash;vested
    at January 1, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 62%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">70,986</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.16</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(44,390</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.49</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non&ndash;vested
    at March 31, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,596</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.61</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2021 and 2020, the Company recorded $32,112 and $0, in stock-based compensation expense related to restricted
stock awards. As of March 31, 2021, unamortized stock-based compensation costs related to restricted share awards was $72,009, which
will be recognized over a weighted average period of 0.47 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 238 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS, CONTINUED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Issuance
of Restricted Stock Units</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s activity in restricted stock units was as follows for the three months ended March 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average<BR> grant date fair<BR> value</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non&ndash;vested
    at January 1, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 62%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,279,284</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.41</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,207,825</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.46</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non&ndash;vested
    at March 31, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,071,459</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.38</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2021 and 2020, the Company recorded $3,559,453 and $0, respectively, in stock-based compensation expense
related to restricted stock units, which is a component of general and administrative expenses in the condensed consolidated statement
of operations. As of March 31, 2021, unamortized stock-based compensation costs related to restricted stock units was $9,416,205 and
will be recognized over a weighted average period of 1.93 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at March 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
    <BR>shares <BR>outstanding</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    <BR> average<BR> exercise price (USD)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average remaining life</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intrinsic
    value</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    at January 1, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,661,178</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.98</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,535,519</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.93</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(851,099</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.17</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    at March 31, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,345,598</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.33</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.9</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,049,152</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable
    at March 31, 2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,345,598</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.33</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.9</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,049,152</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 239 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_150"></A>Financial
Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_012"></A>MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the period from incorporation May 26, 2020 to June 30, 2020</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Stated
in Canadian Dollars)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.8in"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.8in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 240 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #000066; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U><A NAME="e_001"></A>INDEPENDENT
AUDITORS&rsquo; REPORT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders of MagicMed Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Opinion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the financial statements of MagicMed Industries Inc. (the &ldquo;Corporation&rdquo;), which comprise the statement of financial
position as at June 30, 2020, and the statements of loss and comprehensive loss, changes in shareholders&rsquo; equity and cash flows
for the period from incorporation May 26, 2020 to June 30, 2020, and notes to the financial statements, including a summary of significant
accounting policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Corporation
as at June 30, 2020 and its financial performance and its cash flows for the period from incorporation May 26, 2020 to June 30, 2020
in accordance with International Financial Reporting Standards (&ldquo;IFRSs&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Basis
for Opinion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have conducted our audit in accordance with Canadian generally accepted auditing standards (&ldquo;GAAS&rdquo;). Our responsibilities
under those standards are further described in the <I>Auditors&rsquo; Responsibilities for the Audit of the Financial Statements </I>section
of our report. We are independent of the Corporation in accordance with the ethical requirements that are relevant to our audit of the
financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe
that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Material
Uncertainty Related to Going Concern</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
draw attention to Note 1 to the financial statements which indicates that as at June 30, 2020 the Corporation has no revenue generating
activity. As stated in Note 1, this event or condition, indicates that a material uncertainty exists that may cast significant doubt
on the Corporation&rsquo;s ability to continue as a going concern. Our opinion is not modified in respect of this matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Responsibilities
of Management and Those Charged with Governance for the Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, and for such internal
control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement,
whether due to fraud or error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the financial statements, management is responsible for assessing the Corporation&rsquo;s ability to continue as a going concern,
disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either
intends to liquidate the Corporation or to cease operations, or has no realistic alternative but to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
charged with governance are responsible for overseeing the Corporation&rsquo;s financial reporting process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 241 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Auditors&rsquo;
Responsibilities for the Audit of the Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement,
whether due to fraud or error, and to issue an auditors&rsquo; report that includes our opinion. Reasonable assurance is a high level
of assurance, but is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when
it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably
be expected to influence the economic decisions of users taken on the basis of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of an audit in accordance with GAAS, we exercise professional judgment and maintain professional skepticism throughout the audit.
We also:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit
    procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
    The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
    involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtain
    an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances,
    but not for the purpose of expressing an opinion on the effectiveness of the Corporation&rsquo;s internal control.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate
    the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conclude
    on the appropriateness of management&rsquo;s use of the going concern basis of accounting and, based on the audit evidence obtained,
    whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Corporation&rsquo;s
    ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our
    auditors&rsquo; report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our
    opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditors&rsquo; report. However, future events
    or conditions may cause the Corporation to cease to continue as a going concern.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate
    the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial
    statements represent the underlying transactions and events in a manner that achieves fair presentation. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant
audit findings, including any significant deficiencies in internal control that we identify during our audit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence,
and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where
applicable related safeguards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toronto,
    Ontario</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chartered
    Professional Accountants</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    29, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
    Public Accountants</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 242 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_002"></A>Statement
of Financial Position</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">544,977</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,843</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Government
    remittances recoverable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,422</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">551,242</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-current
    assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patents</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,285</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">556,527</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,
                                            11</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">51,217</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">51,217</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo;
    Equity</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share capital</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">396,590</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    reserve</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">151,196</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(42,476</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Shareholders&rsquo; Equity</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">505,310</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Liabilities &amp; Shareholders&rsquo; Equity</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">556,527</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subsequent
    Events</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved
    and authorized for issue by the Board of Directors on September 29, 2020.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;signed&rdquo;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;signed&rdquo;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 243 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_003"></A>Statement
of Loss and Comprehensive Loss</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Period from Incorporation May 26, 2020 to June 30, 2020</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed
in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Professional
    fees</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,190</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Marketing
    fees</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,500</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share-based
    compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,786</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,476</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss and comprehensive loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,476</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted loss per share for the period attributable to common shareholders</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.005</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average number of common shares outstanding &ndash; basic and diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,701,389</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 244 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>MagicMed Industries
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="e_004"></A>Statement of
Changes in Shareholders&rsquo; Equity</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the Period
from Incorporation May 26, 2020 to June 30, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Expressed in
Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Note</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Number of</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Shares</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Share</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Capital</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Equity</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">reserve</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Retained</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Earnings</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(Deficit)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P>
                                                                                 <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Shareholders&rsquo;Equity</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balances at May 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 41%; text-align: left">Shares issued for cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">8,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">40,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">40,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shares and warrants issued for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,050,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">356,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">148,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">505,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,786</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(42,476</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(42,476</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Balances at June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,050,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&nbsp;&nbsp;396,590</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&nbsp;&nbsp;151,196</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&nbsp;&nbsp;(42,476</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">505,310</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 245 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_005"></A>Statement
of Cash Flows</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Period from Incorporation May 26, 2020 to June 30, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed
in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(42,476</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments
    for non-cash items:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share-based
    compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,786</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(39,690</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
    in non-cash working capital:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,843</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Government
    remittances recoverable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,422</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,
                                            11</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">51,217</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from operating activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,262</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investing
    Activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acquisition
    of patents</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,285</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from investing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,285</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing
    Activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from issuance
    of shares</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">40,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of shares and warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,
                                            8</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">505,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from financing activities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">545,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    increase in cash for the period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">544,977</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - beginning of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - end of period</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">544,977</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 246 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_006"></A>Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1.</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nature of operations and formation of the Corporation</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc. (the &ldquo;Corporation&rdquo;) was incorporated under the laws of British Columbia on May 26, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation is building its molecular derivatives library, the Psybrary&trade;, which is a library of novel, patentable pharmaceutical
candidate molecules derived from the structures of known psychedelic agents, starting with psilocybin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation&rsquo;s registered office is located at 777 Hornby Street, Suite 600, Vancouver, BC V6Z 1S4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on a going concern basis which contemplates the realization of assets and the payments of liabilities
in the ordinary course of business. Should the Corporation be unable to continue as a going concern, it may be unable to realize the
carrying value of its assets and to meet its liabilities as they become due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2020 the Corporation has no revenue generating activity. This condition indicates the existence of material uncertainty that
casts significant doubt about the Corporation&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation&rsquo;s ability to continue as a going concern is dependent upon its ability to attain profitable operations and generate
funds therefrom and to continue to obtain financing sufficient to meet current and future obligations. During the period from July 1,
2020 and September 29, 2020, the date of issuance of these financial statements, the Corporation has raised $1,677,880 through a private
placement financing (see note 13). These financial statements do not reflect the adjustments or reclassification of assets and liabilities
which would be necessary if the Corporation were unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Basis of presentation</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Statement of compliance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements have been prepared in accordance with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued
by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
policies in these financial statements are based on IFRS issued and outstanding as of September 29, 2020, the date the Board of Directors
approved the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Basis of measurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation&rsquo;s financial statements have been prepared on the historical cost basis, except for certain financial instruments classified
at fair value upon initial recognition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Functional and presentation currency</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are presented in Canadian dollars, which is the Corporation&rsquo;s functional and presentational currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 247 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant accounting policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant accounting policies set out below have been applied consistently to all periods presented in these financial statements,
unless otherwise indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            instruments</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
                                            and initial measurement</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation initially recognizes financial instruments on the trade date, which is the date on which the Corporation becomes a party
to the contractual provisions of the instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial asset is or financial liability is measured initially at fair value plus/minus, for an item not at fair value through profit
or loss (&ldquo;FVTPL&rdquo;), transaction costs that are directly attributable to its acquisition or use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
asset</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
initial recognition, a financial asset is classified as measured at: amortized cost, fair value through other comprehensive income (&ldquo;FVOCI&rdquo;),
or FVTPL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            asset is held within a business model whose objective is to hold assets to collect contractual
                                            cash flows; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            contractual terms of the financial asset give rise on specified dates to cash flows that
                                            are solely payments of principal and interest on the principal amount outstanding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation currently does not measure any of its financial assets at amortized cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
debt instrument is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            asset is held within a business model whose objective is achieved by both collecting contractual
                                            cash flows and selling financial assets; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            contractual terms of the financial asset give rise on specified dates to cash flows that
                                            are solely payments of principal and interest on the principal amount outstanding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
initial recognition of an equity investment that is not held for trading, the Corporation may irrevocably elect to present subsequent
changes in FVOCI. This election is made on an investment-by-investment basis. The Corporation has not elected to present any assets as
FVOCI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is measured at FVTPL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on initial recognition, the Corporation may irrevocably designate a financial asset that otherwise meets the requirements to
be measured at amortized cost as at FVOCI or FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would
otherwise arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 248 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant
accounting policies (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Business
model assessment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation makes an assessment of the objective of a business model in which an asset is held at a portfolio level because this best
reflects the way the business is managed and information is provided to management. The information considered includes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            stated policies and objectives for the portfolio and the operation of those policies in practice.
                                            In particular, whether management&rsquo;s strategy focuses on earning contractual interest
                                            revenue, maintaining a particular interest rate profile, matching the duration of the financial
                                            assets to the duration of the liabilities that are funding those assets or realizing cash
                                            flows through the sale of the assets;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
                                            the performance of the portfolio is evaluated and reported to the Corporation&rsquo;s management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risks that affect the performance of the business model (and the financial assets held within
                                            that business model) and how those risks are managed;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
                                            managers of the business are compensated &ndash; e.g. whether compensation is based on the
                                            fair value of the assets managed or the contractual cash flows collected; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            frequency, volume and timing of sales in prior periods, the reasons for such sales and its
                                            expectation about future sales activity. However, information about sales activity is not
                                            considered in isolation, but as part of an overall assessment of the Corporation&rsquo;s
                                            stated objective for managing the financial assets is achieved and how cash flows are realized.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Assessment
whether contractual cash flows are solely payments of principal and interest</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this assessment, &lsquo;principal&rsquo; is defined as the fair value of the financial asset on initial recognition.
&lsquo;Interest&rsquo; is defined as consideration for the time value of money and for the credit risk associated with the principal
amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative
costs), as well as profit margin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing whether the contractual cash flows are solely payments of principal and interest, the Corporation considers the contractual
terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing
or amount of the contractual cash flows such that it would not meet this condition. In making the assessment, the Corporation considers:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contingent
                                            events that would change the amount and timing of cash flows;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">leverage
                                            features;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prepayment
                                            and extension terms;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms
                                            that limit the Corporation&rsquo;s claim to cash flows from specified assets (e.g. non-recourse
                                            asset arrangements); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">features
                                            that modify consideration of the time value of money &ndash; e.g. periodical rest of interest
                                            rates</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Reclassifications</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.35pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation would only reclassify a financial asset when the Corporation changes its business model for managing the financial asset.
All reclassifications are recorded at fair value at the date of reclassification, which becomes the new carrying value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets are not reclassified subsequent to their initial recognition, except in the period after the Corporation changes its business
model for managing financial assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 249 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
                                            accounting policies (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
liabilities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation classifies its financial liabilities as measured at amortized cost or FVTPL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers
the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of
the financial asset are transferred or in which the Corporation neither transfers nor retains substantially all of the risks and rewards
of ownership and it does not retain control of the financial asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
derecognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the
portion of the asset derecognized) and the sum of (i) the consideration received (including any new asset obtained less any new liability
assumed) and (ii) cumulative gain or loss that had been recognized in other comprehensive income (&ldquo;OCI&rdquo;) is recognized in
profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
liabilities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modifications
                                            of financial assets and financial liabilities</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
assets </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the terms of a financial asset are modified, the Corporation evaluates whether the cash flows of the modified asset are substantially
different. If the cash flows are substantially different, then the contractual rights to cash flows from the original financial asset
are deemed to have expired. In this case, the original financial asset is derecognized and a new financial asset is recognized at fair
value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the cash flows of the modified asset carried at amortized cost are not substantially different, then the modification does not result
in derecognition of the financial asset. In this case, the Corporation recalculates the gross carrying amount of the financial asset
and recognizes the amount arising from adjusting the gross carrying amount as a modification gain or loss in profit or loss. If such
a modification is carried out because of financial difficulties of the borrower, then the gain or loss is presented together with impairment
losses. In other cases, it is presented as interest income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
liabilities </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially
different. In this case, a new financial liability based on the modified terms is recognized at fair value. The difference between the
carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or
loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when,
the Corporation currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis
or to realize the asset and settle the liability simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 250 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
                                            accounting policies (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
and expenses are presented on a net basis only when permitted under IFRS, or for gains and losses arising from a group of similar transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
                                            value measurement</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date in the principal or, in its absence, the most advantageous market to which the Corporation has access at that
date. The fair value of a liability reflects its non-performance risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
one is available, the Corporation measures the fair value of an instrument using the quoted price in an active market for that instrument.
A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide
pricing information on an ongoing basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there is no quoted price in an active market, then the Corporation uses valuation techniques that maximize the use of relevant observable
inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants
would take into account in pricing a transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price &ndash; i.e. the fair
value of the consideration given or received. If the Corporation determines that the fair value on initial recognition differs from the
transaction price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor
based on a valuation technique for which any observable inputs are judged to be insignificant in relation to the measurement, then the
financial instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition
and the transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the
instrument but no later than when the valuation is wholly supported by observable market data or the transaction is closed out.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an asset or a liability measured at fair value has a bid price and an ask price, then the Corporation measures assets and long positions
at a bid price and liabilities and short positions at an ask price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portfolio
of financial assets and financial liabilities that are exposed to market risk and credit risk that are managed by the Corporation on
the basis of the net exposure to either market or credit risk are measured on the basis of a price that would be received to sell a net
long position (or paid to transfer a net short position) for the particular risk exposure. Portfolio-level adjustment &ndash;e.g. bid-ask
adjustment or credit risk adjustments that reflect the measurement on the basis of the net exposure &ndash; are allocated to the individual
assets and liabilities on the basis of the relative risk adjustment of each of the individual instruments in the portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date
on which the amount could be required to be paid. The Corporation recognizes transfers between levels of the fair value hierarchy as
of the end of the reporting period during which the change has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 251 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
                                            accounting policies (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Credit-impaired
financial assets </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, the Corporation assesses whether financial assets carried at amortized costs and debt financial assets carried at
FVOCI are credit-impaired. A financial asset is &lsquo;credit-impaired&rsquo; when one or more events that have a detrimental impact
on the estimated future cash flows of the financial asset have occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
that a financial asset is credit-impaired includes the following observable data:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            financial difficulty of the borrower or issuer;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            breach of contract such as a default of past due event;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            restructuring of a loan or advance by the Corporation on terms that the Corporation would
                                            not consider otherwise;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is becoming probable that the borrower will enter bankruptcy or other financial reorganization;
                                            or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            disappearance of an active market for a security because of financial difficulties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
loan that has been renegotiated due to a deterioration in the borrower&rsquo;s condition is usually considered to be credit-impaired
unless there is evidence that the risk of not receiving contractual cash flows has reduced significantly and there are no other indicators
of impairment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recognition
of allowance of expected credit losses (&ldquo;ECL&rdquo;) in the statement of financial position</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation recognizes a loss allowance for ECL on trade receivables that are measured at amortized cost. The Corporation&rsquo;s applied
the simplified approach for trade receivables and recognizes the lifetime ECL for these assets. The ECL on trade receivables is estimated
using a provision matrix based on the Corporation&rsquo;s historical credit loss experience, adjusted for factors that are specific to
the customers, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the
reporting date, including time value of money where appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all other financial assets measured at amortized cost or FVOCI, the Corporation recognizes lifetime ECL only when there has been a significant
increase in credit risk since initial recognition. If the credit risk on such financial instruments has not increased significantly since
initial recognition, the Corporation measures the loss allowance on those financial instruments at an amount equal to 12-months ECL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lifetime
ECL represents the ECL that will result from all possible default events over the expected life of a financial asset. In contrast, 12-month
ECL represents the portion of lifetime ECL that is expected to result from default events on a financial asset that are possible within
12 months after the reporting date. In assessing whether the credit risk on a financial asset has increased significantly since initial
recognition, the Corporation compares the risk of default occurring on the financial asset at the reporting date with the risk of default
occurring at the initial recognition. The Corporation considers both quantitative and qualitative factors that are supportable, including
historical experience and forward-looking information that is available without undue cost or effort.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irrespective
of the above assessment, the Corporation presumes that the credit risk on a financial asset has increased significantly since initial
recognition when contractual payments are more than 30 days past due, unless the Corporation has reasonable and supportable information
that demonstrates otherwise. Despite the foregoing, the Corporation presumes that the credit risk on a financial asset has not increased
significantly since initial recognition if the financial asset is determined to have low credit risk at the reporting date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 252 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
                                            accounting policies (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit
risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before
the amount becomes past due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definition
of default:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
internal credit risk management purposes, the Corporation considers a financial asset not recoverable if the customer balance owing is
180 days past due and information obtained from the customer and other external factors indicate that the customer is unlikely to pay
its creditors in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Write-off
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loans
and debt securities are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally
the case when the Corporation determines that the borrower does not have assets or sources of income that could generate sufficient cash
flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement
activities in order to comply with the Corporation&rsquo;s procedures for recovery of amounts due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;&nbsp;&nbsp;&nbsp;Cash
and cash equivalents</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include all cash on demand and all highly liquid investments with a maturity of three months or less, at the time
of purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;Income taxes</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive
income (loss), in which case it is recognized in equity or other comprehensive income (loss).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at period
end, adjusted for amendments to taxes payable with regards to previous years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is recorded using the asset and liability method, providing for temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences do not result
in deferred tax assets or liabilities: the initial recognition of assets or liabilities that affect neither accounting nor taxable loss;
differences relating to investment in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount
of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities,
using tax rates enacted or substantively enacted at the statement of financial position date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the
asset can be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities
and when they relate to income taxes levied by the same taxation authority and the Corporation intends to settle its correct tax assets
and liabilities on a net basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 253 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
                                            accounting policies (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible
assets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets include expenditures related to obtaining patents and technology rights associated with patents. The amortization of patent costs
commences when the associated products are available for commercial sale and is amortized on a straight line basis over its respective
legal life or economic life, if shorter. Amortization methods, useful lives, and residual values are reviewed at each reporting date
and adjusted if appropriate. Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical
knowledge and understanding, are recognized in operations as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
activities involve a plan or design for the production of new, or substantially improved, products or processes related to the Corporation&rsquo;s
Psybrary&trade;. Development expenditures are capitalized only if the relevant IFRS criteria are met. Capitalized development expenditures
are amortized from the beginning of commercial production and sales and are amortized on a straight-line basis over the remaining useful
life of the related patent(s). Development expenditures, in relation to the Corporation&rsquo;s Psybrary&trade;, have not satisfied the
above criteria and are recognized in operations as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment
of intangible assets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the end of each reporting period, the Corporation reviews the carrying amounts of its intangible assets to determine whether there
is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset
is estimated in order to determine the extent of the impairment loss (if any). Intangible assets with indefinite useful life, or those
not yet available for use, are tested for impairment annually. When it is not possible to estimate the recoverable amount of an individual
asset, the Corporation estimates the recoverable amount of the cash generating unity (&ldquo;CGU&rdquo;) to which the asset belongs.
When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual CGUs, or otherwise
they are allocated to the smallest group of CGUs for which a reasonable and consistent allocation basis can be identified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverable
amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are
discounted to their present value using a pretax discount rate that reflects current market assessments of the time value of money and
the risks specific to the asset for which the estimates of future cash flows have not been adjusted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU)
is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an impairment loss subsequently reverses, the carrying amount of the asset (or a CGU) is increased to the revised estimate of its recoverable
amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment
loss been recognized for the asset (or CGU) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -0.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation follows the relative fair value method with respect to the measurement of common shares and warrants issued as units. The
proceeds from the issuance of units are allocated between share capital and warrants. The warrant component is recorded in equity reserve.
Unit proceeds are allocated to common shares and warrants using the Black-Scholes option pricing model and the share price at the time
of financing. If and when the warrants are exercised, consideration paid by the warrant holder, together with the amount previously recognized
in equity reserve, is recorded as an increase to share capital. A forfeiture rate is estimated on the grant date and is adjusted to reflect
the actual number of warrants that vest. When stock options or warrants are cancelled, they are treated as if they have vested on the
date of cancellation and any cost not yet recognized in profit or loss is immediately expensed. Upon expiration of warrants, the amount
applicable to expired warrants is moved to contributed surplus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -18.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -18.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 254 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -18.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -18.9pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -18.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
                                            accounting policies (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
                                            (loss) per share, basic and diluted<BR>
                                            <BR>
                                            Basic earnings (loss) per share is calculated by dividing the profit or loss attributable
                                            to shareholders by the weighted average number of common shares outstanding for the period.
                                            Diluted earnings per share is determined by adjusting the profit or loss attributable to
                                            shareholders and the weighted average number of shares outstanding for the period for the
                                            effects of all potential dilutive shares, which comprise warrants. The calculation of diluted
                                            earnings per share assumes that the proceeds of such exercise would be used to repurchase
                                            common shares at the average market price for the period. However, the calculation of diluted
                                            earnings per share excludes the exercise of warrants that would be anti-dilutive.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
                                            currency translation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monetary
assets and liabilities denominated in foreign currencies are translated into Canadian dollars at the rate of exchange prevailing at the
statement of financial position date. Non-monetary items are translated at rates of exchange in effect when the amounts were acquired
or obligations incurred. Revenues and expenses are translated at the average exchange rate for the period. Foreign currency translation
gains and losses resulting from these translation adjustments are included in the determination of profit or loss in the statement of
loss and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
                                            standards and interpretations not yet adopted</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of new standards, amendments to standards and interpretations are not yet effective at June 30, 2020, and have not been applied
in preparing these financial statements. Management has determined that none of these will have a significant effect on the financial
statements of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Critical
accounting estimates and judgements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of these financial statements requires management to make certain estimates, judgments and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting year.
Actual outcomes could differ from these estimates. These financial statements include estimates which, by their nature, are uncertain.
The impacts of such estimates are pervasive throughout the financial statements and may require accounting adjustments based on future
occurrences. Revisions to accounting estimates are recognized in the year in which the estimate is revised and future years if the revision
affects both current and future years. These estimates are based on historical experience, current and future economic conditions and
other factors, including expectations of future events that are believed to be reasonable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
judgements, estimates and assumptions that have the most significant effect on the amounts recognized in the financial statements include
the fair value of financial instruments (note 5), warrants and fair value of share-based payments (note 7), and intangible assets (note
8).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share
based payments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of share-based compensation expenses are estimated using the Black-Scholes option pricing model and rely on a number of estimates,
such as the expected life of the option, the volatility of the underlying share price, the risk free rate of return, and the estimated
rate of forfeiture of options or warrants granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intangible
assets valuation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation&rsquo;s intangible assets valuation requires management to use judgment in estimating the fair value of its patents. The
fair value of patents are estimated on the basis of costs incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 255 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Estimated
useful lives, impairment considerations and amortization of intangible assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of property, plant and equipment, and intangible assets is dependent upon estimates of useful lives based on management&rsquo;s judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
of definite long-lived assets is influenced by judgment in defining a CGU and determining the indicators of impairment, and estimates
used to measure impairment losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation has classified its financial instruments as at June 30, 2020 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.4in">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FVTPL,
    measured at fair value:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 76%; text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">544,977</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
    liabilities, measured at amortized cost:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">51,217</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Corporation&rsquo;s financial instruments approximates their fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value Hierarchy of Financial Instruments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation has categorized its financial instruments that are carried at fair value, based on the priority of the inputs to the valuation
techniques used to measure fair value, into a three level fair value hierarchy as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 &ndash; fair value is based on unadjusted quoted prices for identical assets or liabilities
                                            in an active market. The types of assets and liabilities classified as Level 1 include cash.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 &ndash; fair value is based on quoted prices for similar assets or liabilities in active
                                            markets, valuation that is based on significant observable inputs, or inputs that are derived
                                            principally from or corroborated with observable market data through correlation or other
                                            means. Currently, the Corporation has no financial instruments that would be classified as
                                            Level 2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 &ndash; fair value is based on valuation techniques that requires one or more significant
                                            inputs that are not based on observable market inputs. These unobservable inputs reflect
                                            the Corporation&rsquo;s assumptions about the assumptions market participants would use in
                                            pricing the asset or liability. Currently, the Corporation has no financial instruments that
                                            would be classified as Level 3.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Corporation did not transfer any financial instruments between Level 1, 2 or 3 during the period from incorporation May 26, 2020 to June
30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible
assets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">During
the period from incorporation May 26, 2020 to June 30, 2020, the Corporation incurred costs of $5,285 relating to obtaining patents.
There was $nil amortization recognized during the period, as the patents had not met the criteria of being available for use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 256 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Authorized:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.5pt; text-align: justify; text-indent: 20.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlimited
common shares without nominal or par value issuable in series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Issued
                                            and outstanding common shares as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balance &ndash; May 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Shares issued &ndash; Founders&rsquo; round (i)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">8,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">40,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Shares and warrants issued for cash (ii)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,050,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">356,590</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance &ndash; June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,050,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">396,590</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
                                            May 26, 2020, the Corporation issued 8,000,000 common shares for gross proceeds of $40,000
                                            to directors and officers of the Corporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
                                            June 26, 2020, the Corporation completed a non-brokered private placement offering issuing
                                            an aggregate of 5,050,000 units at a price of $0.10 per unit for gross proceeds of $505,000,
                                            each unit consisting of one common share and one share purchase warrant. Each warrant, which
                                            vests immediately, entitles the holder to acquire a common share for $0.25 until May 26,
                                            2025. The fair value of these units is allocated as follows: shares - $356,590, warrants
                                            - $148,410 (see note 8). 2,800,000 of these units were issued to directors and officers of
                                            the Corporation. An additional $64,000, for 640,000 units under this offering, was received
                                            in July 2020 (note 13). The issuance of these additional units is not reflected in these
                                            financial statements as it occurred after the statement of financial position date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
continuity of outstanding warrants for the period from incorporation May 26, 2020 to June 30, 2020 is as follows: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify; text-indent: 0.8in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted average exercise price per share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Number outstanding, May 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: left; padding-left: 10pt">Warrants issued (a)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">8,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,786</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">0.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Warrants issued for cash [note 7 (b)(ii)]</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,050,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">148,410</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.25</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance &ndash; June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,050,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">151,196</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
                                            May 26, 2020, the Corporation issued 8,000,000 warrants to directors and officers of the
                                            Corporation. Each warrant, which vests immediately, entitles the holder to acquire one common
                                            share for $0.25 for a period of five years. The fair value of the warrants was determined
                                            to be $2,786.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 257 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants
(continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
estimated fair value of the warrants was determined using the Black-Scholes valuation model with the following assumptions. Expected
volatility was determined on historical volatility of peer companies. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.35in">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    issued (a)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    issued for cash [note 7 (b)(ii)]</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.40</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.36</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    annual volatility</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">85.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">85.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    life (in years)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.92</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    forfeiture rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share
    price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.005</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.07</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercises
    price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.25</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.25</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
13,050,000 warrants outstanding at June 30, 2020 have an exercise price of $0.25, expire on May 26, 2025 and have a weighted average
remaining contractual life of 4.91 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income
Taxes</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
recovery of income taxes differs from the result that would have been obtained by applying the combined federal and provincial tax rate
of 27% to the loss before income taxes. The difference results from the following items:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.35in">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    before taxes</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,476</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Statutory
    income tax rate (%)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27.00</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    recovery at statutory rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,469</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
    in taxes resulting from:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share-based
    compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">752</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    tax assets not recognized</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10,717</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income
    tax expense (recovery)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Deferred
taxes reflect the tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. As at June 30, 2020, the Corporation&rsquo;s deferred income tax asset is $nil,
as a valuation allowance of $10,717 has been applied to eliminate the potential value of non-capital loss carryforwards. Deferred tax
assets have not been recognized because it is not probable that future taxable profit will be available against which the Corporation
will be able to use these benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Corporation has non-capital loss carryforwards of $39,691 which are available for deduction against future taxable income and expire
in the year ending June 30, 2040. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 258 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
risk management</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, the Corporation is exposed to a variety of financial risks. The Corporation has a risk management framework
to monitor, evaluate and manage the principal risk assumed with its financial instruments. The potential risks that may arise form transacting
in financial instruments include credit risk, liquidity risk and market risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 26pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
                                            risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -19pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial
loss. Credit risk is managed by dealing only with counterparties the Corporation believes to be creditworthy. The Corporation is subject
to credit risk through its cash. The Corporation does not believe that it is exposed to an unusual level of credit risk. The Corporation&rsquo;s
cash is held at one financial institution. The Corporation limits its cash holdings to high-quality financial institutions in order to
minimize its credit risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.375in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
                                            Risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
risk refers to the risk that the Corporation will have insufficient cash resources to meet its financial obligations when they become
due. The Corporation manages liquidity risk by reviewing resources to ensure that it will have sufficient liquidity to meet liabilities
as they become due and to support business strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation generates cash flow from raising equity and it aims to partner with firms who will fund the development and testing of its
novel, patentable and licit molecules in exchange for exclusive rights per a negotiated arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2020, the Corporation&rsquo;s contractual cash flows, which were presented under liabilities in these financial statements,
consisted of accounts payable and accrued liabilities, with payments due in less than one year. All of the Corporation&rsquo;s financial
assets as reported on the June 30, 2020 statement of financial position are considered liquid and convertible into cash in less than
one year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.375in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
                                            risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices
whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting similar
financial instruments traded in the market. Market risk is the predominant risk as the Corporation is in the process of raising equity.
The Corporation is exposed to the following market risks:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
Interest rate risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate due to changes in market interest
rates. The Corporation&rsquo;s exposure to interest rate risk relates to its ability to earn interest income on cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value of the Corporation&rsquo;s cash affected by changes of interest rates is minimal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 259 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
risk management (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
                                            risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
risk is the risk that the value of a financial instrument fluctuates as a result of changes in foreign currency exchange rates, which
can be caused by market, political and/or other factors which may be subject to intervention by sovereign governments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation holds liabilities denominated in currencies other than its functional currency. The Corporation is therefore exposed to currency
risk as the value of the liabilities denominated in other currencies fluctuates due to change in exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2020, the Corporation was exposed to currency risk in U.S. dollars in the manner of accounts payable and accrued liabilities
of US$1,937.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Currency
sensitivity</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2020, had the Canadian dollar weakened or strengthened by 10% in relation to the U.S. dollar, with all other variables remaining
constant, net income and comprehensive income for the year would have decreased or increased, respectively, by approximately $194. This
analysis only addresses the impact on the financial instruments with respect to currency movement, and excludes any other economic or
geo-political implications of such currency fluctuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related
party transactions and balances <FONT STYLE="font-weight: normal">(see also notes 7 and 8)</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Key
management personnel includes persons having the authority and responsibility for planning, directing, and controlling the activities
of the Corporation as a whole. The Corporation has determined its key management personnel to the executive officers and directors of
the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Included
in accounts payable and accrued liabilities as at June 30, 2020 is a reimbursable amount of $12,029 payable to directors and officers
of the Corporation. Certain expenses reimbursable to directors and officers amounting to $6,500 were included in marketing fees and $119
were included in professional fees. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital
                                            management</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Corporation&rsquo;s business requires capital for funding current and future operations. The Corporation defines capital to include shareholders&rsquo;
equity, which is comprised of share capital and retained earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Corporation&rsquo;s objectives when managing capital are to safeguard the Corporation&rsquo;s ability to continue as a going concern
in order to pursue business opportunities and to maintain a flexible capital structure that optimizes the costs of capital at an acceptable
risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Corporation manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics
of the underlying assets. To maintain or adjust its capital structure, the Corporation may issue new shares, acquire or dispose of assets,
or adjust the amount of cash. In order to maximize ongoing development efforts, the Corporation does not anticipate the payment of dividends
for the foreseeable future. The Corporation is not subject to any externally imposed capital requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 260 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2020<BR>
(Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsequent
                                            events</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation has evaluated all subsequent events through September 29, 2020, which is the date the financial statements were available
to be issued. Management has determined that except as noted below, no events or transactions occurring after the statement of financial
position date substantially affect the amounts, presentation, and disclosure of the accompanying financial statements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 7, 2020, in connection with the June 26, 2020 non-brokered private placement offering,
                                            the Corporation issued an additional 640,000 units for gross proceeds of $64,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 15, 2020, the Corporation incorporated a wholly-owned subsidiary, MagicMed USA, Inc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of September 25, 2020, the Corporation raised $1,677,880 by way of a brokered private placement
                                            offering of 6,711,520 units at an offering price of $0.25 per unit. Each unit consists of
                                            one common share and one common share purchase warrant. Each warrant entitles the holder
                                            to acquire one common share of $0.25 for a period of five years.</FONT></TD></TR></TABLE>

<P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 261 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_151"></A>Interim
Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_013"></A>MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at and for the Three and Nine-Month Periods Ended</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2021</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited
- Stated in Canadian Dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 262 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_007"></A>Interim
Condensed Consolidated Statement of Financial Position</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at March 31, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(with
comparative figures for June 30, 2020)<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim1_001.jpg" ALT="" STYLE="height: 687px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved
and authorized for issue by the Board of Directors on June 1, 2021</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;signed&rdquo;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;signed&rdquo;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 263 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_008"></A>Interim
Condensed Consolidated Statement of Loss and Comprehensive Loss</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Three and Nine Month Periods Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim1_002.jpg" ALT="" STYLE="height: 671px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 264 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_009"></A>Interim
Condensed Consolidated Statement of Shareholders&rsquo; Equity</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Nine Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim1_003.jpg" ALT="" STYLE="height: 163px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 265 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_010"></A>Interim
Condensed Consolidated Statement of Cash Flows</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Nine-Month Period Ended March 31, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited
- Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim1_004.jpg" ALT="" STYLE="height: 629px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 266 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="e_011"></A>Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature
    of operations and going concern</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements include the accounts of MagicMed Industries Inc. (the &ldquo;Corporation&rdquo;) and its wholly-owned subsidiary
MagicMed USA Inc. (&ldquo;MagicMed USA&rdquo;) (together, the &ldquo;Company&rdquo;). The Corporation was incorporated under the laws
of British Columbia on May 26, 2020. MagicMed USA was incorporated on July 15, 2020 in the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is building its molecular derivatives library, the Psybrary&trade;, which is a library of novel, patentable pharmaceutical candidate
molecules derived from the structures of known psychedelic agents, starting with psilocybin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s registered office is located at 595 Howe Street, 10<SUP>th</SUP> Floor, Vancouver BC, V6C 2T5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Going
concern</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of
assets and the payments of liabilities in the ordinary course of business. Should the Company be unable to continue as a going concern,
it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s ability to continue as a going concern is dependent upon its ability to attain profitable operations and generate funds
therefrom and to continue to obtain financing sufficient to meet current and future obligations. The Company incurred a net loss for
the nine months ended March 31, 2021 of $2,379,369 and at March 31, 2021, the company had a cumulative deficit of $2,421,845 and working
capital of $6,856,903. These interim condensed consolidated financial statements do not reflect the adjustments or reclassification of
assets and liabilities which would be necessary if the Company were unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>COVID-19</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared a global pandemic related to COVID-19. Its impact on global economies has been far-reaching
and businesses around the world have had to cease or limit operations for long or indefinite periods of time. Measures taken to contain
the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered
significant disruptions to businesses worldwide, resulting in an economic slowdown. Global stock markets have also experienced great
volatility and significant declines. Governments and central banks have responded with monetary and fiscal interventions to stabilize
economic conditions. The duration and impact of the COVID-19 pandemic, as well as the effectiveness of the government and central bank
responses, remains unclear at this time. Although there have not been any significant impacts to the Company&rsquo;s operations it is
not possible to reliably estimate the duration and severity of the COVID-19 pandemic, nor its impact on the financial position and results
of the Company in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interim condensed consolidated financial statements as at, and for the nine months ended March 31, 2021 were approved and authorized
for issue by the Board of Directors on June 1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
    of presentation</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement
    of compliance</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s interim condensed consolidated financial statements have been prepared in accordance with IAS 34, <I>Interim Financial
Reporting. </I>These interim condensed consolidated financial statements do not include all notes of the type normally included within
the annual financial statements and should be read in conjunction with the consolidated financial statements of the Company as at, and
for the period from incorporation May 26, 2020 to, June 30, 2020, which have been prepared in accordance with International Financial
Reporting Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards Board and Interpretations of the IFRS Interpretations
Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 267 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
    of presentation (continued)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
    of measurement</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s interim condensed consolidated financial statements have been prepared on the historical cost basis, except for certain
financial instruments classified at fair value upon initial recognition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
    and presentation currency</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
condensed interim condensed consolidated financial statements are presented in Canadian dollars, which is the Company&rsquo;s presentational
currency, unless otherwise indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s functional currency, as determined by management is the Canadian dollar. Management has determined that the functional
Currency of the Corporation is the Canadian dollar and that the functional currency of its US subsidiary is the US dollar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
    of consolidation</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify; text-indent: -21.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interim condensed consolidated statements comprise the accounts of the Corporation and its wholly-owned subsidiary MagicMed USA. Control
exists when the Corporation has the power, directly or indirectly, to govern the financial and operating policies of an entity so as
to obtain benefits from its activities. Inter-company balances and transactions, and any unrealized income and expenses arising from
inter-company transactions, are eliminated in preparing the interim condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify; text-indent: -21.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
    accounting policies</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant accounting policies set out below have been applied consistently to all periods presented in these interim condensed consolidated
financial statements, unless otherwise indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
    and initial measurement</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially recognizes financial instruments on the trade date, which is the date on which the Company becomes a party to the contractual
provisions of the instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial asset or financial liability is measured initially at fair value plus/minus, for an item not at fair value through profit or
loss (&ldquo;FVTPL&rdquo;), transaction costs that are directly attributable to its acquisition or use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -23.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
initial recognition, a financial asset is classified as measured at: amortized cost, fair value through other comprehensive income (&ldquo;FVOCI&rdquo;),
or FVTPL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
    on the principal amount outstanding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 268 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
    accounting policies (continued)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently does not measure any of its financial assets at amortized cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
debt instrument is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial
    assets; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
    on the principal amount outstanding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes
in FVOCI. This election is made on an investment-by-investment basis. The Company has not elected to present any assets as FVOCI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is measured at FVTPL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be
measured at amortized cost as at FVOCI or FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise
arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Business
model assessment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.85in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company makes an assessment of the objective of a business model in which an asset is held at a portfolio level because this best reflects
the way the business is managed, and information is provided to management. The information considered includes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    stated policies and objectives for the portfolio and the operation of those policies in practice. In particular, whether management&rsquo;s
    strategy focuses on earning contractual interest revenue, maintaining a particular interest rate profile, matching the duration of
    the financial assets to the duration of the liabilities that are funding those assets or realizing cash flows through the sale of
    the assets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    the performance of the portfolio is evaluated and reported to the Company&rsquo;s management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risks that affect the performance of the business model (and the financial assets held within that business model) and how those
    risks are managed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    managers of the business are compensated &ndash; e.g. whether compensation is based on the fair value of the assets managed or the
    contractual cash flows collected; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectation about future sales activity.
    However, information about sales activity is not considered in isolation, but as part of an overall assessment of the Company&rsquo;s
    stated objective for managing the financial assets is achieved and how cash flows are realized.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Assessment
whether contractual cash flows are solely payments of principal and interest</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this assessment, &lsquo;principal&rsquo; is defined as the fair value of the financial asset on initial recognition.
&lsquo;Interest&rsquo; is defined as consideration for the time value of money and for the credit risk associated with the principal
amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative
costs), as well as profit margin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 269 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
    accounting policies (continued)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms
of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount
of the contractual cash flows such that it would not meet this condition. In making the assessment, the Company considers:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contingent
    events that would change the amount and timing of cash flows;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">leverage
    features;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prepayment
    and extension terms;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms
    that limit the Company&rsquo;s claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">features
    that modify consideration of the time value of money &ndash; e.g. periodical rest of interest rates</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Reclassifications</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.35pt; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company would only reclassify a financial asset when the Company changes its business model for managing the financial asset. All reclassifications
are recorded at fair value at the date of reclassification, which becomes the new carrying value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets are not reclassified subsequent to their initial recognition, except in the period after the Company changes its business model
for managing financial assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
liabilities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies its financial liabilities as measured at amortized cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -23.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -23.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers
the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of
the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards
of ownership and it does not retain control of the financial asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
derecognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the
portion of the asset derecognized) and the sum of (i) the consideration received (including any new asset obtained less any new liability
assumed) and (ii) cumulative gain or loss that had been recognized in other comprehensive income (&ldquo;OCI&rdquo;) is recognized in
profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
liabilities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 270 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
    accounting policies (continued)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modifications
    of financial assets and financial liabilities </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
assets </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the terms of a financial asset are modified, the Company evaluates whether the cash flows of the modified asset are substantially different.
If the cash flows are substantially different, then the contractual rights to cash flows from the original financial asset are deemed
to have expired. In this case, the original financial asset is derecognized, and a new financial asset is recognized at fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the cash flows of the modified asset carried at amortized cost are not substantially different, then the modification does not result
in derecognition of the financial asset. In this case, the Company recalculates the gross carrying amount of the financial asset and
recognizes the amount arising from adjusting the gross carrying amount as a modification gain or loss in profit or loss. If such a modification
is carried out because of financial difficulties of the borrower, then the gain or loss is presented together with impairment losses.
In other cases, it is presented as interest income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
liabilities </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derecognizes a financial liability when its terms are modified, and the cash flows of the modified liability are substantially
different. In this case, a new financial liability based on the modified terms is recognized at fair value. The difference between the
carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or
loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets and financial liabilities are offset, and the net amount presented in the statement of financial position when, and only when,
the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to
realize the asset and settle the liability simultaneously. Significant accounting policies (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
and expenses are presented on a net basis only when permitted under IFRS, or for gains and losses arising from a group of similar transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value measurement </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date in the principal or, in its absence, the most advantageous market to which the Company has access at that date.
The fair value of a liability reflects its non-performance risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument.
A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide
pricing information on an ongoing basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable
inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants
would take into account in pricing a transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 271 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    accounting policies (continued)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price &ndash; i.e. the fair
value of the consideration given or received. If the Company determines that the fair value on initial recognition differs from the transaction
price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor based on
a valuation technique for which any observable inputs are judged to be insignificant in relation to the measurement, then the financial
instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition and the
transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the instrument
but no later than when the valuation is wholly supported by observable market data or the transaction is closed out.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an asset or a liability measured at fair value has a bid price and an ask price, then the Company measures assets and long positions
at a bid price and liabilities and short positions at an ask price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portfolio
of financial assets and financial liabilities that are exposed to market risk and credit risk that are managed by the Company on the
basis of the net exposure to either market or credit risk are measured on the basis of a price that would be received to sell a net long
position (or paid to transfer a net short position) for the particular risk exposure. Portfolio-level adjustment &ndash;e.g. bid-ask
adjustment or credit risk adjustments that reflect the measurement on the basis of the net exposure &ndash; are allocated to the individual
assets and liabilities on the basis of the relative risk adjustment of each of the individual instruments in the portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date
on which the amount could be required to be paid. The Company recognizes transfers between levels of the fair value hierarchy as of the
end of the reporting period during which the change has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Credit-impaired
financial assets </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, the Company assesses whether financial assets carried at amortized costs and debt financial assets carried at FVOCI
are credit-impaired. A financial asset is &lsquo;credit-impaired&rsquo; when one or more events that have a detrimental impact on the
estimated future cash flows of the financial asset have occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
that a financial asset is credit-impaired includes the following observable data:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify; text-indent: -24.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    financial difficulty of the borrower or issuer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    breach of contract such as a default of past due event;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is becoming probable that the borrower will enter bankruptcy or other financial reorganization; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    disappearance of an active market for a security because of financial difficulties. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
loan that has been renegotiated due to a deterioration in the borrower&rsquo;s condition is usually considered to be credit-impaired
unless there is evidence that the risk of not receiving contractual cash flows has reduced significantly and there are no other indicators
of impairment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 272 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MagicMed
Industries Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    accounting policies (continued)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recognition
of allowance of expected credit losses (&ldquo;ECL&rdquo;) in the consolidated statement of financial position</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a loss allowance for ECL on trade receivables that are measured at amortized cost. The Company&rsquo;s applied the
simplified approach for trade receivables and recognizes the lifetime ECL for these assets. The ECL on trade receivables is estimated
using a provision matrix based on the Company&rsquo;s historical credit loss experience, adjusted for factors that are specific to the
customers, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting
date, including time value of money where appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all other financial assets measured at amortized cost or FVOCI, the Company recognizes lifetime ECL only when there has been a significant
increase in credit risk since initial recognition. If the credit risk on such financial instruments has not increased significantly since
initial recognition, the Company measures the loss allowance on those financial instruments at an amount equal to 12-months ECL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lifetime
ECL represents the ECL that will result from all possible default events over the expected life of a financial asset. In contrast, 12-month
ECL represents the portion of lifetime ECL that is expected to result from default events on a financial asset that are possible within
12 months after the reporting date. In assessing whether the credit risk on a financial asset has increased significantly since initial
recognition, the Company compares the risk of default occurring on the financial asset at the reporting date with the risk of default
occurring at the initial recognition. The Company considers both quantitative and qualitative factors that are supportable, including
historical experience and forward-looking information that is available without undue cost or effort.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irrespective
of the above assessment, the Company presumes that the credit risk on a financial asset has increased significantly since initial recognition
when contractual payments are more than 30 days past due, unless the Company has reasonable and supportable information that demonstrates
otherwise. Despite the foregoing, the Company presumes that the credit risk on a financial asset has not increased significantly since
initial recognition if the financial asset is determined to have low credit risk at the reporting date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit
risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before
the amount becomes past due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definition
of default:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
internal credit risk management purposes, the Company considers a financial asset not recoverable if the customer balance owing is 180
days past due and information obtained from the customer and other external factors indicate that the customer is unlikely to pay its
creditors in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Write-off
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loans
and debt securities are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally
the case when the Company determines that the borrower does not have assets or sources of income that could generate sufficient cash
flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement
activities in order to comply with the Company&rsquo;s procedures for recovery of amounts due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 273 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            accounting policies (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2792in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2208in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
                                            and cash equivalents</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include all cash on demand and all highly liquid investments with a maturity of three months or less, at the time
of purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23.25pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
                                            taxes</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -3.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive
income (loss), in which case it is recognized in equity or other comprehensive income (loss).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at period
end, adjusted for amendments to taxes payable with regards to previous years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is recorded using the asset and liability method, providing for temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences do not result
in deferred tax assets or liabilities: the initial recognition of assets or liabilities that affect neither accounting nor taxable loss;
differences relating to investment in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount
of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities,
using tax rates enacted or substantively enacted at the statement of financial position date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the
asset can be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities
and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and
liabilities on a net basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2792in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2208in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
is stated at cost less accumulated depreciation. Lab equipment is depreciated at a rate of 20% on a declining balance basis from the
date the asset is available for use as intended until the date of disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company regularly reviews its equipment to eliminate obsolete items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
item of equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are
expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal
proceeds and the carrying amount of the asset) is included in the statement of loss and comprehensive loss when the asset is derecognized.
The assets&rsquo; residual values, useful lives and methods of depreciation are reviewed at each reporting date and adjusted prospectively
if appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 274 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            accounting policies (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23.25pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
                                            assets</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets include expenditures related to website development, obtaining patents and technology rights associated with patents. Websites
have a finite useful life and are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method
over the websites&rsquo; estimated useful lives of 3 years. The amortization of patent costs commences when they are available for use
as intended and they are amortized on a straight-line basis over the patent&rsquo;s legal life or economic life, if shorter. Amortization
methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate. Expenditures on research
activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in operations
as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Development
activities involve a plan or design for the production of new, or substantially improved, products or processes related to the Company&rsquo;s
Psybrary&trade;. Development expenditures are capitalized only if the relevant IFRS criteria are met. Capitalized development expenditures
are amortized from the beginning of commercial production and sales and are amortized on a straight-line basis over the remaining useful
life of the related patent(s). Development expenditures, in relation to the Company&rsquo;s Psybrary&trade;, have not satisfied the above
criteria and are recognized in operations as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment
of long-lived assets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the end of each reporting period, the Company reviews the carrying amounts of its equipment and intangible assets to determine whether
there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of
the asset is estimated in order to determine the extent of the impairment loss (if any). Long-lived assets with indefinite useful life,
or those not yet available for use, are tested for impairment annually. When it is not possible to estimate the recoverable amount of
an individual asset, the Company estimates the recoverable amount of the cash generating unity (&ldquo;CGU&rdquo;) to which the asset
belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual CGUs,
or otherwise they are allocated to the smallest group of CGUs for which a reasonable and consistent allocation basis can be identified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverable
amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are
discounted to their present value using a pretax discount rate that reflects current market assessments of the time value of money and
the risks specific to the asset for which the estimates of future cash flows have not been adjusted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU)
is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an impairment loss subsequently reverses, the carrying amount of the asset (or a CGU) is increased to the revised estimate of its recoverable
amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment
loss been recognized for the asset (or CGU) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 275 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            accounting policies (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: -0.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the relative fair value method with respect to the measurement of common shares and warrants issued as units. The proceeds
from the issuance of units are allocated between share capital and warrants. The warrant component is recorded in warrant reserve. Unit
proceeds are allocated to common shares and warrants using the Black-Scholes option pricing model and the share price at the time of
financing. If and when the warrants are exercised, consideration paid by the warrant holder, together with the amount previously recognized
in warrant reserve, is recorded as an increase to share capital. For any warrants that do not vest upon issuance, a forfeiture rate is
estimated on the grant date and is adjusted to reflect the actual number of warrants that vest. Upon expiration of warrants, the amount
applicable to expired warrants is moved to contributed surplus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2792in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2208in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            Options</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&rsquo;s stock option plan, all stock options granted have graded vesting periods and are exercisable up to a maximum of 10
years from the date of grant. Each tranche of an award with graded vesting periods is considered a separate grant at each grant date
for the calculation of fair value, and the resulting fair value is amortized over the vesting period of the respective tranches. The
fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions
upon which the options were granted, the estimated volatility, estimated risk-free rate and estimated forfeitures. The value of the options
granted is recognized over the vesting period in share-based compensation expense in the statement of loss and comprehensive loss, and
in options reserve. Upon exercise, shares are issued from treasury and the amount reflected in options reserve is credited to share capital,
along with any consideration paid. Upon expiration of options, the amount applicable to expired options is moved from options reserve
to contributed surplus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a grant of the share-based payments is cancelled or settled during the vesting period (other than a grant cancelled by forfeiture when
the vesting conditions are not satisfied), the Company accounts for the cancellation or settlement as an acceleration of vesting and
recognizes immediately the amount that otherwise would have been recognized for services over the remainder of the vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount recognized for goods or services received during the vesting period are based on the best available estimate of the number of
equity instruments anticipated to vest. The Company revises that estimate, if necessary, if subsequent information indicates that the
number of share options anticipated to vest differs from previous estimates. On vesting date, the Company revises the estimate to equal
the number of equity instruments that ultimately vested. After vesting date, the Company makes no subsequent adjustment to total equity
for goods or services received if the share options are later forfeited or they expire at the end of the share options&rsquo; life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a grant of the share-based payment is modified during the vesting period (other than a grant cancelled by forfeiture when the vesting
conditions are not satisfied) and the fair value of the new instruments is higher than the fair value of the original instrument, the
incremental fair value granted is included in the measurement of the amount recognized for services received over the period form modification
date until the date when the modified equity instruments vests, in addition to the amount based on the grant date fair value of the original
equity instruments, which is recognized over the remainder of the original vesting period of the original instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 276 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            accounting policies (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2792in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2208in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            Appreciation Rights Plan</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
issued under the Company&rsquo;s Stock Appreciation Rights (&ldquo;SAR&rdquo;) long-term incentive plan are initially measured based
on the fair value when granted. The fair value of outstanding units is re-measured at each reporting date. The associated expense is
recognized in general and administrative expense over the vesting periods of the SARs. Vesting of the SARs occurs over a period of time
determined at the date of the grant, taking into consideration the separate tranches issued. SARs are cash-settled awards, and therefore
the expense is offset to accounts payable and accrued liabilities. Fair value of the SARs is calculated based on the spread of the grant
price and Company&rsquo;s closing stock price at the date of valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2792in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2208in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
                                            (loss) per share, basic and diluted<BR>
                                            <BR>
                                            Basic earnings (loss) per share is calculated by dividing the profit or loss attributable
                                            to shareholders by the weighted average number of common shares outstanding for the period.
                                            Diluted earnings per share is determined by adjusting the profit or loss attributable to
                                            shareholders and the weighted average number of shares outstanding for the period for the
                                            effects of all potential dilutive shares, which comprise outstanding warrants and options.
                                            The calculation of diluted earnings per share assumes that the proceeds of such exercise
                                            would be used to repurchase common shares at the average market price for the period. However,
                                            the calculation of diluted earnings per share excludes the exercise of warrants and options
                                            that would be anti-dilutive.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2792in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2208in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
                                            currency translation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
figures presented in the condensed interim financial statements are reflected in Canadian dollars unless otherwise noted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets
and liabilities denominated in foreign currencies at the statement of financial position date are translated to Canadian dollars at the
foreign exchange rate applicable as at that date. Realized and unrealized exchange gains and losses are recognized through profit or
loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities of foreign operations are translated into Canadian dollars at period-end exchange rates. Income and expenses,
and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting
from translating foreign operations are recognized in other comprehensive income (loss) and accumulated in shareholders&rsquo; equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency translation gains or losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of
which is neither planned nor likely to occur in the foreseeable future and which is substance is considered to form part of the net investment
in the foreign operation, are recognized in other comprehensive income (loss) in the translation reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transactions
and balances</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in foreign currencies are translated using the functional currency spot rate of exchange
at the reporting date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency translation gains and losses resulting from the settlement of such transactions as well as from the translation of monetary
assets and liabilities not denominated in the functional currency of the subsidiary are recognized in the consolidated statement of loss
and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 277 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            accounting policies (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2792in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2208in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
                                            standards and interpretations not yet adopted</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of new standards, amendments to standards and interpretations are not yet effective at March 31, 2021 and have not been applied
in preparing these interim condensed consolidated financial statements. Management has determined that none of these will have a significant
effect on the interim condensed consolidated financial statements of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Critical
accounting estimates and judgements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of these interim condensed consolidated financial statements requires management to make certain estimates, judgments and
assumptions that affect the reported amounts of assets and liabilities at the date of the interim condensed consolidated financial statements
and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. These interim condensed
consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive
throughout the interim condensed consolidated financial statements and may require accounting adjustments based on future occurrences.
Revisions to accounting estimates are recognized in the period in which the estimate is revised and future years if the revision affects
both current and future years. These estimates are based on historical experience, current and future economic conditions and other factors,
including expectations of future events that are believed to be reasonable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
judgements, estimates and assumptions that have the most significant effect on the amounts recognized in the interim condensed consolidated
financial statements include the fair value of financial instruments (note 5), warrants and fair value of share-based payments (note
10), and intangible assets (note 7).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share
based payments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of share-based compensation expenses are estimated using the Black-Scholes option pricing model and rely on a number of estimates,
such as the expected life of the option, the volatility of the underlying share price, the risk free rate of return, and the estimated
rate of forfeiture of options or warrants granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intangible
assets valuation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s intangible assets valuation requires management to use judgment in estimating the fair value of its patents. The fair
value of patents is estimated on the basis of costs incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Estimated
useful lives, impairment considerations and amortization of capital assets and intangible assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of capital assets and intangible assets is dependent upon estimates of useful lives based on management&rsquo;s judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
of definite long-lived assets is influenced by judgment in defining a CGU and determining the indicators of impairment, and estimates
used to measure impairment losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 278 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has classified its financial instruments as at March 31, 2021 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">FVTPL, measured at fair value:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 76%; text-align: justify">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">6,953,091</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Financial liabilities, measured at amortized cost:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">380,046</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&rsquo;s financial instruments approximates their fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value Hierarchy of Financial Instruments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has categorized its financial instruments that are carried at fair value, based on the priority of the inputs to the valuation
techniques used to measure fair value, into a three-level fair value hierarchy as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 &ndash; fair value is based on unadjusted quoted prices for identical assets or liabilities
                                            in an active market. The types of assets and liabilities classified as Level 1 include cash.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 &ndash; fair value is based on quoted prices for similar assets or liabilities in active
                                            markets, valuation that is based on significant observable inputs, or inputs that are derived
                                            principally from or corroborated with observable market data through correlation or other
                                            means. Currently, the Company has no financial instruments that would be classified as Level
                                            2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 &ndash; fair value is based on valuation techniques that requires one or more significant
                                            inputs that are not based on observable market inputs. These unobservable inputs reflect
                                            the Company&rsquo;s assumptions about the assumptions market participants would use in pricing
                                            the asset or liability. Currently, the Company has no financial instruments that would be
                                            classified as Level 3.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company did not transfer any financial instruments between Level 1, 2 or 3 during the three and nine months ended March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Lab
equipment consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cost</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left">Balance, June 30, 2020</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: normal; text-align: left; padding-bottom: 1.5pt">Additions</TD><TD STYLE="width: 2%; font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">17,660</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Balance, March 31, 2021</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">17,660</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Accumulated depreciation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left">Balance, June 30, 2020</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Change for the period</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">1,324</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Balance, March 31, 2021</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">1,324</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net book value</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Balance, March 31, 2021</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">16,336</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 279 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible
assets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Intangible
assets consist of the following:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Website development</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cost</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; font-weight: normal; text-align: left">Balance, June 30, 2020</TD><TD STYLE="width: 2%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 11%; font-weight: normal; text-align: right">5,285</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 11%; font-weight: normal; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 11%; font-weight: normal; text-align: right">5,285</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Additions</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">107,336</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">17,416</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">124,752</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Balance, March 31, 2021</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">112,621</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">17,416</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">130,037</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Accumulated amortization</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left">Balance, June 30, 2020</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Change for the period</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Balance, March 31, 2021</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net book value</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1.5pt">Balance, March 31, 2021</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">112,621</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">17,416</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">130,037</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 280 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
                                            capital</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Authorized:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.5pt; text-align: justify; text-indent: 20.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlimited
common shares without nominal or par value issuable in series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Issued
                                            and outstanding common shares as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim2_001.jpg" ALT="" STYLE="height: 240px; width: 578px"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
                                            July 7, 2020 640,000 units were issued at a price of $0.10 per unit for gross proceeds of
                                            $64,000, under a non-brokered private placement. Each unit consisted of one common share
                                            and one common share purchase warrant. Each warrant, which vested immediately, entitles the
                                            holder to acquire a common share for $0.25 until May 26, 2025. The proceeds on the issuance
                                            of these units is allocated as follows: shares - $45,192, warrants - $18,808 (see note 9).
                                            300,000 of these units were issued to directors and officers of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
                                            September 3, 2020, the Company completed a brokered private placement offering issuing an
                                            aggregate of 6,611,520 common shares at a price of $0.25 per share for gross proceeds of
                                            $1,652,880. Share issuance costs of $187,673 were incurred. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
                                            December 22, 2020, the Company completed a brokered private placement offering issuing an
                                            aggregate of 16,283,766 units at a price of $0.50 per unit for gross proceeds of $8,141,883,
                                            each unit consisting of one common share and one-half of a common share purchase warrant.
                                            All of the common share purchase warrants vest immediately and entitle the holder to acquire
                                            a common share for $0.75 for two years from the date of a public listing of the Company&rsquo;s
                                            shares. The fair value of these units is allocated as follows: shares - $6,945,259 warrants
                                            - $1,196,624 (see note 9). 130,000 of these units were issued to directors and officers of
                                            the Company. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Share
issuance costs in cash of $862,865 were incurred. The agents also received 809,187 units, each unit consisting of one common share and
one-half of a common share purchase warrant. The fair value of these units is allocated as follows: shares - $347,263 warrants - $59,831
(see note 9). In addition, the agents received 1,302,701 agent unit purchase warrants (&ldquo;Agent Unit Purchase Warrants&rdquo;), which
each entitle the agents to acquire one unit at $0.50 per unit with each unit comprising of one common share and one-half of a common
share purchase warrant, with these common share purchase warrants exercisable at $0.75 per common share for two years from the date of
a public listing of the Company&rsquo;s shares. The fair value of these Agent Unit Purchase Warrants was determined to be $311,555 (see
note 9). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40.55pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
                                            February 15, 2021, a holder of 19,200 Agent Unit Purchase Warrants, exercisable at $0.50
                                            per unit exercise their Agent Unit Purchase Warrants for aggregate gross proceeds of $9,600.
                                            Each Agent Unit Purchase Warrant was exercised for a unit with each unit comprising one common
                                            share and one-half of a common share purchase warrant, with these common share purchase warrants
                                            exercisable at $0.75 per common share for two years from the date of a public listing of
                                            the Company&rsquo;s shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 281 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext"><B>9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants
                                            </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuity of warrants for the nine-month period ended March 31, 2021 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim2_002.jpg" ALT="" STYLE="height: 301px; width: 593px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
following summarizes information about warrants outstanding and exercisable as at March 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><IMG SRC="interim2_003.jpg" ALT="" STYLE="height: 222px; width: 595px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
estimated fair value of the warrants was determined using the Black-Scholes valuation model with the following assumptions. Expected
volatility was determined on historical volatility of peer companies. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants issued for cash [note 8 (b)(i)]</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants issued for cash [note 8 (b)(iii) and note 8 (b)(iv)]</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; font-weight: normal; text-align: justify">Risk-free interest rate</TD><TD STYLE="width: 2%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-weight: normal; text-align: right">0.36</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">%</TD><TD STYLE="width: 2%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-weight: normal; text-align: right">0.36</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: justify">Expected annual volatility</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">85.00</TD><TD STYLE="font-weight: normal; text-align: left">%</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">85.00</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: justify">Expected life (in years)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4.92</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">2.25</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: justify">Expected dividend yield</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">0.00</TD><TD STYLE="font-weight: normal; text-align: left">%</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">0.00</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: justify">Share price</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">0.07</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">0.435</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: justify; padding-bottom: 1.5pt">Exercise price</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">0.25</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">0.75</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 282 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
(continued)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
estimated fair value of the Agent Unit Purchase warrants was determined using the Black-Scholes valuation model with the following assumptions.
Expected volatility was determined on historical volatility of peer companies. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Risk-free interest rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">0.36</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected annual volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85.00</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Unit Price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-based
                                            compensation</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Option
Plan </U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
October 5, 2020, a stock option plan was approved by the board of directors of the Corporation. The total common shares to be issued
as a result of the plan is not to exceed 10% of the total outstanding common shares at the time of granting of an option. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
continuity of outstanding options is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim2_004.jpg" ALT="" STYLE="height: 154px; width: 597px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
October 5, 2020, the Company granted 679,830 stock options under an advisory services agreement with an exercise price of $0.25. These
options vest 10% immediately upon issuance and 15% of the remaining will vest every six months thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
fair value of the stock options was determined using the Black-Scholes valuation model with the following assumptions. Expected volatility
was determined on historical volatility of peer companies. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: normal; text-align: justify">Risk-free interest rate</TD><TD STYLE="width: 2%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-weight: normal; text-align: right">0.10</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: justify">Expected annual volatility</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">85.00</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: justify">Expected life (in years)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">10</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: justify">Expected dividend yield</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">0.00</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: justify">Expected forfeiture rate</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">0.00</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: justify">Share price</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">$</TD><TD STYLE="font-weight: normal; text-align: right">0.25</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: justify; padding-bottom: 1.5pt">Exercises price</TD><TD STYLE="font-weight: normal; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: right">0.25</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 283 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
                                            options (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
following summarizes information about stock options outstanding and exercisable as at March 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Expiry date</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options outstanding</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options exercisable</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Exercise price</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Estimated grant date fair value</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted
average remaining contractual life (in years)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; width: 35%">October 5, 2030</TD><TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">679,830</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">67,983</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.25</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">139,694</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9.77</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">679,830</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">67,983</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.25</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139,694</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.77</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Stock
Appreciation Rights Plan</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company established the SAR plan to promote a proprietary interest in the Company by qualified service providers
and to promote further alignment of interests between such qualified service providers and shareholders. Each SAR granted permits the
holder to receive a cash payment equal to the spread of the closing sales price of the stock and the grant price for all vested SARs.
The SARs generally vest either immediately or vest a portion on the first, second and third anniversary of the grant date, and must be
exercised within 5 years from the grant date. The aggregate number of common shares in respect of with SARs have been granted and not
yet exercised shall not at any time exceed 5% of the aggregate number of common shares that are then issued and outstanding. As of March
31, 2021 no SARs have been issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
                                            taxes</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
recovery of income taxes differs from the result that would have been obtained by applying the combined federal and provincial tax rate
of 23% to the loss before income taxes. The difference results from the following items:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 284 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim2_005.jpg" ALT="" STYLE="height: 219px; width: 594px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
                                            taxes (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
significant components of the Company&rsquo;s temporary differences and unused tax losses that have not been included in the interim
condensed consolidated statement of financial position are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim2_006.jpg" ALT="" STYLE="height: 143px; width: 570px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Deferred
tax assets have not been recognized in respect of these items because it is not probable that future taxable income will be available
against which the Company will be able to use these benefits. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">As
at March 31, 2021, the Company has non-capital losses in Canada, which under certain circumstance can be used to reduce the taxable income
of future years. The non-capital losses expire as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="interim2_007.jpg" ALT="" STYLE="height: 102px; width: 404px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            risk management</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, the Company is exposed to a variety of financial risks. The Company has a risk management framework to
monitor, evaluate and manage the principal risk assumed with its financial instruments. The potential risks that may arise form transacting
in financial instruments include credit risk, liquidity risk and market risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 285 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 26pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
                                            risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial
loss. Credit risk is managed by dealing only with counterparties the Company believes to be creditworthy. The Company is subject to credit
risk through its cash. The Company does not believe that it is exposed to an unusual level of credit risk. The Company cash is held at
one financial institution. The Company limits its cash holdings to high-quality financial institutions in order to minimize its credit
risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.375in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
                                            risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
risk refers to the risk that the Company will have insufficient cash resources to meet its financial obligations when they become due.
The Company manages liquidity risk by reviewing resources to ensure that it will have sufficient liquidity to meet liabilities as they
become due and to support business strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates cash flow from raising equity and it aims to partner with firms who will fund the development and testing of its novel,
patentable and licit molecules in exchange for exclusive rights per a negotiated arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            risk management (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at March 31, 2021, the Company had cash of $6,953,091 in order to meet current liabilities. Accounts payable and accrued liabilities
include trade payables and other obligations of $380,046.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.375in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
                                            risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices
whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting similar
financial instruments traded in the market. Market risk is the predominant risk as the Company is in the process of raising equity. The
Company is exposed to the following market risks:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
Interest rate risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate due to changes in market interest
rates. The Company&rsquo;s exposure to interest rate risk relates to its ability to earn interest income on cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value of the Company cash affected by changes of interest rates is minimal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
                                            risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
risk is the risk that the value of a financial instrument fluctuates as a result of changes in foreign currency exchange rates, which
can be caused by market, political and/or other factors which may be subject to intervention by sovereign governments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds liabilities denominated in currencies other than its functional currency. The Company is therefore exposed to currency
risk as the value of the liabilities denominated in other currencies fluctuates due to change in exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at March 31, 2021, the Company was exposed to currency risk in U.S. dollars in the manner of its cash balance of US$291,883 and accounts
payable and accrued liabilities of US$92,172.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Currency
sensitivity</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at March 31, 2021, had the Canadian dollar weakened or strengthened by 10% in relation to the U.S. dollar, with all other variables remaining
constant, net income and comprehensive income for the period would have decreased or increased, respectively, by approximately $19,971
This analysis only addresses the impact on the financial instruments with respect to currency movement and excludes any other economic
or geo-political implications of such currency fluctuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
                                            party transactions and balances <FONT STYLE="font-weight: normal">(see also notes 8 and 9)</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Key
management personnel include persons having the authority and responsibility for planning, directing, and controlling the activities
of the Company as a whole. The Company has determined its key management personnel to be the executive officers and directors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">For
the three and nine months ended March 31, 2021, respectively, professional fee expense of $52,660 and $99,471 was incurred with a company
owned by an officer of the Company. Included in accounts payable and accrued liabilities as at March 31, 2021 is $18,412 (June 30, 2020
&ndash; $nil) payable to this company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
remuneration of key management personnel included in salaries and benefits expense for the three and nine months ended March 31, 2021
was $162,994 and $345,657, respectively. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 286 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Nine-Month Period Ended March 31, 2021<BR>
(Unaudited - Expressed in Canadian dollars)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
                                            management</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company&rsquo;s business requires capital for funding current and future operations. The Company defines capital to include shareholders&rsquo;
equity, which is comprised of share capital, warrant reserve, option reserve, net of deficit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company&rsquo;s objectives when managing capital are to safeguard the Company&rsquo;s ability to continue as a going concern in order
to pursue business opportunities and to maintain a flexible capital structure that optimizes the costs of capital at an acceptable risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics
of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, acquire or dispose of assets,
or adjust the amount of cash. In order to maximize ongoing development efforts, the Company does not anticipate the payment of dividends
for the foreseeable future. The Company is not subject to any externally imposed capital requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company has a remaining research commitment to the University of Calgary of $399,436. Quarterly payments range from $62,875 to $73,968
through June 2022. This agreement provides for research personnel, supplies, equipment and overhead to develop synthetic methods for
novel, patentable drugs using controlled substances. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company also has an agreement with the University of Calgary which permits the Company to use certain facilities without charge including
specific labs and equipment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company has also committed to additional development costs of US$150,000. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
                                            events</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
April 5, 2021, the Company granted 3,004,000 stock options with an exercise price of $0.50. These options vest immediately upon issuance,
with expiry April 5, 2026. 2,625,000 of these options were issued to directors and officers of the Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">On
May 24, 2021, the Company entered into a definitive agreement to be acquired by Enveric Biosciences, Inc., a Nasdaq-listed US company
developing cannabinoid medicines to improve the quality of life for cancer patients. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 287 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_152"></A>Annex
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
Version</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVERIC
BIOSCIENCES, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1306432
B.C. LTD.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1306436
B.C. LTD.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAGICMED
INDUSTRIES INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMALGAMATION
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Dated
effective as of May 24, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 288; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMALGAMATION
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
AMALGAMATION AGREEMENT </B>is made effective as of May 24, 2021 (the &ldquo;<B>Execution Date</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMONG:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC.</B>, a corporation existing under the laws of the State of Delaware</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&ldquo;<B>Parent</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1306432
B.C. LTD.</B>, a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of Parent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&ldquo;<B>HoldCo</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1306436
B.C. LTD.</B>, a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&ldquo;<B>Purchaser</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MAGICMED
INDUSTRIES INC.</B>, a corporation existing under the laws of the Province of British Columbia</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HoldCo
    is a wholly-owned subsidiary of Parent and Purchaser is a wholly-owned subsidiary of HoldCo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent,
    indirectly through Purchaser, wishes to acquire all of the outstanding securities of Company in exchange for securities of
    Parent by way of an amalgamation under the BCBCA (as defined herein), upon the terms and conditions set forth herein such
    that, upon completion of the Amalgamation (as defined herein), the amalgamated corporation will be an indirect wholly-owned
    subsidiary of Parent; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Parties (as defined herein) wish to enter into this Agreement (as defined herein) to set out the terms and conditions of the
    Amalgamation and matters related thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 289; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B>, in consideration of the mutual covenants and agreements herein contained, and other good and valuable consideration
(the receipt and sufficiency of which are hereby acknowledged), the Parties covenant and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERPRETATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
Defined Terms</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Agreement and in the recitals hereto, unless there is something in the context or subject matter inconsistent therewith,
the following terms will have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>1933
Act</B>&rdquo; means the United States Securities Act of 1933 and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Acquisition
Proposal</B>&rdquo; means, other than the transactions contemplated by this Agreement, any offer, proposal or inquiry (written
or oral) from any Person or group of Persons other than the Parties after the date of this Agreement relating to: (a) any direct
or indirect sale, disposition, alliance or joint venture (or any lease, long-term supply agreement or other arrangement having
the same economic effect as a sale), in a single transaction or a series of related transactions, of assets representing 20% or
more of the consolidated assets or contributing 20% or more of the revenue of (as applicable) the Parent, Company or their respective
Subsidiaries (in each case, on a consolidated basis) or of 20% or more of the voting, equity or other securities of (as applicable)
the Parent or Company (or rights or interests therein or thereto); (b) any direct or indirect take-over bid, tender offer, exchange
offer, treasury issuance (excluding treasury issuances resulting from the exercise or conversion of currently outstanding securities)
or other transaction that, if consummated, would result in a Person or group of Persons beneficially owning 20% or more of any
class of voting, equity or other securities or any other equity interests (including securities convertible into or exercisable
or exchangeable for securities or equity interests) of (as applicable) the Parent or Company; (c) any plan of arrangement, merger,
amalgamation, consolidation, share exchange, business combination, reorganization, recapitalization, liquidation, dissolution,
winding up or exclusive license involving the Parent, Company or their respective Subsidiaries; (d) any other similar transaction
or series of transactions involving the Parent, Company or their respective Subsidiaries; or (e) any other transaction, the consummation
of which could reasonably be expected to impede, prevent or delay the transactions contemplated by this Agreement, including the
Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
with respect to any specified Person at any time, means each Person that, directly or indirectly, alone or through one or more
intermediaries, controls, is controlled by, or is under direct or indirect common control with, such specified Person at such
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Agreement</B>&rdquo;
means this amalgamation agreement, the Company Disclosure Statement and the Parent Disclosure Statement, each as may be supplemented,
amended, restated or otherwise modified from time to time in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Amalco</B>&rdquo;
means the corporation resulting from the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Amalco
Common Shares</B>&rdquo; means common shares in the capital of Amalco.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Amalco
Options</B>&rdquo; has the meaning specified in <U>Section 2.5(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Amalco
Redeemable Preferred Shares</B>&rdquo; means the Class A Preferred Shares in the capital of Amalco having the terms set forth
in the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 290; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Amalco
Redemption Consideration</B>&rdquo; means 0.000001 of a share of Parent Common Stock per Amalco Redeemable Preferred Share, being
the consideration payable to holders of Amalco Redeemable Preferred Shares upon the redemption of the Amalco Redeemable Preferred
Shares immediately following the completion of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Amalgamation</B>&rdquo;
means the amalgamation of Company and Purchaser pursuant to Section 269 of the BCBCA as of the Closing Date on the terms and conditions
set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Amalgamation
Application&rdquo; </B>means the amalgamation application in respect of the Amalgamation to be completed and filed with the Registrar
pursuant to Section 275(1)(a) of the BCBCA substantially in the form attached as Schedule &ldquo;A&rdquo; to this Agreement, subject
to any amendments or variations made in accordance with this Agreement with the prior written consent of the Parties, each acting
reasonably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Amalgamation
Resolution</B>&rdquo; means the special resolution of the Company Shareholders with respect to the approval of the Amalgamation,
this Agreement and the transactions contemplated thereby and hereby, to be considered by the Company Shareholders at the Company
Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Laws</B>&rdquo; means, with respect to any Person, any and all applicable law (statutory, civil, common or otherwise), constitution,
treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or other similar requirement,
whether domestic or foreign, enacted, adopted, promulgated or applied by a Governmental Authority that is binding upon or applicable
to such Person or its business, undertaking, property or securities, and to the extent that they have (or are applied as if they
have) the force of law, policies, guidelines, notices and protocols of any Governmental Authority, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Articles</B>&rdquo;
means the articles of Amalco substantially in the form attached hereto as Schedule &ldquo;B&rdquo; and signed by a director of
Amalco, subject to any amendments or variations made in accordance with this Agreement with the prior written consent of the Parties,
each acting reasonably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Authorization</B>&rdquo;
means, with respect to any Person, any order, permit, approval, consent, waiver, license, registration, qualification, certificate
or other similar authorization of or from any Governmental Authority having jurisdiction over the Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Bankruptcy
and Equity Exceptions</B>&rdquo; has the meaning set forth in <U>Section 4.1(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>BCBCA</B>&rdquo;
means the <I>Business Corporations Act </I>(British Columbia).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Breaching
Party</B>&rdquo; has the meaning specified in <U>Section 7.9(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Business
Day</B>&rdquo; means any day other than a Saturday, Sunday or a day observed as a holiday in the Provinces of British Columbia
or Alberta.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Certificate
of Amalgamation</B>&rdquo; means the certificate of amalgamation to be issued under the BCBCA to Amalco pursuant to Section 281
of the BCBCA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing</B>&rdquo;
means the closing of the Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing
Date</B>&rdquo; means the date of the completion of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 291; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>COBRA</B>&rdquo;
means the Consolidated Omnibus Budget Reconciliation Act of 1985.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Code</B>&rdquo;
means the Internal Revenue Code of 1986.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Collective
Agreements</B>&rdquo; means collective agreements and related documents including benefit agreements, letters of understanding,
letters of intent and other written communications (including arbitration awards).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
has the meaning set forth on the first page of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Board</B>&rdquo; means the board of directors of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Board Approval</B>&rdquo; has the meaning set forth in <U>Section 4.1(r)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Broker Warrants</B>&rdquo; means the outstanding warrants of the Company to purchase a unit of the Company at an exercise price
of C$0.50 per unit, each unit comprised of one Company Common Share and one half of one (1/2) Company Warrant, each whole Company
Warrant entitling the holders thereof to one Company Common Share upon payment of the exercise price of C$0.75 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Change in Recommendation</B>&rdquo; has the meaning set forth in <U>Section 9.2(a)(iv)(C)(1)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Circular</B>&rdquo; means the notice of meeting and information circular and proxy statement of the Company and all related materials
at the time required to be mailed to the Company Shareholders in connection with the Company Meeting and all amendments or supplements
thereto, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Common Shares</B>&rdquo; means the common shares in the capital of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Disclosure Statement</B>&rdquo; means the disclosure statement of the Company to be delivered by Company to Parent on or prior
to the Execution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Employees</B>&rdquo; means the officers and employees of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Financial Statements</B>&rdquo; means the (a) audited consolidated financial statements of the Company for the period from incorporation
on May 26, 2020 to June 30, 2020, and the notes thereto; and (b) unaudited consolidated interim financial statements of the Company
for the three and six month periods ended December 31, 2020, consisting of the consolidated statements of financial position as
at the period end and the accompanying consolidated statements of loss and comprehensive loss, changes in shareholders&rsquo;
equity and cash flows, and all notes in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Meeting</B>&rdquo; means the meeting of the Company Shareholders, including any adjournment or postponement thereof, for the purpose
of, among other things, considering and, if thought fit, approving the Amalgamation Resolution and for any other purpose as may
be set out in the notice of the Company Meeting and, other than any annual business proposed to be conducted at the Company Meeting
that is unrelated to the Transaction, agreed to in writing by the Parent, HoldCo and the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 292; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Option Plan</B>&rdquo; means the MagicMed Industries Inc. Stock Option Plan dated January 22, 2021 governing the Company Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Optionholders</B>&rdquo; means the holders of Company Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Options</B>&rdquo; means the outstanding options of the Company to purchase Company Common Shares issued pursuant to the Company
Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Related Persons</B>&rdquo; has the meaning set forth in <U>Section 4.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
SARs</B>&rdquo; means the stock appreciation rights issued pursuant to the Company SARs Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
SARs Plan</B>&rdquo; means the MagicMed Industries Inc. Stock Appreciation Rights Plan dated January 22, 2021 governing the Company
SARs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
SARs Holders</B>&rdquo; means the holders of Company SARs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Securityholders</B>&rdquo; means, collectively, the Company Shareholders, the Company Optionholders, Company SARs Holders, and
the Company Warrantholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Shareholders</B>&rdquo; means holders of Company Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Shareholder Approval</B>&rdquo; means the approval by the Company Shareholders of the Amalgamation Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Support Agreements</B>&rdquo; means the voting agreements between the Parent and each of the directors and executive officers
of the Company dated as of the Execution Date setting forth the terms and conditions upon which such Persons have agreed, among
other things, to vote their Company Common Shares in favor of the Amalgamation Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Termination Payment Event</B>&rdquo; has the meaning set forth in <U>Section 10.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Warrantholders</B>&rdquo; means the holders of Company Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Warrants</B>&rdquo; means the outstanding common share purchase warrants of the Company to purchase Company Common Shares, as
represented by stand-alone warrant certificates or as set forth and provided for in the warrant indenture between the Company
and Capital Transfer Agency ULC dated as of December 16, 2020, as supplemented by a supplemental indenture dated April 1, 2021
between the Company and Olympia Trust Company, as successor warrant agent to Capital Transfer Agency ULC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Confidentiality
Agreement</B>&rdquo; means the confidentiality agreement dated April 19, 2021 between the Parent and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Consideration</B>&rdquo;
means the aggregate number shares of Parent Common Stock to be issued or issuable (a) as Consideration Shares, (b) in respect
of the Amalco Options and (c) in respect of the Company Warrants and the Company Broker Warrants, in each case pursuant to, or
following the consummation of, the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 293; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Consideration
Shares</B>&rdquo; means the shares of Parent Common Stock to be issuable at the Effective Time pursuant to the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Contract</B>&rdquo;
means any contract, agreement, indenture, note, bond, mortgage, instrument, license, sublicense, franchise, lease, arrangement,
commitment, understanding or other right or obligation, whether written or oral, to which a Party or any Affiliate thereof is
a party, or is bound or affected by, or to which any of their respective properties or assets is subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Dissent
Rights</B>&rdquo; means the rights of dissent available under and incompliance with Section 242 of the BCBCA in respect of the
Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Dissenting
Shareholders</B>&rdquo; means any Company Shareholder who validly exercises, and does not withdraw prior to the Effective Time,
Dissent Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effective
Time</B>&rdquo; means the time of completion of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Employee
Plans</B>&rdquo; has the meaning set forth in <U>Section 4.1(bb)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>End
Date</B>&rdquo; means December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Environmental
Laws</B>&rdquo; means all Applicable Laws and agreements with Governmental Authorities and all other statutory requirements relating
to public health and as now or hereafter in effect in any way relating to protection of human health and safety, public welfare,
the environment, or natural resources, including those Laws relating to the storage, handling and use of chemicals, Hazardous
Substances, and those Laws relating to the Release, reporting, discharge, investigation, or remediation of waste materials and
Hazardous Substances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>ERISA</B>&rdquo;
means the Employee Retirement Income Security Act of 1974.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>ERISA
Affiliate</B>&rdquo; means any trade or business (whether or not incorporated) that is or at any relevant time was treated as
a single employer with any Person within the meaning of Section 414 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange
Ratio</B>&rdquo; means an amount equal to .2658.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Execution
Date</B>&rdquo; has the meaning set forth on the first page of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Founder
Lock-Up Agreement</B>&rdquo; has the meaning set forth in <U>Section 7.3(h)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Governmental
Authority</B>&rdquo; means any: (a) multinational, federal, provincial, state, regional, municipal, local or other government,
governmental or public department, ministry, central bank, court, tribunal, arbitral body, commission, commissioner, board, tribunal,
official, minister, bureau or agency, domestic or foreign; (b) subdivision, agent, commission, board or authority of any of the
foregoing, including the Securities Authorities; or (c) quasi-governmental or private body, including any tribunal, commission,
regulatory agency or self-regulatory organization, exercising any regulatory, expropriation or taxing authority under, or for
the account of, any of the foregoing, including any stock exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 294; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Hazardous
Substances</B>&rdquo; means any element, waste or other substance, whether natural or artificial and whether consisting of gas,
liquid, solid or vapor that is prohibited, listed, defined, judicially interpreted, designated or classified as dangerous, hazardous,
radioactive, explosive or toxic or a pollutant or a contaminant under or pursuant to any applicable Environmental Laws, and specifically
including petroleum and all derivatives thereof or synthetic substitutes therefor and asbestos or asbestos-containing materials
or any substance which is deemed under Environmental Laws to be deleterious to natural resources or worker or public health and
safety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>HoldCo</B>&rdquo;
has the meaning set forth on the first page of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>IFRS</B>&rdquo;
means International Financial Reporting Standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>In
the Money Amount</B>&rdquo; means in respect of an option at any time, the amount, if any, by which the aggregate fair market
value, at that time, of the shares subject to the option exceeds the aggregate exercise price under the option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Insider
Lock-Up Agreement</B>&rdquo; has the meaning set forth in <U>Section 7.3(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Intellectual
Property</B>&rdquo; means all of the following, worldwide, whether registered, unregistered or registrable: (a) trademarks and
service marks, trade dress, product configurations, trade names and other indications of origin, applications or registrations
in any jurisdiction pertaining to the foregoing and all goodwill associated therewith; (b) inventions, discoveries, improvements,
ideas, know-how, methodology, models, algorithms, formulae, systems, processes, technology, whether patentable or not, and all
patents, industrial designs, and utility models, and all applications pertaining to the foregoing, in any jurisdiction, including
re-issues, continuations, divisionals, continuations-in-part, re-examinations, renewals and extensions; (c) trade secrets and
other rights in confidential and other nonpublic information; (d) software, including interpreted or compiled Source Code, object
code, development documentation, programming tools, drawings, specifications, metadata and data; (e) copyrights in writings, designs,
mask works, software, content and any other original works of authorship in any medium, including applications or registrations
in any jurisdiction for the foregoing and all moral rights in the foregoing; (f) data and database rights; (g) internet websites,
domain names and registrations pertaining thereto; (h) social media accounts, the usernames and passwords associated therewith,
and all content contained therein; (i) any other intellectual property or proprietary rights of any kind, nature or description;
and (j) any tangible embodiments of the foregoing (in whatever form or medium).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Intellectual
Property Rights</B>&rdquo; has the meaning set forth in <U>Section 4.1(v)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>IRS</B>&rdquo;
means the United States Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Leased
Properties</B>&rdquo; has the meaning set forth in <U>Section 4.1(t)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Liability</B>&rdquo;
or &ldquo;<B>Liabilities</B>&rdquo; means, with respect to any Person, any liability or obligation of such Person of any kind,
character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated,
secured or unsecured, joint or several, due or to become due, vested or unvested, determined, determinable or otherwise, and whether
or not the same is required to be accrued on the financial statements of such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Lien</B>&rdquo;
means any mortgage, charge, pledge, hypothec, security interest, prior claim, encroachment, option, right of first refusal or
first offer, occupancy right, covenant, assignment, lien (statutory or otherwise), defect of title, or restriction or adverse
right or claim, or other third party interest or encumbrance of any kind, in each case, whether contingent or absolute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 295; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Lock-Up
Agreements</B>&rdquo; has the meaning set forth in <U>Section 7.3(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Material
Adverse Effect</B>&rdquo; when used in connection with a Party means any result, change, event, occurrence, effect, state of facts
or circumstance (whether or not constituting a breach of a representation, warranty or covenant set forth in this Agreement) that,
either individually or in the aggregate is or would reasonably be expected to be material and adverse to the business, operations,
results of operations, assets, properties, condition (financial or otherwise) or liabilities (contingent or otherwise) or prospects
of that Party and its Subsidiaries, taken as a whole, and would, or would be reasonably expected to, prevent or materially delay
either Party from consummating the transactions contemplated by this Agreement by the End Date, except any such change, event,
occurrence, effect, state of facts or circumstance resulting from or relating to: (a) any change in general political, economic,
financial, currency exchange, securities, capital or credit market conditions in Canada or the United States; (b) any change or
proposed change in Applicable Laws, IFRS or U.S. GAAP; (c) any change affecting the industries or markets in which such Party
operates; (d) any natural disaster or the commencement or continuity of any act of war, armed hostilities or acts of terrorism;
(e) the announcement of this Agreement or the transactions contemplated hereby; (f) any action taken (or omitted to be taken)
by a Party or its Subsidiaries which is required to be taken (or omitted to be taken) pursuant to this Agreement; (g) any change
in the market price or trading volume of any securities of a Party (it being understood that the causes underlying such change
in market price or trading volume may be taken into account in determining whether a Material Adverse Effect has occurred); (h)
any epidemic, pandemic, disease outbreak (including COVID-19), other health crisis or public health event; or (i) any matter which
has been publicly disclosed or communicated in writing by a Party to the other Party as of the Execution Date and such other Party
has acknowledged receipt of such written communication; provided, however, that with respect to clauses; (a) through to and including
(c), such matters do not have a materially disproportionate effect on such Party and its Subsidiaries, taken as a whole, relative
to companies of similar size operating in the industries or markets in which such Party operates (in which case the incremental
disproportionate effect may be taken into account in determining whether there has been, or is reasonably expected to be, a Material
Adverse Effect), and provided further, however, that unless expressly provided in any particular section of this Agreement, references
in certain sections of this Agreement to dollar amounts are not intended to be, and shall be deemed not to be, illustrative or
interpretive for the purpose of determining whether a &ldquo;Material Adverse Effect&rdquo; has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Material
Contract</B>&rdquo; means each of the following Contracts to which a Party is a party or by which a such Party&rsquo;s assets
or properties are bound:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Contracts with its security holders, any of its Affiliates or any current or former officer, director, employee, any member of
his or her immediate family or any Affiliate of any of the foregoing (collectively, &ldquo;<B>Related Parties</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Contracts with any labor union or association representing any employee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Contracts for the sale of any of the assets of such Party other than in the Ordinary Course or for the grant to any Person of
any preferential rights to purchase any of its assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 296; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Contracts for joint ventures, strategic alliances, partnerships, licensing arrangements, or sharing of profits or proprietary
information;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Licenses for Intellectual Property, except standard end user licenses to the proprietary software and except licenses of commercial
off-the-shelf software available on reasonable terms for a license fee of no more than $10,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Contracts containing covenants of the not to compete with any Person in any line of business, industry or geographical area or
restricting the solicitation, engagement or hiring of any Person or otherwise restricting the operation of a Party&rsquo;s business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Contracts relating to the acquisition (by merger, purchase of equity or assets or otherwise) of any operating business, material
assets or capital stock of any other Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Contracts relating to the incurrence, assumption or guarantee of any Indebtedness or imposing a Lien on any of the assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Contracts giving rise to material Liabilities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
all Contracts obligating a Party to provide or obtain products or services for a period of one (1) year or more or requiring a
Party to purchase or sell a stated portion of its requirements or outputs;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Contracts (i) relating to the employment of, or the performance of services by, any Person, including any current or former employee
or independent contractor, (ii) pursuant to which a Party are or may become obligated to make any severance, retention, change
of control, termination or similar payment to any current or former employee, independent contractor or director, or (C) pursuant
to which a Party is or may become obligated to make any bonus, sales compensation, or similar payment (whether in the form of
cash, stock, or other securities but excluding payments constituting base salary);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
outstanding Contracts of guaranty, surety or indemnification, direct or indirect, by a Party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
Contracts (or group of related Contracts) which involve the expenditure or receipt of more than $25,000 annually or $50,000 in
the aggregate or require performance by any party more than one (1) year from the Execution Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
Contracts with a Governmental Body;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
Contracts (A) imposing any confidentiality obligation on a Party or on any other Person (other than routine nondisclosure agreements
or routine confidentiality provisions contained in agreements entered into by a Party or its Subsidiaries in the Ordinary Course),
(B) containing &ldquo;standstill&rdquo; or similar provisions, or (C) providing any right of first negotiation, right of first
refusal or similar right to any other Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
Contracts related to any broker, distributor, dealer, manufacturer&rsquo;s representative, franchise, agency (foreign or domestic),
continuing sales or purchase, sales promotion, market research, marketing, consulting or advertising;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 297; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
Contracts containing a provision which provides exclusivity to any other Person, that any term of such Contract will be no less
favorable to any other Person either individually or in the aggregate than similar provisions in any other Contract, or any other
similar &ldquo;most favored nation&rdquo; or &ldquo;most favored customer&rdquo; provision in favor of any other Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
Contracts containing an obligation to indemnify any current or former officer or director of a Party and its Subsidiaries or to
indemnify any other Person in connection with the acquisition (whether by means or merger, stock sale or asset sale) of any Person,
except for any such Contract that is no longer in effect and under which no claim has been made or threatened;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
settlement document or Contract with respect to any Proceeding involving a Party (but only to the extent such documents contain
any unfulfilled or continuing obligations of a Party);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
Contracts under which a Party (A) collects or processes personally identifiable information, or (B) transfers personally identifiable
information to a third party for that third party&rsquo;s processing or use;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
real property leases; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
Contracts that are otherwise material to a Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>NASDAQ</B>&rdquo;
means The Nasdaq Stock Market LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>NASDAQ
Listing Application</B>&rdquo; has the meaning set forth in <U>Section 3.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Notice
of Articles</B>&rdquo; means the notice of articles to be issued by the Registrar in respect of Amalco in the form contained in
the Amalgamation Application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Ordinary
Course</B>&rdquo; means, with respect to an action taken by a Person, that such action is consistent with the past practices of
the Person and is taken in the ordinary course of the normal day-to-day operations of the Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Organizational
Documents</B>&rdquo; means, with respect to a Person, (a) the certificate or articles of incorporation, amalgamation, organization
or formation and the by-laws, the partnership agreement or operating or limited liability company agreement (as applicable), and
(b) any documents comparable to those described in clause (a) as may be applicable pursuant to any Applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Other
Filings</B>&rdquo; has the meaning set forth in <U>Section 7.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Owned
Properties</B>&rdquo; has the meaning set forth in <U>Section 4.1(t)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent</B>&rdquo;
has the meaning set forth on the first page of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Board</B>&rdquo; means the board of directors of the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Board Approval</B>&rdquo; has the meaning set forth in <U>Section 5.1(v)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Capital Stock</B>&rdquo; means Parent Common Stock and Parent Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 298; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Common Stock</B>&rdquo; means the common stock, par value $0.01 per share, of the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Disclosure Statement</B>&rdquo; means the disclosure statement of the Parent to be delivered by Parent to Company: (a) on or prior
to the Execution Date, and (b) at the Effective Time as updated to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Employees</B>&rdquo; means the officers and employees of the Parent and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Fairness Opinion</B>&rdquo; means an opinion of Gemini Partners to the effect that, as of the date of such opinion, and subject
to the assumptions, limitations and qualifications set forth therein, the Consideration to be issued by the Parent pursuant to
this Agreement and the Exchange Ratio are fair, from a financial point of view, to the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Financial Statements</B>&rdquo; means the (a) audited condensed consolidated financial statements of the Parent as at, and for
the year ended, December 31, 2020, including the notes thereto, and (b) unaudited condensed consolidated financial statements
of the Parent as at, and for the three months ended March 30, 2021, consisting of the unaudited condensed consolidated balance
sheets, the unaudited condensed consolidated statements of operations and comprehensive loss, the unaudited condensed consolidated
statements of cash flows and the unaudited condensed consolidated statement of changes in shareholders&rsquo; equity (deficit),
including all notes in respect thereof, in each case as contained or incorporated by reference in the Parent SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Intellectual Property Rights</B>&rdquo; has the meaning set forth in <U>Section 5.1(w)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Leased Properties</B>&rdquo; has the meaning set forth in <U>Section 5.1(u)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Meeting</B>&rdquo; means the meeting of the Parent Stockholders, including any adjournment or postponement thereof, for the purpose
of, among other things, considering and, if thought fit, approving the Parent Stockholder Approval Resolutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Options</B>&rdquo; means the outstanding options to purchase Parent Common Stock issued pursuant to the Parent Stock Incentive
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Owned Properties</B>&rdquo; has the meaning set forth in <U>Section 5.1(x)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Preferred Stock</B>&rdquo; means the preferred stock, par value $0.01 per share, of Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Related Persons</B>&rdquo; has the meaning set forth in <U>Section 5.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
SEC Documents</B>&rdquo; has the meaning set forth in <U>Section 5.1(g)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Stock Incentive Plan</B>&rdquo; means that certain 2020 Long Term Equity Incentive Plan, as amended by that certain First Amendment
to the Enveric Biosciences, Inc. 2020 Long Term Equity Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Stockholder Approval</B>&rdquo; means the approval by the Parent Stockholders of the Parent Stockholder Approval Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Stockholder Approval Resolution</B>&rdquo; means the special resolution of the Parent Stockholders approving the Amalgamation
and the related issuance of the Consideration Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 299; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Stockholders</B>&rdquo; means holders of Parent Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Subsidiaries</B>&rdquo; has the meaning set forth in <U>Section 5.1(k)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Support Agreements</B>&rdquo; means the voting agreements between the Company and each of the directors and executive officers
of the Parent dated as of the Execution Date setting forth the terms and conditions upon which such Persons have agreed, among
other things, to vote their Parent Capital Stock in favor of the Parent Stockholder Approval Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Technology</B>&rdquo; has the meaning set forth in <U>Section 5.1(w)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Termination Payment Event</B>&rdquo; has the meaning set forth in <U>Section 10.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parent
Warrants</B>&rdquo; means the outstanding common stock purchase warrants of the Parent to purchase Parent Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parties</B>&rdquo;
means, collectively, the Parent, the Company, HoldCo and the Purchaser, and &ldquo;<B>Party</B>&rdquo; means any one of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Permitted
Liens</B>&rdquo; means, in respect of a Party or any of its Subsidiaries, any one or more of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutory
    Liens for current Taxes which are not delinquent or that are being disputed in good faith by appropriate proceedings, provided
    an appropriate reserve has been established therefor in the Company Financial Statements or Parent Financial Statements, as
    applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inchoate
    or statutory Liens of contractors, subcontractors, mechanics, workers, suppliers, materialmen, carriers and others arising
    in the Ordinary Course, provided that such Liens are related to obligations not due or delinquent and that are not resulting
    from a breach, default or violation by a Party of any Contract or Applicable Law, and are not registered against title to
    any assets of such Party or its Subsidiaries and in respect of which adequate holdbacks are being maintained as required by
    Applicable Law and under U.S. GAAP or IFRS, as applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right reserved to or vested in any Governmental Authority by any statutory provision or by the terms of any lease, license,
    franchise, grant or permit of such Party or its Subsidiaries, to terminate any such lease, license, franchise, grant or permit,
    or to require annual or other payments as a condition of their continuance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">easements,
    including rights of way for, or reservations or rights of others relating to, sewers, water lines, gas lines, pipelines, electric
    lines, telegraph and telephone lines and other similar services and any registered restrictions or covenants that run with
    the land and are shown on a current survey, provided that there has been compliance with the material provisions thereof and
    that they do not, individually or in the aggregate, detract from the ability to use any leased properties and would not reasonably
    be expected to materially and adversely affect the ability of such Party to carry on its business in the Ordinary Course;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 300; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of the Company, the Parent or their respective Subsidiaries, Liens listed and described in the Company Disclosure
    Statement or the Parent Disclosure Statement, as applicable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
is to be construed broadly and includes any natural person, estate, partnership, limited partnership, limited liability partnership,
body corporate, limited liability company, unlimited liability company, joint stock company, trust, estate, unincorporated association,
joint venture or other entity or Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Proceeding</B>&rdquo;
means any action, arbitration, audit, hearing, investigation, claims, inquiries, litigation or suit (whether civil, criminal,
administrative, investigative or informal) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental
Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Proxy
Statement/Prospectus</B>&rdquo; has the meaning set forth in <U>Section 7.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Purchaser</B>&rdquo;
has the meaning set forth on the first page of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Purchaser
Shares</B>&rdquo; means all of the common shares in the capital of Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Registered
Intellectual Property</B>&rdquo; means all patents, all copyrights, marks and Internet domain name registrations and applications
for registration that, in each case, are owned by the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Registrar</B>&rdquo;
means the Registrar of Companies or a Deputy Registrar of Companies for the Province of British Columbia duly appointed under
Section 400 of the BCBCA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Regulatory
Approval</B>&rdquo; means any consent, waiver, permit, exemption, review, order, decision or approval of, or any registration
and filing with, any Governmental Authority, or the expiry, waiver or termination of any waiting period imposed by Applicable
Law or a Governmental Authority, in each case that is required in connection with the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Release</B>&rdquo;
has the meaning prescribed in any Environmental Law and includes any sudden, intermittent or gradual release, spill, leak, pumping,
addition, pouring, emission, emptying, discharge, migration, injection, escape, leaching, disposal, dumping, deposit, spraying,
burial, abandonment, incineration, seepage, placement or introduction of a Hazardous Substance, whether accidental or intentional,
into the environment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Representatives</B>&rdquo;
has the meaning set forth in <U>Section 6.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>S-4
Registration Statement</B>&rdquo; has the meaning set forth in <U>Section 7.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>SEC</B>&rdquo;
means the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Acts</B>&rdquo; means, collectively, the <I>Securities Act</I> (British Columbia), the 1933 Act, and the U.S. Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 301; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Authorities</B>&rdquo; means the British Columbia Securities Commission, the applicable securities commissions and other securities
regulatory authorities in each of the other Provinces of Canada, the SEC and the applicable securities commissions in each of
the states of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Laws</B>&rdquo; means the Securities Acts, all other applicable Canadian provincial securities laws, all other applicable United
States state securities or &ldquo;blue sky&rdquo; laws, and the rules and regulations and published policies under the foregoing
securities laws and applicable exchange rules and listing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Source
Code</B>&rdquo; means, collectively, any software source code, including any portion or aspect of the software source code, or
any proprietary information or algorithm contained in or relating to any software source code, including related documentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subsidiary</B>&rdquo;
means, with respect to a Person, any entity in which such Person directly or indirectly owns, beneficially or of record, (a) an
amount of voting securities of or other interests in such entity that is sufficient to enable such Person to elect at least a
majority of the members of such entity&rsquo;s board of directors or other governing body, or (b) at least 50% of the outstanding
equity or financial interests of such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Superior
Proposal</B>&rdquo; means an unsolicited bona fide written Acquisition Proposal made after the Execution Date by a third party
to (as applicable): (a) the Company or the Company Shareholders, to acquire all of the issued and outstanding Company Common Shares
(other than Company Common Shares owned by the Person making the Superior Proposal, if any); (b) the Parent or the Parent Shareholders,
to acquire all of the Parent Common Shares (other than Parent Common Shares owned by the Person making the Superior Proposal,
if any); (c) the Company, to acquire all or substantially all of the consolidated assets of the Company and its Subsidiaries taken
as a whole; or (d) the Parent, to acquire all or substantially all of the consolidated assets of the Parent and its Subsidiaries
taken as a whole; provided, however, in the case of the immediately preceding clauses (a) through (d), (i) such Acquisition Proposal
is reasonably likely to be completed without undue delay, taking into account all legal, financial, regulatory and other aspects
of such proposal and the Person making such proposal; (ii) any required financing to complete such Acquisition Proposal is available
to the satisfaction of the Company Board or Parent Board, as the case may be, acting reasonably; (iii) such Acquisition Proposal
did not result from a breach of Section 6.1 by (as applicable) the Company, the Parent or their applicable Representatives; (iv)
the proceeds of such Acquisition Proposal are made available to all Company Shareholders or the Parent Shareholders, as the case
may be, on the same terms and conditions; and (v) the Company Board or the Parent Board, as the case may be, determines in good
faith (after receipt of advice from its financial advisors) that such Acquisition Proposal would, taking into account all of the
terms and conditions of such Acquisition Proposal, if consummated in accordance with its terms (but not assuming away any risk
of non-completion), result in a transaction more favorable to the Company Shareholders or the Parent Shareholders, as the case
may be, from a financial point of view than the Transaction (including any adjustment to the terms and conditions of the Transaction
proposed by the Purchaser and/or the Parent pursuant to Section 6.1(f));</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax
Act</B>&rdquo; means the Income Tax Act, R.S.C. 1985 (5th Supp.) c.1, and the regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax
Returns</B>&rdquo; means any and all returns, reports, declarations, elections, notices, forms, designations, filings, and statements
(including estimated tax returns and reports, withholding tax returns and reports, and information returns and reports) filed
or required to be filed in respect of Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 302; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Taxes</B>&rdquo;
means: (a) any and all taxes, duties, fees, excises, premiums, assessments, imposts, levies and other charges or assessments of
any kind whatsoever imposed by any Governmental Authority, whether computed on a separate, consolidated, unitary, combined or
other basis, including all license and registration fees and all employment insurance, health insurance and government pension
plan premiums or contributions, (b) all interest, penalties, fines, additions or other additional amounts imposed by any Governmental
Authority on or in respect of amounts of the type described herein, (c) any Liability for the payment of any amounts of the type
described herein as a result of being a member of an affiliated, consolidated, combined or unitary group for any period, and (d)
any Liability for the payment of any amounts of the type described herein as a result of any express or implied obligation to
indemnify any other Person or as a result of being a transferee or successor in interest to any party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Technology</B>&rdquo;
has the meaning set forth in <U>Section 4.1(v)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Terminating
Party</B>&rdquo; has the meaning set forth in <U>Section 7.9(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Termination
Fee</B>&rdquo; means $4,500,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Termination
Notice</B>&rdquo; has the meaning set forth in <U>Section 7.9(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transaction</B>&rdquo;
means, collectively, the Amalgamation and all transactions undertaken by the Parties in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transaction
Documents</B>&rdquo; means this Agreement, the Amalgamation Application, the Company Disclosure Statement, the Parent Disclosure
Statement and all such further documents, agreements and instruments required to be executed or filed by any Party or any Affiliate
thereof to effect the consummation of the Amalgamation (all of which will be in form and content reasonably satisfactory to each
Party) pursuant to the requirements of Applicable Laws relating to the Amalgamation, or by any other Governmental Authority having
jurisdiction, in order to carry out the terms and objectives of this Agreement, including those required by the Securities Authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Treasury
Regulations</B>&rdquo; has the meaning set forth in <U>Section 2.12</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>U.S.
Exchange Act</B>&rdquo; means the United States Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>U.S.
GAAP</B>&rdquo; means United States Generally Accepted Accounting Principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
Interpretation Not Affected by Headings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
division of this Agreement into articles, sections and subsections, and the insertion of headings herein, are for convenience
of reference only and will not affect in any way the meaning or interpretation of this Agreement. The terms &ldquo;<B>hereof</B>&rdquo;,
&ldquo;<B>herein</B>&rdquo;, &ldquo;<B>hereto</B>&rdquo;, &ldquo;<B>hereunder</B>&rdquo; and similar expressions refer to this
Agreement and not to any particular article, section or other portion hereof, and include any agreement, schedule or instrument
supplementary or ancillary hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 303; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
Meaning of &ldquo;including&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
word &ldquo;<B>including</B>&rdquo;, when following a general statement or term, is not to be construed as limiting the general
statement or term to any specific item or matter set forth or to similar items or matters, but rather as permitting the general
statement or term to refer also to all other items or matters that could reasonably fall within its broadest possible scope.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4
Extended Meanings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Agreement, unless the context otherwise requires, words importing the singular include the plural and vice versa, words importing
the use of either gender include both genders and neuter, and a reference to a Person includes any successor to that Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5
Date for any Action</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the date on which any action is required to be taken hereunder is not a Business Day, such action will be required to be taken
by the applicable Party on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6
Statutory References</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise expressly stated, any reference in this Agreement to a statute includes each regulation and rule made thereunder, all
amendments to such statute, regulation or rule in force from time to time, and any statute, regulation or rule that supplements
or supersedes such statute, regulation or rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7
Currency</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated, all references in this Agreement to amounts of money are expressed in lawful money of the United States of America.
&ldquo;C$&rdquo; refers to Canadian dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8
Invalidity of Provisions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the provisions contained in this Agreement is distinct and severable and a declaration of invalidity or unenforceability of
any such provision or part thereof by a court of competent jurisdiction will not affect the validity or enforceability of any
other provision hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9
Accounting Matters</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated, all accounting terms used in this Agreement with respect to the Purchaser, HoldCo and Parent have the meaning
attributable thereto under U.S. GAAP and all determinations of an accounting nature required to be made hereunder with respect
to the Purchaser and Parent will be made in a manner consistent with U.S. GAAP. Unless otherwise stated, all accounting terms
used in this Agreement with respect to the Company have the meaning attributable thereto under IFRS and all determinations of
an accounting nature required to be made hereunder with respect to the Company will be made in a manner consistent with IFRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10
Interpretation Not Affected by Party Drafting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties acknowledge that their respective legal counsel have reviewed and participated in settling the terms of this Agreement
and the Parties hereby agree that any rule of construction to the effect that any ambiguity is to be resolved against the drafting
party will not be applicable to the interpretation of this Agreement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 304; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11
Made Available</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
phrase &ldquo;<B>Made Available</B>&rdquo; means that an accurate and complete copy of the information or documents (for the avoidance
of doubt, including all amendments, waivers, exhibits and schedules thereto) is available for a Party to download in reviewable
format in the project folder for the Transaction on the electronic documentation site established by Egnyte, Inc. on behalf of
the Company and the Purchaser and Parent, as applicable, at least one (1) day prior to the date of the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12
Company Disclosure Statement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of the representations and warranties in <U>Article 4</U>, Company will deliver the Company Disclosure Statement,
arranged in sections corresponding with the sections of <U>Article 4</U>, to Parent. The disclosure in any section of the Company
Disclosure Statement will qualify the corresponding section of <U>Article 4</U>. Each section of the Company Disclosure Statement
shall be deemed to be disclosed and incorporated by reference in any other section of the Company Disclosure Statement as though
fully set forth in such section of the Company Disclosure Statement for which applicability of such information and disclosure
is reasonably apparent on its face. The fact that any item of information is disclosed in any section of the Company Disclosure
Statement: (a) shall not be construed to mean that such information is required to be disclosed by this Agreement; (b) shall not
be construed as or constitute an admission, evidence or agreement that a violation, right of termination, default, non-compliance,
liability or other obligation of any kind exists with respect to any item; (c) shall not be deemed or interpreted to broaden the
representations and warranties, obligations, covenants, conditions or agreements of the Company or its Subsidiaries contained
in this Agreement; and (d) does not waive any attorney-client privilege associated with such item or information or any protection
afforded by the work-product doctrine with respect to any of the matters disclosed or discussed herein. Neither the specifications
of any dollar amount in any representation, warranty or covenant contained in this Agreement nor the inclusion of any specific
item in the Company Disclosure Statement is intended to imply that such amount, or higher or lower amounts, or the item so included
or other items, are or are not material, and no Person shall use the fact of the setting forth of any such amount or the inclusion
of any such item in any dispute or controversy between the Parties as to whether any obligation, item or matter not described
herein or included in the Company Disclosure Statement is or is not material for purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13
Parent Disclosure Statement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of the representations and warranties in <U>Article 5</U>, Parent will deliver the Parent Disclosure Statement, arranged
in sections corresponding with the sections of <U>Article 5</U>, to Company. The disclosure in any section of the Parent Disclosure
Statement will qualify the corresponding section of <U>Article 5</U>. Each section of the Parent Disclosure Statement shall be
deemed to be disclosed and incorporated by reference in any other section of the Parent Disclosure Statement as though fully set
forth in such section of the Parent Disclosure Statement for which applicability of such information and disclosure is reasonably
apparent on its face. The fact that any item of information is disclosed in any section of the Parent Disclosure Statement: (a)
shall not be construed to mean that such information is required to be disclosed by this Agreement; (b) shall not be construed
as or constitute an admission, evidence or agreement that a violation, right of termination, default, non-compliance, liability
or other obligation of any kind exists with respect to any item; (c) shall not be deemed or interpreted to broaden the representations
and warranties, obligations, covenants, conditions or agreements of the Parent, HoldCo, the Purchaser or their respective Subsidiaries
contained in this Agreement; and (d) does not waive any attorney-client privilege associated with such item or information or
any protection afforded by the work-product doctrine with respect to any of the matters disclosed or discussed herein. Neither
the specifications of any dollar amount in any representation, warranty or covenant contained in this Agreement nor the inclusion
of any specific item in the Parent Disclosure Statement is intended to imply that such amount, or higher or lower amounts, or
the item so included or other items, are or are not material, and no Person shall use the fact of the setting forth of any such
amount or the inclusion of any such item in any dispute or controversy between the Parties as to whether any obligation, item
or matter not described herein or included in the Parent Disclosure Statement is or is not material for purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14
Knowledge</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
any representations or warranty contained in this Agreement is expressly qualified by reference to the knowledge of a Party, it
refers to the actual knowledge of the senior officers of the Party after due inquiry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 305; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
AMALGAMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
Amalgamation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
soon as reasonably practicable after all requisite approvals of the Company Shareholders and each applicable Governmental Authority
with respect to the Transaction are obtained, and the other the conditions set forth herein have been satisfied, waived or released,
each of the Parties covenants to take all such actions as are within its power to control, and use commercially reasonable efforts
to cause other actions to be taken which are not within its power to control, so as to complete the Amalgamation as set forth
in this <U>Article 2</U> and otherwise on the terms, and subject to the conditions, set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
Amalco</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Name. </B>The name of Amalco shall be &ldquo;Enveric Biosciences Canada Inc.&rdquo; or such other name as to be determined
by the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Registered and Records Office. </B>The registered and records office of Amalco shall be 666 Burrard Street, Suite 1700, Vancouver,
British Columbia, V6C 2X8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Authorized Capital and Rights Attaching to Shares. </B>The authorized capital of Amalco shall consist of an unlimited number
of Amalco Common Shares and an unlimited number of Amalco Redeemable Preferred Shares, which shall have the rights, privileges,
restrictions and conditions set out in the Articles of Amalco. No shares of Amalco may be transferred except in compliance with
the restrictions set out in its Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Number of Directors. </B>The number of directors of Amalco shall, until otherwise changed in accordance with the BCBCA, be
a minimum of one (1) and a maximum of five (5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>First Directors. </B>The first directors of Amalco shall be the Persons whose names and addresses are set out below, who shall
hold office until the first annual meeting of shareholders of Amalco or until their successors are elected or appointed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 306; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
    Tamiami Trail N, Suite 200, Naples, FL 34103</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avani
    Kanubaddi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
    Tamiami Trail N, Suite 200, Naples, FL 34103</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: -1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first directors shall hold office until the first annual meeting of the shareholders of Amalco, or until their successors are
duly appointed or elected. The subsequent directors shall be elected each year thereafter in accordance with the Organizational
Documents of Amalco. The management and operation of the business and affairs of Amalco shall be under the control of the board
of directors of Amalco as it is constituted from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Initial Officers. </B>The first officers of Amalco shall be appointed by the board of directors of Amalco in accordance with
the Articles of Amalco.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>Restrictions on Business. </B>There shall be no restrictions on the business which Amalco is authorized to carry on or on the
powers it may exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<B>Fiscal Year End. </B>The fiscal year end of Amalco shall be December 31 of each calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B>First Auditor. </B>The first auditor of Amalco shall be appointed by the board of directors of Amalco in accordance with the
Articles of Amalco, which such auditor shall hold such office until the first annual meeting of shareholders of Amalco following
the Amalgamation, or until their successor is appointed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<B>Articles, Notice of Articles and Amalgamation Application. </B>The Notice of Articles shall be in the form of the notice of
articles forming part of the the Amalgamation Application and the Articles shall be in the form set out in Schedule &ldquo;B&rdquo;
hereto until repealed or amended in the normal manner provided for in the BCBCA, and such Articles shall have been signed by one
of the first directors of Amalco referred to in Section 2.2(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<B>Filings with Registrar. </B>The Company and the Purchaser shall, on or prior to the Effective Time, cause the Amalgamation
Application and any other documents that may be required to give effect to the Amalgamation to be filed with the Registrar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
Effect of Amalgamation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Effective Time, subject to the BCBCA:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company and the Purchaser will be amalgamated and continue as one corporation under the terms and conditions prescribed in
this Agreement and with the effect set out in Section 282 of the BCBCA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
each of the Company and the Purchaser shall cease to exist as entities separate from Amalco;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
the property of each of the Company and the Purchaser will continue to be the property of Amalco;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 307; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Amalco will continue to be liable for the obligations of each of the Company and the Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
any existing cause of action, claim or liability to prosecution with respect to the Company and the Purchaser will be unaffected;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
any civil, criminal or administrative action or Proceeding pending by or against the Company or the Purchaser may be continued
to be prosecuted by or against Amalco;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
any conviction against, or ruling, order or judgment in favor of or against, the Company or the Purchaser may be enforced by or
against Amalco; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
following the redemption of the Amalco Redeemable Preferred Shares as contemplated in Section 2.4(a) of this Agreement, Amalco
shall be a wholly-owned subsidiary of HoldCo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
Treatment of Issued Capital</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions set forth in this Agreement, the following shall occur at the Effective Time (unless otherwise
specified):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
each Company Common Share (other than those held by Dissenting Shareholders) shall be converted into one (1) fully paid and non-assessable
Amalco Redeemable Preferred Share, which Amalco Redeemable Preferred Share shall, immediately following the Amalgamation, be redeemed
by Amalco for the Amalco Redemption Consideration in accordance with the terms of the Amalco Redeemable Preferred Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
immediately following the redemption of the Amalco Redeemable Preferred Shares, the Company Shareholders (other than Dissenting
Shareholders) shall each receive from Parent, as additional consideration for the disposition of their Company Common Shares,
that number of Consideration Shares equal to the product of the Exchange Ratio multiplied by the number of Company Common Shares
held by such Company Shareholder, together with the Amalco Redemption Consideration, and all such Company Common Shares shall
be cancelled;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
each Purchaser Share issued and outstanding immediately prior to the Effective Time shall be converted into one (1) Amalco Common
Share;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
as consideration for Parent issuing the Consideration Shares and the Amalco Redemption Consideration to the Company Shareholders
pursuant to Section 2.4(b) hereof, Holdco shall issue to Parent one common share of Holdco for each such share issued by Parent,
and Holdco shall add to its stated capital an amount equal to the aggregate fair market value of all such shares issued by Parent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
each Company Common Share held by a Dissenting Shareholder shall be cancelled and each Dissenting Shareholder will become entitled
to be paid the fair value of such Company Common Share in accordance with the BCBCA; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 308; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
upon completion of the Amalgamation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    stated capital of the Amalco Redeemable Preferred Shares shall be equal to the value of the aggregate Amalco Redemption Consideration;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    stated capital of the Amalco Common Shares shall be equal to the aggregate paid up capital for purposes of the Tax Act of
    the Purchaser Shares and the Company Common Shares immediately prior to the Amalgamation, less the amount of the stated capital
    added to the Amalco Redeemable Preferred Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stated capital accounts shall be adjusted to recognize payments that may be made to Dissenting Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5
Company Options</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company covenants and agrees in favor of the Purchaser that it shall amend the terms of the Company Options in accordance
section 2.2(b) of the Company Option Plan such that, as at the Effective Time, the Company Optionholders shall be entitled to
receive, for each Company Option held, that number of shares of Parent Common Stock equal to the product of the Exchange Ratio
multiplied by the number of Company Common Shares subject to such Company Option (such amended Company Option, an &ldquo;<B>Amalco
Option</B>&rdquo;), provided that the aggregate number of shares of Parent Common Stock issuable to a holder of Company Options
shall be rounded down to the nearest whole number of shares of Parent Common Stock. Such Amalco Options shall have an exercise
price per share of Parent Common Stock equal to the exercise price per Company Common Share of such Company Option (for any options
with an exercise price set in Canadian dollars, as converted to United States dollars based on the exchange rate quoted by the
Bank of Canada on the Effective Date) immediately prior to the Effective Time divided by the Exchange Ratio, rounded up to the
nearest whole cent, provided that the exercise price of such Amalco Option shall be, and shall be deemed to be, adjusted by the
amount, and only to the extent, necessary to ensure that the In the Money Amount of such Amalco Option does not exceed the In
the Money Amount of such Company Option before the amendment. All other terms and conditions of such Amalco Option will be the
same as the Company Option prior to such amendment, and any document or agreement previously evidencing such Company Option shall
thereafter evidence and be deemed to evidence such Amalco Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Upon the request of a holder of Company Options, the Company and the Parent shall enter into an agreement with the applicable
holder of Company Options (in form and substance satisfactory to Company and Parent, each acting reasonably) whereby such Company
Optionholders would agree to the exchange of all of their Amalco Options immediately following the Effective Time for Parent Options
to purchase the same number of shares of Parent Common Stock subject to such Amalco Option in accordance with <U>Section 2.5(a)
</U>(and otherwise on the same terms and conditions as the Amalco Options). For greater certainty, the Parties intend that the
foregoing exchange of Amalco Options for Parent Options would occur on a rollover basis pursuant to subsection 7(1.4) of the Tax
Act (to the extent available) and that any relevant adjustments to the exercise price of the Parent Options shall be made to reflect
this intention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Parent covenants and agrees that upon any exercise of a Company Option following the Effective Time, the Parent shall promptly
issue and cause the delivery to the holder thereof the necessary number of shares of Parent Common Stock necessary to settle such
exercises in accordance with the terms of the Company Options (as amended as set forth above).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 309; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Parent and the Purchaser covenant and agree that any Company Options that may expire in accordance with the terms of (a) the
Company Option Plan or (b) the Parent Stock Incentive Plan, as applicable, as a result of the holder thereof ceasing to be a service
provider to the Company or Parent (or any affiliate thereof) after the Closing Date shall be confirmed to expire on their normal
expiry date (and the Parent and the Purchaser shall not revoke, and will cause Amalco not to revoke, any authority or approval
taken by the Company prior to the Closing Date in this regard).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
Company Warrants and Company Broker Warrants</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Following the Effective Time, the Parties acknowledge and agree that, in accordance with the terms of the Company Warrants and
Company Broker Warrants, each holder of a Company Warrant or Company Broker Warrant shall be entitled to receive (and such holder
shall accept) upon the exercise of such holder&rsquo;s Company Warrant and Company Broker Warrant, in lieu of Company Common Shares
to which such holder was theretofore entitled upon such exercise, and for the same aggregate consideration payable therefor, that
number of shares of Parent Common Stock which the holder would have been entitled to receive as a result of the Amalgamation contemplated
by this Agreement if, immediately prior to the Effective Date, such holder had been the registered holder of the number of Company
Common Shares to which such holder would have been entitled if such holder had exercised such holder&rsquo;s Company Warrants
or Company Broker Warrants immediately prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Company Warrant and Company Broker Warrant shall continue to be governed by and be subject to the terms of the applicable
Company Warrant and Company Broker Warrant following the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Upon any exercise of a Company Warrant and Company Broker Warrant following the Effective Time, the Parent shall promptly issue
and cause the delivery to the holder thereof the necessary number of shares of Parent Common Stock necessary to settle such exercise
in accordance with the terms of the Company Warrant and Company Broker Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Parent shall at the Effective Time, or as soon as practicable thereafter following the Effective Date, enter into, as successor
to the Company, any supplemental indenture(s) or similar agreement(s) as may be necessary or desirable to give effect to this
Section 2.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
Fractional Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional Parent Common Stock will be issued to Company Shareholders. In lieu of such fractional shares, (a) the number of shares
of Parent Common Stock to be received by a Company Shareholder will be rounded up to the nearest whole share of Parent Common
Stock in the event that a Company Shareholder is entitled to receive a fractional share representing one-half (1/2) or more of
a share of Parent Common Stock, or (b) the number of shares of Company Common Stock to be received by a Company Shareholder will
be rounded down to the nearest whole share of Parent Common Stock in the event that a Company Shareholder is entitled to receive
a fractional share representing less than one-half (1/2) of share of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 310; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8
Exchange of Certificates</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Effective Time and subject to Section 2.9:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
no share certificates representing Amalco Redeemable Preferred Shares shall be issued to Company Shareholders upon completion
of the Amalgamation, and certificates representing Company Common Shares shall be deemed to represent Amalco Redeemable Preferred
Shares and the register of Company Common Shareholders shall be deemed to be the register of holders of Amalco Redeemable Preferred
Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
upon the delivery and surrender by the holder thereof to the Parent of certificates representing, or evidence of ownership on
the Company&rsquo;s share or securities register of, Company Common Shares, the Parent shall cause HoldCo at the Effective Time,
or as soon as practicable thereafter following the date of receipt by the Parent or HoldCo of the certificates referred to above,
deliver to each such holder certificates representing the Consideration Shares to which such holder is entitled;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
the original share certificate of the Purchaser registered in the name of HoldCo shall be cancelled and HoldCo shall be issued
a share certificate for the number of Amalco Common Shares to be issued to HoldCo as provided in <U>Section 2.4(c)</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
certificates or other evidence representing the Company Common Shares shall cease to represent any claim upon or interest in Company
other than the right of the holder to receive, pursuant to the terms hereof, the Consideration in accordance with <U>Section 2.4.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9
Dissenting Shareholders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Shareholders entitled to vote at the Company Meeting will be entitled to exercise Dissent Rights with respect to their Company
Common Shares in connection with the Amalgamation. The Company shall give the Parent notice of any written notice of dissent,
withdrawal of such notice, and any other instruments served pursuant to such Dissent Rights and received by the Company and shall
provide the Parent with copies of such notices and written objections. If a Dissenting Shareholder is ultimately entitled to be
paid fair value for his, her or its Company Common Shares, such shares shall be deemed to have been surrendered to the Company
for cancellation immediately prior to the Effective Time. If a Dissenting Shareholder is ultimately determined not to be entitled,
for any reason, to be paid fair value for his, her or its Company Common Shares, such Dissenting Shareholder shall be deemed to
have participated in the Amalgamation, as of the Effective Time, on the same basis as a holder of Company Common Shares who did
not exercise Dissent Rights in respect of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10
Completion of the Amalgamation and Effective Time</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the satisfaction or waiver of the conditions herein contained in favor of each Party, the Company and the Purchaser shall immediately
deliver the Amalgamation Application and such other documents as may be required under the BCBCA to give effect to the Amalgamation.
The Amalgamation shall become effective at the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11
Parent Guarantee</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parent hereby unconditionally and irrevocably guarantees the due and punctual performance by the Purchaser and HoldCo of each
and every covenant and obligation of the Purchaser and HoldCo arising under the Amalgamation. The Parent hereby agrees that the
Company shall not have to proceed first against the Purchaser and/or HoldCo before exercising its rights under this guarantee
against the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 311; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12
Intended U.S. Tax Consequences</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties shall prior to the Closing Date, cause Holdco (as formed in accordance with Section 7.14) to file an election on Form
8832 to be classified as a disregarded entity with the earliest possible effective date and shall be treated as a disregarded
entity as of its date of formation. The Parties intend for the Amalgamation and the other transactions set forth in Sections 2.1,
2.2, 2.3 and 2.4, including the receipt of Parent Common Stock by the Company Shareholders (the &ldquo;<B>Amalgamation Transactions</B>&rdquo;),
to constitute a single integrated transaction qualifying as a reorganization within the meaning of Sections 368(a)(1)(A) and 368(a)(2)(D)
of the Code, and the rules and regulations promulgated thereunder (the &ldquo;<B>Treasury Regulations</B>&rdquo;) under which
Company Shareholders (other than Dissenting Shareholders) shall receive solely Parent Common Stock in exchange for their Company
Common Shares. The Parties shall adopt this Agreement as a &ldquo;plan of reorganization&rdquo; within the meaning of Sections
1.368-2(g) and 1.368-3(a) of the Treasury Regulations. Each Party agrees to treat: (a) the Parent Common Stock as voting shares
of the Parent for all United States federal income tax purposes; and (b) the Amalgamation Transactions as a single integrated
transaction qualifying as a tax-deferred reorganization within the meaning of Sections 368(a)(1)(A) and 368(a)(2)(D) of the Code
for all purposes to which such treatment is pertinent, including for the purpose of reporting on any United States Tax Return
that such Party may be required to file. Each Party agrees to act in a manner that is consistent with the Parties&rsquo; intention
that the Amalgamation Transactions be treated as a single integrated transaction qualifying as a tax-deferred reorganization within
the meaning of Sections 368(a)(1)(A) and 368(a)(2)(D) of the Code for all United States federal income tax purposes. The Parties
shall cause the Company to provide the Company Shareholders that are United States residents or citizens with a &ldquo;PFIC Annual
Information Statement&rdquo; (as described in Treasury Regulations Section 1.1295-1(g)) for its tax year ended December 31, 2020
and for its short tax year ending on the Closing Date. Within forty-five (45) days after the Closing Date, Parent shall provide
the Company Shareholders with a completed Form 8937 reporting the Amalgamation Transactions as a single integrated transaction
qualifying as a reorganization within the meaning of Sections 368(a)(1)(A) and 368(a)(2)(D) of the Code, and the Treasury Regulations
under which Company Shareholders (other than Dissenting Shareholders) receive solely Parent Common Stock in exchange for their
Company Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13
Registration of the Parent Capital Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Parent Common Stock will be registered under the 1933 Act pursuant to an S-4 Registration Statement and with respect
to the Company Stock Option Plan that is assumed, a newly filed Registration Statement on Form S-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14
Closing Date</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Closing Date will be the date shown on the Certificate of Amalgamation giving effect to the Amalgamation upon the occurrence of
the Company Shareholder Approval and Parent Stockholder Approval and the satisfaction (or waiver) of the other conditions to Closing
as set forth herein, which will be such date as is mutually agreed on by Parent and Company, but not later than the End Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15
Closing</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Closing will take place electronically (or at such other place as may be mutually agreed to by the Parties), at a time to be mutually
agreed on by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 312; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
3</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHAREHOLDER
INFORMATION, LISTING APPLICATION AND MEETING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
Listing Application</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parent shall use commercially reasonable efforts, (a) to the extent required by the rules and regulations of NASDAQ, to prepare
and submit to NASDAQ a notification form for the listing of the shares of Parent Common Stock to be issued in connection with
the Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance) and (b) to the
extent required by NASDAQ Marketplace Rule 5110, to file an initial listing application for the Parent Common Stock on NASDAQ
(the &ldquo;<B>NASDAQ Listing Application</B>&rdquo;) and to cause such NASDAQ Listing Application to be approved prior to the
Effective Time. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with NASDAQ rules
and regulations. The Parent agrees to pay all NASDAQ fees associated with the NASDAQ Listing Application. The Company and its
Subsidiaries will cooperate with the Parent as reasonably requested by the Parent with respect to the NASDAQ Listing Application
and promptly furnish to the Parent all information concerning the Company, its Subsidiaries and its shareholders that may be required
or reasonably requested in connection with any action contemplated by this Section 3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
Company Meeting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will convene and conduct the Company Meeting on or before the date of the Parent Meeting, or such later date as may be
mutually agreed to by the Parent and the Company, and not adjourn, postpone or cancel (or propose the adjournment, postponement
or cancellation of) the Company Meeting without the prior written consent of the Parent, except in the case of an adjournment,
as required for quorum purposes or to otherwise be held on or about the same date as the Parent Meeting or if reasonably required
to solicit proxies in support of the Amalgamation Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
Parent Meeting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parent will convene and conduct the Parent Meeting on or before sixty-five (65) days after the SEC has declared the S-4 Registration
Statement effective, or such later date as may be mutually agreed to by the Parent and the Company, and not adjourn, postpone
or cancel (or propose the adjournment, postponement or cancellation of) the Parent Meeting without the prior written consent of
the Company, except in the case of an adjournment, as required for quorum purposes or to otherwise be held on or about the same
date as the Company Meeting or if reasonably required to solicit proxies in support of the Parent Stockholder Approval Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
Preparation of Filings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties will co-operate in the preparation of any application for any required Authorization and any other orders, registrations,
consents, filings, rulings, exemptions, no-action letters and approvals, and in the preparation of any documents, reasonably deemed
by any of the Parties to be necessary to discharge its respective obligations under this Agreement or otherwise advisable under
Applicable Laws, including in connection with the preparation of the S-4 Registration Statement as provided in Section 7.12 and
the Company Circular as provided in Section 7.13.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 313; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
4</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS
AND WARRANTIES OF COMPANY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
Representations and Warranties of Company</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents and warrants to the Parent, HoldCo and the Purchaser as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Organization and Qualification. </B>The Company is a corporation duly incorporated and validly existing under the laws of the
Province of British Columbia, and has all necessary corporate power, authority and capacity to own its property and assets as
now owned and to carry on its business as it is now being conducted. The Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
    all Authorizations necessary to conduct its business as now conducted, except where the failure to hold such Authorizations
    would not individually or in the aggregate be material to the Company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
    duly registered or otherwise authorized and qualified to do business and is in good standing in each jurisdiction in which
    the character of its properties, owned, leased, licensed or otherwise held, or the nature of its activities, makes such qualification
    necessary, except where the failure to be so qualified or in good standing would not be material the Company. The Company
    is qualified to do business in each jurisdiction set forth on <U>Section 4.1(a)(ii)</U> of the Company Disclosure Statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 148.5pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Authorized and Issued Capital</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    authorized capital of Company consists of an unlimited number of Company Common Shares. As of the close of business on the
    date of this Agreement, there were (A) 37,418,673 Company Common Shares issued and outstanding, (B) outstanding Company Options
    to purchase 3,683,830 Company Common Shares, (C) outstanding Company Warrants to purchase 22,248,577 Company Common Shares,
    and (D) 1,283,501 Company Broker Warrants. <U>Section 4.1(b)(i)</U> of the Company Disclosure Statement sets forth the authorized,
    issued and outstanding Company Common Shares, Company Options, Company Warrants, Company SARs and Company Broker Warrants.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    outstanding Company Common Shares have been duly authorized and validly issued, and are fully paid and non-assessable and
    have not been issued in violation of any pre-emptive rights or in violation of Applicable Laws.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of the Company Common Shares issuable upon the exercise of rights under the Company Option Plan, including outstanding Company
    Options, have been duly authorized and, upon issuance in accordance with their respective terms, will be validly issued as
    fully paid and non-assessable and are not and will not be subject to, or issued in violation of, any pre-emptive rights. No
    Company Options have been granted in violation of Applicable Laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 314; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of the Company Common Shares issuable upon the exercise of rights under the Company Warrants and Company Broker Warrants,
    as the case may be, have been duly authorized and, upon issuance in accordance with their respective terms, will be validly
    issued as fully paid and non-assessable and are not and will not be subject to, or issued in violation of, any pre-emptive
    rights. No Company Warrants or Company Broker Warrants have been granted in violation of Applicable Laws.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Company SARs are issued and outstanding.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as set forth on <U>Section 4.1(b)(vi) of the Company Disclosure Statement,</U> there are no obligations, contingent or otherwise,
    of the Company to (A) repurchase, redeem or otherwise acquire any capital stock or other equity securities of the Company,
    or (B) provide material funds to, or make any material investment in (in the form of a loan, capital contribution or otherwise),
    or provide any guarantee with respect to the obligations of, any Person. There are no outstanding equity appreciation, phantom
    equity, profit participation or similar rights with respect to the Company and its Subsidiaries. There are no bonds, debentures,
    notes or other indebtedness of the Company having the right to vote or consent (or, convertible into, or exchangeable for,
    securities having the right to vote or consent) on any matters on which Company Shareholders (or other equity holders) of
    the Company may vote.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Corporate Authorization</B>. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement. The execution and delivery of, and performance by, the Company of this Agreement, the Parent Support Agreement
and Transaction Document which the Company is a party and the consummation of the Amalgamation and the other transactions contemplated
hereby and thereby have been, or will at Closing be, duly authorized by all necessary corporate action on the part of the Company
and, subject to obtaining the approval of the Amalgamation Resolution, no other corporate actions on the part of the Company are
necessary to authorize this Agreement or to consummate the Amalgamation and the other transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Execution and Binding Obligation</B>. This Agreement and the Parent Support Agreements have been and the Transaction Documents
which the Company is a party, will be, duly executed and delivered by the Company and constitutes a legal, valid and binding agreement
of the Company, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar Applicable Laws affecting or relating to creditors&rsquo; rights generally and
general equitable principles (the &ldquo;<B>Bankruptcy and Equity Exceptions</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>No Conflict. </B>The execution and delivery of, and performance by the Company of its obligations under, this Agreement, the
Transaction Documents to which it is a party, and subject to the receipt of the Company Shareholder Approval, the completion of
the transactions contemplated hereby and thereby, and the performance of its obligations hereunder and thereunder, do not and
will not (or would not with the giving of notice, the lapse of time or the happening of any other event or condition):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">constitute
    or result in a violation or breach of, or conflict with, any of the terms or provisions of its Organizational Documents;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 315; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    as disclosed in <U>Section 4.1(e)</U> of Company Disclosure Statement, require any consent or other action by any Person under,
    constitute or result in a breach or violation of or conflict with, or, with or without notice or lapse of time or both, allow
    any Person to exercise any rights under any of the terms or provisions of any Material Contracts, licenses, leases or instruments
    to which the Company or its Subsidiaries area party or pursuant to which any of its assets or properties may be affected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
    in a breach of, or cause the termination or revocation of, any Authorization held by the Company or its Subsidiaries, or necessary
    to the ownership of the Company Common Shares or the operation of the business of Company or its Subsidiaries; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
    in the violation of any Applicable Law,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
in the case of clause (e)(ii) above, as would not, individually or in the aggregate, be material to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Financial Statements</B>. The Company Financial Statements Made Available to Parent are, or will when completed be, prepared
in accordance with IFRS, consistently applied, and fairly present in all material respects the financial condition of the Company
at the respective dates indicated and for the periods covered. The Company Financial Statements are complete and correct in all
material respects, has been prepared in accordance with IFRS consistently applied without modification of the accounting principles
used in the preparation thereof throughout the periods presented and fairly presents the combined and consolidated financial position,
results of income, and cash flows, as applicable, of the Company and its Subsidiaries as of the dates and for the periods indicated
therein. All books, records and accounts of the Company and its Subsidiaries are accurate and complete and are maintained in all
material respects in accordance with good business practice and all applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>Compliance with Laws</B>. The Company and its Subsidiaries are, and since May 26, 2020, have been, in compliance in all material
respects with Applicable Laws. Since May 26, 2020, neither the Company, its Subsidiaries nor, to the Company&rsquo;s knowledge,
any officer, director or manager of the Company or its Subsidiaries is, nor has been, under any investigation with respect to,
is not nor has been charged or threatened to be charged with, nor has received notice of, any violation or potential violation
of any Applicable Laws or disqualification by a Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<B>Shareholders&rsquo; and Similar Agreements.</B> Except as disclosed in <U>Section 4.1(h)</U> of the Company Disclosure Statement,
the Company is not subject to, or affected by, any unanimous shareholders agreement and is not a party to any shareholder, pooling,
voting, or other similar arrangement or agreement relating to the ownership or voting of the securities of the Company or pursuant
to which any Person may have any right or claim in connection with any existing or past equity interest in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 316; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B>Subsidiaries and Affiliates. </B><U>Section 4.1(i)</U> of the Disclosure Statement sets forth the name of each Subsidiary of
the Company, with respect to each such listed Subsidiary, the jurisdiction in which it is organized, and the jurisdictions, if
any, in which it is qualified to do business. Each Subsidiary is duly organized, validly existing and in good standing under the
Applicable Laws of its jurisdiction and is duly qualified or authorized to do business and is in good standing under the Applicable
Laws of each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification
or authorization, except where the failure to be so qualified, authorized or in good standing would not be material to the Company
and its Subsidiaries (taken as a whole). Each Subsidiary has all requisite power and authority to own, lease and operate its properties
and to carry on its business as now conducted. All of the issued and outstanding equity interests of the Company&rsquo;s Subsidiaries
(the &ldquo;<B>Subsidiary Interests</B>&rdquo;) are held beneficially and of record by the Company as set forth on <U>Section
4.1(i)</U> of the Disclosure Statement, free and clear of any and all Liens (other than arising pursuant to the applicable Organizational
Documents). None of the issued Subsidiary Interests were issued in violation of any purchase or call option, right of first refusal,
subscription right, preemptive right or any similar rights, and are otherwise duly authorized, validly issued, fully paid and
non-assessable. There is no existing option, warrant, call, right or Contract requiring, and there are no convertible securities
of any Subsidiary outstanding which upon conversion would require, the issuance of any other equity interests of any Subsidiary
or other securities convertible into equity interests of any Subsidiary. Except as set forth on <U>Section 4.1(i)</U> of the Disclosure
Statement, the Company does not have, and has never had, any Subsidiaries or Affiliates and, except for such Subsidiary, the Company
does not own, directly or indirectly, any equity securities of any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<B>Internal Accounting Controls. </B>The Company and its Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurances that: (i) transactions are executed in accordance with management&rsquo;s general or specific
authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance
with IFRS and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<B>Auditors.</B> The Company Financial Statements in respect of the period from incorporation on May 26, 2020 to June 30, 2020
have been audited in accordance with Canadian generally accepted auditing standards by independent public accountants as required
by applicable Securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<B>No Undisclosed Liabilities.</B> Except as disclosed in <U>Section 4.1(l)</U> of the Company Disclosure Statement, neither the
Company nor its Subsidiaries have any Liability, whether accrued, absolute, contingent or otherwise, not reflected in the Company
Financial Statements, except Liabilities (i) incurred in connection with this Agreement or the Transaction, (ii) incurred since
December 31, 2020, in the Ordinary Course consistent with past practices or (iii) that would not have, individually or in the
aggregate, be material to the Company and its Subsidiaries. An itemized list setting forth the principal amount of all indebtedness
for borrowed money of the Company (and all accrued interest thereon) as of the Execution Date, including capital leases, is disclosed
in <U>Section 4.1(l)</U> of the Company Disclosure Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<B>Absence of Certain Changes or Events.</B> Since December 31, 2020, other than the transactions contemplated in this Agreement
and as disclosed in <U>Section 4.1(m)</U> of the Company Disclosure Statement, the business of the Company and its Subsidiaries
has been conducted in the Ordinary Course and there has not been any event, circumstance or occurrence which has been or would
be reasonably expected to be, individually or in the aggregate, material to the Company and its Subsidiaries (taken as a whole).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<B>Ordinary Course.</B> Since December 31, 2020, other than as disclosed in <U>Section 4.1(n)</U> of the Company Disclosure Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have conducted their respective businesses only in the Ordinary Course;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 317; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    liability or obligation of any nature (whether absolute, accrued, contingent or otherwise), which has been, or is reasonably
    likely to be material with respect to the Company or its Subsidiaries, has been incurred by the Company or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been any change in the accounting practices used by the Company or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    for Ordinary Course adjustments to employee compensation (other than directors or officers), there has not been any increase
    in the salary, bonus, or other remuneration payable to any employees of the Company or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been any redemption, repurchase or other acquisition of Company Common Shares by the Company, or any declaration,
    setting aside or payment of any dividend or other distribution (whether in cash or otherwise) with respect to the Company
    Common Shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been a material change in the level of accounts receivable or payable, inventories or employees of the Company or
    its Subsidiaries, other than those changes in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    the Company nor its Subsidiaries have entered into, or amended, any Material Contract other than in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been any satisfaction or settlement of any material claims or material liabilities of the Company or its Subsidiaries
    that were not reflected in the Company&rsquo;s Financial Statements, other than the payment or settlement of claims or liabilities
    incurred in the Ordinary Course; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been any amendment or modification to the vesting or exercisability schedule or criteria, including any acceleration,
    right to accelerate or acceleration event or other entitlement under any stock option, restricted stock, deferred compensation
    or other compensation award of any officer or director of the Company or its Subsidiaries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<B>Related Party Transactions.</B> Except as disclosed in <U>Section 4.1(o)</U> of the Company Disclosure Statement, neither the
Company nor its Subsidiaries are indebted to any director, officer, employee or agent of, or independent contractor to, the Company
(except for amounts due in the Ordinary Course as salaries, bonuses and director&rsquo;s fees or the reimbursement of Ordinary
Course expenses). Except as disclosed in <U>Section 4.1(o)</U> of the Company Disclosure Statement, there are no Contracts (other
than employment arrangements) with, or advances, loans, guarantees, liabilities or other obligations to, on behalf or for the
benefit of, any shareholder, officer or director of the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<B>Authorizations and Licenses.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company and its Subsidiaries own, possess or have obtained all Authorizations that are required by Applicable Laws in connection
    with the operation of the business of the Company and its Subsidiaries (taken as a whole) as presently or previously conducted,
    or in connection with the ownership, operation or use of the assets of the Company and its Subsidiaries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 318; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company and its Subsidiaries lawfully hold, own or use, and have complied with, all such Authorizations. Each Authorization
    is valid and in full force and effect, and is renewable by its terms or in the Ordinary Course without the need for the Company
    and its Subsidiaries to comply with any special rules or procedures, agree to any materially different terms or conditions
    or pay any amounts other than routine filing fees.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Proceeding is pending in respect of or regarding any such Authorization and neither the Company, its Subsidiaries, nor, to
    the knowledge of the Company, any of their respective officers or directors has received notice, whether written or oral,
    of revocation, non-renewal or material amendments of any such Authorization, or of the intention of any Person to revoke,
    refuse to renew or materially amend any such Authorization.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
    the Company, its Subsidiaries nor, to the knowledge of the Company, any of their respective officers or directors, own or
    have any proprietary, financial or other interests (direct or indirect) in any such Authorization.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<B>Finders&rsquo; Fees.</B> Except as disclosed in <U>Section 4.1(q)</U> of the Company Disclosure Statement, no investment banker,
broker, finder, financial adviser or other intermediary has been retained by or is authorized to act on behalf of the Company,
its Subsidiaries or any of their officers, directors or employees, or is entitled to any fee, commission or other payment from
the Company, the Subsidiaries, or any of their officers, directors or employees, in connection with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<B>Company Board Approval</B>. The Company Board, after consultation with its financial and legal advisors, has unanimously (i)
determined that the Consideration to be received by the Company Securityholders pursuant to the Amalgamation and this Agreement
is fair to such holders and that the Amalgamation is in the best interests of the Company and the Company Shareholders; (ii) resolved
to unanimously recommend that the Company Securityholders vote in favor of the Amalgamation Resolution; and (iii) authorized the
entering into of this Agreement and the performance by the Company and its Subsidiaries of their respective obligations under
this Agreement, and no action has been taken to amend, or supersede such determinations, resolutions, or authorizations (the &ldquo;<B>Company
Board Approval</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<B>Material Contracts.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
    4.1(s)</U> of the the Company Disclosure Statement sets out a complete and accurate list of all Material Contracts of the
    Company and its Subsidiaries. True and complete copies of the Material Contracts of the Company and its Subsidiaries have
    been Made Available to the Parent and no such Contract has been modified, rescinded or terminated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 319; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Material Contract is legal, valid, binding and in full force and effect and is enforceable by the Company and its Subsidiaries
    in accordance with its terms (subject to the Bankruptcy and Equity Exceptions).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company and its Subsidiaries have performed in all material respects all respective obligations required to be performed by
    it to date under the Material Contracts and the Company and its Subsidiaries are not in breach or default under any Material
    Contract, nor does the Company have knowledge of any condition that, with the passage of time or the giving of notice or both,
    would result in such a breach or default.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the knowledge of the Company, neither the Company nor its Subsidiaries have received any notice (whether written or oral),
    that any party to a Material Contract intends to cancel, terminate or otherwise modify or not renew its relationship with
    the Company or its Subsidiaries, and, to the knowledge of the Company, no such action has been threatened.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<B>Real Property.</B> <U>Section 4.1(t)</U> of the Company Disclosure Statement lists all Owned Properties and all Leased Properties.
Except as set forth on <U>Section 4.1(t)</U> of the Company Disclosure Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries (as applicable) have valid, good and marketable title to all of the real or immovable property
    owned by it (the &ldquo;<B>Owned Properties</B>&rdquo;) free and clear of any Liens, except for Permitted Liens, and there
    are no outstanding options or rights of first refusal to purchase the Owned Properties, or any portion thereof or interest
    therein; in addition, all buildings, structures, fixtures, building systems, and equipment located on the Owned Properties
    are in good condition and repair, and the Owned Properties are in compliance with applicable legal requirements in all material
    respects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    lease, sublease, license or occupancy agreement (in each case, together with any amendments, supplements, notices or ancillary
    agreements thereto) for real or immovable property leased, subleased, licensed or occupied by the Company or its Subsidiaries
    (the &ldquo;<B>Leased Properties</B>&rdquo;) is valid, legally binding and enforceable against the Company or its Subsidiaries,
    as the case may be, in accordance with its terms and in full force and effect, true and complete copies of which (including
    all related amendments, supplements, notices and ancillary agreements) have been Made Available to the Parent, and neither
    the Company nor any of its Subsidiaries is in breach of, or default under, such lease, sublease, license or occupancy agreement,
    and, to the knowledge of the Company, no event has occurred which, with notice, lapse of time or both, would constitute such
    a breach or default by the Company or any of its Subsidiaries or permit termination, modification or acceleration by any third
    party thereunder; <U>Section 4.1(t)(ii)</U> of the Disclosure Statement contains a list of all Owned Properties and Leased
    Properties; no other party to any of the Leased Properties is a Related Persons and, otherwise, does not have an economic
    interest in any Owned Properties or Leased Properties; neither the Company no any of its Subsidiaries has not collaterally
    assigned or granted any other security interest in any of the Leased Properties;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 320; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    third party has repudiated or has the right to terminate or repudiate any such lease, sublease, license or occupancy agreement
    (except for the normal exercise of remedies in connection with Applicable Laws or a default thereunder or any termination
    rights set forth in the lease, sublease, license or occupancy agreement) or any provision thereof; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the leases, subleases, licenses or occupancy agreements has been assigned by the Company or any of its Subsidiaries in
    favor of any Person or sublet or sublicensed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<B>Personal Property; Condition of Personal Property.</B> The Company and its Subsidiaries have good title to all material personal
or movable property of any kind or nature which the Company and the Subsidiaries purport to own, free and clear of all Liens (other
than Permitted Liens). The Company or its Subsidiaries, as lessee, has the right under valid and subsisting leases to use, possess
and control all personal or movable property leased by and material to the Company or its Subsidiaries as used, possessed and
controlled by the Company or its Subsidiaries. All real and tangible personal property of the Company and its Subsidiaries is
in generally good repair and is operational and usable in the manner in which it is currently being utilized, subject to normal
wear and tear and technical obsolescence, repair or replacement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<B>Intellectual Property.</B> <U>Section 4.1(v)</U> of the Company Disclosure Statement sets forth a true and complete list of
all of the Company&rsquo;s Registered Intellectual Property. As to each item, <U>Section 4.1(v)</U> of the Company Disclosure
Statement specifies, as applicable, the jurisdiction in which such item is issued or registered or in which an application for
issuance or registration has been filed, and the issuance, registration and/or application numbers and dates with respect to such
item. Except as would not and would not be reasonably expected to be, individually or in the aggregate, material to the Company
and its Subsidiaries : (i) the Company and its Subsidiaries own all right, title and interest, or have valid licenses (and is
not in material breach of such licenses), in and to all Intellectual Property that is material to the conduct of the business,
as presently conducted, of the Company and its Subsidiaries (collectively, the &ldquo;<B>Intellectual Property Rights</B>&rdquo;);
(ii) all such Intellectual Property Rights that are owned by or licensed to the Company and its Subsidiaries are sufficient, in
all material respects, for conducting the business, as presently conducted, of the Company and its Subsidiaries; (iii) to the
knowledge of the Company, all Intellectual Property Rights owned or leased by the Company and its Subsidiaries are valid and enforceable,
and the carrying on of the business of the Company and its Subsidiaries and the use by the Company and its Subsidiaries of any
of the Intellectual Property Rights or Technology (as defined below) owned by or licensed to the Company or its Subsidiaries does
not breach, violate, infringe or interfere with any rights of any other Person; (iv) to the knowledge of the Company, no third
party is infringing upon the Intellectual Property Rights owned or licensed by the Company or its Subsidiaries, and no Proceeding
is currently pending or threatened with respect to the foregoing; (v) all computer hardware and associated firmware and operating
systems, application software, database engines and processed data, technology infrastructure and other computer systems used
in connection with the conduct of the business, as presently conducted, of the Company and its Subsidiaries (collectively, the
&ldquo;<B>Technology</B>&rdquo;) are sufficient, in all material respects, for conducting the business, as presently conducted,
of the Company and its Subsidiaries; and (vi) the Company and its Subsidiaries own, or has validly licensed or leased (and is
not in material breach of such licenses or leases), such Technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 321; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<B>Restrictions on Conduct of Business.</B> The Company and its Subsidiaries are not a party to or bound by any non-competition
agreement, any non-solicitation agreement, or any other agreement, obligation, judgment, injunction, order or decree which purports
to: (i) limit in any material respect the manner or the localities in which all or any portion of the business of the Company
and its Subsidiaries is conducted; (ii) limit any business practice of the Company and its Subsidiaries in any material respect;
or (iii) restrict any acquisition or disposition of any property by the Company and its Subsidiaries in any material respect.
Neither the Company, any of its Subsidiaries nor any of their respective properties or assets is subject to any outstanding judgment,
order, writ, injunction or decree that would be or would be reasonably expected to be, individually or in the aggregate, material
to the Company or its Subsidiaries or that would or would be reasonably expected to prevent or delay the consummation of the Amalgamation
or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<B>Litigation.</B> Except as set out in <U>Section 4.1(x)</U> of the Company Disclosure Statement, there are no Proceedings pending,
or, to the knowledge of the Company, threatened against or relating to the Company, its Subsidiaries, the business of the Company
and its Subsidiaries or affecting any of its current or former properties or assets by or before any Governmental Authority that,
if determined adverse to the interests of the Company and its Subsidiaries, could potentially result in criminal sanction, or
would be reasonably expected to prevent or delay the consummation of the Amalgamation or the transactions contemplated hereby,
or would, or would be reasonably expected to, materially affect the Purchaser&rsquo;s ability to own or operate the business of
the Company and its Subsidiaries, nor, to the knowledge of the Company, are there any events or circumstances which could reasonably
be expected to give rise to any such Proceeding. There is no bankruptcy, liquidation, winding-up or other similar Proceeding pending
or in progress, or, to the knowledge of the Company, threatened against or relating to the Company or its Subsidiaries before
any Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<B>Corrupt Practices Legislation.</B> Neither the Company, its Subsidiaries nor, to the knowledge of the Company, any of their
respective officers, directors or employees acting on behalf of the Company or its Subsidiaries, has taken, committed to take
or been alleged to have taken any action which would cause the Company to be in violation of the <I>Corruption of Foreign Public
Officials Act</I> (Canada) or or any other applicable anti-bribery, anti-money laundering, anti-bribery or anti-corruption laws
or any law of similar effect of any other jurisdiction, and to the knowledge of the Company, no such action has been taken by
any of its agents, representatives or other Persons acting on behalf of the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<B>Environmental Matters.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    written notice, order, complaint or penalty has been received by the Company or its Subsidiaries alleging that the Company
    or its Subsidiaries is in violation of, or has any liability or potential liability under, any applicable Environmental Law,
    including any health and safety requirements applicable thereto, and there are no Proceedings pending or, to the knowledge
    of the Company, threatened against the Company or its Subsidiaries which allege a violation of, or any liability or potential
    liability under, any applicable Environmental Laws, including any health and safety requirements applicable thereto, and,
    to the knowledge of the Company, no fact or circumstance exists that reasonably could be expected to give rise to any such
    notice, claim, order, complaint or penalty.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 322; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company and its Subsidiaries has all environmental permits necessary for the operation of their respective businesses and
    to comply in all material respects with all applicable Environmental Laws, including any health and safety requirements applicable
    thereto.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    operations of the Company and its Subsidiaries are, and since May 26, 2020, have been, in compliance in all material respects
    with applicable Environmental Laws, including any health and safety requirements applicable thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<B>Employment Matters.</B> Except as disclosed in <U>Section 4.1(aa)</U> of the Company Disclosure Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
    neither the Company nor any of its Subsidiaries has not entered into any written or oral agreement or understanding providing
    for a retention or change of control bonus or severance or termination payments to any director or Company Employee in connection
    with the termination of their position or their employment as a direct result of a change in control of the Company or its
    Subsidiaries (including as a result of the Amalgamation), and (B) no Company Employee has any agreement as to length of notice
    or severance payment required to terminate his or her employment, other than such as results by Applicable Laws from the employment
    of an employee without an agreement as to notice or severance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
    neither the Company nor any of its Subsidiaries is a party to any Collective Agreement with respect to any Company Employees,
    (B) no Person holds bargaining rights with respect to any Company Employees and (C) to the knowledge of the Company, no Person
    has applied or threatened to be certified as the bargaining agent of any Company Employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    trade union has applied to have the Company or its Subsidiaries declared a common or related employer pursuant to Applicable
    Laws;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries are in material compliance with all terms and conditions of employment and all Applicable Laws
    respecting employment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries are not subject to any pending or, to the knowledge of the Company, threatened claim or action
    relating to employment or termination of employment of employees or independent contractors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have not and is not engaged in any unfair labor practice and no unfair labor practice complaint,
    grievance or arbitration proceeding is pending, or to the knowledge of the Company, threatened against the Company or its
    Subsidiaries;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 323; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    labor strike, lock-out, slowdown or work stoppage is pending or to the knowledge of the Company, threatened against or directly
    affecting the Company or its Subsidiaries and no such event has occurred in the last two years;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    independent contractor and consultant has been properly classified by the Company or its Subsidiaries as an independent contractor
    and the Company and its Subsidiaries have not received notification from any Governmental Authority challenging the classification
    of any individual who performs services for the Company&rsquo;s or its Subsidiaries&rsquo; businesses as an independent contractor
    or consultant; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    are no outstanding assessments, penalties, fines, liens, charges, surcharges, or other amounts due or owing pursuant to any
    workplace safety and insurance legislation and there are no orders under applicable occupational health and safety legislation
    relating to the Company or its Subsidiaries which are currently outstanding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<B>Employee Plans.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
    4.1(bb)</U> of the Company Disclosure Statement lists and describes all the pension, benefit, insurance, retirement, compensation,
    deferred compensation, incentive, bonus, employee loan, collective bargaining, profit sharing, commission, performance award,
    option, phantom equity, stock or stock-based, stock purchase, restricted stock, change in control, retention, severance, vacation,
    paid time off, welfare, fringe-benefit and other similar agreement, plan, policy, program or arrangement (and any amendments
    thereto), in each case whether or not reduced to writing and whether funded or unfunded, whether or not Tax-qualified, which
    is or has been maintained, sponsored, contributed to, or required to be contributed to by the Company or its Subsidiaries
    for the benefit of any current or former Company Employee or director, or under which the Company or its Subsidiaries have
    or may have any Liability, contingent or otherwise (collectively, the &ldquo;<B>Employee Plans</B>&rdquo;). The Company and
    the Subsidiaries have furnished to the Purchaser true, correct and complete copies of all the Employee Plans as of the Execution
    Date, together with all related documentation. Since December 31, 2020, no changes have occurred or are expected to occur
    which would materially affect the information required to be provided to the Purchaser pursuant to this provision.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Employee Plan is or is intended to be a &ldquo;registered pension plan,&rdquo; a &ldquo;deferred profit sharing plan,&rdquo;
    a &ldquo;retirement compensation arrangement,&rdquo; a &ldquo;registered retirement savings plan,&rdquo; or a &ldquo;tax-free
    savings account&rdquo; as such terms are defined in the Tax Act.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Employee Plan is and has been operated in accordance with Applicable Laws, in all material respects. The Company and the Subsidiaries
    have made all contributions and paid all premiums in respect of each Employee Plan in a timely fashion in accordance with
    Applicable Laws and the terms of each Employee Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 324; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    than routine claims for benefits, no Employee Plan is subject to any pending action, investigation, examination, claim (including
    claims for income Taxes, interest, penalties, fines or excise Taxes) or any other proceeding initiated by any Person, and,
    to the knowledge of the Company, there exists no state of facts which could reasonably be expected to give rise to any such
    action, investigation, examination, claim or other proceeding.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    insurance policy or any other agreement affecting any Employee Plan requires or permits a retroactive increase in contributions,
    premiums or other payments due thereunder. The level of insurance reserves under each Employee Plan which provides group benefits
    and contemplates the holding of such reserves is reasonable and sufficient to provide for all incurred but unreported claims.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
    of the Employee Plans provide for retiree or post-termination benefits or for benefits to retired or terminated employees
    or to the beneficiaries or dependants of retired or terminated employees, except as required by Applicable Laws.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the requirements of Applicable Laws, no provision of any Employee Plan or of any agreement, and no act or omission of the
    Company or its Subsidiaries in any way limits, impairs, modifies or otherwise affects the right of the Company or its Subsidiaries
    to unilaterally amend or terminate any Employee Plan, and no commitments to improve or otherwise amend any Employee Plan have
    been made.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    advance tax rulings have been sought or received in respect of any Employee Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as set forth in Section 4.1(bb)(ix) of the Company Disclosure Statement, neither the Execution and delivery of this Agreement
    nor the consummation of the Transactions (either alone or in combination with another event) (A) entitle any employee or officer
    of the Company or its Subsidiaries to severance pay, or any other payment that will result in a material Liability to the
    Company, Parent or Purchaser, (B) accelerate the time of payment or vesting, or trigger any payment or funding, through a
    grantor trust or otherwise, or increase the amount of, compensation or benefits due any such employee or officer or trigger
    any other obligation pursuant to, any of the Employee Plans; or (C) result in any breach or violation of, or a default under,
    any of the Employee Plans. Neither the execution and delivery of this Agreement nor the consummation of the Transactions (either
    alone or in combination with another event) result in any payment that could individually or in combination with any other
    such payment constitute an &ldquo;excess parachute payment&rdquo; to a &ldquo;disqualified individual&rdquo; as those terms
    are defined in Section 280G of the Code, without regard to whether such payment is reasonable compensation for personal services
    performed or to be performed in the future.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 325; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<B>Insurance. </B>A true and complete list of all material insurance policies currently in effect that insure the physical properties,
business, operations and assets of the Company and its Subsidiaries is set forth in <U>Section 4.1(cc)</U> of the Company Disclosure
Statement, including the policy name, description, insurer and policy number. Each such material insurance policy currently in
effect that insures the physical properties, business, operations and assets of the Company and its Subsidiaries is valid and
binding and in full force and effect and there is no material claim pending under any such policies as to which coverage has been
questioned, denied or disputed by any insurer or as to which any insurer has made any reservation of rights or refused to cover
all or any material portion of such claim. All material Proceedings covered by any insurance policy of the Company and its Subsidiaries
have been properly reported to and accepted by the applicable insurer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<B>Taxes.</B> The Company has Made Available to the Parent true, correct and complete copies of all Tax Returns, examination reports
and statements of deficiencies for taxable periods, or transactions consummated, for which the applicable statutory periods of
limitations have not expired. Except as disclosed in <U>Section 4.1(dd)</U> of the Company Disclosure Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have duly and timely filed all Tax Returns required to be filed prior to the Execution Date and
    all such Tax Returns are complete and correct in al material respects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have has paid on a timely basis all Taxes which are due and payable, all assessments and reassessments,
    and all other Taxes due and payable by the Company or its Subsidiaries on or before the Execution Date, other than those which
    are being or have been contested in good faith and in respect of which reserves have been provided in the Company Financial
    Statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have provided adequate accruals in accordance with IFRS in the Company Financial Statements for
    any Taxes of the Company or its Subsidiaries for the period covered by such financial statements that have not been paid whether
    or not shown as being due on any Tax Returns;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">since
    December 31, 2019, no material liability in respect of Taxes not reflected in such statements or otherwise provided for has
    been assessed, proposed to be assessed, incurred or accrued by the Company or any of its Subsidiaries, other than in the Ordinary
    Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    the knowledge of the Company, neither the Company nor any of its Subsidiaries have received a Tax refund to which it was not
    entitled;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    material deficiencies, litigation, proposed adjustments or matters in controversy exist or have been asserted with respect
    to Taxes of the Company or its Subsidiaries, and the Company and its Subsidiaries are not a party to any Proceeding for assessment
    or collection of Taxes and no such event has been asserted or, to the knowledge of the Company, threatened against the Company,
    its Subsidiaries or any of its assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 326; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    claim has been made by any Government Authority in a jurisdiction where the Company or its Subsidiaries does not file Tax
    Returns that the Company or its Subsidiaries are or may be subject to Tax by that jurisdiction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    are no Liens (other than Permitted Liens) with respect to Taxes upon any of the assets of the Company or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have withheld or collected all amounts required to be withheld or collected by it on account
    of Taxes and has remitted all such amounts to the appropriate Governmental Authority when required by Applicable Laws to do
    so;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    are no outstanding agreements extending or waiving the statutory period of limitations applicable to any claim for, or the
    period for the collection or assessment or reassessment of Taxes due from the Company or its Subsidiaries for any taxable
    period and no request for any such waiver or extension is currently pending;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions made or imposed in respect of every transaction (or series of transactions) between the Company or its
    Subsidiaries, on the one hand, and any Person, on the other hand, that is (x) a non-resident of Canada for purposes of the
    Tax Act, and (y) not dealing at arm&rsquo;s length with the Company or its Subsidiaries, for purposes of the Tax Act, do not
    differ from those that would have been made between persons dealing at arm&rsquo;s length for purposes of the Tax Act, and
    all documentation or records as required by Applicable Law has been made or obtained in respect of such transactions (or series
    of transactions);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    are no circumstances existing which could result in the application of Section 78 or Sections 80 to 80.04 of the Tax Act,
    or any equivalent provision under provincial Applicable Law, to the Company or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have not received or claimed any credits, subsidies or refunds of Taxes to which they were not
    entitled, including any subsidies under section 125.7 of the Tax Act or any other governmental programs related to COVID-19;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company Common Shares are not &ldquo;taxable Canadian property&rdquo; within the meaning of the Tax Act;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have not participated in any &ldquo;listed transaction&rdquo; within the meaning of Section 1.6011-4
    of the Treasury Regulations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 327; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries have not taken or agreed to take any action that would prevent the Amalgamation Transactions
    from constituting a reorganization qualifying under Section 368 of the Code; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company and its Subsidiaries are not aware of any agreement, plan or other circumstance that would prevent the Amalgamation
    Transactions from qualifying as a reorganization under Section 368 of the Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<B>Accounts and Notes Receivable and Payable</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accounts receivable of the Company and its Subsidiaries reflected on the books and records of the Company and its Subsidiaries
    (except to the extent of the allowance for doubtful accounts reflected on the Financial Statements) represent bona fide and
    valid obligations arising from sales actually made or services actually performed in the Ordinary Course of Business. Subject
    to such reserves, each account receivable either has been or are reasonably expected to be collected in full, without any
    set-off, within ninety (90) days after the day on which it first becomes due and payable. To the knowledge of the Company,
    there are no material disputes with respect to any of the accounts receivable reflected on the Financial Statements that have
    not been reserved for on the Financial Statements.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    accounts payable of the Company and its Subsidiaries as of the Closing Date will be reflected in the books and records of
    the Company or its Subsidiaries. There are no accounts payable of the Company and its Subsidiaries (i) for purchases in material
    excess of usual requirements, (ii) that did not arise in the Ordinary Course, or (iii) that are materially past due. All accounts
    payable of the Company and its Subsidiaries are appropriately reserved for and recorded in accordance with IFRS and reflected
    in the Financial Statements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<B>Disclosure.</B> The information relating to Company and its Subsidiaries to be supplied by or on behalf of Company and its
Subsidiaries for inclusion or incorporation by reference in the S-4 Registration Statement and the Proxy Statement/Prospectus
will not, on the date of filing thereof or the date that it is first mailed to the Parent Stockholders, as applicable, or at the
time of the Parent Meeting or at the time of any amendment or supplement thereof, contain any untrue statement of any material
fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they are made, not false or misleading at the time and in light of the circumstances under
which such statement is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
No Survival of Representations and Warranties</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations and warranties of the Parent in this Agreement (including any representations and warranties incorporated herein
by reference) or in any other Transaction Document shall not survive the Closing. The Company represents, warrants, acknowledges
and agrees that other than as expressly set forth in Article 5 of this Agreement, none of Parent, HoldCo, Purchaser, any of their
Affiliates or stockholders or any of their respective Representatives makes or has made any representation or warranty, either
express or implied, as to the accuracy or completeness of any information provided or made available to the Company, any of its
Subsidiaries, Affiliates or stockholders or any of their respective Representatives (collectively, &ldquo;<B>Company Related Persons</B>&rdquo;)
or any other person in connection with this Agreement, the Amalgamation or any of the other transactions or with respect to any
projections, forecasts, estimates, plans or budgets of future revenues, expenses or expenditures, future results of operations,
future cash flows or future financial condition, or any component of the foregoing, or any other forward looking information,
of Parent, HoldCo, Purchaser or any of their Affiliates, and no Company Related Person has relied on any information or statements
made or provided (or not made or provided) to any Company Related Person other than the representations and warranties of Parent,
HoldCo and Purchaser expressly set forth in Article 5 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 328; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
5</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS
AND WARRANTIES OF PARENT, HOLDCO AND PURCHASER</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
Representations and Warranties of Parent, HoldCo and Purchaser</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parent, HoldCo and the Purchaser jointly and severally represent and warrant to the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Organization and Qualification</B>. Each of the Parent, HoldCo and the Purchaser is a corporation duly incorporated and validly
existing under the laws of the jurisdiction of its incorporation and has all necessary power and authority to own its property
and assets as now owned and to conduct its affairs as now conducted. Each of the Parent, HoldCo and the Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
    all Authorizations necessary to conduct its business substantially as now conducted, except where the failure to hold such
    Authorizations would not individually or in the aggregate be material to the Parent, HoldCo and Purchaser (taken as a whole);
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
    duly registered or otherwise authorized and qualified to do business and is in good standing in each jurisdiction in which
    the character of its properties, owned, leased, licensed or otherwise held or the nature of its activities makes such qualification
    necessary, except where the failure to be so qualified or in good standing would not have a Material Adverse Effect on the
    Parent, HoldCo and Purchaser (taken as a whole).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Authorized and Issued Capital</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    authorized capital stock of the Parent consists of 100,000,000 shares of Parent Common Stock and 20,000,000 shares of Parent
    Preferred Stock. As of the close of business on the date of this Agreement, 21,390,290 shares of Parent Common Stock were
    issued and outstanding and 3,275,407 shares of Parent Preferred Stock were issued and outstanding. The shares of the Parent
    Common Stock trade on the NASDAQ.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    authorized capital of HoldCo consists of an unlimited number of common shares in the capital of HoldCo. As of the close of
    business on the date of this Agreement, there is one (1) common share in the capital of HoldCo issued and outstanding. The
    authorized capital of the Purchaser consists of an unlimited number of Purchaser Shares. As of the close of business on the
    date of this Agreement, there is one (1) Purchaser Share issued and outstanding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 329; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Parent Capital Stock, common shares in the capital of HoldCo, and all Purchaser Shares have been duly authorized and validly
    issued, and are fully paid and non-assessable and have not been issued in violation of any pre-emptive rights or in violation
    of Applicable Laws.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of the Parent Capital Stock issuable upon the exercise of rights under the Parent Stock Incentive Plan, including outstanding
    Parent Options, have been duly authorized and, upon issuance in accordance with their respective terms, will be validly issued
    as fully paid and non-assessable and are not and will not be subject to or issued in violation of any pre-emptive rights.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of the Parent Capital Stock issuable upon the exercise of rights under the Parent Warrants have been duly authorized and,
    upon issuance in accordance with their respective terms, will be validly issued as fully paid and non-assessable and are not
    and will not be subject to, or issued in violation of, any pre-emptive rights. No Parent Warrants have been granted in violation
    of Applicable Laws.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    for rights under the Parent Stock Incentive Plan, there are no issued, outstanding or authorized options, equity-based awards,
    warrants, calls, conversion, pre-emptive, redemption, repurchase, stock appreciation or other rights, or any other agreements,
    arrangements, instruments or commitments of any kind that obligate the Parent, HoldCo the Purchaser or any of their respective
    Subsidiaries, as applicable, to, directly or indirectly, issue or sell any securities of the Parent, HoldCo the Purchaser
    or of any of their respective Subsidiaries, as applicable, or give any Person a right to subscribe for or acquire, any securities
    of the Parent, HoldCo the Purchaser or any of their respective Subsidiaries.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    authorized and unissued Parent Capital Stock is sufficient to consummate the Amalgamation and the other transactions contemplated
    by this Agreement and a sufficient number of shares of Parent Capital Stock have been reserved for issuance to the Company
    Shareholders, holders of Company Options and holders of Company Warrants in accordance with the terms of this Agreement, and
    when issued in accordance with the terms of this Agreement (or the Parent Options and Parent Warrants, as applicable), such
    Purchaser Shares will have been duly authorized and validly issued as fully paid and non-assessable and will not have been
    issued in violation of any pre-emptive rights or in violation of Applicable Laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Corporate Authorization</B>. Each of the Parent, HoldCo and the Purchaser has the requisite corporate power and authority to
enter into and perform its obligations under this Agreement and the Company Support Agreements (as applicable). The execution
and delivery of, and performance by, each of the Parent, HoldCo and the Purchaser of this Agreement and the Parent of the Company
Support Agreements and the consummation of the Amalgamation and the other transactions contemplated hereby have been, or will
at Closing be, duly authorized by all necessary corporate action on the part of each of the Parent HoldCo, and the Purchaser and,
subject to obtaining the Parent Stockholder Approval, no other corporate actions on the part of each of the Parent, HoldCo and
the Purchaser are necessary to authorize this Agreement or to consummate the Amalgamation and the other transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 330; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>HoldCo and Purchaser. </B>Each of HoldCo and the Purchaser was incorporated solely to effect the Amalgamation and neither of
them has carried on any business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Execution and Binding Obligation. </B>This Agreement and the Company Support Agreements has been duly executed and delivered
by each of the Parent, HoldCo and the Purchaser (as applicable), and constitutes a legal, valid and binding agreement of the Parent,
HoldCo and the Purchaser (as applicable), enforceable against it in accordance with its terms, except as enforceability may be
limited by the Bankruptcy and Equity Exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>No Conflict. </B>The execution and delivery of, and the performance by each of the Parent, HoldCo and the Purchaser of its
respective obligations under, this Agreement, and subject to the receipt of the Parent Stockholder Approval, the completion of
the transactions contemplated hereby, and the performance of their respective obligations hereunder and thereunder, do not and
will not (or would not with the giving of notice, the lapse of time or the happening of any other event or condition):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">constitute
    or result in a violation or breach of, or conflict with, any of the terms or provisions of their respective Organizational
    Documents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    as disclosed in <U>Section 5.1(f)</U> of the Parent Disclosure Statement, require any consent or other action by any Person
    under, constitute or result in a breach or violation of or conflict with, or, with or without notice or lapse of time or both,
    allow any Person to exercise any rights under any of the terms or provisions of any Material Contracts, licenses, leases or
    instruments to which the Parent, HoldCo, the Purchaser or any of their Subsidiaries is a party or pursuant to which any of
    their respective assets or properties may be affected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    as disclosed in <U>Section 5.1(f)</U> of the Parent Disclosure Statement, result in a breach of, or cause the termination
    or revocation of, any Authorization held by the Parent, HoldCo, the Purchaser or any of their respective Subsidiaries, or
    necessary to the ownership of the Parent Capital Stock or the Purchaser Shares, or the operation of the businesses of the
    Parent, HoldCo, the Purchaser or any of their respective Subsidiaries; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
    in the violation of any Applicable Law,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
as would not, individually or in the aggregate, be material to Parent and its Subsidiaries, including the Purchaser (taken as
a whole).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 331; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>U.S. Securities Matters and Financial Statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
    has filed with or furnished to the SEC on a timely basis true and complete copies of all forms, reports, schedules, statements
    and other documents required to be filed with or furnished to the SEC by Parent since the January 1, 2021 (all such documents,
    together with all exhibits and schedules to the foregoing materials and all information incorporated therein by reference,
    the &ldquo;<B>Parent SEC Documents</B>&rdquo;). As of their respective filing dates (or, if amended or superseded by a filing
    prior to the date of this Agreement, then on the date of such filing), the Parent SEC Documents complied in all material respects
    with the applicable requirements of the 1933 Act, the U.S. Exchange Act and the Sarbanes-Oxley Act, as the case may be, including,
    in each case, the rules and regulations promulgated thereunder, and none of the Parent SEC Documents at the time they were
    filed (or, if amended or superseded by a subsequent filing prior to the date of this Agreement, as of the date of the last
    such amendment or superseding filing) contained any untrue statement of a material fact or omitted to state a material fact
    required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
    they were made, not misleading.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent
    SEC Documents (A) have been prepared in a manner consistent with the books and records of Parent and its Subsidiaries, (B)
    have been prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form 10-Q of the
    SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), (C) comply
    as to form in all material respects with applicable accounting requirements and the published rules and regulations of the
    SEC with respect thereto and (D) fairly present in all material respects the consolidated financial position of Parent and
    its Subsidiaries as of the dates thereof and their respective consolidated results of operations and cash flows for the periods
    then ended (except as may be indicated in the notes thereto and subject, in the case of unaudited statements, to normal and
    recurring year-end adjustments), all in accordance with GAAP and the applicable rules and regulations promulgated by the SEC.
    Since January 1, 2021, Parent has not made any change in the accounting practices or policies applied in the preparation of
    its financial statements, except as required by GAAP, SEC rule or policy or Applicable Law. The books and records of Parent
    and its Subsidiaries have been maintained in all material respects in accordance with GAAP (to the extent applicable) and
    any other applicable legal and accounting requirements and reflect only actual transactions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Parent has established and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under
    the U.S. Exchange Act). Such disclosure controls and procedures are designed to ensure that information relating to Parent,
    including its consolidated Subsidiaries, required to be disclosed in Parent&rsquo;s periodic and current reports under the
    U.S. Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the rules and forms
    of the SEC, and is made known to Parent&rsquo;s chief executive officer and its chief financial officer by others within those
    entities to allow timely decisions regarding required disclosures as required under the U.S. Exchange Act. The chief executive
    officer and chief financial officer of Parent have evaluated the effectiveness of Parent&rsquo;s disclosure controls and procedures
    and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K
    or Form 10-Q, or any amendment thereto, its conclusions about the effectiveness of the disclosure controls and procedures
    as of the end of the period covered by such report or amendment based on such evaluation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 332; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
    and its Subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rules
    13a-15(f) and 15d-15(f) under the U.S. Exchange Act) which is sufficient to provide reasonable assurance regarding the reliability
    of Parent&rsquo;s financial reporting and the preparation of Parent&rsquo;s financial statements for external purposes in
    accordance with U.S. GAAP including policies and procedures that: (A) require the maintenance of records that in reasonable
    detail accurately and fairly reflect the transactions and dispositions of the assets of Parent and its Subsidiaries; (B) provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
    with U.S. GAAP and that receipts and expenditures of Parent and its Subsidiaries are being made only in accordance with appropriate
    authorizations of the Parent&rsquo;s management and the Parent Board; and (C) provide reasonable assurance regarding prevention
    or timely detection of unauthorized acquisition, use, or disposition of the assets of Parent and its Subsidiaries that would
    materially affect Parent&rsquo;s financial statements. Parent has disclosed, based on its most recent evaluation of Parent&rsquo;s
    internal control over financial reporting prior to the date hereof, to Parent&rsquo;s auditors and audit committee (I) any
    significant deficiencies and material weaknesses in the design or operation of Parent&rsquo;s internal control over financial
    reporting which are reasonably likely to adversely affect Parent&rsquo;s ability to record, process, summarize and report
    financial information and (II) any fraud, whether or not material, that involves management or other employees who have a
    significant role in the preparation of Parent&rsquo;s financial statements or Parent&rsquo;s internal control over financial
    reporting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
    January 1, 2021, (i) neither Parent nor any of its Subsidiaries nor, to the knowledge of Parent, any director, officer, employee,
    auditor, accountant or representative of Parent or any of its Subsidiaries has received or otherwise had or obtained knowledge
    of any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices,
    procedures, methodologies or methods of Parent or any of its Subsidiaries or their respective internal accounting controls,
    including any material complaint, allegation, assertion or claim that Parent or any of its Subsidiaries has engaged in questionable
    accounting or auditing practices and (ii) no attorney representing Parent or any of its Subsidiaries, whether or not employed
    by Parent or any of its Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary
    duty or similar violation by Parent or any of its Subsidiaries or any of their respective officers, directors, employees or
    agents to the Parent Board or any committee thereof or to any director or officer of Parent or any of its Subsidiaries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 333; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the Execution Date, there are no outstanding or unresolved comments in the comment letters received from the SEC staff
    with respect to the Parent SEC Documents. None of the Parent SEC Documents is subject to ongoing review or outstanding SEC
    comment or investigation. Parent has made available to the Company true, correct and complete copies of all written correspondence
    between the SEC, on the one hand, and Parent and any of its Subsidiaries, on the other hand, occurring since January 1, 2021
    through the date of this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
    Parent nor any of its Subsidiaries is a party to, or has any commitment to become a party to, any joint venture, off-balance
    sheet partnership or any similar Contract (including any Contract or arrangement relating to any transaction or relationship
    between or among Parent and any of its Subsidiaries, on the one hand, and any unconsolidated Affiliate, including any structured
    finance, special purpose or limited purpose entity or Person, on the other hand, or any &ldquo;off balance sheet arrangements&rdquo;
    (as defined in Item 303(a) of Regulation S-K under the U.S. Exchange Act)).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent
    is in compliance in all material respects with (i) the provisions of the Sarbanes-Oxley Act and (ii) the rules and regulations
    of NASDAQ, in each case, that are applicable to Parent.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Subsidiary of Parent is required to file any form, report, schedule, statement or other document with the SEC.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<B>Compliance with Laws</B>. Each of the Parent, HoldCo, the Purchaser and their respective Subsidiaries are, and since January
1, 2021, has been, in compliance in all material respects with Applicable Laws. Since January 1, 2021, neither the Parent, HoldCo,
the Purchaser nor any of its or their respective Subsidiaries is or has been under any investigation with respect to, is or has
been charged or threatened to be charged with, or has received notice of, any violation or potential violation of any Applicable
Law or disqualification by a Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B>Governmental Authorization.</B> The execution, delivery and performance by each of the Parent, HoldCo and the Purchaser of
their respective obligations under this Agreement and the consummation by the Parent, HoldCo and the Purchaser of the Amalgamation
and the other transactions contemplated hereby do not require any Authorization or other action by or in respect of, or filing
with or notification to, any Governmental Authority by the Parent, HoldCo, the Purchaser or any of their Subsidiaries other than
filings with the Securities Authorities and NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<B>Shareholders&rsquo; and Similar Agreements.</B> Except as disclosed in <U>Section 5.1(j)</U> of the Parent Disclosure Statement
and in the Parent SEC Documents, neither the Parent, HoldCo nor the Purchaser is subject to, or affected by, any unanimous shareholders
agreement and is not a party to any shareholder, pooling, voting, or other similar arrangement or agreement relating to the ownership
or voting of the securities of the Parent, HoldCo, the Purchaser or of any of their respective Subsidiaries or pursuant to which
any Person may have any right or claim in connection with any existing or past equity interest in the Parent, HoldCo, the Purchaser
or in any of their respective Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 334; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<B>Subsidiaries and Affiliates.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    than the Purchaser, HoldCo and those Subsidiaries and other Affiliates disclosed in the Parent SEC Documents (the &ldquo;<B>Parent
    Subsidiaries</B>&rdquo;), the Parent has no Subsidiaries or other Affiliates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Parent Subsidiary is a corporation, partnership, trust, limited liability company or limited partnership, as the case may
    be, duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, organization
    or formation, as the case may be, and has all requisite corporate, trust, limited liability company or partnership power and
    authority, as the case may be, to own, lease and operate its properties and assets and to carry on its business as now being
    conducted, except where the failure to be so organized, validly existing, qualified or in good standing, or to have such power
    or authority, would not, individually or in the aggregate, reasonably be expected to be material to the Parent.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Parent is, directly or indirectly, the registered and beneficial owner of all of the outstanding common shares or other equity
    interests of each Parent Subsidiary, free and clear of any Liens. All such common shares or other equity interests so owned
    by the Parent have been validly issued and are fully paid and non-assessable, as the case may be, and no such shares or other
    equity interests have been issued in violation of any pre-emptive or similar rights or in violation of Applicable Laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<B>Auditors.</B> The audited Parent Financial Statements have been audited by a Marcum LLP registered accounting firm in accordance
with U.S. GAAP as required by applicable Securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<B>No Undisclosed Liabilities.</B> Except disclosed in <U>Section 5.1(m)</U> of the Parent Disclosure Statement, none of the Parent,
HoldCo, the Purchaser or any of their respective Subsidiaries have any Liability, whether accrued, absolute, contingent or otherwise,
not reflected in the Parent Financial Statements, except Liabilities (i) incurred in connection with this Agreement or the Transaction,
(ii) incurred since December 31, 2020, in the Ordinary Course consistent with past practices or (iii) that would not be, individually
or in the aggregate, material to the Parent. An itemized list setting forth the principal amount of all indebtedness for borrowed
money of the Parent, HoldCo, the Purchaser and any of their respective Subsidiaries (and all accrued interest thereon) as of the
Execution Date, including capital leases, is disclosed in <U>Section 5.1(m)</U> of the Parent Disclosure Statement or the Parent
SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<B>Absence of Certain Changes or Events.</B> Since December 31, 2020, other than the transactions contemplated in this Agreement
and as disclosed in <U>Section 5.1(n)</U> of the Parent Disclosure Statement or the Parent SEC Documents, the business of the
Parent, HoldCo, the Purchaser and their respective Subsidiaries has been conducted in the Ordinary Course and there has not been
any event, circumstance or occurrence which has had or would be reasonably expected to be, individually or in the aggregate, material
to the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 335; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<B>Ordinary Course.</B> Since December 31, 2020, other than the transactions contemplated in this Agreement or as disclosed in
<U>Section 5.1(o)</U> of the Parent Disclosure Statement or the Parent SEC Documents:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent, HoldCo, the Purchaser and their respective Subsidiaries have conducted their respective businesses only in the Ordinary
    Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    liability or obligation of any nature (whether absolute, accrued, contingent or otherwise), which has been, or is reasonably
    likely to be material to the Parent, has been incurred by the Parent, HoldCo, the Purchaser or their respective Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been any change in the accounting practices used by the Parent, HoldCo, the Purchaser or their respective Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    for Ordinary Course adjustments to employee compensation (other than directors or officers), there has not been any increase
    in the salary, bonus, or other remuneration payable to any employees of any of the Parent, HoldCo, the Purchaser or their
    respective Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been any redemption, repurchase or other acquisition of Parent Common Stock by the Parent, or any declaration, setting
    aside or payment of any dividend or other distribution (whether in cash or otherwise) with respect to the Parent Common Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been a material change in the level of accounts receivable or payable, inventories or employees of the Parent, HoldCo,
    the Purchaser or their respective Subsidiaries, other than those changes in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    the Parent nor any Parent Subsidiary has entered into, or amended, any Material Contract other than in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has not been any satisfaction or settlement of any material claims or material liabilities of the Parent, HoldCo, the Purchaser
    or their respective Subsidiaries that were not reflected in the Parent Financial Statements, other than the settlement of
    claims or liabilities incurred in the Ordinary Course; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    for Ordinary Course adjustments, there has not been any increase in the salary, bonus, or other remuneration payable to any
    officers or directors of the Parent, HoldCo, the Purchaser or their respective Subsidiaries or, any amendment or modification
    to the vesting or exercisability schedule or criteria, including any acceleration, right to accelerate or acceleration event
    or other entitlement under any stock option, restricted stock, deferred compensation or other compensation award of any officer
    of the Parent or any Parent Subsidiary.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 336; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<B>Related Party Transactions.</B> Except as disclosed in <U>Section 5.1(p)</U> of the Parent Disclosure Statement or the Parent
SEC Documents, neither the Parent nor any Parent Subsidiary is indebted to any director, officer, employee or agent of, or independent
contractor to, the Parent or any Parent Subsidiary (except for amounts due in the Ordinary Course as salaries, bonuses and director&rsquo;s
fees or the reimbursement of Ordinary Course expenses). Except as disclosed in <U>Section 5.1(p)</U> of the Parent Disclosure
Statement or the Parent SEC Documents, there are no Contracts (other than employment arrangements) with, or advances, loans, guarantees,
liabilities or other obligations to, on behalf or for the benefit of, any shareholder, officer or director of the Parent or any
Parent Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<B>Authorizations and Licenses.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Parent, HoldCo, the Purchaser and their respective Subsidiaries own, possess or have obtained all Authorizations that are
    required by Applicable Laws in connection with the operation of the business of the Parent, HoldCo, the Purchaser and their
    respective Subsidiaries as presently or previously conducted, or in connection with the ownership, operation or use of the
    assets of the Parent, HoldCo, the Purchaser and their respective Subsidiaries.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Parent, HoldCo, the Purchaser and their respective Subsidiaries lawfully hold, own or use, and have complied with, all such
    Authorizations. Each Authorization is valid and in full force and effect, and is renewable by its terms or in the Ordinary
    Course.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Proceeding is pending in respect of or regarding any such Authorization and neither the Parent, HoldCo, the Purchaser, their
    respective Subsidiaries nor, to the knowledge of the Parent, any of their respective officers or directors has received written
    notice of revocation, non-renewal or material amendments of any such Authorization, or written notice of the intention of
    any Person to revoke, refuse to renew or materially amend any such Authorization.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<B>Finders&rsquo; Fees.</B> Except <U>Section 5.1(r)</U> of the Parent Disclosure Statement, no investment banker, broker, finder,
financial adviser or other intermediary has been retained by or is authorized to act on behalf of the Parent or any of its Subsidiaries,
or any of their respective officers, directors or employees, or is entitled to any fee, commission or other payment from the Parent
or any of its Subsidiaries, or any of their respective officers, directors or employees, in connection with the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<B>Parent Board Approval</B>. The Parent Board, after consultation with its financial and legal advisors, has (i) determined that
the Amalgamation, this Agreement the issuance of the Consideration Shares are fair to the Parent Stockholders and in the best
interests of the Parent, HoldCo, the Purchaser, their respective Subsidiaries and the Parent Stockholders; (ii) resolved to recommend
that the Parent Stockholders vote in favor of the Parent Stockholder Approval Resolution; and (iii) authorized the entering into
of this Agreement and the performance by the Parent of its obligations under this Agreement, and no action has been taken to amend,
or supersede such determinations, resolutions, or authorizations (the &ldquo;<B>Parent Board Approval</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 337; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<B>Material Contracts.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
    5.1(t)</U> of the Parent Disclosure Statement and the Parent SEC Documents set out a complete and accurate list of all Material
    Contracts of the Parent, HoldCo, the Purchaser and their respective Subsidiaries. True and complete copies of the Material
    Contracts of the Parent, HoldCo, the Purchaser and their respective Subsidiaries have been Made Available to the Company and
    no such Contract has been modified, rescinded or terminated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Material Contract is legal, valid, binding and in full force and effect and is enforceable by the Parent, HoldCo, the Purchaser
    or their respective Subsidiaries, as applicable, in accordance with its terms (subject to the Bankruptcy and Equity Exceptions).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of the Parent, HoldCo, the Purchaser and their respective Subsidiaries has performed in all material respects all respective
    obligations required to be performed by them to date under the Material Contracts and neither the Parent, HoldCo, Purchaser
    nor any of their respective Subsidiaries is in breach or default under any Material Contract, nor does the Parent have knowledge
    of any condition that, with the passage of time or the giving of notice or both, would result in such a breach or default.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
    of the Parent, HoldCo, the Purchaser or any of their respective Subsidiaries has received any written notice, that any party
    to a Material Contract intends to cancel, terminate or otherwise modify or not renew its relationship with the Parent, HoldCo,
    the Purchaser or any of their respective Subsidiaries, as applicable, and, to the knowledge of the Parent, no such action
    has been threatened.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<B>Real Property.</B> Except as disclosed in <U>Section 5.1(w)</U> of the Parent Disclosure Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable, have valid, good and marketable title to all
    of the real or immovable property owned by the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable
    (the &ldquo;<B>Parent Owned Properties</B>&rdquo;), free and clear of any Liens, except for Permitted Liens, and there are
    no outstanding options or rights of first refusal to purchase the Parent Owned Properties, or any portion thereof or interest
    therein;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 338; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    lease, sublease, license or occupancy agreement (in each case, together with any amendments, supplements, notices and ancillary
    agreements thereto) for real or immovable property leased, subleased, licensed or occupied by the Parent, HoldCo, the Purchaser
    or their respective Subsidiaries, as applicable (the &ldquo;<B>Parent Leased Properties</B>&rdquo;), is valid, legally binding
    and enforceable against the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable, in accordance with
    its terms and in full force and effect, true and complete copies of which (including all related amendments, supplements,
    notices and ancillary agreements) have been Made Available to the Company, and none of the Parent, HoldCo, the Purchaser or
    their respective Subsidiaries, as applicable, is in breach of, or default under, such lease, sublease, license or occupancy
    agreement, and, to the knowledge of the Parent, no event has occurred which, with notice, lapse of time or both, would constitute
    such a breach or default the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable, or permit termination,
    modification or acceleration by any third party thereunder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    third party has repudiated or has the right to terminate or repudiate any such lease, sublease, license or occupancy agreement
    (except for the normal exercise of remedies in connection with a default thereunder or any termination rights set forth in
    the lease, sublease, license or occupancy agreement) or any provision thereof; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the leases, subleases, licenses or occupancy agreements has been assigned by the Parent, HoldCo, the Purchaser or their
    respective Subsidiaries, as applicable, in favor of any Person or sublet or sublicensed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<B>Personal Property; Condition of Personal Property.</B> The Parent, HoldCo, the Purchaser or their respective Subsidiaries,
as applicable, have good title to all material personal or movable property of any kind or nature which the Parent, HoldCo, the
Purchaser or their respective Subsidiaries, as applicable, purport to own, free and clear of all Liens (other than Permitted Liens).
The Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable, as lessee, have the right under valid and subsisting
leases to use, possess and control all personal or movable property leased by, and material to, the Parent, HoldCo, the Purchaser
or their respective Subsidiaries, as applicable, as used, possessed and controlled by the Parent, HoldCo, the Purchaser or their
respective Subsidiaries, as applicable. All real and tangible personal property of the Parent, HoldCo, the Purchaser or their
respective Subsidiaries is in generally good repair and is operational and usable in the manner in which it is currently being
utilized, subject to normal wear and tear and technical obsolescence, repair or replacement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<B>Intellectual Property.</B> Except as would not and would not be reasonably expected to have, individually or in the aggregate,
a Material Adverse Effect with respect to the Parent: (i) the Parent, HoldCo, the Purchaser or their respective Subsidiaries,
as applicable, own all right, title and interest, or have valid licenses (and are not in material breach of such licenses), in
and to all Intellectual Property that is material to the conduct of the business, as presently conducted, of the Parent, HoldCo,
the Purchaser or their respective Subsidiaries, as applicable (collectively, the &ldquo;<B>Parent Intellectual Property Rights</B>&rdquo;);
(ii) all such Parent Intellectual Property Rights that are owned by or licensed to the Parent, HoldCo, the Purchaser or their
respective Subsidiaries, as applicable, are sufficient, in all material respects, for conducting the business, as presently conducted,
of the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable; (iii) to the knowledge of the Parent, all
Parent Intellectual Property Rights owned or leased by the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as
applicable, are valid and enforceable, and, to the knowledge of the Parent, the carrying on of the business of the Parent, HoldCo,
the Purchaser or their respective Subsidiaries, as applicable, and the use by the Parent, HoldCo, the Purchaser or their respective
Subsidiaries, as applicable, of any of the Parent Intellectual Property Rights or Parent Technology (as defined below) owned by
or licensed to the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable, does not breach, violate, infringe
or interfere with any rights of any other Person; (iv) to the knowledge of the Parent, no third party is infringing upon the Parent
Intellectual Property Rights owned or licensed by the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable,
and no Proceeding is currently pending or threatened with respect to the foregoing;; (v) all computer hardware and associated
firmware and operating systems, application software, database engines and processed data, technology infrastructure and other
computer systems used in connection with the conduct of the business, as presently conducted, of the Parent, HoldCo, the Purchaser
or their respective Subsidiaries, as applicable (collectively, the &ldquo;<B>Parent Technology</B>&rdquo;), are sufficient, in
all material respects, for conducting the business, as presently conducted, of the Parent, HoldCo, the Purchaser or their respective
Subsidiaries, as applicable; and (vi) the Parent, HoldCo, the Purchaser or their respective Subsidiaries, as applicable own, or
have validly licensed or leased (and are not in material breach of such licenses or leases), such Parent Technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 339; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<B>Restrictions on Conduct of Business.</B> Neither the Parent, HoldCo, the Purchaser nor any of their respective Subsidiaries
is a party to or bound by any non-competition agreement, any non-solicitation agreement, or any other agreement, obligation, judgment,
injunction, order or decree which purports to: (i) limit in any material respect the manner or the localities in which all or
any portion of the business of the Parent, HoldCo, the Purchaser or their respective Subsidiaries are conducted; (ii) limit any
business practice of the Parent, HoldCo, the Purchaser or their respective Subsidiaries in any material respect; or (iii) restrict
any acquisition or disposition of any property by the Parent, HoldCo, the Purchaser or their respective Subsidiaries in any material
respect. Neither the Parent, HoldCo, the Purchaser nor any of their respective Subsidiaries or any of their respective properties
or assets is subject to any outstanding judgment, order, writ, injunction or decree that would have or would be reasonably expected
to have, individually or in the aggregate, a Material Adverse Effect with respect to the Parent, or that would or would be reasonably
expected to prevent or delay the consummation of the Amalgamation or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<B>Litigation.</B> Except as set out in <U>Section 5.1(aa)</U> of the Parent Disclosure Statement or in the Parent SEC Documents,
there are no Proceedings pending, or, to the knowledge of the Parent threatened, against or relating to the Parent, HoldCo, the
Purchaser or their respective Subsidiaries, the business of the Parent, HoldCo, the Purchaser or their respective Subsidiaries
or affecting any of their respective current or former properties or assets by or before any Governmental Authority that, if determined
adverse to the interests of the Parent, HoldCo, the Purchaser or their respective Subsidiaries, could potentially result in criminal
sanction, or would be reasonably expected to prevent or delay the consummation of the Amalgamation or the transactions contemplated
hereby, or would, or would be reasonably expected to, materially affect the Parent&rsquo;s ability to own or operate the business
of the Parent, HoldCo, the Purchaser or their respective Subsidiaries, nor, to the knowledge of the Parent, are there any events
or circumstances which could reasonably be expected to give rise to any such Proceeding. There is no bankruptcy, liquidation,
winding-up or other similar Proceeding pending or in progress, or, to the knowledge of the Parent, threatened against or relating
to the Parent, HoldCo, the Purchaser or their respective Subsidiaries before any Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<B>Corrupt Practices Legislation.</B> Neither the Parent, HoldCo, the Purchaser, their respective Subsidiaries nor any of their
respective officers, directors or employees acting on behalf of any of them, has taken, committed to take or been alleged to have
taken any action which would cause the Parent or any of its Subsidiaries to be in violation of 18 U.S. Code &sect;201, the Foreign
Corrupt Practices Act, or any other applicable anti-bribery, anti-money laundering, anti-bribery or anti-corruption laws or any
law of similar or any law of similar effect of any other jurisdiction, and to the knowledge of the Parent, no such action has
been taken by any of its agents, representatives or other Persons acting on behalf of the Parent, HoldCo, the Purchaser or their
respective Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 340; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<B>Taxes. </B>The Parent, HoldCo, the Purchaser and their respective Subsidiaries have Made Available to the Company true, correct
and complete copies of all Tax Returns, examination reports and statements of deficiencies for taxable periods, or transactions
consummated, for which the applicable statutory periods of limitations have not expired. Except as disclosed on <U>Section 5.1(dd)
</U>of the Parent Disclosure Statement or the Parent SEC Documents:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent, HoldCo, the Purchaser and their respective Subsidiaries have duly and timely filed all Tax Returns required to be
    filed by them prior to the Execution Date and all such Tax Returns are complete and correct in all material respects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent, HoldCo, the Purchaser and their respective Subsidiaries have paid on a timely basis all Taxes which are due and payable,
    all assessments and reassessments, and all other Taxes due and payable by them on or before the Execution Date, other than
    those which are being or have been contested in good faith and in respect of which reserves have been provided in the Parent
    Financial Statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent, HoldCo, the Purchaser and their respective Subsidiaries have provided adequate accruals in accordance with U.S. GAAP
    in the Parent Financial Statements for any Taxes of the Parent, HoldCo, the Purchaser and their respective Subsidiaries for
    the period covered by such financial statements that have not been paid whether or not shown as being due on any Tax Returns;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">since
    December 31, 2020, no material liability in respect of Taxes not reflected in such statements or otherwise provided for has
    been assessed, proposed to be assessed, incurred or accrued by the Parent, HoldCo, the Purchaser and their respective Subsidiaries,
    other than in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser and their respective Subsidiaries has received a Tax refund to which it was not entitled;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    material deficiencies, litigation, proposed adjustments or matters in controversy exist or have been asserted with respect
    to Taxes of the Parent, HoldCo, the Purchaser or their respective Subsidiaries, and neither the Parent, HoldCo, the Purchaser
    nor their respective Subsidiaries are a party to any Proceeding for assessment or collection of Taxes and no such event has
    been asserted or, to the knowledge of the Parent, threatened against the Parent, HoldCo, the Purchaser or their respective
    Subsidiaries or any of their respective assets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    claim has been made by any Government Authority in a jurisdiction where the Parent, HoldCo, the Purchaser and their respective
    Subsidiaries do not file Tax Returns that the Parent, HoldCo, the Purchaser or their respective Subsidiaries are or may be
    subject to Tax by that jurisdiction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 341; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    are no Liens (other than Permitted Liens) with respect to Taxes upon any of the assets of the Parent, HoldCo, the Purchaser
    or their respective Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent, HoldCo, the Purchaser and their respective Subsidiaries have withheld or collected all amounts required to be withheld
    or collected by it on account of Taxes and has remitted all such amounts to the appropriate Governmental Authority when required
    by Applicable Law to do so;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    are no outstanding agreements extending or waiving the statutory period of limitations applicable to any claim for, or the
    period for the collection or assessment or reassessment of Taxes due from the Parent, HoldCo, the Purchaser or their respective
    Subsidiaries for any taxable period and no request for any such waiver or extension is currently pending;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    closing agreements, private letter rulings, technical advice memoranda or similar agreements or rulings have been entered
    into by the Parent, HoldCo, the Purchaser or their respective Subsidiaries with any taxing authority or issued by any taxing
    authority to the Parent, HoldCo, the Purchaser or their respective Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    are no outstanding rulings of, or request for rulings with, any Governmental Authority addressed to the Parent, HoldCo, the
    Purchaser or their respective Subsidiaries that are, or if issued would be, binding on the Parent, HoldCo, the Purchaser or
    their respective Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser or their respective Subsidiaries is a party to any Contract with any third party relating
    to allocating or sharing the payment of, or liability for, Taxes or Tax benefits (other than pursuant to customary provisions
    included in credit agreements, leases, and agreements entered with employees, in each case, not primarily related to Taxes
    and entered into in the Ordinary Course);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser or their respective Subsidiaries has any liability for the Taxes of any third party under
    Section 1.1502-6 of the Treasury Regulations (or any similar provision under Applicable Laws) as a transferee or successor
    or otherwise by operation of Applicable Laws;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser or their respective Subsidiaries have participated in any &ldquo;listed transaction&rdquo;
    within the meaning of Section 1.6011-4 of the Treasury Regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent has disclosed on its respective United States federal income Tax Returns all positions taken therein that could give
    rise to a substantial understatement of United States federal income Tax within the meaning of Section 6662 of the Code;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 342; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser or their respective Subsidiaries are (and have not been for the five-year period ending
    at the Effective Time) a &ldquo;United States real property holding corporation&rdquo; as defined in Section 897(c)(2) of
    the Code and the applicable Treasury Regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser or their respective Subsidiaries have distributed stock of another Person, or have had
    its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part
    by Sections 355 or 361 of the Code;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser or their respective Subsidiaries has taken or agreed to take any action that would prevent
    the Amalgamation Transactions from constituting a reorganization qualifying under Section 368 of the Code; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none
    of the Parent, HoldCo, the Purchaser or their respective Subsidiaries is aware of any agreement, plan or other circumstance
    that would prevent the Amalgamation Transactions from qualifying as a reorganization under Section 368 of the Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<B>Insurance</B>. A true and complete list of all material insurance policies currently in effect that insure the physical properties,
business, operations and assets of the Parent, HoldCo, the Purchaser and their respective Subsidiaries has been Made Available
to the Company. To the knowledge of the Parent, each material insurance policy currently in effect that insures the physical properties,
business, operations and assets of the Parent, HoldCo, the Purchaser and their respective Subsidiaries is valid and binding and
in full force and effect and there is no material claim pending under any such policies as to which coverage has been questioned,
denied or disputed by any insurer or as to which any insurer has made any reservation of rights or refused to cover all or any
material portion of such claims. All material proceedings covered by any insurance policy of the Parent or its Subsidiaries have
been properly reported to and accepted by the applicable insurer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<B>Disclosure.</B> The information relating to the Parent, HoldCo, the Purchaser or their respective Subsidiaries to be supplied
by or on behalf of the Parent for inclusion or incorporation by reference in the S-4 Registration Statement and the Proxy Statement/Prospectus
will not, on the date the its filed with the SEC or the date it is first mailed to the Parent Stockholders, as applicable, or
at the time of the Parent Meeting, contain any untrue statement of any material fact, or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are
made, not false or misleading at the time and in light of the circumstances under which such statement is made. The S-4 Registration
Statement and the Proxy Statement/Prospectus will comply in all material respects as to form with the requirements of the U.S.
Exchange Act and the rules and regulations thereunder. Notwithstanding the foregoing, no representation is made by the Parent
or the Purchaser with respect to the information that has been or will be supplied by the Company or any of it Representatives
for inclusion in the S-4 Registration Statement and the Proxy Statement/Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 343; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
No Survival of Representations and Warranties</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations and warranties of the Company in this Agreement (including any representations and warranties incorporated herein
by reference) or in any other Transaction Document shall not survive the Closing. Parent represents, warrants, acknowledges and
agrees that other than as expressly set forth in Article 4 of this Agreement, none of the Company, its Subsidiaries, any of its
Affiliates or stockholders or any of its Representatives makes or has made any representation or warranty, either express or implied,
as to the accuracy or completeness of any information provided or Made Available to the Purchaser or any of its Subsidiaries,
Affiliates or stockholders or any of their respective Representatives (collectively, &ldquo;<B>Parent Related Persons</B>&rdquo;)
or any other person in connection with this Agreement, the Amalgamation, the Transaction or any of the other transactions or with
respect to any projections, forecasts, estimates, plans or budgets of future revenues, expenses or expenditures, future results
of operations, future cash flows or future financial condition, or any component of the foregoing, or any other forward looking
information, of the Company, its Subsidiaries or any of its Affiliates, and no Parent Related Person has relied on any information
or statements made or provided (or not made or provided) to any Parent Related Person other than the representations and warranties
of the Company expressly set forth in Article 4 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
ADDITIONAL COVENANTS REGARDING NON-SOLICITATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
Non-Solicitation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as expressly provided in this <U>Article 6</U>, the Company, the Parent and their respective Subsidiaries shall not, directly
or indirectly, through any officer, director, employee, representative (including any financial or other adviser) or other agent
of the Company, the Parent and their respective Subsidiaries (collectively &ldquo;<B>Representatives</B>&rdquo;), or otherwise,
and shall not permit any such Person to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solicit,
    assist, initiate, encourage or otherwise knowingly facilitate (including by way of furnishing or providing copies of, access
    to, or disclosure of, any confidential information, properties, facilities, books or records of the Company, the Parent and
    their respective Subsidiaries or entering into any form of agreement, arrangement or understanding) any inquiry, proposal
    or offer that constitutes or may reasonably be expected to constitute or lead to, an Acquisition Proposal for the Company
    or the Parent;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into or otherwise engage or participate in any discussions or negotiations with any Person (other than the Parties) regarding
    any inquiry, proposal or offer that constitutes or may reasonably be expected to constitute or lead to, an Acquisition Proposal
    for the Company or the Parent, provided that, for greater certainty, the Company or the Parent, as applicable, may advise
    any Person making an unsolicited Acquisition Proposal that such Acquisition Proposal does not constitute a Superior Proposal
    when the Company Board or the Parent Board, as applicable, has so determined;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    a Company Change in Recommendation or Parent Change in Recommendation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accept,
    approve, endorse or recommend, or publicly propose to accept, approve, endorse or recommend, or take no position or remain
    neutral with respect to, any Acquisition Proposal for the Company or Parent; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 344; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accept
    or enter into or publicly propose to accept or enter into any agreement, understanding or arrangement in respect of an Acquisition
    Proposal for the Company or Parent,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
however, that nothing contained in this Section 6.1(a) or any other provision of this Agreement shall prevent the Company Board
or the Parent Board, as the case may be, from engaging in discussions or negotiations with, or responding to enquiries from any
Person that has made an unsolicited written Acquisition Proposal that the Company Board or the Parent Board, as the case may be,
has determined constitutes a Superior Proposal, or providing information pursuant to Section 6.1(d) to any Person where the requirements
of that section are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company and Parent shall, and shall cause their Subsidiaries and Representatives to, immediately cease and terminate, and
cause to be terminated, any solicitation, encouragement, discussion, negotiations, or other activities commenced prior to the
date of this Agreement with any Person (other than the Parties) with respect to any inquiry, proposal or offer that constitutes,
or may reasonably be expected to constitute or lead to, an Acquisition Proposal for the Company or the Parent, and in connection
therewith the Company and the Parent shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
    discontinue access to and disclosure of all information, including any data room, and any confidential information, properties,
    facilities, books and records of the Company, the Parent or any of their respective Subsidiaries; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promptly
    request, and exercise all rights either has to require: (i) the return or destruction of all copies of any confidential information
    regarding the Company, the Parent and their respective Subsidiaries provided to any Person other than the Parent and the Purchaser,
    and (ii) the destruction of all material including or incorporating or otherwise reflecting such confidential information
    regarding the Company, the Parent and their respective Subsidiaries, using their commercially reasonable efforts to ensure
    that such requests are fully complied with in accordance with the terms of such rights or entitlements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company and the Parent represent and warrant that, since January 1, 2021, neither the Company nor the Parent has waived any
confidentiality, standstill, non-disclosure, non-solicitation, use, business purpose or similar agreement, restriction or covenant
to which the Company, the Parent, or any of their respective Subsidiaries is a party, and further covenant and agree that (i)
the Company and the Parent shall take all necessary action to enforce each confidentiality, standstill, non-disclosure, non-solicitation,
use, business purpose or similar agreement, restriction or covenant to which they or any of their respective Subsidiaries is a
party, and (ii) neither the Company, the Parent nor any of their respective Subsidiaries, nor any of their respective Representatives
have or will, without the prior written consent of the Parties (which may be withheld or delayed in the Parties sole and absolute
discretion), release any Person from, or waive, amend, suspend or otherwise modify such Person&rsquo;s obligations respecting
the Company, the Parent, or any of their respective Subsidiaries under any confidentiality, standstill, non-disclosure, non-solicitation,
use, business purpose or similar agreement, restriction or covenant to which the Company, the Parent, or any of their respective
Subsidiaries is a party (it being acknowledged by the Parties that the automatic termination or release of any standstill restrictions
of any such agreement as the result of entering into of this Agreement will not constitute a breach of this <U>Section 6.1(c)</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 345; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If the Company or the Parent (as applicable, the &ldquo;<B>Receiving Party</B>&rdquo;) receives a request for material non-public
information from a Person who proposes to the Receiving Party an unsolicited bona fide written Acquisition Proposal and the board
of directors of the Receiving Party determines, in good faith, that such Acquisition Proposal constitutes a Superior Proposal,
then the Receiving Party may consider such Acquisition Proposal and/or participate and/or engage in discussions and negotiations
with the Person making the Acquisition Proposal and its Representatives and potential financing sources and provide such Persons
with access to information regarding the Receiving Party, subject to the execution of a confidentiality and standstill agreement
which is customary in such situations and which, in any event and taken as a whole, is no less favorable to Receiving Party than
the Confidentiality Agreement; provided that the Receiving Party sends a copy of any such confidentiality and standstill agreement
to the Parent or the Company, as applicable, not later than the next Business Day following its execution and such other Party
(as applicable, the &ldquo;<B>Responding Party</B>&rdquo;) is provided with the terms and conditions of the Superior Proposal,
and a list of, and, at the request of the Responding Party, copies of, the information provided to such Person and immediately
provided with access to similar information to which such Person was provided. For greater certainty, notwithstanding any other
provision of this Agreement, if a Person proposes to a Receiving Party an unsolicited bona fide written Acquisition Proposal,
the Receiving Party may (directly or through its advisors or Representatives) contact the Person proposing such Acquisition Proposal
and its Representatives to clarify the terms and conditions of such Acquisition Proposal so as to determine whether such proposal
is, or would reasonably be expected to lead to, a Superior Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Receiving Party agrees that it will not accept, approve or enter into any agreement, other than a confidentiality and standstill
agreement as contemplated by Section 6.1(d), with any Person providing for or to facilitate any Acquisition Proposal unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    board of directors of the Receiving Party determines that the Acquisition Proposal constitutes a Superior Proposal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of the Company, the Company Meeting has not occurred;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of the Parent, the Parent Meeting has not occurred;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Receiving Party has provided the Responding Party with a notice in writing that there is a Superior Proposal together with
    all documentation related to and detailing the Superior Proposal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ten
    Business Days (the &ldquo;<B>Matching Period</B>&rdquo;) shall have elapsed from the date the Responding Party received the
    notice and documentation referred to in Section 6.1(e)(iv) above from Receiving Party and, if the Responding Party has proposed
    to amend the terms of this Agreement and the Transaction in accordance with Section 6.1(f), the board of directors of the
    Receiving Party shall have determined, in good faith, after consultation with its financial advisors and outside legal counsel,
    that the Acquisition Proposal continues to constitute a Superior Proposal compared to the proposed amendment to the terms
    of this Agreement and the Transaction by the Responding Party;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Receiving Party concurrently terminates this Agreement pursuant to Section 9.2(a)(iii)(B) or 9.2(a)(iv)(B), as applicable;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 346; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Receiving Party has previously, or concurrently will have, paid to the Responding Party the amount required in accordance
    with Section 10.1(b)(ii) or 10.1(d)(ii), as applicable, if such payment is payable in the circumstances.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Receiving Party acknowledges and agrees that, during the Matching Period or such longer period as the Receiving Party may
approve for such purpose (in its sole and absolute discretion), the Responding Party shall have the right, but not the obligation,
to propose to amend the terms of this Agreement and the Transaction. The board of directors of the Receiving Party will review
any proposal by the Responding Party to amend the terms of this Agreement and the Transaction in order to determine, in good faith
in the exercise of its fiduciary duties, whether the Responding Party&rsquo;s proposal to amend this Agreement and the Transaction
would result in the Acquisition Proposal not being a Superior Proposal compared to the proposed amendment to the terms of this
Agreement and the Transaction. If the board of directors of the Receiving Party determines that an Acquisition Proposal is not
a Superior Proposal as compared to the proposed amendment to the terms of this Agreement and the Transaction, it will promptly
enter into the proposed amendment to this Agreement and the Transaction and immediately terminate all discussions with the Person
that proposed the Superior Proposal. If the board of directors of the Receiving Party determines that an Acquisition Proposal
is a Superior Proposal as compared to the proposed amendment to the terms of this Agreement and the Transaction, the Receiving
Party may approve, recommend and/or enter into an agreement to proceed with the Superior Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The board of directors of the Receiving Party shall reaffirm its recommendation of the Transaction (as set forth in the Parent
Board Approval or the Company Board Approval, as applicable) by press release within five Business Days after: (i) any Acquisition
Proposal which the board of directors of the Receiving Party determines not to be a Superior Proposal is proposed announced or
made; or (ii) the board of directors of the Receiving Party determines that a proposed amendment to the terms of this Agreement
and the Transaction would result in the Acquisition Proposal which has been publicly announced or made not being a Superior Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Nothing in this Agreement shall prevent the board of directors of the Receiving Party from responding through a directors&rsquo;
circular or otherwise, only to the extent required by Applicable Laws, to an Acquisition Proposal that it determines is not a
Superior Proposal solely to inform such Peron making the Acquisition Proposal that such proposal has been rejected; provided that
the board of directors of the Receiving Party shall not be permitted to make a Company Change in Recommendation or Parent Change
in Recommendation, as applicable, other than in connection with Section 6.1(e) or in the event that one of the Closing conditions
set forth in Article 8 has not been, and will not be, achieved with respect to a Party and the board of directors of the other
Party determines, acting in good faith and upon the reasonable advice of its legal counsel, that it is necessary to communicate
that fact to its shareholders in order for such board of directors to comply with its fiduciary duties or Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each successive material modification of or amendment to any Acquisition Proposal shall constitute a new Acquisition Proposal
for the purposes of this Section 6.1; provided that the Matching Period in respect of such new Acquisition Proposal shall extend
by an additional five (5) Business Days from the Parent&rsquo;s receipt of the notice thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Notwithstanding the foregoing, nothing in this Agreement (including this Section 6.1) shall prohibit Parent or its Subsidiaries
from discussing and/or negotiating any (i) Acquisition Proposal involving the Parent following the Closing, or (ii) equity or
convertible or exchangeable security financing prior to Closing, in each case, so long as such Acquisition Proposal does not adversely
impact the Transaction and the Company is advised of the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 347; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
Breach by Representatives</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the generality of the foregoing, the Company or the Parent, as the case may be, shall advise their respective Representatives
of the prohibitions set out in this <U>Article 6</U> and any violation of the restrictions set forth in this <U>Article 6</U>
by the Company, the Parent or their respective Representatives is deemed to be a breach of this <U>Article 6</U> by the Company
or by the Parent, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
OTHER COVENANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
Public Communications</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties shall cooperate in the preparation of presentations, if any, to the Company Securityholders and the Parent Stockholders
regarding the Amalgamation. A Party must not issue any press release or make any other public statement or disclosure with respect
to this Agreement or the Amalgamation without the consent of the other Parties (which consent shall not be unreasonably withheld
or delayed), and neither Party may make any filing with any Governmental Authority with respect to this Agreement or the Amalgamation
without the consent of the other Party (which consent shall not be unreasonably withheld or delayed); provided that any Party
that, in the reasonable opinion of its outside legal counsel, is required to make disclosure by Applicable Law may make such disclosure
provided it shall use its commercially efforts to give the other Parties prior oral or written notice and a reasonable opportunity
to review or comment on the disclosure or filing (other than with respect to confidential information contained in such disclosure
or filing). The Party making such disclosure shall give reasonable consideration to any comments made by the other Parties or
their counsel, and if such prior notice is not possible, shall give such notice immediately following the making of such disclosure
or filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
Covenants of the Company Regarding the Conduct of Business</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company covenants and agrees that, subject to Applicable Law, during the period from the date of this Agreement until the
earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, except with the express
prior written consent of the Parent and the Purchaser or as required or permitted by this Agreement or required by Applicable
Law, the Company shall, and shall cause its Subsidiaries to, conduct its business in the Ordinary Course and in accordance with
Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Without limiting the generality of <U>Section 7.2(a)</U>, subject to Applicable Law, the Company covenants and agrees that, during
the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement is terminated
in accordance with its terms, except with the express prior written consent of the Parent or as required or permitted by this
Agreement, the Company shall, and shall cause its Subsidiaries to, use its reasonable best efforts to maintain and preserve intact
the current business organization, assets, properties and business of the Company and its Subsidiaries, maintain in effect all
Authorizations of the Company and its Subsidiaries, keep available the services of the present employees and agents of the Company
and its Subsidiaries and maintain good relations with, and the goodwill of, employees, suppliers, customers, creditors and all
other Persons having business relationships with the Company and its Subsidiaries and, except with the prior written consent of
the Parent, the Company shall not, and shall cause its Subsidiaries not to, directly or indirectly:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any change in its Organizational Documents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">split,
    combine, consolidate or reclassify any shares of its capital stock, undertake any capital reorganization or declare, set aside
    or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 348; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redeem,
    repurchase, or otherwise acquire or offer to redeem, repurchase or otherwise acquire any shares of its capital stock or reduce
    the stated capital in respect of the Company Common Shares or any other shares of the Company or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue,
    grant, deliver, sell, pledge or otherwise encumber, or authorize the issuance, grant, delivery, sale, pledge or other encumbrance
    of any shares of capital stock, securities, options, warrants or similar rights exercisable or exchangeable for or convertible
    into such capital stock, of the Company and its Subsidiaries, except for the issuance of Company Common Shares (A) issuable
    upon the exercise of the currently outstanding Company Options or (B) pursuant to outstanding Company Warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
    (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, in one transaction or in
    a series of related transactions, assets, securities, properties, interests or businesses of any other Person (other than
    pursuant to the transactions contemplated by this Agreement);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reorganize,
    amalgamate, combine or merge the Company or its Subsidiaries with any other Person (other than pursuant to the transactions
    contemplated by this Agreement);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adopt
    a plan of liquidation or resolutions providing for the liquidation or dissolution of the Company or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
    pledge, lease, dispose of, surrender, lose the right to use, mortgage, license, encumber (other than Permitted Liens) or otherwise
    dispose of or transfer any assets of the Company or its Subsidiaries or any interest in any assets of the Company or its Subsidiaries,
    other than the sale of inventory in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any capital expenditure or similar commitments, other than in the Ordinary Course in accordance with the 2021 fiscal year
    budget Made Available to Parent;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any loan or advance to, or any capital contribution or investment in, or assume, guarantee or otherwise become liable with
    respect to the liabilities or obligations of, any Person;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 349; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prepay
    any long-term indebtedness before its scheduled maturity or increase, create, incur, assume or otherwise become liable, in
    one transaction or in a series of related transactions, with respect to any indebtedness for borrowed money or guarantees
    thereof, other than in the Ordinary Course; provided that any indebtedness created, incurred, refinanced, assumed or for which
    the Company or its Subsidiaries becomes liable in accordance with the any of the foregoing shall be prepayable at the Effective
    Time without premium, penalty or other incremental costs (including breakage costs);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into any interest rate, currency, equity or commodity swaps, hedges, derivatives, forward sales contracts or similar financial
    instruments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any bonus or profit sharing distribution or similar payment of any kind;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">grant
    any general increase in the rate of wages, salaries, bonuses or other remuneration of any Company Employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any change in the Company&rsquo;s or its Subsidiaries&rsquo; methods of accounting (except as required by IFRS);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any Tax election, information schedule, return or designation, except as required by Applicable Law and in a manner consistent
    with past practice, settle or compromise any material Tax claim, assessment, reassessment or liability, file any amended Tax
    Return, enter into any material agreement with a Governmental Authority with respect to Taxes, surrender any right to claim
    a material Tax abatement, reduction, deduction, exemption, credit or refund, consent to the extension or waiver of the limitation
    period applicable to any material Tax matter or materially amend or change any of its methods or reporting income, deductions
    or accounting for income Tax purposes except as may be required by Applicable Law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create,
    enter into or increase any severance, change of control or termination pay to (or amend any similar existing arrangement with)
    any Company Employee, director or executive officer of the Company or its Subsidiaries or change the benefits payable under
    any existing severance or termination pay policies with any Company Employee, director or executive officer of the Company
    or its Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    as required by Applicable Law: (A) adopt, enter into or amend any Employee Plan (other than entering into an employment agreement
    in the Ordinary Course with a new Company Employee who was not employed by the Company or its Subsidiaries on the date of
    this Agreement); (B) pay any benefit to any director or officer of the Company or its Subsidiaries or to any Company Employee
    that is not required under the terms of any Employee Plan in effect on the date of this Agreement; (C) grant, accelerate,
    increase or otherwise amend any payment, award or other benefit payable to, or for the benefit of, any director or officer
    of the Company or its Subsidiaries or to any Company Employee; (D) make any material determination under any Employee Plan;
    or (E) take or propose any action to effect any of the foregoing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 350; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel,
    waive, release, assign, settle or compromise any material claims or rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commence,
    waive, release, assign, settle or compromise any Proceedings or governmental investigations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend,
    modify, terminate or waive any right under any Material Contract or enter into any Contract or agreement that would be a Material
    Contract if in effect on the Execution Date;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend,
    modify, terminate, cancel or let lapse any material insurance (or re-insurance) policy of the Company or its Subsidiaries
    in effect on the date of this Agreement, unless simultaneously with such termination, cancellation or lapse, replacement policies
    underwritten by insurance and re-insurance companies of nationally recognized standing providing coverage equal to or greater
    than the coverage under the terminated, cancelled or lapsed policies for substantially similar premiums are in full force
    and effect;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of any assets of the Company or its Subsidiaries, waive, release, surrender, let lapse, grant or transfer any material
    right or value or amend, modify or change, or agree to amend, modify or change any existing material: (i) Authorization or
    (ii) right to use, lease, contract, production sharing agreement, Intellectual Property, or other material document;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">abandon
    or fail to diligently pursue any application for any material Authorizations, licenses, leases, or registrations or take any
    action, or fail to take any action, that could lead to the termination of any material Authorizations, licenses, leases or
    registrations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into or amend any Contract with any broker, finder or investment banker (excluding for greater certainty such agreement noted
    in Section 4.1(q) of the Company Disclosure Statement); or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize,
    agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
Covenants of the Company in Connection with the Transaction</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall perform, and shall cause its Subsidiaries to perform, all obligations required to be performed by the Company or
any of its Subsidiaries under this Agreement, cooperate with the Parent and the Purchaser in connection therewith, and do all
such other commercially reasonable acts and things as may be necessary or desirable in order to consummate and make effective,
as soon as reasonably practicable, the transactions contemplated by this Agreement and, without limiting the generality of the
foregoing, the Company shall and, where appropriate, shall cause each of its Subsidiaries to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
carry out this Agreement in accordance with and subject to the terms hereof, and comply promptly with all requirements imposed
by Applicable Law on it with respect to this Agreement or the Amalgamation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 351; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
use its commercially reasonable efforts to obtain and maintain all third party or other consents, waivers, permits, exemptions,
orders, approvals, agreements, amendments or confirmations that are (i) necessary or advisable to be obtained under the Material
Contracts in connection with the Amalgamation or (ii) required in order to maintain the Material Contracts in full force and effect
following completion of the Amalgamation, in each case, on terms that are reasonably satisfactory to the Parent and the Purchaser,
and without paying, and without committing itself or the Parent or the Purchaser to pay, any consideration or incur any liability
or obligation without the prior written consent of the Parent and the Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
use reasonable best efforts to effect all necessary registrations, filings and submissions of information required by Governmental
Authorities from the Company relating to the Amalgamation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
use reasonable best efforts to, on prior written approval of the Parent and the Purchaser, oppose, lift or rescind any injunction,
restraining or other order, decree, judgment or ruling seeking to restrain, enjoin or otherwise prohibit or adversely affect the
consummation of the Amalgamation and defend, or cause to be defended, any Proceedings to which it is a party or brought against
it or its directors or officers challenging the Amalgamation or this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
not take any action, or refrain from taking any action, or permitting any action to be taken or not taken, which is inconsistent
with this Agreement or which would reasonably be expected to prevent, delay or otherwise impede the consummation of the Amalgamation
or the transactions contemplated by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
use all commercially reasonable efforts to, as promptly as practicable, prepare and file all necessary documents, registrations,
statements, petitions, filings and applications for any Regulatory Approvals and use its reasonable best efforts to obtain and
maintain all Regulatory Approvals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
use all commercially reasonable efforts to cooperate with the Parent and the Purchaser in connection with obtaining any Regulatory
Approvals including providing the Parent and the Purchaser with copies of all notices and information or other correspondence
supplied to, filed with or received from any Governmental Authority;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
concurrently with the Closing, use its reasonable best efforts to cause each of shareholders set forth on <U>Schedule 7.3(h)</U>
to execute a lock-up agreement substantially in the form attached hereto as <U>Schedule &ldquo;D&rdquo;</U> (the &ldquo;<B>Lock-Up
Agreements</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
solicit proxies to be voted at the Company Meeting in favor of the matters to be considered at such meeting, including the Amalgamation
Resolution and against any resolution submitted by any Person that is inconsistent with such resolution and the completion of
the Transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 352; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
promptly notify the Parent and the Purchaser in writing of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    Material Adverse Effect with respect to the Company or its Subsidiaries (taken as a whole) or any change, effect, event, development,
    occurrence, circumstance or state of facts which could reasonably be expected to have a Material Adverse Effect with respect
    to the Company or its Subsidiaries (taken as a whole);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    notice or other communication from any Person alleging that the consent (or waiver, permit, exemption, order, approval, agreement,
    amendment or confirmation) of such Person (or another Person) is or may be required in connection with this Agreement or the
    Amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    notice or other communication from any material supplier, customer or other third party to the effect that such supplier,
    customer or third party is terminating, may terminate or is otherwise materially adversely modifying or may materially adversely
    modify its relationship with the Company or its Subsidiaries as a result of this Agreement or the Amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    notice or other communication from any Governmental Authority in connection with this Agreement (and the Company shall contemporaneously
    provide a copy of any such written notice or communication to the Purchaser); or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    filing, actions, suits, claims, investigations or Proceedings commenced or, to its knowledge, threatened against, relating
    to or involving or otherwise affecting the Company, its Subsidiaries or its assets or properties;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
conduct itself, in all material respects, subject to Applicable Law, so as to keep the Parent and the Purchaser fully informed
as to the material decisions required to be made or actions required to be taken with respect to the operation of its business;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
use reasonable best efforts to provide (and use reasonable best efforts to cause its Representatives to provide) Parent with all
cooperation requested by Parent that is customary to assist it in connection with the consummation of any equity or convertible
or exchangeable security financing (<U>provided</U> that such requested cooperation does not unreasonably interfere with the ongoing
operations of the Company and its Subsidiaries).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
Covenants of the Parent and the Purchaser Regarding the Conduct of Business</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Parent and the Purchaser covenant and agree that, subject to Applicable Law, during the period from the date of this Agreement
until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, except with
the express prior written consent of the Company or as required or permitted by this Agreement, the Parent and the Purchaser shall,
and shall cause their respective Subsidiaries to, conduct their business in the Ordinary Course and in accordance with Applicable
Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 353; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Without limiting the generality of <U>Section 7.4(a)</U>, subject to Applicable Law, the Parent and the Purchaser covenant and
agree that, during the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement
is terminated in accordance with its terms, except with the express prior written consent of the Company or as required or permitted
by this Agreement, the Parent and the Purchaser shall, and shall cause their respective Subsidiaries to, use their commercially
reasonable efforts to maintain and preserve intact the current business organization, assets, properties and business of the Parent,
HoldCo, the Purchaser and their respective Subsidiaries, maintain in effect all material Authorizations of the Parent, HoldCo,
the Purchaser and their respective Subsidiaries, keep available the services of the present employees and agents of the Parent,
HoldCo, the Purchaser and their respective Subsidiaries and maintain good relations with, and the goodwill of, employees, suppliers,
customers, creditors and all other Persons having business relationships with the Parent, HoldCo, the Purchaser and their respective
Subsidiaries and, except as set forth in Section 7.4(b) of the Parent Disclosure Statement or with the prior written consent of
the Company, the Parent and the Purchaser shall not, directly or indirectly, and shall cause their respective Subsidiaries not
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any change in its Organizational Documents, other than the Parent Charter Amendment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">split,
    combine, consolidate or reclassify any shares of its capital stock, undertake any capital reorganization or declare, set aside
    or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redeem,
    repurchase, or otherwise acquire or offer to redeem, repurchase or otherwise acquire any shares of its capital stock or reduce
    the stated capital in respect of the Parent Common Stock or any other shares of the Parent, HoldCo, the Purchaser and their
    respective Subsidiaries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    in connection with an equity or convertible or exchangeable security financing, issue, grant, deliver, sell, or authorize
    the issuance, grant, delivery, sale, pledge or other encumbrance of any shares of capital stock, securities, options, warrants
    or similar rights exercisable or exchangeable for or convertible into such capital stock, of the Parent, HoldCo, the Purchaser
    or their respective Subsidiaries, except for the issuance of Parent Capital Stock (A) issuable upon the exercise of the currently
    outstanding Parent Options, or (B) pursuant to outstanding Parent Warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
    (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, in one transaction or in
    a series of related transactions, assets, securities, properties, interests or businesses of any other Person (other than
    pursuant to the transactions contemplated by this Agreement);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reorganize,
    amalgamate, combine or merge the Parent, HoldCo, the Purchaser or their respective Subsidiaries with any other Person (other
    than pursuant to the transactions contemplated by this Agreement);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adopt
    a plan of liquidation or resolutions providing for the liquidation or dissolution of the Parent, HoldCo, the Purchaser or
    their respective Subsidiaries;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 354; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
    lease, dispose of, surrender, lose the right to use, license or otherwise dispose of or transfer any assets of the Parent,
    HoldCo, the Purchaser or their respective Subsidiaries or any interest in any assets of the Parent, HoldCo, the Purchaser
    or their respective Subsidiaries, other than in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any capital expenditure or similar commitments, other than in the Ordinary Course;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any loan or advance to, or any capital contribution or investment in, or assume, guarantee or otherwise become liable with
    respect to the liabilities or obligations of, any Person;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prepay
    any long-term indebtedness before its scheduled maturity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into any interest rate, currency, equity or commodity swaps, hedges, derivatives, forward sales contracts or similar financial
    instruments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any change in the Parent&rsquo;s or its Subsidiaries&rsquo; methods of accounting (except as required by U.S. GAAP);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any material Tax election, information schedule, return or designation, except as required by Applicable Law and in a manner
    consistent with past practice, settle or compromise any material Tax claim, assessment, reassessment or liability, file any
    amended Tax Return, enter into any material agreement with a Governmental Authority with respect to Taxes, surrender any right
    to claim a material Tax abatement, reduction, deduction, exemption, credit or refund, consent to the extension or waiver of
    the limitation period applicable to any material Tax matter or materially amend or change any of its methods or reporting
    income, deductions or accounting for income Tax purposes except as may be required by Applicable Law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel,
    waive, release, assign, settle or compromise any material claims or rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend
    or modify or terminate or waive any right under any Material Contract or enter into any Contract or agreement that would be
    a Material Contract if in effect on the Execution Date;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend,
    modify, terminate, cancel or let lapse any material insurance (or re-insurance) policy of the Parent, HoldCo, the Purchaser
    or their respective Subsidiaries in effect on the date of this Agreement, unless simultaneously with such termination, cancellation
    or lapse, replacement policies underwritten by insurance and re-insurance companies of nationally recognized standing providing
    coverage equal to or greater than the coverage under the terminated, cancelled or lapsed policies for substantially similar
    premiums are in full force and effect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 355; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of any assets of the Parent, HoldCo, the Purchaser or their respective Subsidiaries, waive, release, surrender, let
    lapse, grant or transfer any material right or value or amend, modify or change, or agree to amend, modify or change any existing
    material: (i) Authorization or (ii) right to use, lease, contract, production sharing agreement, Intellectual Property, or
    other material document;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">abandon
    or fail to diligently pursue any application for any material Authorizations, licenses, leases, or registrations or take any
    action, or fail to take any action, that could lead to the termination of any material Authorizations, licenses, leases or
    registrations; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize,
    agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
Covenants of the Parent and the Purchaser in Connection with the Transaction</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Parent and the Purchaser shall use commercially reasonable efforts to perform, and shall cause their respective Subsidiaries
to perform, all obligations required or desirable to be performed by each of the Parent and the Purchaser or any of their respective
Subsidiaries under this Agreement, cooperate with the Company in connection therewith, and do all such other commercially reasonable
acts and things as may be reasonably necessary or desirable in order to consummate and make effective, as soon as reasonably practicable,
the transactions contemplated by this Agreement and, without limiting the generality of the foregoing, each of the Parent and
the Purchaser shall and, where appropriate, shall cause each of their respective Subsidiaries to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
carry out in accordance with and subject to the terms of this Agreement and comply promptly as practicable with all requirements
imposed by Applicable Law on it with respect to this Agreement or the Amalgamation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
use its commercially reasonable efforts to obtain and maintain all third party or other consents, waivers, permits, exemptions,
orders, approvals, agreements, amendments or confirmations that are (i) necessary or advisable to be obtained under the Material
Contracts in connection with the Amalgamation or (ii) required in order to maintain the Material Contracts in full force and effect
following completion of the Amalgamation, in each case, on terms that are reasonably satisfactory to the Company, and without
paying, and without committing itself or the Company to pay, any consideration or incur any liability or obligation without the
prior written consent of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
use all commercially reasonable efforts to effect all reasonably necessary registrations, filings and submissions of information
required by Governmental Authorities from each of the Parent and the Purchaser relating to the Amalgamation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
prepare and submit the NASDAQ Listing Application and use commercially reasonably efforts to cause such NASDAQ Listing Application
to be conditionally approved prior to the Effective Time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
use all commercially reasonable efforts to oppose, lift or rescind any injunction, restraining or other order, decree, judgment
or ruling seeking to restrain, enjoin or otherwise prohibit or adversely affect the consummation of the Amalgamation and defend,
or cause to be defended, any Proceedings to which it is a party or brought against it or its directors or officers challenging
the Amalgamation or this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 356; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
use all commercially reasonable efforts to, as promptly as practicable, prepare and file all necessary documents, registrations,
statements, petitions, filings and applications for any Regulatory Approvals and use commercially reasonable efforts to obtain
and maintain all Regulatory Approvals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
not take any action, or refrain from taking any action, or permitting any action to be taken or not taken, which is inconsistent
with this Agreement or which would reasonably be expected to prevent, delay or otherwise impede the consummation of the Amalgamation
or the transactions contemplated by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
use all commercially reasonable efforts to cooperate with the Company in connection with obtaining any Regulatory Approvals including
providing the Company with copies of all notices and information or other correspondence supplied to, filed with or received from
any Governmental Authority (provided that, notwithstanding anything to the contrary set forth in this Agreement, each of the Parent
and the Purchaser are under no obligation to take any steps or actions that would, in their sole discretion, affect the Parent
or the Purchaser&rsquo;s right to own, use or exploit its business, operations or assets or those of the Company);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
solicit proxies to be voted at the Parent Meeting in favor of the matters to be considered at such meeting and against any resolution
submitted by any Person that is inconsistent with the completion of the Transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
promptly notify the Company of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    Material Adverse Effect with respect to the Parent or the Purchaser (taken as a whole) or any change, effect, event, development,
    occurrence, circumstance or state of facts which could reasonably be expected to have a Material Adverse Effect with respect
    to the Parent or the Purchaser (taken as a whole);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    notice or other communication from any Person alleging that the consent (or waiver, permit, exemption, order, approval, agreement,
    amendment or confirmation) of such Person (or another Person) is or may be required in connection with this Agreement or the
    Amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    notice or other communication from any material supplier, customer or other third party to the effect that such supplier,
    customer or third party is terminating, may terminate or is otherwise materially adversely modifying or may materially adversely
    modify its relationship with the Parent, HoldCo, the Purchaser or any of their Subsidiaries as a result of this Agreement
    or the Amalgamation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    notice or other communication from any Governmental Authority in connection with this Agreement (and the Parent or the Purchaser
    shall contemporaneously provide a copy of any such written notice or communication to the Company); or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 357; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    filing, actions, suits, claims, investigations or Proceedings commenced or, to its knowledge, threatened against, relating
    to or involving or otherwise affecting the Company, its Subsidiaries or its assets or properties; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
conduct itself, in all material respects, subject to Applicable Law, so as to keep the Company fully informed as to the material
decisions required to be made or actions required to be taken with respect to the operation of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
Investment Canada Act</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parent will file a &ldquo;Notification to Acquire Control of an Existing Canadian Business&rdquo; pursuant to the Investment Canada
Act within 30 days after the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
Directors and Officers of the Parent</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parent will take all actions necessary to cause the number of directors of the Parent to be a minimum of seven (7), of which two
(2) director shall be a designee of the Company and the remaining five (5) of which shall be designated by the Parent. The composition
of the board of directors of the Parent shall satisfy all NASDAQ and SEC requirements. At closing of the Transaction, unless otherwise
agreed to by the Parties, the board of directors of the Parent shall be comprised of the following individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
    Johnson, Executive Chairman and Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Doug Lind, MD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Marcus Schabacker, MD, PhD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    George Kegler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Sol Myer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph Tucker (Company Nominee)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Thompson (Company Nominee)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, upon closing of the Transaction, Dr. Joseph Tucker shall be appointed as Chief Executive Officer of
the Parent; Dr. Jillian Hagel shall be appointed as Chief Technical Officer of the Parent; Dr. Peter Facchini shall be appointed
as Chief Scientific Officer of the Parent; and all other executive officers of the Parent shall remain in their respective positions.
The Parent (and, if applicable, any Subsidiary thereof) shall each enter into an employment agreement with the individuals set
forth in the immediately prior sentence pursuant to which such persons shall serve in their respective capacities, such employment
agreements to be in the forms substantially set forth herein as Schedule &ldquo;C&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
Actions to Satisfy Conditions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall, and shall cause its Subsidiaries to, take all such actions as are within its power to control, and use commercially
reasonable efforts to cause other actions to be taken which are not within its power to control, so as to ensure compliance with
all of the applicable conditions precedent in favor of the Parent as set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Parent shall, and shall cause its Subsidiaries (including the Purchaser), to take all such actions as are within its power
to control, and use commercially reasonable efforts to cause other actions to be taken which are not within its power to control,
so as to ensure compliance with all of the applicable conditions precedent in favor of the Company as set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 358; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9
Notice and Cure Provisions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Each Party shall promptly notify the other Parties of the occurrence, or failure to occur, of any event or state of facts which
occurrence or failure would, or would be reasonably likely to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cause
    any of the representations or warranties of such Party contained in this Agreement to be untrue or inaccurate in any material
    respect at any time from the date of this Agreement to the Effective Time; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
    in the failure, in any material respect, to comply with or satisfy any covenant, condition or agreement to be complied with
    or satisfied by such Party under this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notification provided under this <U>Section 7.10</U> will not affect the representations, warranties, covenants, agreements or
obligations of the Parties (or remedies with respect thereto) or the conditions to the obligations of the Parties under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Parent and the Purchaser may not elect to exercise their right to terminate this Agreement pursuant to <U>Section 9.2</U>
and the Company may not elect to exercise its right to terminate this Agreement pursuant to <U>Section 9.2</U>, unless the Party
seeking to terminate the Agreement (the &ldquo;<B>Terminating Party</B>&rdquo;) has delivered a written notice (&ldquo;<B>Termination
Notice</B>&rdquo;) to the other Party (the &ldquo;<B>Breaching Party</B>&rdquo;) specifying in reasonable detail all breaches
of covenants, representations and warranties or other matters which the Terminating Party asserts as the basis for termination.
After delivering a Termination Notice, provided the Breaching Party is proceeding diligently to cure such matter and such matter
is capable of being cured prior to the End Date, the Terminating Party may not exercise such termination right until the earlier
of (a) the End Date, and (b) the date that is twenty (20) Business Days following receipt of such Termination Notice by the Breaching
Party, if such matter has not been cured by such date. If the Terminating Party delivers a Termination Notice prior to the date
of the Company Meeting or the Parent Meeting, if necessary, unless the Parties agree otherwise, the Company shall postpone or
adjourn the Company Meeting, and the Parent shall postpone or adjourn the Parent Meeting, if necessary, to the earlier of (a)
five (5) Business Days prior to the End Date and (b) the date that is twenty (20) Business Days following receipt of such Termination
Notice by the Breaching Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10
Access to Information; Confidentiality</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the Execution Date until the earlier of the Effective Time and the termination of this Agreement, subject to compliance with
Applicable Laws, each Party will, and will direct its respective Subsidiaries, its Affiliates and its and its Representatives,
as applicable, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">give
    the other Party and their respective Representatives reasonable access to the offices, properties, books and records of such
    Party; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">furnish
    to the other Party and their Representatives such financial and operating data and other information as such Person may reasonably
    request.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any investigation pursuant to this Section 7.10 will be conducted during normal business hours and in such manner as not to interfere
unreasonably with the conduct of the business of the other Party or any Affiliate thereof, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 359; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Parties acknowledge and agree that information and access furnished pursuant to this Section 7.10 shall be subject to all
applicable antitrust and competition laws and the terms and conditions of the Confidentiality Agreement, which shall continue
to apply in full force and effect notwithstanding the execution of this Agreement by the Parties or the announcement of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11
Insurance and Indemnity Agreements.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Closing Date, the Company shall purchase, at the Company&rsquo;s sole expense, the insurance policy set forth in <U>Section
7.11</U> of the Company Disclosure Statement and a customary &ldquo;tail&rdquo; policies of directors&rsquo; and officers&rsquo;
liability insurance providing protection no less favorable in the aggregate than the protection provided by the policies maintained
by the Company and its Subsidiaries which are in effect immediately prior to the Closing Date and providing protection in respect
of claims arising from facts or events which occurred on or prior to the Closing Date and Purchaser and Parent agree to not take
or permit any action to be taken by or on behalf of Company (including Amalco as successor thereto) following the Closing Date
to terminate or adversely affect such directors&rsquo; and officers&rsquo; insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
and Parent agree that, after the Effective Time, Purchaser and Parent and their successors (including Amalco) will not take any
action to terminate or materially adversely affect, and will fulfill its obligations pursuant to, indemnities provided or available
to or in favor of past and present officers and directors of Company pursuant to the provisions of the articles, by-laws or other
constating documents of the Company, applicable corporate legislation and any written indemnity agreements (and each of them),
which have been entered into between the Company and its past or current officers or directors effective on or prior to the date
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12
Proxy Statement/Prospectus</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As promptly as reasonably practicable following the date of this Agreement, the Parent shall prepare and file with the SEC a proxy
statement to be sent to the stockholders of the Parent relating to the meeting of the Parent Stockholders and a Registration Statement
on Form S-4 (including a prospectus) (including all amendments thereto, &ldquo;<B>S-4 Registration Statement</B>&rdquo;) in connection
with the issuance of shares of Parent Capital Stock (and, with respect to the Company Stock Option Plan that is assumed, a newly
filed Registration Statement on Form S-8, as applicable), of which such proxy statement will form a part (such proxy statement
and prospectus constituting a part thereof, the &ldquo;<B>Proxy Statement/Prospectus</B>&rdquo;), and the Company shall, or shall
cause its Affiliates to, prepare and file with the SEC all other documents to be filed by the Parent with the SEC in connection
with the Amalgamation and the other transactions contemplated hereby (the &ldquo;<B>Other Filings</B>&rdquo;) as required by the
1933 Act or the U.S. Exchange Act. The Parent and the Company shall cooperate with each other in connection with the preparation
of the S-4 Registration Statement, the Proxy Statement/Prospectus and any Other Filings. Each Party shall as promptly as reasonably
practicable notify the other Party of the receipt of any oral or written comments from the staff of the SEC on the S-4 Registration
Statement or any Other Filing. The Parent and the Company shall also use their reasonable best efforts to satisfy prior to the
effective date of the S-4 Registration Statement all applicable Securities Laws or &ldquo;blue sky&rdquo; notice requirements
in connection with the Amalgamation and to consummate the other transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 360; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Parent covenants and agrees that the S-4 Registration Statement and Proxy Statement/Prospectus, including any pro forma financial
statements included therein (and the letter to stockholders, notice of meeting and form of proxy included therewith), will not,
at the time that the S-4 Registration Statement and Proxy Statement/Prospectus or any amendment or supplement thereto is filed
with the SEC or the Proxy Statement/Prospectus is first mailed to the Parent Stockholders, at the time of the Parent Meeting and
at the Effective Time, contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not
misleading. The Company covenants and agrees that the information provided by the Company and its Subsidiaries to the Parent for
inclusion in the S-4 Registration Statement and Proxy Statement/Prospectus (including the Company Financial Statements) will not
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
in order to make such information not misleading. Notwithstanding the foregoing, the Parent makes no covenant, representation
or warranty with respect to statements made in the S-4 Registration Statement or Proxy Statement/Prospectus (and the letter to
stockholders, notice of meeting and form of proxy included therewith), if any, based on information furnished in writing by the
Company or its Subsidiaries specifically for inclusion therein. Each of the Parties shall use commercially reasonable efforts
to cause the S-4 Registration Statement and Proxy Statement/Prospectus to comply with the applicable rules and regulations promulgated
by the SEC and to respond promptly to any comments of the SEC or its staff. Each of the Parties shall use commercially reasonable
efforts to cause the S-4 Registration Statement to be declared effective as soon as possible and the Proxy Statement/Prospectus
to be mailed to Parent Stockholders as promptly as practicable after the SEC declares the S-4 Registration Statement to be effective.
Each Party shall promptly furnish to the other Party all information concerning such Party, such Party&rsquo;s Subsidiaries and
such Party&rsquo;s stockholders that may be required or reasonably requested in connection with any action contemplated by this
<U>Section 7.15</U>. If any event relating to the Parent or the Company occurs, or if the Parent or the Company becomes aware
of any information, that should be disclosed in an amendment or supplement to the S-4 Registration Statement and/or Proxy Statement/Prospectus,
then the Parent or the Company, as applicable, shall promptly inform the other Party thereof and shall cooperate with one another
in filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to the Parent
Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company shall, and shall cause its Subsidiaries to, use its reasonable best efforts cooperate with the Parent and provide,
and require its Representatives, advisors, accountants and attorneys to provide, the Parent and its Representatives, advisors,
accountants and attorneys, with all true, correct and complete information regarding the Company and its Subsidiaries that is
required by Applicable Law to be included in the S-4 Registration Statement and/or the Proxy Statement/Prospectus or reasonably
requested from the Parent to be included in the S-4 Registration Statement and/or the Proxy Statement/Prospectus. The information
provided by the Company and its Subsidiaries to be included in the S-4 Registration Statement and/or the Proxy Statement/Prospectus
shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13
Company Circular</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As promptly as reasonably practicable following the date of this Agreement, the Company shall prepare the Company Circular together
with any other documents required by Applicable Laws in connection with the Company Meeting and cause the Company Circular and
such other documents to be mailed to the Company Shareholders and such other Persons as required by Applicable Laws and filed
with applicable securities regulatory authorities and other Governmental Authorities in all jurisdictions where the same are required
to be filed and convene and conduct the Company Meeting at which Company Meeting the Amalgamation Resolution shall be submitted
to the Company Shareholders entitled to vote upon such resolution for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 361; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company covenants and agrees that the Company Circular will not, at the date of the Company Circular contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
made therein, in light of the circumstances under which they were made, not misleading. The Parent covenants and agrees that the
information provided by the Parent and its Subsidiaries (including the Purchaser) to the Company for inclusion in the Company
Circular (including the Purchaser Financial Statements) will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make such information not misleading. Notwithstanding
the foregoing, the Company makes no covenant, representation or warranty with respect to statements made in the Company Circular
based on information furnished in writing by the Parent, its Subsidiaries or its Representatives specifically for inclusion therein.
Each of the Parties shall use commercially reasonable efforts to cause the Company Circular to comply with the applicable Canadian
Securities Laws and the BCBCA. Each Party shall promptly furnish to the other Party all information concerning such Party, such
Party&rsquo;s Subsidiaries and such Party&rsquo;s stockholders that may be required or reasonably requested in connection with
any action contemplated by this <U>Section 7.13</U>. If any event relating to the Company or the Parent occurs, or if the Company
or the Parent becomes aware of any information, that should be disclosed in an amendment or supplement to the Company Circular,
then the Company or the Parent, as applicable, shall promptly inform the other Party thereof and shall cooperate with one another
in filing such amendment or supplement and, if appropriate or required under Applicable Law, in mailing such amendment or supplement
to the Company Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Parent and the Purchaser shall, and shall cause its Subsidiaries to, use its commercially reasonable efforts cooperate with
the Company and provide, and require its Representatives, advisors, accountants and attorneys to provide, the Company and its
Representatives, advisors, accountants and attorneys, with all true, correct and complete information regarding the Parent, HoldCo,
the Purchaser and their Subsidiaries that is required by Applicable Law to be included in the Company Circular or reasonably requested
from the Parent to be included in the Company Circular The information provided by the Parent, HoldCo, the Purchaser and their
Subsidiaries to be included in the Company Circular shall not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14
Conversion of Holdco to ULC</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary in this Agreement, on or before the Closing Date, the Parent shall cause Holdco to become an unlimited
liability company pursuant to, and in accordance with, the provisions of the BCBCA and shall cause Holdco to make all required
filings with the Registrar to effect the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
8</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
CONDITIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
Mutual Conditions Precedent</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties are not required to complete the Amalgamation unless each of the following conditions is satisfied at or prior to the
Closing, which conditions may only be waived, in whole or in part, by the mutual consent of each of the Parties:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Parent Stockholder Approval.</B> The Parent Stockholder Approval shall have been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 362; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Company Shareholder Approval.</B> The Company Shareholder Approval shall have been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>No Injunctions or Restraints; Illegality.</B> No temporary restraining order, preliminary or permanent injunction or other
order (whether temporary, preliminary or permanent) issued by any court of competent jurisdiction or other legal restraint or
prohibition preventing the consummation of the Amalgamation will be in effect, nor will any Proceeding brought by any administrative
agency or commission or other Governmental Authority or instrumentality, domestic or foreign, seeking any of the foregoing be
pending. There will not be any action taken, or any statute, rule, regulation or order enacted, entered, enforced or deemed applicable
to the Amalgamation, which makes the consummation of the Amalgamation illegal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Regulatory Approvals.</B> Each required Regulatory Approval has been made, given or obtained and each such Regulatory Approval
is in force and has not been modified. Any waiting period applicable to the consummation of the Amalgamation under any Regulatory
Approval will have expired or been terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>NASDAQ Listing Application.</B> The NASDAQ Listing Application shall have been approved, if such approval is required to maintain
such listing following the consummation of the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>S-4 Registration Statement</B>. The S-4 Registration Statement shall have become effective under the 1933 Act and shall not
be the subject of any stop order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
Additional Conditions Precedent to the Obligations of the Parent and the Purchaser</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchaser is not required to complete the Amalgamation unless each of the following conditions is satisfied at or prior to the
Closing, which conditions are for the exclusive benefit of the Purchaser and may only be waived, in whole or in part, by the Purchaser
in its sole discretion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Representations and Warranties.</B> The representations and warranties of the Company set forth in <U>Article 4</U> qualified
as to materiality shall be true and correct in all respects, and those not so qualified shall be true and correct in all material
respects as of the Execution Date and the Closing Date as though made on and as of the Execution Date and the Closing Date (as
applicable), except to the extent such representations and warranties speak as of another date (in which case, such representations
and warranties shall be true and correct as of such date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Performance of Covenants.</B> The Company has fulfilled or complied in all material respects with each of the covenants of
the Company contained in this Agreement to be fulfilled or complied with by it on or prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Material Adverse Effect.</B> There shall not have been or occurred a Material Adverse Effect with respect to the Company that
has not been disclosed by the Company prior to the Execution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Certificate</B>. The Company shall have delivered a certificate signed by an executive officer of the Company (without personal
liability), in form and substance reasonably satisfactory to the Parent, dated as of the Closing Date, to the effect that each
of the conditions specified in <U>Section 8.2(a) &ndash; (c)</U> have been satisfied in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 363; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Fairness Opinion</B>. The Company shall have delivered to the Parent a fairness opinion for the Transactions, in form and substance
reasonably satisfactory to the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Financial Statements</B>. The Company shall have delivered audited financial statements for fiscal year 2020 and year-to-date
2021 in accordance with U.S. GAAP to the Parent as required by the SEC rules, as well as any other financial statements as may
be required by the rules and regulations of the 1933 Act and the U.S. Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>No Legal Action.</B> There is no Proceeding (whether, for greater certainty, by a Governmental Authority or any other Person),
excluding any Proceeding initiated by the Parent or the Purchaser, pending or threatened in any jurisdiction to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cease
    trade, enjoin, prohibit, or impose any limitations, damages or conditions on, the Purchaser&rsquo;s ability to acquire, hold,
    or exercise full rights of ownership over, any Company Common Shares, including the right to vote the Company Common Shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit,
    restrict or impose terms or conditions on, the Amalgamation, or the ownership or operation by the Parent and the Purchaser
    of the business or assets of the Parent, HoldCo, the Purchaser, the Company or their respective Subsidiaries, or compel the
    Parent or the Purchaser to dispose of or hold separate any of the business or assets of the Parent, HoldCo, the Purchaser,
    the Company or their respective Subsidiaries as a result of the Amalgamation; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevent
    or materially delay the consummation of the Amalgamation, or if the Amalgamation were to be consummated, have a Material Adverse
    Effect with respect to the Company or its Subsidiaries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<B>Officer&rsquo;s Certificate.</B> The Parent shall have received a certificate in form and substance reasonably satisfactory
to the Parent executed by an officer of the Company (without personal liability) certifying as to (i) an attached copy of each
of the Amalgamation Resolution and the Company Board Approval and stating neither the Amalgamation Resolution nor the Company
Board Approval has been amended, modified, revoked or rescinded, (ii) the incumbency, authority and specimen signature of each
officer of the Company executing this Agreement and (iii) true and complete attached copies of the Organizational Documents of
the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B>Certified Company Securityholder Lists.</B> An officer of the Company will have executed and delivered to Parent at least two
(2) Business Days prior to the Closing Date a certificate in a form and substance reasonably satisfactory to the Parent which
sets forth (i) a true and complete list of the Company Securityholders immediately prior to the Effective Time and the number
and type of Company Common Shares, Company Options, Company SARs or Company Warrants owned by each such Company Securityholder
and (ii) each Company Securityholder&rsquo;s pro rata share of the Consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<B>Certificate of Good Standing.</B> The Company shall have provided the Parent a certificate of good standing (or equivalent)
from the appropriate Governmental Authority of the jurisdiction of incorporation of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 364; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<B>Consents</B>. Evidence in form and substance reasonably satisfactory to the Parent that (i) the Company shall have obtained
or made any consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority
required to be obtained or made in connection with the execution and delivery of this Agreement or the consummation of the transactions
contemplated hereby and (ii) the Company shall have obtained all consents, waivers and approvals set forth on <U>Schedule 8.2(l)
</U>hereof in a form and substance reasonably satisfactory to the Parent and copies thereof shall have been delivered to the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<B>Net Cash</B>. Immediately prior to the Effective Time, the Company shall have unencumbered, unrestricted cash on hand of at
least C$4,000,000 minus any cash expended or to be expended on reasonable and documented out-of-pocket costs primarily related
to the Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<B>Option Plan Amendment</B>. Evidence reasonably satisfactory to the Parent of the amendment to the Company Option Plan described
in <U>Section 2.5(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
Additional Conditions Precedent to the Obligations of the Company</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not required to complete the Amalgamation unless each of the following conditions is satisfied on or before the Effective
Time, which conditions are for the exclusive benefit of the Company and may only be waived, in whole or in part, by the Company
in its sole discretion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Representations and Warranties.</B> The representations and warranties of the Parent and the Purchaser set forth in <U>Article
5</U> shall be true and correct as of the Execution Date and the Closing Date as though made on and as of the Execution Date and
the Closing Date (as applicable), except to the extent such representations and warranties speak as of another date (in which
case, such representations and warranties shall be true and correct as of such date), and the Parent has delivered a certificate
confirming same to the Company, executed by an officer of the Parent (without personal liability) addressed to the Company and
dated as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Performance of Covenants.</B> Each of the Parent and the Purchaser has fulfilled or complied in all material respects with
each of the covenants of the Parent and the Purchaser contained in this Agreement to be fulfilled or complied with by it on or
prior to the Closing Date, and has delivered a certificate confirming same to the Company, executed by an officer of the Parent
(without personal liability) addressed to the Company and dated as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Material Adverse Effect.</B> There shall not have been or occurred a Material Adverse Effect with respect to the Parent that
has not been disclosed by the Parent prior to the Execution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Certificate</B>. The Parent shall have delivered a certificate signed by an executive officer of the Parent (without personal
liability), in form and substance reasonably satisfactory to the Company, dated as of the Closing Date, to the effect that each
of the conditions specified in <U>Section 8.3(a) &ndash; (c)</U> have been satisfied in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Fairness Opinion</B>. The Parent shall have delivered to the Company a fairness opinion for the Transactions, in form and substance
reasonably satisfactory to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 365; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Consents</B>. Evidence in form and substance reasonably satisfactory to the Company that (i) the Parent shall have obtained
or made any consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority
required to be obtained or made in connection with the execution and delivery of this Agreement or the consummation of the transactions
contemplated hereby and (ii) the Parent shall have obtained all consents, waivers and approvals set forth on <U>Schedule 8.3(f)
</U>hereof in a form and substance reasonably satisfactory to the Parent and copies thereof shall have been delivered to the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>Officer&rsquo;s Certificate.</B> The Company shall have received a certificate executed by an officer of the Parent (without
personal liability) certifying as to (i) an attached copy of each of the Parent Stockholder Approval Resolution and the Parent
Board Approval and stating neither the Parent Stockholder Approval Resolution nor the Parent Board Approval has been amended,
modified, revoked or rescinded, (ii) the incumbency, authority and specimen signature of each officer of the Parent executing
this Agreement and (iii) true and complete attached copies of the Organizational Documents of the Parent and the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<B>Certificate of Good Standing.</B> The Parent and the Purchaser shall have provided the Company a certificate of good standing
(or equivalent) from the appropriate Governmental Authority of the jurisdiction of incorporation or formation of the Parent and
the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B>Closing Cash. </B>Immediately prior to the Effective Time, the Parent shall have unencumbered, unrestricted cash on hand of
at least $15,000,000 minus any cash expended or to be expended on reasonable and documented out-of-pocket costs primarily related
to the Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<B>Form 8-K</B>. Parent shall have prepared a Form 8-K as required by the SEC rules and regulations, in a form and substance reasonably
satisfactory to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<B>Directors and Officers</B>. The Parent shall have provided the Company evidence satisfactory to the Company, acting reasonably,
that the appointments and elections contemplated by Section 7.7 will become effective as of the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
Satisfaction of Conditions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
conditions precedent set out in this <U>Article 8</U> are inserted for the benefit of the respective Parties. Any Party may refuse
to proceed with the Closing if the conditions precedent inserted for its benefit are not fulfilled to its reasonable satisfaction
at or prior to the Closing, and it will incur no liability to any other Party by reason of such refusal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5
Right of Waiver</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
conditions precedent set out in this <U>Article 8</U> may be waived in whole or in part by the Party for whose benefit they are
inserted, in such Party&rsquo;s absolute discretion. No such waiver will be of any effect unless it is in writing signed by the
Party granting the waiver or if such Party determines to proceed with the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
9</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
TERM AND TERMINATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
Term</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be effective from the Execution Date until the earlier of the Effective Time and the termination of this Agreement
in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 366; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
Termination</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
This Agreement may be terminated prior to the Effective Time by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    mutual written agreement of the Parties; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
    the Company or the Purchaser if:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent Stockholder Approval Resolution is not approved by the requisite vote at the Parent Meeting provided that a Party may
    not terminate this Agreement pursuant to this <U>Section 9.2(a)(ii)(A)</U> if the failure to obtain the Parent Stockholder
    Approval has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the
    failure of such Party to perform any of its covenants or agreements under this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Amalgamation Resolution is not approved by the necessary Company Securityholders at the Company Meeting provided that a Party
    may not terminate this Agreement pursuant to this <U>Section 9.2(a)(ii)(B)</U> if the failure to obtain the approval of the
    necessary Company Securityholders has been caused by, or is a result of, a breach by such Party of any of its representations
    or warranties or the failure of such Party to perform any of its covenants or agreements under this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
    the date of this Agreement, any Applicable Law is enacted, made, enforced or amended, as applicable, that makes the consummation
    of the Amalgamation illegal or otherwise permanently prohibits or enjoins the Company, the Parent or the Purchaser from consummating
    the Amalgamation, and such Applicable Law has, if applicable, become final and non-appealable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    there shall be in effect a final nonappealable order of a Governmental Authority of competent jurisdiction restraining, enjoining
    or otherwise prohibiting the consummation of the Transactions; <U>provided</U>, that the right to terminate this Agreement
    under this <U>Section 9.2(a)(ii)(D)</U> shall not be available to a party if such order was primarily due to the failure of
    such party to perform any of its obligations under this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Effective Time does not occur on or prior to the End Date, provided that a Party may not terminate this Agreement pursuant
    to this <U>Section 9.2(a)(ii)(E)</U> if the failure of the Effective Time to so occur has been caused by, or is a result of,
    a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants
    or agreements under this Agreement, <I>provided</I>, <I>however</I>, in the event that the SEC has not concluded its review
    of the S-4 Registration Statement by the date which is sixty (60) days prior to the End Date, then either of Parent or the
    Company shall be entitled to extend the End Date for an additional sixty (60) days by providing written notice to the other
    party;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 367; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company if:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Parent or the
    Purchaser under this Agreement occurs that would cause any condition in <U>Section 8.3(a)</U> or <U>Section 8.3(b)</U> not
    to be satisfied, and such breach or failure is incapable of being cured on or prior to the End Date or is not cured in accordance
    with the terms of <U>Section 7.10</U>; provided that any willful breach shall be deemed to be incurable, and; provided, further
    that the Company is not then in breach of this Agreement so as to cause any condition in <U>Section 8.2(a)</U> or <U>Section
    8.2(b)</U> not to be satisfied;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company wishes to enter into a binding written agreement with respect to a Superior Proposal (other than a confidentiality
    and standstill agreement permitted by Section 6.1(d)), in compliance with Section 6.1 and provided that no termination under
    this Section 9.2(a)(iii)(B) shall be effective unless and until the Company shall have paid to the Purchaser the Termination
    Fee required to be paid pursuant to Section 10.1(a);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    the Parent Board or any committee of the Parent Board fails to unanimously recommend or withdraws, amends, modifies or qualifies
    the Parent Board Approval, or publicly proposes or states its intention to do so (a &ldquo;<B>Parent Change in Recommendation</B>&rdquo;)
    (2) the Parent Board or a committee thereof shall have approved or recommended any Acquisition Proposal or authorized the
    Parent to enter into binding written agreement with respect to a Superior Proposal (other than a confidentiality and standstill
    agreement permitted by Section 6.1(d)); or (3) the Parent breaches <U>Article 6</U> in any material respect, provided, however,
    no termination pursuant to this <U>Section 9.2(a)(iii)(C)</U> shall be effective unless and until the Company shall have paid
    to the Purchaser the Termination Fee required to be paid pursuant to <U>Section 10.1</U>; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has occurred a Material Adverse Effect with respect to the Parent that has not been disclosed by the Parent prior to the Execution
    Date;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 368; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent (on its own behalf and on behalf of the Purchaser) if:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Company under
    this Agreement occurs that would cause any condition in <U>Section 8.2(a)</U> or <U>Section 8.2(b)</U> not to be satisfied,
    and such breach or failure is incapable of being cured on or prior to the End Date or is not cured in accordance with the
    terms of <U>Section 7.10</U>; provided that any willful breach shall be deemed to be incurable, and; provided, further that
    the Parent is not then in breach of this Agreement so as to cause any condition in <U>Section 8.3(a)</U> or <U>Section 8.3(b)
    </U>not to be satisfied;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Parent wishes to enter into a binding written agreement with respect to a Superior Proposal (other than a confidentiality
    and standstill agreement permitted by Section 6.1(d)), subject to compliance with Section 6.1 and provided that no termination
    under this Section 9.2(a)(iv)(B) shall be effective unless and until the Parent shall have paid to the Company the Termination
    Fee required to be paid pursuant to Section 10.1(b);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    the Company Board or any committee of the Company Board fails to unanimously recommend or withdraws, amends, modifies or qualifies
    the Company Board Approval, or publicly proposes or states its intention to do so (a &ldquo;<B>Company Change in Recommendation</B>&rdquo;)
    (2) the Company Board or a committee thereof shall have approved or recommended any Acquisition Proposal or authorized the
    Company to enter into binding written agreement with respect to a Superior Proposal (other than a confidentiality and standstill
    agreement permitted by Section 6.1(d)); or (3) the Company breaches <U>Article 6</U> in any material respect; provided, however,
    no termination pursuant to this <U>Section 9.2(a)(iv)(C)</U> shall be effective unless and until the Parent shall have paid
    to the Company the Termination Fee required to be paid pursuant to <U>Section 10.1</U>; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    has occurred a Material Adverse Effect with respect to the Company that has not been publicly disclosed by the Company prior
    to the Execution Date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Party desiring to terminate this Agreement pursuant to this <U>Section 9.2</U> shall give notice of such termination to the
other Party, specifying in reasonable detail the basis for such Party&rsquo;s exercise of its termination right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3
Effect of Termination/Survival</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Agreement is terminated pursuant to <U>Section 9.2</U>, this Agreement shall become void and of no further force or effect
without liability of any Party (or any shareholder, director, officer, employee, agent, consultant or representative of such Party)
to any other Party to this Agreement, except (a) as set forth in <U>Section 11.6</U>, (b) <U>Article 10</U>, and (c) provided
further that no Party shall be relieved of any liability for any fraud or willful breach by it of this Agreement. No termination
of this Agreement will affect the obligations of the Parties contained in the Confidentiality Agreement, all of which obligations
will, in addition to this <U>Section 9.3</U>, <U>Article 10, Article 11</U> (other than <U>Section 11.6</U>) and the defined terms
used in such Section and Article set forth or referenced in <U>Section 1.1</U> hereof, survive termination of this Agreement in
accordance with their respective terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 369; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
10</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERMINATION
AMOUNTS AND OTHER ARRANGEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
Termination Fee</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall pay to Parent and Parent shall be entitled to the Termination Fee (on its own behalf and on behalf of the Purchaser)
upon the occurrence of any of the following events (each a &ldquo;<B>Parent Termination Payment Event</B>&rdquo;) which shall
be paid by Company within the time specified in respect of each such Parent Termination Payment Event:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the Parent pursuant to Section 9.2(a)(iv)(C) [<I>Company Change in Recommendation, Agreement with Respect to an Acquisition
    Proposal or Breach of Non-Solicit</I>]; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the Company pursuant to Section 9.2(a)(iii)(B) [<I>Superior Proposal</I>];</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that the Termination Fee shall not be payable pursuant to this <U>Section 10.1(a)</U> if Parent or Purchaser are then in breach
of any of their respective representations and warranties or any of their covenants or agreements under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If a Parent Termination Payment Event occurs, the Company shall pay the Termination Fee to the Parent, or as the Parent may direct,
as liquidated damages in consideration for the loss of the Parent&rsquo;s and Purchaser&rsquo;s rights under this Agreement, by
wire transfer of immediately available funds, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the Termination Fee is payable pursuant to <U>Section 10.1(a)(i)</U>, the Termination Fee shall be payable within three (3)
    Business Days following such termination; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the Termination Fee is payable pursuant to <U>Section 10.1(a)(ii)</U>, the Termination Fee shall be payable concurrently with
    the execution of the definitive agreement with respect to the Superior Proposal referred to in <U>Section 9.2(a)(iii)(B)</U>;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Parent shall pay to the Company and Company shall be entitled to the Termination Fee upon the occurrence of any of the following
events (each a &ldquo;<B>Company Termination Fee Event</B>&rdquo;) which shall be paid by Parent within the time specified in
respect of each such Company Termination Payment Event:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the Company pursuant to Section 9.2(a)(iii)(C) [<I>Parent Change in Recommendation, Agreement with Respect to an Acquisition
    Proposal or Breach of Non-Solicit</I>]; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the Parent pursuant to Section 9.2(a)(iv)(B) [<I>Superior Proposal</I>];</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that the Termination Fee shall not be payable pursuant to this <U>Section 10.1(c)</U> if Company is then in breach of any of its
representations and warranties or any of its covenants or agreements under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 370; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If a Parent Termination Payment Event occurs, the Company shall pay the Termination Fee to the Parent, or as the Parent may direct,
as liquidated damages in consideration for the loss of the Parent&rsquo;s and Purchaser&rsquo;s rights under this Agreement, by
wire transfer of immediately available funds, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the Termination Fee is payable pursuant to <U>Section 10.1(c)(i)</U>, the Termination Fee shall be payable within three (3)
    Business Days following such termination; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the Parent Termination Payment is payable pursuant to <U>Section 10.1(c)(ii)</U>, the Termination Fee shall be payable concurrently
    with the execution of the definitive agreement with respect to the Superior Proposal referred to in <U>Section 9.2(a)(iv)(B)</U>;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Termination Fee shall be payable by a Party by wire transfer in immediately available funds to an account specified by the
other Party. For greater certainty, in no event shall a Party be obligated to pay the Termination Fee on more than one occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Each of the Parties acknowledges that the agreements contained in this Section 10.1 are an integral part of the transactions contemplated
in this Agreement and that, without those agreements, the Parties would not enter into this Agreement. Each Party acknowledges
that all of the payment amounts set out in this Section 10.1 are payments of liquidated damages which are a genuine pre-estimate
of the damages which the Party entitled to such damages will suffer or incur as a result of the event giving rise to such payment
and the resultant termination of this Agreement and are not penalties and that such payments are intended to be proceeds for the
disposition of the applicable Party&rsquo;s rights under this Agreement. Each Party irrevocably waives any right it may have to
raise as a defence that any such liquidated damages are excessive or punitive. For greater certainty, the Parties agrees that,
upon any termination of this Agreement under circumstances where a Party is entitled to a Termination Fee is paid in full, such
Party shall be precluded from any other remedy against the other Party under Applicable Law or in equity or otherwise (including,
without limitation, an order for specific performance), and shall not seek to obtain any recovery, judgment, or damages of any
kind, including consequential, indirect, or punitive damages, against the Other Party, its Subsidiaries or any of their respective
directors, officers, employees, partners, managers, members, shareholders or Affiliates or its Representatives in connection with
this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Nothing in this Section 10.1 shall relieve or have the effect of relieving any Party in any way from liability for damages incurred
or suffered by the other Party as a result of fraud or an intentional or wilful breach of this Agreement by such Party. Nothing
in this Section 10.1 shall relieve or have the effect of relieving any Party in any way from liability for damages incurred or
suffered by the other Party as a result of fraud or an intentional or wilful breach of this Agreement by such Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 371; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
11</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
GENERAL PROVISIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1
Amendments</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement and the Amalgamation may, at any time and from time to time before or after the holding of the Company Meeting but not
later than the Effective Time, be amended by mutual written agreement of the Parties, without further notice to or authorization
on the part of the Company Securityholders, and any such amendment may, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
change the time for performance of any of the obligations or acts of the Parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
modify any representation or warranty contained herein or in any document delivered pursuant hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
modify any of the covenants contained in this Agreement and waive or modify performance of any of the obligations of the Parties;
and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
modify any mutual conditions contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2
Notices</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice, direction or other communication regarding the matters contemplated by this Agreement must be in writing, sent by personal
delivery, courier, or facsimile (but not by electronic mail) and addressed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    Parent and the Purchaser at:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
FL 34103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
David Johnson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
djohnson@enveric.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
copies to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
and Boone, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
Rockefeller Plaza</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26th
Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10112</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Rick Werner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
Rick.Werner@haynesboone.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
and Boone, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1050
17<SUP>th</SUP> Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
1800</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denver,
CO 80265</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Dan Malone</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
Dan.Malone@haynesboone.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 372; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    the Company at:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
Industries Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
120-4838 Richard Rd SW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calgary,
Alberta T3E 6L1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Dr. Joseph Tucker</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
jtucker@magicmedindustries.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
copies to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greenfield
Law&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120-4838
Richard Rd SW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calgary,
Alberta T3E 6L1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Mike Flach</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
michael@greenfields-law.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Burnet,
Duckworth &amp; Palmer LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
2400, 525-8th Ave SW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calgary,
Alberta T2P 1G1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Syd S. Abougoush</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
sabougoush@bdplaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice or other communication is deemed to be given and received (i) if sent by personal delivery or same day courier, on the
date of delivery if it is a Business Day and the delivery was made prior to 4:00 p.m. (local time in place of receipt) and otherwise
on the next Business Day, (ii) if sent on a Business Day by email before 11:59 p.m. (recipient&rsquo;s time), when transmitted,
(iii) if sent by email on a day other than a Business Day, or if sent by email after 11:59 p.m. (recipient&rsquo;s time), on the
Business Day following the date when transmitted, (iv) if sent by overnight courier, on the next Business Day, or (v) if sent
by facsimile, on the Business Day following the date of confirmation of transmission by the originating facsimile. A Party may
change its address for service from time to time by providing a notice in accordance with the foregoing. Any subsequent notice
or other communication must be sent to the Party at its changed address. Any element of a Party&rsquo;s address that is not specifically
changed in a notice will be assumed not to be changed. Sending a copy of a notice or other communication to a Party&rsquo;s legal
counsel as contemplated above is for information purposes only and does not constitute delivery of the notice or other communication
to that Party. The failure to send a copy of a notice or other communication to legal counsel does not invalidate delivery of
that notice or other communication to a Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3
Further Assurances</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Party will execute and deliver all such further documents and instruments and do all acts and things as the other Parties may,
either before or after the Effective Time, reasonably require to effectively carry out or better evidence or perfect the full
intent and meaning of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4
Time of the Essence</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
is of the essence to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 373; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5
Expenses</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Parties shall be responsible for its own costs and charges incurred with respect to the transactions contemplated herein,
including all costs and charges incurred prior to the date of this Agreement and all legal and accounting fees and disbursements
relating to preparing the Transaction Documents or otherwise relating to the transactions contemplated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6
Injunctive Relief</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties agree that irreparable harm would occur for which money damages would not be an adequate remedy at law in the event that
any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the Parties shall be entitled to injunctive and other equitable relief to prevent breaches or threatened
breaches of this Agreement, and to enforce compliance with the terms of this Agreement without any requirement for the securing
or posting of any bond in connection with the obtaining of any such injunctive or other equitable relief, this being in addition
to any other remedy to which the Parties may be entitled at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7
Waiver</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
waiver of any of the provisions of this Agreement will constitute a waiver of any other provision (whether or not similar). No
waiver will be binding unless executed in writing by the Party to be bound by the waiver. A Party&rsquo;s failure or delay in
exercising any right under this Agreement will not operate as a waiver of that right. A single or partial exercise of any right
will not preclude a Party from any other or further exercise of that right or the exercise of any other right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8
No Third Party Beneficiaries</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties intend that this Agreement will not benefit or create any right or cause of action in favor of, any Person, other than
the Parties and no Person, other than the Parties to this Agreement, is entitled to rely on the provisions of this Agreement in
any Proceeding or other forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9
Entire Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement, together with the Confidentiality Agreement, constitutes the entire agreement between the Parties with respect to the
transactions contemplated by this Agreement and supersedes all prior agreements, understandings, negotiations and discussions,
whether oral or written, of the Parties; provided that to the extent any provisions of the Confidentiality Agreement conflict
with the terms of this Agreement, the terms of this Agreement shall prevail. There are no representations, warranties, covenants,
conditions or other agreements, express or implied, collateral, statutory or otherwise, between the Parties in connection with
the subject matter of this Agreement, except as specifically set forth in this Agreement. The Parties have not relied and are
not relying on any other information, discussion or understanding in entering into and completing the transactions contemplated
by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10
Benefit of the Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will inure to the benefit of and be binding upon the respective heirs, executors, administrators, other legal representatives,
successors and permitted assigns of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 374; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11
Successors and Assigns</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
This Agreement becomes effective only when executed by the Company, the Parent and the Purchaser. After that time, it will be
binding upon and inure to the benefit of the Company, the Parent and the Purchaser and their respective successors and permitted
assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Neither this Agreement nor any of the rights or obligations under this Agreement are assignable or transferable by any Party without
the prior written consent of the other Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.12
Severability</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any provision of this Agreement is determined to be illegal, invalid or unenforceable by any court of competent jurisdiction,
that provision will be severed from this Agreement and the remaining provisions shall remain in full force and effect. Upon such
determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate
in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable
manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13
Governing Law</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement will be governed by and interpreted and enforced in accordance with the laws of the Province of British Columbia and
the federal laws of Canada applicable therein. Each Party irrevocably attorns and submits to the exclusive jurisdiction of the
courts of competent jurisdiction of the Province of British Columbia in any Proceeding hereunder, and waives objection to the
venue of any Proceeding in such court or that such court provides an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.14
Counterparts</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts, each of which will be deemed to be an original and all of which taken
together will be deemed to constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.15
Electronic Execution</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
of an executed signature page to this Agreement by any Party by electronic transmission will be as effective as delivery of a
manually executed copy of the Agreement by such Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.16
Rules of Construction</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties to this Agreement waive the application of any Applicable Law or rule of construction providing that ambiguities in any
agreement or other document shall be construed against the party drafting such agreement or other document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.17
No Liability</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director or officer of the Parent or the Purchaser shall have any personal liability whatsoever to the Company under this Agreement
or any other document delivered in connection with the transactions contemplated hereby on behalf of the Parent or the Purchaser.
No director or officer of the Company shall have any personal liability whatsoever to the Parent or the Purchaser under this Agreement
or any other document delivered in connection with the transactions contemplated hereby on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<B>remainder
of page intentionally left blank</B>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 375; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF </B>the Parties have executed this Amalgamation Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
    BIOSCIENCES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Johnson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1306432
    B.C. LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Johnson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1306436
    B.C. LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Johnson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MAGICMED
    INDUSTRIES INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 376; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_153"></A>Annex
B</B></FONT><B>-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VOTING
AND SUPPORT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
VOTING AND SUPPORT AGREEMENT </B><FONT STYLE="font-weight: normal">(this &ldquo;</FONT><B>Agreement</B><FONT STYLE="font-weight: normal">&rdquo;)
</FONT>is made as of this _____ day of May, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMONG:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">______________________________________________
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the &ldquo;<B>Shareholder</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;
and &ndash;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
corporation existing under the laws of the State of Delaware (the &ldquo;<B>Parent</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;
and &ndash;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1306436
B.C. LTD.</B> , a corporation incorporated under the laws of the Province of British Columbia (the &ldquo;<B>Purchaser</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS
</B>the Shareholder is the registered and/or beneficial owner of that number of issued and outstanding common shares (the &ldquo;<B>Common
Shares</B>&rdquo;) in the capital of MagicMed Industries Inc. (the &ldquo;<B>Company</B>&rdquo;), a corporation existing under the laws
of the Province of British Columbia, set forth on Schedule &ldquo;A&rdquo; attached to this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND
WHEREAS </B>the Shareholder is the holder of that number of securities to purchase Common Shares (the &ldquo;<B>Securities</B>&rdquo;)
set forth on Schedule &ldquo;A&rdquo; attached to this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND
WHEREAS </B>the Parent, 1306432 B.C. Ltd. (&ldquo;<B>HoldCo</B>&rdquo;), the Purchaser and the Company have entered into an amalgamation
agreement concurrently with the entering into of this Agreement (the &ldquo;<B>Amalgamation Agreement</B>&rdquo;) and propose, subject
to the terms and conditions of the Amalgamation Agreement, to consummate an amalgamation as set forth in the Amalgamation Agreement (the
&ldquo;<B>Amalgamation</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND
WHEREAS </B>the Shareholder acknowledges that the Parent, HoldCo and the Purchaser would not enter into the Amalgamation Agreement but
for the execution and delivery of this Agreement by the Shareholder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B> this Agreement witnesses that, in consideration of the premises and the covenants and agreements herein contained, the
parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
1<BR>
INTERPRETATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.1</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
terms used in this Agreement that are not defined herein and that are defined in the Amalgamation Agreement shall have the respective
meanings ascribed to them in the Amalgamation Agreement. For the purposes of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subject
Shares</B>&rdquo; means that number of Common Shares set forth on Schedule &ldquo;A&rdquo; to this Agreement, being all of the Common
Shares owned legally or beneficially, either directly or indirectly, by the Shareholder or over which the Shareholder exercises control
or direction, either directly or indirectly, and shall further include any Common Shares issued upon the exercise by the Shareholder
of Securities, and any Common Shares otherwise acquired by the Shareholder after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 377; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subject
Securities</B>&rdquo; means, the Subject Shares and that number of Securities set forth on Schedule &ldquo;A&rdquo; attached to this
Agreement, being all of the securities owned legally or beneficially by the Shareholder or over which the Shareholder exercises control
or direction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
2<BR>
COVENANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.1</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Covenants of the Shareholder</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shareholder hereby covenants and agrees in favour of the Parent and the Purchaser that, from the date hereof until the termination of
this Agreement in accordance with Article 4, except as permitted by this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    any meeting of shareholders of the Company called to vote upon the Amalgamation Agreement or the transactions contemplated by the
    Amalgamation Agreement or at any adjournment or postponement thereof or in any other circumstances upon which a vote, consent or
    other approval (including by written consent in lieu of a meeting) with respect to the Amalgamation Agreement or the transactions
    contemplated by the Amalgamation Agreement is sought, the Shareholder shall cause its Subject Securities that have the right to vote
    at such meeting to be counted as present for purposes of establishing quorum and shall vote (or cause to be voted) its Subject Securities
    that have the right to vote at such meeting in favour of the approval of the Amalgamation, any other transactions contemplated in
    the Amalgamation Agreement and any other matter necessary for the consummation of the Amalgamation. If the Shareholder is the beneficial
    owner, but not the registered holder, of any of its Subject Securities, the Shareholder agrees to take all actions necessary to cause
    the registered holder and any nominees to vote all of its Subject Securities that have the right to vote at such meeting in accordance
    with this Section 2.1(a);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    any meeting of securityholders of the Company or at any adjournment or postponement thereof or in any other circumstances upon which
    a vote, consent or other approval of all or some of the holders of Subject Securities is sought (including by written consent in
    lieu of a meeting), the Shareholder shall cause its Subject Securities that have the right to vote at such meeting to be counted
    as present for purposes of establishing quorum and shall vote (or cause to be voted) its Subject Securities that have the right to
    vote in respect of such matter against (i) any Acquisition Proposal for the Company, (ii) any action, agreement, transaction or proposal
    that would result in a breach of any representation, warranty, covenant, agreement or other obligation of the Company in the Amalgamation
    Agreement or of the Shareholder under this Agreement, and/or (iii) any matter that could reasonably be expected to delay, prevent,
    impede or frustrate the successful completion of the Amalgamation or any of the transactions contemplated by the Amalgamation Agreement.
    If the Shareholder is the beneficial owner, but not the registered holder, of any of its Subject Securities, the Shareholder agrees
    to take all actions necessary to cause the registered holder and any nominees to vote all of its Subject Securities in accordance
    with this Section 2.1(b);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to section 5.1, the Shareholder agrees not to, directly or indirectly:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solicit,
    assist, initiate, encourage or otherwise knowingly facilitate (including by way of furnishing or providing copies of, access to,
    or disclosure of, any confidential information, properties, facilities, books or records of the Company or any of its Subsidiaries
    or entering into any form of agreement, arrangement or understanding) any inquiry, proposal or offer that constitutes or may reasonably
    be expected to constitute or lead to, an Acquisition Proposal for the Company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 378; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into or otherwise engage or participate in any discussions or negotiations with any Person (other than the Parent, the Purchaser
    and their respective Affiliates) regarding any inquiry, proposal or offer that constitutes or may reasonably be expected to constitute
    or lead to, an Acquisition Proposal for the Company; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accept
    or enter into or publicly propose to accept or enter into any agreement, understanding or arrangement in respect of an Acquisition
    Proposal for the Company,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to section 5.1, the Shareholder shall promptly notify the Purchaser, at first orally, and then as soon as practicable and in any
    event within one (1) business day, if the Shareholder (i) receives or otherwise becomes aware of any inquiry, proposal or offer that
    constitutes or may reasonably be expected to constitute or lead to an Acquisition Proposal for the Company, or (ii) any request for
    copies of, access to, or disclosure of, confidential information relating to the Company or any of its Subsidiaries in connection
    with an Acquisition Proposal for the Company, including but not limited to information, access, or disclosure relating to the properties,
    facilities, books or records of the Company or any of its Subsidiaries. Such notice shall include a description of the material terms
    and conditions of any such Acquisition Proposal, inquiry, proposal, offer or request and the identity of all Persons making the Acquisition
    Proposal (the &ldquo;<B>Offeror</B>&rdquo;), inquiry, proposal, offer or request, and shall attach copies of all written documents,
    material or substantive correspondence or other material received in respect of, from or on behalf of the Offeror.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Shareholder shall not take any other action of any kind, directly or indirectly, which might reasonably be regarded as likely to
    reduce the success of, or delay or interfere with the completion of the transactions contemplated by the Amalgamation Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Shareholder shall, with respect to such matters as may reasonably be in the Shareholder&rsquo;s power or control, cooperate with
    the Company, the Parent and the Purchaser, each acting reasonably, to successfully complete the Amalgamation and the other transactions
    contemplated by the Amalgamation Agreement and this Agreement and to oppose any of the matters listed in Section 2.1(b);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Shareholder shall not exercise any rights of appraisal or rights of dissent provided under any Applicable Laws or otherwise in connection
    with the Amalgamation or the transactions contemplated by the Amalgamation Agreement that the Shareholder may have; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    later than five (5) Business Days prior to the date of the Company Meeting: (i) with respect to any Subject Securities that are entitled
    to vote at the Company Meeting that are in registered form, the Shareholder shall deliver or cause to be delivered, in accordance
    with the instructions set out in the Company Circular and with a copy to the Purchaser concurrently with such delivery, a duly executed
    proxy or proxies directing the holder of such proxy or proxies to vote in favour of the Amalgamation; and (ii) with respect to any
    Subject Securities that are entitled to vote at the Company Meeting and that are held beneficially, the Shareholder shall deliver
    or cause to be delivered, in accordance with the instructions set out in the Company Circular and with a copy to the Purchaser concurrently
    with such delivery, a duly executed voting instruction form to the intermediary through which the Shareholder holds its beneficial
    interest in the Shareholder&rsquo;s Subject Securities, instructing that the Shareholder&rsquo;s Subject Securities be voted at the
    Company Meeting in favour of the Amalgamation. Such proxy or proxies shall name those individuals as may be designated by the Company
    in the Company Circular and such proxy or proxies or voting instructions shall not be revoked without the written consent of the
    Purchaser or upon termination of this Agreement. The Shareholder hereby agrees that neither it nor any person on its behalf will
    take any action to withdraw, amend or invalidate any proxy deposited by the Shareholder pursuant to this Agreement notwithstanding
    any statutory or other rights or otherwise which the Shareholder might have unless this Agreement is terminated in accordance with
    its terms.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 379; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.2</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenants
    of the Parent and the Purchaser</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Parent and the Purchaser agree to comply with its obligations under the Amalgamation Agreement. Each of the Parent and the Purchaser
hereby agree and confirm to the Shareholder that it shall take all steps required of it to consummate the Amalgamation and cause the
Consideration to be made available to exchange for the Subject Shares, in each case in accordance with and subject to the terms and conditions
of the Amalgamation Agreement and the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
3<BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.1</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations
    and Warranties of the Shareholder</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shareholder hereby represents and warrants to and covenants with each of the Parent and the Purchaser as follows, and acknowledges that
the Parent and the Purchaser are relying upon such representations, warranties and covenants in entering into this Agreement and the
Amalgamation Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporation;
    Capacity; Authorization.</B> Where the Shareholder is a corporation or other entity, it is a corporation or other entity duly incorporated,
    amalgamated or organized, as applicable, and validly existing under the laws of the jurisdiction of its incorporation, organization
    or formation as applicable, and has all requisite power, capacity and authority and has received all requisite approvals to execute
    and deliver this Agreement and to perform its obligations hereunder. Where the Shareholder is an individual, he or she has the power
    and capacity and has received all requisite approvals to execute and deliver this Agreement and to perform his or her obligations
    hereunder.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enforceable.
    </B>This Agreement has been duly executed and delivered by the Shareholder, and constitutes a legal, valid and binding agreement
    of the Shareholder enforceable against it in accordance with its terms subject only to any limitation under bankruptcy, insolvency
    or other Applicable Laws affecting the enforcement of creditors&rsquo; rights generally and the discretion that a court may exercise
    in the granting of equitable remedies such as specific performance and injunction.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership
    of Subject Securities. </B>The Shareholder is the sole registered and/or beneficial owner of the Subject Securities. The Shareholder
    does not directly or indirectly control or direct, or own or have any registered or beneficial interest in, any other securities
    of the Company. The Shareholder or any Person named in Schedule &ldquo;A&rdquo; is and will be immediately prior to the Effective
    Time, the registered and/or beneficial owner of the Subject Securities, with good and marketable title thereto, free and clear of
    any and all Liens.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
    Breach. </B>Neither the execution and delivery of this Agreement by the Shareholder, the consummation by the Shareholder of the transactions
    contemplated hereby nor the compliance by the Shareholder with any of the provisions hereof will:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contravene,
    conflict with, or result in any violation or breach of, allow any Person to exercise any rights, require any consent or other action
    by any Person, or constitute a default under, or cause or permit the termination, cancellation, acceleration or other change of any
    right or obligation or the loss of any benefit to which the Shareholder is entitled (including by triggering any rights of first
    refusal or first offer, change in control provision or other restriction or limitation) under the certificate of incorporation, articles,
    by-laws or any other constating documents of the Shareholder, as applicable, or any of the terms, conditions or provisions of any
    note, loan agreement, bond, mortgage, indenture, contract, license, agreement, lease, permit or other instrument or obligation to
    which the Shareholder is a party or by which the Shareholder or any of its properties or assets (including the Subject Securities)
    may be bound;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 380; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    on the part of the Shareholder any filing with (other than pursuant to the requirements of applicable securities legislation (which
    filings the Shareholder will undertake)) or permit, authorization, consent or approval of, any Governmental Authority or any other
    Person; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to compliance with any approval or Applicable Laws contemplated by the Amalgamation Agreement, contravene, conflict with or result
    in a violation or breach of any Applicable Laws;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
each case other than as would not be reasonably expected to have a materially adverse effect on the Shareholder&rsquo;s ability to perform
its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
    Proceedings.</B> There are no claims, actions, suits, arbitrations, inquiries, investigations or proceedings pending, or, to the
    knowledge of the Shareholder, threatened against the Shareholder that, individually or in the aggregate, could reasonably be expected
    to have an adverse effect on the Shareholder&rsquo;s ability to perform its obligations hereunder. The Shareholder is not subject
    to any outstanding judgment, order, writ, injunction or decree that, individually or in the aggregate, could reasonably be expected
    to have an adverse effect on the Shareholder&rsquo;s ability to perform its obligations hereunder.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
    Agreements. </B>No Person has any agreement or option, or any right or privilege (whether by law, pre-emptive or contractual) capable
    of becoming an agreement or option, for the purchase, acquisition or transfer of any of the Subject Securities, or any interest therein
    or right thereto, except pursuant to this Agreement or the Amalgamation Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting.
    </B>The Shareholder has the sole and exclusive right to enter into this Agreement and to vote the Subject Securities as contemplated
    herein. None of the Subject Securities is subject to any proxy, power of attorney, attorney-in-fact, voting trust, vote pooling or
    other agreement with respect to the right to vote, call meetings of shareholders or give consents or approvals of any kind.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consents.
    </B>Subject to compliance with any approval or Applicable Laws contemplated by the Amalgamation Agreement, no consent, approval,
    order or authorization of, or declaration or filing with, any Governmental Authority is required to be obtained by the Shareholder
    in connection with the execution, delivery or performance of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.2</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations
    and Warranties of the Parent and the Purchaser</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Parent and the Purchaser hereby represent and warrant and covenant to the Shareholder, acknowledging that the Shareholder is relying
upon such representations, warranties and covenants in entering into this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporation;
    Capacity; Authorization. </B>Each of the Parent and the Purchaser is a corporation or other entity duly incorporated, amalgamated
    or organized, as applicable, and validly existing under the laws of the jurisdiction of its incorporation, organization or formation
    as applicable, and has all requisite power, capacity and authority and has received all requisite approvals to execute and deliver
    this Agreement and to perform its obligations hereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 381; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enforceable.
    </B>This Agreement has been duly executed and delivered by each of the Parent and the Purchaser and constitutes a legal, valid and
    binding agreement of each of the Parent and the Purchaser enforceable against it in accordance with its terms subject only to any
    limitation under bankruptcy, insolvency or other Applicable Laws affecting the enforcement of creditors&rsquo; rights generally and
    the discretion that a court may exercise in the granting of equitable remedies such as specific performance and injunction.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
    Breach</B>. The execution and delivery of this Agreement by each of the Parent and the Purchaser, the consummation by each of the
    Parent and the Purchaser of the transactions contemplated hereby, and the compliance by each of the Parent and the Purchaser with
    any of the provisions hereof, will not constitute a violation of or default under, or conflict with, any restriction of any kind
    or any contract, commitment, agreement, understanding or arrangement to which it is a party or by which it is bound, other than as
    would not be reasonably expected to have a materially adverse effect on the Parent and the Purchaser&rsquo;s ability to perform its
    respective obligations hereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
4<BR>
TERMINATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.1</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be terminated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    any time upon the written agreement of the Purchaser and the Shareholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the Shareholder: (i) if any of the representations and warranties of the Parent and the Purchaser in this Agreement shall not be
    true and correct in all material respects; or (ii) if the Parent and the Purchaser shall not have complied with the covenants to
    the Shareholder contained in this Agreement; provided that the Shareholder has notified the Purchaser in writing of any of the foregoing
    events and the same has not been cured within 5 Business Days of the date such notice was received by the Purchaser; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the Purchaser if: (i) any of the representations and warranties of the Shareholder in this Agreement shall not be true and correct
    in all material respects; or (ii) the Shareholder shall not have complied with its covenants to the Parent and the Purchaser contained
    in this Agreement, provided that the Purchaser has notified the Shareholder in writing of any of the foregoing events and the same
    has not been cured within 5 Business Days of the date such notice was received by the Shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.2</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
    Termination</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall automatically terminate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    the Effective Time; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the Amalgamation Agreement is terminated in accordance with its terms (other than and excluding any termination pursuant
    to Section 9.2(a)(iii)(B) thereof).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 382; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.3</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Termination</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Agreement is terminated in accordance with this Article 4, the provisions of this Agreement will become void and no party shall
have liability to any other party and the Shareholder shall be entitled to withdraw any form of proxy, voting instruction form or power
of attorney which it may have given with respect of the Subject Securities; provided that neither the termination of this Agreement nor
anything contained in Article 4 will relieve any party from any liability for any breach by it of this Agreement prior to such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
5<BR>
GENERAL</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.1</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiduciary
    Obligations</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchaser agrees and acknowledges that the Shareholder is bound hereunder solely in his or her capacity as a shareholder of the Company
and that the provisions of this Agreement shall not be deemed or interpreted to bind the Shareholder or any of its directors, officers
or principal shareholder in his or her capacity as a director or officer of the Company or any of its Subsidiaries. For the avoidance
of doubt, nothing in this Agreement shall limit or restrict any party from properly fulfilling his or her fiduciary duties as a director
or officer of the Company. Notwithstanding anything else herein to the contrary, nothing in this Agreement shall prevent a Shareholder
who is a member of the board of directors or an officer of the Company from engaging, in such Shareholder&rsquo;s capacity as a director
or officer of the Company or any of its subsidiaries, in discussion or negotiations with a person in response to any bona fide Acquisition
Proposal or Superior Proposal in accordance with the terms of the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.2</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Assurances</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Shareholder, the Parent and the Purchaser will, from time to time, execute and deliver all such further documents and instruments
and do all such acts and things as the other party may reasonably require and at the requesting party&rsquo;s cost to effectively carry
out or better evidence or perfect the full intent and meaning of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.3</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Shareholder, the Parent and the Purchaser hereby consents to the disclosure of the substance of this Agreement in any press release
or any Company Circular or any other documents required to be filed under Securities Laws relating to the Company Meeting or Parent Meeting
and the filing of a copy thereof by the Company on SEDAR or Parent on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth above or as required by Applicable Laws or by any Governmental Authority or in accordance with the requirements of any stock
exchange, the Shareholder shall make no public announcement or statement with respect to this Agreement without the approval of the Parent,
which shall not be unreasonably withheld or delayed. The Shareholder agrees to consult with the Parent prior to issuing each public announcement
or statement with respect to this Agreement, subject to the overriding obligations of Applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.4</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
    of the Essence</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
is of the essence in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.5</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
    Law</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Agreement will be governed by and interpreted and enforced in accordance with the laws of the Province of British Columbia and the
    federal laws of Canada applicable therein.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Each
    party hereto irrevocably attorns and submits to the non-exclusive</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jurisdiction
    of the courts situated in the City of Vancouver and waives objection to the venue of any proceeding in such court or that such court
    provides an inconvenient forum.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 383; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.6</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
    Agreement</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement, including the schedules hereto and the provisions of the Amalgamation Agreement incorporated herein by reference, or that
are for the benefit of a party pursuant to the Amalgamation Agreement, constitutes the entire agreement between the parties with respect
to the transactions contemplated by this Agreement and supersedes all prior agreements, understandings, negotiations and discussions,
whether oral or written, of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.7</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may not be modified, amended, altered or supplemented, except upon the execution and delivery of a written agreement executed
by each of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.8</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any provision of this Agreement is determined to be illegal, invalid or unenforceable by any court of competent jurisdiction, that provision
will be severed from this Agreement and the remaining provisions shall remain in full force and effect. Upon such determination that
any term or other provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions
contemplated hereby are fulfilled to the fullest extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.9</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement becomes effective only when executed by the Shareholder, the Parent and the Purchaser. After that time, it will be binding
upon and enure to the benefit of the Shareholder, the Parent and the Purchaser and their respective successors and permitted assigns.
Neither this Agreement nor any of the rights or obligations under this Agreement are assignable or transferable by any party without
the prior written consent of the other parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.10</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Agreement is terminated, this Agreement shall become void and of no further force or effect without liability of any party (or any
shareholder, director, officer, employee, agent, consultant or representative of such party) to any other party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.11</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice, or other communication given regarding the matters contemplated by this Agreement must be in writing, sent by personal delivery,
courier or electronic mail and addressed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    the Parent and the Purchaser, addressed as follows:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Biosciences, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
    Tamiami Trail N, Suite 200</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
    FL 34103</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Johnson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">djohnson@enveric.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    copies (which shall not constitute notice) to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
    and Boone, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
    Rockefeller Plaza, 26th Floor</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10112</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rick
    Werner</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rick.Werner@haynesboone.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
    and Boone, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1050
    17th Street, Suite 1800</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denver,
    CO 80265</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Malone</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan.Malone@haynesboone.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 384; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    the Shareholder, as set forth on the signature page to this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 77.75pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice or other communication is deemed to be given and received (i) if sent by personal delivery or same day courier, on the date of
delivery if it is a Business Day and the delivery was made prior to 4:00 p.m. (local time in place of receipt) and otherwise on the next
Business Day, (ii) if sent by overnight courier, on the next Business Day, or (iii) if sent by email, on the Business Day following the
date of email. Sending a copy of a notice or other communication to a Party&rsquo;s legal counsel as contemplated above is for information
purposes only and does not constitute delivery of the notice or other communication to that Party. The failure to send a copy of a notice
or other communication to legal counsel does not invalidate delivery of that notice or other communication to a Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.12</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
    Performance and other Equitable Rights</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties agree that irreparable harm would occur, for which money damages would not be an adequate remedy at law, in the event that any
of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly
agreed that the parties shall be entitled to interlocutory, preliminary and permanent injunctive relief, specific performance and other
equitable relief to prevent breaches or threatened breaches of this Agreement, and to enforce compliance with the terms of this Agreement
without the proof of actual damages and without any requirement for the securing or posting of any bond in connection with the obtaining
of any such injunctive or other equitable relief, this being in addition to any other remedy to which the parties may be entitled at
law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.13</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
costs and expenses incurred in connection with this Agreement shall be paid by the party incurring such cost or expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.14</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts (including counterparts by facsimile or electronic copy) and all such counterparts
taken together shall be deemed to constitute one and the same instrument. The parties shall be entitled to rely upon delivery of an executed
facsimile or similar executed electronic copy of this Agreement, and such facsimile or similar executed electronic copy shall be legally
effective to create a valid and binding agreement between the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>[Remainder
of page intentionally left blank. Signature pages follow.]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 385; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B> the parties have executed this Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ENVERIC
    BIOSCIENCES, INC. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signing Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1306436
    B.C. LTD. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signing Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 386; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Print Name of Shareholder)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Signature of Shareholder or Authorized Signatory)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Place of Residency)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Print Name and Title)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 387; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule
&ldquo;A&rdquo;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Options</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    SARs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 388; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_154"></A>Annex
                                            B-2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Voting
Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<FONT STYLE="text-transform: uppercase"><B>Voting Agreement</B></FONT> (this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into
as of [_____], 2021, by and among MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia
(the &ldquo;<U>Company</U>&rdquo;) and each of the undersigned Stockholders of the Parent (as defined below) (the &ldquo;<U>Stockholders</U>&rdquo;).
The Company and Stockholder are each sometimes referred to herein individually as a &ldquo;<U>Party</U>&rdquo; and collectively as the
&ldquo;<U>Parties</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RECITALS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS,
</B>concurrently with the execution of this Agreement, the Company, Enveric Biosciences, Inc., a corporation existing under the laws
of the State of Delaware (&ldquo;<U>Parent</U>&rdquo;) 1306432 B.C. Ltd., a corporation existing under the laws of the Province of British
Columbia and a subsidiary of Parent, and 1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia
and a subsidiary of Parent (&ldquo;<U>Merger Sub</U>&rdquo;) are entering into an Amalgamation Agreement of even date herewith (the &ldquo;<U>Amalgamation
Agreement</U>&rdquo;); providing for, among other things, the amalgamation (the &ldquo;<U>Amalgamation</U>&rdquo;) of Merger Sub and
the Company pursuant to the terms and conditions of the Amalgamation Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS,
</B>as an inducement to enter into the Amalgamation Agreement, and as one of the conditions to the consummation of the transactions contemplated
by the Amalgamation Agreement, the Stockholders have agreed to enter into this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS,
</B>each Stockholder agrees to vote the shares of Parent Capital Stock (as defined in the Amalgamation Agreement) over which such Stockholder
has voting power (the &ldquo;<U>Shares</U>&rdquo;) as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE,</B> for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement
to Vote Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until the Expiration Date (as defined below), at every meeting of the stockholders of Parent, and at every adjournment
or postponement thereof, and on any action or approval by written consent of the stockholders of Parent, in each case, each Stockholder
(in its capacity as a stockholder) shall appear at the meeting or otherwise cause such Stockholder&rsquo;s Shares to be present for purposes
of establishing a quorum and shall vote such Shares in favor of (1) the Amalgamation Agreement and the Amalgamation and the other transactions
contemplated by the Amalgamation Agreement, and (2) any proposal to adjourn or postpone such meeting of stockholders of the Company to
a later date if there are not sufficient votes to approve the Amalgamation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Stockholder is the beneficial owner, but not the record holder, of the Shares, such Stockholder agrees to take all actions necessary
to cause the record holder and any nominees to vote all of such Stockholder&rsquo;s Shares in the manner provided in Section 1(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 389; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of each Stockholder</U>. Each Stockholder represents and warrants to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Stockholder has, or will have, full legal power, authority and right to vote or to direct the voting of all such Stockholder&rsquo;s
Shares then owned of record or beneficially by such Stockholder as described in this Agreement, without the consent or approval of, or
any other action on the part of, any other person. Without limiting the generality of the foregoing, such Stockholder has not entered
into any voting agreement (other than this Agreement) with any person with respect to any of such Stockholder&rsquo;s Shares, granted
any person any proxy (revocable or irrevocable) or power of attorney with respect to any of such Stockholder&rsquo;s Shares, deposited
any of such Stockholder&rsquo;s Shares in a voting trust, or entered into any arrangement or agreement with any person limiting or affecting
his legal power, authority or right to vote such Stockholder&rsquo;s Shares on any matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution and delivery of this Agreement and the performance by such Stockholder of the covenants and obligations hereunder will not
result in any breach or violation of or be in conflict with or constitute a default under any term of any agreement, judgment, injunction,
order, decree, law, regulation or arrangement to which such Stockholder is a party or by which such Stockholder (or any of its assets)
is bound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Agreement shall terminate upon the earliest to occur of (the &ldquo;<U>Expiration Time</U>&rdquo;): (a) the Effective Time; (b)
the date on which the Amalgamation Agreement is terminated in accordance with its terms; and (c) the termination of this Agreement by
mutual written consent of the Parties. Nothing in this Section 4 shall relieve or otherwise limit the liability of any Party for any
intentional breach of this Agreement prior to such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous
Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments,
Modifications and Waivers</U>. No amendment, modification or waiver in respect of this Agreement shall be effective against any party
unless it shall be in writing and signed by the Stockholders and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. This Agreement constitutes the entire agreement among the parties to this Agreement and supersedes all other prior agreements
and understandings, both written and oral, between the parties with respect to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to any
applicable principles of conflicts of law thereof. The parties submit to the exclusive jurisdiction of the state and federal courts located
in Delaware for any action, dispute or proceeding arising out of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment
and Successors</U>. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the parties hereto.
This Agreement and all the provisions hereof may not be assigned by any Stockholder or the Company without the prior written consent
of the other party. The Stockholder is free to transfer its Shares, but any transferee of a Stockholder&rsquo;s Shares must enter into
a joinder to this Agreement (no joinder is required if such Shares are transferred in anonymous open market trading in ordinary brokerage
transactions that are not pre-arranged or pre-solicited).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 390; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third Party Rights</U>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the
parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this
Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree
will remain in full force and effect to the extent not held invalid or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific
Performance; Injunctive Relief</U>. Each Stockholder acknowledges that the Company may be irreparably harmed and that there may be no
adequate remedy at law for a breach of any of the covenants or agreements of the Stockholders set forth in this Agreement. Therefore,
each Stockholder hereby agrees that, in addition to any other remedies that may be available to the Company upon any such breach, the
Company shall have the right to seek specific performance, injunctive relief or any other remedies available to such party at law or
in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, consents, requests, claims, demands and other communications under this Agreement shall be in writing (which shall include
communications by e-mail) and shall be delivered (a) in person or by courier or overnight service, or (b) by e-mail with a copy delivered
as provided in clause (a):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Company:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    Industries Inc.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
    120-4838 Richard Rd SW</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calgary,
    Alberta T3E 6L1Attention: Dr. Joseph Tucker</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
    jtucker@magicmedindustries.com</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy (which shall not constitute notice) to:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greenfield
    Law</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120-4838
    Richard Rd SW</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calgary,
    Alberta T3E 6L1</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Mike Flach</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
    michael@greenfields-law.com</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Burnet,
    Duckworth &amp; Palmer LLP</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    2400, 525-8th Ave SW </FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calgary,
    Alberta T2P 1G1</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Syd S. Abougoush</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
    sabougoush@bdplaw.com</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 391; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to a Stockholder:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    set forth on such Stockholders signature page</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy (which shall not constitute notice) to:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Biosciences, Inc.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
    Tamiami Trail N, Suite 200</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
    FL 34103</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: David Johnson</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
    a copy (which shall not constitute notice) to:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
    and Boone LLP</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
    Rockefeller Plaza, 26th </FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">New York, NY 10012</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Rick Werner, Esq. and Dan Malone, Esq. </FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    rick.werner@haynesboone.com and </FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dan.malone@haynesboone.com
    </FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
to such other address as the parties hereto may designate in writing to the other in accordance with this Section 6(i). Any party may
change the address to which notices are to be sent by giving written notice of such change of address to the other parties in the manner
above provided for giving notice. If delivered personally or by courier, the date on which the notice, request, instruction or document
is delivered shall be the date on which such delivery is made and if delivered by e-mail transmission or mail as aforesaid, the date
on which such notice, request, instruction or document is received shall be the date of delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one
and the same instrument, and shall become effective when counterparts have been signed by each of the parties and delivered to the other
parties; it being understood that all parties need not sign the same counterpart.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings contained in this Agreement are for the convenience of reference only, shall not be deemed to be a part of this Agreement
and shall not be referred to in connection with the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signatures
on the Following Pages</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 392; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>COMPANY</U>:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>MagicMed Industries, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[Signature
Page to Support Agreement]</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 393; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STOCKHOLDER
SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 20%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
    block for individuals</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Individual</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Individual</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
    information for notice:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: -2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
    block for entities:</I></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Entity</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
    information for notice:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: -2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to Support Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 394; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B><A NAME="o_155"></A>Annex C-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enveric
Biosciences, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U><A NAME="ct_002"></A>Lock-Up
Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-Up Agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is executed in connection with the Amalgamation Agreement (the &ldquo;<B><I>Amalgamation
Agreement</I></B>&rdquo;), by and among Enveric Biosciences, Inc., a corporation existing under the laws of the State of Delaware (&ldquo;<B><I>Parent</I></B>&rdquo;),
1306432 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia, 1306436 B.C. Ltd., a corporation existing
under the laws of the Province of British Columbia and a wholly-owned subsidiary of Parent, and MagicMed Industries Inc., a corporation
existing under the laws of the Province of British Columbia (&ldquo;<B><I>Company</I></B>&rdquo;), dated as of [_____], 2021. Capitalized
terms used herein but not defined shall have the meanings ascribed to such terms in the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with, and as an inducement to, the parties entering into the Amalgamation Agreement and for other good and valuable consideration
the receipt and sufficiency of which is hereby acknowledged, the undersigned, by executing this Agreement, agrees that, without the prior
written consent of the Parent, during the period commencing at the Effective Time and continuing until the end of the Lock-Up Period
(as hereinafter defined), the undersigned will not, except as otherwise provided in this Agreement: (1) offer, pledge, sell, contract
to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,
make any short sale or otherwise transfer or dispose of or lend, directly or indirectly, any shares of Parent Common Stock or any securities
convertible into, exercisable or exchangeable for or that represent the right to receive Parent Common Stock (including without limitation,
Parent Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the
Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) whether now owned or
hereafter acquired as a result of securities owned or held by the undersigned (including such securities deemed to be owned or held by
the undersigned as set forth above) at the Effective Date (the <B><I>&ldquo;Securities&rdquo;</I></B>); (2) enter into any swap or other
agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Securities, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise;
or (3) publicly disclose the intention to do any of the foregoing (each of the foregoing restrictions, the &ldquo;<B><I>Lock-Up Restrictions</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the terms of the foregoing paragraph, the Lock-Up Restrictions shall automatically terminate and cease to be effective (i) with respect
to one sixth (1/6) of the Securities at the Effective Time, (ii) with respect to each additional one sixth (1/6) of the Securities, on
each of the following monthly anniversaries of the Effective Time, and (iii) with respect to the balance of the Securities, on the date
that is the five (5) month anniversary of the Effective Time. The period during which the Lock-Up Restrictions apply to the Securities
shall be deemed the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo; with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees that the Lock-Up Restrictions preclude the undersigned from engaging in any hedging or other transaction with respect
to any then-subject Securities which is designed to or which reasonably could be expected to lead to or result in a sale or disposition
of such Securities in violation of the Lock-Up Restrictions (during the Lock-Up Period) even if such Securities would be disposed of
by someone other than the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale
or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to such Securities or
with respect to any security that includes, relates to, or derives any significant part of its value from such Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 395; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the undersigned may transfer any of the Securities, whether or not during the Lock-Up Period (1) as a <I>bona fide</I>
gift or gifts or charitable contribution(s), (2) to any trust for the direct or indirect benefit of the undersigned or the immediate
family of the undersigned, (3) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity
(A) to another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate
(as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or (B) as distributions of Securities
to limited partners, limited liability company members, stockholders or trust beneficiaries of the undersigned or holders of similar
equity interests in the undersigned, (4) by operation of law, such as pursuant to a qualified domestic order or as required by a divorce
settlement, (5) by will, other testamentary document or intestate succession, (6) to any immediate family member, any investment fund,
family partnership, family limited liability company or other entity controlled or managed by the undersigned, (7) to a nominee or custodian
of a person or entity to whom a disposition or transfer would be permissible under clauses (1) through (6) or (8) pursuant to a bona
fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Parent&rsquo;s capital stock
involving a change of control of the Parent, provided that in the event that such tender offer, merger, consolidation or other such transaction
is not completed, the Securities shall remain subject to the restrictions contained in this Agreement; <I>provided,</I> in the case of
clauses (1)&ndash;(7), that (A) such transfer shall not involve a disposition for value, (B) the transferee agrees in writing with Parent
to be bound by the terms of this Agreement and (C) no filing by any party under Section 16(a) of the Exchange Act shall be required or
shall be made voluntarily in connection with such transfer. For purposes of this Agreement, &ldquo;immediate family&rdquo; shall mean
any relationship by blood, marriage or adoption, not more remote than first cousin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the foregoing restrictions shall not apply to: (1) the vesting, settlement, or cash exercise of stock options granted pursuant
to equity incentive plans existing immediately following the Effective Time; <I>provided</I> that it shall apply to any of the Securities
issued upon such exercise; or (2) the vesting, settlement, or cash exercise of warrants into Parent Common Stock or the conversion of
any other security convertible into Parent Common Stock that are outstanding as of the Effective Time; <I>provided, </I>in each case,
that it shall apply to any of the Securities issued upon such conversion or exercise. The undersigned agrees that, to the extent that
the undersigned is a holder of any options or warrants to purchase shares of Parent Common Stock, that during the period commencing at
the Effective Time and ending on the two (2) year anniversary thereof, the undersigned may only exercise such options and warrants for
cash and will not seek to effect any &ldquo;cashless exercise&rdquo; or &ldquo;net exercise&rdquo; of such warrants and/or options (provided
that nothing shall prevent the undersigned from paying the exercise price of options through a &ldquo;same day sale&rdquo; process in
which the undersigned elects to sell through a broker a sufficient number of shares of Parent Common Stock issuable upon the exercise
of such options to fund the exercise price of the options).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 396; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement. All authority
herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs
or personal representatives of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the undersigned shall be released from all obligations under this Agreement if the Amalgamation Agreement
is terminated pursuant to its terms, upon the date of such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that Parent and the Company are entering into the Amalgamation Agreement in reliance upon this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without reference to such State&rsquo;s
or any other state&rsquo;s or other jurisdiction&rsquo;s principles of conflict of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement, and any certificates, documents, instruments and writings that are delivered pursuant hereto, constitutes the entire agreement
and understanding of the Parent and the undersigned in respect of the subject matter hereof and supersedes all prior understandings,
agreements or representations by or among the Parent and the undersigned, written or oral, to the extent they relate in any way to the
subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Holder</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Person Signing</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(and
    indicate capacity of person signing if</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> signing as custodian, trustee,
    or on behalf of an entity)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 397; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="annex_032"></A>Annex
C-2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enveric
Biosciences, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U><A NAME="ct_001"></A>Lock-Up/Leak-Out
Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-Up/Leak-Out Agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is executed in connection with the Amalgamation Agreement (the
&ldquo;<B><I>Amalgamation Agreement</I></B>&rdquo;), by and among Enveric Biosciences, Inc., a corporation existing under the laws of
the State of Delaware (&ldquo;<B><I>Parent</I></B>&rdquo;), 1306432 B.C. Ltd., a corporation existing under the laws of the Province
of British Columbia, 1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia, and MagicMed Industries
Inc., a corporation existing under the laws of the Province of British Columbia (&ldquo;<B><I>Company</I></B>&rdquo;), dated as of [_____],
2021. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Amalgamation Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with, and as an inducement to, the parties entering into the Amalgamation Agreement and for other good and valuable consideration
the receipt and sufficiency of which is hereby acknowledged, the undersigned, by executing this Agreement, agrees that, without the prior
written consent of the Parent, during the period commencing at the Effective Time and continuing until the end of the Lock-Up Period
(as hereinafter defined), the undersigned will not: (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or
dispose of or lend, directly or indirectly, any shares of Parent Common Stock or any securities convertible into, exercisable or exchangeable
for or that represent the right to receive Parent Common Stock (including without limitation, Parent Common Stock which may be deemed
to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and
securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter acquired (the <B><I>&ldquo;Securities&rdquo;</I></B>);
(2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the
Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Parent Common Stock or
such other securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to, the registration of any Parent
Common Stock or any security convertible into or exercisable or exchangeable for Parent Common Stock; or (4) publicly disclose the intention
to do any of the foregoing (each of the foregoing restrictions, the &ldquo;<B><I>Lock-Up Restrictions</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the terms of the foregoing paragraph, the Lock-Up Restrictions shall automatically terminate and cease to be effective (i) with respect
to twenty-eight (28) percent of the Securities, at the Effective time, (ii) with respect to fifty (50) percent of the Securities, on
the date that is the eighteen (18) month anniversary of the Effective Time, (iii) with respect to seventy-five (75)) percent of the Securities,
on the date that is the nineteen (19) month anniversary of the Effective Time, (iii) with respect to the balance of the Securities, on
the date that is the twenty (20) month anniversary of the Effective Time. The period during which the Lock-Up Restrictions apply to the
Securities shall be deemed the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo; with respect thereto. In addition, beginning on the date that
is the eighteen (18) month anniversary of the Effective Time and ending on the date that is the twenty-one (21) month anniversary of
the Effective Time (the &ldquo;<B><I>Leak-Out Period</I></B>&rdquo;), the undersigned may dispose any Securities not subject to the Lock-Up
Restrictions only in accordance with the volume limitations set forth in paragraph (e) of Rule 144 promulgated under the U.S. Securities
Act of1933, as amended (even if the undersigned is not then subject to the requirements of paragraph (e) of such Rule 144 pursuant to
the provisions of Rule 144) (&ldquo;<B><I>Leak Out Restrictions</I></B>&rdquo;); provided that with respect to any shares of Parent Common
Stock issued upon the exercise of options and warrants, the Leak-Out Period shall be deemed to be the period commencing one-hundred and
eighty (180) days after the Effective Time and ending on the date that is three-hundred and sixty (360) days after such date</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 398; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees that the Lock-Up Restrictions and Leak-Out Restrictions preclude the undersigned from engaging in any hedging or other
transaction with respect to any then-subject Securities which is designed to or which reasonably could be expected to lead to or result
in a sale or disposition of such Securities in violation of the Lock-Up Restrictions (during the Lock-Up Period) or Leak-Out Restrictions
(during the Leak-Out Period) even if such Securities would be disposed of by someone other than the undersigned. Such prohibited hedging
or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without
limitation any put or call option) with respect to such Securities or with respect to any security that includes, relates to, or derives
any significant part of its value from such Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the undersigned may transfer any of the Securities, whether or not during the Lock-Up Period (1) as a <I>bona fide</I>
gift or gifts or charitable contribution(s), (2) to any trust for the direct or indirect benefit of the undersigned or the immediate
family of the undersigned, (3) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity
(A) to another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate
(as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or (B) as distributions of Securities
to limited partners, limited liability company members, stockholders or trust beneficiaries of the undersigned or holders of similar
equity interests in the undersigned, (4) by operation of law, such as pursuant to a qualified domestic order or as required by a divorce
settlement, (5) by will, other testamentary document or intestate succession, (6) to any immediate family member, any investment fund,
family partnership, family limited liability company or other entity controlled or managed by the undersigned, (7) to a nominee or custodian
of a person or entity to whom a disposition or transfer would be permissible under clauses (1) through (6) or (8) pursuant to a bona
fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Parent&rsquo;s capital stock
involving a change of control of the Parent, provided that in the event that such tender offer, merger, consolidation or other such transaction
is not completed, the Securities shall remain subject to the restrictions contained in this Agreement; <I>provided,</I> in the case of
clauses (1)&ndash;(7), that (A) such transfer shall not involve a disposition for value, (B) the transferee agrees in writing with Parent
to be bound by the terms of this Agreement and (C) no filing by any party under Section 16(a) of the Exchange Act shall be required or
shall be made voluntarily in connection with such transfer. For purposes of this Agreement, &ldquo;immediate family&rdquo; shall mean
any relationship by blood, marriage or adoption, not more remote than first cousin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the foregoing restrictions shall not apply to: (1) the vesting, settlement, or cash exercise of stock options granted pursuant
to equity incentive plans existing immediately following the Effective Time; <I>provided</I> that it shall apply to any of the Securities
issued upon such exercise; or (2) the vesting, settlement, or cash exercise of warrants into Parent Common Stock or the conversion of
any other security convertible into Parent Common Stock that are outstanding as of the Effective Time; <I>provided, </I>in each case,
that it shall apply to any of the Securities issued upon such conversion or exercise. The undersigned agrees that, to the extent that
the undersigned is a holder of any options or warrants to purchase shares of Parent Common Stock, that during the period commencing at
the Effective Time and ending on the two (2) year anniversary thereof, the undersigned may only exercise such options and warrants for
cash and will not seek to effect any &ldquo;cashless exercise&rdquo; or &ldquo;net exercise&rdquo; of such warrants and/or options (provided
that during the Leak-Out Period nothing shall prevent the undersigned from paying the exercise price of options through a &ldquo;same
day sale&rdquo; process in which the undersigned elects to sell through a broker a sufficient number of shares of Parent Common Stock
issuable upon the exercise of such options to fund the exercise price of the options).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 399; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement. All authority
herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs
or personal representatives of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the undersigned shall be released from all obligations under this Agreement if the Amalgamation Agreement
is terminated prior to the Effective Time pursuant to its terms, upon the date of such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that Parent and the Company are entering into the Amalgamation Agreement in reliance upon this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without reference to such State&rsquo;s
or any other state&rsquo;s or other jurisdiction&rsquo;s principles of conflict of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement, and any certificates, documents, instruments and writings that are delivered pursuant hereto, constitutes the entire agreement
and understanding of the Parent and the undersigned in respect of the subject matter hereof and supersedes all prior understandings,
agreements or representations by or among the Parent and the undersigned, written or oral, to the extent they relate in any way to the
subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Holder</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Person Signing</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(and
    indicate capacity of person signing if</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">signing
    as custodian, trustee, or on behalf of an entity)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 400; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="o_156"></A>Annex
D</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="annex-d_001.jpg" ALT="" STYLE="height: 872px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 401; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="annex-d_002.jpg" ALT="" STYLE="height: 872px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 402; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_157"></A>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    20.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
    of Directors and Officers.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
General Corporation Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
is incorporated under the laws of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(a) of the DGCL authorizes a corporation to indemnify any person who was or is a party, or is threatened to be made a party, to a
threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an
action by or in the right of the corporation), by reason of the fact that the person is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if the person acted
in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation and,
with respect to any criminal action or proceeding, had no reasonable cause to believe the person&rsquo;s conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(b) of the DGCL provides in relevant part that a corporation may indemnify any person who was or is a party or is threatened to be
made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its
favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving
at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
or other enterprise against expenses (including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with
the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to
be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim,
issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the
Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication
of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses
which the Court of Chancery or such other court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL also provides that indemnification under Sections 145(a) and (b) can only be made upon a determination that indemnification of the
present or former director, officer or employee or agent is proper in the circumstances because such person has met the applicable standard
of conduct set forth in Sections 145(a) and (b). Such determination shall be made, with respect to a person who is a director or officer
at the time of such determination, (1) by a majority vote of directors who are not a party to the action at issue (even though less than
a quorum), (2) by a majority vote of a designated committee of these directors (even though less than a quorum), (3) if there are no
such directors, or these directors authorize, by the written opinion of independent legal counsel, or (4) by the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(c) of the DGCL provides that to the extent a present or former director or officer of a corporation has been successful on the merits
or otherwise in defense of any action, suit or proceeding referred to in Sections 145(a) or (b), or in defense of any claim, issue or
matter therein, such person shall be indemnified against expenses (including attorney&rsquo;s fees) actually and reasonably incurred
by such person in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(e) of the DGCL provides that expenses (including attorneys&rsquo; fees) incurred by an officer or director of the corporation in
defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of
the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to
repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized
in Section 145 of the DGCL. Such expenses (including attorneys&rsquo; fees) incurred by former directors and officers or other employees
and agents of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of
another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as
the corporation deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 403; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(g) of the DGCL also empowers a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and
incurred by such person in any such capacity, or arising out of such person&rsquo;s status as such, whether or not the corporation would
have the power to indemnify such person against such liability under Section 145 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102(b)(7) of the DGCL permits a corporation to provide for eliminating or limiting the personal liability of one of its directors for
any monetary damages related to a breach of fiduciary duty as a director, as long as the corporation does not eliminate or limit the
liability of a director for (a) a breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders, (b) acts or
omissions not in good faith or involving intentional misconduct or a knowing violation of law, (c) a violation of Section 174 of the
DGCL (unlawful dividends) or (d) any transaction from which the director derived an improper personal benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certificate of incorporation, as amended, and bylaws of ENVB provide that ENVB will indemnify its directors, officers, employees and
agents to the fullest extent and in the manner permitted by the provisions of the General Corporation Law of the State of Delaware, as
amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders&rsquo;
or directors&rsquo; resolution or by contract. Any repeal or modification of these provisions approved by ENVB&rsquo;s stockholders will
be prospective only and will not adversely affect any limitation on the liability of any directors or officers existing as of the time
of such repeal or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    21.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits
    and Financial Statement Schedules.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
list of the exhibits included as part of this registration statement is set forth in the Exhibit Index that immediately precedes such
exhibits and is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exhibits contain representations, warranties and covenants that were made by the parties to the applicable agreement only for purposes
of such agreement and as of specific dates; were made solely for the benefit of the contracting parties; may be subject to limitations
agreed upon by the contracting parties, including being qualified by any applicable confidential disclosures exchanged between such parties
in connection with the execution of such agreement (which disclosures may include information that has been included in such parties&rsquo;
public disclosures, as well as additional non-public information); may have been made for the purposes of allocating contractual risk
between the contracting parties instead of establishing these matters as facts; and may be subject to standards of materiality applicable
to such parties that differ from those applicable to investors. Additionally, the representations, warranties, covenants, conditions
and other terms of such agreements may be subject to subsequent waiver or modification. For the foregoing reasons, one should not rely
on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition
of the contracting parties or any of their respective subsidiaries or affiliates, which are disclosed in the other information provided
elsewhere in the registration statement or incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENVB
and MagicMed acknowledge that, notwithstanding the inclusion of the foregoing cautionary statements, they are responsible for considering
whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements
in the registration statement not misleading. Additional information about ENVB and MagicMed may be found elsewhere in the registration
statement and ENVB&rsquo;s other public filings, which are available without charge through the SEC&rsquo;s website at www.sec.gov. See
&ldquo;Where You Can Find More Information&rdquo; beginning on page 208.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    22.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Undertakings.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 404; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
    if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set
    forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any material information with respect to the plan of distribution not previously disclosed in this registration statement
    or any material change to such information in this registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability under the Securities Act of 1933, to any purchaser: if the registrant is subject to Rule
    430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
    statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included
    in the registration statement as of the date it is first used after effectiveness. <I>Provided, however</I>, that no statement made
    in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
    incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a
    purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
    statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of
    first use.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
    of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
    to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
    are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller
    to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s annual report pursuant
    to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s
    annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration
    statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
    securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 405; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration
    statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that
    such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings
    by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    every prospectus (a) that is filed pursuant to paragraph (7)(i) above or (b) that purports to meet the requirements of Section 10(a)(3)
    of the Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment
    to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability
    under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating
    to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
    thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
    as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
    of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
    unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of
    expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
    suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
    the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
    of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and
    will be governed by the final adjudication of such issue.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus
    pursuant to Items 4, 10(b), 11, or 13 of Form S-4, within one business day of receipt of such request, and to send the incorporated
    documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to
    the effective date of the registration statement through the date of responding to the request.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction,
    and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became
    effective.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 406; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&dagger;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_152">Amalgamation Agreement, dated May 24, 2021, by and among Enveric Biosciences, Inc., 1306432 B.C. LTD., 1306436 B.C. LTD., and MagicMed Industries, Inc. (attached as Annex A to the proxy statement/prospectus that forms a part of this registration statement).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on January 6, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-2.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.2 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on January 6, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-4.htm" STYLE="-sec-extract: exhibit">Amended and Restated Bylaws of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.4 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on January 6, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Haynes and Boone LLP regarding the validity of securities being registered.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_153">Form
    of Voting and Support Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders
    of MagicMed Industries Inc. named therein (attached as Annex B-1 to the proxy statement/prospectus that forms a part of this registration
    statement).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_154">Form of Voting Agreement, dated as of May 24, 2021, by and among MagicMed Industries Inc. and certain shareholders of Enveric Biosciences, Inc. named therein (attached as Annex B-2 to the proxy statement/prospectus that forms a part of this registration statement).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_155">Form of Lock-Up Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed Industries Inc. named therein (attached as Annex C-1 to the proxy statement/prospectus that forms a part of this registration statement).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">10.4</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="#annex_032">Form of
    Lock-Up/Leak-Out Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed
    Industries Inc. named therein (attached as Annex C-2 to the proxy statement/prospectus that forms a part of this registration
    statement).</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-1.htm" STYLE="-sec-extract: exhibit">Employment Agreement between Dr. Joseph Tucker and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on May 24, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-2.htm" STYLE="-sec-extract: exhibit">Employment Agreement between Peter Facchini and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on May 24, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-3.htm" STYLE="-sec-extract: exhibit">Employment Agreement between Jillian Hagel and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Current Report on Form 8-K, filed with the SEC on May 24, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/890821/000149315221007757/ex21-1.htm" STYLE="-sec-extract: exhibit">List
    of subsidiaries of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 21 of the Company&rsquo;s Annual Report on Form
    10-K, filed with the SEC on April 1, 2021).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-1.htm">Consent of Marcum LLP, independent registered public accounting firm for Enveric Biosciences, Inc.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="ex23-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Zeifmans, independent registered public accounting firm for MagicMed Industries Inc.</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Haynes and Boone LLP (included in Exhibit 5.1).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#poa_031">Power of Attorney (included on signature page to Form S-4).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Gemini Valuation Services, LLC.</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Dr. Joseph Tucker to be named as a director upon the completion of the Amalgamation.</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="ex99-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Brad Thompson to be named as a director upon the completion of the Amalgamation.</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Proxy Card for Special Meeting of Enveric Biosciences, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to Item 601(b)(2) of Regulation S-K, Enveric Biosciences, Inc. agrees to furnish supplementally a copy of any omitted schedule or
    exhibit to the Amalgamation Agreement to the SEC upon request.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    a managent contract.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 407; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Naples, State of Florida on June 21, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
    BIOSCIENCES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ David I. Johnson</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    David I. Johnson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="poa_031"></A>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Know
All Men By These Presents, that each person whose signature appears below constitutes and appoints David I. Johnson and Carter Ward,
and each of them singly, as his true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for
him and in his name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission
any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits
thereto, (ii) act on, sign and file with the Securities and Exchange Commission any related registration statement filed pursuant to
Rule 462(b) under the Securities Act of 1933 and any or all amendments thereto, together with all schedules and exhibits thereto, (iii)
act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection
therewith, (iv) act on and file any supplement to any prospectus included in this registration statement or any such amendment, and (v)
take any and all actions which may be necessary or appropriate in connection therewith, granting unto such agent, proxy and attorney
in fact full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all
intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agents, proxies
and attorneys in fact or any of their substitutes may lawfully do or cause to be done by virtue thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
indicated on June 21, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature
    </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David I. Johnson</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Chief Executive Officer and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    I. Johnson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Carter Ward</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carter
    Ward</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><I>/s/
    George Kegler</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Kegler</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><I>/s/
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sol Mayer</FONT></I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sol
    Mayer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcus Schabacker</FONT></I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Marcus Schabacker</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><I>/s/
    Douglas Lind</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Douglas Lind</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 408; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>





























































































































<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Registration Statement of Enveric Biosciences, Inc. on Form S-4 of our report dated April 1,
2021 with respect to our audits of the consolidated financial statements of Enveric Biosciences, Inc. as of December 31, 2020
and 2019 and for the years ended December 31, 2020 and 2019, which report appears in the Prospectus, which is part of this Registration
Statement. We also consent to the reference to our Firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
21, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="ex23-2_1.jpg" ALT="" STYLE="height: 53px; width: 150px"></TD>
    <TD STYLE="vertical-align: middle; text-align: right; width: 50%"><B>Exhibit 23.2</B></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0.5in; margin: 0pt">We consent to the reference to our firm under the caption &ldquo;Experts&rdquo;
in the Registration Statement (Form S-4 No. 333-XXXXX) and related proxy statement/prospectus of Enveric Biosciences, Inc. for the registration
of shares of common stock of Enveric Biosciences, Inc. and to the inclusion therein of our report dated September 29, 2020 with respect
to our audit of the consolidated financial statements of MagicMed Industries Inc. as at June 30, 2020 and for the period from incorporation
May 26, 2020 to June 30, 2020, which report appears in the related proxy statement/prospectus, which is part of this Registration Statement.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="ex23-2_2.jpg" ALT="" STYLE="height: 54px; width: 220px">&nbsp;</P>

<P STYLE="margin: 0">Zeifmans LLP Chartered Professional Accountants</P>

<P STYLE="margin: 0">Toronto, Ontario, Canada</P>

<P STYLE="margin: 0">June 21, 2021</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex23-2_3.jpg" ALT="" STYLE="height: 54px; width: 680px"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Gemini Valuation Services, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemini
Valuation Services, LLC (&ldquo;Gemini&rdquo;) hereby consents to (i) the inclusion of our opinion letter dated May 21, 2021 (the &ldquo;Opinion&rdquo;)
to the Board of Directors of Enveric Biosciences, Inc. as Annex D to the proxy statement/prospectus that is being filed on or promptly
after the date hereof with the Securities and Exchange Commission in connection with the proposed amalgamation involving Enveric Biosciences,
Inc. and MagicMed Industries Inc., which such proxy statement/prospectus forms a part of the Registration Statement on Form S-4 of Enveric
Biosciences, Inc. (the &ldquo;Registration Statement&rdquo;) that is being filed on or promptly after the date hereof with the Securities
and Exchange Commission, (ii) the references therein to Gemini and (iii) the inclusion therein of (a) the summaries of and excerpts from
the Opinion, (b) the description of certain financial analyses underlying the Opinion and (c) certain terms of our engagement by Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
giving the foregoing consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of
the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the rules and regulations promulgated thereunder, nor do
we admit that we are experts with respect to any part of such Registration Statement within the meaning of the term &ldquo;experts&rdquo;
as used in the Securities Act or the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GEMINI
    VALUATION SERVICES, LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
    Angeles, California</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    21, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Nathan Johnson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nathan
    Johnson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby consents to being named in this proxy statement/prospectus included in the Registration Statement on Form S-4 filed
by Enveric Biosciences, Inc. (including any amendments to such Registration Statement) in connection with the Amalgamation Agreement,
dated as of May 24, 2021, by and among Enveric Biosciences, Inc., 1306432 B.C. LTD., 1306436 B.C. LTD., and MagicMed Industries, Inc.,
as it may be amended from time to time, as a person who will become a director and to the filing of this consent as an exhibit to the
Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    June 21, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    Dr. Joseph Tucker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph Tucker</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>6
<FILENAME>ex99-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby consents to being named in this proxy statement/prospectus included in the Registration Statement on Form S-4 filed
by Enveric Biosciences, Inc. (including any amendments to such Registration Statement) in connection with the Amalgamation Agreement,
dated as of May 24, 2021, by and among Enveric Biosciences, Inc., 1306432 B.C. LTD., 1306436 B.C. LTD., and MagicMed Industries, Inc.,
as it may be amended from time to time, as a person who will become a director and to the filing of this consent as an exhibit to the
Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    June 21, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Thompson</FONT></I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brad
    Thompson</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>s4_001.jpg
<TEXT>
begin 644 s4_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ 0<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH B.<5G:SK5
MGH=H;BZ?']Q%Y9SZ 4[5[[^SM+GN0N]HURJGH3T'ZUXUJ%W=ZI>-=7<K22-T
MST4>@'85,ZBCH>GEF7?6I<TW:*^]^1Z1X/\ $EUX@N-1EGC1(XV3R4 Y4'=G
M)[]!77GL*X#X9IL74?<Q_P#LU=_1"7,KF.94X4\3*%-62M^2'44451Q!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 T]*8[ +DX&.N:KWM[!8VYFN'"J/U/H*\]UO7[C59"J9CMP>$!Z^Y]:Y
MZV(A26NYUX3!U,2]-%W.PUB2TU'3)K5;^V1G  +.,#D'^E<4/"B;O^0K9?\
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MV%]Z31$XWH>N,\$'I118=SF[>QUNY^(7BF/2M;BTQM]M(ZR6:S&5?* ##)&
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0W,I>:;TW-[>@XHH;%8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>interim1_001.jpg
<TEXT>
begin 644 interim1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -H U,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M83Z?:B\D:"8SQ/$2PRK%5.<J1@J/;-3VWB"Y6\BMM3TW[+)=1M+:"*;SC(%
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M** "BBN?\;>)_P#A#O"%]K_V/[9]E\O]QYOE[MTBI][!QC=GIVH Z"BOG_\
MX::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J/^&F
MO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"
MBOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7
M_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\
M:J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X::_ZE
M'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE
M'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\
MX::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J/^&F
MO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"
MBOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7
M_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\
M:J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X::_ZE
M'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE
M'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\
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MT!17S_\ \--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4 ?0%%?/\ _P --?\
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M73_R%1?^OG?_ "0?\#\%_3/H"BOG_P#X::_ZE'_RI?\ VJC_ (::_P"I1_\
M*E_]JI#/H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X:
M:_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X:
M:_ZE'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BO
MG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J /H"BOG_ /X::_ZE'_RI?_:J
M/^&FO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J
M /H"BOG_ /X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /H"BOG_\ X::_ZE'_
M ,J7_P!JKZ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHJGIFJV.LV?VS3KE+BWWM'O3IN5BK#\P: +E%%% !114+W=
MNEW%:-*HN)59TCSRRKC)^@R/SH FHHHH **** "BBB@ HHHH **** "BBB@
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M<#((YP,YJAJ/@3P]JVNQZW>VUT^I18\J=;^X0QX[*%<!1[ #.3ZT1T=^]_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTJRL(F=;9!:VZ1!PF=Q.T#/S,P_X#30,Z2BBBD 4444 %%%% !1110 4444
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MF,'(\SYFWO\ [7 ] *W*;$@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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M[>XLKPV>P;2"NV2(,,C:Q'!4D8/!JS'X0T^\>>X\06NGZO>3LK.TMDOE+M7
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M,X.,DL,CI5=?B/=:A!!J6CV-S>632B,VT6DW4CRKNVLZW"CRACD[<'./O \
M2O\ A^(/3^NQZ-17 W?B_P 01P>+)4M],A_L%@ZJ?,E\Z/R_,P3E=K%2.<$
M]FZU8O\ 4=8O/&GAJ.PO;:WLKJRENFAFM3(21LSR'7G#X'8<\-G@2O;^NC?Z
M ^O]=O\ ,[:BN=\::[?^'=#2_L+:VG/VB**03R,NU7<)D  Y.6'&1QGZ5G:K
MXFU73KMM+D>W%^5:X26VTNZO46$MA T<7(8X8$E@.,@'. @L=G17"VOC'7+N
M^\.6[:1%8C5!.LHNUE66-XPW(C95.TX# DY(.,#K4$_C#7K?P[KNH,NFM-H-
MT\5SB%]MTJA6.P;_ -V=K#DE^>U.W]?-+]4']?G_ ),[R*Y@GDECBFCD>%MD
MJHP)1L X/H<$'!]:EKRN_P#$6M7MCJ'V./3=+N(_$%K:2M'"TWG*_E$%SE"3
MAE!]A@$=:Z(3:^?B1;63ZE9&VCTL32QBR8;R9 &V_O?E)*C!.[ XP>M%MOZZ
M7$VOZ];'945PQ\7ZG;>*--L+K[ \5]=R6K6L",TMH0K,I>4.4)(4'9M4@-WP
M:JW/C/Q!#IGB>_:WTR)=!NRC1 22F:((K$!LKM;#=<$=L=Z$K_UZ+]4/^OS_
M ,F>AT5SMWK%_>ZH^E:*]K#=16B7<DEW$TB@.2$4*K+R=K9.>..#FL_4_%>H
M6JVM@T'V/5WM1<3JEA<:BD1SC;M@ ."0WS$CIT-+;^OZ[!_7]?>=E17$/XWN
M(](T>[U&%-"^V.Z3S:E;2".-D8 *02A3>,E6;&,=">*Z^PEGGL(9;A8EF==S
M")]R?@>X]Z=@+%%<''XQUI5UVZNK;3HK71;UH9XXVDD>6/R@R[#@?-N9?X>Y
M';)6#QS>6MS>/J5E<RZ=%9RW9NDTBZM!"4P?+8S##DC.&&.GW12_K]0MK8[N
MBN?M;[7X;A;G4H[!M+DMFG9[<,KVK  [6+,?,!&?F 7&.G-9/_"6:K!I>F>(
MKF*S.B:A)"I@1&$]NDI 1R^XJ_++E0JXR>3CEV=["OI?^NYVU%<I;ZOK47BG
M6--U&YTV.VAM!=6+I:N&9"2"7S(<[" " !G<#D=*@U#Q+JFF6]AI]T\7]LW%
MNUQ++;:3<W,<8! QY43,W?&2X'!/M2Z7_KK_ )#_ *_K[SLJ*X,>--<>V\/N
M='CMFU&_:QG%VLL3*1N*ND;*#M8*3\Q!&0,'K4?B'Q;X@\-6$UU?-I'F6D:N
M]M%%)(]VI(#,F'S"HSC+JPSWQS3M_7W?YH/Z_/\ R.[6ZMWN7MEGB-PBAFB#
MC<H/0D=0*)KF"V"&>:.(.X1/,<+N8G  SU)/:N"BMKI?B?K[:*+&UN9]*M96
MDG@+JS[Y.6564DD #.>,#K4.JZE!XF\/>&=7GLXH[R'7(86'WO*D64I(%8C.
M"5_$8H2O;Y?FU^@F[7?];7/2**X%_'=]+?13:?8W-W8M=?9VMX](NR^WS-AE
M%QCRB!C.W'0?>SQ7?4NEQ];!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!3FU;3;?4(M/FU"TCO9AF*W>91(_^ZI.3^%.N-3L+2[M[6YOK:&YN"1!
M#)*JO*?]D$Y/X5YSJDDEAX6\7:=J]E>F_EFGN+:Z2V=DFW$>05D VAU.Q0I(
M8;>!5[0X9M0\-^+9=9(>\::2"4E<%%CA7:!W !RP]VR.M*]HN3Z*X[:I=W8]
M"K.M?$&BWNHR:=::O87%]%N\RVBN4>1,'!RH.1@]:J:#-?ZGX'TZ9YO)U"YT
M^-C*\9;9(R#YBN1GDYQD5ROA'1;[PIXC_LK4++2+B>ZM9'M]:M+%89I-I7<L
MX'4G<K9SSCGFJ:M)Q?2Y*=XJ2.U7Q!HKZL=*75[!M2!P;,7*&8'&?N9STYZ5
M<>Y@CN([=YHUFE!,<;, S@=<#J<9KS33;"Y\">(TNO$,>BW]O=B9AKD5BMO=
M1.%:1A(><J5! .<\8-1?\))H=W\3O#NH'7]+EEEMKJ-A%>QNL.[R_+CX8C<>
M?J<XX P)7M_7<;TN>JT444@"BBB@ HHHH **** "BBB@ HHHH ***XOP];I;
M?$SQ5'&TA4V]F^'E9\$^9G&XG ]AQ0M78'M<[2BJ>H74D2I!;!6NYSMC!Z*.
M[GV'ZG [UR'@/3X;WP]JEI?%[N$:Q>+(LYW"8"0CYQT8>W3VH6MP.[HKDM \
M/6L<^KI#'Y>A3SI]FL5XA^5<.57H$9OX1P=N>AYF\,Z/%IFM:O)IL:VVCOY:
M06L0VQ"1=WF.BCA025''!*DT =/1110 4444 %%%<_XV\,?\)CX0OM ^V?8_
MM7E_O_*\S;MD5_NY&<[<=>] '045\_\ _#,O_4W?^4W_ .VT?\,R_P#4W?\
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MW^E:W/HVJVH9([J.)959&QN5XVX8< CT->1_\,R_]3=_Y3?_ +;1_P ,R_\
M4W?^4W_[;2 ]1O\ PEK%Z-#+>(TEFTVZ%W)-=6(=IY-I7HCHJ+ACP!Z'/7+=
M7\#3ZF/$,2:OY-MK2)YBM;[WBD50H(;</DP!\N,]<,,UYA_PS+_U-W_E-_\
MMM'_  S+_P!3=_Y3?_MM._\ 7W?Y(/Z_K[V>N2^&KV/7/[7T_58X+J:VCM;G
MSK7S5=$+$% &7:WS'DEATR#575?!EQ-I&E:;H^IPV,5C=+=LT]H9VFD5M^3A
MTQEB2?7/&*\M_P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MHO_7XA;^OP_(]
M.M/!>JZ=K3RV'BR\M]&EE:>73%MHV&]CN8)*V61"2>!R,\&NRKY__P"&9?\
MJ;O_ "F__;:/^&9?^IN_\IO_ -MI=+!YGT!17S__ ,,R_P#4W?\ E-_^VT?\
M,R_]3=_Y3?\ [;0!] 45\_\ _#,O_4W?^4W_ .VT?\,R_P#4W?\ E-_^VT ?
M0%%?/_\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#MM 'T!17S_P#\,R_]3=_Y
M3?\ [;1_PS+_ -3=_P"4W_[;0!] 45\__P##,O\ U-W_ )3?_MM'_#,O_4W?
M^4W_ .VT ?0%%?/_ /PS+_U-W_E-_P#MM'_#,O\ U-W_ )3?_MM 'T!17S__
M ,,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\ [;0!] 45\_\ _#,O_4W?^4W_ .VT
M?\,R_P#4W?\ E-_^VT ?0%%?/_\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#M
MM 'T!17S_P#\,R_]3=_Y3?\ [;1_PS+_ -3=_P"4W_[;0!] 45\__P##,O\
MU-W_ )3?_MM'_#,O_4W?^4W_ .VT ?0%%?/_ /PS+_U-W_E-_P#MM'_#,O\
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+RHHL]2B98@D<9+,<<#&3D32M_75_G?4):W_ *Z?IT->BBBD,**** "BBB@
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M-_N_LW^K_P">B[O]9\OW-W7^==!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/\ _P 9#_Y_L^C_ (R'_P _V?7T!10!\_\ _&0_^?[/H_XR'_S_ &?7T!10
M!\__ /&0_P#G^SZ/^,A_\_V?7T!10!\__P#&0_\ G^SZ/^,A_P#/]GU] 44
M?/R)^T)&@2-551T51IX I?\ C(?_ #_9]?0%% 'S_P#\9#_Y_L^C_C(?_/\
M9]?0%% 'S_\ \9#_ .?[/KZ HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?BQ>Z=!X>L+6^OX;8S:E:L
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M4^6FWRB,80KM.,#'/%=-0T,****0!1110 4444 %%%% !1110 4444 %%%%
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MKG_?B'_X[7L%% 'C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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M_P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.U[!10!X_\ \-'>#_\
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M_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM>P44 >/_ /#1W@__ *!NN?\
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M=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z /0**\_\ ^%V_#S_H8?\
MR2N/_C='_"[?AY_T,/\ Y)7'_P ;H ] HKS_ /X7;\//^AA_\DKC_P"-T?\
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M/_DE<?\ QN@#T"BO/_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;H
M] HKS_\ X7;\//\ H8?_ "2N/_C='_"[?AY_T,/_ ))7'_QN@#T"BO/_ /A=
MOP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &Z /0**\_P#^%V_#S_H8?_)*
MX_\ C='_  NWX>?]##_Y)7'_ ,;H ] HKS__ (7;\//^AA_\DKC_ .-T?\+M
M^'G_ $,/_DE<?_&Z /0*X^X_Y*_8?]@2;_T='6?_ ,+M^'G_ $,/_DE<?_&Z
MS6^)GPA?51JKW.GMJ((879TF4S9 P#O\K/3CK0M&G_6U@>S0WQS?:DUG%-=>
M&]420ZM:".0RVQCV+.NU5 FR"W7) Y(R0 ,3P6WVX>,+_4+O4-(U6&<31[;L
MQO!$L0,1(1MKKG=P2RD[N]3W/QB^&=Y&L=UK,4Z*ZR*LNGSL RG*L 8^H/(/
M:H;GXK_"J]NX+N[U&TGN;<YAFETR9GB_W6,>1^%'2W]=/\A];G8Z+KB2Z!;3
M:M=6MM?QVD,M]$TJJ8&=0?F!^[DYZUDZ7;7VF^/9X&U!]5MKVS,[S7")YML5
M8!$R@ V-N8@8ZJ3SS7/2_$_X57-]=75SJ5G,]S#Y$N_2IB9(_P"ZY,?SCCH>
M!5BP^+7PMTJV%MIVIVUG;@Y$5OILT:@_18P*=[RYOZ_K8E*RL=EO2X\037#R
M*MOIT)C+,< 2/AF)^B!>?]LUAS)=6_CG2-1M-4.J6FHB2,P2"-A;1;2WF0L@
M&%R%4YSG<O/2L\?&7X;!9%&MQA923(/L$^')&#G]WSQ573?BG\)]&C>/2[ZS
ML4<[F6UTN6(,?4A8QFDM&AOJ>G45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H
M8?\ R2N/_C= 'H%%>?\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-
MT >@45Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW0!Z!17G_\
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MY.W'_P <H_X4E\//^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\
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M5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\
MPI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE>@44 >?_ /"DOAY_T+W_
M ).W'_QRC_A27P\_Z%[_ ,G;C_XY7H%% 'G_ /PI+X>?]"]_Y.W'_P <H_X4
ME\//^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=
MN/\ XY7H%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE>@44
M >?_ /"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY7H%% 'G_ /PI+X>?
M]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'
M*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\
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M_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\ PI+X>?\
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MIO\ ]MH ^@**^?\ _AF7_J;O_*;_ /;:/^&9?^IN_P#*;_\ ;: /H"BOG_\
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MIO\ ]MH ^@**^?\ _AF7_J;O_*;_ /;:/^&9?^IN_P#*;_\ ;: /H"BOG_\
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MIO\ ]MH ^@**^?\ _AF7_J;O_*;_ /;:/^&9?^IN_P#*;_\ ;: /H"BOG_\
MX9E_ZF[_ ,IO_P!MH_X9E_ZF[_RF_P#VV@#Z HKY_P#^&9?^IN_\IO\ ]MH_
MX9E_ZF[_ ,IO_P!MH ^@**^?_P#AF7_J;O\ RF__ &VC_AF7_J;O_*;_ /;:
M /H"BOG_ /X9E_ZF[_RF_P#VVC_AF7_J;O\ RF__ &V@#Z HKY__ .&9?^IN
M_P#*;_\ ;:/^&9?^IN_\IO\ ]MH ^@**^?\ _AF7_J;O_*;_ /;:/^&9?^IN
M_P#*;_\ ;: /H"BOG_\ X9E_ZF[_ ,IO_P!MH_X9E_ZF[_RF_P#VV@#Z HKY
M_P#^&9?^IN_\IO\ ]MH_X9E_ZF[_ ,IO_P!MH ^@**^?_P#AF7_J;O\ RF__
M &VC_AF7_J;O_*;_ /;: /H"BOG_ /X9E_ZF[_RF_P#VVC_AF7_J;O\ RF__
M &V@#Z HKY__ .&9?^IN_P#*;_\ ;:/^&9?^IN_\IO\ ]MH ^@**^?\ _AF7
M_J;O_*;_ /;:^@* "BBB@ HHHH YOQ-::OY%[J%GX@NK""VLV=(+>&!MTBAB
M68R1L<8VC QT-<Q\.=1U_7O!NF^*-4\47##?*UW!)!;K"8U9EZK$&4@ '.[M
M7;>)1=-X<U"*SLIKVXF@>)(8F122P(SEV48&<GG\ZXOP)X5U6+X33^$=:L)]
M.N6AGA,ADBD5A(6(*[';ID9SC\:2NE*WE;[W<>CY;]_PL;MG\0-,O7M1'9WR
M)?QN^G2RHBK>[1DA/GRIQT#A<]JR/#'Q.BU/PW+KFJV,]E;2WIM[1BT964EM
MJ1KAL[N,DL .O.!6=I_@W7;S_A#M/OK/[%!X;W--<><C+<L%VIY84EL'&3N"
M]>AJAIOA;QAHWPQ70+;1;6:^BU,N6E>&3,1?=YL08E0PXQNP1Z55E=_UU6OW
M"Z?UV?ZI?>:WBOXA/<>!O$=WH4UYI6LZ)(B3PSQ1,Z,6 P?OH01GD'M7=^'[
MJ:^\-Z7=W+[YY[2*21L ;F* DX''4UY#J/@3Q.MCX_M;?1YKC^VI+=K)S=Q,
M6"MEMY=P<COGOTSUKU;0EO-/\':?'/I\_P!LMK)$:T#QERZJ!M!W;.2.#NQS
MU%"^%OT_)W_$3^)+U_-6_4YGXB^.+WPC>Z-);0EM/%V@U27;D1Q/N"CV)()S
M_L@=ZZK6/$-IH\5D726YEOIA#:PP%-TK$%N"S*HX!/)'MDX%</K/A75_%7A3
M6CJ*ZW:7-ZQ;^RE-@Z,PP(RKG)P,+G,BG(; &146DZ)KNK> ++P_XP\)S3/8
MIM,BWD/F/M!$;0L).)!P#N*CW[4ELT]_T?\ D-[I_P!>IW%]XHL=/T9-2EBN
M"LD_V:*'8$D>4N4"@,0!D@\D@>]/NO$VG:?HEWJVH&6TMK0[9A,F&#<< #.3
MD@#&<]LCFN?M?#>H7'P_M]#\0VQUK<[+-'<S+YPARQC^<'!E V#(.,YY[UB7
M_@+7=7^%=_X>DNYOM!N?.T^._D622.)2"L4CJ2">#R"0,BAZ7_KM_P '^MQ=
M/Z[_ -?UIU,WCFVBTS6)SIM['>Z7;BYGL)?+67RR"58$.5((!Z'(QTSQ5#PY
MX_?4-#T6:_TN\6_U0%X88S#^\0<LZ_O/NJ"!@X8]E-)9^&5N? ^I6EOX4L?#
M^J7M@]M*L:0+N<H1]Z+.5R>_/M6/!X0O+OX=Z)H^L^'IVGT^V(5K6[B6Z@G4
M@*T3;@F#R>6'0<=J;T;^7ZWM^'];"U2^?Y*WZ_UOZ79W<=]9Q740<1RJ&42*
M5;'N#R#[&IZR_#=MJ5GX;T^WUBY^TZC'"%GEZ[F^O?ZUJ4-68EL%%%%(8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %17/G?99?LVSS]A\O?]W=CC/MFI:9,LCP2+%((Y"I"N5W;3V..
M])[#6YYYX(+7>K71N=1U"WUV(0&_M;F9CYA"D/B-CMV$]&0 =.>HKT:N';PW
MK6J>*XK_ %"&PM([2YBGCN[:4O+*%0J4 *C8K9^;D\<<]:[BJW2)ZL****0P
MHHHH *YWQ/X8?Q&8,^(-9TF& $_\2NZ\AG)[N<'( ' ]S7153U2VGO-.EMK=
MU1I<(S,<80D!L>^W./?%)H:,GP3I[Z?X:A5]0U"_\YVF2;4+@S2E&/R9)_V=
MO  ZFLK5;V&R\::3;+J6HP7T\V)7G,RV<T>"?*4']T7/&-OS<<GL>BU"74;6
M\TR'3H[)K5I-ES'*S+((\<&/ (X[YXQ69+I6MZY&EIKT6F1VT-W'<+)9RR.T
MHC?>@*LHV'(7)#-W''6JO>2?]?U^9/1HYS7-2GM?$UY8W]Y?6E[/*HTF^CNW
M6SC# ;4E0';OR&.'4[L\'TU/&5Y%IMQ9.^I:C:W\LZ+!<J9DLX06 (EQ^Z.0
M",-ELGC'4277A?5'CUO3%%A=:9K$SS/-<NPEMRR@$! I$F-H*G<N./2K5]I.
MNZM9W^AWR:;_ &1<)Y*722NT_E8 (:,IMW8S\P; .#BB.R_K^OU&]W_7]?H=
M+,CR0LD<AC9A@.!DCW'O7&^';V&Y\4:O9:?J.HQ11PJ6MM2,S2B0L<RQK-\P
MCQQ_=ST [Z\TOB!+R_M=.32F@CMD-DTKR963NLN!T(Z%>>.142Z7JT]\NN75
MOIZ:M;V<EO;V\=P[19=@26D*!L'8O 3CGKFDM[ATL0'3KNP\76<>EZC>M#-!
M-)?1W5P]PB]!&ZAV.P[L\+@$ \<4LVG76G^+=+.FW]](LYD;4(;BY>:,QA#A
M@K$B,[RH&S:#D\<<9NCVGQ+M[UFU)O"K6[EI)#;-<>;(V#M7<P(5<X!P.!G
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M/_GUUS_P1+_\9H_X3+XY_P#/KKG_ ((E_P#C-?3]% 'S!_PF7QS_ .?77/\
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M77/_  1+_P#&:/\ A,OCG_SZZY_X(E_^,U]/T4 ?,'_"9?'/_GUUS_P1+_\
M&:/^$R^.?_/KKG_@B7_XS7T_10!\P?\ "9?'/_GUUS_P1+_\9H_X3+XY_P#/
MKKG_ ((E_P#C-?3]% 'S!_PF7QS_ .?77/\ P1+_ /&:/^$R^.?_ #ZZY_X(
ME_\ C-?3]% 'S!_PF7QS_P"?77/_  1+_P#&:/\ A,OCG_SZZY_X(E_^,U]/
MT4 ?,'_"9?'/_GUUS_P1+_\ &:/^$R^.?_/KKG_@B7_XS7T_10!\P?\ "9?'
M/_GUUS_P1+_\9H_X3+XY_P#/KKG_ ((E_P#C-?3]% 'S!_PF7QS_ .?77/\
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M77/_  1+_P#&:/\ A,OCG_SZZY_X(E_^,U]/T4 ?,'_"9?'/_GUUS_P1+_\
M&:/^$R^.?_/KKG_@B7_XS7T_10!\P?\ "9?'/_GUUS_P1+_\9H_X3+XY_P#/
MKKG_ ((E_P#C-?3]% 'S!_PF7QS_ .?77/\ P1+_ /&:/^$R^.?_ #ZZY_X(
ME_\ C-?3]% 'S!_PF7QS_P"?77/_  1+_P#&:/\ A,OCG_SZZY_X(E_^,U]/
MT4 ?,'_"9?'/_GUUS_P1+_\ &:/^$R^.?_/KKG_@B7_XS7T_10!\P?\ "9?'
M/_GUUS_P1+_\9H_X3+XY_P#/KKG_ ((E_P#C-?3]% 'S!_PF7QS_ .?77/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8O>3EW5?NH7W[M@ZA,[1Z4]_ ?AV6ZTJY>UN6FTI EDYOI\PJ#T'S\^ASG(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOKJ"&SOK.<O# <J#!+%T&Y@1OQGY@,XXH2O;S&]+^1Z31112 **** "BBB@
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MY_M18?(%Q]NGSLQC;C?C'?IUYZ\UO;E+E-PW  D9Y _R#2T?U^@?U^ISFG>
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M@E2,,Q([LS>V*V?^$[\'_P#0UZ'_ .#&'_XJFPZLZ"BN?_X3OP?_ -#7H?\
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M?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\
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M /!C#_\ %4AG045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '04CA
MBC!" V."1D _2L#_ (3OP?\ ]#7H?_@QA_\ BJ9+XW\(2PO'_P )=HJ;E(W)
MJ,(9<]Q\W6A@<SH&AZCX4\8VJZM;:/JG]I/*(M8@L%@NTEPSE9",Y4J" <YX
MP:U?#UM!:_$[Q6MO!'$K6UD["- H+$29)QWIVG^)/"-GY;W/CO3M1FC!$<MW
MJ-L&4'K@1A5S[D9]ZIV&J>#K#Q+?:X/B#9S37JJDL$NH6?E[5SL VJ&&W<<?
M-SWS33M]S_2PGK?Y';W MX\75QL40*S!W/"#')_+O6'H>A0VUEJSSVR"'4KM
M[K[+(H*H"% ^4\ G;N/NQKDKJ3PMJFC)I]S\49H(TN&G5XM;MA-R<JK28)(4
MYP >,CDX%7M%O_!^AZ;>6L7Q)6[FN?\ E\OM9M[B:(8P A;*@#DX(/)-2U=/
MT_K^O(?;^OZ_X)9^'^EV.J?"W1[._M(;FUV,3!*@:-L2-@%3P0.N/85J^&]#
MTK3]4U2[TS2K*PB9UMD%K;I$'"9W$[0,_,S#_@-9?AK6O!?AC1DTN#QSIUU;
MQD^4;K4;;<@/. 4"Y&<GG)YZUH6/B_P7I]E%:Q>+-%9(UQN?482S'N3ANI.2
M?K5-ZW_KH+I;^NIU%%<__P )WX/_ .AKT/\ \&,/_P 5704AA1110 5GZWHF
MG>(]'GTG5K?[18S[?,BWLF[:P8<J01R >#6A10!Y_P#\*2^'G_0O?^3MQ_\
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M,Y&<57+K;U_!V_,F^E_3\5<M_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\
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M^.5Z!10!Y_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE>@44 >?\
M_"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y7H%% 'G__  I+X>?]"]_Y
M.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE>@44 >?_P#"DOAY_P!"]_Y.W'_QRC_A
M27P\_P"A>_\ )VX_^.5Z!10!Y_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\
MR=N/_CE>@44 >?\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y7H%%
M'G__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE>@44 >?_P#"DOAY
M_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.5Z!10!Y_\ \*2^'G_0O?\ D[<?
M_'*/^%)?#S_H7O\ R=N/_CE>@44 >?\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z
M%[_R=N/_ (Y7H%% 'G__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#C
ME>@44 >?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.5Z!10!Y_\
M\*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE>@44 >?\ _"DOAY_T+W_D
M[<?_ !RC_A27P\_Z%[_R=N/_ (Y7H%% 'G__  I+X>?]"]_Y.W'_ ,<H_P"%
M)?#S_H7O_)VX_P#CE>@44 >?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\
M)VX_^.5Z!10!Y_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE>@44
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MDOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.5Z!10!Y_\ \*2^'G_0O?\
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M $+W_D[;_P#QR@#Z_HKY _X4E\0_^A>_\G;?_P".4?\ "DOB'_T+W_D[;_\
MQR@#Z_HKY _X4E\0_P#H7O\ R=M__CE'_"DOB'_T+W_D[;__ !R@#Z_HKY _
MX4E\0_\ H7O_ "=M_P#XY1_PI+XA_P#0O?\ D[;_ /QR@#Z_HKY _P"%)?$/
M_H7O_)VW_P#CE'_"DOB'_P!"]_Y.V_\ \<H ^OZ*^0/^%)?$/_H7O_)VW_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M298V3# *,XX]J[7X@6>D>%_#/@G2X-4>6V@UN.:.6ZE7?Y0+%F! 4;!N'(&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6L4[X#AMK;X"<;""P+[>ASNX%/CNX- B\3Z7>%5OKZZFN+.#'S7@DC&!&O\
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MY;Y@>HXY'-'D'2YT]%8=GXIL[NXA1H+FV@N5+6=S.JB.Z 7<=F&+#@$X8*2
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M*Q\3)%;PM&I2&,S1951C 7#,,>A(Z5Z8?"_A]IK:8Z%IAEM55;=S:1[H0IR
MAQ\H!Y&*=;^&=!LX+F"VT338(;H8N(XK2-5F'HX PW4]?6J<DY-^;_\ 2DQ)
M6M_71K]?P.:\26)MKJT?2-/TN^M]/M6/]ENP@:),D>;;MC:CC!7MVY'?J-(D
MM[[P[9/ )EMIK5"@D)60(5&,D<@X]*DN='TR]ACAN].M)XHRI1)8%94V_=P"
M.,=O2K4D4<T+PRQH\3J59&4%6!X(([BIZ-#ZIGCMC%%IWPY_MJ)PDT&I3VTE
M].99_*M6NB'W .&=<*N?FZ9.>M:VC6=D+#6_[)\7Z \%S!&H@TJV\NVMI-V
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M>"K*ZM].OKV\B,,NI7TMX(3D>6K8"\'H2%#$>IKI:** "BBB@ HHHH ****
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M:=+IMC):3R&66W-L@B=B0<[,8Z@'Z\TY?#FA)8QV*:+IRV<4GG1VXM4$:/\
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M-6ZY?P8CE]?O <VMWJLLEN0Q(90JH2/8LK5U% !1110 4444 %%%% !1110
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M5 +,W:W3.NUQN"X4#)ZGG..G?.:VJ.EP\@HHHH **** "BBB@ HHHH ****
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M,D!=1(P(Y!";CD=.M:HT'1UNI;I=)L1<2N)))A;IO=QT8G&21D\^]7R RE6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA,/CMN!Q4[>/OA(^NOK1UZ]&H.NQI5DU!1M_N[1\H7OC&,\]:[S_ (03P?\
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M)7'_ ,;KH/\ A!/!_P#T*FA_^"Z'_P")H_X03P?_ -"IH?\ X+H?_B: .?\
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M##_Y)7'_ ,;KH/\ A!/!_P#T*FA_^"Z'_P")H_X03P?_ -"IH?\ X+H?_B:
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M  NWX>?]##_Y)7'_ ,;KH/\ A!/!_P#T*FA_^"Z'_P")H_X03P?_ -"IH?\
MX+H?_B: .?\ ^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\ Y)7'_P ;KH/^$$\'
M_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H Y_\ X7;\//\ H8?_ "2N
M/_C='_"[?AY_T,/_ ))7'_QNN@_X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?
M_@NA_P#B: .?_P"%V_#S_H8?_)*X_P#C='_"[?AY_P!##_Y)7'_QNN@_X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (F@#G_^%V_#S_H8?_)*X_\
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MKH/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H Y_\ X7;\//\
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M_"[?AY_T,/\ Y)7'_P ;KH/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
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M-JG<0#_%@L3D^F!6[9V&A6>I^&=07XG>''ET&U:TC1O*V2H1MR0)\AL=\D9
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M&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\
MQ5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_
M .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0
M_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C
M#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 5
M0!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045
MS_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"
M=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\
M^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0_
M_!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_
M ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_
M  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#
M_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AK
MT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P
M8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
M%4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%
M%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\
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MV=[?UO:PO/\ K9O]&4O^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\
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M,,D6OP3/)<!IL@*RPKN\L#DDJJC'8X)"6K_K^O\ AT#V_K^O^&8O_#./@_\
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M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#
M_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]
M_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[
M!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X_
M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\
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MC)8KC=D\$CI0NGF-]3C/^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\
MP_\ QJNRUSPW:/J6F3:;"L.L_:XY)+Y !,T*G,@D;JRD?+M/&6&!QQUU+H'4
M\?\ ^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\ P_\ QJO8*PO%TFI1
M:"TFF+,S+-&;A;?_ %Q@W#S/+_VMN<8Y].<4,$>>?\,X^#_^@EKG_?\ A_\
MC5'_  SCX/\ ^@EKG_?^'_XU79^ %M7T*&XT_4Y[BU*LK033-*8Y YSDN2ZG
M'!4]/05UM DSQ_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\
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M_P 'J_\ QZ@#Z?HKY@_X0WXY_P#/UKG_ (/5_P#CU'_"&_'/_GZUS_P>K_\
M'J /I^BOF#_A#?CG_P _6N?^#U?_ (]1_P (;\<_^?K7/_!ZO_QZ@#Z?HKY@
M_P"$-^.?_/UKG_@]7_X]1_PAOQS_ .?K7/\ P>K_ /'J /I^BOF#_A#?CG_S
M]:Y_X/5_^/4?\(;\<_\ GZUS_P 'J_\ QZ@#Z?HKY@_X0WXY_P#/UKG_ (/5
M_P#CU'_"&_'/_GZUS_P>K_\ 'J /I^BOF#_A#?CG_P _6N?^#U?_ (]1_P (
M;\<_^?K7/_!ZO_QZ@#Z?HKY@_P"$-^.?_/UKG_@]7_X]1_PAOQS_ .?K7/\
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M(.%D#D_,?]D@CCMGGP+_ (0WXY_\_6N?^#U?_CU'_"&_'/\ Y^M<_P#!ZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;4-0M=*T^>^OIT@MH$+R2.<!0*EMYTN;:*X3.R5 ZYZX(S0!)1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%9.O>(K/P[!!+>1W+I-,D*F&$L S,%&X]%Y8=35
MK4]4M-(M#<WDA1-P1552[NQZ*JC)9CZ 9H N454T^\EOK=I9;"ZLOF*JESLW
M,.S81FP#Z'!]0*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY(@!]YOXBK%EW'D[>>:Z>F111P1)%#&L<:#:J(,!1Z #I3Z;8!1112 ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>interim1_002.jpg
<TEXT>
begin 644 interim1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .( X<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BN'\0ZOXNTF>R>.XT:.&_U1;&**2QDD>-&+;79Q,H8X4'&!UZ\4
MWQ%J_B70K'3)KR_T^,-K$%M-+!:E5F@<KT#.VP_>!Z^V*%K^7Y?Y@]/Z]?\
M([JBN>E\<^&K?3Y;ZYU1+:"&X^RR?:(WB=9<9V%& ;..>G3GI3I/&F@QVGVH
MWDK1AW1@EK*SKL.'+*%+*H/5B O3F@#?HK$N_%VA6(A:>_'ERHKB6.-Y(T5O
MNL[J"J ]BQ -.\4WFI6'AJ\OM(:U^UP1F5%N8F='P/N_*RD9]<\>AH>@(V:*
MYG0_%J:CX,.MW</DW%NKQWELO6.=#M:,#UW<#UR*@\#>(=5USP]<:MKOV&VV
M3S1^5!&RB$1NRMN=G(;IU 6G;?R#L=;16%;>,=!N9)HUO_*,,)N&-S$\ :(=
M9$+J Z?[2Y'O3;#QIX?U.:VCLKXSFZC>2W98)-DH3[P5MNTL,?=!S[4@-^BO
M-]4\?7>H_#[6M;T1I+">PF= UU8N,HLA3@OA=W&3][;T(S77V_BG1YUO0+W:
MUA&LESYD3IM5AD,-P&Y3@X*Y![46T_KM</Z_0V:*IZ?J=MJ<9>W\X;<;EGMY
M(7&>F5=01^5<Q-JGB>;QW=Z#:7VCPV\=DMY')+ITLC@,Y78<3J"1MSGCKTHZ
MV#I<[.BN;C\46FE_8[+7=7T^74KLNUNMC$_[]!D@K'ESG ]3D\#GBKB>*=&D
MT:/5DNRUI(YC3$+F1G!(*"/;O+Y!&W&>.E &Q17#^%/%[W4/B"ZU6_$T%KJC
M6UMY=HR-M\M&""( N7R3QRV<\#H-X>+-$?2X]02\+PR2&%%2&1I6D&<H(@N_
M>,'*[<C!XHM_7J!M45R?@'7+W7M.U2>^NTNC!J<UO%)'!Y0V+MP-IY'?J2:Z
MR@ HK+\0S:C:Z)<W6F3VL5Q!&TO^DP-*K!5)VX5T()XYS^!KEXO&FIWOA#5)
MD2TL/$>DQ&2]L[B)I8^%+ J ZG8X'#9..>N*%J.VWF=Y17.OXBT_3[V&TU;7
M[>._ALGN;F&-!'$4XS(P;<4 [#?SD]>T^F>+]"UBYMK>PO3*]U"9X#Y,BI*@
MQDJQ4*2,C(!R.XIV%?2YMT5D6GB?1[[4_P"SK>[+7)4L@:)U64#J8W("R =]
MI..]87B_Q5JOA;7=+D\NTFT.;/VTF)A-;J&1/,#;\%<R+D;> #SZ):M+N'?R
M.THKCOB!XMO/#.E0-I4-O->SR(/WZEHXXRZH7(!!/+J ,]3[5T-SJ<6CZ?#+
MJMRAE;"$P0/F:3&<1Q@LQ)P2%&X_6CI<#0HKGF\<^&8[2"YDU>&-)[C[*BR*
MR/YN0"A0C<I&1D$#&><53UKQ_IFG>'+S5+47%RUO<"U:+[)*&CE)  =2H91\
MP/(YR,9R*/Z_+_-!_7]?<SK:*XF_\57%EXWTR.6Y==&N],FN1;?89!/O0IU7
M!D)PQ^4*",'.>V\/%.CO;6%Q%=//'?KOMO(@DE9UXRQ55)51D9)  SSBCI?^
MOZT#K8V**K/+)=Z=YNGS1(\L>Z&66(NHR,@E<J2/;(KC?#FK^+M=\/P:J^I^
M'X#+-)$(&TZ4!BLC)@/]HX)V_P!T]>AHMK8.ESNZ*YT^.O#7FS1KJB2&&Y6U
MF:*)W2*4D !V52%R3C)(&>,YJCX\\6IH6@:FMA?"'5H+8S(?LCSK'W&\K\J;
ML$ N0,]CTI=+C2N['845@2>*],TO3[-]5O"DKV\<LK+"[B,,/OR%%(C4G/S-
M@<5C_$'QDNB^&M2.DZBL6IP0B17%JTZ)G& S ;$9@?EW'GT-4U9V\["C[UCM
MZ*C@8O;QLQRS("3^%24GH).ZN%%%% PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M90\;*$8=?OX/(.!R=%/#-SHVIZ9KNBZ%=%8YIGN]/GOA+<N9413+ODD9"XV
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M_P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0__':] _X03P?_ -"IH?\
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M_AH[P?\ ] W7/^_$/_QVO0/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
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M_P! W7/^_$/_ ,=KT#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\
MB: //_\ AH[P?_T#=<_[\0__ !VC_AH[P?\ ] W7/^_$/_QVO0/^$$\'_P#0
MJ:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H \_\ ^&CO!_\ T#=<_P"_$/\
M\=H_X:.\'_\ 0-US_OQ#_P#':] _X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (F@#S__ (:.\'_] W7/^_$/_P =H_X:.\'_ /0-US_OQ#_\=KT#
M_A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B: //_ /AH[P?_ - W
M7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\ QVO0/^$$\'_]"IH?_@NA_P#B:/\
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MIH?_ (+H?_B: //_ /AH[P?_ - W7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\
MQVO0/^$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")H \__P"&CO!_
M_0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0__':] _X03P?_ -"IH?\ X+H?_B:/
M^$$\'_\ 0J:'_P""Z'_XF@#S_P#X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P!
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M!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B: //_ /AH[P?_ - W7/\
MOQ#_ /':/^&CO!__ $#=<_[\0_\ QVO0/^$$\'_]"IH?_@NA_P#B:/\ A!/!
M_P#T*FA_^"Z'_P")H \__P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0_
M_':] _X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XF@#S_P#X:.\'
M_P#0-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_ ,=KT#_A!/!__0J:'_X+H?\
MXFC_ (03P?\ ]"IH?_@NA_\ B: //_\ AH[P?_T#=<_[\0__ !VC_AH[P?\
M] W7/^_$/_QVO0/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H
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M_$/_ ,=KT#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B: //_\
MAH[P?_T#=<_[\0__ !VC_AH[P?\ ] W7/^_$/_QVO0/^$$\'_P#0J:'_ ."Z
M'_XFC_A!/!__ $*FA_\ @NA_^)H \_\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\
M'_\ 0-US_OQ#_P#':] _X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_
M (F@#S__ (:.\'_] W7/^_$/_P =H_X:.\'_ /0-US_OQ#_\=KT#_A!/!_\
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M/^_$/_QVO0/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H \_\
M^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':] _X03P?_T*FA_^
M"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (F@#S__ (:.\'_] W7/^_$/_P =H_X:
M.\'_ /0-US_OQ#_\=KT#_A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H
M?_B: //_ /AH[P?_ - W7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\ QVO0/^$$
M\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")H \__P"&CO!__0-US_OQ
M#_\ ':/^&CO!_P#T#=<_[\0__':] _X03P?_ -"IH?\ X+H?_B:/^$$\'_\
M0J:'_P""Z'_XF@#S_P#X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_
M ,=KT#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B: //_\ AH[P
M?_T#=<_[\0__ !VC_AH[P?\ ] W7/^_$/_QVO0/^$$\'_P#0J:'_ ."Z'_XF
MC_A!/!__ $*FA_\ @NA_^)H Y?PM\:_#?B[Q'::'866JQW5UOV//%&$&U&<Y
M(D)Z*>U>D5CV/A/PWIEY'>6'A_2K2ZCSLF@LHXW7((.& R,@D?C6Q0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%8/B#QCH?A9X%UFXN+<3D+$ZV<TJ,QSA=R(1NX^[G/M0!O45A6'C'0
M]1U4:7%=2PZ@5WK;7EK+;2.O/*K*JEAP>F:W: "BBB@ HHHH **** "BBB@
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M "J]_:?;]/N+3[1/;^?&T?G6[[)(\C&Y6[$=C5BB@$[&)X:\-_\ "-VT\/\
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M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W
M_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_
MPSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H
M):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'
M_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!
MX_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,
MX^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y
M_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^
M-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX
M/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_
MW_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-
M5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\
M\,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_
M /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_
MX?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\
M,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"
M6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_
M^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!1
M0!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^
M#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H)
M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#
M_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]
M_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[
M!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X_
M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W
M_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_
MPSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H
M):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'
M_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!
MX_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,
MX^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y
M_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^
M-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX
M/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_
MW_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-
M5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;.-H[2XCF=3,O.T.I3Y,<#(+\=JZ33M+T_2+;[-IEA:V4&XMY5M"L:Y/4X4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;[2%33[V=;>&>*XWRH[?=\R/8 H)&,AFQQG%<7X<-G;ZGIVJZ7=QPZU>2?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_=3("D@9ZC!/)IZ75OZ_R]!/K_7]?UV.]HHHJ1A1110 4444 %%%% !1110
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M%7VM87NHKEDS+$C(C9/ ;&>.G\(KE]=^&/A#Q+J;ZEK&ER7=VX +O>3@ #H
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MN;<M#&C6NQPOE_(J@H0PVY&>#R:ET3X>^%?#MI>VNF:/'%!?*%N4>1Y1(!G
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M.T 9QTS0!M455M-2L+_=]CO;:YVLRGR95?!4X8<'J"0#Z5:H **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK1T;2A87.I7AB6&34+@3O$IR%PBISCC<=N3]>^,E]7_786Z1K4444AA1110
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MT/7[/Q!'>26:7"K:W+6T@GB,9WJ 3\IYQSW H U:*** "BBB@ HHHH ****
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M#[0S/"50INV\$]><]..*0&M1110 4444 %%%% !1110 4444 %%%% !1110
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MO70LEK';3Z7_ &C9W#F.ZBV!PL>TG<5/49 &.3SP*\3_ .&FO^I1_P#*E_\
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MAYH1"."5"DY' -<9I/[1(TG2;73U\-3W*6\8C66?4EWE1P,[8%' XZ=JN?\
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M::_ZE'_RI?\ VJ@#Z HKY_\ ^&FO^I1_\J7_ -JH_P"&FO\ J4?_ "I?_:J
M/H"BOG__ (::_P"I1_\ *E_]JH_X::_ZE'_RI?\ VJ@#Z HKY_\ ^&FO^I1_
M\J7_ -JH_P"&FO\ J4?_ "I?_:J /H"BOG__ (::_P"I1_\ *E_]JH_X::_Z
ME'_RI?\ VJ@#Z HKY_\ ^&FO^I1_\J7_ -JH_P"&FO\ J4?_ "I?_:J /H"B
MOG__ (::_P"I1_\ *E_]JH_X::_ZE'_RI?\ VJ@#Z HKY_\ ^&FO^I1_\J7_
M -JH_P"&FO\ J4?_ "I?_:J /H"BOG__ (::_P"I1_\ *E_]JH_X::_ZE'_R
MI?\ VJ@#Z HKY_\ ^&FO^I1_\J7_ -JH_P"&FO\ J4?_ "I?_:J /H"BOG__
M (::_P"I1_\ *E_]JH_X::_ZE'_RI?\ VJ@#Z HKY_\ ^&FO^I1_\J7_ -JH
M_P"&FO\ J4?_ "I?_:J /H"BOG__ (::_P"I1_\ *E_]JH_X::_ZE'_RI?\
MVJ@#US7?#VI:KXAT?4[;4[2VBTUVD6&2R:5G9E*-EA*N!M/''!YYZ5/>Z#=-
MJ5Q>Z9J*V37B+'=AH/-W!00&3YAM?!QD[A@#CBO'/^&FO^I1_P#*E_\ :J/^
M&FO^I1_\J7_VJCI;^M0\SW?3["WTO3K>PM4V6]O&(XUSG@#%6:^?_P#AIK_J
M4?\ RI?_ &JC_AIK_J4?_*E_]JH;OJ!] 45\_P#_  TU_P!2C_Y4O_M5'_#3
M7_4H_P#E2_\ M5 'T!17S_\ \--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4
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M *%0K8 X!(;D'D5YC_PTU_U*/_E2_P#M5'_#37_4H_\ E2_^U4EI;R#OYGT
M    , 45\_\ _#37_4H_^5+_ .U4?\--?]2C_P"5+_[50!] 45\__P##37_4
MH_\ E2_^U4?\--?]2C_Y4O\ [50!] 45\_\ _#37_4H_^5+_ .U4?\--?]2C
M_P"5+_[50!] 45\__P##37_4H_\ E2_^U4?\--?]2C_Y4O\ [50!] 45\_\
M_#37_4H_^5+_ .U4?\--?]2C_P"5+_[50!] 45\__P##37_4H_\ E2_^U4?\
M--?]2C_Y4O\ [50!] 5%=6T-[:36MQ&)()D,<B-T92,$?E7@G_#37_4H_P#E
M2_\ M5'_  TU_P!2C_Y4O_M5#5] 3L>MV?A>X1K"&_U,7ECILBR6<7D;)-RJ
M54RON(? /&%7D G-+IOA[4K+Q?J>MS:I:30WT:1FW2R9&18]VS#F4@GYCGY>
M>V*\C_X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J=WO_6H6TL>JGP]JFHV5I->
M:ONU2PNWN+*\-GL&T@KMDB##(VL1P5)&#P:;J'A;6[JPO/LGB*&RU2^9/M-Y
M'I^Y=B# 1(S)\O?)8L>3[8\L_P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JI
M>7]?UH'6_P#7]:GJ&D^"[MH9(?&&K6OBB%=OV:&XTJ&*.#&<D*,@D\#/8=.I
MJSX?\#:1X<UW5-4LK.RC:\=3"L-HD9MT"!2BD=B1N.,<FO)O^&FO^I1_\J7_
M -JH_P"&FO\ J4?_ "I?_:J=^H6TL?0%%>/^"?CI_P )CXOL= _X1S[']J\S
M]_\ ;O,V[8V?[OEC.=N.O>O8*0!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%<C\0Y[RST2UN[._N;5UO[:-EA8*)%>9%(8XST)Z$=:%ND!UU%(P)
M4A2 V."1G%<5:7L$7Q"CT^WU#4DE,,C745^TPCNB, &!9/EXY),>%QZ]A;V#
MI<[:BN1MI[R/XJW5F]_<RVC:2MPL#L-B.92.  .P YR?SKFO$TU\_CN)]<;Q
M3H^C+-%!9W>FWRK:RDG_ );JN67<WRY)Z$#CK0M;>8/2_D>IT5!=VQNH?)\Z
M2)&/SF)BK$>@8<K]1SZ8ZUS^@6EY:ZQK5G%?W<NDQB-;=KB9II(IB"9 )'RS
M 90_-G!)';% '3T5P_AC6Y-.\-^)=0U2\N;N/3=1NQOF;<_EQ]%'0=!VINC:
ME-+K>G-XB_M6VO[T-)9IYOEV>=N3$%1\NP7)S*.2"5QT M?Z[JX;+7^K'=44
M44 %%%% !1110 4444 %%%% !12'.#C@]JY34]-NK+6M)GT[4KYKR>Z NHY;
MAWAD@"DN?*)VICC!4#D@<YHZV#H=91534E4V,ADDN$A4%I/LRN9&4#D+L^;/
M^[SZ<UQ_AP?\)'H&LV5GK>I6]LUT8HC)*XOK-,+E2TF75B=Q4MD@,/H#N!W=
M%>57>FW?@J+6+^T\2>(=1CMXH8)'U*_,ZVYDD&^0+@#*1X;)!^]]:Z:"5M%\
M:Z=IMI>7-U9:G:S3.EQ=-.8W0J0ZLY)"L&(P#C@8 YII7_KYA_7Y?YG7T5SG
MC&>UL](DN[Y]7,"+\D>E^<) _)W$Q<@<?Q87USD5D2^(-2_L7P_IEA=_;]3U
M&U,LE[:*C_NT4;W3=A"Q+*HW8&3DCC%):CL=U17F]KJ]I>:MINB17.L6T%W-
M<)??;+R07 N$12(=X<[,ABX\L@'''>NB\*7LYU#7=(DGDN8=,NEC@GE?>Y1H
MU?8S'EBI)&3SC&23FG;^OZ]1?U_7W'34444@"BBB@ HKG_&W_"1?\(A??\(I
M_P AO]W]F_U?_/1=W^L^7[F[K_.O'_\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 45\_P#_ !D/_G^SZ/\ C(?_ #_9] 'T!17S_P#\9#_Y_L^C
M_C(?_/\ 9] 'T!17S_\ \9#_ .?[/H_XR'_S_9] 'T!17S__ ,9#_P"?[/H_
MXR'_ ,_V?0!] 5S/CC2-6US2(++2H[)F%U#.[75P\0 CD5P!MC?.=N.V/>O)
M?^,A_P#/]GT?\9#_ .?[/H ]FFN==_M6VABBTT026K&93([2138^4C@!H\\<
M[356WTK5M5NM+O/$$.GP3:=*TR+8S/*)'*%,Y=%*C#-\O/;GBO(_^,A_\_V?
M1_QD/_G^SZ$[ >K)I.MCXC2:V8-/_LUK(6>1=OYV Q??L\K'4XQN]\]JO7-E
MJFKK<V&I6UA'I[N,213N\DB YP4* (>!R&;O7C?_ !D/_G^SZ/\ C(?_ #_9
M]"Z+^NX/7^OD>KWT_C"XM-5@TM-$%PL^RRGEEE"+&1SO 4Y<'L..?;%)X5MO
M&5J)D\0G01#''BVBTPS?,Q.29&DR?Q&<Y).:\I_XR'_S_9]'_&0_^?[/H6@'
MI6B>%-1?0_$.D:_!9);ZK<3S@V=T\I42]5.Z-,;>,'G/H*NP:%JM]<Z3_;9L
MO+TF7SHI+9V+7+A"@9E*@1XW$X!;G'->4?\ &0_^?[/H_P",A_\ /]GT)V_K
MMH']??N?0%%?/_\ QD/_ )_L^C_C(?\ S_9] 'T!17S_ /\ &0_^?[/H_P",
MA_\ /]GT ?0%%?/_ /QD/_G^SZ/^,A_\_P!GT ?0%%?/_P#QD/\ Y_L^C_C(
M?_/]GT ?0%%?/_\ QD/_ )_L^C_C(?\ S_9] 'O[;@IV@%L< G )K@[6T^)G
M]MM/<OX4CLYI0)&C:XDGCAS]U,@*2!GJ,$\FO//^,A_\_P!GT?\ &0_^?[/H
M6CN#VL>N"Z\5R0W)MX-$EEBO2(MTTJ));^A8*2L@XR0&7K^%W2=)DM=0O]5N
MA$M[?B,2)"2414!"C<0"QY/S8';CBO%O^,A_\_V?1_QD/_G^SZ$#U/:H[.]M
M-'N D%I=W\[M)(DTICB<L>A8(QP%POW3G:*R[#PRNAP7FHV<&E6^I?9VCMDC
M@\FUMQG=MPO."V"S=3@<#%>4_P#&0_\ G^SZ/^,A_P#/]GT >P17'BN0V4@L
M]',,ENOVE6N)4>.7N4^0[EQC .T^IJA'X0ET@:5=Z,UO)?:>DT3)<$QQSI*V
M]QE0Q3YP",!L 8QSFO+O^,A_\_V?1_QD/_G^SZ=^J ]0?PO=.E\9]/T>^EU6
MX%Q>"\)DB@*HJH$0I^]QMZDISS[#=T31+;0[)X(,-)+(9IY=H7S'/4X' &
M!V  KQ+_ (R'_P _V?1_QD/_ )_L^D&Y] 45X_X)_P"%R_\ "7V/_"5_\@3]
MY]I_X\_^>;;?]7\WW]O3^5>P4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'>//&.I^"[2/4(= 74[
M#.)GBNRDL7!);9Y9!4 ==WX <UV-8.M:QI%IK.E:??:A90W%Q(P2WFF56D#(
MRCY2>03Q[GBEK=6&O,KQ>*9M8T?3=5\,VMEJ-I>$*S7%XT!C/I@1ODCG(XQC
MO6TVJZ<FHKISW]JM^R[UM3,OFE?4+G)'OBO-=/\ !^I^!OB-:C0R6\*:O.S7
M%L1D6DP1F&/0$C&?P/:L?PKI2:EXAU[1_$FM:A8ZI%K9U&&T7R5-P 08Y$+1
MEV "XPK8QV%6K-Z?ULK?KYK\)=TOZ\_^&]?Q]+LO'&@:AXINO#]MJ-L][;JN
M5\Y?G<[LH@SEBH7)QTS5;7?&4NA^-= T!M-2:'6"ZK<BXVM&5Y.4V<CD?Q>O
MISSW@T_9OC'X\BG!CDN#:R1*PP70(<L/4=L]*J_$*]M8?B_X 26YA1HY)BX9
MP"H; 7/ID@@>I%)+6'G_ ,'_ "&_MVZ?\ ]*GUC3+6_AL+C4;.*\F_U5O).J
MR2?[JDY/X4_^T[ WSV(OK;[6BJSP>:OF*"< E<Y )Z5XEJZ3V^D?$'2=1R_B
M#4M2633X3_K;B/*^4T0ZL% [?=QSBMJSCU#1?$^G^7=P:D-0O8S?:9<KBX@G
M4!'N86ZF,%>>V.._"CK;Y?BK_AL_/L$O=O\ UM_GT/4Y-3L(KY;*2^MDNV3S
M! TJB0KG&[;G.,]ZM5Y9XG\[2_&$E_IMS#=B\N[>*\T2\7#3LNS;+;-U)0$$
MXX&"37J="^&X/1V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH I:IJ4>EV?GNI=V=8HHEZR2,<*H^I/7MUK+U[Q%
M=>'-+M+JZT_[4\T\<$I@D"I$9'"C[WS'[W8<X[5!XL67^V?"LN<6Z:I^]R.,
MF&15_P#'B!]2*S_BGJ%E9>&+9;N\MX&?4;1D$LH4L%F0L1D\X')]!372_?\
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M'<' /8@CK5ZBB@"**!8FD;<S.YRS-U]A]!4M%% !374LA4.4)'WEQD?G3J*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$$UW;P30PR2@2S$B-.K-CJ<#L.YZ"H;+6=+U*>:&PU*SNI8#MF2"=7:,^C '
MC\:Q/#[KJ^K>)+BX4OY=Y]@0$8VQ(BG'XLS'WR*GFTV'4/%VGW\**BZ7%+&T
MJ<;F< "/CJ !DCL=OO@73^OZ_P""'?\ K^O^ ;-[?6FG6KW5]=06MNGWI9Y
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M?$+:1<Q7#Z9]AM[ RQ>:Y+%B6(?RQR1CYCQGN<5YA_PM/XO_ /0A?^4>[_\
MBZ/^%I_%_P#Z$+_RCW?_ ,74M75O7\=&.^M_ZWN=E8Z3X@M]/\ 0/X>O-^CM
M_IO[^WQ&!$T>1^]^;EL\=O?BNN\::9=ZKX:D@L8O.N$G@G6+<%,GERJY4$D
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MA?\ E'N__BZ/Z_K[@OK<]0O[76;V\T<2:;.^E&T=+JS\^-&CG^7:9</AT #
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M-;-ZD9N+;_5&<2YSYN,X7&/4CMS70>(M#O\ 4=074=.TZ[LM7(1;>_MKI$"
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M .A"_P#*/=__ != 'T!17S__ ,+3^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\
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M_A:?Q?\ ^A"_\H]W_P#%T ?0%%?/_P#PM/XO_P#0A?\ E'N__BZ/^%I_%_\
MZ$+_ ,H]W_\ %T ?0%%?/_\ PM/XO_\ 0A?^4>[_ /BZ/^%I_%__ *$+_P H
M]W_\70!] 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\ A:?Q?_Z$+_RCW?\ \70!
M] 45\_\ _"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0O_*/=_\ Q= 'T!17S_\
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MW$11I6+'YB2ZL,GITX'3&!7BG_"T_B__ -"%_P"4>[_^+H_X6G\7_P#H0O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>_B@>X2QGO!"\R(,MM^5B2 #V_$59\,ZW_PD7AC3]9-O]F%Y )O*W[]F>V[
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M, F?SIQLBSV+G _'BJ?Q$EBMOAIKYFF"+_9\B!I"!EBN /J20/J:\WTZ1O\
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M\'_]!+7/^_\ #_\ &J .@_X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE<?\
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M_#_\:H Z#_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &ZY__AG'P?\
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M !JC_AG'P?\ ]!+7/^_\/_QJ@#H/^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
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M /&J .@_X7;\//\ H8?_ "2N/_C='_"[?AY_T,/_ ))7'_QNN?\ ^&<?!_\
MT$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\ P_\ QJ@#H/\ A=OP\_Z&'_R2N/\
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M_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-4 =!_P +M^'G_0P_^25Q_P#&Z/\
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MD*CQ&4)'WELI\C\XZP/^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2ED65B&AG(&<L<; 6P&_AQBG;6PKZ7.JU77M*T0VPU*^AMFNI1% KGF1R0,
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M9/,A($L,T+PR)GIE' 8 X.#CFJ$WBJVA\81>'C;WAF>W\XR+:2L@RP"_,%(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7.C06D%GY4=Q?.\4=S.I:.$K&SC(!&2=N ,C)_(Z&A3:I-I\9U06[R>6C+/
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M2E$7]GM? B?;L&\$, VT-]W=\W7MBNOHH6EP>M@HHHH **** "BBB@ HHHH
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ME+PK93Z;X2T>RNB3/!9Q1R9Z[@@!K7HHIRES-ON3%6204444AA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU#PIK=U<ZA)KNJWSV=A+;7D&IV44$%O$<;DE(@13@@8&X_3&:]7HI-:6\O\
M/_,.M_ZZ?Y'$_"D:?/\ #W1;BU%L\R6WDO)$%+*<Y*$CD=CBLUKBPB7Q=HOB
M$Q_;KZXE>WBD'SW<)C'E^4.KE<8PN2",\9KTBBG+WF_,(Z?G^?\ F>7Z[J<.
MC?\ "O;3Q!JMI%J-O<))=F:=5(_<.I<Y/3=QD\9KI/'MS+:Z'9W\=O+=V5M?
M0SWD4"[V> 'D@#J =K8]JZRBB3;U\[B22T\K?G_F>;ZGJ6D^)_"&LZOX2BFN
MOM$D+7KI;2I]J2-AO10X&X[ R\#GI5YKG2M:\7:9J^D7-I-8P65Q%J<R$&,1
M$+MCD/0$')VGD -D#-=U12_K\+?</^OQ3^_0\)AU7P_!\*(XHK[38PGB$%46
M5!M47>X8'IY?/^[[4>.=3\/'XM6$TEWII$'V &1G3$8\URW/8;2I/L17NU%-
M/5/M_DE^@/5-=_\ -L\P76]"7QKXX9]2T_8NG0[B9DP"%=7[^I0'\!Z5A?#3
M5=-_X0^^L/$EW;337]O&+?S#N^TPB%4$2==S(P8%!R"<XYKVRBET:\K?G_F.
M^M_._P"7^1Y(OV33/$?PXMM<GLEUN.UDCN#,R^;CR\1AB>?O<#U;..:Z+X<:
MG97TGB:.SO8+@)K,SA8I0V$;&" #T)#<]^:[FBJYKMOU_%IDV_3\$_\ ,\\\
M07+Z=XAN'M+NUNENKF(3Z->IMEG=0GSVSCDD#:2,$ J>5YIDVL:-'\6=9%S?
MV*M#H:*_F2J-A#R,P.3P0I!/L:]&HJ+:6]?Q5BKZW]/P=_T/)/#6NV:^#/ J
MB>U#DO"NH3/NCM) A&S 8#S&!VJ&Z>AZ'&N)])MO -G%J4]N)X/%#&-KQ51P
MOVO+G! V_+RV , \X!KW2BKYO>YO/]4_T%;2W];-?J>5^*;[3M"\4W!U75-0
MTC2-1M46WGT^QBFAF8ES(C9AD.YB0W&,Y]JM7T4>B:5ICZ5K(M_LVGK;K%KT
M6([V$D[8V;"E)#MX&,X/*G''I5%3TM_77_,.M_ZZ?Y%#2WDGT"S=;5K*1[9"
M+>3DPG:/E/TZ?A7FT+Q7_@*ST!61/%UI=1N8#Q/'<"8%YR.NPC<Q?H0>O->L
M44[^]?\ K>XE\-OZVL>?3SV]EXZ\5PWCI&]]I<!MT?K.%60/M'\6,C('3(K*
MT:YCB\.?#2YF$D$-N_D2M/&T>Q_L[H =P'5N >A)&,YKU:BB+M;Y?A?_ #&]
M?Z\DOT/.]4N7L/$S?9;NUO8;R_B:71[N/9<;U*+YUNPY8+A6(((&UN1TK4$R
M6GQ2OC-PUQI$(@3O*4DDW!?7&Y<^F17844NEO7\K!W_KK<\@T_4K>\U?P1>Q
M31P6R7-U$;&)<_9"87S'(QRQDR#D$C_=[UE2ZGX>@^'OC9;"\TV)?[9/D""1
M%XWH4V@=OE<C'H2*]THIWM_7FG^@/7^O\2_4X5=6LK?QU-<ZK=6_V"_TZ%-*
MN'(,4N2QD1&Z%FRAQU8 8SBN(:]TF'X4^'GO3#!-:ZW'Y;74?EE1]IW,4+ 9
M&PY)7C&:]QHH3L[^GX.XK?U\K'AUQJ?AU?!_Q,.GWFF+')=$P>1(@#9B3:5Q
MURX;!'4@UT/BSQ?H_A_4M"UR2^MI#/ILD47VCS6MY58H21)''(0W']T@CJ1Q
M7J%8U_IFJOJ9OM+U:&W9XUB>&[M3/& "3E0KH58YY.2#@<4NB7I^5A]WZ_FG
M^AS/@R?P?:_#R*:WN+"[TPW(\Z6.S*JT[2#;E"N[()0 D9P%-=_4%M;^0'9F
M#2R-ND<+C<< =/3  J>FW<2"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=5XY /WAG.*:6JO_ %_743V?]?UY'<:AJ%MI=A->WDHC@B7+-@D^P '))/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@")H%>=)69CL'RKV!]?KCBI:** "BBB@"*.!8Y))
M-S,[GDMZ#H![#)J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BB@
M6)I&W,SN<LS=?8?05+110 4UU+(5#E"1]Y<9'YTZB@!D420Q+&@PJC R<T^B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>interim1_003.jpg
<TEXT>
begin 644 interim1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %L!=8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHH) !). * "BN;M_$E]K,;7'AW3;>\LDD:/[3=79MUE*G!,86-RPS
MD9.T''&1S4^G>+-.O;?4FN2;"?2V*WT-R0#!QD,2#@J1R"#S]>* \C=HKD?%
M'BN^TB/P]<:?:VTMIJE[!;223NP=!(0054#!XSR6X..#774[ %%%%( HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -=;_P!?Y'1(H1%11A5& /:EHHI %%%% !1110 4444 %%%% !1110 4444
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M$G]L:F+F&'[.D.83%Y602AS'N.2,YW9]ZZ2E]E+U_-@]7?T_(**** "BBB@
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MGTQ71V4%A\/_  I9QV>DQK<W<\<30VR! ]Q*<?,V.%!/7G & .@IM?I^)/\
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MC8<=,%@<'FDM=@>AV]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA+;,F[C<SH0<?0-^0K=I=!A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 1W$Z6UO)/()"D:EB(XVD8@>BJ"2?8 FN3\.167B+PM?Z5J&
MG7JP2SW EAO;*6#<DDKLI7>HSP0>.1[&NPHH[I]0OV/(=*\#:_I'A_QKX>>6
M6^ADL5@TF63^*+$A6//J"V/Q'08K2U*:_O8_ UU9:#JTXL+D&YB:V,+QXA9#
MD2;>A/7.#V)KTRBG=W3?E^%_\Q-;_/\ &W^1Y_8WY@^*FOWDNG:LMJVGPQ)/
M_9LY1WC+EPI"<\$8Q][MFN5@^UCX+:[I1TC61J$]Q<"*W.EW&]_,D9U(^3IC
MJ>@Z'!(KVJBDMK?UO<J^M_._X6/,?!MS>:(-?\_1=6,NIWC7=BOV*0"13&H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-Q(1:17*(NYDCX8[L9Y;(^B+Z5TE( HHHH **^8/^$-^.?\ S]:Y_P"#U?\
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M@_X0WXY_\_6N?^#U?_CU'_"&_'/_ )^M<_\ !ZO_ ,>H ^GZ*^8/^$-^.?\
MS]:Y_P"#U?\ X]1_PAOQS_Y^M<_\'J__ !Z@#Z?HKY@_X0WXY_\ /UKG_@]7
M_P"/4?\ "&_'/_GZUS_P>K_\>H ^GZ*^8/\ A#?CG_S]:Y_X/5_^/4?\(;\<
M_P#GZUS_ ,'J_P#QZ@#Z?HKY@_X0WXY_\_6N?^#U?_CU'_"&_'/_ )^M<_\
M!ZO_ ,>H ^GZ*^8/^$-^.?\ S]:Y_P"#U?\ X]1_PAOQS_Y^M<_\'J__ !Z@
M#Z?HKY@_X0WXY_\ /UKG_@]7_P"/4?\ "&_'/_GZUS_P>K_\>H ^GZ*^8/\
MA#?CG_S]:Y_X/5_^/4?\(;\<_P#GZUS_ ,'J_P#QZ@#Z?HKY@_X0WXY_\_6N
M?^#U?_CU'_"&_'/_ )^M<_\ !ZO_ ,>H ^GZ*^8/^$-^.?\ S]:Y_P"#U?\
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M^$-^.?\ S]:Y_P"#U?\ X]1_PAOQS_Y^M<_\'J__ !Z@#Z?HKY@_X0WXY_\
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MSP OJ#3= \%V6@Z-=Z0;V\U"PNBY>&]$1 WDE\%$4_-DYSGVQ7@G_"&_'/\
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M+P?%%XP_X24:QJ;71@%L86,)B,0.0G^KW=><[L^]=)7S!_PAOQS_ .?K7/\
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ML/"UMI^EQV2ZAJEQ(CB0W=S=M+.S 8!+'MS]T #VY-?/G_"&_'/_ )^M<_\
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M#Z?HKY@_X0WXY_\ /UKG_@]7_P"/4?\ "&_'/_GZUS_P>K_\>H ^GZ*^8/\
MA#?CG_S]:Y_X/5_^/4?\(;\<_P#GZUS_ ,'J_P#QZ@#Z?HKY@_X0WXY_\_6N
M?^#U?_CU'_"&_'/_ )^M<_\ !ZO_ ,>H ^GZ*^8/^$-^.?\ S]:Y_P"#U?\
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M(Y=:@OM7T^6X;?=06%\\$5RW3+A>?R(KP_\ X0WXY_\ /UKG_@]7_P"/4?\
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ME1;=YF7 8;EW*S' PK $]B:\7_X0WXY_\_6N?^#U?_CU'_"&_'/_ )^M<_\
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M#Y@"03R<9[#TYYK0\5^++3PK;69FB:>[OKE;6TMT(4R2,<#)/11W-<)\4/\
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MCG4-6$5_HFBQWVD20S2*WVK9<2^6X4E$V[>>P+ G/;&#V=O,MS;13J&"RH'
M;J 1GFO#=9\/ZU\)M?DUWPE*;W1'BDN+K39CD0Q[DW[#Z<CD<@#G(%>VZ=>Q
MZEIEK?1*RQW,*3*&Z@, 1G\ZK1QNA/XK%FBBBD,**** "BBB@ HHHH ****
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MJ^O6NHZ;XBLUM]:TF807)0863(RK#Z@=N.A'7%*.J?<<M&NQV]%%%( HHHH
MCN)X[6VEN)F"Q1(7=CV &2:\VT?XF^)M6\0VVG'X<:M:6D\VPWMRTB(B?WSF
M$ <<XS[9KN]?T:'Q#H5YI%Q<7$$%W'Y<DENP5PIZ@$@CGIT[UY5#X1USX6>)
MM%ET/6+S4/#U[>)97%A<ODQ;R<, ,#U.0!T[@T1^.S"7PZ'>ZEXR:+6;_2]*
ML$OY],MUN;[?<>4(U()"K\K;G(&<':.GS"KJ>*["X\&CQ+9+)<VKV_G11(N9
M)&/ C &?F+?+CGFO/?#"2)\0/BD)Q^\*1E<]=I1\?IBH_A[X1A\8? O3M'U2
MZO+>UEGDE_T9U5F42,0#N5N,\].PHLW'3LG][?\ D-V4M>[7W),Z#PE\0?$O
MB/7X]/OOA_J.CVQ1G>\NGD"K@< !HE!).!C-=W>W+6EI),EM-<NH^6&$ LY[
M 9( ^I( [FO+/#6A^(?AWX_TW1$U:YU7PWJD<BQ+<-EK9HTW?@, #C .>G K
MU6ZN[:SB$EU<Q6Z,P17D<*"Q.  3W)Z"F[631*NF[G%Z!\0KG4?&DWA;6/#E
MSH^H"$SP[KA)UDC'<E> ?H2.#S5GQ/\ $*T\,ZYI6DRZ;?33:C<K;Q3;-D()
M903N/7&X= ?K7*#3=:\(?&;3;B346UBV\0H\#R74:>= (UW8!4 !><\  ]QG
M!H^,?_(U_#[_ +"H_P#0XZ(ZN'F[/[_^&*:UEY*Z^X]$\3>([/PMHSZE>!W7
M>L4<28W2R,<*HSZFJND^*&NO$$_A_4[2*RU:*W6Z$44_G1R1$D95BJG((P05
M'7C-<A\;$D;3/#3XS;IK<!E] .<9IMVDS?M*6#19V+HA,O\ N[G'\R*(:O7N
MU]RN*6B^2?XV/4Z***0!1110!R_C/P/:>.+*.RU'4]1M[-&#F"T:)5=AG#$L
MC'C/3./:JMU\-].U66S.NZIJNLP61!@MKN2)8E(Z$K%&FX]OFSQFNRI"0JEF
M( '))[4+38'J<Y?>"-)O_%]IXF=KB._MK<VP$<@$;H<\,,>YZ$=?I7/2_!K0
M7\.3:!'J6KPZ9->&\:&.2+A\   F,G:,<#/US7?VUU;WL(FM;B*>(DKOB<,N
M0<$9'H01^%34>7];W_/4/Z_3\M#E)/A_I<VM:+K$UU?/?Z3!]GBF,B@RI@CY
MP% Z$_="]:RW^$>B?V#J>B0:AJEMIVI77VJ>&)XL9X(52T9(7('OQUKOZ*'K
M_7G?\]03ML<*/A=8#4=#OFUW67FT2-8K++6^%0=CB+GCCUK3C\"Z;:^*[CQ%
MI]S>V-U=C%W%;R*(KCW964X/NI!Z^IKIZ*=WOZ_CO]X6_KT.9U_P-I6O:CIV
MIM+=V.IZ?Q;7EG(%D5?[IW!E8=>"#U/J:U+G1UN!$RWMW#<1!MMQ$X#;F !8
M@@JW3H05]N!B[/=6]JJ-<3Q0J[B-3(X4,Q. HSU)/05+2Z6#J97A_P /6/AN
MQDM;(.QFF:XGFE(+S2L<L[8 &3[ #T%4]:\&Z9KGB'2M<N'N8[[3"Q@:&0 $
M'J&!!R/IBNAHHZW XZT^&>@6=IK]DANWL]<<R7-N\@VHW7*$ ,.?4FM[0-%A
M\/:):Z5!<7%Q#;1B*-[AE+;0, ?* .!QTK3HHZ6_K0/Z^\XRY^&6@W:I:RO=
M'2DNC>#2PR"W,Q))8_+O/4_*6V^U;/B;POIGBS0)=&U)'^RR8(,3;6C(Z%3@
M@$?0BMJH;>[MKOS/LUQ%-Y;;'\MPVUL X..AP1Q[T=+#OK<Y-/AQ8)XIT_Q&
M-6U8ZE96ZVRNTD161 "/F!C[@\[<>O7FJ$?PCTV*#7(EU[6]NMG-_EK?]X<D
MY'[GY>IZ8ZUWTTT5O"\TTB1Q(,L[L %'J2>E0V.H66J6JW6GWEO=V[$A9;>5
M9$..N""11O\ UWU_,6W]=CD9OA=HL^@Z3IDEWJ/F:0VZQOED1;B#D' (0*1P
M.JFNPM;<VT(5II)Y, -++C<^.YV@ ?@ *GHIW8K'%:Q\,=&U?Q2?$2W^KZ??
MR*%G;3[PPB8  8; SC  X(KHH?#VE0: =#2RC_LUHVB>!LD.&^]DGDDY))/)
M)S6G12Z<O0?6_4Y_2O"-CIE];WC7-W>S6D)M[,W3*WV:(XRB;5&>@&YMS<=:
MS-%\*C3OB)J^MVDFHK!=QD7(N9,QRRDKM\M>N%"GD_WL#@5V=-DECAC:25U1
M%&69C@ >YIWUOZ_B%M+?UH<IXV^'VG^/([>'5-2U."V@)98+21%1F_O-N1B3
M^-+X(^'NC^ K2\M]+ENYA=NK2-=.K-P, #:JC')_.NH@GANK>.>WE2:&10Z2
M1L&5E/0@C@BI*2TN@>MKG,6W@32+6>VV/<M8VMP;JVTYF4P0S$D[U&W=U8D
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M\1(C# _0@503X1^'XM:O=0BO-8AAOG,ES817K);S$G)W*H#$'G@MCGTKO:*
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M20" %QG=TQG':T4+2UN@/6_F<;X@^'5KXC\06>LW>NZQ'<V+[[-8&@"0'@\
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M85^7D%CGUQD'JXXTBC6.-0B( JJHP !T IU%%P"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IDT*7$$D,J[HY%*,,XR",&GT4;@<G)X$@N91%>:QJ=WI
MGE+$;"=T*,JD$!G"B1EXZ%CGOD<5U:J%4*H  & !VI:*+@%%%% !1110 $9&
M#7(>$M#G\(W^H:0D+R:3<W+W=E*@R(=W+1-W&",@]#G'7KU]%"T=P>JL<YJ'
M@O3M1\::;XJFFNEOM/B:**-'41,#N^\"N<_,>A':L3QC\)M'\<:LNH:OJNL
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MGO;K4+F%#&ES>%#(%)Y'R*H[#G&3@9)KA(OA;I>J3^)+6[.JC2]0F67]_/\
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MZE ]R\J3Q!"QD;>2=P;:,^K>]=183OI6@WVL7=G=27%Q*]T]O! SS$'Y8T"
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M4],ME_L?09]8O'Z0I.D"*!U+2/P/H,GVK/L?'-G-X1N=>U"TN-/-G(T%S:2
M-(DRG;L7'#$D@#UR* .IHKG8O$\MM?QV>MV"V$MQ%)/;&*8S"14 +*WRKB0
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M+((H((5WR3R'HB+W/Z#J2!5"7Q#?VD-N+W28X;V]G$-C:)=;V<[2Q,AV[4P
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MY[47V?\ 6C7Z+^DP5OZ\[W_%_P!61B:]90W/Q8\+K.99(KNPNO/A>5C&^U5
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MR5XZ5>/AW;!&EMJ^I6TJ0I"9HW1F95SU#HRY.3R%!],4EHON_)K^NO7<'O\
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MM+\/VFF7,EX9)[O4)5"27ETX>5E'\(P %7OM4 9YQ36COZ?@#U7]=36HHHI
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M+-<WLOFS2,3G+-@9/;Z 5I4V[LE!1112&%%%% !1110 4444 %%%% !1110
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M38/E;!P2HQT.WM78W/AT7L%A++?W4&J6D7EKJ%OL$IR!O!#*58,0"05(S@@
MBC_A&D2S,%OJ>H6SR2^==3Q,GFW38 .]BAQP!]S;C  P*%I\O\]Q[_/_ "M8
MYW3&O=8^*<E[+%;I'I.FFUN/L[F1!/(RN8PY52Q"J"?E&-PJ?PS_ ,E+\;?6
MS_\ 11KJM,TJRT>Q6SL(%AA4EL DEF/)9B>68GDDY)K(TGPB-(\0WVLKK>IW
M,U]M^T13B#RWVC"_=B4C ]"/?-">J]'^(/5/Y?@='1112 **** "D)"J68@
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M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9YKK_$USJND>)=,\7Z9I-[JFGO9M:7EI;PD7"*6#HZQM@DYR"I (KOJ*+O\
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MM%8'J[A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTSCVJ&Z\)7=]$(KKQ?KTD88/M M$R1R,[8 3@X.#QQR#73TA(52S$ #DD]J
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MTZ*[G5GB6_O5M8R%QG+D$]2.BDUS/BG2$GU)]3T:QU33_%)<+!<6T3^3=!2
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MB?7_ +>_6W_ /20<@$=Z* ,#%%(84444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?64T^\C5%N 3:3*>)"!DH0>C <^X!/&"*%J-Z&E1110 4444 %%%% !1110
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M+VRDUG6K/S87CLM-F\\,XQYTP4A<#^ZN2<]SC'2B+M;UO^0/]&OON;E%%%(
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M"JT,[V\R+()%5UZ[7'#*0001U![4[;^0&P;RU%XMF;F$73*76$N-Y48R0O7
MR.?>IJ\[O$LM/^-\-Z8X8 V@S2W$P0*6VR*-S$=< =^PK6F\:SVEG::Q=Z2(
M] NFC"7BW&Z6-7("/)%M 53D<AF(R,@<X%JEY_YM ]'_ %VN==16+<:Y.=:F
MTZPLXKI[6))KG=<>6X5]VT1KM(8G:>I4<]:=J>MR64>GQ0VT;W^H-L@@GF\I
M=P0N0S;6(P >BDY[4@-BBJUG<37$;FXM6MY$<IM+;@<8Y![CT_ITJS0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU_U*/_E2_P#M5'_#37_4H_\ E2_^U4T[->0/5:GIGC/2-,U2=9;RQU6&^MT
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MZ[=ZKI6N:1XOTS1[_4K![$V=[9Q0,MS&I8,KB)L,2#D$8JMX^U&]U[X?J8M
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M^5+_ .U4 ?0%%?/_ /PTU_U*/_E2_P#M5'_#37_4H_\ E2_^U4 ?0%%?/_\
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M2_\ M5 'T!17S_\ \--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4 ?0%%?/\
M_P --?\ 4H_^5+_[51_PTU_U*/\ Y4O_ +50!] 45\__ /#37_4H_P#E2_\
MM5'_  TU_P!2C_Y4O_M5 'T!17S_ /\ #37_ %*/_E2_^U4?\--?]2C_ .5+
M_P"U4 ?0%8_B/P__ ,)'81VG]KZMI>R02>=IESY$C<$;2<'(YZ>PKQ?_ (::
M_P"I1_\ *E_]JH_X::_ZE'_RI?\ VJ@+V/;- T7^P=+6Q_M/4=1VL6^T:C/Y
MTISV+8' [5J5\_\ _#37_4H_^5+_ .U4?\--?]2C_P"5+_[50W<#Z HKY_\
M^&FO^I1_\J7_ -JH_P"&FO\ J4?_ "I?_:J /H"BOG__ (::_P"I1_\ *E_]
MJH_X::_ZE'_RI?\ VJ@#Z HKY_\ ^&FO^I1_\J7_ -JH_P"&FO\ J4?_ "I?
M_:J /H"BOG__ (::_P"I1_\ *E_]JH_X::_ZE'_RI?\ VJ@#Z HKY_\ ^&FO
M^I1_\J7_ -JH_P"&FO\ J4?_ "I?_:J /H"BOG__ (::_P"I1_\ *E_]JH_X
M::_ZE'_RI?\ VJ@#Z HKY_\ ^&FO^I1_\J7_ -JH_P"&FO\ J4?_ "I?_:J
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MPEU!+:6KSD2; K(X0$KRH(8X7GJ*\R_X::_ZE'_RI?\ VJC_ (::_P"I1_\
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MHRC^$#M/7&J$?RBHVV ]E?Q5:I=6T)T[5VBNH$FBN(M/DEB.[^%B@)1AQG<
M.>O6N4_X0ZXTNTT[4K.T.^RUF;4OL$>"5AEW*R*.FX AL#OD#M7#K^TP%4*O
M@\!0, #4N /^_5'_  TU_P!2C_Y4O_M5&SN@Z6?]:6/2RL>I^+[?Q2MKJ$-C
MI^GRP.9+*5)9R[*=HB*^80NTG[O)88SS4-GX<@UGQ!:ZA'H<6D:/9R_:TB-N
ML,UY<D<2.H&5503@-\Q/4#'/G7_#37_4H_\ E2_^U4']IG((_P"$1Q[C4O\
M[533MMT!ZGJMW:'4/B=ILR\II5A,\A]'F954?DCG\JZNOG:Q_:+@T^)DA\(,
MS2,7DDDU3<\C'^)CY7)X ]   , 5ZS\./'7_  L#P]<:M_9WV#R;MK;RO/\
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MOXF\;75OXYL/"<=U<V9:S-U=76GV374V[^%$38^!P225/'IUK+U7XA>(-/\
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M]W.0?P[UB67@;5=#^%$GA339+.YO[B&2&:>YG>-%W@C<N$8G ( 7 ^M>!?\
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M7SI_PNWXA_\ 0P_^25O_ /&Z/^%V_$/_ *&'_P DK?\ ^-T-N[?<2222['M
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M##_Y)6__ ,;H ^OZ*^0/^%V_$/\ Z&'_ ,DK?_XW1_PNWXA_]##_ .25O_\
M&Z /K^BOD#_A=OQ#_P"AA_\ )*W_ /C='_"[?B'_ -##_P"25O\ _&Z /K^B
MOD#_ (7;\0_^AA_\DK?_ .-T?\+M^(?_ $,/_DE;_P#QN@#Z_HKY _X7;\0_
M^AA_\DK?_P"-T?\ "[?B'_T,/_DE;_\ QN@#Z_KF_&ND:_K&BQQ^&]9&EZC#
M.LRR-G9(!GY&P#P<@]#TZ5\R?\+M^(?_ $,/_DE;_P#QNC_A=OQ#_P"AA_\
M)*W_ /C= (^CM%\-:W<ZU9:]XNNM.GU&QA>*UBTZ)UBCW\,Y+G+,0 .@ YXK
M:UC2I]4O])^>,65K<_:9T).YV53Y8 QC 8ANO\(KY7_X7;\0_P#H8?\ R2M_
M_C='_"[?B'_T,/\ Y)6__P ;IWV%8^D/B!<^);'3;2\\.ZA8VS13CSH;E-S7
M6>%B3@\LW'8\]1CG!\:?!S0?$.G:E=Z=IT$'B&[/F+=374VP2%@6) )'3/\
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M-X2\-0>$/"UGHEK(95MD.9&&/,<DDGVR37RY_P +M^(?_0P_^25O_P#&Z/\
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MGB*TO[K3-36$B2S$9,*P[B<1.P0X.T*3PQ&1UR*^=?\ A=OQ#_Z&'_R2M_\
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M0$<.!D]UXP,=Z^:?^%V_$/\ Z&'_ ,DK?_XW1_PNWXA_]##_ .25O_\ &Z+
M?47@_P -1>$_#T6EQR"0B1Y9&5-B[W8L0J]E&< >@K=KY _X7;\0_P#H8?\
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MQ#_Z&'_R2M__ (W0!]?T5\@?\+M^(?\ T,/_ ))6_P#\;H_X7;\0_P#H8?\
MR2M__C= 'U_17R!_PNWXA_\ 0P_^25O_ /&Z/^%V_$/_ *&'_P DK?\ ^-T
M?7Y&1@UY<WPSU2ST?7O#>F7ED-#UFY,YEE+":T!(W*J ;7'R@ EEQ[UXC_PN
MWXA_]##_ .25O_\ &Z/^%V_$/_H8?_)*W_\ C=%AW/HSQ/X7U&?X??\ ")^'
MHK'RGM!:&6\N'C\M0  0%1MQ.#Z?C4OA71_$6A^ DT6<Z;!?V=J8;6YBF>:-
MF .&=612,'' S7S=_P +M^(?_0P_^25O_P#&Z;)\:?B!+&T<FO*Z,"K*UC;D
M$'J"/+H=W?S$K*WD>VV?A[Q)XFL="UV\U"PN==T.\E$4P#+;7L9P&Y5<KR"
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MPNWXA_\ 0P_^25O_ /&Z0SZ"N/">K>(]9AFURUT^TMK/4H[^-K:=II)62-5
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MCMD_>.I(W ,80V<# ^;@8YXKQ=_C1X_D='?749HSN0M8VY*G&,C]WQP2*?\
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M_P DK?\ ^-T=4^P=&NY[YXTTSQYXAO+&X\(ZOHMIIL2B6.29C(TKD<-@Q,N
M.F/7-2K8>.].^'U[]O\ $VFCQ#YAD-_*@^SPQ#' &P < \[>I_&OGN+XT>/X
M(Q'%KJ1H"2%2QMP.3D\>7ZT2_&?Q_.FR;74D7(;:]C;D9!R#S'ZT6T:0=4V>
M_P _P]T7QQHMKK/B32(Y-?GL55Y1/-$H;;Q\H8 #)SC%)\/O >H^ O!5Y:VZ
MZ?+X@N"S-+Y\GD.1G9DE<C /9>?UKP3_ (7;\0_^AA_\DK?_ .-T?\+M^(?_
M $,/_DE;_P#QNA];:7#M?H>T^'?"OQ6LM9MCJOBC27THW'G7<5L@$D@SDC=Y
M(.3P/O=*TOBAX0\1>-8+"RTQ=*AMK2Y6Z\ZYN9 [L 1MVK&0!SUW'Z"O!/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>interim1_004.jpg
<TEXT>
begin 644 interim1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /\!#\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/=__ != 'T!17S__ ,+3^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\ */=__%T
M?0%%?/\ _P +3^+_ /T(7_E'N_\ XNC_ (6G\7_^A"_\H]W_ /%T ?0%%?/_
M /PM/XO_ /0A?^4>[_\ BZ/^%I_%_P#Z$+_RCW?_ ,70!] 45\__ /"T_B__
M -"%_P"4>[_^+H_X6G\7_P#H0O\ RCW?_P 70!] 45\__P#"T_B__P!"%_Y1
M[O\ ^+H_X6G\7_\ H0O_ "CW?_Q= 'T!17S_ /\ "T_B_P#]"%_Y1[O_ .+H
M_P"%I_%__H0O_*/=_P#Q= 'T!17S_P#\+3^+_P#T(7_E'N__ (NC_A:?Q?\
M^A"_\H]W_P#%T ?0%%?/_P#PM/XO_P#0A?\ E'N__BZ/^%I_%_\ Z$+_ ,H]
MW_\ %T ?0%%?/_\ PM/XO_\ 0A?^4>[_ /BZ/^%I_%__ *$+_P H]W_\70!]
M 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\ A:?Q?_Z$+_RCW?\ \70!] 45\_\
M_"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0O_*/=_\ Q= 'T!17S_\ \+3^+_\
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M /BZ/^%I_%__ *$+_P H]W_\70!] 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\
MA:?Q?_Z$+_RCW?\ \70!] 45\_\ _"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0
MO_*/=_\ Q= 'T!17S_\ \+3^+_\ T(7_ )1[O_XNC_A:?Q?_ .A"_P#*/=__
M != 'T!17S__ ,+3^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\ */=__%T ?0%%
M?/\ _P +3^+_ /T(7_E'N_\ XNC_ (6G\7_^A"_\H]W_ /%T ?0%%?/_ /PM
M/XO_ /0A?^4>[_\ BZ/^%I_%_P#Z$+_RCW?_ ,70!] 45\__ /"T_B__ -"%
M_P"4>[_^+H_X6G\7_P#H0O\ RCW?_P 70!] 45\__P#"T_B__P!"%_Y1[O\
M^+H_X6G\7_\ H0O_ "CW?_Q= 'T!17S_ /\ "T_B_P#]"%_Y1[O_ .+H_P"%
MI_%__H0O_*/=_P#Q= 'T!17S_P#\+3^+_P#T(7_E'N__ (NC_A:?Q?\ ^A"_
M\H]W_P#%T ?0%%?/_P#PM/XO_P#0A?\ E'N__BZ/^%I_%_\ Z$+_ ,H]W_\
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M?;@5XC_PM/XO_P#0A?\ E'N__BZ/^%I_%_\ Z$+_ ,H]W_\ %T ?0%%?/_\
MPM/XO_\ 0A?^4>[_ /BZ/^%I_%__ *$+_P H]W_\70!] 45\_P#_  M/XO\
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M_P H]W_\70!] 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\ A:?Q?_Z$+_RCW?\
M\70!] 45\_\ _"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0O_*/=_\ Q= 'T!17
MS_\ \+3^+_\ T(7_ )1[O_XNC_A:?Q?_ .A"_P#*/=__ != 'T!17S__ ,+3
M^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\ */=__%T ?0%%?/\ _P +3^+_ /T(
M7_E'N_\ XNC_ (6G\7_^A"_\H]W_ /%T ?0%%?/_ /PM/XO_ /0A?^4>[_\
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M77>"&  Y#<#;D]3CCKCFI=-O;VZ&+RRBA)0.LEO<>=$P). &*J2< $\=^,T
M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUFTU_2+?4[%F-O,#@.,,I!(*D=B""#]*-]0-"BJ&IZM#I@A5HI;BYG8K!;0
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M;;&4VL00S<<D$=P*UK&_-Z&5[2YM9D52\4X7*YSQE25/3L2/>@"Y15/3+_\
MM*S^T?9+JU^=T\NZCV/\K%<XST.,@]P15R@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHTC(I$8]V('!]*N4>65B4[JYLT51O-7LK&&&6:1W$Q B6")YF?W"H"2.Y.,
M<FI%U&S:Q:]%Q&+5=VZ4G"C!(/Z@BI&6J*S--\0:;JMW/:6LT@NH #)!/!)#
M(%/1@LB@E3_>&1[UR'COQ.GV*S&D:M=P31ZE;Q2&&-EBG#2A'3S"N&(YR$;(
M[T)7:7<.C9Z%116-_P )5HW]I16!NV$LLABB<PR"*209RBR[=A;@_*&SP>*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ML?Q5K@\-^%]0U?RO--K$65"<!FZ 'VR16/<ZAJGAS4-&DOM4;4+75+E;25)(
MHX_(D925,94 [<@C#%CR#GCD6H/1'8445RWC#4M4TN?19+*[BB@N=2@M9HS
M&9E=CNPQ/'  Z>O/3!U2#HV=317/Z[JEPNLZ7H-C,8+F_$LCW 4,T,48&XJ&
M!&XEE R".3P>E&A:I.VKZGH-[.UQ<Z>(G6X955IHI =K,% 7<"K X ' X%"U
M_KL#T.@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKG_ !3XD708;:"(V_VZ\<I!]HDV11A1EY)#V11R?7@=Z .@HK%T3S[C2WNH
MO$,>JFX&8YTCC,"'&/D"8)7/JS'WJGX(U34-5TN^DU*=9YX-1N+8.L80;4<J
M.!]*=M;!TN=-17.>+-8ETLZ7 MU]A@O[K[-+?;5/D91BN-P*@LP"@L".>AJ"
MTN-?+:MIMM=)>-;M&EMJ-U$O#,"7#JFU7*<?="YW 'H32_K^OO!Z'545PNA7
M7BO1_&<>@:[JL.MVUW:274-VEHMN\)1E!5E4XVG<,'KFI/%?BC4+#Q!X?L=-
M*K;7&J):WDQ4'=E6;RUS[ 9/;( [X=MO,3=K^1VU%%%(84444 1W$ABMI9%
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MR,15G,@ZH<*0 V,D\5)XQOUOF\9Z7(_V2:'3LP6T$>V:_!B)\PL!N=%)VX'
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M>(7,GFS"6[EFW.>K?O&;!/<CKWK8I/I\OR#J_F%%%%( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,)']C^U>7^X^P^9MVQJGWO,&<[<].]<_P#\,R_]3=_Y3?\ [;7T!10!\_\
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M/_\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#MM?0%% 'S_P#\,R_]3=_Y3?\
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M )3?_MM?0%% 'S__ ,,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\ [;7T!10!\_\
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M/_\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#MM?0%% 'S_P#\,R_]3=_Y3?\
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M )3?_MM?0%% 'S__ ,,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\ [;7T!10!\_\
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M/_\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#MM?0%% 'S_P#\,R_]3=_Y3?\
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M )3?_MM?0%% 'S__ ,,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\ [;7T!10!\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_T+R2YN_-'$F<;-G7ISGIVH MT444 %%%% !1110 4444 %%%% !16#XO\
M$K>%-!?5/[.FO41U5ECD5 FXX!8L<XR0. 3STK=4Y4'U%'F M%%% !1110 4
M5E^(M8/A_P /WFK?8Y;M;6,RO%$RJVT<DY8@<#)]?0&I]'U#^UM%L=1\KROM
M5NDWE[MVW<H.,\9ZT 7:*J64]W.UR+NR^RB.9DA/FA_-C&,/Q]W//!YXJW0
M4444 %%%% !1110 45GP:A*EK-/JELM@$G:)-TP?>N[:C9'0MD?+U&<5H4 %
M%8'B[Q*?"NCKJ/\ 9TUXGFI$WER*@CW,%!8DYQD@< GFM_M0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,4E21B&#)G:?8D9'8UU-Q=-KWCN^\.S3W=O9V-C%.1;7#P/*\C'G>A#84+C
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M6,,2<Y!/H12IX#AB;19(M<U:.?2(FA@F3[/O>,X&Q_W6&4  8P.F>O-4GO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+8_9MDV_85)>3<01ACP%7MDFL[4_!.H/XEFUK0/$UUHKWFS[="EO'.D^T8#
M/PC8XS@].E+M_7]?C\RNY!K'B>^TM-&EUYKK0[:: /=W%O$D\<5QE1Y4C8<*
MAR?F'7^\,<]?ITIGTVWF:YAN2\8;SH?N29'WE]C5*YTJ^$"QZ?J,<0$0B9+N
MW\]'Y^9F 926.>N<>H-6-&TJ#0]'MM-MBQAMTVJ3]<G@<#D]!P*=]R>Q?HHH
MI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"N$1(V#L?8%E"KGDY]C1'IZK^ONO<)=?1_U]]CKZ***0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% #1%&)6E"*)& 5G Y(&< G\3^=.K+U7Q%IFBC-_-+
M&@QOD2WDD2('O(RJ0@]V(%0Z_P"+=!\+V$=[K.IPVL$IQ&2"YD_W54$GKV%
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M R_?#*S <#G@G(Z9J2;Q?:07N@V[6-\4UH#[-.%38C%-^U_GW X'8$>]<_\
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M[>W(=HK:V"!F5<;CEV50!N'5AUXS6+X*73+@27VF^"F\.(R['^T6$=K-*<]
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MN4]&[?UKO]PGPJ.?!\OS2L%U&[53,S,^T2L!DMSG '7FH]>C6#XM>&+@//\
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M!@@+#.>N,<<D5!HVF?9=0U;43&8CJ,R2>40 0%0+DX[G&?IBB.EP?0V:***
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M ,<H_P"%)?#S_H7O_)VX_P#CE '/_P##1W@__H&ZY_WXA_\ CM'_  T=X/\
M^@;KG_?B'_X[70?\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE '/_\
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M1W@__H&ZY_WXA_\ CM=!_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\
MXY0!S_\ PT=X/_Z!NN?]^(?_ ([1_P -'>#_ /H&ZY_WXA_^.UT'_"DOAY_T
M+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!S__  T=X/\ ^@;KG_?B'_X[1_PT
M=X/_ .@;KG_?B'_X[70?\*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE
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M0!S_ /PT=X/_ .@;KG_?B'_X[1_PT=X/_P"@;KG_ 'XA_P#CM=!_PI+X>?\
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M_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4 <_\ \-'>#_\ H&ZY_P!^(?\
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M'_X[1_PT=X/_ .@;KG_?B'_X[70?\*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\
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MPI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE '/_ /#1W@__ *!NN?\
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M/^A>_P#)VX_^.4 <_P#\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\
MX[70?\*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!S_P#PT=X/_P"@
M;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM=!_P *2^'G_0O?^3MQ_P#'*/\
MA27P\_Z%[_R=N/\ XY0!S_\ PT=X/_Z!NN?]^(?_ ([1_P -'>#_ /H&ZY_W
MXA_^.UT'_"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!S__  T=X/\
M^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X[70?\*2^'G_0O?\ D[<?_'*/^%)?
M#S_H7O\ R=N/_CE '/\ _#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_
M ..UT'_"DOAY_P!"]_Y.W'_QRFK\%_APTCQKH2ETQN47T^5STR/,XH P?^&C
MO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =KH/^%)?#S_H7O_)VX_\
MCE'_  I+X>?]"]_Y.W'_ ,<H Y__ (:.\'_] W7/^_$/_P =H_X:.\'_ /0-
MUS_OQ#_\=KH/^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@#G_^&CO!
M_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KH/^%)?#S_ *%[_P G;C_X
MY1_PI+X>?]"]_P"3MQ_\<H Y_P#X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P!
MW7/^_$/_ ,=KH/\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H Y_\
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M!'0\\.73^OZ_X82ZV_K^O\S,TS5-2\*_#MP)I+R>?47L]&-P2[O&\FV(M_>
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M_J;O_*;_ /;:/^&9?^IN_P#*;_\ ;: /<++1+"PNGN8(I/.8%0TLSR;%X^5
MQ(1>!\JX' XJ35-+M=9T^6PO1,;>48=8IWA+#TW(0<>HSS7A?_#,O_4W?^4W
M_P"VT?\ #,O_ %-W_E-_^VT/71@M#U1?AOX91+-%@U$)9$&U7^U[O$! Q\@\
MWY>..*V=4\/Z9K#P27D#F>#/DSPSO#+&#U D1@P![C/->)?\,R_]3=_Y3?\
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MY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\
M*;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_
M "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\
M^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]
MMH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F_
M_;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?
M^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X
M9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;:
M/H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_
M\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_Z
MF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"B
MOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_
M -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_R
MF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__
M (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH
M_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\
MVV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E
M_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&
M9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#
MZ HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"I
MN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\
MJ;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HK
MY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\
M*;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_
M "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\
M^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]
MMH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F_
M_;: /H"BOG__ (9E_P"IN_\ *;_]MH_X9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?
M^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /H"BOG__ (9E_P"IN_\ *;_]MH_X
M9E_ZF[_RF_\ VV@#Z HKY_\ ^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK;:G87MS/;6M];3S
MVY FBBE5FBSTW '(S[US'C.]N[K5='\,V1(;43)+<D2F(F",#<@< E=Q902
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M5GZ9H&C:*9#I6DV%@9<"0VMLD6_'3.T#/4T>3[?K<=]FN_Z6.9F\-^([^_\
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MBG?<5M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC&"<CI@FN/FBO=4\+>)XX-)U9)#KZ7\:3:?-&TL EC.Y R@L<*QVCYN.E/\
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MGK]_XH3V^[\[G176G:DOPS\3>&TTG4)-1^W3/&JVS;)4>?>K(_W6&#R 21W
MK>\27TSZ[X+E.D:L/(N#/<K'8R3?9U:)T&]HPRYW$< G'6N?_P"&CO!__0-U
MS_OQ#_\ ':;+^T9X1DB=%L=?B9E(#I!!E3ZC,A&?J#0G:WR_!6&]?Q_%W+GA
MO4''A[Q7ID&G7MQ=W6K7\=N$MV:)RQQ\T@&U ,\[R/;-6]4LI=$U/X?:<MIJ
M%VNE';<7%M92RQH/),8)95(&6[=0.3Q7&>&/C+X+\+Q7D<!\5WB7<[7+B[AM
M3B1CEF&PKU/8Y''&*WO^&CO!_P#T#=<_[\0__':%I;Y?@K?Y@];_ #_$VM,O
M&@\9^.+F73M66"XBA,$G]FS[9?+C*,$^3YCDC&.O49%<5H%@VEV6EW^L^ ;W
M7+0Z?'930R:5YEQ:31LQ^6.4#*,''S+QD=>*V_\ AH[P?_T#=<_[\0__ !VC
M_AH[P?\ ] W7/^_$/_QVDM/NM^?^8/7^O3_(TO%$:VNF^%HK'PW=V<4>KQ7K
M6=AIS.+>)<[BXA5E#<@D YYXS@FM329W?XMZU-]AU%+>>P@ACN)+&9(F=&<L
M-Y4+T8<YP>U<S_PT=X/_ .@;KG_?B'_X[1_PT=X/_P"@;KG_ 'XA_P#CM._Z
M_BDOT$]?P_!W.O\ AQ;W.G^'Y].O+2X@G@OKDMYL3*I#2LRE21A@00<C(_'B
MNQKQ_P#X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_ ,=I-CZGL%%>
M/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM 'L%%>/_ /#1W@__
M *!NN?\ ?B'_ ..T?\-'>#_^@;KG_?B'_P".T >P45X__P -'>#_ /H&ZY_W
MXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\ \-'>#_\ H&ZY_P!^(?\ X[1_
MPT=X/_Z!NN?]^(?_ ([0![!17C__  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;
MKG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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M_P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\ \-'>#_\
MH&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([0![!17C__  T=X/\ ^@;KG_?B
M'_X[1_PT=X/_ .@;KG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#
M1W@__H&ZY_WXA_\ CM 'L%%>/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN
M?]^(?_CM 'L%%>/_ /#1W@__ *!NN?\ ?B'_ ..T?\-'>#_^@;KG_?B'_P".
MT >P45X__P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\
M\-'>#_\ H&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([0![!17C__  T=X/\
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M_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM 'L%%>/_ /#1W@__ *!NN?\
M?B'_ ..T?\-'>#_^@;KG_?B'_P".T >P45X__P -'>#_ /H&ZY_WXA_^.T?\
M-'>#_P#H&ZY_WXA_^.T >P45X_\ \-'>#_\ H&ZY_P!^(?\ X[1_PT=X/_Z!
MNN?]^(?_ ([0![!17C__  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X
M[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM 'L%%>
M/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM 'L%%>/_ /#1W@__
M *!NN?\ ?B'_ ..T?\-'>#_^@;KG_?B'_P".T >P45X__P -'>#_ /H&ZY_W
MXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\ \-'>#_\ H&ZY_P!^(?\ X[1_
MPT=X/_Z!NN?]^(?_ ([0![!17C__  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;
MKG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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MO)?7<33"24?>5(U9,A> 6+=>QQ0!9_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
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MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:G'B_P ,FR-Z/$6D_9!)Y1G^VQ[
M^,[=V[&<<XJU_;>D_:;6V_M2R^T7:>9;1?:$W3)C.Y!G+#'<4@,[_A!/!_\
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M.1895<HPZJ<'@CTK*TSQEH>KZ[?Z19ZC:R75F0K()EW,<9;:,Y(7@$COQVH
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M_M6PTK1;6YU76K/RS&@-]-*D23-@?,.=O/7 ]: *?_"">#_^A4T/_P %T/\
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M'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\
MXFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03
MP?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH
M?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\
MB:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G
M_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!_
M_0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+
MH?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_
M (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\
M]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"
MB@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A
M!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:
M'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\
MXFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03
MP?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH
M?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\
MB:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G
M_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!_
M_0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+
MH?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_
M (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\
M]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"
MB@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A
M!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:
M'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\
MXFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03
MP?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH
M?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\
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MC#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4
M=!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__
M  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_
M .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_
M /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__
M !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG
M?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"A
MKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!
MC#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4
M=!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__
M  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_
M .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_
M /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__
M !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG
M?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"A
MKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!
MC#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4
M=!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__
M  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_
M .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_
M /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__
M !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG
M?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"A
MKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!
MC#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4
M=!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__
M  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_
M .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_
M /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__
M !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG
M?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"A
MKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!
MC#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4
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M9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\
MAF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MK
MZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\
MJ;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_
M *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH
M ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_
M "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[
M_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_
M /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F_
M_;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P I
MO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF
M7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/
M^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV
MOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;
MO_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?
M^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B
M@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;
M_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_
M\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y_
M_P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;
M:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_
M -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&
M9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\
MAF7_ *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MK
MZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQN(4 #NQ Y'/(HTK6(=5$Z"&>VN;9PEQ;7  >)B PSM)4@@CE21[T :-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45E>(=?M/#6D3ZG>Q7
M,D$*EW^SPF0@#Z<#\2*TXI!+$DBY =0PS[T .HK/U76K+1UA%RSM-._EP00H
M7DE;T51R<=2>@')(JI+XC$%O:A]*OQJ%T&:+31Y1G*J>23YGE@#(Y+]P.O%
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M.QHHI+G9F&,D$HNQ5XR!R<L<#)IVOZ.-?T:XTQ[ZZLXKA2DKVNP.R$$%<NK
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MX;DQ!22NTE=B*1\O'7]>:6#P5:0W.DW+ZGJ<]QI<;Q02RRIDQL,;6P@'  Y
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M H R>  .3ZT1TO\ UV_I@_Z_'^D:%%%% !1110 4444 %%%% !1110 4444
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MR1+#=O':I/'<(O3*.<!ADX//%3Z]X-EUK3M.\O7+NVUG3F,EOJ@1"^XC#;D
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MSQAITFM"!=,6)[62UM$4KN1GP=^_/8'UQQMJS;> [J"T\/6[ZV'70I]]L1:
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M^(]1AOK_ %2[CO[M8K>58V+,DA&X;54EB!TSC@  5T_A'7;76XIC::X^HK"
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M&.W>A;KY_B)ZI_+\&=+1112&%%'09-82^-O";2B)?%&BF0MM""_BR3Z8W=:
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MH,O+-($1?J3P*+2\M=0M4NK*YAN;>0926&0.C#V(X- $]%%% !1110 4444
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ME^6OXE_Q=J&M/X@\'QZ5?V]K!?7#EDFMFER1$S#=AUR/88YP<G&*TKCQ//\
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M9Z;:K:V-I!:VZ?=B@C"(OT XJQ10 4444 %%%% !1110 4444 %%%% &9?\
MAW0]4NTN]0T;3KNYC "37%JDCJ <@!B"1S6G110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>TM;VY&%9][Y/0C W,<=#6K=:U!:Z=;78AGE:ZVBWMT $DK%=P4!B #@$\D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D_&VI?
MV:^E->W%Q:Z'+,T=_<V\C1F/*_N]SK\R(6ZL",''(&:M^%C.1?E+F:YTGS5_
MLZ::4RL\>P;B')+.N[.&8DGU(Q4'BPWJ7VD2&UFN]$623^T8((C*[ IA"8P"
M70'J ">G!Q3/!FF_V;+J2V,-S;Z%*Z26-O<HR-$2#Y@5& 9$SC"D#!W< 8HC
ML_G^G]+YA+I_7?\ I_(ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#F_'VH3Z9X(U.XM7:.=D6%'7JAD8)D?3=FMI+:*STI;6% D4,/EHHZ !<"J
MWB'1X_$'AZ^TJ5BBW,10./X&_A;\#@_A4%M<WVI:&]O&T5EJT:".87$+2HC=
MSM#+N4\X(8?H12:O&2_K:WYC6Z9F_#/_ ))MH/\ U[#^9IADDF^+RQ2C]U;Z
M*7@R>-SS .?KA5%3Z)X>U3P_X).B)K,1G@A,5K>0V!!BXX)C+MO(//8'TJ9M
M$U&YATW4&O88=>M8#$URUMNCD5L;@\8<<$JIP&X(X)'6Y.\[_P!:HGI;^M[F
M!8:8VO7_ ([T%KR[M+-[V,K-:N%=2\*,X4D'&2.?]XUGZI?^)?#>B>)=%U#4
M3J3QZ3+>:=?E DNT?*RN!P67<I#=Z[-- O+'394TO4T@U">Y-S<74UL)5F8]
M0R KQ@ ## @ <GG-V+2A(DKZD\=W<3P^1,RQ[$*=U523@')/))]^!4-:6\K?
M@4GK?SO^)R7B91IW@WPN]B KVU]8+;A?0D(0/JK,/QKK]:TM=:T:[TQ[FXMD
MN8S&TMLP610>N"00...E9=GX7EC>QAO=0%U8::X>R@\C:ZE5*J9'W'>5!XP%
M]3D\TMO9>(WL[^)M=C\YKHR6EQ)IX&R/.?+9-PW =-V5)Z^A-2:E?S;?Y?\
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MU^&_"/B.[T._LM5DNK79O>"*,H=R*XP3(#T8=JQ_^&CO!_\ T#=<_P"_$/\
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M ,=KH/\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H Y_\ X:.\'_\
M0-US_OQ#_P#':/\ AH[P?_T#=<_[\0__ !VN@_X4E\//^A>_\G;C_P".4?\
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M[\0__':Z#_A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <H Y__AH[P?\
M] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':Z#_A27P\_P"A>_\ )VX_^.4?
M\*2^'G_0O?\ D[<?_'* .?\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US
M_OQ#_P#':Z#_ (4E\//^A>_\G;C_ ..4?\*2^'G_ $+W_D[<?_'* .?_ .&C
MO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =KH/^%)?#S_H7O_)VX_\
MCE'_  I+X>?]"]_Y.W'_ ,<H Y__ (:.\'_] W7/^_$/_P =H_X:.\'_ /0-
MUS_OQ#_\=KH/^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@#G_^&CO!
M_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KH/^%)?#S_ *%[_P G;C_X
MY1_PI+X>?]"]_P"3MQ_\<H Y_P#X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P!
MW7/^_$/_ ,=KH/\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H Y_\
MX:.\'_\ 0-US_OQ#_P#':/\ AH[P?_T#=<_[\0__ !VN@_X4E\//^A>_\G;C
M_P".4?\ "DOAY_T+W_D[<?\ QR@#G_\ AH[P?_T#=<_[\0__ !VC_AH[P?\
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M_AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':Z#_A27P\_P"A>_\
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M_AH[P?\ ] W7/^_$/_QVN@_X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\
M'* .?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVN@_X4E\//\
MH7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QR@#G_ /AH[P?_ - W7/\ OQ#_ /':
M/^&CO!__ $#=<_[\0_\ QVN@_P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.
MW'_QR@#G_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':Z#_A27
MP\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'* .?_P"&CO!__0-US_OQ#_\
M':/^&CO!_P#T#=<_[\0__':Z#_A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'
M_P <H Y__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':Z#_A27P\
M_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'* .?\ ^&CO!_\ T#=<_P"_$/\
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M_P#QVC_AH[P?_P! W7/^_$/_ ,=KH/\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
M0O?^3MQ_\<H Y_\ X:.\'_\ 0-US_OQ#_P#':/\ AH[P?_T#=<_[\0__ !VN
M@_X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QR@#G_\ AH[P?_T#=<_[
M\0__ !VC_AH[P?\ ] W7/^_$/_QVN@_X4E\//^A>_P#)VX_^.4?\*2^'G_0O
M?^3MQ_\ '* .?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVN@_
MX4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QR@#G_ /AH[P?_ - W7/\
MOQ#_ /':/^&CO!__ $#=<_[\0_\ QVN@_P"%)?#S_H7O_)VX_P#CE'_"DOAY
M_P!"]_Y.W'_QR@#G_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\
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MAY_T+W_D[<?_ !R@#G_^&CO!_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\
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M1_PI+X>?]"]_Y.W'_P <H Y__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\
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M>6]19GE586X<D?-R,_6K>KZ/8WOQ3L[2ZB,]I>:-<+-;2NSQ$*\0&$)VKU[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&!.223D\]\U4D\#:#*VF,\-Z6TP8LS_:-Q^Z^G[SG@XR<\<=.*\A_P"&9?\
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M9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\
MAF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH
M ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\
MJ;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_
M *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@*
M*^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_
M "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[
M_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_
M /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F_
M_;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P I
MO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF
M7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/
M^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV
M@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;
MO_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?
M^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z
MHKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;
M_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_
M\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY_
M_P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;
M:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_
M -MH ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&
M9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH ^@**^?_ /AF7_J;O_*;_P#;:/\
MAF7_ *F[_P IO_VV@#Z HKY__P"&9?\ J;O_ "F__;:/^&9?^IN_\IO_ -MH
M ^@**^?_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#Z HKY__P"&9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.NX'!&1W!X(J>O(?A]XQL]'^$&J>(9M+M+.*TNYO]&L0X61R5Q]]F()9@.N
M,<<5M6OC[4+#5?#MMK\5D8?$%NT\#VB,AMB%#;'W,V_A@-PV\_PTVM;>GXJ_
M^8O^#^#M_D=MJ6LZ7HL22ZKJ5G8QR-M1[J=8@Q] 6(R:MQ2QSPI-#(DD4BAD
M=&!5@>001U%>(>,O%6I>-/@YK^M)%:0Z0;A8;>$HWG%5E0>87SCD_P .T8_O
M5ZWX4_Y$_1?^O&#_ - %"6C;\OQ5P;LTN]_P=C7HHHI#"BBB@ HHHH ****
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MV [_ )=*T:*+O^O+0'_G^.H4444@"BBB@ HHHH **** "BBB@ HHHH ****
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M07<+0R-$0&"L,'&01G\*I:EX:BU'PN/#XO[RUM/(%N[P>69'CV[2I+HPY'<
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MI(J;7X  $I((]<G/H*U+#QIJH^)5OX7U"&S>&[TU;V*2W1E:-N<JQ+$,.#R
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M%$=5?S2^\'I^/X';T444@ YQQUKRW3?!_C#3?B7JWB\6NA2KJ$ A-H=1F78
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M<.JL01@#&.?45VE%#U_+\+?D'?S_ ,[_ )GCVK_"+5/^%=VGAK2;JQDN#?\
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MZ *Z.KG'EDX]B4[JX4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR9,$GJ,9XZXZ5REI^T;;V$'DVW@P1H6+'&I9+,>I),623ZFI_P#AIK_J4?\
MRI?_ &JJ;UOYI_-$VTL^S7WG8:9I'B"W^,>L>)I?#UVNFW5@((F\^W+%U5#R
M!)QDH0/J,X&2.,3P)XR'PIU/PV?#<_V^YU47:?Z5;;/+X/)\SK\O3W'O3_\
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M^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z
MHKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E
M_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_
M\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY_
M_P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:
MJ/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_
M -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&
MFO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\
MAIK_ *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH
M ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&FO\
MJ4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_
M *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@*
M*^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_
M "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'
M_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_
M /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?
M_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J
M7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AI
MK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/
M^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ
M@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ^@**^?_ /AIK_J4
M?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z HKY__P"&FO\ J4?_ "I?_:J/^&FO
M^I1_\J7_ -JH ^@**^?_ /AIK_J4?_*E_P#:J/\ AIK_ *E'_P J7_VJ@#Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:($4, 7<",M@=SP2?H:T)C/_ ,- N-1_X\O[#?[)YGW/O+OV^_7/M73P>+?
MEJ[/;^(?#D+L &:.]@4D  #.#Z #\!4>H^)/A[K$*PZGK7AB^B4[E2YNK>50
M?4!B>:71+LFOOO\ YAUD^]OPM_D>*W)O?^&;[O[5O^S_ -K#['NZ>3O&-OMG
M=BOHVPYTRV]/)3^0KE[_ %OX;:K%#%J.J>%+R.#_ %27%Q;R"/\ W0Q..@Z5
M8@\7^"=.T\6NF^(/#4$42D0P1W\,48/7&%/ SZ"AOW6OZT5OT#=I^OXNYXWH
M"V/_  IGXAB80>8+^4@-C<#\NSW^]G'OFHOA_8>(/$=UXE\/ZWJL%CJ-YI\"
M,;^T,TQ@"G:8R)$"X!4]#R<GG-=5\/K?PSH-O?0>)-<\$7OF7S7UM+'J4<S1
M.V 0 ZC;C ^8'\*[NZ\1?#N^NX+N[UGPO<7-OS#--=6[O'_NL3D?A36GS27W
M)+\T$G=NW=O\;G&_$>U:WN_AK:7%V;B2/4HHWN"-ADP$!;!)QGKU[U9^,VD:
M=I7PNUI[&UCMVN[V&>?9_'(74%OR':NDU+6?AIK,J2ZIJ7A.^DC&U'NI[:4J
M/0%B<5)J'B'X=:O;QV^I:QX6O8(SNCCN;FWD5#C&0&) XI.[7SO^*?Z M&O2
MWY_YG*:X;H_$7X;><3_99@?;G[GG^4<?\"QC'XXKAM;;5U\(_$C[#YO]DG6U
M"^7]W;O;S<8[?<S7LDGB'X=3:6NF2ZQX6?3U 5;5KFW,0 Z )G'Z5-#XL\!V
M]B+&'Q!X;BM%78($O(%C"^FT'&/:FWK?U_%IZ_=8(Z)+T_!-?J>?^+;C3+;X
MH_#::*6VB@$+#?N50$*@(,^G/'UKVBN1M/$/PZT](DLM8\+6RP@B,0W-N@3)
MR<8/&3SQ5[_A._!__0UZ'_X,8?\ XJAO2WFW][N2E;[DON.@HKG_ /A._!__
M $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*I%'045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/
M_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#
M_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '04
M5S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/
M_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#
M_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '04
M5S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/
M_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#
M_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '04
M5S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/
M_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#
M_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '04
M5S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/
M_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#
M_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 %;Q
M%8^(G+G2TLKV&2YMY5@N)FA,.QU+88*P8':#C (Y/)X.AX9T-M!TZ:&282SW
M-U+=S%%VH'D;<0H[ =/UJ#_A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@Q
MA_\ BJ%HK ]3H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#B
MJ .@HKG_ /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H Z"BN?\
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MWL=,<!6GAD9[B5"/F4 J%B/;=E^/0]))8-3TW[#:Z'9::VG1((GAFF>%HU&
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MKE_>ZK'=76S>D$L80;45!@&,GHH[UC_\,X^#_P#H):Y_W_A_^-5[!10!X_\
M\,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_
M /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_
MX?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\
M,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"
M6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_
M^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!1
M0!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^
M#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H)
M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#
M_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]
M_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[
M!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X_
M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W
M_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_
MPSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H
M):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'
M_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!
MX_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,
MX^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y
M_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^
M-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX
M/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_
MW_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-
M5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\
M\,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_
M /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_
MX?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\
M,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"
M6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_
M^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!1
M0!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^
M#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H)
M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#
M_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]
M_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[
M!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X_
M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W
M_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_
MPSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H
M):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'
M_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!
MX_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,
MX^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y
M_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^
M-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX
M/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_
MW_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-
M5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>interim2_001.jpg
<TEXT>
begin 644 interim2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P D(# 2(  A$! Q$!_\0
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M_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\
M@NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A
M!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?
M_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)K
MH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X
M03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*F
MA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_X
MFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]
M"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_
M .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y
M_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_
M $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""
MZ'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$
M\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^
M"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@
MHH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!
M/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'
M_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:
M/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*
MFA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\
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M_P %T/\ \37044 <_P#\()X0_P"A4T/_ ,%T/_Q-'_"">$/^A4T/_P %T/\
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MG(%9>J^//$%CI][.^N-"OV21["5H(0+GR[K8)%RGS;H\$X^7!W **=A'IO\
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M\CT?\(]JG_0Y:Y_WYLO_ )'JE9>-OM&B:KK\VG&/1;..62&X28.\PC9U<&/
MV'Y,CD@@C)!XJUH/BM-3T>ZU+4K1])@MV^:6Z$D4;(0"'#2I&<<X/&,@X)&"
M0!__  CVJ?\ 0Y:Y_P!^;+_Y'H_X1[5/^ARUS_OS9?\ R/2>(M0L+WPA>2VN
MIH1/:2RVLUI=E&<HI;*.C G&.<'Z\5S]GXGN_#WA7PW&UH]])=Z5)=/+=7K^
M89$A$I#%E8D,2><\=AB@#H?^$>U3_H<M<_[\V7_R/1_PCVJ?]#EKG_?FR_\
MD>N<M/B=+-+;FYT:.&VEDLT,JWA=E^TQEU^7RQG!&#R.N<]JV_"'C'_A+5FF
MCTNZMK7RTEMYY(I LJ-GC+(HW#'(4NN"/F-%@+'_  CVJ?\ 0Y:Y_P!^;+_Y
M'H_X1[5/^ARUS_OS9?\ R/7)^*=2UOPWKNNW$4EV+:;199K-_/,T?G1D;F*-
MQ$0&& HP<$GFNC\'SSB\UW37FGF@L;N-('N)6E<*T,;D%V)8_,Q/).,XZ 4
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M9?\ R/7044 <_P#\(]JG_0Y:Y_WYLO\ Y'H_X1[5/^ARUS_OS9?_ "/7044
M<_\ \(]JG_0Y:Y_WYLO_ )'H_P"$>U3_ *'+7/\ OS9?_(]=!10!S_\ PCVJ
M?]#EKG_?FR_^1Z/^$>U3_H<M<_[\V7_R/7044 <__P (]JG_ $.6N?\ ?FR_
M^1Z/^$>U3_H<M<_[\V7_ ,CUT%% '/\ _"/:I_T.6N?]^;+_ .1Z/^$>U3_H
M<M<_[\V7_P CUT%% '/_ /"/:I_T.6N?]^;+_P"1Z/\ A'M4_P"ARUS_ +\V
M7_R/7044 <__ ,(]JG_0Y:Y_WYLO_D>C_A'M4_Z'+7/^_-E_\CUT%% '/_\
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M3^SH;N:.5=.@,2RHGEB9B ,[=S;0 ,<DY)/0 9O:;JO]HRW,3V-U:2P, 4N
MN74_=<;688.#P<,,<@5%J.NQZ9>P0W%G=BVE=8S>A5\F-V.%5OFW<G R%(!(
MR10!JT5BP>(UNK::2#3+Z250KPP 1A[B-L[9$R^T*<'[Y4C'(&1F*V\6V5W]
MG,5M=[),"=V55%HQ8H%E!;.2ZLORAL8R<#!H WZ*J7M^MGL18);B>3/EP0[=
MS8ZGYB  ..20.0.I%))J*P3I'/;SQ))((DE8*4+$ C)!)7))49 Y&.ZY +E%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6#/X<>XU*5I+P'39)?M!MA$5D$VW;E90PPN.<!<YYW8XJ\^KQC6$
MTR&VN;B7;NFDB4>7;@CC>Q(Y/95RW0D <T/J\8UA-,AMKFXEV[II(E'EVX(X
MWL2.3V5<MT) '- &)'X*2PO9;[2=1N8KPE?*:]GGO$0!2K J\OS9![$8(';B
MKK:/=?9QI\,ZQV]M'$]K.\6YA.K$EFPXW \9&%ZG!.?EE;Q+9KID]^;>]\J&
MZ-JR_9VW[MX3.WJ%R<[C@8YJ]J>HV^D:9<:A=NJ00(78LZI]!EB%&3QR0/>@
M##A\)R0S,XOX\7DBS:F!;D&YD4Y!0[_W8Z*0=V5 &01FKUAHDEIJ/G/=K+:P
M[_LD BVF+><MN;<=WHN N 2#GK4?_"2F)K(W>CZC:Q73K&9I/)9(78X16*2-
MG<<8*[A\PR15JSUN"]U"2U6"=%&X13OMV3[#A]F&)^4\'<!GMD<T :=%%% !
M1110 4444 %%%% !1110 5F:UH5KKML(KB2[C*JP1K>[E@()&.?+9=P]CQ4V
MFZG#JD4TD,<R"&=X&$T90EE."0#SCT/<<UF3^+K2&WGN%M+EX%F6""4M%$MW
M*QQMB,CKGGN< _PEJ )(]%O((;.R2^B;3;:*,>5)"\D[R(<AC*TAXR!P5S_M
M4JV.K75SH][<7=K$]LC&ZA^RG,C,N#M(E(3'I\_U/6GW&OBSGLTNM,OXHKED
M1IR(RD$C\*CX<G)) RH9<GK3[W7H;+5(K$VMU+NV&6>-5\N#>Q5-V6#'<P(^
M4-CJ<#F@#*D\)3I>:AJEE<Z9::Q=YC%W'I@&V(MDAL.&=SA06+X^485><[^F
M6]W:V,<-[<03S+P6@A,28[ *68CCU8_TK+;Q9:K/<1_8KW"%DMWVIB[=7",L
M?S9!#D+\X4'.02 36M87J:A:+.D;Q')5XI,;HW!PRM@D9!!'!(]"10!9HHHH
M YCQ;87=X('L]-N)[J%6-K=VDZ136TIZ$EV :,_Q+\V<#Y6[9R:/>#Q7_:<F
MB3O.-35A=B6+ A-L(V907R%+@9&,G"G!P,=Q10!Y6WAK53?:@[>&[H)=7-O+
M(MM+;Q)(8[@LS$B4/)E&ZR')(^ZO &J_A*2+7=2FBL[]87M7AB^RFSCA,)0*
ML2@KYA9<<*Y\L<G/.*[^B@=S!\-V=Q:^&%M+JS-L5#JD"!(G"9.T8C=D5L?W
M&V^@7H.;\':'J6G7D;RZ-=68-D(IFN7MV;<BA45)(Y"Q'!.'#8SPR\J?0J*!
M'G5CX?N[*TM)CX<DF%E>N8X&2U2X>)X61R=LGE'+,"<%-P&2N1EEE\,:G<Z?
MX:CNK.YB:QB5/*L);9A;2*1M=FE3*C:,$Q?,.0-P.:]$HH"YPVCZ/>6OC**]
M?PZ(9@MS'>:LTT1^TJSJT9&"9&.% VLJA1D X !M'1+F3QB;Q],VS)<^<FK*
MZ#=;[-OV<\[^I/RXV=&SNXKKZ* .&\-Z'<:;KEO<G1+J!G-ZL]S-<1R-L>8/
M$&/F,Q&,X'."3TR<W+K3=1;Q4;FRL9[-Y2RSWL4Z>1/%L(421[MQD#8PP7H
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M)< )TP"0W7(%00Z?J+K+"FC3VT.I,C2M+)#N@97)=I KD$OG*[-W)YQ79T4
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M/$K/%D8.UB,KD=<4L.FV-M>W%[!96\5U<[?/G2)5>7 P-S 9;';- %FBBB@
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M=3UOR'GN[P_\2TJKHL:!;U6D*[VX)7*!6&TJ-Q.>,"M+2[^]DU"WGGN6D@U
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M.;N\7+%[8*R8LW+!RT7R]2P!^?<.V,$@ZNGV*:?:"%99)G)+R32XWRN>K-@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5=0U&UTNU-S=R[(\
MA0%4NSL>BJJ@LS'L "35JL#Q)'+%=:1J:P37$%A<M)/'#&9'"M&R;U09+$%A
MP 3@G'I0!IZ=JMGJL3O9RE_+8+(CQLCQL0&VLK %6P0<$ \T_4=0M-)T^>_O
MIU@M8%WR2-T _K]*X;Q+J=W=WVGWFG66M0Q*Z2"1+:[7S0LB;U>&-0?N[O\
M6\8'RHV<ATS7S:5XN@9-2N5>WE,;&WN<EV# (D;@@X&WF(E3_=7^('8] !R
M1T-%<]X8WQS:I;E]2DC2='C>^24$AHT)VEP.-V[A>%/& ,"NAH$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGRF& <JN3@CN35N+P_;S6=@+]9FGMEP-M[,W!Y*,Y(:5> /GSG&2*2UUY(=
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M77/_  17O_QFN@HH Y__ (3+2_\ GUUS_P $5[_\9H_X3+2_^?77/_!%>_\
MQFN@HH Y_P#X3+2_^?77/_!%>_\ QFC_ (3+2_\ GUUS_P $5[_\9KH** .?
M_P"$RTO_ )]=<_\ !%>__&:/^$RTO_GUUS_P17O_ ,9KH** .?\ ^$RTO_GU
MUS_P17O_ ,9H_P"$RTO_ )]=<_\ !%>__&:Z"B@#G_\ A,M+_P"?77/_  17
MO_QFC_A,M+_Y]=<_\$5[_P#&:Z"B@#G_ /A,M+_Y]=<_\$5[_P#&:/\ A,M+
M_P"?77/_  17O_QFN@HH Y__ (3+2_\ GUUS_P $5[_\9H_X3+2_^?77/_!%
M>_\ QFN@HH Y_P#X3+2_^?77/_!%>_\ QFC_ (3+2_\ GUUS_P $5[_\9KH*
M* .?_P"$RTO_ )]=<_\ !%>__&:/^$RTO_GUUS_P17O_ ,9KH** .?\ ^$RT
MO_GUUS_P17O_ ,9H_P"$RTO_ )]=<_\ !%>__&:Z"B@#G_\ A,M+_P"?77/_
M  17O_QFC_A,M+_Y]=<_\$5[_P#&:Z"B@#G_ /A,M+_Y]=<_\$5[_P#&:/\
MA,M+_P"?77/_  17O_QFN@HH Y__ (3+2_\ GUUS_P $5[_\9H_X3+2_^?77
M/_!%>_\ QFN@HH Y_P#X3+2_^?77/_!%>_\ QFC_ (3+2_\ GUUS_P $5[_\
M9KH** .?_P"$RTO_ )]=<_\ !%>__&:BN?%6D7=M);R6WB%4D4JQBT:_C8#V
M98@P/N"#72T4 <U:^*=(M+6.WCMO$+)&NU3+H]_(Q'NS1%B?<DFI?^$RTO\
MY]=<_P#!%>__ !FN@HH Y_\ X3+2_P#GUUS_ ,$5[_\ &:/^$RTO_GUUS_P1
M7O\ \9KH** .?_X3+2_^?77/_!%>_P#QFC_A,M+_ .?77/\ P17O_P 9KH**
M .?_ .$RTO\ Y]=<_P#!%>__ !FC_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO
M_GUUS_P17O\ \9H_X3+2_P#GUUS_ ,$5[_\ &:Z"B@#G_P#A,M+_ .?77/\
MP17O_P 9H_X3+2_^?77/_!%>_P#QFN@HH XZ[\46BZK!?6UGK3YC:"56T.]^
M5200X'E<X(Y&1D$\Y !S;C4A=:=>B2>^&J78C1[E/">H"+8C$@>7U)Y/._\
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M%;&GW=A<^.I?$.GZK;W&EKI\MM=^8HC_ +/:-U."<#;N)8D/S\N<XH_XN_\
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MB<-M;S&.#CH<$'\1785Y_P#\7?\ ^I'_ /)NC_B[_P#U(_\ Y-T >@45Y_\
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M&1=]: .ZLV+V-NYA:$M&I\ICDIQ]T_3I4]>?_P#%W_\ J1__ ";H_P"+O_\
M4C_^3= 'H%%>?_\ %W_^I'_\FZ/^+O\ _4C_ /DW0!Z!17G_ /Q=_P#ZD?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>interim2_002.jpg
<TEXT>
begin 644 interim2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $M E$# 2(  A$! Q$!_\0
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M_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\
M@NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A
M!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?
M_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)K
MH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X
M03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*F
MA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_X
MFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]
M"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_
M .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y
M_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_
M $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""
MZ'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$
M\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^
M"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@
MHH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!
M/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'
M_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:
M/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*
MFA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\
MXFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_
M /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\
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M:GH'B"*\N9+2X1(;F*2Z\YC<7)DE5T>0; "P"[3SV&/0,#O<#THHHI %%%%
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M'H?_ (.9O_D6@#H**Y_[9XP_Z >A_P#@YF_^1:/MGC#_ * >A_\ @YF_^1:
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M'H?_ (.9O_D6@#H**Y_[9XP_Z >A_P#@YF_^1:/MGC#_ * >A_\ @YF_^1:
M.@HKG_MGC#_H!Z'_ .#F;_Y%H^V>,/\ H!Z'_P"#F;_Y%H Z"BN?^V>,/^@'
MH?\ X.9O_D6C[9XP_P"@'H?_ (.9O_D6@#H**Y_[9XP_Z >A_P#@YF_^1:/M
MGC#_ * >A_\ @YF_^1: .@HKG_MGC#_H!Z'_ .#F;_Y%H^V>,/\ H!Z'_P"#
MF;_Y%H Z"BN?^V>,/^@'H?\ X.9O_D6C[9XP_P"@'H?_ (.9O_D6@#H**Y_[
M9XP_Z >A_P#@YF_^1:/MGC#_ * >A_\ @YF_^1: .@ILBEXV579"00'7&5]Q
MD$?F*P?MGC#_ * >A_\ @YF_^1:;+<>+IHGC;0]%"NI4E-;G4X/H1;9!]Q0!
MSVCZSKD6NV6@ZUJ=T]T=UY:W$$$2KJ%OM)*/E,*Z':#M*Y# ]ZT6^(^G+:17
M)TS4_+DMENAA8B0IE\HC'F=0Q&<=CQGI4UK;>)+2WM88_#^C,MIGR6FUZXE=
M<@@_.]L6/!(Y-8,_@6YN/O\ A?3@,%=L?BJ^0!2^_: L( 7=R!T!Z4 6_$/Q
M!B30M02RBO['4!'=QPRO'$PBG@0N5/S,#D#(.",=P>*DNOBIH>E)Y.JI<VM[
M$VV:"5H58*%5C(/WFU@0ZD*I+G. N015,>";KSQ,_A;2Y6\V28B;Q1>R*SR+
MM<E6A(.1P<CI5@>%]34JZ>&M*299&E%Q'XEO%F)( (,H@WE<*HVDXPH&.!0,
MZ*U\40WNN2Z7!I]^QB=5>Y"(8@&C,BL2&R 0,=.N,]16[7(VEGXCL=1O;^W\
M/Z.+F]*&=FU^Y<-M&%PK6Y"\>@%7OMGC#_H!Z'_X.9O_ )%H$=!17/\ VSQA
M_P! /0__  <S?_(M'VSQA_T ]#_\',W_ ,BT =!17/\ VSQA_P! /0__  <S
M?_(M'VSQA_T ]#_\',W_ ,BT 7M>O9+#1;F:$R"<H4B,=N\[!SP#Y: LV.I
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MYF_^1:/MGC#_ * >A_\ @YF_^1: .@HKG_MGC#_H!Z'_ .#F;_Y%H^V>,/\
MH!Z'_P"#F;_Y%H Z"BN?^V>,/^@'H?\ X.9O_D6C[9XP_P"@'H?_ (.9O_D6
M@"[KNM1:#IPO9K:XN$,T<.RW"EMSN$7[S 8R1WK%L_'UM?WOV.WT75WN%_UD
M82(F,B4Q,&Q)_"PY(R,<@D9JEXIT[QKXBT0Z?%IV@6K&:*7S&U2=_N.'Q@0*
M1DJ.0>*33?#NKZ1=&ZLO#>DQSF%H6<^)+M]RLQ=B=T!RQ8D[OO<]: +&D^.(
M9=,TXM;:I?W5XTS%([:,20QI-Y99U5R,*64?*6) SCKB]I?CK1-8\2W.A6DQ
M:[@\P9WH0Y1@KC 8LN"?XE7/5<CFL2S\*ZC8+9BV\,:2ALY'D@8^);QF4N<N
M"Q@R58C)4DJ3SBK]EIWB#3KZXN[3P_I$3W#%I(QXANO*+$Y+"(V^P$GDD $T
M =C11S10!RGC.^DM4MIDFF-K9-]JU&"UG,4WD88"08(+!6&2N?F (YZ'-L=;
MEL?&5U"\EU=VI5+:2::X8(GE0&628)R,DO&I"[>?I79W>F6&H&,WMC;7)B<2
M1F:)7V,.C#(X(R<'WIO]DZ;YOF_V?:^9EVW^2N<OC><XZM@9]<<T <Y;^-+F
MYL'O%TE%0S6L<*-=?.PF8<,-GRNJ,K%<GKC(ZU:L?%-Q?^(_[)BTS*0;DO+G
MS&"1R!0=L9* 2C+ $@@@]1BM>#1=*M0@M],LX=A5E\N!5VE1M4C X(' ]!4D
M.FV-M=7-W;V=O!=7.//GBB57DP, LV,MCMG- &"_BNY77'L!I]LT*WOV02B\
M.]L1"1FV;.BYPW/'N>*HV?CZ6\LXI4TN(R-':.R+=$KFXE*JJDH"2%&_H.N.
M.M;NB^&K+1HI?F:]N9BYEN[J.+SI S%BK%$4%<L3C'>K<.BZ5;M&T&F6<31A
M0A2!5*[00N,#C ) ],T 9LWB"[CU%;)-/@<PK&U](;P*L._/"97,A !8YV\=
M,GBN<\,^+)[707$]I=3N7B: SW+.[R7+LR1$MDJJ(4)))PIZ<8KN)=*TZ>[>
M[FL+62Y>(P-,\*EVC/5"Q&2OMTIAT72BK*=,LR&9&8&!>2F A/'5<#'I@8H
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M2=-"RJ-/M LJA) (5PZ@8 /'( JS%%'!"D,,:1Q(H5$10%4#H !T% #Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH X/QS;7]QXDT&+3WN&:5+CS+==
M6N+&.0*@(RT6>03Z<]"<5EZ3X]GTCP#I][)')J;Q^>+I[JZ5)56.78P7&\RD
M%@ Q(!P,L"0#WVI>'=#UF5)=4T;3[Z1%VH]U:I*5'H"P.!3I-"T>6"*"32K%
MX88C#%&UNA5(SC* 8X4X' XXH0'GT/C*Y\,KX@=HI-0@@U6=B+F_.^*%5AR$
M#!F/,G X4=-PR =_3_',]UK!L[G24AA%U<VHECNC(Q:%0^=NP<%3ZY!&.>M;
M$?A#PS#)))%X=TB-Y5*2,ME&"ZGJ"=O(/>GVWA7P[9W<=U:Z!I<%S&Y=)HK.
M-75CU((&03ZT <V_Q#N8_#UGJCZ'SJ,L::>D5PTXF5XRX+>5&SJ0%(*A&YZ$
MC)'21>((?[*T^]N;'4K=KQ5(@^PS221,1TD"*=F/5L"IF\/Z*UC-8MH^GFSF
MD,LMN;9/+D<G)9EQ@G/<U>AABMX4A@C2**-0J(BA54#H !T% ''^,Y8+R?3;
M:&]OHKB+4[>"9;6ZF@RDG)4E&4-D#WQ[9J&Y\?7=L9%&CV[.DM[#@WQ&3;IO
M!_U?1A^1]:Z]],L)=1BU&2QMGOHE*1W+1*9$4]0&QD#VJE>>%/#NH3237N@:
M5<RR-O=YK.-V9L8R21R<<9H Y63XF20VBF31&^V3-;BWACEDE#":)I!N,<3,
M" C#"HW;MG&MKEY<:UX.0V8EL=5O;8R6ME<736<OF!<D$K\^5ZD# .,' -:2
M>$?#4<$T*>'M)6*8*LJ"RC"R!?NAAMYQVSTJU=:'I%]:V]K>:58W%O;D&"*:
MW1TB(&!M!&!@>E 'GTNNZK<+:WR27JRP6VE/#&[E/,,\Q28R(IVL2!CG.WJ,
M'FNUUM[+5?#EYLU]M/M%W+/?V=PBM"%.' D.0A!!!/4<]#6E+IUC<7=O=S6=
MO)<VV?(F>)2\6>#M)&5S[54'AS1SI\]A-IUI<6L\[7$L,T",CR,<EBN,9SWQ
M[]>:;U Y*">XE\.>%M/_ +;DU*"YGDAN=0M;HAI0D4C*/-C().Y5!8'DJ<]3
M52VN;B\3P9K.H>+I=.OYHHBVG/<)'%=*5^<^5C=([$J!UQG@5WO]A:1_90TK
M^RK'^SATM/LZ>2.<_<QCKSTZTR?P_HMUJ$6H7&CZ?->P[?*N9+9&D3;]W:Q&
M1CMCI0!R?AS4M2F\3VK327#"^&H_:8WE9DC\FX5(MJD[4PIQ\H&[.3DUWU5H
M=/LK>\GO(+.WBNKC'G3)$JO+CIN8#)Q[U9I %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9FL)
MDV$HDF1H[N/'ERL@8$X(8 @,,'H<COUJA817EIXPO%G,QM[F#S(C]L>96*D!
MB8VP(B-P "<$9).<5KW^E:=JBQ+J-A:WBPN)(Q<0K)L;^\,@X/O5?_A'=(2T
MOK:WTZSMDO@WVDPVT8\TG.2PVX8\G[P/6@#GX([^]):TU22.\OUN5F$S221Q
M;) HVH'79M&5^0J3G))(!IDAE:QM[:2ZNK/[+8W%PGEW\LI::-PNXR,=TBCK
MM?((89'''1S>'=$N%N5GT>PF%UL^T^;;(WG[/N[\CYL=LYQ5B?2]/NH[:.XL
M+69+5UDMUDA5A"R\*R CY2.Q'2@+F%KCS3RQQRWD]IY6GRW:>3*T>95V\G!^
M8+G[ARIW<@XK#6[OY(-+N)+VZCEU6=H=103N!"!*$P@S^Z()\O*8)W;B20".
MR70=,\F.*6RMIUBN6NHO-@0^7*6+;U&,!LD\CGN222:D;1M+=[UVTVS9KY0M
MV3 I-P , 2<?,,<<YI@1:%O6P>)II)DAGEBCDD8LQ17( +'EB,8R>3C)R>:M
M:C&\VG7$4=S]E=XRJS?W"1@&I;>WAM;>.WMX8X8(E"1QQJ%5%'0 #@"G21I+
M&T<B*Z."K*PR"#U!%(#!\(%8]*>T/VE)K>3;+%/=&YV$@'Y9&)9E.<C=@\]!
MP*Z"JFFZ7I^CV@M-,LK>SM@2PBMXPBY/4X'>K= !1110!F>($W:+.PDFC:/$
MBM%*T9R"".5()'J.AZ'-59K>[C\5VUU+,)+61#%%&D\L9B(4DEDW[)0>>2H*
M\=<\:E_IUCJMHUIJ-G;WELQ!:&XB61"1R,A@14=KH^F6-W+=VFG6=O<RJJ23
M10*CNH  !8#)  &![4 0:1$%CU"#S9W074@4R3.[ $ X#,20,DX&>.V*P-1:
M:W\)6KN+^YL;=Y/M1AU$P3B-2VUO.>1#@$#.7!(]>0=Y?#6C13++;Z99V[>>
M9W\FVC7S'*LI+';DG#'GJ<X/!(+X/#^BVMO!!;Z/I\4-O+Y\,<=LBK')_?4
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MGMB@"W154:E8F6.(7ML9)6=(T$JY=E.& &>2#P?2K"2))G8ZMM)4[3G!'44
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M[U."[MHK2;4;:)XG,<MC9BXWS@C;'*"C;$.?O?*.N67 S7M+_6_[?4W=S>&
MWYM_LT>F,(1&80VXOM).).-^X*<D8Z8Z6YU"*UO;.U=)2]V[(C*A*J54L=QZ
M#@<=S^>+= '):KJEK:>(M0BNM+U*]BFL8X?+ATR::.8YD)3<$*<A@/F('/)'
M-9'A>7Q9I]Y'I=Y;A(H+$B.!C(\8*K\@$@@"[N@.9FX&0HKT2B@=SSV\U;Q
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MSRW$$<;;(T'SM(Q5$4D@;B1W( !!) H?Q%9Q:5'?S1SQAYUMS 4!D24OL*D
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M3/@1@=2HV-DXR,#8>>'6J,WAZ^/B"358['3&G-X72>2X<N(#!Y>W'E\98 E
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MS[DU)9:II^HF46-];71A($@@F5]A(R <'C(YJ&7Q!HL#3++J]A&T$JPRA[E
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MVL1W )([B@#F-+\%ZE::E;WM]JUC?3179NFD?3Y/,+&+RV"LT[;,C!PHVC&
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M <__ ,)#JG_0FZY_W^LO_DBC_A(=4_Z$W7/^_P!9?_)%=!10!S__  D.J?\
M0FZY_P!_K+_Y(H_X2'5/^A-US_O]9?\ R17044 <_P#\)#JG_0FZY_W^LO\
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M9.3U]<\UU=% '/\ VSQA_P! /0__  <S?_(M'VSQA_T ]#_\',W_ ,BUT%%
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M%B@PV<X*XVD0SLK/PKX"U%)7L= \-W2Q2&*0P6<#A''53@<$>E6?^$$\(?\
M0J:'_P""Z'_XFO/6U/Q':R^(&T2UUN"=[^>^C7^QW"7"A8E52TB=#A_E4!CC
M(8<!MG1M?\32>(EBF_M>:VDO;N-4N=):*,1! 86+^4N/FR 2>G7)YH$=3_P@
MGA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-<E)JOC1/"$-U&]_+>S7
M*+=K)8>3+9#8=XC"PR>8F\* PC?Y2>3]X=G:7&OG1-,D-I87%Z\:F\WSRVZJ
M<<E 8BV?]E@M &5J6@?#G1O*_M32/"UCYQ(C^U6UO%O(ZXW 9ZC\ZO\ _""^
M#S_S*NA_^"Z'_P")JCXDEO+_ %C3M+CTZX_=:A;W*W"QLT;1KDN6?;M0CH 6
MR>PKG=5USQ593W$"RZXQCN+U \&D>:"A3-N05A(/S<9''7=0!V'_  @GA#_H
M5-#_ /!=#_\ $U7O?"G@/3+5KJ_\/^&[2W4@-+/9P(@)Z9)&*XT^(_&QTZ1(
M(M4E<FU:6XFTUX'A#1'S1&/L[[L2!1CRW(#'ZCJ-9N+JY\'6=GJJ:@E[J%N8
M9;S2K%YOL[E.24*;U#<CE1C/\/!H LR^%O ,-U;VLN@^&H[BYR8(GLX \N!D
M[1C+8'I4ESX.\$65M)<W7AOP]!;Q*6DEEL855 .Y)7 %<I-HVN(+:TFMW2ZN
M+?2DC-O$[10M;S%Y06&0@ ((W'YN@R:ZG5-6TS4O#%_<7^@7]_;VT[POISV!
MFDF=&P"(^0RDX8$\8()Q38$4WAOX?6^FKJ4VB>&([!E5ENGM;<1$-T(<C&#D
M8YITGA?P!#>6]G+H7AI+JY!:"%K2 /* ,DJN,M@>E8EG (/#/A>ZLM)U2RTZ
MPN)6DLY[5C<(K1RH&,2;F^^PX&<!@>@XHPV%EIQ\'V.I^%M4O];MX[??J%M8
M%TMRHPJ23]E!)) )^[R.:+ =7#X4\!W%Y/9P:!X;ENK?'G0I9P,\6>FY0,C/
MO5C_ (03PA_T*FA_^"Z'_P")K!\.:;J4/B>U6:.X46(U'[3(\3*DGG7"O%M8
MC:^5&?E)VXP<&N^I <__ ,()X0_Z%30__!=#_P#$T?\ "">$/^A4T/\ \%T/
M_P 37044 8]CX3\-Z9>1WEAX?TJTNH\[)H+..-UR"#A@,C()'XUL444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2S=;:_BT[["$<7-T) C <*?WK;GSG)VG/7S#@+0!TD<RR/*BAP8VVMN1E!.
M>"1AASU&1G(Z@U)7&:E;>(&O)S:PZE(HU-)8F-S&J&+8@(PLJD("&X(8Y.=C
M]K]K9ZG)KVMI<)=KI]Q&!%(UR1\V,?N]LA*\=PL9!_OD[@ =)526ZLM.>V@D
M>.!KJ4QPH!CS'(9R !WP&)_&N/%KXFG\/ZC&EG>VL[^2 MQ=^;+(50+)Y>R=
M0@. 1B5"26) _BCM].\1?VEH\MW::C=R0^2?-:\6&")<,)!+$)7WOR"#^\SQ
M\PY- '?T5R_BFSU.ZN[86L&H36_E.JFPOOLS0S9&V1_G7>F,\?-C'W6SQ7M+
M'6H=?6[N!J\X^WE2S748@$!A )$0<#:)!D94N/Q- &KJ7BW2=)O);6\:]5X8
MQ+*T>GW$D:(<_,SJA4#@\D\8.>E;$4L<\*30R+)%(H9'0Y# ]"#W%<Y?W6K6
M7B.[GL_#MY?1R6D<4<J3VZ1EPSGYMT@8+\PR0I/7 /?$\.:#XIT?4A;37.;>
M.S:..2)#]F#8^10#/QM/<0C(&"QH&>@T5Y[>:=XBDT!DL+?6K><W >:*YO!<
M2,=H^:)ENHR$W<[6D _V,'%6!I&MS7^^[?7Y4>\*.R7L<*>08 &(5)!M'F#C
M^,=CR201V5I?VM_Y_P!EG6402M#(5Z*ZXROU&?Z58KS_ ,*:7XBANI)[RWU"
MTN&!,C7=VDD4G[I54;$D;YPZ[BY&<<9.<4FE:5XFWVT.I/JY@-\QG6*9(EV&
M-AN+&YEDV;RI 5EQ_=% '8W6M6%EJ%O8W$DB33D*A\ES&&/16D VJ3V#$$]L
MT6NM6%[J,]A#))]HA&XK)"Z!ESC<C, ' /!*D@9&:I:K<7TFJVMBF@W-U8;D
MDDNEDA"*X8%<AI ^%(#$A3T  .:K+JMZNL27-]X=O+>*)A;6]P\UN0RNZ@D8
ME+<G!QC.%XR3MH UKK6["RU""RN)9$EG(5&\ES&">@:0#:I/8,03VS4,?B32
MYK:XN(IIG2#&X+;2EW!^ZR+MW2*<'#("#@X)P:J:[)?W=[%IB:'=7%C)AI+Q
M)(0B/GY<AI ^%.&)"GH  <U5M&UBQL)+M= FDN[:UCLX[:.:$&8J3EU)? CY
M&-Q#=?E% &I%XFTB9K01W3-]J *$0OA<G:!(<8C)8%0'VDL"!R,5I-<PI<QV
MY<>=("RH.3@=3[#D<^XKDK6PU R/'_8DT$6H&-Y7D>',#I(6<R!7/WL[E";^
M2<[:?KUO>MJ\L=L+Y9+I[0I)9R)&7B1SYJ%F(P &+8!#'=QG!I@=?2!E)(#
ME>" >E<'<:=KKVMO;FSUIX8FN(X3'J@2:-O,_=2R/YN9(]AZ,6;CE6SQ8O\
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M(V7*A7,:EAR/F +#)P236_H\,L5DSSP&"2>5YFA)!,>YB0"5)&<=<$C.<$T
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M,NX1&3&Y@$QM++@D'..,[MGKG@71;JYNXM>\.-%&\DMK'!<P>8C28\P [NY
M].O/ &!@=M!J%O<3K%&Q)>,2QMCY9$/=3WQD9^H]15JN"T_Q;X7BGT^*3Q3H
MP%G$YD<ZC%M+O_ /FY YY^GOC=_X3OPA_P!#7H?_ (,8O_BJ .@HKG_^$[\(
M?]#7H?\ X,8O_BJ/^$[\(?\ 0UZ'_P"#&+_XJ@#H**Y__A._"'_0UZ'_ .#&
M+_XJC_A._"'_ $->A_\ @QB_^*H Z"BN?_X3OPA_T->A_P#@QB_^*H_X3OPA
M_P!#7H?_ (,8O_BJ .@HKG_^$[\(?]#7H?\ X,8O_BJ/^$[\(?\ 0UZ'_P"#
M&+_XJ@#H**Y__A._"'_0UZ'_ .#&+_XJC_A._"'_ $->A_\ @QB_^*H Z"BN
M?_X3OPA_T->A_P#@QB_^*H_X3OPA_P!#7H?_ (,8O_BJ .@HKG_^$[\(?]#7
MH?\ X,8O_BJ/^$[\(?\ 0UZ'_P"#&+_XJ@#1O=42T:6*.WFNKB.$SM#!MW!>
M<<LRJ"2"!DC.#Z&J][X@BM(;>5+*[NA+'Y[K $+0Q<9=@S#(&>B[F/8&N:N?
M&GAV'4]1:V\1:!,;RV40N^J1*@D4,-KL"Q4$,"#@_P 7MG-U+5/#FM:=IEK=
M>)O#MM+' 8;BYM?$#*T:_*"B!"GF!@/XR #@[6Z4 =WJVM)I-NERUE=W-MC?
M+-;A2L$?=VW,"0.N%#'VJF_BRSCDD4VMV06*6K!4Q>.&"%8_FX(8@?/M'<$J
M"1S=[X]L+JV@BL-8\(^0)72=+G7!&616(4+^[.00 3D#T!(.ZJ<FLZ,_DC_A
M*_"Q_LV9I[!O[60><S-NVR#'[L!<ID%\YW8&,4P.^T[68-1;8L4T$V"3%,H!
M!4[77()!*MP<$]B,@@G1K@K#Q=X:%_;O<>)]"22+S9IV34HC'OD/"*206 '\
M6!T'&20-W_A._"'_ $->A_\ @QB_^*I =!17/_\ "=^$/^AKT/\ \&,7_P 5
M1_PG?A#_ *&O0_\ P8Q?_%4 =!17/_\ "=^$/^AKT/\ \&,7_P 51_PG?A#_
M *&O0_\ P8Q?_%4 =!5>>\B@N8+8[FFG)V(HR=H^\Q] ,CGW ZD5C_\ "=^$
M/^AKT/\ \&,7_P 561?^,O"W]LP7">*M(\J6W>U:6'4(2\#$@JP!)XX()P<'
M;D8R0 =/!K5E</J(5V5-/?9/(XVIG:&)!/4 'D^H([52C\3+/I4%];Z7>3M<
ML?LUO%+;L\Z8SO5A+LVXYY8'VS@5Q]CXCT?P[<W+6_C71]7%VZI%'>:G;1",
M+%@$F*+CE0.>,>K<%U[K'AJ]TH1#Q!X6MKN:Z:X=H-=,2VKLI!=&C*/(3U(S
M&&W')]0#KO\ A*(?M$"_V=J'D7";H+CREVR,%W% N[>&"ACRH!VD D\5M0RQ
MSPI-$X>-U#*PZ$'H:\ZM?%^D:3<P0+KWAB;1K&$1P.-:62Y8A<%BA7!8GC.\
M  DG.>-S2?&/A.STNW@E\5Z'YBK\W_$RB."3DC.[MG% '645S_\ PG?A#_H:
M]#_\&,7_ ,51_P )WX0_Z&O0_P#P8Q?_ !5 '045S_\ PG?A#_H:]#_\&,7_
M ,51_P )WX0_Z&O0_P#P8Q?_ !5 '045S_\ PG?A#_H:]#_\&,7_ ,51_P )
MWX0_Z&O0_P#P8Q?_ !5 &Q=WD5FL9DW,\KB..-1EG8\X'X GV )/2J=GKL%[
MJ#VBP7$:_/Y,[A?+GV':^W!)^4\?,!GJ,CFN?U7QMX5%WIU['XET69+:8^8B
MZA"6"LI7<!NY()'OC.,G@TK+Q1HMG<8_X2?PM);VK.+4_P!L(K2+(X)WC!VE
M1D#!;=U.V@#I8?$]M<6-S>PVTTMM'+Y,$D4D,@NG+;<1[7.#NX^?;CO@ FK>
MG:S!J+;!%-!-@DQ3* 05.UQD$@E6X.">Q&003Q9\2:#<03WK^(/"5IJC2Q2K
M##K"/%(T9XWR%5.67Y<[#@ ?>P!5BP\7>&A?V[W'B?0DDB\V:=H]2B,>^0\(
MI)!8 ?Q8'0<9)  .]HHR/6B@#D_%WC&;POJ&G6_V?3/(O1(!<W^I&U1&09P3
MY;#D=.>O:KFE>++&[T'3M2U-X=):^.R*&[G5=[9( 0G&X'&1QD@CBN=U[5/[
M2UG3]0L+C4+7[&DJB.Y\*7\X<R#!S@)Q@=*P7T33/^$8BT2&]UN.,0W"22?\
M(M=DEY75R4Q&-B C[F2"".<@&A =WIOC&SG>_CU:2RTR2VU%]/B$EX,3L I!
M4L%Y(8?* ?QK5M==TB]NOLMIJMC/<9<>3%<(S_*<-P#G@D ^E>4W&C+>#5DN
M=6U+RM1:9SY7@^^5T9_+_B.25'EK\O&<YZ@8NZ?:QVNL)>SW^I21_;+B[DCC
M\)7\;,9D"$!N<8 X.#0!Z/\ \)%HGV*>]_MC3_LEO)Y4T_VE-D3]-K-G /(X
M-:*.KHKHP96&0P.017DTFF:<_AVQTT76LQW-C*C074/AK4(3(B(8U67RPK.0
MC$95E^@&0>AM[WP_#H^G:;]G\2QQ6"*L8M--U2 <#'.U=S+[,6_&@#8;Q-)!
MXXC\.W5BL45Q;&>UO!,2)67[T97:,,!D\$Y S](M/\9V=Q>:C'?O9Z=;P7HL
MK:2XNPK7+[5;A2 !D,N "Q/M6!K5U::UJ<-U)/K$"VUQ#/:^3X:OA)'MR)%+
ME,,'5F7A1C/?%85]I,>H2:NLVIZDD&HF5@L7@^^#QEQ&!\Y!)4")<KP#DGL,
M,9ZF=<T@7CV9U6Q%RC%7A-PF]2%W$%<Y!"\_3FLB\\:Z=;7^D^7<V$VE7ZSD
MZBMZOEQ&,9/.-I'49W#%<S=1Z3J+^(?MQU=TU:)(XS'X9O5>VVQF/(8QMN)!
M/8=2.<U6U&-+X:?(EU=P7%NEP)G3P=?!9GF387VC&#CGJ<GN.E(1WOB/71H/
MAZXU=$MI8H8_,)FN/*C*_P"\%;D]  #DD#BJS>)9QK6A6?\ 9ZBVU:!Y%E:?
M$D3*F\J4VX/!'.[KGBN>.J-%H>EZ=:WNII]DA$%R)O"5[+%=(%VX*;05]>&/
MN#5;=9VVH^'7TZ;58+#18C%';R>%[^1Y 5VM\X50/E Q\IP?7I3 [S6;V]T_
M2YKC3],DU*\48BM8Y5C\P^[MPH]3^AZ5S3^/F70[*_.DO'-)92W]U;33;6@A
MB($FTA3O;+#:/E##G(JH?$=_/H%[:C4-8M]0EGE^SWC^%;MS#$6.T; @4D+P
M"3Z$C.167-%#>:5;P7^I:W=7OV6:RN[MO"UXGG02D%E5%0"-@%4 \@<Y4YI
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MCX;FSFD,LMN;:X\N1R<EF7&"<]S5Z&'XM6\*0P1^!(HHU"HB+=*J@=  .@H
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M /%W_P#J1_\ R;H_XN__ -2/_P"3= 'H%%>?_P#%W_\ J1__ ";H_P"+O_\
M4C_^3= 'H%%>?_\ %W_^I'_\FZ/^+O\ _4C_ /DW0!Z!17G_ /Q=_P#ZD?\
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MY<7EM8_#V&ZN2#/-'#<J\I'3<P&6_&K7_%W_ /J1_P#R;H ] HKS_P#XN_\
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3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>interim2_003.jpg
<TEXT>
begin 644 interim2_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> E,# 2(  A$! Q$!_\0
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M_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\
M@NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A
M!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?
M_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)K
MH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X
M03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*F
MA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_X
MFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]
M"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_
M .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y
M_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_
M $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""
MZ'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$
M\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^
M"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@
MHH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!
M/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'
M_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:
M/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*
MFA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\
MXFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_
M /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVLL*G4HM\RXCW*N+E6)W!P5 ? <;4!(QZA;^+/#]U8PWB:S8""6(S(SW*+E
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MO0I](@U,PP27-S,NZ /Y:RJ^$7# @*SD]>>1]-+4O"<VHG63]OB0ZEIB:?\
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M4L[>-M*B="8KW+F5$#.!NB( &?E8@Y[J!1?J"1/=^$I+I=64W\:C4+Z*[/\
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MZ&B@#G_MGC#_ * >A_\ @YF_^1:/MGC#_H!Z'_X.9O\ Y%KH** .?^V>,/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0,YY]3U= !117,Z4;#5/#-U$-0N+BVANKA6DM[^3S %D8A?-5MXXQ_%TP.E
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MI>?< "K-C+#"XP>,$4 ;]%9^BZ;:Z7IB6]G9PV<)9I!!#$(U3<<XV@ "M"@
MHHHH 155%"JH50,  8 %+110 4444 %%<]XIMXYTLS=64MY:J[?NHX&E(E(_
M=O@=,'/S=%)!R,9$VH:99ZSHZV>J:?#?R1;49;FV\Q!(5 +@,,'&X_,/<>HH
M VZ*YNPL[=?&-U/!',[);B%WN+#RQ"HV[4AF*+O0_,2H9P#C[O0])0 4444
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M_P#![>__ !ZN@HH Y_\ X0W2_P#GZUS_ ,'M[_\ 'J/^$-TO_GZUS_P>WO\
M\>KH** .?_X0W2_^?K7/_![>_P#QZH+GP#H-ZL:W1U:<1R+*@EUJ\;:XZ,,R
M\$=C73T4 <__ ,(;I?\ S]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\ X]7044 <
M_P#\(;I?_/UKG_@]O?\ X]1_PANE_P#/UKG_ (/;W_X]7044 <__ ,(;I?\
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M05\M@<]G['KT )SX<T);^*Q.H:W]JEB:9(_[=OLE%*@G_6^K+^=6/^$-TO\
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M:S?O 1D*20>?F!/'HUO&8;>*)I'E*(%,CGYFP.I]S0!A_P#"&Z7_ ,_6N?\
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MFA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\
MXFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_
M /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\
M0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H
M?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03P
MA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+
MH?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B
M@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\
M(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_
M (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_
MX03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:
M'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B
M:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\
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MP<_>R",=<BC4-9TO23&-2U*SLS(&*?:9UCW!1EB-Q&<#D^E>=:IHNJZN]O\
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MO?\ XS0!T%5&O@FK16!@ES)"TRS?+L^4@%>N[/S ],>]97_"9:7_ ,^NN?\
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M_"9:7_SZZY_X(KW_ .,T =!5>_O$T^PGO)$>1(4+E(P-S8[#) _,@>I%8_\
MPF6E_P#/KKG_ ((KW_XS4=QXOL)+>1(8=;CD*X5V\/WK 'W'E<CVX^HH VM-
MO?[1L(KK[-/;>8N?*G"[U^NTD'\"15JN*\.:[9:+HD%C<)K$TD>>8?#M]'&H
M[*BF,E5 X S^70:O_"9:7_SZZY_X(KW_ .,T =!17/\ _"9:7_SZZY_X(KW_
M .,T?\)EI?\ SZZY_P""*]_^,T :.IZHNF)$3;7%R\C8$=N%+!0,LQW$# '/
M7/8 D@4W4M673K!;Q+2YO(2-[&V"DI'C)<[F&0!V&6/8&N>U;Q!97_D26O\
M;-M/$67>_AR]D!C889<>6,'H0<\$#((XJOJ6OM/8I::;/J%K$C 8G\*7\X:,
M*!L. N>0<GTXQW(!U%MK5O=ZS<:;;HTK6\:O-*LD96,MRJ,N[>"1R/EQCOGB
MM*N,M_$5N-6-Y>#4YECC,=N(_#%]'(H;&[>Y0[LE0< *![\8T_\ A,M+_P"?
M77/_  17O_QF@#H**Y__ (3+2_\ GUUS_P $5[_\9H_X3+2_^?77/_!%>_\
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MZMX5OFDW8Y82;<#T^Z>,COF@#H[C6X+74OLDD,^Q5!DN0%\J-CDA2<YR0">
M1TR1D9?I>J)JD+.+:XMG4C,5P%#[3RK?*2,$<]<]B 017)3ZG8W=V7N3J[6T
MR*;J%/#5\IDD4;0RML.U<=5(;H.>N;>D>(;.PB<W?]M75PVU3(GAR]C&Q1A1
MM\L\XZG/))X P  =C15>RO8M0LX[J%)TC?.!/;O"XP2.4<!AT[CGKTHH L45
MS_\ PD.J?]";KG_?ZR_^2*/^$AU3_H3=<_[_ %E_\D4 =!17/_\ "0ZI_P!"
M;KG_ '^LO_DBC_A(=4_Z$W7/^_UE_P#)% '045S_ /PD.J?]";KG_?ZR_P#D
MBC_A(=4_Z$W7/^_UE_\ )% '045S_P#PD.J?]";KG_?ZR_\ DBC_ (2'5/\
MH3=<_P"_UE_\D4 =!17/_P#"0ZI_T)NN?]_K+_Y(H_X2'5/^A-US_O\ 67_R
M10!T%%<__P )#JG_ $)NN?\ ?ZR_^2*/^$AU3_H3=<_[_67_ ,D4 =!17/\
M_"0ZI_T)NN?]_K+_ .2*/^$AU3_H3=<_[_67_P D4 =!17/_ /"0ZI_T)NN?
M]_K+_P"2*/\ A(=4_P"A-US_ +_67_R10!T%%<__ ,)#JG_0FZY_W^LO_DBC
M_A(=4_Z$W7/^_P!9?_)% '045S__  D.J?\ 0FZY_P!_K+_Y(H_X2'5/^A-U
MS_O]9?\ R10!T%%<_P#\)#JG_0FZY_W^LO\ Y(H_X2'5/^A-US_O]9?_ "10
M!T%%<_\ \)#JG_0FZY_W^LO_ )(H_P"$AU3_ *$W7/\ O]9?_)% '045S_\
MPD.J?]";KG_?ZR_^2*/^$AU3_H3=<_[_ %E_\D4 = <X..M87A;5+[5M%FGO
M?L[745W<6Y,*-&C>7*R X+,1G:.YJ,^(-392#X-UW!XXGLA_[<5AV5M+ID44
M.G^$?%,$*W#W$BG4X9#(S ALEKP]2<G.>>>#S0 W5_%WB'2='GN7@LG^SW\D
M#W<=N[(T*Q[MXB\S=P_R,VXA<%B, @;D&O79\8P:3,L'V:XL#=1LJ.,,K*,"
M0_+)D,3@ %<#.=PK#.F6YT]+%_ _B=X$8LADU6%G4$;2H<WFX*1P5SM/I4OD
M-$MZ;/P5XAMI;I6!=+ZW C)ZF-1=@1DX&=FW..: %U?QO<Z9KFJVSVTT4%I;
M%K<3Z=(J73X!)2??M(&>5V9X)!ZXGA\3:HUSHT3FS;SM3GTV\(MW7>41V#QY
M<[1\G0[NO7BF1 QF])\#:_(;X 7/FW=HRR';M)VFYVJ2,9*@9P,]*A>SCD_L
M_/@?Q-G3Y3-;E=3@!$AZNQ%W^\8Y.2^202.YH [NBN?_ .$AU3_H3=<_[_67
M_P D4?\ "0ZI_P!";KG_ '^LO_DB@#H**Y__ (2'5/\ H3=<_P"_UE_\D4?\
M)#JG_0FZY_W^LO\ Y(H Z"L.YU2]@\:V&E@VYL;JRFF(\MO,5XV0?>W8((?I
MMSQUJ/\ X2'5/^A-US_O]9?_ "167=&2[UF'5Y?!?B7[=!$T43KJ-NJJK=1L
M6["G/&>,\#T& #8U/4=4L]>L(+>.UFL[A9?,C(99(]J%O,WYP%W;5QM_B!SV
MKEK?QQK;^"]4U:6"U6_T]U\V 6DORY56*%0Y('S?ZW.W'S8Q5J""5)8)[CPC
MXHN;B. 0,TFIP%)% /#1F[*M]X\L"?<GFHDTNUC2-5\!^(P4<N&_M* L<J%V
MEOM>63: -A)7 Z4 ;?BWQ%<Z)HUO=V4$\K3RJIE@L'O5A3!)=D1T.WCKGOT/
M2J5IXLO;_6)K2W:U\B198[:4V[G$D<:/O8;QE&\SA>",?>.>(9$GN;KS[KP=
MXCEV7 N(%%];*(2%VX&+O[I&<K]TY^[US))F2[N;K_A!O$"3W,9BD>.]M4P"
M "5VW0V,0%!9<,=HYX% &]X7U.?6O"NEZG=+&L]U;)-((@0H8C)P"2<?B:UJ
MY+2;NXT/3(=.T_P3X@CM8!MC22\M92H]-SW1./09XJ[_ ,)#JG_0FZY_W^LO
M_DB@#H*I:O<7EKI-U/I]M]INXXRT4/'SGTY(S],C/3(ZUF?\)#JG_0FZY_W^
MLO\ Y(J*XUK4+JW>";P7KIC<8.VXLU/X$7.0?<<T 6/"&LOKOAZ"\EN(9YON
M2M'"T)5P!E6C8DHP/!&3Z]ZW:Y'2;NYT6Q6TL_!?B#RP<EI;NTE=SZLS7))/
M0<GH .@J]_PD.J?]";KG_?ZR_P#DB@#H**Y__A(=4_Z$W7/^_P!9?_)%'_"0
MZI_T)NN?]_K+_P"2* &^+->NM$@MA9I"9I?-<M,C,H6.-I&& 1R=N <\9S@X
MQ4FN:KJ,'AI=4TJ. S;$E6"X1F,N[&(UP1AF)P"<X/8U0U.ZFUB!(;[P/KLB
M(V]=MU:(0<$'E;D'!!((Z$$@Y!J"^,NHHJS^#O%"A91,OD:I!#M8+MXV78P,
M=AQR3C)- %RU\27,_CF?19H9[6WCB_=>=IT@6Y;:"QCN-^TXSRNSMP3VZBN0
ML[B6PO;J[MO ^OI-<L&ES=VC*2!C(4W)"G &2 ,X&<U?_P"$AU3_ *$W7/\
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>interim2_004.jpg
<TEXT>
begin 644 interim2_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ": E4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U_P#X03PA
M_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\
M@NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A
M!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?
M_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)K
MH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X
M03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*F
MA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_X
MFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]
M"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_
M .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y
M_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_
M $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""
MZ'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$
M\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^
M"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@
MHH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!
M/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'
M_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:
M/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*
MFA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\
MXFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_
M /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\
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ME=RGH<$ C\15NO%=+L?&FC^%)[338-1A-KIUG%-%()'(F$A\[R5)Y_=8SY9
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M*SLH=;"I]LEND,UNT6X)]H4/*HW9.1DY&TX!.%MY=8U#P_X>71/$E[=Z;/\
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M^_UE_P#)%'_"0ZI_T)NN?]_K+_Y(KH** .?_ .$AU3_H3=<_[_67_P D4?\
M"0ZI_P!";KG_ '^LO_DBN@HH Y__ (2'5/\ H3=<_P"_UE_\D4?\)#JG_0FZ
MY_W^LO\ Y(KH** .?_X2'5/^A-US_O\ 67_R11_PD.J?]";KG_?ZR_\ DBN@
MHH Y_P#X2'5/^A-US_O]9?\ R11_PD.J?]";KG_?ZR_^2*Z"B@#G_P#A(=4_
MZ$W7/^_UE_\ )%'_  D.J?\ 0FZY_P!_K+_Y(KH** .?_P"$AU3_ *$W7/\
MO]9?_)%'_"0ZI_T)NN?]_K+_ .2*Z"B@#G_^$AU3_H3=<_[_ %E_\D4?\)#J
MG_0FZY_W^LO_ )(KH** .?\ ^$AU3_H3=<_[_67_ ,D4?\)#JG_0FZY_W^LO
M_DBN@HH Y_\ X2'5/^A-US_O]9?_ "11_P )#JG_ $)NN?\ ?ZR_^2*Z"B@#
MG_\ A(=4_P"A-US_ +_67_R11_PD.J?]";KG_?ZR_P#DBN@HH Y__A(=4_Z$
MW7/^_P!9?_)%'_"0ZI_T)NN?]_K+_P"2*Z"B@#G_ /A(=4_Z$W7/^_UE_P#)
M%'_"0ZI_T)NN?]_K+_Y(KH** .?_ .$AU3_H3=<_[_67_P D4?\ "0ZI_P!"
M;KG_ '^LO_DBN@HH Y__ (2'5/\ H3=<_P"_UE_\D4?\)#JG_0FZY_W^LO\
MY(KH** .?_X2'5/^A-US_O\ 67_R11_PD.J?]";KG_?ZR_\ DBN@HH Y_P#X
M2'5/^A-US_O]9?\ R11_PD.J?]";KG_?ZR_^2*Z"B@#G_P#A(=4_Z$W7/^_U
ME_\ )%'_  D.J?\ 0FZY_P!_K+_Y(KH** .?_P"$AU3_ *$W7/\ O]9?_)%'
M_"0ZI_T)NN?]_K+_ .2*Z"B@#G_^$AU3_H3=<_[_ %E_\D4?\)#JG_0FZY_W
M^LO_ )(KH** .?\ ^$AU3_H3=<_[_67_ ,D4?\)#JG_0FZY_W^LO_DBN@HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(>--*U
MBZDM;[P_J%S;ZI9H\T5OY[""ZVE?W4B9VG()&>H..>*RM*\9P"RL]5LK.[E7
M5]56RGAO+V7=:2[?F55<,  P8$+M'2NYETVWFU.#4':X^T0(40+<R+'@]<QA
MMC?4@]!Z55OO#FDZC 8;FT^4W(N\QR-&PF'1PRD$'CL>><]30@.<A\?W,^@Z
M#J4>CQ>9JMZ]D83>'$3 N =WE_,/W9[#&>]0Z=\3H;K3YK^\TJ2VM8]*;4LK
M,)&8([(Z8P.Z\'/.>0.E;L7@?P_!8V-E%:3);6%P;JV1;R8>7(<Y(._/<\'C
MD\<TS3O 7AO2\BUL9=AMFM#'-=S3(86;<R;7<C!))Z4#.2U'Q9J>JW/AN[MK
M&\L)QJIA\F66X@@NXVMW<9+1J6&5&<H<$'&0<G7M/B!>ZI+8QZ7H*W+WVE-J
M$*M>",[E<(T9RF!UX;//<#K6^/".BC38=/-M*T$!)A+W4K21$@K\DA;>N 2!
M@C ) Q3[;PMH]GJ=IJ%M:M#<6=K]C@V3R!$A_N[-VWT[9X'H*8BAXG\7GP],
ML,>GFZ=;.:_G!F\O9#%M#;>#N?YAA> <'+"LW1KR_P!8^)>KM)<31V%A;6YM
MXH[IMCB5&/SQ[=I/?.<@@#)!('2ZOX<TG76B;4K3SC$&52)&3*-C<C;2-R'
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M.6RQ(."6W9'% &;XPT'6;^ZL[_1_$-_974$L8CM8W46S)N'F-*N,O\N>IP,
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M/I60GB":?3_MEIH.JW"-)MB0"&-Y4QGS ))%POLVUO\ 9QS5G7[&74] OK*
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M;XUL3:VNIQWM_JEEJ]\MM:@)"!:LR;MAP$88.0<[B,?F :_V/Q?_ -!W0_\
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M%&L?F2_=!QMSSQ\BG QNQG) -/['XO\ ^@[H?_@FE_\ DJC['XO_ .@[H?\
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MQ?\ ]!W0_P#P32__ "51]C\7_P#0=T/_ ,$TO_R57044 <_]C\7_ /0=T/\
M\$TO_P E4?8_%_\ T'=#_P#!-+_\E5T%% '/_8_%_P#T'=#_ /!-+_\ )5'V
M/Q?_ -!W0_\ P32__)5=!10!S_V/Q?\ ]!W0_P#P32__ "51]C\7_P#0=T/_
M ,$TO_R57044 <_]C\7_ /0=T/\ \$TO_P E4?8_%_\ T'=#_P#!-+_\E5T%
M% '/_8_%_P#T'=#_ /!-+_\ )5'V/Q?_ -!W0_\ P32__)5=!10!S_V/Q?\
M]!W0_P#P32__ "51]C\7_P#0=T/_ ,$TO_R57044 <_]C\7_ /0=T/\ \$TO
M_P E4?8_%_\ T'=#_P#!-+_\E5T%% '/_8_%_P#T'=#_ /!-+_\ )5'V/Q?_
M -!W0_\ P32__)5=!10!S_V/Q?\ ]!W0_P#P32__ "51]C\7_P#0=T/_ ,$T
MO_R57044 <_]C\7_ /0=T/\ \$TO_P E4?8_%_\ T'=#_P#!-+_\E5T%% '/
M_8_%_P#T'=#_ /!-+_\ )5'V/Q?_ -!W0_\ P32__)5=!10!S_V/Q?\ ]!W0
M_P#P32__ "51]C\7_P#0=T/_ ,$TO_R57044 <_]C\7_ /0=T/\ \$TO_P E
M4?8_%_\ T'=#_P#!-+_\E5T%% '/_8_%_P#T'=#_ /!-+_\ )5'V/Q?_ -!W
M0_\ P32__)5=!10!S_V/Q?\ ]!W0_P#P32__ "51]C\7_P#0=T/_ ,$TO_R5
M6!8>,;K5O%4<3/=6.FR74]I8%(8VCO)8MP<2.2S+RK$ *O"_>.<"NR^-]!N-
M6N;CQ.-=^RZ;+<I8+ID<(\TY\M<KEF'RMQD'@>M '3_8_%__ $'=#_\ !-+_
M /)5'V/Q?_T'=#_\$TO_ ,E5D^"/$LVL:KJ%D-3&JVL5M;W4=WA 5:3=NB.Q
M0/E*=QD9P<UFZ3XIUB7X@?V3?WDL+27=PL=N\4?V6:W0':89 NXR@[=RECCY
MN!@4 =1]C\7_ /0=T/\ \$TO_P E4?8_%_\ T'=#_P#!-+_\E5@_V]K>G_$_
M^S;[4HI-.N;*::.T^QF(1E-I41RG_7,026 X&#Q2^$_$^I7^J:,EY<M/%K6E
M/J(C:-%%LP9!L0J 2N)/XBQR.O:@#=^Q^+_^@[H?_@FE_P#DJC['XO\ ^@[H
M?_@FE_\ DJN@KB/B'K6IZ)%8W$<M]:Z/N)O;ZQB222W.Y=I975OW>-^<#.0.
MW! -?['XO_Z#NA_^":7_ .2J/L?B_P#Z#NA_^":7_P"2JT]'N3>:-9W)NH;L
MRPJ_VB 827(^\H[ ]:NT <_]C\7_ /0=T/\ \$TO_P E4?8_%_\ T'=#_P#!
M-+_\E5T%% '/_8_%_P#T'=#_ /!-+_\ )5'V/Q?_ -!W0_\ P32__)5)XHU*
MYM9]&TZTG>VDU2]^SFXC16:)1&\A*A@5R=@'(/4\5'X8U?4->\)O.)(EOTFG
MM1-(F5+1R-&'*@C/W<D#'/I0!+]C\7_]!W0__!-+_P#)5'V/Q?\ ]!W0_P#P
M32__ "567H5UXJTO2_$/]N7']L-8LQLKFWM-DESA-Q41KP2&.T8ZD&JGPVU?
M4M2;4$U?Q!?WUW&(V-C?Z.MA+:@[N2%SN#8ZY/W: .OTR'6(O-_M6_L;K./+
M^RV3P;>N<[I7SV],8/7/!6A10!R4OBSPG+JMO?#QUID:0HR&V6_MO+DSW8D%
ML\#HPZ5E7<_P[N+58(/%FDV6S4!J4;6VHVX*3]R V5P><@@]371?\()X0_Z%
M30__  70_P#Q-'_"">$/^A4T/_P70_\ Q- '(P0^ ;;2]*T^/Q]:^5I=ZU[
MQU.U+%R6.&.WE?F;WYZ]*@T_3?AU8VSVK^/+6[M7L'T]H9]3M0#$[ESRBJV<
MD\Y[UVO_  @GA#_H5-#_ /!=#_\ $T?\()X0_P"A4T/_ ,%T/_Q- ')M%\/#
M&77QM8I?"\6\2_74[;SHW5-B@9&S:$^7!4Y'7).:TAJ_@K_A)[;7CXZT]KB"
MT:T$3:E;&-U)W$GC=DD \$#CIBMK_A!/"'_0J:'_ ."Z'_XFC_A!/"'_ $*F
MA_\ @NA_^)H P?$%_P" ?$4L<ESXQTR!Q#);2&WU. >;!)C?&V2>#M'(PPQP
M1S4FFZMX'TO7]0U>#QMIK/?1QQO;OJ-MY2",83;C#<#/5CU^E;7_  @GA#_H
M5-#_ /!=#_\ $T?\()X0_P"A4T/_ ,%T/_Q- '-75UX!;59]63Q;IKR&0W2V
M8U2W$1N/*\OS.3G=MXP6V]\9YKFO#%CX+?P7!;:YXLLH-2DLX+:4?VM:,;80
MOO41E25QN^;YMV> ?0>E?\()X0_Z%30__!=#_P#$T?\ "">$/^A4T/\ \%T/
M_P 30!RMS_P@5WJ&I7LWCRS::_,#-_Q,K4"*2$@QNF%Z@C.#D')R"*BFMOA[
M+]FQXZM$,"72EEU.US*UQGS9&R#\QSD8PH[#'%=?_P ()X0_Z%30_P#P70__
M !-'_"">$/\ H5-#_P#!=#_\30!S<=QX#2PTNR?QS8RP:<83$LFIVQW>5]S)
M ^7MDIM)Q@DC(J_9^)_#-O?:O._CW362]=6AC;587%MA N8P>%R1G;R,\\Y-
M:O\ P@GA#_H5-#_\%T/_ ,31_P ()X0_Z%30_P#P70__ !- '(7EO\/[ZWNE
MN/'EFUS=6 T^:[&HV@D>$,3C 7;G!VYVYQ[\TAM?A^YM3+X_MY&MEM5C+:K;
M<?9W+1G  '\1!XY&._-=A_P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70
M_P#Q- '/6UWX!AMM=M9_&>FW=OK<KRW4<^I6X +KM(4IM(& !R3T^M17=QX)
MOO"G_"/77Q"MY8,Q_OWU.U,NU""JYV[<9 YQDXY)KIO^$$\(?]"IH?\ X+H?
M_B:/^$$\(?\ 0J:'_P""Z'_XF@#%TC5O!&CKJJP^.-/D&I7#W,ADU.W!C=@
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M@GA#_H5-#_\ !=#_ /$T '_"=^#_ /H:]#_\&,7_ ,51_P )WX/_ .AKT/\
M\&,7_P 51_P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q- !_PG?@
M_P#Z&O0__!C%_P#%4?\ "=^#_P#H:]#_ /!C%_\ %4?\()X0_P"A4T/_ ,%T
M/_Q-'_"">$/^A4T/_P %T/\ \30 ?\)WX/\ ^AKT/_P8Q?\ Q5'_  G?@_\
MZ&O0_P#P8Q?_ !5'_"">$/\ H5-#_P#!=#_\31_P@GA#_H5-#_\ !=#_ /$T
M '_"=^#_ /H:]#_\&,7_ ,51_P )WX/_ .AKT/\ \&,7_P 51_P@GA#_ *%3
M0_\ P70__$T?\()X0_Z%30__  70_P#Q- !_PG?@_P#Z&O0__!C%_P#%4?\
M"=^#_P#H:]#_ /!C%_\ %4?\()X0_P"A4T/_ ,%T/_Q-'_"">$/^A4T/_P %
MT/\ \30 ?\)WX/\ ^AKT/_P8Q?\ Q5'_  G?@_\ Z&O0_P#P8Q?_ !5'_"">
M$/\ H5-#_P#!=#_\31_P@GA#_H5-#_\ !=#_ /$T '_"=^#_ /H:]#_\&,7_
M ,51_P )WX/_ .AKT/\ \&,7_P 51_P@GA#_ *%30_\ P70__$T?\()X0_Z%
M30__  70_P#Q- !_PG?@_P#Z&O0__!C%_P#%4?\ "=^#_P#H:]#_ /!C%_\
M%4?\()X0_P"A4T/_ ,%T/_Q-'_"">$/^A4T/_P %T/\ \30 ?\)WX/\ ^AKT
M/_P8Q?\ Q5'_  G?@_\ Z&O0_P#P8Q?_ !5'_"">$/\ H5-#_P#!=#_\31_P
M@GA#_H5-#_\ !=#_ /$T '_"=^#_ /H:]#_\&,7_ ,51_P )WX/_ .AKT/\
M\&,7_P 51_P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q- !_PG?@
M_P#Z&O0__!C%_P#%4?\ "=^#_P#H:]#_ /!C%_\ %4?\()X0_P"A4T/_ ,%T
M/_Q-'_"">$/^A4T/_P %T/\ \30 ?\)WX/\ ^AKT/_P8Q?\ Q5'_  G?@_\
MZ&O0_P#P8Q?_ !5'_"">$/\ H5-#_P#!=#_\31_P@GA#_H5-#_\ !=#_ /$T
M '_"=^#_ /H:]#_\&,7_ ,51_P )WX/_ .AKT/\ \&,7_P 51_P@GA#_ *%3
M0_\ P70__$T?\()X0_Z%30__  70_P#Q- !_PG?@_P#Z&O0__!C%_P#%4?\
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M_P#H:]#_ /!C%_\ %4?\)WX/_P"AKT/_ ,&,7_Q5'_"">$/^A4T/_P %T/\
M\31_P@GA#_H5-#_\%T/_ ,30!GZOXD\$ZQ!"K^,=)MYK>4307$&HP;XG (R-
MQ*G@D8((P3Q5"'4?!%G!'#8^/;6T6."6+]SJT&&>1MS2D'(,F<D'&!N/%;__
M  @GA#_H5-#_ /!=#_\ $T?\()X0_P"A4T/_ ,%T/_Q- '+Z/+X+T?3K^S_X
M67)>_:T">?>:_$\L P?]4P(V=<_@*V=-\3^#M/C'F>-M+O;C8(S=76HV_F,H
M)(!V;1QD]OKFK_\ P@GA#_H5-#_\%T/_ ,31_P ()X0_Z%30_P#P70__ !-
M&AIFO:/K7F_V5JUC?^3CS/LMPDNS.<9VDXS@_D:*-,T'1]%\W^RM)L;#SL>9
1]EMTBWXSC.T#.,G\S10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>interim2_005.jpg
<TEXT>
begin 644 interim2_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #; E(# 2(  A$! Q$!_\0
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M_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\
M@NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A
M!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?
M_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)K
MH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X
M03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*F
MA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_X
MFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]
M"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_
M .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y
M_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_
M $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""
MZ'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$
M\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^
M"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@
MHH Y_P#X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!
M/"'_ $*FA_\ @NA_^)H_X03PA_T*FA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'
M_P""Z'_XFC_A!/"'_0J:'_X+H?\ XFN@HH Y_P#X03PA_P!"IH?_ (+H?_B:
M/^$$\(?]"IH?_@NA_P#B:Z"B@#G_ /A!/"'_ $*FA_\ @NA_^)H_X03PA_T*
MFA_^"Z'_ .)KH** .?\ ^$$\(?\ 0J:'_P""Z'_XFC_A!/"'_0J:'_X+H?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'/6NAKSF[\ :A#=K_98L/L@%@5CGGEW0&VE+;48JQ(*D\DYS]>/1J "BBB@
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M[9KC+/QA=W.GW#)XI\R2"X\S"2VDDCVK0@NYVQ[ 8SN; R"4*[FSF@=CM_\
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M_P#$T?\ "">$/^A4T/\ \%T/_P 37044 <__ ,()X0_Z%30__!=#_P#$T?\
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ME6-W%>1 /,Z9!ELG+ LC8'"L6R W.5/+#&WKZ .?_P"$$\(?]"IH?_@NA_\
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MVK,MQ*DZE(2OW@Y!PI'?/2DDUG2XH;2:34K-(KQE6U=IU"SEONA#GYB>V.M
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MXR^:]-HH!LX6XEU[5KCQ NE^)BESIMV%BM+2& @IY<;%'WJYW'YP&R.<\$#
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MVCT^(R+MDDS*X]&8[B/S-6Z* "BBB@#!U:XO;K7;71;.]DL!);R7,MS"B-(
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M:JX8CYF_T8;2#QRV6)SGM5A/# 2\CN#K&HN8[YKU480[=S*5*<1YVX8]\^]
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MW40GH[!I ' Y7*\E@@W MQ2'8[&BO,-.\5W$T-E+-XI5TBN)(+XPRVSA(_.
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MYUSG:V]&([C*%3SUX&-*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<\<4[PUK<UVT*OJ,>IVD[3107:*OSF,XW93"L&7K@ !E;'!  !U5%%% '/\
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M1E>4\A 0<%O;K6G0!S__  D.J?\ 0FZY_P!_K+_Y(H_X2'5/^A-US_O]9?\
MR17044 <_P#\)#JG_0FZY_W^LO\ Y(H_X2'5/^A-US_O]9?_ "17044 <_\
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M_K+_ .2*/^$AU3_H3=<_[_67_P D5T%% '/_ /"0ZI_T)NN?]_K+_P"2*/\
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M;62Q6NDQM9V=LB1I<.$DEB9R0?W0PIWDAL$A@#M-1?\ "DOAY_T+W_D[<?\
MQRC_ (4E\//^A>_\G;C_ ..4 :VHZ'J5S! L-KI6V:TDL[JU9V6*))""6C(3
MY\8(*D)NX.5QBJ<7A:_M-2,D&GZ2T']IK>!VG978+!Y6X@1$;]V6Z]^M5?\
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M ).W'_QR@#T"BO/_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <H ]
MHKS_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QR@#T"BO/_\ A27P
M\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H ] HKS_\ X4E\//\ H7O_ "=N
M/_CE'_"DOAY_T+W_ ).W'_QR@#T"BO/_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?
M]"]_Y.W'_P <H ] HKS_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\
MQR@#T"BO/_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H ] HKS_\
MX4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QR@#T"BO/_ /A27P\_Z%[_
M ,G;C_XY1_PI+X>?]"]_Y.W'_P <H ] HKS_ /X4E\//^A>_\G;C_P".4?\
M"DOAY_T+W_D[<?\ QR@#T"BO/_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^
M3MQ_\<H ] KD+WPU?7WCBRU=X[1$LR3'?12LD[1GK R!=K+[ECCL >:SO^%)
M?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<H ] HKS_P#X4E\//^A>_P#)
MVX_^.4?\*2^'G_0O?^3MQ_\ '* /0**\_P#^%)?#S_H7O_)VX_\ CE'_  I+
MX>?]"]_Y.W'_ ,<H ] HKS__ (4E\//^A>_\G;C_ ..4?\*2^'G_ $+W_D[<
M?_'* /0**\__ .%)?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<H [2XLY
MY[ZWN(]3N[>*+[]M$L1CF_WBR%A_P%A5RO/_ /A27P\_Z%[_ ,G;C_XY1_PI
M+X>?]"]_Y.W'_P <H ] HKS_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[
M<?\ QR@#1T[PU?1>.)M=N8[2%O),+SVTK;KU?X?-CVA5*^N6/N!Q77UY_P#\
M*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'H%%>?_\ "DOAY_T+W_D[
M<?\ QRC_ (4E\//^A>_\G;C_ ..4 >@45Y__ ,*2^'G_ $+W_D[<?_'*/^%)
M?#S_ *%[_P G;C_XY0!Z!17G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)
MVX_^.4 >@53^QS_VI]K_ +3N_(V;?L6V+RL_WL[-^?\ @6/:N+_X4E\//^A>
M_P#)VX_^.4?\*2^'G_0O?^3MQ_\ '* /0**\_P#^%)?#S_H7O_)VX_\ CE'_
M  I+X>?]"]_Y.W'_ ,<H ] HJM8V%MIFGVUA:1>7;6T2PPIN)VHH 49/)P .
%M% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>interim2_006.jpg
<TEXT>
begin 644 interim2_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "/ CH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U5O"_@%-2
M336T+PTM^Z>8MJ;2#S63^\%QDC@\XHL_#'@#4);B*RT/PS<R6S^7.D-I YB;
M^ZP ^4\'@U-XEBL-0U"PTU]1@M-5*R3V#%U\U)%QAU4G+#&X$=U+ \$UDW?B
M*\ATF.:^,FB>;J7V6_N_D(M,1_?#.I78S*H#,,8<=#T -K_A!/"'_0J:'_X+
MH?\ XFC_ (03PA_T*FA_^"Z'_P")KE(?$&LW-]I5C<^)K>RCGLKR4S)!$)9U
MBD CF4OE0&3YN%VXWD#D%=C3O%6IWO@RUU"'3I[F:335G-]"(G@,NWY@$$GF
M$@Y^4+U&,T[ :?\ P@GA#_H5-#_\%T/_ ,31_P ()X0_Z%30_P#P70__ !-<
MWJ'B2.T\/A[3QPEXLUWY<6H[K6-8SY9;RY)BIB'(R2(RV" %)YK+'C/4[E0P
M\4V45Q)I%K>6-I#%$3=W!WAX@6R7#,N"$ (R,8P<E@.TC\&>"9I)8X_#7A]Y
M(6"RJMC"2A(! (V\'!!Y[$4L_@OP5;023W'AGP_%#&I9Y)+"%54#J22O KE+
M[7+R[UGRKKQ&MK#9^($@D-MY2+%&UMN5'+AO^6F5R>I)P < 9GB'Q3!?)XDT
M^\UJTN+)]/O-MI=26X>*:)P$ C4;E]1O8L2,[5QRAV.]?P;X)B:%9/#?A]&F
M;;$&L807."<+\O)P">.P-2?\()X0_P"A4T/_ ,%T/_Q-9GB"\TT:EX,O#-:,
M[W;?9I"ZY=6MY.$;N&)3IU)7VK.T/Q-J-\)IQK44F[399[V*XC0+I-RI&(VV
M@,J\OP^YOW>0>M 6.D_X03PA_P!"IH?_ (+H?_B:/^$$\(?]"IH?_@NA_P#B
M:Y?_ (2:Z/@HW8\1QI(E[Y3WLM[9[90%R5@F$?DG/;>BDX(.T\CI=0U66+PA
M:WZ7,ULLJP^=>21H7@C;&Z5@,H" <D\J.N"!B@0__A!/"'_0J:'_ ."Z'_XF
MC_A!/"'_ $*FA_\ @NA_^)KDO$GBR72]!M7LO&$,\ICGFAO6-M%%=!&&%+E6
M#D [<1*"Q'5*AOO%NH%M6N[?QCI\<%KJUM;(B0Q-&()?*)))).1E_FSCA^.F
MQV [/_A!/"'_ $*FA_\ @NA_^)JM'X6\ S7\UA%H/AI[V!0TMNMG 9(P>A9<
M9 /O57;K5EJD^BW'B#4IVO@DEA>_9H,PHF/-#%8=F>G+#G< ,$$US>CZI#::
M EX/$;31R:Q<VMQJ[?9G:PC9W8'=Y>U0Y6+.X%?F&,#&$.QV_P#P@GA#_H5-
M#_\ !=#_ /$T?\()X0_Z%30__!=#_P#$US%CK.M:EJVC:5-XECM!=VETZR00
M0B>Y\N4".5=X9<.GS8"X(W$=MMW3KSQ!+J,5I<WFI;)HOLOG&&$!+F)OWC_Z
MK[K+R#DC[PP#B@1M?\()X0_Z%30__!=#_P#$TR?P7X*MH))[CPSX?BAC4L\D
MEA"JJ!U))7@5Q&J>.[RVNM=%IXFM$,=G=/#%=- 7@FBD4 ")0&4%2<>8[$GG
M: ,&3QQJ/G>'[K3+_P 1!;>?26O+:9X[?9J$A)/EJ2I&$ 0@+A\,#N)&:+#L
M=L/ O@\@$>%="(/?^SX?_B:/^$$\(?\ 0J:'_P""Z'_XFLFS\0&;QM;6<6M1
M7-K-"IBM+2>!MH\K=NE0KYN#G*NC%3D @=3VU CG_P#A!/"'_0J:'_X+H?\
MXFC_ (03PA_T*FA_^"Z'_P")KH** .?_ .$$\(?]"IH?_@NA_P#B:/\ A!/"
M'_0J:'_X+H?_ (FN@HH Y_\ X03PA_T*FA_^"Z'_ .)H_P"$$\(?]"IH?_@N
MA_\ B:Z"B@#G_P#A!/"'_0J:'_X+H?\ XFC_ (03PA_T*FA_^"Z'_P")KH**
M .?_ .$$\(?]"IH?_@NA_P#B:/\ A!/"'_0J:'_X+H?_ (FN@HH Y_\ X03P
MA_T*FA_^"Z'_ .)H_P"$$\(?]"IH?_@NA_\ B:Z"B@#G_P#A!/"'_0J:'_X+
MH?\ XFC_ (03PA_T*FA_^"Z'_P")KH** .?_ .$$\(?]"IH?_@NA_P#B:/\
MA!/"'_0J:'_X+H?_ (FN@HH Y_\ X03PA_T*FA_^"Z'_ .)H_P"$$\(?]"IH
M?_@NA_\ B:Z"B@#G_P#A!/"'_0J:'_X+H?\ XFC_ (03PA_T*FA_^"Z'_P")
MKH** .?_ .$$\(?]"IH?_@NA_P#B:/\ A!/"'_0J:'_X+H?_ (FN@HH Y_\
MX03PA_T*FA_^"Z'_ .)H_P"$$\(?]"IH?_@NA_\ B:Z"B@#G_P#A!/"'_0J:
M'_X+H?\ XFC_ (03PA_T*FA_^"Z'_P")KH** .?_ .$$\(?]"IH?_@NA_P#B
M:/\ A!/"'_0J:'_X+H?_ (FN@HH Y_\ X03PA_T*FA_^"Z'_ .)H_P"$$\(?
M]"IH?_@NA_\ B:Z"B@#G_P#A!/"'_0J:'_X+H?\ XFC_ (03PA_T*FA_^"Z'
M_P")KH** .?_ .$$\(?]"IH?_@NA_P#B:/\ A!/"'_0J:'_X+H?_ (FN@HH
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MRC LC@Y=@04#?>4\9 R#2:M)IR?#S5&GU"*]TJ*138W=W*L@*Y0KB0GY\,2
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M>9N9&74(M1M=6FT[0KO7D>.:-HQ%*IMSN<%U(VM*.#T8L2,D@UH?\);\0_\
MHF'_ )7[?_"C_A+?B'_T3#_ROV_^% [F9X?UA-+FLUL]9M!97'B"]LA81")8
M\$RNO/+;MVS&"!AP,'J8D\7>(%T2>]NM?TFU)O;6-U,BS/:EY=LL3#RXQ'@=
MF+L K?,>"-C_ (2WXA_]$P_\K]O_ (4?\);\0_\ HF'_ )7[?_"@&SN[:)X;
M:**2XDN'10#-(%#.?4[0%R?8 >U2UY__ ,);\0_^B8?^5^W_ ,*/^$M^(?\
MT3#_ ,K]O_A0(] HKS__ (2WXA_]$P_\K]O_ (4?\);\0_\ HF'_ )7[?_"@
M#T"BO/\ _A+?B'_T3#_ROV_^%'_"6_$/_HF'_E?M_P#"@#T"BO/_ /A+?B'_
M -$P_P#*_;_X4?\ "6_$/_HF'_E?M_\ "@#T"BO/_P#A+?B'_P!$P_\ *_;_
M .%'_"6_$/\ Z)A_Y7[?_"@#T"BO/_\ A+?B'_T3#_ROV_\ A1_PEOQ#_P"B
M8?\ E?M_\* /0**\_P#^$M^(?_1,/_*_;_X4?\);\0_^B8?^5^W_ ,* /0**
M\_\ ^$M^(?\ T3#_ ,K]O_A1_P );\0_^B8?^5^W_P * /0**\__ .$M^(?_
M $3#_P K]O\ X4?\);\0_P#HF'_E?M_\* /0**\__P"$M^(?_1,/_*_;_P"%
M'_"6_$/_ *)A_P"5^W_PH ] HKS_ /X2WXA_]$P_\K]O_A1_PEOQ#_Z)A_Y7
M[?\ PH ] HKS_P#X2WXA_P#1,/\ ROV_^%'_  EOQ#_Z)A_Y7[?_  H ] HK
MS_\ X2WXA_\ 1,/_ "OV_P#A1_PEOQ#_ .B8?^5^W_PH ] HKS__ (2WXA_]
M$P_\K]O_ (4?\);\0_\ HF'_ )7[?_"@#T"BO/\ _A+?B'_T3#_ROV_^%'_"
M6_$/_HF'_E?M_P#"@#T"BO/_ /A+?B'_ -$P_P#*_;_X4?\ "6_$/_HF'_E?
MM_\ "@#T"BO/_P#A+?B'_P!$P_\ *_;_ .%'_"6_$/\ Z)A_Y7[?_"@#T"BO
M/_\ A+?B'_T3#_ROV_\ A1_PEOQ#_P"B8?\ E?M_\* /0**\_P#^$M^(?_1,
M/_*_;_X4?\);\0_^B8?^5^W_ ,* /0**\_\ ^$M^(?\ T3#_ ,K]O_A1_P )
M;\0_^B8?^5^W_P * /0**\__ .$M^(?_ $3#_P K]O\ X4?\);\0_P#HF'_E
M?M_\* /0**\__P"$M^(?_1,/_*_;_P"%'_"6_$/_ *)A_P"5^W_PH ] HKS_
M /X2WXA_]$P_\K]O_A1_PEOQ#_Z)A_Y7[?\ PH ] HKS_P#X2WXA_P#1,/\
MROV_^%'_  EOQ#_Z)A_Y7[?_  H ] HKS_\ X2WXA_\ 1,/_ "OV_P#A1_PE
MOQ#_ .B8?^5^W_PH ] HKS__ (2WXA_]$P_\K]O_ (4?\);\0_\ HF'_ )7[
M?_"@#T"BO/\ _A+?B'_T3#_ROV_^%'_"6_$/_HF'_E?M_P#"@#T"BO/_ /A+
M?B'_ -$P_P#*_;_X4?\ "6_$/_HF'_E?M_\ "@#T"BO/_P#A+?B'_P!$P_\
M*_;_ .%'_"6_$/\ Z)A_Y7[?_"@#T"BO/_\ A+?B'_T3#_ROV_\ A1_PEOQ#
M_P"B8?\ E?M_\* /0**\_P#^$M^(?_1,/_*_;_X4?\);\0_^B8?^5^W_ ,*
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M/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\
M!S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'
M_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\
MR+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;
M/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\
M!S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'
M_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\
MR+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;
M/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\
M!S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'
M_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\
MR+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;
M/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\
M!S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'
M_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\
MR+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;
M/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\
M!S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'
M_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\
MR+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;
M/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\
M!S-_\BT?;/&'_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'
M_0#T/_P<S?\ R+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\
MR+7044 <_P#;/&'_ $ ]#_\ !S-_\BT?;/&'_0#T/_P<S?\ R+6GK%Y/I^C7
MMY:VCW<\$#R1VZ?>E8 D*/<U@>!O$=SXDLI[F2^L+V%7(62VA:!XVW$&.2)F
M8J0 ""3R#TXR0"Y]L\8?] /0_P#P<S?_ "+1]L\8?] /0_\ P<S?_(M=!10!
MS_VSQA_T ]#_ /!S-_\ (M'VSQA_T ]#_P#!S-_\BUT%% '/_;/&'_0#T/\
M\',W_P BU6LE\5V$30P:)HHB+EEC;6IB(\]0O^B\#.>.V<# P!U-% '/_;/&
M'_0#T/\ \',W_P BU'/)XLN8PDFA:*5#!L+K<ZY(.1G%MR/;H>]=)10!S_VS
MQA_T ]#_ /!S-_\ (M'VSQA_T ]#_P#!S-_\BUT%% '+1IXK34)KTZ+HTDTB
MA 7UJ4B-!_"H^R\ GD]R<9.  .E@:9K>)KB...<H#(D;EU5L<@,0"1GO@9]!
M4E% !17G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4 >@45Y_P#\
M*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'H%%>?_\ "DOAY_T+W_D[
M<?\ QRC_ (4E\//^A>_\G;C_ ..4 >@45Y__ ,*2^'G_ $+W_D[<?_'*/^%)
M?#S_ *%[_P G;C_XY0!Z!17G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)
MVX_^.4 >@45Y_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'H%%>
M?_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_ ..4 >@45Y__ ,*2^'G_
M $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!Z!17G_P#PI+X>?]"]_P"3MQ_\
M<H_X4E\//^A>_P#)VX_^.4 >@45Y_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7
MO_)VX_\ CE 'H%%>?_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_ ..4
M >@45Y__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!Z!17G_P#P
MI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4 >@45Y_P#\*2^'G_0O?^3M
MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'H%%>?_\ "DOAY_T+W_D[<?\ QRC_ (4E
M\//^A>_\G;C_ ..4 >@45Y__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G
M;C_XY0!Z!17G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4 >@45Y
M_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE 'H%%>?_\ "DOAY_T+
MW_D[<?\ QRC_ (4E\//^A>_\G;C_ ..4 >@45Y__ ,*2^'G_ $+W_D[<?_'*
M/^%)?#S_ *%[_P G;C_XY0!Z!17G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>
M_P#)VX_^.4 >@45Y_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE '
MH%%>?_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_ ..4 >@45Y__ ,*2
M^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!Z!17G_P#PI+X>?]"]_P"3
MMQ_\<H_X4E\//^A>_P#)VX_^.4 >@45Y_P#\*2^'G_0O?^3MQ_\ '*/^%)?#
MS_H7O_)VX_\ CE 'H%%>?_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_
M ..4 >@45Y__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!Z!17G
M_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4 =U=PR7%I+%#.UO(ZD
M)*@!*'L<'@U@^'?"\FDZMJ&K7D]I+J%]A96M+7R$90S$%@68L_S8R3T ';)P
M_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'* /0**\_\ ^%)?#S_H
M7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@#T"BO/\ _A27P\_Z%[_R=N/_ (Y1
M_P *2^'G_0O?^3MQ_P#'* /0**\__P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"
M]_Y.W'_QR@#T"BO/_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*
M.TL-,M].,WD27;^<^]OM%W+/@_[/F,VT>PP*N5Y__P *2^'G_0O?^3MQ_P#'
M*/\ A27P\_Z%[_R=N/\ XY0!Z!17G_\ PI+X>?\ 0O?^3MQ_\<KM["PMM,T^
MVL+./R[6VB6&%-Q.U% "C)Y. !UH LT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>interim2_007.jpg
<TEXT>
begin 644 interim2_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 90# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W*XUC3+2_
M@L+G4;2&\N/]3;R3JLDG^ZI.3^%36E]:7\;R6=U!<(CM&S0R!PKJ<%21W!ZB
MN'^*WDZ=H^G>)%NHK74=)O8WMGD8#S Y"R1]>05))'^S4?B[7=6TJ;0K#1+V
MRM[>^CD<:C=3*D4DWRE%+^7(#OW,=H +?PL* /0Z*\X;Q9J"_$*SL#JA^RR7
M+6=U:^2J1PO]F$H*LR[V.3U) (XV<9.A\.M2U37]&@U:ZU\7\2M<6[Q+#$ S
M+,=CED P=@Z 8(8' [@';]*K66H66I6_VBPN[>ZAW%/,@D#KN'!&0<9%>83^
M*=6NTUNVNM1\M19ZC]KA\M%_L[RWVP<D9'F(2?GSNZK@5?M]4N- ^"NG:IHW
ME7-PUM;--/A<#=L61V*J1E%R,E6QMY#8- 'I-%>5:MXGU?2]%T>^O/%=FH:4
MK=?8I(9O,M6;8MPK-",LA9,E5"'T[4V'Q=JW_"<R:?#KYN[4:DENL'EPG-LU
MJ)&FW*@/RM@[ON\X.<C !ZE;W-O=P^=;3QS19*[XW#+D$@C([@@@^XJ6O'O#
MWBJ[GL/!MM;>(;:!M1N[Z"Z$45N-Y!<HVT* &R4/& 2W(.:U!XDU>V\;66D-
MKTEVGG-I]T#:1PJ)1:B0.O!)8MS][;S@+QD@'I$ES;PS0PRSQI+.2L2,X#2$
M#)"CN< GCL*EKQKP_P"(+M$\#R76MK?75Z]ZTL-TL!990C852$#J=QV\'/S$
M>@IMQXZUY?"E]?+K:K+';V4K3F"("WNI)"LMM@KCY5&=I^=>[<T[ >ST5RG@
M?7+C6!KEO<WR7CZ?JDMLD@"!O+ !7<% '<C.!T[G-=72 **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .?^V>,/^@'H?\ X.9O_D6C[9XP_P"@'H?_
M (.9O_D6I_$5UJUA8/>Z:;1DME\R6&>-F:<#JB$, AQT)#<GI51]<U :P L5
MO_9YN_L(1E82>9Y>_?NSC;GY-NW/\6[^&@"3[9XP_P"@'H?_ (.9O_D6C[9X
MP_Z >A_^#F;_ .1:K-J^N6<MY8W(L9KKS($M;B*!TC'FDC#H78DIM+'##<"/
MN]:U]$OY[^Q<W2QBY@FDMY3$"$9D8C< 22 1@XR<9QDXS0!1^V>,/^@'H?\
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M:+ R(3D$GYB[\+EF./E&%7G.II.FS6(N)KRYCN;VY</-+'$8D.%"J%4LQ
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M-NXCGMTJPNF>+%N7N!KFB^8ZA3G29R !GH/M6!U[=>,]!4GV/Q?_ -!W0_\
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M_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\
MA._!_P#T->A_^#&+_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T
M->A_^#&+_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+
M_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"
MBN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"BN?_ .$[
M\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"BN?_ .$[\'_]#7H?
M_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#B
MJ/\ A._!_P#T->A_^#&+_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!
M_P#T->A_^#&+_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_
M^#&+_P"*H Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*
MH Z"BN?_ .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"BN?_
M .$[\'_]#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"BN?_ .$[\'_]
M#7H?_@QB_P#BJ/\ A._!_P#T->A_^#&+_P"*H Z"LW6X;F;393;ZK+IAC4N9
MXHXV(P._F*PQZ\9]Q5'_ (3OP?\ ]#7H?_@QB_\ BJS=8\3>%-5AACC\?Z?8
M>7()-UK?VA+D= PD#C //3K0!MN^LW'A5'@CACUB2V0E7D\M4D(&[!*OC'.,
MJ1G&167_ &AJ4>BZ+*EW<"1[](+P7L,9F8%RK)F,*@P>-RJ00..N:H_\)-H)
M$L ^(]C'$88U2==1LVE#@DLV&0J"W /4>@7'*WNM>"[NRM+5/'.G6PMKA;GS
M(=0M2TK@EOFW!ARQR< ?@*8=#?GM;Y?$%K,FM7GDNS,]CY</D[ N.OE^9]XK
M_'W].*S->UV\M]>@M(Q>0:= T)N[JVAC<[I&PJMO^ZG3<55F^8?=P34LGC/P
M>TS3KXMT42^48T_XF,.%[Y')Z\>O0<5BC5/!]RUM<7WCG36G\N-;R--3MO+N
MV0[E+\#HV>4"9Z$8X" Z6UGU&XUO7+*2]18XUA-L8X0#"&#9ZD[FR,Y/'3CK
MF3P\U\(+R&]O&O1!=-'!=.B*\J #[P0!<ABR\ ?=Z9KGGUSPD;[4[N/XA6<,
ME_&D9$>H6F(-HP#'E2<\G[Q;K],6=(\4>$]*M3!)X\TZ^Z!7N=0M054# 4",
M(N/PS[]* .PHJGINK:;K-NUQI>H6E] KE&DM9EE4-@'!*DC."#CW%% &7_P@
MGA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%3
M0_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70_
M_$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X
M0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__
M  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q
M-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_
M /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_
M *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\
MP70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?
M\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%
M30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70
M_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!1
M0!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@
MGA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%3
M0_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70_
M_$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X
M0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__
M  70_P#Q-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q
M-=!10!S_ /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_
M /P@GA#_ *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_
M *%30_\ P70__$T?\()X0_Z%30__  70_P#Q-=!10!S_ /P@GA#_ *%30_\
MP70__$T?\()X0_Z%30__  70_P#Q-=!10!3TW2=-T>W:WTO3[2Q@9R[1VL*Q
M*6P!DA0!G  S["BKE% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>annex-d_001.jpg
<TEXT>
begin 644 annex-d_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2X Z # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5O&S!%+GEV/15'4D^@YJA>>+=%T^WMYKJYFC^T1F6.(VLIE\L=7:,+O51W+
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M3[^],>SLYM5@U#*_:H8WA5E8<JQ!(/KRH-8>B^,;2YLTMM<QI>J(NVXMKO\
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M3[0MP1TAWH NX]LUK%)-\O5/\C&3;2YNC7Y_Y'H]<'X$ _X2WQOQ_P Q)?\
MT$UW#SQ);F=I%$2KO+D\!<9SFO// &J6<OB_Q:JSC-W?"2WR"/-4*02N>O2L
MX)\LOZZFLVN:/]=#T63F-L^AKR;PW9W_ (+TBP\0V*O<:'>6D<NI6H.6A?',
MJ#N/4>E>HZA>VVG6,MS=RK%"B\LQKGO -Y::GX&TZUW*[Q6JPW$+=5XP0P_
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MM,ADCM))[3[2)TD?)AEC500IP.<+M&,D8KTRBJE)MM]W?[]02L<KIOB74/\
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MB@   Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !534WEBTNZ>&U^URK$Q6WX_>G'W>>.>G-6ZS];TK^V]'GT[[??6'G;
M?])L)O*F3#!OE;!QG&#[$T,$>>:;X6BT?QI87/@^WU;2XGGSJ]A-$ZV@C*DD
MJ6^1GSM \MF ]A6/<Z9JEK\._'^ER:/J3W=WJL\MO'%:/)YJR,A5E*@[A@$D
MC.,<XKJ_^%6?]3[XY_\ !Q_]A1_PJS_J??'/_@X_^PH>UOZW3_0:=G?^NO\
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M ,''_P!A0M&_,?2P[6K2^A\?Z9XAN+&YDL#I<UH\4,1G:&5F!&Y4!/S#@D#
MQR<5P^AZ1K%C??#4ZCIFI.+&*[>X/V*5Q;+)GRE8A3@C@8ZCOBNV_P"%6?\
M4^^.?_!Q_P#84?\ "K/^I]\<_P#@X_\ L*%I_7K_ )C;O_7R_0X*"SU./X-6
MVF/HNL_;5UH2_9QILY<1B4.6QLX&#^?'6MO5+#5=8\:>-3IEAJ,1U#0T@M+B
M6SEA220 $KO90 <''./TKHO^%6?]3[XY_P#!Q_\ 84?\*L_ZGWQS_P"#C_["
MDU?^O)+]!=;_ -?$Y?J846F:G>Z_X-NM.T.^MX[+29K.XDDA\G[/(8PH!W[2
M0&!.1G.<C-1^"_#US9^'1+JG_"0IJ^EV5U;-:/:#R2'R2498LS;B%(PS'-=#
M_P *L_ZGWQS_ .#C_P"PH_X59_U/OCG_ ,''_P!A3D^:_G?\6W^K%%*-O*WX
M67Z(X?PIIFI6=]\,@^C:I#]A2[2]+:?,HA,A(7>=N!D]_P :=J^D:M%\.?'&
MD'1=3DO;O7'GMTBLY)/,1I$8,I4$$85N1TQ@X) /;?\ "K/^I]\<_P#@X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.?4KZRN;I+6SU%-1,@!"X$<T/ W$@Y=02>Y%>@T=+CZV"BBBD 4444 %%%%
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MD'E,J!CG!#IP>&(&,<D<9T;GQA8V%I"+>RU&^*V:7<L< 622" CAY"SC)X/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,XYZUIOX;O\ 5-1GU76+/2VN)+,6(LA*\T+1&0-(68HI)(' VX&.^:ZHM/\
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M>3P*ICM4.<,Y+ G@$X4,0.2 *WD=9$5T8,K#((.011Y@+1110 4444 %%%%
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M];_YDVM_7I_D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@*,8XQ5S:<I/O?\ &UON(@FHQ7:WX?YF1\.IH#8ZM:Q6=SITD%^XDTV8 +:
MJI5$VDC:1AN.,L<<5V=4M.TN'34F*/)+/._F3SRD%Y6P!DX '0 8  &.!5VD
MQH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@?-R*YF&^U'0XO$6I6-\T4</BA(GMO*5EE1S"C!BP)Z-D%2.1SFFE>R[K];
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6H&WN8M0BD6*00BX2)ML<I* -EE(.01T!&._8_#R^N;_ ,'0O=7$EQ+%<7$
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M!7[*D"B+!Y(V 8Y^E&FZ/I>C1-%I>FV=C&YW,EK L0)]2% H6U@>]S"D8O\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "H;IKA+25K6..6X"DQI+(45F[
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M =KOB;0I=?L[:&&\2W>WN4N,2P>=%+MS\KIN7<.<]1R >U.=G+W=KBC>VO\
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M24@:66]MX':65D(5Y%7@A3US@GL"3STJ35O"<FL:II]S<7L'EV5PMQ&XM/\
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M#>QP_87<F&:W\Z.3< ,@;AAQ_"W.,G@YK&'@.Y/@]/#<^HV-U:JACW7&F[\
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M2W>XN9HX84&7DD8*JCU)/ KR#4;:^A\(^)[0Z=J]Q<7.NQ7$6W39"TJ9A<N
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M-WNKZ0=8OKV._358Q>VPBEED7 D5(A'&5W)N7&T9)J5Y^7Z?Y_@RGV7G^O\
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M557F"*N%)W$GL6 4>I(JEX6\8+JL<T.L3:=9ZC]OGM(;6.?F3RC@[=V"_?D
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M5+JRN8;FWD&4EAD#HP]B.#7F&A6.I6?AKP9+<Z;?"#19Y?M]N;9C(&*NJNJ
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M%$\:22HC2-M0,P!8XS@>IP#69IMY?7FJZD7EMFTZ%UBM]D3!RVT%B6W$,,G
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MT [O1_UN-=UT_P" ;5IX7:RTZ2QCUW5FAV>7;F1HF:V7IA28_FXXR^\UF_\
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MMH7F!0=7.P':O;)P,\4W4/%NAZ5(B7E[Y995=F$+NL2L<*TC*I$8)Z%R!1Y
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MB53(4VGF*,! 0 ,N=HP.1SF[YGBNT\F6X_LN\22>-)(K>"2-H(RP#'<7;S,
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M_P#F<)J.EZQ=^.]8GCTF<6-UHIL(KMI8MADRS?=W[P/F SMZCICFJ)T#6?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY,"=V;!8_D 35&7Q$(6N!)I=\OV>=8Y.8N$;.V7_ %G*G'0?/R/EYKR+3_[
MU&U\.M,FGWEA9^)+RW&Y$E2.!A*8D[_*3MVCH?EQVKW$6MMCBWB W^9]P#YO
M[WU]Z+:7_KH_U$][?UU7Z(FK#TCQ"VJ:_K6E-826S:8\:[WD5O-#@D, ,X&
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MX[J.5D#VY^29!]UPI)*Y_NDDC'4UI4M@W&2RQP1/+-(L<:#+.YP%'J2:<"&
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MW>^'H+&QL;5-5M[EG>X9Y&AEA.U@%&T,N[&/F!(S]WO35G;^NO\ DR4[J_\
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MUQ.N^)=>TE9;R%=-N+ ZI!91[HY$=$9E1SG<0Y#,1_#C:3STJAJGC7Q#9_\
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ME:+9SX,!Q&,\+F(D'YFY_P!H^@Q-9^"H-/-H]EK&IV\T$"6TDJ&+-S&F=BR
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M+H%WQXVN-R$@C:.,[?:B^\#6=\=9/]IZE!_;$217?DO'AMJ["P!0X)7@]NX
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MJ^ISIIEHUG##+Y&QXF&"KXB!.0%&01]T>^6P_#O38FTU7U'59K?3)3)96[W
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M6SAMVFDG,:!#++MW/@8R=H S] !4U%%^@!1110 4444 %%%% !1110 4444
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M4B*%P%8AB<9.,=B.O%>NT4[ZW_KI_D@\OZZ_YG%Z<P_X2K5/%"6=[;:8UA%
M5:RE6:>178EO)V^9P"!DKD]N!6EXNE%WX*NY;6P.J)-&C+ @=MZE@=VU2&;
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MOI_P62DU!+K_ , C\,W<NA>%-7_LR.QMU7Q!<P*T^$AMT,N-VT%=V.,(I!/
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M[74]#N=(N3*UM<PM#(0_SD,.3GUK%/@>$M=R'7-6,UW8K832DP[FC4D@X\K
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M4D[L[D(&<XRH&!C&,5J6EK#96<-I;ILA@C6.-<YPH& /R% =2:BBBD,****
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M*N(]BL^]W0%6)8[<,O !PP-5+'PUJLNC^'/#UWI[PIHEU#,^H&6,QS"+./+
M8OEN,[E7&3R>^MX5BU2'Q'XCEO=%N[.WOKI;B":66%E8+&D>"$D8@DJ3TQCN
M#Q5)*_W_ *?\'0'M_7G_ , W]5UFQT6&.6^E=?-?RXDBB>621L$X5$!9C@$\
M#H":SSXW\-B+3I/[6A_XF.X6B ,7E(SD!<;@01C! YXZ\5%XJMM3N+C26L+-
MKB&.X8W#0F)9XE*$ HTA 49.&*G=@G%<?IV@^(+"#PI:MH%VXTS5;FXGD%U
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M#+Y,B/!(DJR=D,14/N.1A=N3D8%<1J'AW7M5UWQ#=?V1=V\,UU9W-OF\2(W
MA&UD#Q2;D)SE3QT&<59D\*7%O)8Z[H^A7D5W!?)=7-G?ZCYT]R!&\?WVE= 0
M&!7YAG'..*2UW&_(V?!?B"\UW4_$:7%T)[>TO%CMA]F,!1#&&VLK?,&!.#NY
MR.@Z5M:MK&G:?=Z?:7>J"SN+N8+!$,%IR.JX(/R\C)&,>HK&\)V&KV_B/Q)?
M7^FK9VNH7$4\&^X5Y.(E4AE7('3KN//J.2WQQ:ZI<W?AV33=(N=06RU);N?R
M984VHJL,?O'7).[CMP<D4W]GY!_-\R]:^.O#5[)"EIJB3K-<&U26*)VB\W^X
M9 NT$]LD9[9K=N9TM;66XD61DC4N1&A=B!Z* 23["O*CHWB4^'I+?_A&+[SW
M\2#4]GVBUXA\X2=?-QNP,8]?;FO5V!>)AC!9>A[4G\%UO_P$_P ] ^UY?\'_
M "/.7\?W6H:=X8U>SE-G97VJ"UNHI[-U9D.XKM=N#PH!*@Y)P",8KL(/%6C7
M&F2:A%<R&&.8P,AMY!*)1U3RBN\M_L[<FN$M-"\1V?ASP;IKZ!<22:3J(FN6
MCN(,;%WC<,N,YW@@=< YP< M?PUKUY?:E>RZ/?Q1IK9U"*!+]()+F)H/*(22
M*7*.,;L$@$'&>3AZ;?U]G_@@_P"OOE_P#TG2]6L=:LA=Z?.)H=Q0DJ596!P5
M96 *D=P0"*BUW4GTG1Y[J&,2W/$=O$>DDK$*B_0L1GVJKX7T>UTBRN#;:=<V
M/VJ8SR1W5TUQ,SD %G8NXSQV8CBL_7++5M:\46-JD6HV&FV8:==1MFMF#3%<
M ;9-QP 6'W,Y(Z 9*:Z($^I8\/\ BRWO_!D>NZJ\-B859;X,<+!*AVNO/N./
MJ*?#XX\/7'E"&]DD,UO]I@"6LI,\?K&-OSD9Y5<D=Q7(PZ3XDT"\\5:?;:/J
MFKZ=JB&2&Z>:S1OM#(5<E0Z *?EYV@Y!X/4RZ5IVOV^H^"I)O#MZD>E:;+;7
M;>?;':[(JC&)>1\F?H1WR ]]?3\G?\5^(;?C^EOS_ ZY_%^AKI5KJ2WCRV]T
M2L AMY))'*YW 1JI?(P<C'&#G%9=YXDGN/$GA-M*OX)=&U4S;PL66DVQ,P.X
MG@9QQ@'(Z]JYW1-'\2VNFZ7:SZ#<P1QWMX\[)/;>>JRN60J^\[4PQ#;2'XXR
M.IH^B^(-/_X0B&7P_=[-(>X%W*+F A0X9%(S)ENH8\9QZGBA?$OZZ,'L[>9V
MK>,_#L=XUK+JD4+"0Q"2<-'$\@."BRL C,#P54DCTIT'B_0KC5?[-COO](S(
MJEH76-RGWPLA78Q7G(!)&#Z5P>E6E\MQ9SW-AJ"Z!9ZE-?6KP1P$ NS@,9//
MWO'\[' B!Y') YMVNB^(4UW1M0N=&GS8W]T\L<$\"0B.1'"M%&& .21DM\^2
M>QH72X/2]CJ8/'OABZ6WD@U5)(;B5H8IEB<Q-(O5=^W:#QP">>V:G3Q?HCV$
M]Y]KD6.WF%O)&]M*LRRG&$\HKO+'(P O.>,UP4&D>)8_#5A9GPS?">'Q"=1=
M1<VW$/G&3KYO7#8QZ@]N3;FTWQ*NM:Y/#X>N/(NM5@N5D,EJ9#$D81FBW.0K
MY4$%L?*3@AJ$OZ_\!_S?W _Z_'_)?>;^I_$/2K2TTRXLQ=727U\+3,=G,QC(
M/SAD"[@X .%QNSVP#6G:^)=&F?59X]966*Q94N5; 2V;'W<[0<D]022#QQTK
MBH/#.O6]M;;=+F=K3Q,VHA7NHW:6!@PW!BW)&[D-@\'&:?<^'-?U74O$[-I<
MMFMU?6=Y:O+/$4G\C9E#M<LN[;P2.F,XZ4EY_P!?#_F_N!_U]\O^!]YUK>.?
M#<=E>7=QJ0M8[/:;A;N&2"1 WW3Y;J&Y[8'/:KNF^(M*U:]FM+*Y:2>*-965
MHG3=&WW74L '4X/*Y%</XJT+6O$$.LZI!H5S#=7&D-ID-F\T'F.S/N+L1(4"
MC Q\Q/)XK4TNTU@_$&WU&?0[NVL1HR6;3230';(&WD$+(3CMD#K[<TTN_P#6
MC_KYB?E_6J_S?W'<$X&37)>&/%\VM^(-3TZYMHX(T1+G3F&<W%L25WGG^\I/
M;AEJ]XP?56T*2TTG3[JZFNB(9'MI(D:&,\.X\QE!;;G ]<9XKEM4\-ZYHGB#
MP]K&D'5M<:T#6\T$C64*I;,N"HVK'DY"D#D?*>G=1WU]/Z_KN-[:?U_7^1UM
M[XOT'3;V2UO=12W:(A999$80Q,1D*\N-BL1@A2P)R.*A3QSX9EU$Z?#J\$UR
MLB1,L(:159\[064%1G:>I]/45Q5[8ZE>ZIK*1:;J!T*?48[JX^S+;NQDB"%B
MLC7"E?F0!@$;E3AN>-W3=/U&_P#%7BFZ?3[FTL=5LX8K6\=XB&VHRYVJY89W
M@C('0YP>*.E_+]!NU[?UN=!:>*]$O;N2UAO@)$B,^9(WC5XQU=&8!74=V4D"
MJTGCKPU#;7<]QJ:VT=HH>7[1#)$=I.%90R@NI/ *Y![5R,'@.2_T-[&YTJ^M
M-5@L9+2*_N=5DN(/F3:3$AE8J#@9!5<#ITIFJ>%+JZ\,:J]MX7U0:Y/8/8 W
M6L?:=P;'W#).P"9&>=K>W--V$O,[0^-=!\R:,7<KR11+,8TM)F9XST=%"9D7
MW7('>I[CQ3HUMIUM?F[,MO<Q^=";>%YF=.,L%12VT9&3C SSBN76#7#XNM]2
M/AR_%M'H;6C?O[;/G$A@N/-]MN>F3Z<UCZ3X5UBVTCP_)?Z-JCFSL&L+FSL]
M4%O,IW!A(K1S*KJ>006!X'%#7;^M7_DOO$O/^M%_P?N.WD\<^&DG$":K'/,;
M;[6(K9'G<Q<?,%0$]"#CKCGH#52X\;V,NO:7I%D;J1=3M&N(KR"TDD4*=H0@
MA2/XLDGA<#.,UB6NA7^B>*(&TSPQ=KI5KHTMG$([J%_G9Q(%S)+N[8R>,GTY
MJ'PKH&OZ9-X1GNM(>+[!IL]C=*UQ%^Z9F0A_E8Y4A3TR<XR!UII)_P!?XO\
M) VTOZ\O^"=GH6JS7DU_IM[L_M#3I%CE9%VK*K*&20#MD=NQ!K:KB]/NS;ZK
MXD\4+;2SV,IA@B\DH#)'$#OE&YE!4%V'7D+P#QGLU(90PS@C/-+HF/JQ:***
M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5>]LHM0M'MIGG6-\9,$[POP<\.A##\#7/_ !!O
M]0TKP?<ZAIEY):W-O)$P9(T?<"ZJ5(93Q@GI@\=:YGQ=XB\1:/J/BE=/U8".
MTTF&^@2>VC<1,7=6"X"GD*/O%L'/!H6O]>C'U_KO8])M[>&T@2"! D:#A1_G
MK[U+7GFM>)M8\*7ER\UVVIP2://J"1R1(A@DBVC V $H=_\ %DC'4T^\U+Q'
MI&H:9 NKB]75[2=PUQ:IBTE2/S RA I*=L,2>GS>H]%=_P!;_P"3$M?Z]/\
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M<=HR<9/I7GDOC"Y-A:6>GW&JW=]<WWV.5);:"&\MB(2Y&U]D18[<@D;<'@'
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MU_K?_(E-=/ZV_P T3T444AA1110 4444 %%%% !1110 4444 %%%% !1110
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MS_K?_)BZ7_KI_F;-_P"!/#NI?:OM-E+B[G%Q.(KN:(/(,?-A'&/NJ>.I4'J
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M:_0$^W]=2:W\#>'[6YL;B.VN2]A";>V$E].ZI&>J;6<@@],$'@ =AB./X?\
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MC&2!UI+?^O/_ "![?U_74[&3P)X:G=FGTM)E-R;L12RN\:RG.65"VU<Y).
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M)))0$D_2A+0'O_7D24444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGHIWTL 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^2 0#D#I7)ZTEG<W?B:/Q0L$.L$ Z*OF;I% A7'V5L!BWF9SM )XR.E>K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKQG/!'&#0NE_Z_X8-T[?U_PYT.H^,9;?QS8>%['3DN9+B-I)[B6X,20A<$@
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MS G=&T4AVL!C*CMSQ61<:+<^%["V_P"$=_M6XN([6.T%G?6)N(KV(,Y57=5
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M?4K.*^F_U5L\ZK(_T4G)_"N9U+QC)/XKD\.:'J6B+?P1)(T=[*6,SDMF%=K
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M,EB50*2YRW [GN:;5B;_ -?U_6A)1112&%%%% !1110 4444 %%%% !1110
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M-S</PD4-[&[M] &R:V:\2NUUBX^#;Q/I5@=)BDDDDNDNRUQ%&L[,SI$45=X
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M"D@G(XYIJ^W]?UK^(/\ K^OE^!#>^"]!U"XNI[FSD+W3I+-LN945G0@J^U6
M##:/F !P,9Q6\% 7;SC&.O/YUDKXGT=]633!=_Z3(S)'F)Q'(Z_>19,;&88.
M5!R,'BKFH:E::5:_:+R7RX]P50%+,['HJJH)9CV !)I=/(.IDV_@C0;:VU&W
M6VN9(=2!^UI/?3S"4G&6.]SAN!\PP>!S4<_@#PS<B8S:<\DLUN+:6=KJ8S/$
M/X3)NWX/0\\C@Y'%1:OXWT^V\'ZIK>G-)<O9(ZF+[-+OCE"Y"R)MW(.F2P
MYS5KPLU]<V3WMQJUU>P7"JT4=Y8?9I(6_B&-J$KG&,KG'\39HMO_ %_6@>8D
M'@W1;&^L]0@@O6NK"$PVQ.H3MM3^YAI-I!XZ^@]!2Z1I?F>(+WQ%<:<]C=75
MO';"*5D:0(A8Y8HS+DENQ/"CZ5BZ7JWBS4;[78)-6T&VCTJZ\@R/I<I#CRU?
M<?\ 21M^]COTI-;\3^(_"]_83:E'87NEM 9;_P"QV\BR6P78K2*3(=ZAGSC:
M"%]<4^W];A;=+^K'<NB21M&ZAD8$,K#((]#7.P> ?#-O+;2)II+6C,UKYEQ*
MXMRV,^6&8A.@P%QCMBH+K4/$%YKT=OHVJ:,+&XLS=0/+8R3$@%1C<LR@@[LY
M 'T/6H-%\0ZQ=^!K_4M0FT^+5K5IHWCCMG$<,D9(V%3)N;)&005R&''JN[_K
M>WYA>^G];7+$?PY\,Q1P1I;7P2WN#=1+_:EUA)3U<?O/O=>?<^IJW?\ @KP]
MJ<]Y+>Z?YWVPHUQ&TTGERLF-K%-VW<, 9QG''2L-]1\:PZ[I&E3ZAH*2W]M+
M,[+IDS"%H]F5_P"/CYOO]>.G2M7PMXAO=4U'6=+U".V:YTJ9(FN;3(BFW+NX
M4DE6'0KDX]:=OZ^Y?Y!Y^GZV_4FE\$^'IH;Z'[ 8XKY%CN$@N)(E=5 4 !6&
MWA0#C&0 #D58D\+Z//HUII,]H9[*T=)((YIGD*,ARIW,Q8X]STXZ<5F^)]4U
MZPUW1+/2[K38H-2F:W;[59O*T;+&\FX%94!!VXQCWSVJCIOC2_-AXH-[:0WL
M^@YQ-IZL(KKY-^U02Q5AT(RV*5]+_P!:?\.%M4OZU_X8Z74_#^FZO/;W%W%*
M+BWSY4\%Q)!(H/4;XV4X.!D9P<5H11)!$L4:A448 ':N4T37-8UBULKJUO-'
MO[2]#_Z3:1/BU.PE59=YW_,,$Y3TP,Y$GA#5->UK2+^XU"XTT3)<SVT'V>T=
M54QNR;F!E)8$@' *XZ9[AV:NNPKWU-*^\+:-J5\UY=69::10LH69T2=1T$J*
M0L@'8,#4-_X+T#4Y[N:ZLG9KM46<)<2QJ^S&TE58#<,##8R!QFJNB^(KB/2H
M)]>N;>6ZNIY(X(M/L9<X1BI.T-(Q'&2W &1GUKH4O(9;%;V,N\#1^8I5&)9<
M9X7&<^V,TMD-:E ^&M+:[AN7AF=X6,D:O<RLBN?X]A;;NY/S8R.QJK9>"M#T
MZWF@M(KV))I6F<C4;@MO8$,P8R;E)R<D$9JGH/CW3M6T ZK.MQ;*UQ)#'&]I
M+ODPS!0B[<R-M7)"9P<CM6]I6L6&MVK7.GW FC5S&X*LC1N.JLK ,K#T(!HL
M!)I^G6FE64=G90B&"/.U02>2<DDGDDDDDGDD\UFZGX0T/5[FZGO;-Y'NX1!<
M!;B1%E0=-RJP!([-C([&I-4\4Z-HMSY%_>>4X"LY$3NL2L<*TC*"(P3T+$ T
M7?BC1K'4([*XO-DKR+%N$3F-7;&U6D V*QR,!B"<C%&^H;#(?"6D0:VNL(EY
M]N$8B\QM0G92@'"E"^TCO@C&>>O-1CP5X?338M/CL6CMX93-#Y=Q*CPMSRCA
MMR=3PI P2.E9VJ?$WPOIMK>R1W[7DMJSQM%:P22_O%4L5)52!P#R3C@\\&K,
M7CC28]#L-0OY+B%[J#SO*%C.7 4#>VP(6" G[Q&WD<\T+57_ *[A:SM_78N?
M\(EHYU6RU,Q7)O+)2L$AO9N ?O9&_#$]RP).!G.!6V0""#R#6!)XHT+^TX8_
M[>B5OL37AA5E*-!P?-9L9  Z?, <G@XX=IWC+0-7N;2"QO\ SFO$=[=Q#((Y
M=OW@KE=I88Y7.<<XQ3MT#S&6G@K0+&>UFMK.1'M'=K<?:I2L>\890"V A_N?
M=]JJ3^"O#NG1175OX?EOGLY?/M;1)RPC<GK$DL@C3UP,#CUQ5KQIJ&MZ5X?>
M]T%;.2\22-1!=1,XEWL$"@JZ[3EASS].],A\6P7?@B+Q#:Q%WFB'EVYX8SD[
M1&???P:5]&^P[;7ZE?2O"D-SH=Y;:U;-_IFHRZ@(EF*O 6?<GSH00PP.5/7.
M":O1>#- @GN+B"P,-S<L&EN(II$F8[2N?,#;LX)[]3GKS61X:\9R2^#=.UKQ
M'/;K<:AEH8-/LY6; SE0@+LY&"20  .W&:VY?%FB1:;:7XO#-;WBE[?[/#),
M\BCJ0B*6P._''?%-JV@D[B)X1T*/["5L<-8N[P/YK[MS_?+-G+[NIW9R>35-
MOA]X<>QOK)[:\:WOY1/=(=2N3YKCN?WGY^N!GH,3-XN\.W;Z>EKXBMF:[N!'
M MK(DIF88)C/#8ZC/0C(Y%3R^*='35!I?VX+=O(84+0N8O-QGR_,QLW]]F[=
M[4M?Z^7_  /P"_\ 7W_\'\3%U_P3:?9KF]TRRN;K4)HXH)1)JDX:2!6!*J6<
M@-@$@G'S'.0235[P]ILT%Y]J6VUBQ@,;));ZGJ;7;.V1@@&615 &>0P)SR.*
MI>$/%>I:EKFJ:)KD=JEY;.[VLMM&T:7$*N8RVUF8@AE.1GN*9I_BW4M4^(=[
MI,(LX-%L[;SC+)$S23D.R,5;>%50RGDJ<[3ZY#7YZ_U_6X-?@=/K&C66O:;+
MIVHI+):R\2)'.\6\>A*,"1ZC.#5.3PGI$MK:P-'=_P"BJ4AF6^G695)R5\T/
MO*]."Q' ]!3K/Q5HM]-/%#>A7@B,[>=$\0,7_/12X =/]I<CWK!LO%DNI_$F
MWTVSO"^EOIDD_D/9O"V\.@#[G +*03@J IYY/82UL'2_]=#</A+1?[3L-16V
MECN-/C,=KY5S*B1J>HV*P4Y[Y'.!G.*VF4,I4YP1C@X/YBLS4_$6D:->6=IJ
M%]'!<WC%;>$Y+R$#)P "?_KD#J:I1^-_#TJ0NM\X26?[/N:VE41RYV[),K^Z
M)/ #[<]J6^@;:DUIX1T6SLGLTMII;=[A;EDNKJ6?]Z&WAAYC,0=W)QU/7-,G
M\&Z'=:Q<:K/;W$MW<1&"8O>S%'C((*&/?LV\GC&,\]:D;Q9HB:PNE->$732^
M0/W,GE^;C/E^9MV;\<[=V?:J\7CKPU/)L@U1)@+H6;211N\:S'&%9PNU<Y !
M)P3P.:-_Z^7_   O;^OF077@VQLM.N9-&M"VHBQ>S@-S>S,K(>B,69L@'ID'
M'; JAI7ALW$<4#V'B#38%0Q7"WFN23"5"N-J!)W YQ\WR$8XZXK>;Q9HJ:RN
ME->$732^0/W,GEF7&?+\S;LWXYV[L^U,G\9>'K2\>UNM4BMRCF-I9U:.'>.J
M>:P"%_\ 9W9]J-_G_7ZA_7]?<,3P3H$>EV>G):3)!8DFU9;R82P9ZA)=^]1C
MC ;&.*L?\(OI?]J6NI;;L75LI6)A?3A0"<G*;]K9."20<X&<XI7\4:-'JJ::
M]YMN)',:$Q/Y3..2@DQLW_[.[/M5*+Q[X7G5'AU:.2%YS;"=(W:(2?W3(!M4
MGMDC/;-.[>H6)[_P;H6I:7_9MQ9N+(SM<&&"YEA#2,VXL=C#/S'//0XQTI\G
MA72);N"Z:*Y%Q#$L/FK>3*TB#HLA#YE'7[^[J?6G0>*='N(+R9;MD%G((ITF
MADB=&.-HV,H8[LC&!\V>,U5?QUX:BL1=SZK';QFX%J5N(WBD64_P&-@&!Y!Y
M'3GI27]?D _4/!7A[4[BYFNM/W&Z01W")-)'',!TWHK!6(XP2"1BMFUM;>QM
M(K6UA2&WA0)''&N%11P !Z5RVM?$+2M-TN6YMENKB6*\BLY(A9S;HW<CEEV@
MXP<C^]P!G-=7!,MQ!',@<)(H8"1&1@#ZJP!!]B :%L#W)**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)&LL;1NH9
M&!5@>X-.I"0 23@#J32>VH'EO_"&^)H;"PEM]@O]'N6L[ &8%7LFW(7;T;:R
MG'7]T.YJ[XP\.ZS?KJ6GZ?IK/92:/]FMI+:6*$M(-V$E8D.5Z;0/EY;=UKT&
MUN8;VUBNK:0203('C<=&4C(-2U3OU_K^M_6XT[.Z_K7^EZ'#:5::PGCYM3GT
M*[AM/[&BM!*TT!_>*Q<C D)[XSC&1Z<U0TW2?$5O\/[ZS71&BU!M3DN%@G:W
MD9HWG\S<GS,F\*>-W 8>G->D447_ *^=R4K?UY6/);[P_P"(DAU:&#0-0N!=
MZS::A&[WD#MY<8B+ABTH.[*$8''3!Q4VM:!XAU6Y\7M%H5Q&M]+92VAEG@_>
M^0R[AQ(<$@$C.!ZD5ZI10G_7W?Y(;U_KU_S.'UW2]9GU2+5-&M+ZQU5S$CRI
M=1M;/&#DB>-CS@%AE%+>AQ6UXQTB[USPQ<V5BT8N]\<T0D)".T;JX4GL#MQ^
M-;U%+I8.MSB]9TW4?$6FP7<>AMIVH6]W;7+Q7$D1>Y$3[O+W1LPV\M@L1SV&
M<UA^*_#^MZY;Z[JEMH=REUJ%C#8163S0"0;9"[2.?,V =  &)]O3NM?\0V?A
MRSANKV.Y>.6=(%\B(OAG.!N/11D]21^=:U-/JOZV_P D!PUKIFH:AXYU.XO]
M"N8-+O=(BLS)-+ 06!8LI59&/1\9QU![8)98^&-;O?!.J:3JLBQ7K6KZ=:S>
M9OW0KD)(<="V1D=>!7>44OZ_&_Z@M/Z\K?H>6:IX4NKKPQJKVWA?5!KD]@]@
M#=:Q]IW!L?<,D[ )D9YVM[<UOZ[I5Y?:5IUS;Z;JMOJEM;;89;*ZA26!SM!1
MPS^6Z\ D98?+QSBNGLM5M[VZNK51)%<VS8DAE7:V#G:X]5.#@CT(Z@@7:;=U
M_7]=02L>;'0O$NIZ_?+J-E)#]L\/+ILNI0R1>4+CYF9E7?OVY; ^7J.@'-2W
M.CZSJ%KHBS:'/!+H43GY9H6^U/Y)B"Q'?PI)R2^SH./3T2BD]?Z]?\V"T_KT
M_P D>8:%H_B"TF\!1S^'[N--(M98+R0SVY"%D" C$A+#C/ Z$=\BNJ\=:7?:
MMX>CBT^W^T3PWMM<>4'52ZQRJS %B!G /4BNEHJG)MW\[_C<27Y6_/\ S//+
MG0=:&G^)](_LUKA=?EDE2Z$T?EVWF1JA60%@QVE>-JMGCI7;P1-IFCQ0QQR7
M36T 140J'EVKC W$#)QW('O5RBIZ6_K30?6YY3X?T"73+.6>]^&\UQK/VZ:[
MBNPUD'!:4O'F7SMXP" >O<<BNI@LKG6KS6-/UW0)TL;R!(WF=X3%*5!#;0LC
M.N2<KD9XYP:ZVBCR_KHOT#K<Y3P3H6K:"NJ6VJ7?VQ#<*+2Y8@O)"J*J[_\
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MMM ,VM>(+_6OAS<WS7]V);:5C8M)&@C5<;C."IRI/RGOZUU,$NL7.OZ?)?\
MAZX6%K.6*>198&CB,C(P4CS-S8"X)"D$],CIU5%);6_KL#WN<5X:\)7OAOQ9
M=>3-YF@?9F%E&S9:V9G#-'ZE>,KZ9(]*;<^&-3'CXSVPC_X1^_,=W?J2,BXB
MX3 Z_-\A/_7/WY[>BFGMY?U_7H@[^?\ 7]>K.#\6Z7/JGC'29[CPA+K6EV5O
M.LF[[*ZL\FS;M261>FTY) Z\9J7P5H.H:5K>KW2Z=_8VB7(3[-I7FHQ209WR
M80E$SQ\JDBNWHI+3^NX/7^NQP_CG2[G6=8T"$^&I=7TVUN6GNLM;F,J8W0#;
M(X)(+ ],>AS3=.L_$GABVNO#^FZ8;NP1"VEWWG1*L(.2(IE9MQ"GC<H;((XR
M*[JBA.RL#U.!L_#$B>.+;6-,T.30MI;^TI%FC\F^4J<!41CD[CG<RJ?K5O1H
MM<\,'4-.&B3ZE!-?37-M=6\\*(%E<OMD#NK @D\J&X_*NSHHOI8#B=2\.W*Z
M%I\:VM_)J-JLLJ7.E721212NP)4>8RJR'<<AN,(..E=/HB:DFAV2:P\<FI"%
M1<O%]TOCDBK]%'2P'F>D>&]?TW3]"FDTYGET6_NI6M4GCW7*2F0!D);:" ZX
M#%>ISCOU'AC2+FTU'6]7NH&M7U6X246K,K-$JQJGS%25W$@DX)'3DUTE%._]
M?=_D@>O]>O\ FSCAINH:?XHULR:,=5TO63&Y97BQ"RH$99%D890@ Y4,>O%9
M<O@YIM8U&#4]'O[^TO;K[5%-#JTD=M&<*0LD7FK]UEX*HV1CI7HM%):6\@>I
MYY!H>LW=EX^MI-*EM&U=I#9O-+$5D!A$8^X[$<KGD#@CW +O2O$%W::5;MH\
ML40TI[64P7$*31R;5 5Y-VX1G'2,DY S7H=%)JZM_6S7ZCOK?^NG^1YCING>
M(;#4?#,\GAJ^=-.T-[*?9<6W^M(3 &91D?NSS[CWQ!HNB>(K.R\"6T_AZ[5M
M(GE-XWVBW(0,CH",2Y/WP>.< ]^*]5HJ^9\W-_6[?ZLFVEOZVL87BPWQTJ)-
M/TNXU"7[5!(8X9(DVJDBN23(ZCHI QGDCMS7/VGA?4--\0:C?)!+-H^3J%II
MR,@D%Y(I609+!<#D\G&7)SQ7>T5/0JYY?H6D>);3PYX9TZXT&X@^Q>;#=F.>
MW\Y=P^5D?>=L9R0VTA^.!CK5L]-\0:18^%[:TTN9=:T^VN8Y ##<8B9QU5IH
MP0W!#;PV5^Z><>M5E:GX=TS5[F*YNHIEN8EV)/;7,MO(%_N[XV5BOL3BAO6X
MCA6TR_32?"]CI>BZI<'2-5$]Z)Y;=)(^&)_Y:[3GS00%) '&01BMSP]IVHZ.
MD^D7NA_;($OIKRVOA)$8R'D,@R&;>L@W$<*1P/F';K;:UALX!#!&$0$G&<DD
M\DDGDDGJ3R:FIW_K[O\ (7]?G_F>;7&@>(-4LK:^LK"?1M:LM1G:)[F2)P]O
M/(Q?_5NPX5@V#_$HQFB;PUJ3>)M1LK32;NVTJ?0O[)AOS+"0C N=Y42;\?,.
M<9SV[UZ312\OZVM_7F5=WO\ UO?^O(\O?P//JN@7,)T>]L=:2R:V2YOM6DNH
M6S@E8P97(1BHSN52!VK7M+;Q!?>.]*UJ?0?L-M#ITMI<B>ZC+*S,K90(6W#Y
M>,XZG.,8/<T4^9WO_75?J3;2W]=/\CD?%MIJ=SXA\,3V.E7%Y!97K3W$D<L2
MA%,;)T=U).6SP.@/?BN6O-'\23Z%KUNOAN]\Z\UZ*_@0W%MS$'C8DGS< _NS
MQZL/?'J]%).W]>:?Z(;U_KU7ZL\SN='\17>K6UY+HMPGV?7$O!'#/ D1@((W
M;0XW2#(W%^<_=)%4KS1_$L^B:[;IX9O?.O=>COX5-Q;?ZI6C8DGS>#^[/'^T
M/?'K-%"TV_K;_) ]?Z]?\V>:76C>(KK5[>[ET:=1;:XMV%AG@CB: @C=M# M
M( 1N+\Y^Z2*IP6M\+IY9=/U >';;5Y-11[9(&PP=B6\PSAS'G+%1%GG )'7U
M>L6U\)Z-97+36UO-&I;?]G%U*;<-G.1"6\L'(SD+UYHCH_Z\O\OO!ZI_UW_S
M.3T[P:8=1>WU+2-1O1%J#WUM>C59!;9,AD4F'S1M=<D<(0<<GDUEMH_B5O#-
MW:#PS?"XE\1#4E7[3:_ZGSA+U\W&<+C'J1VYKUJBFG:W]=O\D#U_KU_S9Y?J
M7AS7=3\0>(+A=(NX8)KFSNK=C>)%YXA&UD#1R;T8YRIXZ<XIVK^&;D:&7T?P
MQJBW=WJ-I<W*76HI/,1"X8EFDG8?=&!AC[XKTZBDM+6!ZWN>5ZOH/B+4=7\1
M7,6@W*1W%[I]S;[[B#,JV[+O Q(<$@$C.!ZD'BO48F=HD:1 CD LH;.T^F>]
M/HHZ6#K<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *R/%,"7/A/5HI#(%-I*<QR,AX4GJI!K7I&4,I5@"I&"".#4R
M7-%H<79IGD6EF^DTCPQH.F3,8;C1UN#YNM3VS&;"<+(JNWR@@^6,+ANF.*EU
MNZUE-$%I>ZU-/K.GZ-+<3&PNVMX5D5BJS-(-I<_*1LV%2<YQQ7H\OAW1)].C
MTZ;1M/DL8SE+9[5#$I]0I&!3[C1-)NY89;G2[*:2%#'$\ENC&-2,%5)' (XP
M*N;YKM=;_K^5_P !02C:_3_@'GT,E]JOB2XM[K7-2^SR>&X;P10W'DA)22"R
ME "/NYZ]R.G%+X=U+4'O_ =Y-J-Y+)K%A*;U9)V:.0K&K*0GW5(.>5 )[YKM
M%\&^%T9F7PWHZLR>6Q%C$"5QC:?EZ8XQZ4^/PGX<ADMI(O#^E(]J<V[+9Q@P
MG.[Y#CY>3GCO3NKW_K[7^:^XFSM;^ME_E?YF)XJ:Z/C;PI;1ZI>V]K=R7"3V
M\$H19 L3,,D#=G\>.HP>:Y6*]O[?1(;Y=6U%YK+Q/_9T9DNW96MS.$*N,XD^
M4_>?)]Z]-O=!T?4KR&\OM)L;JZAQY4T]LCNF#D;6(R.>>*I_\(9X6^S_ &?_
M (1K1_(+^9Y?V&+;NQC=C;C..]*+M;^NJ?Y77S*>O]>37ZK[CB[&3Q3K6IG4
M[>[MK0VVJ26]R)-4EX@$A41FU\KRPQ7:5;.2<'.#BL^RNM23P[I6H/KVJ379
M\2/8-(]SP\+3M&5* ;#P 0=O'; XKU!M"T=K[[<VE6)N_+\KSS;IYFS&-N[&
M<8[53_X0OPJ(5A'AG1O*5]ZI]@BP&Z9 V]>!S[4+2WR_/]?U!Z_C^3_+]#SO
M7I9DT?Q5ICWES+:V.N6"P&XG:5XE9H6(WN2V,DGDG%7M>U/4_#NJZU:Z3>W%
MQ9>5:22-=7;N+1Y)BK_O6#E%*<]"%Z@5Z!!X=T2UEN9;?1]/ADN@1</';(IF
M!.3O('S<\\U-::3IMA8&QL]/M+:S.<V\,*I&<]?E QS0GI_79+] >K_KO<\N
MUFW\4Z1ILAEUQ[2VDU&Q^S0VNIR7<BI)($</++&'*GJ!GU'(XK8UV*[\,7#W
ML]WJNH:);0'S'CU-A<699V)=DR!*N" -V2-G /-=:WA+PV]DEDWA[26M(W,B
M0&RC,:L>K!<8!]ZM7&C:7=S0S7.FV<TL!#1/) K-&1T*DCC';%"=A&#J3D?$
MCPZT#',UC=B8#O&/+*D_1B/S-=96;;:.D>HW6H74OVFYG7R@67"QPYR(U7T[
MD]2?8 "[:VMO96L=M:016]O$NV.*) B(/0 < 4NEA]26BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O?7UKIEC/?7LZ06T"%Y
M)'/"J.IK";QG;6Z1W-_I>IV&FRE0E_<QHL1W$!=P#ET!SU=5'K5;XEZ1?:UX
M(NK;3X6GN$EBG\A>LJI(K%1[D \5F>+_ !'I?B3P3J&C:/.E[JU_;^1'I\9S
M/$S8&9$ZQA<Y);&,4?U_7]>H'H(((R.117B6K:?IVC6'CS1KY;=KF?3+>>"-
MHP6N)$A(:55QR0XR6'0\FM'1H- UWXD+;W$QG)T2UE^S37$BLDZN&XC8@HP"
MH< #CG'/+2N]/ZW_ ,A7=KO^MO\ /\#URL?4O$5O8Z@NFP6MUJ&HF/SOLEHJ
M[@F<;F9V5%&>FYAG!QFMBO/X)8_"OQ+\0:CK4JVVG:K!;M;7T[!84,8*M&SG
MA3D@@'&<\4EO8KHV=7I'B"TU>:YM42:VOK7;]HL[E0LL6X9!."00?[RDC@\U
MJG...M>*>.+;^WY_%/B:RDG&DVVAK:QW,,C1I=2[]^5*D;T4'&>5.>^*V#_8
M;ZS=W.D7,,6E?V-,NL3V\QCC\[*^7O=2,2CY\\[L=>U#^&_];-_I^*"VMOZZ
M?Y_@>GV[3M;QM<QQQSE1O2.0NJGT#$ D>^!22M.'B$,<;J7Q*7D*E5P>5 !W
M'..#CJ>>,'Q'0+WP]?7?P^BO-3M)E_LB>.[@EO,QY"  /&6VYR7'(YQSG'#=
M#UO1RG@?&L6V^VUB[@6/[9\J0_O1&"F[&.8P"1G! !YJN7WK>?ZM$WTO_6US
MW6BO'3$EQID1#1IX_35-QPV+H1_:#G/<P>4?]S'O6-/?>'K72->OH=2M6N[?
MQ1$UK/)>>9(B;HLE69B<%0^3W"G/ X45=_UY?Y_@QO2_]=_\OQ/>ZCGD:*WD
MD2)IG12RQH0"Y Z D@9/N0*<CK(BNC!D895E.01ZBN%\23:=_P )U;VWB81#
M1Y+'_0OM/^I:ZW_,.>/,VA=O?KCFI=]AKN=)X7UT>)O#EKJXMFMA<;B(6<,5
MPQ7DCZ5L5XCX1FTZ32/#T/B)(U\-QV-RA.HH4MS<^<"N[S %)V'Y2>^<'(JT
M\=_;Z-I5OJEU:P^'6O;Q4EU>V:X@$6X?9Q*/,3Y=N[:6./N^U4UV$D]G_6Y[
M)17D-W8)H6BZ?=/K.CZVEC'*8K?48S%',CME/LSEGPXP44_,2...M>JZ?()M
M-M91!);AX480R?>CR!\I]QTHL*Y9HKSWX@2:6/%O@R.^O$C9[YU:*2Z**T9B
M<<IN (+;1DCOCOBN6T>_TZ9!9BXM)/"MKX@O%NXU=3;Q0%&,(<#@1%B>OR\"
MDM?Z\_\ @C>G]>O^1Z_J6J6NE0Q2W<FP33QV\8[L[L%4#\3^0-7*\3U73+ V
M,DI@MI_#$?B.S-@TBJ\*0L%\W83D"(L<<?+UQQ7M%N(A;1"! D(0;%"[0%QP
M,=N.U.VE_P"MD#WM_6Y)4%[.]K8SW$<#W#Q1LZPH5#.0,X!8@ GW(K@/B*-.
MO-6MM/O8X'E;3[AX!?'=!NXY2/&7F&.,," 36)IM_INH)I2^)YHI[*70;<Z;
M)<MN1[G!\W:3_P MON8_BZX[U+UBVOZW_P AJUTG_6W^9Z7X>UO^W_#%EK4=
MJT?VJ#SE@WAB/;/ S4?A7Q ?$VA)J9LWLRTTL1A=PY4I(R<D<9^7MGZGK7F/
MAF]TV31_!]OXB0+H)TMHT^VQ%(&NPZXW;P 3MSL)X)SCFLC05T&ZO/".F7D[
M -?ZC#+;7,TD:R1L9=GRL0&W%L;@"23MSD8K1KWFE_6K_P B4_=NSW^BO'[K
M2/M/B*ZL)]:T_2;^TO$;3!-9O)>>0BKM6"0S#<I (90IYW9R:TK.:VTSQ9-:
M%["^^W/<SM?VN5OK,;7YG7DLB_,BL<=@!WJ-U=#\CTZBN \!21V>JW6BK!I=
MPUK;JS:EI>0LA+<K,G.V8_>/))Y/'2N\EBCFA>*5%DC=2K(PR&!Z@CO1+1:"
M3N<U=^-;:-]&:SM)+NUU._:Q%RLBJD;*S GKDYV-C QQR1Q745X-I[>'K'P]
MX3LG:QL[@^(W-T@*PL0KS*-Y&"< J.>@91T(S>BU"W33M>T_1[NPCTBU\0C[
M0BQ^?!!:M&,EHT=?W7F9S@@?>SP#3MII_7P_YE-:_P!=Y?Y'M=,FFBMX))II
M%CBC4L[N<!0.22?2N5\!:='IVG7GV76+/4K&>?SK?[!!Y=M " "D7SO\N1G
M. 2:N>.M,O-9\#:SIVG\W4]JRQKG&X_W?QZ?C4RT01U9"/&MN]A)J::1JSZ2
MD9E%^L*%'4#.53?YI!['9COG'-=*CB2-7'1@"*Y70O%^@76D6MD+B**^2!8Y
M-*<8N4(4 H8?O?IC'M7+:Y'IT][XGB\0K'#J6 =!5R!,JB%=OV;'.[S,YV<Y
MQGC%5+1M+^O^"*.J5]#U6BO$7;26U?Q+#XCOK66^7P];-<)<W>X+<A7W;5+8
M5@VS& ,$@C!/)#?:--<^&V34+=;K4_#DXO)(;O9+/*%3;O=6W%@RN!DYX8#H
M12EHF_Z^U_\ (_B@6O\ 7^'_ .2_ ]NHKQWPHVG20>"KC0W1]5BM!_:[6WS2
M>1Y!XF]]^S8&_#BLW3+S1(M1L[LW=M8V=]H]XEQ)]J*3O(K(1]HF!7,PR>,
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MY3%4&68D9/ (H\_Z[AY'>RRQPQ-+*ZQQH,L[G  ]2:(I8YX4FAD22*10R.C
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M CP<'#;B0W'2JY7>W]=?\F%]+_UT_P SO5N8'N9+9)XVGB56DB#@L@;."1U
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M*#D%C@@#G.1Z!I_V[^SX/[2-N;W8/.-MN\LMWV[N<?6CI<.MBS1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115/5=
M1BTC2KK4)TE>*WC,C+#&78@#L!S2;25V-*[LC+T_PJMAXGO=>&L:C//>(J2P
M2^3Y6U<[  L88;=QQSD]\U!%X'LU@U^"XU'4+J+7"6NDE:,;25VY0HBD?* .
M<]/KFIIWQ*\/RZ387&H7GV6\N;071M6MY?,"A=S%5V[BO!PP!!P<9K63QAH+
MZG%IZWQ,\KB)&\F3RS(5W;/,V[-^.=N<^U4TUI\A7Z_,R;[X=6VH17:3Z]K.
M;RS2QN7#09EB4L1G,6 ?F(^4#\^:MP^"TBUI=5.NZL]P+(6."85'ECG^&('.
M?FSGK[<5+%XZ\-3R;(-428"Z%FTD4;O&LQQA6<+M7.0 2<$\#FKZ>(--DOI+
M-)I#)&YC9_(D\O> 25\S;L) 4Y /&.:+O?\ K^M?Q"W3^OZT_ Q[GP'975W)
M?RZEJ)U)KB.=;T&(2)Y>X(H41["H#L.5).>3TI1X"T]8WV7^HI/]N>_@N%D3
MS+>5QAMIV8(/.0P8<UH:9XMT36+F2WLKTM(D7G_O(9(@\6<>8A=0'3/\2DCW
MJA=_$#08-.O[J&>:X:TMC=>4EM(&EC'&^/*C>F?XURHZDTF[+^OZ_KU&DV[%
MR^\+P:C'IQNM0OWN;"?[1'=!T$C-M*'("[0"I(PJCU&#S5*+P%8J^J-/J&H7
M7]H7*7;>:T8,,R8VO&50$$!5')(XYSDYDTGQ9INK3:1$=0DM]0NK8S_8&@:,
MR#;RQ5UW!00<'(!]35N+Q?H4U^MDM_B1]PC=XG2*4KRP24J$<C!R%)Q@^E-W
M3MZ_U^'X$IW5_P"OZU_$S]1\!VNJZ9>6EYJVIR3WJI'<7O[D321H25CXCV*N
M3GY5!/<U<L/"JV/B277&U?4;FYEM4M7CF\D1E%Y'"QJ<Y)/7N>V &V7CCPYJ
M4MJEEJ2SB[E:"&1(G,;R+G*[]NT'@D GD<C-7K;7].O+Y[2"65Y%D,6[[/((
MV< EE60KM8C:<X)P1@\T*XV1:GX>BU#4(]1@O;O3[](S";FTV;GC)SL8.K*1
MGD<9'8C)JC%X(L;?6-*U"UO;Z#^S4D2*W0QF-_,.9&<LA8ECR3N^F.:L>+_$
ML?A3P_+J4D$TS;UCC6.)G&YB "VT<#G\>@Y(K C\;?8?%VLIJUZZZ1#86]W;
MQBPD62%7+ABZX+\;1DD #/('=1\OZZ_J#\_ZZ'6ZYHUMX@T2[TF\:1;>Z38[
M1-AAWR"0><^U8C^!HWU.ZU#^W]8$]S9_8G.8"!'DGC,1YR2?Q]  -#4_%VAZ
M/Y?VV]*AXA-F.&24)&3@.Y12$3_:; ]ZK6OB^VN_&MSX=C@N=T-NDOG?99-C
M%MQ^_C:%PO!)P2< DBBU]/ZV_P @OI?^MR&P\"VVE0V L-7U2WGLX%M?M"F$
MO-"I)5) 8RI"Y(!"AAZ\FM^ZL!<:7+8)<3P!XS'YT94R*",9!8$$_4&H-8U_
M2O#]O%/JU]%:1S2K#&9#]]ST '^<50E\<>'H8[IY+R5?LC[+A3:3;H>,[G79
ME4QSO(V^]#][?^OZO^(+38CA\%64'AK3]%%]?$:<0UG>;D$\! (!!"!3@$CE
M3D=<T:EX.75?[-:XUW51-87 N4E7R,R2 8#,#%C@9&%"CD\9YJ[#KNE7&NW-
MG#JZ/<6UL)9[52I2-3@AV;&0<$<;NG..]49?&.DW]I/;Z9J\$&HO"S6BW<+(
M9< D/&C[#*O'521[T.3^)^O]?<"5]/E_7W_B1Q> [*&XMY8M2U)5MK]]0@BW
MQE8Y'W;QRF2IWMU)(SP14-S\.[&?37T^/5M5M[9K[[>$B>([9-_F8&Z,\;_F
M]>V<<4WP=XUM=4\/Z0M]=O+JUSIXNG"VS@2X W["%VL03RJY(]*TO"'BB+Q9
MH[7\5O/ !-(@66!X_E#L%P6 #' &<$X.15--.W;_ #_S0KIJ_?\ X/\ P2QJ
M/ANRU34=*O[IYS<::Y>-E8+YF0,AP!R,A6P,<J*9)X9A_MB?4;6_OK,W.#=P
M6[(([@@8!8,I(;  RI4\#GBL:^\3W.D?$&XL]0NBVDKI8NDAM[)Y)%;S I)V
M!F;H3P  #STS6U<^+-$M;"WOFO?,M[B/SHWMXGFS'W<A%)"CNQP!W-2GI?\
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M>,\XQ4EMXQTW_A'['4[QKB)KF'S#$+*8R< ;V$>TOL!/WL8P0<X-/7?^NO\
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M\>^-00=H*H P. "6!)&>>:K6OA-+-+MX-8U)+R[<R7%W^YWR-@*"5\OR^ H
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MVJK'-<DZ2";T&RG4QX&>Z?-P,_+G(YZ5L6MS'>6L5S%O\N5 Z^9&R-@C(RK
M$'V(!HZ!U):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *IZO;27NBWUK#CS9K>2-,G R5('\ZN44I*Z:8T[.YYMI&E
M:_#K'@DW.@7$<.E:?);7,WVB!@C,B*#@/D\H>@/!'?("7NB>(;C6H;E](F*V
MNNK=J+>>&.%X,$;PNX%GP06+\_W<BNZU?7-,T&U2YU2\CM8I)!$A<\NYZ* .
M2?85H53=WS>?ZW)M96\O\T>37FC^)9]$UVW3PS>^=>Z]'?PJ;BV_U2M&Q)/F
M\']V>/\ :'OC<DTG7(-?-SHEE=V<5R\LM]!=W,4EG+D,!A0Q=9"VTG: O)R2
M:[VBETM_6UBKZW_K>YY7;>$]=OID6ZL+FT^TZ#/ILLCSPE+>5BNW9'&V%CX.
M-HSC&ZMV33]5UCP;>:9=>'UL]473)+)+B26)D<E-O[ME);:2 ?F"]N.*Z>'7
M-,N-:N-'AO(Y-0MXQ)- O)C4]-W8=1QUK0HE[RMW_P"#_FQ1?*[KI_P/\D><
M_P!FZ]/K?A-WT*ZA@LM/EMKF87$!\EI$5 <>9DX*DG&>",9.0%M/#FK/HGA[
M0+G3)(UT*YAG:^$L12X$0.!&-V[<W .X*!D\GOVTNMZ;#K4&CR7D0U&>,RQV
MV<N4&<MCL.#R:+W6]-TZ_LK&[O(XKJ^<I;0GEI"!DX [#UZ4[MN_=_C=O\Q)
M65NR_"UOR/-;?1O$L>B:1;-X9O1+;^(GU&5?M%M\L)D=QSYO)P^,>H/MGI+#
M2=6L/%T4NFV][9:7-)++?PW%Q'+;,6W8,(!+HY;#$8"X)[UVM%"=OZ\DOT&]
M?Z\V_P!3FO'NE7NL^$+JST^'SKKS(94BWA=^R57(!) SA3U(%<WJ=AX@N=9\
M572>&[PIJ&CI9VY6XM\-(-X/60$#]X.H_A/MGTFJFHZE::5;?:+N1E0L%541
MI'=CT544%F/!X )J6E9I]?U5AIM-/M_G<\SU+P_XGU'P\^GMHTT>_0$M%\JX
M@1C.H(*S.&W,O3:%)7YCNZ\=-HVFZK:^-I=2FTYDM+O2[:!G:5,PR1E]RL 2
M2?F&,9'7GUZ;3-4L]9T^.^L)O.MI,[6VE3D'!!! ((((((R,5!+X@TF'5++3
M7OX?MM\I:VA4[FD4 DL,=L \GBK<G?S?_!(2]VW1?I;_ ",7X@V6I:AH=I;Z
M7IDU],M_;SLL4D2;4CD5SDNR]0,#'?TKGM8TOQ!>S^.3%X>O=FK6$5O9DSVX
MWNJLAS^]X'SYY[ ]\ ^FT5/E_73_ "+OK?\ K>YYC':ZJ-8OK_5/#EW:Z:WA
MX6$K3W-OC>FXD'9(Q"D' ..O85'I-MK-J]K<:MI6JO<Q::^G6"+%;1*VY0VU
MR+A\O\@^8A%X/ )KO]=O-#MM-DAU^ZL(+*X!B9;V5$20'M\Q -0Z+I&CV@$N
MG2R7 4?(TM]+=",$#A-[ML!&.F.*'K>_]7O_ )L2TM_6UO\ )'$Z%I'B&TF\
M!QS^'[N--)M98+V0SVY5"R! 1B0EA\N>!T([\5T_@+3=1T?PV-.U&T\B2&>8
MJWF*PD#2NP88)P,,.N#UX'?J**IRNV^_^=Q6_K\#DM3L=4LO'2:]:::^H02:
M=]B,<,L:/&_F;PS;V4;>W!)]C7-V_@6^TB2Q>XM+[4X'M&@N8-,U)[4PNTKR
M''[R,2)^\*\G/RCCDUZC14K3^O7_ #'_ %_7W%'1M.@TG1[33[:W%O!;QA(X
M1(7V*.@W$DFN"&A^(9-?TR\GTF4"SUJ6=A!/"D'D.LBAT0,"S?,I8N-V2<9!
MKTNBG?WN8.ECDM/T+4;/QA?+Y:_V%+*-0B;S!D7##:R;>N,_/GU-8-GHGB :
M_HE_=:1,OV+4+IIEAGA2!8Y%<*\<:L,Y)!)8;\D]C7I=%):6\@>M_,\E?1_$
MK>&+RS'AB]^T2^(AJ*I]IM?]3YPEZ^;C.%QCU([<U?U?1/$-_J4L_P#8\^V+
M6+:]B6">"..2)2NXL P+R@ YW\<#:>*]+IKR(F-[JNX[1DXR?2FG:WE_P/\
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MM[=2#Y;QA)/-8AL JW7G[M=1#X"\,P36\BZ6K?99C/;QR32/' Y[QHS%4]<
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M-=VZ6,%W$7B1#$69U91M ROR@C.3[FK.H>!O#VJ&]^UV4K?;F5KD)=S1B4J
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MNK%EB\Y8FZ2#$FQE_P!UC],UGZ?X9U#5_ VG/>7:'6!<PZB)F4A)'CQL##J
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MNM1NK>P2&[L(;>98KF29S*A;+,SH"^0P^8D'C&#UIO6_S_6WZ$QT2OY?I?\
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M>ZA!-;K<V>HV#BZGDW3")FCRT&,>7"0W+9(8[A@<52CK;S_R_P Q=+_UN_\
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M><XYK(\,WVGW'AOPRM]<VT_AN*YODU!IY0\2R%V,0G))&"&)^?@DJ>XH6O\
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MU%J"F_VOBY$9E/FB3OY6S.,_+]W':L6WO_#UGH:ZA%J=HUW!XMQ!<RW?F2)
M90#AV8G:8^IS@CDYZT)7=OZZ?Y_@RGI_7K_E^*/<+34[6^N[VVMY \EG((IL
M=%8J&Q]<$?G5RO O%%MX=L!XQ,OV6QOSK%LUNT;^0[1,(BW*XRA_>-@\9!;J
M,C>\:V'A^W:?3;.WME+:5<7MK]ID+PEV)8O;IU:7(SN##:"#@Y-2W:-_ZVN-
M*\K+^M4OU/5[VPL]3M'M+^T@N[9\;H9XQ(C8.1E3P>:BAU"R_M-](@91/;P+
M*T: 8C0DA?I]T\>U>9P2:+K=Z(/%-Y&+>ZTRS.D74TH4!RIWM#(>!-OQR/FZ
M=JBUKP_HU]XP\36\VEVUS=W&@Q/9FXM0TKR@2@N,KG=PF6Z],]JJ7NW^?X7_
M ,A0?-;Y?C;_ #/7JQ]<TW2Y(6U6[T.UU*[LHS)!O@C:4%?F 1G^Z<CU%>7Q
M:KI"ZCX6U&U66X=?#EQ#<3:?"7EW+''A"R@X92&X;[I/.,U+X8O=(TW6+V6&
M[TVUL;GP\)CY$WR.ZLP9I'.!))S\S8!SP:4URWMTO^%_SL$'>U^MOQM^5SU'
MP]JZZ_X=T_5UA,*WD"S",MN*AAG&>]:5<E\,[J"X^&F@O!,DHCLD1_+8-M91
M@J<=P>U>>Z=>:'_;VEW[75O96MY#J$-[*]R4N6.,@7$HVX<<X7JHZ&G4M&;2
M_K?_ "%&[BF>WT5X MIX<3X4^'=9DO5CU"6[MH)I_P"T'4N!<;F#C?ABJDGD
M94<\5L^/++1+%=4TZQMX(9+;27N[3[2Y=48N[EK5.H?.27# *-O!%#5OZ\D_
MU&M7;^M['LU%>'ZG>>&K[5?%\MQJ5G=*= @D3SKWS%$X#\J"Q 8$QXQT+#&"
M>9-5UG3;R'3IM0NK._:ZT&$6KSWL, M+GY@9E:1UYSU9,NNSIR*3T_KU_P @
M6O\ 7I_G^![917CFHV'VB:RTS5=?TM+&72X19:AJ*R7B27!+^8\$S3KMDR5(
M)).,8X!%(ZZ$OC/4;'7-6M[XIX;C$YO9]JO*"<L8F8A&VA6QU&<]3FB6E_G^
M%_\ +\4"U_#\;?Y_@SV2BO#])U6RB_X02[LK^T_MF]TNXBGD,ZF2>3RP(TD)
M.3^\& #T(P*=:V=DVD7.K3^)=/@FBTR2+4K2U@DM;AI"GRFY<SEMX<8#$#.2
M.AQ1/W;^5_P_K\0CK9=[?B>VDA022 !R2:JZ9J5MJ^GQWUF^^WD+;'[, Q&1
M[''%>1^&Y] _M?P;:P7%A(^H>'Y(;R/S%<W!"Q[5D!)W$$2  ],,!TQ77?"2
M"P@^'U@EI;P13887?EQ!290Q!WX'+   YY'%4XV;7;_-H2=TG_6US1UWQK;:
M3IMY>6MI)?BSO8[*?RY%58W;;R23R!O4' )SVZFNHKPC6DT'2M \9P.EE8WD
MFO1HN%6*0Q;X7 ##! ^\PY[,1T)K1U+5M L-;\7V-I/!]BEBL96AL[E45G+D
M2.[ -A,%/,;!^4\]:4=5_79/]2GH_P"N]CUK4M3M=)M/M-Y($C,B1+ZLS,%4
M#W)(JY7A%Y;:6VA:]:R1:9):6?B"RG2*&("""!_*W,BG(5""V2, \GH<5[C9
MK;I90):1I';*@$2(FQ57'  [#':BVE_ZVN3?6W];DU%%%(84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116?KUW=6&@7]Y
M91Q27,$#R1K,Y520,\D G]*4G978TKNQH45Y+87>KW.N^ ]2GMUGU*ZTJX.S
M[<YBDQ&A5WRN$)W'.U6//5@*Z)OB19KH.G7DJ6-I>7KS1B&^OU@A1HF*R RE
M3QD8&%).1P.<4U;?^M;"6NQW%%8OA;Q);>*M BU6U3:K,\;('#@.K%2 PX89
M'!'48KGQ\0;O^S[[5)/#[PZ=IU\UI>M)=KYT84J"X1058 MR-PX'&:+:V_K^
MM4'2_P#7]:,[JBN0;QM-%XCL]-GTD107MS+;6[O<XG<HI._R2H_=G:<,&/4<
M#-<[KGQ \17/A#5[_2O#PLTM))K6:XN;Y=\#H57(5%;<<L<8. 1U-):_UYI?
MJ.W]?UZ'J-%<D?$7V?Q-8V.K:-##<_V;-=F^2995C52N]$)4.1]TDD+T'7MD
MVWQ9TV:Y:/RK69'LI;R 65\EQ)B-=Q25 !Y;XZ#+#@\\4?U_7W"6O]?UW/0Z
M*R=!U:?6+%;J2*R$3HK)+9WGVB-\YX#;5/ QV[^U96H>+;Z#Q'J&B66AF>:T
ML1>K+-=+%'*N<8& Q'1AR.H[#FAZ;@M=CJZ*X_3O'+7UUHN[2FCL]9M'N+21
M9]\N44,59 N!P>"&.>X%1:?XWU&_U&;31H<$>HFP^WV]L]_\^W<!LF'EYB?D
M<88=>>*;37]=MP3O_7<[6BN4T7Q9?:UIVB7,6EVZ2:@\GVB$WC$VJH2&/^K^
M9@<*1QR1R>M7?$_BBT\-0VOGR6B37<ACA^V72V\60I8EY"#@<8X!.2.*3TW!
M:F]17 :=\3?[7ETF'3]',\E_//;-(+Q##'+$I) <9+J< A@O0YY/RU!J7C76
M;W3]"ETRPMH9KC63I]U%+=L 'C9LJ'$9RIV'YL9QQMY.'9A_7]?<>C45P=]\
M4--L=7%H38R1K=BRE5-03[2LI.W(@QDH&XW$@]\8YK2\,^*]0\27$I_L"2SM
M(;B>VEEEND9TDC(&-JYR#D\@G&WOG-):[ ]-SJJR]<TNYU2WMQ:7_P!CGMYA
M.C-$)8V(! #ID;ASG@@Y .>*S]4UU+3QAIFE-HK7$T]O//;W>Z/*E%^9$R<@
MG*C)VCGJ>:R]+^(%SJ,6C7$FA_9K;5;F:TC9[L,Z2IOQE54C:?+/.<@]B.2+
M78-OZ\CI]/T^ZBF-WJ-U#<WIC\K?! 88PN<\*68\\9RQZ<8K1KSWPYXRU7^P
M9+O5K2WDN;K5I+&SC@NB=\GF,NT[D&Q5"]1N) )P#Q72:'XBEU'5-0TC4+$6
M6IV(1Y(XYO.C>-\[71]JDC@@@J""*=OZ^Y_J&W]?+]#>HKD=8\4+IGB>YMO^
M$?DN+BUTJ2\CN5>(/)&&4,BY.0,\G)'W> >*71/&<^J:AI%M=:4+1-6T\WUL
MXN?,;C;N5AM 'WP003GN >*$K[?UO_DP>G]>G^:.MHK(UK6VTR:QL[6V6ZU"
M^=DMX7E\M/E4LS,^#A0!V!/(XK+3Q;?2FRL4T,Q:W<^<?LES<>7&JQ$!G\P(
M25.X;2$YST%(#JZ*X?\ X6*S1Z>J:%<M=7&I-I=Q%YZ!;:<<D%CRP(Y! Z=<
M'BFR_$*XMX LN@N]VFKKI4\<%TK1QNVTJP=@I8$,"/EZ\''6FE?;^MO\U]X?
MU^?^3.ZHKBY?B##96^HKJEO:V5Y9WRV.R2] @9F0.K&5E7:NTY/RY&#@'C,6
ME_$B#68UM;"UM[C5FNWM5AAO0]NQ5-Y<3A>4VXY"YSQBEOL#TW.YHK@-7\4>
M)#<>&H[?2(K.6\U"2WN;>ZN63)1'.%81G,9V[@V,G &!DXMP>,[6 ZU*VBFU
MNX=4BT_RPZ;[J9U0(S%> ,,.220H_"FE?^O3_,/Z_/\ R.THKA-5^(=SH=MJ
ML>H: QU+3H8[AH+:[5XI(G)4.)&53@,,$;<^@(YK<TKQ%/>^(;[1KRP6UGM[
M>*ZC*S^8'C<L!GY1M8%3D#(]":$K[ ]#?HKG]4U[4-/\2V&EIIUJ]O?12F&Z
MDO&3]ZBEO+*B,XSZYZ!N.,'-T7QK?:YIMI<VND6[S27$\,\"7Q)C$1()5C&
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ME:>26R5)>7YSYC97 ^[@$COFD/P^-PNI)=ZE$([ZVMXMMG:"#R)(6+(\?S,
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M,A!50 5/R@_\"';HDUW23J TTZM8-J&S>;99T$A&,[MF<XQS]*%=6?\ 7]:
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M[?0007"W4\#1P,60>7(R<$\GIUP/H*O3ZS:,UW:6-[83ZG I_P!%:Y (?:2
MX&67.,].G:D]/S_)_P"0;_E^:_S+MLLZVL:W4L<LX4"1XHRBL>Y"DL0/;)^M
M<.GP^U&WM=)M;?7X!;Z9J+W\2RZ>6+$LY"DB4?\ /1@3WP.!@YU_!WBV#Q%H
MFG2W5S91:K=0&=K**4;U7<1D*3NQQUK7AUO2;B^GLH-4LI;NW&9H$N$:2,>K
M*#D?C3V8NEOZ['*P> ]0CN[Z^;781>RZC_:-K+'8E1!(8_+964R'>A3 Q\IZ
MG/3'86,5W%!_IUS'<7!Y9HHC&G3^%2S$#ZL:@37='E29X]5L76",2RLMPA$:
M'(W-SP.#R?0UB:WXM-I+X?FTN33[S3=2O1;2W0GW!003E-ORGA3R3QQP>ROL
MOZ_K0;ZLF\5^'=2\02Z8;/5;:R2QNDNPLMDTQ>1<[1D2)A>3D=?<4_5_#U_J
M?B30]5CU*WACTQG<P-:,YE+J5;YO,&WY3QP<'KGI6I%K6E3Z8VIPZG926"Y+
M723J8ACKEP<<?6L7Q1XJ.G^";KQ!H,EAJ*0@,'\_=$1G!(*9W$9Z9'U%"T?S
M_/0-_P BC)X$NVU!KI-8AXU5=20R66Z3C(,;OO&Y0#A< ;1ZU4N/A]K%QIFI
MV;>(;(?;]334G<:8WRLI5MH'G],HGZ^O&YXQ\51^&O#US=13Z>=26W::"UN[
MCRS,%&6VC[S8&>!^8ZUHKKMA;V6GR:E?V=I->(GEI+,L?F.0#A0QYZ]*:TV_
MK;_) W?5]?Z_4R;OPC/J.O6.J7E_;^99EV26WL_*G)8,-IDWGY &'R[<DJ"3
M699_#=HELH;O5(;BW@L[FRF1;+RVN(YMN69MY_>?+DMSGT%=A)K&F178M)-1
MM$N2RH(6G4.6.2!MSG)VG'T/I3K+5=.U(N+"_M;KRR5?R)E?:0<$'!XP:72P
M7,FPT#4H=%ETG4-92[MOLYMXG2U\N785*@R-N8,P&.0%^E9-CX'U.SU#P[.^
MNVTL.C6K6HB.GD&5&55;YO-XX48X/.>HP!VLDB11M)(ZHBC+,QP /4FJEIK.
MEW]P;>SU*SN)EC64QPSJ[!&Z-@'.#V-.]W?^NO\ FPMI;^NG^2.=MO!#P6EK
MI+:A')H5G.MQ;6AMB)597WHK2;\,@;G&T'@9)YSFGX>ZP=)>Q_X2&RRVK_VL
M9/[+;[^\/MQY_P!W</7./SKL[;6M*O;FXMK74[*>>V_U\45PK-%_O '*_C3[
M35=.OY7BL[^UN9$4.R0S*Y522 2 > 2#^1H3>_\ 7]:('_7X_P";^\I^)=#'
MB/PU>Z.]P8#=1;/.5-VTY!!VYYY'3/XUGGPO?P:C-J-AJT,-W>0QPWS2V?F+
M($SM9 '78P#$#)88 R">2WQUXM7PMX?N[BUGTYM4CB,L5I=W&QI%'4A1\S8]
M!CZBMB;7-,LWM8;[4K*VN;H#RHIIU1I#Z*"<GKVI)77]=O\ (-BGINGS:"VE
MZ/IJH=*M[<QN'B;>N!PWF;MI)/5=N>2<C&#)KF@G59["]M[D6VHZ?(TEM,\?
MF("RE6#)D;E(/8@\#FM"_P!1L=*M&N]1O+>SME(#37$JQH">!EF(%58_$6AS
M7!MXM9TYYQ#YYC6Z0MY>-V_&<[<$'/3!H;OK_7]?H!S5WX#O;B_M-035[9+U
M=034;J1K%F6:1$\M54>:-B!<\$L<G.?7N*S#XCT,06LYUG3A#=MMMI/M2;9C
MG&$.?F.?2M.GTL&[N%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LKQ,';POJBQ6!U!VM9%%HK%3-E3\N1R,^W-:M%
M)JZL-.SN>,W]E//;>)C<Z5J-VE[X?@BME_L:55\Y3( BIM+*5)4C>2PZYP :
MV-)@CF\6>'[<Z1?I8GP\UG<>9ILT<0<E#L<E !PK]?YFO3JYZ]\5Z([W-A_;
M+V<P23_24B(5=G#['=#&S*>HYQW%5?\ K[_\Q=/Z\O\ (QO!%M>1W<VF7L;>
M7X>+65M*W(E5L,C?58MBY]S5G7EELO&UEJEW875YI1L);4FWMVN#!(S*<F-
M6PRC&0#TYK6\-7NF7=I<+IUQ<3R1S$7374+13&4@$ET95()&,?*!C&.*VZ'N
MK_\ #]_O#N<$+&+0/$MI>?V7=G05TK[%;0PVLEPT#>9D@HH9@&7;SC^'!Q7-
MZ-H3:'XH\+/>:/=DVT=\[2QZ?),+>.1RT$9=5(RHW# /RY/KS[#12O\ U]_^
M8/:W]=/\CR#18+V#PQ;7ENFLZ=JMC->K"DFCS2QR1R3;A&T97=@C805QC!R>
M"*LW-MJ5UXKWV^C3Z;JEWX9>U>:&S<0Q71VLJ&8+M^4# .<#&,YXKU:BAZ_U
MY6&GK?\ K>YY*\-Y>WWA$:9X=U*TGL;.YLYV>T,2VKM$J#+M@,H;G*EL\XR>
M*AC\.V\^@B;4H?$5U?Z=IDEH;"XTQ#"I9<;5\N ><-ZJ1AFQPQQR:]6O]3L-
M*MC<ZC?6UG #@RW$JQKGZL0*?:7EK?VR7-G<PW-NXRDL+AU8>Q'!HE[R?G?\
M?^'8E[K7R_ \XL[);/PSX,DAT&>*Y18X[BY&G2F:U=8BF6B !.264,P*C.?2
MJ6A6&H6$/@YI=,U(BPU'4$G!M&#+O\S8Q   5LCYAA>>HKUIF"J6.< 9X&3^
M0ID$RW$$<R!PDBA@)$9& /JK $'V(!JG)N3EY_Y_YLGETL>2V6FW4VEZW!I^
MD7D%M'XDCOS:O820">U#(3Y895#<H3M'/'3D9C\:Z4=8M_$>K6FCWTMM>V=O
M!# VFR^;+<J[$R>44W+M3Y=Y ZX!KUV2X2*6&-ED+2L54K&S $ GYB!A1QU.
M!GCJ:EI=O+_@+]$7?7^N]SA=#EW?$R^E@T^_@LY=(MHDDDL)H8BZ,Y*Y90,A
M7''U'4$4FKBXL?'^H7[V%]-:SZ$($DMK9Y1O61B5^4'G##CJ>V:[NBE+56]?
MQO\ YBCI^'X6_P CQO1UN+*V\!Q1Z%JGFVFG7,-W'_9T\85VC ".VP!=SJ><
M^_0YJ?2K"^DO;=DTR_ACD\-W%E'"=/DBCMY 5(BW.-Q[_,[8;&1U->NT4Y/F
MOYW_ !O_ )@M+6Z6_ YKPF=GP^TV*^LKF,06$<4\$]LV\[8P&'EXW'N,8Y[9
MR*\ZTFV^S^&?"%J- U.*2UUV2>XC_L><>7'F3YC^[Z8=/\J<>T"1&=D#J67&
MY0>1GIFG4W*\W+O_ )W$E:/+_6UCR59+B.XUTC0]1='\1QW,<LFFW!$4>Q1Y
MRH #)AD(P,]0Q!'6>ST*]E\'ZWLMKE-5T_6)M2LGN;?RC(P8.I&  0XRIV\<
MFO3I[F"V0O/-'$H4L2[   #)/X"LE);'Q?I4-WIVK3MILN]&^S!0MPN2K*2R
M%@,@\J5/O4ZVT\OT_P BM+W?];_HP\+.UYHZZM+"T,VIG[4R./F56 "*?<(%
MS[YKA]1TF[>#QIHK:3=27NL7GG6,HMV,6#&BK(90-J;64G!(;C@'->I*JH@1
M0 JC  ["EIMJ]UM_PW^2$KI:[_U_F>6ZCX;N+S6-8TW6;S7U@OY8I;=M/M8Y
M(I0B( #*86:)@RD\LHYR.];/Q3L4O?!(MSIL^H3_ &F Q)%:/<.N'4LWRJ2O
MR!AGCKCOBNYJA;:UIMYJUWI=M>12WMFJM<0H<F+=TSV!/IUHOM]_W!M_7<XC
MQ!I!7Q(EPO\ :MGHU[8&$G2M.28K(S%G$L;0NR[P5Y '*_-VJ+3M$@T34;S2
M]6TW4[_1[[3K>SM9G@:Y8(FX-%(8URF<ALD >^17I+ND<;22,JHH)9F. !ZD
MTQKA%N(X,2%Y%+*1&Q7 QG+ ;0>1@$Y/..AI(-SS75_#\EYKFK6&IRZ_;Z;J
M44"VRZ?:1SIL5 /+=_*D:-@P)R6"_-D'.:GT?1[6\\6>,-,FTR\AL]1M((C-
M+9.B3,JLLC>85"LV6!SGGJ,XKTBBCR]0\UY?@><1Z?X@UGP)J,-S:S0:K;VA
MTZ)74(9@A^=TSD8D 4#/''I5"\\/3ZCI&KZCIDFOWFHSVL5O/;ZC:I:B2..1
M6,0411AB5WJ&&1@XS7I]Y>6]A:R75U*L4,8RSM^0^I)XQ5;2=:L-;MY)K"5W
M6*0Q2+)"\3QN.JLC@,IY!Y'>G=MM_P!?TPV_K^MCD-*D>\^)T>JVFAZE!8S:
M,MN\\]H;<1N)"0K!]IX QP#V[<U'XCBM4^)=K=3Z-=W%LVD7%O=S1:7+.DFX
MH41F5"&X#\<XSCO7?+<(]S) %DWQJK$F-@I!SC#$8)XY )(XSC(J6D^GS_&_
M^8+2_P OPM_D>.>&X9K'3_AW -&U2"6SN)_M@&ESKY6]'7+G9@ LR\]._09K
MMO%*7-KXET#5VL[F\TVT\])TMX6F>)W4!)?+4%FQAA\H)&[TS76T4V[@<#+8
M0Z/K>AZI9:9=IH-M%= P16LDDD4LK*PD\H N ?G'3*YZ 5S:Z#]@UW0;F71;
MMH6UZXO(E73Y)/LELZ$*&*J?+!DPVTXQG) P<>Q44)V=P>JLSQ%85N=2LVF\
M/ZJYB\5RWBO)HMQA+5P?F!,? +;21UR,D<5>^SZG/J&J7-O;ZW:VD'B$WKF'
M3V$K0M!L$D22QE9,."2 I/<#.*]?=UC1G=@JJ,EB< "LO2O$>E:U<306%RTD
ML2J[*\+QY1ONNNY1N4X.&7(/8T1TT7];?Y ];O\ KK_F<);:+_8&JZ5K%O%K
M>I:2;JYGN1<6F9HY944"5;=(U8#(8$!,C<3C!K1OM.BL-7\(7&D:/>)IMO=W
M3M'' Y*&6-B"5/* L3][ &><5UNIZ_I.CK$=0OX8#-.MM&I.6:5L84 <YY!^
MG/2M*A/;R!Z_,\?T_3[DQ:A]CT>^AL;;Q.NHR6K:?)#YUMM !C5E&[##=M'/
MR].1F+QCH_\ :46NZM;Z+>S6M_-8_9X#ILK2-+&Y,LOE;-R?N_EW,!G!'.1G
MV6JM_J=AI5L;G4;ZVLX <&6XE6-<_5B!23M;R_X'^2!ZM^?_  ?\SDO#\I;X
ME:_)'8W\-I/9VHBDEL98HG9-X8!F4#(#*/\ ]1JGKB75EXL\3W#:=?S07FB1
M0P26UJ\P9U,H*_*#SEUXZ\YZ D=W:7]G?Q++9W<%S&RAU>&0."IS@@CL<'GV
MJQ1)75O)K[[C3L[^GX6_R/'(+2^EC\+V6G:=J-I=+X<N+)YGTZ:)(9W1 H=B
MF%^9&.3]>XS:30K2YT6YOKR'Q'=WEOI;V36-YIB!%R!M55C@7SL. 05+ =<B
MO6:BGN$MT5G60AG5!Y<;.<DX&0H.!ZD\#J<4YOGOYW_&_P#F*/NV\K?A_P ,
M>8Q://!X4\'WMK::C8BTB1;_ .QV"_:T81% QBDB8MM8L/NDX;(JY+X=_L;P
MI;ZAHD6J7T]AJ7]I0QW,02>57.)D6,(FW*N^%*CFNXUC6=.T#39=1U6[CM;2
M/&Z1\]3T  Y)]AS5Y6#H&4Y5AD&FY-MR\_\ @B2LDOZ[?J>?>']&U?3_ !5=
MVE[!(^FSN-7,V/D6=U*/" .N&^8#V%<[864Z^&#%:Z+J,$5KXK6\$']G2Q$6
MQFR&1"H) '8#CN!7LE(S!5+,0% R2>U).VO;]'?]+#>O]>37ZW/'-;6:ZMOB
M(\>B:L;B_$"VG_$KF+2%8U7Y2$P0&!Y!QWZ<UW7BZTNM?^&NHVUA;RR7-U8X
MCAD0QN20#@JV"#['%=)]IB\^*(;V,J%U98V9,#'5@-HZC )YYQG!J:ETMZ?@
M._O<W]:_\,<-8V"Z[XJM]0CTZX@TZ+2I+*Z^UVK0&=F9,)L< L%"MSC'S<$\
MTSP9#=6TUS87\4AA\-[[.WDVES*K8=2 ,DD1;%]<DUV]U"]Q:R11W,ML[KA9
MH@I=#ZC<"N?J"*@LM.BLK5X!)+(TC%Y9G;#R,>K$J!@_0 #MBG?^OG?]7]Y-
MNG]=O\AUM>0ZEIXN;4LT<BG;O1D8'D$%6 *D$$$$ BO)[6"YA\)>!--N]%U0
MRV&J*]TATZ601JGF L<*>,LN#WZC(!QZ]!!%;0+#"@2-1@**DI;.Z\OPU'TM
MZ_BK'C_V?4Y[_5+BWMM;M+2#Q";UC#I[+*T+0;!)&DL963#@D@ GN!G%=[X.
MTBVTG3KLVL^I31W=RUT7U"(1.68#=B,(FP9'0J.<UIV.MZ;J=]>V5E>1SW%B
MP2Y1,GRV.< GIG@\=N]6;J]M;*&26ZN(H8XXVE=I'"A47JQ]AD<T7M'Y?U^0
M/5_U_74\5N[*!]'U6U3PUJ6/^$GCO+:,:)/@0;H][J/+X&U7R.I].>=;4[?4
M+_5/&"V&EZBT$EQ8SB)[.2);N*+:)D0NH5B0,8S\P]17J&F:G9ZQIT.H:?.)
M[2<;HY5! 89QD9^E6Z:;5O+_ "7^2!V>O?\ S?\ F>+^+X7U>[\375MX8U:>
MVO\ 1(H8';2W!^T*[[?D(WAAQSMXQG(&">MUA+V ^'O$ND:=<SW*1?8IX# R
M2>5*!@LK ,-LBH3D<#=7=T4)V5OZZ_YAUO\ UT_R1YUJNG"P^('AD6=A=-)#
M87%O-?QV,C*&< 1[Y%7'WMYY/&23C-8]M#?)8^"K,^'=4;4M(U ?;B+4@9,;
MAY!*V$8,QW$AC[\X!]=HH3M_7G?]0>O]>5CR".TU.VT32-,30]3GNM/\2O<S
M*EL57RC+*X=7;"L"K#D'CH<<5/8Q7:>(= O'TC4+2"TU*],UM'I\K+#YBR?.
M9""TFXD'<IV?-C' KU-KA$N8X"LF^168$1L5 &,Y8# // )R><=#56]UO3=.
MO[*QN[R.*ZOG*6T)Y:0@9. .P]>E";7]>5OT"6M_ZZM_J<Y\-#*OAVZCGM+R
MUD&HW4FRZM9("5>5G4@.HR"".E9\#7VB^(##90WUWI$CW-U<0W&FOOLRV\EH
MI57]YN8D;!N;#>E>A44GK]UOPL!XYX=CGL=/^'L0T;5(IK2>?[8/[+G7RMZ.
MOSG9@ LR\_CT&:=:6\C:AHES?Z#?QV,45_#<V(TJ65(-XSM)*LTN[GYN5)/
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M-JWV.Y^W6@?0YHRF"\1^7[3Z[=X1OH">]>FZ;JUAK&F1ZE87*3V4@)28 A2
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MV Z@$D#M26G]>G_!^\'J8KZKXCAU3Q1I-I<R:C<6D%M<VI:.)'42%MZ+P%.
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M"3VTHP\;C(850MO"^CVUG<VHLS-'=)Y4YNI7G>5.<*SR%F*C)P,X&>*2TO\
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MS-[B69E2-_)<Q;V&50R8V!B"#M)!]JX?PWH>OV&I^#DNM NHX=*M[J"XG-Q
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M!G(X;/48I+IZ?HP?7U_5?\$ZJ;Q[X8M;6ZN+K5%M4M2HE6YADA<;L[2$=0S
MX." 0<'%3Q^,=#F8+#=2ROO="L=K*[+MQN+ +E5Y'S'"G(P>:XC6_"MU=^&-
M4?3_  MJJZS>6ZV;?;-7%PQ4.&^5I)V&P$'T;)^[R:Z'Q/I=_J$%M?:=8ZI;
M:O%;[;>>TNH4:-FZI*K-L= 0,_>_V>:?3^NP'8QNLL:R(<JP# ^H-.JE837N
M([>]MF\Y($:6Y0KY3R$?,%&[=P>>5 P1R:NT/<2=T%%%%(84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0]'9@G=71W%%<I=^,)++0(-2G@TW;<RQQ0S1ZCNM27!.YIMF57C&=O4BI/\
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M\_U;L3;2W];6/(O$&@VB:W<:%)J.EZ+I_P!FB727O;9Y2C$L6-N_G($D#'H
M3C;CCBK5O:Z9>ZWJ-AXNO635DD@;2[J3]S.T0C0YM\Y(8N'W*N3S@YXKU.BD
MG;^OZU&]3SGPFNA:)XM\:7$\5A831WBN9GC6(I"T49R6(&%+Y/)P3GOFO0G6
M&ZMV5E26&5<$$!E=2/R(-%Q%YUN\?FO%N&"Z$ @>V15/2;_2;NV,&DWMI<Q6
MN(66VF601$#&TX)P1Z&D]5;R#K<\6T]O#UCX>\)V3M8V=P?$;FZ0%86(5YE&
M\C!. 5'/0,HZ$9NV^I^'U&IZ.DEG)IJ>)-D5OYZK9QHT6?WHP1Y9</A< %P!
MD<U[9133[_UM_E^(/R_K?_/\#PRRMM)GT_PL-2@L;F&R\0WEK+O@#)&G[W9'
MM;)52=FU#_L]\5ZWXH-^/"6JG20WV_[))]G"#YMVTXQTY]*V**&[JW]=/\OQ
M!:2YOZW?^9XRD.GV>CZMK-MKMI<6<MF(;RRT6U:T*R%U_>3LTDA1QDAB5W;<
MDYQ4,$\5B->M;%K8:4NH6$]S;Z6K");1E'F,B@\H2!N90 1FO9DN[:2ZDM4N
M(FN(E#21*X+H#G!(Z@'!Q]*6YNK>S@:>ZGB@A7[TDKA5'U)XHOK<5M+'E/BP
M>$]-\'C^Q]3M4TZ\UBTE5(;E1;QXE7>(BN H 4LP4\<GBMSP3>:4OCGQ?IFE
M7%I]G26"9(+=UVAC'B1@!_M 9QWZ\UW]%"=OZ\E_D#5_Z\VSS;Q2NA0?%"R?
M7Y8%T^?1YQ*M],?()$D8&58[!^7)QWQ6'L@?1]#TO5X@Z3"^-BFJ9, AW_N0
MT9&Z27;MV+E2!DYS7H=QX>OIO'5KXA74K=;>"U>U^R&T)9E8AB?,\S@Y4?P]
M,_6NBI6]VW];O_,J_O7_ *V1X;X?70?$>L^$+'4KZ.^:X\/R0W5O)>LVYQLP
MI7=PV QXP?ESVXT++P/X?URU\::4FE6$>J1:E*UH_P!F7?" B-'SCA"<\=""
MW7FO8JH:M/+#;Q>1J%E8R/*J![N/>KY.-JC>GS'@#D_0TY.^WG^+N):?A^"9
MSO@I[37RWBG^S8[:Y>!+),Q!701_ZQ<XS@2%E_X *S_%UEII^)?A2ZOK*UDW
M172+)-"&W2 (T8SCE@=Q'?KBNWTZQCTVPAM(BS+&.6;JY/)8^Y))/UJU1)W=
M_P"NO^8EHFOZ_K1'CUE%'/8:,\#1IX\CU%#?!6_TGRS*?-$G<Q;.F?E^[CM7
M;_$JTCO?AQKT;VZSE;-W12F[# 9! ]1US7544GJK?UT_R*3M*_\ 77_,\>>;
MP=+XML[-I=)738_#<N8-R)""75^5X!XR_P#X][UF:?=KK>@>'8M4UC28=,DT
MA8H;C4[<W$0N58AP&$J!)0NS!.3UQWKW2BFW??\ K5_Y_@):?UY+_(R]"A?3
MO#=E#=W[7;6\ 5[N5/+,@4??().,@9Y-><ZQ+<^-]*\1:GI3:+/I^T06]]+J
MAB:U\@[]^T1,!E_FR6&5V]!S7K5%)W;;ZA&R5CRG4O&6E^)/ F@:O+=6L\ N
MXEU*P::-$E;8VZ)RY"#GY@'(#8 SR*YZ\71$T?3;V;6H5BF\11?9[6/6S)%;
M6V]28RB2F(;1R=O"@CFO6]3M)=:>UNM'UB"&>QF;[T0N(2V,$.H93D G&&!&
M:NZ?836TDMS=SI<7LRHLLD<7EIA<X"KEB!DL>6)YZ]*::O?SO^7]>0NEOZZ_
MUYGF/B#0;1-;N-"DU'2]%T_[-$NDO>VSRE&)8L;=_.0)(&/0 G&W''%0ZAI]
MUJ6M7=CJWB&PL-2C:%M-N;K3V-VR+&A+6[><N"6#;D"D\G.<BO8Z*$[#9X5K
M=QH/E_$EY-0MY;NW:*2T,MWO:.81CF/<QVL)"1\O0_+[5?U'4;6#Q%J,/AN\
MMA>7WAQ)2MK*&>>7?DOA6!>3RR2#G<1WKV&>ZM[4(;B>*$.X1#(X7<Q. !GJ
M2>U$=S!--+#%/&\L6/,17!9,],CM26UOZVL#_K[U_D>*:O9:9;^#/%&IVWB7
M3)+2XL-AM=*A:TB6Y4Y4O^^;]ZV<%3@MCD'%0>)7T&:;7+#39+&X%SX66=HH
MG64RSH=RN>I:0(<YZXYKW>BG_7X OZ^]?Y&5X<33E\.6*Z7%;QV1B!C6WC"Q
MG/)( &,$Y.1US7E^O^%XHYM>\,Z7H]H)1*FN6+?91M0!?F0'&,F2,+C^ZY["
MO9:*&[RYE_75?<[!%6CRO^OZ5SQ[Q)/HTOA*R\52K%I]SJNKVERK.XA9XU=!
M\^"-X" M\V<9)XI=<U_1SJ/Q*4:K9$OI,*(!.OS,(Y%('/)W,H^K =Z]9:\M
M4N#;M<PK.(S*8RX#!!U;'7'O3X)X;F".>WE26&10Z21L&5E/(((X(I/5-=-?
MQ27Z#B^5I]K?@[F7X8N+>^\):5+;S)-"]G& \3Y!PH!P1W!!%>46$6F-HDUM
M8R"3Q3;Z_*MB3(TETD8N0"<L2WE[ 0QZ'OS7M,-S#=VYEM+B*5<LHD1@ZA@2
M".#V(((]JQ/"/AZ]\.6-W;7>HP7OGW<MT&BM3#M,C%F&"[9&3QT_&JO>;E_6
M]_Z\B$K04?ZVL<&]E)J?BF[&H:[IVFZS;:DTL*-9,;U[<-E%CD\X;HF3@A5P
M.<\@FH/#5EX0N?"7B;4KR:QNTM;V]B2>[NO.58V8>6"78@@E4*DYR0".:]DH
MJ&O=<?*Q=_>OYW/&M 'AP:?X9^WII*^&'T@_:&;RQ;-?_NP?._A\S .-W.<]
MZJ0VEBVN>%-/UJ[9X9KV^BM[>ZNV&^S(=8<H6[YP"1D@@9[5[A15N5Y<W]=?
M\[>A*5E;^OZZ^IX-J8\-65E\18(KZ!Y+$0FP$]\TSPR+& #&78D,'RO'(/'M
M77^']0T:+XHI!IUY9#[=H<<LBPS*3<3;\[C@_,^SG)R<<]*]*J*XNK>TC$ES
M/%"C,$#2.%!8G &3W)[4D[6_KHT#5[_UU3_3\3C?'KZ=+?Z)8:E'"Z7$DNQ;
MUO\ 1&8+P'7!\Q^?D7(Y!.>*X_0=;L%_X5I#<ZI;FXC>ZC=9)AN4['1003D<
MX4 ]^*]GHI1T=_ZZ_P"8WJ<+\.M2L;^^\6BTO+>X/]LR28BD#?*40!N.Q*M@
M^QJ'Q"NER^-+F+Q=]E&C/81K8&\($1FW/YFW/ EQMQCYL=.]>@44/IZ6_"P=
M_,\7\K2%F\!0^+3ITFHEIA+_ &D(S,;?9)Y/F;^>NW&?XO>O1O'=FE[X!UV!
MK=9\V,I2,IN^8(2I ]00"*Z*BB?O1:]1Q?+)2]#QJTF\(OXA\+6;RZ4FGKH%
MP9H"R)$2WEL2R\ YPYYZ[2>U9^E7L6K>&/#L-_JNDQZ,+.>W,VIP&XMUF67"
MJV)4".$VE2Q]<5[K13;N[_UNW^I*5DE_6R7Z&/X7LYM/\,6%G-J+ZC)#'L^U
MNA0R@$X."2>F.<G/7O7&>%8='O;J&?49_)\96EW.9TW[;F4%V 5A]YH,%2/X
M1@'C%>ET4-W;8):6/'K2&*YT_1FB,:^.TU!/MZAA]I\LRGS1*.IAV9QGY<;<
M=JT['P_I=EXBU/P6=(M38WES'JT8-L#'Y(QN7IC(D4 #TDXZ5Z=10G;^O3]5
M<;U_KU_SL>06E@U]XA:34->TW3=9L]1DD>$6;+>O;"1L()/.&82A'(3:O7J"
M:Q-)U#P_8Z1X>OH=2M/MJ>)YHQ</=!Y1;F1P1N8D["I0GL<@GDYKW4W,"W2V
MIGC%PR&18BXWE00"P'7 )'/N*EHB[6^7Y_K_ )A+6_S_ "?Y7/%WOM*7Q?I^
MIB:"T8:Y<V]Y/<38N]ACDPLCC;Y<>0-B'/&T@]:S=+O_  ]9Z/X?O(M1LS=K
MXGFB$\ET))!;F1PP+,2=A4H3G@Y!/)S7O5%$7:W]=?Z^\):W_KO_ )_@>-:7
MI.CKHNNVT3:1IUU'KT[2+>6P\B6)2S)%/C&(]N6&3@8! ->B>"M074_#45RE
MA'9*99!Y<+EXGPY^>-B!E&Z@X'!KH:IRZMIT.HQ:=+J%K'?2C=';-,HD<>H7
M.326UO3\/^&!ZZ^OXGD_B&YT[_A+);Y'@AO;/7K1)IKE\W*1G:I"8QY4!!/4
ML&);IFLG5[SP_#IWC:[CU&UDN[;6H)+*62[\V2-OW9)C+,2.D@X[*1T&![U4
M2W5N]T]JL\37$:AWB#@NJGH2.H!P?RIQ=K?UV_R_$'K?^N_^?X'B?B:[TK4/
M#OB.34FCE\1+?*]KU>5K4RQ^48<<F(KC.W@G.>:]MMYDN+:*9-P21 R[T*G!
M'<$ @^QYJ2BC96_K:P/5W_KN%%%%( HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "JVHW$UIIEU<6\*S3Q1,\<32! [ 9 +'
M@#W/2K-4]6TRWUK2+O3+O?\ 9[J)HI-C;6VD8.#2>V@U:^IQFF>.=08:Z+I+
M34/[/TY+^)[")XUDW!_W8W,P?!3[ZG!STXIDGC'Q);S26L=KHNH2G3/[4699
MI;=$C_N%0LF\^AW*#Z#%7]0\+2:98ZEJ-G>ZO?ZA-IPLBOF1!G52=K#"KAEW
M'H1G'3/-9>A^&H9+2:QT>]UFULKM&CO3-H]O8L 5ZK_HR%G/ SAAC=WP:<M;
M\O;_ #_X'Y NE_ZV_P"#^9+'XSUV/1M(N;V*R6768HY+8VEE<7)A'E;W+Q)E
MGYQC!'!Y/&3''X_U:6TM;273I['5)?/)DDTB[F1DB90'6!0) K[QC<1MYR2>
MO1CP=:+H6F::M_?+)I8 L[Y6C$\6 5'(3:1M.,%2".N3S4MWX6BN_LDYU/4(
MM2ML[-1C,8F(8 ,""AC*G:/EV8XR #52M=VVO^'3_@DJ]E<YS3O&/B;5M5TG
M3_[*M=,>^L)YV-['+YD<D;A?]6=AVG((!()![8Y72_&NL74/AN]N8; 6VJ7;
MV,L,2/O211)F17+8VYC/RE2>?O5N3>#UFUZVUD:WJD=U;V[P(%,)4A^6)#1G
MDD ]<#   '%4+?X<VUK9Z5:QZ]K'EZ9=O>6Y/V<GS&SG=^ZY'S/_ -]'T&$K
M7_KN_P! >VG]:?YE"W\>:O?:G:-8:7+=65U<26_E_P!FW2>2 6"RM<%3&5)4
M9 '&>IQ3=(\:Z]>6WA^\O(=-CAU6]GL6BA21FC9?,VN&+ $?N\$8YZY'0=+:
M^%8["2<66J:C;VDK-(MFC1F**1CN+IE"PYYV[BO^S67;?#FUM+;2K>/7M8,6
MEW;7D 8V_,C9SN/E<CYG_P"^C[8(VZ^7_!&^MOZ['/Z'XCU_3O"LVH7M[:S)
M+J]Q#+=G3Y'6U59) 7=5DRRDJJC&T(#R3BO1M)O!J&F0W:W-K<I*"R36IS&Z
MY.".3VQGWS679>$HM,M[B'3]5U*V6:>6X78\;>6TA)8*&0@C+$_,"<]\ "M'
M1=&M=!TN/3[/?Y2,SEG.6=F8LS'&!DDD\ #G@"B^GW?D@>_WF#XAUWQ!:>*]
M-T32;?3=M_;3R)/=-(Q5XQG!5<?+DKWSUZ8YRW\>:J^I*+339;JWBO?L4\$&
MF73DX;8\JS@>6 IS\I&<#J#Q73WWAJ.^\3Z?KK:C>QS6".D5O'Y7E$/][=E"
MW.!_$.G&.<I#X8AM=4N+NUO[ZW@N9#+/8QLGD22'JW*EE)[[6 /<<FDNE_ZU
M_P @?6WE_P ']#G)?&FL-IMEKMM'8?V5>:C'910/&YFVM-Y?FEPV.<$[-O<?
M-VJ&7QGX@A\/7U\W]F-/8ZZ-.D MI LL1D1,@>9E6^?.<D<=*K^+O#J:#IUG
M'IAUFXMGUFWN_L$%NUQ' !*'D9=D9=1U."Q&>@KH+WP#IFII?))?:FEI?W27
MLEM',(U64%3N4A0XSM&06Z\C!YIQMO\ U]E_YA+M_77_ ('W&1K'CG7]/LO%
MLL6GZ:TNB31+&K328:-UW;CQRW*_+P.OS&K6J>*=>TVY7394M?M\D;W,<EMI
MUU>((@0$5DB^8,26!;.. <'.!+>?#:UO5UA)-?UH1ZNR-=(&@.0@ 4 F(D8
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M]0F$TIS!A6"%!@>5C 7'#9'R@]:U-$T6VT'3OL=JTCAI'FDDE(+22.=S,<
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MWF,312Q-RP8>7NY//!'H,#BG6_@Z"!8U.J:C*+:-H['S3$WV(%=N8_D^8A>
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M%>RO_6W_  1U%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=+=A^\]J2\_Z_I?B#\OZ_K\B/5O%3R6.EW_A[6X[NSGUN*SG<PJV59P"B-@
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M_P#7]6O\['7V_BW1;Z^ M=3N))4LFNFL%MF#F/*X<H4W@\C XR&S@\$<PGQ
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M*01/,8D/\3!%.!W)[#DXKG/&FC:]KCZI#:Z7*;>[TGRH6AFAB8S?,=DS;MQ
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M7,I;( (8'.3PO2F[+4$G_7JU^AWMWKFF6.J66F7-Y''?7Q86T'):3:"2<#H
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M  @<\Y/-:]YXFU;PU=7\#W9OHTT.*^@C>)$$4F_RR!C!*\@X9B>#\U2M5?\
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MYN)K86DDAU.Y):(#&W_6?CGKDD]2321>!] AT^+3TMKDV<051 U].R,JYPK
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M4LEG"]!YUS)-L']U=[':O X&![4W4= T_5-0LKZ[6X-Q8MOMVCNI8PI[DJC
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M2.OM@ZOA3PK_ &+)&\^A>';.XA3R_MFFPA9+@=,D>6NS.,D!F^M==13YGO\
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M-/1-#US2]7\2WCV^F%-0\MK1([IQ@QQB-0X\KY00 >-V.F#UKL**'K_7<7_
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M"AB3VR0. 3STK;HOI_7]; %%%%( HHHH **** "BBB@ HHHH **** "BBB@
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MJ1J,EF. !ZYH3MO_ %I;_@C:OM_6M_\ @' ^(5TN7QI<Q>+OLHT9["-; WA
MB,VY_,VYX$N-N,?-CIWKE_*TA9O 4/BTZ=)J):82_P!I",S&WV2>3YF_GKMQ
MG^+WKV2">*Y@CG@E26&10Z21L&5E/(((ZBI*%[K7]=_QU_! ];_UV_#0X;XJ
MV=G<>$[:2\MH)88-1M69IHPRQIYJAR<]!M)!]LYKB/$-UX9EN/'^RXT\"VTR
MV%E&)%7RI$1PNQ>-K*Q4# R"0.^*]KCNK>::6&*>*26$@2HK@LF>F1V_&I:2
MT_KT_P AW_KYW/&M0 \2ZC+'?>(-*L#<6]O)I-U<6K32D>6NYK:03* ^_<"
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M+FRDLYXQ);R1F)XVY#*1@@_A7+1?#ZSCETZ0ZSK3MI@=;'=<*/(5@!CA!O
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M8%964Y)=@1P,  8 QD]:SYK:^A^*6NOH8T^WNY-(MY7:X@+K(WF2#Y@K*<D
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MK_UK8V:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>annex-d_002.jpg
<TEXT>
begin 644 annex-d_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2X Z # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN+.;S?-#[\[F''\/09QZGM>U[Q;H_ANZT^VU*]MX);Z7RXQ+*$"@ DL2>@&
M/J0*P?#?FS?$?7=1BTB_@L+ZSMMES/;&!6=-X(*OA\_,/X>W..,W/&4%R=8\
M*WD-I<7$5IJ1>;R(BY0-"Z@D#MD@9Z#/.*+?#\OU#O\ UT1T#ZSI4>I)IKZE
M9K?R#<EJ9U$K#U"9R1^%7J\KNM'OKCPUJ?AN:QNSK=QJ;W=O=BV<Q#,VY)?.
M VJ53C&X-Q@#I7IEYO73KC;$9W$38B!P9#CIGMFD](W_ *VO_P  /M6_K?\
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M4_M&T_L_;O\ M?GKY6WUWYQC\:Y'Q;! WQ"\)79TJYN#;O,9KF+3Y)A&I0A
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ME9!LVJ6$?)P'QCUQWP6UO_7?_+\25LG_ %T_S_ ]6FUO2K>*VEFU.RCCNO\
MCW=[A0)N,_(2?FXYXI+C6])M+NWM+G5+*&YN?]1#)<(KR_[JDY;\*\MT6WU*
MT\%Z7=VD6KV6L6-O+;"VN-(EEBN%:0D1.A4,HX7Y@5 SR3C%2^*8-3OHM6C.
MA7=K<-'8RLEK9O.+G8RLP$F"H"$L B@,<9Y!X+:_UY?YAK;^O/\ R_$]0N=7
MTVSO8+.ZU"T@NKC_ %,$LRJ\O^ZI.3^%8UMXUT;4[G6;*RU?3XKC3LJ\DTJL
MJD 9<KN4E%) )R.<C(K$CLX6USQ!9:]I%[>6^JW$5Q:3):R.KHJ)MC+*/W15
ME)^<J/FSGK6)XAT^X;1OB'93Z)?7,E[.)K,)9/,'8PQJA4J#R&4\C[N,G'%+
MU_K;\M2NIZ9>ZSIFE6\,NI:G96J2D*DD\RQ*Y_V=QY^E.N]7TRP7=>:C:6X\
MLRYFG5/D&,MR>@R.>G-<;$S6WB'^U=0T^_N--O=(AM8%2PED>-P6+H\84LF[
M*\L ..3TKGM T5O#WB7PZ=0TF\>2TTFZ2:>/3Y9A'N<-%$9$4@E4W* "<=!U
M&6UO_7?_ "7WDK;^O+_/\#UR">&Y@CGMY4EAD4,DD;!E8'H01U%9LGBKP[%]
MJ\S7M+3[(X2XW7D8\EB< /S\IR",'TK&^&*SQ> =/M[FUN[:>#S(VBNH'B9?
MG)'# '&",8X_*J?B30KRZ\37-G;6\IT_Q#8_9KV=%RL#1G[Q]"R,R@^H'I2E
MH[+^NHUJM?ZUL=-<Z]I826&+6M,BNOLWVA/-F5@L9Z2E=P)3ISD ^M9>H>-;
M"WU:;0[2[L)M82R:X2*6X$:N^,JG&3DC+8&2 /?-<A?Z?J=[\)M836M)N)]5
M^S"P@A6V>9Y&BRJ2*H4D98LP;'3!S6BTD\'BB34SINIM:7'AQ(49+&4L)%=B
M59=NY6P1P1D]@:)Z)V\_R;7Z#CTO_6J3_4Z7PEXHM_$.B:;+-=62ZI<V:74M
MG%*-R!AUV$E@ON:N>)/$-CX7T*YU74)52*%?E4L 9&[*/<FO.?#*36<WPZA&
MD:G UI9S0WA.F3(L3.H #L4P,NI.?QZ'-=K\1+.YO_ &L6UG;R7%P\/R11+N
M9L,#@ =3@=*J=D]._P"J_0F&KL_ZW*D'CJW/BFYMKJ[TF'1%T^.\@OQ= K)O
M<IRQPHY!&!GMSVKIKW5],TV"*>^U&TM892%CDGF5%<GH 2>37GE[.MSXVU:^
MDT;56A;P]]FC=M*G;<^YB4!"'DAEX_ \@@9VGV&H2:?H,FI-X@M+*31(]/E%
MKIHEDBE4D2+)')"[JK#&&  .WD]*5M-/ZW_R7];M=_ZV7^;/7P0P!!!!Y!'>
MN;7Q/=ZEJ=[9^']-AO5L)?(NKBYNC!&),9*)A'+,,C/ '/6M/0-.CTG0+'3X
MFN&BMH5B0W+!I"HX&X@ 9Q7)>&VN/!-SJVF:G8:A+;7.H2WEI>6EI)<K(LAW
M%6$2LRL#QR #V-&G-86MCJ+;Q!!_9US>:HJZ3';3-#)]KF10N,<ELXP<Y'/3
M'TJT-8TPV]O<#4;,P7',$HG7;+QGY3G!X!/'I7-:X;UM?T#7)K"Z.F6;S^;#
M'$9I5+(%CE\M 6_O# R0&&1UQQKZ)]E\6:5J+:+>-:S:]+>0JNFRN;:!H=N6
MPA\O=+AMIP>A(&#@6NC_ *_X?<;T5_Z_I'J4?B+1)OLGE:SI[_;"5MMMTA\\
MCJ$Y^;\*=<:[H]I.L%SJMC#,T@B6.2X16+GHH!/7VZUY3>+,WA_Q&L.C:L)9
MO$D5U"JZ3<!GB$D;%P-F<?)(?_VAF?R[22?XA:59Z+<33:E,BVZ063!2[VZG
MYVVXC(9MQ+XYSWI+:_\ 6R_S_ =M;?UNT>I3ZSI=KJ$.GW&I6<5[-_JK:2=5
MDD_W5)R?PIMQKFD6DWDW.JV,,OF+%LDN$5M[?=7!/4]AWKR_6[#4Q]KMCIM]
MYEO>Z=+(\%E)-]M$9C#2F3!'&"-B88;<G()JOJ]HOV7XCBRT'45DU!HOLGE:
M1.IF8(-Q4A.?GR<^O/?-.R_KY?Y_@):GJD?B/0Y9KN&/6=.>6S5FN46Z0M %
M^\7&?E [YZ5>M;JWO;6.YM)XKBWE7='+$X=''J"."*X'5X+FWUW3[W3H)A%X
MCMET^[S&T;QN 665E;!!">:#D9X%>@QQI#$D<:A40!54#  '046T_K^NPK_U
M_7S'4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%0W<3SVDL4=Q);NZD+-$%+(?4;@5S]012;LK@9]IXFTB_U5M-M
MKHO= ,R@Q.$D"G#;'(VO@\':3@]:UJ\?T.XU_2?"'@T6.NOY.I7XMIDN+:-R
MBDN?D8 8^Z?O!CD]0!@]"EYXBO9];T^+7WAN-"AB G%I$!=RF,N6D4@X4\#"
M;3UY]&[)7_K2S?YA9WM_6[7Z'?T5YCIGB3Q'XBU!E&I+IUO/X?BU*.."U1GB
MD8D?>?<&&5/;H<<$9JUH/B36;J_\'7%S?>;#KME))/;>2BI&Z1JP9"!NSR0<
ML1Z 4^5WM_77_)BOI?\ KI_F>B45RGB_4+^"YL[/3]2EM7EBFD,=I"DMS(5
MV[0ZE%0$_,S8ZJ 1FL#3_$/B+5[KP;&=3BM8=8TR6>Y\FU4R"144[E9B0.6&
M!MP,<YSPEK_7K_D-Z?UZ?YGI5%>7:7XAUXP^'M9O]:F.FO?3:=?QB"%59UD>
M.*4G9E=S*H8 @9(QCFNW\/\ V^;1WNI]0DN'NW>:W,T2 0QL3Y:X0+D!<'GG
MD\TVM+_U_6H=;?UU_P C:HKS#3_$7B0>&=/U^YU87,AU8V,]FMM&D<J&X,0*
M\%PPX(^;&!@@]:L'Q%K8\56"0ZH9[6[U*>Q9$ME-K&JHY7#D+(T@*_-ABN0P
MX(HL_P"OO_4/Z_K[CT5W2.-I)&544$LS'  ]2:<#D9%>,ZM<>)M8^%^M:I?>
M)) L+W-L]O;6D<:R[9]@.X@L!@,, \@CG@D]1/>ZIX6\2VJZGXBOKS1[NRE\
MH30VZE+A!NP2D2YR@8@>JG.:+?U\KA_7XV.^HK/T2"^M]&M8]2O)+N]V S32
M*BDL>2,(JC Z=.U:%#5G8$[A1112 **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L/6/#,>LZQI>I/J5];2:;(988X/*V,Q!4EMR,3E21P1U]>:W*
M*.MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *P]&\-1Z-J^J:BFI7UR^I2"6:.?RMBL  "NU%(PH
MY)Z>O-;E% !1110!GII?_$T-]/>7%P5),$,@0)!D8.W:H)SZL6/)QC-:%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM4+-(!@.3CEL$\]:=_>N+HU_74\MEBU=O 7BC6?^$KUT7FF75]#"ZW"A71"
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M;5'2+_=4C _"K\$$-M!'!;Q)%#&H1(XU"JJC@  < 4[Z6_K:P/?^NY)1112
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MO%DBDA+;2V]E0C#8!&TGD8R,XMMXQUB/Q!9Z+-X7>*XO5F>WF>^C,3*@!R2
M6'4 C;QGC=4.N>!-0\065Y]MUJU&HW-NMH;B/3V$<<(?>0L?FYW%@N6+$<<
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MW'J<YXQN:'HUOH6EI8V[,X#O(\C=7=V+,Q^I)JY--M_UN_TM\R(II)/^M/\
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MGY8RF>!@$5;N8]&,'C.T682ZZ-49M'#3-)<^;Y494Q%B6ZGDC@#KQ0E?^O\
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M19'V%0DH+%E)7^+!!SVQ6J^N>,(O%<&@3Q:&AN;:XN(;I/-? 1E"[HR5Y^8
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M/7J1CCK7-WGC?Q#:P^(+M[72XX-%U**V>)?,D::)]G1LJ%;#@YP1VQW*6O\
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MJX.Y2P8X8]5R .,'U!\._3]/Z_S!:F'>?#JVOH-:AFU[6-FLRK+=!3;CE0
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MRXQC]SP/E7_OD>^>G36-+DN_LB:E9M<Y8>2LZE\J 6^7.> 03Z9%5_\ A)]
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M$M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI-S;66IVFLV^G+9O87&G&X@O!N8A'VY,?.?F)7 8;O2DU6U26?X@1-X=OO\
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M+G^%L@=A38/ 'AZVF2:""^CDCM?L:%=3N?DAQC8/WG ^G?GKS52=[V\_R?\
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M$!IU..3^[4H#CE<M]>*AT3PSJFB:+J5H);2Z<!X-,1G9%CM\DHCMM)!!8@D
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M-=4\\RE=X48<H05!;=NVX!Y%85GX&U&7X?PZ'J::8UW:WINXURT]O-^\+[9
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MC# J"?6MGPYKEA=>+/ P?4[>6Y?P\Z.&G#.9&\HX/.=QVM[\&JY?>MY_H_\
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M)+=BTB,K0Q,JL5').6(' R?PXR>*\JO-6T#3]<U.*PO5\FZ\,H\ZZ=<J)99
MW#;N?GV'.XY.WGD"HUN]+TW2?'L$-SI5M9S:/#+;PV3[8"SQR)E,G#DG:"P
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M,7M$\&:N]Y<>1 +5SYGG&+!Q\OS @C)P.O/3O7EVCWGAB^UGP@M[J5E/;_\
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M &XV^2V:))(E0?-(7P$4 ]R6 _&N&;6)=&^(^IZMK=I]C6'0?.>..\,Z$>:
M-I8*%)P 0 !GG)ZTNMGY_P"87NN9>7]?B>GT5P5I\4]*<ZHEV]ANL84N!)8Z
M@ES#(CML ,F%"L&(!!X&0<D55?XLP1VFH-'I\%_<63P!QIFHQSPE)6VJWF$+
MR&P"N,@D=N:+ >CT5QEYXTU*TN-:M3H4)N=+MUO&!OL(\!#'.?+R'^1OEP1Q
M]ZJNM?%+3=+@$L8LV*VD5Y+#=7Z6\IC<;@L2$'S'P,X^4<CGF@/+^OZU.]HK
MS_Q5XD;6_#&MV^D6;7-O!IWGW%P+MK=H]\9D0)M&68#:Q!*C!QDYQ6]H]ZVG
M?#S3KQ+6>[>'3(G6"W7=)(1&/E4=R:+;WZ?\'_(+WM;K_P #_,Z*BN"F^(\U
MGINOS7.BI+=:,D4DT-E?+*A5P2,NRJ01@Y&TGIC-3ZMX^N="-TNH:"Y=+%K^
MV6WNE?S8D(WAMP78R[@2!NR.A)XH_K]0_K^OO.VHKC+GQS>:>ZK>Z"W^D6+7
MMFMO=J[2A "Z-N"A& ;/!8$ \YXI+/QO?W=GIDAT$0W&KJC:=&]Z"LF8C(Q=
M@I*!<8SM;.1@=0'9_P!?UY,5]+G:45PLGQ$E@FCLI=!F_M$:DFG7$27"&.)W
M 9&#G!967)'RCH<XXHU+XAW.CV>I?;= =K_3YX8YH+:Z5TV2G$<@=@I()XQM
MR#[<TEKM_6W^:'_7Y_Y,[JBN/M_$MS)XO@TS5/"YM+L6UQ-!=">.;=&K*"(]
MOS#=E200O( YZU2'CW49C?6@T>WM=032WU&WBEO"S*H.-LZ[ 8WY!V_,.HSQ
M2;LKC2N['>T5YY9^/)M+\): VK/I::I?V0G0WFIB"*1 JY9I&3ASN'RA3SGG
M S76>&/$-KXI\/6NL6BE8IP?D8@E64E6&1P>0>1UJW%IM=B4[I/N:]%%%2,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,O
M=-N;^^C\^YA.G1LDHMU@/F-(IR"S[L%<X. H.0.>U:=%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17,<LMM(D$
MPAE9<+(4W;3ZX/6I:* .'F^':SVNM WT%O<:E+#*IM+/RH8GB?>CF/>=S$XW
M'<-V!THO/A[+J>H:A?W^O3&YO(K<?Z/;I&D4L+;DD4'<W#9X+'J<YXQW%%"=
MM@.2U[PQK?B'PX=,NM=LTF:6-WFCTY@A",'&$\W()(&3N(P. .M6=+\.ZC9>
M+M1URZU.VG2^MXH6MX[-HRGEYVD,9&_O-D8]/3GI**:=OZ^0?U^IS5WX7N1J
MNH7NE:E'9C4U5;Y)+;S2Q5=H:,[UV-MXY##@<=<U(? [:9>32Z-J*6D,FF1Z
M>L,MMYH41[@K9WJ3]\Y'4G'(Y!["BETL'6YP-I\/;^%/#D$^MVDUKHUM):F,
M:>RF='78V6\X[3MQV/.3[#43PUK4?A^?1AK\#V_D&WMI)+$F1$*[?WA$@$F%
M/& G(!.>E=511+WKWZ@M&FNAF>'M,FT7P]8:7/<QW+VD*P"9(C&&"C .TLV#
M@#//7TZ5R-_\/M8OH=;A_P"$ALDCU6^BO7_XEC$QF/;A0?/Y'R+G\?7CT&BF
MVV^9[_T_T$E96_K^M3B+SP7K5WJ&O78UZQ0ZO9)9NO\ 9CGRU4,,C]]R<.WZ
M>G-J'PGJ-M_9M[!JUHNL65H;+[0;%C#+#D$!H_-SD;1R''.>,<5UM%+^OS_S
M8_Z_+_)'%VG@2>P\1:7J=MJD(CM&N))HY+0EYY)SF1MXD 7H,#:<8[U5OO &
MK7MCXCM#K]FB:Y<+.Y&FL3$ %7 _?<\(O/U]>.^HH_K\G^B#S_KK_FSB+_P1
MJNHZEJ5W+K\$7V[3DL7$%BRLNTD[@QE/5F;(QT.,YY++CX>SW=IK-O+JMNBZ
MG90VS+;V/EK"T18JRKO/R_-]W_QZNZHHN!QUSX+O=1\0?;]1U:VN+233GTZ>
MU%D49XWY8AQ)P<@8^4X'')^:I8O"-_MLENM6@N/[+1ETTFR*^6Q0H'EQ)^\(
M4G[NP<GVQUE%'E_77_-_>']?U]R."T[P!JFGP>&(!KUH\>A2NZ_\2Y@9@P*D
M$^=Q\K'GGG!QVKH?$.@3:U<:9-#>1PFRG,IBGM_.BERI'*[EY&<@YX/8UN44
M[W XN/P/=1^&)-"?4;"ZMG>9L7>F^8N))"^<>8/F&X@'('0XXKJ-,T]-,T>T
MTY999TMH5A$DQW.X48RQ[FKE%+I8#A5^&EJ-,M+0ZC*7M;XSQ2B, K!R/L_7
M[NQBN??..U;EQH5['K\NJZ5J45J;E$2[AGMC,D@3.&7#J4;!QGD=.*WJ*+A_
M7ZF5KNA0Z_X?FTFYGE42*NV=<;T=2&5_3(8 USMQX!O-5U&2^UG7VFDDT_["
MZVEHL"L-Q8/RSD$'!X(Y'IQ7;T4!Y'.3^';_ %31)].UK5UN&8#R9K6V\AD9
M6#*Y!=@S!E![#VJGKOA77?$'ATZ9=^(+-93+&S3)IK!2$8./D\[[Q91DYQC(
M &<UU]% '%7?@W5[S4=;O'URR#:KIZV+*-.?$87=\P_?<_??CZ>AS-I7A+5=
M%-M)9ZY;B7[/%;78>Q9HYEC!",J^;E'V\$Y8'&<5U]%']?G_ )A_7Y?Y'(:C
MX+NI[K57T_6?LL.KVWD7T<UL)BS!-@D0[EVMC&<@@XZ#K5Y_#$C>!O\ A&QJ
MMQO%L+=;PHH< <#Y5P,8&,=QWSS70T4=+!UN>5>-=!/AWP9XGU"[U2R"WVFQ
M6@@CM1;H)$W;?+^<]=Q^7D\=:F\4V48\":MXCU/7+2\W:-+:V+PQB*()(!T.
M]M[L0HR" <<**]/HH;;30UHT_P"NG^1P5CX=NO$&AVNH'7K2X<Z:UM8RQ6F8
MHDD50[,!)\[X7&05 _NUHQ>#IXM%T& :C%_:FB+MM;P6I\MAL*8>/?D@KC.&
M'(R".E=913;NVU_6_P#FR4K)+^NWZ'E7C:TM?#XTB>[UBTBU74=>M[F>YD41
MI\B%<B,L<(HV]6/7D\UNZKX$OM6TR^1];MQJ&H3P2W-R;$E-D)!2.-/,!49&
M<EF/+>HQW%%):+^O+_(;U?\ 7G_F<MJ/A?4M0\3VFL?VQ!"D%E)9M%'9MO/F
M8W,K^9\IRH(X./?K5#3_  !/9O;F758'2/39M.D6&Q\OS%<@[\[S\_R\DYSZ
M"NXHHZ6_KK_FP\_ZZ?Y'(6O@V_L++1S9ZU&FI:7;_9$N)+/=%)#A04:,.#_
MIR'SGVXKHX8;^.6'S+R&2(*WG P$,SD\%3NPJCG@ACTY];E%-MMW8K)!1112
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@]QG!K)@\!Z!;W%E/%%?B2RC,5LQU2Z/E(1@JN9.!C'Y#T%"_K[G_F-[??\
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MMQ!%:W6HW:ZM>3+;K EJ)((8U/\ JS)M0Y(R"Y;Y>Q-=-%X5T6#2+[24L_\
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M^29%>,)M8H,$%68GI\PK2^'MWK>L>';+6]6U5;G[9;Y^SK;)&L;!V^8$<\C
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M&E=V'S>(+.#Q-;: T=Q]LN8'N$;RB(]JX!^<\$\C@9QD9QD5HV\KS0+))!)
MQSF.0J6'/?:2/UKRV2.R@\;^&GA\07+MJ&DW92YEO/,8R,(\-'OR%)YPH&WY
M>!UJ;2+O7-1\!^&-12:XU)EBDFO+==0:WN+@!N'5P1NVGJI(4[@#VJFK+7^M
M6OT%OM_6ESU"BO--,O?^$SOKJT@UO4[&.'3;:XTUQ.T<AW!MTL@! EPP"D-E
M>.G.:BU2XE@O_&\4FLWHA31K>[@D6^D0))MD^>/#?("RKPN >G>E+W4V_-_<
M.*YG9>2^_P#X<]0HKRV'6;J'3]+UZZN;K4='-C:QR7%CJ1#VLIP':2+($N21
MDG<PYP.M7UU*_P!%UN9+]+RYGO9+F33KJ"]:6WGVH[+"T.<1E5X^5<$J"3FG
M)<M[]+_A?_*Y,7S)/O8]#K*F\06<'B:VT!TN/MES \Z-Y1\O:N ?G/!/(X&<
M9&<9%>;P7_BVRT+_ (2FVN[66"32Y9)(CJ<UV9Y@FY72)HE6(J0<JIQCMD5>
MM?[/L_B+X2G369;L7VFW+*]U>&3S';R^4W'Y=W/RK@<<#K3Y=;/^M'_D%]+_
M -=/\ST^BN2\=J]G:6&O)=7D4>FW4<ES'#=21QR0%@'WJK ,%SNY'\)'0FN9
MT2:>X\07?AZ>[U017MS'J5C(=0G9Q9[3D!]^0-R#(S_RT%2M?Z_KIK\F-Z?U
M_7E]Z/29+^.WBGENT>VBBD""20KB3. "NTDX).,'!R.G3-/3O$-GJ>MZGI,$
M=RMQIWE^<98BBG?NQMSRP^4\XQZ$UY=K"37_ (<U>&_U*_N_LGBR"".1[ED9
M4WPC'R%0,9.,#@\CGFK6LQ^1?^/;JQU&\A:PTNTEMY8;MPVY(Y"I9\Y?IR&)
M!SSFFN[_ *TB_P!1VULOZU:/7:*K:?.USIMK.Y!:6%')'J0#7-:W)-J'C>PT
M*>XNK;3I;":XW6UP\#2RJZ *'0AOE!)P#SGG(H::=OZ_K0E.ZYOZZ?YG37ME
M%J%H]M,\ZQOC)@G>%^#GAT(8?@:?;V\-I D$"!(T'"C_ #U]Z\HAN]<O6\-6
M]SKFHK#)K-W8%XI ANH$63:[,!DGY<9!QWQG!KM?%<-SI?PYU);35+V.XLK!
MFCO"ZM,Q1<@LQ')..3C/)Q@TF[1YOZZ?YE)<TE'^NWZ'3T5YA<#5;6'P]90W
M]W=KK,/FSM>ZM+; RK$F$25$9DW?,VU<9*GW!)(M6\.1:%K?B'699$LKQ[6_
M\C4)3!Y3DB)I =H9D+*&)49ZGI3:L[/T_3^O4E.Z3757_4]+FE>+R]D$DNYP
MIV%1L!_B.2.![9/M4E><ZDE[I3^%;B'5-2B&H:T#/;RW32*R2!F"'>20%"J-
MH(7KP:J6;>)]=U!M0BNK>U6WU22VNE?5IU/D"0IY?V<1[5<KM*N&W$D'/. )
M-_UZ?YC>G]>O^1ZC17C>H75]I%O-:I?:K/=^'=4-W=,VHSDRV!96&\;_ )_E
M8 9_YYM[@[%]<W[R:3#93326VNS7%QFXU:XM@0,&*-) '9,J2VU=N<'MQ2W5
MU_7]:_<.UM_Z_K3[STIW$<;.0Q"@DA02?P Y-9OA_7K3Q+I":G9).D#R21A9
MX]CY1RIRO4<@]>?4"N)TY]8;6=,\,>)-7('V:XF$ME>2*T[K( B&8!&)1#S@
M#/?/(K1^$\\$G@KR8;I+AX;ZZ21@X9@?.<C=CH2"#^--+?\ KK87]?A<Z/1/
M$-GK[Z@MI'<H;"Y-K+Y\1C)<*&X!YQAAU _*M:O(KH/;6GCW4K74+NUU&SU8
MR6JPW#*'D\J+:K1@XD#'Y<$'VYK2NA<Z-XBO]+GO]2)\0VJ'3]]],WV>;=ME
M2/+_ "XWAQCD -S@8H2O;Y?E?_,'HW_74]+HK+U&R$?ABZLXIKKY+5D207#^
M=D+P?,SNW<=<YKSBQUJ1)/A[-+K\L4]_I4JSF>^8I(XA&QG0MM+;R>2,D_2E
MZ?UO_E^(=+_UT_S/6ZR];U6UTZ&&&>UEO9;QS%#:1*K-,P4L0-Y"]%)Y(%<_
MX.O+FWU*31=5AO8M5CMA.[O?M=07*EL&1"QRO/\ "0H&< 8J+QCI5M>^-?"+
M32WB&2XF0B&]FA&!"Y& C#!SU(Y(X)QQ3MJEW_X/^0D]&^W]?J=?IUX-0T^&
MZ%M<6PD7/DW,?ER)[,O8U:KRN\OM5F\,ZEXBBU"]AURSU1[>&T%PWE%1-L2%
MH<[6W*0<D;N<@]*U_"=K>WOBGQ!)>:YJDXT[4]D,33@1E6@4E&4  @%N.."H
M/7.1*_\ 7H_U!Z?UZK]#I]<L-(U%;2WU1<NTW^BLDCQRK(%).QT(93M#=".*
MJ^$;_2M2TV>?28KQ8X[A[>1KTN9F9.#N,A+G'3YN?:L+QI96L_COP=+<37$2
M^=<AFCNY(0 L);^%ACW/<<'CBN:LY)M.T^;5+:^NXY1XQ>#RTG98FCDG".K(
M/E;(.<L"0>A%$5?Y_P":7ZCE_7W-_H>Q4Q(HXRYCC12YW,5&-Q]3ZFO,]/F\
M4:QJO]J075K;?9=5>"Y6;5)L>0)"HB-KY6P,5VD-NR<@YP<5O_$JYN[+PLEU
M9ZE<6#I>VZN\#*NY&E5&!)!P,,3QCIZ<4K;>?ZV_S!]?+]+_ .1V%%>1^,)+
M[3)/$5KINK:D;6VM;6^W_;Y2UM,TQ5EW[L[63)V$[1C( IOC+5I[/6O%\-CX
MAO+65-#BO(HH[W=MD#/NV*Q.W*A<[0#SGC.:%J@ZV/1+7PGHUE<M-;6\T:EM
M_P!G%U*;<-G.1"6\L'(SD+UYK:KS2ZL+JR\6^&+1_$FM26>K).UQ;R7FT%EA
M7[C* ZY))P&X/3%5M,U+4+K5K+0)]1O)-&?4KVWCOEN666=(T4I&9@0V0Q<9
M!R?+ZGFG;I_6F@KZ7_K74]4HKS"!O$,T-[96\]QJ5IIFJR1QQG4&M[BZMUC4
M[1,""Y1VQR1NQACUIDVL:CXGNK&PT=YH[>;33<VYN]4ELIC+YC*WS1H_F%,#
M*YV\@G.12]/ZTN,]2I",@CU]*QK&;5+7P:DUX\-[JL-H3(UODI-*JG[O ZD>
M@KC-/N+]8/!FJVVJ7MU<ZRRQZC"]R[QNK1,SLJ9Q$4(_@"^^:=M;?UU_R"^E
MSIM*U+3K+5'TW3M.U6XC,YMYM09FN$651DH\CN9,#.,D;03C.>*U[O4;#2(Y
M@RD,D+W30V\)=V4$;F"J,DY(^M<O\.=,MK-=>EAENW8:M<Q8FO)91@/P<.Q&
M[U;J>Y-4+^RM5^+&J7$DUPCC0ED4?:Y%0L7=<;=VTC ^[C&><9YJ9/W4_*_X
M7&E=OU_6QW.C:K;ZYHMGJMJLBV]W$LT8D #!2,C(!/-6;>5YHM\EO) VYALD
M*DX!(!^4D8/4<YP><'BO*?"1N+*W\ 0PZE>HNIZ3-%,GGDH-L:LC*AR@9<GD
M#GOFK>C3:YJ?@/1[B*YN-3F2[N6N83J#6T]U&LC@;9%QROR_+E5/ ) JY))O
MR_SL2FVE_72YZA6+>>*]&LKJ2VDN)I98CMF^S6LLZP'@_O&C5A'P0?F(XYI_
MAW48=7\-6E]9M<>7-&2OVHYD4Y((8]R""._2N9^%DZVG@R:UU"01ZE9W=Q_:
M0F.&60R,VYL]BI!![BIMOY#Z7.WM;NWOK2*ZM)XY[>50\<L;!E8'H01UI9Y7
MA12EO).2ZJ5C*@J"<%CN(X'4XY] >E>+>'5U"*_T@IJE[::)JVOWWV:VAD\I
M)+<H[*00-V"P)&#CD$<X-:D]_JEKM@@UJ^:QM/%$%E!(9]YGB;87C=SEG"L6
M7KZ@YQ5)7:\_^!_F#TO_ %W_ ,CUJHEE=KF2(V\BHBJ1,2NUR<Y P<Y&.<@#
MD8SSCR75;S4[2P\97YUW4Y)M*UB 6FZY*HBD1$H53:K+\Y&T@COUR:O:QK>K
MZ5J/C<VVHW4WV>*R:$.RD6BR%@[*N, *"3D@G@9)Q26O]>G^8/3^O,]1HKS?
M55O](UF^L=*UC438SZ+->2227)G>WE0C8R/)NVAP6XZ<$@"F^&+N]AUOP>)-
M3O;C^U-#>6Z6YN&D#NJQ%6"DX4_,PR ,]\GFA*_]>O\ DP>G]>G^9Z54%Y9V
MVH6<UI>01SV\RE)(I%RK*>H(KFO&,WF7VE::EY=H]P9G^S6LYMC*J+U:96#(
MJD@_+DGTQFN0T&\U35[GP1'>:YJ+17^GW?VJ**XV"0Q\!BZ@/GYNN0> 1@YS
M*U_KU_R!Z:GH^F^'].TE@ULMRQ7[AN;N6X\L8QA/,9MHQV7%)H/B&S\1074U
MG'<(EM<O;.+B(QMO7&?E/('/< ^U>?Z'K5YJ%EX:TF_U*Z2UNKJ^@DNEN&26
M8PNRQ1F4$,"1SD$,=O7K6U\,I+98O$EI%>"XD@UNXW;I0\@4D8+=^<'D]<&J
MMK\OU7^8GI]_^?\ D=+I7B&SUC4=4L;:.Y67395BG\Z(Q@L1D;<\D8[XP<C&
M:UJ\@UXS6MQ\1]4MKZ[M[BQDM9X?(G:,;UA7[P7&X'H5;(]JM>(]7NSJLU]8
MZG>EK74K&W;%R8880Y3?$(@2)B0V2648W<'Y<417,E\OQ&]&_F>JT5YW?*^D
M^+=5TB34-1;^WK96TW?J$Q\J0-ME6/YOEQN5_EQP".@Q5&^3Q+?:KJ]EI-Y'
M;2Z/+$EK+>:Q/&5B$:,6DB\MA,&^8;G8GKC!&2)7M_7K]P/^OT/4J*:A)12V
M,D#..E<!XHC?3?%3!KS4O(UNR>WMXTU&:-8[M2I4( V$+#T_N'U.4P6UST!B
M54D*6(&=HZG\ZJ-J4,44)N$DAGEB:46Q7?)A0"PPF[)&0.">>F:\XT6XO=5\
M*7<DNIZG;:EH6GRVEQ*EU(<W*ELLP<E6.$!RP)Q)QVQ%I4,5]XK\#7][=W;3
MR^'S*\AO95WN##C.& .2QR#PW?/%.W]?)O\ 05[*[_K;_,]%\/Z[:^)-&BU2
MR29+>5G51,FQ_E8J<CMRI]_I6G7C_A>6;3M,\&W4%]=#[7K%U:RP^>?*>,M.
M<;/NY!4$-C/OBNY\>Z7>:AX9GFTZZOH+VS_TB);2ZDA\[;RT;;&&0P!'L3D4
M2LM>G_#?YC2UM_6[_P CIZ*\TO\ 6WO--7Q'I5[>)8ZA>6=D)!<N8XH"RB20
M*255LDH6QD8ZU1\4G4M*MO%VG6&IZFUC::7%?02F]E:6VGW-E1*6WD%5W;6)
M_*BVMG_6W^8+7;^OZ9ZS17DGBO5I;7Q#K,5GXBN[65_#1O(XX[W=^^0YRB,2
M%)5>=H!QD]>:[[PG8R6VB6]S+J%]>2W<$,TANIC)M;RU!V_W0>I'3)-%M+_U
MU_R%?^ODG^INT5P.DBYU^\U'4)=<N[&_TW5GA:!9CY*P(P C:+(4[UYWD$Y;
M(/&*R&U#59O#,/B6*_O5UP:M]F:R\]C$5^TF/R3#G;D)SNQNXSFA*]OE^-K?
MF-Z7_K:_^1ZK17D&J7FIVEAXROSKNIR3:5J\ M-UR51%(B)0JFU67YR-I!'?
MKDUT-WJ%]I'B=[B_2[N;6]NA#8W-I?,T:-MXAD@R /F!^90Q.>2,4NE_ZVN#
MWM_6]COJ*\M\.#Q1JR:;K)U.&UMKRWD2]*ZI).[2%#CRX7B\N%T8<@<<'.<9
MJKX=O+^2R\"7=SJ^HW$NK_:+>\\V[?;(FR1AA00 P*C# !O>G9WM_77_ "#S
M/5K>Z@O86DMY1)&'>,LI_B5BK#\""/PK/T3PWIGA[[5_9L=Q']JD\V;S;N6;
M<YZM^\9L$]R.O&>E<W\)K:WMO!<?E2RM(\\Y=9+EY-N)I ,!F.W..V,G).35
MGXFS7MKX.>YL-2NK">.Y@&^W906#2*A!)!.,-GC'(';BAJSTZV_&W^8=_*_X
M7_R-O2/#>F:%<WMQI\=PDM[)YMP9;N64._\ >P[$ ]LC'  ["E'B"S/B@^'@
MEQ]L%L;K<8B(]@8+PQZG+=L].<5Q>L6NL+XB_P"$;T^\N)8VM&NX)+O69K:0
MR-(V=KI&QD5/E^0G ##(/&)-,6_D\>:7#J5[$^H_\(W(D]S:G(+^<H+KN'KS
MR,>U)?Y_@G_D#TO_ %U7Z,] MY7FBWR6\D#;F&R0J3@$@'Y21@]1SG!YP>*>
M[B.-G(8A020H)/X <FO)-+UC6KWP[X;L#=/=&_FO5EN+C4I+1I625MB>=&C,
M#C)"KC.W'08K3TY]8;6=,\,>)-7('V:XF$ME>2*T[K( B&8!&)1#S@#/?/(I
MM ]-_P"M3MO#^O6GB72$U.R2=('DDC"SQ['RCE3E>HY!Z\^H%:E<-\)YX)/!
M7DPW27#P7UTDC!PS ^<Y&['0D$'\:Q+R_P!5G\-:EXCBU"]AURSU1[>&T%PP
MB*B;8D+0YVG<I!R1NYR#TIM>]9>7XV_S#O\ /\+_ .1ZC)%',FR6-77(.&&1
MD<BGUY%K=UJ<$/C^[.N:F9-)D@FLE%R46)C&'VX3:&7+8VMD$8SD\UZS YD@
MC<XRR@G'TI):7![V_KI_F24444@"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *" 1@\BBJ>K:@FDZ1>:C)&\J6L+S,D8RS!
M1G _*AC2N[(K1^&- B618]#TQ%E#B0+:1@.'QO!XYS@9]<4@\+>'EL?L*Z#I
M8L\EOLXLX_+R<$G;C'\(_(>E8=YXTO;/P[;ZR--T^ZMY9X(B]IJ7F)B5]F5;
MRQN(RI(('4\\<ON_')T[6-8T^]TX V7V86[0W&\W+3L512"H"'(YY(]Z=GM_
M73_,5^IT%WHFDWYMS>:797)MB# 9K='\HCIMR/E_"ENM&TN^N5N;O3;.XG1#
M&LLT"NRH>"H)&<'/(K@?'E_J-]X,U!=3TF>QNK"\M60V]TSPW :11\KX3?P2
M"K+@''L:Z_1]?GO]<U32+RQ2UN;$1R#RY_-62.0':WW5P?E((Y^IH2O_ %Y
M]/Z\R\^B:3+/#/)I=D\T!#0R-;H6C(&,J<<<<<4Z'2-,M[YKZ#3K2*\9=C7"
M0*LA7.<%@,XSS65K6M1V7BG0M-DT<W+7;2M!=ED_<NL;$A0>=Q''88;KVK(T
M_P"(-Q>1:;=3:$UK9WFI/IK,]TK21RAF4':JD$$J0?FX/3(YH6NW]= >F_\
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M/KN*RDNKC1(XX[34AIU]MO=QC=G50T?R#>/G4G=L//>G9WM_7;];?,FZM?\
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MDU&.<AIYTC6&2$D/&V-QX; ) /4$9YPMGX^GN(-*NI=&$5M>7[:;*1=!GBN
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MT<K*P>138Q8=AG!/R\GD\^YJQ9^&]"T^Y>YLM%TZVN)$*/+#:HC,IZ@D#)'
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MM/LAT+3#;;0GDFTCV;0=P&W&,9)./7FM"TM+:PM8[6SMX;>WB&V.*% B(/0
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M!E< 9QA1R!DUW%G=17UE!>0$M#/&LJ$C&589'\Z=M!7)Z***0PHHHH ****
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M6';Y;!C(P; 49! R?0<5T'B763X>\.WVKBSDO!:1&5H8W520.IRQQ@#GN>.
M>E7[.X^U64%QMV^;&K[<YQD9Q0MM.EE^"_R![Z]?Z_4Y[5?#.IZYH0LM1UB
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MI6)8>"ITTWQ!8ZGJ<=S'K%RUR6MK8P-"[ #@EWSC:I'T.<YXZ^BJ;;;;Z_\
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M'4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"J&(!GC<$N6^4Y##&2,87K73GPU;7.GW%IJMU=:J)XC#(]V4!V'L!&JJO;D
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M!X&"SL$<O@*PVEN?F);''!KU"UG%U:0W &!+&K@>F1FN5N_A];WDFM-)KNL
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MS'<6<@2$(<2Y02Y0H<#ECDD#C.1W5</X3TZ_LO&GB:\N/#UQ8VVHRQRP3O)
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MT9@%=1W920*R]3^(>B6>BZG?6\D]Q+8V_GF 6LJLZGA7 91F,G^,97WKFD\
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M_J!^P7Y\.KJYU!WM4MV)>-@682-.K;=R9*B(G@@$THZVO_6W^;^X;ZV_K?\
MX'WG?3>*=%@U&.QDO0)9'$:OY;F+>1D(90-@8CHI.?:J<7CWPO.J/#JT<D+S
MFV$Z1NT0D_NF0#:I/;)&>V:YV#P@6U2\AU'2=1U""6^:_MKI-5D2V&6\Q0\'
MFC#*>!A"#@9(YQEMH_B5O#-W:#PS?"XE\1#4E7[3:_ZGSA+U\W&<+C'J1VYI
MQUM?^M5^6OW _+^M'_P/O/0H/%.CW$%Y,MVR"SD$4Z30R1.C'&T;&4,=V1C
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M>:VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "FRQQS1/%*BO&ZE65AD,#U!%.HH QK3PKI
M%B)?L\-PI>-H@QNYF:)#U6(EB8AP.$V]!Z"I=#\/:;X<M7M=,2>.!W+E);J6
M8 DDDCS&;&223CJ3FM2B@#$3PEHR?VGN@N)5U,$7:3WDTJ29&/NNY"\8' &
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M6D!R',6[86R =Q7/ YJE<^ ?#MW_ &D)[>[<:FP:\']HW $Q'3(\SH.F!QC
MZ5TM%("G9:9;Z><P-<D>6D6);J64!5&!@.Q /J>I[DU<HHHO< HHHH ****
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MHH **** "BBB@ HHHH **** .1^)>D7VM>"+JVT^%I[A)8I_(7K*J2*Q4>Y
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MX@:?9ZE9P0/IUO<0Q6]T(Q)<8?<1M8;F/R;ASG(SG-=-<SZ)J&MQOXEFL9=
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M3'+95UZ)*#DL,D_-DFN[HIW!ZGEWB2_T2V^)UY%>:M';F7P_,DP>_,>QMRD
M?,-A*C/RX) S6+X0O]%M-0^'+VU[9K>W>GS0W;"=3))\@VHYSG[X( /0@@>E
M>UT41=K?UW_S_ ):W_KM_D<!\0=SZOI45_<Z;;:')#,LTFJ6IGM?.RFP.!(@
M!QNVLQQGWQ7.7>G^'-/U/P18:[J.DZK.DLR-<WD4:M)!LD\H$.S$H&("DD@D
M CFO8J*(NW]>O^8/4\=8:-_;7CX^'%TO^V41#;FT2,S*/+ F*;2&SG.=I!W=
M>:C:S-KIFH:KH>N65Y8SFW6_L]#LFA6-%E4RNP$KD2%"P8<,0/:O9J*4=/Z_
MK0'J>2^+=)\*-X U6ZT$VESI[W-K.8X-LEM;XD579 !M0E<[L?CUY]1T]+2/
M3X$L(XH[14 A2)-B!>VT#@#TJS13Z6_K:P=@HHHI %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 53U74K?1M)N]2NV*V]K$
MTTA R=JC)Q[U<JGJVEVVM:1=Z9>*6MKJ)HI IP<$8X/K2=[:#5KZG-R>-+VR
MNX+?4M!:-[VVDN+ 6UTLIFV+N,;[@@1]O/4KP?FI-#\<S:M<Z"MQI(M+?6[1
MY[9_M/F,&0!BK*%  P<@Y/N!4K>$]1N/)DO=7MI[BR@DAL'^PE5BWKM+R#S/
MG;;QP4')XJCIO@75-.E\,,==M)(M!A>%5&G,#,K#:<GSC@[0.QYR>^!6E_Z\
M_P#@$ZV_K?3_ ()W5<9#XYNFUN/3I]#:-[F&>:UB%TOVAA%VDB8*(]W\)W$>
MN*Z/29+^?3\ZCY?G[F >.)H@RYX;8S,5^A)_#H.3L_ .I:?)I\UOKMJ9[$W
M2273BQE$HY,N)06<'DMD9]!UJ7?^OG_P"NA/HWCZ75#H$T^C_9+/6A*L$AN@
M[HZ!FPRA<;2JDYW9SP1WK$\1ZQ/KUQX4U*&Q:/3'UN%;:X^UMNE7+<M$ %VG
M:"I))]ES6EI_P_U.QMO#-N==M)(M#D=P/[.8&<,&4@GSN/E8\\\X..U./P\O
M!96&F1>(GBTW3KY;NR1;-3-$!N(0NS%6 +<'9TZYJ]+I^?Z_Y$OX6O)_D_\
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M)Y[@^7\O\'/7D<9[JR:^OM!@:\#6-_-;CSA"R.89"O.TG<IP>G4?6FTU>_\
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MX0!204." .#T[UU5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)DE:&>9D)E9EV@H%8G;@DG=M.0O%3_\ "6Z$+Y[1K]8Y%5VWR1ND3A!E]LA
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M5N4NB\OZ_4+:M?U_6AY/IVB^)(-'\*VLGAR]22PU::ZN2+BVPD;&3!&)>?\
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MC,8Q^]RPSSQV]^*]0HIW=[_UU_S%96M\OZ^X\=\C5])705O=$N8;AO%,]U%
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MQ1M>EP%.?EE 0%'&.5P1[U$OP_U7_B4*WB*%$T[3)=.5H+!DD974+O#>:=K
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MVRD&B6CVB+_9S#S0P"Y)\[@X5?QSZX'*3:;/X6\6>$M%;Q)IIOC/?3Q/):[
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M;2V32.Z.5+DR"4#<2@P=N!D\&JLO@;6KC1?$6FS>(+$KK<C22.FF.#$655;
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M+@*(T\K[/W^\#N"]\[JQ-8ET??X^_M&_M9=0ATRV=?-N]YCN@C;C&"WRL)"
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ME1)#('7(.",CC(((I=$Q];$]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%
M=+</:R+:2Q17!7]V\L9D13ZE0RDCVR/K4M% %'3-/-A',TLJS75Q)YL\JIL#
MO@#@9.    ,G@=35ZBB@ HHHH **** "BBB@ HHHH **** .?\8>'[OQ-HZ:
M?:ZA#98N(YFDDMC-G8P<  .N.0,]>,_6MZ,.(D$K*T@ W,J[03W(&3@>V33J
M*/( HHHH **** "J]O9QV\L\P9WEG8,[N>>. !CH /\ .35BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;6P>9JT5F6VOZ=>7SVD$LKR+(8MWV>01LX!+*LA7:Q&TYP3@C!YK29@JECG
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MBSCS$9U =<\;ER.1ZTL7CCP]/&9(;V61?LOVQ2EI,?,AXRR83Y\9&0N2.X%
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MO!,R,RD<<E&9>V>#7.>+8]6D\1^';BQT*\O[?3[A[B>2&:!>&B= H$DBDG+
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MCN!L1V,I*EQD,0-I7&.<US$MSK>D6GQ&U6QUVX-Q97),:W,,<B8$,;< *""
M=HYV@=5)YKT.7POI,NI#43!*MT4$<CQW,J"90, 2A6 DP/[X-07W@K0-1_M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,(OW58#@%>2<4EJ_N&]%<](\3>(F\.PV$HL)+I;J]AM&99%01>8P4,<\GKT
M/X=:UKIKE+9VM(HI9P/D260QJ3[L%8C\C7B]\+)Y_$XL[9EL4\0V%W(\5NRQ
M"+]V9)-P&W&=S$@]#GH<U;UVRLI-"\:7&AD)X?:UAE@:SD*0/<@MYA3:0&&-
MF['RD]><TXJZ7]=O\W_6P]_Z\SV,=.:*\F\363ZKXHU&PU+6M-TJ1EA.DS7=
MFTDP&P9:V?S4 ??NRH!)XSD$5:%OI6H>(]6LO%=T8=46>%]*N'/E3>4(T/\
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M0E2,C/IUY]*&K7;!:VMU-JBO-O%U]-J>C^'=2:&%F76;,Q&PU S0S!G!.#A
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M/@J"F5#-P6QG;Z<=2$E^($[Z)%J-GHP.V.=[O[9=>1%;M"VUXS+L8%R<[1@
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M\):EI+65Q8ZS;K=QVD5G=&2R+17$<>=A">8"C@$\[B.>GITLL$[67DQW.V7
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M?*DGF'8A(.1AB0<9JG:^ +B"[LIGU>&5;6\GN#NLOGG6565ED??EF ? ;C@
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MK<VIW=\NOV*M<:6NF%3ICG:@R=W^OZY)]NGID]+X>TR;1?#UAI<]S'<O:0+
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MMLSCC=77T47[?UM_D#U_KU_S. U3X?ZOJ7_"2(/$%G'%KDD;2#^S&8Q*@ 4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*-,NKF[UK0_"4=_J$=J='&I7MPUV[SW#,0H02L2RC)).T@] ,"K<7S./5?\
M!_R)B[Q4NC_X'^9Z717 WK2Z%XTTGPZ+S4+C2=<@G3RY;N5I;>2,!MR3;O,
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M5FD>>.0E,/F0DD###ABO(P!7>4V@"BBBD 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLQF01KDY4!2>>F<.IQG.&!Z&N;M_A_"+"VM+S4IKH0)(PD:,%VN7)S.2V[+
M$!<YQUY."-)_!'AN1[9SI40-M$88@K,H5203P#@G(!R><@'.0* -Y9(VD:-7
M4NF-R@\KGID5!?:A9Z79R7=_=0VUM']Z69PJC\35!O"NBE5$=D+=QSYUK(\$
MI]<R(0QSWR>:EM_#VE6UQ]H6T66XSD37#M,X/LSDD?A0!+9ZB;Z9Q%:7*6X4
M%;B9/+#GT"MAOQ( ]":O444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6?J<.L2^5_9-]8VN,^9]KLWN-W3&-L
MJ8[]<YR.F.="B@#G_L?C#_H.Z'_X)IO_ )*JE-X>\2SZC'?2ZYI+RQJ J'3K
MGRA@Y#>7]KV;O]K&?>NMHH Y_P"Q^,/^@[H?_@FF_P#DJC['XP_Z#NA_^":;
M_P"2JZ"B@#E=2B\8VNE7EPNN:*6B@=P%T>4$D*3Q_I)Y_ _2JUC:Z[H^A6P3
MQ5X>%BB#;<S:9(1)GG<7-U@EB22>Y-=G5&#1=*MKQKN#3+**Y;DS1P*KG_@0
M&: .5LKSQGK0WZ?J>DI9$LIO)M%FA)QWC1K@EAGN0!Z9JWI_A_Q/IHD:/7=&
MDN)L&>XETB5I)2.A8_:OK@# '8 5UM4=6U)-,LQ)@//*XAMXL_ZV5N%7Z=R>
MP!/04 <MJ*^+;Z^.A0^(M)262$R7,L&DR*T$?0<FY."YR!T. Q!! K4BT[Q9
M!"D,6M:"D<:A45=%E 4#@ ?Z56GHUA+I^G+'=3+/>R$RW4ZIM$DAZD#L.@ [
M  =JT* .?^Q^,/\ H.Z'_P"":;_Y*H^Q^+_^@[H?_@FF_P#DJN@K&\0RB6&V
MT@)(SZG)Y#; ?EB +2DD?=&P%0?[S+ZT <]%;>+_ !)$91X@TJ'3EE(B>#3I
MD-T!D%B5N<A,_=*M\PYZ$9TK'1/$FF6<=I8:GX=MK:,82*'0Y54?@+JNG50J
MA5 "@8 ':L?Q ([VWBT0RA9-1;RW56PWD#F4^H!7Y,CH77VH P-#T[Q;<F;6
MSKND>9J"H463296$<*Y\L*!<# ()<@Y(+D9X&-C['XP_Z#NA_P#@FF_^2JWU
M544*H"J!@ #  I: .?\ L?C#_H.Z'_X)IO\ Y*H^Q^,/^@[H?_@FF_\ DJN@
MHH Y_P"Q^,/^@[H?_@FF_P#DJC['XP_Z#NA_^":;_P"2JZ"B@#G_ +'XP_Z#
MNA_^":;_ .2J/L?C#_H.Z'_X)IO_ )*KH** .?\ L?C#_H.Z'_X)IO\ Y*H^
MQ^,/^@[H?_@FF_\ DJN@HH Y_P"Q^,/^@[H?_@FF_P#DJC['XP_Z#NA_^":;
M_P"2JZ"B@#G_ +'XP_Z#NA_^":;_ .2J/L?C#_H.Z'_X)IO_ )*KH** .?\
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ML8A+(EPXDBV-P)%<$;DR".=I]<4=+@=-16<^M:9:1PB\U:P21XU<,9E0."0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2UFVL;>^AU.TCM[K3[J2RE2(SPESA9"NTYW!3@\ACC.#71_;/&'_ $ M#_\
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MBUH:9-K$OF_VM8V-KC'E_9+Q[C=USG=$F.W3.<GICD T**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-ZBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex23-2_1.jpg
<TEXT>
begin 644 ex23-2_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< 04# 2(  A$! Q$!_\0
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M!/)3.1^IKN=6^)F@Z9H,&I+.)C.FZ*%<[B< X/''4=:'"2!5H-73.THKP_\
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M9Y2WXDYKZM\&Z(N@>&+2Q"@.J@R8[MCG^5?/?PPT'^W?&$"NH,-NIE?(X(!
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M1_\ 7%OYBOI0]#7S9\&O^1\C_P"N+?S%?29Z&NBM\1.%^ ^2_'7_ ".NJ_\
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M)GB7QL_Y'7_MDO\ Z"M=7\!_^0;J?^^G_LU;WC3X9+XMUK^T#=+%\H7:2>P
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MJ*HTI*3G/<?1116)U!1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex23-2_2.jpg
<TEXT>
begin 644 ex23-2_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  0,# 2(  A$! Q$!_\0
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M[G+I&NP(%R"/F'S<5Z\UK-86T%IHUG900C(Y&Q(AZA%'S?3*_6@#C=!T2V\
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2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex23-2_3.jpg
<TEXT>
begin 644 ex23-2_3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ ]T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F5%+,0% R23P!2U7O\
M_D'7/_7)_P"1H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2;E#!<C<1D#/./\D4M5W_Y",/_ %RD_FE %BBBB@ HHHH
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M., CH1[T 107S7,T&W"JPD# $,"5QT-7ZI"P$29AE<2+O*LQ!Y;KGCVJ[VH
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M'<8LESK-K9,4>:5Y85D8LI^0D9./Q-+%+JT\<,(N9?*+N=ZJ=V H(!/UK?\
M#>H/J^@6U[.B!Y4!8 <5JJD2C:JH!Z "@#A[E=1-@1+)/*)HFW J?E(< $?@
M*!>:E%9/';2SRVV]%,S*0R@YW8__ %5W)5#P57\J3RH@FS8@4_PX&* .5TXZ
ME=SV2374@B +,54C<.< YI^O75W'J!C,LT,2Q[HC$I.]N.#P?>FZAJ^K6GBF
MVL+6R4V+#YI !QUKJ72-L%U4XZ;A0!SFAV<LFJ7=U="3S'5<JP^4'GI734@Q
MR1CGTI: "BBB@ HHHH **** "BBB@ J 7EJ9O)%S"9>FS>-WY55UN5XM,;RV
M*%W6,N/X02 32/H>FFU,(M8U '$@'S#WW=: -*FNZ1(7D954<EF. *YZ"\U"
MYBTR&&Y$;31/OD9 V=IX;Z_XU%?RWLND:A;3W*L]M*H:01@>8IQ@8[?_ %J
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MI\'VS?J-RH8W"[4C;D)'V'X]30!9&J:>2 +ZV)/0"9?\:M.ZHA=V"JHR23@
M5BFPM+C6%BBM((XK4!Y"D8!9S]T<=AU_*M#5/^03=_\ 7%_Y&A[7!;V+0(8
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MW;O:N>6[AFUK3[N2ZA+N7RBR@B)=OR@^_/YT=;!TN=#+=VT,BQRW$4;MT5W
M)_"G33PVZ;YI8XTZ;G8 ?K6-;65M??VG+<Q1R2&=T#,H)4  #'I4&GHFH7%@
METBRI'9;@CC()W8SCZ"@#H1-$T7FK(ACQG>&&,?6FPW,%RI:":.4#J48-C\J
MYR6-$,]@H"VS7\:E1TP0"1^8K1%O#9^(+<6T21++ X=44 '!!!P* ->BBB@
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MI]?2M"SDF9Y4E+$+@J7*;N?4*:G6V@0L5AC4MG)" 9S3HXHX5VQ1HB^BJ *
M,E;RZCMHYVE\PNDAVE1@8Z=*222YD\M))'"EXV#'R\Y)]!GCTK7$,:A0(T 7
M.W"CC/7%-%K;A&001!6Y9=@P?K0!DOJ5RDI3=G8#$?E',A)VG]!^=3BYN!B0
MS9(G$)BVCD9QGUSWK0\B+)/E)DD,3M'4=#]:/(B\WS?*3S/[^T9_.@#&EFN0
MEE<;S+*RNV"  O'8 5I7,S1VL1CD_P!8RKYI X![^E6!#$-N(T&S[ORCY?I1
MY4?E>5Y:^7C&W'&/I0!E/OGO88993(D<Y&=J_-\N>>,9'2I;V:5-01(G";]B
MEMH)P2WK5]8(D"A8D4*<J H&/I2M%&SAVC4L,8)'/% &<EQ.\QMVN"FUI/WF
MT9.,8'3'?]*K075RMLJQ$@10JPQL"G/]XL>GTK9:WA<8>&-AG=@J#SZTAMH#
MLS!&=GW<H/E^GI0!G+=W 9Y#-G%QY8AP.G\\_P"%1?;KP6IFW$;XV8;MF%/^
MR <G\:U(K.&&5Y0@,C,6W$#(SV!]*1XK6(DM%&#*=I^0?,3V- %-Y[B.<VYG
M)W-'^\*C*YSGMCMW]:@CFG25H8W=MTLA+H$R<8_O<5L-#$^[=&C;AALJ#D>]
M--K;F/RS!%LSG;L&,_2@#+^UW;QS2><$,4*OM4*03SGGGCCL:N6.0]VS2$_O
M3UQQP*M>3%AAY:88;3\HY'I2K&BNSJBAF^\0.3]: ,@W\\9++(TJM"T@W(%'
M'0@#G'UJ=I9D,,0O YD< N%7*#;GZ<XXXJPPLK:0YCB1L;CB/L3CTIZV]L8V
MC$""//*F/ )^F.: *+W4P6<K=J?(C# A1B0\]?RQQ2B]F\O+/AC<[,8'W>N*
MOFW@8H3#&=GW<J/E^GI3)Q:Q.LLL2;V8 ,(]S$_@,T 9;S7+V"F2X9O.MW8C
M:HP1CIQ4J23_ &\0),55C\S!%R<(#Z5I)'"T:XB4*%PH*8P#VP>E*MO"A!2&
M-2.A"@8[4 90O+F2WD8S^6T4._(4?.<D=_IV]:UXR6B1CU*@FJT^GPW&T-\J
M#@*JKCWYQD?@:M    < 4 >3_&)9'>U&#Y6U/IG+UI2Z-'??#RQ>R 8P1[R%
MYSP,_H*Z;QAX=3Q#H[P@#SUPT9]QG_&N,\ :S)I]P^BW^1&[84,.AZ8_E75!
MODO'='BXN,?;NG5^&HK)]F;'@O5HM0TY]%O,;E!"ACU&<_UK!F2X\&>)MZAC
M;LQQV#+GI4WBG3)O#FLKJ=D"L+,&!'8XY'\ZL:OKVE>*=%B!G2"]CP6$@([<
M]*T5K\R^%[GG2YW3]E/2K2^%]T'Q*LK:]T*'7+<C>H )'<9_^O6UX U*34?!
M4;2G+1ADS[ D#^5>:>)O$0N=*MO#NG2FY 8;G X8D]!^0KU7P;HSZ)X-@MI1
MB5D+N/<DG^M8U-(<K/5PC]I7=1*UTK^IYKHV@?VU:ZQ) I%Y:N)(F Y)&3C]
M!6W?^(3K7P[NH)_EO;8JDBD\\,.<?E5[X90R1WVK^9&RAG7&X=?O5E_$/PU<
M:?=/J&G*PM[G F1>>?I^ KG/6+<GB.?0O .E0VC*MQ<KA7)QM&!S^HK/NA=Z
M5:#4K?Q3%<72$,\(E!W>WWJFU+0;J_\  6D74,)>2U7YHSP2,#_"HDU3PFUL
MH.@7)NCP8P7QG_OJ@#9U6^U74_#-EXBTR>594'[Z%"2" 2"?TJI;>(=5\:ZS
M9VU@\UK;0J#<LA/4XSS^!J_KFJ1Z9X7MM.T:SDBENQQ&03L!))ZY[_SK&T6U
MU'P%K5N+A3):WJKYI5<[3_\ 6W4 ;6KZE?6OQ#TVPCNY1;M'\R;N&.&Z_E1X
MK@<ZNYN_$J6=L1\D(8;A^&ZJ^N*\WQ-TN:-&,9B^]CCHU9,TEKIWC;4)?$5I
M-<1NS>20"0!GCH?2@"SX9\2W6FZ[)IOV\:C:LNY)-W3&?<UZQ7BEL4N/&7VB
MUT^2UMVC.Q2IY'//>O:Z "BBB@ HHHH **** "BBB@"*XMX[JW>"9=T;C!%9
MAT>[9?(?5YVM>FS8H<CT+]:V** *7]G(MW:31L$2V1D6,#J"!W_"H9]($Z7Z
MF<C[65.0OW" /SZ5IT4 9+Z3=^<)H=2:*9HPDS"%3YF.AQV-);Z'Y$<*?:F<
M17)G!9>3QT//ZUKT4 4I-.2:]GGD?*30>2R8[9/.?QJK%HTP>%;C4))[:%@T
M<)0#ITR>]:]% %'6?^0-=_\ 7(U<09B4?[-.HH R?[#4Z?:VK3G]PQ)<+C<I
MSE<9[@U8DTQ);JXE=\I-"(B@&,8SSG\:O44 9<6E7/GI)<ZB]P(LF%3&%VG&
M,G'WJN65JME:) &WD9+.1C<QY)JQ10!5L;/[%$\2ONC,C,BXQL!YQ[\YI;VT
M^V1QIOV;)5DSC.<'.*LT4 1SQ^=;R19QO4KG'3(IMI;_ &6SAM]V[RT"[L8S
M@5-10!5L[/[*UPQDWM-*9"<8QV _#%)JG_()N_\ KB_\C5NBA[ M[D5M_P >
ML/\ N+_*L]])N(Y9&L=1>UCD8LT?EAQD]<9Z5JT4/>X+16,I]% MXA!=21W,
M;F03L Y9B,'(/7BHUT.4M<O-?O+)<0&)F:,<>X / ]JV:* *4NG^:EDOFX^R
MNK?=^]@8]>*IR:',WGQ1ZE)%:3,S-"(QG)Z_-UQ[5LT4 93:/*J6[6UZT$\4
M0B:01@AU'JIJ,:"4MBB7CB87!G28J"5)&.1WK9HH S+/2IK?4/MD]\]Q(8RC
M;D"CKD8QTK3HHH **** "BBB@ HHHH *KW__ "#KG_KD_P#(U8J&[1I;*>-!
MEFC90/4D4 34444 %!&01110!5L+3[#81VWF;]@/S8QGG/2I;:.6*!4GF\Z0
M9S)L"Y_ 5+10!FWNBV=W;21I!!#(_/FB$9'.:NF!!:F",*B;"H"C 'X5+11Y
M 4QIZG2H[%Y&(1%42+P01T(].145MILZ72W%W?-<O&"(_P!V$"YZ].IK1HH
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MMBB@#/O8U:[1IH9)H?+( 12<-GVZ?6JYA<R_ZF3[3YVX2;3]STW=.G&*V**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>24
<FILENAME>amrh-20210331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: amrh%2D20210331 S%2D4 DFN.xfr; Date: 2021%2D06%2D20T09:09:19Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8014000A -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:amrh="http://ameri100.com/20210331">
    <link:schemaRef xlink:href="amrh-20210331.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-12to2021-01-14_us-gaap_CommonStockMember_custom_OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-12</xbrli:startDate>
        <xbrli:endDate>2021-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-14_us-gaap_CommonStockMember_custom_OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-09</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-04to2021-03-05_custom_ExclusiveLicenseAgreementMember_custom_DiverseBiotechIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amrh:DiverseBiotechIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-04</xbrli:startDate>
        <xbrli:endDate>2021-03-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SkincareAssetsAndLicenseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amrh:SkincareAssetsAndLicenseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_DiverseBioLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amrh:DiverseBioLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_SkincareAssetsAndLicenseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amrh:SkincareAssetsAndLicenseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_DiverseBioLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amrh:DiverseBioLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember28047046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RestrictedStockMember56142828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_InitialMeasurementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-03to2021-04-09_us-gaap_SubsequentEventMember_custom_WardEmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:WardEmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-03</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-14_us-gaap_WarrantMember_custom_OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-11_us-gaap_WarrantMember_custom_OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitiesJanuaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:WarrantLiabilitiesJanuaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitiesFebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:WarrantLiabilitiesFebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember15731484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SubsequentMeasurementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SubsequentMeasurementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:JanuaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrh:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-12to2021-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-12</xbrli:startDate>
        <xbrli:endDate>2021-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-10to2021-02-11_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-10</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-30_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember11849796">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember86367453">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amrh:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-06to2019-02-07_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-06</xbrli:startDate>
        <xbrli:endDate>2019-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-07_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-05_custom_MarchTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:MarchTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:FormerExecutiveDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-04to2019-03-05_custom_MarchTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:MarchTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:FormerExecutiveDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-04</xbrli:startDate>
        <xbrli:endDate>2019-03-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-08_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:NoteAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:FormerExecutiveDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-07to2019-07-08_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:NoteAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:FormerExecutiveDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-07</xbrli:startDate>
        <xbrli:endDate>2019-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-19to2019-09-20_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:NoteAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-19</xbrli:startDate>
        <xbrli:endDate>2019-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-20to2019-11-21_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:NoteAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-20</xbrli:startDate>
        <xbrli:endDate>2019-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-08to2019-12-09_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:NoteAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-08</xbrli:startDate>
        <xbrli:endDate>2019-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-07to2020-01-08_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-07</xbrli:startDate>
        <xbrli:endDate>2020-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-07to2020-01-08_custom_JulyTwoThousandNineteenNoteMember_us-gaap_CommonStockMember_custom_LenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-07</xbrli:startDate>
        <xbrli:endDate>2020-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-08_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-05to2020-05-06_custom_MayTwoThousandNineteenAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:MayTwoThousandNineteenAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-05</xbrli:startDate>
        <xbrli:endDate>2020-05-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-11to2020-01-12_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-11</xbrli:startDate>
        <xbrli:endDate>2020-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-11to2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:DecemberTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-11</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:DecemberTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember_custom_EventOfDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:DecemberTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:EventOfDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:DecemberTwoThousandNineteenNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember_custom_EventOfDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amrh:EventOfDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-23to2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:LenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-23</xbrli:startDate>
        <xbrli:endDate>2020-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-29to2020-12-30_custom_FebruaryTwoThousandTwentyNoteMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-29</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-09to2020-01-10_custom_SecuredPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:SecuredPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-09</xbrli:startDate>
        <xbrli:endDate>2020-01-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-10_custom_SecuredPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:SecuredPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-05to2020-05-06_custom_FirstNoteAmendmentMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FirstNoteAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-05</xbrli:startDate>
        <xbrli:endDate>2020-05-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-05to2020-05-06_custom_FirstNoteAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FirstNoteAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-05</xbrli:startDate>
        <xbrli:endDate>2020-05-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-06_custom_FirstNoteAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FirstNoteAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-22_custom_SecondNoteAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:SecondNoteAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-23_custom_SecondNoteAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:SecondNoteAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-23_custom_SecondNoteAmendmentMember_custom_AlphaCapitalAnstaltMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:SecondNoteAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrh:AlphaCapitalAnstaltMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-29to2020-12-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-29</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MarchTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:MarchTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:AprilTwoThousandNineteenConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DecemberTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:DecemberTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:NotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:AprilTwoThousandNineteenConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_DecemberTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:DecemberTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandTwentyNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_AlphaNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:AlphaNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:AprilTwoThousandNineteenConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_JulyTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:JulyTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_DecemberTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:DecemberTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandTwentyNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_AlphaNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:AlphaNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember_custom_CADMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrh:CADMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_CADMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrh:CADMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MeasurementInputSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amrh:MeasurementInputSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-02_custom_SkincareAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amrh:SkincareAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-10-02_custom_SkincareAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amrh:SkincareAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SkincareAssetsAndLicenseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amrh:SkincareAssetsAndLicenseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-04to2019-01-05_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:BusinessAdvisorServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-04</xbrli:startDate>
        <xbrli:endDate>2019-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-04to2019-01-05_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember_us-gaap_CashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:BusinessAdvisorServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-04</xbrli:startDate>
        <xbrli:endDate>2019-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-04to2019-01-05_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:BusinessAdvisorServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-04</xbrli:startDate>
        <xbrli:endDate>2019-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-05to2020-01-06_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:BusinessAdvisorServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-05</xbrli:startDate>
        <xbrli:endDate>2020-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-30to2020-01-02_custom_MrDavidStefanskyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:MrDavidStefanskyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-30</xbrli:startDate>
        <xbrli:endDate>2020-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-30to2020-05-01_custom_MrHenochCohnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:MrHenochCohnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-30</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-29to2020-12-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-29</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember_custom_VendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:VendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amrh:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-23to2020-09-25_us-gaap_CommonStockMember_custom_SeptemberPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:SeptemberPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-23</xbrli:startDate>
        <xbrli:endDate>2020-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-23to2020-09-25_us-gaap_SeriesBPreferredStockMember_custom_DecemberPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:DecemberPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-23</xbrli:startDate>
        <xbrli:endDate>2020-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-19to2020-07-21_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-19</xbrli:startDate>
        <xbrli:endDate>2020-07-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-21_us-gaap_CommonStockMember_custom_FebruaryTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-21_us-gaap_CommonStockMember_custom_MarchTwoThousandNineteenNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:MarchTwoThousandNineteenNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-19to2020-07-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-19</xbrli:startDate>
        <xbrli:endDate>2020-07-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember_currency_CAD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-22to2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrh:FebruaryTwoThousandTwentyNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-22</xbrli:startDate>
        <xbrli:endDate>2020-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-10_custom_AlphaCapitalAnstaltMember_custom_AmalgamationAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrh:AlphaCapitalAnstaltMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:AmalgamationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-06_custom_EnvericBiosciencesIncMember_custom_AmalgamationAmendmentAgreementMember_us-gaap_CommonStockMember_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrh:EnvericBiosciencesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:AmalgamationAmendmentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrh:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-26_custom_EnvericBiosciencesIncMember_custom_SecondAmalgamationAmendmentAgreementMember_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrh:EnvericBiosciencesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:SecondAmalgamationAmendmentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrh:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-24to2020-05-26_custom_EnvericBiosciencesIncMember_custom_SecondAmalgamationAmendmentAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrh:EnvericBiosciencesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:SecondAmalgamationAmendmentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-24</xbrli:startDate>
        <xbrli:endDate>2020-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-10to2020-08-12_custom_EnvericBiosciencesIncMember_custom_TenderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrh:EnvericBiosciencesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:TenderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-10</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CanadaRevenueAgencyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CanadaRevenueAgencyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-12to2021-01-14_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-12</xbrli:startDate>
        <xbrli:endDate>2021-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-14_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrh:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-09</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-03to2021-03-05_custom_ExclusiveLicenseAgreementMember_custom_DiverseBiotechIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrh:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amrh:DiverseBiotechIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-03</xbrli:startDate>
        <xbrli:endDate>2021-03-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-09to2021-03-10_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-09</xbrli:startDate>
        <xbrli:endDate>2021-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-10_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_PreferredStockMember73568718">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember73568718">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember73568718">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">108789</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">4096891</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">25786625</us-gaap:Assets>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-4894881</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">-11759557</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">-15010268</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-1811601</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">3415641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">18991678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-2699278</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">-65454</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">2625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">2625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">52620</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">53114</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2368464</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3039163</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2484208</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-4894881</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_PreferredStockMember73568718" unitRef="USD" decimals="0">-4955</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember73568718" unitRef="USD" decimals="0">-11622</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">56598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3261786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5993342</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-24320</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">32754</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">100951</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15222770</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-11759557</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember73568718" unitRef="USD" decimals="0">-181277</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">194499</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">33952988</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-15010268</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-145541</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">108789</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">4096891</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">25786625</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-30_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">262500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">3275407</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">262500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">3275407</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-3250711</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-1098461</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-6864676</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-2410673</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2410673</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-1098461</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-6864676</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-3250711</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">35736</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-12698</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-169655</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-6667</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-6667</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-12698</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-169655</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">35736</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-3162278</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-893922</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-3888785</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-647860</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">136640</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">120872</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">3591565</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1977155</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">624052</us-gaap:ShareBasedCompensation>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1817721</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">2362177</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">108789</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">2279170</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">23424448</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-11622</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">-181277</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">-145541</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">3039163</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">15222770</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">33952988</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">53114</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">100951</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">194499</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-10-02_custom_SkincareAssetsMember" unitRef="USD" decimals="0">1900546</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2625</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">32754</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2021-01-01to2021-03-31" unitRef="Shares" decimals="INF">16220661</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">5653820</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">5753598</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">5287145</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" decimals="INF">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="USDPShares" decimals="INF">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">-1.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1157645</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">681250</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">626947</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">65075</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">700710</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">767298</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-3214975</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-1111159</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-7034331</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-2417340</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">3514286</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-261759</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1247359</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">114139</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-6764997</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-836702</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-5617317</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-2296534</us-gaap:OperatingIncomeLoss>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">6607045</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">836702</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">5443234</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">2296534</us-gaap:SellingGeneralAndAdministrativeExpense>
    <amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember_custom_VendorsMember" unitRef="Shares" decimals="INF">433047</amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares>
    <amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">85942</amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares>
    <amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">433047</amrh:StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">173482</amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">756523</amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember_custom_VendorsMember" unitRef="USD" decimals="0">756523</amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">859</amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">172623</amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4330</amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">752193</amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable>
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-675000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-44143</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-59278</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-7632</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">267002</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">919968</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">24881733</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1212196</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">5531270</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">560000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <amrh:AccruedInterest contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <amrh:AccruedInterest contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">28519</amrh:AccruedInterest>
    <amrh:AccruedInterest contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">156619</amrh:AccruedInterest>
    <amrh:AccruedInterest contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">13684</amrh:AccruedInterest>
    <amrh:GainsLossesOnInducementExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-298714</amrh:GainsLossesOnInducementExpense>
    <amrh:GainsLossesOnInducementExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <amrh:GainsLossesOnInducementExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-802109</amrh:GainsLossesOnInducementExpense>
    <amrh:GainsLossesOnInducementExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">66208</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">49588</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">636497</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-104340</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <amrh:WorkingCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1597920</amrh:WorkingCapital>
    <amrh:WorkingCapital contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">22797501</amrh:WorkingCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-12to2021-01-14_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="Shares" decimals="INF">2221458</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="Shares" decimals="INF">3007026</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-12to2021-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2221458</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-02-10to2021-02-11_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3007026</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="USD" decimals="0">12800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">21614488</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2021-01-12to2021-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2021-02-10to2021-02-11_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-03-31" unitRef="Shares" decimals="INF">9699242</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">5489861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-03-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">5979611</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-03-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">3279284</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">70986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-01to2021-03-31_custom_OptionsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">369361</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">1504593</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" decimals="INF">380920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_custom_OptionsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">3604348</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_us-gaap_RestrictedStockMember56142828" unitRef="Shares" xsi:nil="true" />
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">7456578</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">1419070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">3251406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember11849796" unitRef="Shares" decimals="INF">3275407</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">929765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">303891</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" decimals="INF">55306</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember86367453" unitRef="Shares" decimals="INF">262500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember" unitRef="Shares" decimals="INF">797373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">2619689</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-03-31_custom_SkincareAssetsAndLicenseAgreementsMember" unitRef="USD" decimals="0">1944689</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-03-31_custom_DiverseBioLicenseAgreementMember" unitRef="USD" decimals="0">675000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2020-10-02_custom_SkincareAssetsMember" unitRef="USD" decimals="0">1944689</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2020-12-31_custom_SkincareAssetsAndLicenseAgreementsMember" unitRef="USD" decimals="0">1944689</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2021-01-01to2021-03-31_custom_SkincareAssetsAndLicenseAgreementsMember">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2021-01-01to2021-03-31_custom_DiverseBioLicenseAgreementMember">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-10-01to2020-10-02_custom_SkincareAssetsMember">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">257512</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-03-31_custom_SkincareAssetsAndLicenseAgreementsMember" unitRef="USD" decimals="0">257512</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-03-31_custom_DiverseBioLicenseAgreementMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31_custom_SkincareAssetsAndLicenseAgreementsMember" unitRef="USD" decimals="0">-126968</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">2362177</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-03-31_custom_SkincareAssetsAndLicenseAgreementsMember" unitRef="USD" decimals="0">1687177</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-03-31_custom_DiverseBioLicenseAgreementMember" unitRef="USD" decimals="0">675000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31_custom_SkincareAssetsAndLicenseAgreementsMember" unitRef="USD" decimals="0">1817721</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000" unitRef="USD" decimals="0">32112</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">3559453</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">1977155</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">535587</us-gaap:AllocatedShareBasedCompensationExpense>
    <amrh:UnamortizedStockOptionExpense contextRef="From2021-01-01to2021-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">0</amrh:UnamortizedStockOptionExpense>
    <amrh:UnamortizedStockOptionExpense contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">0</amrh:UnamortizedStockOptionExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">797373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">929765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">369361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">689832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2021-01-01to2021-03-31" unitRef="Shares" decimals="INF">560404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">246408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">341172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">929765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">369361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">1.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" decimals="INF">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">1.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">0.72</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">2.50</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">3.80</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">1.94</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" decimals="INF">1.66</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">0.88</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">0.36</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">2.50</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF">3.80</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-03-31">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-12-31">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">2537245</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">636156</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">2537245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">636156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-03-31">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <amrh:PaymentOfUpfrontInvestment contextRef="From2021-03-04to2021-03-05_custom_ExclusiveLicenseAgreementMember_custom_DiverseBiotechIncMember" unitRef="USD" decimals="0">675000</amrh:PaymentOfUpfrontInvestment>
    <amrh:PaymentOfUpfrontInvestment contextRef="From2021-03-03to2021-03-05_custom_ExclusiveLicenseAgreementMember_custom_DiverseBiotechIncMember_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">675000</amrh:PaymentOfUpfrontInvestment>
    <amrh:ClassOfWarrantOrRighExercisable contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">6345598</amrh:ClassOfWarrantOrRighExercisable>
    <amrh:ClassOfWarrantOrRighExercisable contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3251406</amrh:ClassOfWarrantOrRighExercisable>
    <amrh:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">3.33</amrh:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable>
    <amrh:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.95</amrh:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable>
    <us-gaap:Cash contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">43714</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1578460</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">22657150</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-03-30_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">22900000</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-10-02_custom_SkincareAssetsMember" unitRef="USD" decimals="0">44143</us-gaap:Cash>
    <us-gaap:NotesIssued1 contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesIssued1 contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">32149</us-gaap:NotesIssued1>
    <amrh:WarrantsIssuedInConjunctionWithNotesPayable contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <amrh:WarrantsIssuedInConjunctionWithNotesPayable contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">17851</amrh:WarrantsIssuedInConjunctionWithNotesPayable>
    <amrh:WarrantsIssuedInConjunctionWithNotesPayable contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">32149</amrh:WarrantsIssuedInConjunctionWithNotesPayable>
    <amrh:WarrantsIssuedInConjunctionWithNotesPayable contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">24875</amrh:WarrantsIssuedInConjunctionWithNotesPayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-851099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-274816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3661178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2021-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">6345598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">219510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">303891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3535519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">84381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3222331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.98</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">3.33</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.95</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">3.02</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember">P4Y10M25D</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember">P1Y0M22D</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember">P4Y11M19D</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">4.93</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">3.21</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.96</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">4.17</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">-3.00</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember">P4Y10M25D</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember">P4Y11M19D</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding>
    <amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested contextRef="AsOf2021-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">6049152</amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested>
    <amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">8040545</amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable>
    <amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable contextRef="AsOf2021-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">6049152</amrh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-03-31">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-03-31">0000890821</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-03-31">false</dei:AmendmentFlag>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-03-31">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">5311414</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">10095109</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">19449975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">5311414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">10095109</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF">19449975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingCostsAndExpenses contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">6764997</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">836702</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CommonStockVotingRights contextRef="From2021-01-01to2021-03-31">The holders of the Company's common stock are entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockVotingRights contextRef="From2020-01-01to2020-12-31">The holders of the Company's common stock are entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <amrh:InducementExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">298714</amrh:InducementExpense>
    <amrh:InducementExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <amrh:InducementExpense contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000" unitRef="USD" decimals="0">298714</amrh:InducementExpense>
    <amrh:InducementExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-802109</amrh:InducementExpense>
    <amrh:InducementExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember28047046">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s activity in restricted stock units&#13;was as follows for&amp;#160;the&amp;#160;three months ended March 31, 2021:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average&lt;br /&gt;&#13;grant date fair&lt;br /&gt;&#13;value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,279,284&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.41&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,207,825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,071,459&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s activity in restricted common&#13;stock was as follows for the three months ended March 31, 2021:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;br /&gt;&#13;average&lt;br /&gt;&#13;grant date&lt;br /&gt;&#13;fair&lt;br /&gt;&#13;value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 63%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,986&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(44,390&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember28047046" unitRef="Shares" decimals="INF">3279284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000" unitRef="Shares" decimals="INF">70986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-12-31_us-gaap_RestrictedStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2021-03-31_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">26596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">2071459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember28047046" unitRef="USDPShares" decimals="INF">4.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000" unitRef="USDPShares" decimals="INF">4.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember28047046" unitRef="USDPShares" decimals="INF">4.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000" unitRef="USDPShares" decimals="INF">4.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_us-gaap_RestrictedStockMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2021-03-31_us-gaap_RestrictedStockMember" unitRef="USDPShares" decimals="INF">3.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember28047046" unitRef="Shares" decimals="INF">1207825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000" unitRef="Shares" decimals="INF">44390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">675000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">3275407</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">3275407</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-03-31_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">72009</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">9416205</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000">P5M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GeneralAndAdministrativeExpenseMember">P1Y11M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">560404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember28047046" unitRef="Shares" decimals="INF">325410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockMember28079000" unitRef="Shares" decimals="INF">42125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">378800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">448713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-07to2020-01-08_custom_JulyTwoThousandNineteenNoteMember_us-gaap_CommonStockMember_custom_LenderMember" unitRef="Shares" decimals="INF">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-12-30to2020-01-02_custom_MrDavidStefanskyMember" unitRef="Shares" decimals="INF">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <amrh:ProceedsFromWarrantExercise contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">3267245</amrh:ProceedsFromWarrantExercise>
    <amrh:ProceedsFromWarrantExercise contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">157952</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">174083</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-01-14_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="USDPShares" decimals="INF">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember" unitRef="USDPShares" decimals="INF">2.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember" unitRef="USDPShares" decimals="INF">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember" unitRef="USDPShares" decimals="INF">1.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember" unitRef="USDPShares" decimals="INF">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember_currency_CAD" unitRef="USDPShares" decimals="INF">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-05-06_custom_EnvericBiosciencesIncMember_custom_AmalgamationAmendmentAgreementMember_us-gaap_CommonStockMember_custom_SeriesBWarrantsMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2021-01-12to2021-01-14_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="USD" decimals="0">10000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="USD" decimals="0">12800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2021-01-12to2021-01-14_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="USD" decimals="0">8806087</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_OfferingMember" unitRef="USD" decimals="0">11624401</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1920390</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">681250</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">626947</us-gaap:LiabilitiesCurrent>
    <amrh:WarrantLiabilitiesNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <amrh:WarrantLiabilitiesNoncurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">6168000</amrh:WarrantLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">681250</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">6794947</us-gaap:Liabilities>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">-3813000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2020-02-23to2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" decimals="0">32149</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">50000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">50000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromNotesPayable contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1319910</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1812410</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">238000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2019-02-06to2019-02-07_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember" unitRef="USD" decimals="0">60000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2019-12-11to2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">40000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2020-01-09to2020-01-10_custom_SecuredPromissoryNoteMember" unitRef="USD" decimals="0">1500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">21078690</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">231597</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1534746</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-69957</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">34235</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-86677</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">-63596</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">17903</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">43714</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1578460</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-03-31" unitRef="USD" decimals="0">22657150</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">275311</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">113671</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockIssued1 contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssued1 contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">173482</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">756523</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:SalariesAndWages contextRef="From2021-04-03to2021-04-09_us-gaap_SubsequentEventMember_custom_WardEmploymentAgreementMember" unitRef="USD" decimals="0">295000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages contextRef="From2019-12-30to2020-01-02_custom_MrDavidStefanskyMember" unitRef="USD" decimals="0">15000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages contextRef="From2020-03-30to2020-05-01_custom_MrHenochCohnMember" unitRef="USD" decimals="0">10000</us-gaap:SalariesAndWages>
    <amrh:AnnualPerformanceBonusesPercentage contextRef="From2021-04-03to2021-04-09_us-gaap_SubsequentEventMember_custom_WardEmploymentAgreementMember" unitRef="Pure" decimals="INF">0.50</amrh:AnnualPerformanceBonusesPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-01-14_us-gaap_WarrantMember_custom_OfferingMember" unitRef="Shares" decimals="INF">1666019</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-02-11_us-gaap_WarrantMember_custom_OfferingMember" unitRef="Shares" decimals="INF">1503513</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="Shares" decimals="INF">130920</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-05-06_custom_EnvericBiosciencesIncMember_custom_AmalgamationAmendmentAgreementMember_us-gaap_CommonStockMember_custom_SeriesBWarrantsMember" unitRef="Shares" decimals="INF">8100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-05-26_custom_EnvericBiosciencesIncMember_custom_SecondAmalgamationAmendmentAgreementMember_custom_SeriesBWarrantsMember" unitRef="Shares" decimals="INF">8100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-03-10_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">851099</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2021-01-14_us-gaap_WarrantMember_custom_OfferingMember" unitRef="USDPShares" decimals="INF">4.9519</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2021-02-11_us-gaap_WarrantMember_custom_OfferingMember" unitRef="USDPShares" decimals="INF">4.90</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2021-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" unitRef="USDPShares" decimals="INF">4.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-01-14_us-gaap_WarrantMember_custom_OfferingMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-02-11_us-gaap_WarrantMember_custom_OfferingMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember">P4Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember">P4Y10M25D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="AsOf2021-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitiesJanuaryWarrantsMember" unitRef="USD" decimals="0">3164000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="AsOf2021-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_WarrantLiabilitiesFebruaryWarrantsMember" unitRef="USD" decimals="0">3004000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="AsOf2021-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">6168000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember" unitRef="USDPShares" decimals="INF">4.21</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" unitRef="USDPShares" decimals="INF">4.95</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember" unitRef="Pure" decimals="INF">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="Pure" decimals="INF">84.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" decimals="INF">0.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember" unitRef="USDPShares" decimals="INF">4.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" unitRef="USDPShares" decimals="INF">4.95</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember" unitRef="Pure" decimals="INF">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="Pure" decimals="INF">84.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" decimals="INF">0.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember" unitRef="USDPShares" decimals="INF">3.07</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" unitRef="USDPShares" decimals="INF">4.95</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember" unitRef="Pure" decimals="INF">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="Pure" decimals="INF">84.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" decimals="INF">0.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputSharePriceMember" unitRef="USDPShares" decimals="INF">3.07</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" unitRef="USDPShares" decimals="INF">4.95</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputDiscountRateMember" unitRef="Pure" decimals="INF">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="Pure" decimals="INF">84.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" decimals="INF">0.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember_custom_CADMember" unitRef="Pure" decimals="INF">1.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_CADMember" unitRef="Pure" decimals="INF">0.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" unitRef="Pure" decimals="INF">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember" unitRef="Pure" decimals="INF">96.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" decimals="INF">2.31</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-12-31_custom_MeasurementInputSharesMember" unitRef="Pure" decimals="INF">130920</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-01-13_custom_InitialMeasurementMember_custom_JanuaryWarrantsMember" unitRef="Shares" decimals="INF">1821514</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-02-12_custom_InitialMeasurementMember_custom_FebruaryWarrantsMember" unitRef="Shares" decimals="INF">1714005</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember" unitRef="Shares" decimals="INF">1821514</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember" unitRef="Shares" decimals="INF">1714005</us-gaap:ClassOfWarrantOrRightOutstanding>
    <amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability contextRef="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember" unitRef="USD" decimals="0">4846000</amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability>
    <amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability contextRef="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember" unitRef="USD" decimals="0">5135000</amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability>
    <amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability contextRef="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember15731484" unitRef="USD" decimals="0">9981000</amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability>
    <amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue contextRef="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember" unitRef="USD" decimals="0">-1682000</amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue>
    <amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue contextRef="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember" unitRef="USD" decimals="0">-2131000</amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue>
    <amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue contextRef="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember15731484" unitRef="USD" decimals="0">-3813000</amrh:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember" unitRef="USD" decimals="0">3164000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember" unitRef="USD" decimals="0">3004000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2020-12-31_custom_SubsequentMeasurementMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2021-03-31_custom_SubsequentMeasurementMember" unitRef="USD" decimals="0">6168000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2020-12-31_custom_SubsequentMeasurementMember_custom_JanuaryWarrantsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2020-12-31_custom_SubsequentMeasurementMember_custom_FebruaryWarrantsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">157714</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">191640</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NatureOfOperations contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&amp;#160;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;1&#13;- BUSINESS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 111pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Nature of operations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Enveric Biosciences, Inc. (&amp;#8220;Enveric Biosciences,&#13;Inc.&amp;#8221; &amp;#8220;Enveric&amp;#8221; or the &amp;#8220;Company&amp;#8221;) (formerly known as Ameri Holdings, Inc.) (&amp;#8220;Ameri&amp;#8221;) is a pharmaceutical&#13;company developing innovative, evidence-based cannabinoid medicines. The head office of the Company is located in Naples, Florida.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 10, 2020, the Company entered into an Amalgamation&#13;Agreement (as amended on May 6, 2020), (the &amp;#8220;Amalgamation Agreement&amp;#8221;) with Jay Pharma Merger Sub, Inc., a company organized&#13;under the laws of Canada and a wholly owned subsidiary of the Company (&amp;#8220;Merger Sub&amp;#8221;), Jay Pharma Inc., a company organized&#13;under the laws of Canada (&amp;#8220;Jay Pharma&amp;#8221;), Jay Pharma ExchangeCo., Inc. a company organized under the laws of British Columbia&#13;and a wholly owned subsidiary of the Company (&amp;#8220;ExchangeCo&amp;#8221;), and Barry Kostiner, as the Company Representative, which provided&#13;that, among other things, Merger Sub and Jay Pharma would be amalgamated and would continue as one corporation (&amp;#8220;Amalco&amp;#8221;),&#13;with Amalco continuing as a direct wholly owned subsidiary of ExchangeCo and an indirect wholly owned subsidiary of Ameri, on the terms&#13;and conditions set forth in the Amalgamation Agreement. On August 12, 2020, the Company, Jay Pharma and certain other signatories thereto&#13;entered into a tender agreement (the &amp;#8220;Tender Agreement&amp;#8221;), which provided that, among other things, Ameri would make a tender&#13;offer (the &amp;#8220;Offer&amp;#8221;) to purchase all of the outstanding common shares of Jay Pharma for the number of shares of Enveric common&#13;stock equal to the exchange ratio set forth in the Tender Agreement, and Jay Pharma would become a wholly-owned subsidiary of Ameri, on&#13;the terms and conditions set forth in the Tender Agreement. The Tender Agreement terminated and replaced in its entirety the Amalgamation&#13;Agreement. On December 30, 2020, the Company, Jay Pharma, Merger Sub, and ExchangeCo&amp;#160;completed&amp;#160;the&amp;#160;Offer&amp;#160;and Jay Pharma&#13;became a wholly owned subsidiary of the Company. The transaction was treated as a reverse acquisition and recapitalization and accordingly,&#13;the historical financial statements prior to the date of the Business Combination in these unaudited condensed consolidated financial&#13;statements are those of Jay Pharma.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: -35.95pt"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2020 and continuing into 2021, the world has&#13;been, and continues to be, impacted by the novel coronavirus (COVID-19) pandemic. COVID-19 and measures to prevent its spread impacted&#13;our business in a number of ways. The impact of these disruptions and the extent of their adverse impact on our financial and operating&#13;results will be dictated by the length of time that such disruptions continue, which will, in turn, depend on the currently unknowable&#13;duration and severity of the impacts of COVID-19, and among other things, the impact of governmental actions imposed in response to COVID-19&#13;and individuals&amp;#8217; and companies&amp;#8217; risk tolerance regarding health matters going forward and developing strain mutations.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NatureOfOperations contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE&amp;#160;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;1&#13;- BUSINESS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Nature of operations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Enveric Biosciences, Inc. (&amp;#8220;Enveric Biosciences, Inc.,&amp;#8221; &amp;#8220;Enveric&amp;#8221; or the &amp;#8220;Company&amp;#8221;) (formerly known as Ameri Holdings, Inc.) (&amp;#8220;Ameri&amp;#8221;) is a pharmaceutical company developing&#13;innovative, evidence-based cannabinoid medicines. The head office of the Company is located in Naples, Florida.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 10, 2020, the Company entered into&#13;an Amalgamation Agreement (as amended on May 6, 2020), (the &amp;#8220;Amalgamation Agreement&amp;#8221;) with Jay Pharma Merger Sub, Inc.,&#13;a company organized under the laws of Canada and a wholly owned subsidiary of the Company (&amp;#8220;Merger Sub&amp;#8221;), Jay Pharma&#13;Inc., a company organized under the laws of Canada (&amp;#8220;Jay Pharma&amp;#8221;), Jay Pharma ExchangeCo., Inc. a company organized&#13;under the laws of British Columbia and a wholly owned subsidiary of the Company (&amp;#8220;ExchangeCo&amp;#8221;), and Barry Kostiner,&#13;as the Company Representative, which provided that, among other things, Merger Sub and Jay Pharma would be amalgamated and would&#13;continue as one corporation (&amp;#8220;Amalco&amp;#8221;), with Amalco continuing as a direct wholly owned subsidiary of ExchangeCo and&#13;an indirect wholly owned subsidiary of Ameri, on the terms and conditions set forth in the Amalgamation Agreement. On August 12,&#13;2020, the Company, Jay Pharma and certain other signatories thereto entered into a tender agreement (the &amp;#8220;Tender Agreement&amp;#8221;),&#13;which provided that, among other things, Ameri would make a tender offer (the &amp;#8220;Offer&amp;#8221;) to purchase all of the outstanding&#13;common shares of Jay Pharma for the number of shares of Enveric common stock equal to the exchange ratio set forth in the Tender&#13;Agreement, and Jay Pharma would become a wholly-owned subsidiary of Ameri, on the terms and conditions set forth in the Tender&#13;Agreement. The Tender Agreement terminated and replaced in its entirety the Amalgamation Agreement. On December 30, 2020, the Company,&#13;Jay Pharma, Merger Sub, and ExchangeCo consummated the Tender Agreement and Jay Pharma became a wholly owned subsidiary of the&#13;Company. The transaction was treated as a reverse acquisition and recapitalization and accordingly, the historical financial statements&#13;prior to the date of the Business Combination in these consolidated financial statements are those of Jay Pharma. The transaction&#13;is further described in Note 7.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2019, a novel strain of coronavirus,&#13;COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the&#13;United States. As the COVID-19 continues to spread in the United States, the Company may experience disruptions that could severely&#13;impact the Company. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact the Company&amp;#8217;s&#13;business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate&#13;geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States&#13;and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States to&#13;contain and treat the disease. The Company is in process of monitoring COVID-19&amp;#8217;s potential impact on the Company&amp;#8217;s&#13;operations.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&amp;#160;3&amp;#160;&amp;#8211; INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2021, the Company&amp;#8217;s intangible&#13;assets consisted of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;&#13;Carrying&lt;br /&gt;&#13;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;&#13;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 41%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Skincare Assets and License Agreements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,944,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(257,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,687,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Diverse Bio License Agreement&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;675,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;675,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,619,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(257,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,362,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2021 and 2020,&#13;the Company recognized amortization expense of $136,640 and $0, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Acquisition of Diverse Bio License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On March 5, 2021, the Company&#13;entered into an Exclusive License Agreement (the &amp;#8220;DB Agreement&amp;#8221;) with Diverse Biotech, Inc. (&amp;#8220;Diverse&amp;#8221;), pursuant&#13;to which the Company acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively, the &amp;#8220;Agents&amp;#8221;)&#13;with the goal of alleviating the side effects that cancer patients experience. Under the terms of the DB Agreement, Diverse has granted&#13;the Company an exclusive license to its intellectual property rights covering the Agents and its products. In exchange, the Company has&#13;granted Diverse the right to information relating to the Agents developed for the express purpose of using such information to obtain&#13;patent rights, which right terminates upon the issuance or denial of the patent rights.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Under the DB Agreement, the&#13;Company will maintain sole responsibility and ownership of the development and commercialization of the Agents and its products. Diverse&#13;has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its products containing the Agents,&#13;at any time during or after the term of the DB Agreement. If Diverse intends to license, sell, or transfer any other molecules linked&#13;with cannabinoids not granted to the Company under the terms of the DB Agreement, the Company will have the first right, but not the obligation,&#13;to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay Diverse an up-front investment payment&#13;in the amount of $675,000, as well as a running royalty starting with the first commercial sale by the Company to a third party in an&#13;arms&amp;#8217;-length transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The term of the DB Agreement&#13;shall continue for as long as the Company intends to develop or commercialize the new drugs, unless earlier terminated by either Party.&#13;The Agreement may be terminated by either party upon ninety (90) days written notice of an uncured material breach or in the event of&#13;bankruptcy or insolvency. In addition, the Company has the right to terminate the DB Agreement at any time upon sixty (60) days&amp;#8217;&#13;prior written notice to Diverse.&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 &amp;#8211; INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 2, 2020, the Company purchased skincare&#13;assets for an aggregate of $1,944,689 in stock and cash, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;44,143&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,900,546&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,944,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recorded the skincare assets as a definite&#13;lived intangible asset with a four year useful life.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2020, the Company&amp;#8217;s intangible assets consisted&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Gross &lt;br /&gt;&#13;Carrying &lt;br /&gt;&#13;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Accumulated &lt;br /&gt;&#13;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Skincare Assets and License Agreements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,944,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(126,968&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,817,721&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&amp;#160;5&amp;#160;- SHARE CAPITAL AND OTHER EQUITY&#13;INSTRUMENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Authorized Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holders of the Company&amp;#8217;s common stock are&#13;entitled to one vote per share. Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by&#13;the Board of Directors out of legally available funds. Upon the liquidation, dissolution, or winding up of the Company, holders of common&#13;stock are entitled to share rateably in all assets of the Company that are legally available for distribution. As of December 31, 2020,&#13;100,000,000 shares of common stock and 20,000,000 shares of Series B Preferred Stock were authorized under the Company&amp;#8217;s articles&#13;of incorporation. The Company&amp;#8217;s Series B preferred stock is convertible by the holder at any time into common stock at a rate of&#13;one to one.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Conversion of Series B Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2021, holders&#13;of an aggregate of 3,275,407 shares of Series B Preferred Stock converted their shares into 3,275,407 shares of common stock. Following&#13;those&amp;#160;conversions,&amp;#160;no Series B Preferred stock shares remain outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Offerings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 14, 2021, the Company completed an offering&#13;of 2,221,458 shares of Common Stock and pre-funded warrants at approximately $4.50 per share and a concurrent private placement of warrants&#13;to purchase 1,666,019 shares of Common Stock at $4.9519 per share, exercisable immediately and terminating five years after the date of&#13;issuance for gross proceeds of approximately $10,000,000. The net proceeds to the Company after deducting financial advisory fees and&#13;other costs and expenses were approximately $8,806,087.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 11, 2021, the Company completed an offering&#13;of 3,007,026 shares of Common Stock and a concurrent private placement of warrants to purchase 1,503,513 shares of Common Stock at $4.90&#13;per share, exercisable immediately and terminating five year from the date of issuance for gross proceeds of approximately $12,800,000.&#13;The net proceeds to Enveric from the offering after deducting financial advisory fees and other costs and expenses were approximately&#13;$11,624,401.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Exercise Price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Grant Date Fair Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate Intrinsic Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 35%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding &amp;#8211; January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired forfeited, or cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(560,404&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding &amp;#8211; December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;369,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;636,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;369,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;636,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s stock based compensation expense&#13;related to stock options for the three months ended March 31, 2021 and 2020 was $0 and $0, respectively. As of March 31, 2021, the Company&#13;had $0 in unamortized stock option expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended&amp;#160;March 31, 2021,&amp;#160;the&#13;Company exchanged options to purchase 560,404 shares of common stock for 325,410 restricted stock units and 42,125 restricted stock awards.&#13;In connection with this exchange, the Company recognized $298,714 in inducement expense related to the increase in fair value of the new&#13;awards over the old awards, which is included in general and administrative expenses on the Company&amp;#8217;s statement of operations and&#13;comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s activity in restricted common&#13;stock was as follows for the three months ended March 31, 2021:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;br /&gt;&#13;average&lt;br /&gt;&#13;grant date&lt;br /&gt;&#13;fair&lt;br /&gt;&#13;value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 63%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,986&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(44,390&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three months ended March 31, 2021 and 2020,&#13;the Company recorded&amp;#160;$32,112&amp;#160;and $0, in stock-based compensation expense related to restricted stock awards. As of March 31,&#13;2021, unamortized stock-based compensation costs related to restricted share awards was $72,009, which will be recognized over a weighted&#13;average period of 0.47 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Issuance of Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s activity in restricted stock units&#13;was as follows for&amp;#160;the&amp;#160;three months ended March 31, 2021:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average&lt;br /&gt;&#13;grant date fair&lt;br /&gt;&#13;value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,279,284&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.41&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,207,825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non&amp;#8211;vested at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,071,459&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three months ended March 31, 2021 and 2020,&#13;the Company recorded&amp;#160;$3,559,453&amp;#160;and $0, respectively, in stock-based compensation expense related to restricted stock units,&#13;which is a component of general and administrative expenses in the condensed consolidated statement of operations. As of March 31, 2021,&#13;unamortized stock-based compensation costs related to restricted stock units was $9,416,205 and will be recognized over a weighted average&#13;period of 1.93 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes information about shares&#13;issuable under warrants outstanding at March 31, 2021:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant&lt;br /&gt;&#13;shares&lt;br /&gt;&#13;outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;br /&gt;&#13;average&lt;br /&gt;&#13;exercise price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average remaining life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intrinsic value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,661,178&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,535,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(851,099&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,345,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,049,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,345,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,049,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Authorized Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The holders of the Company&amp;#8217;s common stock&#13;are entitled to one vote per share. Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared&#13;by the Board of Directors out of legally available funds. Upon the liquidation, dissolution, or winding up of the Company, holders&#13;of common stock are entitled to share rateably in all assets of the Company that are legally available for distribution. As of&#13;December 31, 2020, 100,000,000 shares of common stock were authorized under the Company&amp;#8217;s articles of incorporation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 30, 2020, the Company amended its&#13;articles of incorporation to designate and authorize 20,000,000 shares of Series B preferred stock. The Company&amp;#8217;s Series&#13;B preferred stock is convertible by the holder at any time into common stock at a rate of one to one.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Conversion of Series B Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 30, 2020, a holder of the Company&amp;#8217;s&#13;Series B Preferred Stock converted 250,000 shares of Series B Preferred Stock into 250,000 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Issuance of Common Stock for Accounts Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2020, the&#13;Company issued 433,047 shares of common stock to various vendors in connection with the payment of accounts payable of $756,523.&#13;The shares were valued at the book value of the accounts payable, as that value was more readily determinable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Shares Issued in Exchange for Services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2019, the&#13;Company issued 38,116 shares to consultants in exchange for services. The Company valued these shares at $88,465.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;September Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 25, 2020, the Company issued 36,871&#13;shares of its common stock for gross proceeds of $250,000 and net proceeds of $227,500.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;December Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 8, 2020, the Company issued 221,225&#13;shares of its Series B preferred stock for gross proceeds of $300,000 and net proceeds of $260,500.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Conversion of Related Party Advance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 21, 2020, the Company issued 239,326&#13;shares of common stock in exchange for the February 2019 Note (face value of $66,000), the March 2019 Note (face value of $150,000)&#13;and related party advances in the amount of $22,000. Given that the holder of these notes and advances is a related party, this&#13;was treated as a capital transaction and no gain or loss was recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Exercise Price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Grant Date Fair Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate Intrinsic Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 35%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding &amp;#8211; January 1, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;689,832&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;448,713&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expired, forfeited, or cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(341,172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding &amp;#8211; December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;797,373&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;378,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired forfeited, or cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(246,408&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding &amp;#8211; December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,537,245&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,537,245&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s stock based compensation&#13;expense related to stock options for the years ended December 31, 2020 and 2019 was $1,977,155 and $535,587, respectively. As of&#13;December 31, 2020, the Company had $0 in unamortized stock option expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilized the Black-Scholes option-pricing&#13;model to determine the fair value of these stock options, using the assumptions as outlined below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Stock Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Dividend Yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Risk-Free Interest Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.5 &amp;#8211; 4.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock price &amp;#8211; Based on closing price&#13;of the Company&amp;#8217;s common stock on the date of grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Weighted average risk-free interest rate &amp;#8212;Based&#13;on the daily yield curve rates for U.S. Treasury obligations with maturities, which correspond to the expected term of the Company&amp;#8217;s&#13;stock options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Dividend yield &amp;#8212;The Company has not paid&#13;any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable&#13;future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Expected volatility &amp;#8212;Based on the historical&#13;volatility of comparable companies in a similar industry.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Expected term &amp;#8212;The Company has had no&#13;stock options exercised since inception. The expected option term represents the period that stock-based awards are expected to&#13;be outstanding based on the simplified method provided in Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) No. 107, Share-Based Payment,&#13;which averages an award&amp;#8217;s weighted-average vesting period and expected term for &amp;#8220;plain vanilla&amp;#8221; share options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 24, 2020, the Company issued warrants&#13;to purchase 130,920 shares of common stock to the lender of the February 2020 Note. The warrants are exercisable at $0.38 USD ($0.50&#13;CAD) per share, are fully vested at the date of issuance, and expire on February 24, 2025. The warrants were accounted for as a&#13;component of equity, as the instrument contains no features which would preclude such classification. As discussed in Note 4, the&#13;warrants were recorded as a discount in the amount of $50,000 on the note payable and amortized over the term of the note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes information&#13;about shares issuable under warrants outstanding at December 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Warrant &lt;br /&gt;&#13;shares &lt;br /&gt;&#13;outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;br /&gt;&#13;average&lt;br /&gt;&#13;exercise price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average remaining life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Intrinsic value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at January 1, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;219,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84,381&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;303,891&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,222,331&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(274,816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,251,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,251,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,040,545&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <amrh:ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-03-31_custom_InitialMeasurementMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The key inputs into the Black Scholes valuation model&#13;for the initial valuations are below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;January 13, 2021&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;February 12, 2021&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 53%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,821,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,714,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</amrh:ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock>
    <amrh:ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-03-31_custom_SubsequentMeasurementMember15731484">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The key inputs into the Black Scholes valuation model&#13;for the Level 3 valuations as of March 31, 2021 are below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,821,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,714,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</amrh:ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2021, the Company&amp;#8217;s intangible&#13;assets consisted of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;&#13;Carrying&lt;br /&gt;&#13;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;&#13;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 41%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Skincare Assets and License Agreements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,944,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(257,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,687,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Diverse Bio License Agreement&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;675,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;675,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,619,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(257,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,362,177&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2020, the Company&amp;#8217;s intangible assets consisted&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;&#13;Carrying&lt;br /&gt;&#13;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;&#13;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 46%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Skincare Assets and License Agreements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,944,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(126,968&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,817,721&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Exercise Price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Grant Date Fair Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate Intrinsic Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 35%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding &amp;#8211; January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired forfeited, or cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(560,404&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding &amp;#8211; December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;369,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;636,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;369,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;636,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Exercise Price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Grant Date Fair Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate Intrinsic Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 35%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding &amp;#8211; January 1, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;689,832&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;448,713&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expired, forfeited, or cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(341,172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding &amp;#8211; December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;797,373&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;378,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Expired forfeited, or cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(246,408&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding &amp;#8211; December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,537,245&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,537,245&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes information about shares&#13;issuable under warrants outstanding at March 31, 2021:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant&lt;br /&gt;&#13;shares&lt;br /&gt;&#13;outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;br /&gt;&#13;average&lt;br /&gt;&#13;exercise price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average remaining life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intrinsic value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,661,178&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,535,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(851,099&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,345,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,049,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,345,598&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,049,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes information&#13;about shares issuable under warrants outstanding at December 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Warrant &lt;br /&gt;&#13;shares &lt;br /&gt;&#13;outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;br /&gt;&#13;average&lt;br /&gt;&#13;exercise price (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average remaining life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Intrinsic value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at January 1, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;219,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84,381&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;303,891&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,222,331&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(274,816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,251,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,251,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,040,545&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated&#13;financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S.&#13;GAAP&amp;#8221;) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information&#13;and footnotes required by U.S. GAAP for complete financial statements. Management&amp;#8217;s opinion is that all adjustments (consisting&#13;of normal accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#13;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited condensed&#13;consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December&#13;31, 2020 and related notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the SEC on April 1, 2021.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;have been prepared in accordance and in conformity with the accounting principles generally accepted in the United States of America&#13;(&amp;#8220;U.S. GAAP&amp;#8221;) and the applicable rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;)&#13;regarding consolidated financial information.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity&#13;with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the&#13;date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement&#13;uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant&#13;areas requiring management&amp;#8217;s estimates and assumptions include determining the fair value of transactions involving common stock&#13;and the valuation of stock-based compensation. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities&#13;at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject&#13;to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be&#13;significant. Significant areas requiring management&amp;#8217;s estimates and assumptions include determining the fair value of transactions&#13;involving common stock and the valuation of stock-based compensation. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The reporting currency of the Company is the United&#13;States&amp;#160;Dollar.&amp;#160;The financial statements of companies located outside of the U.S. are measured in their functional currency,&#13;which is the local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are translated&#13;using public exchange rates at the balance sheet date. Income and expense items are translated using average monthly exchange rates.&#13;Shareholders&amp;#8217; equity accounts and non-monetary assets are translated at their historical exchange rates. Translation adjustments&#13;are included in accumulated other comprehensive loss in the accompanying balance sheets.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The reporting currency of the Company is the&#13;United States dollar. The financial statements of companies located outside of the U.S. are measured in their functional currency,&#13;which is the local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are&#13;translated using public exchange rates at the balance sheet date. Income and expense items are translated using average monthly&#13;exchange rates. Shareholders&amp;#8217; equity accounts and non-monetary assets are translated at their historical exchange rates.&#13;Translation adjustments are included in accumulated other comprehensive loss in the accompanying balance sheets.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid investments&#13;purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as&#13;of March 31, 2021 and December 31, 2020.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid investments&#13;purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents&#13;as of December 31, 2020 and December 31, 2019.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <amrh:WarrantLiabilityPolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for warrants for shares of the&#13;Company&amp;#8217;s common stock that are not indexed to its own stock as liabilities at fair value on the balance sheet. Such warrants are&#13;subject to remeasurement at each balance sheet date and any change in fair value is recognized as a component of other expense on the&#13;statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise&#13;or expiration of such common stock warrants. At that time, the portion of the warrant liability related to such common stock warrants&#13;will be reclassified to additional paid-in capital.&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;</amrh:WarrantLiabilityPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is computed by dividing net&#13;loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed using&#13;the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common&#13;shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using the treasury stock method)&#13;and convertible notes. The computation of basic net loss per share for the three months ended March 31, 2021 and 2020 excludes potentially&#13;dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully diluted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Potentially dilutive securities outlined in the table&#13;below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the three months ended March&amp;#160;31,&amp;#160;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the three months ended March&amp;#160;31,&amp;#160;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,979,611&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,504,593&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;380,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted stock units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,279,284&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted stock awards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,986&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;369,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,604,348&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total potentially dilutive securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,699,242&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,489,861&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is computed by dividing&#13;net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is&#13;computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period.&#13;Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using&#13;the treasury stock method) and convertible notes. The computation of basic net loss per share for the years ended December 31,&#13;2020 and 2019 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the&#13;same for both basic and fully diluted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Potentially dilutive securities outlined in&#13;the table below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would&#13;have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,251,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;303,891&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;55,306&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Series B Preferred Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,275,407&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;262,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Options to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;797,373&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total potentially dilutive securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,456,578&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,419,070&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject the&#13;Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal&#13;depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company&#13;is not exposed to significant risks on such accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject&#13;the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the&#13;Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes&#13;the Company is not exposed to significant risks on such accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows Accounting Standards Codification&#13;(&amp;#8220;ASC&amp;#8221;) 820&amp;#8211;10 &amp;#8220;Fair Value Measurement&amp;#8221; of the Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;)&#13;Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial&#13;instruments. ASC 820&amp;#8211;10 establishes a framework for measuring fair value and expands disclosures about fair value measurements.&#13;To increase consistency and comparability in fair value measurements and related disclosures, ASC 820&amp;#8211;10 establishes a fair value&#13;hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The three (3) levels of fair value hierarchy defined&#13;by ASC 820&amp;#8211;10 are described below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 62px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Level 1&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Level 2&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Level 3&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Pricing inputs that are generally unobservable inputs and not corroborated by market data.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial assets or liabilities are considered Level&#13;3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one&#13;significant model assumption or input is unobservable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy gives the highest priority&#13;to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If&#13;the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is&#13;based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of the Company&amp;#8217;s financial&#13;assets and liabilities, such as cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their&#13;fair values due to the short-term nature of these instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses Level 3 of the fair value hierarchy&#13;to measure the fair value of its warrant liabilities. The Company revalues such liabilities at every reporting period and recognizes gains&#13;or losses as change in fair value of warrant liabilities in the condensed consolidated statements of operations that are attributable&#13;to the change in the fair value of the warrant liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides the financial liabilities&#13;measured on a recurring basis and reported at fair value on the balance sheet as of March 31, 2021 and indicates the fair value hierarchy&#13;of the valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2021&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant liabilities &amp;#8211; January Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,164,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant liabilities &amp;#8211; February Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value as of March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,168,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had no assets or liabilities measured&#13;at fair value at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Both the January and February Warrants are classified&#13;as Level 3, for which there is no current market for these securities such as the determination of fair value requires significant judgment&#13;or estimation. Changes in fair value measurement categorized within Level 3 of the fair value hierarchy are analyzed each period based&#13;on changes in estimates or assumptions and recorded as appropriate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Initial Measurement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company established the initial fair value of&#13;its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes valuation model in order to determine their&#13;value. The key inputs into the Black Scholes valuation model for the initial valuations are below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;January 13, 2021&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;February 12, 2021&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 53%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,821,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,714,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Subsequent measurement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the changes in fair value&#13;of the warrant liabilities:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total Warrant Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 47%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Initial value of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,846,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,135,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,981,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,682,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,131,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,813,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value as of March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,164,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,168,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The key inputs into the Black Scholes valuation model&#13;for the Level 3 valuations as of March 31, 2021 are below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,821,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,714,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying value of the Company&amp;#8217;s financial&#13;instruments, including cash and accounts payable, notes payable and convertible notes payable, approximate fair value because of&#13;the short-term nature of such financial instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2019, the Financial Accounting Standards&#13;Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2019-12, Income Taxes (Topic 740: Simplifying the Accounting for Income Taxes (&amp;#8220;ASU 2019-12&amp;#8221;),&#13;which removes certain exceptions to the general principles in Topic 740. ASU 2019-12 is effective for the fiscal years beginning after&#13;December 15, 2020, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-10, &amp;#8220;Codification&#13;Improvements.&amp;#8221; The new accounting rules improve the consistency of the Codification by including all disclosure guidance in the&#13;appropriate Disclosure Section (Section 50) that had only been included in the Other Presentation Matters Section (Section 45) of the&#13;Codification. Additionally, the new rules also clarify guidance across various topics including defined benefit plans, foreign currency&#13;transactions, and interest expense. The new accounting rules were effective for the Company in the first quarter of 2021. The adoption&#13;of the new accounting rules did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Earnings&#13;Per Share (Topic 260), Debt&amp;#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&amp;#8212;Stock Compensation (Topic 718),&#13;and Derivatives and Hedging&amp;#8212;Contracts in Entity&amp;#8217;s Own Equity (Subtopic 815-40): Issuer&amp;#8217;s Accounting for Certain Modifications&#13;or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and&#13;reduce diversity in an issuer&amp;#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options&#13;(for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective&#13;for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption&#13;permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until&#13;October 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&amp;#8217;s condensed consolidated&#13;financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated subsequent events and transactions&#13;that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as described in these&#13;financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the&#13;financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated subsequent events and&#13;transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as&#13;described in these financial statements, the Company did not identify any subsequent events that would have required adjustment to&#13;or disclosure in the financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Potentially dilutive securities outlined in the table&#13;below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the three months ended March&amp;#160;31,&amp;#160;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the three months ended March&amp;#160;31,&amp;#160;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,979,611&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,504,593&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;380,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted stock units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,279,284&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted stock awards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,986&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;369,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,604,348&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total potentially dilutive securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,699,242&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,489,861&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Potentially dilutive securities outlined in&#13;the table below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would&#13;have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,251,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;303,891&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;55,306&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Series B Preferred Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,275,407&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;262,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Options to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;797,373&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total potentially dilutive securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,456,578&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,419,070&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides the financial liabilities&#13;measured on a recurring basis and reported at fair value on the balance sheet as of March 31, 2021 and indicates the fair value hierarchy&#13;of the valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2021&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant liabilities &amp;#8211; January Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,164,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant liabilities &amp;#8211; February Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value as of March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,168,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <amrh:ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the changes in fair value&#13;of the warrant liabilities:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total Warrant Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 47%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Initial value of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,846,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,135,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,981,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,682,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,131,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,813,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value as of March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,164,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,168,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</amrh:ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock>
    <amrh:OfferingCostsPolicy contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company allocates offering costs to the different&#13;components of the capital raise on a pro rata basis. Any offering costs allocated to common stock are charged directly to additional paid-in&#13;capital. Any offering costs allocated to warrant liabilities are charged to general and administrative expenses on the Company&amp;#8217;s&#13;statement of operations.&lt;/p&gt;</amrh:OfferingCostsPolicy>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;Note&#13;2 &amp;#8211; SUMMARY OF Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated&#13;financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S.&#13;GAAP&amp;#8221;) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information&#13;and footnotes required by U.S. GAAP for complete financial statements. Management&amp;#8217;s opinion is that all adjustments (consisting&#13;of normal accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#13;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited condensed&#13;consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December&#13;31, 2020 and related notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the SEC on April 1, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity&#13;with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the&#13;date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement&#13;uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant&#13;areas requiring management&amp;#8217;s estimates and assumptions include determining the fair value of transactions involving common stock&#13;and the valuation of stock-based compensation. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The reporting currency of the Company is the United&#13;States Dollar. The financial statements of companies located outside of the U.S. are measured in their functional currency, which is the&#13;local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are translated using public&#13;exchange rates at the balance sheet date. Income and expense items are translated using average monthly exchange rates. Shareholders&amp;#8217;&#13;equity accounts and non-monetary assets are translated at their historical exchange rates. Translation adjustments are included in accumulated&#13;other comprehensive loss in the accompanying balance sheets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid investments&#13;purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of&#13;March 31, 2021 and December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for warrants for shares of the&#13;Company&amp;#8217;s common stock that are not indexed to its own stock as liabilities at fair value on the balance sheet. Such warrants are&#13;subject to remeasurement at each balance sheet date and any change in fair value is recognized as a component of other expense on the&#13;statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise&#13;or expiration of such common stock warrants. At that time, the portion of the warrant liability related to such common stock warrants&#13;will be reclassified to additional paid-in capital.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company allocates offering costs to the different&#13;components of the capital raise on a pro rata basis. Any offering costs allocated to common stock are charged directly to additional paid-in&#13;capital. Any offering costs allocated to warrant liabilities are charged to general and administrative expenses on the Company&amp;#8217;s&#13;statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is computed by dividing net&#13;loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed using&#13;the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common&#13;shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using the treasury stock method)&#13;and convertible notes. The computation of basic net loss per share for the three months ended March 31, 2021 and 2020 excludes potentially&#13;dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully diluted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Potentially dilutive securities outlined in the table&#13;below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the three months ended March&amp;#160;31,&amp;#160;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the three months ended March&amp;#160;31,&amp;#160;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,979,611&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,504,593&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;380,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Restricted stock units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,279,284&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Restricted stock awards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;70,986&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Options to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;369,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,604,348&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total potentially dilutive securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,699,242&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,489,861&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject the&#13;Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository&#13;insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed&#13;to significant risks on such accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows Accounting Standards Codification&#13;(&amp;#8220;ASC&amp;#8221;) 820&amp;#8211;10 &amp;#8220;Fair Value Measurement&amp;#8221; of the Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;)&#13;Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial&#13;instruments. ASC 820&amp;#8211;10 establishes a framework for measuring fair value and expands disclosures about fair value measurements.&#13;To increase consistency and comparability in fair value measurements and related disclosures, ASC 820&amp;#8211;10 establishes a fair value&#13;hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The three (3) levels of fair value hierarchy defined&#13;by ASC 820&amp;#8211;10 are described below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 62px; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;i&gt;Level 1&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;i&gt;Level 2&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;i&gt;Level 3&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Pricing inputs that are generally unobservable inputs and not corroborated by market data.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial assets or liabilities are considered Level&#13;3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one&#13;significant model assumption or input is unobservable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy gives the highest priority&#13;to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If&#13;the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is&#13;based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of the Company&amp;#8217;s financial&#13;assets and liabilities, such as cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their&#13;fair values due to the short-term nature of these instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses Level 3 of the fair value hierarchy&#13;to measure the fair value of its warrant liabilities. The Company revalues such liabilities at every reporting period and recognizes gains&#13;or losses as change in fair value of warrant liabilities in the condensed consolidated statements of operations that are attributable&#13;to the change in the fair value of the warrant liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides the financial liabilities&#13;measured on a recurring basis and reported at fair value on the balance sheet as of March 31, 2021 and indicates the fair value hierarchy&#13;of the valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Level&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;March 31, 2021&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font-size: 10pt"&gt;Warrant liabilities &amp;#8211; January Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,164,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrant liabilities &amp;#8211; February Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Fair value as of March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,168,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had no assets or liabilities measured&#13;at fair value at December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Both the January and February Warrants are classified&#13;as Level 3, for which there is no current market for these securities such as the determination of fair value requires significant judgment&#13;or estimation. Changes in fair value measurement categorized within Level 3 of the fair value hierarchy are analyzed each period based&#13;on changes in estimates or assumptions and recorded as appropriate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Initial Measurement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company established the initial fair value of&#13;its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes valuation model in order to determine their&#13;value. The key inputs into the Black Scholes valuation model for the initial valuations are below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;February Warrants&lt;/b&gt; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;i&gt;January 13, 2021&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;i&gt;February 12, 2021&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font-size: 10pt"&gt;Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,821,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,714,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Value (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Subsequent measurement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the changes in fair value&#13;of the warrant liabilities:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total Warrant Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Fair value as of December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 47%"&gt;&lt;font style="font-size: 10pt"&gt;Initial value of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,846,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,135,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,981,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Change in fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,682,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,131,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3,813,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Fair value as of March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,164,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,168,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The key inputs into the Black Scholes valuation model&#13;for the Level 3 valuations as of March 31, 2021 are below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;January Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;February Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font-size: 10pt"&gt;Term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Stock price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,821,514&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,714,005&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Value (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2019, the Financial Accounting Standards&#13;Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2019-12, Income Taxes (Topic 740: Simplifying the Accounting for Income Taxes (&amp;#8220;ASU 2019-12&amp;#8221;),&#13;which removes certain exceptions to the general principles in Topic 740. ASU 2019-12 is effective for the fiscal years beginning after&#13;December 15, 2020, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-10, &amp;#8220;Codification&#13;Improvements.&amp;#8221; The new accounting rules improve the consistency of the Codification by including all disclosure guidance in the&#13;appropriate Disclosure Section (Section 50) that had only been included in the Other Presentation Matters Section (Section 45) of the&#13;Codification. Additionally, the new rules also clarify guidance across various topics including defined benefit plans, foreign currency&#13;transactions, and interest expense. The new accounting rules were effective for the Company in the first quarter of 2021. The adoption&#13;of the new accounting rules did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Earnings&#13;Per Share (Topic 260), Debt&amp;#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&amp;#8212;Stock Compensation (Topic 718),&#13;and Derivatives and Hedging&amp;#8212;Contracts in Entity&amp;#8217;s Own Equity (Subtopic 815-40): Issuer&amp;#8217;s Accounting for Certain Modifications&#13;or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and&#13;reduce diversity in an issuer&amp;#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options&#13;(for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective&#13;for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption&#13;permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until&#13;October 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&amp;#8217;s condensed consolidated&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated subsequent events and transactions&#13;that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as described in these&#13;financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the financial&#13;statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;Note&#13;3 &amp;#8211; SUMMARY OF Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;have been prepared in accordance and in conformity with the accounting principles generally accepted in the United States of America (&amp;#8220;U.S.&#13;GAAP&amp;#8221;) and the applicable rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) regarding consolidated&#13;financial information.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity&#13;with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the&#13;date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement&#13;uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant&#13;areas requiring management&amp;#8217;s estimates and assumptions include determining the fair value of transactions involving common stock&#13;and the valuation of stock-based compensation. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The reporting currency of the Company is the United&#13;States dollar. The financial statements of companies located outside of the U.S. are measured in their functional currency, which is the&#13;local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are translated using public&#13;exchange rates at the balance sheet date. Income and expense items are translated using average monthly exchange rates. Shareholders&amp;#8217;&#13;equity accounts and non-monetary assets are translated at their historical exchange rates. Translation adjustments are included in accumulated&#13;other comprehensive loss in the accompanying balance sheets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid investments&#13;purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of&#13;December 31, 2020 and December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Intangibles&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has finite-lived intangible assets. Finite-lived&#13;intangible assets are amortized over their estimated useful lives. Research and development costs are expensed as incurred. Following&#13;initial recognition of the finite-lived intangible asset, the asset is carried at cost less any accumulated amortization. Amortization&#13;of the asset begins when the asset is available for use. Amortization is recorded in general and administrative expenses on the Company&amp;#8217;s&#13;consolidated statement of operations. The Company periodically reviews its owned intangible assets for recoverability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long Term Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates the carrying value of long-lived&#13;assets subject to amortization whenever events or changes in circumstances indicate that an impairment may exist. An impairment charge&#13;is recognized when the asset&amp;#8217;s carrying value exceeds its net undiscounted future cash flows and its fair market value. The amount&#13;of the charge is the difference between the asset&amp;#8217;s carrying value and fair market value.&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 25, 2016, FASB issued ASU 2016-02, Leases&#13;(Topic 842). This update will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for&#13;the rights and obligations created by those leases. The new guidance will also require additional disclosures about the amount, timing&#13;and uncertainty of cash flows arising from leases. On January 1, 2020, the Company adopted this ASU, which did not have a material impact&#13;on the Company&amp;#8217;s financial position and results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilizes an asset and liability approach&#13;for financial accounting and reporting for income taxes. The provision for income taxes is based upon income or loss after adjustment&#13;for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects&#13;of differences between the financial reporting and tax basis of the Company&amp;#8217;s assets and liabilities at the enacted tax rates in&#13;effect for the years in which the differences are expected to reverse.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates the recoverability of deferred&#13;tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will&#13;not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause&#13;changes to previous estimates of tax liabilities. In management&amp;#8217;s opinion, adequate provisions for income taxes have been made.&#13;If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Tax benefits are recognized only for tax positions&#13;that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount&#13;of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &amp;#8220;unrecognized tax benefits&amp;#8221;&#13;is recorded for any tax benefits claimed in the Company&amp;#8217;s tax returns that do not meet these recognition and measurement standards.&#13;As of December 31, 2020 and December 31, 2019, no liability for unrecognized tax benefits was required to be recorded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s policy for recording interest&#13;and penalties associated with tax audits is to record such items as a component of operating expenses. There were no amounts accrued for&#13;penalties and interest for the years ended December 31, 2020 and 2019. The Company does not expect its uncertain tax positions to change&#13;during the next twelve months. Management is currently unaware of any issues under review that could result in significant payments, accruals&#13;or material deviations from its position.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has identified its United States and Canadian&#13;federal tax return, its state and provincial tax returns in Florida and Ontario, CA as its &amp;#8220;major&amp;#8221; tax jurisdictions. The&#13;Company is in the process of filing its corporate tax returns for the years ended December 31, 2020 and December 31, 2019. Net operating&#13;losses for these periods will not be available to reduce future taxable income until the returns are filed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows Accounting Standards Codification&#13;(&amp;#8220;ASC&amp;#8221;) 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring&#13;such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more&#13;readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes&#13;option-pricing model to determine the grant date fair value of stock-based awards under ASC 718. The estimated fair value is amortized&#13;as a charged to earnings on a straight-line basis depending on the terms and conditions of the award, and the nature of the relationship&#13;of the recipient of the award to the Company. The Company records the grant date fair value in line with the period over which it was&#13;earned. For employees and consultants, this is typically considered to be the vesting period of the award. The Company estimates the expected&#13;forfeitures and updates the valuation accordingly.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is computed by dividing net&#13;loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed using&#13;the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common&#13;shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using the treasury stock method)&#13;and convertible notes. The computation of basic net loss per share for the years ended December 31, 2020 and 2019 excludes potentially&#13;dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully diluted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Potentially dilutive securities outlined in the table&#13;below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,251,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;303,891&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;55,306&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Series B Preferred Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,275,407&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;262,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Options to purchase shares of common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;929,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;797,373&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total potentially dilutive securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,456,578&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,419,070&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject the&#13;Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository&#13;insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed&#13;to significant risks on such accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying value of the Company&amp;#8217;s financial&#13;instruments, including cash and accounts payable, notes payable and convertible notes payable, approximate fair value because of the short-term&#13;nature of such financial instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated subsequent events and transactions&#13;that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as described in these&#13;financial statements, the Company did not identify any&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;subsequent events that would have required adjustment&#13;to or disclosure in the financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <dei:DocumentType contextRef="From2021-01-01to2021-03-31">S-4</dei:DocumentType>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">22409</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <amrh:NotesPayableExcludingConvertibleNotespayable contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">446415</amrh:NotesPayableExcludingConvertibleNotespayable>
    <amrh:NotesPayableExcludingConvertibleNotespayable contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">293921</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">288631</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">68453</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <amrh:PaymentsForPurchaseOfLicenseAgreement contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">44143</amrh:PaymentsForPurchaseOfLicenseAgreement>
    <amrh:PaymentsForPurchaseOfLicenseAgreement contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">22000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2020-07-19to2020-07-21" unitRef="USD" decimals="0">22000</us-gaap:ProceedsFromRelatedPartyDebt>
    <amrh:ProceedsFromOfferingAndReverseMergerProceeds contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">3372500</amrh:ProceedsFromOfferingAndReverseMergerProceeds>
    <amrh:ProceedsFromOfferingAndReverseMergerProceeds contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">227500</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2020-09-23to2020-09-25_us-gaap_CommonStockMember_custom_SeptemberPrivatePlacementMember" unitRef="USD" decimals="0">250000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2020-09-23to2020-09-25_us-gaap_SeriesBPreferredStockMember_custom_DecemberPrivatePlacementMember" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <amrh:ProceedsFromIssuanceOfPrivatePlacementOne contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">260500</amrh:ProceedsFromIssuanceOfPrivatePlacementOne>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">17851</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-02-23to2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" decimals="0">17851</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <amrh:CommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">101713</amrh:CommonStockIssuedInConjunctionWithNotePayableModification>
    <amrh:CommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">22266</amrh:CommonStockIssuedInConjunctionWithNotePayableModification>
    <amrh:ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">679569</amrh:ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock>
    <amrh:ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <amrh:CommonStockIssuedForSkincareLicense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1900546</amrh:CommonStockIssuedForSkincareLicense>
    <amrh:CommonStockIssuedForSkincareLicense contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <amrh:NotesPayableIssuedToConsultantForPrepaidServices contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <amrh:NotesPayableIssuedToConsultantForPrepaidServices contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">150000</amrh:NotesPayableIssuedToConsultantForPrepaidServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">88465</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember_custom_ConsultantMember" unitRef="USD" decimals="0">88465</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">381</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">88084</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2020-01-05to2020-01-06_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember" unitRef="Shares" decimals="INF">127856</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember_custom_ConsultantMember" unitRef="Shares" decimals="INF">38116</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">38116</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:LiquidationBasisOfAccountingTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;NOTE&#13;2 &amp;#8211; LIQUIDITY&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"&gt;&lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has incurred continuing losses&#13;from its operations and as of December 31, 2020, had an accumulated deficit of $11,759,557 and working capital of $1,597,920. Since&#13;inception, the Company&amp;#8217;s operations have been funded principally through the issuance of debt and equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 14, 2021, the Company completed&#13;a registered direct offering of 2,221,458 shares of common stock at approximately $4.50 per share for gross proceeds of approximately&#13;$10,000,000. On February 11, 2021, the Company completed a registered direct offering of 3,007,026 shares of common stock for gross&#13;proceeds of approximately $12.8 million. As of March&amp;#160;30,&amp;#160;2021, the Company had cash on hand of approximately $22.9 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company believes that, as a result of&#13;these transactions, it currently has sufficient cash and financing commitments to meet its funding requirements.&amp;#160;Accordingly,&#13;management has since reevaluated the Company&amp;#8217;s liquidity and financial condition and determined that sufficient capital&#13;exists to sustain operations through one year from the issuance of these financial statements and therefore substantial doubt&#13;has been alleviated.&amp;#160;Notwithstanding, the Company expects that it will need to raise additional financing to accomplish its&#13;development plan over the next several years. The Company&amp;#160;will require&amp;#160;additional funding through debt or equity financing&#13;in the future. If the Company is unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope&#13;of its planned development, which could&amp;#160;impact&amp;#160;its financial condition and operating results.&lt;/p&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &amp;#8211; NOTES PAYABLE AND CONVERTIBLE&#13;NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2020 the Company had no notes payable or convertible&#13;notes payable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2019, the Company&amp;#8217;s notes payable and convertible&#13;notes payable consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 48%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;66,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;66,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2019 Convertible Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,079&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;293,921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;191,640&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,700&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;188,940&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,525&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;751,640&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(11,304&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;740,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Notes payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;451,640&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;446,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible notes payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,079&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;293,921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2020 and 2019,&#13;interest expense and amortization of debt discount consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the Year Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Interest Expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization of Debt Discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Interest Expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization of Debt Discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 34%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,840&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,840&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2019 Convertible Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,842&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;17,142&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,704&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;98,046&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 2020 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,545&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,912&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,457&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Alpha Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;86,762&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;181,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;268,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;156,619&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;288,631&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;445,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68,453&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;81,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 7, 2019, the Company received $60,000&#13;in exchange for a promissory note with a director for $66,000, including an original issue discount of $6,000 (the &amp;#8220;February&#13;2019 Note&amp;#8221;). The note had no stated interest rate and was due on May 8, 2019. The Company amortized the full $6,000 original&#13;issue discount in the statement of operations and comprehensive loss through December 31, 2019. On July 21, 2020, the Company converted&#13;the February 2019 Note into common stock, as further described in Note 6.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 1, 2019, the Company entered into&#13;a consulting agreement with its former executive director. In connection with the consulting agreement, on March 5, 2019, the Company&#13;issued a note payable to its former executive director for $150,000 (the &amp;#8220;March 2019 Note&amp;#8221;). The note had no interest&#13;and was due and payable on March 4, 2020. The consulting agreement expired on February 1, 2020. On July 21, 2020, the Company converted&#13;the March 2019 Note into common stock, as further described in Note 6.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 8, 2019, the Company entered into a&#13;note agreement (the &amp;#8220;July 2019 Note&amp;#8221;) with a limited liability company (the &amp;#8220;Lender&amp;#8221;). One of the principals&#13;of the Lender is the brother of a former member of the Company&amp;#8217;s Board of Directors. The Note&amp;#8217;s face value was $157,714&#13;and the original issue discount was $19,714 for total gross proceeds of $138,000, implying an interest rate of 12.5% per annum.&#13;The Company could, without premium or penalty, at any time and from time to time, prepay all or any portion of the Note. The maturity&#13;date of the Note was September 8, 2019. On September 20, 2019, the Company entered into an amendment to the July 2019 Note (the&#13;&amp;#8220;Amendment&amp;#8221;). The Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge&#13;financing of greater than or equal to $1,500,000, or (b) November 7, 2019. On November 21, 2019, the Company entered into an amendment&#13;for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing&#13;of greater than or equal to $1,500,000, or (b) December 9, 2019. In consideration for this amendment, the Company agreed to pay&#13;an aggregate extension fee of $33,926, which was added to the principal balance of the note. On December 9, 2019, the Company entered&#13;into an additional amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion&#13;of a bridge financing of greater than or equal to $1,500,000, or (b) January 7, 2020. The Company also agreed to pay the previously&#13;outstanding extension fees of $33,926 on or before March 1, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 8, 2020 the Company entered into&#13;an amendment to the July 2019 Note (the &amp;#8220;January 8 Amendment&amp;#8221;). The January 8 Amendment extended the maturity date&#13;for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) April&#13;1, 2020. In consideration for the January 8 Amendment, the Company granted 55,000 shares of the Company&amp;#8217;s common stock to&#13;the Lender. The Company accounted for this amendment as a modification, where the shares paid as a fee were valued at $45,725 and&#13;recorded as a discount against the note payable and amortization over the term. On May 6, 2020, the Company entered into an amendment&#13;(the &amp;#8220;May 2020 Amendment&amp;#8221;) whereby both parties agreed to extend the maturity date of the July 2019 Note to September&#13;30, 2020. The Company accounted for this amendment as a modification, as the present value of the future cash flows pre-modification&#13;and post-modification were not greater than or equal to 10%. On January 12, 2020, the Company repaid $157,714 of the July 2019&#13;Note. On December 31, 2020 the Company paid the remaining unpaid balance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 12, 2019, the Company received&#13;$40,000 in exchange for a promissory note with a lender, including an original issue&amp;#160;discount of $4,000 (the &amp;#8220;December&#13;2019 Note&amp;#8221;). The December 2019 Note bore interest at a rate of ten percent (10%) on its face value per annum. In the case&#13;of an event of default, the interest rate would increase to 24% per year. The December 2019 Note matured on January 31, 2020. The&#13;promissory note with the lender and the Company was converted into 170,333 shares of common stock on December 30, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 24, 2020, the Company received&#13;$50,000 in exchange for a promissory note with a lender (the &amp;#8220;February 2020 Note&amp;#8221;). The February 2020 Note bore interest&#13;at a rate of 10% on its face value per annum. In the case of an event of default, the interest rate would increase to 24% per year.&#13;The note matured on July 31, 2020. The February 2020 Note was convertible into the Company&amp;#8217;s common stock at any time at&#13;a conversion price of $0.38 per share. The Company recorded a beneficial conversion feature of $17,851 and valued the warrants&#13;issued (using relative fair value) at $32,149. The Company recorded the total value as a note discount and is amortizing the discount&#13;over the term of the February 2020 Note using the effective interest method. The Company valued the beneficial conversion feature&#13;and warrants using the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Beneficial Conversion Feature&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;CAD $ 1.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;CAD $ 1.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;CAD $ 0.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;CAD $ 0.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend Yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;96.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Risk-Free Interest Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;130,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;17,851&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;32,149&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On December 30, 2020, the February 2020 Note was converted into&#13;190,004 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#160;entered into a Secured Promissory&#13;Note, dated January 10, 2020 (the &amp;#8220;Note&amp;#8221;), by and among Enveric Biosciences, Inc. and Alpha Capital Anstalt (&amp;#8220;Alpha&amp;#8221;),&#13;pursuant to which, on January 10, 2020, Enveric Biosciences, Inc. received aggregate gross proceeds of $1,500,000. Pursuant to&#13;the Note, the aggregate obligations of Enveric Biosciences, Inc. under the Note were automatically, immediately prior to the consummation&#13;of the amalgamation, converted into shares of Enveric Biosciences, Inc. common stock, subject to the terms and provisions of the&#13;Note. Pursuant to the Note, upon conversion of the term loans made by the lenders subject to the terms of the Note, Enveric Biosciences,&#13;Inc. was required to cause Ameri to issue each lender warrants to purchase Ameri Common Stock. Upon consummation of the amalgamation,&#13;Enveric Biosciences, Inc. agreed to cause Ameri to register the resale of the warrant shares. The Note bears interest at 7% per&#13;annum and was due on March 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 6, 2020, the Company entered into an&#13;amendment to the Note (the &amp;#8220;First Note Amendment&amp;#8221;). Pursuant to the First Note Amendment, Alpha waived previous defaults&#13;on the Note, and extended the maturity date of the Note to June 30, 2020. In exchange for the First Note Amendment, the Company&#13;and Alpha agreed that (i) at the Effective Time, Ameri would issue to the holder of a certain note issued by Enveric Biosciences,&#13;Inc., series B warrants (the &amp;#8220;Series B Warrants&amp;#8221;) to acquire 8,100,000 shares of common stock of the Company resulting&#13;from the amalgamation, and (ii) providing for certain registration rights, pursuant to a registration rights agreement, of the&#13;Series B Warrants and the shares issuable upon exercise of the Series B Warrants. The Series B Warrants shall be exercisable for&#13;a period of five years commencing on the ninetieth (90th) day after the later of the last day of the Lock-up Period and leak-out&#13;Period (accelerated or otherwise) set forth in the Lock-up agreement to be executed by the holders of Enveric Biosciences, Inc.&#13;securities in connection with the Amalgamation, at a price of $0.01 per share, and shall also be exercisable on a cashless basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 23, 2020, the Company and Alpha entered&#13;into a second amendment to the Note (the &amp;#8220;Second Note Amendment&amp;#8221;). The Second Note Amendment revised the principal&#13;amount of the Note from $1,500,000 to $2,000,000, which was advanced as of the date of the Second Note Amendment. The rights and&#13;securities granted to Alpha under the terms of the Note were extended to the additional $500,000 advance contemplated by the Second&#13;Note Amendment pursuant to the terms of the Second Note Amendment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 12, 2020, the Company and Alpha entered&#13;into the Third Note Amendment. The Third Note Amendment extended the maturity date to be the earlier of (a) January 1, 2021 and&#13;(b) an event of default that accelerates the maturity of the Note. The Third Note Amendment also revised the Note to account for&#13;the change in structure from an amalgamation to a stock-for-stock exchange offer. As a result, references to the Amalgamation Agreement&#13;and the amalgamation were revised to be references to the Tender Agreement and the Offer. The Third Note Amendment also revised&#13;the event of default regarding a failure of the amalgamation to be consummated by March 31, 2020 to be an event of default if the&#13;Offer was not consummated by January 1, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 30, 2020, the Note&amp;#160;in the&#13;amount of $2,000,000&amp;#160;was converted into 2,473,848 shares of common stock.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <amrh:TenderAgreementDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 &amp;#8211; TENDER AGREEMENT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On January 10, 2020,&#13;the Company entered into an amalgamation agreement (the &amp;#8220;Amalgamation Agreement&amp;#8221;) with Enveric Biosciences, Inc. Merger&#13;Sub, Inc. (&amp;#8220;Merger Sub&amp;#8221;), a wholly owned subsidiary of Ameri, and Enveric Biosciences, Inc. Exchange Co, Inc. (&amp;#8220;ExchangeCo&amp;#8221;),&#13;a wholly owned subsidiary of Ameri. The Amalgamation Agreement provided that the Company would merge into Merger Sub and be amalgamated&#13;and operate as one company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Prior to the execution&#13;and delivery of the Amalgamation Agreement, Alpha entered into agreements with Enveric Biosciences, Inc. pursuant to which Alpha&#13;agreed, subject to the terms and conditions of such agreements, to purchase, immediately prior to the consummation of the Amalgamation,&#13;shares of Enveric Biosciences, Inc.&amp;#8217;s common stock (or common stock equivalents) and warrants to purchase Enveric Biosciences,&#13;Inc.&amp;#8217;s common stock for an aggregate purchase price of $3.5 million. The consummation of the transactions contemplated by&#13;such agreements was conditioned upon the satisfaction or waiver of the conditions set forth in the Amalgamation Agreement. After&#13;consummation of the Amalgamation, Enveric Biosciences, Inc. agreed to cause Ameri to register the resale of the Ameri Common Stock&#13;issued and issuable pursuant to the warrants issued to the investors in the Jay Pharma Pre-Closing Financing.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Contemporaneously&#13;with the Amalgamation Agreement, the Company entered into sublicense agreements with Tikkun Pharma, Inc. (&amp;#8220;Tikkun Pharma&amp;#8221;).&#13;The sublicense agreements with Tikkun Pharma allows the Company to utilize (a) Tikkun Pharma&amp;#8217;s sublicense with a third party&#13;for certain autoimmune applications, and (b) acquire and use Tikkun Pharma&amp;#8217;s internally developing intellectual property,&#13;branding, and formulations in regards to skincare.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On April 20, 2020,&#13;the Company received a notice from the lenders of the Note, stating that the Company was in default for not closing the amalgamation&#13;with Ameri by March 31, 2020, and that the entire Note was due in full. On May 6 and May 26, 2020, the Company and Alpha amended&#13;the Note and the Amalgamation Agreement, as described in below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 6, 2020, the Company entered into an&#13;Amalgamation Amendment Agreement (the &amp;#8220;Amendment&amp;#8221;) to amend the Amalgamation Agreement described in Note 7. Pursuant&#13;to the Amendment, the parties agreed that (i) at the Effective Time, Ameri Holdings, Inc. shall issue to the holder of a certain&#13;note issued by Enveric Biosciences, Inc., series B warrants (the &amp;#8220;Series B Warrants&amp;#8221;) to acquire 8,100,000 shares of&#13;common stock of the company resulting from the amalgamation, and (ii) providing for certain registration rights, pursuant to a&#13;Registration Statement on Form S-4, of the Series B Warrants and the shares issuable upon exercise of the Series B Warrants. The&#13;Series B Warrants shall be exercisable for a period of five years commencing on the ninetieth (90th) day after the later of the&#13;last day of the Lock-up Period and leak-out Period (accelerated or otherwise) set forth in the Lock-up agreement to be executed&#13;by the holders of Enveric Biosciences, Inc. securities in connection with the Amalgamation, at a price of $0.01 per share, and&#13;shall also be exercisable on a cashless basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 26, 2020, the Company entered into the&#13;second amendment to the Amalgamation Agreement (the &amp;#8220;Second Amendment&amp;#8221;) to amend the Amalgamation Agreement described&#13;in Note 7. The purpose of this amendment was to clarify that the Series B Warrants were to acquire 8,100,000 shares of common stock&#13;Enveric Biosciences, Inc. (to be approximately 3,675,035 shares of common stock of the company resulting from the Amalgamation),&#13;as well as to clarify the exchange ratio already agreed upon.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 12, 2020, Ameri, Enveric Biosciences,&#13;Inc., and certain other signatories thereto entered into a tender agreement (the &amp;#8220;Tender Agreement&amp;#8221;), which provided&#13;that, among other things, Enveric Biosciences, Inc. would become a wholly owned subsidiary of Ameri, on the terms and conditions&#13;set forth in the Tender Agreement. The Tender Agreement terminated and replaced in its entirety the Amalgamation Agreement. Upon&#13;completion of the Tender Agreement on December 30, 2020, (i) holders of outstanding common shares of Enveric Biosciences, Inc.&#13;other than Alpha will be entitled to receive the number of shares of Resulting Issuer common stock issuable in accordance with&#13;the Exchange Ratio, and (ii) Alpha will be entitled to receive shares of Series B Preferred Stock, which are convertible into shares&#13;of Resulting Issuer common stock subject to a 9.99% beneficial ownership blocker, pursuant to the Alpha Exchange Agreement. Each&#13;outstanding Enveric Biosciences, Inc. option, whether vested or unvested, and warrant that has not previously been exercised will&#13;exchanged for Resulting Issuer stock options and Resulting Issuer warrants, in each case convertible into the number of shares&#13;of Resulting Issuer common stock equal to the Exchange Ratio. Each outstanding Enveric Biosciences, Inc. option, whether vested&#13;or unvested, and warrant that has not previously been exercised will be exchanged for Resulting Issuer stock options and Resulting&#13;Issuer warrants, in each case, convertible into the number of shares of Resulting Issuer common stock equal to the Exchange Ratio.&lt;/p&gt;</amrh:TenderAgreementDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 &amp;#8211; INCOME TAXES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The tax effects of temporary differences that give rise to significant&#13;portions of the deferred tax assets and deferred tax liabilities are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Net operating loss carryovers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets, gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets (liabilities), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The change in the Company&amp;#8217;s valuation allowance is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Beginning of year&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;505,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Increase in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;498,158&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;End of year&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,344,180&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of the provision for income&#13;taxes with the amounts computed by applying the statutory federal income tax rate to loss from operations before the provision&#13;for income taxes is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Canada federal statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Provincial taxes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(11.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(11.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Non-deductible expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Effective income tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2020 and 2019, the Company&#13;had net operating loss carryovers of $5,057,176 and $3,788,788, respectively, for Canadian federal income tax purposes, which begin&#13;to expire in 2029. The ultimate realization of the net operating loss is dependent upon future taxable income, if any, of the Company.&#13;Based on losses from inception, the Company determined that as of December 31, 2020 and 2019 it is more likely than not that the&#13;Company will not realize benefits from the deferred tax assets. The Company will not record income tax benefits in the financial&#13;statements until it is determined that it is more likely than not that the Company will generate sufficient taxable income to realize&#13;the deferred income tax assets. As a result of the analysis, the Company determined that a valuation allowance against the deferred&#13;tax assets was required of $1,340,152 and $1,004,029 as of December 31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 10 - &lt;font style="font-variant: small-caps; text-transform: uppercase"&gt;SUBSEQUENT&#13;EVENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Registered Direct Offerings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 14, 2021, the Company completed&#13;a registered direct offering of 2,221,458 shares of common stock at approximately $4.50 per share for gross proceeds of approximately&#13;$10,000,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 11, 2021, the Company completed&#13;a registered direct offering of 3,007,026 shares of common stock for gross proceeds of approximately $12.8 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stockholder Demand Letter&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 21, 2021, the Company received a&#13;stockholder litigation demand letter from the law firm of Purcell Julie &amp;#38; Lefkowitz LLP, on behalf of James Self, a purported&#13;stockholder of our Company. The letter demands that the Company (i) deem ineffective the December 30, 2020 amendment to our Amended&#13;and Restated Certificate of Incorporation in which the Company effected a one-for-four reverse stock split of its common stock&#13;due to the manner in which non-votes by brokers were tabulated, (ii) seek appropriate relief for damages allegedly suffered by&#13;the company and its stockholders or seek a valid stockholder approval of the amendment and reverse stock split, and (iii) adopt&#13;adequate internal controls to prevent a recurrence of the alleged misconduct. The Company disputes that the amendment was ineffective&#13;or that there were any inadequate internal controls related to the same. However, to eliminate any questions about the amendment,&#13;the Company intends to seek to ratify the amendment at a special stockholders&amp;#8217; meeting pursuant to Section 204 of the Delaware&#13;General Corporation Law. This special stockholders&amp;#8217; meeting is scheduled to occur on May 14, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Development and Clinical Supply Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On February 22, 2021,&#13;the Company entered into a Development and Clinical Supply Agreement (the &amp;#8220;Agreement&amp;#8221;) with PureForm Global, Inc. (&amp;#8220;PureForm&amp;#8221;),&#13;pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&amp;#8220;API&amp;#8221;) for the Company&amp;#8217;s&#13;development plans for cancer treatment and supportive care. Under the terms of the Agreement, PureForm has granted the Company&#13;the exclusive right to purchase API and related product for cancer treatment and supportive care during the term of the Agreement&#13;(contingent upon an initial minimum order volume during the first thirty (30) days from the effective date) and has agreed to manufacture,&#13;package and test the API and related product in accordance with specifications established by the parties. All inventions that&#13;are developed jointly by the parties in the course of performing activities under the Agreement will be owned jointly by the parties&#13;in accordance with applicable law; however, if the Company funds additional research and development efforts by PureForm, the parties&#13;may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information to the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The initial term of&#13;the Agreement is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual agreement of&#13;the parties. The Agreement may be terminated by either party upon thirty (30) days written notice of an uncured material breach&#13;or immediately in the event of bankruptcy or insolvency. The Agreement contains, among other provisions, representation and warranties,&#13;indemnification obligations and confidentiality provisions in favor of each party that are customary for an agreement of this nature.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On March 5, 2021,&#13;the Company entered into an Exclusive License Agreement (the &amp;#8220;Agreement&amp;#8221;) with Diverse Biotech, Inc. (&amp;#8220;Diverse&amp;#8221;),&#13;pursuant to which the Company has acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively,&#13;the &amp;#8220;Agents&amp;#8221;) with the goal of alleviating the side effects that cancer patients experience. Under the terms of the&#13;Agreement, Diverse has granted the Company an exclusive license to its intellectual property rights covering the Agents and its&#13;products. In exchange, the Company has granted Diverse the right to information relating to the Agents developed for the express&#13;purpose of using such information to obtain patent rights, which right terminates upon the issuance or denial of the patent rights.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Under the Agreement,&#13;the Company will maintain sole responsibility and ownership of the development and commercialization of the Agents and its products.&#13;Diverse has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its products containing&#13;the Agents, at any time during or after the term of the Agreement. If Diverse intends to license, sell, or transfer any other molecules&#13;linked with cannabinoids not granted to the Company under the terms of this Agreement, the Company will have the first right, but&#13;not the obligation, to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay Diverse an&#13;up-front investment payment of $675,000, as well as a running royalty starting with the first commercial sale by the Company to&#13;a third party in an arms&amp;#8217;-length transaction. The term of the Agreement shall continue for as long as the Company intends&#13;to develop or commercialize the new drugs, unless earlier terminated by either Party.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Exercise of&#13;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 10, 2021, the Company received $3,267,245&#13;from the exercise of warrants to purchase 851,099 shares of common stock.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Intangibles&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has finite-lived intangible assets.&#13;Finite-lived intangible assets are amortized over their estimated useful lives. Research and development costs are expensed as&#13;incurred. Following initial recognition of the finite-lived intangible asset, the asset is carried at cost less any accumulated&#13;amortization. Amortization of the asset begins when the asset is available for use. Amortization is recorded in general and administrative&#13;expenses on the Company&amp;#8217;s consolidated statement of operations. The Company periodically reviews its owned intangible assets&#13;for recoverability.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long Term Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates the carrying value of long-lived&#13;assets subject to amortization whenever events or changes in circumstances indicate that an impairment may exist. An impairment charge&#13;is recognized when the asset&amp;#8217;s carrying value exceeds its net undiscounted future cash flows and its fair market value. The amount&#13;of the charge is the difference between the asset&amp;#8217;s carrying value and fair market value.&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 25, 2016, FASB issued ASU 2016-02, Leases&#13;(Topic 842). This update will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for&#13;the rights and obligations created by those leases. The new guidance will also require additional disclosures about the amount, timing&#13;and uncertainty of cash flows arising from leases. On January 1, 2020, the Company adopted this ASU, which did not have a material impact&#13;on the Company&amp;#8217;s financial position and results of operations.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilizes an asset and liability&#13;approach for financial accounting and reporting for income taxes. The provision for income taxes is based upon income or loss after&#13;adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent&#13;the tax effects of differences between the financial reporting and tax basis of the Company&amp;#8217;s assets and liabilities at the&#13;enacted tax rates in effect for the years in which the differences are expected to reverse.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates the recoverability of&#13;deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred&#13;tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon&#13;an audit and cause changes to previous estimates of tax liabilities. In management&amp;#8217;s opinion, adequate provisions for income&#13;taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of&#13;reserves may be necessary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Tax benefits are recognized only for tax positions&#13;that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest&#13;amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &amp;#8220;unrecognized tax&#13;benefits&amp;#8221; is recorded for any tax benefits claimed in the Company&amp;#8217;s tax returns that do not meet these recognition&#13;and measurement standards. As of December 31, 2020 and December 31, 2019, no liability for unrecognized tax benefits was required&#13;to be recorded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s policy for recording interest&#13;and penalties associated with tax audits is to record such items as a component of operating expenses. There were no amounts accrued&#13;for penalties and interest for the years ended December 31, 2020 and 2019. The Company does not expect its uncertain tax positions&#13;to change during the next twelve months. Management is currently unaware of any issues under review that could result in significant&#13;payments, accruals or material deviations from its position.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has identified its United States and Canadian federal&#13;tax return, its state and provincial tax returns in Florida and Ontario, CA as its &amp;#8220;major&amp;#8221; tax jurisdictions. The Company&#13;is in the process of filing its corporate tax returns for the years ended December 31, 2020 and December 31, 2019. Net operating&#13;losses for these periods will not be available to reduce future taxable income until the returns are filed.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows Accounting Standards Codification&#13;(&amp;#8220;ASC&amp;#8221;) 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions,&#13;requiring such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded&#13;at the more readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The&#13;Company uses the Black-Scholes option-pricing model to determine the grant date fair value of stock-based awards under ASC 718.&#13;The estimated fair value is amortized as a charged to earnings on a straight-line basis depending on the terms and conditions of&#13;the award, and the nature of the relationship of the recipient of the award to the Company. The Company records the grant date&#13;fair value in line with the period over which it was earned. For employees and consultants, this is typically considered to be&#13;the vesting period of the award. The Company estimates the expected forfeitures and updates the valuation accordingly.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2019, the Company&amp;#8217;s notes payable and convertible&#13;notes payable consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 46%"&gt;&lt;font style="font-size: 10pt"&gt;February 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;66,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;66,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;March 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;April 2019 Convertible Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,079&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;293,921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;July 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;191,640&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,700&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;188,940&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;December 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;44,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,525&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;751,640&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(11,304&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;740,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Notes payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;451,640&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;446,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;300,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,079&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;293,921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2020 and 2019,&#13;interest expense and amortization of debt discount consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the Year Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Interest Expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization of Debt Discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Interest Expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization of Debt Discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 34%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,840&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,840&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2019 Convertible Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,842&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;17,142&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,704&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;98,046&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 2019 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 2020 Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,545&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,912&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,457&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Alpha Note&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;86,762&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;181,906&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;268,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;156,619&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;288,631&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;445,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,370&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68,453&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;81,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company valued the beneficial conversion&#13;feature and warrants using the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Beneficial Conversion Feature&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Stock Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;CAD $ 1.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;CAD $ 1.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;CAD $ 0.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;CAD $ 0.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Dividend Yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;96.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Risk-Free Interest Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;130,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Value (USD)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;17,851&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32,149&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <amrh:ScheduleOfAssetsPurchasedTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;44,143&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,900,546&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,944,689&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</amrh:ScheduleOfAssetsPurchasedTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The tax effects of temporary differences that give rise to significant&#13;portions of the deferred tax assets and deferred tax liabilities are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Net operating loss carryovers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets, gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Deferred tax assets (liabilities), net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The change in the Company&amp;#8217;s valuation allowance is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Beginning of year&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;505,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Increase in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;498,158&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;End of year&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,344,180&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,004,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of the provision for income&#13;taxes with the amounts computed by applying the statutory federal income tax rate to loss from operations before the provision&#13;for income taxes is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the year ended December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Canada federal statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Provincial taxes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(11.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(11.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Non-deductible expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19.1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Effective income tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilized the Black-Scholes option-pricing&#13;model to determine the fair value of these stock options, using the assumptions as outlined below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Stock Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Dividend Yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;84.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Weighted Average Risk-Free Interest Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.5 &amp;#8211; 4.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesPayable contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesPayable contextRef="AsOf2019-03-05_custom_MarchTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember" unitRef="USD" decimals="0">150000</us-gaap:NotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2019-02-07_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember" unitRef="USD" decimals="0">66000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2019-07-08_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember" unitRef="USD" decimals="0">157714</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-06-22_custom_SecondNoteAmendmentMember" unitRef="USD" decimals="0">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-06-23_custom_SecondNoteAmendmentMember" unitRef="USD" decimals="0">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-06-23_custom_SecondNoteAmendmentMember_custom_AlphaCapitalAnstaltMember" unitRef="USD" decimals="0">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-07-21_us-gaap_CommonStockMember_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">66000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-07-21_us-gaap_CommonStockMember_custom_MarchTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">11304</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember" unitRef="USD" decimals="0">6000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-07-08_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember" unitRef="USD" decimals="0">19714</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">4000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_custom_MarchTwoThousandNineteenNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">6079</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">2700</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">2525</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_custom_NotesPayableMember" unitRef="USD" decimals="0">5225</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">6079</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2019-02-07_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2019-03-05_custom_MarchTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2019-07-08_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember" unitRef="Pure" decimals="INF">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember_custom_EventOfDefaultMember" unitRef="Pure" decimals="INF">0.24</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember_custom_EventOfDefaultMember" unitRef="Pure" decimals="INF">0.24</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2020-01-10_custom_SecuredPromissoryNoteMember" unitRef="Pure" decimals="INF">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-02-06to2019-02-07_custom_FebruaryTwoThousandNineteenNoteMember_srt_DirectorMember">2019-05-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-03-04to2019-03-05_custom_MarchTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember">2020-03-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-07-07to2019-07-08_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember">2019-09-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-12-11to2019-12-12_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember">2020-01-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-02-23to2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember">2020-07-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-09to2020-01-10_custom_SecuredPromissoryNoteMember">2020-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-05-05to2020-05-06_custom_FirstNoteAmendmentMember">2020-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="From2019-07-07to2019-07-08_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember_custom_FormerExecutiveDirectorMember" unitRef="USD" decimals="0">138000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2019-09-19to2019-09-20_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember">The Company entered into an amendment to the July 2019 Note (the "Amendment"). The Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) November 7, 2019.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2019-11-20to2019-11-21_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember">The Company entered into an amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) December 9, 2019.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2019-12-08to2019-12-09_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember">The Company entered into an additional amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) January 7, 2020.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2020-01-07to2020-01-08_custom_JulyTwoThousandNineteenNoteMember">The January 8 Amendment extended the maturity date for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) April 1, 2020.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2020-05-05to2020-05-06_custom_MayTwoThousandNineteenAmendmentMember">The Company entered into an amendment (the "May 2020 Amendment") whereby both parties agreed to extend the maturity date of the July 2019 Note to September 30, 2020. The Company accounted for this amendment as a modification, as the present value of the future cash flows pre-modification and post-modification were not greater than or equal to 10%.</us-gaap:DebtInstrumentMaturityDateDescription>
    <amrh:AggregateExtensionFee contextRef="From2019-12-08to2019-12-09_custom_NoteAgreementMember_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">33926</amrh:AggregateExtensionFee>
    <us-gaap:DebtInstrumentFeeAmount contextRef="AsOf2020-01-08_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">45725</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:RepaymentsOfDebt contextRef="From2020-01-11to2020-01-12_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">157714</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2020-01-01to2020-12-31_custom_LenderMember_custom_DecemberTwoThousandNineteenNoteMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">170333</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2020-12-29to2020-12-30_custom_FebruaryTwoThousandTwentyNoteMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">190004</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2020-05-05to2020-05-06_custom_FirstNoteAmendmentMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">8100000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2020-12-29to2020-12-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2473848</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2020-12-29to2020-12-30_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">250000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2020-07-19to2020-07-21_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">239326</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2020-02-24_custom_LenderMember_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2020-05-06_custom_FirstNoteAmendmentMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2020-12-29to2020-12-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">751640</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">66000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31_custom_MarchTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">150000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">191640</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">44000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31_custom_NotesPayableMember" unitRef="USD" decimals="0">451640</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">740336</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">66000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31_custom_MarchTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">150000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">293921</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">188940</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">41475</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31_custom_NotesPayableMember" unitRef="USD" decimals="0">446415</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2019-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">293921</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">156619</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">13370</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2020-01-01to2020-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">13970</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2020-01-01to2020-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">53342</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2020-01-01to2020-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" decimals="0">2545</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2020-01-01to2020-12-31_custom_AlphaNoteMember" unitRef="USD" decimals="0">86762</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2019-01-01to2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">13370</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2019-01-01to2019-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2019-01-01to2019-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="From2019-01-01to2019-12-31_custom_AlphaNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">288631</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">68453</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">3840</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">5842</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">44704</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">1427</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" decimals="0">50912</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31_custom_AlphaNoteMember" unitRef="USD" decimals="0">181906</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">6000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">17142</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">43836</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">1475</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31_custom_AlphaNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-02-22to2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember_us-gaap_WarrantMember" unitRef="USD" decimals="0">50000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">445250</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">81823</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">3840</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">19812</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">98046</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">1427</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-12-31_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" decimals="0">53457</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-12-31_custom_AlphaNoteMember" unitRef="USD" decimals="0">268668</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">6000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-12-31_custom_AprilTwoThousandNineteenConvertibleNotesMember" unitRef="USD" decimals="0">30512</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-12-31_custom_JulyTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">43836</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-12-31_custom_DecemberTwoThousandNineteenNoteMember" unitRef="USD" decimals="0">1475</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-12-31_custom_FebruaryTwoThousandTwentyNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-12-31_custom_AlphaNoteMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">32149</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LongTermDebtMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember_custom_CADMember" unitRef="Pure" decimals="INF">1.10</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:LongTermDebtMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_CADMember" unitRef="Pure" decimals="INF">0.51</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:LongTermDebtFairValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">17851</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtTerm contextRef="AsOf2020-12-31">P0Y</us-gaap:LongTermDebtTerm>
    <us-gaap:ProfessionalFees contextRef="From2019-01-04to2019-01-05_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember" unitRef="USD" decimals="0">15000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2019-01-04to2019-01-05_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember_us-gaap_CashMember" unitRef="USD" decimals="0">7500</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2019-01-04to2019-01-05_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7500</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2020-01-05to2020-01-06_custom_BusinessAdvisorServicesAgreementMember_custom_ConsultantMember" unitRef="USD" decimals="0">12500</us-gaap:ProfessionalFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2020-09-23to2020-09-25_us-gaap_CommonStockMember_custom_SeptemberPrivatePlacementMember" unitRef="Shares" decimals="INF">36871</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2020-09-23to2020-09-25_us-gaap_SeriesBPreferredStockMember_custom_DecemberPrivatePlacementMember" unitRef="Shares" decimals="INF">221225</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2021-01-12to2021-01-14_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">2221458</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">3007026</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2020-09-23to2020-09-25_us-gaap_CommonStockMember_custom_SeptemberPrivatePlacementMember" unitRef="USD" decimals="0">227500</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2020-09-23to2020-09-25_us-gaap_SeriesBPreferredStockMember_custom_DecemberPrivatePlacementMember" unitRef="USD" decimals="0">260500</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2021-01-12to2021-01-14_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2021-02-09to2021-02-11_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">12800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-02-24_custom_FebruaryTwoThousandTwentyNoteMember">2025-02-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">0.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">5.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">1.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AlternativeInvestmentMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" unitRef="Pure" decimals="INF">0</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember" unitRef="Pure" decimals="INF">84.7</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" decimals="INF">0.37</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput contextRef="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember" unitRef="Pure" decimals="INF">5.92</us-gaap:AlternativeInvestmentMeasurementInput>
    <amrh:FairValueTerm contextRef="From2020-01-01to2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">P1Y6M</amrh:FairValueTerm>
    <amrh:FairValueTerm contextRef="From2020-01-01to2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">P4Y2M12D</amrh:FairValueTerm>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember">P0Y0M29D</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
    <amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember">P1Y0M22D</amrh:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="AsOf2020-01-10_custom_AlphaCapitalAnstaltMember_custom_AmalgamationAgreementMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="From2020-05-24to2020-05-26_custom_EnvericBiosciencesIncMember_custom_SecondAmalgamationAmendmentAgreementMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3675035</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <amrh:CommonStockBeneficialOwnershipBlockerPercentage contextRef="From2020-08-10to2020-08-12_custom_EnvericBiosciencesIncMember_custom_TenderAgreementMember" unitRef="Pure" decimals="INF">0.0999</amrh:CommonStockBeneficialOwnershipBlockerPercentage>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-12-31_us-gaap_CanadaRevenueAgencyMember" unitRef="USD" decimals="0">5057176</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-12-31_us-gaap_CanadaRevenueAgencyMember" unitRef="USD" decimals="0">3788788</us-gaap:OperatingLossCarryforwards>
    <amrh:OperatingLossCarryforwardsExpirationYear contextRef="From2020-01-01to2020-12-31">2029</amrh:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1004029</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1340152</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">505871</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1004029</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1340152</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1004029</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1340152</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1340152</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">498158</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">-0.115</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">-0.115</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.191</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.206</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2020-01-01to2020-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2019-01-01to2019-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2021-01-14_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember_us-gaap_SubsequentEventMember" unitRef="USDPShares" decimals="INF">4.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2021-03-09to2021-03-10_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">3267245</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-233240</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">-32316</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">262500</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">262500</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5262042</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5311414</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5659857</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">3275407</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10095109</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">19449975</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">22266</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">113</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22153</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">11256</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">3591565</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">535587</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">535587</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3591565</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">32149</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">32149</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">24875</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">24875</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">32149</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">32149</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">17851</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">17851</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17851</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17851</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">227500</amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement>
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">369</amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement>
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">227131</amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement>
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacement contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesIssuedPrivatePlacement contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">36871</amrh:StockIssuedDuringPeriodSharesIssuedPrivatePlacement>
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">260500</amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne>
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">2212</amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne>
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">258288</amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne>
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedPrivatePlacementOne contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">221225</amrh:StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1900546</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5720</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1894826</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">571987</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumShares contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">4816189</amrh:FinancingAndConversionOfNoteIncludingPalladiumShares>
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumShares contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">30417</amrh:FinancingAndConversionOfNoteIncludingPalladiumShares>
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4030</amrh:FinancingAndConversionOfNoteIncludingPalladiumShares>
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumShares contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4781742</amrh:FinancingAndConversionOfNoteIncludingPalladiumShares>
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumShares contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumShares contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumSharestoShares contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">3041682</amrh:FinancingAndConversionOfNoteIncludingPalladiumSharestoShares>
    <amrh:FinancingAndConversionOfNoteIncludingPalladiumSharestoShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">402988</amrh:FinancingAndConversionOfNoteIncludingPalladiumSharestoShares>
    <amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">841878</amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares>
    <amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3301</amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares>
    <amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">838577</amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares>
    <amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">330122</amrh:StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares>
    <amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">101713</amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification>
    <amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">216</amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification>
    <amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">101497</amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification>
    <amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">21625</amrh:AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">1977155</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1977155</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">-2500</amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock>
    <amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2500</amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock>
    <amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">-250000</amrh:StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares>
    <amrh:StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">250000</amrh:StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares>
    <amrh:StockIssuedDuringPeriodValueAcquisitionsOne contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">650000</amrh:StockIssuedDuringPeriodValueAcquisitionsOne>
    <amrh:StockIssuedDuringPeriodValueAcquisitionsOne contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueAcquisitionsOne contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">22241</amrh:StockIssuedDuringPeriodValueAcquisitionsOne>
    <amrh:StockIssuedDuringPeriodValueAcquisitionsOne contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">627759</amrh:StockIssuedDuringPeriodValueAcquisitionsOne>
    <amrh:StockIssuedDuringPeriodValueAcquisitionsOne contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueAcquisitionsOne contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesAcquisitionsOne contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2224077</amrh:StockIssuedDuringPeriodSharesAcquisitionsOne>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="0">-32754</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">679569</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5130</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">674439</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">32754</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">-3275407</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">512978</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3275407</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOffering contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">4617087</amrh:StockIssuedDuringPeriodValueIssuedDirectOffering>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOffering contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOffering contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">22213</amrh:StockIssuedDuringPeriodValueIssuedDirectOffering>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOffering contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4594874</amrh:StockIssuedDuringPeriodValueIssuedDirectOffering>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOffering contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOffering contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesIssuedDirectOffering contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesIssuedDirectOffering contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2221334</amrh:StockIssuedDuringPeriodSharesIssuedDirectOffering>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">7016401</amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">30070</amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6986331</amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne>
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodValueIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <amrh:StockIssuedDuringPeriodSharesIssuedDirectOfferingOne contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3007026</amrh:StockIssuedDuringPeriodSharesIssuedDirectOfferingOne>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">298714</us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">298714</us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:ExerciseOfWarrants contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0">3267245</amrh:ExerciseOfWarrants>
    <amrh:ExerciseOfWarrants contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <amrh:ExerciseOfWarrants contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8511</amrh:ExerciseOfWarrants>
    <amrh:ExerciseOfWarrants contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3258734</amrh:ExerciseOfWarrants>
    <amrh:ExerciseOfWarrants contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <amrh:ExerciseOfWarrants contextRef="From2021-01-01to2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <amrh:ExerciseOfWarrantsShares contextRef="From2021-01-01to2021-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <amrh:ExerciseOfWarrantsShares contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">851099</amrh:ExerciseOfWarrantsShares>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&amp;#160;4&amp;#160;&amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is periodically involved in legal proceedings,&#13;legal actions and claims arising in the normal course of business. Management believes that the outcome of such legal proceedings, legal&#13;actions and claims will not have a significant adverse effect on the Company&amp;#8217;s financial position, results of operations or cash&#13;flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stockholder Demand Letter&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 21, 2021, the Company received a stockholder litigation&#13;demand letter from the law firm of Purcell Julie &amp;#38; Lefkowitz LLP, on behalf of James Self, a purported stockholder of the Company.&#13;The letter demands that the Company (i) deem ineffective the December 30, 2020 amendment to our Amended and Restated Certificate of Incorporation&#13;in which the Company effected a one-for-four reverse stock split of its common stock due to the manner in which non-votes by brokers were&#13;tabulated, (ii) seek appropriate relief for damages allegedly suffered by the company and its stockholders or seek a valid stockholder&#13;approval of the amendment and reverse stock split, and (iii) adopt adequate internal controls to prevent a recurrence of the alleged misconduct.&#13;The Company disputes that the amendment was ineffective or that there were any inadequate internal controls related to the same. However,&#13;to eliminate any questions about the amendment, the Company ratified the amendment at a special stockholders&amp;#8217; meeting pursuant to&#13;Section 204 of the Delaware General Corporation Law. This special stockholders&amp;#8217; meeting occurred on May 14, 2021. On May 14, 2021,&#13;the Company filed a certificate of validation with the State of Delaware to ratify the reverse stock split on December 30, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Development and Clinical Supply Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On February 22, 2021, the&#13;Company entered into a Development and Clinical Supply Agreement (the&amp;#160;&amp;#8220;PureForm&amp;#160;Agreement&amp;#8221;) with PureForm Global,&#13;Inc. (&amp;#8220;PureForm&amp;#8221;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&amp;#8220;API&amp;#8221;)&#13;for the Company&amp;#8217;s development plans for cancer treatment and supportive care. Under the terms of the&amp;#160;PureForm&amp;#160;Agreement,&#13;PureForm has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during&#13;the term of the Agreement (contingent upon an initial minimum order volume during the first thirty (30) days from the effective date)&#13;and has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.&#13;All inventions that are developed jointly by the parties in the course of performing activities under the&amp;#160;PureForm&amp;#160;Agreement&#13;will be owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development&#13;efforts by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical&#13;information to the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The initial term of the&amp;#160;PureForm&amp;#160;Agreement&#13;is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual agreement of the parties. The&amp;#160;PureForm&amp;#160;Agreement&#13;may be terminated by either party upon thirty (30) days written notice of an uncured material breach or immediately in the event of bankruptcy&#13;or insolvency. The Agreement contains, among other provisions, representation and warranties, indemnification obligations and confidentiality&#13;provisions in favor of each party that are customary for an agreement of this nature.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Appointment of Chief&#13;Financial Officer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;On April 9, 2021, John M. Van&#13;Buiten resigned from his position as the Company&amp;#8217;s chief financial officer, effective May 15, 2021. Mr. Van Buiten&amp;#8217;s resignation&#13;was not the result of any disagreement regarding any matter relating to the Company&amp;#8217;s operations, policies, or practices.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;On April 9, 2021, Carter J. Ward,&#13;56, was appointed as the Company&amp;#8217;s chief financial officer, effective May 15, 2021 (the &amp;#8220;Effective Date&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In connection with Mr. Ward&amp;#8217;s&#13;appointment as chief financial officer, Mr. Ward entered into an employment agreement with the Company on April 9, 2021 (the &amp;#8220;Ward&#13;Employment Agreement&amp;#8221;), effective as of May 15, 2021, pursuant to which Mr. Ward will receive a base salary of $295,000 (&amp;#8220;Base&#13;Salary&amp;#8221;) and is eligible to receive annual performance bonuses of up to 50% of his Base Salary, as determined from time-to-time&#13;by the Company&amp;#8217;s board of directors.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 &amp;#8211; COMMITMENTS AND CONTINGENGIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 5, 2019, the Company entered into&#13;a business advisor services agreement. Pursuant to the terms of the agreement, the consultant provided business advisory, marketing,&#13;and investor relations services in exchange for $15,000 per month, of which $7,500 was payable in cash and $7,500 was payable in&#13;the Company&amp;#8217;s common shares. On January 6, 2020, the Company terminated its business advisory services agreement and agreed&#13;to settle the amounts due under the agreement by (a) paying $12,500 in cash upon the completion of a bridge financing; and (b)&#13;issuing 127,856 shares of the Company&amp;#8217;s common stock, as described in Note 6.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 1, 2020, the Company entered into&#13;an agreement with Mr. David Stefansky to serve as President and Secretary of the Company to serve until the closing Amalgamation&#13;Agreement. The Company agreed to pay Mr. Stefansky $15,000 per month and future issuance of options to purchase 650,000 shares&#13;of common stock subject to the approval of the Board of Directors. On May 1, 2020, this agreement was terminated (see Note 8).&#13;On May 1, 2020, the Company and Mr. David Stefansky terminated Mr. Stefansky&amp;#8217;s agreement to serve as President and Secretary&#13;of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 1, 2020, the Company entered into an&#13;agreement with Mr. Henoch Cohn to serve as the Company&amp;#8217;s President and Secretary until the consummation of the Amalgamation&#13;Agreement. The Company paid Mr. Cohn $10,000 per month. On December 30, 2020 the agreement between the Company and Mr. Henoch Cohn&#13;was terminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is periodically involved in legal&#13;proceedings, legal actions and claims arising in the normal course of business. Management believes that the outcome of such legal&#13;proceedings, legal actions and claims will not have a significant adverse effect on the Company&amp;#8217;s financial position, results&#13;of operations or cash flows. On January 21, 2012, the Company received a demand letter from an individual purporting to be a stockholder.&#13;See Note 10 for more information.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amrh:InterestExpenses contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true" />
    <amrh:InterestExpenses contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-261759</amrh:InterestExpenses>
    <amrh:InterestExpenses contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="0">445250</amrh:InterestExpenses>
    <amrh:InterestExpenses contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="0">81823</amrh:InterestExpenses>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>amrh-20210331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: amrh%2D20210331 S%2D4 DFN.xfr; Date: 2021%2D06%2D20T09:09:19Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8014000A -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6IObP9z5Z86ekhvWBybQkqzyEtTX8fwiC/yQQ2UYgH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:amrh="http://ameri100.com/20210331" elementFormDefault="qualified" targetNamespace="http://ameri100.com/20210331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://ameri100.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit" id="StatementsOfChangesInShareholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/Business" id="Business">
	  <link:definition>00000007 - Disclosure - Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000008 - Disclosure - Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable" id="NotesPayableAndConvertibleNotesPayable">
	  <link:definition>00000010 - Disclosure - Notes Payable and Convertible Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000011 - Disclosure - Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/CommitmentsAndContingengies" id="CommitmentsAndContingengies">
	  <link:definition>00000012 - Disclosure - Commitments and Contingengies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments" id="ShareCapitalAndOtherEquityInstruments">
	  <link:definition>00000013 - Disclosure - Share Capital and Other Equity Instruments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/TenderAgreement" id="TenderAgreement">
	  <link:definition>00000014 - Disclosure - Tender Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000015 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000016 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables" id="NotesPayableAndConvertibleNotesPayableTables">
	  <link:definition>00000019 - Disclosure - Notes Payable and Convertible Notes Payable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000020 - Disclosure - Intangible Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables" id="ShareCapitalAndOtherEquityInstrumentsTables">
	  <link:definition>00000021 - Disclosure - Share Capital and Other Equity Instruments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000022 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000023 - Disclosure - Liquidity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/LiquidityDetailsNarrative10-k" id="LiquidityDetailsNarrative10-k">
	  <link:definition>00000024 - Disclosure - Liquidity (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k">
	  <link:definition>00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" id="SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails">
	  <link:definition>00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" id="SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k">
	  <link:definition>00000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" id="SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails">
	  <link:definition>00000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" id="SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails">
	  <link:definition>00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Black Scholes Valuation Models of Warrant Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" id="SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails">
	  <link:definition>00000031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" id="NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k">
	  <link:definition>00000032 - Disclosure - Notes Payable and Convertible Notes Payable (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" id="NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k">
	  <link:definition>00000033 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Notes Payable and Convertible Notes Payable (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" id="NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k">
	  <link:definition>00000034 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Interest Expense and Amortization of Debt Discount (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" id="NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k">
	  <link:definition>00000035 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Beneficial Conversion Feature and Warrants (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k" id="IntangibleAssetsDetailsNarrative10-k">
	  <link:definition>00000037 - Disclosure - Intangible Assets (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" id="IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k">
	  <link:definition>00000038 - Disclosure - Intangible Assets - Schedule of Assets Purchased (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" id="IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails">
	  <link:definition>00000039 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" id="IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k">
	  <link:definition>00000040 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative" id="CommitmentsAndContingengiesDetailsNarrative">
	  <link:definition>00000041 - Disclosure - Commitments and Contingengies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k" id="CommitmentsAndContingengiesDetailsNarrative10-k">
	  <link:definition>00000042 - Disclosure - Commitments and Contingengies (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" id="ShareCapitalAndOtherEquityInstrumentsDetailsNarrative">
	  <link:definition>00000043 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" id="ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k">
	  <link:definition>00000044 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" id="ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails">
	  <link:definition>00000045 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" id="ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k">
	  <link:definition>00000046 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" id="ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails">
	  <link:definition>00000047 - Disclosure - Share Capital and Other Equity Instruments - Schedule Of Restricted Stock Units and Awards Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" id="ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k">
	  <link:definition>00000048 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Fair Value Assumption of Stock Option (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" id="ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails">
	  <link:definition>00000049 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" id="ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k">
	  <link:definition>00000050 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/TenderAgreementDetailsNarrative10-k" id="TenderAgreementDetailsNarrative10-k">
	  <link:definition>00000051 - Disclosure - Tender Agreement (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k" id="IncomeTaxesDetailsNarrative10-k">
	  <link:definition>00000052 - Disclosure - Income Taxes (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" id="IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k">
	  <link:definition>00000053 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" id="IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k">
	  <link:definition>00000054 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" id="IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k">
	  <link:definition>00000055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k" id="SubsequentEventsDetailsNarrative10-k">
	  <link:definition>00000056 - Disclosure - Subsequent Events (Details Narrative) (10-K)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="amrh-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="amrh-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="amrh-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="amrh-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" name="StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" name="StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AccruedInterest" name="AccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_GainsLossesOnInducementExpense" name="GainsLossesOnInducementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_UnamortizedStockOptionExpense" name="UnamortizedStockOptionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_PaymentOfUpfrontInvestment" name="PaymentOfUpfrontInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ClassOfWarrantOrRighExercisable" name="ClassOfWarrantOrRighExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" name="ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WarrantsIssuedInConjunctionWithNotesPayable" name="WarrantsIssuedInConjunctionWithNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_InducementExpense" name="InducementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ProceedsFromWarrantExercise" name="ProceedsFromWarrantExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WarrantLiabilitiesNoncurrent" name="WarrantLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AnnualPerformanceBonusesPercentage" name="AnnualPerformanceBonusesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" name="ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" name="ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_OfferingCostsPolicy" name="OfferingCostsPolicy" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_NotesPayableExcludingConvertibleNotespayable" name="NotesPayableExcludingConvertibleNotespayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_PaymentsForPurchaseOfLicenseAgreement" name="PaymentsForPurchaseOfLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ProceedsFromOfferingAndReverseMergerProceeds" name="ProceedsFromOfferingAndReverseMergerProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ProceedsFromIssuanceOfPrivatePlacementOne" name="ProceedsFromIssuanceOfPrivatePlacementOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_CommonStockIssuedInConjunctionWithNotePayableModification" name="CommonStockIssuedInConjunctionWithNotePayableModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" name="ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_CommonStockIssuedForSkincareLicense" name="CommonStockIssuedForSkincareLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_NotesPayableIssuedToConsultantForPrepaidServices" name="NotesPayableIssuedToConsultantForPrepaidServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_TenderAgreementDisclosureTextBlock" name="TenderAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ScheduleOfAssetsPurchasedTableTextBlock" name="ScheduleOfAssetsPurchasedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AggregateExtensionFee" name="AggregateExtensionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FairValueTerm" name="FairValueTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_CommonStockBeneficialOwnershipBlockerPercentage" name="CommonStockBeneficialOwnershipBlockerPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement" name="StockIssuedDuringPeriodValueIssuedPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement" name="StockIssuedDuringPeriodSharesIssuedPrivatePlacement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" name="StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" name="StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares" name="FinancingAndConversionOfNoteIncludingPalladiumShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" name="FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" name="StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" name="StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" name="AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" name="AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" name="StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" name="StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueAcquisitionsOne" name="StockIssuedDuringPeriodValueAcquisitionsOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne" name="StockIssuedDuringPeriodSharesAcquisitionsOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering" name="StockIssuedDuringPeriodValueIssuedDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering" name="StockIssuedDuringPeriodSharesIssuedDirectOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne" name="StockIssuedDuringPeriodValueIssuedDirectOfferingOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" name="StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ExerciseOfWarrants" name="ExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ExerciseOfWarrantsShares" name="ExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_InterestExpenses" name="InterestExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_OfferingMember" name="OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_OptionsToPurchaseSharesOfCommonStockMember" name="OptionsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_DiverseBiotechIncMember" name="DiverseBiotechIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SkincareAssetsAndLicenseAgreementsMember" name="SkincareAssetsAndLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_DiverseBioLicenseAgreementMember" name="DiverseBioLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_InitialMeasurementMember" name="InitialMeasurementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WardEmploymentAgreementMember" name="WardEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WarrantLiabilitiesJanuaryWarrantsMember" name="WarrantLiabilitiesJanuaryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_WarrantLiabilitiesFebruaryWarrantsMember" name="WarrantLiabilitiesFebruaryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_JanuaryWarrantsMember" name="JanuaryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FebruaryWarrantsMember" name="FebruaryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SubsequentMeasurementMember" name="SubsequentMeasurementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FebruaryTwoThousandNineteenNoteMember" name="FebruaryTwoThousandNineteenNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_MarchTwoThousandNineteenNoteMember" name="MarchTwoThousandNineteenNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FormerExecutiveDirectorMember" name="FormerExecutiveDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_NoteAgreementMember" name="NoteAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_JulyTwoThousandNineteenNoteMember" name="JulyTwoThousandNineteenNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_LenderMember" name="LenderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_MayTwoThousandNineteenAmendmentMember" name="MayTwoThousandNineteenAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_DecemberTwoThousandNineteenNoteMember" name="DecemberTwoThousandNineteenNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_EventOfDefaultMember" name="EventOfDefaultMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FebruaryTwoThousandTwentyNoteMember" name="FebruaryTwoThousandTwentyNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SecuredPromissoryNoteMember" name="SecuredPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_FirstNoteAmendmentMember" name="FirstNoteAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SecondNoteAmendmentMember" name="SecondNoteAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AlphaCapitalAnstaltMember" name="AlphaCapitalAnstaltMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AprilTwoThousandNineteenConvertibleNotesMember" name="AprilTwoThousandNineteenConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_NotesPayableMember" name="NotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AlphaNoteMember" name="AlphaNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_CADMember" name="CADMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_MeasurementInputSharesMember" name="MeasurementInputSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SkincareAssetsMember" name="SkincareAssetsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_BusinessAdvisorServicesAgreementMember" name="BusinessAdvisorServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_MrDavidStefanskyMember" name="MrDavidStefanskyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_MrHenochCohnMember" name="MrHenochCohnMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_VendorsMember" name="VendorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SeptemberPrivatePlacementMember" name="SeptemberPrivatePlacementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_DecemberPrivatePlacementMember" name="DecemberPrivatePlacementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AmalgamationAgreementMember" name="AmalgamationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_EnvericBiosciencesIncMember" name="EnvericBiosciencesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_AmalgamationAmendmentAgreementMember" name="AmalgamationAmendmentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_SecondAmalgamationAmendmentAgreementMember" name="SecondAmalgamationAmendmentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_TenderAgreementMember" name="TenderAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_TenderAgreementAbstract" name="TenderAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" name="ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>amrh-20210331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: amrh%2D20210331 S%2D4 DFN.xfr; Date: 2021%2D06%2D20T09:09:19Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8014000A -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ameri100.com/role/DocumentAndEntityInformation" xlink:href="amrh-20210331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/BalanceSheets" xlink:href="amrh-20210331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/BalanceSheetsParenthetical" xlink:href="amrh-20210331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="amrh-20210331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:href="amrh-20210331.xsd#StatementsOfChangesInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfCashFlows" xlink:href="amrh-20210331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/Business" xlink:href="amrh-20210331.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/Liquidity" xlink:href="amrh-20210331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets" xlink:href="amrh-20210331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengies" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/TenderAgreement" xlink:href="amrh-20210331.xsd#TenderAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes" xlink:href="amrh-20210331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SubsequentEvents" xlink:href="amrh-20210331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsTables" xlink:href="amrh-20210331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxesTables" xlink:href="amrh-20210331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/LiquidityDetailsNarrative" xlink:href="amrh-20210331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/LiquidityDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#LiquidityDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative" xlink:href="amrh-20210331.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#IntangibleAssetsDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengiesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/TenderAgreementDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#TenderAgreementDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#IncomeTaxesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#SubsequentEventsDetailsNarrative10-k" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableExcludingConvertibleNotespayable" xlink:label="loc_amrhNotesPayableExcludingConvertibleNotespayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_amrhNotesPayableExcludingConvertibleNotespayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesNoncurrent" xlink:label="loc_amrhWarrantLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_amrhWarrantLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InducementExpense" xlink:label="loc_amrhInducementExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_amrhInducementExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InterestExpenses" xlink:label="loc_amrhInterestExpenses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_amrhInterestExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AccruedInterest" xlink:label="loc_amrhAccruedInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_amrhAccruedInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_GainsLossesOnInducementExpense" xlink:label="loc_amrhGainsLossesOnInducementExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_amrhGainsLossesOnInducementExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentsForPurchaseOfLicenseAgreement" xlink:label="loc_amrhPaymentsForPurchaseOfLicenseAgreement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_amrhPaymentsForPurchaseOfLicenseAgreement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromWarrantExercise" xlink:label="loc_amrhProceedsFromWarrantExercise" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_amrhProceedsFromWarrantExercise" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromOfferingAndReverseMergerProceeds" xlink:label="loc_amrhProceedsFromOfferingAndReverseMergerProceeds" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_amrhProceedsFromOfferingAndReverseMergerProceeds" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromIssuanceOfPrivatePlacementOne" xlink:label="loc_amrhProceedsFromIssuanceOfPrivatePlacementOne" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_amrhProceedsFromIssuanceOfPrivatePlacementOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/Business" xlink:title="00000007 - Disclosure - Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable" xlink:title="00000010 - Disclosure - Notes Payable and Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengies" xlink:title="00000012 - Disclosure - Commitments and Contingengies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="00000013 - Disclosure - Share Capital and Other Equity Instruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/TenderAgreement" xlink:title="00000014 - Disclosure - Tender Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables" xlink:title="00000019 - Disclosure - Notes Payable and Convertible Notes Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="00000021 - Disclosure - Share Capital and Other Equity Instruments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/LiquidityDetailsNarrative" xlink:title="00000023 - Disclosure - Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/LiquidityDetailsNarrative10-k" xlink:title="00000024 - Disclosure - Liquidity (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:title="00000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:title="00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Black Scholes Valuation Models of Warrant Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:title="00000032 - Disclosure - Notes Payable and Convertible Notes Payable (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:title="00000033 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Notes Payable and Convertible Notes Payable (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:title="00000034 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Interest Expense and Amortization of Debt Discount (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:title="00000035 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Beneficial Conversion Feature and Warrants (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000036 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k" xlink:title="00000037 - Disclosure - Intangible Assets (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:title="00000038 - Disclosure - Intangible Assets - Schedule of Assets Purchased (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:title="00000039 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:title="00000040 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative" xlink:title="00000041 - Disclosure - Commitments and Contingengies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k" xlink:title="00000042 - Disclosure - Commitments and Contingengies (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="00000043 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:title="00000044 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:title="00000045 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:title="00000046 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="00000047 - Disclosure - Share Capital and Other Equity Instruments - Schedule Of Restricted Stock Units and Awards Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:title="00000048 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Fair Value Assumption of Stock Option (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:title="00000049 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:title="00000050 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/TenderAgreementDetailsNarrative10-k" xlink:title="00000051 - Disclosure - Tender Agreement (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k" xlink:title="00000052 - Disclosure - Income Taxes (Details Narrative) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:title="00000053 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:title="00000054 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:title="00000055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10-K)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k" xlink:title="00000056 - Disclosure - Subsequent Events (Details Narrative) (10-K)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>amrh-20210331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: amrh%2D20210331 S%2D4 DFN.xfr; Date: 2021%2D06%2D20T09:09:19Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8014000A -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ameri100.com/role/DocumentAndEntityInformation" xlink:href="amrh-20210331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/BalanceSheets" xlink:href="amrh-20210331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/BalanceSheetsParenthetical" xlink:href="amrh-20210331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="amrh-20210331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:href="amrh-20210331.xsd#StatementsOfChangesInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfCashFlows" xlink:href="amrh-20210331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/Business" xlink:href="amrh-20210331.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/Liquidity" xlink:href="amrh-20210331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets" xlink:href="amrh-20210331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengies" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/TenderAgreement" xlink:href="amrh-20210331.xsd#TenderAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes" xlink:href="amrh-20210331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SubsequentEvents" xlink:href="amrh-20210331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsTables" xlink:href="amrh-20210331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxesTables" xlink:href="amrh-20210331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/LiquidityDetailsNarrative" xlink:href="amrh-20210331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/LiquidityDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#LiquidityDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative" xlink:href="amrh-20210331.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#IntangibleAssetsDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengiesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/TenderAgreementDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#TenderAgreementDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#IncomeTaxesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#SubsequentEventsDetailsNarrative10-k" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacement_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacement_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacementOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacementOne_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacementOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacementOne_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FinancingAndConversionOfNoteIncludingPalladiumShares" xlink:label="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumShares_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" xlink:label="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumSharestoShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumSharestoShares_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" xlink:label="loc_amrhStockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="loc_amrhAdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhAdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="loc_amrhAdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhAdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" xlink:label="loc_amrhStockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueAcquisitionsOne" xlink:label="loc_amrhStockIssuedDuringPeriodValueAcquisitionsOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueAcquisitionsOne_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesAcquisitionsOne" xlink:label="loc_amrhStockIssuedDuringPeriodSharesAcquisitionsOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesAcquisitionsOne_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedDirectOffering" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOffering_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOffering_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOfferingOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOfferingOne_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOfferingOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOfferingOne_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium" xlink:label="loc_us-gaapAdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExerciseOfWarrants" xlink:label="loc_amrhExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhExerciseOfWarrants_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExerciseOfWarrantsShares" xlink:label="loc_amrhExerciseOfWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhExerciseOfWarrantsShares_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:label="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="39" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/Business" xlink:title="00000007 - Disclosure - Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable" xlink:title="00000010 - Disclosure - Notes Payable and Convertible Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengies" xlink:title="00000012 - Disclosure - Commitments and Contingengies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="00000013 - Disclosure - Share Capital and Other Equity Instruments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/TenderAgreement" xlink:title="00000014 - Disclosure - Tender Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InitialMeasurementMember" xlink:label="loc_amrhInitialMeasurementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhInitialMeasurementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SubsequentMeasurementMember" xlink:label="loc_amrhSubsequentMeasurementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhSubsequentMeasurementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_amrhScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_amrhScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables" xlink:title="00000019 - Disclosure - Notes Payable and Convertible Notes Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="00000021 - Disclosure - Share Capital and Other Equity Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/LiquidityDetailsNarrative" xlink:title="00000023 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OfferingMember" xlink:label="loc_amrhOfferingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhOfferingMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WorkingCapital" xlink:label="loc_amrhWorkingCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhWorkingCapital_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/LiquidityDetailsNarrative10-k" xlink:title="00000024 - Disclosure - Liquidity (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WorkingCapital" xlink:label="loc_amrhWorkingCapital_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhWorkingCapital_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) (10-K)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhOptionsToPurchaseSharesOfCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhOptionsToPurchaseSharesOfCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:title="00000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhOptionsToPurchaseSharesOfCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhOptionsToPurchaseSharesOfCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesJanuaryWarrantsMember" xlink:label="loc_amrhWarrantLiabilitiesJanuaryWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhWarrantLiabilitiesJanuaryWarrantsMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesFebruaryWarrantsMember" xlink:label="loc_amrhWarrantLiabilitiesFebruaryWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhWarrantLiabilitiesFebruaryWarrantsMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:title="00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Black Scholes Valuation Models of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InitialMeasurementMember" xlink:label="loc_amrhInitialMeasurementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhInitialMeasurementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SubsequentMeasurementMember" xlink:label="loc_amrhSubsequentMeasurementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhSubsequentMeasurementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JanuaryWarrantsMember" xlink:label="loc_amrhJanuaryWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhJanuaryWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryWarrantsMember" xlink:label="loc_amrhFebruaryWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhFebruaryWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SubsequentMeasurementMember" xlink:label="loc_amrhSubsequentMeasurementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhSubsequentMeasurementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JanuaryWarrantsMember" xlink:label="loc_amrhJanuaryWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhJanuaryWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryWarrantsMember" xlink:label="loc_amrhFebruaryWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhFebruaryWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" xlink:label="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" xlink:label="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:title="00000032 - Disclosure - Notes Payable and Convertible Notes Payable (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MarchTwoThousandNineteenNoteMember" xlink:label="loc_amrhMarchTwoThousandNineteenNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMarchTwoThousandNineteenNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JulyTwoThousandNineteenNoteMember" xlink:label="loc_amrhJulyTwoThousandNineteenNoteMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhJulyTwoThousandNineteenNoteMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MayTwoThousandNineteenAmendmentMember" xlink:label="loc_amrhMayTwoThousandNineteenAmendmentMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMayTwoThousandNineteenAmendmentMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberTwoThousandNineteenNoteMember" xlink:label="loc_amrhDecemberTwoThousandNineteenNoteMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhDecemberTwoThousandNineteenNoteMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandTwentyNoteMember" xlink:label="loc_amrhFebruaryTwoThousandTwentyNoteMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandTwentyNoteMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecuredPromissoryNoteMember" xlink:label="loc_amrhSecuredPromissoryNoteMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhSecuredPromissoryNoteMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FirstNoteAmendmentMember" xlink:label="loc_amrhFirstNoteAmendmentMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFirstNoteAmendmentMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecondNoteAmendmentMember" xlink:label="loc_amrhSecondNoteAmendmentMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhSecondNoteAmendmentMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FormerExecutiveDirectorMember" xlink:label="loc_amrhFormerExecutiveDirectorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhFormerExecutiveDirectorMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_LenderMember" xlink:label="loc_amrhLenderMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhLenderMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NoteAgreementMember" xlink:label="loc_amrhNoteAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhNoteAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_EventOfDefaultMember" xlink:label="loc_amrhEventOfDefaultMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhEventOfDefaultMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaCapitalAnstaltMember" xlink:label="loc_amrhAlphaCapitalAnstaltMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_amrhAlphaCapitalAnstaltMember_310" xlink:type="arc" order="312" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AggregateExtensionFee" xlink:label="loc_amrhAggregateExtensionFee_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_amrhAggregateExtensionFee_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_340" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_340" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:title="00000033 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Notes Payable and Convertible Notes Payable (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MarchTwoThousandNineteenNoteMember" xlink:label="loc_amrhMarchTwoThousandNineteenNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMarchTwoThousandNineteenNoteMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AprilTwoThousandNineteenConvertibleNotesMember" xlink:label="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JulyTwoThousandNineteenNoteMember" xlink:label="loc_amrhJulyTwoThousandNineteenNoteMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhJulyTwoThousandNineteenNoteMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberTwoThousandNineteenNoteMember" xlink:label="loc_amrhDecemberTwoThousandNineteenNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhDecemberTwoThousandNineteenNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableMember" xlink:label="loc_amrhNotesPayableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhNotesPayableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:title="00000034 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Interest Expense and Amortization of Debt Discount (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AprilTwoThousandNineteenConvertibleNotesMember" xlink:label="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JulyTwoThousandNineteenNoteMember" xlink:label="loc_amrhJulyTwoThousandNineteenNoteMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhJulyTwoThousandNineteenNoteMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberTwoThousandNineteenNoteMember" xlink:label="loc_amrhDecemberTwoThousandNineteenNoteMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhDecemberTwoThousandNineteenNoteMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandTwentyNoteMember" xlink:label="loc_amrhFebruaryTwoThousandTwentyNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandTwentyNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaNoteMember" xlink:label="loc_amrhAlphaNoteMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhAlphaNoteMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaapInterestExpenseDebtExcludingAmortization_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebtExcludingAmortization_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:title="00000035 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Beneficial Conversion Feature and Warrants (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MeasurementInputSharesMember" xlink:label="loc_amrhMeasurementInputSharesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_amrhMeasurementInputSharesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CADMember" xlink:label="loc_amrhCADMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_amrhCADMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMeasurementInput" xlink:label="loc_us-gaapLongTermDebtMeasurementInput_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMeasurementInput_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaapLongTermDebtFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtFairValue_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm" xlink:label="loc_us-gaapLongTermDebtTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtTerm_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000036 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExclusiveLicenseAgreementMember" xlink:label="loc_amrhExclusiveLicenseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhExclusiveLicenseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBiotechIncMember" xlink:label="loc_amrhDiverseBiotechIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_amrhDiverseBiotechIncMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentOfUpfrontInvestment" xlink:label="loc_amrhPaymentOfUpfrontInvestment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhPaymentOfUpfrontInvestment_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k" xlink:title="00000037 - Disclosure - Intangible Assets (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsMember" xlink:label="loc_amrhSkincareAssetsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:title="00000038 - Disclosure - Intangible Assets - Schedule of Assets Purchased (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsMember" xlink:label="loc_amrhSkincareAssetsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_20" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:title="00000039 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsAndLicenseAgreementsMember" xlink:label="loc_amrhSkincareAssetsAndLicenseAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsAndLicenseAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBioLicenseAgreementMember" xlink:label="loc_amrhDiverseBioLicenseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhDiverseBioLicenseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:title="00000040 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsAndLicenseAgreementsMember" xlink:label="loc_amrhSkincareAssetsAndLicenseAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsAndLicenseAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_20" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative" xlink:title="00000041 - Disclosure - Commitments and Contingengies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WardEmploymentAgreementMember" xlink:label="loc_amrhWardEmploymentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhWardEmploymentAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AnnualPerformanceBonusesPercentage" xlink:label="loc_amrhAnnualPerformanceBonusesPercentage_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhAnnualPerformanceBonusesPercentage_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k" xlink:title="00000042 - Disclosure - Commitments and Contingengies (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_BusinessAdvisorServicesAgreementMember" xlink:label="loc_amrhBusinessAdvisorServicesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhBusinessAdvisorServicesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ConsultantMember" xlink:label="loc_amrhConsultantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhConsultantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MrDavidStefanskyMember" xlink:label="loc_amrhMrDavidStefanskyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhMrDavidStefanskyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MrHenochCohnMember" xlink:label="loc_amrhMrHenochCohnMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhMrHenochCohnMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaapCashMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCashMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="00000043 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OfferingMember" xlink:label="loc_amrhOfferingMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhOfferingMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_UnamortizedStockOptionExpense" xlink:label="loc_amrhUnamortizedStockOptionExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhUnamortizedStockOptionExpense_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InducementExpense" xlink:label="loc_amrhInducementExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhInducementExpense_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:title="00000044 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_VendorsMember" xlink:label="loc_amrhVendorsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhVendorsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ConsultantMember" xlink:label="loc_amrhConsultantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhConsultantMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SeptemberPrivatePlacementMember" xlink:label="loc_amrhSeptemberPrivatePlacementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhSeptemberPrivatePlacementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberPrivatePlacementMember" xlink:label="loc_amrhDecemberPrivatePlacementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhDecemberPrivatePlacementMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MarchTwoThousandNineteenNoteMember" xlink:label="loc_amrhMarchTwoThousandNineteenNoteMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMarchTwoThousandNineteenNoteMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandTwentyNoteMember" xlink:label="loc_amrhFebruaryTwoThousandTwentyNoteMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandTwentyNoteMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD" xlink:label="loc_currencyCAD_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyCAD_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:label="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_UnamortizedStockOptionExpense" xlink:label="loc_amrhUnamortizedStockOptionExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhUnamortizedStockOptionExpense_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_180" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_180" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:title="00000045 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:title="00000046 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) (10-K)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="00000047 - Disclosure - Share Capital and Other Equity Instruments - Schedule Of Restricted Stock Units and Awards Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:title="00000048 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Fair Value Assumption of Stock Option (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueTerm" xlink:label="loc_amrhFairValueTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFairValueTerm_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:title="00000049 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRighExercisable" xlink:label="loc_amrhClassOfWarrantOrRighExercisable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRighExercisable_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:label="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_20" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_20" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_20" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_20" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:title="00000050 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRighExercisable" xlink:label="loc_amrhClassOfWarrantOrRighExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRighExercisable_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:label="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_30" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/TenderAgreementDetailsNarrative10-k" xlink:title="00000051 - Disclosure - Tender Agreement (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaCapitalAnstaltMember" xlink:label="loc_amrhAlphaCapitalAnstaltMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_amrhAlphaCapitalAnstaltMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_EnvericBiosciencesIncMember" xlink:label="loc_amrhEnvericBiosciencesIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_amrhEnvericBiosciencesIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AmalgamationAgreementMember" xlink:label="loc_amrhAmalgamationAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhAmalgamationAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AmalgamationAmendmentAgreementMember" xlink:label="loc_amrhAmalgamationAmendmentAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhAmalgamationAmendmentAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecondAmalgamationAmendmentAgreementMember" xlink:label="loc_amrhSecondAmalgamationAmendmentAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhSecondAmalgamationAmendmentAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementMember" xlink:label="loc_amrhTenderAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhTenderAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SeriesBWarrantsMember" xlink:label="loc_amrhSeriesBWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_amrhSeriesBWarrantsMember_10" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CommonStockBeneficialOwnershipBlockerPercentage" xlink:label="loc_amrhCommonStockBeneficialOwnershipBlockerPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhCommonStockBeneficialOwnershipBlockerPercentage_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k" xlink:title="00000052 - Disclosure - Income Taxes (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaapCanadaRevenueAgencyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCanadaRevenueAgencyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_amrhOperatingLossCarryforwardsExpirationYear_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhOperatingLossCarryforwardsExpirationYear_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:title="00000053 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:title="00000054 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details) (10-K)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:title="00000055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10-K)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k" xlink:title="00000056 - Disclosure - Subsequent Events (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_RegisteredDirectOfferingMember" xlink:label="loc_amrhRegisteredDirectOfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhRegisteredDirectOfferingMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExclusiveLicenseAgreementMember" xlink:label="loc_amrhExclusiveLicenseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhExclusiveLicenseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBiotechIncMember" xlink:label="loc_amrhDiverseBiotechIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_amrhDiverseBiotechIncMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentOfUpfrontInvestment" xlink:label="loc_amrhPaymentOfUpfrontInvestment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhPaymentOfUpfrontInvestment_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" xlink:type="arc" order="5" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>amrh-20210331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: amrh%2D20210331 S%2D4 DFN.xfr; Date: 2021%2D06%2D20T09:09:19Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8014000A -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OfferingMember" xlink:label="amrh_OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OfferingMember" xlink:to="amrh_OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_OfferingMember_lbl" xml:lang="en-US">Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="amrh_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="amrh_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="amrh_OptionsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OptionsToPurchaseSharesOfCommonStockMember" xlink:to="amrh_OptionsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_OptionsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExclusiveLicenseAgreementMember" xlink:label="amrh_ExclusiveLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ExclusiveLicenseAgreementMember" xlink:to="amrh_ExclusiveLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBiotechIncMember" xlink:label="amrh_DiverseBiotechIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DiverseBiotechIncMember" xlink:to="amrh_DiverseBiotechIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_DiverseBiotechIncMember_lbl" xml:lang="en-US">Diverse Biotech, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsAndLicenseAgreementsMember" xlink:label="amrh_SkincareAssetsAndLicenseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SkincareAssetsAndLicenseAgreementsMember" xlink:to="amrh_SkincareAssetsAndLicenseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SkincareAssetsAndLicenseAgreementsMember_lbl" xml:lang="en-US">Skincare Assets and License Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBioLicenseAgreementMember" xlink:label="amrh_DiverseBioLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DiverseBioLicenseAgreementMember" xlink:to="amrh_DiverseBioLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_DiverseBioLicenseAgreementMember_lbl" xml:lang="en-US">Diverse Bio License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InitialMeasurementMember" xlink:label="amrh_InitialMeasurementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_InitialMeasurementMember" xlink:to="amrh_InitialMeasurementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_InitialMeasurementMember_lbl" xml:lang="en-US">Initial Measurement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WardEmploymentAgreementMember" xlink:label="amrh_WardEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WardEmploymentAgreementMember" xlink:to="amrh_WardEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WardEmploymentAgreementMember_lbl" xml:lang="en-US">Ward Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesJanuaryWarrantsMember" xlink:label="amrh_WarrantLiabilitiesJanuaryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilitiesJanuaryWarrantsMember" xlink:to="amrh_WarrantLiabilitiesJanuaryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WarrantLiabilitiesJanuaryWarrantsMember_lbl" xml:lang="en-US">Warrant Liabilities - January Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesFebruaryWarrantsMember" xlink:label="amrh_WarrantLiabilitiesFebruaryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilitiesFebruaryWarrantsMember" xlink:to="amrh_WarrantLiabilitiesFebruaryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WarrantLiabilitiesFebruaryWarrantsMember_lbl" xml:lang="en-US">Warrant Liabilities - February Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JanuaryWarrantsMember" xlink:label="amrh_JanuaryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_JanuaryWarrantsMember" xlink:to="amrh_JanuaryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_JanuaryWarrantsMember_lbl" xml:lang="en-US">January Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryWarrantsMember" xlink:label="amrh_FebruaryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FebruaryWarrantsMember" xlink:to="amrh_FebruaryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FebruaryWarrantsMember_lbl" xml:lang="en-US">February Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Stock Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Discount Yield [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Expected Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SubsequentMeasurementMember" xlink:label="amrh_SubsequentMeasurementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SubsequentMeasurementMember" xlink:to="amrh_SubsequentMeasurementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SubsequentMeasurementMember_lbl" xml:lang="en-US">Subsequent Measurement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="amrh_FebruaryTwoThousandNineteenNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FebruaryTwoThousandNineteenNoteMember" xlink:to="amrh_FebruaryTwoThousandNineteenNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FebruaryTwoThousandNineteenNoteMember_lbl" xml:lang="en-US">February 2019 Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MarchTwoThousandNineteenNoteMember" xlink:label="amrh_MarchTwoThousandNineteenNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MarchTwoThousandNineteenNoteMember" xlink:to="amrh_MarchTwoThousandNineteenNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_MarchTwoThousandNineteenNoteMember_lbl" xml:lang="en-US">March 2019 Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FormerExecutiveDirectorMember" xlink:label="amrh_FormerExecutiveDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FormerExecutiveDirectorMember" xlink:to="amrh_FormerExecutiveDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FormerExecutiveDirectorMember_lbl" xml:lang="en-US">Former Executive Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NoteAgreementMember" xlink:label="amrh_NoteAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NoteAgreementMember" xlink:to="amrh_NoteAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_NoteAgreementMember_lbl" xml:lang="en-US">Note Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JulyTwoThousandNineteenNoteMember" xlink:label="amrh_JulyTwoThousandNineteenNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_JulyTwoThousandNineteenNoteMember" xlink:to="amrh_JulyTwoThousandNineteenNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_JulyTwoThousandNineteenNoteMember_lbl" xml:lang="en-US">July 2019 Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_LenderMember" xlink:label="amrh_LenderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_LenderMember" xlink:to="amrh_LenderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_LenderMember_lbl" xml:lang="en-US">Lender [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MayTwoThousandNineteenAmendmentMember" xlink:label="amrh_MayTwoThousandNineteenAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MayTwoThousandNineteenAmendmentMember" xlink:to="amrh_MayTwoThousandNineteenAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_MayTwoThousandNineteenAmendmentMember_lbl" xml:lang="en-US">May 2019 Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberTwoThousandNineteenNoteMember" xlink:label="amrh_DecemberTwoThousandNineteenNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DecemberTwoThousandNineteenNoteMember" xlink:to="amrh_DecemberTwoThousandNineteenNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_DecemberTwoThousandNineteenNoteMember_lbl" xml:lang="en-US">December 2019 Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_EventOfDefaultMember" xlink:label="amrh_EventOfDefaultMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_EventOfDefaultMember" xlink:to="amrh_EventOfDefaultMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_EventOfDefaultMember_lbl" xml:lang="en-US">Event of Default [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandTwentyNoteMember" xlink:label="amrh_FebruaryTwoThousandTwentyNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FebruaryTwoThousandTwentyNoteMember" xlink:to="amrh_FebruaryTwoThousandTwentyNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FebruaryTwoThousandTwentyNoteMember_lbl" xml:lang="en-US">February 2020 Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecuredPromissoryNoteMember" xlink:label="amrh_SecuredPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SecuredPromissoryNoteMember" xlink:to="amrh_SecuredPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SecuredPromissoryNoteMember_lbl" xml:lang="en-US">Secured Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FirstNoteAmendmentMember" xlink:label="amrh_FirstNoteAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FirstNoteAmendmentMember" xlink:to="amrh_FirstNoteAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FirstNoteAmendmentMember_lbl" xml:lang="en-US">First Note Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecondNoteAmendmentMember" xlink:label="amrh_SecondNoteAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SecondNoteAmendmentMember" xlink:to="amrh_SecondNoteAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SecondNoteAmendmentMember_lbl" xml:lang="en-US">Second Note Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaCapitalAnstaltMember" xlink:label="amrh_AlphaCapitalAnstaltMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AlphaCapitalAnstaltMember" xlink:to="amrh_AlphaCapitalAnstaltMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AlphaCapitalAnstaltMember_lbl" xml:lang="en-US">Alpha Capital Anstalt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AprilTwoThousandNineteenConvertibleNotesMember" xlink:label="amrh_AprilTwoThousandNineteenConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AprilTwoThousandNineteenConvertibleNotesMember" xlink:to="amrh_AprilTwoThousandNineteenConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AprilTwoThousandNineteenConvertibleNotesMember_lbl" xml:lang="en-US">April 2019 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableMember" xlink:label="amrh_NotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NotesPayableMember" xlink:to="amrh_NotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_NotesPayableMember_lbl" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaNoteMember" xlink:label="amrh_AlphaNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AlphaNoteMember" xlink:to="amrh_AlphaNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AlphaNoteMember_lbl" xml:lang="en-US">Alpha Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CADMember" xlink:label="amrh_CADMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CADMember" xlink:to="amrh_CADMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_CADMember_lbl" xml:lang="en-US">CAD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Dividend Yield [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Expected Volatility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_2_lbl" xml:lang="en-US">Weighted Average Risk-Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MeasurementInputSharesMember" xlink:label="amrh_MeasurementInputSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MeasurementInputSharesMember" xlink:to="amrh_MeasurementInputSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_MeasurementInputSharesMember_lbl" xml:lang="en-US">Number of Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsMember" xlink:label="amrh_SkincareAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SkincareAssetsMember" xlink:to="amrh_SkincareAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SkincareAssetsMember_lbl" xml:lang="en-US">Skincare Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_BusinessAdvisorServicesAgreementMember" xlink:label="amrh_BusinessAdvisorServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_BusinessAdvisorServicesAgreementMember" xlink:to="amrh_BusinessAdvisorServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_BusinessAdvisorServicesAgreementMember_lbl" xml:lang="en-US">Business Advisor Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ConsultantMember" xlink:label="amrh_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ConsultantMember" xlink:to="amrh_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US">Cash [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MrDavidStefanskyMember" xlink:label="amrh_MrDavidStefanskyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MrDavidStefanskyMember" xlink:to="amrh_MrDavidStefanskyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_MrDavidStefanskyMember_lbl" xml:lang="en-US">Mr. David Stefansky [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MrHenochCohnMember" xlink:label="amrh_MrHenochCohnMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MrHenochCohnMember" xlink:to="amrh_MrHenochCohnMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_MrHenochCohnMember_lbl" xml:lang="en-US">Mr. Henoch Cohn [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_VendorsMember" xlink:label="amrh_VendorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_VendorsMember" xlink:to="amrh_VendorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_VendorsMember_lbl" xml:lang="en-US">Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SeptemberPrivatePlacementMember" xlink:label="amrh_SeptemberPrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SeptemberPrivatePlacementMember" xlink:to="amrh_SeptemberPrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SeptemberPrivatePlacementMember_lbl" xml:lang="en-US">September Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberPrivatePlacementMember" xlink:label="amrh_DecemberPrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DecemberPrivatePlacementMember" xlink:to="amrh_DecemberPrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_DecemberPrivatePlacementMember_lbl" xml:lang="en-US">December Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD" xlink:label="currency_CAD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CAD" xlink:to="currency_CAD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="currency_CAD_lbl" xml:lang="en-US">CAD [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_2_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected life (in years) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AmalgamationAgreementMember" xlink:label="amrh_AmalgamationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AmalgamationAgreementMember" xlink:to="amrh_AmalgamationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AmalgamationAgreementMember_lbl" xml:lang="en-US">Amalgamation Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_EnvericBiosciencesIncMember" xlink:label="amrh_EnvericBiosciencesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_EnvericBiosciencesIncMember" xlink:to="amrh_EnvericBiosciencesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_EnvericBiosciencesIncMember_lbl" xml:lang="en-US">Enveric Biosciences, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AmalgamationAmendmentAgreementMember" xlink:label="amrh_AmalgamationAmendmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AmalgamationAmendmentAgreementMember" xlink:to="amrh_AmalgamationAmendmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AmalgamationAmendmentAgreementMember_lbl" xml:lang="en-US">Amalgamation Amendment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SeriesBWarrantsMember" xlink:label="amrh_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SeriesBWarrantsMember" xlink:to="amrh_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecondAmalgamationAmendmentAgreementMember" xlink:label="amrh_SecondAmalgamationAmendmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SecondAmalgamationAmendmentAgreementMember" xlink:to="amrh_SecondAmalgamationAmendmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SecondAmalgamationAmendmentAgreementMember_lbl" xml:lang="en-US">Second Amalgamation Amendment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementMember" xlink:label="amrh_TenderAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_TenderAgreementMember" xlink:to="amrh_TenderAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_TenderAgreementMember_lbl" xml:lang="en-US">Tender Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CanadaRevenueAgencyMember" xlink:to="us-gaap_CanadaRevenueAgencyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CanadaRevenueAgencyMember_lbl" xml:lang="en-US">Canadian Federal Income Tax Purposes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_RegisteredDirectOfferingMember" xlink:label="amrh_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_RegisteredDirectOfferingMember" xlink:to="amrh_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders' Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Advance from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableExcludingConvertibleNotespayable" xlink:label="amrh_NotesPayableExcludingConvertibleNotespayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NotesPayableExcludingConvertibleNotespayable" xlink:to="amrh_NotesPayableExcludingConvertibleNotespayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_NotesPayableExcludingConvertibleNotespayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesNoncurrent" xlink:label="amrh_WarrantLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilitiesNoncurrent" xlink:to="amrh_WarrantLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WarrantLiabilitiesNoncurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Extinguishment of note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InducementExpense" xlink:label="amrh_InducementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_InducementExpense" xlink:to="amrh_InducementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="amrh_InducementExpense_lbl" xml:lang="en-US">Inducement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InterestExpenses" xlink:label="amrh_InterestExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_InterestExpenses" xlink:to="amrh_InterestExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_InterestExpenses_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement_lbl" xml:lang="en-US">September 2020 private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement_lbl" xml:lang="en-US">September 2020 private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne_lbl" xml:lang="en-US">December 2020 private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne_lbl" xml:lang="en-US">December 2020 private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Acquisition of Tikkun Pharma IP</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Acquisition of Tikkun Pharma IP, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FinancingAndConversionOfNoteIncludingPalladiumShares" xlink:label="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares" xlink:to="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares_lbl" xml:lang="en-US">Alpha financing and conversion of Alpha Note, including Palladium shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" xlink:label="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" xlink:to="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares_lbl" xml:lang="en-US">Alpha financing and conversion of Alpha Note, including Palladium shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" xlink:label="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" xlink:to="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares_lbl" xml:lang="en-US">Exchange of warrants for common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" xlink:label="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" xlink:to="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares_lbl" xml:lang="en-US">Exchange of warrants for common shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" xlink:to="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification_lbl" xml:lang="en-US">Common stock issued in conjunction with note payable modification</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" xlink:to="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification_lbl" xml:lang="en-US">Common stock issued in conjunction with note payable modification, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" xlink:label="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" xlink:to="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series B preferred stock to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" xlink:to="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Conversion of Series B preferred stock to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueAcquisitionsOne" xlink:label="amrh_StockIssuedDuringPeriodValueAcquisitionsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueAcquisitionsOne" xlink:to="amrh_StockIssuedDuringPeriodValueAcquisitionsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueAcquisitionsOne_lbl" xml:lang="en-US">Merger with Ameri Holdings, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesAcquisitionsOne" xlink:label="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne" xlink:to="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne_lbl" xml:lang="en-US">Merger with Ameri Holdings, Inc, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued in connection with note extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued in connection with note extension</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedDirectOffering" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering_lbl" xml:lang="en-US">January 2021 registered direct offering</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering_lbl" xml:lang="en-US">January 2021 registered direct offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne_lbl" xml:lang="en-US">February 2021 registered direct offering</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne_lbl" xml:lang="en-US">February 2021 registered direct offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium" xlink:label="us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium" xlink:to="us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium_lbl" xml:lang="en-US">Induced conversion of stock options into restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series B preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExerciseOfWarrants" xlink:label="amrh_ExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ExerciseOfWarrants" xlink:to="amrh_ExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExerciseOfWarrantsShares" xlink:label="amrh_ExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ExerciseOfWarrantsShares" xlink:to="amrh_ExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ExerciseOfWarrantsShares_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:label="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:to="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_lbl" xml:lang="en-US">Common stock issued for accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:label="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:to="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_lbl" xml:lang="en-US">Common stock issued for accounts payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued in conjunction with notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature issued with note payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Foreign exchange gain/loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AccruedInterest" xlink:label="amrh_AccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AccruedInterest" xlink:to="amrh_AccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AccruedInterest_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_GainsLossesOnInducementExpense" xlink:label="amrh_GainsLossesOnInducementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_GainsLossesOnInducementExpense" xlink:to="amrh_GainsLossesOnInducementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="amrh_GainsLossesOnInducementExpense_lbl" xml:lang="en-US">Inducement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentsForPurchaseOfLicenseAgreement" xlink:label="amrh_PaymentsForPurchaseOfLicenseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_PaymentsForPurchaseOfLicenseAgreement" xlink:to="amrh_PaymentsForPurchaseOfLicenseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="amrh_PaymentsForPurchaseOfLicenseAgreement_lbl" xml:lang="en-US">Purchase of Tikkun Pharma license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromWarrantExercise" xlink:label="amrh_ProceedsFromWarrantExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ProceedsFromWarrantExercise" xlink:to="amrh_ProceedsFromWarrantExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ProceedsFromWarrantExercise_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Advances from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromOfferingAndReverseMergerProceeds" xlink:label="amrh_ProceedsFromOfferingAndReverseMergerProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ProceedsFromOfferingAndReverseMergerProceeds" xlink:to="amrh_ProceedsFromOfferingAndReverseMergerProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ProceedsFromOfferingAndReverseMergerProceeds_lbl" xml:lang="en-US">Offering and Reverse Merger proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">September 2020 private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromIssuanceOfPrivatePlacementOne" xlink:label="amrh_ProceedsFromIssuanceOfPrivatePlacementOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ProceedsFromIssuanceOfPrivatePlacementOne" xlink:to="amrh_ProceedsFromIssuanceOfPrivatePlacementOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="amrh_ProceedsFromIssuanceOfPrivatePlacementOne_lbl" xml:lang="en-US">December 2020 private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of foreign exchange rate on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash - beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash - end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature issued with note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantsIssuedInConjunctionWithNotesPayable" xlink:label="amrh_WarrantsIssuedInConjunctionWithNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantsIssuedInConjunctionWithNotesPayable" xlink:to="amrh_WarrantsIssuedInConjunctionWithNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WarrantsIssuedInConjunctionWithNotesPayable_lbl" xml:lang="en-US">Warrants issued in conjunction with notes payable issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Shares of common stock issued for note payable extensions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Shares of common stock issued for accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="amrh_CommonStockIssuedInConjunctionWithNotePayableModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CommonStockIssuedInConjunctionWithNotePayableModification" xlink:to="amrh_CommonStockIssuedInConjunctionWithNotePayableModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="amrh_CommonStockIssuedInConjunctionWithNotePayableModification_lbl" xml:lang="en-US">Common stock issued in conjunction with note payable modification</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableIssuedToConsultantForPrepaidServices" xlink:label="amrh_NotesPayableIssuedToConsultantForPrepaidServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NotesPayableIssuedToConsultantForPrepaidServices" xlink:to="amrh_NotesPayableIssuedToConsultantForPrepaidServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_NotesPayableIssuedToConsultantForPrepaidServices_lbl" xml:lang="en-US">Notes payable issued to consultant for prepaid services</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" xlink:label="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" xlink:to="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock_lbl" xml:lang="en-US">Conversion of related party advances and notes payable into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CommonStockIssuedForSkincareLicense" xlink:label="amrh_CommonStockIssuedForSkincareLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CommonStockIssuedForSkincareLicense" xlink:to="amrh_CommonStockIssuedForSkincareLicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_CommonStockIssuedForSkincareLicense_lbl" xml:lang="en-US">Common stock issued for skincare license</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable and Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingengies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Share Capital and Other Equity Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementAbstract" xlink:label="amrh_TenderAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_TenderAgreementAbstract" xlink:to="amrh_TenderAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_TenderAgreementAbstract_lbl" xml:lang="en-US">Tender Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementDisclosureTextBlock" xlink:label="amrh_TenderAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_TenderAgreementDisclosureTextBlock" xlink:to="amrh_TenderAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="amrh_TenderAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Tender Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilityPolicyTextBlock" xlink:label="amrh_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilityPolicyTextBlock" xlink:to="amrh_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OfferingCostsPolicy" xlink:label="amrh_OfferingCostsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OfferingCostsPolicy" xlink:to="amrh_OfferingCostsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_OfferingCostsPolicy_lbl" xml:lang="en-US">Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long Term Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" xlink:label="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" xlink:to="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Black Scholes Valuation Models of Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" xlink:label="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" xlink:to="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Notes Payable and Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Expense and Amortization of Debt Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Beneficial Conversion Feature and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfAssetsPurchasedTableTextBlock" xlink:label="amrh_ScheduleOfAssetsPurchasedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ScheduleOfAssetsPurchasedTableTextBlock" xlink:to="amrh_ScheduleOfAssetsPurchasedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ScheduleOfAssetsPurchasedTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets Purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units and Awards Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumption of Stock Option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WorkingCapital" xlink:label="amrh_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WorkingCapital" xlink:to="amrh_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued during period, shares, new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash on hand</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Accrued for penalties and interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant measurement term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Value (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value as of December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" xlink:label="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" xlink:to="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability_lbl" xml:lang="en-US">Initial value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" xlink:label="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" xlink:to="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Fair value as of March 31, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_LegalEntityAxis_2_lbl" xml:lang="en-US">Series [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_2_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument, interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt instrument maturity date description</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AggregateExtensionFee" xlink:label="amrh_AggregateExtensionFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AggregateExtensionFee" xlink:to="amrh_AggregateExtensionFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AggregateExtensionFee_lbl" xml:lang="en-US">Aggregate extension fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Issuance of granted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt instrument fee amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt conversion converted instrument shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt conversion converted instrument value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants Value (USD)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMeasurementInput" xlink:label="us-gaap_LongTermDebtMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMeasurementInput" xlink:to="us-gaap_LongTermDebtMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMeasurementInput_lbl" xml:lang="en-US">Beneficial Conversion Feature measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US">Beneficial Conversion Feature measurement input Value (USD)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US">Beneficial Conversion Feature measurement input Term (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentOfUpfrontInvestment" xlink:label="amrh_PaymentOfUpfrontInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_PaymentOfUpfrontInvestment" xlink:to="amrh_PaymentOfUpfrontInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_PaymentOfUpfrontInvestment_lbl" xml:lang="en-US">Payment of up-front investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross carrying amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset useful life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_2_lbl" xml:lang="en-US">Common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AnnualPerformanceBonusesPercentage" xlink:label="amrh_AnnualPerformanceBonusesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AnnualPerformanceBonusesPercentage" xlink:to="amrh_AnnualPerformanceBonusesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_AnnualPerformanceBonusesPercentage_lbl" xml:lang="en-US">Annual performance bonuses percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_2_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Stock issued during period shares issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalariesAndWages_2_lbl" xml:lang="en-US">Wages and salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting rights, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of shares issued in conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_UnamortizedStockOptionExpense" xlink:label="amrh_UnamortizedStockOptionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_UnamortizedStockOptionExpense" xlink:to="amrh_UnamortizedStockOptionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_UnamortizedStockOptionExpense_lbl" xml:lang="en-US">Unamortized stock option expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Option to purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_InducementExpense" xlink:to="amrh_InducementExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_InducementExpense_2_lbl" xml:lang="en-US">Inducement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Stock based compensation, not yet recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Stock based compensation, period for recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xml:lang="en-US">Debt instrument, exchange of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of common stock under private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xml:lang="en-US">Gross proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt instrument, face value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Advance from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants exercise per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants and rights outstanding, maturity date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of warrants discount</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:label="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract_lbl" xml:lang="en-US">Share Capital And Other Equity Instruments - Schedule Of Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares, Expired, forfeited, or cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired, forfeited, or cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Expired, forfeited, or cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract_2_lbl" xml:lang="en-US">Share Capital And Other Equity Instruments - Schedule Of Stock Options Details</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xml:lang="en-US">Number of Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Outstanding at December 31, 2020</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Exercisable at December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Nonvested at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares, Nonvested at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Non-vested at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, Non-Vested at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueTerm" xlink:label="amrh_FairValueTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FairValueTerm" xlink:to="amrh_FairValueTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_FairValueTerm_lbl" xml:lang="en-US">Fair value term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrant shares outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrant shares outstanding, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrant shares outstanding, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrant shares outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRighExercisable" xlink:label="amrh_ClassOfWarrantOrRighExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ClassOfWarrantOrRighExercisable" xlink:to="amrh_ClassOfWarrantOrRighExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ClassOfWarrantOrRighExercisable_lbl" xml:lang="en-US">Warrant shares outstanding, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise Price, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:label="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:to="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_lbl" xml:lang="en-US">Weighted average remaining life, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_lbl" xml:lang="en-US">Weighted average remaining life, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_lbl" xml:lang="en-US">Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:to="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_lbl" xml:lang="en-US">Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_lbl" xml:lang="en-US">Weighted average remaining life, Outstanding at beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_2_lbl" xml:lang="en-US">Weighted average remaining life, Outstanding at December 31, 2020</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_2_lbl" xml:lang="en-US">Weighted average remaining life, Exercisable at December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants to acquire shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Number of shares issued during amalgamation</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CommonStockBeneficialOwnershipBlockerPercentage" xlink:label="amrh_CommonStockBeneficialOwnershipBlockerPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CommonStockBeneficialOwnershipBlockerPercentage" xlink:to="amrh_CommonStockBeneficialOwnershipBlockerPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_CommonStockBeneficialOwnershipBlockerPercentage_lbl" xml:lang="en-US">Common stock beneficial ownership blocker, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryovers</link:label>
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OperatingLossCarryforwardsExpirationYear" xlink:label="amrh_OperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OperatingLossCarryforwardsExpirationYear" xlink:to="amrh_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards, expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryovers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets (liabilities), net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xml:lang="en-US">Beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Increase in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xml:lang="en-US">End of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Canada federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Provincial taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Sale of common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Sale of common stock, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Share price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrants exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AccruedInterest" xlink:to="amrh_AccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AccruedInterest_doc" xml:lang="en-US">Accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ClassOfWarrantOrRighExercisable" xlink:to="amrh_ClassOfWarrantOrRighExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ClassOfWarrantOrRighExercisable_doc" xml:lang="en-US">Warrant shares outstanding, exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:to="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable_doc" xml:lang="en-US">Weighted average exercise price, exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DiverseBiotechIncMember" xlink:to="amrh_DiverseBiotechIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_DiverseBiotechIncMember_doc" xml:lang="en-US">Diverse Biotech, Inc. [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ExclusiveLicenseAgreementMember" xlink:to="amrh_ExclusiveLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ExclusiveLicenseAgreementMember_doc" xml:lang="en-US">Exclusive License Agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_GainsLossesOnInducementExpense" xlink:to="amrh_GainsLossesOnInducementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_GainsLossesOnInducementExpense_doc" xml:lang="en-US">Inducement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OptionsToPurchaseSharesOfCommonStockMember" xlink:to="amrh_OptionsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_OptionsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Options To Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_PaymentOfUpfrontInvestment" xlink:to="amrh_PaymentOfUpfrontInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_PaymentOfUpfrontInvestment_doc" xml:lang="en-US">Payment of up-front investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments forfeited in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments granted in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, expired, forfeited, or cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, outstanding at beginning of the year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:to="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value, exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SkincareAssetsAndLicenseAgreementsMember" xlink:to="amrh_SkincareAssetsAndLicenseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SkincareAssetsAndLicenseAgreementsMember_doc" xml:lang="en-US">Skincare Assets and License Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:to="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares_doc" xml:lang="en-US">Common stock issued for accounts payable, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:to="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable_doc" xml:lang="en-US">Common stock issued for accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_UnamortizedStockOptionExpense" xlink:to="amrh_UnamortizedStockOptionExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_UnamortizedStockOptionExpense_doc" xml:lang="en-US">Unamortized stock option expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantsIssuedInConjunctionWithNotesPayable" xlink:to="amrh_WarrantsIssuedInConjunctionWithNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WarrantsIssuedInConjunctionWithNotesPayable_doc" xml:lang="en-US">Warrants issued in conjunction with notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="amrh_WarrantsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WarrantsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Warrants To Purchase Shares Of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WorkingCapital" xlink:to="amrh_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DiverseBioLicenseAgreementMember" xlink:to="amrh_DiverseBioLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_DiverseBioLicenseAgreementMember_doc" xml:lang="en-US">Diverse Bio License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_InducementExpense" xlink:to="amrh_InducementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_InducementExpense_doc" xml:lang="en-US">Inducement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ProceedsFromWarrantExercise" xlink:to="amrh_ProceedsFromWarrantExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ProceedsFromWarrantExercise_doc" xml:lang="en-US">Proceeds from warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OfferingMember" xlink:to="amrh_OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_OfferingMember_doc" xml:lang="en-US">Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilitiesNoncurrent" xlink:to="amrh_WarrantLiabilitiesNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WarrantLiabilitiesNoncurrent_doc" xml:lang="en-US">Warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilityPolicyTextBlock" xlink:to="amrh_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" xlink:to="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Black Scholes Valuation Models of Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_InitialMeasurementMember" xlink:to="amrh_InitialMeasurementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_InitialMeasurementMember_doc" xml:lang="en-US">Initial Measurement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SubsequentMeasurementMember" xlink:to="amrh_SubsequentMeasurementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SubsequentMeasurementMember_doc" xml:lang="en-US">Subsequent Measurement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" xlink:to="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Fair Value of Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WardEmploymentAgreementMember" xlink:to="amrh_WardEmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WardEmploymentAgreementMember_doc" xml:lang="en-US">Ward Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AnnualPerformanceBonusesPercentage" xlink:to="amrh_AnnualPerformanceBonusesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AnnualPerformanceBonusesPercentage_doc" xml:lang="en-US">Annual performance bonuses percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilitiesJanuaryWarrantsMember" xlink:to="amrh_WarrantLiabilitiesJanuaryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WarrantLiabilitiesJanuaryWarrantsMember_doc" xml:lang="en-US">Warrant Liabilities - January Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_WarrantLiabilitiesFebruaryWarrantsMember" xlink:to="amrh_WarrantLiabilitiesFebruaryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_WarrantLiabilitiesFebruaryWarrantsMember_doc" xml:lang="en-US">Warrant Liabilities - February Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_JanuaryWarrantsMember" xlink:to="amrh_JanuaryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_JanuaryWarrantsMember_doc" xml:lang="en-US">January Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FebruaryWarrantsMember" xlink:to="amrh_FebruaryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FebruaryWarrantsMember_doc" xml:lang="en-US">February Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" xlink:to="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability_doc" xml:lang="en-US">Initial value of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" xlink:to="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue_doc" xml:lang="en-US">Change in fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OfferingCostsPolicy" xlink:to="amrh_OfferingCostsPolicy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_OfferingCostsPolicy_doc" xml:lang="en-US">Offering Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NotesPayableExcludingConvertibleNotespayable" xlink:to="amrh_NotesPayableExcludingConvertibleNotespayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_NotesPayableExcludingConvertibleNotespayable_doc" xml:lang="en-US">Notes payable excluding convertible notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_PaymentsForPurchaseOfLicenseAgreement" xlink:to="amrh_PaymentsForPurchaseOfLicenseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_PaymentsForPurchaseOfLicenseAgreement_doc" xml:lang="en-US">Purchase of Tikkun Pharma license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ProceedsFromOfferingAndReverseMergerProceeds" xlink:to="amrh_ProceedsFromOfferingAndReverseMergerProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ProceedsFromOfferingAndReverseMergerProceeds_doc" xml:lang="en-US">Offering and Reverse Merger proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ProceedsFromIssuanceOfPrivatePlacementOne" xlink:to="amrh_ProceedsFromIssuanceOfPrivatePlacementOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ProceedsFromIssuanceOfPrivatePlacementOne_doc" xml:lang="en-US">The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CommonStockIssuedInConjunctionWithNotePayableModification" xlink:to="amrh_CommonStockIssuedInConjunctionWithNotePayableModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_CommonStockIssuedInConjunctionWithNotePayableModification_doc" xml:lang="en-US">Common stock issued in conjunction with note payable modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" xlink:to="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock_doc" xml:lang="en-US">Conversion of related party advances and notes payable into common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CommonStockIssuedForSkincareLicense" xlink:to="amrh_CommonStockIssuedForSkincareLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_CommonStockIssuedForSkincareLicense_doc" xml:lang="en-US">Common stock issued for skincare license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NotesPayableIssuedToConsultantForPrepaidServices" xlink:to="amrh_NotesPayableIssuedToConsultantForPrepaidServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_NotesPayableIssuedToConsultantForPrepaidServices_doc" xml:lang="en-US">Notes payable issued to consultant for prepaid services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_TenderAgreementDisclosureTextBlock" xlink:to="amrh_TenderAgreementDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_TenderAgreementDisclosureTextBlock_doc" xml:lang="en-US">Tender Agreement [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ScheduleOfAssetsPurchasedTableTextBlock" xlink:to="amrh_ScheduleOfAssetsPurchasedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ScheduleOfAssetsPurchasedTableTextBlock_doc" xml:lang="en-US">Schedule of Assets Purchased [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FebruaryTwoThousandNineteenNoteMember" xlink:to="amrh_FebruaryTwoThousandNineteenNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FebruaryTwoThousandNineteenNoteMember_doc" xml:lang="en-US">February 2019 Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MarchTwoThousandNineteenNoteMember" xlink:to="amrh_MarchTwoThousandNineteenNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_MarchTwoThousandNineteenNoteMember_doc" xml:lang="en-US">March 2019 Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FormerExecutiveDirectorMember" xlink:to="amrh_FormerExecutiveDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FormerExecutiveDirectorMember_doc" xml:lang="en-US">Former Executive Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NoteAgreementMember" xlink:to="amrh_NoteAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_NoteAgreementMember_doc" xml:lang="en-US">Note Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_JulyTwoThousandNineteenNoteMember" xlink:to="amrh_JulyTwoThousandNineteenNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_JulyTwoThousandNineteenNoteMember_doc" xml:lang="en-US">July 2019 Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_LenderMember" xlink:to="amrh_LenderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_LenderMember_doc" xml:lang="en-US">Lender [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MayTwoThousandNineteenAmendmentMember" xlink:to="amrh_MayTwoThousandNineteenAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_MayTwoThousandNineteenAmendmentMember_doc" xml:lang="en-US">May 2019 Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DecemberTwoThousandNineteenNoteMember" xlink:to="amrh_DecemberTwoThousandNineteenNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_DecemberTwoThousandNineteenNoteMember_doc" xml:lang="en-US">December 2019 Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_EventOfDefaultMember" xlink:to="amrh_EventOfDefaultMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_EventOfDefaultMember_doc" xml:lang="en-US">Event Of Default [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FebruaryTwoThousandTwentyNoteMember" xlink:to="amrh_FebruaryTwoThousandTwentyNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FebruaryTwoThousandTwentyNoteMember_doc" xml:lang="en-US">February 2020 Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SecuredPromissoryNoteMember" xlink:to="amrh_SecuredPromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SecuredPromissoryNoteMember_doc" xml:lang="en-US">Secured Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FirstNoteAmendmentMember" xlink:to="amrh_FirstNoteAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FirstNoteAmendmentMember_doc" xml:lang="en-US">First Note Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SecondNoteAmendmentMember" xlink:to="amrh_SecondNoteAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SecondNoteAmendmentMember_doc" xml:lang="en-US">Second Note Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AlphaCapitalAnstaltMember" xlink:to="amrh_AlphaCapitalAnstaltMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AlphaCapitalAnstaltMember_doc" xml:lang="en-US">Alpha Capital Anstalt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AggregateExtensionFee" xlink:to="amrh_AggregateExtensionFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AggregateExtensionFee_doc" xml:lang="en-US">Aggregate extension fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AprilTwoThousandNineteenConvertibleNotesMember" xlink:to="amrh_AprilTwoThousandNineteenConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AprilTwoThousandNineteenConvertibleNotesMember_doc" xml:lang="en-US">April 2019 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_NotesPayableMember" xlink:to="amrh_NotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_NotesPayableMember_doc" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AlphaNoteMember" xlink:to="amrh_AlphaNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AlphaNoteMember_doc" xml:lang="en-US">Alpha Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CADMember" xlink:to="amrh_CADMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_CADMember_doc" xml:lang="en-US">CAD [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MeasurementInputSharesMember" xlink:to="amrh_MeasurementInputSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_MeasurementInputSharesMember_doc" xml:lang="en-US">Measurement Input, Number of Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SkincareAssetsMember" xlink:to="amrh_SkincareAssetsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SkincareAssetsMember_doc" xml:lang="en-US">Skincare Assets [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_BusinessAdvisorServicesAgreementMember" xlink:to="amrh_BusinessAdvisorServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_BusinessAdvisorServicesAgreementMember_doc" xml:lang="en-US">Skincare Assets and License Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ConsultantMember" xlink:to="amrh_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ConsultantMember_doc" xml:lang="en-US">Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MrDavidStefanskyMember" xlink:to="amrh_MrDavidStefanskyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_MrDavidStefanskyMember_doc" xml:lang="en-US">Mr. David Stefansky [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_MrHenochCohnMember" xlink:to="amrh_MrHenochCohnMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_MrHenochCohnMember_doc" xml:lang="en-US">Mr Henoch Cohn [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_VendorsMember" xlink:to="amrh_VendorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_VendorsMember_doc" xml:lang="en-US">Vendors [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SeptemberPrivatePlacementMember" xlink:to="amrh_SeptemberPrivatePlacementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SeptemberPrivatePlacementMember_doc" xml:lang="en-US">September Private Placement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_DecemberPrivatePlacementMember" xlink:to="amrh_DecemberPrivatePlacementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_DecemberPrivatePlacementMember_doc" xml:lang="en-US">December Private Placement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FairValueTerm" xlink:to="amrh_FairValueTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FairValueTerm_doc" xml:lang="en-US">Fair value term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_doc" xml:lang="en-US">Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AmalgamationAgreementMember" xlink:to="amrh_AmalgamationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AmalgamationAgreementMember_doc" xml:lang="en-US">Amalgamation Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_EnvericBiosciencesIncMember" xlink:to="amrh_EnvericBiosciencesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_EnvericBiosciencesIncMember_doc" xml:lang="en-US">Enveric Biosciences, Inc. [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AmalgamationAmendmentAgreementMember" xlink:to="amrh_AmalgamationAmendmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AmalgamationAmendmentAgreementMember_doc" xml:lang="en-US">Amalgamation Amendment Agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SeriesBWarrantsMember" xlink:to="amrh_SeriesBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SeriesBWarrantsMember_doc" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SecondAmalgamationAmendmentAgreementMember" xlink:to="amrh_SecondAmalgamationAmendmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_SecondAmalgamationAmendmentAgreementMember_doc" xml:lang="en-US">Second Amalgamation Amendment Agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_TenderAgreementMember" xlink:to="amrh_TenderAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_TenderAgreementMember_doc" xml:lang="en-US">Tender Agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CommonStockBeneficialOwnershipBlockerPercentage" xlink:to="amrh_CommonStockBeneficialOwnershipBlockerPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_CommonStockBeneficialOwnershipBlockerPercentage_doc" xml:lang="en-US">Common stock beneficial ownership blocker, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_OperatingLossCarryforwardsExpirationYear" xlink:to="amrh_OperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_OperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">Operating loss carryforwards, expiration year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_RegisteredDirectOfferingMember" xlink:to="amrh_RegisteredDirectOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_RegisteredDirectOfferingMember_doc" xml:lang="en-US">Registered Direct Offering [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement_doc" xml:lang="en-US">Value of stock issued for private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement_doc" xml:lang="en-US">Number of shares issued for private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne_doc" xml:lang="en-US">Value of stock issued for private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne_doc" xml:lang="en-US">Number of shares issued for private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares" xlink:to="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FinancingAndConversionOfNoteIncludingPalladiumShares_doc" xml:lang="en-US">Alpha financing and conversion of Alpha Note, including Palladium shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" xlink:to="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares_doc" xml:lang="en-US">Alpha financing and conversion of Alpha Note, including Palladium shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" xlink:to="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares_doc" xml:lang="en-US">Exchange of warrants for common shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" xlink:to="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares_doc" xml:lang="en-US">Exchange of warrants for common shares, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" xlink:to="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification_doc" xml:lang="en-US">Common stock issued in conjunction with note payable modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" xlink:to="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification_doc" xml:lang="en-US">Common stock issued in conjunction with note payable modification, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" xlink:to="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock_doc" xml:lang="en-US">Conversion of Series B preferred stock to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" xlink:to="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares_doc" xml:lang="en-US">Conversion of Series B preferred stock to common stock, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueAcquisitionsOne" xlink:to="amrh_StockIssuedDuringPeriodValueAcquisitionsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueAcquisitionsOne_doc" xml:lang="en-US">Merger with Ameri Holdings, Inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne" xlink:to="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesAcquisitionsOne_doc" xml:lang="en-US">Merger with Ameri Holdings, Inc, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedDirectOffering_doc" xml:lang="en-US">January 2021 registered direct offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering_doc" xml:lang="en-US">January 2021 registered direct offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne" xlink:to="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne_doc" xml:lang="en-US">February 2021 registered direct offering,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" xlink:to="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne_doc" xml:lang="en-US">February 2021 registered direct offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ExerciseOfWarrants" xlink:to="amrh_ExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ExerciseOfWarrants_doc" xml:lang="en-US">Exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ExerciseOfWarrantsShares" xlink:to="amrh_ExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_ExerciseOfWarrantsShares_doc" xml:lang="en-US">Exercise of warrants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_InterestExpenses" xlink:to="amrh_InterestExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="amrh_InterestExpenses_doc" xml:lang="en-US">Amount of the cost of borrowed funds accounted for as interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_2_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CAD" xlink:to="currency_CAD_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CAD_2_lbl" xml:lang="en-US">Canada, Dollars</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_2_lbl" xml:lang="en-US">Operating Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_GainsLossesOnInducementExpense" xlink:to="amrh_GainsLossesOnInducementExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_GainsLossesOnInducementExpense_3_lbl" xml:lang="en-US">GainsLossesOnInducementExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_PaymentsForPurchaseOfLicenseAgreement" xlink:to="amrh_PaymentsForPurchaseOfLicenseAgreement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_PaymentsForPurchaseOfLicenseAgreement_3_lbl" xml:lang="en-US">PaymentsForPurchaseOfLicenseAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ProceedsFromIssuanceOfPrivatePlacementOne" xlink:to="amrh_ProceedsFromIssuanceOfPrivatePlacementOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ProceedsFromIssuanceOfPrivatePlacementOne_3_lbl" xml:lang="en-US">ProceedsFromIssuanceOfPrivatePlacementOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_CommonStockIssuedInConjunctionWithNotePayableModification" xlink:to="amrh_CommonStockIssuedInConjunctionWithNotePayableModification_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_CommonStockIssuedInConjunctionWithNotePayableModification_3_lbl" xml:lang="en-US">CommonStockIssuedInConjunctionWithNotePayableModification</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_TenderAgreementDisclosureTextBlock" xlink:to="amrh_TenderAgreementDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_TenderAgreementDisclosureTextBlock_3_lbl" xml:lang="en-US">TenderAgreementDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_2_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_2_lbl" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:to="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>amrh-20210331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: amrh%2D20210331 S%2D4 DFN.xfr; Date: 2021%2D06%2D20T09:09:19Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x8014000A -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ameri100.com/role/DocumentAndEntityInformation" xlink:href="amrh-20210331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/BalanceSheets" xlink:href="amrh-20210331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/BalanceSheetsParenthetical" xlink:href="amrh-20210331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="amrh-20210331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:href="amrh-20210331.xsd#StatementsOfChangesInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/StatementsOfCashFlows" xlink:href="amrh-20210331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/Business" xlink:href="amrh-20210331.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/Liquidity" xlink:href="amrh-20210331.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets" xlink:href="amrh-20210331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengies" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/TenderAgreement" xlink:href="amrh-20210331.xsd#TenderAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes" xlink:href="amrh-20210331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SubsequentEvents" xlink:href="amrh-20210331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsTables" xlink:href="amrh-20210331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxesTables" xlink:href="amrh-20210331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/LiquidityDetailsNarrative" xlink:href="amrh-20210331.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/LiquidityDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#LiquidityDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:href="amrh-20210331.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:href="amrh-20210331.xsd#NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative" xlink:href="amrh-20210331.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#IntangibleAssetsDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:href="amrh-20210331.xsd#IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#CommitmentsAndContingengiesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:href="amrh-20210331.xsd#ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/TenderAgreementDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#TenderAgreementDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#IncomeTaxesDetailsNarrative10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:href="amrh-20210331.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:type="simple" />
    <link:roleRef roleURI="http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k" xlink:href="amrh-20210331.xsd#SubsequentEventsDetailsNarrative10-k" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableExcludingConvertibleNotespayable" xlink:label="loc_amrhNotesPayableExcludingConvertibleNotespayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_amrhNotesPayableExcludingConvertibleNotespayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesNoncurrent" xlink:label="loc_amrhWarrantLiabilitiesNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_amrhWarrantLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InducementExpense" xlink:label="loc_amrhInducementExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_amrhInducementExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InterestExpenses" xlink:label="loc_amrhInterestExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_amrhInterestExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacementOne" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedPrivatePlacementOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedPrivatePlacementOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FinancingAndConversionOfNoteIncludingPalladiumShares" xlink:label="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares" xlink:label="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumSharestoShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFinancingAndConversionOfNoteIncludingPalladiumSharestoShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" xlink:label="loc_amrhStockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="loc_amrhAdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhAdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="loc_amrhAdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhAdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" xlink:label="loc_amrhStockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueAcquisitionsOne" xlink:label="loc_amrhStockIssuedDuringPeriodValueAcquisitionsOne" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueAcquisitionsOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesAcquisitionsOne" xlink:label="loc_amrhStockIssuedDuringPeriodSharesAcquisitionsOne" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesAcquisitionsOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedDirectOffering" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOffering" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOffering" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne" xlink:label="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOfferingOne" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueIssuedDirectOfferingOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne" xlink:label="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOfferingOne" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesIssuedDirectOfferingOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium" xlink:label="loc_us-gaapAdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExerciseOfWarrants" xlink:label="loc_amrhExerciseOfWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExerciseOfWarrantsShares" xlink:label="loc_amrhExerciseOfWarrantsShares" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:label="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AccruedInterest" xlink:label="loc_amrhAccruedInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_amrhAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_GainsLossesOnInducementExpense" xlink:label="loc_amrhGainsLossesOnInducementExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_amrhGainsLossesOnInducementExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentsForPurchaseOfLicenseAgreement" xlink:label="loc_amrhPaymentsForPurchaseOfLicenseAgreement" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_amrhPaymentsForPurchaseOfLicenseAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromWarrantExercise" xlink:label="loc_amrhProceedsFromWarrantExercise" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_amrhProceedsFromWarrantExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromOfferingAndReverseMergerProceeds" xlink:label="loc_amrhProceedsFromOfferingAndReverseMergerProceeds" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_amrhProceedsFromOfferingAndReverseMergerProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ProceedsFromIssuanceOfPrivatePlacementOne" xlink:label="loc_amrhProceedsFromIssuanceOfPrivatePlacementOne" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_amrhProceedsFromIssuanceOfPrivatePlacementOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantsIssuedInConjunctionWithNotesPayable" xlink:label="loc_amrhWarrantsIssuedInConjunctionWithNotesPayable" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_amrhWarrantsIssuedInConjunctionWithNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CommonStockIssuedInConjunctionWithNotePayableModification" xlink:label="loc_amrhCommonStockIssuedInConjunctionWithNotePayableModification" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_amrhCommonStockIssuedInConjunctionWithNotePayableModification" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableIssuedToConsultantForPrepaidServices" xlink:label="loc_amrhNotesPayableIssuedToConsultantForPrepaidServices" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_amrhNotesPayableIssuedToConsultantForPrepaidServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" xlink:label="loc_amrhConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_amrhConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CommonStockIssuedForSkincareLicense" xlink:label="loc_amrhCommonStockIssuedForSkincareLicense" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_amrhCommonStockIssuedForSkincareLicense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/Business" xlink:title="00000007 - Disclosure - Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="loc_us-gaapLiquidationBasisOfAccountingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLiquidationBasisOfAccountingTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable" xlink:title="00000010 - Disclosure - Notes Payable and Convertible Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengies" xlink:title="00000012 - Disclosure - Commitments and Contingengies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="00000013 - Disclosure - Share Capital and Other Equity Instruments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/TenderAgreement" xlink:title="00000014 - Disclosure - Tender Agreement">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementAbstract" xlink:label="loc_amrhTenderAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementDisclosureTextBlock" xlink:label="loc_amrhTenderAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhTenderAgreementAbstract" xlink:to="loc_amrhTenderAgreementDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilityPolicyTextBlock" xlink:label="loc_amrhWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_amrhWarrantLiabilityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OfferingCostsPolicy" xlink:label="loc_amrhOfferingCostsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_amrhOfferingCostsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InitialMeasurementMember" xlink:label="loc_amrhInitialMeasurementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhInitialMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SubsequentMeasurementMember" xlink:label="loc_amrhSubsequentMeasurementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhSubsequentMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_amrhScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_amrhScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables" xlink:title="00000019 - Disclosure - Notes Payable and Convertible Notes Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ScheduleOfAssetsPurchasedTableTextBlock" xlink:label="loc_amrhScheduleOfAssetsPurchasedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_amrhScheduleOfAssetsPurchasedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="00000021 - Disclosure - Share Capital and Other Equity Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaapSummaryOfValuationAllowanceTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfValuationAllowanceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/LiquidityDetailsNarrative" xlink:title="00000023 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OfferingMember" xlink:label="loc_amrhOfferingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WorkingCapital" xlink:label="loc_amrhWorkingCapital" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/LiquidityDetailsNarrative10-k" xlink:title="00000024 - Disclosure - Liquidity (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WorkingCapital" xlink:label="loc_amrhWorkingCapital" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhOptionsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhOptionsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k" xlink:title="00000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_amrhOptionsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_amrhOptionsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesJanuaryWarrantsMember" xlink:label="loc_amrhWarrantLiabilitiesJanuaryWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhWarrantLiabilitiesJanuaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WarrantLiabilitiesFebruaryWarrantsMember" xlink:label="loc_amrhWarrantLiabilitiesFebruaryWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhWarrantLiabilitiesFebruaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails" xlink:title="00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Black Scholes Valuation Models of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InitialMeasurementMember" xlink:label="loc_amrhInitialMeasurementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhInitialMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SubsequentMeasurementMember" xlink:label="loc_amrhSubsequentMeasurementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhSubsequentMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JanuaryWarrantsMember" xlink:label="loc_amrhJanuaryWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhJanuaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryWarrantsMember" xlink:label="loc_amrhFebruaryWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhFebruaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SubsequentMeasurementMember" xlink:label="loc_amrhSubsequentMeasurementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhSubsequentMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JanuaryWarrantsMember" xlink:label="loc_amrhJanuaryWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhJanuaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryWarrantsMember" xlink:label="loc_amrhFebruaryWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_amrhFebruaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" xlink:label="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" xlink:label="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k" xlink:title="00000032 - Disclosure - Notes Payable and Convertible Notes Payable (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MarchTwoThousandNineteenNoteMember" xlink:label="loc_amrhMarchTwoThousandNineteenNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMarchTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JulyTwoThousandNineteenNoteMember" xlink:label="loc_amrhJulyTwoThousandNineteenNoteMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhJulyTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MayTwoThousandNineteenAmendmentMember" xlink:label="loc_amrhMayTwoThousandNineteenAmendmentMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMayTwoThousandNineteenAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberTwoThousandNineteenNoteMember" xlink:label="loc_amrhDecemberTwoThousandNineteenNoteMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhDecemberTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandTwentyNoteMember" xlink:label="loc_amrhFebruaryTwoThousandTwentyNoteMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandTwentyNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecuredPromissoryNoteMember" xlink:label="loc_amrhSecuredPromissoryNoteMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhSecuredPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FirstNoteAmendmentMember" xlink:label="loc_amrhFirstNoteAmendmentMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFirstNoteAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecondNoteAmendmentMember" xlink:label="loc_amrhSecondNoteAmendmentMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhSecondNoteAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FormerExecutiveDirectorMember" xlink:label="loc_amrhFormerExecutiveDirectorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhFormerExecutiveDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_LenderMember" xlink:label="loc_amrhLenderMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhLenderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NoteAgreementMember" xlink:label="loc_amrhNoteAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhNoteAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_EventOfDefaultMember" xlink:label="loc_amrhEventOfDefaultMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_amrhEventOfDefaultMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaCapitalAnstaltMember" xlink:label="loc_amrhAlphaCapitalAnstaltMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_amrhAlphaCapitalAnstaltMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AggregateExtensionFee" xlink:label="loc_amrhAggregateExtensionFee" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_amrhAggregateExtensionFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k" xlink:title="00000033 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Notes Payable and Convertible Notes Payable (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MarchTwoThousandNineteenNoteMember" xlink:label="loc_amrhMarchTwoThousandNineteenNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMarchTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AprilTwoThousandNineteenConvertibleNotesMember" xlink:label="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JulyTwoThousandNineteenNoteMember" xlink:label="loc_amrhJulyTwoThousandNineteenNoteMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhJulyTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberTwoThousandNineteenNoteMember" xlink:label="loc_amrhDecemberTwoThousandNineteenNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhDecemberTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_NotesPayableMember" xlink:label="loc_amrhNotesPayableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k" xlink:title="00000034 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Interest Expense and Amortization of Debt Discount (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AprilTwoThousandNineteenConvertibleNotesMember" xlink:label="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhAprilTwoThousandNineteenConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_JulyTwoThousandNineteenNoteMember" xlink:label="loc_amrhJulyTwoThousandNineteenNoteMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhJulyTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberTwoThousandNineteenNoteMember" xlink:label="loc_amrhDecemberTwoThousandNineteenNoteMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhDecemberTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandTwentyNoteMember" xlink:label="loc_amrhFebruaryTwoThousandTwentyNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandTwentyNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaNoteMember" xlink:label="loc_amrhAlphaNoteMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhAlphaNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaapInterestExpenseDebtExcludingAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebtExcludingAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k" xlink:title="00000035 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Beneficial Conversion Feature and Warrants (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MeasurementInputSharesMember" xlink:label="loc_amrhMeasurementInputSharesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_amrhMeasurementInputSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CADMember" xlink:label="loc_amrhCADMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_amrhCADMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMeasurementInput" xlink:label="loc_us-gaapLongTermDebtMeasurementInput" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaapLongTermDebtFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm" xlink:label="loc_us-gaapLongTermDebtTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000036 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExclusiveLicenseAgreementMember" xlink:label="loc_amrhExclusiveLicenseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhExclusiveLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBiotechIncMember" xlink:label="loc_amrhDiverseBiotechIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_amrhDiverseBiotechIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentOfUpfrontInvestment" xlink:label="loc_amrhPaymentOfUpfrontInvestment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhPaymentOfUpfrontInvestment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k" xlink:title="00000037 - Disclosure - Intangible Assets (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsMember" xlink:label="loc_amrhSkincareAssetsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k" xlink:title="00000038 - Disclosure - Intangible Assets - Schedule of Assets Purchased (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsMember" xlink:label="loc_amrhSkincareAssetsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails" xlink:title="00000039 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsAndLicenseAgreementsMember" xlink:label="loc_amrhSkincareAssetsAndLicenseAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsAndLicenseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBioLicenseAgreementMember" xlink:label="loc_amrhDiverseBioLicenseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhDiverseBioLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k" xlink:title="00000040 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SkincareAssetsAndLicenseAgreementsMember" xlink:label="loc_amrhSkincareAssetsAndLicenseAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_amrhSkincareAssetsAndLicenseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative" xlink:title="00000041 - Disclosure - Commitments and Contingengies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_WardEmploymentAgreementMember" xlink:label="loc_amrhWardEmploymentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhWardEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AnnualPerformanceBonusesPercentage" xlink:label="loc_amrhAnnualPerformanceBonusesPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhAnnualPerformanceBonusesPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k" xlink:title="00000042 - Disclosure - Commitments and Contingengies (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_BusinessAdvisorServicesAgreementMember" xlink:label="loc_amrhBusinessAdvisorServicesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhBusinessAdvisorServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ConsultantMember" xlink:label="loc_amrhConsultantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MrDavidStefanskyMember" xlink:label="loc_amrhMrDavidStefanskyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhMrDavidStefanskyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MrHenochCohnMember" xlink:label="loc_amrhMrHenochCohnMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhMrHenochCohnMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaapCashMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCashMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="00000043 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OfferingMember" xlink:label="loc_amrhOfferingMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_UnamortizedStockOptionExpense" xlink:label="loc_amrhUnamortizedStockOptionExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhUnamortizedStockOptionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_InducementExpense" xlink:label="loc_amrhInducementExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhInducementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k" xlink:title="00000044 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_VendorsMember" xlink:label="loc_amrhVendorsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhVendorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ConsultantMember" xlink:label="loc_amrhConsultantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_amrhConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SeptemberPrivatePlacementMember" xlink:label="loc_amrhSeptemberPrivatePlacementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhSeptemberPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DecemberPrivatePlacementMember" xlink:label="loc_amrhDecemberPrivatePlacementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhDecemberPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandNineteenNoteMember" xlink:label="loc_amrhFebruaryTwoThousandNineteenNoteMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_MarchTwoThousandNineteenNoteMember" xlink:label="loc_amrhMarchTwoThousandNineteenNoteMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhMarchTwoThousandNineteenNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FebruaryTwoThousandTwentyNoteMember" xlink:label="loc_amrhFebruaryTwoThousandTwentyNoteMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_amrhFebruaryTwoThousandTwentyNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD" xlink:label="loc_currencyCAD" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyCAD" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:label="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:label="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhStockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_UnamortizedStockOptionExpense" xlink:label="loc_amrhUnamortizedStockOptionExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhUnamortizedStockOptionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails" xlink:title="00000045 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:label="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k" xlink:title="00000046 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:label="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="00000047 - Disclosure - Share Capital and Other Equity Instruments - Schedule Of Restricted Stock Units and Awards Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:label="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k" xlink:title="00000048 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Fair Value Assumption of Stock Option (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:label="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_FairValueTerm" xlink:label="loc_amrhFairValueTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhFairValueTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails" xlink:title="00000049 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:label="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRighExercisable" xlink:label="loc_amrhClassOfWarrantOrRighExercisable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRighExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:label="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k" xlink:title="00000050 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:label="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRighExercisable" xlink:label="loc_amrhClassOfWarrantOrRighExercisable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRighExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:label="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhClassOfWarrantOrRightWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:label="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/TenderAgreementDetailsNarrative10-k" xlink:title="00000051 - Disclosure - Tender Agreement (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementAbstract" xlink:label="loc_amrhTenderAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amrhTenderAgreementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AlphaCapitalAnstaltMember" xlink:label="loc_amrhAlphaCapitalAnstaltMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_amrhAlphaCapitalAnstaltMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_EnvericBiosciencesIncMember" xlink:label="loc_amrhEnvericBiosciencesIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_amrhEnvericBiosciencesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AmalgamationAgreementMember" xlink:label="loc_amrhAmalgamationAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhAmalgamationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_AmalgamationAmendmentAgreementMember" xlink:label="loc_amrhAmalgamationAmendmentAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhAmalgamationAmendmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SecondAmalgamationAmendmentAgreementMember" xlink:label="loc_amrhSecondAmalgamationAmendmentAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhSecondAmalgamationAmendmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_TenderAgreementMember" xlink:label="loc_amrhTenderAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhTenderAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_SeriesBWarrantsMember" xlink:label="loc_amrhSeriesBWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_amrhSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_CommonStockBeneficialOwnershipBlockerPercentage" xlink:label="loc_amrhCommonStockBeneficialOwnershipBlockerPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhCommonStockBeneficialOwnershipBlockerPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k" xlink:title="00000052 - Disclosure - Income Taxes (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaapCanadaRevenueAgencyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCanadaRevenueAgencyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_amrhOperatingLossCarryforwardsExpirationYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhOperatingLossCarryforwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:title="00000053 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k" xlink:title="00000054 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k" xlink:title="00000055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k" xlink:title="00000056 - Disclosure - Subsequent Events (Details Narrative) (10-K)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_RegisteredDirectOfferingMember" xlink:label="loc_amrhRegisteredDirectOfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_amrhRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_ExclusiveLicenseAgreementMember" xlink:label="loc_amrhExclusiveLicenseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_amrhExclusiveLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_DiverseBiotechIncMember" xlink:label="loc_amrhDiverseBiotechIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_amrhDiverseBiotechIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="amrh-20210331.xsd#amrh_PaymentOfUpfrontInvestment" xlink:label="loc_amrhPaymentOfUpfrontInvestment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_amrhPaymentOfUpfrontInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359598501608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592280872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 22,657,150<span></span>
</td>
<td class="nump">$ 1,578,460<span></span>
</td>
<td class="nump">$ 43,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">767,298<span></span>
</td>
<td class="nump">700,710<span></span>
</td>
<td class="nump">65,075<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">23,424,448<span></span>
</td>
<td class="nump">2,279,170<span></span>
</td>
<td class="nump">108,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,362,177<span></span>
</td>
<td class="nump">1,817,721<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,786,625<span></span>
</td>
<td class="nump">4,096,891<span></span>
</td>
<td class="nump">108,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">626,947<span></span>
</td>
<td class="nump">681,250<span></span>
</td>
<td class="nump">1,157,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Advance from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_NotesPayableExcludingConvertibleNotespayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">446,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">293,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total liabilities</a></td>
<td class="nump">626,947<span></span>
</td>
<td class="nump">681,250<span></span>
</td>
<td class="nump">1,920,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_WarrantLiabilitiesNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">6,168,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,794,947<span></span>
</td>
<td class="nump">681,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">32,754<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">194,499<span></span>
</td>
<td class="nump">100,951<span></span>
</td>
<td class="nump">53,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">33,952,988<span></span>
</td>
<td class="nump">15,222,770<span></span>
</td>
<td class="nump">3,039,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(15,010,268)<span></span>
</td>
<td class="num">(11,759,557)<span></span>
</td>
<td class="num">(4,894,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(145,541)<span></span>
</td>
<td class="num">(181,277)<span></span>
</td>
<td class="num">(11,622)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">18,991,678<span></span>
</td>
<td class="nump">3,415,641<span></span>
</td>
<td class="num">(1,811,601)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 25,786,625<span></span>
</td>
<td class="nump">$ 4,096,891<span></span>
</td>
<td class="nump">$ 108,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_NotesPayableExcludingConvertibleNotespayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable excluding convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_NotesPayableExcludingConvertibleNotespayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_WarrantLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_WarrantLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592262344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,275,407<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,275,407<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">19,449,975<span></span>
</td>
<td class="nump">10,095,109<span></span>
</td>
<td class="nump">5,311,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">19,449,975<span></span>
</td>
<td class="nump">10,095,109<span></span>
</td>
<td class="nump">5,311,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359591686040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 6,607,045<span></span>
</td>
<td class="nump">$ 836,702<span></span>
</td>
<td class="nump">$ 5,443,234<span></span>
</td>
<td class="nump">$ 2,296,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">157,952<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">174,083<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,764,997<span></span>
</td>
<td class="nump">836,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,764,997)<span></span>
</td>
<td class="num">(836,702)<span></span>
</td>
<td class="num">(5,617,317)<span></span>
</td>
<td class="num">(2,296,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">233,240<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_InducementExpense', window );">Inducement expense</a></td>
<td class="num">(298,714)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">802,109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">3,813,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_InterestExpenses', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(261,759)<span></span>
</td>
<td class="nump">445,250<span></span>
</td>
<td class="nump">81,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">3,514,286<span></span>
</td>
<td class="num">(261,759)<span></span>
</td>
<td class="nump">1,247,359<span></span>
</td>
<td class="nump">114,139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,250,711)<span></span>
</td>
<td class="num">(1,098,461)<span></span>
</td>
<td class="num">(6,864,676)<span></span>
</td>
<td class="num">(2,410,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">35,736<span></span>
</td>
<td class="num">(12,698)<span></span>
</td>
<td class="num">(169,655)<span></span>
</td>
<td class="num">(6,667)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Comprehensive loss</a></td>
<td class="num">$ (3,214,975)<span></span>
</td>
<td class="num">$ (1,111,159)<span></span>
</td>
<td class="num">$ (7,034,331)<span></span>
</td>
<td class="num">$ (2,417,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic and diluted</a></td>
<td class="nump">16,220,661<span></span>
</td>
<td class="nump">5,653,820<span></span>
</td>
<td class="nump">5,753,598<span></span>
</td>
<td class="nump">5,287,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_InducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inducement expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_InducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_InterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_InterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359586768232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Series B Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,625<span></span>
</td>
<td class="nump">$ 52,620<span></span>
</td>
<td class="nump">$ 2,368,464<span></span>
</td>
<td class="num">$ (2,484,208)<span></span>
</td>
<td class="num">$ (4,955)<span></span>
</td>
<td class="num">$ (65,454)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">262,500<span></span>
</td>
<td class="nump">5,262,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
<td class="nump">88,084<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">88,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with note extension</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">22,153<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in connection with note extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">535,587<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">535,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in conjunction with notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange gain/loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,667)<span></span>
</td>
<td class="num">(6,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,410,673)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,410,673)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 2,625<span></span>
</td>
<td class="nump">$ 53,114<span></span>
</td>
<td class="nump">3,039,163<span></span>
</td>
<td class="num">(4,894,881)<span></span>
</td>
<td class="num">(11,622)<span></span>
</td>
<td class="num">(1,811,601)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">262,500<span></span>
</td>
<td class="nump">5,311,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable', window );">Common stock issued for accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">172,623<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">173,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares', window );">Common stock issued for accounts payable, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">85,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in conjunction with notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature issued with note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,851<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange gain/loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,698)<span></span>
</td>
<td class="num">(12,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,098,461)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,098,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,598<span></span>
</td>
<td class="nump">3,261,786<span></span>
</td>
<td class="num">(5,993,342)<span></span>
</td>
<td class="num">(24,320)<span></span>
</td>
<td class="num">(2,699,278)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,659,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 2,625<span></span>
</td>
<td class="nump">$ 53,114<span></span>
</td>
<td class="nump">3,039,163<span></span>
</td>
<td class="num">(4,894,881)<span></span>
</td>
<td class="num">(11,622)<span></span>
</td>
<td class="num">(1,811,601)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">262,500<span></span>
</td>
<td class="nump">5,311,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement', window );">September 2020 private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">227,131<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">227,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement', window );">September 2020 private placement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne', window );">December 2020 private placement</a></td>
<td class="nump">$ 2,212<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">258,288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">260,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne', window );">December 2020 private placement, shares</a></td>
<td class="nump">221,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition of Tikkun Pharma IP</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,720<span></span>
</td>
<td class="nump">1,894,826<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,900,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquisition of Tikkun Pharma IP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FinancingAndConversionOfNoteIncludingPalladiumShares', window );">Alpha financing and conversion of Alpha Note, including Palladium shares</a></td>
<td class="nump">$ 30,417<span></span>
</td>
<td class="nump">$ 4,030<span></span>
</td>
<td class="nump">4,781,742<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,816,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares', window );">Alpha financing and conversion of Alpha Note, including Palladium shares, shares</a></td>
<td class="nump">3,041,682<span></span>
</td>
<td class="nump">402,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares', window );">Exchange of warrants for common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,301<span></span>
</td>
<td class="nump">838,577<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">841,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares', window );">Exchange of warrants for common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification', window );">Common stock issued in conjunction with note payable modification</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">101,497<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">101,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification', window );">Common stock issued in conjunction with note payable modification, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock option expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,977,155<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,977,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock', window );">Conversion of Series B preferred stock to common stock</a></td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares', window );">Conversion of Series B preferred stock to common stock, shares</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueAcquisitionsOne', window );">Merger with Ameri Holdings, Inc.</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22,241<span></span>
</td>
<td class="nump">627,759<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesAcquisitionsOne', window );">Merger with Ameri Holdings, Inc, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,224,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,130<span></span>
</td>
<td class="nump">674,439<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">679,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series B preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable', window );">Common stock issued for accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,330<span></span>
</td>
<td class="nump">752,193<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">756,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares', window );">Common stock issued for accounts payable, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">433,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in conjunction with notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature issued with note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,851<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange gain/loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(169,655)<span></span>
</td>
<td class="num">(169,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,864,676)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,864,676)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 32,754<span></span>
</td>
<td class="nump">$ 100,951<span></span>
</td>
<td class="nump">15,222,770<span></span>
</td>
<td class="num">(11,759,557)<span></span>
</td>
<td class="num">(181,277)<span></span>
</td>
<td class="nump">3,415,641<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">3,275,407<span></span>
</td>
<td class="nump">10,095,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueIssuedDirectOffering', window );">January 2021 registered direct offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22,213<span></span>
</td>
<td class="nump">4,594,874<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,617,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering', window );">January 2021 registered direct offering, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,221,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne', window );">February 2021 registered direct offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 30,070<span></span>
</td>
<td class="nump">6,986,331<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,016,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne', window );">February 2021 registered direct offering, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,007,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,591,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,591,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium', window );">Induced conversion of stock options into restricted stock awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">298,714<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">298,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B preferred stock</a></td>
<td class="num">$ (32,754)<span></span>
</td>
<td class="nump">$ 32,754<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series B preferred stock, shares</a></td>
<td class="num">(3,275,407)<span></span>
</td>
<td class="nump">3,275,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,511<span></span>
</td>
<td class="nump">3,258,734<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,267,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ExerciseOfWarrantsShares', window );">Exercise of warrants, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">851,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange gain/loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,736<span></span>
</td>
<td class="nump">35,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,250,711)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,250,711)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 194,499<span></span>
</td>
<td class="nump">$ 33,952,988<span></span>
</td>
<td class="num">$ (15,010,268)<span></span>
</td>
<td class="num">$ (145,541)<span></span>
</td>
<td class="nump">$ 18,991,678<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19,449,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued in conjunction with note payable modification, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_AdjustmentsToAdditionalPaidInCapitaShareslCommonStockIssuedInConjunctionWithNotePayableModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued in conjunction with note payable modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_FinancingAndConversionOfNoteIncludingPalladiumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alpha financing and conversion of Alpha Note, including Palladium shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_FinancingAndConversionOfNoteIncludingPalladiumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alpha financing and conversion of Alpha Note, including Palladium shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_FinancingAndConversionOfNoteIncludingPalladiumSharestoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesAcquisitionsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger with Ameri Holdings, Inc, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesAcquisitionsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for accounts payable, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Series B preferred stock to common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesConversionOfSeriesBPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange of warrants for common shares, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesExchangeOfWarrantsForCommonSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>January 2021 registered direct offering, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesIssuedDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>February 2021 registered direct offering, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesIssuedDirectOfferingOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesIssuedPrivatePlacementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueAcquisitionsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger with Ameri Holdings, Inc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueAcquisitionsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Series B preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange of warrants for common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueIssuedDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>January 2021 registered direct offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueIssuedDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>February 2021 registered direct offering,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueIssuedDirectOfferingOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueIssuedPrivatePlacementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid-in capital (APIC) from recognition of substantial premium at which convertible debt instrument is issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359587508424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,250,711)<span></span>
</td>
<td class="num">$ (1,098,461)<span></span>
</td>
<td class="num">$ (6,864,676)<span></span>
</td>
<td class="num">$ (2,410,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">233,240<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_AccruedInterest', window );">Accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,519<span></span>
</td>
<td class="nump">156,619<span></span>
</td>
<td class="nump">13,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(3,813,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,631<span></span>
</td>
<td class="nump">68,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,591,565<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,977,155<span></span>
</td>
<td class="nump">624,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_GainsLossesOnInducementExpense', window );">Inducement expense</a></td>
<td class="nump">298,714<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">802,109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">136,640<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120,872<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(66,208)<span></span>
</td>
<td class="num">(49,588)<span></span>
</td>
<td class="num">(636,497)<span></span>
</td>
<td class="nump">104,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(59,278)<span></span>
</td>
<td class="num">(7,632)<span></span>
</td>
<td class="nump">267,002<span></span>
</td>
<td class="nump">919,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,162,278)<span></span>
</td>
<td class="num">(893,922)<span></span>
</td>
<td class="num">(3,888,785)<span></span>
</td>
<td class="num">(647,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_PaymentsForPurchaseOfLicenseAgreement', window );">Purchase of Tikkun Pharma license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,143)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of license agreement</a></td>
<td class="num">(675,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(675,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44,143)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of offering costs</a></td>
<td class="nump">21,614,488<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,319,910<span></span>
</td>
<td class="nump">1,812,410<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(157,714)<span></span>
</td>
<td class="num">(191,640)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ProceedsFromWarrantExercise', window );">Proceeds from warrant exercises</a></td>
<td class="nump">3,267,245<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ProceedsFromOfferingAndReverseMergerProceeds', window );">Offering and Reverse Merger proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,372,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">September 2020 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ProceedsFromIssuanceOfPrivatePlacementOne', window );">December 2020 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,881,733<span></span>
</td>
<td class="nump">1,212,196<span></span>
</td>
<td class="nump">5,531,270<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign exchange rate on cash</a></td>
<td class="nump">34,235<span></span>
</td>
<td class="num">(86,677)<span></span>
</td>
<td class="num">(63,596)<span></span>
</td>
<td class="nump">17,903<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">21,078,690<span></span>
</td>
<td class="nump">231,597<span></span>
</td>
<td class="nump">1,534,746<span></span>
</td>
<td class="num">(69,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash - beginning of period</a></td>
<td class="nump">1,578,460<span></span>
</td>
<td class="nump">43,714<span></span>
</td>
<td class="nump">43,714<span></span>
</td>
<td class="nump">113,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash - end of period</a></td>
<td class="nump">22,657,150<span></span>
</td>
<td class="nump">275,311<span></span>
</td>
<td class="nump">1,578,460<span></span>
</td>
<td class="nump">43,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature issued with note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_WarrantsIssuedInConjunctionWithNotesPayable', window );">Warrants issued in conjunction with notes payable issuances</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,851<span></span>
</td>
<td class="nump">32,149<span></span>
</td>
<td class="nump">24,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Shares of common stock issued for note payable extensions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">32,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares of common stock issued for accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 173,482<span></span>
</td>
<td class="nump">756,523<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_CommonStockIssuedInConjunctionWithNotePayableModification', window );">Common stock issued in conjunction with note payable modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,713<span></span>
</td>
<td class="nump">22,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_NotesPayableIssuedToConsultantForPrepaidServices', window );">Notes payable issued to consultant for prepaid services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock', window );">Conversion of related party advances and notes payable into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">679,569<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_CommonStockIssuedForSkincareLicense', window );">Common stock issued for skincare license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,546<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_CommonStockIssuedForSkincareLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for skincare license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_CommonStockIssuedForSkincareLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_CommonStockIssuedInConjunctionWithNotePayableModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued in conjunction with note payable modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_CommonStockIssuedInConjunctionWithNotePayableModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of related party advances and notes payable into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_GainsLossesOnInducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inducement expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_GainsLossesOnInducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_NotesPayableIssuedToConsultantForPrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable issued to consultant for prepaid services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_NotesPayableIssuedToConsultantForPrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_PaymentsForPurchaseOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of Tikkun Pharma license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_PaymentsForPurchaseOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ProceedsFromIssuanceOfPrivatePlacementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ProceedsFromIssuanceOfPrivatePlacementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ProceedsFromOfferingAndReverseMergerProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering and Reverse Merger proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ProceedsFromOfferingAndReverseMergerProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ProceedsFromWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ProceedsFromWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_WarrantsIssuedInConjunctionWithNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in conjunction with notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_WarrantsIssuedInConjunctionWithNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359597235576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;<font style="font-variant: small-caps; text-transform: uppercase">1
- BUSINESS</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 111pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nature of operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Enveric Biosciences, Inc. (&#8220;Enveric Biosciences,
Inc.&#8221; &#8220;Enveric&#8221; or the &#8220;Company&#8221;) (formerly known as Ameri Holdings, Inc.) (&#8220;Ameri&#8221;) is a pharmaceutical
company developing innovative, evidence-based cannabinoid medicines. The head office of the Company is located in Naples, Florida.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2020, the Company entered into an Amalgamation
Agreement (as amended on May 6, 2020), (the &#8220;Amalgamation Agreement&#8221;) with Jay Pharma Merger Sub, Inc., a company organized
under the laws of Canada and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), Jay Pharma Inc., a company organized
under the laws of Canada (&#8220;Jay Pharma&#8221;), Jay Pharma ExchangeCo., Inc. a company organized under the laws of British Columbia
and a wholly owned subsidiary of the Company (&#8220;ExchangeCo&#8221;), and Barry Kostiner, as the Company Representative, which provided
that, among other things, Merger Sub and Jay Pharma would be amalgamated and would continue as one corporation (&#8220;Amalco&#8221;),
with Amalco continuing as a direct wholly owned subsidiary of ExchangeCo and an indirect wholly owned subsidiary of Ameri, on the terms
and conditions set forth in the Amalgamation Agreement. On August 12, 2020, the Company, Jay Pharma and certain other signatories thereto
entered into a tender agreement (the &#8220;Tender Agreement&#8221;), which provided that, among other things, Ameri would make a tender
offer (the &#8220;Offer&#8221;) to purchase all of the outstanding common shares of Jay Pharma for the number of shares of Enveric common
stock equal to the exchange ratio set forth in the Tender Agreement, and Jay Pharma would become a wholly-owned subsidiary of Ameri, on
the terms and conditions set forth in the Tender Agreement. The Tender Agreement terminated and replaced in its entirety the Amalgamation
Agreement. On December 30, 2020, the Company, Jay Pharma, Merger Sub, and ExchangeCo&#160;completed&#160;the&#160;Offer&#160;and Jay Pharma
became a wholly owned subsidiary of the Company. The transaction was treated as a reverse acquisition and recapitalization and accordingly,
the historical financial statements prior to the date of the Business Combination in these unaudited condensed consolidated financial
statements are those of Jay Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="text-transform: uppercase"><b><i>COVID-19</i></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: -35.95pt"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2020 and continuing into 2021, the world has
been, and continues to be, impacted by the novel coronavirus (COVID-19) pandemic. COVID-19 and measures to prevent its spread impacted
our business in a number of ways. The impact of these disruptions and the extent of their adverse impact on our financial and operating
results will be dictated by the length of time that such disruptions continue, which will, in turn, depend on the currently unknowable
duration and severity of the impacts of COVID-19, and among other things, the impact of governmental actions imposed in response to COVID-19
and individuals&#8217; and companies&#8217; risk tolerance regarding health matters going forward and developing strain mutations.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;<font style="font-variant: small-caps; text-transform: uppercase">1
- BUSINESS</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nature of operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Enveric Biosciences, Inc. (&#8220;Enveric Biosciences, Inc.,&#8221; &#8220;Enveric&#8221; or the &#8220;Company&#8221;) (formerly known as Ameri Holdings, Inc.) (&#8220;Ameri&#8221;) is a pharmaceutical company developing
innovative, evidence-based cannabinoid medicines. The head office of the Company is located in Naples, Florida.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2020, the Company entered into
an Amalgamation Agreement (as amended on May 6, 2020), (the &#8220;Amalgamation Agreement&#8221;) with Jay Pharma Merger Sub, Inc.,
a company organized under the laws of Canada and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), Jay Pharma
Inc., a company organized under the laws of Canada (&#8220;Jay Pharma&#8221;), Jay Pharma ExchangeCo., Inc. a company organized
under the laws of British Columbia and a wholly owned subsidiary of the Company (&#8220;ExchangeCo&#8221;), and Barry Kostiner,
as the Company Representative, which provided that, among other things, Merger Sub and Jay Pharma would be amalgamated and would
continue as one corporation (&#8220;Amalco&#8221;), with Amalco continuing as a direct wholly owned subsidiary of ExchangeCo and
an indirect wholly owned subsidiary of Ameri, on the terms and conditions set forth in the Amalgamation Agreement. On August 12,
2020, the Company, Jay Pharma and certain other signatories thereto entered into a tender agreement (the &#8220;Tender Agreement&#8221;),
which provided that, among other things, Ameri would make a tender offer (the &#8220;Offer&#8221;) to purchase all of the outstanding
common shares of Jay Pharma for the number of shares of Enveric common stock equal to the exchange ratio set forth in the Tender
Agreement, and Jay Pharma would become a wholly-owned subsidiary of Ameri, on the terms and conditions set forth in the Tender
Agreement. The Tender Agreement terminated and replaced in its entirety the Amalgamation Agreement. On December 30, 2020, the Company,
Jay Pharma, Merger Sub, and ExchangeCo consummated the Tender Agreement and Jay Pharma became a wholly owned subsidiary of the
Company. The transaction was treated as a reverse acquisition and recapitalization and accordingly, the historical financial statements
prior to the date of the Business Combination in these consolidated financial statements are those of Jay Pharma. The transaction
is further described in Note 7.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="text-transform: uppercase"><i>COVID-19</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, a novel strain of coronavirus,
COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the
United States. As the COVID-19 continues to spread in the United States, the Company may experience disruptions that could severely
impact the Company. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact the Company&#8217;s
business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate
geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States
and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States to
contain and treat the disease. The Company is in process of monitoring COVID-19&#8217;s potential impact on the Company&#8217;s
operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359597222776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"><font style="font-variant: small-caps; text-transform: uppercase"><b>NOTE
2 &#8211; LIQUIDITY</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has incurred continuing losses
from its operations and as of December 31, 2020, had an accumulated deficit of $11,759,557 and working capital of $1,597,920. Since
inception, the Company&#8217;s operations have been funded principally through the issuance of debt and equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 14, 2021, the Company completed
a registered direct offering of 2,221,458 shares of common stock at approximately $4.50 per share for gross proceeds of approximately
$10,000,000. On February 11, 2021, the Company completed a registered direct offering of 3,007,026 shares of common stock for gross
proceeds of approximately $12.8 million. As of March&#160;30,&#160;2021, the Company had cash on hand of approximately $22.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that, as a result of
these transactions, it currently has sufficient cash and financing commitments to meet its funding requirements.&#160;Accordingly,
management has since reevaluated the Company&#8217;s liquidity and financial condition and determined that sufficient capital
exists to sustain operations through one year from the issuance of these financial statements and therefore substantial doubt
has been alleviated.&#160;Notwithstanding, the Company expects that it will need to raise additional financing to accomplish its
development plan over the next several years. The Company&#160;will require&#160;additional funding through debt or equity financing
in the future. If the Company is unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope
of its planned development, which could&#160;impact&#160;its financial condition and operating results.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593148824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-variant: small-caps; text-transform: uppercase"><b>Note
2 &#8211; SUMMARY OF Significant Accounting Policies</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S.
GAAP&#8221;) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. Management&#8217;s opinion is that all adjustments (consisting
of normal accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March
31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited condensed
consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December
31, 2020 and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on April 1, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the
date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement
uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant
areas requiring management&#8217;s estimates and assumptions include determining the fair value of transactions involving common stock
and the valuation of stock-based compensation. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Foreign Currency Translation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is the United
States Dollar. The financial statements of companies located outside of the U.S. are measured in their functional currency, which is the
local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are translated using public
exchange rates at the balance sheet date. Income and expense items are translated using average monthly exchange rates. Shareholders&#8217;
equity accounts and non-monetary assets are translated at their historical exchange rates. Translation adjustments are included in accumulated
other comprehensive loss in the accompanying balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash and cash equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of
March 31, 2021 and December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Warrant Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for warrants for shares of the
Company&#8217;s common stock that are not indexed to its own stock as liabilities at fair value on the balance sheet. Such warrants are
subject to remeasurement at each balance sheet date and any change in fair value is recognized as a component of other expense on the
statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise
or expiration of such common stock warrants. At that time, the portion of the warrant liability related to such common stock warrants
will be reclassified to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Offering Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company allocates offering costs to the different
components of the capital raise on a pro rata basis. Any offering costs allocated to common stock are charged directly to additional paid-in
capital. Any offering costs allocated to warrant liabilities are charged to general and administrative expenses on the Company&#8217;s
statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Loss per Share </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is computed by dividing net
loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed using
the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common
shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using the treasury stock method)
and convertible notes. The computation of basic net loss per share for the three months ended March 31, 2021 and 2020 excludes potentially
dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully diluted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Potentially dilutive securities outlined in the table
below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the three months ended March&#160;31,&#160;2021</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the three months ended March&#160;31,&#160;2020</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Warrants to purchase shares of common stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">5,979,611</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">1,504,593</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Convertible notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">380,920</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Restricted stock units</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,279,284</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Restricted stock awards</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">70,986</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Options to purchase shares of common stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">369,361</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,604,348</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total potentially dilutive securities</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,699,242</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,489,861</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the
Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository
insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed
to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value Measurement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows Accounting Standards Codification
(&#8220;ASC&#8221;) 820&#8211;10 &#8220;Fair Value Measurement&#8221; of the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;)
Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial
instruments. ASC 820&#8211;10 establishes a framework for measuring fair value and expands disclosures about fair value measurements.
To increase consistency and comparability in fair value measurements and related disclosures, ASC 820&#8211;10 establishes a fair value
hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The three (3) levels of fair value hierarchy defined
by ASC 820&#8211;10 are described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 62px; text-align: justify"><font style="font-size: 10pt"><i>Level 1</i></font></td>
    <td style="width: 10px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><i>Level 2</i></font></td>
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><i>Level 3</i></font></td>
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial assets or liabilities are considered Level
3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one
significant model assumption or input is unobservable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy gives the highest priority
to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If
the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is
based on the lowest level input that is significant to the fair value measurement of the instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s financial
assets and liabilities, such as cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their
fair values due to the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses Level 3 of the fair value hierarchy
to measure the fair value of its warrant liabilities. The Company revalues such liabilities at every reporting period and recognizes gains
or losses as change in fair value of warrant liabilities in the condensed consolidated statements of operations that are attributable
to the change in the fair value of the warrant liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides the financial liabilities
measured on a recurring basis and reported at fair value on the balance sheet as of March 31, 2021 and indicates the fair value hierarchy
of the valuation inputs the Company utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Level</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2021</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font-size: 10pt">Warrant liabilities &#8211; January Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">3</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">3,164,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Warrant liabilities &#8211; February Warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">3</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,004,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Fair value as of March 31, 2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6,168,000</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had no assets or liabilities measured
at fair value at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Both the January and February Warrants are classified
as Level 3, for which there is no current market for these securities such as the determination of fair value requires significant judgment
or estimation. Changes in fair value measurement categorized within Level 3 of the fair value hierarchy are analyzed each period based
on changes in estimates or assumptions and recorded as appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Initial Measurement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company established the initial fair value of
its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes valuation model in order to determine their
value. The key inputs into the Black Scholes valuation model for the initial valuations are below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>January Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>February Warrants</b> &#160;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><i>January 13, 2021</i></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><i>February 12, 2021</i></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><font style="font-size: 10pt">Term (years)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Stock price</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.21</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.62</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercise price</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.95</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.95</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84.7</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84.7</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Risk free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.5</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.5</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Number of shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,821,514</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,714,005</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Value (per share)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.00</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Subsequent measurement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the changes in fair value
of the warrant liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>January Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>February Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total Warrant Liability</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Fair value as of December 31, 2020</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 47%"><font style="font-size: 10pt">Initial value of warrant liability</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">4,846,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">5,135,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">9,981,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Change in fair value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,682,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,131,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,813,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Fair value as of March 31, 2021</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,164,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,004,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,168,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key inputs into the Black Scholes valuation model
for the Level 3 valuations as of March 31, 2021 are below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>January Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>February Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font-size: 10pt">Term (years)</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">4.8</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">4.9</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Stock price</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.07</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.07</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercise price</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.95</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.95</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84.7</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84.7</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Risk free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.9</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Number of shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,821,514</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,714,005</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Value (per share)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.74</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.75</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued ASU No. 2019-12, Income Taxes (Topic 740: Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;),
which removes certain exceptions to the general principles in Topic 740. ASU 2019-12 is effective for the fiscal years beginning after
December 15, 2020, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10, &#8220;Codification
Improvements.&#8221; The new accounting rules improve the consistency of the Codification by including all disclosure guidance in the
appropriate Disclosure Section (Section 50) that had only been included in the Other Presentation Matters Section (Section 45) of the
Codification. Additionally, the new rules also clarify guidance across various topics including defined benefit plans, foreign currency
transactions, and interest expense. The new accounting rules were effective for the Company in the first quarter of 2021. The adoption
of the new accounting rules did not have a material impact on the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings
Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718),
and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications
or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and
reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective
for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption
permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until
October 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Subsequent Events</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as described in these
financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the financial
statements.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-indent: -35.95pt"><font style="font-variant: small-caps; text-transform: uppercase"><b>Note
3 &#8211; SUMMARY OF Significant Accounting Policies</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance and in conformity with the accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;) and the applicable rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding consolidated
financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the
date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement
uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant
areas requiring management&#8217;s estimates and assumptions include determining the fair value of transactions involving common stock
and the valuation of stock-based compensation. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Foreign Currency Translation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is the United
States dollar. The financial statements of companies located outside of the U.S. are measured in their functional currency, which is the
local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are translated using public
exchange rates at the balance sheet date. Income and expense items are translated using average monthly exchange rates. Shareholders&#8217;
equity accounts and non-monetary assets are translated at their historical exchange rates. Translation adjustments are included in accumulated
other comprehensive loss in the accompanying balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash and cash equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of
December 31, 2020 and December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Intangibles</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has finite-lived intangible assets. Finite-lived
intangible assets are amortized over their estimated useful lives. Research and development costs are expensed as incurred. Following
initial recognition of the finite-lived intangible asset, the asset is carried at cost less any accumulated amortization. Amortization
of the asset begins when the asset is available for use. Amortization is recorded in general and administrative expenses on the Company&#8217;s
consolidated statement of operations. The Company periodically reviews its owned intangible assets for recoverability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Impairment of Long Term Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the carrying value of long-lived
assets subject to amortization whenever events or changes in circumstances indicate that an impairment may exist. An impairment charge
is recognized when the asset&#8217;s carrying value exceeds its net undiscounted future cash flows and its fair market value. The amount
of the charge is the difference between the asset&#8217;s carrying value and fair market value.<b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 25, 2016, FASB issued ASU 2016-02, Leases
(Topic 842). This update will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for
the rights and obligations created by those leases. The new guidance will also require additional disclosures about the amount, timing
and uncertainty of cash flows arising from leases. On January 1, 2020, the Company adopted this ASU, which did not have a material impact
on the Company&#8217;s financial position and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes an asset and liability approach
for financial accounting and reporting for income taxes. The provision for income taxes is based upon income or loss after adjustment
for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects
of differences between the financial reporting and tax basis of the Company&#8217;s assets and liabilities at the enacted tax rates in
effect for the years in which the differences are expected to reverse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the recoverability of deferred
tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will
not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause
changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate provisions for income taxes have been made.
If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221;
is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards.
As of December 31, 2020 and December 31, 2019, no liability for unrecognized tax benefits was required to be recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s policy for recording interest
and penalties associated with tax audits is to record such items as a component of operating expenses. There were no amounts accrued for
penalties and interest for the years ended December 31, 2020 and 2019. The Company does not expect its uncertain tax positions to change
during the next twelve months. Management is currently unaware of any issues under review that could result in significant payments, accruals
or material deviations from its position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has identified its United States and Canadian
federal tax return, its state and provincial tax returns in Florida and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The
Company is in the process of filing its corporate tax returns for the years ended December 31, 2020 and December 31, 2019. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows Accounting Standards Codification
(&#8220;ASC&#8221;) 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of stock-based awards under ASC 718. The estimated fair value is amortized
as a charged to earnings on a straight-line basis depending on the terms and conditions of the award, and the nature of the relationship
of the recipient of the award to the Company. The Company records the grant date fair value in line with the period over which it was
earned. For employees and consultants, this is typically considered to be the vesting period of the award. The Company estimates the expected
forfeitures and updates the valuation accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is computed by dividing net
loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed using
the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common
shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using the treasury stock method)
and convertible notes. The computation of basic net loss per share for the years ended December 31, 2020 and 2019 excludes potentially
dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully diluted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Potentially dilutive securities outlined in the table
below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2019</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Warrants to purchase shares of common stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">3,251,406</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">303,891</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Convertible notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">55,306</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Series B Preferred Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,275,407</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">262,500</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Options to purchase shares of common stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">929,765</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">797,373</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total potentially dilutive securities</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,456,578</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,419,070</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the
Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository
insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed
to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Fair Value</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying value of the Company&#8217;s financial
instruments, including cash and accounts payable, notes payable and convertible notes payable, approximate fair value because of the short-term
nature of such financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Subsequent Events</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as described in these
financial statements, the Company did not identify any</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">subsequent events that would have required adjustment
to or disclosure in the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359596966632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable and Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable and Convertible Notes Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8211; NOTES PAYABLE AND CONVERTIBLE
NOTES PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2020 the Company had no notes payable or convertible
notes payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2019, the Company&#8217;s notes payable and convertible
notes payable consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Discount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 48%"><font style="font: 10pt Times New Roman, Times, Serif">February 2019 Note</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">April 2019 Convertible Notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,079</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">293,921</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">July 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">191,640</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,700</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">188,940</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">December 2019 Note</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,525</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">41,475</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">751,640</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(11,304</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">740,336</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Notes payable</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">451,640</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(5,225</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">446,415</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Convertible notes payable</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,079</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">293,921</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2020 and 2019,
interest expense and amortization of debt discount consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the Year Ended December 31,</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Interest Expense</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Amortization of Debt Discount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Interest Expense</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Amortization of Debt Discount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 34%"><font style="font: 10pt Times New Roman, Times, Serif">February 2019 Note</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,840</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,840</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">April 2019 Convertible Notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,970</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,842</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19,812</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,370</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17,142</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">30,512</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">July 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">53,342</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,704</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">98,046</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43,836</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43,836</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">December 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,427</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,427</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,475</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,475</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">February 2020 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,545</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,912</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">53,457</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Alpha Note</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">86,762</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">181,906</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">268,668</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">156,619</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">288,631</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">445,250</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,370</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,453</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">81,823</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notes Payable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 7, 2019, the Company received $60,000
in exchange for a promissory note with a director for $66,000, including an original issue discount of $6,000 (the &#8220;February
2019 Note&#8221;). The note had no stated interest rate and was due on May 8, 2019. The Company amortized the full $6,000 original
issue discount in the statement of operations and comprehensive loss through December 31, 2019. On July 21, 2020, the Company converted
the February 2019 Note into common stock, as further described in Note 6.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 1, 2019, the Company entered into
a consulting agreement with its former executive director. In connection with the consulting agreement, on March 5, 2019, the Company
issued a note payable to its former executive director for $150,000 (the &#8220;March 2019 Note&#8221;). The note had no interest
and was due and payable on March 4, 2020. The consulting agreement expired on February 1, 2020. On July 21, 2020, the Company converted
the March 2019 Note into common stock, as further described in Note 6.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2019, the Company entered into a
note agreement (the &#8220;July 2019 Note&#8221;) with a limited liability company (the &#8220;Lender&#8221;). One of the principals
of the Lender is the brother of a former member of the Company&#8217;s Board of Directors. The Note&#8217;s face value was $157,714
and the original issue discount was $19,714 for total gross proceeds of $138,000, implying an interest rate of 12.5% per annum.
The Company could, without premium or penalty, at any time and from time to time, prepay all or any portion of the Note. The maturity
date of the Note was September 8, 2019. On September 20, 2019, the Company entered into an amendment to the July 2019 Note (the
&#8220;Amendment&#8221;). The Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge
financing of greater than or equal to $1,500,000, or (b) November 7, 2019. On November 21, 2019, the Company entered into an amendment
for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing
of greater than or equal to $1,500,000, or (b) December 9, 2019. In consideration for this amendment, the Company agreed to pay
an aggregate extension fee of $33,926, which was added to the principal balance of the note. On December 9, 2019, the Company entered
into an additional amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion
of a bridge financing of greater than or equal to $1,500,000, or (b) January 7, 2020. The Company also agreed to pay the previously
outstanding extension fees of $33,926 on or before March 1, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 8, 2020 the Company entered into
an amendment to the July 2019 Note (the &#8220;January 8 Amendment&#8221;). The January 8 Amendment extended the maturity date
for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) April
1, 2020. In consideration for the January 8 Amendment, the Company granted 55,000 shares of the Company&#8217;s common stock to
the Lender. The Company accounted for this amendment as a modification, where the shares paid as a fee were valued at $45,725 and
recorded as a discount against the note payable and amortization over the term. On May 6, 2020, the Company entered into an amendment
(the &#8220;May 2020 Amendment&#8221;) whereby both parties agreed to extend the maturity date of the July 2019 Note to September
30, 2020. The Company accounted for this amendment as a modification, as the present value of the future cash flows pre-modification
and post-modification were not greater than or equal to 10%. On January 12, 2020, the Company repaid $157,714 of the July 2019
Note. On December 31, 2020 the Company paid the remaining unpaid balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 12, 2019, the Company received
$40,000 in exchange for a promissory note with a lender, including an original issue&#160;discount of $4,000 (the &#8220;December
2019 Note&#8221;). The December 2019 Note bore interest at a rate of ten percent (10%) on its face value per annum. In the case
of an event of default, the interest rate would increase to 24% per year. The December 2019 Note matured on January 31, 2020. The
promissory note with the lender and the Company was converted into 170,333 shares of common stock on December 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 24, 2020, the Company received
$50,000 in exchange for a promissory note with a lender (the &#8220;February 2020 Note&#8221;). The February 2020 Note bore interest
at a rate of 10% on its face value per annum. In the case of an event of default, the interest rate would increase to 24% per year.
The note matured on July 31, 2020. The February 2020 Note was convertible into the Company&#8217;s common stock at any time at
a conversion price of $0.38 per share. The Company recorded a beneficial conversion feature of $17,851 and valued the warrants
issued (using relative fair value) at $32,149. The Company recorded the total value as a note discount and is amortizing the discount
over the term of the February 2020 Note using the effective interest method. The Company valued the beneficial conversion feature
and warrants using the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Beneficial Conversion Feature</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock Price</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">CAD $ 1.10</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">CAD $ 1.10</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">CAD $ 0.51</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">CAD $ 0.51</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend Yield</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">N/A</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expected Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">96.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Risk-Free Interest Rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.31</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">130,920</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Value (USD)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17,851</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">32,149</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Term (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On December 30, 2020, the February 2020 Note was converted into
190,004 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#160;entered into a Secured Promissory
Note, dated January 10, 2020 (the &#8220;Note&#8221;), by and among Enveric Biosciences, Inc. and Alpha Capital Anstalt (&#8220;Alpha&#8221;),
pursuant to which, on January 10, 2020, Enveric Biosciences, Inc. received aggregate gross proceeds of $1,500,000. Pursuant to
the Note, the aggregate obligations of Enveric Biosciences, Inc. under the Note were automatically, immediately prior to the consummation
of the amalgamation, converted into shares of Enveric Biosciences, Inc. common stock, subject to the terms and provisions of the
Note. Pursuant to the Note, upon conversion of the term loans made by the lenders subject to the terms of the Note, Enveric Biosciences,
Inc. was required to cause Ameri to issue each lender warrants to purchase Ameri Common Stock. Upon consummation of the amalgamation,
Enveric Biosciences, Inc. agreed to cause Ameri to register the resale of the warrant shares. The Note bears interest at 7% per
annum and was due on March 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 6, 2020, the Company entered into an
amendment to the Note (the &#8220;First Note Amendment&#8221;). Pursuant to the First Note Amendment, Alpha waived previous defaults
on the Note, and extended the maturity date of the Note to June 30, 2020. In exchange for the First Note Amendment, the Company
and Alpha agreed that (i) at the Effective Time, Ameri would issue to the holder of a certain note issued by Enveric Biosciences,
Inc., series B warrants (the &#8220;Series B Warrants&#8221;) to acquire 8,100,000 shares of common stock of the Company resulting
from the amalgamation, and (ii) providing for certain registration rights, pursuant to a registration rights agreement, of the
Series B Warrants and the shares issuable upon exercise of the Series B Warrants. The Series B Warrants shall be exercisable for
a period of five years commencing on the ninetieth (90th) day after the later of the last day of the Lock-up Period and leak-out
Period (accelerated or otherwise) set forth in the Lock-up agreement to be executed by the holders of Enveric Biosciences, Inc.
securities in connection with the Amalgamation, at a price of $0.01 per share, and shall also be exercisable on a cashless basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 23, 2020, the Company and Alpha entered
into a second amendment to the Note (the &#8220;Second Note Amendment&#8221;). The Second Note Amendment revised the principal
amount of the Note from $1,500,000 to $2,000,000, which was advanced as of the date of the Second Note Amendment. The rights and
securities granted to Alpha under the terms of the Note were extended to the additional $500,000 advance contemplated by the Second
Note Amendment pursuant to the terms of the Second Note Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 12, 2020, the Company and Alpha entered
into the Third Note Amendment. The Third Note Amendment extended the maturity date to be the earlier of (a) January 1, 2021 and
(b) an event of default that accelerates the maturity of the Note. The Third Note Amendment also revised the Note to account for
the change in structure from an amalgamation to a stock-for-stock exchange offer. As a result, references to the Amalgamation Agreement
and the amalgamation were revised to be references to the Tender Agreement and the Offer. The Third Note Amendment also revised
the event of default regarding a failure of the amalgamation to be consummated by March 31, 2020 to be an event of default if the
Offer was not consummated by January 1, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 30, 2020, the Note&#160;in the
amount of $2,000,000&#160;was converted into 2,473,848 shares of common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593206888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;3&#160;&#8211; INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2021, the Company&#8217;s intangible
assets consisted of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Useful Life</font></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross<br />
Carrying<br />
Amount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated<br />
Amortization</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 41%"><font style="font: 10pt Times New Roman, Times, Serif">Skincare Assets and License Agreements</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,944,689</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(257,512</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,687,177</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Diverse Bio License Agreement</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">675,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">675,000</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,619,689</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(257,512</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,362,177</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2021 and 2020,
the Company recognized amortization expense of $136,640 and $0, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Acquisition of Diverse Bio License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On March 5, 2021, the Company
entered into an Exclusive License Agreement (the &#8220;DB Agreement&#8221;) with Diverse Biotech, Inc. (&#8220;Diverse&#8221;), pursuant
to which the Company acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively, the &#8220;Agents&#8221;)
with the goal of alleviating the side effects that cancer patients experience. Under the terms of the DB Agreement, Diverse has granted
the Company an exclusive license to its intellectual property rights covering the Agents and its products. In exchange, the Company has
granted Diverse the right to information relating to the Agents developed for the express purpose of using such information to obtain
patent rights, which right terminates upon the issuance or denial of the patent rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Under the DB Agreement, the
Company will maintain sole responsibility and ownership of the development and commercialization of the Agents and its products. Diverse
has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its products containing the Agents,
at any time during or after the term of the DB Agreement. If Diverse intends to license, sell, or transfer any other molecules linked
with cannabinoids not granted to the Company under the terms of the DB Agreement, the Company will have the first right, but not the obligation,
to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay Diverse an up-front investment payment
in the amount of $675,000, as well as a running royalty starting with the first commercial sale by the Company to a third party in an
arms&#8217;-length transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The term of the DB Agreement
shall continue for as long as the Company intends to develop or commercialize the new drugs, unless earlier terminated by either Party.
The Agreement may be terminated by either party upon ninety (90) days written notice of an uncured material breach or in the event of
bankruptcy or insolvency. In addition, the Company has the right to terminate the DB Agreement at any time upon sixty (60) days&#8217;
prior written notice to Diverse.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8211; INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 2, 2020, the Company purchased skincare
assets for an aggregate of $1,944,689 in stock and cash, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%; text-align: justify"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">44,143</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Common stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,900,546</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,944,689</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded the skincare assets as a definite
lived intangible asset with a four year useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2020, the Company&#8217;s intangible assets consisted
of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Gross <br />
Carrying <br />
Amount</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Accumulated <br />
Amortization</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 46%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 15%; padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 15%; padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 15%; padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Skincare Assets and License Agreements</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,944,689</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(126,968</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,817,721</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593215048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingengies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingengies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;4&#160;&#8211; COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is periodically involved in legal proceedings,
legal actions and claims arising in the normal course of business. Management believes that the outcome of such legal proceedings, legal
actions and claims will not have a significant adverse effect on the Company&#8217;s financial position, results of operations or cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stockholder Demand Letter</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 21, 2021, the Company received a stockholder litigation
demand letter from the law firm of Purcell Julie &#38; Lefkowitz LLP, on behalf of James Self, a purported stockholder of the Company.
The letter demands that the Company (i) deem ineffective the December 30, 2020 amendment to our Amended and Restated Certificate of Incorporation
in which the Company effected a one-for-four reverse stock split of its common stock due to the manner in which non-votes by brokers were
tabulated, (ii) seek appropriate relief for damages allegedly suffered by the company and its stockholders or seek a valid stockholder
approval of the amendment and reverse stock split, and (iii) adopt adequate internal controls to prevent a recurrence of the alleged misconduct.
The Company disputes that the amendment was ineffective or that there were any inadequate internal controls related to the same. However,
to eliminate any questions about the amendment, the Company ratified the amendment at a special stockholders&#8217; meeting pursuant to
Section 204 of the Delaware General Corporation Law. This special stockholders&#8217; meeting occurred on May 14, 2021. On May 14, 2021,
the Company filed a certificate of validation with the State of Delaware to ratify the reverse stock split on December 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Development and Clinical Supply Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On February 22, 2021, the
Company entered into a Development and Clinical Supply Agreement (the&#160;&#8220;PureForm&#160;Agreement&#8221;) with PureForm Global,
Inc. (&#8220;PureForm&#8221;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#8220;API&#8221;)
for the Company&#8217;s development plans for cancer treatment and supportive care. Under the terms of the&#160;PureForm&#160;Agreement,
PureForm has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during
the term of the Agreement (contingent upon an initial minimum order volume during the first thirty (30) days from the effective date)
and has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.
All inventions that are developed jointly by the parties in the course of performing activities under the&#160;PureForm&#160;Agreement
will be owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development
efforts by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical
information to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The initial term of the&#160;PureForm&#160;Agreement
is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual agreement of the parties. The&#160;PureForm&#160;Agreement
may be terminated by either party upon thirty (30) days written notice of an uncured material breach or immediately in the event of bankruptcy
or insolvency. The Agreement contains, among other provisions, representation and warranties, indemnification obligations and confidentiality
provisions in favor of each party that are customary for an agreement of this nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Appointment of Chief
Financial Officer</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On April 9, 2021, John M. Van
Buiten resigned from his position as the Company&#8217;s chief financial officer, effective May 15, 2021. Mr. Van Buiten&#8217;s resignation
was not the result of any disagreement regarding any matter relating to the Company&#8217;s operations, policies, or practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On April 9, 2021, Carter J. Ward,
56, was appointed as the Company&#8217;s chief financial officer, effective May 15, 2021 (the &#8220;Effective Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In connection with Mr. Ward&#8217;s
appointment as chief financial officer, Mr. Ward entered into an employment agreement with the Company on April 9, 2021 (the &#8220;Ward
Employment Agreement&#8221;), effective as of May 15, 2021, pursuant to which Mr. Ward will receive a base salary of $295,000 (&#8220;Base
Salary&#8221;) and is eligible to receive annual performance bonuses of up to 50% of his Base Salary, as determined from time-to-time
by the Company&#8217;s board of directors.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8211; COMMITMENTS AND CONTINGENGIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 5, 2019, the Company entered into
a business advisor services agreement. Pursuant to the terms of the agreement, the consultant provided business advisory, marketing,
and investor relations services in exchange for $15,000 per month, of which $7,500 was payable in cash and $7,500 was payable in
the Company&#8217;s common shares. On January 6, 2020, the Company terminated its business advisory services agreement and agreed
to settle the amounts due under the agreement by (a) paying $12,500 in cash upon the completion of a bridge financing; and (b)
issuing 127,856 shares of the Company&#8217;s common stock, as described in Note 6.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2020, the Company entered into
an agreement with Mr. David Stefansky to serve as President and Secretary of the Company to serve until the closing Amalgamation
Agreement. The Company agreed to pay Mr. Stefansky $15,000 per month and future issuance of options to purchase 650,000 shares
of common stock subject to the approval of the Board of Directors. On May 1, 2020, this agreement was terminated (see Note 8).
On May 1, 2020, the Company and Mr. David Stefansky terminated Mr. Stefansky&#8217;s agreement to serve as President and Secretary
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, the Company entered into an
agreement with Mr. Henoch Cohn to serve as the Company&#8217;s President and Secretary until the consummation of the Amalgamation
Agreement. The Company paid Mr. Cohn $10,000 per month. On December 30, 2020 the agreement between the Company and Mr. Henoch Cohn
was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is periodically involved in legal
proceedings, legal actions and claims arising in the normal course of business. Management believes that the outcome of such legal
proceedings, legal actions and claims will not have a significant adverse effect on the Company&#8217;s financial position, results
of operations or cash flows. On January 21, 2012, the Company received a demand letter from an individual purporting to be a stockholder.
See Note 10 for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593099640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share Capital and Other Equity Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;5&#160;- SHARE CAPITAL AND OTHER EQUITY
INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of the Company&#8217;s common stock are
entitled to one vote per share. Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by
the Board of Directors out of legally available funds. Upon the liquidation, dissolution, or winding up of the Company, holders of common
stock are entitled to share rateably in all assets of the Company that are legally available for distribution. As of December 31, 2020,
100,000,000 shares of common stock and 20,000,000 shares of Series B Preferred Stock were authorized under the Company&#8217;s articles
of incorporation. The Company&#8217;s Series B preferred stock is convertible by the holder at any time into common stock at a rate of
one to one.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Conversion of Series B Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2021, holders
of an aggregate of 3,275,407 shares of Series B Preferred Stock converted their shares into 3,275,407 shares of common stock. Following
those&#160;conversions,&#160;no Series B Preferred stock shares remain outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Offerings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 14, 2021, the Company completed an offering
of 2,221,458 shares of Common Stock and pre-funded warrants at approximately $4.50 per share and a concurrent private placement of warrants
to purchase 1,666,019 shares of Common Stock at $4.9519 per share, exercisable immediately and terminating five years after the date of
issuance for gross proceeds of approximately $10,000,000. The net proceeds to the Company after deducting financial advisory fees and
other costs and expenses were approximately $8,806,087.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2021, the Company completed an offering
of 3,007,026 shares of Common Stock and a concurrent private placement of warrants to purchase 1,503,513 shares of Common Stock at $4.90
per share, exercisable immediately and terminating five year from the date of issuance for gross proceeds of approximately $12,800,000.
The net proceeds to Enveric from the offering after deducting financial advisory fees and other costs and expenses were approximately
$11,624,401.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Exercise Price (USD)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value (USD)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Remaining Contractual Term (years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value (USD)</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding &#8211; January 1, 2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">929,765</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.53</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.50</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expired forfeited, or cancelled</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(560,404</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.65</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding &#8211; December 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">369,361</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.35</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.2</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">636,156</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at December 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">369,361</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.35</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.2</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">636,156</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock based compensation expense
related to stock options for the three months ended March 31, 2021 and 2020 was $0 and $0, respectively. As of March 31, 2021, the Company
had $0 in unamortized stock option expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended&#160;March 31, 2021,&#160;the
Company exchanged options to purchase 560,404 shares of common stock for 325,410 restricted stock units and 42,125 restricted stock awards.
In connection with this exchange, the Company recognized $298,714 in inducement expense related to the increase in fair value of the new
awards over the old awards, which is included in general and administrative expenses on the Company&#8217;s statement of operations and
comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Restricted Stock Awards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s activity in restricted common
stock was as follows for the three months ended March 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">shares</p></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted<br />
average<br />
grant date<br />
fair<br />
value</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at January 1, 2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 63%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,986</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.16</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(44,390</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.49</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">26,596</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.61</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2021 and 2020,
the Company recorded&#160;$32,112&#160;and $0, in stock-based compensation expense related to restricted stock awards. As of March 31,
2021, unamortized stock-based compensation costs related to restricted share awards was $72,009, which will be recognized over a weighted
average period of 0.47 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Issuance of Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s activity in restricted stock units
was as follows for&#160;the&#160;three months ended March 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average<br />
grant date fair<br />
value</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at January 1, 2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,279,284</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.41</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,207,825</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.46</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,071,459</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.38</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2021 and 2020,
the Company recorded&#160;$3,559,453&#160;and $0, respectively, in stock-based compensation expense related to restricted stock units,
which is a component of general and administrative expenses in the condensed consolidated statement of operations. As of March 31, 2021,
unamortized stock-based compensation costs related to restricted stock units was $9,416,205 and will be recognized over a weighted average
period of 1.93 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about shares
issuable under warrants outstanding at March 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Warrant<br />
shares<br />
outstanding</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted<br />
average<br />
exercise price (USD)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average remaining life</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic value</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at January 1, 2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,661,178</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.98</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,535,519</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.93</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(851,099</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.17</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,345,598</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.33</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,049,152</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,345,598</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.33</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,049,152</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of the Company&#8217;s common stock
are entitled to one vote per share. Holders of common stock are entitled to receive ratably such dividends, if any, as may be declared
by the Board of Directors out of legally available funds. Upon the liquidation, dissolution, or winding up of the Company, holders
of common stock are entitled to share rateably in all assets of the Company that are legally available for distribution. As of
December 31, 2020, 100,000,000 shares of common stock were authorized under the Company&#8217;s articles of incorporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 30, 2020, the Company amended its
articles of incorporation to designate and authorize 20,000,000 shares of Series B preferred stock. The Company&#8217;s Series
B preferred stock is convertible by the holder at any time into common stock at a rate of one to one.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Conversion of Series B Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 30, 2020, a holder of the Company&#8217;s
Series B Preferred Stock converted 250,000 shares of Series B Preferred Stock into 250,000 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Issuance of Common Stock for Accounts Payable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2020, the
Company issued 433,047 shares of common stock to various vendors in connection with the payment of accounts payable of $756,523.
The shares were valued at the book value of the accounts payable, as that value was more readily determinable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Shares Issued in Exchange for Services</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2019, the
Company issued 38,116 shares to consultants in exchange for services. The Company valued these shares at $88,465.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>September Private Placement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2020, the Company issued 36,871
shares of its common stock for gross proceeds of $250,000 and net proceeds of $227,500.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>December Private Placement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 8, 2020, the Company issued 221,225
shares of its Series B preferred stock for gross proceeds of $300,000 and net proceeds of $260,500.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Conversion of Related Party Advance</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 21, 2020, the Company issued 239,326
shares of common stock in exchange for the February 2019 Note (face value of $66,000), the March 2019 Note (face value of $150,000)
and related party advances in the amount of $22,000. Given that the holder of these notes and advances is a related party, this
was treated as a capital transaction and no gain or loss was recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Number of Shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Exercise Price (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Grant Date Fair Value (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Remaining Contractual Term (years)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Aggregate Intrinsic Value (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 35%"><font style="font-size: 10pt">Outstanding &#8211; January 1, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">689,832</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.94</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.94</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">448,713</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.99</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.49</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expired, forfeited, or cancelled</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(341,172</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.99</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.36</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Outstanding &#8211; December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">797,373</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.99</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.72</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">378,800</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.94</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5.22</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Expired forfeited, or cancelled</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(246,408</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.94</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">0.88</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Outstanding &#8211; December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">929,765</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.53</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2.50</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6.1</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,537,245</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">929,765</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.53</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2.50</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6.1</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,537,245</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock based compensation
expense related to stock options for the years ended December 31, 2020 and 2019 was $1,977,155 and $535,587, respectively. As of
December 31, 2020, the Company had $0 in unamortized stock option expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilized the Black-Scholes option-pricing
model to determine the fair value of these stock options, using the assumptions as outlined below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%; text-align: justify"><font style="font-size: 10pt">Stock Price</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5.92</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Dividend Yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Expected Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84.7</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Weighted Average Risk-Free Interest Rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.37</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Expected life (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.5 &#8211; 4.2</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock price &#8211; Based on closing price
of the Company&#8217;s common stock on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Weighted average risk-free interest rate &#8212;Based
on the daily yield curve rates for U.S. Treasury obligations with maturities, which correspond to the expected term of the Company&#8217;s
stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dividend yield &#8212;The Company has not paid
any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable
future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expected volatility &#8212;Based on the historical
volatility of comparable companies in a similar industry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expected term &#8212;The Company has had no
stock options exercised since inception. The expected option term represents the period that stock-based awards are expected to
be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 107, Share-Based Payment,
which averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain vanilla&#8221; share options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 24, 2020, the Company issued warrants
to purchase 130,920 shares of common stock to the lender of the February 2020 Note. The warrants are exercisable at $0.38 USD ($0.50
CAD) per share, are fully vested at the date of issuance, and expire on February 24, 2025. The warrants were accounted for as a
component of equity, as the instrument contains no features which would preclude such classification. As discussed in Note 4, the
warrants were recorded as a discount in the amount of $50,000 on the note payable and amortized over the term of the note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information
about shares issuable under warrants outstanding at December 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Warrant <br />
shares <br />
outstanding</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted <br />
average<br />
exercise price (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted average remaining life</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Intrinsic value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><font style="font-size: 10pt">Outstanding at January 1, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">219,510</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">2.95</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">0.08</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Issued</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">84,381</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3.21</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Outstanding at December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">303,891</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.02</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.06</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,222,331</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.96</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(274,816</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3.00</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,251,406</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.95</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.97</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,251,406</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.95</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.97</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,040,545</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359595348408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tender Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_TenderAgreementAbstract', window );"><strong>Tender Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_TenderAgreementDisclosureTextBlock', window );">Tender Agreement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8211; TENDER AGREEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 10, 2020,
the Company entered into an amalgamation agreement (the &#8220;Amalgamation Agreement&#8221;) with Enveric Biosciences, Inc. Merger
Sub, Inc. (&#8220;Merger Sub&#8221;), a wholly owned subsidiary of Ameri, and Enveric Biosciences, Inc. Exchange Co, Inc. (&#8220;ExchangeCo&#8221;),
a wholly owned subsidiary of Ameri. The Amalgamation Agreement provided that the Company would merge into Merger Sub and be amalgamated
and operate as one company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Prior to the execution
and delivery of the Amalgamation Agreement, Alpha entered into agreements with Enveric Biosciences, Inc. pursuant to which Alpha
agreed, subject to the terms and conditions of such agreements, to purchase, immediately prior to the consummation of the Amalgamation,
shares of Enveric Biosciences, Inc.&#8217;s common stock (or common stock equivalents) and warrants to purchase Enveric Biosciences,
Inc.&#8217;s common stock for an aggregate purchase price of $3.5 million. The consummation of the transactions contemplated by
such agreements was conditioned upon the satisfaction or waiver of the conditions set forth in the Amalgamation Agreement. After
consummation of the Amalgamation, Enveric Biosciences, Inc. agreed to cause Ameri to register the resale of the Ameri Common Stock
issued and issuable pursuant to the warrants issued to the investors in the Jay Pharma Pre-Closing Financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Contemporaneously
with the Amalgamation Agreement, the Company entered into sublicense agreements with Tikkun Pharma, Inc. (&#8220;Tikkun Pharma&#8221;).
The sublicense agreements with Tikkun Pharma allows the Company to utilize (a) Tikkun Pharma&#8217;s sublicense with a third party
for certain autoimmune applications, and (b) acquire and use Tikkun Pharma&#8217;s internally developing intellectual property,
branding, and formulations in regards to skincare.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 20, 2020,
the Company received a notice from the lenders of the Note, stating that the Company was in default for not closing the amalgamation
with Ameri by March 31, 2020, and that the entire Note was due in full. On May 6 and May 26, 2020, the Company and Alpha amended
the Note and the Amalgamation Agreement, as described in below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 6, 2020, the Company entered into an
Amalgamation Amendment Agreement (the &#8220;Amendment&#8221;) to amend the Amalgamation Agreement described in Note 7. Pursuant
to the Amendment, the parties agreed that (i) at the Effective Time, Ameri Holdings, Inc. shall issue to the holder of a certain
note issued by Enveric Biosciences, Inc., series B warrants (the &#8220;Series B Warrants&#8221;) to acquire 8,100,000 shares of
common stock of the company resulting from the amalgamation, and (ii) providing for certain registration rights, pursuant to a
Registration Statement on Form S-4, of the Series B Warrants and the shares issuable upon exercise of the Series B Warrants. The
Series B Warrants shall be exercisable for a period of five years commencing on the ninetieth (90th) day after the later of the
last day of the Lock-up Period and leak-out Period (accelerated or otherwise) set forth in the Lock-up agreement to be executed
by the holders of Enveric Biosciences, Inc. securities in connection with the Amalgamation, at a price of $0.01 per share, and
shall also be exercisable on a cashless basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 26, 2020, the Company entered into the
second amendment to the Amalgamation Agreement (the &#8220;Second Amendment&#8221;) to amend the Amalgamation Agreement described
in Note 7. The purpose of this amendment was to clarify that the Series B Warrants were to acquire 8,100,000 shares of common stock
Enveric Biosciences, Inc. (to be approximately 3,675,035 shares of common stock of the company resulting from the Amalgamation),
as well as to clarify the exchange ratio already agreed upon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 12, 2020, Ameri, Enveric Biosciences,
Inc., and certain other signatories thereto entered into a tender agreement (the &#8220;Tender Agreement&#8221;), which provided
that, among other things, Enveric Biosciences, Inc. would become a wholly owned subsidiary of Ameri, on the terms and conditions
set forth in the Tender Agreement. The Tender Agreement terminated and replaced in its entirety the Amalgamation Agreement. Upon
completion of the Tender Agreement on December 30, 2020, (i) holders of outstanding common shares of Enveric Biosciences, Inc.
other than Alpha will be entitled to receive the number of shares of Resulting Issuer common stock issuable in accordance with
the Exchange Ratio, and (ii) Alpha will be entitled to receive shares of Series B Preferred Stock, which are convertible into shares
of Resulting Issuer common stock subject to a 9.99% beneficial ownership blocker, pursuant to the Alpha Exchange Agreement. Each
outstanding Enveric Biosciences, Inc. option, whether vested or unvested, and warrant that has not previously been exercised will
exchanged for Resulting Issuer stock options and Resulting Issuer warrants, in each case convertible into the number of shares
of Resulting Issuer common stock equal to the Exchange Ratio. Each outstanding Enveric Biosciences, Inc. option, whether vested
or unvested, and warrant that has not previously been exercised will be exchanged for Resulting Issuer stock options and Resulting
Issuer warrants, in each case, convertible into the number of shares of Resulting Issuer common stock equal to the Exchange Ratio.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_TenderAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_TenderAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_TenderAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tender Agreement [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_TenderAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359597234744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8211; INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">As of December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred tax assets:</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Net operating loss carryovers</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">1,340,152</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt"><font style="font-size: 10pt">Deferred tax assets, gross</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,340,152</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-size: 10pt">Less: valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,340,152</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,004,029</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Deferred tax assets, net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Deferred tax assets (liabilities), net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The change in the Company&#8217;s valuation allowance is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2019</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Beginning of year</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">505,871</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Increase in valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,340,152</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">498,158</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">End of year</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,344,180</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the provision for income
taxes with the amounts computed by applying the statutory federal income tax rate to loss from operations before the provision
for income taxes is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2019</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Canada federal statutory rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">(15.0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">(15.0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Provincial taxes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(11.5</font></td>
    <td><font style="font-size: 10pt">)%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(11.5</font></td>
    <td><font style="font-size: 10pt">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Permanent differences</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Non-deductible expenses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.5</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.9</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">19.1</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">20.6</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Effective income tax rate</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2020 and 2019, the Company
had net operating loss carryovers of $5,057,176 and $3,788,788, respectively, for Canadian federal income tax purposes, which begin
to expire in 2029. The ultimate realization of the net operating loss is dependent upon future taxable income, if any, of the Company.
Based on losses from inception, the Company determined that as of December 31, 2020 and 2019 it is more likely than not that the
Company will not realize benefits from the deferred tax assets. The Company will not record income tax benefits in the financial
statements until it is determined that it is more likely than not that the Company will generate sufficient taxable income to realize
the deferred income tax assets. As a result of the analysis, the Company determined that a valuation allowance against the deferred
tax assets was required of $1,340,152 and $1,004,029 as of December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359598365688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 - <font style="font-variant: small-caps; text-transform: uppercase">SUBSEQUENT
EVENTS</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Registered Direct Offerings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 14, 2021, the Company completed
a registered direct offering of 2,221,458 shares of common stock at approximately $4.50 per share for gross proceeds of approximately
$10,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2021, the Company completed
a registered direct offering of 3,007,026 shares of common stock for gross proceeds of approximately $12.8 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stockholder Demand Letter</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 21, 2021, the Company received a
stockholder litigation demand letter from the law firm of Purcell Julie &#38; Lefkowitz LLP, on behalf of James Self, a purported
stockholder of our Company. The letter demands that the Company (i) deem ineffective the December 30, 2020 amendment to our Amended
and Restated Certificate of Incorporation in which the Company effected a one-for-four reverse stock split of its common stock
due to the manner in which non-votes by brokers were tabulated, (ii) seek appropriate relief for damages allegedly suffered by
the company and its stockholders or seek a valid stockholder approval of the amendment and reverse stock split, and (iii) adopt
adequate internal controls to prevent a recurrence of the alleged misconduct. The Company disputes that the amendment was ineffective
or that there were any inadequate internal controls related to the same. However, to eliminate any questions about the amendment,
the Company intends to seek to ratify the amendment at a special stockholders&#8217; meeting pursuant to Section 204 of the Delaware
General Corporation Law. This special stockholders&#8217; meeting is scheduled to occur on May 14, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Development and Clinical Supply Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On February 22, 2021,
the Company entered into a Development and Clinical Supply Agreement (the &#8220;Agreement&#8221;) with PureForm Global, Inc. (&#8220;PureForm&#8221;),
pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#8220;API&#8221;) for the Company&#8217;s
development plans for cancer treatment and supportive care. Under the terms of the Agreement, PureForm has granted the Company
the exclusive right to purchase API and related product for cancer treatment and supportive care during the term of the Agreement
(contingent upon an initial minimum order volume during the first thirty (30) days from the effective date) and has agreed to manufacture,
package and test the API and related product in accordance with specifications established by the parties. All inventions that
are developed jointly by the parties in the course of performing activities under the Agreement will be owned jointly by the parties
in accordance with applicable law; however, if the Company funds additional research and development efforts by PureForm, the parties
may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The initial term of
the Agreement is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual agreement of
the parties. The Agreement may be terminated by either party upon thirty (30) days written notice of an uncured material breach
or immediately in the event of bankruptcy or insolvency. The Agreement contains, among other provisions, representation and warranties,
indemnification obligations and confidentiality provisions in favor of each party that are customary for an agreement of this nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On March 5, 2021,
the Company entered into an Exclusive License Agreement (the &#8220;Agreement&#8221;) with Diverse Biotech, Inc. (&#8220;Diverse&#8221;),
pursuant to which the Company has acquired an exclusive, perpetual license to develop five therapeutic candidates (collectively,
the &#8220;Agents&#8221;) with the goal of alleviating the side effects that cancer patients experience. Under the terms of the
Agreement, Diverse has granted the Company an exclusive license to its intellectual property rights covering the Agents and its
products. In exchange, the Company has granted Diverse the right to information relating to the Agents developed for the express
purpose of using such information to obtain patent rights, which right terminates upon the issuance or denial of the patent rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Under the Agreement,
the Company will maintain sole responsibility and ownership of the development and commercialization of the Agents and its products.
Diverse has agreed not to develop or commercialize any agent or product that would compete with the Agents, or its products containing
the Agents, at any time during or after the term of the Agreement. If Diverse intends to license, sell, or transfer any other molecules
linked with cannabinoids not granted to the Company under the terms of this Agreement, the Company will have the first right, but
not the obligation, to negotiate an agreement with Diverse for such cannabinoids. The Company has also agreed to pay Diverse an
up-front investment payment of $675,000, as well as a running royalty starting with the first commercial sale by the Company to
a third party in an arms&#8217;-length transaction. The term of the Agreement shall continue for as long as the Company intends
to develop or commercialize the new drugs, unless earlier terminated by either Party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Exercise of
Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 10, 2021, the Company received $3,267,245
from the exercise of warrants to purchase 851,099 shares of common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592190008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S.
GAAP&#8221;) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. Management&#8217;s opinion is that all adjustments (consisting
of normal accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March
31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited condensed
consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December
31, 2020 and related notes thereto included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on April 1, 2021.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance and in conformity with the accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) and the applicable rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;)
regarding consolidated financial information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the
date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement
uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant
areas requiring management&#8217;s estimates and assumptions include determining the fair value of transactions involving common stock
and the valuation of stock-based compensation. Actual results could differ from those estimates.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities
at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject
to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be
significant. Significant areas requiring management&#8217;s estimates and assumptions include determining the fair value of transactions
involving common stock and the valuation of stock-based compensation. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Foreign Currency Translation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is the United
States&#160;Dollar.&#160;The financial statements of companies located outside of the U.S. are measured in their functional currency,
which is the local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are translated
using public exchange rates at the balance sheet date. Income and expense items are translated using average monthly exchange rates.
Shareholders&#8217; equity accounts and non-monetary assets are translated at their historical exchange rates. Translation adjustments
are included in accumulated other comprehensive loss in the accompanying balance sheets.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Foreign Currency Translation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is the
United States dollar. The financial statements of companies located outside of the U.S. are measured in their functional currency,
which is the local currency. The functional currency of the Company is the Canadian dollar. Monetary assets and liabilities are
translated using public exchange rates at the balance sheet date. Income and expense items are translated using average monthly
exchange rates. Shareholders&#8217; equity accounts and non-monetary assets are translated at their historical exchange rates.
Translation adjustments are included in accumulated other comprehensive loss in the accompanying balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash and cash equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as
of March 31, 2021 and December 31, 2020.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash and cash equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents
as of December 31, 2020 and December 31, 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Warrant Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for warrants for shares of the
Company&#8217;s common stock that are not indexed to its own stock as liabilities at fair value on the balance sheet. Such warrants are
subject to remeasurement at each balance sheet date and any change in fair value is recognized as a component of other expense on the
statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise
or expiration of such common stock warrants. At that time, the portion of the warrant liability related to such common stock warrants
will be reclassified to additional paid-in capital.<i>&#160;</i></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_OfferingCostsPolicy', window );">Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Offering Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company allocates offering costs to the different
components of the capital raise on a pro rata basis. Any offering costs allocated to common stock are charged directly to additional paid-in
capital. Any offering costs allocated to warrant liabilities are charged to general and administrative expenses on the Company&#8217;s
statement of operations.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Intangibles</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has finite-lived intangible assets.
Finite-lived intangible assets are amortized over their estimated useful lives. Research and development costs are expensed as
incurred. Following initial recognition of the finite-lived intangible asset, the asset is carried at cost less any accumulated
amortization. Amortization of the asset begins when the asset is available for use. Amortization is recorded in general and administrative
expenses on the Company&#8217;s consolidated statement of operations. The Company periodically reviews its owned intangible assets
for recoverability.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long Term Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Impairment of Long Term Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the carrying value of long-lived
assets subject to amortization whenever events or changes in circumstances indicate that an impairment may exist. An impairment charge
is recognized when the asset&#8217;s carrying value exceeds its net undiscounted future cash flows and its fair market value. The amount
of the charge is the difference between the asset&#8217;s carrying value and fair market value.<b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 25, 2016, FASB issued ASU 2016-02, Leases
(Topic 842). This update will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for
the rights and obligations created by those leases. The new guidance will also require additional disclosures about the amount, timing
and uncertainty of cash flows arising from leases. On January 1, 2020, the Company adopted this ASU, which did not have a material impact
on the Company&#8217;s financial position and results of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes an asset and liability
approach for financial accounting and reporting for income taxes. The provision for income taxes is based upon income or loss after
adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent
the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets and liabilities at the
enacted tax rates in effect for the years in which the differences are expected to reverse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the recoverability of
deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred
tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon
an audit and cause changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate provisions for income
taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of
reserves may be necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest
amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax
benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition
and measurement standards. As of December 31, 2020 and December 31, 2019, no liability for unrecognized tax benefits was required
to be recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s policy for recording interest
and penalties associated with tax audits is to record such items as a component of operating expenses. There were no amounts accrued
for penalties and interest for the years ended December 31, 2020 and 2019. The Company does not expect its uncertain tax positions
to change during the next twelve months. Management is currently unaware of any issues under review that could result in significant
payments, accruals or material deviations from its position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has identified its United States and Canadian federal
tax return, its state and provincial tax returns in Florida and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The Company
is in the process of filing its corporate tax returns for the years ended December 31, 2020 and December 31, 2019. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows Accounting Standards Codification
(&#8220;ASC&#8221;) 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions,
requiring such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded
at the more readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The
Company uses the Black-Scholes option-pricing model to determine the grant date fair value of stock-based awards under ASC 718.
The estimated fair value is amortized as a charged to earnings on a straight-line basis depending on the terms and conditions of
the award, and the nature of the relationship of the recipient of the award to the Company. The Company records the grant date
fair value in line with the period over which it was earned. For employees and consultants, this is typically considered to be
the vesting period of the award. The Company estimates the expected forfeitures and updates the valuation accordingly.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Loss per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is computed by dividing net
loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed using
the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common
shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using the treasury stock method)
and convertible notes. The computation of basic net loss per share for the three months ended March 31, 2021 and 2020 excludes potentially
dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully diluted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Potentially dilutive securities outlined in the table
below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended March&#160;31,&#160;2021</font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended March&#160;31,&#160;2020</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants to purchase shares of common stock</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,979,611</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,504,593</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Convertible notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">380,920</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted stock units</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,279,284</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted stock awards</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,986</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Options to purchase shares of common stock</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">369,361</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,604,348</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Total potentially dilutive securities</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,699,242</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,489,861</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is computed by dividing
net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is
computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period.
Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants (using
the treasury stock method) and convertible notes. The computation of basic net loss per share for the years ended December 31,
2020 and 2019 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the
same for both basic and fully diluted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Potentially dilutive securities outlined in
the table below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would
have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2019</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Warrants to purchase shares of common stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">3,251,406</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">303,891</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Convertible notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">55,306</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Series B Preferred Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,275,407</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">262,500</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Options to purchase shares of common stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">929,765</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">797,373</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total potentially dilutive securities</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,456,578</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,419,070</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the
Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal
depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the
Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes
the Company is not exposed to significant risks on such accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value Measurement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows Accounting Standards Codification
(&#8220;ASC&#8221;) 820&#8211;10 &#8220;Fair Value Measurement&#8221; of the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;)
Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial
instruments. ASC 820&#8211;10 establishes a framework for measuring fair value and expands disclosures about fair value measurements.
To increase consistency and comparability in fair value measurements and related disclosures, ASC 820&#8211;10 establishes a fair value
hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The three (3) levels of fair value hierarchy defined
by ASC 820&#8211;10 are described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 62px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Level 1</i></font></td>
    <td style="width: 10px">&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Level 2</i></font></td>
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Level 3</i></font></td>
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial assets or liabilities are considered Level
3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one
significant model assumption or input is unobservable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy gives the highest priority
to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If
the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is
based on the lowest level input that is significant to the fair value measurement of the instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s financial
assets and liabilities, such as cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their
fair values due to the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses Level 3 of the fair value hierarchy
to measure the fair value of its warrant liabilities. The Company revalues such liabilities at every reporting period and recognizes gains
or losses as change in fair value of warrant liabilities in the condensed consolidated statements of operations that are attributable
to the change in the fair value of the warrant liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides the financial liabilities
measured on a recurring basis and reported at fair value on the balance sheet as of March 31, 2021 and indicates the fair value hierarchy
of the valuation inputs the Company utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2021</b></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font: 10pt Times New Roman, Times, Serif">Warrant liabilities &#8211; January Warrants</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,164,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Warrant liabilities &#8211; February Warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,004,000</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fair value as of March 31, 2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,168,000</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had no assets or liabilities measured
at fair value at December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Both the January and February Warrants are classified
as Level 3, for which there is no current market for these securities such as the determination of fair value requires significant judgment
or estimation. Changes in fair value measurement categorized within Level 3 of the fair value hierarchy are analyzed each period based
on changes in estimates or assumptions and recorded as appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Initial Measurement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company established the initial fair value of
its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes valuation model in order to determine their
value. The key inputs into the Black Scholes valuation model for the initial valuations are below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>January Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>February Warrants</b>&#160;&#160;</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>January 13, 2021</i></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>February 12, 2021</i></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 53%"><font style="font: 10pt Times New Roman, Times, Serif">Term (years)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.21</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.62</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercise price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.5</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.5</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,821,514</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,714,005</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Value (per share)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.00</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Subsequent measurement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the changes in fair value
of the warrant liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>January Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>February Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total Warrant Liability</b></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fair value as of December 31, 2020</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 47%"><font style="font: 10pt Times New Roman, Times, Serif">Initial value of warrant liability</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,846,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,135,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,981,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Change in fair value</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,682,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,131,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,813,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fair value as of March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,164,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,004,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,168,000</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key inputs into the Black Scholes valuation model
for the Level 3 valuations as of March 31, 2021 are below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>January Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>February Warrants</b></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%"><font style="font: 10pt Times New Roman, Times, Serif">Term (years)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.8</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.07</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.07</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercise price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.9</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.9</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,821,514</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,714,005</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Value (per share)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.74</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.75</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Fair Value</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying value of the Company&#8217;s financial
instruments, including cash and accounts payable, notes payable and convertible notes payable, approximate fair value because of
the short-term nature of such financial instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued ASU No. 2019-12, Income Taxes (Topic 740: Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;),
which removes certain exceptions to the general principles in Topic 740. ASU 2019-12 is effective for the fiscal years beginning after
December 15, 2020, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company&#8217;s
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10, &#8220;Codification
Improvements.&#8221; The new accounting rules improve the consistency of the Codification by including all disclosure guidance in the
appropriate Disclosure Section (Section 50) that had only been included in the Other Presentation Matters Section (Section 45) of the
Codification. Additionally, the new rules also clarify guidance across various topics including defined benefit plans, foreign currency
transactions, and interest expense. The new accounting rules were effective for the Company in the first quarter of 2021. The adoption
of the new accounting rules did not have a material impact on the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings
Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718),
and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications
or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and
reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options
(for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective
for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption
permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until
October 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s condensed consolidated
financial statements.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Subsequent Events</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as described in these
financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the
financial statements.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Subsequent Events</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events and
transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Other than as
described in these financial statements, the Company did not identify any subsequent events that would have required adjustment to
or disclosure in the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_OfferingCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_OfferingCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592181000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Potentially dilutive securities outlined in the table
below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended March&#160;31,&#160;2021</font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended March&#160;31,&#160;2020</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants to purchase shares of common stock</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,979,611</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,504,593</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Convertible notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">380,920</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted stock units</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,279,284</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted stock awards</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,986</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Options to purchase shares of common stock</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">369,361</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,604,348</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Total potentially dilutive securities</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,699,242</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,489,861</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></font></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Potentially dilutive securities outlined in
the table below have been excluded from the computation of diluted net loss per share because the effect of their inclusion would
have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2019</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Warrants to purchase shares of common stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">3,251,406</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">303,891</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Convertible notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">55,306</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Series B Preferred Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,275,407</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">262,500</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Options to purchase shares of common stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">929,765</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">797,373</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total potentially dilutive securities</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,456,578</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,419,070</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides the financial liabilities
measured on a recurring basis and reported at fair value on the balance sheet as of March 31, 2021 and indicates the fair value hierarchy
of the valuation inputs the Company utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2021</b></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font: 10pt Times New Roman, Times, Serif">Warrant liabilities &#8211; January Warrants</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,164,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Warrant liabilities &#8211; February Warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,004,000</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fair value as of March 31, 2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,168,000</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock', window );">Schedule of Fair Value of Warrant Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the changes in fair value
of the warrant liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>January Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>February Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total Warrant Liability</b></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fair value as of December 31, 2020</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 47%"><font style="font: 10pt Times New Roman, Times, Serif">Initial value of warrant liability</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,846,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,135,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,981,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Change in fair value</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,682,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,131,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,813,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fair value as of March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,164,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,004,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,168,000</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock', window );">Schedule of Black Scholes Valuation Models of Warrant Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key inputs into the Black Scholes valuation model
for the initial valuations are below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>January Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>February Warrants</b>&#160;&#160;</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>January 13, 2021</i></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>February 12, 2021</i></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 53%"><font style="font: 10pt Times New Roman, Times, Serif">Term (years)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.21</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.62</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercise price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.5</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.5</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,821,514</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,714,005</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Value (per share)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.00</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock', window );">Schedule of Black Scholes Valuation Models of Warrant Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key inputs into the Black Scholes valuation model
for the Level 3 valuations as of March 31, 2021 are below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>January Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>February Warrants</b></font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%"><font style="font: 10pt Times New Roman, Times, Serif">Term (years)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.8</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.07</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.07</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercise price</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.9</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.9</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,821,514</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,714,005</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Value (per share)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.74</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.75</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value of Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ScheduleOfFairValueOfWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Black Scholes Valuation Models of Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ScheduleOfNonVestedValuationModelsOfWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amrh_InitialMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593164392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable and Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Notes Payable and Convertible Notes Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2019, the Company&#8217;s notes payable and convertible
notes payable consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Gross</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Discount</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 46%"><font style="font-size: 10pt">February 2019 Note</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">66,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">66,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">March 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">April 2019 Convertible Notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">300,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(6,079</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">293,921</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">July 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">191,640</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(2,700</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">188,940</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">December 2019 Note</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">44,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,525</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">41,475</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">751,640</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(11,304</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">740,336</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Notes payable</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">451,640</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(5,225</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">446,415</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Convertible notes payable</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">300,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(6,079</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">293,921</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Interest Expense and Amortization of Debt Discount</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2020 and 2019,
interest expense and amortization of debt discount consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">For the Year Ended December 31,</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Interest Expense</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Amortization of Debt Discount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Interest Expense</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Amortization of Debt Discount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 34%"><font style="font: 10pt Times New Roman, Times, Serif">February 2019 Note</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,840</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,840</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">April 2019 Convertible Notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,970</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,842</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19,812</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,370</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17,142</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">30,512</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">July 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">53,342</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,704</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">98,046</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43,836</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43,836</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">December 2019 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,427</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,427</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,475</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,475</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">February 2020 Note</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,545</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,912</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">53,457</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Alpha Note</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">86,762</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">181,906</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">268,668</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">156,619</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">288,631</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">445,250</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,370</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,453</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">81,823</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Beneficial Conversion Feature and Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company valued the beneficial conversion
feature and warrants using the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Beneficial Conversion Feature</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Stock Price</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">CAD $ 1.10</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">CAD $ 1.10</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Exercise Price</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">CAD $ 0.51</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">CAD $ 0.51</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Dividend Yield</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">N/A</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">96.0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Weighted Average Risk-Free Interest Rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.31</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Number of Shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">130,920</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Value (USD)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">17,851</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">32,149</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Term (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359597173880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ScheduleOfAssetsPurchasedTableTextBlock', window );">Schedule of Assets Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%; text-align: justify"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">44,143</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Common stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,900,546</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,944,689</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Components of Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2021, the Company&#8217;s intangible
assets consisted of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Useful Life</font></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross<br />
Carrying<br />
Amount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated<br />
Amortization</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 41%"><font style="font: 10pt Times New Roman, Times, Serif">Skincare Assets and License Agreements</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,944,689</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(257,512</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,687,177</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Diverse Bio License Agreement</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">675,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">675,000</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,619,689</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(257,512</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,362,177</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2020, the Company&#8217;s intangible assets consisted
of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Gross<br />
Carrying<br />
Amount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated<br />
Amortization</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Net</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 46%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Skincare Assets and License Agreements</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,944,689</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(126,968</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,817,721</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ScheduleOfAssetsPurchasedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Assets Purchased [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ScheduleOfAssetsPurchasedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359591668264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Exercise Price (USD)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value (USD)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Remaining Contractual Term (years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value (USD)</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding &#8211; January 1, 2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">929,765</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.53</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.50</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Expired forfeited, or cancelled</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(560,404</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.65</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding &#8211; December 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">369,361</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.35</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.2</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">636,156</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at December 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">369,361</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.35</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.2</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">636,156</font></td>
    <td></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Number of Shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Exercise Price (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Grant Date Fair Value (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted Average Remaining Contractual Term (years)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Aggregate Intrinsic Value (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 35%"><font style="font-size: 10pt">Outstanding &#8211; January 1, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">689,832</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.94</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.94</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">448,713</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.99</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.49</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expired, forfeited, or cancelled</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(341,172</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.99</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.36</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Outstanding &#8211; December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">797,373</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.99</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.72</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">378,800</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.94</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5.22</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Expired forfeited, or cancelled</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(246,408</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.94</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">0.88</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Outstanding &#8211; December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">929,765</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.53</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2.50</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6.1</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,537,245</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">929,765</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.53</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2.50</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6.1</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,537,245</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Schedule of Fair Value Assumption of Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilized the Black-Scholes option-pricing
model to determine the fair value of these stock options, using the assumptions as outlined below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%; text-align: justify"><font style="font-size: 10pt">Stock Price</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">5.92</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Dividend Yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Expected Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">84.7</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Weighted Average Risk-Free Interest Rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.37</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Expected life (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.5 &#8211; 4.2</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about shares
issuable under warrants outstanding at March 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Warrant<br />
shares<br />
outstanding</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted<br />
average<br />
exercise price (USD)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average remaining life</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic value</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at January 1, 2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,661,178</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.98</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,535,519</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.93</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(851,099</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.17</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,345,598</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.33</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,049,152</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,345,598</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.33</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,049,152</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information
about shares issuable under warrants outstanding at December 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Warrant <br />
shares <br />
outstanding</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted <br />
average<br />
exercise price (USD)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted average remaining life</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Intrinsic value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><font style="font-size: 10pt">Outstanding at January 1, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">219,510</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">2.95</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 10pt">0.08</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Issued</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">84,381</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3.21</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Outstanding at December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">303,891</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.02</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.06</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,222,331</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.96</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(274,816</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3.00</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,251,406</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.95</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.97</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,251,406</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1.95</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.97</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,040,545</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units and Awards Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s activity in restricted common
stock was as follows for the three months ended March 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">shares</p></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted<br />
average<br />
grant date<br />
fair<br />
value</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at January 1, 2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 63%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,986</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.16</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(44,390</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.49</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">26,596</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.61</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units and Awards Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s activity in restricted stock units
was as follows for&#160;the&#160;three months ended March 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average<br />
grant date fair<br />
value</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at January 1, 2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,279,284</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.41</font></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,207,825</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.46</font></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Non&#8211;vested at March 31, 2021</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,071,459</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.38</font></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593189128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">As of December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred tax assets:</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%; padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Net operating loss carryovers</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">1,340,152</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt"><font style="font-size: 10pt">Deferred tax assets, gross</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,340,152</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-size: 10pt">Less: valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,340,152</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,004,029</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Deferred tax assets, net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Deferred tax assets (liabilities), net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Valuation Allowance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The change in the Company&#8217;s valuation allowance is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2019</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Beginning of year</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">505,871</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Increase in valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,340,152</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">498,158</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">End of year</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,344,180</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,004,029</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the provision for income
taxes with the amounts computed by applying the statutory federal income tax rate to loss from operations before the provision
for income taxes is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2020</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">For the year ended December 31, 2019</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Canada federal statutory rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">(15.0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">(15.0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Provincial taxes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(11.5</font></td>
    <td><font style="font-size: 10pt">)%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(11.5</font></td>
    <td><font style="font-size: 10pt">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Permanent differences</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Non-deductible expenses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.5</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.9</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">19.1</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">20.6</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Effective income tax rate</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592266840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,010,268)<span></span>
</td>
<td class="num">$ (11,759,557)<span></span>
</td>
<td class="num">$ (4,894,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,797,501<span></span>
</td>
<td class="nump">$ 1,597,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">3,007,026<span></span>
</td>
<td class="nump">2,221,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from offering cost</a></td>
<td class="nump">$ 11,624,401<span></span>
</td>
<td class="nump">$ 8,806,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amrh_OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amrh_OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592291864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,010,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,759,557)<span></span>
</td>
<td class="num">$ (4,894,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,797,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,597,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,614,488<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,657,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,578,460<span></span>
</td>
<td class="nump">$ 43,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">3,007,026<span></span>
</td>
<td class="nump">2,221,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593229000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359591690056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued for penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592081800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">9,699,242<span></span>
</td>
<td class="nump">5,489,861<span></span>
</td>
<td class="nump">7,456,578<span></span>
</td>
<td class="nump">1,419,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">5,979,611<span></span>
</td>
<td class="nump">1,504,593<span></span>
</td>
<td class="nump">3,251,406<span></span>
</td>
<td class="nump">303,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">380,920<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">55,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">3,279,284<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">70,986<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_OptionsToPurchaseSharesOfCommonStockMember', window );">Options to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">369,361<span></span>
</td>
<td class="nump">3,604,348<span></span>
</td>
<td class="nump">929,765<span></span>
</td>
<td class="nump">797,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_OptionsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_OptionsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359586785320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) (10-K) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">9,699,242<span></span>
</td>
<td class="nump">5,489,861<span></span>
</td>
<td class="nump">7,456,578<span></span>
</td>
<td class="nump">1,419,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">5,979,611<span></span>
</td>
<td class="nump">1,504,593<span></span>
</td>
<td class="nump">3,251,406<span></span>
</td>
<td class="nump">303,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">380,920<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">55,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,275,407<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_OptionsToPurchaseSharesOfCommonStockMember', window );">Options to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">369,361<span></span>
</td>
<td class="nump">3,604,348<span></span>
</td>
<td class="nump">929,765<span></span>
</td>
<td class="nump">797,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_OptionsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amrh_OptionsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359596976744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis (Details) - Fair Value, Recurring [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">$ 6,168,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liabilities - January Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">3,164,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liabilities - February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">$ 3,004,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrh_WarrantLiabilitiesJanuaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrh_WarrantLiabilitiesJanuaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrh_WarrantLiabilitiesFebruaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrh_WarrantLiabilitiesFebruaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359590407336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Black Scholes Valuation Models of Warrant Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant measurement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | January Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant measurement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,821,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | January Warrants [Member] | Stock Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | January Warrants [Member] | Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | January Warrants [Member] | Discount Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | January Warrants [Member] | Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | January Warrants [Member] | Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant measurement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | February Warrants [Member] | Stock Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | February Warrants [Member] | Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | February Warrants [Member] | Discount Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | February Warrants [Member] | Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember', window );">Initial Measurement [Member] | February Warrants [Member] | Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant measurement term</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares | shares</a></td>
<td class="nump">1,821,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Value (per share)</a></td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Warrants [Member] | Stock Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Warrants [Member] | Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Warrants [Member] | Discount Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Warrants [Member] | Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">84.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Warrants [Member] | Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant measurement term</a></td>
<td class="text">4 years 10 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares | shares</a></td>
<td class="nump">1,714,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Value (per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Warrants [Member] | Stock Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Warrants [Member] | Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Warrants [Member] | Discount Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Warrants [Member] | Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">84.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Warrants [Member] | Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amrh_InitialMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amrh_InitialMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrh_JanuaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrh_JanuaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrh_FebruaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrh_FebruaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359586790504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liabilities (Details) - Subsequent Measurement [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability', window );">Initial value of warrant liability</a></td>
<td class="nump">9,981,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue', window );">Change in fair value</a></td>
<td class="num">(3,813,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of March 31, 2021</a></td>
<td class="nump">6,168,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">January Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability', window );">Initial value of warrant liability</a></td>
<td class="nump">4,846,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue', window );">Change in fair value</a></td>
<td class="num">(1,682,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of March 31, 2021</a></td>
<td class="nump">3,164,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember', window );">February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability', window );">Initial value of warrant liability</a></td>
<td class="nump">5,135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue', window );">Change in fair value</a></td>
<td class="num">(2,131,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of March 31, 2021</a></td>
<td class="nump">$ 3,004,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueInitialValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amrh_SubsequentMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrh_JanuaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrh_JanuaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrh_FebruaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrh_FebruaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359578659816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable and Convertible Notes Payable (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Jul. 21, 2020</div></th>
<th class="th"><div>May 06, 2020</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Jan. 12, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
<th class="th"><div>Jan. 08, 2020</div></th>
<th class="th"><div>Dec. 12, 2019</div></th>
<th class="th"><div>Dec. 09, 2019</div></th>
<th class="th"><div>Nov. 21, 2019</div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
<th class="th"><div>Jul. 08, 2019</div></th>
<th class="th"><div>Mar. 05, 2019</div></th>
<th class="th"><div>Feb. 07, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 23, 2020</div></th>
<th class="th"><div>Jun. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,319,910<span></span>
</td>
<td class="nump">$ 1,812,410<span></span>
</td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,800<span></span>
</td>
<td class="nump">448,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,813,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion converted instrument shares issued</a></td>
<td class="nump">2,473,848<span></span>
</td>
<td class="nump">239,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion converted instrument value</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember', window );">February 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember', window );">February 2019 Note [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember', window );">February 2019 Note [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  08,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember', window );">March 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember', window );">March 2019 Note [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember', window );">March 2019 Note [Member] | Former Executive Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  04,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember', window );">July 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The January 8 Amendment extended the maturity date for the July 2019 Note until the (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) April 1, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember', window );">July 2019 Note [Member] | Note Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into an additional amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) January 7, 2020.<span></span>
</td>
<td class="text">The Company entered into an amendment for the July 2019 Note that extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) December 9, 2019.<span></span>
</td>
<td class="text">The Company entered into an amendment to the July 2019 Note (the "Amendment"). The Amendment extended the maturity date for the Note until the earlier of (a) the completion of a bridge financing of greater than or equal to $1,500,000, or (b) November 7, 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_AggregateExtensionFee', window );">Aggregate extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember', window );">July 2019 Note [Member] | Former Executive Director [Member] | Note Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  08,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember', window );">July 2019 Note [Member] | Lender [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_MayTwoThousandNineteenAmendmentMember', window );">May 2019 Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into an amendment (the "May 2020 Amendment") whereby both parties agreed to extend the maturity date of the July 2019 Note to September 30, 2020. The Company accounted for this amendment as a modification, as the present value of the future cash flows pre-modification and post-modification were not greater than or equal to 10%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember', window );">December 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember', window );">December 2019 Note [Member] | Lender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember', window );">December 2019 Note [Member] | Lender [Member] | Event of Default [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember', window );">December 2019 Note [Member] | Lender [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion converted instrument shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember', window );">February 2020 Note [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion converted instrument shares issued</a></td>
<td class="nump">190,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember', window );">February 2020 Note [Member] | Lender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember', window );">February 2020 Note [Member] | Lender [Member] | Event of Default [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_SecuredPromissoryNoteMember', window );">Secured Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FirstNoteAmendmentMember', window );">First Note Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FirstNoteAmendmentMember', window );">First Note Amendment [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion converted instrument shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_SecondNoteAmendmentMember', window );">Second Note Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_SecondNoteAmendmentMember', window );">Second Note Amendment [Member] | Alpha Capital Anstalt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_AggregateExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate extension fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_AggregateExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amrh_FormerExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amrh_FormerExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_NoteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_NoteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amrh_LenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amrh_LenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_MayTwoThousandNineteenAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_MayTwoThousandNineteenAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amrh_EventOfDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amrh_EventOfDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_SecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_SecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FirstNoteAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FirstNoteAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_SecondNoteAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_SecondNoteAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=amrh_AlphaCapitalAnstaltMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=amrh_AlphaCapitalAnstaltMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359590338424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable and Convertible Notes Payable - Schedule of Notes Payable and Convertible Notes Payable (Details) (10-K)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">$ 751,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(11,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">740,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember', window );">February 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember', window );">March 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_AprilTwoThousandNineteenConvertibleNotesMember', window );">April 2019 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(6,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">293,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember', window );">July 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">191,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(2,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">188,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember', window );">December 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(2,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">41,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_NotesPayableMember', window );">Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">451,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(5,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">446,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(6,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net</a></td>
<td class="nump">$ 293,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_AprilTwoThousandNineteenConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_AprilTwoThousandNineteenConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359591979816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable and Convertible Notes Payable - Schedule of Interest Expense and Amortization of Debt Discount (Details) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense</a></td>
<td class="nump">$ 156,619<span></span>
</td>
<td class="nump">$ 13,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount</a></td>
<td class="nump">288,631<span></span>
</td>
<td class="nump">68,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">445,250<span></span>
</td>
<td class="nump">81,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember', window );">February 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount</a></td>
<td class="nump">3,840<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">3,840<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_AprilTwoThousandNineteenConvertibleNotesMember', window );">April 2019 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense</a></td>
<td class="nump">13,970<span></span>
</td>
<td class="nump">13,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount</a></td>
<td class="nump">5,842<span></span>
</td>
<td class="nump">17,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">19,812<span></span>
</td>
<td class="nump">30,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember', window );">July 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense</a></td>
<td class="nump">53,342<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount</a></td>
<td class="nump">44,704<span></span>
</td>
<td class="nump">43,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">98,046<span></span>
</td>
<td class="nump">43,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember', window );">December 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember', window );">February 2020 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount</a></td>
<td class="nump">50,912<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">53,457<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_AlphaNoteMember', window );">Alpha Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense</a></td>
<td class="nump">86,762<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount</a></td>
<td class="nump">181,906<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 268,668<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_AprilTwoThousandNineteenConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_AprilTwoThousandNineteenConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_JulyTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_DecemberTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_AlphaNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_AlphaNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359578595016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable and Convertible Notes Payable - Schedule of Beneficial Conversion Feature and Warrants (Details) (10-K)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants Value (USD)</a></td>
<td class="nump">$ 32,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants Term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Beneficial Conversion Feature measurement input Value (USD)</a></td>
<td class="nump">$ 17,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Beneficial Conversion Feature measurement input Term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price [Member] | CAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">1.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMeasurementInput', window );">Beneficial Conversion Feature measurement input</a></td>
<td class="nump">1.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Exercise Price [Member] | CAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMeasurementInput', window );">Beneficial Conversion Feature measurement input</a></td>
<td class="nump">0.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">96.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Weighted Average Risk-Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">2.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amrh_MeasurementInputSharesMember', window );">Number of Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">130,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amrh_CADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amrh_CADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=amrh_MeasurementInputSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=amrh_MeasurementInputSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359591722280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,640<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 120,872<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrh_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Diverse Biotech, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_PaymentOfUpfrontInvestment', window );">Payment of up-front investment</a></td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_PaymentOfUpfrontInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of up-front investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_PaymentOfUpfrontInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amrh_DiverseBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amrh_DiverseBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593058056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,619,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsMember', window );">Skincare Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 1,944,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592332472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Assets Purchased (Details) (10-K) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 22,657,150<span></span>
</td>
<td class="nump">$ 1,578,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">194,499<span></span>
</td>
<td class="nump">$ 100,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 2,619,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsMember', window );">Skincare Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,944,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592269544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Components of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 2,619,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(257,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,362,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsAndLicenseAgreementsMember', window );">Skincare Assets and License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,944,689<span></span>
</td>
<td class="nump">$ 1,944,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(257,512)<span></span>
</td>
<td class="nump">126,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1,687,177<span></span>
</td>
<td class="nump">$ 1,817,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_DiverseBioLicenseAgreementMember', window );">Diverse Bio License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_DiverseBioLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_DiverseBioLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592263848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Components of Intangible Assets (Details) (10-K) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 2,619,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">257,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,362,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsAndLicenseAgreementsMember', window );">Skincare Assets and License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,944,689<span></span>
</td>
<td class="nump">$ 1,944,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">257,512<span></span>
</td>
<td class="num">(126,968)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1,687,177<span></span>
</td>
<td class="nump">$ 1,817,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amrh_SkincareAssetsAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359597308664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingengies (Details Narrative) - Subsequent Event [Member] - Ward Employment Agreement [Member]<br></strong></div></th>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Base salary</a></td>
<td class="nump">$ 295,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_AnnualPerformanceBonusesPercentage', window );">Annual performance bonuses percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_AnnualPerformanceBonusesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual performance bonuses percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_AnnualPerformanceBonusesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_WardEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_WardEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359590262856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingengies (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 06, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Jan. 05, 2019</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,800<span></span>
</td>
<td class="nump">448,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=amrh_ConsultantMember', window );">Consultant [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=amrh_MrDavidStefanskyMember', window );">Mr. David Stefansky [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Wages and salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of granted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=amrh_MrHenochCohnMember', window );">Mr. Henoch Cohn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Wages and salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrh_BusinessAdvisorServicesAgreementMember', window );">Business Advisor Services Agreement [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period shares issued for services</a></td>
<td class="nump">127,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrh_BusinessAdvisorServicesAgreementMember', window );">Business Advisor Services Agreement [Member] | Consultant [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrh_BusinessAdvisorServicesAgreementMember', window );">Business Advisor Services Agreement [Member] | Consultant [Member] | Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amrh_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amrh_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amrh_MrDavidStefanskyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amrh_MrDavidStefanskyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amrh_MrHenochCohnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amrh_MrHenochCohnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_BusinessAdvisorServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_BusinessAdvisorServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359587226120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the Company's common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the Company's common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,614,488<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,800<span></span>
</td>
<td class="nump">448,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_InducementExpense', window );">Inducement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,714<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (802,109)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,977,155<span></span>
</td>
<td class="nump">$ 535,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_UnamortizedStockOptionExpense', window );">Unamortized stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,559,453<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock based compensation, not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,416,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,112<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_InducementExpense', window );">Inducement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock based compensation, not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">3,007,026<span></span>
</td>
<td class="nump">2,221,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from offering cost</a></td>
<td class="nump">11,624,401<span></span>
</td>
<td class="nump">$ 8,806,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">1,503,513<span></span>
</td>
<td class="nump">1,666,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="nump">$ 4.9519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,275,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,275,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_InducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inducement expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_InducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_UnamortizedStockOptionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized stock option expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_UnamortizedStockOptionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amrh_OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amrh_OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359585728152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th"><div>Jul. 21, 2020</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the Company's common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the Company's common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable', window );">Common stock issued for accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,482<span></span>
</td>
<td class="nump">$ 756,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Advance from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of warrants discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,631<span></span>
</td>
<td class="nump">68,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,977,155<span></span>
</td>
<td class="nump">535,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_UnamortizedStockOptionExpense', window );">Unamortized stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember', window );">February 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of warrants discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember', window );">February 2020 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights outstanding, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 24,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of warrants discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,912<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember', window );">February 2020 Note [Member] | CAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt instrument, exchange of common stock issued</a></td>
<td class="nump">2,473,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable', window );">Common stock issued for accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 4,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares', window );">Common stock issued for accounts payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,942<span></span>
</td>
<td class="nump">433,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | February 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | March 2019 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | February 2020 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt instrument, exchange of common stock issued</a></td>
<td class="nump">190,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | September Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock under private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable', window );">Common stock issued for accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares', window );">Common stock issued for accounts payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | February 2020 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of warrants discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt instrument, exchange of common stock issued</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable', window );">Common stock issued for accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares', window );">Common stock issued for accounts payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | December Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock under private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for accounts payable, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodSharesCommonStockIssuedForAccountsPayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_UnamortizedStockOptionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized stock option expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_UnamortizedStockOptionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_FebruaryTwoThousandTwentyNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrh_MarchTwoThousandNineteenNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amrh_SeptemberPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amrh_SeptemberPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amrh_VendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amrh_VendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amrh_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amrh_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amrh_DecemberPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amrh_DecemberPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359586668568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract', window );"><strong>Share Capital And Other Equity Instruments - Schedule Of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at beginning</a></td>
<td class="nump">929,765<span></span>
</td>
<td class="nump">797,373<span></span>
</td>
<td class="nump">689,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares, Expired, forfeited, or cancelled</a></td>
<td class="num">(560,404)<span></span>
</td>
<td class="num">(246,408)<span></span>
</td>
<td class="num">(341,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at end</a></td>
<td class="nump">369,361<span></span>
</td>
<td class="nump">929,765<span></span>
</td>
<td class="nump">797,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable at ending</a></td>
<td class="nump">369,361<span></span>
</td>
<td class="nump">929,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired, forfeited, or cancelled</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.94<span></span>
</td>
<td class="nump">1.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at end</a></td>
<td class="nump">1.35<span></span>
</td>
<td class="nump">1.53<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at ending</a></td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at beginning</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
<td class="nump">1.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Expired, forfeited, or cancelled</a></td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at end</a></td>
<td class="nump">3.80<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exercisable</a></td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Outstanding</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 636,156<span></span>
</td>
<td class="nump">$ 2,537,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 636,156<span></span>
</td>
<td class="nump">$ 2,537,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, expired, forfeited, or cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, outstanding at beginning of the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359592223800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract', window );"><strong>Share Capital And Other Equity Instruments - Schedule Of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at beginning</a></td>
<td class="nump">929,765<span></span>
</td>
<td class="nump">797,373<span></span>
</td>
<td class="nump">689,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,800<span></span>
</td>
<td class="nump">448,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares, Expired, forfeited, or cancelled</a></td>
<td class="num">(560,404)<span></span>
</td>
<td class="num">(246,408)<span></span>
</td>
<td class="num">(341,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding at end</a></td>
<td class="nump">369,361<span></span>
</td>
<td class="nump">929,765<span></span>
</td>
<td class="nump">797,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable at ending</a></td>
<td class="nump">369,361<span></span>
</td>
<td class="nump">929,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="nump">1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired, forfeited, or cancelled</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.94<span></span>
</td>
<td class="nump">1.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at end</a></td>
<td class="nump">1.35<span></span>
</td>
<td class="nump">1.53<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at ending</a></td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at beginning</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
<td class="nump">1.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Expired, forfeited, or cancelled</a></td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at end</a></td>
<td class="nump">3.80<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exercisable</a></td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Outstanding at December 31, 2020</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Exercisable at December 31, 2020</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 636,156<span></span>
</td>
<td class="nump">$ 2,537,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 636,156<span></span>
</td>
<td class="nump">$ 2,537,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, expired, forfeited, or cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, outstanding at beginning of the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareCapitalAndOtherEquityInstrumentsScheduleOfStockOptionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359676970792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments - Schedule Of Restricted Stock Units and Awards Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Nonvested at beginning | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="nump">70,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(44,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Nonvested at end | shares</a></td>
<td class="nump">26,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested at beginning | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted | $ / shares</a></td>
<td class="nump">4.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested | $ / shares</a></td>
<td class="nump">4.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-Vested at end | $ / shares</a></td>
<td class="nump">$ 3.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Nonvested at beginning | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="nump">3,279,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(1,207,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Nonvested at end | shares</a></td>
<td class="nump">2,071,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested at beginning | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted | $ / shares</a></td>
<td class="nump">4.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested | $ / shares</a></td>
<td class="nump">4.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-Vested at end | $ / shares</a></td>
<td class="nump">$ 4.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359676881064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments - Schedule of Fair Value Assumption of Stock Option (Details) (10-K)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Fair value</a></td>
<td class="nump">5.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Fair value</a></td>
<td class="nump">84.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Weighted Average Risk-Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Fair value</a></td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life (in years) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueTerm', window );">Fair value term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life (in years) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_FairValueTerm', window );">Fair value term</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_FairValueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_FairValueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359590389464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments - Schedule of Warrants (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at beginning</a></td>
<td class="nump">3,661,178<span></span>
</td>
<td class="nump">303,891<span></span>
</td>
<td class="nump">219,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrant shares outstanding, Issued</a></td>
<td class="nump">3,535,519<span></span>
</td>
<td class="nump">3,222,331<span></span>
</td>
<td class="nump">84,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrant shares outstanding, Forfeited</a></td>
<td class="num">(851,099)<span></span>
</td>
<td class="num">(274,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at end</a></td>
<td class="nump">6,345,598<span></span>
</td>
<td class="nump">3,661,178<span></span>
</td>
<td class="nump">303,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ClassOfWarrantOrRighExercisable', window );">Warrant shares outstanding, Exercisable</a></td>
<td class="nump">6,345,598<span></span>
</td>
<td class="nump">3,251,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise Price, Outstanding at beginning</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Issued</a></td>
<td class="nump">4.93<span></span>
</td>
<td class="nump">1.96<span></span>
</td>
<td class="nump">3.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">4.17<span></span>
</td>
<td class="num">(3.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end</a></td>
<td class="nump">3.33<span></span>
</td>
<td class="nump">1.98<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding', window );">Weighted average remaining life, Outstanding</a></td>
<td class="text">4 years 10 months 25 days<span></span>
</td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">1 year 22 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding', window );">Weighted average remaining life, Exercisable</a></td>
<td class="text">4 years 10 months 25 days<span></span>
</td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 6,049,152<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable', window );">Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 6,049,152<span></span>
</td>
<td class="nump">$ 8,040,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ClassOfWarrantOrRighExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant shares outstanding, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ClassOfWarrantOrRighExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments forfeited in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments granted in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359586678184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Equity Instruments - Schedule of Warrants (Details) (10-K) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at beginning</a></td>
<td class="nump">3,661,178<span></span>
</td>
<td class="nump">303,891<span></span>
</td>
<td class="nump">219,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrant shares outstanding, Issued</a></td>
<td class="nump">3,535,519<span></span>
</td>
<td class="nump">3,222,331<span></span>
</td>
<td class="nump">84,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrant shares outstanding, Forfeited</a></td>
<td class="num">(851,099)<span></span>
</td>
<td class="num">(274,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at end</a></td>
<td class="nump">6,345,598<span></span>
</td>
<td class="nump">3,661,178<span></span>
</td>
<td class="nump">303,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ClassOfWarrantOrRighExercisable', window );">Warrant shares outstanding, Exercisable</a></td>
<td class="nump">6,345,598<span></span>
</td>
<td class="nump">3,251,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise Price, Outstanding at beginning</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Issued</a></td>
<td class="nump">4.93<span></span>
</td>
<td class="nump">1.96<span></span>
</td>
<td class="nump">3.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">4.17<span></span>
</td>
<td class="num">(3.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end</a></td>
<td class="nump">3.33<span></span>
</td>
<td class="nump">1.98<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning', window );">Weighted average remaining life, Outstanding at beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 22 days<span></span>
</td>
<td class="text">29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding', window );">Weighted average remaining life, Outstanding at December 31, 2020</a></td>
<td class="text">4 years 10 months 25 days<span></span>
</td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">1 year 22 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding', window );">Weighted average remaining life, Exercisable at December 31, 2020</a></td>
<td class="text">4 years 10 months 25 days<span></span>
</td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 6,049,152<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable', window );">Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 6,049,152<span></span>
</td>
<td class="nump">$ 8,040,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ClassOfWarrantOrRighExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant shares outstanding, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ClassOfWarrantOrRighExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments forfeited in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments granted in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359591981464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Tender Agreement (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>May 06, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=amrh_AlphaCapitalAnstaltMember', window );">Alpha Capital Anstalt [Member] | Amalgamation Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=amrh_EnvericBiosciencesIncMember', window );">Enveric Biosciences, Inc. [Member] | Amalgamation Amendment Agreement [Member] | Common Stock [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to acquire shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=amrh_EnvericBiosciencesIncMember', window );">Enveric Biosciences, Inc. [Member] | Second Amalgamation Amendment Agreement [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to acquire shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=amrh_EnvericBiosciencesIncMember', window );">Enveric Biosciences, Inc. [Member] | Second Amalgamation Amendment Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued during amalgamation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,675,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=amrh_EnvericBiosciencesIncMember', window );">Enveric Biosciences, Inc. [Member] | Tender Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_CommonStockBeneficialOwnershipBlockerPercentage', window );">Common stock beneficial ownership blocker, percentage</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_CommonStockBeneficialOwnershipBlockerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock beneficial ownership blocker, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_CommonStockBeneficialOwnershipBlockerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=amrh_AlphaCapitalAnstaltMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=amrh_AlphaCapitalAnstaltMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_AmalgamationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_AmalgamationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=amrh_EnvericBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=amrh_EnvericBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_AmalgamationAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_AmalgamationAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amrh_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amrh_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_SecondAmalgamationAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_SecondAmalgamationAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_TenderAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_TenderAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359593210536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 1,340,152<span></span>
</td>
<td class="nump">$ 1,004,029<span></span>
</td>
<td class="nump">$ 505,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember', window );">Canadian Federal Income Tax Purposes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryovers</a></td>
<td class="nump">$ 5,057,176<span></span>
</td>
<td class="nump">$ 3,788,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards, expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359677442936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryovers</a></td>
<td class="nump">$ 1,340,152<span></span>
</td>
<td class="nump">$ 1,004,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">1,340,152<span></span>
</td>
<td class="nump">1,004,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(1,340,152)<span></span>
</td>
<td class="num">(1,004,029)<span></span>
</td>
<td class="num">$ (505,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets (liabilities), net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359597235576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Valuation Allowance (Details) (10-K) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning of year</a></td>
<td class="nump">$ 1,004,029<span></span>
</td>
<td class="nump">$ 505,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">1,340,152<span></span>
</td>
<td class="nump">498,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">End of year</a></td>
<td class="nump">$ 1,340,152<span></span>
</td>
<td class="nump">$ 1,004,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359684974024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10-K)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Canada federal statutory rate</a></td>
<td class="num">(15.00%)<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Provincial taxes</a></td>
<td class="num">(11.50%)<span></span>
</td>
<td class="num">(11.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Permanent differences</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">19.10%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140359586852152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) (10-K) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrh_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Diverse Biotech, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_PaymentOfUpfrontInvestment', window );">Payment of up-front investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercise</a></td>
<td class="nump">$ 3,267,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="nump">851,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Exclusive License Agreement [Member] | Diverse Biotech, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrh_PaymentOfUpfrontInvestment', window );">Payment of up-front investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,007,026<span></span>
</td>
<td class="nump">2,221,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of common stock, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrh_PaymentOfUpfrontInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of up-front investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrh_PaymentOfUpfrontInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrh_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrh_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amrh_DiverseBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amrh_DiverseBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amrh_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amrh_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4<=^-J )IK[OVY*.AO$?,B3'#,EW:D-SH!ROC%&*'YA.'=%YB<$:%5HCOG
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MJ.7A$NWPH,6FO25Z%%J+NOU:<)9S:0#P^TI F]T]& ?]5>;L7U!+ P04
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MD;;[6KP&7P&G*]C.CN8$&TAHB2P$'(0,Z<$&ZB^&$DI..CX.MF)WY(;WF40
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M'?#R+.!%-Q/A!'[QS2C=9M7*S,;LZZ*LE;>1W^53KK#E<.HS1]AUM9&)NIW
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MB*" '!'0$7P.& YQXO.Y2+=)0V8\]<V@@^:Z5LG1(L912/@0&*>Q2X"Q#49
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M-![R?$R2D6#8!9DC<B1@/.06"K;@E8CC(!R!H2=(S$V0&II^Y3VIYZPHS*:
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MZGH,H7:UE-F25=80>O/$+[F'3&D ;@,YLCQ62Q_FH&80AY6I5<[F F(-6.
M[8DO,G1TJ6M!EA@M\&PK$[O#H/BXRGI'DH"KN-C*4[D1:EDN+>[[7>'J0Q,1
MI5$.WY8*#2"E<J!XH8Q*%S(#_;F,O<QAA$)?@6TR[MI>'J%.3^H"5S6;SK:4
MZ1J,@@YA/<:K)N1.%II[E+P(N;/"FV2]L&%>@!7O*WI0M)_BRWOENIEM]G"V
M8Z^,"2SYC>A4)NA;V#=4=TDK74N >55MD0 '(:5:^&):=!ZN4AI1)%#)'/P7
MH2(&T5@T;5VC-* '+_MM[441Y1,,0MD-$U]J7(_02E*BR3P+^+J?K\W(I ]A
M&2I$5Y,O=\(EZ>#"O@673?7Q.MA<#8?AXF_+R(I*X18*-X+$_8\M +._NX?
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ML1PP%K=&W8HHW# @O(T-M9,DX^YK;$9W4,$648'\]"QE48?)N1DL WK:FYE
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MN?'>E.$G,1-A:0/>+PQ\:AY(0?=Q^OB_4$L#!!0    ( (.HU5*9;_QPZ00
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M].NJ;-9.ORASDP_,OWYX_F3ZP +/X*#AM%-_VN?3!U=\G=8C/9LD>CJ>3H8
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M=6W*;*??(U1%9\>8K@28'R)L(O+$JM3;%25VY:>J*-!#>?\0Q6@!9,*BRDB
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M_F/H@#V;PG#;ZM7>+5K)1;5E!%<3X4PR5"KV*BDC7^YZX[ ,8#?'7P="BL*
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MB H3OF<4"S]L=9,E-7:GDZ?0J;G-?<%L,#/HK3V/;O$%TR V3^8S.AA*W0H
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M()*JGRS&@Y+H,21OLA YTRU,KGW=A&&RK]U;2;]!&039O07A)8@%BY5YQ#U
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M75O XY;!E6$0SPXG(="YY^MQCSF-PX$+#P,F(D,O6C>;LFUJG) X8O4RJM]
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MXTD83]YZE(-A.)E._0=I9>J65+D,?1)YIPHN]R5#W>A:P?"0+0J1%H@_BB)
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MGCB3Z0KFL  ,=:67YL[JN;6Y!DA:FQ(&N9PF+E-XVH)NU$OZ+*Q:EPXF66?
MK%N;V])DV0:_M^N:Q]9 V,\Y$7*#ZX 4_\>_74PFHV]^'MX,U=^NKM[1Y_$W
MQQHP$8;4MG0KW9+G<L9*PIP\U5=E[9+,ZO$(N?#>WC89?WES\C]#TILR!=*R
MS0 7W^BTT'E1PS1)UJ3 I2S#<4A7-+/"F1=%4<.C0&-I?VL<[GZ^T4BG1CJ)
M/F1Q9FNK^_@WU&],#MB+'W!7X_-OX*C6+D?RX-3JI:F) )/^"LC"/#_"8W$5
MLE,!83F2E"$/R\9DU3&=FDLM4I/;Q%85H@628O3"N!)/JI6#]@!EO^E0OUW#
MN=!IP9, KA6-1@;4R]):O6*]MJC7L($R62JOEAI$@+CG5W9PO"Y/ :,0_#TC
M_;RTOY79  7:/JS!4-@T++:QIL1%D!!07KN:VS+H_Q EN+)]8JMBL>UENZZ6
M19.EN"H:4A0[&/-KD[.A(IE%"AZ?:)M6>,Z3ZGDR(B$L;4:SL+C D-+61>"Y
M%_QKUL<@"E=Y#F<*,KLNREH#:6@(09!/_@O(R6!<(/7FY35^?P7ZE6G/HSZ0
M_%/ XE'&J$>! 9G"?$>=<O6FW<L_!Q= _-4*("$Q*D8.W4$.7)V66J\!NLT<
MX*%L<!4^*P\1E1?8&YLTI:N=//'R(5F:_)8.;.4J\I".\#E9$$[#+Z5@-D,
MLX]K$:H,#YB-63 ;LX-'^'-%:O82 &*%#.FS&)\V YT_'R/+ WS9JPV=\U1T
MGBT8"D16H.\>\C2HP,I\!-T/2R%W304NZIKYSPBX6  T"'*@*@#_S IE!$F!
MQVW-(S-GYBZ3<Z(!"KGM3[&7:!R'V /04>D43AE."A\&$'1%6H45A_K%!K\
M!,U-W926S$75(1[ KVKFOQ*QL#5K*G@.EU& +;:LP4D'0??"9VE;%>KM7NJ
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M#1%EX#>Y73AQVR/WH\@S#O&1&@^>E0K:VR\7E,"J  3 'GBHL \FZ+/LSC2
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M"?2VID4M9W+;-7K5)#P7*!KJ:';TW[@RB!Z"QY:%JS#TYP(L7<*E5X3QE:+
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MB0_ ]_CW)?P'7"#\J:#O_Q]02P,$%     @ @ZC54@@X9>Y3!@  GA,  !D
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MP&[0#YT'H6D&P/MA'0ICU_<",("UP'-]/W)N]WIV@H+:]@2=ABZQT6 QB-P
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M78#_3Z4TRQ=KH+OL._@'4$L#!!0    ( (.HU5+K-.,.,@0  ',*   9
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MRYRF0E16@-YG4IK=QAIHY\S9/U!+ P04    " "#J-52J]D/W10#   ?"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R55EUOFS 4_2L6VD,KM0$<
MOE(ED=IDT3:M6]2HZ\.T!P<NB57 U#9)*^W'SP:"\D%0EH=@PSGGGGLOMAEN
M&7\5:P")WM,D$R-C+65^9YHB7$-*1(_ED*DG,>,ID6K*5Z;(.9"H)*6)B2W+
M,U-",V,\+._-^7C("IG0#.8<B2)-"?]X@(1M1X9M[&X\T=5:ZAOF>)B3%2Q
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MC&XL@VH[4&L86?L[N9;&WG _+&W3!N4<['HAI3D8[IKWOX'T+U!+ P04
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M"P]M(2<-TVNQOX5.S\SR98(I]T7[SM?W4-8H+:H.;#*H*&]7\MK580 (@Q.
ML .$+N\VD,MR231)8BGV2%IOPV8W3JI#F^0HMTU)M32WU.!TDK;-0")'*2TX
MS6E&N$97628:KBDOT$HPFE%0Z#-*S2^Q;1A8[QM")7HBK %T2T$2F96.Q1X1
M5_ [7C=:(;-;0]9(:<D61%&%SI:@"67JW'#^XAD-_+X]0+4!^?TWAY9RA.YA
M!PQ->K<8:U,+JPAGG>Y%JSL\H?N!R#&:!",4^F'PF"[1V:?S]RS85+(O9]B7
M,W2TTQ.T+MF=3?982BUVYK#VM>R2*(@N?-^/\>Y(T$D?=/+7H,]$2MNT>THV
ME%'=-NLKX8WM;'>K3A3K7<1I'W'Z 9DM-AK(G 31]*3,61]T]A\R;V C_UEG
MU(>,/J S^J.=$]\_HA,/GJ>==.;?*RA7B$%ND/[XBZ&0[?1H#2UJ]V(W0IOW
M[[:E&;@@K8.YSX70!\,.@7Z$)S\!4$L#!!0    ( (.HU5*-_:I.N 4   4E
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;+6:76_;-A2&_PIA[*(#
M-DNB2,<I' .UW6(=EB&(L1;#L M:IF,B^G IJFF _?B1$BVJM<E(D7P36Y;X
M\O"0?%Z2T>PIXX_YGE(!OB5QFM^,]D(<WGI>'NUI0O)Q=J"IO+/+>$*$O.0/
M7G[@E&S+0DGL0=^?> EAZ6@^*W^[X_-95HB8I?2.@[Q($L*?%S3.GFY&P>CX
MPSU[V OU@S>?'<@#75/QU^&.RRNO5MFRA*8YRU+ Z>YF]"YX^W[BJP+E$Y\8
M?<H;WX%JRB;+'M7%Q^W-R%<1T9A&0DD0^?&5+FD<*R49QQ<M.JKK5 6;WX_J
M'\K&R\9L2$Z76?R9;<7^9C0=@2W=D2(6]]G3;U0W""N]*(OS\B]XTL_Z(Q 5
MN<@275A&D+"T^B3?="(:!4); :@+P+8%0ET@;%L Z0+HAP(!LA3 ND#9=*]J
M>YFX%1%D/N/9$^#J::FFOI39+TO+?+%4#92UX/(ND^7$?%T-$)#MP)H]I&S'
M(I(*\"Z*LB(5+'T =UG,(D9S\"M8RV&Z+6*JGE[$)'I4OV2QO/>)Q 4I>_XV
MV](X5T]\)IPKK3\8V;"8":7Q9D4%87'^\\P3,GH5@Q?I2!=5I- 2Z2WA8Q &
MOP#HP^ GX(%\3SC-J[]GY)9NN0]T,P8!;"VW<LO]3E(I%[:6>^^66]&H;JS_
M?7%/]G#=S;#N9ECJ(8O>L2\22O*"4SG3!1"4)^<B<RMA\$P)SQTQA75,H5/I
MGN6/X .G%'Q,92PT%^">" K^N:7)AO)_'56@N@K4N=DL/13B7+LKJ6DII?CZ
M=0['83#SOIX) -<!8&< 'U,Y[DD,;AL!'-L'_@-RU!1J]NDX\S9MG]153X;J
M\I5;Z>4NOZICNG(J_5FHUBDX5!-#IL ^X2JI2:,_@BD,<(#.=\FTCF'JC$&A
MBH(W!QE'6?<Y%*TJB:OOQL)D<K[BZ[KBZXN,!7EO+3()VSO.HE;3(_ -_?W!
M)LA*:S5G"!I#RPP)&@X47"HO[[]1'K&<=DB-(6;0'9GVU, SJ;G&EM080@9N
M1/9(S8KEI86#OQF-MZU28Z@:#(?5E=9JSF/?DA=#U> R6"V'S$&N4>D6?,IB
MN6*1ZY+G5LDQV VZ<]>>G$KKNI&<*1I?6?)C,!NX.=LC/SU<.3 (#MP,[I:C
MZ4F._+%M:AD8![UH+)>'O+,U0\-=V)V[%G->OB#ULCM#@V+H1G$7?UYJK>\,
M^BI OF_I&]A8K+K1V\:BEUH#-ZH/+14;WL)>O+4/BNX>#0UMX7"T7<+352P:
M3Z E,0:XL!=PG8GI;M+0P!8.!]NEUFIGTM# %O:"K3,WW5T:&LC"X2"[U%HM
M7!H:Q,(+(?;U-AT: H?#K7R76JN=38<&MV&OE:\S03U\.C0@#H=; R^U5BN?
M#AN'!&XDKXM-3K\4JN8!-]&AH6_8G;X6IUZ\((4JIP;7(,E2L<]!, 5;\NP\
M2S&$#MV$[F+="ZW5>F\=&B"';B"WL>Z%UFANKX/QE:UN ^+0#>(>0Z6[?X>&
MP^%P'%YHK:9'A6/?1AJ#XM"-XGZIZ>[@R' 8#<?A!3IW F%S<&0XC-P<[I>=
M[AZ.#(#1< !>:*T6'HX,?M'%\/MZ%T>-\]WAUL8+K=7.Q9$A+W*3MU^*^IR"
M&RJCX9;)"W1Z)N&/KRU9,G!&?>'\JBTW,AA&W3%L,_(7I(Y&'OA')X?X)2='
MAM7(S>I.3JZU6F_"L0$S=H.YE9-KC1^<W%:W 3+N"^0AM^+8X!@/B&-\>B9L
MMW)LB(S[$GG@W3@V-,8#TAB?.ZFP>3EN_,.M+XT'WI!C0V$\((6U5@LSQX;!
M^'(,?KV;8X-H/.!*&9\>"]O='!OZXKXKY4MMRR<&S9,!U\R3T[.+4SOW&F^0
MJ!>$;@E_8&D.8KJ3I7R)]!'@U3LWU87(#N5+)9M,B"PIO^XIV5*N'I#W=UDF
MCA?J/97ZS:?Y_U!+ P04    " "#J-52-O(K("X#  !P"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6RU5MMNXC 0_14KVH=6VFWB!%*H *F4K;:K
M14)%;1]6^V#"0*PZ-K4=:/]^;2<$*D@DI/*2^#)SYLS%H^EMA'Q5*8!&[QGC
MJN^E6J]N?%\E*61$78D5<'.S$#(CVFSETE<K"63NE#+FAT$0^QFAW!OTW-E$
M#GHBUXQRF$BD\BPC\F,(3&SZ'O:V!X]TF6I[X ]Z*[*$*>BGU42:G5^AS&D&
M7%'!D81%W[O%-T,<6P4G\4QAH_;6R+HR$^+5;A[F?2^PC(!!HBT$,;\UW %C
M%LGP>"M!O<JF5=Q?;]'OG?/&F1E1<"?8"YWKM.]U/#2'!<F9?A2;7U ZU+9X
MB6#*?=&FE T\E.1*BZQ4-@PRRHL_>2\#L:<0XAJ%L%0('>_"D&,Y(IH,>E)L
MD+32!LTNG*M.VY"CW&9EJJ6YI49/#Z9%-I!8H"E=<KJ@">$:W2:)R+FF?(DF
M@M&$@D(_T-34Q#QG8*7O"97HF;#<[5Z(E%;O#R4SRJBV\A<CT(0R=6DU\YF"
MMQR,R!B(RB5D=OUW#-D,Y+^>KXTOEI&?E+R'!>^PAG>$QH+K5*&?? [SS_J^
MB4$5B' ;B&'8"#@F\@I%^#L*@Q _34?HXMME VQ4Q3=RL*T:6!>FM0L34392
M(TB<SUM;P3'?&S'M0[U1*Y) WS,O48%<@S= #61;%=E6(]D';C)'6,G7D-V4
M:65E6C^.D2TP8X=IF\!ZT.UV<! 8S]9'R+0K,NU&,G<IX4M E*-%%<-CYML'
MYG]$'1S5VH\K^_%IF3,5DJ15B1RC$A]0B7'<J65R73&Y;F3RF_#<OM'RD:F:
M9_,)NU-A=\Y0GXV8I]=GMR+;/4-]=@^RTNJTXMJLX&#7.H,OJ= 2YE.)FKH(
MZRGL=6_\U45:(NZSB7#<JB<3[LB$S61@)D\N5+SKI/@<K;09]/1:Q;MFBL_1
M3?%A.VWCJ%V?GET_Q5_34/&1CAKBJ+ZCXUU+Q5_>4TO$]GZY!L&1<O7WAJ ,
MY-*->@JY.::8AZK3:IR\+8:HG7@QBQI62\H58K PJL'5M;$NB_&NV&BQ<B/5
M3&@SH+EE:D9BD%; W"^$T-N--5 -V8/_4$L#!!0    ( (.HU5(\$4X?3 L
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MU1TY0E^8QGGQ/WBJKH4C$*YSEBXK86[!,DK*O^1GY8F: +(5 E8E8)D*X$H
M[PDH3;(K 7N_!5<AX%0"CJE);B7@FK;@50*>Z3WXE8!OVD)0"02F+2"XB1PT
M%MD&>S_::I%-N%$CWHY*9!-PM!]QM<@FY*@1<U4(T2;HR#CJ:!-VU(B[4F03
M>+0?>;7()O2H$7NER";X:#_ZZBS<1-_:C[Y:9!-]JT1.R8@",%/"R.EQECZ!
M3%S/]8D7!:4*><Z5*!%$O6,9_S;B<NST)F4T![?DF=S'%)!D!L[3Y)%F+!+O
M=[\]F%)&HC@'-R3+B #A(3A \-WOA^ =^'$W!0>_'AY/&+=*Z)Z$E04?2@LL
MA053&HX!AD? @A9L$3_7BU^MXS&PD%)\JA>_)L\ NDKI"[WT1WK/&[>5XA\[
M;"?)&"!+*?[)1%SMN<\&XM!7BE\:Q*TT'@4MXE<&XC!0BO^N%[])'S=A;Q7_
MHA>_HRLN#I7BUP:=KG1=J_A-5Z?+N+BC%/]JT.N@IQ2_-6@=EQF#6L3_,!=O
MZS;?3-)=+7YG+-YZ[]^[ L?[O(65K?\P$6]-V D'[Y:^UI:^5J$/*^_FGH'+
M)&?9FE>I#/SYA5\ +AE=YO_6J,=;];A0;VOAOBKQW18JK;@HYM_G*Q+2DQ&O
MUG.:/=+1*=#896_MLK5VU8>8I,M&K:K^-CI;&QVMC;=9&E(ZR\$\2Y>=5MYJ
ME1E96>9>J<<I](C9T.,IPB@($.]MCW6OM%SG(\O>O^ZN>9V%?0CE93O.<;?.
M<;7.^9I%#U%"8A#E^9J"692'Z3IA;>GL-@U%&-KM[7O;]CUM^Y>\69*$%*1S
M\)"1A-$9R!>$N[:M!Y6ZW)H)V/-]N.^JYF6V[7L(MYOJ;TWUM:9^H F=1V'$
MG146W;Z8B\XI8>NLM;_[38=YOH/:K0BV5@1:*SZ2* ./)%X7+GL2]5O"VIQU
M&S2:?X=]'K%]=_VA;;!_7B(H*U;808_EDKOPCJ7A7^#/:[J\IYF.EJA6"Z,A
M<(PD[I&E-;UHH-8-RI>B]T:RU;(CEZDU:ZVGK49/M6P/^[:_&Z+SM@MQ@"VW
MO3,A.:X@_<!B=!]%=VNU'S>A!(M_"KODN(+T PNOC+(UR9Z+ZJ"8O1AU$#DF
M(&>0#B*YBMX,K'I-+TA "5^DIZ_&R^ _H'=Z2I(B?Q#O2T@B/26+!FH]>,[=
M!\A2$8%SU&2EZRI[L24!9^D!I_?O-,IHR-+,Q+>61)\U"/JL6J6K1U^_>NIK
MI6W'MVI"6))<E@&YC$/\U6JB2A=B"2I+#ZH>>5YI<O<\H;! HLS2U[=[CCCB
MKQGEH& @(ZP])*^O<7=ME52T]%2\%L52Q)[!3&5:E_PS\(_^\<LOS4GCKD42
M@98>@7P2'"[ZC3*6Y)PU".<LR3E+S[D^O>^-RSPL*8CU%%2Y^ 5##)88Q(-@
M$$L,8H,*T'R(P4T,(D?-05Q;&=!S4.-=L5%%,W#QDX9KL<C;:\3!$H'8'L35
MDG!83[BNU8\;W#*)UCE7\@KK>=.;K3=ZA2](,TDRW$4R/5MO.N6S,;!+N&K7
MQ+#D']9/F:_6<<\*'DOTX6"(7F=+;-EZ;/5@:Z5I9WKFJ7J?+1EFHUZ(6=8C
M#&8T#[-H)7:SV[8,.G1_7U!P19*B.O7!&=<_*]J@/QE_R>=_C%^PV^"<@T-\
MNA=5[I,H+KXX((?%WS!=KF):;+.G<T# ?1;-'K@\]V821LE#N=A#N4ZAD/"K
M,D#_7G-7LQ3\BHYXZA[QY#T2GQ_<'X*S5<9;J%::Q[K@2GK;/>E--?#^;#?A
M;3N>Y2@"+-EMZ]G]C7*H%>USC\RX26T[3W:S<D6.YR'%RIM=6[O5EZZ*[.0#
M1_'^C(>(EJG5G;>VA+D]R,S;ELRV>S&[5]9<=>@66<-KEA5)G@$MA@*Q4,)[
M+>_$9#:+A%K>C<DVG10YPWN]4:KM)1@E61SQI.&]9:A<VS#!:\VV<D/O-4[Z
M__7,E(9%&H!JJ[/--5_>Q#7\?8MG#L1GHRVI1X=C(-3U0O?_WFLWZ6/I-:_5
M:[LY+FL=6U^KG#UP&Q[$G14W7:W$MU4]5Y6F.CXQ#E0KI[:L;>P7U39&9??+
M$"M+(WN0TLB1I9&C+XWZS7VN*VVF(Y@C"R1'7\28EVC7E:8=&P*U";*0<'H5
M$MTSA.L.A<@:._ W79AD>>%T30WU,X+K#OGB;(7)<HLC:PY'7W/L+AY&M=T_
M1?ES72G<W4A5;WPZM6UA_:Q2G<!?!$:SUZQ3.+):<=Q!<E6BTGG#'=;/3G/O
MU''4SI:T=/2T% MWA:_E<&7B1HD\9Q#DN1)Y;C_D]:DJIQVZS:J"<OPO'6E!
M4"L$P-."R]P_@_N4+<"*9"RB.2!B<)F)8;DL#%K* MXEVDJP%/#,9^6PO3G/
M5Q8;&RM)6("6JR\KBRBO&4KX&[!,9]$\"HEPR9'X2#14+'EL-A0WK<_78@,=
MA"1?@'F</N7BLG=U^>(TXRK-V>ZG3_RFQ?Z#NAY!\#==O>'*@<;MFHE7M5^O
MQ0Q7CB+N(,>'7#D4N'J4]SGGT;*IZZCFNJXDOZLGO\:%3>3J[ED"WAUDING6
MSL[HJ_E^.V&7;O,$C:U>I'0EX5T]X<UC>^DVBV%;;8&DNZNG>^\BZ+)#(8)C
MJ"V"7#DRN/HMDJXBZ+)#OCA<BY'!NJ@G!Q.O:S#ID0O\DXO':HUH6CY@8I(G
MGH2;-\A6B2?IYKUQC7S9H="R.[J')\'H=6TC]PM%WTK0DX#T!ME&\20//8.-
MXM>>6?I6-5*O$)$',5:<KO,D33T]36N')7AY\]J=0J]V M$;Q.^2CIX!'5]]
M5JQJ9,?O 6>WZ@"F!*37<:)0ZW?S@=F7^//A$![W)=%\?;G6YUCRA=]<&=#L
M'?J2>OX;4^^B0V'GH.A+ZOFO6QFXZ) O'ILP&A1]R3_?Y"QYD2&K+ K;S2I5
M>+58P3'V%:&29/3U9.Q[M/?";]EP5I_M]24#_0X&FI[NO?";Q22VD!TH+) T
M](V/!';3X(6EB5\[<CW( 1I?PL_O=5#0)$GU"CM+DT!B,M!7B7<T7(NE #[-
M6/)Q(>5!,9UY!A*5P2#%7R Q&+SE<<%/@>J<C(+'@61>T.O 8'>H/W4H]+HB
M+=$7Z-'7A>-/G?*9(8X#R<1 S\2/4<9=4VY3]%FS"R3L@D&6/@/)LN!U)V*F
M'?+%0V(8FKA5$BW0%X,&H]RT4K$[RD'5@R.U)T<Z"CU=1%]RWAO6G_08I.1#
ML/;(!S0X+?/:,GNZ::5>9_M(]TP#K#TT O4LY$1/D]D+D@K!VA,=$ _CZMK#
M&;!K+:_/_M_WC3K=<R+%E3_:KM3B'\':(Q]03S2]]WD"G,6K!0'G9!4Q7@F>
M\?LC9@4-@K7G0N @U!,_=2*;T'.K=WB:JX*M/I_4?IU _$H+'W8>>#,@IG,N
M",=B:2 K?_>D?,/25?&#!?<I8^FR>+F@A%>0X@+^_3SEL:C>B-] V/[\S.E_
M 5!+ P04    " "#J-52R)=2P.(#  #$$P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6RUF%UOVS84AO\*(>PB!99(/)1D.[ --#&Z95N+H$&[BV(7
MM$S'0B71(RF[_?<C9554JH_%!'QCBQ+?\Q[2QX](SH]<?)4[QA3ZEF>%7'@[
MI?:WOB^3'<NIO.%[5N@G6RYRJG13//MR+QC=5*(\\R$(8C^G:>$MY]6]1[&<
M\U)E:<$>!9)EGE/Q_8YE_+CPL/?CQL?T>:?,#7\YW]-G]L34I_VCT"V_B;))
M<U;(E!=(L.W">XMO[\+ "*H>GU-VE*UK9(:RYORK:3QL%EY@,F(92Y0)0?77
M@=VS+#.1=![_UD&]QM,(V]<_HK^K!J\'LZ:2W?/L[W2C=@MOZJ$-V](R4Q_Y
M\7=6#R@R\1*>R>H3'>N^@8>24BJ>UV*=09X6IV_ZK9Z(E@#P@ !J 51YGXRJ
M+%=4T>5<\",2IK>.9BZJH59JG5Q:F%_E20G]--4ZM?S %9/HD7ZGZXPA6FS0
M/2\.3*C4M%\^O49/NB@VI;[D6W2.\FK%%$TS^09=X>#ZSS=S7^G<309^4N=Y
M=\H3!O)<L>0&$?PK@@#//CVMT-4O/T7Q]<B;X4,S?*C"DL&P:X4>"JE$J4M-
MH2]_Z0[H0;%<_C,2GC3A214^' C_F^!2]@WV)(LJF?GC'):3",=A,/<//79A
M8Q>.VJU2F?"R4'V.)V7<<KS&F 1AOV/4.$:CCA]8KUG4,9N$ 2%QOUG<F,6C
M9N_86I0:'54-5!6&OKQG^9J)L=]JTD2?7*(4IDWXJ5LI3#MS%<=!,% )L\9M
MYEP)HTKS%KB5>YJPA:<Q+YDX,&^)1B8 !Q8U@4NQU*I7S@!ND0V/VKVG(MF=
M5RO8<@-?!!S8D@,[HJ/6M:<+1\'P?%EX8'=ZC$L=BL8"!CL1!G<1,SH+EC%X
M'#)O]R+-3E73?9^]IH0L;_!%@(,M<; C<G"7.208F3Q+'>R.G5KZX@T4!Y-9
MOR=8JH 35:!+%9B1&> !/XL5&,?*'V5VYAL(6JN1BU %+%7 D2K00Y79\(H$
M+%7 G2K0LRB!R5 9@F4&.#$#>I@QG<X&QVB9 >/,T(O3J@C.+ M+"K@(*<"2
M AQ) 5U2A.$@*,"" MQ! 3V@@ BB?D]B04&<0$&ZH AQ.!FRLYP@XYQXN0-Z
M13T0BPERF5U+:]OBNF_I8B(<V;@0BPGBC@G2@XD(!@O"8H(X88)T,1&&<8B'
M_"PFR#@FAO?'KZD.2PMR$5H02POB2 MRWKJ"6%P0=UR0L]85H<5%Z(2+6A7]
MW[K";YW)F/,MO1MY3@N),K;5PN!FHB.(TY'1J:'XOCJF67.E>%Y=[AC=,&$Z
MZ.=;KDNF;IB3G^;@;OD?4$L#!!0    ( (.HU5)T_GV[D@0   <8   9
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M';+\?6TG1%0%U$,OQ&//>V_>X''<"+E3!8!&;R7C:NX56E=W&*NT@)*HD:B
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M7UQK:4ZIP>GDD6O"<[IA@.Z5 JW0X $TH4RA+T1*8IL\1(/ OWD:HAOTNGY
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M.*B #:ZIOA6[3]#E,[5\N:"J^46[SM=S4%XK+5@'-@H8X>T7/W9U& #\\!5
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M%+(=X*VA1=7,P+709J(VRZUY\T!:!W.^$4(_&W:L]J]H]AM02P,$%     @
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M5PLB<)IQ\ $SAE7*O09OP/W= KSZY?5T+*0U2N8XUIK/*\VH1_,E>3@%$)X
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M:4VE[2FIK;[NY\C>SW^T$K7XIF&AW"<F/7;5&(#L&/ 3ZG!Q1(6_JS_D'"M
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M$9P0I@CD[TM*Q>Y!O43;ORF>_0M02P,$%     @ @ZC54D!X2)F6!P  P"<
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M1 G)K21Z,>>*I9E$'YD03.?H2_3"F[SZ^25ZA3Y=S]&+'UZ>C!48I56/X\:
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M=;'Z1A6KZEVBFT*I8EE=+CB#E=,#X/?; NBXN=&O)VU>VCO[#U!+ P04
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M$)BO7I9#6'FAQ;88?%9"FS&J.(W-X(K2+C#/UT+HEPL;H!Z%%W\#4$L#!!0
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MY9Q>+D2^*2;712[D'%Q<KH%&P)2!_'V9Y^*P4#>HWY9,_@=02P,$%     @
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MXPIH!$P9R/>+/!>[@5J@OF,:_P]02P,$%     @ @ZC54M>P@:Y( P  !0L
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MV04TOY?2/'9LG=)4OJOO4$L#!!0    ( (.HU5*/YL4;M (   ,'   9
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;(U576_:,!3]*U:TAU9JFP\2H!4@
MM635JHD.M>OV,.W!)!>(ZMB9;0C]][MV0DK;$%5"Q!_WG'ONL7P]*H5\5FL
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M*Z[QD0/*=L#OA93F4+$#-,^FZ5]02P,$%     @ @ZC54B(0-A10 P  X@H
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MYT39C/$1"M(8X'PD\ S6'?.F:)ZULY]02P,$%     @ @ZC54DY?+Y,A P
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M70ESUX%CLAU_93E?E5FWZ@82X5=MQU]@>_VT>\6RL;C,V9KE4S_5BUDSC.S
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ @ZC54LH4T(XV!   CR4
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M/C==+W]9?N\<W>,7G /\;_'X!5!+ P04    " "#J-52C^&W:=,!   V(0
M$P   %M#;VYT96YT7U1Y<&5S72YX;6S-VLENPC 4!=!?0=E6Q'@('01LVFY;
M%OT!-WE 1!);MJ'P]W7"(+6BJ(A*O1LB8OO=%ULZFV3TMK7D>YNZ:OPX681@
M'QCS^8)J[5-CJ8DC,^-J'>)?-V=6YTL])R8&@R'+31.H"?W0UD@FHR>:Z545
M>L^;>-N7IADGCBJ?]!YW$]NL<:*MK<I<ASC.UDWQ+:6_3TCCRFZ.7Y36W\0)
M"3N9T([\'+!?][HFY\J">E/MPHNNXRRVJ9@/VXI\>K[$B1[-;%;F5)A\5<<E
MJ;>.=.$71*&NTEW1F_/)(>XP[7[YU?E=F7.!<>;4&>OCB3FZ/.YP).WJOHV%
MR(7R_",>$V/IJY^/VM,NJ/AE=MS>#^.6W7EXUEVNW^.O9WRL?V$? J0/"=*'
M NDC ^EC"-+'+4@?=R!]W(/TP0<HC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5
MH\@J4&05*+(*%%D%BJP"15:!(JM D56@R"I09!4HLDH4626*K!)%5HDBJT21
M5:+(*E%DE2BR2A19)8JL"D56A2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%(FN&
M(FN&(FN&(FN&(FN&(FN&(FOVG[*^&[/\ZS?Y[36M==D<\EGWN<3D$U!+ 0(4
M Q0    ( (.HU5('04UB@0   +$    0              "  0    !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @ @ZC54IJ:5B?N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ @ZC5
M4IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "#J-52'C[KI:,"  #1!P  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ @ZC5
M4OS@!KT_!0  UQ4  !@              ("!Y@H  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( (.HU5*M[Y)^  ,   4+   8
M      " @5L0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "#J-52YWV$OU0%  #6%   &               @(&1$P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ @ZC54H+F1Y=V#   <UH  !@
M             ("!&QD  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( (.HU5(1<$_>3PD  'DK   8              " @<<E  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "#J-52T:G060,)  "H
M'@  &               @(%,+P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ @ZC54IEO_'#I!   QPH  !@              ("!A3@
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( (.HU5(*AR?J
MDAL  -1>   8              " @:0]  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "#J-52,[]U[_\.  #++0  &0
M@(%L60  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (.H
MU5(.>]QJ3 <  )L1   9              " @:)H  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ @ZC54GEI?.2O"P  ,1\  !D
M         ("!)7   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "#J-52^XIP+24/  #9+P  &0              @($+?   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (.HU5+1E$F*UP@  '(9
M   9              " @6>+  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ @ZC54MNL\=TL!0  I@P  !D              ("!=90
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "#J-52$]I2
M,5<*  !N&0  &0              @('8F0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( (.HU5(ND7$#*AT  #9H   9
M  " @6:D  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M@ZC54@@X9>Y3!@  GA,  !D              ("!Q\$  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "#J-52>W:09_D$   I#   &0
M            @(%1R   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( (.HU5+G3V C+@,  #8(   9              " @8'-  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ @ZC54O:R&RY'!@
M^!,  !D              ("!YM   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "#J-52ZS3C#C($  !S"@  &0              @(%D
MUP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (.HU5*K
MV0_=% ,  !\)   9              " @<W;  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ @ZC54O']SCZ4 P  _@L  !D
M     ("!&-\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (.HU5)Y/COD8@(  ,X%   9              "
M@>/O  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ @ZC5
M4HW]JDZX!0  !24  !D              ("!?/(  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " "#J-52-O(K("X#  !P"P  &0
M        @(%K^   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( (.HU5(\$4X?3 L  (I&   9              " @=#[  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ @ZC54LB74L#B P  Q!,
M !D              ("!4P<! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " "#J-52=/Y]NY($   '&   &0              @(%L"P$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( (.HU5*B=]H.
MFP,  /D.   9              " @340 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ @ZC54I-B]P2( @  \08  !D
M ("!!Q0! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "#
MJ-522JAM93$"  !6!0  &0              @('&%@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( (.HU5+8./CLIP(  /@'   9
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M970T,BYX;6Q02P$"% ,4    " "#J-52D0;@;Y@&   U'@  &0
M    @(%^* $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M (.HU5) >$B9E@<  , G   9              " @4TO 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ @ZC54O],I<.:!   J!,  !D
M             ("!&C<! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " "#J-52+J*;ZOP$   /%@  &0              @('K.P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( (.HU5*.W2WIJ@,
M !8/   9              " @1Y! 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ @ZC54@[NJ]L$ P  +@D  !D              ("!
M_T0! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "#J-52
M(9#[848$   Y$0  &0              @($Z2 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (.HU5(KB*N;>00  &\2   9
M      " @;=, 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ @ZC54M>P@:Y( P  !0L  !D              ("!9U$! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "#J-52C^;%&[0"   #!P
M&0              @('F5 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( (.HU5(7RNYOQ0(  ' (   9              " @=%7 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ @ZC54C7VN.^.
M @  < 8  !D              ("!S5H! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " "#J-52U[J80ND"  !""0  &0
M@(&270$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( (.H
MU5(B$#844 ,  .(*   9              " @;)@ 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ @ZC54DY?+Y,A P  $!(   T
M         ( !.60! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "#J-52EXJ[
M',     3 @  "P              @ &%9P$ 7W)E;',O+G)E;'-02P$"% ,4
M    " "#J-52RA30CC8$  "/)0  #P              @ %N: $ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ @ZC54@P_D/SE 0  ?R$  !H
M     ( !T6P! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ @ZC54H_AMVG3 0  -B$  !,              ( ![FX! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     $  0 !W$0  \G !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>238</ContextCount>
  <ElementCount>367</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/StatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Notes Payable and Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable</Role>
      <ShortName>Notes Payable and Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingengies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/CommitmentsAndContingengies</Role>
      <ShortName>Commitments and Contingengies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Share Capital and Other Equity Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments</Role>
      <ShortName>Share Capital and Other Equity Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Tender Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/TenderAgreement</Role>
      <ShortName>Tender Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Notes Payable and Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables</Role>
      <ShortName>Notes Payable and Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ameri100.com/role/IntangibleAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Share Capital and Other Equity Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables</Role>
      <ShortName>Share Capital and Other Equity Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ameri100.com/role/IncomeTaxes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/Liquidity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Liquidity (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/LiquidityDetailsNarrative10-k</Role>
      <ShortName>Liquidity (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/Liquidity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative10-k</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesDetails10-k</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Valuation Inputs on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Black Scholes Valuation Models of Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Black Scholes Valuation Models of Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueOfWarrantLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Notes Payable and Convertible Notes Payable (Details Narrative) (10-K)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableDetailsNarrative10-k</Role>
      <ShortName>Notes Payable and Convertible Notes Payable (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayableTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Notes Payable and Convertible Notes Payable (Details) (10-K)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfNotesPayableAndConvertibleNotesPayableDetails10-k</Role>
      <ShortName>Notes Payable and Convertible Notes Payable - Schedule of Notes Payable and Convertible Notes Payable (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Interest Expense and Amortization of Debt Discount (Details) (10-K)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfInterestExpenseAndAmortizationOfDebtDiscountDetails10-k</Role>
      <ShortName>Notes Payable and Convertible Notes Payable - Schedule of Interest Expense and Amortization of Debt Discount (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Notes Payable and Convertible Notes Payable - Schedule of Beneficial Conversion Feature and Warrants (Details) (10-K)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ameri100.com/role/NotesPayableAndConvertibleNotesPayable-ScheduleOfBeneficialConversionFeatureAndWarrantsDetails10-k</Role>
      <ShortName>Notes Payable and Convertible Notes Payable - Schedule of Beneficial Conversion Feature and Warrants (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/IntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Intangible Assets (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IntangibleAssetsDetailsNarrative10-k</Role>
      <ShortName>Intangible Assets (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Intangible Assets - Schedule of Assets Purchased (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IntangibleAssets-ScheduleOfAssetsPurchasedDetails10-k</Role>
      <ShortName>Intangible Assets - Schedule of Assets Purchased (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Intangible Assets - Schedule of Components of Intangible Assets (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IntangibleAssets-ScheduleOfComponentsOfIntangibleAssetsDetails10-k</Role>
      <ShortName>Intangible Assets - Schedule of Components of Intangible Assets (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Commitments and Contingengies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative</Role>
      <ShortName>Commitments and Contingengies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/CommitmentsAndContingengies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Commitments and Contingengies (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/CommitmentsAndContingengiesDetailsNarrative10-k</Role>
      <ShortName>Commitments and Contingengies (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/CommitmentsAndContingengies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative</Role>
      <ShortName>Share Capital and Other Equity Instruments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Share Capital and Other Equity Instruments (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative10-k</Role>
      <ShortName>Share Capital and Other Equity Instruments (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/ShareCapitalAndOtherEquityInstrumentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails</Role>
      <ShortName>Share Capital and Other Equity Instruments - Schedule of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfStockOptionsDetails10-k</Role>
      <ShortName>Share Capital and Other Equity Instruments - Schedule of Stock Options (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Share Capital and Other Equity Instruments - Schedule Of Restricted Stock Units and Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails</Role>
      <ShortName>Share Capital and Other Equity Instruments - Schedule Of Restricted Stock Units and Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Fair Value Assumption of Stock Option (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfFairValueAssumptionOfStockOptionDetails10-k</Role>
      <ShortName>Share Capital and Other Equity Instruments - Schedule of Fair Value Assumption of Stock Option (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails</Role>
      <ShortName>Share Capital and Other Equity Instruments - Schedule of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Share Capital and Other Equity Instruments - Schedule of Warrants (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/ShareCapitalAndOtherEquityInstruments-ScheduleOfWarrantsDetails10-k</Role>
      <ShortName>Share Capital and Other Equity Instruments - Schedule of Warrants (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Tender Agreement (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/TenderAgreementDetailsNarrative10-k</Role>
      <ShortName>Tender Agreement (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/TenderAgreement</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Income Taxes (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IncomeTaxesDetailsNarrative10-k</Role>
      <ShortName>Income Taxes (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IncomeTaxes-ScheduleOfValuationAllowanceDetails10-k</Role>
      <ShortName>Income Taxes - Schedule of Valuation Allowance (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails10-k</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="amrh-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Subsequent Events (Details Narrative) (10-K)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ameri100.com/role/SubsequentEventsDetailsNarrative10-k</Role>
      <ShortName>Subsequent Events (Details Narrative) (10-K)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ameri100.com/role/SubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>amrh-20210331.xml</File>
    <File>amrh-20210331.xsd</File>
    <File>amrh-20210331_cal.xml</File>
    <File>amrh-20210331_def.xml</File>
    <File>amrh-20210331_lab.xml</File>
    <File>amrh-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001493152-21-014911-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-014911-xbrl.zip
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M=($>W,T"4'0>1.=FI]S+0PK*HJ"\@Q<CY^S61DMDVTB+23C'3<69,I,I,',
M<P\?*2@+;NE^)"_=T>O8T?/SDL(TIU.=6IZG:WGV\%9B#U"IY7D2EN<P0;G'
M8IK*@JR(DD"!.5S+<UB@I);GB5J>O88I/V;E *;X;R4=O77_8MT_69ZCFMH7
MW40N0N87*TS'^LNQW;\N=!LM7,L^#M#BC??:=%S;PR_)B*O:RY!ZKG9PK-F]
M[AKH9GEM:OJSKGFJX9."OTHRO&MD8P 5139!6J,!-!3-%,UYT!P+64K!LHDH
MVK0M0&%)87D8EHT'=V/H"V-6"F'Y605K:C\F0P!;]@K9ES_ .,-&VHF@]#!_
M&H>H+RW[N-^M)L5P:O*Z/AA##$U7"E\*WUK-6@RNPF9M'/5-F;7*F)V&^,4K
M-G^T459FF&<<,"M.009P:-/-<H[]_H\H)089S*LW,F^G !Y<FQ.4O^3V@4'>
M]/8!8RCA]D&%B@K5$0I5>E-38N?;W)M:7!:;\D+"(6<6RN)LS+-UR"(5LYZ*
M6;,8QU JC'&,N88QSG$P1G@A!']S%.,4X^4P3J!4^#8)8ZYIC/.P5VPN/=D9
MQ3C%>$F,\S&SH\"-*3MK$N-!$*$2A)3BOZ<G ^1A8BE<LJ)QGV1M>XNEW3F5
MX2L^ <WH2$Z<71_ZFL^UK./H&5]Q*G'918RHQNZGQD[4"TH H:ED3PG^-U2]
M\+>\N3W*XLP<YJAMC+2C!4:NV7>M7*38-4MNY2+%XI2:V\XY;K.=<SQ5-+U3
M--L;%5<X)2A1,J:YHS07BQ_>8"F^RX>?7: %^?=18JQ>LZ<65.?B=_<'Z(+(
M#I'6\ TV13-%\V$TIR/@-K!L+C"S!EB&#Y.Z*3?+"[14/6/@1N/Q0C;O[/<5
M?LU:Z6,5EL-Y]>4%Y^B*A)VVV RZ/%G_2@5L'%C\F!?W25M&"/W]"_#BE=I.
M#4A4#FYWZTK#<&G2<JH)DM1N&@Y<C\]J:E90-E83C"&$_D&JQX].,)JU2#!X
M"GLJXZANR.L-5@\_BYT%V")J_^BL_OZHX(%;X 1692SP1@,Y@Z/!+';+$^&=
ME*A VBT\J#N.91^!ICZ(YCUS[EI?<K%8L"(W.PWA)QZ"0#'3$\RDPPZXQFM,
M[PH[N-)MQR7AH,F[]E/<(7>P@FZ+O0Y^*(ILBM_31LYF0Z1HZ0%:DEMA?-F;
M<AO*8YZ/V4&6J9W2NN^<<;<+CQ>EA847Z,+W;^&%7BQ\^,#<6#^IY^I:=U5C
MC@D:^GU D\C(,[Z&]/>?T*-J7!)^Q0;>R>ICA>0>Y^71GK<&>N#IFQ^P0B6_
MH2.HZ;)]S09%-5Y#+P&(PT6VCA8-==07.R8HS->V;F3P(U;N'[/F2#HE[(1%
M,3:<%D1H@A#5%<>?^W <F0CM H*HQ%OU507U>.2KOSW5$UGJC!Y*I['L&8V/
M3@<$AY,IZ*&R=X?*GJ<)',84/8P,X# R>)31\PS56'5AB1Z)>G<D&CRFCCBY
MXAA2'0:')W*!>@+82<V3XJ1@\T]ZHNOUB:[7G3IW88J>Z 9VHALDRNB)CFJL
MNK!$3W2]/M$-$E/T1-?;$]T@\41/=!0GL=#UY$7M9Z0ZGDV"::_-M>?>/:DV
MNK7U1:J:S?G\XCC@DYXP[FF2O,(]Q)+#P"I"S_Q%M;4-$03)$;.[NS!.NQ<:
MRJ/8#\;+'\A>Z [%XR&N4$BV!\DU6KA(N\"U?D!#?U6/95\M \1=O#AQD!#)
M_,,R5%<W8!:GBH],-IPX-+[JSO<K&Z%K^*6-'/>4]<=N7IP(2,($FRR#\TB<
MW+M1X2?8[)GZ\8, 5[6+DHB_Z^8")C]W'.0>R>)?Z:;NHD_Z,]) QE7S$5]=
M^!,\>_VL_LNRSPW5<>)YPQE<Z!8'>(V:P<$F<Y>-W<533/01$^E,7K;,=7T<
M2HTZ=S+A,S>U3V"/F<ZF32N%U '.'.L6E' :BV&[>OA;"K%SYCFZB8!IVK/N
M6/8=LI^!1<Z.SL?GENEX!B;P.!"UK]%Q/L[4XY$Y5%XXS?<>^+S%0FHQA%T+
M=R,-P'R3[J0Z3Q3Y_49^$2[@]81= ?\_7&+D6370=G61:,VIU'4D=<=6UX8*
MWU"K^_16#(/88BG6FEVF-MYQ"UNC1]\$8HOT0V^T:F\0.\'&8!YY43[;%RIP
M]<Y%2]5TO@_\.N807+)GV[%N3!0Q*P*:1GL3XS&$&&@D&'(#FM^1:2V>SJTG
M\]@!DYYIUQI&* ,6*>:1:]"YMJFJ")N"CIRS6QLMD6TC[8CLT,@"(WZSFR69
M6M+ZVC/[SIUF37<^V%UIDV*B)YCH>>7-/6F8.P^WX<[T!Y!BV4?BNF_NK%?'
MUIA@==>[XG R1 ]"^-B.DOU&<9\.D#T,C-_HXEFLIR7\+1T&\AU:N^2#6UM_
M!I)N#741<Q!07-?B#_0>'%W35?OU3L4@CUD>0:WYO8O0M=Z>E6EVB>'7&=SW
MV''IO,<CQWU#MFZ=Z-^_$A3\.\"OC+FH\Z4RYO<8+4<#Y@%=IX0K5!@Z>"D;
M]@(=@,M)U4?IAX$PK"HMR<8P<< VU:LH'V"/O\U#S]':YV83S4)U][;<&>2.
M<@_+X7:\7*T-ZQ4A O^;M0O0/0[A3R6UAA_OG&_7YL_PW'T4.CV 3@\=;!M#
MA!_S(JURT\LJ-\FM'B]4TU9I03# H[:-S,4K+OU D5''I<%YP%%__)"_N-3#
ML:)O8P#!&'QH:!9%8KCA_:GBX,$C\7EV#\F"Q[0$][NVUOA8K^G<AGX<Y[TH
M]C1T#+=1VZGAV*7V._0<JG1SC^Q5H/A@T_CKLV[J*V]UJH#9YDI]^_%7'(GN
M#X__F>!TUPJNE\?16O"L_J!X;@?/<4Y3/!=UKQR5M3DT&Z^W;A5N2F'2+4QB
M31:G'73:I.O=W7IWU523KGT/MH0>6A$;YRHWYMA$_>]S=:V[JC''$#52F;WS
ME6H\JBL5WV"DDW^/+BQ*0_K[3^A1-2X)O>GZX5E\JM>]M2_O>,]*=.)CZSPH
M+.D8QJAN^EI"BB7(7^)^._KB3+><A8[,!7*NS<4>V8$):V1%\PK1)HZ<1),&
MNFW@N3V[)6P//SN2L1TK-A1A*T7%=E!S$$:?@<%NY5V*50UH3M[Y(O)^A^ U
M6BZII[+=NFSG7QTJ6X#[I@\N,(:X*:[0E)R=D(E*A6P -FOZD"C%KGD+E+/@
M&RV8@\>8@CD=BB=V7140SWN@"=FIY:;RUHB\9?*Z:U!/8T>QW*#&(&LUX.%<
M-55-_8J>D>FA^2,.;QHV5$.\  RM%;I7?\P]]\FR@?0OZBIUU;=S\L<:Y+##
M0TY!T"\0M.(VYXBWR _Q\_\6#[MAOJ)'W<&]2+0+W48+]V:Y!!K,QY2AB5-R
MT;\];(D\#W[SB^<9QR:U'3F0.>NA6'A%.;$OXWH_2CK=F /4%]N8 _%H=&.F
M(DA%\&A%,&;?I&2IJ:V-'[.S<&OCQUR.[%XJ5U2NAB97Z:T-H[[PUH;%HU%'
M"H<+EK)"*(Y"K,[]Y8^%X3GZ,_J4:B^3E,T+>,)VT)ENN6CQM/&U4*%L6"CW
M>5T.K%V]A'Q%!N!2NP5,O]X#-8ZZP'Y5Y^PU_DV\ZD\V9+J64"P(A254:+H$
MOC_&;".A'$MEJXQL-0Z>XNI=B/DAFSJY4,#T S!).UMH+!@H1S ^+?3<PT+/
MPPG2I_#I"7PZ#MZG..@?#EJXG2A6-?MHD#"@N(WA;"44+MVKC"ZV#KKNW:][
MUUO%7--T["=2C5M5UZ[-('GEI/"PEP=T"\FSA5 8]0Q&'6\M% _]Q4/76\Y7
MY*JZB;1+U39U\W'@Z2P%09$]>;K)Y-ED*' Z!T['VPI%0)\0T/5&,E\LO)5'
M+K=OW"=D8\;9Z FS]QGYD<TG!9#<_*#;39[M)LNIK B2/%6X*454MXCJ>!^B
MT!@$--HOKH0;C].[N=[=S=51=(DL;:-Q0A0^/85/LNR!T*5*H7<V5(444"$4
M+E1E4%]\SWSQPU0E%$8]@U&/5 SURW;NEQVF4J' Z1PX/5(CU*$_$!_;,)4-
MA== X-6I2J+I%;WTP0VE;CZ%3R_ATZ,N>=0G1U5( 15"X4)5!O6]]<SW-DQ5
M0F'4,QCU2,503USGGKAA*A4*G,Z!TR,U0GUL _&Q#5/9T,#;_B*JW1K]?OTN
MZFKKM:N-:\%[S\5VHS0FJ.^D#ZXVKLSNPK5P04CATA.X]$AE4!])SWPDPU0E
M%$8]@U&/5 SUF'3N,1FF4J' Z1PX/5(CU-4V$,?(,)4-A== X-6D2O),W0?)
MM[N+K75>(=7Q;/11=RR1YY3W\$SXLO"KY!#X;3O>?_>DVLC9.43 +_)0Z3&
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M2;%CT(!OUEO0CVG4:J_T8TKY#)]AS*6F$)^CUCMM^67Z,:'AZ)WV/$7]F-+
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MW;9?0;R*9H8?3"$J.E#I7*7" Y5,5YJ;KJ[AI$+]&=VA!>A*[,WP"](@#:\
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M)K&5O:>W2Q1MBE7:M^>V&N,KT0,KITH']E)SWJH=*;>RW>:?\% 6H:R)?0(
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M%X^D&63=\/^INT_?3 LHMI]QD1;_/A_W/C(7H-#]-*DH"N!,=70GO*E_#0(
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M@6XR7]2U@=EZ95BVKJF3TT#6C<D$E@R\<<3@?6>48!(BEVR80Z[%J"83+_%
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M8#$QRS!C&VP$&(*<[$"(= Q/'V<:?!P2>>8YV#YR,+4/>,GP,/YB T&>J7J
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M^;Y#!ZWKA]0BPW! ($!P<,PN^?=:U;3PWTDR."#C'/CR@,\"OR-0Q-CQ!B3
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MCC*(" 8VV3BN!8"Q#@(H<<C-HQ\_%'\EO,EZP$$S?BRG2N*A_.F%$4L!*6&
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MJ;__$G(%TP-VP-JS%R"]B.$$=C3C=S:<#$P& YFQGFRQJOSP2UQHWQ?I<)!
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M9LX]3J)^6ZB05HH,OHMDAEFAG(_<W) FK6<@=<$^GAT2^VH3K<(!=KDG'JM
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MF17-6.H!.UL''CLI7-OPZ-C4; QE67W;<&700F&4]>[6_0EER,&GJ3@2IK2
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MXI)JPWTN=D=2[8E0T@IUX8;?FE!B,N>7MB24"(2B8'(V+)0(A&F"R=F"4"*
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MRR<U]QL86_5R\;^&WY#98_@X?C/Y'D;]1,0/^,&/.'4)_AR% WB+?+B[5)N
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M1\OM-EJ[<1[KUR#7HOGO;\#@"/D+5]H+76&SL;-%DU<W:2]OJ3?$HCD/Z^*
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MP00K8.]PA=BEE]S3V0WP'WBH<$T<!U0OYOC4AA[Y"8&R[Y"9 @G(1#I]$(J
M"2+=\$R9"" E@ M@,>"#$>H^R%0D5BP##VP:L-_)C]H7$R=5G .O!]N2/4G
ME1[G^"G!4M%:9"*M_6 YH[KDX<@1\X4"]+6 ]OBC;AN,/^1]_O1E6V5?%_SX
M;*PH7X8$F_XG.]DEJ@./QMN?E.V49_KKP/V&^KZ!#E9@QWMN9J"%80P-_*3P
MX(V*>=:DP2.S5:0THEH0BT$$1@(VV@$X/<<$/\BY3_>6OJ^C?&#[M!! @>$?
M)<@<]-S+$-:B\ :>"NW7Y'VS)ZRJ^M!!/V' !I,7!Q(@45H-H#D>2#7$/B(
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M3K'K35XWF2M-7IJ"W,KR:A=%93D,%6VCJL?,'A#)38[HC1ZDK^["_#*QD$-
MF69"5,X;ZS''7,^KB$-W47NV^4#E% /ZB&K0J,&9Q@+J)',WI%&H+9Y* ?X_
M^,(T2AI3?/[=H\ML6^.%][00R>BV;![,")3O?O[6UG!7,;YD$TA<T&FQBAJA
ML[.%:X0*=Z3=MKMRJO5^E,TL-LYR(F=OCW8Z_W$O.M1C1;A<<)+-;A42K29]
M^3E&JQZ-OF?"?=97-LF,NX2,/<M47FS T2[?BO/N>;.#SI;Q_._ Y+PUW#$O
MI]97,_MI![Q!]Q[&>Z9XD;4ASDZ_@JD-/QUJ!\MWD9HXH)5D="9,W.,<XC&-
M\Y3?5#O>7.[72*%@&H? *:'&,:K";:J%3E)HP:*]K-0>33D;\M[V^1&9AO6V
MB_RWS+\SS=RQ,0YW%Z>&Y)>5;0MM%[IQU:NNJB:N/=.3R!ZTT N>_J#F3'DK
M'G+R,RBAW34Q[]B.0SRLANW:,QC[JL$CNH3'L33!\&/B9S%2_3&4U&G*3L8L
M0O?J^=46=WE.HJ^"08R>@N>6TS>KG=NZ)SCP%0YNP;B<K]H7<DNN<""*#G *
MI'G..]+7;@;W$4X(RKV)'%B5&%#U,:_$=B#F00X"C;_[0SQI%Z1*=13/?%PW
MXM*;-7]G(;6^?+Y#\4/NE/VQ-4];I<_HZ+!<%(W5'@'ZDU."?,<,M2-K3,L7
MTZS1:%G&Y4NR<0\;C88U&LT-XW$3CHN2^[/3G-^_>XMI#B<XBBUYNR F=,^H
M_>M3U:FMP[%\Q-)NN-_GW=\-]:VAS+EUN.QVRO'5KFW-+[F+R#B;M]/!=N7Z
MO!OZH/LW'PHQ]SI'8EXE,G9'*+_'MN\B])TG*0)_2Z>\_*G4Y[X[Y_WBGX^X
MF ,7NR65U8#FAP@GY9GY5/MXAMUV[?Q(T-M QNZ(9FQ@XPRQ.)QFRF-9!19Y
M[>TQUFL+79ROFJ0WB8N-R>C=Z]"YK22,+4.^.S+L2VE.T-XR;,/M-AMNI_'Z
MNR8WW/,&9ICMD)6S N60&QV=F,$U\SI?%SJ?.>#8G*':K)UMM;_R3B&C5=O_
M'+1@+])8;K)^(G[/*#5J!S)9=AIIU95W-/,LL8H62WE>!-3TJL5C\=JQ>.V8
M%K*;:2%'/"Z 1VXX7CUS?A/8W"7U=:($8B*E^]7KLUL=GG3$Q"O%Q,J8_-GJ
M1*6OM,_G3Q;Z:*4!5S;,F#? L;(4EZU5^[;=;OML316JN_?F<KCJN(U6YV!P
M=;84KGINK]O8]<KGM8]NNJQHT+,5776O:G%/&NY9M[G:8MPYEETT;_003Z8)
M(O E;'T\F76?3,OM-EH[=#+K5P#7HH8?8Z,'!_DVU8GF0MRVFH8-<\"RK%"K
MF%>V!OMVO7/-7MJ[9Q^'R>WAX:RF7<OQ<-9P.(MV)WDI6BL%]T'T+EFX IY@
MTE7PNF&%705?V2+T6!J_H%9PC'(>HW-[&^7<I![\@H:=RU?X[J'+N5U;='3V
M?CJ;E\52;PU8VI '8X[]'5*%;ZM67Z@HY57'85>"C$W(]7DW=*SP/5QB/E;X
M;MPO.L<VCA6^QPK?8X7O*R7H8X7O*ZGPG=>^>?TDO4E<;$Q&O[*(ZOY"OCLR
M[%CANUMD-==.CQ6^K\%0;=3.MTJLNX:,-='SJX_4XI=-X(8*8K\)# LY%SSL
M%8M3K^,HA'\/>/@FP;?QTME2J*H(\B[5]7X,\_JL9KW1X^G)^:1Q"Z\WJ1?Z
M7NSS/,UW$?S3.>&]=)O-^J]7%S?OS(^-7]]2ZWJP@"]NOCM?HAI]_A2;['X,
M!]%(.+?>3YQ+?1N-Y< Y;]=_<6[D:!P 9%1B#&!8BV.@O?B>M3*NH+YN ^ 2
MH#P/(Q:C" =F#T#.>S@,XN= J/$/*MBO1MBC&Q6V/@ZXEME 5W.L57"PAA@.
M5:]^G00PE D.SZ9XFM,7@/J0)B$/@10(%(/I1H<KX5P:>.' "\&3X_D13T$?
M8Z?^-!4^]^8WOZ=":ECY+I,^S2+U)<Y929U[#Z#P'!QN$>.A 1J]0:HGEU:,
M7N;<!7/(^:C: YFV E3_=9!&3/1X#$3T0+\VS>)?3AOP1XO2+B.?AI[@>1",
M'T<X?U8C+R<^.KD00/1R&HXS(BI^0X\.3F22BG#PE _*SE=P^IB3,@@RG^@H
M".#$DT$0T>AD0P4\)YB@L2:7.._S1V^04.%S)_H?G?I;'D.,DWJB$(BO+T2H
MUA*^'CW\E>9J7W.9/T/TV0/"!/*>^&2[\U9M@2"QMP&LX_L2_P5;>&)D(VH8
M'UZ01#C3!L[N*=^4-XBC!'-N8AEER*/ AHF%#%\ ^0*D?>#:H4R=<>"%"0W
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M*+H(WCG)+^8TIGOS23W.E_-;8S\#+-2,#5<!S5@[E!B/QD_:GT8*BYFWF,:
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M[4YW6E\0;)R:9U_!<;QIU[@_J=4'XBZF1@,ZX("-#.UW")(W#<IZY,Q'>YQ
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MHV-CW8=EZD6Q7"#=JCU9E$G]<X@VY]),"BZ"-/>(PJ=($P<=BHV>-_5:JTL
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M$]+K5O[XD87J1"INP\+?"VX5@@G9:]ZO8^\P;&5A@PG 99@@_0=W=ZE<C:2
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MQ 1_GR6*(A=5SE:;U7.OW)_O)NLG !<@]0-.UDMVHCE?H^Z<.I6R^\&+05K
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MRO%#Z398".<ETB0T5;'L%"EHE>R)T*.L85V83<H5@V5B*YR"4,@ZMJ'5-N%
MN8!5GNV!9$].5X"+5I?VS%44/M+YY+E/R93Z/E)+GRM;3)#DB$Z0.F-\?79!
MH"ZS[.MR533D/WNA=Z=S/WX 1+]E_AW75'J)=O-3ZC%0=5JPL_';@?>H^&A$
MD;0^:;(!>J05CZJ;S_$RN# Y6N.!T6TT?)5G+:,L,:Z*1'&;3<H49QP9: O$
M#\I&2!$"DRQMI6A4-E^E>[&/G#>"=RAZXG$<M%3HB;H! /);!K<S6!ZT?RP)
MU(6W!F375@G,49(QPVP"ZH.F#)0/\0/\4:7;A *>3."2/Q1.LDM[4:A8)ED4
M!IPL0P792OU0,0@MKZN9(D)4)K",1_6S=$&(GYZ1X.HHO0QN@UCFV4^LJ=DP
M(-^![D+)2RHF$J!Y]O_;^_;G1HULX7^%RLUNS53)#B"04.9^4Z6Q/=E)S=BN
ML9-4?DJUH&6Q0:#P\./^]=\YW8! $A)OD*U;>W<]MM1]WJ\^?=KSHQ)4$+8I
M<23">\9XVHT1I<N!XA?G< IF#*N35#X.(>BF;X5G>-.U-V4D2/0;!'8"/D"#
M 1+1,-&&D"I?\9ZCE_15:MTBP*_8R^UR)LQ%4,AIH[#<<!B)EV',[=%DN2^.
M;4.:\5,FR-<-XAK\\G/F_>*M,:0#V&B#"INHKU%)WG&.3JEF-,:_4VTZBD).
MBNLK?F 0E1%=@Y=WL1LH$GS@V KB"(O'%I[GZ";+H/C1)E,N@W66Q,F;:X0]
M&2SB8@>D>$CNV.D**.P455*94D9W8&PG'H\-,:0;A'Q&&!. V$8,YT8HDS%<
M.+[;OG%IQZ'\F)L'.:R"$R=LNPR2$ST:EFB^MH'L D1UUB,:*MM?>"DOB[5N
M=I<(FXL#FUUWX?V2+SRKCIJ3>=DW[!-BW07A  'LE "FLG[%,,H,3Z71"2&5
MF*MQUUF?P=N0F#=DTR*P%2'$Y%6YG)V'*[QU<XZG"XCX;UCN-H0[GP4:[ [&
MQDB0.'+B-G 07DWC70<&CRWBR:6QH02V?+; L1B$?>K&]B%,< ;"Q13%'I=(
MF/,E^:_C)LWV9I"1/A"(2I>AS687?CUF5N=@)U%-64\)OR=%4V#EUX<M6WP.
M%$_,,.'=(>'0$;XJ3ZI,QTB'E^LC%F8%C !BVIV33L*Y'3R&YO"R6^:FE;+>
M.P9-'*@J(-W FC"A_\YO)US@L=8Q%!G81>0S/N8EB<>;*SB$KQ$(TW7UX"X*
M*^!#1MRQS6N.R>[,NXM4:^98T@8I6@IG B-SZI=1\0P">>PP#).[1.V"=18Q
M[O :1-0,E.B\"5O*>502=R0F/Q!&@>&R893&NQ=9%0#+][R:OZ00J4*.-GUB
M&.-]*]Y",.?=9[Q?DUV3=1_-*$&/HA_NL7DQD@7,$'<:)C@='J8Q+0PSN?41
M<6+W\&_A8 @$@5<C#GV>P\+,%P,A+A]%!/V$T[O.[O2%8V%^Q,86G:U<D]UY
M6#H&M7@/7C@)A[?48EL%O_^0WC+)#L+IQ-TGB "RG9^=WV<!C>?!\:$YCT[8
M00PK;X#%Q$XN=K9+!#SVQ1SWS$*@>$&&3W-*W-7@[6_AI0&>#L99'Q,F!'$0
M$Y+W_D>DXRVP\(U$JR-PTUR9\7V!<(7-6SBI*(8+@+=!-QXW)3"W!89(W)7&
M#3GO'.!Z8/*KRD@&?N;O"G2YLIP72F,<,2(A+/)@)6@,_%Y6X<%UHJ3&9#ZF
M G;3L=O X98)S-*HK L"8><O+SV!_,^IZ?.*.Q;55T;\H40]10^#V(RA13E]
MQ-;\HO V\<W\DL[\>]2CCD88[4RL-J>H)2-\FUWK!ZO%E#_D(!LAB2/FPK;+
MQ"<8 SV?QBR:1VT?IQ=B."BGAVXWAQO^@B-I&#Q'-E6V;4)=AOT#)UKEF)A.
MFR:35<^4W?QOT2BC_,]YK$_A<4;CM=/= S0Y@"W[ JU:Z5V5T0A;\;LBRRLD
MZ-F)EOT7SIJL5N47+7@#?5'KE)?=1<6BPOQ]52S J;KA;P_/O,I]O!C6Q<GF
MXX*\&$U7KFEQ';M89VU,WX[WZ9BA^#84[AUX@''=+\.\/UJVRY/A8"+G?>JD
M__[OU\ J'ISWCRW21!J,E#>@C?)@7,SHO&IME#1M,*F![<W[RAS9?0Y\XXII
MV72ZG?>+:E^P2@JC*"52F%[4JHZ1VF"@5#GOHWKU*$5>\_6&N:)( V5<(U<Z
M"6FRX)+Y ][1KRTZ]Q.HYR'/O>,3JR)UFGH>JK$"4;,O4XW5(@%9O41MES6]
M>0SLG20-AJ)2'\E;L+TGK4EKC2(.AL.J[S<>(FKST6Y/$ZP.(#I!7F6G3D.*
M_&>\R=:3DT&LTR J;R:,.#K6O%,'<N5,[Q1M=*E<RFB@2#6R\!1MG'SV$4-^
M'-%&\@C5/D4>31G'8N>[I\BCS<BCR)'T*?+H(0>+G:+7&'FLWZ1/C"S=<RUB
M^W9>;'P[O$.1?0GM<Z$[Q-$C(N$%Y/ >,Q\8N3&>T@!LA6APW"NZ7B$!&!=
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MSYZ'7SF>G_[M$R MV(Z?+3.2^*^R8D&6[N+GZ0,L_0 ?N$(*XD2TSS0[+6G
M;.X+U8;#B3SZWY^R 3W0/4#W-P\4LQM[#S?5<7:%-09C$]KO=$5>\!->9A@=
MYA]2(A>1ZP%YLQEI$YA=I.5'(4C[\%"$&FLT[Q8$9!\C:&I(.6_ 5:^.9O9^
M))#GD&U5EJ2Q.!P.TUS+CV$3] &:R),$?<0"*7(E2DS YRA]HD3AY+8*^IJT
MH_6J;Y)0 3]9&0\U13L._+!9GGJ?;MWP-99BF.[HU.I8D,=AXG^X6RT'>L/)
M$!UB?>BM/YHXYEXOR6YZ2JT<ZH"'NLU 6SP?9M9=]X!=-[ZY:FPY$1(S2X0%
M$=K+?AYVU&IB<K;@Y@'K '^(Z^+,WWV]W8<[)<>J-%(RJYWI/6J"IZ46VD9A
M;[1AME'(:VQ:&^YMR&X4BXJA_:0SH:^A3W1?HVBCL!?L[E(Z,"W5>]*J"/57
MQWZXI^YR*U<M8I 52+H2(4QRS9+[-69P:X2M9H-:(V0U&DQY,IS(4B-05C2(
MFC91FB%?#09/4L9J([ 5-6C*2)%JAJ2ZP2HB5%$_T!6?(8H?N7K6K<#@)@W;
M;<G^,X7T?*;]*CD:28GVWKQ[UP@SGB5',.>[-S0<CL5.0=Y7!&SD>D9#L-9H
M-:7AI,=,J69XU>%0D7N+6RG;W9' 5;TQ+JN*VEM&L NS.1'11N-1MR*UR^SV
MU8;M@[56&]:U8]F':&$;UA%#^F:/"@KZ(7O4E9CO-RZ'H$KNS$]&H_M:MRY=
MFL&RCF!2UK11LFOTX*9U0%DX?!QIBCIL&<C: \9T-41+IH6=(U2C15:U9.#5
M.685VRN4<?)XNG-LJB?]DB*/>X10]7E$$ZE/XE8DH)0T:2*.>F![:ZQCIHJ%
MG2-49Z YEEJW:[6&EFF[-M2&?9*\.NQ:LI;9.4(-1*FU*T<WX:E\)LN[+F@5
MZ33[@[@NR36F:^/XHK!<[$@-Z@B[%465U?UY:SE("H?6FJ3)PP8 :3-\;@7H
M.GW)1)/V5Y+J![^:OYAHHC)J&>*Z8]VN1+M8/#M4U+9A+A*SRB-M--):,EQ-
MQ:6M %UK/Y#:B+UH+;YL!>*Z8\BN1+N!:F:[D6$8G>$XZN\X5-V["7S/!\SP
M&MK.#M?#8<I0EI3$F?>^+?9U#(0SS/D(CU60<3\GW4&P^1W66LOZ8M-=QQ?3
MRWR#1:34P)A]X#6-RM4S=773JX2->*YF-$D4P2:>-5]60*2QE@5'O/8^ /!_
M]^W]\5;\<_?R^+\[)A;,J>>Q>[>?*?6R%3 >E"(E!J5\P@>MX/M3X]'T'/>.
MNH_ ("_CJAMX%"^P_'P)$6OH2LT@2 ':*T3633S$6^3 ;:P>(6J%6MYKQS",
M"^,;3U+BJD&34B@70N2.X"-[C$C7 2X._TA<,/EBWX,W\(B^IP-@DI@+ S^K
MAV<WQ_=TP3H^$I_>6D2G.R]<9%RV&(ZT<<(D%4&B30+LN?>T&5J5I80L2ZEY
MFEV20N)W61DI^,_*85GX3A],CUT>Y_->;O!E>8@U-I3Y+IAY])\ *,,&J.4G
M#T0WJM8;^LC1#"+VLY1CSGFS]!F*XEA,7C^KB3YHLDR#NJP<^!UDW'S$YVVZ
M-28[<FXY;?8+8= J^G6:DEVU![%'=.C2CNQPJ.+F9;C.J=.9%=D5;FAU4F=?
M]IDY/FWW]=6\(^A4_K5\&?"^66K,3GXB'C5PW@@%%!'#*2[VP!31^_2R_LPM
MG\PP?2*N<<.?U?V%;?O%O@76.$;TF%_XEE\JH2QU4))]<W62P+Y%+/I%P,/G
M.UD$E,XGD^,@8)6=V1]1[G<7%*I*H7HNRP6(6"\F_2-D%6E4BDACLX2<6N!T
M\"T]?+_]D7H^#TCJJ*_Q9R^C9XIQ7'#.JEKBS#H/=*VAQ%1Z_2QO/FSP#=R^
M(H2OS^+CL\F1SGDKG\/>8K59I#Z$"[XA7A(7-B0KUJVM.NJ>\\=#:H-KA;$?
M3K7^9MKF,EA&4=&M].?H6SBC*[5]^X"1YQ1@RI_R-TF^/ A;:;-W[=C<\EW]
M$X 2KJ]1)Z/ #3/XG2X)$-!^@'C7=R&P#8B%$'V"H-NV-X]F]AP2[6["P?JX
M^$V>1%CW"[?C(OM>F=PDNX1DE_M-]LBNQ!5E'3;QS.1VW/CR^LV-R\8ASRP:
M/3]L/MA9C]FFIF1G/H 8?P!LW@-9<JIL%+++E>2'F\\G5D.R,,F\S>5V5<0R
M9YW)RGK6F1Q7_J^P1<'4/YF.IYO4UF$96]\L:,&21HJ<T4"B,G3-+*&/57&H
M%B!N+G*DS$$"+/Y4M&X2Z^;)IJZW,%?L#6OJ9CPZL2:E!E(8D5)+S$K,0<I[
M-L)J@VHY7J>88$)7!H5-&;M9L>J'_?#5\3PVB6/NN&@4]KV9G3B<LXE!OM-'
M:H,8/P".VU'AKL9,=2R-$S7=;" J@;L]$* 4N,.QIL%_BH#+.)/],8@E3%YS
M^I,2-V^6BK6@B.MYU]Z> <.KL_?DF;_L'C_?/K4LYPG'T)<=LB*)HL( ++!7
M/>#E:Q(8*J*DRAV )VDYP .=2)T8U@%=*66IR./\JEP-W)IX7@'<7USX2G.$
M9,N7!J(F\N0#XIH6F<QT^!F\7,MG85AX^:\FF6$]PZ1-(W)PI[(X;=N&S;TO
M%I@$?+%W3/LJ.XIF4WB* M$ $H5O0"@334H>OE?%X6H^ISHOG>C.DL*7L*3T
M'>-E'3C/E_8_4SQRLO#QL,!WW)?4AXOS)NMEND3H7 -<[:!Z@(/]1362BRN;
ML"I1K<P\ Q2+XK@;H$91*\.\;E&[I$; CGGW],<55+MD.: 8"+4C4$Z9VD7@
MVL'73W !R-?#MO7Z>#$N*%F[H&D0JY(,4B?=8!7I7=$TJ)(7FTCEC$.)!*IY
M&I1CN)R<%- )#;#(:]H!Y$EAPM2NQ=RU?:V -V4I\P">:$=BAW:WU&7UREWY
M00?-9EFG^,JYNKNG*H7$CK;T^-W#\#0C:AC9*5 2>^HU[B4;8KV_?"_84!Z-
MY>1(NGW@;(+^"S%M#\L$U+NQKYZQ:!"8W@++MMDOZ4@)A9#X,YU%D[M2^Z85
M<>>^*<J<R<.AG+Q7?7#7!L LE?N6V;=PGG@VE(?2J )UN!+MOPP7U0EK>I5D
ME+YGL05!*1 W*^H]!'&3BB6.GE2 3%0VN[UJ)UX9R(:2I$B;W9!5(8M,1$FV
M'E+14B"4(<Y(G6C)*_1U$:=&F1_*8U41&X>QS'M<HCA1)7&S-:\R:%+WLK4)
M0JG7RA1E,DGFDX>I@^OS0^?+ (,OWJ+(COQO_ 7==?!7V#/)LCQ*WHXYM&=3
M0!9D;R[77CMLQ;H[)&G8)\).X]=\;XEI?+'#5I=<EX@DM5>H?*<^!%#4N"(N
MM@IES,%H73RFNAXL POR-H-]']NH7+K AS^CO*Y62$,+4K<D9UDP258/6XH$
M3%L-J\9_ ]X.ZMT[&=+(OC[;[$'[3GG'#@WO$?.ML&;Q8+-5,KOU<^1/&QU9
M$PG"@$0[:\- ]X!(A7V&.E15;?SF:=2$R^H;:@<]WK$A5-X+GJ2^"2?<-ZP:
M\^$]\7XU*,)1^,BP&KNWA;E0A7-CBE1A&%I HO HK%X@43QE5;1Q0>GK!(FN
MXH-*L+;B\"M!6"&//3;!:<_%5N-(ESZSC*'OJV;NA;47FKD7P@HA10_]TEY4
M^Z.9^SER1)K9:Y^Y%]8^:F9=/O,(-+.O/G,_1[K4S(OU'&EL-OC#]!?\5SA&
M\3/%$4 Y.O .YTP;@U7K JT[E O/DCU^E#L-F)I H15KW03@Y8WX*Q?*]DQ^
M(VP]?D_0:>C6! I'9"/J"O1>G8WH*BQLA*UUVP@^\&5/ P3_]>:DU3HBI&@D
M;4D0VL&@3F/6$J0%1\^,)L?"@BJ-2V,)7R@^#CRKF:BVF-&F)4K.W6E2/?8/
MX2\+847.W-BU)*31Y.OR4+2&1QFCN]FH*!\7IJ4#S?9 K&!^54W&N4?'Q)!.
MC' 9KO3%#C>FW@?> ZD ;Y%&X,2PN!(W5G>]WRF*JI*SXSZY><- M]U_7P7$
M8I&N.I;%_I*[0L*N311-[K$D-=^E7XGPG33K-R7V63?:QM(DV;.:&[;T'&33
M)K8.GY[:QKJ4<3/'=R: 4E: MY=NB641PPR6?+$Z;*6B22.0\F@6<@DHVD*C
M<N0Z%!5I?$R(%K/!BC@4CPF[\E99&6O26)&/"=D:0MY6>-)(Q%L&<M]ITCAD
M/F2F2".MBF!%8'>&?PD'AD,NXQ2R-J3WQ117SSJ;?G,SCYY)^NRX(>2U>39-
MD;1QGLSX(#2MX]5J9;QVH L6R8=BGNIQCYE4WI%I0TT=CX\;^X:+.?5SJ_VB
MSD$<6C/UJ&SR@?)M(9A31,AW<AL#'3T&"F[FOX'-QA/B02YZFEOR@F\#?',,
M<V[J[!I3+84A41KCP(#FH>T=76IW*;U"JIC+D7%,U%N6@0H%,5%2)N.W3;T:
M/%ZO\&G&(^9 D;N0?EB)K),0:10?A+2 4>D+S5M/2K'-P^<7#]X KN?093R6
MU#(WEJO!WF^2=3J_HET,VQMCT2Y>%9SE227ZT2[:A=2TWDV:K-;MM#;W3D)%
M:Y[TV@UTE8^$SN1\?5O%H.\)40HF1:^8$H5,>$]%O.$Z6\,,:+_H5@RA#@Z;
MF.TYI'/E<>D7I<JD7IV39ZO_I:9VX5$.S';MW3#,K9XZ502QH&^3927/(5-'
M]"Z?88SD\5C-<\FD(\P:=EI5Z=Z^5VI0[#-[>65%/'3(N!.X(EV"21.<N)QW
M1W7X)#ZFV-##&VW 5#W+8 /E\S61'@2Z<0H4]F;CB3J:'#%V;;=EUPYWP5YM
M:9BS5[O?W*K@-<>*,GP5$MM\^W?];&NY)[P95U"PQ^F8[']M VU[Q;">:LI>
M8G=R>Z*CJ"FK2++]%D\EX)LG1=VW2R1Y,M:.!_VR1C/W4TRUX)_S#FGZ7<8Z
MWKY01M)8U/*T?.Z"H WP.YC*40W.PJ6@N .PU^2O<#U&G2C:6#D&)%NY"5Z1
M#UU= F]#>P^]X-8.K.6J6M)P>$#&LR&L)$$9=;NBKF L2B,EU]V'#"!:0J)S
MAU "U(+IF2B.\T]OZ9P/%0H?$VTT+#"LJ7-4._ /91C2#Q?1F$HWXR5J5NO,
M*YV@V_*HK*/8<0RR;CC+.Y[PB^T!Q? ;?(NIC\^B^\3V3?BB2Y=FL*S#H\@3
M;9Q\=[@92'M%CV;[:[M$J,9VVB[1J##9Z@U+<]VML9U*0"/>\>J9NKKI)>XG
MUF%!A_)H+"O1A8_M/>H!H?:(NCHDQ0)F396DMFA4Y5D-51O'.6+C@-80J]9
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M;!E67:/*7DY561&32P"#YT=)3"L'$\[M[HL-:T[])TKMG7*7P#;.I]>RUZ"
M]"?&*=10%Q4 -[K9VFZH*P!&XPUUD6'9;JH3>$-=,K[A'5,04&1U3.UHBV+'
M:88)!I*E2[RE*:S;S&BZR^H\;+4(3; DLN!NZ:#S6)]]U)CLL#[=+\RT>/[5
M,\[_KGT>7>X]TOG2X1L)9_)(6H]XW-RAXO8YGH=55%D5:]I=FJQWAY]S/.$G
M:?(P>_/__>EYYEKFS_C?\,__#U!+ P04    " "#J-52MKD4(2 3   :X
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M/+'D*SK'XOV4#WN<B'>3]J*R&<.3#WOB!95._+S);R#:_N/<C4$$:<TK.M+
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M@J1\GVO_RO=PX3:H L'ORP0GR,1YEAPZL,,'=@A'XTCO@_&5'"WF98XB$)#
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MA6>A\64'3'[&B$+J/+SDOJ%^3K9AP%;D6O BMKR/(<-JD^R1Q2A)55 &(M)
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MFX_K-8:'B>6+?]U!AOB3_P)02P,$%     @ @ZC54M^;]1Y'.@  K(X$ !4
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M:R(F&RH*08[1QS'Z^#-''Z=\$G@[D_#LV0T2O@((^R[\!4F<W@"O*<R\JA]
M40"NRX_B=BGW(&]TI])ZDG6*@ZE[6BH:UP.*.GHSA')RW:&/V0N.3T-ZO>FQ
MSD2\H]=)Y#XX+'\+?>N0*+T&TF"$F9W3FO:4I*VY0KJ@5YZVWC"O#H5(.]H*
MC#1%L@$W6,/Y/U-AOI;P#;?(GI%RF75+_F# *O$ FC3#[W3D5??:6S3] 6;O
MAH%-"ZY GS#*,XKV?FVZ%/ZFSDZ\V?"S(TMS5ML58I!-C6 U/L]V0R<G[ />
MY]';EH[.\;;%Z.\<_9VCOW/T=^+U>(W^SM'?.?H[1W_G8$Z'H[]S]'>B\'?>
M\@,=8<?7?$P219J.,TFG@?DZ59P8]W0B<*(-Q,'9@BOC+D\<AZN>G&BVKHCV
M[$23K<9#<:(5KU3\PR<19^"!]RW>HT@?\&;5)[ZE^8,[C^JV=JL)RB8I:9."
M-O'[@KI)1MZ$_ZL@<))2..86CKZV%^%K*V;O\2I_7T9P<AZE%]_=E=QGIM49
MM^^K ?_HCCP%[764JQP96IWM>+*:8 *@J98(/J=4UW!B=DUU"CGJ2^IU]+-B
M-Z(Z_>KTMN2*:C(7U9#6,85]63Y>[>Z-OY G$FA;56G_P1A6#2F@N]Q;JX.[
MC+19EB7#6+>W.E!I3%:5H(9A?+O&>R &N6.=&(9USCP%*>-OM8WR;B=$ME@]
M20%0Z[E"NH[7%M.6VU])%]PF5\DKN@(-M12KUEAI)SL65"UY#:2PFTC38&$V
M?P8!M9'C\,5W[OT@C4G\IQ,F3K1:!_EU\AM4O2T9,9U)LYO6H,.,Z=51&YQS
M<A_M@4Y]=UL9"WOC(V$'/.I;-F#G?NB$KN\$93;6&Z5-%$NR5]0;P-9M$_VW
MZAOP,?2(YW'@N-_YC[PS*V*)7ZE'@HWZE\0@BW:^/306[4RIFN1DE6*<&6&B
M14[:I$3;&.<<XYQ#C'.R*"Y!Q'^JPL-_M8'FUB6A$_D4./?QMD!3I.<]F.!^
M7.)ZTL\)^Q:R1^+R=8QXX&%!, 0W[_E,IY0NU2&ZIU-<KU"@/+&9@*O7,UK^
M>%3)%2?=]D/-^SZ%::D[U:/;]#(%2'KS@H.NL"4]9D=]IQ,WE;B2>%#LMHLE
MC%Y:S+'0T4L[>FEQV?R!>VF;^&0'[(%M[&]MN\X!8F[D706<CY:J3#>4M(1X
M2-8?+!N5TA8E#2A7GTO;7:3@'K@-OHI3=%'9.H)5%D36QXZU5XI=C1)V6V\6
M*,R6WAB8J+.-JF2G=\72US94*4>JGK9B@AJS2HY<+2-8HX%5XL^>N27Q63L(
M:SK;NM"\-XH0+^#"B@Q($:$3X;<;;NZ;XKC;U]:MY[UA!%@!EU-D*&8WN'^G
M@1.+\.>J*9+U_6V%YO=&4\(.A.@[9(C>^.S[>43(!=]-1(2UFI_P&+/W T56
MP1*$[GO+Z*Y/K]/02\^[["J)6>R$GA\N[DBTA#%5]9R]L02E=G!=CP,(.<O[
M5AGQ5=UL!V)UE&$#6L^-Z:!8EP[E$C,-O<JEGOA!U.-@2&&;K9UX\4>6_Y4=
M-413-=Q (=9C2\-]ASJ/L<C/;)RU>-1%C98Q0W',4-QO+H\9BEA"'V.&XIBA
M.&8H#C5#T6S>W("SY@9V*ALSYC ?O<:,N5[LC76P4-J@,6-N"'E</T/&W#!N
M'[>Y:XRP)-4??OSP+:1\!Q,]"0N:U6:Y(7Q=</W 3V^ LNWBNVO?RBH="U[A
M.OD<_GO,G7%M.G8#3>$N&,CO\M0["U?0^M _)7C5RZ9 3!]A^M2\DP<G7/!N
MQ>!]*MO.QU^@?M7+0&,_TF?HXY+&A%T[*\'A-/1*CZ"4_Y('$B[%'!&%^\&G
M'=^^J<8WTF$F^3@3)_0FI6]4_KH.6$R*#V%XMU&\!G,1LCA*-,,88 >;>Z!M
MHA0!C=K&:*(:"D J^Q()XP.I-+_-@=Q55=?6FH]*)GH92*AKQV^3JO/R'=S#
MCF]*(FP9*D-XGM <.)A]47L#V*L':NTPN/M![QYHPO@>X)*OV3$AH3#_6IX2
M:5];CA/E]*CQFJ@9 9<]PX>.KWSPAS:8J#O:VNPW 423"PB-=X;1^,\D:#5!
ME/ULW<-M@H4>$Q 4K>_C@A.CCI@I9\-31G.U^LZ.!C$_M#D!5RS3D^24N.EG
MVTP4K;ZSHP',E@:<@,B8GC,UYNWN!^=DU<;"5WO.WASB1T6;#WCK;!B3]'5%
MXEUSKGS&:*3&0M)C]F8 :Y:2?E#VIE>J<S]BL?BZGMF FL_>#& ]DA,/BOR#
MZ9)EPC/KZ<L<;#][\QF_T!74@U+_;"%;]$YXB*_F%Z'G/_E>XD"O./&V0%/,
M'BR8:@U7OS4(1'3CA@19%./!?[RC9V'LQ_ S/75LJ@;I/[E7CH0$,3UYX$CY
MM0$F2G=8=X#W6>Q$"_-3/R(N'Q T:;S1=IO>O6)[3"LJXP$\Q)@^P]!H2:*S
M9[Z)%*%'I<33O8^L3^]NL/T1T.,)=(H91N2+B&3+ 2@WL5)GUH# =WF 5=YR
MH0%14.%J/A6I,@NBCD8"S3%OY^24@R;!+BPE.L6U^4L:.IO?W/%_,<=-]5%5
MXJ/Q0'8BF')TZ'XL88UMV@(9Y=:O>T7H-4::'N07$5'?%ZMI:2O$TW9F434W
M8*S'<O)'D4YX]F?";?H)73[2,.5?:@<5W09@#[48K]D1VH6K0JPJ%P1H;L?&
MZ4F<ZC" U:*9@ >S=3(&(>K:JYS6)0UO8^I^5^T\=IKV?V33FBE4AVKXD&;!
MP3O@>AAZ/O:&13'>#[<2PU@4 PT4*(W+X(IBG#UQ2J_FIQG#TM--7=/9T2?D
MA3!@JD$;\<F(QX@1]Y<%?7KM$3^;%/P?*0"I\/D/LR]DX029 Q*P"+S53B/,
MMJ".7O"XV(^0%=$VWL1J7%0B,0I0V.UB;EJB*)?IQE+O=4V>!H\/SHGSZ,=.
M,.43SE$LS&#[V=N^XXR0LE)M:D$AVRY44+YS"9^BRJUF;U'DY7U17,+;)1G"
MP/IAMO8"K.Q(6]MA(+A(J0<W+W8ANHZH2XC'SCGK>AA!/08"DIQ\T%1CNHEW
M[KADNA05;6&4H!X#04E./FAR,*'T+726E*\&_^*'G?S!$EVX:KH.$C>0#Z01
MCFWJR\]6I#X"[YH?O?@?G(7V;7_9&(.$5,U0/T[$/;']ZL1))':]G -=+,M]
M!HG=+@.='O7-;$HN&$N<4)2_%\SH;4NV^PP$*Q4#$%8?L<ZK4\+<R$]?=VHS
MQ4K=!X)@ UX@,#\9=DPL%A%9< +.1"$CX8(Y)U#IJMJVV"6O(!P2\V?+B2_B
M-<ECAQ%/Q$PYS4XFRR+?YWBU:<+/)VDNU@\G\K*WTMC?TUJ1%R$WO3[U_AY1
M)DN7,?\Q[%K1->?@61Y5P18^"QJ>$LF@#XE$ZXS8NO*'(8QNR&.F:4RUHZFV
M' @J]62#<"#PK&1^.V$X<@\>\3;LIBL$$QLRXDF>I6HVSD"@;,,4"#0JYTS)
M5;MA,'UF2X&QUA #@K<!/R"RJ+PV)3:.2<A%[OI.L&'HG(AMN?:97V^TH>.M
M9 V$WK)3IZ@&._7^F;!XF6:.K&NIPQA+NPT$3 T>0-0LNW>49B7;Q^UC;?,1
M!H)E,W9 6$N>('Q5CTL//C8JDPQ71WZ[3W7D[><?V]15'JLIC]647WPUY9.(
M>+Z(SZ:5VA4/?]6TQ9P;*2$;Q @3&LJWHVI;6WKA"Q:R# WL=[+V!P1E-J8)
MT- 5A;D17F'XHD_ISY@7K6U*P7EA2;RR@CM;#?J_M+,K-5I/6D]KC7&AHEQ)
M] 6/^M;F<<+X5H^QJ?MGXK-,GM*]$-@!\]JBHAU$!Q\XXI\14;YGH-'5SGY)
MA8$:L5H)X-M!=0D>RA6Q&X!1KY[CDSQXDV#')WE0+8?CDSSZS!E?[JP]R8,A
MAF'B19[^'@'M\CV> 3R0I,D%"(9A-*:/D1_4D%.-_,@OS38:9&:I%$X3E%IP
M!-JEP;R@5+?Z(L-%CPG0O SNG1X4,7(3S_3T^<98.52MK#&YW7 (KX@!5$/2
MM5U*$L@A4)=0DW2;?<0-DS8/$&@?43W^>N)$T<H/%\URUK=[S5 \-O.E61[>
M+@<08*@.GX;O-P\0.8@-TV<<0_!]H>'BCD1+^:V#<JMA@+)#L4;4$W5^W/J.
M]=FSN+0D^DPS/4OO+V6W*M8*I\R2>V<N2VY-UR0G+.U<)DTT$L1-UM2-R7(=
M<S$FRP%+[9@L-R;+C<ER8[(<FIC&F"R';]$:D^7&9+DQ6:[O=7Y,EAN3Y<9D
MN:&!AW)%')/EQF0Y1&B,R7*HEL,Q66Y,EC. U$^?+&<C/6L 270M. (!&TQZ
MU@#2YO28 (W2X-*S!I QI\\(:&<,PU*SQM[]X'RLVEB9:L\A9,SIL@%NK$T;
M&?&*C%+XE5:S]_@%74<R)-3WEF->E<P"P>;9LQLD7I9_5 3RX1VR[@BS(Q30
M?5$$E9NQ \%J^9P#9X=<1V3I)TL83F77@>"HR8?I#75WT[+1#!P(2"#E&I$W
MU E;DOJ)O/^Z*)\R5>N]N52M#463#4F3G*9TI#558XI6QUR,*5K FHLQ1>LK
M<<3<$^1?A(])?,>_*/>QPST&X&E7L8O.4M81K'+JROK8\;DKQ:Y&";OOW2Q0
MF/WOQL!$'7:LDIU6?D^K@ZON6*EZ6G+8:TPJ.7!U? QDU3Q[YK;$9^WPJ^EL
MRYN_-X80+\;]^)T!^4C<6%P_>O(]?L01K_(UQQ,:PU8PP "L4I:,AP8Z0C?5
MRM]IX,1I*G!38&N[VXHF[(TIS(WQD$)'<-[X[/MY1$CY"<VFF,)CV(I)[ VL
M@J6^XA.UYET>\I9UL16YT(=#BP.L@8STF3;UX;S2;  G\EK&NKZ3T%C\RI?U
M&/2TWH:_T+L.G% G*ZN;K]DY^M?CV_#=PCVDB\]3,'Q=PNR=L*5OO285GDQ/
MI8:Z^+LE7T.G$YH"?"(U'>NX$V?HQE\\Q.PJB5GLA"+B7MV.P-.XR2BS3T,(
MCC;F"&DR@HR/=G@.'S\I7I9WTC*Z1565=IB)GL/'K> "Z5I:KGRCOW;*>@T#
M,R4'H-, #U[%^XUZ0!7-AX?0-NF@1P$/-/)EK]IR>( HE[72^Z!]YEU=A'S=
M78C<IBECI$B8NA0K=.P_;5PF6UE3'ZI94YMA)MDX18K3I!C*:I;3;>S$1#/!
MJ:ZMU=/ZFAY%6E.U'9J,)ECXU5-Q+:<#R6,21\:K>>F$*?>3 LVM^4L!V5,=
MHI'NL\NG?;[7O*2AL_G-'?\7<UPA63CDL/;H-!W(CJ-3C@[=CR6LODQ;(&/V
M0':H"+TZ&=-[(8SO';[X;EJ6<Q&1E"ZIZU'1RU:*1=L91YMQ!LY3RXOQ#0FX
M@?&NG2A>E;D]7I7_(K>93<; ;4B;2P.=)Z1,J"H$5-?6CHUL(7@8.>QQOOT@
MPFSA.H"Q5\MVZHL+0N38IS%Q'RY"5WYIO;ZU+4LFF0)4CVAPPEA>T[;O-%:=
M(Y*]H[2?K3PQ[7.W!OFF0U_ O,@#L5?S;X^<'>%??B(L+B\%E:D!=\ K=0VZ
M-4[4F-R$\ 7+CZU<A0CN18X>P]%CV#%,YT*X_"SW1+SJ!#M>?77^2:.3P&%,
M?B9J- CN0U$+>:#S.4IXV'"@DS77>" [YZDVF&FC+I,8OM.6+>@QG]-Z5X]>
M3W&WW_W0=:(U.;(C7%U32ZF1;2<<57,SO$7Y[Q%E[:QKVM/6W2[M#9(6 Z8/
M=YW#]HV1>1)\\>>2S:U.[P'#5V$"^8&Q5+DG^\5U$KD/(O5:6:+GD_H$N5V(
M)_]E\054Y7;&8^5XK!R/E>.Q<B!GB_%8.1XKQV/E>*P<CY5UKR<Z[ &>;N*O
MMB*TVAN=@DBD1\ 3NES2\#:F[G?%S8UJ2_RBKR,8J:9WZ$#!#I,6 ^#> =WI
M6]R&IJ'(0=P-].?'Y/IC^.>FQ_#-E_*'S(&P[W@<'X_CXW%\/(Z/Q_'Q.#X>
MQ\?C./+C^#3TJK<OFAS1X>X_R[%=SJ'I!5V97]WHZI"JFZVJNP9 TF(-1 >M
MO346"?XPV'-HA0FDGIP.70C#A:[$P/!VNE/7399)>A5$[R&SYF,-&5H92QK^
M(F1@7Q))>2-YOR&#N"8?W&L.T<$'YMJ\.^S,R3>FWHR^OM'7-_KZ1E_?Z.L;
M?7VCKV_T]0W3C633UX??$_%3)S/@78S[\$0,&%H92\.;H_MX(@8,XII\#==1
MGYX(D<7FQ^NB9B=\,^&'"\())WJU9-\=55T.I1'7[V]OQASKRHX^A1?F4[A-
M[AGY,^'4GST)%E:J%[C #KA]!0H^T9FH&GJ5+R'!7>R<]54R5R*$_01O$B3,
MIW)#0*)^#[M"M:J>;VUS6Z]1*6>.%"#T1^JQ]CFV4.Y8^WRL?3[6/C>K"+UZ
MHO]P(N]L^1C0[&5"K?1%:1]+IL] V7,E6TC7X%LG<"*?"+;_<!9$=F2KM$3O
MJ*HEV+3C&)@9TS!,G.":1',:+9W0)<<T3!AA_#<N)YV3 TP/=4>\<F] O\8>
M$:F'$$Y,>K.WEW!,0!J=A3^_LW \B&$[&H\'L?$@-A[$!GP0.TX8MQB,3;TG
MG]'HED1/OLMWOEHG,KW.PSV:Z?/7S_+,HK@T:_E/U1G+?S6[$UM+D1WO^4^^
MQ[?4@)'D;8&F2 TD3' _)^1VTO_#CQ_2)V6$JCWXCW?TC._E)2\6U;&I&J1G
M8ZA$0H*8GCPZ-X)HP41I]+H#O%=CQX_1C//O*,Q:M5G?!FR/:4/E7)A>* $Y
M?XU.'4[V;<SU+63?5U)IUS?N_7TC,T*7, /)_IWAX@!?HW^0D+H<_X=0(?AJ
MP]G[@0J]EA%(X.\1%%84OD+^?V=_)OZ3$Z1;5*DK0]8'Z79-@W)PW;?]L"2+
M(]^-B5=/?/UO58??_4:UX^[0 *_Z\.3^HL/G ,&G$"AWB3:4!G5.EZ!8I06;
M-K;*[QB9L[N+OD[A'<L+?6' !%_Q:G/=7Y&"+.^&VQYK\5RS2[6+5(58598K
MT-Q2&K*6Q*D. U@-I EX,)LT8Q#B-E>;FMU*JU5M:BNW1#Y1P)KD.J]U6S9.
MUQ&=$R;4UPG.B2R_JMIR]A%KGH^,8 @'VWGY0ETN&$N(=YI$?KBX)I%/O=L'
M)R(L^_WY)C0DVS0T&0<]A"W8Z2=&UF<>(WJ0Z@CN)UC6' :A.<?B13NQF'.[
M[60R+$*VQZM-D_Q]^>D/)_*N'E-/X=]YPYA=A)D>*DH==/ Q_,K0$<\:3KP^
M$S)3'DZ<1S]V J[W5_$#B;)-PD7(S[E)F@^@=WG[;34M,QU[D@^>)F:FPT^R
M\2>E#XPWN<?DS!>6G%D0G];9N9JG.P1-1\INEX$X42!>T>URRH2JCN=U;2V[
M3D Y4R7E6'TF^R$R"&]):]10NTGXH8;OJ8^O^9@DBHBGY3"1=++E.I%,%MJ(
M=G"&V3[9C>Y]7?>^Y</?Z-Y';:I&]_Z+=^_7$8_>O?]6AH9EX_1'>AM!6>=E
MJUGO^7DM4-@E&$+ =AZ>*$/C>[X3K6X=D8*H<V"%NR#?%JAX19>$5Z)3U.R]
MFI>N["B+7&GTM5>23([#C@=?4PKX=@W=(HAZ/V$<Y5ZO25S-^3G/#Q?2[/'M
M1K;V!PWF!Y72#LK6=J4K$8%15\6L-,-MC&IY0I=RIHR7,2A@MN$O]*X#)]1Y
M0Z&;K]DQ<O7X-HQ&[B%=A*9P\+J$V=S:TC?4I_VLI!@AJ6W,0OBJLR;89?;)
MDG7O<I&@#7B'0/YD^0B[2=U/Z?[&\6 WM]_T;Y[4=.-:_=.CK2$ ./:."_.&
M6*]9M'37Q![&9<9!;&V_!'T1NG1)-ODBXE-"/M*]O[03[I. !K\U?D.4&*DV
M98IN=G;J.O+70@S[!KP+T#!OB0T#BWJG^W<2DBA-]IQZ2RY\ONRG"9=GS\+
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MP(#O_IL"6]M]9JG\[=Z8PMR EA,9G#<^^WX>$7+!S5+$#\MM)BL\ABW/P][
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M@;* /PQ_TBB (9\-2O$U6*[#2)=LM8 03>G:78<"( .NTT +ZU3?!%-^G%]
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MGIFR1^RI;)\+LKU6Q^#5V'T4'+QOS&&-<'NC5_81&I3.7':_?.K=NR^@[2<
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M"\?!6R/57^NS;IA@T[6+*-;'(*K%PTW81-#J&=M6%NB430 HG;.EVSG;DBC
MNAPP-.A3'O$W6W#2OM-B51%2O7 DTYBA9IM$"2CMU$C'_+LNT\<TCS)^IQ0E
ML-[>&5K5!I?3=$YW-7TAY0:7]"7[Z-%NAT-?0#@VVABFIJ5.&R@_+2 ;'.51
M=U4 E40?)%\_T,=UR KRC "TJI:A0C@^RH"K^=>7!LHW"<0QOUH1E,"AD_S&
M.37-8D8[5@B=+F0(W)P+@$J#H9,1HGZIT+_LGQ E(/Q2=Y(S7,5ERO*9.W>P
M@2X,)R8QQ\Z?]13!<-$%K6FYL>I[/4+-3G^FN(7%XV.)'\FWSE]JG-,WZ"ZP
M-,Q (>@M*D +M#O$ETH%)XH1FG ?LY5%N!5&2PQE%)2_F+*@@3:/[,#WY'4K
M<A.]TC^Q)TZ:!X9^9F&SESG/X\ARL2AZUBQ?\IX>:9ZJ$A(K[?<SP3O-_+8)
MP6.]2<$CU<*)151^N,U$[+27B"%L)8XA:W82,?"-1.RXCXB!;2/>XC7O+)5V
M!2.*^:2/"F2?-V,9,(11 !LSI1,#N!C9/DW<G(#1%SI;3O>3Y:G2#[L6XMLW
MN1LX=EGV)8 AYB384@<7;Y^NCMMB^EZOZN='!,3KK:F]D]UME; ;7CI*6^J'
M&VDMS%*/O1IE4!QV02P_T6?,-:;&#M%JV_?AMTB;U^&=&E!3CN< @$FM:0-_
MW+1;G;Y_6G*MT)'FB^0?FZJF5NH3AFL5?O\!6NB&'5Q-_/;VK@ZDU99VE.3S
M_\DSGTX=U)QG9)33;*?1!>55' !/FN% 2JES6N(DI2$N[.I$/\9W'/PF$?0:
M3J@$.H@D%*3 ,$L)39AF,$'42L(*3#[95&F.JVH1_[%)JY3MJZE)HY3VR1P#
MY#Y]%*)@.*3')TQJ&FG4$X?%IM$<KDG;[+!%.58)N'J2@M?,MP?R8!AF 5*:
M&1_$6FAO$8&>5CD_\O;(V;F=]HZD/61A1@(K&I!>FJ.)X#3;QT,1GSU:!JY/
MG/[O8'JL!)1PHP5#:?XV:/#\A1[+88J9YU3E3H9R.M($K-BK^\TE[6;4,(FT
MG2X8NCD"%K-M-!&?C3X07O:1\Y.7UF_>E'B5;E2I12WTO"9WMC5CD+C9I 2&
M>[9(A=B8GAY/XT16Z< &1DF_LN^!P?V=I6L#PR0U-FFR[D"S6Z^I6<%=[9N$
M7OFJ*=0TK3HK)U0,G-S!KH0$XQLL0"I9UJ3M_'1WIDW8&:A))J<7/RC?,$"L
M;"DJA;Y)<_2*H[*"DEZUOYBSS"RN5PFU?+89GG3R8+R!!4C-87(O9* Y@@8[
M$/4-564/-,B&(ILT0Y]6$"2]3%GP''EE.Q@%XICFP0Y1+!2S5"/F6 8DGS0/
M;KA2R6&T]+:]0=9PQ"0:\;.H*BP/B=%KP)O76.+5;G#@_>RL*6Y_-=<EKI>?
MUJ1QZ$#XC'GPSL@DH[2W>V!FR-UE,+5H\!YNAT^XP[J-$]^LCYD.Z=*M$I!A
MX2+-TQI?I<\TT&9(>=U5+[.:YV?%K(P8O2>FU0E..D>@\D?3X^84&=9E%K5)
MGRJ\W&17Z5+SK)V%*@SRB<;8$7"K=P D%,!*CIT:>111!;1A&B@C*J'>SRE6
MJR*_JXOXL_H!]I$,O F+$J$8/$\%444E0P54S^&A_;9(34\C=.UAC1?2.<<L
M#0,OWMT6L7P4;6.QT.(P1M%J$<>;U2:CH4T6H1U3"H(QPIH,M62MHA1HD6B3
M+9 \(-Y*H[XX?&)_Q*J]>),2$,+V#+ D)]$XF'%NB]4Q#NXM>@\X]_5V +\/
MUW%(/0W<+-\2+]RXT[LHBVB6_T6>_!H]8F7R($',:^8?!<A!VIZ1#)CNK0 F
M'#Q$%485E9WK6;5%GF^B[ :7RZ)<T=P\)T5.5ON5,L^LM9:_Q&76)FRSF!E5
M@C/%#:?@\YDB6F\UT0-7I7]K=$-MY435$^$]_<?Y'YOT.<IH!A?E'46E-*#1
MV@*DL,-#9%&4)XC]2T\+UIVSF[)8XHJ>=T;9!58.!:*8Y^2K4I"CE*L#&3#<
M40"3I%?MQ&BNJU!WR-CF)4]<<[:AS\GQM&_]A#8717F'R^<T5@S*3B7 F]Y-
MQ"\\I$2+:1+WH(05A/@+@,.D/HAX<%0UI85J]"ES+7@-IT(HACV27YESKAH5
M(-ZX?WY0U(0Q/)S3XK1A(.WW82,M9-7Y34\4C*?6X],=X:!G)H]*IG"TS[3#
M>V-6&]=TO606<G?6I?10)6&QT//_C):%&>*#6AHE0 RT0RIL+6Q6#[BD82W-
MT-)E6H%-/WWJ0Y,2 .)I4AOJ-:!33I^Z4.!;,Y5)\UZZ'RC4RZ*JZE)I79?,
MJ7,#B,7TT>2T)C. TRC+<'+RVEZ): 258^^NI7HE[WZJ8,#NW8J$0_^]V*&\
M5U,7:$W@/K%]/MY52*>)PT=_]'LY2_-(%CGL;]*IOTH8X!K "%58IPT\&$ME
M2==IO+G>TK4UOR$@-1D$=KNTI@H :101?6P<R!BSR%CI.)'GVF_N52LJPE;9
M:^H$)X,&=PRL-,'X?R>X\BV>!ZI$?7JGU5XZ0"7FQ[)D&.#KQ((_J3#384\O
M$Q*#QA]PD+//1L';$8\5\.YT1RL=G%G6$,=LZND,V&)SA67NF<)AOL "<W8R
MDY'".ZB</.(,U#./6'^XS)--S"Q4=6I! L#QGP&8&%;?2N[KUMF>IB?GJW56
MO&+<G%G(6?BQ8!>A<,((5[$(Z/[OIT55?RSJO^/Z%L?%8T[]E(+F,W[/YR1H
M]FKK^[_9/A:\%_FRT'9V=D3?N4>ON";3L[:(M]Y1^8!Q493-GZB<:MO5-X@W
MT:6U%>REGTL1O/W.KS/;WB,T!_/T*+[<EA,PC:_79Y7 S9,GXC>^L(Y?R$28
M3+7'F["PWE>ZBS+<',9T.]$]>R_S>[(,J*)8<W_(K0C/8;W.QHW"4*SUP7B_
M": %WT6*$&B[R1-<TCWK9_K4[3J+^/(CD-^2/RE^P]'=M. 4P7L6F@!6A!,!
MR^\PK@<OJCNU8AAO1!QQE1+&L4&3C+>87H&X=G-'-F4$\D?VYBD<DKD , 2>
M@EIRH647#L\\@^J]-$O 6+^:V\G"G!5ID1KG/TNB8WYPR=,0<<L/1VZBLGY5
M94W6R<-K("NTPE6.Y)G=WV =J#TP6E.U4/<W9"$1YR^XC-,*LS/U[<-T;1R$
M/ )J2D'0CJEW,T(9&(*;$NQ"#8!D8/Y $^*EA,^$HQ-.]8?J4#(SRXRR3AO>
MTP4SM#L"5E*4QL?S@&94;$LX0JNF#)200D#D/MS;TP[@1A1[R*97'MJW05&R
MIY<>%#$(;%U[&JW3.LH( Z_K)US2VV_UZW;J4MW%3SC9=#/0YG3S#-=1FE6+
M!R)')IZRP[A]ENXMNF'_5=*=FNZOZ.#N:QY[I-%^J/D"(I] [!N(?P3UOH*.
M4?LA=+U$?._X>C_Q._M:FN\83M ;&/BVU$QA"Y+O>%WBSU5-^XQ?$3[BM4/R
M\X^[FBP[YHQ?41FIOE_ MTF/4$\3135ZP(]IGI/_>",]\:(HESBEZ:;IM.W\
M99WR[9@NUF>F!K'X[B'U5.MJW&?/-7X46M(R7P:;>S73Q<D1/7BE1=)_+4H4
MTPT1>N'B0$,> PT8?E<O?,@XSV>EFMI(YR$#YV#.=W>LE&;W*7K(\*S3-LEW
M#FDP4%;3/GNA\)&WUP=5)MJX]TZSZ8%O9\;6\RZ_8KI+AI/%,RZC1SS8')[?
M+^J_?D@=UK%*9QI,=9]^XVLR"].%W>)&!34Z;9_'B&G]:^$6P#GLB.F07,9>
MJM_K8A",>]%&AP"H!6=/\_87DU!'Q;>]\+0R?==Q\4VN3@.,?=9?/Z11SK%*
M9UK?@AFY?*]ZYQFL9E@:ZX[D9_&%[#XRC251/9$;X/M^C_4]5^OPX-_3QR&M
M>D,9;^S@3!-1541U^7/#\RU_9^KJS1SZHIU!7Y>G[?0Y2-??#<_!N()]5/O>
M7,,N8(*O8*'4P%1_ 6P1^R<;Z  M9,,9OZ>A;@\KVMD&.=74WM>@YO+] QK$
MW*MUCX.6_<??6">?8/KTT:G[%*3=J@=SY3TX>\A;O(I2.E4_+7(64;R),IJ7
M\GO=AH-O)-YWL<)4M;"CY1=&\%EM>-N-'J,K /5*0+0(],TKCLKJ+X,9PAMQ
M'VK?JZI05=:E($@.R7WL4-7[=!\38+P9]S'=]KVX#Z"SC_VLSRZ)U6E>I;%L
MV>'A>X=T'F:LMID.P8<?@[.,\&6J<,?T\;%DUPU0)R[9#(#45_?C_(:5XV%$
M%SYXH .WHN)F&I]'7P/:7^>TU:'#6@ZN?^X[TF#R \QEV#S7I5'SN0.-P N8
MP1Y8,IPY331?)V':<+)TFNJB<JJ,.6+E]HD U/I@_U7KU)'W]WE86P->;78.
MF3NP[K]+?1G/(8.A .4&YJGB^<9T6">3<UX F6;WU&-)"\\ >'U\P.=B8-9#
M$"IAWT=D-(CF#,>838-_>'^$R$CT[D Y?L"'-V^.X[M4PK[/<9PY?@@S/&$/
MANV9W#]%>=,"W3LG\Z3O</_^0<SJIE;K7N9SKA^'=&<BE/&F5^./4*?WIE(#
M&*MK.#OVWEKCS[^-WB^O5#^=?_CMPU_%33/8W-_?R!:.L7I^84XM6 <??_YM
M='!YI?KIX,-OOYF$CM/L-O=SKG9HQWV'-<$$=%<IG/&.4\PWD&7#OJJ\GRGL
M%=K;&+/<&\.S,X%U) %G(;OSD474;(@]LB,+^E0*6M(CBV=^9$$^=/ROI2\\
M%_4V#T3G:I80JVM8'@O"\GMN7_7G7+7#\TW.^-Z&;YK8+"$V!O[EFZ;6R%3?
M]-9W&H#1W6%^_.?<G]A#FA6+E<,O '<T%EF-RYS4Z#.^9)5!*^H#CJI-R>KV
M,E]OQF_Z.>KZ',^<S!F\,FFC""VFQ 7TF+@7'3EGRO?3]1T:1B*["#,2\)8Q
M1PJLNW<T^#7XP*^$I&Y.1#BQ N)=)KMNXBZYCQ9]^-RO'SI]^B#FZA,J<R_S
M$H?OOJG]2G>[%:\Y-\<A_8><W]2^H[JBFLT+?RW3??# >_2HXF;NQ\W7@@^3
MWDRT[ZA'Z+*J-H>__Z:NF=YS(?Z:8_#1 ^^KD@J<N;_VOOB6^ZQHIDN_[1((
M']K^U"',\][2_M(4N]UF>O-EXSW-HJJZ7C:?ORYOT\>GW@T/V3+4J.)M!6\)
MOEO3&^2#NT('D"Z.;(^9U_:=T]FJZS@D5PB.!GZ^Y[U5^>[9GW>& FF[ $95
M&,\EL*<7/OUYBF9E-B$5"PA$A^PQ)E3]G%[# 0Z,L1Y$'=B[C#5W&?O9T/#G
M(+J%'" 7X8CID)W$I.J?TTTX 7JSCF)*+3B[BE![*/^:(D-\WA=*53C3V-OC
M2++%?ZVS:<)>C7UY03=R7,W6[O+8%@;#V^_! F>*O[%-(E4RG',F'-POF> =
M\GQOUT8),VCJL<'P"_ JQ.AFRBZC5)8N]_NR@#\WXYYSRZN;F0[OD-W,KHTR
MIYN9BNW-NID=*\39S7B:S3R8*^G!>!NAJ[6J>^!A^!Y$=SU!V5C><?AU'(&J
M>>@A/(. N&H/4P7CSC_G:T7A.[MA01\*R5OL\+I-A# P_KR=WKR#,?7-(UA+
M"??UUDE[(@]V1=A#>,@+BCTT#:RMBP[>FUU6[%XGNVQ@#.)E:-:R^@DCFB;[
MS1]VA5]A3]ZW I,0'FS-[-HE0K]Z &T/ _2&TYOO#CO7S"Y[3Y ?2#C95&F.
MJVH1DRJKTG[EU9@T;LW#O*Y+^D]J#)MV+ZHJ?<R5-S)W+=3G3:[]5$#_YLQN
M)0:?I>W5#/7CM6N"]2EJ3YX#7:Z2'K'S.SK7RSL<;TIB-ZY.HRS#R<EK(U<U
M@M)[>CL6"<<5[]L@Q5V5"M4%BBC'2MS=6UFBN%BMBAQ5] G:0W&5U;A'=+7$
MS.*_3NUMEH6#<IU.%>+D0JU*/AQ7ZF*.*5TV2IDT2DC'I%/Q590]DO^A'YTK
M7(WU5?9:] G.\3*-TRB[_I+CLGI*UR>DJ,^XO"'3(3(3(U,E::R3:Q'^@M*F
M&;>-0W/3#\[9'4"/F7G:\^'HH2L'%6U!Z(&7=(3675E G/TU043Z3/YX551D
M;"O+UV51TC6&*KN!3L&G4S8#[SM:M71P(EI#%!PBKE'1*J&,:*&8JA5DLJ-]
MOGX'%Z@&>?ZR3DOF??^.HW%Z*D==;T[/U9S.V]DJ!F?7%+1CHEU+2-86<(1P
M5X1Q-]BC7SO#2UR6.+F/7LA2#=<57;7Q_94L*[Y$N?*E>BM-GY[.P92^R[-0
M"\Y.=ZQC;K::J(Y>4,1TCUA&0,[(J%6'2DOG\=>IA* T=1NA'=2A[1RX0_<Z
ME,]%W9]+@M.V2AKAH(0< -9RCTEZI5E=U%'F1+(^1BNO^$@5 FU SCB&>=I(
MM'_AS@7TN.&N<%7]=$CC%_%<MM7 1(,Z@!Y8+<N('/#.OT5HU?5S7$,ET%4:
M/:09VUIWX-)8*RBMY"9H&394@3L/E^*TH!SZ)MMJ_L5(P,,<>7Z E)!I"O!Q
M0Y[TP[L +>9%$\96GC[1F(G+?+$J-KG*B[@7X].M3#6RSUK7,L XGHG Q:CI
MN,3TL#W-72=1A^F"_@U.#/T4V./V(T4#<SWGRR6.^5,C<;'"Q*A;,O^_Q;39
MR?#&[:HO<$(6[QEQSO6&('D=""OJ:2\E^W10>ZR*/LWW4"RT%>#^3!*.&J,\
M2B*TY*JH:G51270.J,NTWOP\C^*:^8H=>XJJ0&@=1&^X:[^0EP9F5-_9A#']
M;\KB.<W9X3I9:V H6Z,V=I[A9!.S.V$[5%:_$&C,%@UT9?.VA(-BL !;8"TN
M5U&.Z0-Y*2FOQ*2^#XFZ'XL\X38^9/C\A4:J[^*JY<5!H[/.:%=BR\HZ*(IK
M#!".LHK\>"M+HP.H\"'1O1V1IH<0[/TKT#K'A"J:.K4YI#"&>>P:][!?P)X.
MR>VG%X[2?)/FC\VYN.L<2%Y ^#ZA,\Q,=YDV<"9K( L[.6T!*&4EL+,!TR)U
MQA:\BS)\O621OK*8\\O\OHSR*F+S.%D;NNC#N]LR"?VX26DAXRLK1TTP?OA6
M)=RLTJ1A)7&YF' ON79H5G,!H-O5 ;Y=P_*-=B C2\]0E@*6+*D8@<WU,A+W
M^GB> ;2"B -9,"." :# *?H;O_-(+SUP-P&$3#=E$6.<5!>DM9K;>6U^8=7$
M1*_BDU0VX/O$TLF#(9<%2,E6(%-!M'K0E_:299OH^5\7;=M[J7ZC%&I<SGO-
M5A6[T+]FV]VYMKU=.P,CV,6+11R7;'[%KS_VFU?V^^])$7MK*?(MEC,BZL^-
MFL;2@!-NNG,I,LWG8M^&J.=]/XT(JAWLP+H\D8BWVF":*\P#". ;VM$2YX<0
M0E/A+*57'/!)6M0X?KK,XP]X_%*O3@Y6 ^I!"F&37!HUXD>(*'R+?N,Z_SM(
M:YR_Q-FF(KBN"#GR"B\>2\PR$2E:Q2 /JW7LP H;6:T6:M10IQ>VK7Z.TKRB
M%XQP=9U?YLDF9J D1U46XK!:R@JK&/O7RK6'3D&:I4G\>E_<-)-0OM%VO>SE
M&E#T)GM56,WEC%N\8,P*0/<%:HM =UV*G":] BNFZW(AFK9)P7:]_+0F?\WK
M2Y:YF_Y):$JU**RF,^(4EMU<@;;+9GW,=,C4OU4*TN, I=$3>  (&RSBP:L8
MA\R'\;881%:]*[0L2I07^7'!D"',H*&(7?D=+KW2''U]D_\]_Y"?W>=_(_^X
M^YIJKZ+ZB)6"7Z+5.B,3\Z]OWO_]WS^\_^'L:_+A-6D#S#8WGBB.=5%28$L"
M@7;$(N>)>$D)=)Y"G&7]5!TA\DDBGQ)1G*,D>JW>2N\\\"=6WWH_G%(;\N,#
MEFF?;N)UP%"T188>7OGN1B.W;H8FUNUH=T3#[IAN(=*NQC'2#LFO-: O^K7R
M6^D]!_R*^5OO.>YUX;O?/'*$?[Y><X!/(;_UWN)6#[Y[2F_6]Z\^$G[5-/F=
M@#]O+_K7JND 5TW-5IIZ+<SF&&=1C2^BM&2IS/?7_29\_(WTK^F6&SL0FW(1
M)M:84#<MV;UV  =WNU?5.BUQTBT6K\M3&LE.HSY",'8ZF+?&X)UK8CJCV:>/
MMHOS(T1\>]Q^_R!IKAY>/=#:Y>-OB\83+)]*V\+BB;1PU/W3OBT*C\ZAZD"Z
M\CVV7/D>2U:^1[+U[G8U3"?1W?,W:?>.*:1YRY_RB>T_:X\8UP"D_A"F"WQ.
M\YC8PN^=+O)D'!!5*0)4;!6!4<T-M4"/1AUQ?;9!((2"54$#4UAH#+_*=\9>
MP^'G!SR$IA>$PT7(W'X1Q_1R5T4Z%G7$7%!L[KT4"XP,^[1)^Q!,\SP1W9Z*
MFC*HVZ"%M+<FP_1^>0TP5VE1 ;8LL2WO(.CA:,Q47@3APZ<\6A5EG?X3)\RV
M9I]8$4:JE8;5EC90QRW5TVF:J]V<#AA2VEYM:B]KGQ;Y/S8YN]/[:UH_?2QJ
MK.R=#KJP6L\=N/)&6-/CTIP>0;2%H"^D%#)+(\4$[7XMRBD!PPZZ,!MW>LAP
MU[B2F.%K0#'#OQ;E9WJ$%JW3.LK$%AS\#*R19-B$=N!"*.92@>\065Y;,2G
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M4(J302:.>O)A#PTV#Q7^8\-@FQI$(PNK3<Q A<[5:<!IF<Z5=#$J.[E8AU*
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M(=%S/(:#LBXWA$/JV;.;QT1M,KG.H[@TN:LP[3@F>IY']U,K6'(8IU<M<6W
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MB+YMY+#U"L)/K5Y!X&-.BD$IE .N,&GTL$%#+^1-3%!T'4=//L?Z^.5+(O)
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M)_CAXHZKR'&@3/T!=C_@26LD0 +S^#9;+IWX93:_]1=A?@$+TPW%UUPT;C5
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MH=C_/4Z4&K]SGF7'Q1]WKW"BQZ3H@EO.N:#<Y"RH[(1<G+I.&.A*INJ%O(L
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M/RU8]F"R/:FWI;2?Q7GGFU"E[K]>P-C68 E<O6OU",/_C]Z]^=J< O#3T"D
MD[_PC_^7S008^?9N,P'(;N8V$Z!!/KGY91VD\BF.$E6AK2$^9J/]6^(S^F1;
MF\7R>F/_;1;+.(X7!@Z[L?DU;!:+S6(9KD3S*'379K$<0ARSC<VW62Q]/G#7
M>/48: ;T2<0KC^7O'\\#\;Z]ZGRL5^K$L_E8XSO'&-PUQ^S%L_E8-A^KVYH^
MNN05FY#U6@/^;;A_WV"^ENMIE]L,:"H,XJ%[Q7D"6/+LYZQN\PS[S3,<FT4=
M7[*D]7ADQPZ3/,.Q)9[8/$.;9PC1Z[%Y>VR>H<TSW$.>X9@-XNAYAF-]5*O'
M](D#SU$<LV4=/4=QU-/CM>4WOG^E(>4VO_& \QO?C\V,;O,;A\IOO&'\M[Z;
MEL\V?@G]_ 6O7&K)U$W])_%LE^K=HY_[27J<S2<;6LK\QYR:?(2"GLF*(/LH
M$NZRN7I4[$Y,)<525VNG6YYVYN 8UZ@:SU5O/ G,+NL/P2EPJ[1%QDXB734$
M%?+7B53(,.0+V1W_S/395R!0:S8BX=<HKR1FHA_T6L7%;O@)O>O ":_XGGL:
MB=O>$ '-JJ_14()&!>XM"EG%_R9%'5.3:@>FSTR=K21ICI;//"A"C<J@%!B1
MX-FF4_#-[1=#<.O=T))[T4%N%B 1L%N;1G;.B?GI\>[!"<L3XE44/G%!,&^P
M'$9S$K *?RC.8OT:K-JB\MI#Y+1RVXZQPE#F.@7HNR:^,C>#<O KZV_Y!,;4
MQ3H%Z)L[OBXV@_*::W&,\(2 6KN#CBXW2.70_%S#R@TCN+Y7ZM >^20X"6R>
MR3#G-9*39*C<E/Y#2^G,%*3\$_+JOGTD)*GNQB2B50RAH^XM83UX=3^4TX_!
M):#_R&@Z:FXFL%<:,;26P31)LF4NN*TX"6V5]%]ZJY(N2)GDM$PVQ-3+I]OJ
MZ39DR(8,V9"AT88,?6:.6"@%=1?A8Y;JHX?D/48$B9P)(C%%303J(H-4?6A@
MH],V $JT G;J%.;+>5X"2!?>H>^)[9#4JZ &+IDP#B!=J<[JV?,C$P$JI_Z3
M[_$#\@U?@TPU0#4&MD.PLR[H!43D/E\G/-??WZ* BSK@IS)34"7=L9UBG?%4
MBN4 )_B-GWP]CYE([6$<J[3-!%>-@58EOB^%T OH +5BM:J);-RVRWVU+[:;
ML+=E?E<@PRSO29Q6T./_JB/'?_7'C;#=22XU_.^5/],X):MO,-L45S9^%+%*
MM7Y%)E2U!Q;MMM2:);HB=9"K!4BDG_W07V;RI82WJ35!6S'J0ML1:2,OB*O
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MI.?-YI5:J-KC&J O$;!T"EC'#<#9,'7?;MC"3T3Q$>_4CYF;SN9S%OOA0ED
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M,2YX;6Q02P$"% ,4    " "#J-52MKD4(2 3   :X   $0
M@ $3#@$ 86UR:"TR,#(Q,#,S,2YX<V102P$"% ,4    " "#J-52\XG][V81
M  !UV   %0              @ %B(0$ 86UR:"TR,#(Q,#,S,5]C86PN>&UL
M4$L! A0#%     @ @ZC54M^;]1Y'.@  K(X$ !4              ( !^S(!
M &%M<F@M,C R,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( (.HU5(Q0;AEBF,
M +D$!@ 5              "  75M 0!A;7)H+3(P,C$P,S,Q7VQA8BYX;6Q0
M2P$"% ,4    " "#J-52AH0CQV]+  !*Z@4 %0              @ $RT0$
K86UR:"TR,#(Q,#,S,5]P<F4N>&UL4$L%!@     &  8 B@$  -0< @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
